Skip to main content

Full text of "Psychopharmacology abstracts"

See other formats 


U-vC-£X  TASLr, 


MOT  To  pr  r. 


■"''SeON(.y""-'S«AW... 


liVi'Xv:- 


''''      '  /H:. 


PSYCHOPHARMACOLOGY  ABSTRACTS  is  a  pubUcation  of  the  National  Clearinghouse 
for  Mental  Health  Information  of  the  National  Institute  of  Mental  Health.  It  is  a 
speciahzed  information  medium  designed  to  assist  the  Institute  in  meeting  its  obligation 
to  foster  and  support  laboratory  and  clinical  research  into  the  nature  and  causes  of 
mental  disorders  and  methods  of  treatment  and  prevention.  Specifically,  this  information 
service  is  designed  to  meet  the  needs  of  investigators  in  the  field  of  psychopharmacology 
for  rapid  and  comprehensive  information  about  new  developments  and  research  results. 
For  information  or  correspondence  with  the  National  Institute  of  Mental  Health 
concerning  Psychopharmacology  Abstracts,  changes  of  address,  or  removal  of  names  from 
the  mailing  list  see  the  inside  back  cover  page. 


The  Secretary  of  Health,  Education,  and  Welfare  has  determined  that  the  publication  of 
this  periodical  is  necessary  in  the  transaction  of  the  public  business  required  by  law  of  this 
Department.  Use  of  funds  for  printing  this  periodical  has  been  approved  by  the  Director 
of  the  Office  of  Management  and  Budget  through  December  31 ,  1976. 


NATIONAL  CLEARINGHOUSE  FOR  MENTAL  HEALTH  INFORMATION 
PSYCHOPHARMACOLOGY  ABSTRACTS 


Volume  14 


Cumulative  Index 


June  1977 


Page 

Author  Index     Al 

Subject  Index SI 


Carrie  Lee  Rothgeb,£'<izYo/' 

Bette  L.  Shannon,  Managing  Editor 


U.S.  DEPARTMENT  OF  HEALTH,  EDUCATION,  AND  WELFARE 

Public  Health  Service 

Alcohol,  Drug  Abuse  and  Mental  Health  Administration 

National  Institute  of  Mental  Health 

National  Clearinghouse  for  Mental  Health  Information 

5600  Fishers  Lane 

Rockville,  Maryland  20857 


Publication  No.  (ADM)  78-150 
Printed  1978 


For  sale  by  the  Superintendent  of  Documents,  U.S.  Government  Printing  Office,  Washington,  D.C. 
20402.  Subscription  price  per  year  in  the  United  States,  Canada,  and  Mexico:  $16.90;  other 
countries,  $21.15.  Single  copy  $3.70.  Cumulative  Index  issue  $2.25.  The  Clearinghouse  does  not  sell 
copies  of  Psvchopharmacology  Abstracts.  Persons  wishing  to  subscribe  by  the  year  or  to  purchase  smgle 
copies  should  send  their  orders,  accompanied  by  check  or  money  order,  directly  to  the  Supermtendent 
of  Documents. 


AUTHOR  INDEX 


I  The  6  digit  number  is  the  abstract  occes 


nbcr   The  nexf  two  digits  are  the  issue  number,  digits  after  hyphen  ore  the  category  number.  I 


AADAMSOOA     226900  01-13 
AALBERSJA     236667  02-15 

ABBOTT  D     240278  03-17 

ABBRUZZESE  G     244589  04-09 

ABOALA  EN     240839  03-09 

ABDALLAH  AH     238846  03-03,  248284  04-03 

ABE  K     22714101-10,239346  03-11 

ABET     227806  01-1) 

ABEL  EL     231227  01  17.  234626  02-14,  238766 
03-03 

ABRAMS  R     253617  04-09 

ABREU  LA     237924  02-03 

ABREU  RR     237924  02-03 

ABUZZAHAB  FS     239681  03-17,  253048  04-08 

ACETO  MD     248009  04-03 

ACHTE  KA     244023  04-17 

ACKEJ     237026  02- n 

ACKENHEIL  M     240218  03-08,  240219  03-1 1 
240220  03-14 

ACKER/WANN  RF     239272  03-04 

ACOSTA-URQUIDI  J     239261  03-03 

ADACHI  Y     241297  03-03 

ADAM  K     239059  03- 1 4,  24 1 753  03- 1  7 

ADAMS  AJ     235759  02-14 

ADAMS  CBT     230739  01-13 

ADAMS  MD     238809  03-03,  243800  04-03   2494  U 
04-03 

ADAMS  PM     235564  02-03 

ADAMSON  L     239059  03- 1 4,  24 1 753  03- 1 7 

ADDABBO  A     244588  04-09 

ADLERJE     238157  02-03 

ADRIANOV  OS     236261  02-03 

AEBERLI  P     248539  04  02 

AGEEL  AM     251989  04-04 

AGHAJANIAN  GK     226400  01-03,  227126  01-04 
229431  01-03,  236519  02-03,  239957  03-03 
240073  03-03,  243882  04-03,  244072  04-03' 
246846  04-03,  247211  04-03 

AGID  Y     230854  01-03,  249899  04-03 

AGNATI  L     229462  01-03,  232507  01-03   248288 
04-03 

AGRANOFF  BW     235320  02-04 

AGRUP-ANDERSSON  L     226408  01-08 

AGUILAR  SJ     227821  01-08 

AGURELL  S     246891  04-11 

AHLFORS  U     246623  04-09 

AHMAD  S     225890  01-15 

AIBA  H     245986  04-11 

AITKEN  WC     226305  01-04 

AKAMATSU  T     227808  01-15,  244779  04-15 

AKERA  T     231006  01-03 

AKIYAMA  R     241405  03-03 

AKPINAR  S     229038  01-07,229473  01-13   241275 
03-10 

ALSHALTCHIB     241759  03-10 

ALARCON  RD     252941  04-09 

ALBANO  C     244589  04-09 

ALBELDA  SM     242743  03-04,  250984  04-04 

ALBERT  J     237901  02-13,  245650  04-08 

ALBERT  JM     228225  01-08 

ALBERTSON  TE     249241  04-06 

ALBRECHT  J     251417  04-15 

ALECU  C     22635101-13 

ALEKSANDROVA  GM     228552  01-03 

ALEKSANDROWICZ  JW     230640  0117 

ALEVIZOS  PN     228224  01-08 

ALEXANDER  KS     238487  02-01 

ALEXANDER  PE     238489  02-08 

ALEXIANU  D     229118  01-15 

ALFORD  GS     252674  04-04 

ALFORD  HF     252674  04-04 

ALHAVA  E     239043  03-05,  241414  03-03 

ALI  B     239662  03-03 

ALIVISATOS  SGA     250081  04-03 

ALKANA  RL     238748  03-13 

ALKER  PC     233377  02-12 

ALLAM  M     251004  04-10 

ALLEN  D     236529  02-06 

ALLEN  GS     243797  04-03 

ALLEN  JE     251827  04-14 

ALLEN  MD     252656  04-15 

ALLEN  RP     247377  04-15 


ALLIKMETS  LK     242544  03-03,  244455  04-04 

ALMEIDA  MP     236526  02-06 

ALPERN  HP     237731  02-04 

ALPERT  M     253036  04-15 

ALTAMURA  AC     238988  03-11,  249673  04-13 

ALTMANJL     23994103-11 

ALTMAN  N     245840  04-13 

ALTSHULER  H     237755  02-04,  238787  03-04 

249004  04-06 
ALTURA  BM     229474  01-03,  251905  04-03 

253113  04-03 
ALTURA  BT     251905  04-03,  2531 13  04-03 
ALVAN  G     245653  04-13 
AMADUCCI  L     227219  01-07 
AMAMOTO  H     229761  01-08 
AMAN  MG     247378  04-15 
AMATRUDA  TT     226405  01-04 
AMBUEL  JP     240538  03-11 
AMDISEN  A     236806  02-16 
AMICARELLA-BOYLE  R     238771  03-03 
AMICO  DJD     239685  03-03 
AMIN  M     253057  04-11 
AMIN  MM     235356  02-07,  235361  02-09 
ANANTH  J     228242  01-11,  230012  01-15,  230780 
01-08,  235358  02-07,  235360  02-07,  235826 
02-10,  237896  02- 10 
ANCONA  L     229529  01-14 
ANDEN  N     249669  04-04,  249670  04-04    251226 

04-02,  251227  04-02 
ANDERMANN  F     226737  01-13 
ANDERSEN  H     247875  04-04,  253643  04-04 
ANDERSEN  P     232606  02-03 
ANDERSON  AD     237920  02-03 
ANDERSON  DJ     245596  04-05 
ANDERSON  EG     23261 1  02-03 
ANDERSON  JAD     252381  04  1 1 
ANDERSON  M     249783  04-01 
ANDERSON  MH     234826  02- 1 7 
ANDERSON  PF     227130  01-04 
ANDERSON  TR     243779  04-03,  2531 10  04-03 
ANDERSON  WH     242269  03-17 
ANDERSSON  BE     250941  04-04 
AN  DO  F     241381  03-03 
AN  DO  K     237701  02-04 
ANDRADE  NM     253051  04-08 
ANDREW  RJ     245712  04-04,  245713  04-04 
ANDREYEVA  Nl     236369  02-03 
ANDRY  DEK     238159  02-03 
ANGELINI  F     246665  04-03 
ANGRIST  B     233961  02-13,  237725  02-08 
ANGST  J     23199101-15,237992  02-08   238864 

03-08,  251118  04-09 
ANISIMOVVN     241983  03-05 
ANISMAN  H     237703  02  04,  237778  02-04 

245486  04-04,  250074  04-04 
ANLEZARK  G     228050  01-03,  241934  03-05 
ANNABLE  L     228225  01-08,  231037  01  08,  251828 

04-08 
ANNAU  Z     238722  03-04 
ANSARI  AN     248537  04  01 
ANTELMAN  SM     227343  01-03,  229475  01-04 
ANTONACCIO  AAJ     231039  01-03 
ANTONIJEVIC  S     250943  04-07 
ANUMONYEA     237775  02-10 
ANZIVINO  F     244476  04-11 
APPEL  JB     230876  01-04,  242750  04-04 
APPLETON  WS     247880  04- 1 7 
APRISON  MH     241205  03-04,  250067  04-04 
ARAI  E     251990  04-04 
ARAKI  Y     245597  04-03 
ARCHER  RA     249276  04-02 
ARCIOLI  I     231367  01-08 
AREFOLOV  VA     228551  01-03,  236233  02-03 

236713  02-03,  241982  03-05 
ARENDSEN  D     248648  04-02 
ARGENTAG     230827  01-09 
ARGUELLES  AE     229369  01-15 
ARGYROPOULOS  G     243198  04-1 1 
ARIKAWA  K     229026  01-07 
ARISON  BH     238684  03-03 
ARNOLD  LE     227571  01  11,  238825  03-03,  239932 

03-11 
ARNONE  A     231368  01-09 
ARONY  AJ      246425  04-09 


ARSENIC     229118  01-15,239089  03-05 
ARUSHANYAN  EB     231248  01-04 
ARUSHANYAN  Y8     228546  01-03,  231071  01-03 
ARY  M     250078  04-03,  2501 14  04-03 
ASBERG  M     240216  03-09 
ASHFORD  J     241918  03-04,  243758  04-04 
ASHFORD  JR     232519  01-14,  232520  01-13 

232521  01-14 
ASHMORE  J     238683  03-06 
ASNINA  W     236369  02  03 
ASPER  H     239862  03-03 
ASSAEL  BM     246993  04-13,  246994  04-13 
ASSAF  RAE     238531  02-13 
ASSELAAAN  P     251239  04-11 
ATANASIO  G     230991  01  11 
ATIN  J      245612  04-02 
ATKINS  HL     248537  04-01 
ATTEWELL  PA     240074  03-14 
AUBERT  C     237709  02-03,  237710  02-03 
AUTORE  A     244476  04  1 1 
AUYONG  TK     239662  03-03 
AVADHANI  NG     237871  02-03 
AVAKYAN  RM     231071  01  03 
AVIS  HH     230865  01-04 
AVNI  J     247777  04  03 
AXELRAD  AD     252006  04-08 
AXELRODJ     234919  02-03,237170  02-03   243795 

04-03 
AXELSSON  R     237902  02-13,  238552  02-13 
AXELSSON  S     251119  04-08 
AYALA  GF     241805  03  03 
AYD  FJ     232937  02-17 
AYHAN  H     241224  03-04 
AYNSLEY-GREEN  A     247715  04-15 
AYVAZOV  KG     228546  0103 
AZARNOFF  DL     231003  01-03 
AZCARATE  CL     246184  04  15 
AZZARO  AJ     238700  03-03 

B 

BAG     233815  02-08 

BAAR  H     238866  03  11 

BAASTRUP  P     236361  02  08,  240217  03-09 
248955  04-10 

BAB  Bl  N I  M     232530  0 1  07,  237 1 06  02-04,  245602 
04-04,  248959  04-04,  249623  04-02 

BACH  D     244725  04-03 

BACK  G     252222  04-03 

BADINAND  A     245116  04-05 

BADZINSKI  S     229439  01-16 

BAEKELAND  F     229091  01-11 

BAER  R     226777  01-09 

BAEZ  LA     250084  04-03 

BAHERSJ     237890  02-03 

BAHRKE  G     238320  02-03 

BAILEY  J     230742  0115 

BAILEY  PT     226943  0104 

BAILEE  AM     229906  0116 

BAIN  G     238755  03-04,  249271  04-02 

BAIOCCHI  L     235367  02-09 

BAK  IJ     239834  03  04 

BAKER  J     226349  0114 

BAKER  M     239058  03-14 

BAKER  TO     237717  02-04,  237718  02-04 

BALDESSARINI  RJ     226405  01-04,  237244  02-03, 
246150  04  04,  250928  04-17,  251699  04-04 

BALESTRA  V     244591  04- 13 

BALLARD  JE     253041  04-15 

BALLETTO  AJ     238684  03-03 

BALLINGER  BR     235545  02-17,  243716  04-15 

BALSTER  RL     238794  03-04,  238813  03-04,  250066 
04-04,  251976  04  04 

BAN  TA     227820  01   14,  229459  01-11,  230780 
01-08,  230812  01-08,  231034  01-08,  231035 
01-09,  231607  01  17.  235355  02-17.  235356 
02-07,  235357  02-07,  235359  02-07.  235361 
02-09,  235363  02-09.  235369  02-07,  235370 
02-09.  242249  03-09,  253053  04-07,  253054 
04  1 1 ,  253055  04  11 ,  253059  04- 1 1 
BANERJEE  SP     248701  04  03 
BARASI  S     241923  03  03 

BAR  BEAU  A     226932  0 1  -04,  25 1 648  04  1 1    253695 
04-03 


e 
S 

i 

> 
I 

s 

I 

•e 
2 


A-l 


Author  Index 


Psychopharmacology  Abstracts 


BARBOUR  BH     240843  0315 

BARCHAS  JD     238729  03-03,  241902  03-17 

BAREGGI  SR     246993  04- 1 3,  246994  04-13 

BARFKNECHT  CF     239660  03-01 

BARKAI  A     238681  03-03 

BARKER  E     245001  04-14 

BARKER  JL     226398  0103 

BARKER  K     244686  04-11 

BARKER  LA     245594  04-04 

BARKER  P     245621  04-14 

BARKOV  NK     241987  03-03,  244352  04-04 

BARLOW  TS     250110  04-03         ' 

BARNES  CD     238823  03-03,  239982  03-03 

BARNES  SE     245344  04-11 

BARON  J     244874  04-03 

BARON  M     246629  04-09 

BARR  GA     243346  04-04 

BARR  M     252825  04-13 

BARRACO  RA     239673  03-04 

BARRATT  ES     235564  02-03 

BARRETT     249144  04-11 

BARRETT  AM     237745  02-04 

BARRETT  JE     250111  04-04 

BARRETT  RJ     239850  03-04 

BARRY  H     230840  01-03,  238756  03-04,  239086 

03-03 
BARRY  HI     248283  04-02 
BARRY  WU     234711  02-09 
BARTEN  H     235628  02-17 
BARTHWAL  JP     238712  03-03,  239661  03-03 
BARTLETT  JR     241210  03-13 
BARTOLETTI  M     232530  01-07,  237106  02-04, 
245602  04-04,  248959  04-04,  249623  04-02 
BARTOLI  JF     241350  03-01 
BARTOLOMEJ     253110  04-03 
BARTRAM  SF     226763  01-03 
BARZAGHI  F     252030  04-04 
BASKER  MA     252381  04-11 
BATAILLE  M     237015  02-17 
BATTENBERG  ELF     236875  02-06 
BATTISTAA     251649  04-07 
BAUDIS  P     234420  02-14 

BAUDRY  M     226651  01-02 

BAUER  RH     228160  01-04 

BAUGHN  RL     246286  04-03 

BAUM  MJ     244343  04-04 

BAUMANN  P     237700  02-03 

BAUMANN  PA     251394  04-03 

BAUMEL  IP     237758  02-03 

BAUMLER  G     240644  03-14 

BAUST  W     240260  03  11 

BAYLISS  PFC     227210  01-07,  227225  01-09 

BAYLOR  MR     238700  03-03 

BEAR  ES     237813  02-15 

BEAROSLEY  P     227128  01-04 

BEAUBIEN  AR     249929  04-05,  250655  04-03 

BEAUMONT  G     245468  04-09,  252142  04-17 

BEAUNE  P     241350  03-01 

BEAUTRAIS  AL     239853  03-14 

BECH  P     240055  03-09,  241425  03-15,  243089 
04-13,  249927  04-15 

BECHTEL  P     240762  03-11 

BECK  L     238727  03-03 

BECKER  BA     230007  01-04 

BECKER  CE     247089  04-15 

BECKER  M     245301  04-04 

BECKER  RA     240977  03-11 

BECKETT  AH     237980  02-01,  237981  02-02 

BECKNER  JS     237753  02-03,  238813  03-04 

BEDA  E     244467  04-10 

BEDERKAJP     238696  03-04 

BEECHER  MD     251988  04-04 

BEER  B     231112  01-17 

BEJ  AJ     233361  02-01 

BELEGAUD  J     244874  04-03 

BELENDIUK  KT     247021  04-03 

BELL  JA     238704  03-04 

BELL-MIDURA  M     237253  02-11 

BELLAMY  G     238683  03-06 

BELLEAU  R     229034  01-04 

BELLUZZI  JD     232508  01-03 

BELLVILLE  JW     226828  01-15,  237734  02-14, 
251825  04-14 

BELMAKER  R     239728  03-09 

BELOZERTSEV  YA     228546  01-03,  236371  02-04 

BELPAIRE  FM     244131  04-13 

BELSEY  RE     245806  04-15 

BEMPORADJR     241990  03-15 

BENASSI  P     229550  01-11 


BENDER  AD     246970  04-13 

BENDER  DA     227712  01-03,235629  02-08 

BENESOVA  0     242732  03-04,  251991  04-04 

BENGTSSON  A     226408  01-08 

BENINGTON  F     227692  01-03,  230453  01-03 

BENKERT  0     233684  02-17 

BENNETT  EL     237264  02-04 

BENNETT  JP     226936  01-12 

BENNIE  FH     252653  04-09 

BENOITO     22809101-11 

BENOWITZ  NL     247089  04-15,  252327  04-13, 

252825  04-13,  253609  04-13 
BENSEMANA  D     233336  02-03 
BENSON  R     23161101-09 
BENTLEY  RG     252520  04-05 
BENZI  G     247012  04-03 
BEREGI  L     237118  02-03 
BERESEWICZM     236429  02-10 
BERGANDE  F     241232  03-03 
BERGER  FM     245646  04-09 
BERGER  PA     250417  04-13 
BERGERT  BJ     2371 55  02-03 
BERGEY  B     227826  01-09 
BERGAAANN  F     239860  03-04 
BERGNER  PE     245842  04-08 
BERGOFSKY  EH     251820  04-03 
BERGONZI  P     229557  01-14 
BERL  S     237140  02-03 
BERLIN  A     246891  04-11 
BERNARD  BK     250068  04-02 
BERNARD  P     249304  04-03 
BERNARDO  DL     244701  04-15 

BERNASCONI  S     237240  02-03,  237742  02-03, 
237743  02-03,  241235  03-03 

BERNER  P     244043  04-03 

BERNHEIM-CHALTELAIN  C     240657  03-1 1 

BERRY  DG     230862  01-03 

BERTEAU  P     242898  04-11 

BERTILSSON  L     226430  01-07,  232325  01-03, 
237863  02-03,  241253  03-03,  245653  04-13 

BERTOLINO  A     229551  01-11,  252220  04-03 

BERTOLLINI  A     246665  04-03 

BERTONCELLI  R     244476  04-1 1 

BERTRAND  M     245650  04-08 

BESSON  JM     232328  01-03 

8ESS0N  M     241247  03-03,  252217  04-03 

BESZTERCZY  A     235358  02-07 

BEVAN  P     251705  04-03 

BEYEL  V     233829  02-08 

BHAGAVAN  HN     232639  02-04 

BHARGAVA  HN     250079  04-04 

BHATNAGAR  RK     238826  03-03,  248408  04-03 

BHATNAGAR  SP     238484  02-06 

BHATTACHARYA  P     241343  03-03 

BIAMINOG     231317  01-15 

BIANCHETTI  A     237834  02-02 

BIANCHI  L     246148  04-04 

BIANCHI  S     248410  04-03 

BIASCI  G     230993  01-11 

BIBLE  HH     250984  04-04 

BICKEL  MH     230820  01-15,  247129  04-03 

BICKFORD  RG     238507  02-14 

BIEL  JH     233946  02-01 

BIERNER  R     225932  01-08,  229446  01-08 

BIGELOWA     227826  01-09 

BIGELOW  G     240831  03-14 

BIGELOW  LB     233817  02-08 

BIGGINS  JG     247209  04-04 

BIGGS  JT     231318  01-13,  238486  02-16,  253314 
04-09 

BIGLER  ED     231719  01-03,  239858  03-03 

BILLEWICZ-STANKIEWICZ  J     227635  01-03 

BILLINGS  RE     238683  03-06 

BINITIE  A     237730  02-15 

BIRCH  H     225932  01-08,  238748  03-13 

BIRCH  NJ     250725  04-13 

BIRKAMYER  W     23391 7  02-1 1 

BIRKETT  DJ     226829  01-13 

BISCHEL  MD     240843  03-15 

BISOGNI  A     23099101-11 

BISSETTE  G     232618  02-03 

BITHELL  V     226871  01-03 

BIXLER  EO     245652  04-11,252230  04-11 

BJARNASON  DF     232865  02-15 

BLACK  IB     226935  01-03 

BLACKMAN  DE     226852  01-04,  226854  01-04, 
246306  04-04,  250070  04-04,  251670  04-04 

BLACKMAN  JG     232333  01-03 

BLACKWELL  B     248976  04-08,  252991  04-17 


SLAIN  S     237728  02  04 

BLAKIS  M     239943  03-15 

BLASBERG  RG     231002  01-03 

BLASIG  J     239854  03-03,  24 1 223  03-04,  25 1 400 

04-03 
BLATCHLEY  RJ     226902  01-16 
BLAUSTEIN  MP     237751  02-03 
BLAZER  DG     225873  01-15 
BLEULERM     251118  04-09 
BLEVINS  RD     251420  04-13 
BLOOM  AS     238769  03-03 
BLOOM  F     229318  01-03,  232512  01-03 
BLOOM  FE     236875  02-06,  238471  02-03,  243183 

04-17,  252012  04-03 
BLOOM  W     247483  04-08 
BLOSSER  J     249484  04-03 
BLUM  K     238789  03-03 
BLUMBERG  H     249269  04-04 
BLUMER  D     245863  04-08 
BLUNDELL  JE     250938  04-03,  253315  04-11 
BOAL  D     233974  02-1 1,  251649  04-07 
BOARETTI  AC     228241  01-11 
BOSON  DP     227769  01-17,  250266  04-1 7 
BODNAR  RJ     239272  03-04 
BODOG  G     244355  04-15 
BOECKLER  W     238846  03-03,  248284  04-03 
BOEGMAN  RJ     253407  04-03 
BOERNER  U     247089  04-15 
BOGAERT  MG     237160  02-03,  244131  04-13 
BOGDANOWICZ  E     234046  02-09,  234047  02-1 1 
SOGLIOLO  C     229552  01-17 
BOHN  E     238320  02-03 
BOIARDI  A     246992  04-13 
BOILEAU  R     253041  04-15 
BOISSIER  JR     227207  01-06,  237708  02-04, 
249677  04-04,  249678  04-04,  251216  04-04, 
251217  04-03,  252032  04-04 
BOISSL  KW     242503  03-08 
BOJDECKI  K     234047  02-11 
BOKSAY  IJE     251407  04-17 
BOLLA  K     252444  04-1  7,  252446  04-14,  252448 

04-07,  252450  04-11 
BOLLER  F     233295  02-14 
BOLME  P     229462  01-03,  232507  01-03 
BOND  NW     226852  01-04 
BONESE  K     250066  04-04 
BONFIGLI  L     229553  01-17 
BONFITTO  M     230860  01-03 
BONKOWSKI  L     244199  04-03 
BONTA  IL     245599  04-03 
BORALESSA  H     250932  04-07 
BORBELY  AA     246388  04-04 
BORGAONKAR  D     248222  04-10 
BORGMAN  RJ     246150  04-04,  251699  04-04 
BORISON  HL     232333  01-03 
BORISON  R     249309  04-03,  249310  04-03 
BORISON  RL     238077  02-03,  238820  03-03, 

238841  03-03,  248162  04-01,  249311  04-03 
BORROMEI  A     239700  03-11 
BORZELLECAJF     238815  03-03 
BOS  ERH     235630  02-09 
BOS  IN  TR     243798  04-03 
BOSSLE  PC     248538  04-02 
BOSSONI  G     237834  02-02 
BOSZORMENYI  Z     252447  04-10 
BOTHWELL  S     238981  03-10 
BOTTER  PA     229370  01-11 
BOTWINICK  CY     245614  04-02 
BOUDENE  C     244874  04-03 
BOUDIER  HS     238321  02-03 
BOULANGER  M     237118  02-03,  237119  02-03 
BOULAYM     244638  04-03 
BOULLIN  DJ     230739  01-13 
SOU  LOS  BM     238745  03-03 
BOULTON  AA     250379  04-03 
BOURDOIS  PS     227391  01-05 
BOURGOIN  S     247213  04-03,  249512  04-03 
BOUSQUET  WF     226865  01-03 
BOUVIERJ     242898  04-11 
BOWER  BD     245344  04-11 
BOWERS  MB     230010  01-11,240076  03-12 
BOWMAN  FJ     238769  03-03 
BOWAMN  RE     228139  01-04 
BOYD  EH     244693  04-03 
BOYD  ES     244693  04-03 
BOYKO  SS     228547  01-04 
BOYNOVA  II     236714  02-04 
BRACKBILL  RM     241521  03-04 
BRACS  P     230856  01-03 


A-2 


VOLUME   14,  AUTHOR  INDEX 


Author  Index 


BRADEN  DH     227746  01-09 

BRADFORD  HF     241206  0303 

BRADSHAW  CM     251 705  04-03 

BRADY  JV     227137  01  04,  240014  03-04 

BRAESTRUP  C     247875  04-04,  250361  04-04, 
253643  0404 

BRAGAJC     241870  03-17 

BRAHEN  LS     244298  04-11 

BRALET  J     243777  0403 

BRAMBILLA  F     230839  01-08 

BRANCH  MN     245303  04-04 

BRANCHEY  MH     237696  0214.  244501  04-08 

BRANCONNIER  RJ     226478  01 -1 1 

BRANDES  D     247032  04-03 

BRANDMAN  ES     241133  03-14 

BRANISTEANU  DD     226855  01-03 

ERASE  DA     237891  02-03,  241245  03-04,  249316 
04-03,  253112  04-04 

BRASSEUR  R     240032  03-09 

BRAUDE  MC     235671  02-05,  238807  03-05, 
243181  04-04,  249267  04-04,  249268  04-03 
249270  04-04,  249290  04-03 

BREBBIAAF     237696  02-14 

BREBBIA  DR     237696  0214 

BREESE  GR     230841  01-03,  232609  02-04,  232618 
02-03,  233970  02-03,  246149  04-03,  2501 10 
04-03 

BREMKAMP  H     230866  01-16 

BRESSLER  R     238715  03-03 

BREZENOFF  HE     241346  03-03 

BRIANT  RH     238316  02-03 

BRIDGER  WH     234811  02-12,  237732  02-04 

BRIDGERS  WF     229476  01-03 

BRIDGES  PK     241210  03-13 

BRIESCH  ST     243878  04-04 

BRIGGS  AH     238789  03-03 

BRIGGS  FN     237245  02-03 

BRINKMANN  R     244896  04-14 

BRION  S     227217  01-09 

BRIZZEE  KR     239832  03-03 

BROCCO  MJ     238694  0304,  249268  04-03 
249270  04-04,  249290  04-03 

BROCHIER  F     240166  03-11,  242899  04-11 

BRODIE  NH     247030  04-11 

BRODY  TM     230919  01-03,  231006  01-03 

BROEKKAMP  CL     252033  04-03 

BROMHAM  BM     238975  03-08 

BRONAUGH  RL     238758  03-03,  247212  04-03 
249232  04-15 

BROOKS  DC     237780  02-04 

BROOKSHIRE  KH     241521  03-04 

BROPHY  PD     227106  01-04 

BROSNAN  RD     251003  04-15 

BROWN  AL     250414  04-11 

BROWN  B     235759  02-14 

BROWN  CP     251982  04-04 

BROWN  CR     232622  02-14 

BROWN  EC     225869  01-17 

BROWN  JE     238720  03-04 

BROWN  JGE     227550  0111 

BROWN  LE     244693  04-03 

BROWN  PJ     232622  02-14 

BROWN  TCK     243064  04-15 

BROWN  WT     251712  04-15 

BROWNE  RC     238843  03-04 

BROWNE  RG     241573  03-03 

BRUCK  J     233718  02-15 

BRUCKNER  S     232503  01-13 

BRUDZYNSKI  S     232483  01-04 

BRUGMANS  M     244685  04-04 

BRUMBACK  RA     233499  02-15 

BRUNSWICK  DJ     238775  03-01 

BRUSCHI  WC     246123  04  17 

BRUYNOOGHE  F     229128  01-14 

BUCHSBAUM  M     244664  04-09,  246629  04-09 

BUCKINGHAM  RL     231009  01-03 

BUCKLEY  JP     229477  01-04,  238810  03-03 

246967  04-04 
BUCZKO  W     250936  04-03 
BUDA  M     232624  02  03 
BUDAI  Z     231008  01-03 
BUDDEBERG  C     238855  0315 
BUEGEL  D     236663  02-10 
BUEHLER  JD     250332  04-06 
BUENO  OFA     251977  04-04 
BUNKER  P     249671  04  04 
BUNNEY  BS     229431  01-03,  236519  02-03,  243882 

04-03,  247211  04-03 
CUNNEY  WE     227785  01-09,  243440  04-03 


BURCH  LS     23551 1  02-04 

BURCHFIEL  JL     249983  04-03 

BURCKHARDT  WA     253137  04-13 

BURDOCK  GA     227389  01-03 

BURES  J     239861  03-04 

BURESOVA  0     239861  03-04 

SURGE  KG     227074  01-04,  239284  03-04 

BURGEL  P     251409  04-04 

BURGISON  RM     238737  03-03 

BURKED     226960  01-11 

BURKI  HR     239862  03-03,  246671  04-03,  250360 

04-02 
BURKS  CD     233448  02-04 
BURNETT  GB     231609  01-08 
BURNS  RS     247147  04-15 
BUROW  J     243234  04-04 
BURRELL  CD     239679  03-17 
BURROWS  GD     250491  0410 
BURSUCK  L     237102  02-14 
BURT  DR     240077  03-03,  243483  04-03,  247862 

04-03 
BURTON  MJ     242748  04-04 
BURY  J     246126  04-17 
BUSBY  AM     251003  04-15 
BUSCH  H     242751  04-17 
BUSH  HD     250019  04-04 
BUSH  MAF     250019  04-04 
BUSHING  JA     246851  04-03 
BUSHNELL  PJ     228139  01-04 
BUSSONE  G     246992  04-13 
BUSTOS  G     251178  04-03 
BUTTAR  HS     238710  03-03 
BUTTER  HJ     245012  04-14 
BUTTERICK  JR     242003  0301 
BUTTERWORTH  RF     253695  04-03 
BUTTERY  JE     241777  03-16 
BUXBAUM  DM     249249  04-03 
BYMASTER  FP     238840  03-03,  246848  04-03 
BYRD  LD     246854  04-02 


CACCAMO  LP     24 1 357  03- 1 5 

CACCIA  MR     246992  04-13,  246995  04-1 1 

CACCIA  S     238322  02-03 

CADEJFJ     227413  01-09 

CAFFEY  E     225718  01-09,  227731  01-17,  236359 

02-08,  252954  04-09 
CAGOSSI  M     229529  01-14 
CAILLE  G     237901  02-13 
CAIN  DP     232905  02-03 
CALDERINI  G     237740  02-03,  246993  04-13, 

246994  04-13 
CALDWELL  J     250723  04-03 
CALLAHAN  EJ     228224  01-08 
CALNE  DB     239685  03-03,  245647  04-13,  246699 

04-15 
CALVO  JM     238503  02-03 
CAMACHO  JG     238349  02-03 
CAMBRIA  E     246694  04-11 
CAMERON  OG     242750  04-04 
CAMMELLI  E     245595  04-03 
CAMPAILLAG     229553  01-17 
CAMPBELL  AB     233968  02-04 
CAMPBELL  C     250944  04-11 
CAMPBELL  M     228224  01-08,  229921  01-1 1, 

247386  04-17,  247480  04-08 
CAMPBELL  P     235360  02-07 
CANALE  D     246694  04-11 
CANDY  JM     241930  03-03 
CANNON  E     244195  04-12,  252519  04-03 
CANNON  JG     241313  03-03 
CANOJP     229906  01-16 
CANTER  JW     235286  02-15 
CANTOR  A     252174  04-03 
CANTWELL  DP     247385  04-17 
CAPONE  T     244298  04-11 
CAPPELL  H     233488  02-14 
CARABALLO  F     232613  02-03 
CARCHMAN  R     238808  03-03,  238816  03-03 
CARDER  B     241243  03-04 
CARDO  B     237103  02-04,  248964  04-04,  250982 

04-04 
CARENZI  A     226851  01-03,  237156  02-04,  244514 

04-03 
CAREY  RJ     237777  02-03 
CARINO  MA     236524  02-04,  238695  03-03, 

249280  04-04 
CARL  J  L     230834  01-03 


CARLINI  EA     251977  04-04,  251981  04-04 

CARLSON  RH     239863  03-04 

CARLSSON  A     244037  04-17,  251374  04-08 

CARMEN  J  S     227785  01-09 

CARMICHAEL  FJ     246850  04-03 

CARMONA  A     244691  04-03 

CARNASCIALI  E     235988  02-15 

CARNEVALE  A     24891 5  04-05 

CARNEY  JM     249246  04-04 

CARNEY  MWP     22771 1  01-1 1,  240663  03-08 

CARNEY  PA     249246  04-04 

CAROL  M     252209  04-04 

CARPENTER  DC     249929  04-05 

CARPENTER  DO     235588  02-03 

CARPENTER  JA     232517  01-17,  232518  01-14, 

232521  01-14 
CARRARA  S     229554  01-16 
CARRUBA  MO     240643  03-03,  252030  04-04, 

252201  04-03 
CARRUTHERS  M     25116104-10 
CARSON  VG     249298  04-03,  251 181  04-03 
CARTER  DA     244676  04-04 
CARTER  EA     251179  04-03 
CARTER  SB     245233  04-13 
CASATI  C     230827  01-09 
CASEY  DE     227570  01-11 
CASH  RJ     230835  01-03 
CASSANO  GB     229554  01-16,  253393  04-03 
CASTAGNOLI  N     236520  02-03,  249234  04-05 
CASTROGIOVANNI  P     229554  01-16 
CATAGNI  CF     229552  01-17 
CATALANOA     229550  01-11 
CATANIA  AC     240016  03-04 
CATRAVAS  G     249484  04-03 
CAT  RAVAS  J  D     227389  0 1  -03 
CAU  SA  P     232502  0 1  -03,  232528  0 1  -02 
CAUTHEN  SE     251180  04-01 
CAVALIERI  R     233295  02-14 
CAVERO  I     240064  03-03 
CERRETA  KV     238763  03-03,  249297  04-03 
CESPUGLIO  R     238503  02-03 
CHABOTM     231037  01-08 
CHADWICK  D     230855  01  03,  237977  02-13 
CHAIMOVITZ  M     239860  03-04 
CHAIT  LD     238794  03-04,  243800  04-03,  249418 

04-03 
CHAKRABARTY  I     241343  03-03 
CHALHUB  E     251654  04-15 
CHAMBERLAIN  JH     237718  02-04 
CHAMBERS  WR     23727102  14 
CHAN  AWK     249261  04-04 
CHAN  TL     229445  0108 
CHANCE  MRA     225569  01-04,  237715  02-04, 

246310  04-04 
CHANDRA  B     231654  01-11 
CHANDRA  0     246672  04-08 
CHANG  BL     233276  02-01 
CHANG  C     251698  04-01 
CHANG  CC     248409  04-03 
CHANG  H     228068  01-08 
CHANG  K     253693  04-03 
CHANG  KJ     227400  01-03 
CHANGS     238486  02-16 
CHANG  SS     231318  01-13 
CHAPEL  JL     229037  01-11 
CHAPAAAN  CR     238687  03  04 
CHARETTE  R     228225  01-08 
CHARUVASTRA  CV     239943  03- 1 5 
CHASE  R     239261  03-03 
CHASE  TN     233975  02-11,  250942  04-11 
CHASIN  M     229464  01-03 
CHAUDHURY  PC     235348  0209 
CHEMBURKAR  PB     250332  04-06 
CHEN  C     226532  01-04 
CHEN  HT     243951  04-03 
CHEN  PC     241378  03-04 
CHEN  PO     231316  01-04 
CHENEY  DL     241252  03-03,  244514  04  03,  247146 

04-03,  248700  04-03 
CHENG  HC     248408  04-03 
CHENG  RS     241243  03-04 
CHENOWETH  MB     239979  03-04 
CHENPANICH  K     239646  03  14 
CHERANYA     244636  04-06 
GHERKIN  A     237260  02-04,  239852  03-04 
CHERMAT  R     237708  02-04,  251217  04-03 
CHERNOBROVKINA  TV     236717  02-03 
CHESAREK  W     250078  04-03 


A-3 


Author  Index 


Psychopharmacoiogy  Abstracts 


CHESHER  GB     226764  01  04,  227130  01-04, 

230856  01-03,  239859  0303,  244894  04-04, 

251561  04-13 
CHESSA  P     244690  04-04 
CHETANASILPIN  P     239646  03-14 
CHIAN  CY     226944  01-05 
CHIAPPA  KH     236667  02-15 
CHICHKANOV  GG     228553  01-03 
CHIEL  HJ     238726  03-03 
CHIEN  C     252006  04-08 
CHIN  L     238706  03-04,  251989  04-04 
CHIOU  WL     253693  04-03 
CHIRSTENSEN  DE     232807  02-11 
CHITTO  G     248291  04-03 
CHIU  E     250491  04-10 
CHIU  P     231010  01-03 
CHIUEH  CC     237154  02-03 
CHLOPOCKA-WGZNIAK  AA     243985  04-09 
CHMELAR  M     234430  02  13 
CHO  AK     229478  0103,  238682  03-03,  246316 

04-03,  248637  04-01,  251181  04-03 
CHODERA  A     240237  03-04 
CHOMA  P     238845  03-04 
CHOPRA  Y     245593  04-05 
CHOTTARD  JC     241350  03-01 
CHOU  DDT     238702  03-03 
CHOU  SN     243797  04-03 
CHOUDHURY  PC     231603  0110 
CHOUINARD  G     228225  01-08,  231037  01-08, 

251828  04-08 
CHRISTENSEN  JA     245296  04-03 
CHRISTENSEN  JM     250657  04  13 
CHRISTENSEN  S     239046  0305 
CHRISTIAN  ST     227692  01-03 
CHRISTIANSEN  J      243089  04-13 
CHRISTODOULIDES  H     245967  04-08 
CHRISTOFFERSEN  T     239044  03-03 

CHRITENSEN  S     239041  03-05 

CHRUSCIEL  L     229043  01-17 

CHRUSCIEL  M     2291120117 

CHRUSCIEL  TL     229112  0117 

CHUANG  HL     240937  03-02 

CHUN  AHC     246968  04-03,  246969  04-17 

CHUNG  H     240933  0303 

CHURCH  AC     244680  04-04 

CIACCIO  El     243793  04-03 

CIARAMITARO  DA     238773  03-03 

CICERO  TJ     226848  01-05 

CIUREZU  T     236794  02-11 

CLAEYS  M     237274  02-16 

CLARE  A     235429  02  08 

CLARE  RA     243085  04-15 

CLARK  EL     245649  04-11 

CLARKE     229639  01-04 

CLARK  EC     229479  01-04 

CLARK  JA     249675  04-03 

CLARK  ML     229441  01-16,  229444  01-08,  251777 
04-06,  251778  04-16 

CLARK  MSG     249675  04-03 

CLARK  R     249459  04-03 

CLARK  RE     235356  02-07,  235357  0207 

CLARK  S     226903  01-14 

CLAVERIA  LE     246699  04-15 

CLAY  MM     249278  04-04 

CLAY  PM     249536  04-16 

CLEARY  PA     237726  02-08 

CLEMENT-CORMIER  YC     230600  01  03,  230602 
01-13 

CLEREJ     229083  011! 

CLEVENGERJW     232623  02-13 

CLIMAN  M     227820  0114,231034  01-08 

CLINESCHMIDT  BV     24491104-04 

CLODY  DE     248600  04-03 

CLOUGH  JM     241256  0303 

CLOW  DJ     251103  04-11 

CLYNE  KE     253154  04-15 

COBBY  JM     232519  0114,232520  01-13 

COCCHI  R     235998  02-10,  239615  03-09 

COCCHIA  MA     243865  04  03 

COHEN  G     248603  04-03,  248699  04-03 

COHEN  HB     238748  03  13 

COHEN  MN     248593  0411 

COHEN  Y     230450  01-03 

COHN  M     238792  03-03,  247514  04-03,  248276 
04-03,  252221  04-03 

COHN  ML     227386  01-04,  238792  03-03,  247514 
04-03,  248276  04-03,  252221  04-03 

COLASANTI  B     227701  01  03,  230836  01-04, 
230880  01  04 


COLDWELL  BB     231007  01  03,  250655  04-03 

COLE  AP     230424  01-15 

COLE  HF     238735  03-03 

COLE  JO     226478  01-11,  230863  01-14,  236307 

02-08,  251830  04-13,  253037  04-15 
COLE  SO     244679  04-04,  248394  04-04 
COLEMAN  JH     225869  01-17,  246187  04-15 
COLEMAN  M     239936  03-13 
COLLARD  J     227764  01-06,244433  04-17 
COLLET  A     242898  04-11 
COLLICE  M     246993  04-13,  246994  04-13 
COLLIER  B     248724  04-03 
COLLIER  TJ     238757  03-04 
COLLIGNON  P     244450  04-1 1,  244451  04-1 1 
COLLINS  AC     237731  02-04,  241225  03-04 
COLLINS  P     251719  04-07 
COLLINS  PJ     247480  04-08 
COLLU  R     248275  04-05,  253700  04-03 
COLNER  G     239932  03-1! 
COLONNA  F     231367  01-08 
COLPAERT  EC     237744  02-04,  241228  03-04, 
250355  04-03,  250656  04-03,  251429  04-03, 
253394  04-04 
COMBS  DT     247148  04-15 
COMBS  LW     232623  02-13 
COMMITTEE  ON  DRUGS  AAP     24581 1  04-15 
CONCHA  I     251178  04-03 
CONFORTO  C     239641  03-11 
CONNER  JT     237734  02-14 
CONNERS  CK     247375  04-11,  247379  04-14 
CONNOR  JD     239961  03-03 
CONSEILLER  C     232328  01-03 
CONSOLO  S     232510  01-03,  248291  04-03,  248410 

04-03 
CONSROE  PF     244071  04-12 
CONSTANT  J     229078  01-16 
CONSTANTINESCU  E     252711  04-03 
CONSTANTINIDIS  J     226915  01-09 
CONWAY  AC     238837  03-03 
CONWAY  JL     249983  04-03 
COOKJD     231004  01-03 
COOK  L     229461  01-04,  232509  01-04,  238697 

03-04 
COOK  RB     238476  02-01 
COOLS  A     238321  02-03 
COOLS  AR     237104  02-03,  237270  02-06,  237786 

02-03,  244215  04-04,  252033  04-03 
COOMBESJ     252859  04-17 
COOMBES  S     252859  04-17 
COONS  EE     250278  04-03 
COOPER  B     23084!  01-03 
COOPER  BR     232609  02-04,  233970  02-03,  246149 

04-03,  250110  04-03 
COOPER  J K     238484  02-06 
COOPER  SF     237901  02-13,  245650  04-08 
COOPER  TB     229438  01-16,  236529  02-06,  245842 

04-08,  247208  04-03 
COPER  H     234316  02-03,  237109  02-04,  241242 

03-03,  24896!  04-03 
COPPEN  A     226187  01-!0,  230742  01-15,  237994 

02-10 
CORBETT  L     246186  04-08 
CORCIA  RM     230838  01-04 
CORCORAN  ME     230475  01-03,  230478  01-03 
CORKEY  RF     237242  02-03 
CORRADO  R     247147  04-15 
CORSICO  R     237102  02-14 
CORSINI  GU     237733  02-1! 
CORSON  EO     238825  03-03 
CORSON  SA     238825  03-03 
CORYELL  MR     237871  02-03 
COSCIA  L     232502  01-03,232528  01-02 
COSCINA  DV     228142  01-04 
COSGROVE  KA     249299  04-03 
COSSIDENTE  A     229552  01-17 
COSTA  D     242863  04-15 

COSTA  E     226185  01-04,  226851  01-03,  226857 
01-03,  226961  01-17,  229463  01-03,  229466 
01-03,  232325  01-03,  232506  01-03,  232513 
01-03,  232514  01-03,  232921  02-03,  236674 
02-03,  237156  02-04,  237172  02-03,  239977 
03-03,  240699  03-03,  241252  03-03,  243041 
04-03,  244514  04-03,  248698  04-05,  248700 
04-03,  250362  04-03 
COSTA  J  L     22673 1  01-13,  244202  04-04 
COSTALL  B     227133  0103,  227135  01-04,  23778! 
02-03,  238319  02-04,  239964  03-04,  240063 
03-03,  248290  04-06,  248407  04-04,  250358 
0404,  25203!  04-03 


COSTELLO  CE     247090  04-15 

COSTENTIN  J     227996  01-03 

COTE  G     229033  01-03 

COTE  M     251829  04-08 

COTTJM     250110  04-03 

COTZIAS  GC     237253  02-11 

COUCH  JR     237138  02-11 

COUGHENOUR  LL     238842  03-04 

COULSON  GE     236708  02-04 

COURSIN  DB     232639  02-04 

COVI  L     229449  01-09,  252941  04-09 

COVINGTON  J S     234114  02-11 

COWAN  A     237100  02-03,  250354  04-04 

COWARD  JK     251698  04-01 

COX  B     250078  04-03,  250082  04-03,  2501 14 

04-03 
COX  CM     238718  03-04 
COXJR     229368  01-11 
COX  R     226729  01-04 
COX  RD     227703  01-04,  250089  04-04 
COX  RH     247729  04-02 
COX  VC     239290  03-04 
COY  DH     248349  04-03 
COYLE  I     237721  02-05,  242744  03-17 
CRADDOCK  D     243869  04-1 1 
CRAIG  CR     230836  01-04 
CRAIG  JC     229442  01-16 
CRAIGMILL  AL     249263  04-03 
CRAMER  H     240447  03-03,  243023  04-09 
CRAMER  MB     238477  02-02 
CRANE  AM     245594  04-04 
CRANE  G     247209  04-04 
CRAVEN  C     231010  01-03 
CRAVISO  GL     238686  03-03 
CREESE  I     229434  01-03,  240077  03-03,  243483 
04-03,  247862  04-03,  248703  04-03,  250088 
04-03 
CREVELING  CR     238798  03-03 
CRISP  AH     240423  03-11 
CRISWELL  HE     250062  04-04 
CRONHOLM  B     239002  03-09 
CROOK  TH     250726  04-11 
CROSSET  P     247683  04-04,  247730  04-03 
CROSSLAND  J     245596  04-05 
CROW  TJ     239841  03-04 
CROWDERMK     234713  02-15 
CROWLEY  WR     238822  03-03 
CSILLAGM     252450  04-11 
CUATRECASAS  P     229436  0 1  -03 
CUBEDDU  XL     246844  04-03 
CUCULIC  Z     237828  02-08 
CUDILLO  CA     24431 1  04-04,  250012  04-04 
CULLINAN  T     237141  02-14 
CULVER  B     247207  04-04 
CUMMINS  JT     236522  02-03 
CUNNINGHAM  RF     249243  04-03 
CUNNINGHAM  WL     227385  01-04 
CURRY  SH     237750  02-06 
CURTIS  DR     241921  03-03 
CURZON  G     239959  03-03,  241210  03-13,  241925 

03-03 
CUSHMAN  P     229039  01-15,  243088  04-15 
CUTHBERT  MF     245233  04-13 
CUTIS  DR     243762  04-03 
CUTLER  MG     225569  01-04,  237715  02-04,  237727 

02-04,  246310  04-04 
CYGAN  D     237778  02-04 


DAMATOMR     230577  01-04 

DELIA  G     226410  01-10 

DAFNY  N     246145  04-03 

DAHL  KE     238347  02-04 

DAHL  SG     250422  04-07 

DAHLSTROM  A     249669  04-04 

DALEVA  L     240205  03-05 

DALLY  P     249537  04-16 

DALTON  R     252381  04-1 1 

DALTON  WS     243087  04-14,  245648  04-14 

DALY  J     238798  03-03 

DALY  JW     240242  03-03,  253109  04-03 

DALZELL  HC     248651  04-02,  248652  0402 

DAMAMME  P     242898  04-1 1 

DAMASSA  DA     238800  03-04 

DAMICO  DJ     237729  02-04 

DANA  N     247683  04-04 

DANDIYA  PC     245593  04-05 

DANIELL  JR     233448  02-04 


A-4 


VOLUME  14,  AUTHOR  INDEX 

DANIELS  JD     226397  01-03 
DANIELS  S     226869  01-03 

DANKE  F     238862  03-15 

DANKOVA  JB     249317  04-05 

DAROEN  J     249293  04-03 

DARKEN  RA     244113  04-15 

DARLEY  CF     230871  01-14 

DARLING  M     243085  04-15 

DARNOWSKI  RJ     239659  03-01 

DARVAS  F     231008  01-03 

DASBERG  H     241427  03-10 

OAUL  CB     249003  04-05 

DAVANZO  JP     244685  04-04 

DAVENPORT  JW     228143  01-04 

DAVID  J     248649  04-02 

DAVID  0     251572  04-11 

DAVID  R     247480  04-08 

DAVIDSON  DL     250944  04-11 

DAVIDSON  J     232838  02-17 

DAVIDSON  JM     238800  03-04 

DAVIES  B     230118  01-17 

DAVIES  OS     243085  04-15 

DAVILA  D     237739  02-03 

DAVILA  T     237739  02-03 

DAVIS  DP     238476  02-01 

DAVIS  HP     250060  04-14 

DAVIS  J     230816  0109 

DAVIS  JE     228750  01-11 

DAVIS  JM     229440  01-14,  232616  02-04   232827 
02-08,  233967  02-08,  235803  02-08,  236303 
02-17,  236751  02-08,  238696  03-04,  239678 
03-17,  239933  03-08,  252847  04-08,  253018 
04-08 

DAVIS  KL     250417  04-13 

DAVIS  M     227126  01-04,  240062  03-04,  241754 
03-17 

DAVIS  VE     243778  04-03 

DAVIS  WM     226766  01-03,  227389  01-03,  230825 
01-04,  250021  0404,  250658  04-04 

DAVISON  MA     239963  03-03 

DAW  NW     236863  02-03 

DAY  T     247206  04-04 

DE  ALMEIDA  LUIZ  AMC     228241  01-1  1 

DEANGELISL     226827  01-03 

DE  BELLEROCHE  JS     241206  03-03 

DE  BELLIS  AM     245595  04-03 

DE  BERNARDI  M     244453  04-15 

DE  BOER  B     2387 1 2  03-03,  239662  03-03 

DE  BUCK  R     227771  01-08,  237025  02-10 

DE  CAROLIS  AS     237707  02-04,  247485  04-04 

DE  CROUSAZ  G     240762  03-11 

DE  GAETANO  G     237240  02-03 

DE  JONG  W     246673  04-03 

DE  JONGHE  F     252760  04-09 

DE  LA  VEGA  CE     230743  01-11,  239305  03- 1 3 

DE  LISIO  G     241234  03-13 

DE  MAIO  D     229555  01-17 

DE  MARCHI  F     232530  01-07 

DE  MOL  J     240033  03-11 

DE  SOUSA  A     235348  02-09 

DE  VERA  H     243793  04-03 

DE  WIED  D     239851  03-03,  246853  04-04 

DEBUS  G     233683  02-17 

DECKARD  BS     241687  0304 

OECSI  L     239275  03-04 

DEEN  HG     238743  03-03 

DEFEUDIS  FV     238349  02-03,  249672  04-04 

DEFEUDIS  PA     249672  04-04 

DEGANI  N     250779  04-11 

OEGENHARDT  T     234289  02-11 

DEHAVEN  RN     249074  04-03 

DEKABAN  AS     233832  02-13 

DEKIRMENJIAN  H     229440  01-14 

DEL  CASTILLO  J     249783  04-01 

DELPRIOREM     231368  01-09 

DELINI-STULA  A     251225  04-03,  251397  04-03 

DELL  H     237120  02-05 

DELLA  BELLA  D     230860  01-03 

DELLARIA  S     249765  04-17 

DEILUNTO  A     244588  04-09 

DELONG  FL     238085  02-14 

DELORENZO  RJ     240746  03-03 

DEMEL  I     229044  01-11 

DEMETRESCUM     238830  03-03 

DEMETRIADES  J     238684  03-03 

OEMIRJIAN  C     231304  01-03 

DEMOULIN  A     248224  04-13 

DENCKERH     2522310413 


DENCKER  SJ     243089  04-13,  246623  04-09 

252231  04-13 
DENCKLAMB     241990  03-15 
DENIKER  P     247554  04-09 
DENNEY  D     227570  01-11 
DEONNA  T     240762  03-11 
DERKERVORKIAN  K     253058  04-1 1 
DEROGATIS  LR     244063  04-17 
DEROSA  ER     232781  0208 
DESMEDT  LKC     225571  01-04 
DESOUSAA     231603  01-10 
DETTBARN  WD     249295  04-03 
DEUPREE  JD     239962  03-03 
DEUTSCH  M     235365  02-08,  235366  02-08 
DEVIC  M     237096  02-11 
DEVIVO  DC     251654  04-15 
OEWEER  B     241330  03-04 

DEWEY  WL     237753  02-03,  238765  03-03,  238769 
03-03,  238815  03-03,  246852  04-04,  251534 
04-03 
DEWS  PB     229429  01-06,  2501 12  04-04 
Dl  MASCIO  A     244701  04-15 
Dl  REDA  L     252220  04-03 
DIAL  EJ     249278  04-04 
DIAMOND  Bl     238725  03-03,  240474  03-03, 

249257  04-03,  249258  04-03 
DIAMOND  F     253036  04-15 
DIAZ  PM     238753  03-03 
D I C  K  P     24 1 760  03-08,  24 1  763  03- 1 5,  24 1 765 

03-15,  247711  04-09 
DICK  WC     252137  04-17 
DICKINSON  WA     238006  02-04 
DIEHL  LW     232260  01-15 
DIETZ  DD     227387  01-03 
DIEZ  JA     239581  03-03 
DILL  RE     251143  04-04 
DIL/WAN  VM     241983  03-05 
DIMICCO  J     237758  02-03 
DINGELL  JV     249245  04-03,  249284  04-03 
DINKELKAMP  T     237992  02-08 
DINNENDAHL  V     241246  03-03,  246389  04-03 

251416  04-03,  251432  04-03 
DINOVO  E     229446  01-08,  251776  04-16 
DIONNE  R     237758  02-03 
DIPOJONO  B     239269  03-1 1 
DISMUKES  RK     238798  03-03 
DITTMER  TU     251118  04-09 
DITTRICH  A     240645  03-14 
DITTRICH  VT     238735  03-03 
DJOJODIBROTO  RD     230859  01-03 
DOCHERTY  JP     231277  01-08,  238491  02-13 

238493  02-17 
DODD  KL     251103  04-11 
DODGE  P     248648  04-02,  248651  04-02 
DODGE  PW     248647  04-02.  248652  04-02 
DODRILL  CB     240473  03-15,  240475  03-14 

251937  04-13 
DOEPPS     238855  03-15 
DOGGETT  NS     225574  01-03 
DOHERTYJP     238489  02-08 
DOLAN-GUTCHER  K     227137  01-04 
DOLEZAL  V     234503  02-14 
DOLFINI  E     230827  01-09 
DOLLERY  CT     2383 1 6  02-03,  243085  04- 1 5 
DOLPHIN  A     248289  04-04 
DOMINO  EF     238709  03-03,  241872  03-08   248629 

04-13,  252825  04-13 
DONALD  JF     245468  04-09 
DONALDSON  D     235236  02-14 
DONALDSON  I     251239  0-1-11 
DONALDSON  IM     241929  03-03,  249076  04-04 
DONELSON  AC     238709  03-03 
DONLEY  P     245521  04-09 
DONLON  M     238736  03-03 
DONLON  PJ     228240  01-08 
DONLON  PT     252006  04-08 
DOORENBOS  H     235630  02-09 
DORAAAN  JD     237825  02-11 
DORMER  RA     250711  04-17 
DORR  M     244687  04-04 
DORRIS  RL     238731  03-03,  241919  03-03   243760 

04-03,  251143  04-04 
DOTTI  A     229556  01-08 
DOUSTJNL     225935  0108 
DOUSTJWL     225935  01-08 
DOWNES  H     230454  01-03 
DOWNS  DA     227127  01-04,240018  03-04   241250 

03-04 
DOWRICK  PW     247743  04-11 


Author  Index 

DOYLE  LN     228243  01-11 

DRAF  W     238866  03-11 

DRAFFAN  GH     243085  04-15 

DRAGHI  SC     228037  01-09 

DRAGULEA  G     229118  01-15 

DRAPER  R     245138  04-10 

DRASKOCZY  PR     247777  04-03 

DRAWBAUGH  R     227132  01-04,  238713  03-04 

DRAY  A     237783  02-03,  252521  04-03 

DREN  A     248648  04-02,  248651  04-02 

DREN  AT     248647  04-02,  248652  04-02 

DRESSEA     227763  01-04 

DREW  GM     252025  04-03 

DREW  WG     248008  04  04 

DREWNOWSKI  A     230875  01-04 

DREYFUS  JF     227216  01-09 

DREYFUSS  J      247130  04-03,  253323  04-07 

DRISCOLL  P     239865  03-04 

DROLETA     251829  04-08 

DRYBANSKI  A     227637  01-04 

DRYDEN  WF     244199  04-03 

DUBINSKY  B     246967  04-04 

DUBNITSKAYA  EB     244349  04-10 

DUBOIS  EL     232865  02-15 

DUBOIS  J     229078  01-16 

DUCHARME  JR     253700  04-03 

DUCHATEAU  JC     239576  03-04 

DUDEK  BC     244680  04-04 

DUDGEON  KL     237759  0203 

DUDLEY  GE     248538  04-02 

DUFFY  FH     249983  04-03 

DUFRASNE  M     237015  02-17 

DUGAL  R     237901  02-13,  2-^5650  04-08 

DUGAS  M     229081  01-14 

DUGGAN  AW     235866  02-03,  244203  04-03 

DUHAULTJ     237118  02-03,237119  02-03 

DUNCAN  DL     228160  01-04 

DUNDEE  JW     238531  02-13 

DUNN  AJ     237155  02-03 

DUNN  MJ     246856  04-13 

DUNNER  DL     234203  02-09,238977  03-15    244495 

04-09,  247582  04-09 
DUNNIGAN  D     248648  04-02 
DUPONT  RL     250711  04  17 
DURDEN  DA     250379  04-03 
DURHAM  HD     238710  03-03 
DUTTA  SN     249033  04-03 
DUVHOK  C     239042  03-14 
DYER  DC     230453  01-03 
DZOUIC  MR     245599  04-03 


EARNHARDT  JT     238809  03-03,  243800  04-03 

249418  04-03 
EBBUTT  AF     252138  04-11 
EBEN  E     240218  03-08,  240219  03-1 1,  240220 

03-14 
EBERT  MH     244574  04-09 
EBSTEIN  R     239728  03-09 
ECCLESTON  D     227205  01  09 
ECKMANN  F     241736  03-15 
ECOFFET  M     240657  03-11 
EDELSON  A     237105  02-04,  248956  04-04 
EDGARIAN  H     251905  04-03,  2531 13  04-03 
EDNEY  SM     230454  01-03 
EDWARDS  DA     239284  03-04 
EDWARDS  JA     227695  01-02 
EDWARDS  SJ      249304  04-03 
EGAN  SM     252200  04-03 
EICH  JE     243013  04-04 
EICHENBAUM  H     235320  02-04 
EICHENBERGER  E     246671  04-03 
EICHSTADTKE     238476  02-01 
EINON  D     230828  01-04 
EISENSTEIN  N     230577  01-04 
EKDAWI  MY     227215  01-09 
EKIEL  I     234046  02-09 
EKSTRAND  R     245653  04-13 
ELCHISAK  MA     238768  03-04 
ELITHORN  A     230580  01-15 
ELLEN  P     226305  01-04 
ELLINWOOD  EH     233965  02-03,  251754  04-15 
ELLIOTT  GR     241902  03-17,  242002  03-02 
ELLIOTT  H     251238  04-17 
ELLIS  RD     251180  04-01 
ELLISON  G     251063  04  04 
ELLMAN  SJ     239272  03-04 
ELMQVIST  D     227140  01-14 


A-5 


Author  Index 

ELSDONDEW  RW     251159  0410 

ELWAN  0     251004  04-10 

EMSON  PC     226399  01-03 

ENDELL  W     252222  04-03 

ENDOM     236696  02  15 

ENDO  T     231316  01-04 

ENEVER  RP     246317  04-01 

ENGEL  J     249670  04-04 

ENNA  SJ     226407  01-03,  23251 1  0103 

ENULESCU  0     252713  04-11 

ERCAN  ZS     226762  01-03 

ERDAAANN  G     244681  04-03 

ERHARDT  PW     239660  03-01 

ERHAAANN  M     239943  03-15 

ERICKSEN  SE     253018  04-08 

ERILL  S     248629  04-13 

ERLANDSSON  K     226408  01-08 

ERVIN  GN     246149  04-03 

ERWIN  VG     237920  02-03 

ESCANDE  M     234597  02-09 

ESKRIDGE  NK     250084  04-03 

ESSMAN  WB     229642  01-09,245873  04-17 

ESTLER  CJ     248951  04-03 

ETO  J     229761  01-08 

EUBANKS  EE     226734  01-04 

EVANS  BM     235563  02-13 

EVANS  CD     252138  04-11 

EVANS  HL     231005  01-04 

EVANS  J  PM     241979  03-04 

EVANS  JR     229448  01-08 

EVANS  LEJ     229693  01-09 

EVERETT  GM     238728  03-03 

EVERETT  HC     232864  02-15 

EXTEIN  I     230010  01-11 

EZZAT  MA     242267  03-15 


FABRE  LF     24 1 278  03- 1 0,  248532  04- 1 0 

FACCHINI  G     244476  04-11 

FAHIMM     229037  0111 

FAHNDRICH  C     237109  02-04,  241242  03-03, 

248961  04-03 
FAINMAN  F     238828  03-03 
FAIRBAIRN  JW     237784  02-01 ,  237982  02-01 
FALTER  H     252149  04-04 
FANG  VS     226869  01-03,  23431 1  02-03,  239931 

03-08 
FANIELLE  J     250266  04-17 
FARAJ  BA     243834  04-06 
FARBERJ     241678  03-03 
FARIELLO  RG     233299  02-03 
FARNEBO  LO     250937  04-03 
FAURBYE  A     240048  03-15 
FECHTER  LD     238722  03-04 
FEDAN  JS     248413  04-03 
FEDER  R     239258  03-14 
FEDERMAN  EJ     250175  04-15 
FEDINETS  P     252017  04-04 
FEENEY  DM     238811  03-04 
FEIGELSON  JL     238977  03-15 
FEIGENSON  JS     251651  04-07 
FEINBERG  AP     250088  04-03 
FEINGLASS  SJ     238789  03-03 
FEINSILVER  DB     225826  01-08 
FEJER  D     236046  02-17 
FELDMAN  JM     237927  02-13 
FELDMAN  S     228978  01-17 
FELOMULLER  F     249785  04-04 
FELIX  D     240523  0303 
FELLMAN  JH     251185  04-03 
FENNER  H     2313170115 
FENOGLIO  CM     247208  04-03 
FENSKE  M     239828  03-03 
FENSTERMACHER  JD     231002  01-03 
FERGUSON  CP     248538  04-02 
FERNANDES  M     251408  0417 
FERNER  UJ     253052  04-08 
FERNGREN  H     246891  04-11 
FERNSTROM  JD     226873  01-03,  233290  02-03, 

238676  03-03,  241472  03-17 
FERRANDO  R     245114  0406 
FERRARI  E     239695  03-15 
FERRIS  RM     249273  04-03,  249308  04-03 
FFRRO  FM     229559  01-10 
FERUTTAAM     231367  01-08 
FIBIGER  HC     227134  01-03,  232915  02-03,  241300 

03-04,  244676  04-04 
FIELDING  S     249272  0404,  249304  04-03 


FIEVE  RR     23081 7  01  -03,  234203  02-09,  234699 
02-09,  244495  04-09,  245416  04-09,  247582 
04-09 
FIGLER  MH     242892  04-04 
FILE  SE     241932  03-04 
FILLION  G     237890  02-03 
FILLION  M     237890  02-03 
FILLOUX  B     246273  04-15 
FINCH  CE     247588  04-03 
FINDLEYJD     227137  01-04 
FINDLEY  U     245647  04-13 
FINK  M     230781  01-14,  241275  03-10 
FINKELFARB  E     251977  04-04 
FINN  BW     238347  02-04 
FINNEGAN  K     236523  02-04 
FINZEN  A     253103  04-17 
FIORIELLO  G     237834  02-02 
FIRSOV  VK     241982  03-05 
FISCHBACH  R     229826  01-13 
FISCHER  E     229827  01-09 
FISCHER  G     228550  01-03 
FISCHER  JF     248637  04-01 
FISCHER  P     238516  02-11 
FISCHER  R     241428  03-12 
FISCHER-CORNELSSEN  KA     253052  04-08 
FISCHMAN  MW     250076  04-14 
FISHER  JV     248851  04-15 
FISHER  LA     238783  03-03,  239958  03-04,  252516 

04-03 
FISHERS     253043  04-16 
FJERDINGSTAD  E     241221  03-04 
FJERDINGSTAD  EJ     241221  03-04 
FLACH  FF     228037  01-09 
FLEISCHHAUER  J     239822  03-1 5,  241 762  03-09 
FLEISCHMAN  RW     235671  02-05 
FLEISHER  LN     231301  01-04 
FLEISSJL     230817  01-03 
FLEMENBAUM  A     252955  04-1 7 
FLEMING  DE     239858  03-03 
FLOMMC     235759  02-14 
FLOOD  JF     237264  02-04 
FLORES-MERCADO  F     2451 36  04- 1 1 
FLORIOV     246148  04-04 
FLORU  L     239823  03-08 
FLYNN  EJ     229480  01-03,  238763  03-03,  249297 

04-03 
FOCK  S     241798  03-03 
FOLDES  FF     252223  04-03 
FONSECA  NM     251981  04-04 
FONTANA  AF     234700  02-08 
FORD  RD     238813  03-04 
FORDVB     228726  01-11 
FORINO  V     229550  01-11 
FORNARO  P     253393  04-03 
FORNEY  RB     243087  04-14,  245648  04-14 
FORNI  PJ     247089  04-15 
FORREST  AD     231609  01-08 
FORREST  IS     229481  01-03,  238818  03-01,  249328 

04-01 
FORREST  WH     232622  02-14 
FORSMAN  A     237152  02-16 
FORSTER  EB     237774  02-10 
FORTUNE  DH     237781  02-03 
FOSSOM  LH     248697  04-03 
FOSTER  BB     235534  02-17 
FOTHERGILL  LA     233300  02-01 
FOURIEZOS  G     249749  04-03 
FOWLER  JS     248537  04-01 
FOWLER  SJ     245608  04-02 
FOWLKES  DK     245822  04-13 
FOX  KA     243788  04-04 
FRACCHIA  J     233829  02-08,  246694  04-1 1 
FRANCHIMONT  P     248224  04-13 
FRANCHINI  CL     231367  01-08 
FRANCOIS  G     247544  04-15 
FRANCOS  £     245967  04-08 
FRANK  GB     238710  03-03 
FRANK  PI     227223  01-16 
FRANKE  K     226840  01-03,237116  02-13 
FRANKEL  D     237720  02-04 
FRANKLIN  KBJ     246774  04-03 
FRANKOVA  S     251991  04-04 
FRANKS  HM     249674  04-14 
FRANTZ  AG     245840  0413 
FRASSANITO  LS     235992  02-11 
FRATTA  W     244690  04-04 
FRAZIER  SH     243863  04-09 
FREE  CA     229464  01-03 


Psychopharmacology  Abstracts 

FREEDMAN  DX     23431 1  02-03,  246303  04-14, 

247021  04  03 
FREEDMAN  R     240242  03-03,  253109  04-03 
FREEAAAN  H     237646  02-08 
FREEMAN  HS     248650  04-02 
FREESE  ML     250516  04-10 
FRENCH  SW     237756  02-03 
FRESTON  JW     245806  04-15 
FREUDENTHAL  J     241359  03-02 
FREY  H     233301  02-03,  25301 1  04-07 
FREYBERGER  H     226778  01-09 
FRICKE  NL     232815  02-15 
FRIEDEL  RO     229482  01-03,  244089  04-03 
FRIEDHOFF  AJ     249035  04-01 ,  253036  04-1 5 
FRIEDMAN  E     241254  03-03,  245601  04-04, 
247215  04-03,  247216  04-09,  247480  04-08, 
249002  04-03 
FRIEDMAN  Ml     227125  01-04 
FRIEL  P     251937  04-13 
FRIOU  GJ     232865  02-15 
FROEHLING  S     246440  04-14 

FROHWIRTH  C     229081  01-14 

FRUENSGAARD  K     238551  02-09,  246623  04-09 

FRUMKIN  K     251978  04-04 

FU  WLH     252757  04-03 

FUENTES  JA     227783  01-03,  233947  02-03,  237776 
02-03,  250376  04-03 

FUJIMURAH     241397  03-04 

FUJITAK     233832  02-13 

FUJITATS     251185  04-03 

FUJITANI  Y     241375  03-04 

FUJIWARA  M     241363  03-04,  241398  03-04 

FUKUDA  T     241372  03-04,  245597  04-03 

FUKUDA  Y     246319  04-03 

FULLER  JL     226532  01  -04,  244680  04-04 

FULLER  RW     226765  01-03,  238691  03-03,  241339 
03-03,  246151  04-03,  246847  04-03,  248605 
04-02 

FUNK  K     250058  04-03 

FURGESON  MD     251 143  04-04 

FURTADOJD     250193  04-14 

FURUKAWA  K     241393  03-03 

F  U  R  U  KAWA  T     24 1 406  03-03 

FUXE  K  229462  01-03,  229483  01-03,  232507 
01-03,  248288  04-03,  250937  04-03,  251649 
04-07 

FYRO  B     230824  01-09 


GABRY     237117  02-03 

GABRIEL  E     237647  02-14,  239835  03-15,  243438 

04-15 
GABRIELLI  F     244591  04-13 
GAHWILER  BH     232906  02-03,  237880  02-03, 

239836  03-03,  244205  04-03 
GAIARDI  M     232530  01-07,  237106  02-04,  245602 

04-04,  248959  04-04 
GAILIS  L     229033  01-03 
GAILLARD  J     226915  01-09,  239819  03-14 
GAIND  R     251158  04-10 
GAIRADI  M     249623  04-02 
GAITOJ     251929  04-04 
GAJDZINSKAH     244462  04-06 
GAL  EM     232614  02-03,  246151  04-03 
GAL  J     238682  03-03,  249234  04-05 
GALE  KN     238699  03-03 
GALEA-DEBONO  A     251239  04-1 1 
GALEONE  F     247969  04-09 
GALEY  D     244216  04-04 
GALLAGER  DW     226400  01-03,  239957  03-03, 

246846  04-03 
GALLAGHER  BB     237758  02-03 
GALLAHER  EJ     249264  04-04 
GALLANT  DM     237899  02-08,  247483  04-08, 

251718  04-11 
GALLEGOS-TORRES  J     245136  04-11 
GALLIC     241276  03-14 
GAL  VAN  L     235364  02-08 
GAMBI  D     229557  01-14,  229559  0110 
GAMBLE  JAS     238531  02-13 
GAME  CJA     241921  03-03,  243762  04-03 
GANDELMAN  R     245406  04-04 
GANDOLFO  C     244589  04-09 
GANES  T     232606  02-03,  232607  02-03 
CANS  P     241350  03-01 
GARATTINI  S     232510  01-03,  237240  02-03, 

237740  02-03,  237742  02-03,  237743  02-03, 

248159  04-03,  248291  04-03,  250936  04-03 


A-6 


VOLUME   14,  AUTHOR  INDEX 


Author  Index 


GARAU  L     249664  04-03 

GARCIA  J     238866  03-1 1,  246661  04  03,  246662 

04-03 
GARDNER  M     239980  03-04 
GARDOS  G     236307  02-08.  251830  04-13,  253037 

04-15 
GARFINKEL  BD     235322  02-11,  245786  04-14, 

252798  04- 11 
GARMAN  MW     237260  02-04 
GARVER  DL     238696  03-04 
GASCON  AL     233336  02-03 
GASSERJC     226828  01-15 
GAUCHY  C     244636  04-06 
GAUTIERJ     251829  04-08 
GAY  PE     230838  01-04,  244679  04-04,  248394 

04-04,  250008  04-04 
GAYEVYY  MD     236234  02-03 
GAYRAL  L     234597  02-09 
GAZZANIGAMS     251939  04-14 
GAZZARD  BG     241754  03-17 
GEAGEA  C     235358  02-07 
GEBHART  GF     229484  01-04,  249248  04-03 
GEDDES  PG     251776  04  16 
GEDYE  JL     250414  04-11 
GEHRMANN  JE     249251  04-03 
GEIGER  PF     238706  03-04,  238734  03-03 
GEISLERA     251129  04-17 
GEISSBUHLER  F     237709  02-03,  237710  02-03 
GELASHVILI  DB     236261  02-03 
GELLER  I     238750  03-04,  246821  04-05 
GELLERT  V     249247  04-04,  249291  04-03 
GENIESER  N     247480  04-08 
GENT  M     242248  03-09 
GENTIL  V     246312  04-13 
GEORGE  R     246661  04-03,  246662  04-03,  251238 

04-17 
GEORGIYEV  VP     236368  02-07 
GERALD  MC     238315  02-03,  238475  02-01, 

241257  03-03,  251983  04-03 
GERBERSHAGEN  U     238866  03-1  1 
GEREVICH  J     252446  04-14 
GERHAROS  HJ      237156  02-04 
GERLACH  J     230823  01-08,  237702  02-03,  239023 

03-08 
GERNAM     242212  03  11 
GERNER  RH     227785  01-09 
GEROLD  M     240064  03-03 
GERSHON  ES     246629  04-09 
GERSHON  S     227702  01-04,  230816  01-09,  230878 

01-04,  231112  01-17,  232615  02-04,  233961 

02-13,  236528  02-03,  237725  02-08,  237903 

02-08,  237922  02-03,  241241  03-04,  241254 

03-03,  242251  03-09,  245601  04-04.  247215 

04-03,  247216  04-09,  249001  04-04,  249002 

04-03,  249283  04-03,  251720  04-08 
GERSON  S     226405  01-04,  247777  04-03 
GESSA  GL     237733  02- 1 1 ,  2445 1 3  04-03,  244690 

04-04 
GESSNER  PK     249317  04-05,  249318  04-03 
GEYER  H     241241  03-04 
GEYER  HM     238839  03-03 
GEYER  MA     248947  04-03,  250377  04-01,  253255 

04-04 
GHONEIM  MM     230830  01-14,  237722  02-14 
GHOSE  K     226187  01-10,227210  01-07 
GHOSH  AK     243782  04-03 
GHOSH  JJ     241343  03-03,  243182  04-03,  253406 

04-03 
GHOSH  P     238798  03-03 
GHOSH  S     243782  04-03 
GIANTURCO  D     253061  04-11 
GIANUTSOS  G     227132  01  04,  239826  03-04, 

249139  04-04 
GIBB  JW     238693  03-03,  252027  04-03 
GIBBINS  RJ     232517  01-17,232518  01-14 
GIBBONS  JL     243346  04-04 
GIBBONS  P     244686  04-11 
GIBBS  J     245612  04  02 
GIBBS  M     242742  03-04 
GIBBS  ME     253290  04  04 
GIBSON  JE     249296  04-02 
GIEOT  WR     238795  03-03,  249240  04-03 
GIELEN  L     244215  04  04 
GIERLICHS  HW     251418  04  11 
GIGON  PL     226928  01-03 
GIL  AD  I     240643  03-03 
GILBERT  J     240657  03-11 
GILBERT  JC     243801  04  03 
GILBERT  MM     248975  04  10 


GILDEN  L     241328  03-03 

GILL  CA     240022  03-04 

GILLIES  AHB     245856  04  13 

GILLIES  R     241222  03-03 

GILLIN  JC     227802  01-04,  232324  01-11,  233817 

02-08,  234798  02-08,  235801  02-15,  236672 

02-04,  236750  02-08,  241474  03-14,  243013 

04-04,  243822  04-14,  244195  04-12,  248160 

04-10,  251 128  04-09,  252519  04-03 
GIMES  G     252450  04-11 
GINESTET  D     247543  04-09 
GINGRICH  RL     245649  04-11 
GINSBORG  BL     251703  04-03 
GINSBURG  BE     239581  03-03 
GIORDANO  J     235286  02-15 
GIORGUIEFF  M     241247  03-03,  252217  04-03 
GIOVINE  A     252220  04-03 
GIRAROI  P     232779  02-09 
GIRTANNER  B     229083  01-11 
GISPEN  WH     239851  03-03 
GITTELMAN-KLEIN  R     229053  01-11,  247381 

04-17,  247382  04-14 
GIULIANI  E     232502  01-03,  232528  01-02 
GIUSTI  GV     248915  04-05 
GLASER  GH     240746  03-03 
GLASSGOLDJM     248163  04-02 
GLASSMAN  AH     229443  01-09,  245784  04-09 
GLEES  P     246587  04-03 
GLENNON  RA     249318  04-03 
GLESER  GC     235534  02-17 
GLICK  EN     252136  04-11 
GLICK  S     226729  01-04 
GLICK  SD     227703  01-04,  231301  01-04,  240750 

03-04,  24131 1  03-04,  245594  04-04,  249485 

04-04,  250089  04-04 
GLITTERSTAM  K     226411  01-09 
GLOWINSKI  J     230854  01-03,  241247  03-03, 

244636  04-06,  249512  04-03,  252217  04-03 
GO  K     241397  03-04 
GODSCHALK  M     245599  04-03 
GODSE  DD     228142  01-04,  238774  03-01 
GOGERTY  JH     248539  04-02,  250080  04-03 
GOLABEK  M     234047  02-11 
GOLDBERG  DM     2501 13  04-04 
GOLDBERG  MA     237825  02-11 
GOLDBERG  ME     249027  04-03 
GOLDBERG  SR     24001 1  03-04,  240012  03-04, 

240017  03-04,  250113  04-04 
GOLDEN  GS     251962  04-11 
GOLDFINGER  SS     253691  04-03 
GOLDFRANK  L     252733  04-15 
GOLDMAN  D     253038  04-15 
GOLDMAN  H     226874  01-04,  241428  03-12 
GOLDMAN  P     245307  04-13 
GOLDMAN  R     244725  04-03 
GOLDSMITH  RS     245806  04-15 
GOLDSTEIN  A     239939  03-11,  241244  03-04 
GOLDSTEIN  DB     238701  03-03,  241240  03-17 
GOLDSTEIN  JM     253392  04-04 
GOLDSTEIN  M     238758  03-03,  247212  04-03, 

247216  04-09,  251649  04-07 
GOLDSTEIN  MJ     229448  01-08 
GOLDSTEIN  S     248976  04-08 
GOLLUB  LR     226853  01-04 
GOLOVANOVA  LA     244349  04-10 
GOLUB  M     230864  01-04,  234739  02-04 
GOMENI  R     241234  03-13 
GOMEZ  J     249537  04-16 
GOMEZ  L     235360  02-07 
GOMEZ-LOZANO  P     242250  03-10 
GONCALVES  N     234217  02-08 
GOODALE  DB     245598  04-03 
GOODALL  EB     237777  02-03,  244214  04-04 
GOODGOLDA     248612  04-11 
GOODLET  I     237748  02-03,241924  03-03 
GOODMAN  J     228142  01-04 
GOODMAN  JM     240843  03-15 
GOODMAN  P     251964  04-03 
GOODSON  WH     240243  03-15 
GOODWIN  BL     227212  01-07 
GOODWIN  DW     242947  04  15,  244960  04-13 
GOODWIN  FK     233964  02-14,  234797  02  09, 

243023  04  09,  243819  04-13,  244574  04  09, 

250389  04-13 
GOODWIN  JC     250725  04-13 
GORDON  E     226899  01-09 
GORDON  EK     248464  04-13 
GORDON  JH     234067  02  03 
GORDON  JW     251951  04-04 


GORDON  P     231480  01-12 

GORELICK  DA     226991  01-12,  237732  02  04 

GORINSON  HS     251428  04-05 

GORKIN  VZ     236369  02-03 

GORNY  D     227635  0103 

GORODETZKY  CW     240934  03-03 

GOSENFELD  L     252847  04-08 

GOSWAAAI  SN     228217  01-09,  240697  03-15 

GOTESTAM  KG     245298  04-03,  250941  04-04 

GOTO  Y     228322  01-17,229504  01-11 

GOTSICK  JE     248008  04-04 

GOTTESFELD  Z     237098  02-03,  237105  02-04, 

248956  04-04,  248957  04-03 
GOTTFRIES  CG     226408  01-08,  226409  01-08. 

227769  01-17,  227770  01  08 
GOTTSCHALK  LA     225932  01  -08,  229446  01  08, 

251776  04-16 
GOTTWALD  K     237123  02  13 
GOUDIE  AJ     225572  01-03,  226871  01-03,  230829 

01-04,  237713  02-04,  250939  04-02,  252522 

04-03 
GOUJET  MA     237708  02-04 
GOVONI  S     226406  01  03,  250356  04-03 
GRABOWSKA  M     237785  02-03,  251226  04-02, 

251227  04-02 
GRAD  B     235368  02-09 
GRAHAM  GG     226829  0113 
GRAHAM  JDP     252200  04-03 
GRAHAM  N     231609  01-08 
GRAHAME-SMITH  DG     230739  01-13,  239960 

03-03,  241979  03-04 
GRAM  LF     243089  04- 1 3,  2472 1 0  04- 1 3 
GRAMSCH  C     251400  04-03 
GRANCHELLI  FE     248646  04-02 
GRANDJEAN  EP     253587  04  12 
GRANT  I     226922  01-15 
GRANT  LD     239856  03-04 
GRASDIJK  L     241207  03-03 
GRATTON  L     235357  02-07,  235362  02-09 
GRAVES  J      248160  04  10 
GRAYJA     230875  01-04,  234918  02-03,  244217 

04-04 
GRAY  R     243865  04-03 
GRECH  0     237981  02-02 
GREEN  A     252231  04-13 
GREEN  AR     239960  03-03,  241979  03-04,  245600 

04-04,  251704  04-04 
GREEN  BL     235534  02-17 
GREEN  DE     238818  03-01,  249328  04-01 
GREEN  JP     229485  01-04,  238674  03-03 
GREEN  JR     239658  03-13 
GREEN  L     226409  01-08 
GREEN  R     251181  04-03 
GREEN  RA     251128  04  09 
GREEN  RD     246842  04-03 
GREEN  SE     235509  02-04 
GREENAN  E     243897  04-15 
GREENBERG  AS     239936  03  1 3 
GREENBERG  I     230876  01-04 
GREENBERG  LM     244932  04-15.  247380  04  14 
GREENBLATT  DJ     226840  01-03.  2371 16  02  13. 

237928  02-15.  244701  04-15.  250780  04  17, 

25 1  755  04  1 7,  252656  04- 1 5,  253495  04  1  5 
GREENBLATT  M     234378  02-17 
GREENGARD  P     226961  01-17,  229318  01-03, 

230600  01-03.  230602  01-13.  231014  01-03. 

231021  01-17.  232506  01-03.  237171  02-03 
GREENSLADE  FC     244685  04  04 
GREENSTEIN  R     229852  01-17 
GREENSTEIN  S     226729  01-04.  240750  03-04 
GREENWALD  ES     247978  04-15 
GREENWOOD  DT     227208  01-02 
GREENWOOD  MH     246312  04-13 
GREER  CA     237731  02-04 
GREGERJ     234289  02  11 
GREIL  W     233682  02-17 
GREVEN  HM     246853  04  04 
GRIECOM     229039  0115 
GRIFFITH  FF     226405  01-04 
GRIFFITH  JD     231319  01-13.  238797  03  13 
GRIFFITHS  R     240831  03  14 
GRIFFITHS  RR     227137  01  04,  240014  03  04 
GRIGORYEVA  ON     231119  0104 
GRILLY  DM     230868  01-04 
GRINGRAS  M     252139  04  17 
GRISANTI  G     237834  02  02 
GROENEWOUD  ET     230859  0103 
GROL  CJ      248949  04-01.  252523  04-03 
GRONSKAJ      232483  0104 


A- 7 


Author  Index 


Psychophormacology  Abstracts 


GROPPETTI  A     252030  0404,  252201  04-03 

GROSS  CJ     243797  04-03 

GROSS  D     238866  03-1! 

GROSS  MD     247878  04-11 

GROSSER  Bl     237864  02-03 

GROSSMAN  J     227330  01 -n 

GROVES  JE     245841  04-08 

GRUEN  PH     245840  04-13 

GRUENKE  LD     229442  01-16,  249234  04-05 

GRUNBERGER  J     226612  01-09 

GRUNDIG  E     244692  04-03 

GRUNHAUS  L     239728  03-09 

GRUZELIER  J     235629  02-08 

GSELL  S     237458  02-10 

GUASTALLAA     230839  01-08 

GUAZELLI  M     241234  03-13 

GUELFI  J     227216  01-09 

GUERIOT  C     229081  01-14 

GUERRIERO  FJ     243788  0404 

GUERRINI  A     230839  01-08 

GUHA  D     249033  04-03 

GUIDOTTI  A     226185  01-04,  226851  01-03,  226857 

01-03,  229466  01-03,  232514  01-03,  232921 

02-03,  237172  02-03,  243041  04-03,  244514 

04-03,  248698  04-05,  250362  04-03 
GUIGNARD  JP     246273  04-15 
GUILLAMON  A     244217  04-04 
GULATI  OD     235670  02-03,  238764  03-03,  246817 

04-03,  246822  04-03 
GULDBERG  HC     252173  04-03 
GUMULKA  SW     241246  03-03,  251416  04-03, 

251432  04-03 
GUNBY  B     227772  01-14 
GUNDERSON  JG     225826  01-08 
GUNNE  L     250943  04-07 
GUPTAS     229039  01-15 
GUPTA  TK     238475  02-01 
GUREVICH  Ml     236831  02-03 
GURLAND  M     249002  04-03 
GURURAJ  VJ     251827  04-14 
GUT  I     230007  01-04 
GUZ  I     227218  01-09 
GUZEK  JW     248952  04-03 
GYE  RS     230739  01-13 
GYLYSJA     237717  02-04 
GYSLING  E     248909  04-15 
GYSLING  K     251178  04-03 


H 


HADA  H     228310  01-13 

HADNAGYC     23716102-15 

HAEFELY  W     228051  01-03,  229465  01-03,  232515 
01-03,  241315  03-03,  241316  03-03,  241317 
03-03,  241318  03-03,  241319  03-03,  251399 
04-03 

HAEGERSTROM-PORTNOY  G     235759  02-14 

HAEUSLER  G     240064  03-03 

HAFNERJ     250727  04-10 

HAFNER  RJ     240423  03-11 

HAGEDORN  H     249674  04-14 

HAGQUIST  WW     228143  01-04 

HAHER  EJ     245842  04-08 

HAIDVOGL  M     233717  02-11 

HAIGLER  HJ     240073  03-03 

HAILEY  DM     230424  01-15 

HALARIS  AE     23431 1  02-03,  247021  04-03 

HALL  JG     244203  04-03 

HALL  ME     241301  03-04,  241689  0304 

HALL  R     229693  01-09 

HALLAS  R     248648  04-02 

HALLER  L     225873  01-15 

HALLE Y  J     231039  0103 

HALPERN  LM     251937  04-13 

HAMBERGER  B     250937  04-03 

HAMEL  AR     229165  01-11 

HAMILL  WT     234700  02-08 

HAMILTON  LW     241546  03-04 

HAMILTON  M     227213  01-16 

HAMMAR  WJ     238837  03-03 

HAMMOND  C     226960  01-11 

HAMMOND  KR     231066  01-14 

HAMMOND  N     235629  02-08 

HAMON  M     247213  04-03,249512  04-03 

HANBAUER  I     239977  03-03 

HANCE  AJ     239857  03-04 

HANCOCK  JC     238740  03-03 

HANDA  T     241374  03-04 

HANDRICK  GR     248651  04-02,  248652  04-02 


HANEY  WG     233276  02-01 

HANIN  I     238708  03-03,  239086  03-03,  241254 

03-03,  246275  04-13,  248700  04-03 
HANLON  OP     238762  03-01 
HANLON  TE     226901  01-14,  226902  01-16,  239824 

03-11 
HANSEN  CE     24021  7  03-09,  248955  04-10 
HANSON  K     238507  02-14 
HARAC     241367  03-04 
HARAT     228315  01-11,243092  04-17 
HARBANS  L     239826  03-04 
HARBAUER  H     236150  02-17 
HARBISON  RD     249223  04-03 
HARCLERODE  J     226763  01-03 
HARGRAVE  R     237897  02-08 
HARMATZJ     227569  01-14,229457  01-11, 

229840  01-11 
HARMATZJS     237116  02-13 
HARRER  G     242720  03-17 
HARRI  MNE     239091  03-05 
HARRISON     229464  01-03 
HARRIS  JE     237244  02-03 
HARRIS  LS     233292  02-04,  233293  02-04,  237753 

02-03,  238765  03-03,  238808  03-03,  246852 

04-04,  248646  04-02 
HARRIS  PB     249267  04-04 
HARRIS  RA     237870  02-03,  238814  03-04,  249275 

04-04 
HARRIS  RT     241278  03-10,  248532  04-10 
HARRIS  S     240614  03-17 
HART  FD     252135  04-17 
HARVEY  DJ     243787  04-03 
HARVEY  JA     237875  02-03,  241251  03-04,  247214 

04-05 
HASEGAWA  K     238566  02-04 
HASEGAWA  M     246971  04-03 
HASHIGUCHI  K     228325  01-08 
HASKAYNE  L     246699  04-15 
HASKELL  D     250056  04-15 
HASLAM  MT     238975  03-08 
HASSAN  MA     251004  04-10 
HASSANEIN  R     237138  02-11 
HASSLER  R     239834  03-04 
HASSOURI  H     251649  04-07 
HATA  T     241374  03-04 
HATEGAN  D     252711  04-03 
HATOTANI  N     249123  04-13 
HATTON  DC     231701  01-03 
HAUBRICH  DR     248600  04-03 
HAUER  B     237705  02-04 
HAUSER  OCR     248163  04-02 
HAUSNERM     234503  02-14 
HAVDALA  HH     249258  04-03 
HAVDALA  HS     238725  03-03 
HAWKINGS  JR     251165  04-10 
HAWKINS  DF     243085  04-15 
HAWLINAA     251418  04-11 
HAYASHI  S     252757  04-03 
HAYDEN  D     238807  03-05 
HAYDEN  DW     235671  02-05 
HAYES  PE     246187  04-15 
HAYES  TA     245001  04-14 
HEACOCK  A     235320  02-04 
HEADLEY  PM     235863  02-03,  235866  02-03 
HEALEYML     252816  04-04 
HEATH  RG     249003  04-05 
HECKMATT  JZ     251103  04-11 
HEDDEN  MP     229264  01-04 
HEER-CARCANO  L     251979  04-04 
HEIDRICH  R     234291  02-11 
HEIJNEN  HJ     252033  04-03 
HEIKKILA  RE     248699  04-03,  253691  04-03 
HEILMAN  RD     244685  04-04 
HEIMAN  MF     247877  04-07 
HEIMANN  H     237121  02-17 
HEINEMANN  H     241232  0303 
HEINRICH  K     239823  03-08,  251 1 18  04-09 
HEISE  A     251414  04-03 
HEISERJF     225932  01-08 
HEISLER  S     248909  04-15 
HELLER  B     229827  01-09,  248515  04-03 
HELLSTROM  B     246891  04-11 
HELMCHEN  H     235354  02-17 
HENDERSON  LM     243797  04-03 
HENDRY  lA     244200  04-03 
HENNIES  RS     228143  01-04 
HENRICSON  S     227140  01-14 
HENRIKSSON  BG     245297  04-04 
HENRY  GM     244664  04-09 


HENSLEYVR     249674  04-14 

HENSLEY  WJ     249674  04-14 

HERBERG  K     246932  04-15,  249367  04-13 

HERBERG  U     246774  04-03,  250075  04-04 

HERBET  A     249899  04-03 

HERCZEG  T     237760  02-03 

HERIZAEL     251185  04-03 

HERJANIC  BL     233499  02-15 

HERMAN  RL     248600  04-03 

HERMAN  ZS     227637  01-04,  232484  01-04 

HERMANN  W     251408  04-17 

HERNANDEZ  L     231700  01-03 

HERR  F     245295  04-04 

HERRIDGE  CF     239820  0309 

HERRMANN  W     229473  01-13 

HERRAAANN  WM     229038  01-07,  232532  01  14 

HERTRICH  0     239782  03-15 

HERVONEN  H     235649  02-03 

HERY  F     24721 3  04-03,  24951 2  04-03 

HERZ  A     237736  02-03,  237737  02-03,  239854 

03-03,  241223  03-04,  251433  04-03 
HESE  R     230818  01-10 
HESS  SM     229464  01-03 
HIDAKA  H     253450  04-04 
HIEB  £     237115  02-14 
HIGSONJE     246970  04-13 
HIGUCHI  M     229504  01 -n 
HILEY  CR     241248  03-03 
HILL  R     241242  03-03 
HILL  SE     249535  04-09 
HILL  SY     242947  04-1  5,  244960  04-13 
HILLMAN  H     25341 1  04-03 
HILLS  M     227139  01-03 
HIMBERG  JJ     229907  01-14 
HINDMARCH  I     237122  02-14 
HINDS  CJ     233278  02-01 
HINE  B     227702  01-04,  230878  01-04,  232615 

02-04.  245601  04-04,  249001  04-04 
HINGTGEN  JN     241205  03-04,  250067  04-04 
HIPPIUS  H     233684  02-17,  240218  03-08,  240219 

03- 1 1 ,  240220  03- 1 4,  240705  03- 1 7,  25 1 1 1 8 

04-09 
HIPPS  PP     238486  02-16 
HIRAI  T     229725  01-14 
HI  ROM     249253  04-04 
HIROSE  K     241388  03-03 
HIRSCH  AAJ     226873  01-03,  238676  03-03 
HIRSCHHORN  ID     244683  04-04 
HIRSH  K     238698  03-04 
HIRST  M     248513  0403 
HITRI  A     250081  04-03 
HITZEMANN  6A     241245  03-04 
HITZEMANN  RJ     241245  03-04 
HIXSON  B     238764  03-03 
HIXSON  EJ     243798  04-03 
HO  B     249310  04-03 
HO  IK     238791  03-03,  241338  03-03,  249254 

04-05,  249292  04-03 
HO  PPK     238691  03-03 
HOEBEL  BG     231  700  01-03,  243878  04-04 
HOEHN  MM     249232  04-15 
HOEYJR     227924  01-11 
HOFFER  BJ     238471  02-03,  240242  03-03 
HOFFMAN  DJ     246968  04-03,  246969  04-17 
HOFFAAAN  PF     237813  02-15 
HOFFAAAN  WE     251 142  04-03,  252170  04-03 
HOFFMEISTER  F     233681  02-06,  240020  03-04, 

246855  04-04,  251414  04-03 
HOFMANN  G     226612  01-09,243438  04-15 
HOFMANN  HP     246674  04-04 
HOGAN  TP     229650  01-14 
HOJER  B     243086  04-13 
HOKFELT  T     232507  01-03 
HOK IN-NEAVERSON  M     253 1 37  04- 1 3 
HOLOEN  JMC     227765  01-08 
HOLE  K     252173  04-03 
HOLFORT  S     250657  04-13 
HOLINKA  CF     247588  04-03 
HOLLAND  OB     251320  04-17 
HOLLAND  RPC     251003  04-15 
HOLLAND  WH     238486  0216 
HOLLETT  CR     238784  03-03 
HOLLISTER  AS     230841  01-03,  246149  04-03 
HOLLISTER  LE     229315  01- II,  233514  02-17, 

243861  04-09,  248850  04-15,  250417  04-13 
HOLLSTEIN  H     240261  03  15 
HOLLT  V     239854  03-03 
HOLMAN  RB     241902  03-17 
HOLMES  JC     241345  03-03 


A-8 


rOLUME   14,  AUTHOR  fNDEX 


Author  index 


OLMSTEDT  BR     229486  01-03 

OLMSTRANO  J     250945  04-07 

OLOWIECKI  J     230818  01-10 

OLT  J     245612  04-02 

OLTZMAN  SG     237754  02-04,  241314  03-04, 

251975  04-04 
OLZ  RW     236873  0203 
OLZ  WC     240022  03-04 
OLZ/VWN  PS     246303  04  14 
ONDA  F     241382  03-04 
ONECKER  H     229041  01-03,  234316  02-03 
ONIG  WMM     237704  02-04,  248285  04-02 
ONTELA  S     253055  04- 1 1 ,  253056  04- 1 1 ,  253057 

04-11 

OPKINSON  G     239348  03-09 
OPPER  M     239943  03-15 
ORIBE  M     241378  03-04 
ORIKAWA  S     246309  04-07 
ORITA  A     228977  01-05,  236524  02-04,  238695 

03-03,  249280  0404 
ORN  AS     226761  01-03,  229435  0103,  238317 

02-01,  250357  04-01 
ORNG  JS     246848  04-03,  250380  04-03 
ORNYKIEWICZ  0     233299  02-03,  244039  04-1  7 
OROWSKI  R     252028  04-04 
ORVATH  L     239089  03-05 
ORWITZ  D     232324  01-11 
OTZ  M     227330  01-11 
OUGHTON  GW     225890  01-15 
OULIHAN  WJ     248539  04-02 
OUSE  CR     251703  04-03 
OUSE  KM     253595  04-09 
OUSER  VP     230835  01-03,  240886  03-03,  240916 

03-04,  242894  04-04 
OUSTON  AB     251103  04-11 
OWARD  JL     249273  04-03,  249308  04-03 
OWARD  ML     229650  01-14 
OWES  JF     248651  04-02,  248652  04-02 
OWLETT  L     230015  01-10 
RACHOVEC  JP     246425  04-09 
RDINA  PO     246152  04-03,  247131  04-03,  253135 

04-03 
RUSKA  RE     238715  03-03,  238773  03-03,  241574 

03-03 

SU  LL     250377  04-01 
U  J     249254  0405 
UANGA     235286  02-15 
UANG  CL     226849  01-03 
UANGJH     237746  02-03 
UBBARD  RB     240074  03-14 
UCKER  HB     238684  03-03 
UDICK  JP     240065  03-03 
UESTIS  RD     22757101-11,239932  03-11 
UFFMAN  RD     238790  03-03 
UG  R     228094  01-14 
UGHES  J     227774  01-03,  233300  02-01 
UGHEST  JP     245600  04-04 
UGUE  M     241275  03-10 
UGUET  R     242900  04-11 
UIDOBRO  F     249288  04-04 
U1D0BR0-T0R0  JP     249288  04-04 
ULL  RC     246300  0410 
ULLIN  RP     250725  04-13 
ULSEBUS  R     249138  04-04 
UNT  HF     251428  04-05 
UNT  W     246856  04-13,249293  04-03 
UNTER  J     234309  02-03 
UNTER  P     229693  01-09 
UPPERT  FA     230831  01-04 
URT  SW     253018  04-08 
URWIC  MJ     229437  01-09 
USSAIN  SMA     250414  04-11 
USTONJP     246388  04-04 
USZKA  L     225935  01-08 
UTCHINGS  DE     251428  04-05 
UTCHISON  MT     249242  04-03 
UTTENLOCHER  PR     237826  02-03,  251952  04-1 1 
UXTABLE  RJ     238715  03-03,  238773  03-03 
UY  ND     229033  01-03,  229034  01-04 
VIDBERG  EF     240217  03-09,  248955  04-10 
WANG  K     248648  0402 
YNESMD     227132  0104 
YTTEL  J     241416  03-03 


3SEN  1     243089  04-13 
IHIMARU  I     227220  01-09 


IDANPAAN-HEIKKILA  J     226927  01-03,  227696 

01-03 
IDZOREK  S     236317  02-15 
IGLAUER  C     240015  03-04 
IISALO  E     253011  04-07 
IKEDA  C     249269  04-04 
IKEDA  S     241385  03-03 
IKEDA  Y     241399  03-04 
ILHAN  M     241313  03-03 
ILLIG  R     247715  04-15 
ILSON  D     248724  04-03 
IMAZ  F     235359  02-07 
IMMICH  H     241736  03-15 
INABA  T     250423  04-13 
I N AN AGA  K     229026  01-07,  229064  0 1  -08,  244528 

04-08,  249120  04-08 
INGALL  GB     238693  03-03 
INGVAR  DH     227140  01-14,  230867  01-14 
INOKI  R     251070  04-03 
INOUE  K     229026  01-07,  229064  01-08 
INOUE  N     226932  01-04 
lORDANOV  Y     236811  02-17 
lORIO  LC     248539  04-02,  250080  04-03 
IRVIN  CW     229715  01-11 
IRWIN  P     230781  01-14 
ISAAC  L     238838  03-03 
ISAACSON  RL     252148  04-05 
ISERI  Y     229504  01-11 
ISHIDA  R     241384  03-03 
ISHIDAT     229761  01-08 
ISHll  S     241273  03-14 
ISHIKAWA  K     241401  03-04 
ISHIKAWA  T     246319  04-03 
ISRAEL  Y     246850  04-03 
ISSELBACHER  KJ     251 179  04-03 
ITIL  TM     225721  01-17,  226725  01-16,  227826 

01-09,  229038  01-07,  229470  01-14,  229473 

01-13,  232532  01-14,  232635  02-11,  241275 

03-10 
ITO  K     241384  03-03 
ITO  N     241405  03-03 
ITO  T     241383  03-03,243782  04-03 
ITOH  H     228226  01-09,  252181  04-17,  253034 

04-15 
ITOH  K     228226  01-09 
ITOH  T     241381  03-03 
ITONAGAY     228325  01-08 
ITURRIAN  WB     233277  02-06 
IVERSEN  LL     226349  01-14,  229435  01-03,  249680 

04-04 
IVERSEN  SD     226349  01-14,  226937  01-04,  229434 

01-03,  230831  01-04,  234917  02-04 
IVES  JO     239938  03-10 
IWAMOTO  ET     237870  02-03,  2531 12  04-04 
IWASAKI  T     241399  03-04 
IWASAWA  Y     238563  02-03 
I  WAT  A  H     247013  04-03,249253  04-04 
IWINSKA  B     229681  01-04 
IZQUIERDO  I     227138  01-04,  230570  01-04 
IZQUIERDOJA     237108  02-04 


JAASKELAINEN  J     237162  02-17 

JACKLER  F     239272  03-04 

JACKSON  DE     251988  04-04 

JACKSON  DM     226764  01-04,  227130  01-04, 

230856  01-03,  239859  03-03,  244894  04-04, 

249669  04-04,  249670  04-04 
JACKSON  J  A     238696  03-04 
JACOB  J     237890  02-03 
JACOBI  P     238516  02-11,239682  03-15 
JACOBOWITZ  DM     238673  03-03,  244202  04-04 
JACOBS  BL     226734  01-04,  241505  03-12,  249078 

04-03,  250083  04-04 
JACOBS  D     251964  04-03 
JACOBS  J  R     229264  01-04 
JACOBS  LS     243822  04-14,  251 128  04-09 
JACOBSON  J     249271  04-02 
JACOBSSON  L     22641 1  01-09,  226412  01-08, 

244189  04-07 
JACOBY  JH     233290  02-03 
JACOUET  YF     252209  04-04 
JAGOOA  A     238765  03-03 
JAHN  U     241231  03-04 
JAILLON  P     240657  03-11 
JAIM-ETCHEVERRY  G     249666  04-03 
JAIN  RC     230780  01-08 
JAISWAL  RK     238712  03  03 


JAKIMOW  B     236429  02-10 

JAKLINSKA  A     234522  02-03 

JALFRE  M     241315  03-03,  241316  03-03,  241317 

03-03,  241318  03-03,  241319  03-03 
JAMES  DTD     234918  02-03 
JAMES  RJ     244113  04-15 
JAMES  SH     247147  04-15 
JAMMESJL     251966  04-11 
JANCAR  VG     246425  04-09 
J  AN  DH  YALA  BS     2388 1 0  03-03 
JANKEW     233683  02-17 
JANOS  A     239992  03-14 
JANOWSKY  D     230816  01-09 
JANOWSKY  DS     233967  02-08,  239933  03-08 
JANSSEN  H     237786  02-03 
JANSSEN  HJ      244215  04-04 
JANSSEN  PAJ     232529  01-04,  237744  02-04, 

241228  03-04,  250355  04-03,  251429  04-03, 

253394  04-04 
JANZIK  H     240692  03-15 
JARBE  TUC     241258  03-04,  242737  03-04,  245297 

04-04 
JAROSZYNSKI  J     236421  02-08 
JARVIK  L     229460  01-11 
JARVIK  ME     248583  04-09,  249671  04-04 
JARVISJAE     241249  03-05 
JASINSKI  DR     231319  01-13 
JATON  AL     241927  03-04,  251405  04-03 
JATSA  K     226900  01-13 
JAVOY  F     230854  01-03,  249899  04-03 
JEFFERSON  JW     237909  02-15,  253137  04-13 
JENDEN  DJ     238828  03-03,  249298  04-03,  251 181 

04-03 
JENKINS  DG     252138  04-11 
JENNER  FA     253593  04-04 
JENNER  P     230855  01-03,  237977  02-13,  241929 

03-03,  248289  04-04,  249628  04-03 
JENSEN  J      2371 10  02-04,  244651  04  03 
JENSEN  K     238551  02-09,  246623  04-09 
JEONG  Y     241357  03-15 
JEPPSSONJ     238998  03-15 
JERMINI  C     253587  04-12 
JERUSSI  TP     241311  03-04 
JHAMANDAS  K     252023  04-03 
JIMERSON  DC     243440  04-03 
JOBE  PC     238706  03-04,  238734  03-03 
JOFFE  JM     243789  04-03 
JOFFE  P     233377  02-12 
JOH  TH     238759  03-03,  246845  04-03 
JOHANNESEN  M     251129  04-17 
JOHANSON  CE     240013  03-04,  250066  04-04 
JOHANSSON  JO     241258  03-04,  242737  03-04, 

245297  04-04 
JOHANSSON  R     246387  04-13 
JOHNSON  AK     244469  04-04 
JOHNSON  AM     249419  04  04 
JOHNSON  CA     249671  04-04 
JOHNSON  CL     238674  03-03 
JOHNSON  DAW     238996  03-08,  252763  04-08 
JOHNSON  FN     243804  04-04,  248516  04-03, 

249381  04-04 
JOHNSON  G     230119  01-17 
JOHNSON  GF     237165  02-10 
JOHNSON  K     238765  03-03 
JOHNSON  KM     238769  03-03 
JOHNSON  L     251215  04-04 
JOHNSON  LC     238507  02-14 
JOHNSON  R     241730  03-13 
JOHNSON  RD     227212  01-07 
JOHNSON  WC     227825  01-10 
JOHNSTON  M     229693  01-09 
JOHNSTON  RE     226865  01-03 
JOHNSTONE  EC     228208  01-15,  251985  04-10 
JONAS  S     248612  04-11 
JONAS  WZ     246629  04  09 
JONES  BC     241668  03-04,  251989  04-04 
JONES  BE     230879  01-04,  244674  04-06 
JONES  BJ     241918  03-04,  243758  04-04 
JONES  CN     239856  03-04 
JONES  DG     241206  03-03 
JONES  DJ     249286  04-03 
JONES  GL     237243  02-03 
JONES  GR     237980  02-01 
JONES  JM     239533  03-04 
JONES  JT     229264  01-04 
JONES  RF     226960  01-11 
JONES  RT     235759  02-14,  252327  04-13,  252825 

04  13,  253609  04-13 
JONSSON  G     241196  03-03 


A-9 


Author  Index 


Psychopharmacology  Abstract 


JONSSON  J     250943  04  07,  250945  04  07 

JONSSON  S     2511)9  04-08 

JORI  A     230827  01-09,  238322  02  03,  250936 

0403 
JOSEPH  MH     226399  0103 
JOSHI  VG     236665  02-09 
JOSLIN  RS     250332  04-06 
JOST  M     246388  04  04 
JOUVET  M     23531  7  02-04,  2521  71  04-04 
JOVANOVIC  UJ     240710  03-11 
JOYCE  CRB     231066  01-14 
JOYCE  D     235509  02  04 
JUBIZ  W     245806  04-15 
JUDD  A     253593  04-04 
JUDD  LL     226922  01-15,  240074  03-14 
JUHL  RP     253154  04-15 
JUHOS  E     232638  02-13 
JULIEN  RM     249242  04-03 
JUN  HW     233277  02-06 
JUNG  M     238782  03-03 
JUNG  AAJ     238781  03  04 
JUNGE  C     230866  01-16 
JUNGHANI  J     227391  01-05 
JUS  A     244497  04-15,  250991  04-15,  251829 

04-08 
JUS  K     244497  04  15,  250991  04-15,  251829 

04-08 
JUST  WW     244681  04-03 
JUTKOWITZ  R     251960  04-13 
JUVANCZ  P     245304  04-04 


KADLETSOVA  0     244456  04-04 

KADOBAYASHll      251214  04-03 

KAESS  H     232503  01-13 

KAFKA  MS     236873  02-03 

KAI  Y     229026  01-07 

KAISER  J     243234  04-04 

KAJARIA  SM     230907  01-08 

KAKITAY     229725  01-14 

KALANT  H     237720  0204,  242741  03-03 

KALDORA     252990  04-17 

KALES  A     245652  04-11,252230  04-11 

KALES  JD     245652  04)1,252230  04-11 

KALOTKIN  M     252793  04-11 

KAMDAR  BV     238478  02-01 

KAAAEI  C     241375  03-04,  247039  04  03 

KAMENICKAV     234430  02  13 

KAMENOV  G     236363  02-10 

KAMEYAMA  T     24)370  03-04,  24)37)  03  04, 

242205  03-04 
KAMP  R     237120  02-05 
KANABUS  P     244050  04-08 
KANAPA  DJ      25)959  04  05 
KANE  FJ     233828  02)5 
KANG  S     238674  03-03 
KANNER  M     236523  02  04 
KANTAMANENI  BD     241210  03-13 
KANTO  J     229042  0113,237735  02-13 
KANTOR  SJ     229443  01  09,  245784  04-09 
KANZLER  MB     229437  01-09 
KAPLAN  J     236750  02  08 
KAPLAN  LJ     242743  03-04 
KAPLAN  NM     251320  04-17 
KARASAWA  T     241393  03  03 
KARASU  TB     245840  04  13 
KARBOWSKI  M     238765  03-03 
KARCZMAR  AG     249299  04-03 
KARLER  R     2310)0  01  03,  238767  03-03 
KARIINERW     249765  04)7 
KARNIOL  IG     225570  0)03,  249622  04-07 
KAROBATH  M     237244  02-03,  237647  02-14, 

239835  03  15,  244043  04  03 
KAROUM  F     238761  03  03 
KARPIAK  SE     226)86  0104 
KARPOVVN     231248  0104 
KARR  G     226903  01-14 
KASICH  AM     241274  03)4 
KASSOUNY  ME     238720  03-04 
KASTIN  AJ     248349  04-03,250082  04  03 
KATAOKA  K      226739  01-03 
KATO  AC     248724  04-03 
KATO  N     229068  01  03,  234673  02  09,  251214 

04  03 
KATO  S     228211  01-17 
KAISUNO  1      228325  01-08 
KA)Z  FH     233001  02  13 
KAI/  MM     22572)  01  17 


KATZ  RL     237734  02  14 

KATZ  S     247381  04-17,  248603  04-03 

KATZMAN  R     231304  01-03 

KAUFMAN  RD     226828  01-15 

KAUL  PN     229441  01-16,  229444  01-08,  251777 

04  06,  251778  04-16 
KAWAJIRI  T     229761  01-08 
KAWAKITAY     229504  01-11 
KAWASAKI  H     241389  03  03 
KAWASHIMA  K     236527  02-03 
KAY  DC     246304  04-13 
KAY  EJ     249158  04-04 
KAYAAAKCALAN  S     226762  01-03 
KAZAMATSURI  H     22821101-17 
KEBABIAN  JW     229318  01-03,  230600  01-03, 
230602  01-13,  234919  02-03,  237170  02-03 
KEEHN  JD     236708  02-04 
KEELER  MH     245524  04-17 
KEESEY  RR     243790  04-03 
KELFER  DA     231533  01-04 
KELLAMS  JJ     232840  02-08,  253049  04-08 
KELLEHER  RT     229428  01-04,  240010  03-04, 

240012  03-04,  240017  03-04 
KELLER  HH     251399  04-03 
KELLER  J K     248646  04-02 
KELLETTJM     230742  01-15 
KELLEY  M     225572  01-03 
KELLNER  R     22822)  0)08,  231992  01-15,  249625 

04-11,  250516  04-10,  253050  04-11 
KELLOGG  C     245608  04-02 

KELLY  D     251155  04-14 

KELLY  JT     236663  02-10 

KELLY  PH     226937  01-04,  234918  02-03,  237866 
02-03,  248286  04-03,  248287  04-02,  249680 
04-04,  251704  04-04 

KENNARD  0     226761  01-03,  23831  7  02-01 , 
250357  04-01 

KENNEDY  G     251239  04-11 

KENNY  F     239348  03-09 

KENT  EW     252017  04-04 

KESSLER  C     237899  02-08 

KETAI  R     235419  02-17 

KEY  BJ     241930  03-03,  24631 1  04-03 

KHACHATURIAN  ZS     230840  01-03,  238708  03-03, 
239086  03-03 

KHALSAJH     226766  01-03 

KHANNA  JM     237720  02-04 

KHAZAN  N     227701  01-03,  230880  01-04,  251533 
04-04 

KHURANA  R     243088  04-15 

KICZAK  J     232545  01-17,234045  02-15 

KIDD  MR     251)80  04-01 

KIDSON  MA     227550  01-1) 

KIELHOLZ  P     244040  04-10 

KIELY  WF     232865  02-15 

KIESSLINGM     240447  03-03 

KILLAM  KF     237755  02-04,  239857  03-04,  249251 
04-03,  249267  04-04,  249268  04-03,  249270 
04-04,  249290  04-03 

KILLIAM  EK     237755  02-04 

KIM  J      237920  02-03 

KIMJS     23983403-04 

KIMISHIMA  K     241379  03-04 

KIMURA  S     228325  01-08,229626  01-11 

KINDEL  GH     249299  04-03 

KING  CD     238744  03-04,  249281  04-02 

KING  GW     238794  03-04 

KINGJM     239290  03-04 

K I NG  LJ     230834  0 1  03,  24 1 256  03-03 

KING  SM     228420  01-14 

KINNARD  WJ     246967  04-04 

KIRAN  BK     246820  04  04 

KIRBYMJ      240802  03-13 

KIRCHMAN  A     227701  01-03 

KIREMITCI  N     253641  04-11 

KIRK  L     240048  03-15 

KIRMAN  B     249525  04-17 

KIRSHNER  N     241294  03-13 

KIRSTEIN  R     252733  04-15 

KISARA  K     241380  03-04,242202  03-03 

KISHI  R     241377  03-04 

KISS  C     252450  04-11 

KITA  T     241374  03-04 

KITAHAMA  K     249676  04-04,  252171  04-04 

KITAHARA  T     229026  01-07 

KITAMURA  S     229725  01-14 

KIYOMOTO  A     238563  02  03 

KJELLBERG  B     230869  01-04 

KLARA  PM     239832  03  03 


KLATZO  I     239577  03-03 
KLAWANS  HL     237729  02-04,  239685  0303, 
247683  04-04,  247730  04-03,  251959  04-05 
KLEE  WA     232960  0203,  2371 75  02-03,  238571 

02-03,  239787  03-03 
KLEIN  DF     228223  01-08,  228978  01-17,  229451 
01-10,  239937  03-09,  247381  04-17,  247382 
04-14,  253047  04-08 
KLEIN  HE     246672  04-08 
KLEINKNECHT  RA     235236  02-14 
KLEINLOGEL  H     226728  01-03 
KLEINROK  Z     227636  01-04,  237032  02-04 
KLEMM  WR     250071  04-06 
KLERAAAN  GL     229450  01-09,  241936  03-08 
KLETT  CJ     225718  01-09 
KLICH  R     240711  03-11 
KLIEB  J     236708  02-04 
KLINE  NS     226794  01-09,  231991  01-15,  247208 

04-03 
KLING  R     227330  01-11 
KLINGNERA     231035  01-09 
KLOPPER  JH     251951  04-04 
KLOSAJ     232527  01-01 
KLYGULO  TA     244456  04-04 
KLYSNER  R     251129  04-17 
KNAPP  S     233958  02-03,  234805  02-03,  246849 

04-03,  252514  04-03 
KNAUTH  P     229236  01-09 
KNESEVICH  JW     253314  04-09 
KNOBDL  E     249622  04-07 
KNOBEL  M     249772  04-11 
KNOLL  B     249787  04-17 
KNOLL  J     249787  04-1  7,  252223  04-03 
KOBAYASHI  H     238717  03-04 
KOBAYASHI  M     251990  04-04 
KOCH  M     236663  02-10 
KOCH-BOURDOUXHE  S     237013  02-09 
KOCH-WESER  J     226840  01-03,  237116  02-13, 
237928  02-15,  250780  04-17,  252656  04- 15 
KOCHANSKYGE     227569  01-14 
KOCURJ     234097  02-12 
KOE  BK     237242  02-03,  238738  03-01 
KOEPKE  HH     246184  04-15,248975  04-10 
KOGAN  FJ     238079  02-03,  238693  03-03,  25202; 

04-03 
KOH  S     247013  04-03 
KOHLERC     229083  01-11,252173  04-03 
KOHLER  M     249144  04-11 
KOHLMEYER  K     240708  03-17 
KOKKINIDIS  L     237703  02-04 
KOLAKOWSKA  T     246612  04-17 
KOLANSKY  H     237651  02-15 
KOLASIEWICZ  W     242745  04-04 
KOLODNY  E     245863  04-08 
KOMENDANTOVA  MV     228552  01-03,  236373 

02-03 
KOMISARUK  BR     238822  03-03 
KOMISKEY  HL     241255  03-03 
KOMISSAROV  IV     231251  01-04,  241980  03-03 
KOMLOS  M     246318  04-04 
KONDO  H     234673  02-09,  249124  04-14 
KONIG  L     240741  03-14,  244188  04-08 
KONIG  P     226612  01-09 
KONIG  U     251071  04-12 
KONSTORUMMG     231072  01-06 
KOPANDA  RT     231771  01-04,  249005  04-04 
KOPELL  BS     230871  01-14 
KOPIN  IJ     227777  01-03,  238673  03-03,  246843 

04-03,  247028  04-03,  248464  04-13 
KORB  RJ     231629  01-14 

KORFJ     226727  01-03,  238997  03-13,  241207 
03-03,  241912  03-08,  245510  04-09,  249984 
04-03 
KORFF  FA     242861  04-17 
KORNETSKY  C     230864  01-04,  234739  02-04, 

238755  03-04,  249271  04-02 
KOROLENKO  TA     228548  01-03 
KORR  H     239855  03-03,  239864  03-03 
KORSON  L     239938  03-10 
KORTTILA  K     232531  01  13 
KOSAJE     230836  01-04 
KOSEKI  Y     241381  03-03 
KOSHELEVA  OV     236235  02  03,  236712  02-04 
KOSLOW  SH     239307  03-03,  241253  03-03 
KOSOCZKY  1     231008  01-03,252445  04-02 
KOSS  MC     239963  03-03 
KOSTERLITZ  HW     233300  02-01 
KOSTOPOULOS  GK     232621  02-03,  248725  04-01 
KOSTREZEWA  RM     239832  03-03 


A-10 


>LUME  14,  AUTHOR  INDEX 

Author  Index 

IN  J     236318  02  15 

LAFFRANCHINI  S     239748  03-14 

LEHMANN  HE     227820  01-14,  229459  01-1  1, 

ORII  M     246309  04-07 

LAGENDIJKA     245599  04-03 

230780  01-08,  231034  01-08,  231035  01-09, 

ORII  T     229064  01-08 

LAGERWEY  C     237270  02-06 

235355  02-17,  235356  02-07,  235363  02-09, 

AKIEWICZ  R     241328  03-03 

LAIDLAWJ     225890  01-15 

235370  02-09,  235773  02-08,  242249  03-09, 

;ARYN  I     240237  03-04 

LAJTHA  A     240065  03-03 

253053  04  07,  253054  04  1 1 ,  253055  04- 1 1 , 

lOVSKAYA  MM     2361 74  02  04 

LAKE  CR     239305  03-13 

253059  04  11,  253060  04-11 

,EMER  GW     248437  04  04 

LAL  H     227132  01-04,  232617  02-03,  238713 

LEHMANN  K     240740  03-03 

,GH-SORENSEN  P     240217  03-09,  248955  04-10 

03-04,  248274  04-03,  249139  04-04,  249272 

LEHTI  H     227136  01  15 

,IKER  H     246707  04-15 

04-04,  249289  04-04,  250656  04-03 

LEIBOWITZ  M     248612  04-11,  248613  04-11 

■KOWSKI  AJ      228244  0117 

LAL  S     230743  01-1 1,  237747  02-03,  249785  04-04 

LEIBOWITZ  SF     23261 0  02-03,  245929  04-02, 

1  VA     253062  04-17 

LAMB  P     242267  03-15 

245930  04-02 

,MER  M     248976  04-08 

LAMBERT  GA     249002  04-03 

LEICKERT  KH     242502  03-14 

,MP  P     239023  03-08 

LAMBERT  P     252181  04-17 

LEITH  NJ     239850  03-04,  249255  04-03 

,UER  B     243085  04-15 

LAMBORN  KR     239938  03-10 

LEMBERGER  L     243087  04-14,  245648  04-14, 

.YNACK  BJ     252221  04-03 

LAMBRECHTS  P     237270  02-06 

248628  04-12,  249260  04-07 

BS  H     252018  04-03 

LAMON  S     230838  01-04 

LEMKE  TL     238477  02  02 

ISKOTT  H     246674  04-04 

LAMPEN  EL     247743  04-11 

LENA  B     236118  02-11 

WMER  EC     238756  03-04 

LANDSBERG  L     241299  03-03 

LENAERTS  FM     232529  01-04 

JHNAN  G     251160  04-10 

LANEJD     241205  0304 

LENNOX  WJ     248538  04-02 

JTJANSEN  P     227761  01-17,  239023  03-08 

LANGE  E     244188  04-08 

LENTZ  S     238819  03  04 

/OBOK  GK     231251  01-04,  236257  02-04 

LANGEMANN  H     237158  02-03 

LENTZEN  H     251392  04  03 

lEGER  BK     238080  02-13 

LANGLEY  A     238690  03-03 

LENZ  G     239835  03-15,  243438  04-15 

IGER  E     250209  04-15 

LANKOSZJ     229515  01-10 

LEONARD  BE     239849  03-03 

IPER  J     244311  04-04 

LANNER  G     243198  04-11 

LEONARD  DP     227550  01-11 

ISKEMPER  G     232364  01-14 

LAO  L     230834  0103 

LERERMP     251569  04  14 

ISKEMPER  HL     232364  01-14 

LAPIERRE  Y     241203  03-03 

LERER  RJ     251569  04-14 

ISZEWSKA  A     240240  03-03 

LAPIERRE  YD     225686  01-15,  231036  01-10, 

LERISSONJ     242898  04-11 

SA  G     244050  04-08 

245012  04-14,  247484  04-10,  251431  04-15 

LERNERCB     252327  04-13 

SPIN-EXNER  K     229044  01-11 

LAPRADE  B     238487  02-01 

LERNERSE     247147  04  15 

«  C     227131  01-04,  242739  03-04 

LARKIN  RP     231707  01-04 

LESHEM  M     250938  04-03 

lA  S     227808  0 1  - 1 5,  244779  04- 1 5 

LARMORE  CK     237759  02-03 

LETARTE  J     253700  04-03 

lA  K     227808  01-15,244779  04-15 

EARNED  D     230027  01-15 

LEUTNER  V     226778  01-09,  239029  03-14,  240706 

)0Y     241384  03-03 

LAROUCHE  B     235357  02-07 

03-17 

HNLEJC     242269  03-17 

LARRISON  SB     251180  04-01 

LEVANDER  SE     239002  03-09 

FERLE  8     237647  02  14 

LARSEN  F     241244  03-04 

LEVANDOWSKYM     248163  04-02 

;E  T     241273  03  14 

LASCHKA  E     241223  03-04,  251402  04-04 

LEVENSONAJ     241277  03-08 

lAR  MJ     226407  01-03,  227400  01-03,  24721 1 

LASSEN  JB     227129  01-04,  245296  04-03,  252029 

LEVER  JD     237738  02  03 

4-03.  249074  04-03,  249303  04-03,  252219 

04-04 

LEVI  G     246665  04-03 

4-03 

LASTG     233079  02-11 

LEVI  RN     248543  04-16 

IN  D     238764  03-03 

LASTRUCCI  P     235988  02-15 

LEVIN  BE     243791  04-03 

IN  DM     230876  01-04 

LASZLO  D     239992  03-14 

LEVIN  K     245863  04-08 

INEG     236348  02-17 

LATIMER  PR     227746  0109 

LEVIN  RM     249287  04-03 

;OPULOS  A     232779  02-09 

1  All  Rl      2S7R9S  04-13 

LEVINE  HD     252061  04-14 

CSAR  A     229465  01-03,  232515  01-03 

LAUDER  JM     252018  04  03 

LEVINEJ     232902  02  16 

KARNI  S     249678  04-04 
LBERGMP     238797  03  13 
MKURA  K     226406  01-03 

LAUERJW     251717  04-11 
LAURENT  B     229035  01-03 
LAURENT  JP     238503  02-03 

LEVINE  MS     238716  03  03 
LEVINE  TE     238081  02-04 
LEVITT  M     230817  0103 

MRS     238712  03-03 
MSHIRO  H     243094  04-17 

LAURITSEN  B     239023  03-08 
LAVOIEJ      246273  04-15 
LAVRETSKAYA  EF     236714  02-04 
LAVRETSKAYA  YF     236715  02-03 
LAWSON  J     247020  04-03 
LAWSON  T     240278  03-17 
LE  BARS  D     232328  01-03 

LEVITT  RA     232938  02  1  7,  238006  02  04 
LEVY  DL     246303  04- 1 4 

ABARACHI  T     234203  02-09,  244495  04-09 

JO  H     241391  03-03 

JZE  H     238320  02-03 

IZER  W     243194  04-10 

'PER  OJ     246275  04-13 

WISHI  Y     242204  03-03 

LEVY  RH     239658  03  13 

LEVY  S     233279  02-03 

LEWANDER  T     233962  02  03.  245298  04-03 

LEWI  PJ     239683  03  06 

LEWICKA  H     244050  04-08 

LEWIN  E     251964  04-03 

WMITSU  M     228074  01-11 

LE  BLANC  AE     233488  02-14 

LEWIS  BD     232624  02  03 

WMOTO  S     245986  04-11 

LE  BRUN  Y     233974  02-11 

LEWIS  BF     232838  02  1  7 

IIBARA  H     238564  02-04,  241 376  03  04, 

LE  CLECOH  G     247151  04-04 

LEWIS  DE     238838  03  03 

41400  03-04 

LE  FLOCH  ML     252217  04  03 

LEWIS  AAJ     241 100  03  03,  244202  04-04,  252200 

ilHARA  M     228226  01-09 

LE  MOAL  M     244216  04-04,250982  04  04 

04-03 

[LAND  AA     226901  01-14,  226902  01-16, 

LEAF  R     230838  01-04 

LEWIS  PJ     245647  04  13 

39824  03-11 

LEAKE  CD     238814  03  04 

LEWIS  VA     249248  04-03 

iOCHKIN  IG     236372  02  04 

LEALMAN  GT     25110304-11 

LI  WAN  PO  A     246317  04-01 

!OCHKINA  Al     236265  02-03 

LEANDER  JD     233292  02  04,  233293  02-04, 

LIBET  B     238717  03-04 

!OIWA  Y     241403  03-03,  242201  03-03 

249266  04-04 

LICHTENSTEIGER  W     237158  02-03 

!OSAWA  A     2371 72  02-03,  241 388  03-03, 

LEBLANC  AE     237720  02-04,  242741  03-03 

LIDBRINK  P     232507  01-03 

43041  04-03 

LEBOEUF  G     253700  04-03 

LIDEN  CB     247090  04-15 

iTZ  P     242733  0304 

LECANUETJ     241330  03-04 

LIEB  J      23898103  10 

iTZ  PD     251149  04-17 

LECRUBIERY     239607  03-17 

LIEBERMAN  A     233974  02-11,  248612  04-11, 

;TZMAN  S     238757  03-04 

LEE  A     231771  01-04,  249005  04-04 

248613  04  11,  251649  04  07 

iSIN  D     253057  04-11 

LEE  BH     233277  02-06 

LIEBMAN  JM     241307  03-04,  249486  04-03 

.UHARAT     228325  01-08 

LEE  C     251701  04-01 

LIEBMANN  JA     237784  02-01 

SCHER  CL     242746  04-04 

LEE  CA     230919  01-03 

LIEBSCHUTZJ     238719  03-03 

ICL  J     248647  04-02,  248648  04-02 

LEE  CR     249535  04-09 

LIEBSON  1     240831  03-14 

ICHUKOVA  P     236732  02-09 

LEE  CY     244203  04-03 

LIEFF  BD     238201  02  03 

LEE  GM     238812  03-03 

LIENHART  R     237158  02-03 

L 

LEE  IP     250109  04  03 

LIIVAMAGI  J     226900  01-13 

LEE  JH     244501  04-08,  247481  04-07 

LIUEQUIST  R     229907  01-14,  246315  04-14 

WURA  G     22955101-11 

LEE  M     247484  04-10 

LIUEOUIST  S     249670  04-04 

ELLA  FS     246586  04-03 

LEE  T     248466  04-03 

LIN  R     249188  04  01 

HANCE  R     244497  04-15,  250991  04-15 

LEE  Y     248648  04-02 

LIN  Y     247846  04-06 

ORBIERE  M     243482  04-03 

LEE-SON  S     233289  02-03 

LINAUER  W     233917  02  11 

OURSIERE  RB     251996  04-08 

LEEMING  FC     229487  01-04 

LINDBERG  D     246623  04  09 

ER  M     232704  02-10,  236360  02-08 

LEES  P     243759  0403 

LINDLT     240447  03-03 

ER  MH     227209  01-17,  241758  03-10,  246312 

LEEUWIN  RS     230859  01-03 

LINET  01     248533  04-11 

4-13 

LEFEVER  GS     246842  04-03 

LING  W     239943  03  15 

INSKY  H     232510  01  03,  248291  04-03, 

LEFKOWITZ  SS     226944  01-05 

LINNOILAM     229907  01-14,241417  03-15, 

48410  04-03 

LEGROSJJ      248224  04-13 

246315  04  14,  247967  04-11 

URON  P     250359  04  03 

LEHMANN  H     251546  04-08 
A-11 

LINSEMAN  MA     237099  02  03 

Author  Index 

LION  JR     231610  0109,  245016  0409.  246184 

04  1  5 
I  lONEL  NOW     250932  04-07 
LIPINSKI  JF     250928  04  17 
LIPMAN  RS     229449  01  09,  252941  04-09 
LIPPERT  B     238781  0304,  238782  0303 
LIPPMANN  W     244316  04-02,  244678  04-03 

249313  04-03 
LIPTON  MA     232618  02-03 
LIST  AF     226763  01-03 
LITKENHOUS  EE     240243  03  15 
LITTLE  SRCJ     231609  01-08 
LITTLETON  JM     241926  03-03 
LIFTMAN  P     226840  01-03 
LIU  S     226849  01  03,  227390  01-03 
LIVENGOOD  D     238736  03-03,  246998  04-03 
LIVREA  P     252220  04-03 
UUNGBERG  T     243348  04-04,  250086  04-04 
UUNGDAHL  A     232507  01-03 
LLEWELLYN  ME     240015  03  04 
LLINAS  JJ     241435  03-17 
LLOYD  KG     233299  02-03 
LODGE  D     235863  02-03,  235866  02-03   241921 

03-03,  243762  04-03 
LODGE  JW     237787  02-16 
LODGE  PATCH  IC     246699  04-15 
LOEFFLER  KO     238818  03-01,  249328  04-01 
LOEFFLER  U     233278  02-01 
LOEW  DM     241927  03-04,249419  04-04    249668 

04-04,  251405  04-03 
LOFSTRANDH  S     238678  03-03 
LOGAN  RW     251103  04-11 
LOH  H     250087  04-02 
LOH  HH     23)01 1  01  03,  237870  02-03,  237891 

02  03,  238814  03-04,  241245  03-04    241338 

03-03,  249275  04-04,  249316  04-03,  253107 

04-03,  253108  04-04,  253112  04-04 
LOHMANN  F     231317  0115 
LOMAX  P     250078  04-03,  2501 14  04-03 
LOMEN  P     248533  04-11 
LONG  JP     241313  03-03,  248408  04-03 
LONGENECKER  HE     238743  03-03 
LONGO  VG     237707  02-04,  246148  04-04,  247485 

04  04 
LONGUSKI  PA     250012  04-04 
lONNQVISTJ     227136  0115 
LONOWSKI  DJ      238006  02-04 
LOO  H     247554  0409 
LOOMIS  TA     249264  04  04 
LOONEY  RL     233448  02-04 
lOPEZJB     241777  0316 
LOPEZ  7AN0N  A     227221  01-09 
LORENS  SA     244214  04-04,  252173  04-03 
LORENZO  AV     237873  02-03 
LOSEY  EG     248834  04-03,  249930  04-03,  251 184 

0-103 
LOVCHIKOV  VA     236249  02-03 
LOVE  G     238819  03-04 
LOVEJOY  FH     247090  04  15 
LOVERING  EG     238485  0202 
LOWE  G     245305  04  04 
LOWENSTAM  I     228908  01-11 
LU  K     237738  02  03 
LU  KM     243951  04-03 
LUCIERGW     250109  04  03 
lUrOTJB     249266  04  04 
I IJHDORF  K     230823  01-08,  239023  03-08 
LUIIMANN  RAUCH  R     237153  02-05 
lUMBRERAS  N     248515  04  03 
LUNDWALL  LK     229091  01-11 
IIJNZERM     230580  0115 
LUSH  IE     230870  01-04 
lUlHRA  YK     243181  04-04 
LUTZ  EG     247784  04-15 
LYDIARD  RB     248697  04-03,  249291  04-03 
lYNCHHD     234826  02-17 
tYON  WE     237271  02-14 
LYIIf  LD     238741  03-03,  239958  03  04,  252516 

0.103 
lYUBIMOV  Bl     228547  01  04,  241986  03-03 

24  1 989  03  03 

M 

MAAS  JW     229489  0103 
MA(AVOYMG     246305  04  13 
MA((ANNFLI   K      226903  01   14 
MA((UIIOtHMJ     239010  03  15 
MA(  DONALD  Ml      252848  04-08 


Psychopharmocology  Abstracts 


MACFARLANE  IR     237100  0203 

MACGREGOR  RR     248537  04-01 

MAC  KAY  MC     241990  03-15 

MACKINTOSH  JH     225569  01-04,  237715  02-04, 

237727  02-04,  246310  04-04 
MACLEAN  Ki     241926  03-03 
MACLEOD  SM     250779  04-11 
MACNEILL  AL     252137  04-17 
MACPHAIL  I     245469  04-11 
MACPHAIL  RC     226853  01-04,  230842  01-04, 

238844  03-04,  2531 1 1  04-04 
MACRI  J     238828  03-03 
MADLE  RA     251149  04-17 
MADSEN  JA     245806  04-15 
MADTES  P     238349  02-03 
MAEKAWA  T     246319  04-03 
MAENGWYN-DAVIES  GD     229488  01-04,  238673 

03-03 
MAGIN  F     238866  03-11 
MAGNUS  RV     245137  04-10 
MAGOS  L     241 249  03-05,  250090  04-04 
MAGOUR  S     237109  02-04,  241242  03-03,  248961 

04-03 
MAGRINI  G     240762  03-11 
MAHAPATRASB     227214  01-09 
MAHON  WA     250423  04  13 
MAICKEL  RP     243798  04-03,  247729  04-02 
MAINVILLE  CA     238485  02-02 
MAITRE  L     251225  04-03,  251395  04-03,  251398 

04-03 
MAJOVSKI  LV     238510  02-11 
MAKI  M     229907  01-14 
MAKMAN  MH     231304  01-03,  238739  03-03 
MALEC  D     227636  01-04 
MALEN  C     237118  02-03,237119  02-03 
MALICK  JB     253392  04-04 
MALIK  NA     238996  03-08 
MALLACH  HJ     237123  02-13 
MALLINGERAG     246275  04-13 
MALLOY  KP     2388)0  03-03 
MALOFF  P     228139  01-04 
MALOR  R     226764  01-04,  227130  01-04,  244894 

04-04 
MALTZMAN  I     249798  04-09 
MANBER  M     248862  04-15 
MANDEL  MR     245841  04-08 
MANDEL  P     237723  02-04,  241222  03-03,  241348 

03-03 
MANDELL  AJ     233958  02  03,  246849  04-03, 

250377  04-01,  252514  04-03,  253255  04-04 
MANGOLD  B     230002  01-11 
MANGONI  A     237733  02-11 
MANIAN  AA     236521  02-03,  237174  02-01, 

237241  02-03,  238777  03-03,  239582  03-03 

252515  04-05 
MANNING  FJ     250061  04-04 
MANNING  RA     248880  04-03 
MANOWITZ  P     247847  04-03 
MANSUY  0     241350  03-01 
MANTEGAZZA  P     252030  04-04,  252201  0403 
MANTILLA-PLATA  8     249223  04-03 
MANZO  L     244453  04-15 
MAO  CC     226857  01-03,  229466  01-03,  232514 

0)03 
MAPLE  PJ     238820  03-03 
MARCHAND  A     247208  04-03 
MARCONCINI-PEPEU  I     249664  04-03 
MARCUS  RJ     249307  04-03 
MARCUSSON  J     226410  0)10 
MARCY  R     227694  01-03,248514  04-04 
MARDER  JE     244701  04-15 
MARGOLIN  Dl     247683  04-04 
MARGOSES  N     238864  03-08 
MARGULES  DL     244202  04-04 
MARIETTA  MP     250107  04-03,  250108  04-03 
MARINIJL     251826  04-15 
MARJERRISON  G     243860  04-09 
MARKEY  SP     237274  02-16 
MARKINVA     24)989  03-03 
MARKOFF  RA     230015  0110 
MARKOMIHELAKIS  H     251986  04  14 
MARKOWITZ  R     249271  04-02 
MARKS  DF     239853  03-14,  246305  04  13 
MARKS  I     250727  04-10 
MARKS  V     241256  03-03 
MARK/M     249272  04-04 
MARLEY  E     241978  03  03,  243848  04-03 
MARQUIS  WJ     234810  02-04,  237718  02-04 
MARRIOTT  PF     253531  04  15 


MARROSU  F     237733  02-11 
MARSDEN  CA     239959  03-03,  241925  03-03 
MARSDEN  CD     230855  01-03,  237781  02-03 
237977  02-13,  241929  03-03,  241934  03-05, 
248289  04-04,  249076  04-04,  249628  04-03 
249629  04-04,  249679  04-04,  250358  04-04 
250722  04-15,  251239  04-11 
MARSHALL  A     248513  04-03 
MARSHALL  J  A     246300  04-10 
MARSHMAN  JA     232517  01-17,  232518  01-14 
MARTENS  H     251118  04-09 
MARTENSSON  E     237152  02-16,  237902  02-13, 

238552  02-13 
MARTINA     251979  04-04 
MARTIN  BR     237753  02-03 
MARTIN  GE     239087  03-03,  252024  04-03 
MARTIN  GF     226478  01-11 
MARTIN  GM     251629  04-05 
MARTIN  ICA     238978  03-15 
MARTIN  JC     245405  04-05 
MARTIN  RL     253595  04-09 
MARTIN  WR     237752  02-03,  244674  04-06 
MARTIN  YC     233946  02-01 
MARTINEZ  G     251178  04-03 
MARTINEZ  M     237624  02-1 1 
MARTINI  M     235992  02-11 
MARTRES  M     226651  01-02 
MARTZ  R     243087  04-14,  245648  04-14 
MARUKO  K     243094  04-17 
MARUYAMA  S     241386  03-03 
MARVOLA  M     25 1 1 30  04  02 
MARWAHA  J     238710  03-03 
MARX  M     227695  01-02 
MARZULLO  G     249035  04-01 
MASANES  P     249144  04-11 
MASE  GB     230990  01-09,  230992  01-09 
MASELLI  A     237624  02-11 
MASHKOVSKIY  MD     236369  02-03 
MASLANKAA     23884103-03 
MASON  AS     251751  04-17 
MASON  ST     234917  02-04 
MASSARI  VJ     248414  04-05 
MASSERANO  JM     238744  03-04 
MASSOTTI  M     247485  04-04 
MASTER  RS     230907  01-08 
MASUDA  K     233077  02-04 
MASUDA  Y     241393  03-03,  247039  04-03 
MATHIEU  LF     249929  04-05,  250655  04-03 
MATHUR  PP     2377o0  02  03,  241344  03-03 
MATHURA  CB     241680  03-04 
MATSUBARA  I     246971  04-03 
MATSUDA  H     231316  01-04,  241378  03-04 
MATSUOA  T     243094  04-17 
MATSUMOTO  H     244050  04-08 
MATSUNAGA  M     24274103-03 
MATSUURA  H     227808  0115,244779  04-15 
MATTE  AC     237714  02-04 
MATTHEW  H     250715  04-15 
MATTHEWS  WD     239961  03-03 
MATTHYSSE  S     238464  02-08 
MATTILAAAJ     246315  04-14 
MATTSSON  B     226410  0110,226413  01-11, 

226414  01-1  1,  226430  01-07 
MATUSSEK  N     233682  02-17,  246672  04  08 
MAUGER  JW     238487  02-01 
MAWDSLEY  C     250944  04-11 
MAXION  H     238516  02-11,239682  03-15 
MAXMEN  JS      2466)7  04  17 
MAXSON  SC     237706  02-03 
MAY  J     249257  04-03,  249309  04-03 
MAY  PRA     229448  0) -08 
MAY  V     239783  03)5 
MAYER  B     240692  03-15 
MAYER  DY     240251  03  15 
MAYSOV  Nl     2363/0  02-03 
MAZAYEVA  NA     244349  04-10 
MAZURKIEWICZ  KWILECKI  IM     230853  01-03 
MCARTHURAW     248172  04-11 
MCBRIDE  WJ     250067  04  04 
MCCABE  GP     247217  04  14 
MCCABE  L     226901  0114 
MCCABE  OL     239824  03  11 
MCCALLUM  NK     233279  02-03 
MCCARDLE  K     238698  03-04 
MCCARTHY  K     238736  03-03 
MCCARTY  RC     242749  04-04 
MCCLAIN  LD     227692  0)03 
MCCONNELL  WR     238815  03-03 
MCCOY  TH     253106  04  03 


A-12 


HUME  14,  AUTHOR  INDEX 


Author  Index 


CURDY  RL     245524  04-17 

DERMEO  JO     248650  04-02 

DOWELL  FH     250927  04-1),  251651  04-07 

FARLAIN  RA     251718  04-11 

GHIE  RL     247030  04-11 

GILL  TE     242743  03-04,  250984  04  04 

GILVERAY  IJ     238484  02-06 

GLAMERY  M     251961  04-11 

GLASHAN  TH     237726  02-08 

GRATH  SD     230104  Ol-n 

GUFFIN  JC     244911  04-04 

INOEWAR  I     237748  02-03 

KEARNEY  JW     240021  03-04 

KFNZIE  GM     233969  02-03,  248650  04-02 

KINNEY  WT     247889  04-04,  248437  04-04 

LARTY  DO     230763  01-13 

LEAN  JR     238842  03-04 

WAHON  RE     238683  03-06 

WASTER  SE     247214  04-05 

WILLAN  DE     233292  02-04,  233293  02-04. 

38749  03-04,  247845  04-04,  249266  04-04, 
52816  04-04 

WURTREY  KD     243778  04-03 

WURTRY  R.J     249232  04-15 

'JAMEE  HB     239941  03-11 

^lAUGHTON  N     234918  02-03 

»JEILLYAS     240423  03  11 

^UTT  B     253041  04-15 

5HARRY  L     237745  02-04 

:H0ULAA/\  R     248701  04-03 

)INA  E     240850  03-08 

)1NA  MA     249286  04-03 

)VEDEV  OS     241988  03-03 

)ZIHRADSKY  F     252178  04-03 

)ZIHRADSZKY  K     248349  04  03 

X  R     231278  01-06,  237863  02-03,  238678 

3  03,  241253  03  03 

HILANE  L     226900  01-13 

HTA  JM     235348  02-09 

ERJP     246970  04  13 

NECKE  RO     237260  02-04 

SCH  RA     227128  01-04 

TES  J      240642  03-03,  243951  04  03 

.ANCON  J     231037  01-08 

.DRUM  as     241934  03-05 

.TZER  HL     238977  03-15 

.TZER  HY     226869  01-03,  230826  01-03, 

36523  02-04,  239931  03-08,  243813  04-03 

TZER  L     251533  04-04 

JDELSJ     238775  03-01 

JDELSON  WB     226848  01-05,  229924  01-14 

12947  04-15,  244960  04-13 

>IDESLON  V\/B     243822  04-14 

JDEZ  JS     237253  02-1 1,  238347  02-04 

JOLEWICZ  J     230817  01  03,  231410  0117 

JDOZA  C      252694  04-11 

JDUNI  G     231368  0109 

JETREY  D     232328  0103 

JKES  DB     253255  04-04 

TON  MK     253107  04-03,253108  04-04 

<SE  S     241798  03-03 

<TASTI  M     233917  02  11 

iALI  7     253135  04-03 

!EU  GP     244690  04-04 

(LIS  S     233829  02-08,  246694  04-1 1 

!RILL  DMR     228431  01-11 

ISIHA  FS     233296  02-13,238318  02-04, 

38750  03  04,  238836  03-03,  246821  04-05 
;SING  RB     238783  03-03,  239958  03  04 
52516  04-03 

CALF  B     238782  03-03 

CALF  M     247380  04-14 

CALFF  M     230742  0115 

IRICE  E     227768  01  09 

CORAKH  Y     236732  02-09 

VALDf  SP     230830  01-14,237722  02  14 

'ENDORF  R     240705  03-17 

'FR  H     237124  02  08,  240707  03  09 

'fR  ME     23170101-03 

'FR  RE     239941  03-11 

'ER  W     248222  04  10 

'EPSON  LR     243778  04-03 

:EY  E     247032  04  03 

ZEK  KA     244682  04  04 

DAUGH  LD     226528  0104 

HA  KK     238484  02-06 

-KE  DH     231995  0115.  237899  02  08,  247483 

1-08,  251718  04  11 

EON  C     248222  04  10 


MIHAILOVA  D     237981  02-02 

MIKAMI  M     251214  04-03 

MIKKELSEN  LI     227572  01-09 

MIKSIC  S     238713  03-04 

Ml  LEY  WM     253485  04-04 

MILIARESSIS  E     237862  02-03 

Ml  LEAN  C     245016  04-09 

MILLARD  BJ     246317  04-01 

MILLER  AF     242151  03-14 

MILLER  I     247130  04-03 

MILLER  Jl     248538  04-02 

MILLER  MA     2500T9  04-04 

MILLER  MH     244684  04-04 

MILLER  R     241929  03-03 

MILLER  RJ     229435  01-03,  241248  03-03,  241347 

03-03,  248286  04-03,  248287  04-02 
MILLICHAPJG     225783  01-14 
MiLLOY  S     241575  03-03 
MILLS  L     235676  02-11 
MILMORE  JE     250333  04-03 
MILNE  JF     229460  01-11 
MILNE  RJ     232333  01-03 
MILSON  JA     243803  04-04 
MILSTEIN  SL     226903  01-14 
MILSTEIN  V     232840  02-08,  253049  04-08 
MILSTOC  M     244495  04-09 
MINDHAM  RHS     242267  03-15,  250722  04-15 
MINDUS  P     239002  03-09 
MINN  FL     242251  03-09,  251719  04-07 
MIR  P     242251  03-09,  251720  04-08 
MIREYLEES  SE     241924  03-03 
MIRIN  SM     239941  03-11 
MIRSKY  AF     239848  03-04 
MISHRA  RK     231304  01-03,  238739  03-03,  238784 

03-03 
MISRA  PC     225699  01-15 
MISRA  RS     239661  03-03 
MISSLIN  R     237723  02-04 
MISU  Y     242204  03-03 
MISUREC  J     234419  02-11,234430  02-13 
MITCHELL  CL     238837  03-03 
MITCHELL  DN     238697  03-04 
MITRAG     243182  04-03 

MITROFANOV  VS     228547  01-04,  241989  03-03 
MITSUMOTO  H     233295  02-14 
MITTAG  TW     245594  04-04 
MIURA  S     228214  01  15,  252181  04-17,  253034 

04-15 
MIXICH  G     241231  03-04 
MIYAGAWA  K     236696  02-15 
MIYAKE  H     229626  01-11 
MIYAMOTO  H     228325  01-08 
MIYAMOTO  K     228327  01-09 
MIYAUCHl  1      241364  03-04,  246664  04-04 
MIZUSHIMA  S     236696  02-15 
MJORNDAL  T     226413  01-11,  251131  04-03 
MOAN  E     233829  02-08 
MODAK  AT     230451  01-03,  253106  04-03 
MODONESI  C     231368  01-09 
MOFFAT  JA     252023  04-03 
MOFFETT  RB     238478  02-01 
MOGILNICKA  E     250361  04-04 
MOHAMMED  S     238672  03-03 
MOHAMMED  YS     237117  02-03 
MOHLER  H     229465  01-03,  232515  01-03 
MOISAN  D     247544  04-15 

MOIZESZOWICZ  J     237102  02-14,  240838  03-1  7 
MOJA  EA     236672  02-04,241474  03-14 
MOLANDER  L     237107  02-04,  239042  03-14, 

245296  04-03.  248960  04-02 
MOLINOFF  PB     244315  04-03 
MOLLER  N     227762  01-04 
MOLLOY  BB     246151  04-03,  246847  04-03,  246848 

04  03 
MOMOSE  T     241273  03-14 
MONACO  F     242212  03  11 
MONEY  J      248222  04-10 
MONTEL  H     248979  04-03,  248980  04-03 
MONTEVERDI  T     230990  01-09,  230992  01-09 
MONTGRAIN  N     246126  04-17 
MONTI  JM     246818  04-04 
MOORE  J     232840  02-08 
MOORE  JD     251824  04  16 
MOORE  KE     233973  02  03,  237154  02-03,  245598 

04  03 
MOORE  MS     250073  04-06 
MOORE  WT     237651  02-15 
MOOSMAYER  A     237123  02-13 
MORA  F     242748  04-04 


MO  RAN  EC     247889  04-04 

MORETON  JE     251533  04-04 

MORGAN  BA     233300  02-01 

MORGAN  DW     245521  04-09 

MORGAN  JP     233296  02-13,238672  03-03 

MORGAN  M     246821  04-05 

MORGAN  WW     238790  03-03 

MORGANTI  A     249673  04-13 

MORGENROTH  VH     226856  01-03,  233971  02-03, 

241296  03-03 
MORI  M     241405  03-03 
MORIHISA  JM     249485  04-04 
MORIN  AM     236522  02-03 
MORIN  RD     227692  01-03,  230453  01-03 
MO R LAND  J      239044  03-03 
MORMONT  C     245971  04-06 
MORRANTJCA     227750  01-11 
MORRIS  HR     233300  02-01 
MORRIS  RJ     245649  04-11 
MORRISON  HL     248437  04-04 
MORSE  WH     240009  03-04,  240019  03-04,  2501 13 

04-04 
MORSELLI  PL     237740  02-03,  241234  03-13, 

242212  03-1 1,  246993  04-13,  246994  04-13, 

247131  04-03 
MORTIAUX  H     244215  04-04 
MORZORATI  SL     238823  03-03 
MOSES  F     238675  03-03 
MOSHKOVSKIY  YS     236715  02-03 
MOSKOWITZ  MA     238719  03  03 
MOSNAIM  AD     248162  04-01 
MOSS  J     227777  01-03,  247028  04-03 
MOTOMURA  H     229760  01-09 
MOYANO  CZ     245014  04-08 
MOYER  KE     243346  04-04 
MRSUUA  BB     239577  03-03 
MRSUUA  BJ      239577  03-03 
MUELLER  PS     247482  04-09 
MUIZELAARJP     230877  01-06 
MUKAI  T     228325  01-08 
MUKHERJEE  BP     238754  03  04 
MULAS  ML     249664  04-03 
MULDAWER  MD     22822101-08 
MULLENIX  P     247207  04-04 
MULLER  D     250209  04-15 
MULLER  E     234291  02-11 
MULLER  EE     240643  03-03 
MULLER  WE     251176  04-01,251177  04-01 
MULLER  OERLINGHAUSEN  B     235354  02-17, 

251417  04  15 
MUNKVAD  I     239023  03-08 
MONRO  A     239014  03-11 
MUNRO  HN     238719  03-03 
MONRO  JF     250944  04-11 
MURAKAMI  E     229504  01-11 
MURASE  Y     229068  01-03 
MURATA  T     228311  01  11 
MURAVCHICK  S     251820  04-03 
MURAYAMA  S     241385  03-03 
MURDOCK  HR     232623  02-13,  237872  02-13 
MURPHY  D     248160  04-10 
MURPHY  DL     226731  01  13,  237716  02-14, 

239305  03-13,  244664  04  09 
MURPHY  JE     227226  01-09,  227227  01-07,  245468 

04-09 
MURPHY  PJ     238683  03-06 
MURRIN  LC     250085  04-03 
MUSACCHIOJM     238686  03-03 
MUSCETTOLAG     237274  02-16 
MUSTY  RE     246819  04  04,  249622  04-07 
MUTSCHLER  E     240704  03-17 
MUZIO  M     244591  04-13 
MYCEK  AAJ     229490  01-03,  241346  03-03 
MYERS  PR     246998  04-03 
MYERS  RD     226938  01  04,  227382  01-06.  239087 

03-03,  252024  04  03 
MYLLYLA  VV     239090  03-03 
MYSLINSKI  NR     238737  03-03 
MYTILINEOU  C     248699  04-03 


N 


NABESHIMA  T     241370  03-04,  241371  03-04, 

242205  03-04 
NACHON  M     229827  01-09 
NADITCH  MP     233377  02-12 
NAG AHAMA  F     229504  0111 
NAGAMI  GT     246316  04-03 
NAGARAJAN  K     248649  04-02 


X 

> 

i  ^ 

\  ^' 

I  S 

■6 
P 

II* 


A-13 


Author  Index 


Psychopharmacology  Abstracts 


NAGASAKA  Y     252757  04-03 

NAGASHI  M     228308  01-08 

NAG  AT  A  T     244528  04-08,  249120  04-08 

NAGATSU  T     241360  03-03 

NAGY  A     243089  04-13,  246387  04  13,  246623 

04  09,  252231  04  13 
NAGY  J     239275  03-04 
NAHUNEK  K     234419  02-11,234430  02-13 
NAIK  SR     243041  04-03 
NAIR  NPV     235365  02-08 
NAIR  NVP     253055  04-11 
NAITO  Y     241388  03-03 
NAITOH  F     238565  02  03,  241366  03-03 
NAKAHARA  H     241373  03-04 
NAKAHARA  T     246314  04-08 
NAKAMURA  K     241369  03-03,  241369  03-03 
NAKAAAURA  Y     229504  01-11 
NAKANO  T     244528  04  08 
NAKANO  U     241406  03-03 
NAKAYA  S     241381  03  03 
NAKAZAWA  Y     229064  01-08,  246309  04-07 
NAMMATHAO  B     248514  04-04 
NANDI  AR     251006  04-07 
NANDI  BR     251776  04  16 
NARASIMHACHARI  N     249188  04-01 
NAROD  ME     237756  02-03 
NATHAN  BA     242882  04-04 
NATHANSON  JA     23717102-03 
NAUSIEDA  PA     251959  04-05 
NAVA  V     244587  04  08 
NAYLOR  GJ      247711  04-09 
NAYLOR  R     250414  04-11 
NAYLOR  RJ      227133  01-03,  227135  01-04,  237781 

02-03,  238319  02-04,  239964  03-04,  240063 

03-03,  248290  04-06,  248407  04-04,  250358 

04-04,  252031  04-03 
NAZAR  BL     226763  01-03 
NECKERS  L     226401  01-03,  232325  01-03,  238677 

03-03,  241253  03-03 
NEFF  NH     227783  01-03,  228032  01-03,  233947 

02-03,  237776  02-03,  238761  03-03,  250376 

04-03 
NEILL  DB     251138  04-04 
NEISS  ES     229036  01  07,  253323  04-07 
NEISV\/ORTH  JT     251149  04-17 
MELIUS  D     235336  02  15 
NELSON  HL     242248  03  09 
NELSON  JF     247588  04  03 
NEMEROFF  CB     232618  02-03 
NEMTSOV  AV     231070  01-03.  236265  02-03 
NEREANTIU  F     239089  03-05 
NESMELOV  NB     241987  03-03 
NETTER  P     226898  01-09 
NEUMEYER  JL     238319  02  04,  248286  04-03 

248287  04-02 
NEVILLE  M     238804  03-04 
NEWBERG  DC     252024  04-03 
NEWMAN  H     228224  01  08 
NEYE  J     231317  01-15 
NEZIROGLU  FA     233870  02-11 
NG  KT     253290  04-04 
NG  LKY     226870  01-03 
NICHOLS  WK     252027  04-03 
NICKLAS  WJ     237140  02-03 
NICOLESCU  P     239039  03-05 
NICOLL  RA     247513  04  03 
NICOTERA  M     247969  04-09 
NiEDERHOFF  H     243194  04  10 
NIELSEN  NP     244587  04  08 
NIEMEGEERS  C      249289  04-04,  250656  04-03 
NIEMEGEERS  CJE     225571  01-04,  230452  01  04, 

232529  01-04,  237744  02  04,  241228  03-04, 

241229  03  04,  250355  04-03,  251429  04-03, 

253394  04  04 
NIES  A     239938  03-10 
NIESSNER  G     244045  04  11 
NIETOD     235364  02-08 
NIGHTINGALE  SL     250711  04  1  7 
NIKAIDO  RS     235587  02-04 
NIKOLICS  K     248349  04-03 
NIKOLOV  R     240205  03  05 
NIKOLOVA  M     240205  03-05 
NING  JL     240850  03  08 
NISHIDA  H     228074  01-11 
NISHIKUBOM     249123  04-13 
NISHIMORI  T     231316  01-04 
NISS  Al     236725  02-08 
NISSEN  C     248349  04-03 
NISTICO  G     252034  04-03 


NISTRI  A     235327  02-08,  241922  03-03,  245595 

04  03 
NITSCH  F     239834  03-04 
NIXON  RA     241298  03-03 
NOBLE  EP     225932  01-08,  238748  03-13,  241222 

03-03 
NOGUCHI  T     229760  01-09 
NOMURA  J     249123  04-13 
NOMURA  Y     241361  03-03,  241366  03-03,  249667 

04-03 
NORDBERGA     251175  04-03 
NORDGREN  L     251119  04-08 
NORDQVIST  M     238316  02-03 
NOREN  M     226412  01-08 
NORTON  S     247207  04-04 
NOSAKA  H     241379  03-04 
NOTSU  Y     241382  03-04 
NOVICK  WJ     238839  03-03 
NOVIN  D     230872  01-04 
NOWACZYK  T     23531 7  02-04,  245304  04-04 
NOWAK  JZ     240238  03-03 
NOWAK  T     238719  03-03 
NOWLIN  JB     246440  04-14 
NOZAKI  M     238704  03-04 
NUESSLE  NO     233276  02-01 
NUWJAN  R     23261  7  02-03,  248274  04-03 
NUNEZ  AH     240850  03-08 
NUNN  WD     236801  02-13 
NUNZIATA  A     232502  01-03 
NURIMOTO  S     241384  03-03 
NUROWSKA  K     243986  04-08,  244049  04-08 
NUTTJG     231319  01-13 
NYBERG  G     237152  02-16,  237902  02-13 


OAKLEY  GP     229349  01-17 

OBERINKJI     230877  01-06 

OBOYLEJH     230763  01-13 

OBRIEN  CP     229852  01-17 

OBRIEN  EMD     236118  02-11 

OCHI  Y     249124  04-14 

ODUTOLA  A     248725  04-03 

OEHME  M     235589  02-06 

OETTINGER  L     238510  02-11 

OFFERMEIER  J     250940  04-03 

OGAWA  H     241400  03-04 

OGAWA  N     227818  01-11,229064  01-08 

OGAWA  Y     241388  03-03 

OGELTREE  AM     227569  01-14 

OGILVIE  A     245469  04-11 

OGITA  K     252181  04-17 

OGLE  CW     251986  04-14 

OGREN  S     232507  01-03 

OGREN  SO     250937  04-03 

OGRIS  E     233718  02-15 

OGURA  C     227808  01-15,244779  04-15 

OHARA  H     247030  04-11 

OHASHI  M     238563  02-03 

OHASHI  T     238758  03-03 

OHMAN  R     237152  02-16 

OHSHIMA  M     246309  04-07,  249120  04-08 

OHTAKA  T     232703  02-04 

OJEMANN  LM     251937  04-13 

OKA  M     241375  03-04,  241388  03-03,  247039 

04-03 
OKA  T     241394  03-03,  241395  03-03,  241396 

03-03,  241402  03-03 
OKAGE  T     241374  03-04 
OKAMOTO  H     247013  04-03 
OKAMOTO  M     238770  03-03 
OKUIZUMl  K     238564  02-04,  241376  03-04, 

241400  03-04 
OKUMA  T     227808  01-15,  228327  01-09,  244779 

04-15 
OLDS  ME     232332  01-04,  239980  03-04,  239981 

03-04 
OLDS  SW     229295  01-11 
OLEARY  MH     246286  04-03 
OLESEN  OV     2371 10  02-04,  244651  04-03 
OLESHANSKY  MA     228032  01-03,  250376  04-03 
OLIVER  J      248464  04-13 
OLKONIEMI  J     229907  01-14 
OLLING  M     241359  03-02,251419  04-03 
OLMSTED  CA     238812  03-03 
OLSEN  DM     231010  01-03 
OLSEN  JL     237787  02-16 
OLSEN  MR     227461  01-17 
OLSEN  RW     238779  03-03 


OLSNERV     228550  0103 

OLSON  RK     237731  02-04 

OMBRATO  M     230993  01-11,  247969  04-09 

ONEILL  JJ     236521  02-03,  238777  03-03 

ONOJK     241994  03-04 

ONO  N     241406  03-03 

ONO  S     243094  04-17 

ONO  T     248358  04-03 

ONODERA  K     242202  03-03 

OOMURA  Y     248358  04-03 

OPMEER  FA     241246  03-03 

OPPENHEIM  RW     228630  01-04 

OPRESCU  M     242863  04-15 

ORBACH  L     235361  02-09,  242249  03-09 

ORCUTTJC     244315  04-03 

ORDONEZ  LA     232613  02-03 

ORELAND  L     226413  01-11 

ORLANSKY  H     248699  04-03,  253691  04-03 

ORLOFF  ER     237699  02-04 

ORLOV  BN     236261  02-03 

ORME  AE     237264  02-04 

ORME  M     245653  04-13 

OSAWA  T     230475  01-03 

OSBORNE  NN     243799  04-03 

OSE  E     246623  04-09 

OSGOOD  PF     238805  03-02 

OSHEAL  FE     229715  01-11 

OSHEROFF  R     251966  04-11 

OS  HI  MAM     229064  01-08 

OSMAN  MY     237117  02-03 

OSNES  J     239044  03-03 

OSTERHOLM  KG     249250  04-03 

OSWALD  I     239059  03-14 

OTERO  JB     239848  03-04 

OTHMER  E     229924  01-14 

OTIS  LS     241244  03-04 

OTT  J     234291  02-11 

OTTEN  U     251393  04-03,  251434  04-03 

OUGHOURLIAN  JM     247554  04-09 

OURI  P     227222  01-09 

OURY  M     244450  04-11,24445104-11 

OVERSTREET  DH     247209  04-04 

OVERTON  DA     249025  04-04 

OYE  I     239044  03-03 

OZAKI  M     241365  03-03 

OZAWA  H     241364  03  04,  246664  04-04 

OZKURTS     246820  04  04 


PAALZOW  G     237697  02-04,  252026  04-03 

PAALZOW  L     237697  02-04,  252026  04-03 

PAC  0 WS  K A  A     23404  7  02- 1 1 

PADJEN  A     232512  01-03 

PALFAI  T     242733  03-04 

PALFREYMAN  ES     249675  04-03 

PALFREYMAN  MG     249675  04-03 

PALLETTJ     226899  01-09 

PALLIS  CA     246699  04-15 

PALM  U     226411  01-09 

PALMER  DS     237756  02-03 

PALMER  GC     237241  02-03,  238680  03-03,  239085 

03-03,  239582  03-03,  249286  04-03 
PALMER  L     245653  04-13 
PALUBA  M     243986  04-08 
PAMPLIN  W     249249  04-03 
PANASYUK  LV     228551  01-03,  236233  02-03, 

236713  02-03,  241982  03-05 
PANDHI  V     251215  04-04 
PANDINA  RJ     246819  04-04 
PANELLJ     239943  03-15 
PANG  DC     237245  02-03 
PANITCH  ML     245001  04-14 
PAOLINO  RM     226865  01-03,  249672  04-04 
PAPAV     235998  02-10 
PAPAVASILIOU  PS     237253  02-11 
PAPESCHI  R     226726  01-03,  237698  02-03,  237736 

02-03,  237737  02-03,  241224  03-04,  253393 

04-03 
PAPROCKI  J     253051  04-08 
PARE  CMB     227139  01-03,  245233  04-13 
PARENT  A     244638  04-03 
PARENT  M     250266  04-17 
PARKER  ES     238748  03-13 
PARKER  J     253593  04-04 
PARKER  LA     252859  04-17 
PARKER  RB     238842  03-04 
PARKER  T     238828  03-03 
PARKESJD     250722  04-15,251239  04-11 


A-14 


VOLUME  14,  AUTHOR  INDEX 


Author  Index 


PARLI  CJ     248605  04-02 

PARMAR  SS     238712  03-03,  239661  03-03, 

239662  03  03 
PAROLI  E     229549  01-15 
PARRY  0     241923  03-03 
PARS  HC     238805  03-02 
PARS  HG     248646  04-02,  248647  04-02,  248651 

04-02 
PARSON  N     237734  02-14 
PARUTA  AN     238487  02-01 
PASCHELKE  G     239854  03-03 
PASHUK  LK     236373  02-03 
PASIUD-WANIEK  J     234046  02-09 
PASQUALI  E     243198  04-11 
PASTERNAK  GW     252219  04-03 
PASTERNAK  V     239860  03-04 
PATARNELLO  L     229558  01-17 
PATAY  M     247151  04-04 
PATCH  ICL     239001  03-15 
PATEL  BC     237729  02-04,  247730  04-03 
PATEL  DM     239659  03-01 
PATHAK  D     228221  01-08 
PATLAK  C     231002  01-03 
PATON  WDM     243787  04-03 
PATRICK  RL     238729  03-03 
PATTERSON  CD     227826  01-09 
'AUL  CJ     231007  01-03 
PAULSON  GW     241900  03-15 
'AWLOWSKI  GJ     237900  02-10 
^AWLOWSKI  L     250058  04-03 
^AZDERNIK  TL     251700  04-03 
'EARL  J     252520  04-05 
'EARLMAN  C     245301  04-04 
'ECKNOLD  JC     231034  01-08,  231035  01-09, 

235355  021  7,  235359  02-07,  235361  02-09, 

235362  02-09,  235363  0209,  235367  02-09 

235368  02-09,  235369  02-07,  235370  02-09 

242249  03-09,  253053  04  07 
'EDIGO  NW     246852  04-04 
'EEKE  HVS     230865  01-04 
'EET  M     247711  04-09 
'EIRIS  JB     250932  04-07 
'EIXOTO  MPB     253051  04-08 
'ELC  I     237025  02-10 
'ELCHAT  G     244497  04-15,  250991  04-15 
'ELET  J     246273  04-15 
^ELIKAN  EW     238845  03-04 
'ELZER  NL     238718  03-04 
'ENNA  MW     231610  01-09 
'ENOT  C     239829  03-04 
'ENTREATH  VW     243799  04-03 
>ENTTILA  A     227136  01-15 
'ENTYUK  AA     241986  03-03 
'EPEU  G     249664  04-03 
'EPPERCORN  MA     245307  04-13 
'EREL  JM     229437  01-09,  229443  01-09,  238776 

03-01 
>ERERA  HV     246715  04-11 
>EREX  HC     253049  04-08 
'EREZ  DE  LA  MORA  M     232507  01-03 
'EREZ-CRUETJ     226870  01-03 
'EREZ-LOPEZ  R     236658  02-10 
'ERI  G     248291  04-03 
'ERINGER  E     241929  03-03,  249628  04-03 
'ERKINS  R     239058  03-14 
'ERLOFF  MM     245649  04-11 
'ERRAUD  J     227391  01-05 
'ERRIS  C     226410  01-10,226412  01-08 
'ERRY  KW     226765  01-03,  241339  03-03,  246847 

04-03 
'ERSINGER  MA     252149  04-04 
'ERSSON  G     226410  01-10 
■ERTA     249138  04-04 
'ERT  CB     250378  04-03 
'ETEROVA  E     234420  02-14 
'ETERS  DAV     230853  0103 
'ETERS  HD     251432  04-03 
'ETERS  J     249771  04-10 
'ETERS  MA     238723  03-03 
'ETERS  UH     240709  03-08 
'ETERSEN  GO     243089  04-13 
'ETERSEN  H     238487  02-01 
'ETERSEN  RC     23871103-14 
ETERSON  DW     231437  01-04 
ETERSON  JM     243789  04-03 
ETIT  P     245116  04-05 
ETIT  TL     252148  04-05 
ETOCZ  L     231008  01-03,  252445  04-02 
ETRIEA     246699  04-15 


PETRUCH  F     240692  03-15 

PETTERSON  U     230824  01-09 

PETTIGREWJD     226397  01-03 

PETZOLD  GL     230600  01-03,  230602  01-13 

PFEIFFER  E     253061  04-11 

PFEIFFER  K     249798  04-09 

PFLUEGER  AB     244911  04-04 

PHEBUS  L     238783  03-03,  239958  03-04,  252516 

04-03 
PHILIPPU  A     251392  04-03 
PHILIPS  SR     250379  04-03 
PHILLIPS  AG     235587  02-04,  241300  03-04, 

244676  04-04 
PHILLIPS  KC     245305  04-04 
PHILLIPS  Ml     251142  04-03,  252170  04-03 
PHILLIPS  N     237903  02-08 
PHILLIPS  P     249004  04-06 
PHILLIS  JW     232621  02-03,  248725  04-03 
PIALL  EM     241256  03-03 
PIATEK  W     248952  04-03 
PICCHIONI  AL     238706  03-04,  251989  04-04 
PICHOT  P     227216  01-09,  240444  03-)7 
PICK  GR     236801  02-13 
PICKENS  R     250010  04-04 
PICKWORTH  WB     238703  03-03,  238772  03-03 
PIDEVICH  IN     241982  03-05 
PIERI  L     228051  01-03,  232515  01-03 
PIERI  M     228051  01-03 
PIERS  DA     235630  02-09 
PIETRUSZEWSKA  I     244050  04-08 
PI  CACHE  RM     235629  02-08 
PIHKANEN  TA     246623  04-09 
PIHL  R     247420  04-04 

PIJNENBURG  AJJ     237704  02-04,  248285  04-02 
PILC  A     240238  03-03 
PILLING  JB     226349  01-14 
PINDER  RM     239964  03-04 
PINEAU  R     244497  04-15,  250991  04-15,  251829 

04-08 
PINES  A     251006  04-07 
PINTO  A     232781  02-08 
PINTO  F     229557  0114,229559  01-10 
PIRCH  JH     243953  04-14,  249250  04-03 
PI  RES  P     244497  04-15,  250991  04-15 
PISARSKI  W     229680  01-04 
PISZKIEWICZ  FF     237174  02-01 
PITLICK  WH     239658  03-13 
PITTNER  H     251415  04-03 
PLACIDI  GF     229554  01-16,  241234  03-13,  253393 

04-03 
PLAKUN  E     246617  04-17 
PLANCHE  R     237095  02-11 
PLANCHE  S     237095  02-1 1 
PLANZ  G     251418  04-11 
PLANZ  R     251418  04-11 
PLECH  A     227637  01-04 
PLETSCHER  A     244038  04-17 
PLEUVRY  BJ     237741  02-03 
PLONK  JW     237927  02-13 
PLOTNIKOFF  N     248647  04-02,  248651  04-02, 

248652  04-02,  251701  04-01 
PLUTCHIK  R     227330  01-11 
PODDAR  MK     243182  04-03 
POIGNANT  J     244899  04-04 
POKORNYA     233828  02-15 
POLC  P     232515  01-03 
POLDINGER  W     241759  03-10 
POLK  A     250332  04-06 
POLLARD  GT     249273  04-03 
POLLOCK  M     248172  04-11 
POLOSAC     238771  03-03 
POL  VAN  N     227826  0 1  -09,  24 1 275  03- 1 0 
POLYAKOVA  AG     236261  02-03 
POLZIN  R     239982  03-03 
POMERLEAU  G     246126  04-17 
POND  SM     226829  01-13 
POOL  0     247483  04-08 
POPOVA  NK     228549  01-04 
POPPING  A     251980  04-04 
PORFIRYEVA  RP     228547  01-04,  236232  02-03 
PORGES  SW     231629  01-14 
PORSOLT  RD     249668  04-04 
PORTA  M     246993  04-13,  246994  04-13 
POST  A     246970  04-13 
POST  ML     226761  01-03 

POST  RM     227785  01-09,  231771  01-04,  234797 
02-09,  237169  02-04,  240241  03-04,  243023 
04-09,  243024  04-17,  243440  04-03,  243819 


04-13,  243820  04-17,  249005  04-04,  250389 
04-13 
POTGIETER  B     250940  04-03 
POTTER  JJ     247032  04-03 
POTTER  LS     248394  04-04 
POUST  Rl     246275  04-13 
PRADA  JA     244674  04-06 
PRADHAN  SN     226943  01-04,  238754  03-04, 

249033  04-03 
PRANGE  AJ     232618  02-03,  2501 10  04-03 
PRASTKA  GJ     235678  02-17 
PRAY  BJ     227745  01-15 
PREACHE  MM     249296  04-02 
PREDESCU  V     236794  02-1 1 
PREDOMINATO  M     226827  01-03 
PRESLEY  R     237738  02-03 
PRESSLICH  0     226612  0)09 
PRESTON  KL     238696  03-04 
PREZIOSI  P     252034  04-03 
PRICE  MTC     232915  02-03 
PRIEN  R     236359  02-08 
PRIEN  RF     225718  01-09,  227731  01-17,  229458 

01-11,  252954  04-09 
PRIEST  RG     226898  01-09 
PRIVOLNEVA  TP     236714  02-04 
PROCACCINI  RL     241344  03-03 
PROCOPIU-CONSTANTINESCU  T     229113  01-14 
PROCTOR  DL     248008  04-04 
PROCTOR  LR     246303  04-14 
PROSSER  TD     226865  01-03,  244688  04-03 
PROTAIS  P     227996  01-03 
PROUDFIT  HK     23261 1  02-03 
PROZOROVSKIY  VB     231072  01-06 
PRUSKAUER-APOSTOL  B     226351  01-13 
PRUSOFF  B     229450  01-09,  238981  03-10 
PRYOR  GT     241244  03-04 
PRYTZ  S     240054  03-13 
PRZEWLOCKI  R     237785  02-03 
PUDWILL  CR     250107  04-03,  250108  04-03 
PUECH  AJ     252032  04-04 
PUERTO  A     253255  04-04 
PUGLIESE  A     237624  02-11 
PUGSLEY  T     244316  04-02,  244678  04-03,  249313 

04-03 
PUJOL  J     232624  02-03 
PUOLAKKAJO     226927  01-03 
PURDY  RE     249242  04-03 
PURI  SK     238845  03-04,  249139  04-04 
PURVIS  CR     245469  04-11 
PUTZOLU  S     235367  02-09,  235368  02-09,  235369 

02-07 
PUZYNSKI  S     234047  02-11,  236429  02-10 
PYCOCK  C     228050  01-03,  237781  02-03,  240063 

03-03,  243803  04-04,  249076  04-04,  249629 

04-04,  249679  04-04,  250358  04-04 
PYNE  E     237696  02-14 
PYNNONEN  S     253011  04-07 
PYSZKO  J     242527  03-07 


QUADAGNO  DM     242743  03-04 

QUARANTOTTI  BP     237707  02-04 

QUARTERMAIN  D     245614  04-02 

QUATTRONE  A     241235  03-03 

QUENON  BA     235320  02-04 

QUERMONNE  AAA     227694  01-03,  248514  04-04 

QUIK  M     244314  04-03 

QUISMORIO  FP     232865  02-15 

QUITKIN  F     228223  01  -08,  239937  03-09,  253047 

04-08 
QUOCK  RM     240936  03-03 


RAABE  W     241805  03-03 

RAAFAT  H     251006  04-07 

RABINER  CJ     253047  04-08 

RACAGNI  G     241252  03-03,  244514  04-03,  247146 

04-03,  250362  04-03 
RACHIDA     22824101-11 
RACK  PH     226897  01-15 
RAD  A  RT     228240  01-08,  249625  04-1 1,  250516 

04-10,  253050  04-11 
RADKO  KA     231070  01-03 
RADOJP     232638  02-13 
RADULOVACKI  M     231009  01-03 
RAFAELSEN  OJ     240055  03-09,  249927  04-15 
RAFT  D     232838  02-17 


e 

I 
% 

I 


A-15 


Author  Index 


Psychopharmacology  Abstracts 


RAHEEM  KA     244692  04-03 

RAHEJA  S     230907  01-08 

RAHMAN  M     251006  04-07 

RAHN  KH     251418  04-11 

RAI K  HMAN  LM     2367 1 5  02-03 

RAINEYJM     234713  02-15 

RAI  NOVA  L     248551  04-03 

RAITERI  M     246665  04-03 

RAJPUT  AH     245235  04-11 

RAMDOHR  B     231317  01-15 

RAMOS  JS     238734  03-03 

RAMSAY  AC     235545  0217,243716  0415 

RANDALL  PK     226850  01-03 

RANDALL  RE     237813  02-15 

RANDRUP  A     230869  01-04,  237107  02-04, 

247875  04-04,  248960  04-02,  253643  04-04 
RANE  A     243086  04  13 
RAPINJ     230450  01-03 
RAPPW     226412  01-08 
RAPPORT  MM     226186  01-04,248604  04-03 
RASKIN  A     250726  04-11 
RASMUSSEN  K     240048  03-15 
RASTOGI  RB     241203  03-03,  243792  04-03, 

246152  04-03 
RATCLIFFE  JG     230763  01-13 
RATHBUN  RC     248605  0402 
RATTAN  S     249278  04-04 
RAU WS  AG     24 1 359  03-02,  25 1 4 1 9  04-03 
RAVARIS  CL     239938  03-10 
RAYEVSKIY  KS     236370  02-03 
RAZ  A     244725  04-03 
RAZDAN  RK     248646  0402,  248647  04-02, 
248651  04-02,  248652  04-02 

RAZZAK  A     241398  03-04 

REA  TH     248538  04-02 

REAK  CJ     243780  04-03 

REAVEY-CANTWELL  NH     237760  02-03,  239659 
03-01,  241344  03-03,  250332  04-06 

RECCHIAM     242212  0311 

RECH  RH     234810  02-04,  237718  02-04 

RECHARDT  L     235649  02-03 

RECKER  RR     245651  04-13 

REEPMEYER  JC     238476  02-01 

REGALADO  RG     252141  04-07 

REGAN  J  D     251420  04-13 

REGINALDI  D     232779  02-09 

REICHARD  G     246970  04-13 

REICHMAN  J     229924  01-14 

REICHMAN  JD     242947  04-15,  244960  04-13 

REID  D     226899  01-09 

REID  JL     246843  04-03 

REID  LD     250019  04-04 

REIDERER  P     233917  02-11 

REINERT  H     227391  01-05 

REINIS  S     249030  04-03,  249031  04-03,  249032 
04-04 

REIS  DJ     229491  01-03,  238759  03-03,  246845 
04-03 

REISBY  N     243089  04-13 

REISECKER  F     237124  02-08 

REISLER  KL     230840  01-03,  238708  03-03 

REITER  LW     227384  01-03 

REMY  M     241760  03-08 

RENAUD  B     232624  02-03 

RENNERT  H     236348  02-17 

REUTER  CJ     250935  0417 

REVUELTA  A     226851  01-03,  236674  02-03, 
248698  04-05 

REVUSKY  S     246093  0404,  252859  04-17 

REY-BELLET  JJ     241760  03-08 

REYES  E     238680  03-03 

REYNOLDS  EH     230855  01-03,  237977  02-13 

REYNOLDS  GP     237993  02-15 

REZEK  M     230872  01-04 

RHEES  RW     237864  02-03 

RICCIO  A     242212  03-11 

RICCOBONI  FA     249251  04-03 

RICH  J     252223  04-03 

RICHARDS  DJ     241274  0314 

RICHARDS  RK     226926  01-04 

RICHARDS  WA     228686  01-11 

RICHELSON  E     23291  7  0203,  238692  03-03 

RICHENSA     225890  01-15 

RICHTER  NA     251983  04-03 

RICKELS  K     245649  04-11 

RIDING  J     239014  0311 

RIOLON  SA     238839  03-03 

RIE  ED     240538  03-11 

RIE  HE     226069  01  14.  240538  03-11 


RIEBLE  R     238866  03-11 

RIEGE  WH     239852  03-04 

RIEGER  B     238782  03-03 

RIEGLE  GD     240642  03-03 

RIFFEE  WH     24 1 257  03-03,  24 1 576  03-03 

RIFKIN  A     239937  03-09,  253047  04-08 

RIGGENBACH  H     240064  03-03 

RIGGI  F     230839  01-08 

RIGTER  H     251980  04-04 

RIKLAN  M     229165  01-11,23714102-14 

RILEY  CC     238846  03-03,  248284  04-03 

RILEY  PG     238476  02-01 

RIMESTAD  S     227766  01-11 

RIMON  R     239728  03-09 

RISBERG  A     227140  01-14,230867  01-14 

RISBERGJ     230867  01-14 

RISMGNDO  N     244899  04-04 

RISNERME     230879  01-04 

RISSE  GL     251939  04-14 

RISSO  AM     239641  03-11 

RITTER  K     238866  03-11 

RITTER  RC     238804  03-04 

RITTER  S     238718  03-04 

RIVAE     247131  04-03 

RIVA  M     237834  02-02 

RIVERA-CALIMLIM  L     229492  01-13,  230918 

01-03,  233296  02-13,  238732  03-03,  241920 

03-03 
RIZK  MM     238708  03-03 
ROBBINS  T     226349  01-14 
ROBBINS  TW     23771 1  02-04,  237712  02-04 
ROBERGE  AG     244638  04-03 
ROBERTS  MHT     241923  03-03 
ROBERTSON  L     229840  01-11 
ROBINSON  CA     249267  04-04 
ROBINSON  DS     239938  03-10 
ROBINSON  JA     245521  04-09 
ROBINSON  SE     249305  04-06 
ROBINSON  WW     227137  01-04 
ROBSON  RD     249304  04-03 
ROBY  D     248284  04-03 
ROBY  DM     238846  03-03 
ROCCA  E     246992  04-13 

ROCCATAGLIATA  G     231369  01-11,  244589  04-09 
ROCH  M     238828  03-03 
ROCHE  J     237927  02-13 
ROCHETTE  L     243777  04-03 
ROCHFORD  J     247482  04-09 
RODDA  BE     243087  04-14,  245648  04-14 
RODGERS  JR     23831 7  02-01 ,  250357  04-01 
RODNICK  EH     229448  01-08 
RODOVAA     234419  02-11 
RODRIGUEZ-SIERRA  JF     238822  03-03 
ROERIG  DL     243780  04-03 
ROFFLER-TARLOV  S     249233  04-03 
ROGERS  ME     247586  04-01 
ROGERS  SC     249536  04-16 
ROHRBACH  KW     249273  04-03 
ROIZEN  M     227777  01-03.  247028  04-03 
ROLLEMA  H     248949  04-01 ,  252523  04-03 
ROLLS  ET     242748  04-04 
ROLSTEN  C     247587  04-02 
ROMAN  I     229115  0113,236793  02-14 
ROMANIUK  A     232483  01-04 
ROMERO  JA     234919  02-03,  2371  70  02-03,  241471 

03-17,  243795  04-03 
ROMILAA     229115  01-13,236793  02-14 
ROMILDO  BUENO  J     247968  04-08 
ROMMELSPACHER  H     249074  04-03 
RONCAGLIONI  MC     237240  02-03 
RONIGER  JJ     237899  02-08,  247483  04-08 
ROONEY  JFF     239010  03-15,  251006  04-07 
ROOS  B     251374  04-08 
ROPARTZ  P     237723  02-04 
ROPS  RH     252033  04-03 
ROSECRANS  JA     238768  03-04,  244683  04-04 
ROSEN  TS     251428  04-05 

ROSENBAUM  AH     227572  01-09,  23471 1  0209 
ROSENBAUM  D     251960  04-13 
ROSENBERG  FJ     248646  04-02 
ROSENBERG  HC     238770  03-03 
ROSENBERGER  PB     252793  04-1 1 
ROSENBLOOM  MJ     23087101-14 
ROSENFELD  H     245649  0411 
ROSENKRANTZ  H     235671  02-05,  238807  03-05, 

243181  04-04 
ROSINA  PL     231367  01-08 
ROSKOSKI  R     238826  03-03 
ROSLOFF  BN     231438  01-03 


ROSNERJ     229369  0115 

ROSS  A     251149  04-17 

ROSS  DC     228978  01-17 

ROSSJJ     247130  0403 

ROSS  R     240599  03-17 

ROSS  RA     238759  03-03,  246845  04-03 

ROSSANDA  M     246993  04- 13,  246994  04-13 

ROSZELL  DK     228977  01-05 

ROSZKOWSKI  AP     227695  0102 

ROTH  ES     251185  04-03 

ROTH  RH     226856  01  03.  233971  02-03,  236519 

02-03,  237921  02-03,  241295  03-03,  241296 

03-03,  24721 1  04-03,  250085  04-03 
ROTH  T     248976  04-08 
ROTH  WT     230871  01-14 
ROTH-SCHECHTER  BE     241348  03-03 
ROTHFELD  B     240916  03-04 
ROT  ROSEN  J     247215  04-03,  249002  04-03 
ROUND  E     253411  04-03 
ROUSOS  AP     237897  02-08 
ROUTTENBERG  A     238757  03-04 
ROUZIOUXJM     245116  04-05 
ROVARO  E     237102  02-14 
ROVERE  C     230839  01-08 
ROWAN  MG     237784  02-01,237982  02-01 
ROWE  H     248628  04-12,  249260  04-07 
ROWE  ML     238485  02-02 
ROY  M     251648  04-11 
ROY  PE     229033  01  03,  229034  01-04,  229035 

01-03 
ROY  VM     229693  01-09 
ROZDILSKY  B     245235  0411 
RUBIN  DC     238719  03-03 
RUBIN  L     227330  01-11 
RUBOTTOM  GM     249783  04-01 
RUCH  W     239862  03-03 
RUCH-MONACHON  MA     241315  03-03.  241316 

03-03,  241317  03-03,  241318  03-03.  241319 

03-03 
RUDOLPH  SA     231014  01-03 
RUDY  TA     239576  03-04.241255  03-03 
RUDY  V     246629  04-09 
RUEST  E     246694  04-11 
RUHLANDW     243180  04-11 
RUIZ  M     246818  04  04 
RUIZ-NAVARRO  JF     235366  02-08 
RUSSELL  IS     252209  04-04 
RUSSO  RM     251827  04-14 
RUSTERHOLZ  DB     239660  03-01 
RUSTIN  TA     244107  04-11 
RUTHER  E     240218  03-08,  240219  03  1 1,  240220 

03-14 
RUTHVEN  CRJ     227212  01-07 
RUTLEDGE  CO     238688  03-03,  241345  03-03, 

249232  04-15 
RUWITCH  JF     231318  01-13 
RYAN  EA     250080  04-03 
RYAN  MS     248976  04  08 
RYBAK  PG     241986  03-03 
RYBAKOWSKI  J     234044  02-09,  243979  04-09, 

243985  04-09 
RYZNARJ     230997  01-11 
RZEWUSKA-SZATKOWSKA  M     236421  02-08 


SAARIO  I     229907  01-14,  241417  03-15.  246315 

04-14 
SAARMA  J     226900  01-13.  235365  02-08 
SAARMA  M     226900  01-13 
SAAVEDRAJM     241208  03-03 
SABA  P     247969  04-09 
SABBATINI  F     229560  01-11 
SABELLI  HC     238725  03-03,  240474  03-03.  248162 

0401,  249257  04  03,  249258  04-03,  249309 

04-03,  249310  04-03,  24931 1  04-03 
SACHAR  EJ     245840  04  13 
SACHS  C     241196  03-03 
SAC K  RL     233964  02- 1 4,  234797  0209 
SACKLERAM     251215  04-04 
SACKS  C     226737  01-13 
SADOWSKY  CH     243791  04-03 
SAELENSJK     249304  04-03 
SAFER  DJ     247377  04-15 
SAFRAMJ     229349  01   17 
SAGALES  T     248629  04  13 
SAHAKIAN  BJ     237712  02-04 
SAITOH     242200  03-03 
SAITO  K     241361  03-03 


A-16 


rOLUME   14,  AUTHOR  INDEX 

Author  Index 

AITO  M     228226  0109 

SCHEIBJ     239932  03-11 

SENAULT  B     241227  03-04 

AITO  S     238563  02  03.  241401  03-04 

SCHEIN  R     250084  04-03 

SENGUPTA  D     241343  03-03 

AKABE  T     246319  0403 

SCHELLEKENS  KHL     232529  01-04 

SEPINWALL  J     229461  01-04,  232509  01-04, 

AKALIS  G     229445  0108,  251719  04-07 

SCHELLINGJ     240762  03-11 

238697  03-04 

AKAMOTO  K     238565  02-03,  241378  03-04 

SCHENKER  S     241730  03-13 

SEPPALAT     246315  04-14 

AKUMAA     228226  01-09 

SCHERBERGERRR     232503  01-13 

SEREGI  A     246318  04-04 

AKURAOA  S     241380  03-04 

SCHERMANN  H     251408  04-17 

SERGEYEV  PV     236717  02-03 

AKURADA  T     242202  03-03 

SCHEURLEN  HR     241736  03-15 

SERRA  MT     238818  03-01,  249328  04-01 

AKURAI  S     228214  01-15 

SC  H 1  AVON  M     239022  03- 1 0 

SERRANO  L     243759  04-03 

AKURAI  Y     246314  04-08 

SCHIELE  BC     225867  01-08 

SERRANO  M     228225  01-08 

ALAMA  Al     249027  04-03 

SCHIFF  AA     238975  03-08,  247030  04-1 1 

SERTEL  H     243085  04-15 

ALETU  B     232532  01-14 

SCHILDKRAUT  JJ     234804  02-03,  241937  03-09, 

SETHI  BB     231604  01-05 

ALETU  M     232532  01-14 

247777  04-03 

SETHI  N     231604  01-05 

ALIMOV  RM     231069  01-04 

SCHILKRUT  R     240218  03-08,  240219  03-11, 

SETOGAWA  T     227808  01-15.  244779  04-15 

ALLER  CF     243879  04-04 

240220  03-14 

SETYONEGORO  RK     239269  03-1 1 

ALLOU  C     244958  04-11 

SCHILLER  GD     247209  04-04 

SEVER  PS     249633  04-03,  250723  04-03 

ALVADORINI  F     247969  04-09 

SCHILLING  A     245649  04-11 

SEVIOUR  PW     226937  01-04 

ALVENDYG     247217  04-14 

SCHLEMMER  RF     238696  03-04 

SHABSHELOWITZ  H     233290  02-03 

ALVENMOSER  F     244692  04-03 

SCHMALBACH  NL     242746  04-04 

SHADER  Rl     227569  01-14,  229457  01-11,  229840 

ALZMAN  C     227569  01-14,229457  01-11, 

SCHMIDT  D     233280  02-13 

01-11,  236300  02-17,  237116  02  13,  237928 

229840  01-11,  236300  02-17 

SCHMIDT  DE     239976  03-03,  249295  04-03, 

02-15,  243864  04-09,  250780  04-17,  251755 

ALZMAN  PM     226856  01-03 

249300  04-03 

04-17,  252656  04-15 

AM  J     247586  04-01 

SCHMIDT  RH     238826  03-03 

SHAGASS  C     251984  04-13 

AMANIN  R     237240  02-03,  237742  02-03,  237743 

SCHMITT  H     237118  02-03,237119  02-03 

SHAGSIOR  BJ     237787  02-16 

02-03,  241235  03-03,  248159  04-03 

SCHNEIDER  E     238516  02-11 

SHAH  NS     229264  01-04,  235670  02-03,  238764 

AMBANDHAM  R     251961  04-11 

SCHNEIDER  PJ     249245  04-03 

03-03,  241349  03-04,  246817  04-03 

AMBROOKS  JE     239010  03-15 

SCHNELL  RC     226865  01-03,  244688  04-03 

SHAH  PB     250332  04-06 

AMORAISKI  T     247587  04-02 

SCHNIEDEN  H     250082  04-03 

SHAH  RK     248649  04-02 

AMOYLOV  NN     241986  03-03 

SCHNOLL  SH     247147  04-15 

SHAIN  W     238736  03-03,  246998  04-03 

AMPSON  P     247143  04-17 

SCHOCK  G     234289  02  11 

SHANNON  PJ     227550  01-11 

AMUEL  D     237105  02-04,  248956  04-04 

SCHOENFELD  Rl     252824  04-04 

SHAPIRO  AK     235628  02  17 

ANCHEZ  TE     240850  03-08 

SCHOLFIELD  CN     237875  02-03 

SHAPIRO  E     235628  02-17 

ANDERS  B     241225  03-04,  250284  04  04 

SCHOLTYSIK  G     226728  01-03 

SHAPOVAL  LN     23683102-03 

ANDERS  DG     230562  01-11 

SCHOLTZ  J     244043  04-03 

SHARE  JB     239074  03-11 

ANDERS-8'JSH  E     226400  01-03,  246851  04-03, 

SCHONECKE  OW     235782  02-1 1 

SHARMA  RP     249265  04-05 

248414  04-05 

SCHONHOFER  PS     241246  03-03,  251432  04-03 

SHAROV  PA     228547  01-04 

ANDLER  M     227212  01-07.  237993  02-15,  245233 

SCHONYW     244896  04-14 

SHARPE  LG     238703  03-03.  238772  03-03 

04-13 

SCHOOLER  NR     229445  01-08 

SHARPLES  D     239684  03-13 

ANGER  DJ     226852  01-04,  226854  01-04,  246306 

SCHOU  M     253064  04-17 

SHATTUCK  D     243865  04-03 

04-04,  250070  04-04,  251670  04-04 

SCHREIBER  EC     247130  04-03,  253323  04-07 

SHAW  GG     245596  04-05 

ANGHVI  1     236528  02-03,  237903  02-08,  237922 

SCHREIBER  HL     239863  03-04 

SHAW  JA     245521  04-09 

02-03,  241241  03-04,  249283  04-03 

SCHREINER  HC     238977  03-15 

SHAWJM     247130  04-03 

ANNELLAJJ     245806  04-15 

SCHUBERT  D     243482  04-03 

SHAW  SG     242748  04-04 

ANSONE  M     247778  04-02,  249026  04-04 

SCHUFFEL  W     235782  02-11 

SHAYWITZ  BA     251951  04-04 

ANTER  RM     237738  02-03 

SCHULERME     227695  01-02 

SHEARD  MH     240062  03-04.  251826  04-15 

ANTINI  V     230860  01-03 

SCHULZ  H     244896  04-14 

SHELLENBERGER  MK     234067  02-03,  238716  03-03 

ANTOS  CA     226528  01-04 

SCHULZE  G     251409  04-04 

SHELLSHEAR  ID     245856  04-13 

ANTOS  MOREIRA  M     241875  03-09 

SCHUPF  N     250278  04-03 

SHEPPARD  C     233829  02-08,  246694  04-1 1 

APRONOV  NS     236716  02-03 

SCHUREN  K     231317  01-15 

SHERMAN  A     24615104-03 

ARACENI  C     229529  01-14 

SCHUSTER  CR     242747  04-04,  250076  04-14 

SHERMAN  AD     232614  02-03 

ARAF  K     247381  04-17 

SCHUSTER  P     237647  02-14,  243438  04-15 

SHERMAN  WR     238486  02-16 

ARI  A     246319  04-03 

SCHWABACH  G     247877  04-07 

SHERWIN  AL     226737  01-13 

ARKAR  C     253406  04-03 

SCHWARK  WS     243790  04-03 

SHIBATAD     229026  01-07 

ATHANANTHAN  G     237903  02-08,  242251  03-09, 

SCHWARTZ  J     22665101-02 

SHIBUYA  T     231316  01-04,  241378  03-04 

251720  04-08 

SCHWARTZ  JC     227996  01-03 

SHIGEHISA  T     242205  03-04 

ATINOFF  E     252174  04-03 

SCORZA-SMERALDI  R     250476  04-07 

SHIGENAGAY     251070  04-03 

ATO  K     23 1 3 1 6  0 1  -04,  24 1 378  03-04 

SCOTTOJC     247546  04-17 

SHIH  T     230840  01-03,  238708  03-03,  239086 

ATOM     230478  01-03,237782  02-03 

SCOVILLE  B     239680  03-17 

03-03 

ATOH  H     241382  03-04,  241403  03-03,  242201 

SCUDDER  CL     238745  03-03.  249299  04-03 

SHILLADYDD     229493  01-06 

03-03 

SEBO  J     252446  04-14,  252448  04-07,  252450 

SHIMAT     229760  01-09 

ATOH  M     251433  04-03 

04-11 

SHIMADAA     229725  01-14 

ATOH  Y     241382  03-04 

SEDVALL  G     230824  01-09 

SHIMIZU  M     241375  03-04,  241383  03-03,  241393 

ATTERFIELDJH     247385  04-17 

SEEMAN  P     248466  04-03 

03-03,  247039  04-03 

AVAGEC     239824  03-11 

SEGAL  DS     234809  02-04,  238843  03-04.  241307 

SHIMIZU  S     241377  03-04 

AVIGNANO-BOWMAN  J     230863  01-14 

03-04,  248947  04-03,  249486  04-03,  253255 

SHINY     228068  01-08 

AWA  A     24 1 396  03-03,  24 1 402  03-03 

04-04 

SHINN  B     253485  04-04 

AWADA  M     237782  02-03 

SEGAL  JL     249243  04-03 

SHIOMI  H     241373  03-04 

AWINSKY  1     232638  02-13 

SEGAL  M     251072  04-03,  252012  04-03 

SHIRAKAWA  1     249622  04-07 

AXEN  1     229350  01-15 

SEGAWAM     241373  03-04 

SHIROTAM     241376  03  04 

AXEN  L     229350  01-15 

SEGAWA  T     238565  02-03.  241361  03-03,  241366 

SHOEMAN  DW     231003  01-03 

AXENA  B     242248  03-09 

03-03,  249667  04-03 

SHOJI  T     241380  03-04 

AYED  AJ     236754  02-09 

SEGHETTI  E     237834  02-02 

SHOPSIN  B     230816  01-09,  236528  02-03.  237725 

AYERS  AC     226728  01-03,  246671  04-03,  250360 

SEIBEL  1     251118  04-09 

02-08,  247216  04-09 

0402 

SEIDEL  G     252222  04-03 

SHORE  H     247420  04-04 

CATTON  B     226858  01-03 

SEIDEN  LS     230842  01-04,  233968  02-04,  238844 

SHORE  PA     238730  03-03,  241919  03-03,  243760 

CHACHT  U     238839  03-03 

03-04,  253111  04-04 

04-03 

CHAEFERA     246318  04-04 

SEIDLER  FJ     253110  04-03 

SHORT  PH     249274  04-04 

CHAEFFER  JC     246316  04-03,  248637  04-01 

SEIFERT  R     230866  01-16 

SHOSTAK  M     229443  01-09,  238776  03-01, 

CHAFFNER  R     232515  01-03,  251399  04-03 

SEILER  N     239855  03-03 

245784  04  09 

CHAIN  RJ     250682  04-05,  251949  04-1 1 

SEKERKE  HJ     246851  04-03 

SHOTTON  E     246317  04-01 

CHAUY  AV     248349  04-03 

SELENATI  A     246993  04-13,  246994  04-13 

SHOULSON  1     250942  04-n 

CHANBERG  SM     231004  01-03,  241294  03-13 

SELIGER  DL     246313  04-04 

SHUDO  1     242200  03-03 

CHAPPI  R     241763  03  15 

SELIVANOVA  AT     23671 1  02-04 

SHULL  CM     247847  04-03 

CHARF  M     252230  04-11 

SELL  AB     251981  04-04 

SHULL  HJ     241730  03-13 

CHARFMB     245652  04-11 

SELLERS  EM     250779  04-11 

SHUSTER  L     249274  04-04 

CHECHTER  MD     238768  03-04 

SELLINGER  OZ     227387  01-03 

SICE  J     252061  04-14 

CHECHTER  PJ     238781  03-04 

SELTZER  V     237976  02-03 

SICILIANI  0     239022  03  10 

CHEDL  R     244692  04  03 

SEMAL  C     233817  02-08 

SIEGEL  B     227330  01-11 

CHEFF  TJ     239298  03  17 

SEMERARO  S     244476  0411 

A-17 

SIEGEL  SR     237813  02-15 

Author  Index 


Psychopharmacology  Abstracts 


SIEMENS  AJ     238766  03-03,  249261  0404 

SIEW  C     238701  03-03 

SIGGINS  GR     238471  02-03 

SIGNORET  J     248223  04-04 

SILBERFARB  PM     246617  04  17 

SILLANPAA  M     253011  04-07 

SILVERSTONE  T     240086  03-17,  251156  04-10 

SIMM     226899  01-09 

SIMANTOV  R     252219  04-03 

SIMEON  J     232635  02-11 

SIMIONESCU  L     242863  04-15 

SIMKE  JP     249304  04-03 

SIMON  G     243794  04-03 

SIMON  H     244216  04-04,250982  04-04 

SIMON  JR     249074  04-03,  249303  04-03 

SIMON  M     246661  04-03,  246662  04-03 

SIMON  P     227207  01-06,  237708  02-04,  249677 

0404,  249678  04-04,  251216  04-04,  251217 

04-03,  252032  04-04 
SIMON  W     235589  02-06 
SIMOPOULOS  AM     232781  02-08 
SIMPSON  G     237696  02  14 
SIMPSON  GM     229438  01-16,  231993  01-15, 

236529  02-06,  237828  02-08,  244501  04-08, 

245842  04-08,  247481  04-07 
SIMPSON  LL     231113  01-17 
SIMS  T     226305  01-04 
SINGER  G     237721  02-05,  242744  03-17,  251982 

04-04 
SINGH  AN     242248  03-09 
SINGH  JM     229286  01-04 
SINGH  MM     250989  04-15 
SINGH  SB     245884  0411 
SINGH  SP     239661  03-03,  239662  03-03 
SINGHAL  RL     241203  03-03,  243792  04-03, 

246152  04-03,  253135  0403 
SINYUKHIN  VN     236369  02-03 
SIOMOPOULOS  V     245019  04-15,  250196  04-13 
SIRIS  E     238491  02-13 
SIRIS  SG     231277  01-08,  238489  02-08,  238491 

02-13,  238493  02-17 
SISHTA  SK     252131  04-11 
SITARAM  N     232760  02  1 4,  243822  04- 1 4 
SIVARAMAKRISHNA  N     246822  04  03 
SIVOKHINA  NV     242702  03-14 
SJODEN  P     250013  04-04 
SJOERDSMA  A     238781  03-04,  238782  03-03 
SJOGREN  J     238998  03-15 
SJURSEN  EH     241109  03-04 
SKINNER  D     247206  04-04 
SKOLNICK  P     240242  03-03,  253109  0403 
SKOTT  A     251374  04-08 
SKOU  M     236806  02-16 
SKOWRONSKAJ      23642102-08 
SKUSE  N     226960  01-11 
SKYLER  J     243440  04-03 
SLANGEN  J     244691  04-03 
SLATER  S     239305  03-13 
SLEATOR  EK     247376  04-17 
SLIKKER  W     238694  03-04,  249251  04-03 
SLOMAN  L     235322  02-1 1,  245786  04-14,  252798 

04-11 
SLOTKIN  TA     243779  04-03,  243796  04-03, 

253110  0403 
SLOVITER  HA     243782  04-03 
SMALL  AM     247480  04-08 
SMALL  JG     232840  02-08,  253049  04-08 
SMART  RG     236046  02-17 
SMEE  ML     247206  04-04 
SMELT2ER  DJ     227571  01-11,  239932  03-11 
SMERALDI  E     250476  04-07 
SMIALOWSKA  M     237785  02-03 
SMIDT  NA     248172  04-11 
SMILEY  KA     238767  03-03 
SMITH  DF     225573  01  04,  246673  04-03,  252198 

04-03 
SMITH  DH  249459  04-03 
SMITH  DJ  243789  04-03 
SMITH  ER  238800  03-04 
SMITH  GP  245612  04-02 
SMITH  HE  246851  04-03 
SMITH  J B  229639  01-04 
SMITH  JE  241205  03-04 
SMITH  N  232617  02-03,  238713  03-04 
SMITH  RC     229440  01  14,  232616  02-04,  250076 

04-14 
SMITH  RV     239660  03-01 
SMITH  SE     228997  01-13,235638  02-17 
SMITH  SG     250021  04-04,  250658  04-04 


SMITH  SJ     229494  01  -03 

SMITH  TP     230825  01-04 

SMITH  TW     233300  02-01,  253495  04-15 

SMITH  VK     229449  01-09,  252941  04-09 

SMOLEN  VF     232623  02-13,  237872  02-13 

SMULEVICH  AB     244349  04-10 

SMYTH  RD     237760  02-03,  241344  03-03,  250332 

04-06 
SNEAD  OC     237826  02-03 
SNELL  D     238814  03-04,  249275  04-04 
SNIBBE  JR     244875  04-17 
SNIFFIN  C     251830  04-13,  253037  04-15 
SNISARENKO  AA     244449  04-04 
SNODDY  HD     238691  03-03 
SNODGRASS  RE     232762  02-1 7,  246033  04-1 7 
SNODGRASS  SR     237873  02-03,  249983  04-03 
SNYDER  BD     240614  03-17 
SNYDER  SH     226407  01-03,  226936  01-12,  227400 

01-03,  235802  02-08,  240077  03-03,  243483 

04-03,  246996  04-03,  247862  04-03,  248701 

04-03,  248703  04-03,  249301  04-03,  250088 

04-03,  250378  04-03,  252219  04-03,  252515 

04-05 
SODERBERG  U     250013  04-04 
SOFIA  RD     226826  01-03,  248283  04-02 
SOKOL  GH     226840  01-03 
SOKOL  M     253037  04-15 
SOLARO  F     239641  03-11 
SOLDINGER  SM     236318  02-15 
SOLIMAN  KFA     238751  03-03 
SOLOMON  J     243865  04-03 
SOLOMON  TA     248283  04-02 
SOLOW  C     250856  04-17 
SOLYOM  C     235826  02-10 
SOLYOM  L     235826  02-10,  237896  02-10 
SOMAN  I  P     248647  04-02 
SOOKM  D     235826  02-10 
SORIAAACHI  M     226739  01-03,  237881  02-03 
SOSKIN  RA     251752  04-17 
SOSSI  N     249284  04-03 
SOTELO  C     249899  04-03 
SOUBRIE  P     249677  04-04,  249678  04-04,  251216 

04-04 
SOUIEF  M     251004  04-10 
SOULAIRAC  A     244874  04-03 
SOURKES  TL     237747  02-03,  244314  04-03, 

247690  04-17 
SOYKA  LF     243789  04-03 
SPANIS  CW     250060  04-14 
SPANO  PF     226406  01-03,  250356  04-03 
SPARSER  SB     238687  03-04,  248697  04-03, 

249247  04-04,  249291  04-03 
SPATZ  H     229827  01-09 
SPATZ  M     239577  03-03 
SPAULDING  TC     251534  04-03 
SPECIALE  SG     235317  02-04 
SPECTOR  NL     236526  02-06 
SPECTOR  S     236526  02-06,  236527  02-03 
SPEHLMANN  R     230457  01-03 
SPENCER  CA     230763  01-13 
SPENCER  PSJ     252134  04-17 
SPENCER  RF     232838  02-17 
SPERANSKAYA  NP     236372  02-04 
SPETH  RC     249295  04-03 
SPIKER  DG     231318  01-13 
SPIKER  M     238811  03-04 
SPIKER  MD     239582  03-03 
SPILKER  BA     252520  04-05 
SPIRAKIS  C     237890  02-03 
SPISSU  A     237733  02-11 
SPOERRI  PE     246587  04-03 
SPOHN  HE     251996  04-08 
SPOONERJ     241754  03-17 
SPRAGUE  GL     249263  04-03 
SPRAGUE  RL     231629  01-14,  247376  04-17, 

248593  04-11 
SPRING  C     247380  04-14 
SPRINGER  NS     232815  02-15 
SQUIRE  LR     250060  04-14 
SQUIRES  RF     245296  04-03 
SREBRO  B     252173  04-03 
STAAK  M     237123  02-13 
STAHL  JM     226305  01-04 
STAIBAG     228550  01-03 
STALLONE  F     234203  02-09,  247582  04-09 
STANCER  HC     228142  01-04,  238774  03-01 
STANOEN  S     241234  03-13 
STANES  MD     251982  04-04 
STANESCU  A     252713  04-11 


STANEVA-STOYTCHEVA  D     248551  0403 

STANFORD  J     241459  03-08 

STANLEY  ME     233291  02-03 

STARK  P     249276  04-02 

STARKE  K     248979  04-03,  248980  04-03 

STARLING  LM     230739  01-13 

STARMER  GA     239859  03-03,  249674  04-14 

STAVINOHA  WB     230451  01-03,  249286  04-03, 

253106  04-03 
STAWARZ  RJ     249255  04-03 
STEELE  TH     237759  02-03 
STEFAN  IK  P     234309  02-03 
STEFANKO  S     245599  04-03 
STEICHEN  FM     238792  03-03 
STEIN  L     232508  01-03 
STEINBERG  H     244687  04-04 
STEINERAL     229318  01-03 
STEINER  FA     240523  03-03 
STEINER  SS     239272  03-04 
STELLA  B     230818  01-10 
STENBERG  VI     239661  03-03 
STENCKA  K     244050  04-08 
STEPANIAN  K     235305  02-11 
STEPHANYW     251418  04-11 
STEPHENS  DN     250075  04-04 
STEPHENSON  JBP     251103  04-11 
STEPHENSON  JD     252034  04-03 
STEPOCHKINA  NA     241988  03-03 
STERLING     227820  01-14 
STERN  G     247712  04-17 
STERN  JJ     24431 1  04-04,  250012  04-04 
STERNBERG  DE     248583  04-09 
STETTNER  U     239673  03-04 
STEVENS  W     237864  02-03 
STEVENSON  J     250491  04-10 
STEWART  CN     232639  02-04 
STEWART  JA     253053  04-07,  253054  04-1 1, 

253055  04-1 1,  253056  04-1 1,  253059  04-1 1 
STEWART  JT     233277  02-06 
STEWART  M     24771 1  04-09 
STEWART  AAJ     235545  02-17 
STEWARTS     240538  03-11 
STEWART  WJ     237728  02-04,  247863  04-04 
STILL  CN     249367  04-13 
STILLMAN  R     236750  02-08 
STILLMAN  RC     243013  04-04 
STIMMEL  GL     227560  01-17 
STINUS  L     237103  02-04,248964  04-04 
STITZEL  RE     238700  03-03 
STITZER  ML     237874  02-04 
STJERNHOLMMR     23300102-13 
STOCK  G     241232  03-03 
STOCK  K     246389  04-03 
STOCKARDJJ     236667  02-15 
STOCKDALE  S     2371 15  02-14,  237926  02-1 1 
STOFF  DM     227802  01-04,  236672  02-04,  241474 

03-14,  244195  04-12 
STOICAL     252713  04-11 
STOKES  JD     238745  03-03 
STOKES  PE     236801  02-13 
STOLERMAN  IP     249671  04-04 
STOLK  JM     229495  01-02,  238762  03-01,  243791 

04-03 
STOLL  PM     236801  02-13 
STOLE  RE     226865  01-03,  244688  04-03 
STOLLER  K     251825  04-14 
STOLMAN  S     230919  01-03,  23101 1  01-03 
STOLTMAN  WP     232623  02-13 
STONE  J     241129  03-03 
STONE  R     250423  04-13 
STONE  TW     237925  02-03,  243805  04-03 
STONE  WN     235534  02-17 
STORES  G     230368  01-11 
STORLIEN  LH     251629  04-05 
STRAHILEVITZ  M     23751102  17 
STRATTEN  WP     226945  01-04 
STRAUGHAN  DW     252521  04-03 
STRAUMANISJJ     251984  04-13 
STRAUSS  ME     245559  04-08 
STRETCH  R     237699  02-04 
STRICKER  EM     227125  01-04,  243815  04-03, 

243879  04-04 
STRIPLING  JS     237731  02-04 
STROMBOM  U     251226  04-02 
STRUENING  EL     235628  02-17 
STRUMIA  E     232530  01-07 
STRZELCZYK  M     238674  03-03 
STUBBS  DF     248532  04-10 
SU  MJ     248409  04-03 


A-18 


VOLUME   14,  AUTHOR  INDEX 


Author  Index 


SUCHANEK-FROHLICH  H     233698  02-07 

SUDILOVSKYA     231112  01-17 

SUENAGA  N     241372  03-04 

SUENAGE  N     245597  04-03 

SUGAWARA  K     241365  0303,  246664  04-04 

SUGERMAN  AA     231994  01-15,  247482  04-09 

SUGIMORI  M     248358  04-03 

SUGRUE  MF     237748  02-03,  241924  03-03 

SUH  KY     228072  01-15 

SULLIVAN  JW     238697  03-04 

SULLIVAN  MF     238806  03-03 

SULSER  F     226400  01-03,  229497  01-03,  245115 

04-03,  249255  04-03,  249305  04-06 
SULTAN  WE     248538  04-02 
SULZBACHER  SI     233513  02-17 
SUAAAN  A     229552  01-17 
SUMMERFIELD  A     235509  02-04 
SUNAMI  Y     228327  01-09 
SUNDARESAN  PR     230918  01-03,  233296  02-13 
SUNDWALL  A     251175  04-03 
SUNG  YF     241314  03-04 
SUNGURBEY  K     241275  03-10 
SUNIER  A     229370  01-11 
SURAN  AA     249294  04-03 
SURI  AK     251158  04-10 
SURIA  A     229463  01-03,  232513  01-03 
SU  WAN  A  AB     24 1 849  03-09 
SUZUKI  JS     251977  04-04 
SUZUKI  M     241370  03-04,  241371  03-04 
SUZUKI  0     237923  02-03 
SUZUKI  T     228214  01-15 
SVARE  B     245406  04-04 
SVENSON  TH     227126  01-04 
SVESTKAJ     234419  02-11 
SWANN  JW     235588  02-03 
SWANSON  GD     251825  04-14 
SWARTZBURG  M     247482  04-09 
SWEET  RD     250927  04-1 1,  251651  04-07 
SWETT  C     225722  01-15,  253661  04-15 
SYMES  AL     237747  02-03 
SYNDER  SH     232511  01-03 
SYVALAHTI  EKG     229042  01-13 
SZABADI  E     251705  04-03 
SZCZAWINSKA  K     240237  03-04 
SZE  PY     226401  01-03,  237706  02-03,  239581 

03-03 
SZECHTMAN  H     227343  01-03 
SZOBOR  A     252449  04-07 


TABAKOFF  B     238675  03-03 

TABET  P     249693  04-11 

TACHIBANA  H     229064  01-08,  246309  04-07 

TADANO  T     242202  03-03 

TADOKORO  S     238564  02-04,  241376  03-04, 

241400  03-04 
TAGLIAMONTE  A     244513  04-03 
TAHEDL  A     237124  02-08 
TAKAGI  H     241373  03-04,  242204  03-03 
TAKAHASHI  H     233281  02-14 
TAKAHASHI  R     225570  01-03,  228226  01-09 

246314  04-08 
TAKAHASHI  RN     249622  04-07 
TAKAHASHI  S     234673  02-09,  249121  04-08 

249124  04-14 
TAKAI  H     246971  04-03 
TAKAMI  N     241365  03-03 
TAKANO  N     241399  03-04 
TAKIMOTO  GS     246316  04-03 
TAKISHITA  S     241372  03-04 
TALALAYENKO  AN     231251  01-04,  236257  02-04 

236828  02-04,  241980  0303 
TALENS  GM     227384  01-03 
TAMAI  A     227808  01-15,244779  04-15 
TAMAKI  Y     253450  04  04 
TAMIR  H     248604  04-03 
TAAAURAA     228334  01-09 
TANABE  K     241379  03  04 
TANABE  T     242200  0303 
TANAKA  A     241361  03-03 
TANAKA  M     229064  01-08,  244528  04-08 
TANAKA  T     238717  03  04 
TANAKA  Y     249667  04-03 
TANG  AH     240019  03-04 
TANGHEAJ     229128  0114 
TANI  N     249121  04  08 
TANNER  NS     229498  01  03,  233361  02-01 
TANSELLA  M     239022  03  10 


TARCZYNSKA  K     236421  02-08 

TARIKAS  H     243482  04-03 

TARISKAJ     252444  04-17 

TARSY  D     249629  04-04,  249679  04-04 

TARYAN  S     227550  01-11 

TASHKIN  DP     237787  02-16 

TASSIN  JP     244636  04-06 

TAUBE  HD     248979  04-03,  248980  04-03 

TAUKULIS  H     246093  04-04 

TAYLOR  FH     247514  04-03,  248276  04-03,  252221 
04-03 

TAYLOR  KM     226850  01-03,  250333  04-03 

TAYLOR  M     225572  01-03,  250939  04-02 

TAYLOR  MA     253617  04-09 

TAYLOR  RJ     245016  04-09 

TEALEJD     241256  03-03 

TEAS  DC     234682  02-03 

TECCEJJ     230863  01-14 

TEIGEN  JR     228224  01-08 

TEIGER  DG     248646  04-02 

TEITELBAUM  H     249484  04-03 

TEITELMAN  G     249666  04-03 

TEMKOV  I     236363  02-10,  236732  02-09 

TEMPLER  Dl     252131  04-11 

TEN  HAMM     241359  03-02 

TEPLAN  I     248349  04-03 

TEPPEMA  L     238321  02-03 

TERNAUX  JP     247213  04-03,  249512  04-03 

TERRELL  CL     238727  03-03 

TERRIS  BZ     248647  0402,  248651  04-02 

TESSEL  RE     230874  01  04,  238688  03-03 

TETSCHE  K     241221  03-04 

TEUTSCH  H     242503  03-08 

TEYCHENNE  PF     245647  04-13,  246699  04-15 

THADDEU  R     227138  01-04 

THAETE  LG     238723  03-03 

THATCHER  JW     230830  01-14 

THATCHER  KM     241681  03-04 

THEISS  P     226726  01-03,  237736  02  03,  237737 
02-03,  241224  03-04 

THEL  S     244681  04-03 

THIELEMANN  H     243340  04-01 

THIERRY  AM     237103  02-04,  248964  04-04 

THIESSEN  I     235676  02-n 

THOA  NB     226870  01-03,  227777  01-03,  237862 
02-03,  238673  03-03,  247028  04-03 

THOENEN  H     251393  04-03,  251434  04-03 

THOMAS  BH     231007  01-03 

THOMAS  J  R     23551)  02-04 

THOMAS  RC     235589  02-06 

THOMNSE  K     244651  04-03 

THOMPSON  DM     250073  04-06 

THOMPSON  H     237725  02-08 

THOMPSON  J     251158  04-10 

THOMPSON  K     251996  04-08 

THOMPSON  LW     246440  04-14 

THOMPSON  MK     251163  04-11 

THOMPSON  RD     231700  01-03 

THOMPSON  RM     238488  02-01 

THOMSEN  J     251129  0417 

THOMSEN  K     237110  02-04 

THOR  DH     233418  02-03 

THORNTON  EW     226871  01-03,  230829  01-04, 

237713  02-04,  252522  04-03 
THORNTON  WE     227745  01-15,  253391  04-15 
THURMOND  A     244686  04-1 1 
THUT  PD     238737  03-03,  238847  03-04 
TIKAL  K     251991  04-04 
TILSON  HA     234810  02-04,  237717  02-04,  237718 

02-04 
TINKLENBERG  JR     230871  01-14,  241474  03-14 
TISSOT  R     226915  01-09,  239819  03-14 
TITTON  JA     228241  01-11 
TIZABI  Y     237862  02-03,  238673  03-03 
TJIOE  SA     236521  02-03,  238777  03-03 
TOBIAS  LL     252848  04-08 
TODA  N     252757  04-03 
TOGLIA  JU     251961  04  1 1 
TOGNONI  G     241234  03-13 
TOLMACHEVA  NS     236370  02  03 
TOLMAN  KG     245806  04-15 
TOLOSA  ES     237253  02-11,251958  04-13 
TOMIZAWA  S     241394  03-03,  241395  03-03 
TOMOSKY  TK     242749  04-04 
TOMOV  T     236363  02-10 
TONDO  L     232779  02-09 
TONG  TO     247089  04-15 
TONGE  SR     237976  02-03 
TONKOPIY  VD     231072  01-06 


TONON  GC     226406  01-03,  250356  04-03 

TOOMEY  TC     232838  02-17 

TOPIARA     234653  02-17 

TORDOFF  AFC     241979  03-04,  245600  04-04 

TORRADOA     246273  04-15 

TORRELIO  M     227702  01-04,  232615  02-04, 
237108  02-04,  245601  04-04,  249001  04-04 

TORRES  A     235364  02-08,  253056  04-1 1 

TORRIELLI  MV     232530  01-07 

TOSCANO  L     237834  02-02 

TOTARO  JA     24491 1  04-04 

TOTH  F     252450  04-11 

TOTH  K     252446  04- 1 4,  252450  04- 1 1 

TOUCHARD  FM     2491 44  04-1 1 

TOWEYJP     251428  04-05 

TRABERT  N     233296  02-13 

TRABKA  J     243234  04-04 

TRABUCCHI  M  226406  01-03,  233815  02-08, 
241252  03-03,  247146  04-03,  248700  04-03, 
250356  04-03 

TRAFTON  CL     251989  04-04 

TRANIER  Y     238781  03-04 

TRENCHARD  A     2271 39  01  -03 

TRESNAK  NJ     238837  03-03 

TRETHOWAN  WH     253374  04-17 

TREUL  S     237926  02-11 

TREVOR  AJ     250107  04-03,  250108  04-03 

TRI  TB     247148  04-15 

TRICK  KLK     239818  03-10,252144  04-17 

TRIMBACH  C     226734  01-04 

TROFIMENKO  SP     236234  02-03 

TROSKOJE     243814  04-03 

TROUPIN  AS     239658  03-13,  251937  04  13 

TRUDINGER  BJ     243085  04-15 

TRUHAUT  R     244874  04-03,  2451 14  04-06 

TRUIJENS  CL     253381  04-14 

TRUITT  EB     238849  03-03 

TRULSON  M     226734  01-04 

TRULSON  ME     239978  03-04,  249078  04-03, 
250083  04-04 

TRUMBO  DA     253381  04-14 

TRZEBIATOWSKA-TRZECIAK  0     243979  04  09 

TSAI  CC     252847  04-08 

TSANG  B     253135  04-03 

TSCHABITSCHER  H     233718  02-15 

TSENG  L     249315  04-03,  253107  04-03,  253108 

04-04 
TSILLI  Yl     228548  01-03 
TSO  TOT     239857  03-04,  239979  03  04 
TSUANG  MT     244498  04-09 
TSUCHIE  H     244779  04-15 
TSUJIMURA  R     249123  04-13 
TSUKADA  Y     226932  01-04,  253695  04-03 
TSURUMI  K     241397  03  04 
TSUTSUMI  E     250423  04  13 
TSVETANOVA  Y     236732  02-09 
TUBERGEN  DG     252825  04-13 
TUCHINDA  P     239646  03-14 
TUCKER  A     242742  03-04 
TUMAAH     229452  01-17 
TUNNICLIFF  G     253695  04  03 
TUOMIKOSKI  S     246623  04-09 
TUOMISTOJ     251700  04-03 
TUOMISTO  L     251700  04-03 
TURIN  J     247877  04  07,  252006  04-08 
TURANO  P     229439  0116 
TURKANIS  SA     231010  01-03,  238767  03-03 
TURKER  RK     226762  01-03 
TURNBULL  KW     251703  04-03 
TURNBULL  WU     250077  04-04 
TURNER  DM     247731  04-03 
TURNER  EG     238787  03-04,  239523  03-04 
TURNER  P     226187  01-10,  227139  01-03,  227210 
01-07,  240086  03  17,  240802  03-13,  251162 
04-13,  251986  04-14 
TURNER  WJ     229439  0116 
TUTTLE  JB     232917  02-03 
TUTTLE  WW     238735  03  03 
TWYCROSS  RG     252143  04  11 
TYBER  MA     245523  04-15 
TYCHSEN  RL     250073  04-06 
TYE  NC     230828  01-04 
TYRER  P     251157  04-10 
TYRER  S     250725  04-13 
TZENG  SF     238791  03  03,  249292  04-03 


A-19 


Author  Index 


Psychopharmacology  Abstracts 


U 

UEKI  S  241363  03-04.  241367  0304,  241389 
03-03,  241390  03-03,  241398  03-04 

UHLENHUTH  EH     232781  02-08,  246303  04-14 

UHLIR  F     230997  0111 

ULUS  IH     246820  04-04 

UMEDA  T     250423  04-13 

UNGAR  F     250081  04  03 

UNGERLEIDER  LG     250278  04-03 

UNGERSTEDT  U  238471  02-03,  243348  04-04, 
248288  04-03,  250086  04-04 

URETSKY  NJ     237873  02-03 

URSCHEL  CW     238743  03-03 

URSIN  R     252216  04-03 

USDIN  E     233941  02-03,  237829  02-17 

UTZINGER  R     253536  04-03 

UYENO  ET     238788  0304 

UZUNOV  P     236674  02-03 


VACCHINI  F     229557  01-14 

VADDADI  K     226897  01-15 

VALARINO  F     236658  02-10 

VALATX  J     249676  04-04,  252171  04-04 

VALDMAN  AV     2361  74  02-04 

VALENTINE  M     251005  04-10 

VALLE-JONES  JC     247030  04-11 

VALLIANT  PM     252149  04-04 

VALZELLI  L     245873  04-17 

VAMOS  MJ     247743  04-11 

VAN  BRUGGEN  JAA     225571  01-04 

VAN  BUREN  J     238724  03-03 

VAN  DEN  BOGAARO  JH     252033  04-03 

VAN  DEN  BURG  W     235630  02-09 

VAN  DEN  DRIESSCHE  J     247151  04-04 

VAN  DER  HELM  HJ     252760  04-09 

VAN  DER  HEYDEN  JAM     248285  04-02 

VAN  DER  KOLK  BA     236300  02-17 

VAN  DURME  R     237025  02-10 

VAN  GELDER  GA     227385  01-04 

VAN  GELDER  NM     226737  01-13 

VAN  HART  DA     230835  01-03 

VAN  HEMERT  JCJ     238982  03-1 1 

VAN  KAMMEN  DP     231019  01-17,  231277  01-08, 

237716  02-14,  238489  02-08,  238491  02-13, 

238493  02-17,  248160  04-10 
VAN  LAERE  E     240033  03  11 
VAN  MAANEN  EF     238672  03-03 
VAN  PRAAG  HM     235630  02-09,  238997  03-13, 

241912  03-08,  245510  04-09 
VAN  PUTTEN  T  230562  01-11 
VAN  RIPER  DA  238762  03-01 
VAN  ROSSUM  JM     237104  02-03,  237270  02-06, 

237704  02-04,  238321  02-03,  248285  04-02, 

252033  04-03 
VAN  SPANNING  HW     230819  01-03 
VAN  WOERT  MH     251960  04-13 
VAN  2ANTEN  AK     235630  02  09 
VAN  ZOEREN  JG     243815  04-03 
VAN  ZWIETEN  PA     230819  01-03 
VANDERHEEREN  FAJ     244131  04-13 
VANINI  M     230990  01-09,  230992  01-09 
VANOV  SK     241274  03-14 
VARADYA     240916  03-04 
VARADY  G     252448  04-07 
VARGA  E     244501  04-08 
VASSAR  HB     226826  01-03 
VAUGHEN  CM     238849  03-03 
VAUPEL  DB     237752  02-03 
VAZQUEZ  AJ     240474  03-03,  249309  04-03 
VEALE  WL     242736  03-03 
VELKOV  V     236364  02-10 
VENCOVSK Y  E     234420  02- 1 4,  234438  02- 1 7 
VENDSBORG  PB     240054  03-13,  240055  03-09, 

249927  04-15,  25112904-17 
VERBURG  D     236318  02-15 
VERDEAUX  G     247554  04-09 
VEREVKINA  IV     236369  02-03 
VERGARA  L     235366  02  08,  253054  04- 1 1 
VERGNES  M     239829  03-04 
VERHAEGEN  JJ     225936  01-08 
VERNIER  VG     249459  04-03 
VERSIANI  CALDEIRA  MV     247968  04-08 
VERTUA  R     226827  01-03 
VESELl  ES     244060  04-03 
VETULANI  J     245 1 1 5  04-03,  249255  04-03 
VI ALA  A     229906  0116 


VIANNA  FILHO  U     247968  04-08 

VICENTINI  L     240643  03-03,  252030  04-04,  252201 

0403 
VIGELAND  K     242868  04-11 
VIGOURET  JM     241927  03-04,  249419  04-04, 

251405  04-03 
VIGRAN  R     241222  03-03 
VIKHLYAYEV  Yl     244456  04-04 
VILC  M     234653  02-17 
VILLABLANCA  J     249307  04-03 
VILLENEUVE  A     251829  04-08 
VILLENEUVE  R     244497  04-15,  250991  04-15 
VINCI  M     229561  01-17 
VISHNUVAJJALA  BR     238475  02-01 
VITOROVIC  M     244620  04-08 
VIUKARI  M     247967  04-11 
VIUKARI  NMA     237162  02-17 
VIVIAN  S     246586  04-03 
VIZI  ES     252223  04-03 
VLAHOV  V     248552  04-03 
VLAYEV  S     236364  02-10 
VOGEL  B     251649  04-07 
VOGEL  GW     244686  04-11 
VOGEL  JR     242882  04-04 
VOGEL  WH     249036  04-03 
VOICULESCU  V     226351  01-13 
VOISIN  C     237118  02-03,237119  02-03 
VOITH  K     245295  04-04 
VOLICER  L     238845  03-04 
VOLLE  RL     226855  01-03 
VOLPEJJ     251654  04-15 
VON  CRAMON  D     244896  04-14 
VON  KNORRING  L     226410  01-10,  244189  04-07 
VON  PETRYKOWSKI  W     243193  04-10 
VON  SCHENCK  H     226877  01-17 
VON  SCHOULTZ  B     226414  01-11 
VON  SHNARTZENFELD  I     228550  01-03 
VONVOIGTLANDER  PF     238478  02-01,  248834 

04-03,  249930  04-03,  25!  184  04-03 
VORNE  M     226927  01-03,  227696  01-03 
VOSPALEK  DM     239856  03-04 
VOSSMER  A     243865  04-03 
VRANCKX  CH     227767  01-08 
VREEBURG  JTM     244343  04-04 
VUKOVICH  RA     253323  04-07 


W 


WACHTEL  H     252028  04-04 

WADA  JA     230475  01-03,  230478  01-03 

WADE  ON     226829  01-13 

WAGENAAR  WA     253381  04-14 

WAGERS  PW     240843  03-15 

WAGNER  BM     247208  04-03 

WAGNER  JG     247846  04-06 

WAJDA  I     237746  02-03,  240065  03-03 

WAKE  A     230478  01-03 

WALDMANN  K     234289  02-11 

WALDMEIER  PC     251225  04-03,  251395  04-03, 

251398  04-03 
WALINDERJ      251374  04-08 
WALKER  CA     238751  03-03 
WALKER  J     251964  04-03 
WALKER  J R     234682  02-03 
WALKER  P     248222  04-10 
WALL  FJ     250516  04-10 
WALL  M     240064  03-03 
WALLACE  JE     238789  03-03 
WALLACH  MB     230878  01-04,  233963  02-03 
WALLER  MB     239087  03-03 
WALLIN  BG     251071  04-12 
WALTER  GF     231629  01-14 
WALTERS  J     251239  04-11 
WALTERS  JR     233971  02-03,  241295  03-03, 

241296  03-03,  24721 1  04-03,  250085  04-03 
WALTON  KG     246150  04-04,  251699  04-04 
WANG  PEL     248600  04-03 
WANG  PL     228390  01-04 
WANG  RIH     237115  02-14,  237926  02-11,  243780 

04-03 
WANG  SC     238702  03-03 
WARNERS     237734  02-14 
WARBURTON  DM     242265  03-17 
WARD  J W     251949  04-11 
WARNECKA-PRZYBYLSKA  M     232545  01-17, 

234045  02-15 
WARNER  AM     245789  04-15 
WARNER  W     238808  03-03 
WARNES  H     246296  0415 


WARSH  JJ     238774  03-01 

WASER  PG     246388  04-04,  251979  04-04 

WATANABE  H     241391  03-03 

WATANABE  K     241391  03-03.  243094  04-17, 

249253  04-04,  250682  04-05 
WATANABE  M     228226  01  09,  245986  04-1 1 
WATANABE  S     241367  03-04,  241389  03-03, 

241390  03-03 
WATANABE  Y     241394  03-03,  241395  03-03 
WATERS  IW     226849  01-03,  227389  01  -03, 

227390  01-03 
WATKINS  JW     250077  04-04 
WATSON  E     233291  02-03,  245300  04-03 
WATSON  J     237696  02-14 
WATSON  Y     247711  04-09 
WATTS  DT     238808  03-03 
WATTS  G     231749  01-17 
WAUD  BE     233289  02-03 
WAUD  DR     233289  02-03 
WAUQUIER  A     230452  01-04,  232529  01-04, 

241229  03-04,  249289  04-04,  250656  04-03 
WAX/WAN  S     248543  04-16 
WAY  EL     237870  02-03,  241338  03-03,  249288 

04-04,  250079  04-04,  250087  04-02,  2531 12 

04-04 
WAY  WL     250107  04-03,250108  04-03 
WAYNER  MJ     242744  03-1 7,  248358  04-03 
WDOWI AK  M     232545  01-17,  234045  02- 1 5 
WEAVER  LC     231006  01-03 
WEAVER  S     249004  04-06 
WEBER  A     253587  04-12 
WEBER  RO     251407  04-17 
WEBSTER  CD     235322  02-11,  245786  04-14, 

252798  04-11 
WEI  E     250087  04-02 
WEICHSEL  M     243814  04-03 
WEIDLER  DJ     247846  04-06 
WEINBERG  WA     233499  02-15 
WEINBERGER  J     237140  02-03 
WEINBERGER  SB     249268  04-03,  249270  04-04, 

249290  04-03 
WEINER  BE     248947  04-03 
WEINER  N     238690  03-03,  246844  04-03 
WEINER  WJ     251959  04-05 
WEINGARTNER  H     243013  04-04 
WEINMAN  J     230580  0115 
WEINRYB  I     245949  04-06 
WEINTRAUB  ST     230451  01-03,  253106  04-03 
WEISER  G     237124  02-08 
WEISS  AN     231318  01-13 
WEISS  B     249287  04-03 
WEISS  G     247384  04-14 
WEISS  GB     238714  03-03 
WEISS  GK     23881103  04 
WEISS  J     244692  04-03 
WEISSMAN  A     248406  04-02 
WEISSMAN  L     251824  04-16 
WEISSMAN  MM     229450  01-09,  238981  03-10 
WEITHORN  CJ     240599  03-17 
WELBEL  L     231983  0110,  243986  04-08,  244049 

04-08 
WELBURN  PJ     239859  03-03 
WELCH  J     249304  04-03 
WELIKY  I     229036  01-07 
WELTMAN  AS     251215  04-04 
WEMMER  D     239932  03-11 
WENDLANDT  S     239841  03-04 
WENDLER  H     233717  02-11 
WENGER  GR     237757  02-04,  2501 12  04-04 
WEPIERREJ     230450  01-03 
WERNECKE  0     243180  04-11 
WERNER  G     244681  04-03 
WERNER  SS     236667  02-15 
WERNER  TE     250021  04-04 
WERRY  JS     247378  04-15,  247743  04-11,  243593 

04-11 
WESELUCHA  P     229515  01-10 
WESLEY  VH     241225  03-04 
WESTJW     244136  04-11 
WEST  NR     249036  04-03 
WEST  SK     227923  01-11 
WEST  WL     225766  01-11,  249253  04-04 
WESTERINK  BHC     226727  01-03.  241207  03-03, 

249984  04-03,  252523  04-03 
WESTERMANN  KH     250058  04-03 
WESTFALL  OP     248413  04-03 
WESTFALL  FC     241247  03-03,  252217  04-03 
WESTON  PF     247206  04-04 
WHALEY  K     228208  01-15 


A-20 


VOLUME   14,  AUTHOR  INDEX 

Author  Index 

WHEATLEY  D     229471  01-13,  248977  04-09 

WOODWARD  DJ     240242  03-03 

ZATZ  M     234919  02-03,  2371 70  02-03,  237921 

WHEATLEY  DP     227224  01-09 

WOODWARD  WA     252520  04-05 

02-03,  243795  04-03 

WHEATLEY  J     237713  02-04 

WOODY  GE     229852  01-17 

ZAWADZKI  Z     229684  01-14 

WHEELDEN  JA     252793  04  11 

WOOLLEY  DE     227384  01-03 

ZEBROWSKA-LUPINA  1     227636  01-04,  237032 

WHEELER  TJ     225572  01-03.  252522  04-03 

WORRALL  EP     247711  04-09 

02-04 

WHELAN  JE     241978  0303.  243848  04-03 

WORSHAM  E     241546  03-04 

ZEMLAN  FP     243878  04-04 

WHELIHAN  W     237141  02-14 

WORZ  R     238866  03-11 

ZEMLYANKIN  AS     23671102-04 

WHELPTON  R     237750  02-06 

WRAAE  0     253411  04-03 

ZEMPJW     226528  01-04 

WHISHAW  IQ     242736  03-03 

WRIGHT  DG     233295  02-14 

ZENTALL  SS     251154  04-14 

WHITE  A     238816  03-03 

WRIGHT  J     238682  03-03 

ZENTALL  TR     251154  04-14 

WHITE  HL     249273  04-03,  249308  04-03 

WRIGHT  JM     248724  04-03 

ZETLER  G     237705  02-04 

WHITE  JH     240522  03-17 

WRIGHT  MW     229650  01-14 

ZETTLER  G     249624  04-04 

WHITE  PR     250107  04-03,  250108  04-03 

WURSTER  RM     240014  03-04 

ZHARKOVSKIY  AM     242544  03-03,  244455  04-04 

WHITE  TG     246671  04-03 

WURTMAN  RJ     233290  02-03,  238719  03-03, 

ZHURAVLEVA  GV     236369  02-03 

WHITEHOUSE  LW     231007  01-03 

238726  03-03 

ZIANCE  RJ     238689  0303 

WHITESIDES  GH     242749  04-04 

WURZBURGER  RJ     236527  02-03 

ZIEGLER  DK     237138  02-11 

WHITFIELD  LR     251777  04-06,  251778  04-16 

WUTTKE  W     233681  02-06,  239828  03-03,  240020 

ZIEGLER  MG     239305  03-13 

WHITMAN  RM     235534  02-17 

03-04,  246855  04-04,  251414  04-03 

ZIEGLGANSBERGER  W     251433  04-03 

WHYTE  MP     238796  03-13 

WYATT  HJ     236863  02-03 

ZIEHER  LM     249666  04-03 

WIDELITZ  H     237871  02-03 

WYATT  RJ     227802  01-04,  232324  01-11,  233817 

ZIELEMAN  M     249984  04-03 

WIDELITZ  MM     237871  02-03 

02-08,  234798  02-08,  235801  02-15,  236672 

ZIGMOND  AAJ     227125  01-04,  229499  0104 

WIDLOCHER  D     239607  03-17 

02-04,  236750  02-08,  238761  03-03,  241474 

ZILM  DH     250779  04-11 

WIOMAN  M     238316  02-03 

03-14,  243822  04-14,  244195  04-12,  251128 

ZIMMER  U     228493  01-03 

WIECHERT  V     244298  04-11 

04-09,  252519  04-03 

ZIMMERBERG  B     240750  03-04 

WIECHMANN  M     244681  04-03 

WYLLIE  MG     243801  04-03 

ZIMMERMAN  AW     233832  02-13 

WIECK  HH     239768  03-17 

WYMAN  SM     245789  04-15 

ZIMMERMANN  RL     253048  04-08 

WIEDEKING  C     248222  04-10 

WYNDOWEJ     237896  02-10 

ZINGERMAN  AM     242702  03-14 

WIESEL  F     251131  04-03 

ZINKIN  S     241330  03-04 

WIESEN  RL     237926  02-n 

Y 

ZIRNISA     237174  02-01 

WIESLER  B     243194  04-10 

ZIS  AP     227134  01-03 

WILBERT  DE     225932  01-08.  236318  02-15 

YAGER  RD     251951  04-04 

ZITRIN  CM     22945101-10 

WILDMAN  RW     229169  01-15.  229169  01-15 

YAGI  G     228323  01-17,  252181  04-17 

ZIVKOVIC  B     226185  01-04,  232921  02-03, 

WILEY  RA     238476  02-01 

YAGI  K     237923  02-03 

248698  04-05 

WILK  S     233291  02-03.  245300  0403.  247216 

YAKSH  TL     239576  03-04 

ZOL FAGH ARI  M     2339 74  02- 1 1 .  25 1 649  040 7 

04-09 

YAMADA  K     241372  03-04 

ZOUBOK  B     247481  04-07 

WILKENING  D     238739  03-03 

YAMAGUCHI  E     229026  01-07 

ZSILLAG     250362  04-03 

WILKINSON  GR     241730  03  13 

YAMAGUCHI  T     249123  04-13 

ZUNG  WWK     243862  04-17,  25306)  04-1 1 

WILKUS  RJ     251937  04-13 

YAMAMOTO  1     241338  03-03 

ZWEIG  JS     236520  02  03 

WILLARD  DH     238806  03-03 

YAMAMOTO  K     238971  03-03,  241388  03-03 

ZWERLING  1     227330  01-11 

WILLARD  SP     228503  01-04 

YAMAMOTO  T     24 1 297  03-03,  24 1 363  03-04, 

ZWIRNER  PP     249668  04-04 

WILLEMSJL     237160  02-03 

241390  03-03 

WILLERJ     240657  03-11 

YAMAMURA  H     229025  0110 

WILLIAMS  CH     247020  04-03 

YAMAMURA  HI     227400  01-03,  238715  03-03, 

WILLIAMS  CL     250984  04-04 

238773  03-03,  249074  04-03,  249301  04-03, 

WILLIAMS  EJ     232623  02  13.  237872  02-13 

252515  04-05 

WILLIAMS  FM     243085  04-15 

YAMAMURA  S     238563  02-03 

WILLIAMS  JM     227099  01-04 

YAMANE  H     249121  04-08 

WILLIAMS  R     238845  03-04.  241754  03-17 

YAMAUCHI  1     249120  04-08 

WILLIAMS  RT     250723  04-03 

YAMAUE  S     228324  01-08 

WILSON  JT     243086  04-13 

YAMAZAK 1  T     229026  0 1  -07,  229504  01-11 

WILSON  MC     242747  04-04 

YANAGIDA  T     228309  01-17 

WILSON  RM     228221  01  08 

YANG  HT     233947  02-03 

WINDORFERA     240723  03-17 

YANG  RK     250175  04-15 

WINGER  G     237874  02-04 

YARYURA-TOBIAS  JA     233870  02-1 1 

WINN  M     248648  04-02.  248652  04-02 

YEHUDA  S     237097  02-03 

WINSON  J     251061  04-03 

YELLIN  AM     244932  04-15,  247380  04-14 

WINSTEAD  DK     240278  03-17 

YERSHOVAVP     228554  01-05 

WINTER  JC     230837  01-04,  245299  04-04,  249262 

YOKEL  RA     250010  04-04 

04-04 

YONEDA  R     241374  03-04 

WINTER  M     243794  04-03 

YORK  DH     238819  03-04 

WINTERS  WO     238795  03-03,  249240  04-03 

YORK  JL     245299  04  04,  249262  04-04 

WISE  CD     232508  01-03 

YORKSTON  N     251164  04-08 

WISE  RA     249749  04-03 

YOSHIDA  K     241383  03-03,241393  03-03 

WITIAK  DT     238475  02-01 

YOSHIDA  T     228325  01-08 

WITTEK  F     239823  03-08 

YOSHIMURAM     249124  04-14 

WITTENBORN  JR     25364104-11 

YOSHIZAKI  T     241388  03-03 

WITTER  A     246853  04-04 

YOUDIM  MBH     239960  03-03,  241931  03-03 

WITZELL-OSTLUND  G     226408  01-08 

YOUNG  DN     238716  03-03 

WNEK  D     230838  0104 

YOUNG  GA     251533  04-04 

WOGGON  B     238864  03-08.  24 1  76 1  03-08.  25 1 1 1 8 

YOUNG  LD     229717  01-11 

04-09 

YOUNG  RC     245612  04-02 

WOJCIAK  Z     240237  03-04 

YU  RK     237826  02-03 

WOLF  AP     248537  04-01 

YUNGER  LM     241251  03-04 

WOLF  G     238719  03-03 

YUWILER  A     237105  02-04,  248956  04-04 

WOLF  HH     248880  04-03 

WOLF  R     226612  01-09 

z 

WOLFARTH  S     242745  04-04 

WOLFSON  SK     238792  03-03 

ZABIKJE     226992  01-04 

WOLLERT  U     251176  04-01.251177  04-01 

ZACCHEI  AG     238684  03-03 

WOLTERS  RJ     233361  02-01 

ZAIMOV  K     236732  02-09 

WONG  DT     238840  03-03.  246848  04-03,  250380 

ZAJACZKOWSKA  A     244050  04-08 

04-03 

ZAJACZKOWSKA  M     227635  01-03 

WOOD  PL     253407  0403 

ZAKOWSKA  DABROWSKA  T     234044  02-09 

WOOD  WG     239863  03-04 

ZAKUSOV  VV     236232  02-03 

WOODBURY  DM     237243  02-03 

ZALICK  DH     237624  02-11 

WOODRUFF  ML     231701  01-03 

ZALIPSKY  JJ     239659  03-01 

WOODS  JH     227127  01-04,  230874  01-04,  237874 

ZAMBOTTI  F     240643  03-03,  252030  04-04, 

0204,  240015  03  04,  240018  03-04,  241250 

252201  04-03 

03  04,  249246  0404 

A-21 

SUBJECT  INDEX 


ITht'  Subiect  Index  is  niachino  generated.  Keywords  in  the  titles  of  abstrocts  appear  olphaheticolly  in  the  left  hand  margin,-  under  each  keyword  is  o  list  of  titles  in  which  the 
keyword  appears   The  spelling  of  words  in  the  titles  of  abstracts  has  not  been  changed;  hence,  two  spellings  of  the  some  word  may  appear  in  this  index     for  example, 
BEHAVIOR  ond  BEHAVIOUR  I 


COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P  CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDR0XYTRYPTA/\AINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
iT4 

THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
iBDOMINAL 

EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02-11 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
ABILITIES 

EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
kBIUTY 

THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY. 

227385  01-04 
ON  THE  ABILITY  OF  NARCOTIC  ANTAGONISTS  TO  PRODUCE  THE 
NARCOTIC  CUE. 

251429  04-03 
kBLATION 

EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  03-03 
ABNORMAL 

EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241109  03-04 
kBNORMALITIES 

CHLORPROMAZINE-INDUCED  ELECTROCARDIOGRAM  ABNORMALITIES. 

231037  01-08 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDENCE 
OF  OPHTHALMOLOGICAL  ABNORMALITIES. 

244779  04-15 
IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AND 
ELECTROCARDIOGRAPHIC  ABNORMALITIES  IN  HYPERACTIVE 
CHILDREN. 

245001  04-14 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
ABNORMALITY 

SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
VBOIISHES 

SELF-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST. 

246774  04-03 
kBRUPT 

MEDICAL  EFFECTS  OF  ABRUPT  NEUROLEPTIC  WITHDRAWAL. 

251996  04-08 
kBSENCE 

PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL. 

227132  01-04 
LEARNING  IN  THE  ABSENCE  OF  FOREBRAIN  NORADRENALINE. 

234917  02-04 
EFFECTS  OF  INTRAVENTRICULAR  6  HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE. 

239828  03-03 
VERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE. 

251939  04  14 
kBSINTHE 

MARUUANA,  ABSINTHE  AND  THE  CENTRAL-NERVOUS-SYSTEM. 

249783  04  01 


ABSORBING 

THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYT0CHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-01 
ABSORPTION 

IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02-13 
INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION. 

237116  02-13 
PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL. 

237123  02-13 
THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 

SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES. 

237981  02-02 
THE  INFLUENCE  OF  FOOD  ON  SIDE-EFFECTS  AND  ABSORPTION  OF 
LITHIUM. 

238998  03-15 
IMPAIRED  ABSORPTION  OF  CHLORPROMAZINE  IN  RATS  GIVEN 
TRIHEXYPHENIDYL. 

241920  03-03 
ABSORPTION,  DISTRIBUTION  AND  EXCRETION  OF  TRIFLUOPERAZINE  IN 
RATS. 

249036  04-03 
CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04-06 
ABSORPTION  OF  LITHIUM  FOLLOWING  ADMINISTRATION  OF  SLOW- 
RELEASE  AND  CONVENTIONAL  PREPARATIONS. 

250725  04-13 
INTESTINAL  ABSORPTION,  DEMETHYLATION,  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-13 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  (SQ-10996)  IN 
HUMANS. 

253323  04-07 
ABSORPTIVE 

DISTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRACT 
OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01-03 
ABSTINENCE 

CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC 

INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINE-DEPENDENT 
RATS. 

227702  01-04 
ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 

DEPENDENT  RATS  BY  DELTA9-THC. 

232615  02-04 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE. 

245601  04-04 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9  THC  DURING 
ABSTINENCE  IN  MORPHINE-DEPENDENT  RATS 

249001  04-04 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 
ABUSE 

THE  USE  OF  TRANQUILIZERS  IN  THE  TREATMENT  OF  MIXED  DRUG 
ABUSE 

229044  01   11 
MISUSE  AND  ABUSE  OF  DIAZEPAM:  AN  INCREASINGLY  COMMON 
MEDICAL  PROBLEM 

229852  01-17 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02  17 


e 
% 

I 
s 

I 

t 


S-l 


Silbject  Index 


Psychopharmacoiogy  Abstra< 


EXPERIMENTAL  HUMAN  DRUG  SELF-ADMINISTRATION:  METHODOLOGY 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE 

240831  03-14 
PENTAZOCINE  ABUSE  AND  PROBLEMS  OF  WITHDRAWAL 

246617  04-17 
MAO  INHIBITORS  HAVE  POTENTIAL  FOR  ABUSE. 

248339  04-15 
URGENT  PHARMACOTHERAPY  FOR  DRUG  ABUSE. 

251755  04- 17 
BENZODIAZEPINE-INDUCED  STATE  DEPENDENT  LEARNING:  A 
CORRELATIVE  OF  ABUSE  POTENTIAL? 

252674  04-04 
ACCELERATION 

NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
ACCESS 

ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  0104 
SELF-ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS:  THE 
EFFECTS  OF  UNLIMITED  ACCESS. 

250066  04-04 
ACCESSIBILITY 

STATE  DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST. 

243013  04-04 
A^CH 

EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04-03 
ACCIDENT 

NARCOSIS  INTRODUCTION  WITH  FLUNITRAZEPAM  IN  ACCIDENT 
SURGERY. 

244045  04-1 1 
ACCIDENTAL 

ENCEPHALOPATHY  SUBSEQUENT  TO  ACCIDENTAL  POISONING  WITH 
CHLORPROMAZINE. 

239089  03-05 
ACCIDENTAL  POISONING  WITH  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

252656  04- 15 
ACCUMATISED 

AMPHETAMINE  TOXICITY  IN  TEMPERATURE  ACCLIMATISED  MICE. 

23909)  03-05 
ACCUMULATE 

THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS 

228551  01-03 
ACCUMULATION 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE. 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-03 
LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
Ll-f   SENSITIVE  MICROELECTRODE 

235589  02-06 
THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02-03 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS 

24 1 979  03-04 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
I:  N-ARYLALKYL  AND  N-ARYLOXYALKYL  DL-AMPHETAMINES  AND 
RELATED  COMPOUNDS 

2463 1 6  04-03 
STUDIES  ON  ACCUMULATION  OF  (I4C)  MESCALINE  IN  BRAIN 

HOMOGENATES:  EFFECTS  OF  PSYCHOTROPIC  AND  OTHER  AGENTS. 

246817  04-03 
ACCUMULATION  OF  NOREPINEPHRINE  (NE)  BY  RAT  ORGANS  IN  VIVO. 

246822  04-03 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
II:  N  ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D-AMPHETAMINES, 
AND  3ARYL0XYPR0PYLAMINES 

248637  04-01 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC  ACID. 

250085  04-03 


ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 
ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RA 
OCCIPITAL  CORTEX. 

253691  04 
ACETAZOLAMIDE 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSAAAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01 
ACETYLATED 

EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  0^ 
ACETYLATOR 

THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  C 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZII 

251985  O-i 
ACETYLBUFOTENINE 

BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
DIMETHYLTRYPTAMINE  AND  5-METH0XY-N,N  DIMETHYLTRYPTAMir 

249317  0': 
ACETYLCHOLINE 

THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 

ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLI, 
IN  STRESS. 

227635  01 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS. 

228550  01 
DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 

CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  01 
RAT  TISSUES. 

230451  01 
THE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457  01 
PHARMACOLOGIC  STUDIES  OF  NARCOLEPSY  INVOLVING  SEROTONIN, 
ACETYLCHOLINE,  AND  MONOAMINE-OXIDASE.  {UNPUBLISHED  PAPEf 

232324  01 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINi 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  T 
RAT  SPINAL  CORD. 

235863  02 
EFFECTS  OF  (-)DELTA9-TETRAHYDR0CANNABIN0L  ON  REGIONAL  BRAIN 
ACETYLCHOLINE  IN  THE  RAT. 

238709  03 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE 
MOUSE  BRAIN 

238765  03 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  * 
AMPHETAMINE  AND  (  t  OR-)  P-CHLOROAMPHETAMINE. 

239976  03 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOV 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAI 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PH.D. 
DISSERTATION). 

241680  03 
EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FROG 
SPINAL  CORD. 

241922  03 
ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE. 

244203  04 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  Vl 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245.593  04 
DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04 


S-2 


/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-04 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
EFFECT  OF  NOMIFENSINE  ON  ACETYLCHOLINE  AND  CHOLINE  IN  THE  RAT 
STRIATUM  AND  BRAINSTEM. 

248291  04-03 
ACETYLCHOLINE,  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 
HYPOTHALAMUS. 

248358  04-03 
FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 

AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 

CLOZAPINE  AND  CHLORPROMAZINE. 

248600  04-03 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 

ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE. 
,  248700  04-03 

THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-03 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04-03 
ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 

TREATED  AND  STRESSED  MICE. 

249299  04-03 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN. 

249300  04-03 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 

REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  04-03 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO 

251175  0403 
EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R0-4- 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM. 

251181  04-03 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 
ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

25221  7  04-03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
kCETYLCHOllNESTERASE 

THE  EFFECT  OF  SYMPATHOLYTIC  AND  SYMPATHOMIMETIC  AGENTS  ON 
ACETYLCHOLINESTERASE  AND  CHOLINESTERASE  ACTIVITY,  IN  VITRO. 

243794  04-03 
IVCETYLTRANSFERASE 

6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC  ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS 

238826  03-03 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 
ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04-03 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 


EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R0-4- 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM 

251181  04-03 
ACH 

CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-03 
ACHETA-DOMESTICUS 

PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG  INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PH  D.  DISSERTATION). 

241994  03  04 
ACHIEVEMENT 

INFLUENCE  OF  PSYCHOPHARMACEUTICALS  ON  ACHIEVEMENT 
MOTIVATION:  III.  DIFFERENTIAL  INFLUENCE  ON  CONTENT  CATEGORIES. 

240644  03-14 
ACID 

ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID.  ACID. 

233278  02-01 
NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES. 

241298  03-03 
INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE- 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04-13 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  04-05 
ACID-DIETHYLAMIDE 

ANTAGONISM  OF  D-LYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,5,6  TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 
(THPC). 

230453  01-03 
ACIDOSIS 

SUIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02-15 
ACOUSTIC 

EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01-04 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE. 

237706  02-03 
STUDIES  ON  ACOUSTIC  PRIMING.  (PH.D.  DISSERTATION). 

238201  02-03 
P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
ACPC 

NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES. 

241298  03-03 
ACQUISITION 

EFFECT  OF  P-CHLOROPHENYLALANINE  ON  THE  ACQUISITION  OF 
TOLERANCE  TO  ETHANOL  AND  PENTOBARBITAL 

237720  02-04 
THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 

CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE 

237723  0204 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH  DOPAMINE 

239841  03  04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS 

246819  04-04 
THE  EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT 

251979  04-04 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE, 

251989  0404 
ACTH 

STUDY  OF  SEROTONIN  AND  ACTH  BRAIN  LEVELS  AND  BEHAVIOR, 

229498  01-03 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH 

236716  02  03 


S-3 


Subject  Index 


Psychopharmacology  Abstrac 


ACTH4-9 

CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04-04 
ACTING 

STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01-03 
BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS. 

233973  02-03 
IS  METOCLOPRAMIDE  A  DIRECTLY  ACTING  DOPAMINE  RECEPTOR 
ANTAGONIST?, 

241929  03-03 
EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-04 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM. 

247012  04-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 

HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS-INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN. 

251416  04-03 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
ACTION 

DRUG  ACTION  IN  MANAGEMENT  OF  HYPERTENSION. 

225766  01-11 
MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINOL 
(R2)  ON  RAT  STRIATUM. 

226851  01-03 
EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 
HYPNOTICS  AND  SLEEP:  CLASSIFICATION.  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS, 

228094  01-14 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
ON  THE  MECHANISMS  OF  ACTION  OF  AMINOPYRINE. 

228552  01-03 
BEHAVIOR  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION  OF 
BENZODIAZEPINES. 

229461  01-04 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 

BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-03 
INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -  STUDIES 

ON  RAT  CEREBELLUM. 

229466  01-03 
PSYCHOTROPIC  ACTION  OF  SEX  HORMONES. 

229470  01-14 
THE  MECHANISM  OF  ACTION  OF  AMPHETAMINE  IN  BRAIN. 

229491  01-03 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 

EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01-03 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM: 

EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  01-03 
PHARMACOLOGICAL  STUDIES  OF  DRUG  ACTION  ON  CNS,  WITH  SPECIAL 
REFERENCE  TO  EFFECTS  OF  MAPROTILINE. 

231316  01-04 
STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 
ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PHD 
DISSERTATION). 

231438  01-03 


THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 
SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BRA 
NUCLEI.  (UNPUBLISHED  PAPER). 

232325  01 
STUDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01 
MECHANISM  OF  ACTION  OF  BENZODIAZEPINES. 

232506  01 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION 

BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01 
BEHAVIORAL  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTIO 

OF  BENZODIAZEPINES. 

232509  01 
ACTION  OF  THE  BENZODIAZEPINES  ON  THE  CHOLINERGIC  SYSTEM. 

232510  01 
PROBLEMS  IN  THE  ELECTROPHYSIOLOGICAL  ANALYSIS  OF  THE  SITE  OF 

ACTION  OF  BENZODIAZEPINES. 

232512  01 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 

PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01 
EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 

BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM. 

232514  01 
A  NEUROPHYSIOLOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 

PSYCHOTOMIMETICS  (LSD-25,  DOM  AND  KETAMINE). 

232703  02 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARAAACOKINETICS  OF 
PSYCHOTROPIC  DRUGS. 

233682  02 
GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION. 

23481 1  02 
ON  THE  INTRACELLULAR  MECHANISM  OF  ACTION  OF  IMIPRAMINE  ANI 
DIAZEPAM. 

236232  02 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURON 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02 
INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIDOL. 

236369  02 
CLINICAL  EVALUATION  OF  THE  ANTIDEPRESSIVE  ACTION  OF  THE 
PREPARATION  AZAFEN. 

236429  02 
RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02 
THE  ACTION  OF  CHLORPROAAAZINE,  TRIFLUOPERAZINE  AND  DROPERID' 

ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02 
VESTIBULAR  TEST  IN  INVESTIGATING  THE  SPECTRUM  OF  ACTION  OF 

PSYCHOTROPIC  AGENTS. 

236714  02- 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 

DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02- 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02- 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS. 

237782  02- 
BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 

COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02- 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 
ACTION  OF  DIAZEPAM. 

238531  02- 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTIOI 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02- 
INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

23875''  03- 
DOPAMINE  AND  PSYCHOACTIVE  DRUG  ACTION:  A  FURTHER 
EVALUATION. 

238768  03-1 
CENTRAL  ACTION  OF  AMPHETAMINE-INDUCED  MYDRIASIS  IN  THE  DOG 

238772  03-1 


S-4 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS. 

238809  03-03 
THE  EFFECTS  OF  DEITA9-TETRAHYDR0CANNABIN0L  ON  ACTION 
POTENTIALS  IN  THE  MOLLUSC  APLYSIA. 

239261  03-03 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03-04 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03-03 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  03-03 
DUAL  ACTION  OF  MORPHINE  AND  REL>^TED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03-04 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  ELECTRODERMAL  RESPONSE 
IN  THE  CAT. 

239963  03-03 
HALLUCINOGENIC  INDOLEAMINES:  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS. 

240073  03-03 
CENTRAL  ACTION  OF  NORMETANEPHRINE.  EFFECT  ON  THE  BEHAVIOR  OF 
RATS. 

240240  03-03 
ON  THE  MECHANISMS  OF  ACTION  AND  KINETICS  OF  LITHIUM. 

240740  03-03 
THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL.  (PH.D.  DISSERTATION). 

240933  03-03 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE, 

241919  03-03 
INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDROXYDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS. 

242200  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

243760  04-03 
PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS. 

244072  04-03 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY:  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04-04 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTEM 
IN  LIMBIC  FOREBRAIN. 

245115  04-03 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 

246856  04-13 
STUDIES  ON  THE  MECHANISM  OF  LITHIUM  ACTION:  PRELIMINARY 
REPORT. 

247208  04-03 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
PENTOBARBITAL:  ACTION  ON  FROG  MOTONEURONS. 

247513  04-03 


ENHANCEMENT  BY  CHLORPROMAZINE  OF  HYPERGYLCEMIC  ACTION  OF 
DIAZOXIDE. 

247715  04-15 
DIFFERENTIAL  EFFECTS  OF  ALPHA  MT  ON  ANORECTIC  AND 
STIMULATORY  ACTION  OF  AMPHETAMINES. 

247729  0402 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN. 

248286  04-03 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 

ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

248287  04-02 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 

POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
STUDIES  ON  THE  ROLE  OF  PHENETHYLAMINE  IN  METHYLAMPHETAMINE 
ACTION  MECHANISM. 

248515  04-03 
MORPHINES  PROCONVULSANT  ACTION:  IMPORTANCE  OF  ENDOGENOUS 
NOREPINEPHRINE. 

248880  04-03 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLTVSMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  04-10 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  BY 
PINEAL  METABOLITES. 

249240  04-03 
THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-03 
STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN-RELEASING 
HORMONE  (TRH)  IN  RABBITS. 

249280  04-04 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION. 

249286  04-03 
ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING-SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6. 

249676  04-04 
MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 
THERMOSTATS. 

250078  04-03 
THE  MECHANISM  OF  ACTION  OF  FENFLURAMINE. 

250936  04-03 
COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 
INCIDENCE  OF  SIDE-EFFECTS. 

252006  04-08 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS.  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS  COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04-03 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  AAALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
ACTIONS 

EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 
BENZODIAZEPINES. 

229465  01-03 
FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE  DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-04 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 
ACTIONS  OF  BENZODIAZEPINES. 

232511  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 
BENZODIAZEPINES. 

232515  01-03 
THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 
CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02-11 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 


S-5 


Subject  Index 


Psychopharmacology  Abstract! 


ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  0203 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
SYNTHESIS  AND  BIOLOGICAL  ACTIONS  OF  2-SUBSTITUTED 
QUINOLIZIDINES. 

238477  02-02 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03-03 
ACTIONS  OF  6  HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
CENTRAL  ACTIONS  OF  HALLUCINOGENIC  DRUGS. 

244071  04-12 
THE  ACTIONS  OF  SPERMIDINE  AND  SPERMINE  ON  THE  CENTRAL- 
NERVOUS-SYSTEM. 

245596  04-05 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  04-01 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC). 

249309  04-03 
CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

24931 1  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 
ON  THE  ACTIONS  OF  COMPOUNDS  RELATED  TO  DOPAMINE  AT  A 
NEUROSECRETORY  SYNAPSE 

251703  0403 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-03 
ACTIVATE 

CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF  I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  04-03 
ACTIVATING 

ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT 

237716  02  14 
COURSE  AND  RESULTS  OF  TREATMENT  WITH  THREE  ACTIVATING 
NEUROLEPTIC  DRUGS. 

244049  04-08 
ACTIVATION 

TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01-03 
IN  VIVO  ACTIVATION  OF  RAT  PINEAL  CAMP  PHOSPHODIESTERASE  BY 
ISOPROTERENOL   (UNPUBLISHED  PAPER). 

228032  01-03 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATION 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES. 

229115  01-13 
ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3- 
MONOOXYGENASE.  (UNPUBLISHED  PAPER). 

237172  02-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES 

238729  03  03 
IN  VIVO  AND  IN  VITRO  ACTIVATION  OF  SOIUBLE  TRYPTOPHAN- 
HYDROXYLASE  FROM  RAT  BRAINSTEM 

249512  0403 


ACTIVATOR 

RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-0 
ACTIVE 

REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRONh 
MARIJUANA  SMOKERS. 

229039  OM 
DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE. 

230424  01-1 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  02-1 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02-C 
EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING. 

237264  02-C 
MONOAMINE  OXIDASE  ACTIVE  SITE;  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (14C)  SELECTIVE  INHIBITORS. 

241931  03-C 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-C 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-C 
CENTRAL-NERVOUS-SYSTEM  ACTIVE  5-OXOHEXAHYDROCINNOLINES. 

248649  04-C 
BACLOFEN  (BF):  AN  UNUSUAL  CNS  ACTIVE  AGENT. 

249304  04-C 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-( 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 
AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT. 

250074  04-C 
INFLUENCE  OF  PHARMACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD-PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS. 

251414  04-( 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEAAS. 

251534  04-( 
THE  EFFECT  OF  DEI  TA9  TETRAHYDROCANNABINOL  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT. 

251979  04-( 
ACTIVITIES 

DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01 -( 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY 

233077  02-( 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE-OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK. 

237923  02-( 
ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  B 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

238503  02-( 
THE  EFFECT  OF  DL-254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS 

238846  03-( 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-( 
ACTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2)    INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR 

241372  03-1 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-1 
CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  TH 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  LOCOMOTOR  ACTIVITIES  IN 
THE  RAT. 

242205  03-( 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 
ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  04-( 


S-6 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES, 

244316  04-02 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE.  NEW  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 
EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  04-03 
ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS 

250360  04-02 
VITY 

BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01-13 
INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

226935  01-03 
OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01-04 
TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY 

227130  01-04 
THE  EFFECT  OF  DIAZEPAM  AND  TRIFLUOPERAZINE  ON  BLOOD  SUPPLY 
AND  CARDIAC  ACTIVITY. 

228553  01  03 
EVALUATION  OF  NEW  COMPOUNDS  FOR  PSYCHOTROPIC  ACTIVITY, 

229477  01-04 
CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-13 
THE  EFFECTS  OF  METIAMIDE  ON  THE  ACTIVITY  STRESS  ULCER  IN  RATS. 

230835  01-03 
DIFFERENTIAL  EFFECTS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY. 

230840  01-03 
TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  01-03 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN. 

230863  01-14 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY: 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
LATERAL  GENICULATE  MULTIPLE-UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES 

231719  0103 
BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT 

232606  02-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  02-03 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 

ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02  03 
THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY). 

233077  02  04 


IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY. 

233300  02-01 
EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED  BY 
LITHIUM  CARBONATE. 

233499  02-15 
CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-04 
EFFECTS  OF  SCOPOLAMINE  ON  HABITUATION  OF  EXPLORATORY 
ACTIVITY  IN  RATS. 

235509  02-04 
DRUG-INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT. 

235866  02-03 
AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  02-04 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02-03 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02-10 
EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS. 

236519  02-03 
THE  EFFECT  OF  CHRONIC  SELF  ADMINISTRATION  OF  D  AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE.  PART  2,  INVOLVEMENT 
OF  BRAIN  AND  5  HYDROXYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 
OF  FENFLURAMINE. 

237119  0203 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245  02-03 
EFFECTS  OF  SCOPOLAMINE,  D  AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE 

237703  02-04 
DOSE-RESPONSE  EFFECTS  OF  SCOPOLAMINE  ON  ACTIVITY  IN  AN  OPEN- 
FIELD. 

237728  0204 
MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  THE 
ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  02-03 
THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT. 

237742  02-03 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  t  )  AMPHETAMINE  ON 

LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02-04 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT. 

237780  02-04 
INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE: 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02  03 
EFFECTS  OF  METHAMPHE  FAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE  HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS   (PH  D    DISSERTATION) 

238079  02-03 
EFFECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
MODULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE  (TPH)  ACTIVITY  BY 
BRAIN  TRYPTOPHAN  (TP)  CONTENT, 

238677  03-03 
TRYPTOPHAN-HYDROXYLASE  IN  DISCRETE  NUCLEI:  COMPARISON  OF 

ACTIVITY  IN  VITRO  AND  IN  VIVO. 

238678  03-03 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 

TRYPTOPHAN  &  PREVENTED  BY  D  TRYPTOPHAN 

238698  0304 
ANTICONVULSANT  ACTIVITY  OF  NEWER  SUBSTITUTED  TRIAZOLES. 

238712  0303 


S-7 


Subject  Index 


Psychopharmacology  Abstract 


COMPARISON  OF  THYROID  RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS 

238744  03-04 
THE  REVERSAL  OF  APOMORPHINE-ELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE-HYDROXYLASE  ACTIVITY  BY 
NEUROLEPTICS, 

238758  03-03 
PURIFICATION  OF  (3H)TAURINE  OF  HIGH  SPECIFIC  ACTIVITY. 

238773  03-03 
GAMMA-ACETYLENIC-GABA  (AMIN0-4-HEX-5-YN0IC  ACID);  A  GABA- 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY. 

238781  03-04 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 
INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE-INDUCED 
LOCOMOTOR  ACTIVITY  IN  MICE. 

238842  03-04 
AGE-RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (MA)  IN  MICE. 

238847  03-04 
ANXIETY  AND  EEG  ALPHA  ACTIVITY  IN  NEUROTIC  PATIENTS. 

239022  03-10 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION. 

239086  03-03 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 
ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL  PHENOTHIAZINES. 

239662  03-03 
INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03-04 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS;  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  03-03 
EFFECTS  OF  P-CHLOROAMPHETAMINE  ON  LOCOMOTOR  ACTIVITY  AND 
BRAIN  5-HYDROXYINDOLES. 

239958  03-04 
QUIPAZINE;  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM,  MONOAMINE  OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-03 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS. 

240237  03-04 
PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FOR 
ANOREXIA  NERVOSA. 

240423  03-11 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 

AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY;  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
5-HYDROXY  L-TRYPTOPHAN-DECARBOXYLASE  ACTIVITY;  MICROASSAY 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI 

241208  03-03 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE. 

241253  03-03 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIMARY  HYPERTENSION. 

241294  03-13 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT;  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 


DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT;  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT;  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  TH 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-1 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 

ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-1 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III). 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390  03-1 
TOLERANCE  TO  THE  ACTIVITY  ENHANCING  EFFECT  OF  D-AMPHETAMINE 
(PH.D.  DISSERTATION). 

241575  03-1 
HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RA 
BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE. 

241989  03 J 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-711  IN  A  HOSPICE  ENVIRONMENT. 

242900  04- 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS;  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-1 
THE  CHEMICAL  CONTROL  OF  NEURONAL  ACTIVITY.  (UNPUBLISHED 
PAPER). 

243183  04- 
NEONATAL  HYPERTHYROIDISM;  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE 

243792  04-' 
EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 

HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04- 
THE  EFFECT  OF  SYMPATHOLYTIC  AND  SYMPATHOMIMETIC  AGENTS  ON 

ACETYLCHOLINESTERASE  AND  CHOLINESTERASE  ACTIVITY,  IN  VITRO. 

243794  04- 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 

ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04- 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY; 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04- 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVE 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-1 
MOUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELTA9- 
TETRAHYDROCANNABINOL  AND  PILOCARPINE. 

244682  04- 
FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY;  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04- 
IS  THERE  AN  INCREASE  IN  MONOAMINE-OXIDASE  ACTIVITY  IN 
DEPRESSIVE  ILLNESS?. 

245233  04- 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RA 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04- 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04- 
PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RAT! 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04-' 
THE  EFFECT  OF  ADRENALINE  ON  HUMAN  PLATELET  MAO  ACTIVITY. 

246312  04- 
CAFFEINE  AND  CHLORDIAZEPOXIDE;  EFFECTS  ON  MOTOR  ACTIVITY  IN 
THE  CHRONIC  THALAMIC  RAT. 

246388  04-1 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD 

246673  04-1 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-1 


S-8 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04-04 
MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 
GROUPS  OF  RATS. 

247207  04-04 
THE  EFFECT  OF  VARIOUS  CHLORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYLASE  ACTIVITY. 

247212  04-03 
AROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 
HIPPOCAMPUS. 

247420  04-04 
ANTICONVULSANT  ACTIVITY  OF  DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED  WITH  THREE  OTHER  DRUGS. 

248283  04-02 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMINE 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY. 

248285  04-02 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 
ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

248287  04-02 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 

EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-03 
LITHIUM  EFFECTS  UPON  COMPONENTS  OF  ACTIVITY  IN  RATS. 

248516  04-03 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 
ANALOGS  OF  FLUPHENAZINE. 

248538  04-02 
SYNTHESIS  AND  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ACTIVITY  OF 

SOME  BICYCLIC  AMIDES. 

248539  04-02 
SYNTHESIS  AND  DOPAMINERGIC  ACTIVITY  OF  ( -I-  OR-)-  (-t^)-   AND  (-)  2- 

DIPROPYLAMINO-5-HYDROXYTETRAHYDRONAPHTHALENE. 

248650  04-02 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  IN 
THE  GUINEA-PIG  INTESTINE. 

248703  04-03 
SYNTHESIS  AND  NEUROLEPTIC  ACTIVITY  OF  ISOMERIC 
THIENOBENZOTHIAZINES. 

248949  04-01 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
RAPHE  NEURONS:  DEPRESSION  OF  ACTIVITY  BY  L-5- 
HYDROXYTRYPTOPHAN. 

249078  04-03 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  IN 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121  04-08 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249)39  04-04 
EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 
NUCLEUS  RAPHE  DORSALIS. 

249249  04-03 
EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-03 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE. 

249274  04-04 
EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 

SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT. 

249278  04-04 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 

NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 

RATS. 

249291  04-03 
BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE- 

COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N  N 

DIMETHYLTRYPTAMINE  AND  5-METH0XY-N,N  DIMETHYLTRYPTAMINE. 

249317  04-05 
CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 

5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS. 

249318  04-03 


CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 
PLASAAA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04- 13 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04-04 
EFFECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04-03 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 
OR  /WAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX:  RELATION  TO 
ANALGESIC  ACTIVITY. 

250355  04-03 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
( -I- )  TRANYLCYPROMINE  IN  AN  ANIMAL  MODEL. 

250376  04-03 
CLONAZEPAM  IN  THE  TREATMENT  OF  CHOREIFORM  ACTIVITY. 

250932  04-07 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  AAAN. 

25107!  04)2 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 
MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 

DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  04-03 
ANTIDEPRESSANT  AND  ANTICONVULSANT  ACTIVITY  OF  PHENYL-4-0X0  2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED  PIPERAZINES. 

251701  04-01 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA. 

251704  04-04 
INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS. 

252027  04-03 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
ANTICHOLINERGIC  ACTIVITY  OF  ANTIPSYCHOTIC  DRUGS  IN  RELATION  TO 
THEIR  EXTRAPYRAMIDAL  EFFECTS. 

252520  04-05 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

2527)1  04-03 
INCREASED  ERYTHROCYTE  NA -t^    PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04-13 
NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AND 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  04-03 
ACTS 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE, 

248409  04-03 
ACUITY 

EFFECTS  OF  ALCOHOL  AND  MARUUANA  ON  DYNAMIC  VISUAL  ACUITY-  I 
THRESHOLD  MEASUREMENTS. 

235759  02-14 
ACUTE 

ACUTE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FOR 
ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS. 

225572  01-03 
A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROMAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES. 

226412  01-08 
ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  0) -03 


I 

I 

r 

I 


S-9 


Subject  Index 


Psychopharmacology  Abstracts 


ACUTt  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN 

226870  01-03 
ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN. 

227386  01-04 
HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG, 

227389  01-03 
DEPRESSION  AND  THE  ACUTE  SCHIZOPHRENIC  PROCESS. 

228240  01-08 
PIRACETAM  IN  A  CASE  OF  ACUTE  CEREBRAL  HYPOXEMIA:  CASUISTIC 
REPORT 

229128  01-14 
CHLORPROMAZINE  METABOLISM  AND  CLINICAL  RESPONSE  IN  ACUTE 
SCHIZOPHRENIA:  A  PRELIMINARY  REPORT 

229445  01  08 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 

CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 
LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 

COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS. 

229448  01  08 
THE  MEDICAL  PHARMACOLOGICAL  MANAGEMENT  OF  ACUTE 
PSYCHOSES 

229717  01-11 
A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIDE 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM. 

230104  01  11 
SCHEDULE-INDUCED  ORAL  NARCOTIC  SELF-ADMINISTRATION:  ACUTE 
AND  CHRONIC  EFFECTS. 

233293  02-04 
INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACUTE 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS. 

233377  02-12 
ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  EXTRAPYRAMIDAL  MOTOR 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  02-11 
PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD 

234311  02-03 
ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE 

237158  02-03 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS    -  ACUTE  MORPHINE  ADMINISTRATION. 

237736  02-03 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN. 

237922  02-03 
TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  LOXAPINE 
PARENTERALLY 

238551  02-09 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD.  TRYPTAMINE  (T),  5  HTP, 
METHOXAMINE  (M)  AND  D  AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-04 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 
AMINES 

238751  03-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03  04 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03-04 
A  DOUBLE  BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA       . 

238996  03  08 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  ME  FHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD 

239042  03-14 


ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 
POLYURIA. 

239046  03-05 
ACUTE  CONFUSIONAL  STATES. 

239607  03-17 
ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
PCHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIAAALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  03-04 
TREATMENT  OF  ACUTE  SCHIZOPHRENIA  WITH  SULPHORIDAZINE. 

240850  03-08 
INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN 
ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  03-08 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE. 
(PH.D.  DISSERTATION). 

241576  03-03 
NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
A  PRIAAATE  MODEL  OF  ACUTE  DYSTONIC  REACTION  TO  NEUROLEPTICS. 

241934  03-05 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 
INTRAVENOUS  LORAZEPAM  IN  THE  ACUTE  ANXIETY  CRISIS:  A 
PRELIMINARY  REPORT  ON  60  CASES. 

242250  03- 10 
PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES. 

242751  04-17 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  04-17 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
ACUTE  POISONING  BY  MEANS  OF  A  VETERINARY  USED  SULFONE:  A  CASE 
STUDY. 

245116  04  05 
TECHNIQUE  OF  FLUPHENAZINE-DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES 

246186  04-08 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE 

246661  04-03 
HOMOVANILLIC-ACID  AND  5HY0R0XYIND0LEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04-13 
PHENCYCLIDINE  -  STATES  OF  ACUTE  INTOXICATION  AND  FATALITIES. 

247147  04-15 
A  DOUBLE-BLIND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTE 
SCHIZOPHRENICS. 

248976  04  08 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN, 

249233  04-03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMAAA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  0403 
ACUTE  TOLERANCE  TO  BARBITURATE  IN  THE  RAT. 

250077  04-04 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETICS 
OF  (I4C)IMIPRAMINE  IN  RAT:  ACUTE  STUDY 

250655  04-03 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 


S-10 


k^OLUME  14,  SUBJECT  INDEX 


Subject  Index 


ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE. 

251989  04-04 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H  5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04-03 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT 

252519  04-03 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOHOL  WITHDRAWAL. 

252694  04-11 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04-08 
ACUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS 

253617  0409 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION;  A  CONTROLLED  STUDY. 

253684  04-11 
\DAPTATION 

CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

234797  02-09 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

243819  04-13 
ADAPTIVE 

ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 
OF  VARIOUS  PSYCHOACTIVE  DRUGS. 

234810  02-04 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR. 

243234  04-04 
\DAPTIVENESS 

ADAPTIVENESS  AND  BEHAVIOR  OF  THE  ELDERLY  SUBJECT. 

242898  04-11 
\ODICT 

CONTINGENT  NALOXONE  (N-ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01  14 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03-11 
VDDICTION 

METHYLPHENIDATE  ADDICTION  -  EFFECT  REVERSAL  IN  WITHDRAWAL. 

238862  03-15 
HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS. 

239939  03-11 
\DOICTIVE 

ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION. 

250019  04-04 
VDDICTS 

ASSISTING  MULTIPLE  DRUG  ADDICTS.  PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY 

237095  02- II 
THERAPEUTIC  ATTEMPTS  WITH  LITHIUM  IN  YOUNG  DRUG  ADDICTS. 

238988  03-11 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03  15 
^ODITIVE 

THE  FOOD  ADDITIVE  HYPOTHESIS,  LEAD,  AND  HYPERACTIVITY. 

251572  04  II 
VDDITIVES 

AN  INVESTIGATION  ON  THE  DOSE  RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
VOENINE 

ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10  2  ARYLIMINO-3  ACETYLAMINO-4  THIAZOLIDONYL  PHENOTHIAZINES. 

239662  03-03 


ADENOSINE 

REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01-03 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02-10 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
EVIDENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 
TRIPHOSPHATASES  FROM  BRAIN, 

239962  03-03 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-OOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 
CENTRAL  GAMAAA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04-03 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
ADENYLATE-CYCLASE 

LSD  AND  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  VARIOUS  RAT 
BRAIN  AREAS. 

226406  01-03 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  AAAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01-03 
INTERACTIONS  OF  OPIATE  RECEPTORS  WITH  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

232960  02-03 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR 

ALTERATIONS  IN  3H  ALPRENOLOL  BINDING  AND  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

237170  02-03 
OPIATE  RECEPTORS  AS  REGULATORS  OF  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER), 

237175  02-03 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE  CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN, 

237241  02-03 
OPIATE  RECEPTORS  AND  ADENYLATE-CYCLASE  IN  NEUROBLASTOMA  X 
GLIOMA  CELL  LINES,  (UNPUBLISHED  PAPER) 

238571  02-03 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA, 

238739  03-03 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03-03 
LITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 
IN  HUMANS 

239728  03-09 


I 

% 

\ 

•0 

2 
t 


S-ll 


Subject  Index 


Psychopharmacology  Abstracts 


COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 
ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON. 

241347  03-03 
LIMITING  FACTORS  IN  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE. 

250359  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
ADENYICYCLASE 

CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE. 

249294  0403 
ADH 

DOSE-RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 

SECRETION  OF  ADH:  EFFECTS  OF  CLOFIBRATE  AND  CARBAMAZEPINE. 

232638  02-13 
ADJUNCT 

USE  OF  BETA-BLOCKERS  AS  AN  ADJUNCT  IN  BEHAVIOURAL  TECHNIQUES. 

251158  04-10 
ADJUSTMENT 

SIMPLIFIED  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01-16 
ADMINISTERED 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE. 

226400  01-03 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 
CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 
CONDITIONED  REFLEX  IN  THE  CAT. 

239275  03-04 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03-04 
DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN 
ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  03-08 
TOLERANCE  TO  CENTRALLY  ADMINISTERED  PHENOBARBITAL. 

241346  03-03 
STUDY  ON  HEAD-TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE. 

241380  03-04 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-04 
BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE- 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
DIMETHYLTRYPTAMINE  AND  5-METH0XY-N,N  DIMETHYLTRYPTAMINE. 

249317  04-05 
ADMINISTERING 

PROBLEMS  INVOLVED  IN  ADMINISTERING  L-DOPA. 

239695  03-15 
ADMINISTRATION 

BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01-04 
BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY. 

226737  01-13 
INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 


PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01-03 
ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOAAATOSTATIN. 

227386  01-04 
BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION. 

228224  01-08 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  DELTA9-TRANS- 
TETRAHYDROCANNABINOL  (DELTA9THC)  IN  GUINEA-PIGS. 

229033  01-03 
A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS. 

229458  01-11 
BARBITAL-INDUCED  CROSS-TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION. 

231070  01-03 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING.  (UNPUBLISHED 
PAPER). 

231771  01-04 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORAMNCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02-14 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN. 

233970  02-03 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D- 
AMPHETAMINE  ADMINISTRATION. 

234809  02-04 
ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 

OF  VARIOUS  PSYCHOACTIVE  DRUGS. 

234810  02-04 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 

PSYCHIATRIC  HOSPITAL. 

235545  02-17 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION    - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER). 

237169  02-04 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  02-04 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASAAA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS  -  ACUTE  MORPHINE  ADMINISTRATION. 

237736  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS  -  CHRONIC  MORPHINE  ADMINISTRATION. 

237737  02-03 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 

ACTION  OF  DIAZEPAM. 

238531  02-13 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 
AMINES. 

238751  03-03 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT. 

238755  03-04 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 

ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03-04 


S-12 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN 

238790  03-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 

BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAAAATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
6HYDR0XYD0PAMINE  (60HDA)  ADMINISTRATION  TO  NEONATAL  RATS 

FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03-03 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03-04 
AGE-RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
EFFECT  OF  LONG-LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS. 

239992  03-14 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  03-04 
LONG-TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS. 

241300  03-04 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE. 

241338  03-03 
EFFECTS  OF  LONG-TERM  ADMINISTRATION  OF  LEVOMETHIOMEPRAZINE 
TO  RATS. 

241381  03-03 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES. 

241416  03-03 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE 
(PH.D.  DISSERTATION). 

241576  03-03 
TICS  FOLLOWING  METHYLPHENIDATE  ADMINISTRATION:  A  REPORT  OF 
20  CASES. 

241990  03-15 
BIOAVAILABILITY  OF  TWO  CARBAMAZEPINE  PREPARATIONS  DURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS. 

242212  03-11 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS. 

242732  03-04 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-04 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS. 

244456  04-04 
INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARAAACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIAL 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR. 

244899  04-04 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION, 

245789  04-15 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION 

246387  04-13 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

246891  04-11 
GIC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 


SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D-AMPHETAMINE 
ADMINISTRATION. 

247683  04-04 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRONIC 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE. 

247777  04-03 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE.  I.  EFFECT  ON  THE 
MORPHINE  TOLERANCE. 

249030  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  II,  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE. 

249031  04-03 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION, 

249032  04-04 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 

ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION.  AND 
DURATION  OF  TREATMENT, 

249223  04-03 
CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS 

249232  04-15 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION. 

249268  04  03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-03 
OPIATE  RECEPTOR  BINDING  -  ENHANCEMENT  BY  OPIATE 
ADMINISTRATION  IN  VIVO. 

250378  04-03 
ABSORPTION  OF  LITHIUM  FOLLOWING  ADMINISTRATION  OF  SLOW- 
RELEASE  AND  CONVENTIONAL  PREPARATIONS. 

250725  04-13 
ANATOMICAL  AND  BEHAVIORAL  EFFECTS  OF  COLCHICINE 
ADMINISTRATION  TO  RATS  LATE  IN  UTERO. 

252148  04-05 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-03 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 

AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS. 

253111  04-04 
GAMMA-AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION. 

253392  04-04 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5  HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AND 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  04  03 


S 

i 

> 

t 

I 

■c 

2 
ffj 
t 


S-13 


Subject  index 


Psychopharmacology  Abstracts 


ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  IF  LSD 

253700  04-03 
ADMINISTRATIVE 

ADMINISTRATIVE  AND  JUDICIAL  PROBLEMS  IN  PSYCHOPHARMACOLOGY. 

237121  02-17 
ADMIHED 

THE  IMMEDIATE  EFFECTS  OF  CHLORPROMAZINE  IN  NEWLY  ADMITTED 
SCHIZOPHRENIC  PATIENTS 

234700  02-08 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS 

237828  02-08 
CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRENIC 
PATIENTS:  A  PILOT  STUDY 

251828  04-08 
ADOLESCENCE 

PRESENT  ASPECTS  OF  PSYCHOPHARAAACOTHERAPY  IN  CHILDHOOD  AND 
ADOLESCENCE. 

236150  02-17 
ADOLESCENT 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  {PH.D 
DISSERTATION). 

228726  01-11 
A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS. 

247483  04-08 
ADOLESCENTS 

STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04- 11 
ADRENAL 

REGULATION  OF  5-HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
BRAIN  BY  ADRENAL  GLUCOCORTICOIDS 

226401  01-03 
INTERACTIONS  OF  DELTA9-TETRAHYDR0CANNABIN0L,  ADRENAL 
STEROIDS,  AND  ETHANOL. 

226763  01-03 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION. 

236801  02-13 
THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAT 
ADRENAL  MEDULLA. 

243779  04-03 
EFFECTS  OF  RESERPINE  ON  MATURING  ADRENAL  MEDULLA. 

243796  04-03 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-03 
ADRENALECTOMIZED 

EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS. 

251990  04-04 
ADRENALINE 

THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO- 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01-04 
THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 
ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS. 

227635  01-03 
LITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 
IN  HUMANS. 

239728  03-09 
THE  EFFECT  OF  ADRENALINE  ON  HUMAN  PLATELET  MAO  ACTIVITY. 

246312  04  13 
ADRENERGIC 

INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF 
STIMULATION  BEHAVIOR  IN  RATS. 

226943  01-04 
THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01-03 


THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-03 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313  03-03 
THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS.  4TH 
REPORT.  COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

241919  03-03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

243760  04-03 
INGESTION  IN  THE  SATIATED  RAT;  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04  03 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE. 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE. 

249257  04-03 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT. 

251820  04-03 
ADRENO 

PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS 

236828  02-04 
ADRENOMIMETIC 

PHARMACOLOGICAL  ANALYSIS  OF  SOME  ADRENOMIMETIC  EFFECTS  OF 
SEROTONIN. 

241982  03-05 
ADULT 

BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE. 

241414  03-03 


S-14 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA, 

244200  04-03 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS 

246970  04-13 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHY0R0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT 

249785  04-04 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04-04 
TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04-02 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  W/ITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE. 

251981  04-04 
DUITS 

COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
CHANGES  IN  PSYCHOACTIVE  DRUG  USE  AMONG  ADULTS  IN 
METROPOLITAN  TORONTO   -  1971-1974. 

236046  02- 1  7 
CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS. 

237900  02-10 
DVANTAGES 

ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 
VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES. 

244188  04-08 
DVERSE 

ADVERSE  REACTIONS  ASSOCIATED  WITH  MOOD-ALTERING  DRUGS. 

231995  01  15 
INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACUTE 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS. 

233377  02-12 
METHAQUALONE  WITH  PSYCHOTROPIC  DRUGS:  ADVERSE  INTERACTION. 

253531  04  15 
DViCE 

DEPARTMENT  SEEKS  ADVICE  ON  SAFETY  OF  PSYCHOTROPICS. 

251232  04- 17 
EROSOl 

AN  INHALATION  AEROSOL  OF  DELTA9-TETRAHYDR0CANNABIN0L. 

237787  02-16 
ETHIOPS 

BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOPS).  AETHIOPS). 

230869  01-04 
FFECT 

THE  EFFECTS  OF  LSD  ON  THE  EXPRESSION  OF  AFFECT  IN 
PSYCHOTHERAPY  (PH.D.  DISSERTATION). 

231480  01-12 
6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03-03 
EVIDENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 
TRIPHOSPHATASES  FROM  BRAIN. 

239962  03-03 
ANTIDEPRESSANT  DRUGS  AFFECT  DOPAMINE  UPTAKE. 

247021  04  03 
FFECTIVE 

THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS   LONG 
TERM  EFFECTS  AND  SIDE-EFFECTS. 

226612  01-09 
PRECLINICAL  STUDIES  OF  RUBIDIUM  IN  AFFECTIVE  ILLNESS. 

229495  01-02 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS 

230763  01-13 
CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02  14 


ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  02-09 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02-09 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 
DISORDERS. 

236303  02-17 
THE  COURSE  OF  TREATMENT  IN  SCHIZOPHRENIA  AS  RELATED  TO  THE 
APPEARANCE  OF  AFFECTIVE  DISORDERS. 

236421  02-08 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIAAARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
PROPHYLAXIS  OF  AFFECTIVE  DISORDERS:  CURRENT  STATUS  OF 
KNOWLEDGE. 

239937  03-09 
BIOGENIC  AMINES  AND  AFFECTIVE  DISORDERS. 

241937  03-09 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES. 

243985  04-09 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
LITHIUM  PROPHYLAXIS  IN  AFFECTIVE  DISORDERS. 

245416  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
AFFERENT 

EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS;  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
AFFINITY 

HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 
INNERVATION  IN  RAT  BRAIN. 

226739  01-03 
BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  01-03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN. 

238715  03-03 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE  IN 
MOUSE  BRAIN. 

238765  03-03 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
AFTER-DISCHARGE 

INTRACELLUIAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA  PIG  NODOSE  GANGLION. 

232333  01-03 
EFFECTS  OF  ANTIDEPRESSANT  DRUGS  ON  AMYGDALOID  AFTER- 
DISCHARGE  IN  RATS, 

24/039  04-03 
AFTER-DISCHARGES 

LATERAL  GENICULATE  MULTIPLE-UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES.     . 

231719  01-03 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES. 

239858  03-03 
AGAROSE 

ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID.  ACID. 

233278  02-01 


e 

9 
I 

% 

\ 

•fl 

t 


AGE 


227750  01-11 


MEDICINES  AND  MENTAL-ILLNESS  IN  OLD  AGE. 

DRUGS  FOR  MENTAL  DISORDERS  OF  OLD  AGE, 

229315  01-11 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02-04 


S-15 


Subject  Index 

EFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCED  AMNESIA  IN  MICE. 

245614  04-02 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04-13 
DEPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04-03 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATION 
IN  RATS. 

251409  04-04 
AN  OVERVIEW  OF  PSYCHOPHARMACOLOGY  OF  OLD  AGE. 

253062  04-17 
AGE-RELATED 

AGE-RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
AGED 

A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS. 

229458  01  11 
CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-11 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3- 
CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  04-11 
AGES 

CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01-04 

KINETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  RATS 
OF  DIFFERENT  AGES, 

234316  02-03 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES-  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
AGGRESSION 

PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL. 

227132  01-04 
METHADONE  INDUCED  BEHAVIORAL  CHANGES:  CIRCULAR  MOVEMENTS 
AGGRESSION,  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
DRUGS,  AGGRESSION,  AND  NEUROCHEMISTRY 

229488  01-04 
TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENSORY 
DEPRIVATION. 

233418  02-03 
EFFECTS  OF  HASHISH  ON  ISOLATION  INDUCED  AGGRESSION  IN  WILD 
MICE 

237714  02-04 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT    EFFECTS  OF 
PHYSOSTIGMINE. 

239829  03-04 
APOMORPHINE-INDUCED  AGGRESSION:  AN  EVALUATION  OF  POSSIBLE 
SENSITIZING  FACTORS  IN  THE  RAT. 

248008  04-04 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 
TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04-02 
EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  04-06 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS), 

253485  04-04 
AGGRESSIVE 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PH  D 
DISSERTATION). 

228726  01-11 
DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM), 

230865  01  04 
INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS 

230878  01-04 


Psychopharmacology  Abstracts 


EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS. 

236371  02-04 
EFFECTS  OF  SOME  PSYCHOTROPIC  DRUGS  ON  AGGRESSIVE  BEHAVIOR  IN 
RATS. 

238754  03-04 
DEPRESSED  5-HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03-13 
AMANTADINE:  AGGRESSIVE  EFFECT;  EFFECT  ON  APOMORPHINE-INDUCED 
AGGRESSIVITY  IN  THE  RAT. 

241227  03-04 
THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 
ACTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  04-04 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEN 
AND  OLFACTORY  STIMULI. 

245406  04-04 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
AGGRESSIVITY 

CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY. 

238673  03-03 
AMANTADINE:  AGGRESSIVE  EFFECT,  EFFECT  ON  APOMORPHINE-INDUCED 
AGGRESSIVITY  IN  THE  RAT. 

241227  03-04 
AGING 

EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT. 

240642  03-03 
CHLORPROAAAZINE,  CATECHOLAMINES  AND  AGING  IN  MICE. 

247587  04-02 
EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 

UTERI  OF  AGING  RATS, 

247588  04-03 
AGITATION 

ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
AGONIST 

STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY. 

233300  0201 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  03-03 
METHYLPHENIDATE  AS  A  CHOLINERGIC  AGONIST:  FURTHER 
OBSERVATIONS. 

238708  03-03 
CF-25-397,  DIDEHYDR0-METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE,  A 
NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST. 

241927  03-04 
THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSD  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  04-03 
LSD  AS  AN  AGONIST  AT  MESOLIMBIC  DOPAMINE  RECEPTORS. 

249680  04-04 
AGONISTS 

EFFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  02-04 
BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS. 

233973  02-03 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 


S-16 


UME  14,  SUBJECT  INDEX 


Subject  Index 


OMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  0303 
IDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS. 

239977  03-03 
EINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  04-04 
iTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04-04 
HE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04-03 
lORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE:  INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS. 

250079  04-04 
HE  EFFECT  OF  CARBON  DISULFIDE  ON  THE  STEREOTYPIC  EFFECT  OF 
DOPAMINE  AGONISTS. 

250090  04-04 
^FECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
HE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
■FECTS  OF  ALPHA-ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE-  AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  04-03 
APHOBICS 

(POSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION. 

250727  04-10 
277 

LOT  OPEN-LABEL  STUDY  OF  LENPERONE  (AHR-2277),  A 
BUTYROPHENONE,  IN  ANXIETY. 

241278  03-10 

ILECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-03 
SIA 

ODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE. 

248289  04-04 

roN 

;UROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE. 

238516  02-11 
>5 
'JTIPSYCHOTIC  EFFECTS  OF  AL-1965. 


251720  04-08 


IE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROMAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  01-05 
lANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  03-03 
UN 

lANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY, 

235629  02-08 
.CTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

239684  03-13 
NDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUMAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN 

244131  04-13 
NDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04-03 
TERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    ■  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
TERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN      II.  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 


AlCOHOL 

INTERACTIONS  OF  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 

BLOOD  VESSELS. 

229474  01-03 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 

FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL,  ON 

PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING. 

229907  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  I.  THEORETICAL 

CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01  17 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  II.  FIVE 
EXPERIMENTS. 

232518  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  Ill,  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAAAATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORAAANCE;  APPLICATION  OF 
MATHEAAATICAL  MODELS, 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAAAATE  IN  THE  BLOOD. 

232520  01-13 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAAAATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  V.  SUMMARY 
AND  CONCLUSIONS 

232521  01  14 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 

PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02-14 
EFFECTS  OF  ALCOHOL  AND  AAARIJUANA  ON  DYNAMIC  VISUAL  ACUITY:  I. 
THRESHOLD  MEASUREMENTS, 

235759  02-14 
PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL. 

237123  02-13 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03  14 
REDUCTION  OF  ALCOHOL  SELECTION  BY  PARGYLINE  IN  MICE 

241225  03  04 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 
INTERACTION  OF  ALCOHOL  AND  BENZODIAZEPINE  HYPNOTICS. 

242947  04  15 
THE  INTERACTION  BETWEEN  DRUGS,  ALCOHOL  AND  DRIVING  AN 
AUTOMOBILE. 

244453  04-15 
SALSOLINOL  DIFFERENTIALLY  AFFECTS  MICE  SELECTED  FOR  SENSITIVITY 
TO  ALCOHOL. 

244680  04-04 
THE  MORNING  AFTER:  RESIDUAL  EEC  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04-13 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04-04 
DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04  13 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
COMPARISON  BETWEEN  INTRAVENOUS  AND  INTRAGASTRIC  ALCOHOL 
SELF-ADMINISTRATION. 

250021  04-04 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

250111  04-04 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOliOL  WITHDRAWAL 

252694  04-11 
ALCOHOLIC 

TREATMENT  OF  ALCOHOLIC  METHADONE  MAINTENANCE  PATIENTS  WITH 
DISULFIRAM 

237624  02  11 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE.  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03  15 


C9 


£ 

0 

I 

2 


S-17 


Subject  Index 


Psychopharmacology  Abstract) 


PROPRANOLOL  EFFECT  ON  TREMOR  IN  ALCOHOLIC  WITHDRAWAL. 

250779  04-1) 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOIIC  PATIENTS  AFTER  WITHDRAWAL 

251718  04-11 
RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY.  NOT  JUST 
TASTED 

252859  04  17 
ALCOHOLICS 

PLASMA  LEVELS  OF  CHLORPROTHIXENE  IN  ALCOHOLICS. 

226413  01-11 
AN  EXPERIMENTAL  THERAPY  AND  RE-EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE.  (PH  D.  DISSERTATION). 

228750  01-11 
DRUG  TREATMENT  IN  A  REHABILITATION  CENTER  FOR  CHRONIC 
ALCOHOLICS. 

228908  01  11 
EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE  BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  01-11 
TREATMENT  OF  DEPRESSION  IN  ALCOHOLICS. 

245521  04-09 
ALCOHOLISM 

A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIDE 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM. 

230104  01-11 
EVALUATION  OF  DISULFIRAM  TREATMENT  OF  CHRONIC  ALCOHOLISM. 

237026  02-11 
ALCOHOLISM:  A  GENERAL  HOSPITAL  MFK<;  thf  THALLENGE. 

244136  04-11 
ALCOHOLS 

SOLUBILITY  OF  STRAIGHT-CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT-CHAIN  ALCOHOLS. 

238487  02-01 
ALDEHYDES 

EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
ALDOSTERONE 

EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 
AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTQMIZED  RATS. 

251990  04-04 
ALIMEMAZIN 

STUDIES  ON  SLEEP  EFFECTS  OF  ALIMEMAZIN  (THERALENE) 

240710  03-11 
ALIMENTARY 

INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARMACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIAL 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR, 

244899  04-04 
ALKALI 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR;  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS 

237098  02-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II    INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  04-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS 

248957  04-03 
ALKALOIDS 

INTRACELLULAR  RECORDING  OF  AFTER  DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION. 

232333  01-03 
NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 
OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  04-03 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN 

248286  04-03 
APORPHINES  16  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 

ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS  ACCUMBENS. 

248287  04-02 

ALKYL 

SOLUBILITY  OF  STRAIGHT  CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT-CHAIN  ALCOHOLS. 

238487  02-01 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 
SUBSTITUTION  IN  SULFUR  AND  CAR80CYCLIC  ANALOGS 

248652  04-02 


ALKYLATING 

IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  Wt2099. 

238686  03-0 
ALLEVIATING 

ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS;  A  DOUBLE-BUND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-1 
ALLOSTERIC 

TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  OK 
ALPHA-AORENERGIC 

POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848  01 -C 
DIFFERENTIAL  BLOCKADE  OF  ALPHA-ADRENERGIC  RECEPTORS  BY 
CHLORPROMAZINE. 

238672  03-C 

ALPHA-ADRENOCEPTOR 

EFFECTS  OF  ALPHA-ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE-  AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  04-( 
ALPHA-ADRENOCEPTORS 

EFFECTS  OF  ALPHA-ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE-  AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  04-( 
ALPHA-ADRENORECEPTOR 

NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMEN 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-( 

ALPHA-ADRENORECEPTORS 

DIFFERENT  Al  PHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-1 

ALPHA-BUNGAROTOXIN 

ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE. 

244203  04-1 
ALPHA-DIMETHYL-M-TRYAMINE 

EVALUATION  OF  THE  ANTINOCICEPTIVE  EFFECTS  OF  4,ALPHA-DIMETHYt 
M-TRYAMINE  {H77-77)  IN  THE  RAT. 

252026  04-1 
ALPHA-METHYL 

THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINOACIOS  C 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-1 
ALPHA-METHYL-DOPA 

THE  INTERACTION  BETWEEN  ALPHA-METHYL-DOPA  AND  TRICYCLIC 
ANTIDEPRESSANTS. 

230819  01-1 
EFFECTS  OF  EARLY  POSTNATAL  ALPHA-METHYL-DOPA  TREATMENT  ON 
BEHAVIOR  IN  THE  RAT. 

245304  04J 
ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING-SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6. 

249676  04-1 
AlPHA-METHYL-M-TYROSINE 

REGIONAL  ROLE  OF  CATECHOLAMINES  IN  ALPHA-METHYL-M-TYROSINE 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROUSAL. 

234067  02j 
STUDIES  ON  THE  MECHANISM  OF  DEPLETION  OF  STRIATAL  DOPAMINE 
BY  ALPHA  METHYL-M-TYROSINE. 

237873  02-1 
AlPHA-METHYL-P-TYROSINE 

MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 
INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P-TYROSIN 
ON  SCHEDULE-CONTROLLED  PERFORMANCE  IN  RATS. 

238844  03- 
CATECHOLAMINES  IN  BRAIN  ISCHEMIA  -  EFFECTS  OF  ALPHA-METHYL-F 
TYROSINE  AND  PARGYLINE. 

239577  03- 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDROXYDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS. 

242200  03- 
ENHANCEMENT  OF  RESERPINEELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-P-TYROSINE. 

249002  04- 
EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04- 


S-18 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT;  EFFECTS  OF  THE  INJECTION  OF  P  CHLOROPHENYLALANINE 
AND  OF  ALPHA-METHYLP  TYROSINE. 

250982  04-04 
LPHA-METHYITYROSINE 

MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  01-04 
ATTENUATION  BY  ALPHA-METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 
CONDITIONED  TASTE  AVERSION  IN  RATS 

237713  02-04 
LPHA-RECEPTOR 

EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX. 

251394  04-03 
LPRENOLOL 

TRANQUILIZATION  EFFECT  OF  BETA-BLOCKADE  ALPRENOLOL;  A  CLINICAL 
STUDY. 

228311  01-11 
ITERATION 

ALTERATION  OF  MEMBRANE  INTEGRITY  OF  DELTAl- 
TETRAHYDROCANNABINOL. 

229035  01-03 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
BARBITAL  ALTERATION  OF  CENTRAL-NERVOUS-SYSTEM  SENSITIVITY  TO 

HEXOBARBITAL  IN  THE  RAT. 

244688  04-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  Of 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
ALTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 
(LIORESAL  (R)). 

251398  04-03 
ITERATIONS 

5-HYDROXYTRYPTAMINE  14C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 
HYPNOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS. 

228094  01-14 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN. 

233970  02-03 
EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 

METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
LIPIOOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 

AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR: 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER) 

237170  02-03 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATUM 
AND  HYPOTHALAMUS  SLICES. 

238714  03  03 
MARUUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03-04 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWING  6- 
HYDROXYDOPAMINE  LESIONS. 

238735  03-03 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTAS 
TETRAHYDROCANNABINOL  (DELTA8-THC). 

241926  03-03 


NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE. 

243792  04-03 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

246152  04-03 
DRUG-INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT. 

249250  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
ALTERED 

ALTERED  5-HT  METABOLISM  WITH  CLONAZEPAM,  DIAZEPAM  AND 
DIPHENYLHYDANTOIN. 

230855  01-03 
ALTERED  HYPOTHERMIC  RESPONSIVENESS  TO  (  t  )  AMPHETAMINE. 

239685  03-03 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYOROCANNABINOL 

240645  03-14 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION. 

246996  04-03 
ALTERED  PATTERN  OF  DOPA  METABOLISM. 

251185  04-03 
ALTERING 

VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE.  (PH.D.  DISSERTATION). 

241689  03-04 
ALTERNATE 

ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  01  04 
ALTERNATION 

EFFECTS  OF  SCOPOLAMINE,  D  AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  02-04 
ALTERS 

DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS. 

238741  03  03 
ALUMINUM 

INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION. 

237116  02-13 
AAAANTADINE 

PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01   14 
AMANTADINE:  AGGRESSIVE  EFFECT;  EFFECT  ON  APOMORPHINE-INDUCED 
AGGRESSIVITY  IN  THE  RAT. 

241227  03-04 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AAAANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
A  CONTROLLED  TRIAL  OF  AMANTADINE  IN  DRUG-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

244701  04  15 
AMANTADINE  DECREASES  D-AMPHETAMINE  STIMULATION  AND 
INCREASES  D-AMPHETAMINE  ANOREXIA  IN  MICE. 

249459  04  03 
AAABIENT 

INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02-03 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN. 

242736  03  03 
AMBLYOPIA 

BICUCULLINE  REVERSAL  OF  DEPRIVATION  AMBLYOPIA  IN  THE  CAT 

249983  04  03 
AMBULATORY 

AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS. 

228225  01-08 
ON  THE  EFFECTIVENESS  OF  PSYCHIATRIC  AMBULATORY  STATIONS 

234289  02-11 


5 


a 
2 

03 
I 

i 


S-19 


Subject  Index 


Psychopharmacology  Abstract! 


AMFONEIIC-ACIO 

AMFONELICACID  FACILITATION  OF  IMPULSE-INDUCED  STRIATAL 
DOPAMINE  RELEASE. 

238730  03-03 
AMIDES 

SYNTHESIS  AND  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ACTIVITY  OF 
SOME  BICYCLIC  AMIDES. 

248539  04-02 
AMINE 

INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  {LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01-03 
CHEMISTRY  AND  PHARMACOLOGY  OF  BIOGENIC  AMINE  UPTAKE. 

229478  01-03 
BIOGENIC  AMINE  EFFECTS  ON  CNS  PHOSPHOLIPID  METABOLISM. 

229482  01-03 
THE  EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  ON  BRAIN  AMINE 
CONCENTRATION  AND  TURNOVER  IN  WHOLE  RAT  BRAIN  AND  IN 
VARIOUS  REGIONS  OF  THE  BRAIN. 

230856  01-03 
THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-03 
METABOLIC  0-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  1  2,5 
DIMETHOXY-4-METHYLPHENYL  2  AMINOPROPANE. 

236520  02-03 
COMPARATIVE  PHARMACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  ON 
BIOGENIC  AMINE  SYSTEMS. 

238728  03-03 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
EFFECTS  OF  TRAZODONE  ON  BEHAVIOR  AND  BRAIN  AMINE  CONTENT  OF 
MICE. 

247485  04-04 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 
FOLLOWING  BRAIN  AMINE  DEPLETION. 

249138  04-04 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
EFFECTS  OF  MAZINDOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

252201  04-03 
AMINERGIC 

THE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS. 

248159  04-03 
AMINES 

BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
ANALYSIS  OF  DRUGS  AND  PSYCHOACTIVE  PHENOLIC  AMINES. 

229486  01-03 
THE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457  01-03 
INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS. 

230878  01-04 
BEHAVIORAL  EFFECTS  OF  DIBUTYRYL-CYCLIC-AMP  AND  BIOGENIC 
AMINES  IN  RATS. 

232484  01-04 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARIJUANA  ON  EEG 
PATTERNS  IN  CATS. 

235564  02-03 
BIOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO, 

237755  02-04 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 
AMINES, 

238751  03-03 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 
BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 


STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (II).  RELATIONSHIP 
BETWEEN  EMOTIONALITY  AND  DEFECATION. 

241371  03-0. 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AMINE: 
WITH  PSYCHOTROPIC  DRUGS. 

241378  03-0 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGK 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-0 
BIOGENIC  AMINES  AND  AFFECTIVE  DISORDERS. 

241937  03-0 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAII 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-0 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246661  04-C 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE. 

246662  04-0 
D-AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENK 

AMINES  IN  SYNAPTOSOMES. 

246665  04-C 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-C 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04-C 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-C 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251 130  04-C 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS. 

251392  04-C 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-C 
AMINO 

NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPOR 
MECHANISMS  IN  TISSUES. 

241298  03-C 
INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE- 
OXIDASE  AND  L  AROMATIC  AMINO  ACID  DECARBOXYLASE, 

245647  04-1 
AMINO-ACIO 

COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
A1.0N0AMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-( 
THE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 
AND  MONOAMINE  SYNTHESIS. 

241472  03-1 
AMINO-ACIDS 

SERUM  AMINO-ACIDS  AND  BRAIN  TRYPTOPHAN  UPTAKE. 

227712  01-( 
THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS  0 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS 

231009  01-( 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINE, 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  TH 
RAT  SPINAL  CORD. 

235863  02-( 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-( 
ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMI 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-( 
INJECTIONS  OF  AMINO-ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASI 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03-( 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 
AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPU: 
STRIATUM, 

241206  03-( 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME.  Ill: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 


S-20 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES- 

244692  04-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
V1INO-4-HEX-5-ENOIC-ACID 

A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL-GABA  (AMINO-4-HEX-5-ENOIC-ACID)  AND  GAMAAA-ACETYLENIC- 
GABA  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03-03 
MINO-4-HEX-S-YNOIC-ACID 

GAMMA-ACETYLENIC-GABA  (AMIN0-4-HEX-5-YN0IC-ACID):  A  GABA- 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY. 

238781  03-04 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 

INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL-GABA  (AMIN0-4-HEX-5-EN0IC-ACID)  AND  GAMAAA-ACETYLENIC- 
GABA  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03-03 
MINOPHYLLINE 

L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANTAGONISTIC  INTERACTION 
WITH  ETHANOL  IN  HUMANS. 

238748  03-13 
MINOPROPANE 

METABOLIC  0-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  1  2,5 
DIMETHOXY-4-METHYLPHENYL  2  AMINOPROPANE. 

236520  02-03 
MINOPYRINE 

ON  THE  MECHANISMS  OF  ACTION  OF  AMINOPYRINE. 

228552  01-03 
VtlNOTRANSFERASE 

THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

25271 1  04-03 
VHTRIPTYUNE 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 
AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS. 

228225  01-08 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  02-11 
APPARENT  PHARMACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901  02-13 
BIOTRANSFORMATION  OF  AMITRIPTYLINE  IN  THE  DOG. 

238684  03-03 
A  DOUBLE-BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS. 

238981  03-10 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS. 

239818  03-10 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  03-15 
DECOMPOSITION  OF  AMITRIPTYLINE  HYDROCHLORIDE  IN  AQUEOUS 
SOLUTION:  IDENTIFICATION  OF  DECOMPOSITION  PRODUCTS. 

246317  04-01 
EFFECT  OF  FENFLURAMINE  ON  STEADY-STATE  PLASMA  LEVELS  OF 
AMITRIPTYLINE  (ABSTRACT). 

250943  04-07 
MNESIA 

CYCLOHEXIMIDE-INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY  IN 
RATS. 

242742  03-04 
EFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCED  AMNESIA  IN  MICE. 

245614  04-02 
VtNESIC 

AN  AMNESIC  EFFECT  OF  BENZODIAZEPINES  IN  RATS'. 

251216  04-04 
MOBARBITAl 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04-15 


MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  04-03 
AMOBARBITAL-INDUCED 

COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
AMOXAPINE 

THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS. 

237696  02-14 
AMP 

ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMIC 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS.  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
AMPHETAMINE 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORAMNCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPUS- 
STRIATUM. 

226937  01-04 
SCOPOLAMINE  AND  AMPHETAMINE  EFFECTS  ON  DISCRIMINATION: 
INTERACTION  WITH  STIMULUS  CONTROL. 

227131  01-04 
HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 

227389  01-03 
STUDIES  ON  THE  CNS  AVAILABILITY  OF  AMPHETAMINE  FROM 
AMPHETAMINIL. 

229041  01-03 
THE  MECHANISM  OF  ACTION  OF  AMPHETAMINE  IN  BRAIN. 

229491  01-03 
ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-03 
EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01-04 
COCAINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
METABOLISM  IN  VIVO. 

230834  01-03 
EFFECTS  OF  PRIOR  EXPERIENCE  ON  DIFFERENTIAL  LEARNING  UNDER 
AMPHETAMINE. 

230868  01-04 
A  COMPARISON  OF  FENFLURAMINE  AND  AMPHETAMINE  IN  MAN. 

23131901-13 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  P-CHLOROAMPHETAMINE 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  02-03 
BEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS. 

233965  02-03 
DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA: 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS. 

233967  02-08 
KINETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  RATS 
OF  DIFFERENT  AGES. 

234316  02-03 
EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS. 

236371  02-04 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 

DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02-04 


i 


S-21 


Subject  Index 


Psychopharmacoiogy  Abstract 


BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  A/WT  AND  (  t  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  ANALYSIS  OF 

AMPHETAMINE  AND  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  IN 
RATS, 

237718  02-04 
EFFECT  OF  AMPHETAMINE  AND  FENFLURAMINE  ON  BRAIN 
NORADRENALINE  AND  M0PEG-S04, 

237740  02-03 
ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 
STRIATAL  LESIONS. 

237777  02-03 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  t  )  AMPHETAMINE  ON 

LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES 

237778  02-04 
IN  VITRO  METABOLIC  STUDIES  USING  THE  METABONATES  OF 

AMPHETAMINE,  2  NITROSO-I-PHENYLPROPANE  AND 
BENZYLMETHYLKETOXIME 

237980  02-01 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS   (PH.D.  DISSERTATION). 

238077  02-03 
AMPHETAMINE  TACHYPHYLAXIS  IN  THE  PITHED  GUINEA-PIG. 

23831  5  02-03 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
N-HYDROXYAMPHETAMINE:  A  MAJOR  METABOLITE  OF  AMPHETAMINE  IN 
RABBIT  LIVER  EXTRACT. 

238682  03-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 

MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  03-06 
COMPARATIVE  PHARMACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  ON 

BIOGENIC  AMINE  SYSTEMS. 

238728  03  03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03  04 
THE  EFFECTS  OF  ASCORBIC-ACID  (AA)  PRETREATMENT  ON 
AMPHETAMINE  (A)  EXCRETION  IN  MAN. 

238797  03-13 
DOSE  RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME) 

238825  03-03 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 

238843  03-04 
AGE  RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
AMPHETAMINE  TOXICITY  IN  TEMPERATURE  ACCLIMATISED  MICE 

239091  03-05 
ALTERED  HYPOTHERMIC  RESPONSIVENESS  TO  (  i  )  AMPHETAMINE. 

239685  03-03 
AMPHETAMINE  AND  THE  REWARD  SYSTEM:  EVIDENCE  FOR  TOLERANCE 
AND  POST-DRUG  DEPRESSION 

239850  03  04 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  i  ) 
AMPHETAMINE  AND  (  i  OR  )  P-CHLOROAMPHETAMINE 

239976  03-03 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN-  I    STUDIES  ON  AMPHETAMINE    RELATIONSHIP 
BtTWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS 

241234  03-13 
Df  lERMINAllONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  (  i  )  AMPHETAMINE. 

241257  03-03 
EFFECTS  OF  THE  D  ISOMERS  AND  L  ISOMERS  OF  AMPHETAMINE  ON 
UPIAKE    RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5  HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN 

241345  03-03 


THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYTOCHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-1 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  01 
ADULT  AND  DEVELOPING  MICE. 

241414  03-1 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE 
(PH.D.  DISSERTATION). 

241576  03- 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSIC 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORAMTION. 

241930  03- 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  TH 
SKELETAL  MUSCLES. 

241988  03- 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04- 
COMPARATIVE  PSYCHOPHARAAACOLOGY  OF  COCAINE  AND 
AMPHETAMINE. 

243820  04- 
THE  EFFECT  OF  AMPHETAMINE  STEREOISOMERS  ON  THE  FUNCTION  OF 
DOPAMINE  SYNAPSES  IN  VITRO. 

244043  04 
EFFECTS  OF  AMPHETAMINE,  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF-STIMULATION  IN  THE  RAT. 

244214  04 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE. 

244513  04 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VI' 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE 

244514  04 

BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04 
AMPHETAMINE  PSYCHOSIS:  OVERVIEW  AND  A  HYPOTHESIS. 

245019  04 
THE  DURATION  OF  TOLERANCE  TO  THE  ANOREXIGENIC  EFFECT  OF 
AMPHETAMINE  IN  RATS. 

245298  04 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  (  I  )  AMPHETAMINE  AND  RELATED  COMPOUNDS. 

246149  04 
BENZODIAZEPINES  AND  AMPHETAMINE  ON  AVOIDANCE  BEHAVIOUR  It 
MICE 

247778  04 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDRO/ 
OR  MINIMAL-BRAIN  DYSFUNCTION. 

247878  04 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  04 
AMPHETAMINE    EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 
RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  Al 
3H-N0RFPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBR> 
CORTEX 

248699  04 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR 
1  NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 
MONKEYS  MAINTAINED  ON  NALTREXONE. 

249270  04 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS 

249272  04 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHFTAMIN 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE 

249274  04 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  (  )  AMPHETAMIN 
AND  L-DOPA. 

249419  04 
LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIMULATION 
FACILITATED  BY  MORPHINE  AND  (  ■  )  AMPHETAMINE 

249486  04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMIN 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04 


S-22 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 
ADMINISTRATION:  DETERMINATION  OF  REINFORCEMENT  MAGNITUD 

250010  04-04 
THOUGHT  DISORDER  IN  AMPHETAMINE  PSYCHOSIS:  A  CASE  REPORT. 

250196  04-13 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  04-04 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04-03 
EFFECT  OF  HALOPERIDOL  ON  (  O  AMPHETAMINE  SELF-ADMINISTRATION 

250658  04-04 
TOLERANCE  TO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA-PIG) 
THAT  METABOLIZE  IT  DIFFERENTLY 

250723  04-03 
ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF-ADMINISTERING  RATS. 

250941  04-04 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04-03 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA. 

251704  04-04 
A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE. 

251951  04-04 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04-04 
0ELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAMINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
RATE-DEPENDENT  EFFECT  OF  AMPHETAMINE  IN  RATS:  EXTENSION  TO 
BETWEEN  SUBJECTS  EFFECT. 

251988  04-04 
EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 
AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS. 

251990  04  04 
AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORMED 
SINGLY  AND  IN  COMBINATION. 

253381  04  14 
PHETAMINE-ENHANCED 

INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 
AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03  04 
PHETAMINE-INOUCED 

EFFECTS  OF  A  DOPAMINE-BETA-HYDROXYLASE  INHIBITOR  ON 
AMPHETAMINE-INDUCED  HYPERACTIVITY  IN  RATS. 

226766  01-03 
METHADONE  INTERACTION  WITH  APOMORPHINE  AND  AMPHETAMINE- 
INDUCED  TURNING. 

226945  01  04 
THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712  02-04 
ATTENUATION  BY  ALPHA-METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 

CONDITIONED  TASTE  AVERSION  IN  RATS. 

237713  02-04 
CENTRAL  ACTION  OF  AMPHETAMINE-INDUCED  MYDRIASIS  IN  THE  DOG. 

238772  03  03 
AMPHETAMINE-INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAIN 
DIFFERENCES,  POLYDRUG  EFFECTS  AND  MECHANISM. 

238789  03-03 
THE  AMPHETAMINE-INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM 

240065  03  03 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMINOBUTYRIC  ACID  LEVELS  TO 
INFLUENCE  AMPHETAMINE  INDUCED  STEREOTYPED  BEHAVIOR 

247730  0403 
DOPAMINERGIC  NATURE  OF  AMPHETAMINE-INDUCED  PECKING  IN 
PIGEONS 

248408  04-03 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE 

249274  04  04 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT. 

252519  04  03 


AMPHETAMINE-IIKE 

THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE-LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-03 
CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 
AMPHETAMINE-LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 
TEMPERATURE. 

249316  04-03 
AMPHETAMINE-TYPE 

TREATMENT  OF  REACTIONS  TO  AMPHETAMINE-TYPE  STIMULANTS. 

251754  04-15 
AMPHETAMINES 

DISSOCIATION  OF  RAT  BRAIN  POLYRIBOSOMES  IN  VIVO  BY 
AMPHETAMINES. 

237871  02-03 
THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES. 

237981  02-02 
EFFECTS  OF  METHOXYLATED  AMPHETAMINES  ON  THE  MAZE 
PERFORAAANCE  BY  THE  RAT. 

238788  03-04 
NMR  SIUDY  OF  AMPHETAMINES  USING  EUROPIUM  SHIFT  REAGENTS. 

239660  03  01 
DIFFERENTIAL  EFFECTS  OF  ALPHA  MT  ON  ANORECTIC  AND 
STIMULATORY  ACTION  OF  AMPHETAMINES. 

247729  04-02 
CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

249311  04-03 
AMPHETAMINES  PARADOXICAL  EFFECTS  MAY  BE  PREDICTABLE. 

251154  04-14 
AMPHETAMINIL 

STUDIES  ON  THE  CNS  AVAILABILI I Y  01  AMPHE  TAMINt  I  ROM 
AMPHETAMINIL. 

229041  01-03 
THE  STABILITY  OF  AMPHETAMINIL:  SYNTHESES  WITH  AMPHETAMINIL. 

232527  01-01 
AMPT 

EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVFAII  ISOl  t  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-03 
AMI 

BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  i  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
AMT  CATALEPSY  AND  HYPOKINESIA:  INTERACTION  WITH  MORPHINE 
AND  COCAINE 

241224  03-04 
AMYGDALA 

EFFECTS  or  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02-03 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDAIA. 

238739  03-03 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  fONDIllONIO  RfrirxE<;  or  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
INTERACTING  EFFECTh  UL  AMYtvLvu.'X  liMUNS  WIIH 

CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  RATS 

248394  04-04 
AMYGDALOID 

EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS. 
PAPIO  PAPIO. 

230475  01  03 
ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01-03 
CHANGES  IN  EXCITABILITY  OF  AMYGDAIOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE 

241232  03  03 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR. 

243234  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN01  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-04 
EFFECTS  OF  ANTIDEPRESSANT  DRUGS  ON  AMYGDALOID  AFTER 
DISCHARGE  IN  RATS. 

247039  0403 


I 


^ 


00 

I 

tti 


S-23 


Subject  Index 


AMYLOBARBITONE 

SODIUM  AMYLOBARBITONE  AND  THE  PATThKNINf^.  FFFECT^ 

24421  7  04-04 

ANABOLIC 

CNS  STIMULANTS  AND  ANABOLIC  SUBSTANCES  IN  GEROPSYCHIATRIC 
THERAPY. 

229459  01-11 

ANAESTHESIA 

THE  EFFECT  OF  DELTA9TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 

ANAFRANIL 

A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION 

228327  01-09 
TREATMENT  OF  DEPRESSION  IN  GERIATRICS  WITH  ANAFRANIL. 

229370  01-11 
ANAFRANIL  IN  OBSESSIVE-COMPULSIVE  NEUROSIS. 

237896  02-10 
ANAFRANIL  IN  THE  MANAGEMENT  OF  LONG-TERM  PAIN:  A  PRELIMINARY 
REPORT. 

252141  04-07 
ANALEPTIC 

STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN-RELEASING 
HORMONE  (TRH)  IN  RABBITS. 

249280  04-04 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
ANALGESIA 

MORPHINE  ANALGESIA:  BLOCKADE  BY  RAPHE  MAGNUS  LESIONS. 

23261 1  02-03 
ASCENDING  CATECHOLAMINE  SYSTEMS  AND  MORPHINE  ANALGESIA. 

232915  02-03 
AN  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS. 

233336  02-03 
STRUCTURE-ACTIVITY  RELATIONSHIPS  IN  ANALOGS  OF  DELTA9- 
TETRAHYDROCANNABINOL:  TACHYCARDIA  VS.  ANALGESIA. 

238805  03-02 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS. 

239851  03-03 
THE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA:  FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY. 

249248  04-03 
NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA    -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE 
MICROINJECTION  INTO  MOUSE  BRAIN. 

250062  04-04 
SOME  ASPECTS  OF  THE  PHARMACOLOGY  OF  ANALGESIA. 

252134  04-17 
ANALGESIC 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-04 
THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  MAN. 

232531  01-13 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822  03-03 
THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX:  RELATION  TO 
ANALGESIC  ACTIVITY. 

250355  04-03 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  04-04 

ANALGESICS 

A  STUDY  OF  THE  EFFECT  OF  DAMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-04 
GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04-04 
FURTHER  STUDIES  ON  SELF-ADMINISTRATION  OF  ANTIPYRETIC 

ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITH 
CODEINE  IN  RHESUS  MONKEYS 

246855  04-04 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04-04 


Psychopharmacology  Abstra< 

ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04 
CROSS-TOLERANCE  BETWEEN  MORPHINE  AND  OTHER  ANALGESICS. 

251408  0/ 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  0^ 

ANALGETIC 

ANALGETIC  EFFECTS  OF  LANTHANUM:  CROSS-TOLERANCE  WITH 
MORPHINE. 

237870  O: 
ANALOG 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  0: 
PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

238317  0: 
SOME  PHARAAACOLOGICAL  PROPERTIES  OF  CYCLOCHOLINE,  A  REACT! 
ANALOG  OF  CHOLINE. 

238828  0 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION 
SHAKING  MOVEMENTS  IN  THE  RAT. 

250087  0 

ANALOGS 

CONFORMATIONALLY  CONSTRAINED  ANALOGS  OF  MESCALINE  II. 

233361  0 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 
ADENYLATE-CYCLjASE  in  NEURONAL  AND  GLIAL  ENRICHED  FRACTIC 
FROM  RAT  BRAIN. 

237241  0 
EFFECT  OF  ANGIOTENSIN-II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELE 
OF  C14-5-HYDR0XYTRYPTAMINE  BY  RAT  BRAIN. 

237739  0 
NOVEL  ANALOGS  OF  TRICYCLIC  PSYCHOPHARMACOLOGICAL  AGENTS 

238476  0 
INHIBITION  OF  DOPAMINE-BETA-HYDROXYLASE  BY  SOME  ANALOGS  C 
METHIMAZOLE. 

238691  C 
STRUCTURE-ACTIVITY  RELATIONSHIPS  IN  ANALOGS  OF  DELTA9- 
TETRAHYDROCANNABINOL:  TACHYCARDIA  VS.  ANALGESIA. 

238805  C 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313 C 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RJ 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  C 
RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSU 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  C 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 

ANALOGS  OF  FLUPHENAZINE. 

248538  C 
DRUGS  DERIVED  FROM  CANNABINOIDS.  1.  NITROGEN  ANALOGS, 

BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  ( 
DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROG 
AND  CARBOCYCLIC  ANALOGS. 

248647 ( 
DRUGS  DERIVED  FROM  CANNABINOIDS.  5.  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  ( 
DRUGS  DERIVED  FROM  CANNABINOIDS.  3.  SULFUR  ANALOGS, 
THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  ( 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 

SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  ( 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASl 

THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMIN: 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  ( 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASl 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMIN 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  ( 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITOR 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  1 

ANALOGUE 

EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIDE,  A  CHO 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594  I 


S-24 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


ANALOGUES 

CEREBRAL  ARTERIAL  SPASM.  PART  4-.  IN  VITRO  EFFECTS  OF 

TEMPERATURE.  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN  INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY, 

243797  04-03 
PRESSOR  EFFECTS  OF  TRYPTAMINE  ANALOGUES. 

243798  04-03 
EFFECTS  OF  INTRAVENTRICULAR  P-CHLOROAMPHETAMINE  AND  ITS 

ANALOGUES  ON  CEREBRAL  5-HT. 

246151  04-03 
ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF-ADMINISTERING  RATS. 

250941  04-04 
ANALOGUES  OF  S-ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-01 
ANALYSES 

PSYCHOLOGICAL  ANALYSES  OF  PATIENTS  SUFFERING  FROM 
HYPOTHYROIDISM. 

232364  01-14 
ANALYSIS 

OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PH.D. 
DISSERTATION). 

226992  01-04 
ANGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  AND 
BIOCHEMICAL  ANALYSIS.  (PH.D.  DISSERTATION). 

227106  01-04 
ANALYSIS  AND  DISPLAY  OF  PSYCHOPHARMACOLOGICAL  DATA. 

228978  01-17 
DRUGS  AND  PSYCHOTHERAPY  IN  DEPRESSION  REVISITED:  ISSUES  IN  THE 
ANALYSIS  OF  LONG-TERM  TRIALS. 

229450  01-09 
BEHAVIOR  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION  OF 
BENZODIAZEPINES. 

229461  01-04 
ANALYSIS  OF  DRUGS  AND  PSYCHOACTIVE  PHENOLIC  AMINES. 

229486  01-03 
RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX  -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE. 

230570  01-04 
BEHAVIORAL  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION 
OF  BENZODIAZEPINES. 

232509  01-04 
PROBLEMS  IN  THE  ELECTROPHYSIOLOGICAL  ANALYSIS  OF  THE  SITE  OF 
ACTION  OF  BENZODIAZEPINES. 

232512  01-03 
CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  POLYETHYLENE-GLYCOL-4000  BY  IR  SPECTRAL 
ANALYSIS. 

233276  02-01 
ANALYSIS  OF  VARIANCE  STUDY  OF  A  SLEEP  INDUCING  DRUG. 

233698  02-07 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02- 17 
BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  ANALYSIS  OF 
AMPHETAMINE  AND  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  IN 
RATS. 

237718  02-04 
BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA. 

237872  02-13 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA 

238486  02-16 
GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE    IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-11 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS 

240064  03-03 
AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS   (PH  D 
DISSERTATION). 

241129  03-03 
PHARMACOLOGICAL  ANALYSIS  OF  SOME  ADRENOMIMETIC  EFFECTS  OF 
SEROTONIN. 

241982  03-05 


ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-AAACHINE  TRACKING  SYSTEMS 

UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03-14 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 

RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 

OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 

MORPHINE  TREATED  CATS. 

244215  04-04 
ANALYSIS  OF  HORMONAL  MEDIATION  OF  DRINKING  BEHAVIOR. 

244469  04-04 
LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM. 

247012  04-03 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
GLC  ANALYSIS  OF  THIORIDAZINE,  MESORIDAZINE  AND  THEIR 
METABOLITES. 

251776  04-16 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG  TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-17 
AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS:  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE. 

253052  04-08 
ANALYTICAL 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01  03 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
ANALYZED 

THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUAAAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04  13 
ANATOMICAL 

ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  BY 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

238503  02-03 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04-04 
ANATOMICAL  AND  BEHAVIORAL  EFFECTS  OF  COLCHICINE 

ADMINISTRATION  TO  RATS  LATE  IN  UTERO. 

252148  04-05 
ANDROGEN 

RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  04-04 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEN 
AND  OLFACTORY  STIMULI. 

245406  04-04 
EFFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR  OF 
THE  OVARIECTOMIZED  EWE, 

248223  04-04 
ANDROGENS 

DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 
ANEMIA 

COOMBS-POSITIVE  HEMOLYTIC  ANEMIA  PROVOKED  BY 
CHLORPROMAZINE. 

237161  02-15 
ANESTHESIA 

RETROACTIVE  AND  PROACTIVE  EFFECTS  OF  ANESTHESIA  ON  FOLLOWING 
IN  CHICKS, 

241330  03-04 
ANTIDEPRESSANT  DRUGS  AND  ANESTHESIA. 

247544  04-15 
EFFECTS  OF  HALOTHANE  ANESTHESIA  ON  THE  BIODISPOSITION  OF 
KETAMINE  IN  RATS. 

250108  04-03 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04-12 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 


i33 


"fii 


?© 


h 


S-25 


Subject  Index 


Psychopharmacology  Abstracts 


ANESTHESIOIOGIC 

ANESTHESIOLOGIC  CONSIDERATIONS  IN  PSYCHIATRIC  CONVULSIVE 
THERAPY. 

249765  04-17 

ANESTHETIC  ^    ^ 

RELATIONSHIPS  BETWEEN  ANESTHETIC  SUBSTANCES,  CONVULSIONS, 
AND  PSYCHIC  DISTURBANCES 

229118  01-15 

IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099. 

238686  03-03 

ANESTHETICS 

LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-03 
EFFECTS  OF  INTRAVENOUS  ANESTHETICS  ON  CONTINUOUS  AVOIDANCE 
BEHAVIOR  IN  THE  RAT. 

241314  03-04 

ANESTHETIZED 

RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS. 

238809  03-03 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  04-03 
ANGIOTENSIN 

SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN  AND 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERTATION). 

228493  01-03 
•ANGIOTENSIN-II 

EFFECT  OF  ANGIOTENSIN-II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 
OF  C14-5HYDR0XYTRYPTAMINE  BY  RAT  BRAIN. 

237739  02-03 
THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II 

252170  04-03 
ANGIOTENSIN-INDUCED 

ANGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  AND 
BIOCHEMICAL  ANALYSIS.  (PH.D.  DISSERTATION). 

227106  01-04 

ANIMAL 

ANIMAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN). 

227208  01-02 
THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE. 

229037  01-11 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
FLUPHENAZINE:  DIFFICULTIES  AND  LIMITATIONS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
USE  OF  THE  IMMOBILITY  REFLEX  (ANIMAL  HYPNOSIS)  IN 
NEUROPHARMACOLOGICAL  STUDIES 

250071  04-06 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
(  I  )  TRANYLCYPROMINE  IN  AN  ANIMAL  MODEL. 

250376  04-03 

ANIMALS 

EVALUATING  POTENTIAL  ANTIDEPRESSANTS  IN  ANIMALS. 

227207  01-06 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS 

237270  02-06 
CLONAZEPAM-INDUCED  CHANGES  IN  5-HYDROXYTRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  MAN, 

237977  02  13 
NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03-03 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPnC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 

ANIMALS. 

240237  03-04 

CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  03-04 


EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS.  4TH 
REPORT   COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIAAALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  04-17 
RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  0401 

A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

250935  04-17 

ANORECTIC 

FENFLURAMINE  AND  5-HYDROXYTRYPTAMlNE.  PART  2:  INVOLVEMENT 
OF  BRAIN  AND  5-HYDROXYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 
OF  FENFLURAMINE. 

237119  02-03 

DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION?. 

240802  03-13 

ANORECTIC  DRUrS. 

243869  04-11 

DIFFERENTIAL  EFFECTS  OF  ALPHA  MT  ON  ANORECTIC  AND 
STIMULATORY  ACTION  OF  AMPHETAMINES. 

247729  04-02 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 

ANORECTICS 

THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 

^^^^^  237742  02-03 

ANOREXIA 

CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
INHIBITION  OF  DRUG-INDUCED  ANOREXIA  IN  RATS  BY  METHYSERGIDE. 

237745  02-04 
FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE-INDUCED  ANOREXIA. 

237748  02-03 
ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 

STRIATAL  LESIONS. 

237777  02-03 

PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FOR 

ANOREXIA  NERVOSA. 

240423  03-11 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 

AND  AFTER  PHENOTHIAZINE  TREATMENT. 

243193  04-10 
SOMATIC  ORIENTED  TREATMENT  OF  ANOREXIA  NERVOSA, 

243194  04-10 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 

INDUCED  BY  (  n  AMPHETAMINE  AND  RELATED  COMPOUNDS. 

246149  04-03 
AMANTADINE  DECREASES  D-AMPHETAMINE  STIMULATION  AND 
INCREASES  D-AMPHETAMINE  ANOREXIA  IN  MICE. 

249459  0403 
HYPOTHALAMIC  LESIONS  AND  DRUG-INDUCED  ANOREXIA. 

250938  04-03 
ANOREXIA  AND  CONDITIONED  TASTE  AVERSIONS  IN  THE  RAT. 

251629  04-05 
EFFECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-03 

ANOREXIC 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION) 

227074  01-04 
CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS. 

237900  02- 10 

COMP/^RISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECTS  OF 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT. 

250939  04-02 

ANOREXIGENIC 

THE  DURATION  OF  TOLERANCE  TO  THE  ANOREXIGENIC  EFFECT  OF 

AMPHETAMINE  IN  RATS.  245298  04-03 


S-26 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


SUBJECTIVE  EFFECTS  OF  TWO  ANOREXIGENIC  AGENTS  -  FENFLURAMINE 
AND  AN  448  IN  NORMAL  SUBJECTS. 

250945  04-07 
BEHAVIOURAL  EFFECTS  OF  A  NEW  NONPHENYLETHYLAMINE 
ANOREXIGENIC  AGENT;  MAZINDOL. 

252030  04-04 
EFFECTS  OF  MAZINDOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

252201  04-03 
KNOXrC 

CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  02-13 
\NTAGONISES 

LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIMULATION 
FACILITATED  BY  MORPHINE  AND  (  t  )  AMPHETAMINE. 

249486  04-03 
ANTAGONISM 

A  STUDY  OF  INHIBITORY  ANTAGONISM  IN  CAT  VISUAL  CORTEX. 

226397  01-03 
ANTAGONISM  OF  D-LYSERGIC  ACID  DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,5,6  TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 
(THPC). 

230453  01-03 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INOUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIOOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE. 

237976  02-03 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

238318  02-04 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 
ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03-04 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  04-04 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 
NEUROLEPTIC  ANTAGONISM  OF  DYSKINETIC  PHENOMENA. 

248407  04-04 
DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 
INDOLEAMINES  IN  BRAIN. 

250081  04-03 
LIMITING  FACTORS  IN  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE. 

250359  04-03 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-03 
ANTAGONISM  BY  SULPIRIDE  OF  THREE  APOMORPHINE-INDUCED  EFFECTS 
IN  RODENTS. 

252032  04-04 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES 

252757  04-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
ANTAGONISMS 

ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMIC 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-03 
ANTAGONIST 

STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN 

229435  01-03 


THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290  02-03 
IS  METOCLOPRAMIDE  A  DIRECTLY  ACTING  DOPAMINE  RECEPTOR 
ANTAGONIST?. 

241929  03-03 
THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSD  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  04-03 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
ANTAGONISTIC 

L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANTAGONISTIC  INTERACTION 
WITH  ETHANOL  IN  HUMANS. 

238748  03-13 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS. 

250354  04-04 
ANTAGONISTS 

EFFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION, 

233292  02-04 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA, 

236863  02-03 
EFFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG  INDUCED  HYPOTHERMIA 
IN  MICE  AND  RATS, 

237100  02-03 
EFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 
BEHAVIOR  OF  THE  SQUIRREL-MONKEY. 

237754  02-04 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-03 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
A  BEHAVIORAL  PARADIGM  FOR  THE  EVALUATION  OF  NARCOTIC 
ANTAGONISTS. 

239941  03-11 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I,  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS, 

241223  03-04 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM, 

244205  04-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2-RECEPT0R  ANTAGONISTS  IN  THE 
RAT  CEREBRAL  CORTEX 

248725  04-03 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA-MULATTA 

249267  04-04 
CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 
5  HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS. 

249318  04-03 
MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE:  INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS 

250079  04-04 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS, 

250354  04  04 
5-HT  ANTAGONISTS  IN  RAT  HIPPOCAMPUS, 

251072  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS, 

251402  04-04 


00 

331 

« 


i 

h 

i 

3K 


S-27 


Subject  Index 


Psychopharmacology  Abstracts 


ON  THE  ABILITY  Of  NARCOTIC  ANTAGONISTS  TO  PRODUCE  THE 
NARCOTIC  CUE 

251429  04-03 
EFFECTS  OF  ALPHA  ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE   AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  04-03 
ANTI-HLA 

INTERFERENCE  BETWEEN  ANTLHLA  ANTIBODIES  AND  CHLORPROMAZINE. 

250476  04-07 
ANTIACETYLCHOIINE 

ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS. 

250360  04-02 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04-03 
ANTIANDROGEN 

RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  04-04 
47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04-10 
ANTIANESTHETIC 

COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
ANTIANXIETY 

A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

227914  01-10 
A  COMBINATION  OF  ANTIANXIETY  DRUGS:  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP 

228207  01-10 
CLINICAL  USE  OF  ANTIANXIETY  DRUGS. 

237165  02-10 
EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03-04 
THE  EFFECT  OF  DL  254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS. 

238846  03-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  CEREBRAL  MONOAMINE 
TURNOVER. 

241392  03-03 
MEDICAL  PRACTICE  WITHOUT  ANTIANXIETY  DRUGS. 

245524  04-17 
THE  ANTINICOTINIC  EFFECTS  OF  DRUGS  WITH  CLINICALLY  USEFUL 
SEDATIVE  ANTIANXIETY  PROPERTIES. 

248009  04-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE. 

249678  04-04 

ANTIAUTISTIC 

ANTIAUTISTIC  EFFECT  OF  FLUPENTHIXOL. 

227771  01-08 
ANTIBIOTICS 

ANTIBIOTICS  AND  MEMORY. 

239673  03-04 
ANTIBODIES 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  01-04 
ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  01-15 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 

WITH  CHLORPROMAZINE. 

232865  02-15 
ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID  ACID. 

233278  02-01 
EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAL  TO  MICE. 

241403  03-03 
INTERFERENCE  BETWEEN  ANTI-HLA  ANTIBODIES  AND  CHLORPROMAZINE. 

250476  04-07 
ANTIBODY 

EVIDENCE  FOR  A  DOPAMINE  RECEPTOR  ANTIBODY. 


ANTICARCINOGENIC 

ARE  NEUROLEPTIC  DRUGS  ANTICARCINOGENIC?. 


238736  03-03 
241736  03-15 


ANTICHOLINERGIC 

OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECTS  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

226411  01-09 
STUDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01-13 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
ANTICHOLINERGIC  ACTIVITY  OF  ANTIPSYCHOTIC  DRUGS  IN  RELATION  TO 
THEIR  EXTRAPYRAMIDAL  EFFECTS. 

252520  04-05 
ANTICOAGULANT 

CHANGES  IN  ANTICOAGULANT  TOLERANCE:  I.  INFLUENCE  OF  SEDATIVES 
AND  PSYCHOPHARMACEUTICALS. 

235336  02- 15 
ANTICONVULSANT 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  02-03 
METABOLISM,  DISTRIBUTION  AND  ANTICONVULSANT  PROPERTIES  OF 
N  N  DIMETHOXYMETHYL-PHENOBARBITAL  IN  THE  RAT. 

237758  02-03 
ANTICONVULSANT  ACTIVITY  OF  NEWER  SUBSTITUTED  TRIAZOLES. 

238712  03-03 
INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2-ARYLIMIN0-3-ACETYLAMIN0-4-THIAZ0LID0NYL  PHENOTHIAZINES. 

239662  03-03 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 

ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  04-03 
OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
ANTICONVULSANT  ACTIVITY  OF  DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED  WITH  THREE  OTHER  DRUGS. 

248283  04-02 
ANTIDEPRESSANT  AND  ANTICONVULSANT  ACTIVITY  OF  PHENYL-4-0X0-2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED  PIPERAZINES. 

251701  04-01 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

252711  04-03 

ANTICONVULSANTS 

COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  0203 

ANTICONVULSIVE 

EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
ANTIDEPRESSANT 

SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  WITH  PARTICULAR 
REFERENCE  TO  DOTHIEPIN. 

226897  01-15 
VILOXAZINE  (VIVALAN)  -  A  NEW  ANTIDEPRESSANT. 

227224  01-09 
A  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ANTIDEPRESSANT. 

227695  01-0: 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  Otic 
THE  PHARMACOLOGIC  MEANING  OF  SUCCESSFUL  ANTIPSYCHOTIC 
ANTIDEPRESSANT  COMBINATIONS. 

230010  01-11 


S-28 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  0110 
POISONING  BY  TRICYCLIC  ANTIDEPRESSANT  DRUGS:  GENERAL  AND 
PHARMACOKINETIC  CONSIDERATIONS 

230820  01-15 
A  CLINICAL  TRIAL  WITH  NOMIFENSIN,  A  NEW  ANTIDEPRESSANT  DRUG. 

231035  01-09 
THE  USE  OF  ANTIDEPRESSANT  DRUGS  IN  SCHIZOPHRENIA. 

231277  01-08 
TRICYCLIC  ANTIDEPRESSANT  OVERDOSE:  CLINICAL  PRESENTATION  AND 
PLASMA  LEVELS. 

231318  0113 
STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 
ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL   (PH  D 
DISSERTATION). 

231438  01-03 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK- 
ACTING  BUT  SHORT-LASTING  ANTIDEPRESSANT. 

235630  02-09 
INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIDOL. 

236369  02-03 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  02-11 
BASIC  DERIVATIVES  OF  6,7  DIHYDROINDOLOBENZAZEPINE  AND  6H 
INDOLOBENZOXAZEPINE  AS  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

237834  02-02 
EVALUATION  OF  CESIUM  CHLORIDE  AS  ANTIDEPRESSANT. 

238836  03-03 
PHARMACOLOGY  OF  R-806,  A  TETRACYCLIC  ANTIDEPRESSANT. 

238837  03-03 
PHARMACOLOGICAL  STUDIES  WITH  HP-505,  A  POTENTIAL 

ANTIDEPRESSANT  COMPOUND. 

238839  03-03 
RELATIONSHIP  BETWEEN  ANTIDEPRESSANT  EFFECT  AND  PLASMA  LEVEL 
OF  NORTRIPTYLINE.  CLINICAL  STUDIES. 

240217  03-09 
EXPLORATION  OF  THE  ANTIDEPRESSANT  POTENTIAL  OF  IPRINDOLE. 

241241  03-04 
ANTIDEPRESSANT  PREDICTABILITY:  CARTAZOLATE. 

242251  03-09 
CLINICAL  EXPERIENCES  WITH  A  NEW  ANTIDEPRESSANT,  ICI-58834. 

244189  04-07 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  IF  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES.  (UNPUBLISHED  PAPER). 

244574  04-09 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTEM 
IN  LIMBIC  FOREBRAIN. 

245115  04-03 
NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-03 
DEPRESSION  AND  ANTIDEPRESSANT  DRUGS, 

245646  04-09 
ANTIDEPRESSANT  DRUGS  AFFECT  DOPAMINE  UPTAKE. 

247021  04-03 
EFFECTS  OF  ANTIDEPRESSANT  DRUGS  ON  AMYGDALOID  AFTER- 
DISCHARGE  IN  RATS 

247039  04-03 
EFFICACY  AND  TOLERANCE  LIMITS  IN  THE  USE  OF  ANTIDEPRESSANT 
DRUGS. 

247543  04-09 
ANTIDEPRESSANT  DRUGS  AND  ANESTHESIA. 

247544  04-15 
A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 

ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE  CHLORHYDRATE  (CIBA  34276BA). 

247554  04-09 
3ARYLQUIN0LIZIDINES,  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

247586  04-01 
CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 
ANTIDEPRESSANT  TREATMENT, 

247969  04-09 
MEMORY  FUNCTIONS  IN  DEPRESSION:  IMPROVEMENT  WITH 
ANTIDEPRESSANT  MEDICATION, 

248583  04-09 


CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-94) 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  04-09 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
( -H  )  TRANYLCYPROMINE  IN  AN  ANI/WAL  MODEL. 

250376  04-03 
THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  04-11 
PSYCHOMETRIC  ASSESSMENT  OF  THE  THERAPEUTIC  EFFICIENCY  OF 
ANTIDEPRESSANT  AGENTS. 

251004  04-10 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX. 

251394  04-03 
CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND. 

251407  04-17 
ANTIDEPRESSANT  AND  ANTICONVULSANT  ACTIVITY  OF  PHENYL-4-0X0-2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED  PIPERAZINES. 

251701  04-01 
THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIENTS 
WITH  PASSIVE-DEPENDENT  PERSONALITY  TRAITS, 

251717  04-11 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AND 
PSYCHOTIC  PATIENTS 

253641  04-11 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY, 

253684  04  11 
ANTIDEPRESSANTS 

OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECTS  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

226411  01-09 
EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  DRUG  METABOLISM, 

226829  01-13 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS 

226849  01-03 
HOSTILITY,  SOMATIC  SYMPTOMS  AND  RECOVERY  WITH 
ANTIDEPRESSANTS, 

226898  01-09 
EVALUATING  POTENTIAL  ANTIDEPRESSANTS  IN  ANIMALS. 

227207  01-06 
THE  METHODOLOGY  OF  TRIALS  OF  ANTIDEPRESSANTS  FOR  DEPRESSED 
INPATIENTS. 

227213  01  16 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
NEUROLEPTICS  AND  ANTIDEPRESSANTS  ON  CENTRAL  MONOAMINE 
NEURONS. 

229483  01-03 
THE  INTERACTION  BETWEEN  ALPHA  METHYL-DOPA  AND  TRICYCLIC 
ANTIDEPRESSANTS. 

230819  01  03 
CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS  -    A 
RISK  IN  THE  USE  OF  THESE  DRUGS. 

23131701  15 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  ANTIDEPRESSANTS 
AND  LITHIUM. 

232762  02-17 
THE  USE  OF  BETHANECHOL  CHLORIDE  WITH  TRICYCLIC 
ANTIDEPRESSANTS. 

232864  02-15 
EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESSION 
(INTRODUCTORY  REPORT). 

234046  02-09 
LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 
DO  TRICYCLIC  ANTIDEPRESSANTS  WORK^. 

237162  02-17 
A  REVIEW  OF  THE  CARDIOVASCULAR  EFFECTS  AND  TOXICITY  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

237909  02  15 


s 

i 


S-29 


Subject  Index 


Psychopharmacology  Abstracts 


PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS 

238317  02-01 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA. 

238486  02-16 
RADIOIMMUNOASSAY  OF  TRICYCLIC  ANTIDEPRESSANTS. 

238775  03-01 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE-BLIND  TRIAL. 

239348  03-09 
FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

239684  03- 13 
COMBINATION  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  MAOI  IN 
DEPRESSION. 

240839  0309 
OVERDOSAGE   -  THE  RISE  AND  FALL  OF  TRICYCLIC  ANTIDEPRESSANTS. 

243064  04-15 
PSYCHOTHERAPY  AND  TRICYCLIC  ANTIDEPRESSANTS. 

243860  04-09 
CLINICAL  USE  OF  TRICYCLIC  ANTIDEPRESSANTS. 

243861  04-09 
THE  ROLE  OF  RATING  SCALES  IN  THE  USE  OF  ANTIDEPRESSANTS. 

243862  04- 17 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
THE  RELATIONSHIP  BETWEEN  HIATUS  HERNIA  AND  TRICYCLIC 
ANTIDEPRESSANTS:  A  REPORT  OF  FIVE  CASES. 

245523  04-15 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG- 
INFORMATION-CENTER:  THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04-13 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR 

249301  04-03 
EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5HYDR0XYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
INHIBITION  OF  PHENYLETHYLAMINE  METABOLISM  IN  VIVO  -  EFFECT  OF 
ANTIDEPRESSANTS. 

251184  04-03 
DO  TRICYCLIC  ANTIDEPRESSANTS  WORK?. 

253314  04-09 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX 

253691  04-03 
ANTIDEPRESSED 

PSYCHOTROPIC  DRUGS  AND  THE  ANTIDEPRESSED  PERSONALITY. 

240251  03-15 
ANTIDEPRESSIVE 

DEPLETION  OF  S-ADENOSYL-L  METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS 

226850  01-03 
CLINICAL  PHARMACOLOGY  OF  SO  10996,  A  POTENTIAL  ANTIDEPRESSIVE 
AGENT. 

229036  01-07 
CLINICAL  EXPERIENCE  IN  USING  MAPROTILINE,  A  NEW  ANTIDEPRESSIVE 
MEDICINE. 

229760  01-09 
CLINICAL  EVALUATION  OF  THE  ANTIDEPRESSIVE  ACTION  OF  THE 
PREPARATION  AZAFEN 

236429  02-10 
PLASMA  LEVELS  AND  ANTIDEPRESSIVE  EFFECT  OF  IMIPRAMINE. 

243089  04-13 
SULPIRIDE  AS  A  CURRENT  ANTIDEPRESSIVE  TECHNIQUE:  WHAT  CAN  BE 
SAID  AND  THOUGHT  ABOUT  IT  TODAY?. 

244433  04-17 


SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  04-10 
COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE-BLIND  MULTICENTRE  TRIAL. 

251118  04-09 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  (SQ-10996)  IN 
HUAMNS. 

253323  04-07 

ANTIDEPRESSIVES 

THE  CLINICAL  PHARMACOLOGY  OF  ANTIDEPRESSIVES. 

227209  01  17 
ANTIDIURETIC 

EFFECT  OF  ANTIDIURETIC  DRUGS  IN  RATS  WITH  LITHIUM-INDUCED 
POLYURIA. 

239041  03-05 

ANTIDOPAMINERGIC 

ANTIDOPAMINERGIC  AND  ANTIMUSCARINIC  EFFECTS  OF 
DIBENZODIAZEPINES:  RELATIONSHIP  TO  DRUG-INDUCED 
PARKINSONISM. 

241248  03-03 
ANTIDOPAMINERGIC  EFFECTS  OF  APOMORPHINE  IN  PATIENTS  WITH 
DYSKINESIAS. 

251958  04-13 

ANTIDOTE 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
ANTIEPILEPTIC 

BEHAVIORAL  EFFECTS  OF  ANTIEPILEPTIC  DRUGS. 

230368  01-11 
ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01-03 
THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAAAAZEPINE  (TEGRETOL). 

249242  04-03 
ANTIESTROGEN 

DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 

ANTIHISTAMINIC 

EFFECTS  OF  ANTIHISTAMINIC  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM. 

238838  03-03 
ANTIHYPERTENSIVE 

THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

2514)8  04-11 

ANTIAAANIC 

BIOCHEMICAL  VS  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH 
SPECIAL  REFERENCE  TO  THEIR  ANTIMANIC  EFFECT 

227/63  01-04 
ATARAXIC  AND  ANTIMANIC  EFFECTS  OF  THIOXANTHENES. 

227768  01  09 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  II:  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES.  (UNPUBLISHED  PAPER). 

244574  04-09 

ANTIMIGRAINE 

DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
-  AN  ANTIMIGRAINE  COMPOUND. 

229473  01-13 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  0211 
ANTIMUSCARINIC 

ANTIDOPAMINERGIC  AND  ANTIMUSCARINIC  EFFECTS  OF 
DIBENZODIAZEPINES:  RELATIONSHIP  TO  DRUG-INDUCED 
PARKINSONISM. 

241248  03-03 

ANTINICOTINIC 

THE  ANTINICOTINIC  EFFECTS  OF  DRUGS  WITH  CLINICALLY  USEFUL 
SEDATIVE  ANTIANXIETY  PROPERTIES. 

248009  04-03 

ANTINOCICEPTIVE 

MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  THE 
ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  0203 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03  04 


S-30 


S^OLUME  14,  SUBJECT  INDEX 


Subject  Index 


ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-03 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-04 
EVALUATION  OF  THE  ANTINOCICEPTIVE  EFFECTS  OF  4.ALPHA-DIMETHYL- 
MTRYAMINE  (H77-77)  IN  THE  RAT. 

252026  04-03 
IVNTINUCLEAR 

ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  01-15 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE. 

232865  02-15 
IVNTIOBESITY 

STRATEGIES  AND  TACTICS  IN  THE  USE  OF  ANTIOBESITY  DRUGS. 

253315  04  11 
IVNTIOXIDANT 

AN  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
ANTIPARKINSON 

OPEN  WITHDRAWAL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 
INDUCEO  PARKINSON  SYNDROME. 

239822  03-15 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY?. 

247359  04-15 
ANTIPARKINSONIAN 

A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS. 

235992  02-11 
ANTIPARKINSONIAN  AGENTS  AND  FLUPHENAZINE-DECANOATE. 
DECANOATE. 

236317  02-15 
IMPLICATIONS  OF  PHENOTHIAZINE  SIDE-EFFECTS:  A  STUDY  OF 
ANTIPARKINSONIAN  AGENTS  IN  AN  OLDER  POPULATION. 

238978  03-15 
THE  ANTIPARKINSONIAN  EFFICACY  OF  BROMOCRIPTINE. 

251649  04-07 
ANTIPHENOBARBITAl 

EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAL  TO  MICE. 

241403  03  03 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 
ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL  INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE 

242201  03-03 
ANTIPSYCHOTIC 

GUIDELINES  FOR  ANTIPSYCHOTIC  DRUG  USE. 

227731  01-17 
PHARMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS. 
WITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 
EFFECTS. 

227762  01-04 
FLUPENTHIXOL  AND  FLUPENTHIXOL  DECANOATE,  WITH  SPECIAL 
REFERENCE  TO  THEIR  ANTIPSYCHOTIC  EFFECT. 

227770  01-08 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  TO 
ANTIPSYCHOTIC  DRUGS 

227808  01-15 
THE  PHARMACOLOGIC  MEANING  OF  SUCCESSFUL  ANTIPSYCHOTIC 
ANTIDEPRESSANT  COMBINATIONS. 

230010  01-11 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
ARE  BENZODIAZEPINES  ANTIPSYCHOTIC  AGENTS'. 

23381 5  02-08 
ARE  BENZODIAZEPINES  ANTIPSYCHOTIC  AGENTS?. 

235327  02-08 
MAINTENANCE  ANTIPSYCHOTIC  THERAPY:  IS  THE  CURE  WORSE  THAN 
THE  DISEASE?. 

236307  02-08 
PRACTICAL  CONSIDERATIONS  ON  TREATMENT  WITH  ANTIPSYCHOTIC 
DRUGS. 

236359  02-08 
PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 
MEDICATION.  {UNPUBLISHED  PAPER). 

238489  02-08 
LACK  OF  A  RELATION  BETWEEN  THE  ANTIPSYCHOTIC  AND  THE 
EXCITABILITY  DEPRESSANT  PROPERTIES  OF  MAJOR  TRANQUILIZERS. 

238710  0303 


CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
NEUROPHARMACOLOGICAL  EFFECTS  OF  PENFLURIDOL,  A  NEW 
ANTIPSYCHOTIC  AGENT. 

241384  03-03 
COMPARISON  TRIAL  OF  TWO  ANTIPSYCHOTIC  DRUGS: 
CHLORPROMAZINE  AND  CLOZAPINE. 

241760  03-08 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS. 

242269  03-17 
DRUG  THERAPY:  NEUROLOGIC  SYNDROMES  ASSOCIATED  WITH 
ANTIPSYCHOTIC  DRUG  USE. 

246061  04-15 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL 

250357  04-01 
MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 

DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  04-03 
ANTIPSYCHOTIC  EFFECTS  OF  AL-1965. 

251720  04-08 
BASIC  PRINCIPLES  IN  THE  USE  OF  ANTIPSYCHOTIC  AGENTS 

251751  04-17 
ANTICHOLINERGIC  ACTIVITY  OF  ANTIPSYCHOTIC  DRUGS  IN  RELATION  TO 
THEIR  EXTRAPYRAMIDAL  EFFECTS. 

252520  04-05 
MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS. 

253018  04-08 
ANTIPSYCHOTICS 

ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04-05 
ANTIPYRETIC 

FURTHER  STUDIES  ON  SELF  ADMINISTRATION  OF  ANTIPYRETIC 
ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITH 
CODEINE  IN  RHESUS  MONKEYS 

246855  04-04 
ANTISCHIZOPHRENIC 

DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04-03 
ANTISEIZURE 

GAMMA-ACETYLENIC-GABA  (AMINO-4-HEX-5-YNOIC-ACID);  A  GABA 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY. 

238781  03-04 
ANTISOCIAL 

PSYCHOPHARMACOLOGY  IN  THE  PREVENTION  OF  ANTISOCIAL  AND 
DELINQUENT  BEHAVIOR. 

247385  04-17 
47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING 

248222  04-10 
ANTITREMORGENIC 

EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC). 

249309  04-03 
ANXIETY 

A  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 
THE  TREATMENT  OF  STATES  OF  ANXIETY. 

226410  0110 
ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLORDIAZEPOXIDE  IN 
AN  INTENSIVE  DESIGN  STUDY. 

228221  01-08 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01-11 
THE  TREATMENT  OF  PSYCHOTIC  ANXIETY. 

229559  01-10 
A  CONTROLLED  EVALUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS. 

230907  01-08 


?0 

s 

P 


S 

s 

i 
S 


S-31 


Subject  Index 


Psychopharmacoiogy  Abstracts 


LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY:  DOUBLE-BLIND  TRIAL 

236658  02- 10 
THE  USE  OF  DOTHIEPIN  IN  THE  TREATMENT  OF  PSYCHONEUROTIC 
ANXIETY  WITH  DEPRESSIVE  FEATURES. 

237774  02-10 
A  BRIEF  ANXIETY  RATING  SCALE  IN  EVALUATING  ANXIOLYTICS. 

237926  02-11 
ANXIETY  AND  EEG  ALPHA  ACTIVITY  IN  NEUROTIC  PATIENTS. 

239022  03-10 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO, 
DRUG  AND  A  FOOD  DRINK. 

239059  03-14 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
A  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESSION 
ANXIETY  STATES. 

239938  03-10 
BETA-BLOCKERS  IN  ANXIETY  AND  STRESS. 

240694  03-10 
LORAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

241274  03-14 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME. 

241275  03-10 
PILOT  OPEN-LABEL  STUDY  OF  LENPERONE  (AHR-2277),  A 

BUTYROPHENONE,  IN  ANXIETY. 

241278  03-10 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03- 10 
INTRAVENOUS  LORAZEPAM  IN  THE  ACUTE  ANXIETY  CRISIS:  A 
PRELIMINARY  REPORT  ON  60  CASES. 

242250  03-10 
A  CASE  OF  PHOBIC  ANXIETY  DEPERSONALIZATION  SYNDROME  (ROTH). 

243094  04-17 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 
LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERLAY 
(A  DOUBLE-BLIND  CROSSOVER  STUDY). 

250193  04-14 
COMPARISON  OF  LOW  DOSES  OF  HALOPERIDOL  AND  DIAZEPAM  IN 
ANXIETY  STATES. 

250491  04-10 
EXPOSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM, 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION. 

250727  04-10 
BETA-ADRENERGIC  BLOCKING  DRUGS  FOR  ANXIETY. 

251155  04-14 
REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 

IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21ST  1975. 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  04-10 
A  PRACTICAL  CLASSIFICATION  OF  MORBID  ANXIETY 

251157  04-10 
CLINICAL  TRIALS  OF  OXPRENOLOL  IN  ANXIETY. 

251159  04-10 
WORRYING  ABOUT  ANXIETY. 

251161  04-10 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 

ANXIOLYTIC 

ANXIOLYTIC  DRUGS. 

232704  02-10 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
ANXIOLYTIC  MEDICATIONS. 

241758  03-10 
ANXIOLYTIC  PHARMACOTHERAPY  IN  GENERAL  PRACTICE. 

241759  03-10 
CLINICAL  RESPONSE  TO  A  POTENTIAL  NONSEDATIVE  ANXIOLYTIC. 

251719  04-07 

ANXIOLYTICS 

A  BRIEF  ANXIETY  RATING  SCALE  IN  EVALUATING  ANXIOLYTICS. 

237926  02-11 
ANXIOUS 

(  1 INICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01-10 


CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01-10 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS. 

248975  04-10 
APHAGIC 

REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  04-04 

APLYSIA 

ORGANIZATION  OF  RECEPTORS  FOR  NEUROTRANSMITTERS  ON  APLYSIA 
NEURONES. 

235588  02-03 
THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTION 
POTENTIALS  IN  THE  MOLLUSC  APLYSIA. 

239261  03-03 

APOMORPHINE 

DIFFERENTIAL  EFFECTS  OF  SEROTONIN  ON  TURNING  AND  STEREOTYPY 
INDUCED  BY  APOMORPHINE. 

226405  01-04 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPUS- 
STRIATUM. 

226937  01-04 

METHADONE  INTERACTION  WITH  APOMORPHINE  AND  AMPHETAMINE- 
INDUCED  TURNING, 

226945  01-04 

APOMORPHINE  AND  PSYCHOPATHOLOGY. 

230743  01-11 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE  NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT. 

237747  02-03 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02  03 
GAMMA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL. 

237786  02-03 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02-04 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
THE  EFFECT  OF  DL-254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS. 

238846  03-03 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS. 

242732  03-04 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE 

244514  04-03 
ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04-04 
PENFLURIDOL  BLOCKADE  OF  APOMORPHINE:  DEPENDENCE  OF  DURATION 
ON  SPECIES  AND  ENDPOINT 

248406  04-02 
ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-P  TYROSINE 

249002  04  03 
CARDIOVASCULAR  EFFECTS  OF  CENTRAL  MICROINJECTIONS  OF 
APOMORPHINE  IN  CATS. 

249033  04-03 


S-32 


•LUME  14,  SUBJECT  INDEX 


Subject  Index 


STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  (  )  AMPHETAMINE 
AND  L-DOPA. 

249419  04-04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-04 
EFFECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04-03 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS. 

250089  04-04 
CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE- 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS 

250114  04-03 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  04-04 
DIESTER  DERIVATIVES  AS  APOMORPHINE  PRODRUGS. 

251699  04-04 
ANTIDOPAMINERGIC  EFFECTS  OF  APOMORPHINE  IN  PATIENTS  WITH 
DYSKINESIAS. 

251958  04-13 
IMORPHINE-EUCITED 

THE  REVERSAL  OF  APOMORPHINE-ELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE-HYDROXYLASE  ACTIVITY  BY 
NEUROLEPTICS. 

238758  03-03 
THE  EFFECT  OF  VARIOUS  CHLORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE 
HYDROXYLASE  ACTIVITY. 

247212  04-03 
)MORPHINE-INDUCED 

THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE- 
INOUCED  AND  LSD-INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01  05 
APOMORPHINE-INDUCED  HYPERTHERMIA  IN  THE  RABBIT:  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE.  (PH.D.  DISSERTATION). 

240936  03-03 
AMANTADINE:  AGGRESSIVE  EFFECT,  EFFECT  ON  APOMORPHINE  INDUCED 
AGGRESSIVITY  IN  THE  RAT. 

241227  03-04 
SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D  AMPHETAMINE 
ADMINISTRATION. 

247683  04-04 
APOMORPHINE-INDUCED  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS. 

247875  04  04 
APOMORPHINE  INDUCED  AGGRESSION:  AN  EVALUATION  OF  POSSIBLE 
SENSITIZING  FACTORS  IN  THE  RAT. 

248008  04-04 
INHIBITION  AND  POTENTIATION  OF  APOMORPHINE-INDUCED 
HYPERMOTILITY  IN  RATS  BY  NEUROLEPTICS. 

252029  04  04 
ANTAGONISM  BY  SULPIRIDE  OF  THREE  APOMORPHINE-INDUCED  EFFECTS 
IN  RODENTS 

252032  04-04 
>RPHINE 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN, 

248286  04-03 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 

ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUSACCUMBENS. 

248287  04-02 
>RPHINES 

TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 

ROLE  OF  GROWTH  HORMONE 

237253  02-11 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 

MECHANISMS  IN  RAT  BRAIN 

248286  04  03 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 

ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUSACCUMBENS. 

248287  04-02 
'EARANCE 

APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RE5ERPINE 

230836  01  04 
THE  COURSE  OF  TREATMENT  IN  SCHIZOPHRENIA  AS  RELATED  TO  THE 
APPEARANCE  OF  AFFECTIVE  DISORDERS. 

236421  02-08 


APPETITE 

CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS. 

237900  02  10 
DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION^. 

240802  03  13 
APPLICATIONS 

PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOHOL  WITHDRAWAL. 

252694  04-11 
APPRAISAL 

CLOZAPINE  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA,  A 
CRITICAL  APPRAISAL 

246671  04-03 
APPREHENSION 

ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE  BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
APPROACH 

5-HYDROXYTRYPTAMINE  14C  AND  DEXAMPHETAMINE  14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  APPROACH  TO 
SCHIZOPHRENIA. 

228308  CI  08 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINAIION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01-16 
PSYCHOPHARMACOLOGY    A  BIOLOGICAL  APPROACH. 

232938  02-17 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE    RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234  03-13 
RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHILDHOOD 
HYPERKINESIS 

249772  04-11 
APPROACHES 

PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
ARECOLINE 

EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04  03 
ARKANSAS 

TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG 
INFORMATION  CENTER:  THE  TRICYCLIC  ANTIDEPRESSANTS 

245822  04  13 
AROMATIC 

THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01  03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES 

238683  03-06 
DRUGS  DERIVED  FROM  CANNABINOIDS    5    DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE  CHAINS. 

248648  04  02 
AROUSAL 

THE  EFFECT  OF  IMIPRAMINE  ON  AROUSAL  FROM  HIBERNATION 

228549  01  04 
REGIONAL  ROLE  OF  CATECHOLAMINES  IN  ALPHA-METHYL  M  TYROSINE 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROU,SAL 

234067  02  03 
DRUGS,  AROUSAL.  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-14 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS 

246311  0403 


I 

es 

0 


s 

2 
as 

h 

I 

I 


S-33 


Subject  Index 

DOSE-RELATFD  EffECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS^ 

247206  04-04 
AROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 
HIPPOCAMPUS. 

247420  04-04 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHFTAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS) 

253485  04-04 

ARREST 

RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02-04 

ARTERIAL 

ASTONINH  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 
PSYCHOTROPIC  DRUGS 

240261  03-15 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
DIFFERENTIAL  EFFECTS  OF  ETHYLALCOHOL  ON  CONTRACTION  OF 
ARTERIAL  SMOOTH  MUSCLE. 

251905  04-03 
DIFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAl  SMOOTH  MUSCLE 

253113  04-03 

ARTERIES 

RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01-13 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES. 

252757  04-03 
ARTERY 

CEREBRAL  ARTERIAL  SPASM.  PART  4.  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN  INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASH  AR  ARTERY 

243797  04-03 

ARYl 

EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04-03 
ASCENDING 

ASCENDING  CATECHOLAMINE  SYSTEMS  AND  MORPHINE  ANALGESIA. 

232915  02-03 
BEHAVIORAL  EFFECTS  OF  L  5  HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT: 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 

ASCORBIC-ACID 

THE  EFFECTS  OF  ASCORBIC-ACID  (AA)  PRETREATMENT  ON 
AMPHETAMINE  (A)  EXCRETION  IN  MAN 

238797  03-13 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 

ASIAIIA 

XEROSTOMIA  AND  ASIAIIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 
THEIR  TRFATMENl  WITH  TPMP  (TRITHIO-P-METHOXYPHENYLPROPENE). 

233718  02-15 
ASPARTATE 

THF  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES 

252711  0403 

ASSAY 

CHLORPROMAZINE  EXCRETION:  ISOTOPE  VERSUS  CHEMICAL  ASSAY 

229481  01-03 
ANTIACfTYLCHOLINt  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)0UINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WIIH  CONVENTIONAL  METHODS. 

250360  04  02 


Psychopharmacology  Abstract 


ASSAYS 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC-ACID  AND  5-HYDROXYTRYPTOPHAN 
(UNPUBLISHED  PAPER). 

231278  01-1 
IMPROVED  ASSAYS  OF  CHLORPROMAZINE  AND  ITS  METABOLITES. 

238818  03-1 
ASSEMBLY 

THE  TOKYO  ASSEMBLY  OF  THE  WORLD  MEDICAL  ASSOCIATION. 

248166  04- 

ASSESSING 

ASSESSING  THE  SAFETY  AND  EFFICACY  OF  INTERNATIONAL  TRIALS  IN 
PSYCHOPHARMACOLOGY.  (UNPUBLISHED  PAPER). 

232902  02- 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINI 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

252798  04- 

ASSESSMENT 

OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECTS  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

226411  01- 

THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICA 

TRIAL. 

226899  01 

CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

231034  01 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE-BLIND  CONTROLLED  TRIAL. 

231609  01 

INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WITH 
PSYCHOACTIVE  DRUGS  -  NEW  METHODS  IN  THE  ASSESSMENT  OF 
CHANGE. 

235355  02 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    -  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 
PSYCHIATRIC  HOSPITAL. 

235545  02 
THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE. 

239010  03 
A  RETROSPECTIVE  ASSESSMENT  OF  THE  LONG-TERM  EFFECTS  OF 

DOTHIEPIN. 

239820  03 

CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRON 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  03 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRON 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  0^ 

ASSESSMENT  OF  CEREBPOSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHRO/WATOGRAPHY. 

245300  0' 
ASSESSMENT  OF  DIAZEPAM  AFTER  THREE  YEARS  USE  IN  CHILD 

PSYCHIATRY. 

249144  0^ 

ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF-ADMINISTERING  RATS. 

250941  0' 
PSYCHOMETRIC  ASSESSMENT  OF  THE  THERAPEUTIC  EFFICIENCY  OF 
ANTIDEPRESSANT  AGENTS. 

251004  0- 

NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION. 

251149  a 
RELATIONSHIP  BETWEEN  OBJECTIVE  AND  SUBJECTIVE  ASSESSMENT  0 
EXPERIMENTALLY-INDUCED  FATIGUE. 

253587  0. 

ASSISTANCE 

REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS. 

239641  O: 

ASSISTING 

ASSISTING  MULTIPLE  DRUG  ADDICTS.  PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY. 

237095  O: 

ASSOCIATION 

ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM. 

229349  0 


S-34 


ILUME  14,  SUBJECT  INDEX 


Subject  Index 


ASSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 
CLEFTS 

229350  CM  5 
FLUPHENAZINE-DECANOATE  IN  ASSOCIATION  WITH  OTHER 
PSYCHOTROPIC  DRUGS  (PRELIMINARY  NOTE). 

22956T0M7 
THE  TOKYO  ASSEMBLY  OF  THE  WORLD  MEDICAL  ASSOCIATION. 

248166  04-17 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04  11 
OCIATIVE 

THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
ONIN-H 

ASTONIN-H  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 
PSYCHOTROPIC  DRUGS. 

240261  03  15 
MMETRIC 

CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS. 

250358  04  04 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
MMETRY 

DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  03-03 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 
AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
.RACTICS 

ON  THE  THIN  LAYER  CHROMATOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04-01 
.RAXIC 
ATARAXIC  AND  ANTIMANIC  EFFECTS  OF  THIOXANTHENES. 

227768  01  09 
XIA 

CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION 

236696  02-15 
IMS 

EFFECTS  OF  D  AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-04 
ASE 

THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  02  03 
MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245  02-03 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 
ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  0403 
lA 

EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313  03-03 
lUM 

A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM 

248603  04-03 
OPINE 

THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 
ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS. 

227635  01  03 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20- YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-17 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE 

245305  04-04 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD 

248724  04-03 


INTERACTION  OF  ATROPINE  OR  METHYLATROPINIUM  WITH  FOUR 
EFFECTS  OF  TWO  CHOLINERGIC  DRUGS. 

251217  04-03 
ATROPINE-INDUCED 

OXOTREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 
METABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
ATROPINESTERASE 

RESOLUTION,  PURIFICATION  AND  CHARACTERIZATION  OF  RABBIT 
SERUM  ATROPINESTERASE  AND  COCAINESTERASE. 

251180  04-01 
ATTACK 

A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
ATTACKS 

SLEEP  ATTACKS. 

240260  03-1 1 
ATTENTION 

THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN 

231629  01-14 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT. 

238755  0304 
MEASUREMENT  OF  ATTENTION  DEFICIT  IN  THE  COURSE  OF 
INTOXICATIONS. 

244896  04  14 
DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL 

246305  04-13 
ATTENTIONAL 

EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-11 
ATTENTIVE 

INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03  04 
ATTENUATED 

TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTASPLENDENS). 

242892  04-04 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE. 

245601  04-04 
ATTENUATION 

ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC. 

232615  02-04 
ATTENUATION  BY  ALPHA-METHYLTYROSINE  OF  AMPHETAMINE  INDUCED 
CONDITIONED  TASTE  AVERSION  IN  RATS 

237713  02-04 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L  AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT. 

237716  02-14 
ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 
STRIATAL  LESIONS. 

237777  02  03 
LYSERGIC-ACID-DIETHYLAMIDE  AND  MESCALINE  INDUCED  ATTENUATION 
OF  THE  EFFECT  OF  PUNISHMENT  IN  THE  RAT. 

252824  04-04 
ATTITUDES 

PROVIDERS  AS  PRESCRIBERS:  ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY. 

227923  OMl 
ATTRIBUTED 

PROLONGED  PSYCHOSIS  ATTRIBUTED  TO  PHENCYCLIDINE.  REPORT  OF 
THREE  CASES. 

234713  02  15 
ATYPICAL 

ATYPICAL  AND  SEVERE  FORMS  OF  DEPRESSION 

234597  02-09 
AUDIOGENIC 

INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE 

237706  02-03 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES 

25271  1  04  03 


c 
I 


dS 

§1 
I 

s- 


S-35 


Subject  Index 


Psychopharmacology  Abstract 


AUDIOVISUAL 

DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS. 

251978  04-04 
AUDITORY 

EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMMATURE  RAT. 
(PH.D.  DISSERTATION). 

231533  01  04 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENTOBARBITAL 
ON  AUDITORY  EVOKED  RESPONSES. 

234682  02-03 
EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  04-04 
AUTISM 

PHARMACOTHERAPY  IN  EARLY  INFANTILE  AUTISM. 

229921  01-11 
AUTOAAATED 

THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE. 

239010  03-15 
AUTOMATIC 

AUTOMATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE  AND 
NORADRENALINE  TRANSMISSION. 

250086  04-04 
AUTOMOBILE 

THE  INTERACTION  BETWEEN  DRUGS,  ALCOHOL  AND  DRIVING  AN 
AUTOMOBILE 

244453  04-15 
AUTOMUTILATION 

AUTOMUTILATION  INDUCED  BY  CLONIDINE  IN  MICE. 

241398  03-04 
AUTONOMIC 

THE  THERAPY  OF  AUTONOMIC  REGULATORY  DISTURBANCES  THROUGH 
DRUGS 

232260  01-15 
HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 
CURARIZED  RATS. 

244691  04-03 
AUTOOXIDATION 

EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

236521  02-03 
AUTORADIOGRAPHIC 

THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  IN 
THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  02-03 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE  IN  THE  MOUSE. 

239855  03-03 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALINE 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX-JACCHUS. 

239864  03-03 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTAS    AND  DELTA9TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIX  JACCHUS 

244681  04-03 
AUTORADIOGRAPHIC  DISTRIBUTION  STUDY  OF  14C  DOPA  IN  CAT  BRAIN. 

253393  04-03 
AVAILABILITY 

STUDIES  ON  THE  CNS  AVAILABILITY  OF  AMPHETAMINE  FROM 
AMPHETAMINIL 

229041  01  03 
AVERAGE 

INTRAVENOUS  L  DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04  09 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0  METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
AVERSION 

C0NDI1I0NED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02-14 
ATTENUATION  BY  ALPHA  METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 
CONDITIONED  TASTE  AVERSION  IN  RATS 

237713  02-04 
CYCLOHEXIMIDE  INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY  IN 
RATS 

242742  03  04 
HORMONAI   INFLUENCES  ON  IHE  EXTINCTION  OF  CONDITIONED  TASTE 
AVERSION 

251980  04-04 


RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-1 
AVERSIONS 

EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01 -( 
FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 
UCS  HABITUATION. 

241521  03-( 
TASTE  AVERSIONS  INDUCED  BY  D-AMPHETAMINE:  DOSE-RESPONSE 
RELATIONSHIP. 

242882  04-( 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04-1 
ANOREXIA  AND  CONDITIONED  TASTE  AVERSIONS  IN  THE  RAT. 

251629  04-( 
AVERSIVE 

THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  II 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-1 
EFFECTS  OF  HALOPERIDOL  ON  AVERSIVE  THRESHOLD  OF  RATS. 

240886  03-1 
THE  EFFECTS  OF  MEPROBAAAATE  UPON  THE  AVERSIVE  THRESHOLD  OF 
RATS. 

242894  04-1 
AVERSIVE  EFFECTS  OF  REPEATED  INJECTIONS  OF  THC  IN  RATS. 

249158  04-1 
AVERSIVELY 

TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04- 
AVIAN 

REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSI 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01- 
AVOIDANCE 

FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS.  (PH.D.  DISSERTATION). 

226991  01- 
THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO- 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01- 
5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFEC 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPEI 

227802  01- 
EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDITIONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION.  (PH.D. 
DISSERTATION). 

228503  01- 
MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  01- 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01- 
THE  INFLUENCE  OF  D,L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248  01- 
AVOIDANCE  BEHAVIOR  IN  VITAMIN-B6  DEFICIENT  RATS. 

232639  02- 
INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

235511  02- 
EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING. 

237264  02- 
EFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 
BEHAVIOR  OF  THE  SQUIRREL-MONKEY. 

237754  02- 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS 

238564  02- 
IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE 

239841  03- 
EFFECTS  OF  INTRAVENOUS  ANESTHETICS  ON  CONTINUOUS  AVOIDANCE 
BEHAVIOR  IN  THE  RAT     ^ 

241314  03- 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULATIO 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS 

241375  03- 


S-36 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECTS  OF  INTRA  AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

241918  03-04 
THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

243758  04-04 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

243804  04-04 
EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIDE,  A  CHOLINE 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594  04-04 
DOSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT. 

246313  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-04 
BENZODIAZEPINES  AND  AMPHETAMINE  ON  AVOIDANCE  BEHAVIOUR  IN 
MICE. 

247778  04-02 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 
COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-04 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

249381  04-04 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORMANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04-14 
CHRONIC  DELTA9-TETRAHYDR0CANNABIN0L.  TRANSIENT  AND  LASTING 

EFFECTS  ON  AVOIDANCE  BEHAVIOR. 

250061  04-04 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 

AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT. 

250074  04-04 
EFFECTS  OF  CHLORPROMAZINE  ON  AVOIDANCE  AND  ESCAPE 
RESPONDING  IN  HUMANS. 

250076  04-14 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT. 

251979  04-04 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 
ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE. 

251989  04-04 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE-BETA-HYDROXYLASE  INHIBITORS. 

253450  04-04 

^KE 

THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS    III 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04-03 

)NAL 

SPECIFIC  AXONAL  EFFECTS  OF  A  CONVULSANT  BARBITURATE. 

249258  04-03 
INS 

A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-06 
IPLASMIC 
AXOPLASMIC  TRANSPORT  OF  NOREPINEPHRINE  IN  THE  RAT  BRAIN. 

243791  04-03 
MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW. 

253407  04-03 
ITOMY 

EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04-03 
13028 

THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
(AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  04-04 


AZAFEN 

EFFECT  OF  AZAFEN  ON  THE  ELECTROENCEPHALOGRAM. 

234430  02- 1 3 
CLINICAL  EVALUATION  OF  THE  ANTIDEPRESSIVE  ACTION  OF  THE 
PREPARATION  AZAFEN. 

236429  02-10 
AZAPEROL 

AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONE 
TRANQUILIZER  AZAPERONE. 

241359  03-02 
AZAPERONE 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONE 
TRANQUILIZER  AZAPERONE 

241359  03-02 
EFFECTS  OF  AZAPERONE  ON  CARDIOVASCULAR  AND  RESPIRATORY 
FUNCTIONS  IN  THE  HORSE. 

243759  04-03 
A23I87 

lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER). 

236873  02-03 
B-9 

SYNAPTOSOMAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P-CHLOROAMPHETAMINE  OR  B  9  LESIONS. 

248414  04-05 
BABOON 

BIOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO. 

237755  02-04 
CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 
BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  04-02 
BABOONS 

EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS, 
PAPIO-PAPIO. 

230475  01-03 
BACKGROUND 

THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02-03 
BACLOFEN 

BACLOFEN  (BE):  AN  UNUSUAL  CNS  ACTIVE  AGENT. 

249304  04-03 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
ALTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 

(LIORESAL  (R)). 

251398  04  03 
BARBITAL 

EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03  03 
BARBITAL  ALTERATION  OF  CENTRAL-NERVOUSSYSTEM  SENSITIVITY  TO 
HEXOBARBITAL  IN  THE  RAT. 

244688  04-03 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RATS 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04-04 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ETHANOL  AND  BARBITAL. 

249262  04-04 
EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT. 

249278  04-04 
BARBITAL-INDUCED 

BARBITAL-INDUCED  CROSS  TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
BARBITURATE 

IMMUNOLOGIC  INVESTIGATION  OF  BARBITURATE  PHARMACOLOGY. 

229480  01-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOAAATOSENSORY  AREAS  IN  THE  CAT. 

232606  02-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  02-03 


i 


s 


s 


S-37 


Subject  Index 


Psychopharmacology  Abstrac 


BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 

COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02-04 
PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
LOSS  OF  INHIBITION  IN  SPINAL  CORD  DURING  BARBITURATE 
WITHDRAWAL 

238770  03-03 
BARBITURATE  INTOXICATION:  MORBIDITY  AND  MORTALITY. 

240843  03-15 
SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  0405 
SPECIFIC  AXONAL  EFFECTS  OF  A  CONVULSANT  BARBITURATE. 

249258  04-03 
BARBITURATE  RESPONSE  IN  IMMUNIZED  MICE. 

249297  04-03 
ACUTE  TOLERANCE  TO  BARBITURATE  IN  THE  RAT. 

250077  04-04 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 
AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORMED 
SINGLY  AND  IN  COMBINATION. 

253381  04-14 
BARBITURATE-INDUCED 

THE  POTENTIATION  OF  BARBITURATE-INDUCED  NARCOSIS  BY 
PROCARBAZINE. 

250109  04-03 
BARBITURATE-LIKE 

STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE-LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON. 

240205  03-05 
BARBITURATE-TOLERANCE 

BRAIN  LIVER  INTERRELATIONSHIP  IN  BARBITURATE-TOLERANCE. 

229490  01-03 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE. 

241348  03-03 
BARBITURATE-TOLERANT 

INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE  TOLERANT  AND  NONTOLERANT  RATS. 

226849  01-03 
BARBITURATES 

INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS. 

226849  01-03 
INTERACTIONS  OF  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 
BLOOD  VESSELS. 

229474  01-03 
CONTRACTOR  EFFECT  OF  BARBITURATES  ON  SMOOTH  MUSCLE 

230454  01-03 
BARBITAL  INDUCED  CROSS  TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
CURB  ON  BARBITURATES. 

231749  01-17 
CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  POLYETHYLENE-GLYCOL-4000  BY  IR  SPECTRAL 
ANALYSIS. 

233276  02-01 
A  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM 

233289  02-03 
IHE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  02-03 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX 

237875  02-03 
SOLUBILIIY  OF  STRAIGHT  CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT-CHAIN  ALCOHOLS. 

238487  02-01 
PTRMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 

WITH  VARYING  METHYLSULFINYLMETHIDE  CARBANION. 

238488  02-01 
PASSIVI  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 

AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES 

238763  03-03 


RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE.  AND  MALE  MICE. 

238766  03 

INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS  -  I.  STRUCTURE  ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  ir 
RAT  LIVER. 

241297  03 

EFFECTS  OF  BARBITURATES  ON  BLOOD-PRESSURE  IN  LIDOCAINE 
INJECTED  SHR. 

241405  03 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 

DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RA 

241406  03 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 

TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04 
BARBITURATES. 

250715  04 
BARRIER 

EFFECTS  OF  CAFFEINE  AND  ETHANOL  ON  THE  BLOOD-BRAIN  BARRIER  I 
RATS. 

252222  04 
BASAL 

INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  TH 
CEREBELLUM. 

241386  03 
BASELINE 

EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  04 
BASILAR 

RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01 
CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGIC/l 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04 
BATTERY 

THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  01 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY. 

229650  01 
A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02 
BC-51 

THERAPY  OF  PSYCHOPHARMACEUTICAL  SIDE-EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID,  BC-5!). 

239782  03 
BEAGLE 

TOXICITY  OF  MARIJUANA  AND  TOBACCO  SMOKING  IN  THE  BEAGLE. 

229034  01 
THE  EFFECT  OF  CHRONIC  MARIHUANA  SMOKING  ON  THE  BEAGLE  DOG 

238806  03 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEC  IN  THE 
NATURALLY  EPILEPTIC  BEAGLE. 

238811  03 
BEAM 

ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  i 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA. 

238486  02 
BEHAVIOR 

DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDEI 
IN  SCHOOL  CHILDREN. 

225783  01 
EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIO 
OF  MATURE  OFFSPRING 

226528  01 
RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D- 
AMPHETAMINE  ON  TIMING  BEHAVIOR 

226729  01 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 

MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT. 

226852  01 
RATE-DEPENDENT  EFFECTS  OF  DRUGS  ON  THE  VARIABLE-INTERVAL 
BEHAVIOR  OF  RATS 

226854  01 
INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF 
STIMULATION  BEHAVIOR  IN  RATS. 

226943  01 


S-38 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELf- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PH.D. 
DISSERTATION). 

226992  01-04 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  BEHAVIOR 
PHARMACOLOGICAL  ASPECTS. 

228309  01  17 
NEUROTRANSMITTER  INFLUENCES  ON  AMTING  BEHAVIOR  IN  MALE 
RATS.  (PH.D.  DISSERTATION). 

228390  01-04 
FHE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE. 

229037  01-11 
ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01-14 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01-04 
(MIPRAMINE,  BEHAVIOR  THERAPY,  AND  PHOBIA 

229451  01-10 
3EHAVI0R  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION  OF 
BENZODIAZEPINES. 

229461  01-04 
=OLICACID  AND  BEHAVIOR. 

229476  01-03 
DRUG  SCHEDULE  INTERACTIONS  AND  INTERCURRENT  BEHAVIOR. 

229479  01-04 
DRUGS,  BEHAVIOR,  AND  THE  CHOLINERGIC  NERVOUS  SYSTEM. 

229485  01-04 
STUDY  OF  SEROTONIN  AND  ACTH  BRAIN  LEVELS  AND  BEHAVIOR. 

229498  01-03 
NEUROPHARMACOLOGY  OF  BRAIN  MONOAMINES  AND  BEHAVIOR. 

229499  01-04 
EFFECTS  OF  D-AMPHETAMINE,  CHLORPROMAZINE,  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACED 
RESPONDING  SCHEDULES. 

229639  01-04 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM). 

230865  01-04 
THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-03 
DRUGS  AND  BEHAVIOR:  A  PRIMER  IN  NEUROPSYCHOPHARMACOLOGY 

231227  01-17 
EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-04 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01-04 
iVVOIDANCE  BEHAVIOR  IN  VITAMIN-B6  DEFICIENT  RATS. 

232639  02-04 
EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-11 
i/IOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

233870  02- 11 
DRUG-INDUCED  STEREOTYPED  BEHAVIOR:  SIMILARITIES  AND 
DIFFERENCES. 

233963  02-03 
EATECHOLAMINES,  DRUGS,  AND  BEHAVIOR:  MUTUAL  INTERACTIONS. 

233968  02-04 
rHE  EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON 

BEHAVIOR  AND  DOPAMINE  METABOLISM. 

233969  02-03 
\DAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 

OF  VARIOUS  PSYCHOACTIVE  DRUGS. 

234810  02-04 
NERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM 

235511  02-04 
MODIFICATION  OF  BETA-PHENYLETHYLAMINE-INDUCED  STEREOTYPED 
BEHAVIOR  BY  NEUROLEPTIC  AGENTS 

236672  0204 
:FFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I   GLUTAMIC  ACID  AND  GABA  IN  BRAIN  REGIONS 

237098  02-03 
:FFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR   II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 

237105  0204 


CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER) 

237169  02-04 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS 

237701  02  04 
EFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 
BEHAVIOR  OF  THE  SQUIRREL-MONKEY. 

237754  02-04 
THE  EFFECT  OF  PHENCYCLIDINE  AND  KFTAMINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  PICLON 

237757  02-04 
EFFECTS  OF  CARBON  DISULFIDE  ON  OPERANT  BEHAVIOR  IN  PIGEONS, 
(PH.D.  DISSERTATION). 

238081  02-04 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347  02-04 
CHANGES  IN  THE  SELF  STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHPINF    ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-04 
EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG  NAIVE  RATS, 

238697  03-04 
MARIJUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NORFPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03-04 
EFFECTS  OF  SOME  PSYCHOTROPIC  DRUGS  ON  AGGRESSIVE  BEHAVIOR  IN 
RATS. 

238754  03-04 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03-03 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-04 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR, 

238800  03-04 
EFFECTS  OF  HALLUCINOGENS  ON  OPERANT  BEHAVIOR 

238814  03-04 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR 

2388 1 9  03  04 
EFFECTS  OF  LITHIUM  ON  CHRONIC  ETHANOL  CONSUMPTION  AND 
BEHAVIOR. 

238849  03-03 
INFLUENCE  OF  SECOBARBITAl  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03-04 
DEPRESSED  5-HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03-13 
INTRODUCTION:  THE  CONTROL  OF  BEHAVIOR  BY  CONSEQUENT  DRUG 
INJECTIONS 

240009  03-04 
CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 

INJECTIONS  OF  DRUGS. 

240010  03-04 
STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 

CONTROL  BEHAVIOR 

24001 1  03-04 
DRUG  EFFECTS  AND  THE  ENVIRONMENTAL  CONTROL  OF  BEHAVIOR. 

240021  03-04 
CENTRAL  ACTION  OF  NORMETANEPHRINE    EFFECT  ON  THE  BEHAVIOR  OF 
RATS 

240240  03-03 
BEHAVIOR  DISORDERS  IN  CHILDHOOD  AND  THEIR  TREATMENT. 

240711  03  11 
EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG 

240916  03-04 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6 
HYDROXYDOPAMINE,  (PHD    DISSERTATION) 

241100  0303 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241109  03-04 


00 

JO 


■ft 


% 

r-' 
I 

2K 


S-39 


Subject  Index 

EUFLAVINE    EFFEf  T  ON  BRAIN  HEAVY  (VilTAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVluR  IN  GOLDRSH. 

241221  03-04 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES. 

241231  03-04 
INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  03-04 
SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIL  (MERIONES  UNGUICULATUS). 

241311  03-04 
EFFECTS  OF  INTRAVENOUS  ANESTHETICS  ON  CONTINUOUS  AVOIDANCE 
BEHAVIOR  IN  THE  RAT. 

241314  03-04 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  03-04 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 
THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 

AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 

BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (II).  RELATIONSHIP 

BETWEEN  EMOTIONALITY  AND  DEFECATION. 

241371  03-04 
ACTIONS  OF  6HYDR0XYD0PAMINE  INJECTED  INTRAVENTRICULARLY 

INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  THE  METABOLISM  OF 

BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  03-04 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 

RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  03-04 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AMINES 

WITH  PSYCHOTROPIC  DRUGS. 

241378  03-04 
CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERAL!  Y  IN  SUBSTANTIA  NIGRA. 

241382  03-04 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS.  4TH 
REPORT    COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SQUIRREL-MONKEY 
INCENTIVE  COMPETITION  BEHAVIOR.  (PHD    DISSERTATION). 

241668  03-04 
PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA)    (PH.D.  DISSERTATION). 

241994  03-04 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-04 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  THE  PREDATORY  BEHAVIOR 
OF  ONYCHOMYS  TORRIDUS. 

242749  04-04 
TWENTY-FOUR  HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTASPLENDENS). 

242892  04-04 
ADAPTIVENESS  AND  BEHAVIOR  OF  THE  ELDERLY  SUBJECT. 

242898  04-11 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDR0SARPAN-7n  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR 

243234  04-04 
TOLERANCE   PHYSICAL  DEPENDENCE  AND  OPIOID-SEEKING  BEHAVIOR: 
DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE. 

244202  04-04 
DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA  REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 
ANALYSIS  OF  HORMONAL  MEDIATION  OF  DRINKING  BEHAVIOR. 

244469  04-04 


Psychopharmacology  Abstra< 


RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  Ml( 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  0^ 
INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARMACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIA 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR. 

244899  0' 

STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPIN 

IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM 

18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 

WITH  BEHAVIOR  AND  CHARACTER. 

244958  0. 
THE  EFFECT  OF  METHYLPHENIDATE  ON  SENSORY  PERCEPTION  IN 
VARYING  DEGREES  OF  HYPERKINETIC  BEHAVIOR. 

245012  0. 
EFFECTS  OF  EARLY  POSTNATAL  ALPHA-METHYL-DOPA  TREATMENT  Oh 
BEHAVIOR  IN  THE  RAT. 

245304  0. 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEI 
AND  OLFACTORY  STIMULI. 

245406  0 
CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 
BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  0 
PSYCHOPHARMACOLOGY  IN  THE  PREVENTION  OF  ANTISOCIAL  AND 
DELINQUENT  BEHAVIOR. 

247385  0 
EFFECTS  OF  TRAZODONE  ON  BEHAVIOR  AND  BRAIN  AMINE  CONTENT 
MICE. 

247485  0 
SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUCE 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D-AMPHETAMINE 
ADMINISTRATION. 

247683  0 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMINOBUTYRIC-ACID  LEVELS 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730  Q 
47-XYy  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDIN 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  Q 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISl 

AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  C 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISl 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS 

248957  C 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHIN 

TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  C 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVI 
FOLLOWING  BRAIN  AMINE  DEPLETION. 

249138 C 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  AN 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  C 
FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  C 
SOME  EFFECTS  OF  PARATHION  ON  THE  SCHEDULE-CONTROLLED 
BEHAVIOR  OF  THE  PIGEON. 

249266  C 

INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MIC 

WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIAT 

249679  C 
ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATOR> 
BEHAVIOR  IN  FEMALE  RATS. 

250012 C 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-F 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013 C 
CHRONIC  DELTA9-TETRAHYDR0CANNABIN0L.  TRANSIENT  AND  LASTI 
EFFECTS  ON  AVOIDANCE  BEHAVIOR. 

250061  ( 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACI 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCE 
BEHAVIORAL  EXCITATION. 

250067  C 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D-AMPHETAMINE  AND 
PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

2501 12  ( 
A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTOR 
INFANT  BEHAVIOR  VARIABILITY. 

2501 75 C 
MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

251063 C 


S-40 


/OLUME  14,  SUBJECT  INDEX 


BEHAVIOR  AND  ENDOCRINE  EFFECTS  OF  3,4,5 
TRIMETHOXYAMPHETAMINE  IN  MALE  MICE. 

25t2I5  04-04 
SCHEDULE  DEPENDENT  EFFECTS  OF  CHLORDIAZEPOXIDE  ON  OPERANT 
BEHAVIOR  IN  RATS. 

251670  04-04 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

25199)  04-04 
DRUGGING  TO  SUPPRESS  BEHAVIOR. 

252315  04-17 
EHAVIORAl 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOW/ING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  01-04 
ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01  11 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01-04 
UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS 
(UNPUBLISHED  PAPER). 

226731  01-13 
BEHAVIORAL  EFFECTS  IN  RATS  FOLLOWING  INTRASTRIATAL 
MICROINJECTION  OF  MANGANESE. 

226932  01-04 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN. 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01-06 
ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN. 

227386  01-04 
BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION. 

228224  0108 
ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO:  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01-04 
METHADONE-INDUCED  BEHAVIORAL  CHANGES.  CIRCULAR  MOVEMENTS 
AGGRESSION,  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
BEHAVIORAL  EFFECTS  OF  ANTIEPILEPTIC  DRUGS, 

230368  01-11 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING,  (UNPUBLISHED 
PAPER). 

231771  01-04 
BEHAVIORAL  EFFECTS  OF  DIBUTYRYL-CYCLIC-AMP  AND  BIOGENIC 
AMINES  IN  RATS. 

232484  01-04 
BEHAVIORAL  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION 
OF  BENZODIAZEPINES. 

232509  01-04 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5  7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-03 
BEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS. 

233965  02-03 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN. 

233970  02-03 


Subject  Index 

BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS. 

233973  02-03 
BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D- 
AMPHETAMINE  ADMINISTRATION. 

234809  02-04 
DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-04 
THYROTROPIN-RELEASING  HORMONE  TRHINDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-04 
MODIFICATION  OF  THE  BEHAVIORAL  EFFECTS  OF  CHOLINOMIMETICS  BY 
PHENTOLAMINE. 

237032  02-04 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  +  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
BEHAVIORAL  AND  NEUROPHARAAACOLOGICAL  ANALYSIS  OF 

AMPHETAMINE  AND  2,5  OIMETHOXY-4-METHYLAMPHETAMINE  IN 
RATS. 

237718  02-04 
BEHAVIORAL  SUPERSENSITIVITY  TO  5-HYDROXYTRYPTOPHAN-INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT. 

237729  02-04 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02-04 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE.  (PH.D.  DISSERTATION). 

238159  02-03 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE. 

238687  03-04 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT, 

238722  03-04 
LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS, 

238741  03-03 
DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC)  AND  1 1-0H-DELTA9- 
THC:  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS. 

238813  03-04 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03-04 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES, 

239858  03-03 
NICOTINE-LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

239865  03-04 
A  BEHAVIORAL  PARADIGM  FOR  THE  EVALUATION  OF  NARCOTIC 
ANTAGONISTS, 

239941  03-11 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 

AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
BEHAVIORAL  DISINHIBITION  BY  MESCALINE. 

241243  03-04 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT- 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS, 

241251  03-04 
BEHAVIORAL  EFFECTS  OF  PENFLURIDOL  IN  RATS 

241376  03-04 
BEHAVIORAL  EFFECT  OF  PHTHALAZINOPHTHALAZINEDIONE  (L-5418), 

241397  03-04 
THE  BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  EFFECTS  OF  TAURINE 
(PH,D,  DISSERTATION). 

241574  03-03 


00 

ye 

i 


■Hi 


I 


"[:. 

5 
jB 

3K 


S-41 


Subject  Index 


Psychopharmacology  Abstracts 


MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS'  (PHD. 
DISSERTATION). 

241680  03-04 
BEHAVIORAL  TERATOGENESIS:  A  CRITICAL  EVALUATION 

242744  03- 17 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE 

243181  04-04 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 
AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04-04 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
{AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG 

245295  04-04 
CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE  OF 
SATIETY  IN  RATS. 

245612  04-02 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04-04 
ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN?. 

247382  04-14 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04  05 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
BEHAVIORAL  EFFECTS  OF  L-DOPA  AND  THYROTROPIN-RELEASING 
HORMONE  IN  SCHIZOPHRENIC  PATIENTS.  A  PRELIMINARY  REPORT. 

249120  04-08 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04-04 
KETOCYCLAZOCINE:  BEHAVIORAL  EFFECTS  IN  PIGEONS  AND  MONKEYS. 

249246  04-04 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA-MULATTA 

249267  04-04 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
RELATIONSHIP  BETWEEN  THE  BEHAVIORAL  AND 

ELECTROENCEPHALOGRAPHIC  EFFECTS  OF  CHLORPROMAZINE  AND 
FLUPHENAZINE  IN  RATS. 

249623  0402 
DOGMATIL  AND  BEHAVIORAL  PROBLEMS  IN  MIGRANT  WORKERS. 

249693  04- 11 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG  INDUCED 
BEHAVIORAL  EXCITATION 

250067  04-04 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE,  NALOXONE  AND 
NALORPHINE  IN  THE  SOUIRREL-MONKEY  AND  THE  PIGEON. 

250113  04-04 
FRONTAL-STRIATAL  CONTROL  OF  BEHAVIORAL  INHIBITION  IN  THE  RAT 

251138  04-04 
IMPORTANCE  OF  O-METHYLATION  IN  DOPAMINE-INDUCED  MOTOR  AND 
BEHAVIORAL  PHENOMENA. 

251143  04-04 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATION 
IN  RATS. 

251409  04-04 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE. 

251981  04-04 
ANATOMICAL  AND  BEHAVIORAL  EFFECTS  OF  COLCHICINE 
ADMINISTRATION  TO  RATS  LATE  IN  UTERO. 

2.52148  04-05 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS. 

252149  04-04 
BEHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  04-04 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE-BETAHYDROXYLASE  INHIBITORS. 

253450  0404 


BEHAVIORAUY 

BEHAVIORALLY  INDUCED  SENSITIVITY  TO  THE  DISCRIMINABLE 
PROPERTIES  OF  LSD. 

230876  01-04 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04-03 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
BEHAVIORS 

THE  CHEMISTRY  OF  REWARD  AND  RELATED  BEHAVIORS. 

229475  01-04 
CHOLINERGIC  MEDIATION  OF  INSTRUMENTAL  AND  CONSUMMATORY 
BEHAVIORS. 

233448  02-04 
LONG-TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS. 

241300  03-04 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS: 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04-04 
BEHAVIOUR 

EFFECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  MOUSE. 

225569  01-04 
THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
TRANSPLACENTAL  EFFECTS  OF  DRUGS  ON  HEARING,  VISION,  AND 
BEHAVIOUR. 

227391  01-05 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 
A  1,4  BENZODIAZEPINE,  TEMAZEPAM  (K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02-14 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
CANNABIS  RESIN  AND  SEXUAL  BEHAVIOUR  IN  THE  LABORATORY 
MOUSE. 

237715  02-04 
THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 

CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE. 

237723  02-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  THE  LABORATORY  MOUSE  AND  RAT. 

237727  02-04 
BRAIN  DOPAMINE  AND  JUMPING  BEHAVIOUR  IN  MICE. 

237746  02-03 
EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 

APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT 

237747  02-03 
GAMMA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL. 

237786  02-03 
QUIPAZINE:  ITS  EFFECTS  ON  RAT  BRAIN  5  HYDROXYTRYPTAMINE 
METABOLISM.  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-03 
ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS. 

239978  03-04 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 
PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  0304 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR    -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 

BRAIN,  BEHAVIOUR  AND  DRUGS. 

242265  03-17 


S-42 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE, 

243803  0404 
EFFECTS  OF  0ELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  MICE;  COMPARISON  BETWEEN  TWO  VEHICLES. 

244687  04-04 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  04-04 
EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIDE,  A  CHOLINE 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594  04-04 
DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 

ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH 

245595  04-03 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 

ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION. 

245600  04-04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK.  I.  EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245712  04-04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 

CHICK.  II.  EFFECTS  PRESENT  IN  BOTH  SEXES. 

245713  04-04 
THE  EFFECTS  OF  TRANQUILLIZING  DRUGS  ON  TIMING  BEHAVIOUR  IN 

RATS. 

246306  04-04 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04-04 
BENZODIAZEPINES  AND  AMPHETAMINE  ON  AVOIDANCE  BEHAVIOUR  IN 
MICE. 

247778  04-02 
EFFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR  OF 
THE  OVARIECTOMIZED  EWE. 

248223  04-04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 
CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA  INDUCED 
GNAWING  OF  MICE. 

248960  04-02 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 
COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-04 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS-COERULEUS  IN  RATS. 

249076  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS, 

249485  04-04 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-04 
AUTOMATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE  AND 
NORADRENALINE  TRANSMISSION. 

250086  04-04 
CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS, 

250358  04-04 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  04-04 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  0403 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN 

252523  04-03 


THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 
BEHAVIOURAL 

BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION: 
POSTSYNAPTIC  SUPERSENSITIVITY? 

229434  01-03 
BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOFS).  AETHIOPS). 

230869  01-04 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

2383)8  02-04 
STUDIES  ON  THE  BEHAVIOURAL  EFFECTS  OF  TRYPTOPHAN  AND  P- 
CHLOROPHENYLALANINE. 

239959  03-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR   -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  0304 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

241979  03-04 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE, 

243792  04-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS 

244215  04-04 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 

THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT, 

244216  04-04 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 

AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE, 

246148  04-04 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
FEEDING  AND  WITHDRAWAL, 

246310  04-04 
DOSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS, 

247206  04-04 
COMPARISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECTS  OF 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT. 

250939  04-02 
BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE. 

250942  04-11 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE:  RELATION 
TO  TISSUE  LEVELS  OF  THE  DRUG 

251131  04-03 
USE  OF  BETA-BLOCKERS  AS  AN  ADJUNCT  IN  BEHAVIOURAL  TECHNIQUES. 

251158  04-10 
BEHAVIOURAL  EFFECTS  OF  A  NEW  NONPHENYLETHYLAMINE 
ANOREXIGENIC  AGENT;  MAZINDOL 

252030  04-04 
BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFECTS  OF 
CHOLERA  TOXIN. 

252034  04-03 
BENSERAZID 

TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO  4-4602). 

233917  02-11 
BENSERAZIDE 

THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS, 

251418  04-11 
SIX-YEAR  RESULTS  OF  TREATMENT  WITH  LEVODOPA  PLUS  BENSERAZIDE 
IN  PARKINSONS  DISEASE, 

251648  04-11 
BENZAMIOES 

THE  SUBSTITUTED  BENZAMIDES. 

247546  04- 17 
BENZILATE 

ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS;  A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS. 

250360  04-02 


I 


A' 

is 


S-43 


Subject  Index 


Psychopharmacology  Abstracts 


BENZOATE 

ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 
BEHAVIOR  IN  EEMALE  RATS. 

250012  04-04 
BENZOCr  AMINE 

BENZOCTAMINE  IN  THE  TREATMENT  OF  NEUROSIS  -  AN  UNCONTROLLED 
CLINICAL  STUDY. 

235356  02-07 
BENZODIAZEPINE 

INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -  STUDIES 
ON  RAT  CEREBELLUM. 

229466  01-03 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS. 

232530  01-07 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
A  1,4  BENZODIAZEPINE,  TEMAZEPAM  {K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02-14 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03-04 
INTERACTION  OF  ALCOHOL  AND  BENZODIAZEPINE  HYPNOTICS. 

242947  04-15 
DIFFERENTIAL  PHARMACOTHERAPY  FOR  NEUROTIC  STATES 
(COMPARATIVE  EFFECTIVENESS  OF  BENZODIAZEPINE  DERIVATIVES). 

244349  04-10 
EFFECTS  OF  THIENODIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04-07 
FLURAZEPAM  HYDROCHLORIDE,  A  BENZODIAZEPINE  HYPNOTIC. 

250780  04-17 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN  -  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 

ALBUMIN    -  II.  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 
BENZODIAZEPINE-INDUCED 

BENZODIAZEPINE-INDUCEO  STATE-DEPENDENT  LEARNING:  A 
CORRELATIVE  OF  ABUSE  POTENTIAL?. 

252674  04-04 
BENZODIAZEPINES 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
BEHAVIOR  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION  OF 
BENZODIAZEPINES. 

229461  01-04 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 

BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 

BENZODIAZEPINES. 

229465  01-03 
THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 
MECHANISM  OF  ACTION  OF  BENZODIAZEPINES. 

232506  01-03 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 

BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01-03 
EFFECTS  OF  BENZODIAZEPINES  ON  CENTRAL  SEROTONERGIC 

MECHANISMS. 

232508  01-03 
BEHAVIORAL  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTION 

OF  BENZODIAZEPINES. 

232509  01-04 
ACTION  OF  THE  BENZODIAZEPINES  ON  THE  CHOLINERGIC  SYSTEM. 

232510  01-03 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 

ACTIONS  OF  BENZODIAZEPINES. 

232511  01-03 
PROBLEMS  IN  THE  ELECTROPHYSIOLOGICAL  ANALYSIS  OF  THE  SITE  OF 

ACTION  OF  BENZODIAZEPINES. 

232512  01-03 


EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 
BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM. 

232514  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 

BENZODIAZEPINES. 

232515  01-03 
ARE  BENZODIAZEPINES  ANTIPSYCHOTIC  AGENTS?. 

233815  02-08 
ARE  BENZODIAZEPINES  ANTIPSYCHOTIC  AGENTS?. 

235327  02-08 
EFFECTS  OF  MORPHINE  AND  BENZODIAZEPINES  ON  LIMBIC  SYSTEM. 

238702  03-03 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

241921  03-03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

243762  04-03 
BENZODIAZEPINES  AND  REPRODUCTION  OF  SWISS-WEBSTER  MICE. 

243788  04-04 
VORACIOUSNESS  INDUCED  IN  CATS  BY  BENZODIAZEPINES. 

244690  04-04 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 
THE  RAT  BRAIN. 

247213  04-03 
BENZODIAZEPINES  AND  AMPHETAMINE  ON  AVOIDANCE  BEHAVIOUR  IN 
MICE. 

247778  04-02 
AN  AMNESIC  EFFECT  OF  BENZODIAZEPINES  IN  RATS?. 

251216  04-04 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  04-03 
BENZOPYRANOPYRIDINES 

DRUGS  DERIVED  FROM  CANNABINOIDS.  1.  NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  04-02 
BENZOPYRANOPYRROLES 

DRUGS  DERIVED  FROM  CANNABINOIDS.  1.  NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  04-02 
BENZOPYRENE 

EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04-03 
BENZOQUINOUZINE 

RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 
BENZOTHIAZOLES 

SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
BENZTROPINE-INDUCED 

BENZTROPINE-INDUCED  RELEASE  OF  DOPAMINE  FROM  BRAIN  IN  VIVO. 

245598  04-03 
BENZYLAMINE 

IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  04-03 
BENZYUDENEAMINOOXYCARBONIC-ACID 

WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES. 

241231  03-04 
BENZYIMETHYLKETOXIME 

IN  VITRO  METABOLIC  STUDIES  USING  THE  METABONATES  OF 
AMPHETAMINE,  2-NITROSO-l-PHENYLPROPANE  AND 
BENZYLMETHYLKETOXIME. 

237980  0201 
BETA-ADRENERGIC 

REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01-03 
CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 


S-44 


'OLUME  14,  SUBJECT  INDEX 


RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER). 

237170  02-03 
DIFFERENTIAL  INTERACTIONS  OF  PENTOBARBITAL  AND  PHENOBARBITAL 
WITH  BETA-ADRENERGIC  MECHANISMS. 

238725  03-03 
EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
THERAPEUTIC  COMBINATION  OF  PSYCHOPHARMACEUTICALS  AND  BETA- 
ADRENERGIC  BLOCKERS. 

239783  03-15 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARAAACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
BETA-ADRENERGIC  BLOCKING  DRUGS  FOR  ANXIETY. 

251155  04-14 
REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 

IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21ST  1975 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  04-10 
BETA-ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 

SYMPTOMS   -  A  CASE  FOR  CONTROLLED  STUDIES. 

251164  04-08 
ITA-ALANINE 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
:TA-AMINOPROPIONITRILE 

EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIVAL 
OF  MALE  LAF-J  MICE. 

246586  04-03 

;ta-blockade 

TRANQUILIZATION  EFFECT  OF  BETA-BLOCKADE  ALPRENOLOL-  A  CLINICAL 
STUDY. 

228311  01-11 
BETA-BLOCKADE  IN  LITHIUM  TREMOR. 

230742  01-15 
TA-BLOCKERS 

BETA-BLOCKERS  IN  ANXIETY  AND  STRESS. 

240694  03-10 
USE  OF  BETA-BLOCKERS  AS  AN  ADJUNCT  IN  BEHAVIOURAL  TECHNIQUES. 

251158  04-10 
CLINICAL  EXPERIENCE  WITH  BETA-BLOCKERS  IN  CONSULTANT 
PSYCHIATRIC  PRACTICE. 

251165  04-10 
BETA-BLOCKERS  AND  THE  CENTRAL-NERVOUS-SYSTEM. 

253529  04-17 
TA-BIOCKING 

STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
TA-CARBOUNES 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINE 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  THE 
RAT  SPINAL  CORD, 

235863  02-03 
rA-OIETHYlAMINOETHYL-DIPHENYLPROPYLACETATE 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  03-04 
rA-01ETHYLAMINOETHYLDIPHENy|.PROPYLACETATE 
EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT. 

249278  04-04 
FA-HYDROXYIATED 

EFFECTS  OF  BETA  HYDROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA. 

238777  03-03 
rA-MIMETICS 

STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA  BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
A-PHENYIETHYLAMINE 
BETA  PHENYLETHYLAMINE  (PEA)  AND  THE  NEUROPSYCHIATRIC 
DISTURBANCES.  (UNPUBLISHED  PAPER). 

241474  03-14 
A-PHENYIETHYLAMINE-INOUCED 
MODIFICATION  OF  8ETA-PHENYLETHYLAMINEINDUCED  STEREOTYPED 
BEHAVIOR  BY  NEUROLEPTIC  AGENTS. 

236672  0204 


Subject  Index 

BETA-PHENYLISOPROPYLAMINES 

SYNTHESIS  OF  0-TRANSMETHYLATED  CATECHOLAMINES  AND 
PSYCHODYSLEPTIC  BETA-PHENYLISOPROPYLAMINES  (PH  D 
DISSERTATION). 

242003  03-01 
BETA-RECEPTOR 

LITHIUM  TREMOR   -  COMBINATION  TREATMENT  WITH  BETA-RECEPTOR 
BLOCKERS?. 

240741  03-14 
SOME  STUDIES  OF  BETA-RECEPTOR  BLOCKING  DRUGS  ON  THE  CENTRAL- 
NERVOUS-SYSTEM  IN  MAN. 

251162  04-13 
BETHANECHOL 

THE  USE  OF  BETHANECHOL  CHLORIDE  WITH  TRICYCLIC 
ANTIDEPRESSANTS. 

232864  02-15 
BETTA-SPLENDENS 

TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04-04 
BEVERAGES 

RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-17 
BIAS 

STRONG  MEANING-RESPONSE  BIAS  IN  SCHIZOPHRENIA. 

245559  04-08 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 
BrBLIOGRAPHY 

SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

229112  01-17 
A  BIBLIOGRAPHY  ON  THE  BIOLOGY  AND  PHARMACOLOGY  OF  LITHIUM   - 
APPENDIX  II. 

253064  04-17 
BICUCULLINE 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
BICUCULLINE  REVERSAL  OF  DEPRIVATION  AMBLYOPIA  IN  THE  CAT. 

249983  04-03 
BICYCUC 

SYNTHESIS  AND  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ACTIVITY  OF 
SOME  BICYCLIC  AMIDES. 

248539  04-02 
BILATERAL 

BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
BILAYER 

THE  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 
BILIARY 

BIOTRANSFORMATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS. 

226928  01  03 
BILIARY  ELIMINATION  OF  DIAZEPAM  IN  MAN, 

250423  04-13 
BIMOLECULAR 

lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM 
(UNPUBLISHED  PAPER). 

236873  02-03 
BINDING 

REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 
STEREOSPECIFIC  BINDING  OF  D-LYSERGIC-ACID  DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS, 

226936  01-12 
BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2  5  6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  01-03 
SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01-0.'^ 
DIPHENYLHYDANTOIN  POTENCY  AND  PLASMA  PROTEIN  BINDING. 

231003  01-03 


3 
I 


32 


S-45 


Subject  Index 


Psychopharmacology  Abstrac 


CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 

CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER) 

S-HVDROXYTRYPTAMINE  BINDING  TO  SYNAPTIC  MEMBRANES  FROM  RAT 
BRAIN. 

237890  02-03 
BINDING  OF  GLYCINE  AND  GAMMA-AMIN08UTYRIC-ACID  TO 
SYNAPTOSOAAAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 

LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 

INHIBITORY  EFFECTS  OF  RING  SUBSTITUTED  TRYPTAMINES. 
r.^T^^^  238674  03-03 

FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
MONOAMINE  OXIDASE  ACTIVE  SITE,  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (I4C)  SELECTIVE  INHIBITORS. 

241931  03-03 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04-03 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUMAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN. 

244131  04-13 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04- 1 3 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04-03 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 
THE  RAT  BRAIN. 

rrrn^^    ^  247213   0403 

EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS.  , 

247588  04-03 
THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSD  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  04-03 
IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN? 

248604  04-03 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  IN 
THE  GUINEA-PIG  INTESTINE. 

^„    ^  248703  04-03 

DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 
INDOLEAMINES  IN  BRAIN. 

250081  04-03 
ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS   A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS. 

250360  04-02 
OPIATE  RECEPTOR  BINDING  -    ENHANCEMENT  BY  OPIATE 
ADMINISTRATION  IN  VIVO. 

250378  04-03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOZIDE 
AND  CHLORPROMAZINE  METABOLITES. 

252515  04-05 
BIOASSAY 

A  METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG. 

244674  04-06 
BIOAVAILABtllTY 

PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY 

232623  02-13 
BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA 

237872  02-13 


BIOAVAILABILITY  OF  TWO  CARBAAAAZEPINE  PREPARATIONS  CURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS. 

242212  03 
BIOBEHAVIORAl 

THE  BIOCHEMICAL  AND  BIOBEHAVIORAL  PROFILE  OF  5- 
METHOXYTRYPTAMINE.  (UNPUBLISHED  PAPER). 

239307  03 
BIOCHEMICAL 

BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY. 

226737  01 
ADVANCES  IN  BIOCHEMICAL  PSYCHOPHARMACOLOGY. 

226961  01 
ANGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  ANC 
BIOCHEMICAL  ANALYSIS.  (PH.D.  DISSERTATION). 

227106  01- 
BIOCHEMICAL  IDENTIFICATION  OF  THE  /WAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR. 

227400  01- 
BIOCHEMICAL  VS  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS   WITH 
SPECIAL  REFERENCE  TO  THEIR  ANTIMANIC  EFFECT. 

227763  01- 
RECENT  VIEWS  IN  PSYCHOPHARAAACOLOGY,  ITS  BIOCHEMICAL  ASPECT 

228310  01- 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5  7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02- 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARMACOKINETICS  OF 
PSYCHOTROPIC  DRUGS. 

233682  02- 
DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-1 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II    BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS. 

235367  02-1 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  III. 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS. 

235368  02-( 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  I   AN 

UNCONTROLLED  CLINICAL  TRIAL  IN  DEPRESSION. 

235369  02-( 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02-( 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  f 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-C 
DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
DOPA  AND  L-5-HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  02-C 
PERFUSION  WITH  L-5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  02-0 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-0 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE    GAMMA- 
VINYL-GA8A  (AMIN0-4-HEX-5-EN0IC-ACID)  AND  GAMMA-ACETYLENIC- 
GABA  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03-0: 
BIOCHEMICAL  RESEARCH  INTO  PSYCHOSIS:  RESULTS  OF  A  NEW 
RESEARCH  STRATEGY. 

238997  03- 1: 
THE  BIOCHEMICAL  AND  BIOBEHAVIORAL  PROFILE  OF  5- 
METHOXYTRYPTAMINE.  (UNPUBLISHED  PAPER). 

239307  03-0; 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I.  INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-OJ 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAAAAGE. 

240219  03-11 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  III    PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT. 

240220  03- 14 


S-46 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


SOME  RECENT  ADVANCES  IN  THE  BIOCHEMICAL  PHARMACOLOGY  OF 
GAMMA-AMINOBUTYRICACID  (GABA).  (UNPUBLISHED  PAPER). 

240699  03-03 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PH.D. 
DISSERTATION). 

241680  03-04 
THE  GENETIC.  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH.D.  DISSERTATION). 

241687  03-04 
BIOCHEMICAL  RESEARCH  IN  SCHIZOPHRENIA:  RESULTING  IN  A  NEW 
RESEARCH  STRATEGY. 

241912  03-08 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
BIOCHEMICAL  PHARMACOLOGICAL  BASES  FOR  THE  CLINICAL  USE  OF  L- 

DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME. 

244039  04- 17 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT   -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  Ml- 
THE  INCORPORATION  OF  0-GLUC0SE14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE. 

246851  04-03 
A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE-OXIDASE  INHIBITORS 
(MAOIS). 

249308  04-03 
BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE. 

250942  04-11 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE   RELATION 
TO  TISSUE  LEVELS  OF  THE  DRUG. 

251131  04-03 
DIFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 
lOCHEMISTRY 

BIOCHEMISTRY  AND  THE  SEARCH  FOR  THERAPEUTIC  AGENTS. 

245949  04-06 
lODISPOSmON 

BIODISPOSITION  OF  KETAMINE  IN  THE  RAT:  SELF-INDUCTION  OF 
METABOLISM. 

250107  04-03 
EFFECTS  OF  HALOTHANE  ANESTHESIA  ON  THE  BIODISPOSITION  OF 

KETAMINE  IN  RATS. 

250108  04-03 
lOElECTRIC 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 
CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-04 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880  02-03 
lOGENIC 

BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
CHEMISTRY  AND  PHARMACOLOGY  OF  BIOGENIC  AMINE  UPTAKE. 

229478  01-03 
BIOGENIC  AMINE  EFFECTS  ON  CNS  PHOSPHOLIPID  METABOLISM. 

229482  01-03 
THE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457 01  03 
INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS. 

230878  01  04 
BEHAVIORAL  EFFECTS  OF  DIBUTYRYL-CYCLICAMP  AND  BIOGENIC 
AMINES  IN  RATS 

232484  01-04 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARUUANA  ON  EEG 
PATTERNS  IN  CATS 

235564  02-03 
BIOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO. 

237755  02-04 


COMPARATIVE  PHARAAACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  ON 
BIOGENIC  AMINE  SYSTEMS. 

238728  03-03 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 
AMINES. 

238751  03-03 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 
BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (II).  RELATIONSHIP 

BETWEEN  EMOTIONALITY  AND  DEFECATION. 

241371  03-04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4)    ROLE  OF  MONOAMINERGIC 

MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
BIOGENIC  AMINES  AND  AFFECTIVE  DISORDERS. 

241937  03-09 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
D  AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENIC 
AMINES  IN  SYNAPTOSOMES. 

246665  04-03 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-03 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS. 

251392  04-03 
EFFECTS  OF  MAZINOOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE 

252201  04-03 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-03 
BIOLOGICAL 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER). 

226731  01-13 
PSYCHOPHARMACOLOGY:  A  BIOLOGICAL  APPROACH. 

232938  02-17 
QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS 

233277  02-06 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  0204 
SYNTHESIS  AND  BIOLOGICAL  ACTIONS  OF  2-SUBSTITUTED 
QUINOLIZIDINES. 

238477  02-02 
GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 
ANALOGS  OF  FLUPHENAZINE. 

248538  04-02 
ANALOGUES  OF  S-ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-01 
BIOLOGY 

A  BIBLIOGRAPHY  ON  THE  BIOLOGY  AND  PHARMACOLOGY  OF  LITHIUM   - 
APPENDIX  II. 

253064  04-17 


s 
i 


s 

I 

I 

IS- 


S-47 


Subject  Index 


Psychopharmacology  Abstracts 


BIOSYNTHESIS 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  PROSTAGLANDIN  BIOSYNTHESIS 
IN  VITRO. 

238320  0203 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE  BETA-HYDROXYLASE  IN  LOCUS- 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE. 

238759  03-03 
THE  AMPHETAMINE-INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM. 

240065  03-03 
EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3-ACETYLCH0LINE 
BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES. 

241254  03-03 
THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES. 

241301  03-04 
BIOSYNTHETIC 

EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04-03 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
BIOTRANSFORMATION 

BIOTRANSFORMATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS. 

226928  01-03 
BIOTRANSFORMATION  OF  AMITRIPTYLINE  IN  THE  DOG. 

238684  03-03 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04-04 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO. 

251175  04-03 
BIPERIDEN 

NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE. 

238516  02-11 
BIPHASIC 

DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  ( -l- )  AMPHETAMINE. 

241257  03-03 
BIPOLAR 

THE  FORGOTTEN  TREATMENT  MODALITY  IN  BIPOLAR  ILLNESS: 
PSYCHOTHERAPY. 

231611  01-09 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
BIRTH 

CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 
BITING 

PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID, 

237705  02-04 
APOMORPHINE-INDUCEO  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS. 

247875  04-04 
DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCCO- 
LINGUAL  DYSKINESIAS. 

252031  04-03 
BIVENTER 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE 

248409  04-03 
BLACK 

ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-03 
BLAST 

EFFECT  OF  CHLORPROMAZINE  ON  THE  REACTION  OF  BLAST 
TRANSFORMATION  OF  LYMPHOCYTES. 

236373  02-03 


BLM 


THE  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 


BLOCK 

INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01-03 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03-03 
AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  03-15 
BLOCKADE 

CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORAAANCE  IN 
THE  RAT. 

226305  01-04 
DOPAMINE  RECEPTOR  BLOCKADE  AND  THE  NEUROLEPTICS,  A 
CRYSTALLOGRAPHIC  STUDY. 

226761  01-03 
MORPHINE  ANALGESIA:  BLOCKADE  BY  RAPHE  MAGNUS  LESIONS. 

23261 1  02-03 
DISRUPTION  OF  BRAIN  STIMULATION-INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE. 

235587  02-04 
PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE.  (UNPUBLISHED  PAPER). 

238491  02-13 
DIFFERENTIAL  BLOCKADE  OF  ALPHA  ADRENERGIC  RECEPTORS  BY 
CHLORPROMAZINE. 

238672  03-03 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602. 

239957  03-03 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION. 

241930  03-03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART, 

242204  03-03 
EFFECTS  OF  DOPAMINE  RECEPTOR  BLOCKADE  ON  SELF-STIMULATION  IN 
THE  MONKEY. 

242748  04-04 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04-03 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 

ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 
IN  THE  RAT, 

246843  04-03 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 

HALOPERIDOL. 

248274  04-03 
PENFLURIDOL  BLOCKADE  OF  APOMORPHINE:  DEPENDENCE  OF  DURATION 
ON  SPECIES  AND  ENDPOINT. 

248406  04-02 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-03 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION. 

249268  04-03 
NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA  -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE, 

249271  04-02 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 

AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS, 

249272  04-04 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 

THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS, 

249930  04-03 
REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 
IN  PSYCHIATRY.  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21  ST  1975. 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY 

251156  04  10 
BETA  ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 
SYMPTOMS    -  A  CASE  FOR  CONTROLLED  STUDIES. 

251164  04-08 
EFFECTS  OF  GABA  BLOCKADE  ON  LATERAL  HYPOTHALAMIC  SELF- 
STIMULATION 

252017  04-04 


S-48 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04-03 
ICKAGE 
BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  01-03 
CKERS 

INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF- 
STIMULATION  BEHAVIOR  IN  RATS 

226943  01-04 
THERAPEUTIC  COMBINATION  OF  PSYCHOPHARMACEUTICALS  AND  BETA- 
ADRENERGIC  BLOCKERS. 

239783  03-15 
LITHIUM  TREMOR  -  COMBINATION  TREATMENT  WITH  BETA-RECEPTOR 
BLOCKERS?. 

240741  03-14 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX. 

251394  04-03 
CKING 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS. 

237782  02-03 
CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
BETA-ADRENERGIC  BLOCKING  DRUGS  FOR  ANXIETY. 

251155  04-14 
REPORT  OF  A  SYMPOSIUM  ON  BETA  ADRENERGIC  RECEPTOR  BLOCKADE 

IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21  ST  1975. 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  04-10 
SOME  STUDIES  OF  BETA-RECEPTOR  BLOCKING  DRUGS  ON  THE  CENTRAL- 
NERVOUS-SYSTEM  IN  MAN. 

251162  04-13 
DIFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 

IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
CKS 

NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN. 

238840  03-03 
OD 

DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01-03 
THE  EFFECT  OF  DIAZEPAM  AND  TRIFLUOPERAZINE  ON  BLOOD  SUPPLY 
AND  CARDIAC  ACTIVITY. 

228553  01-03 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
PLASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  01-16 
BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN. 

229440  01-14 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 

SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01-16 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01-08 
INTERACTIONS  OF  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 
BLOOD  VESSELS. 

229474  01-03 


DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE,-  APPLICATION  OF 
MATHEAAATICAL  MODELS. 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  0'-13 
CHANGES  IN  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 

NEUROLEPTICS  AND  THYMOLEPTICS. 

234045  02-15 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II.  BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS. 

235367  02-09 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT 

236528  02-03 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
TRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS. 

244588  04-09 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  ON 
STEADY-STATE  BLOOD  LEVELS. 

245842  04-08 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04  03 
ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CEREBRAL 
BLOOD  CIRCULATION. 

248552  04-03 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  IN 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121  04-08 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY!  10140,  ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04-03 
CHLORPROMAZINE  METABOLISM  Vllh  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS 

251778  04-16 
BLOOD-BRAIN 

EFFECTS  OF  CAFFEINE  AND  ETHANOL  ON  THE  BLOOD  BRAIN  BARRIER  IN 
RATS. 

252222  04-03 
BIOOO-PRESSURE 

THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  MAN 

232531  01-13 
EFFECTS  OF  BARBITURATES  ON  BLOOD-PRESSURE  IN  LIDOCAINE 
INJECTED  SHR. 

241405  03-03 
BLOOD-PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04-15 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 

HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS 

248551  04-03 
INFLUENCE  OF  PHARMACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD-PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS. 

251414  04  03 
BODY 

SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

229112  0117 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01-04 
REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT. 

232617  02-03 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE  LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE 

237891  02-03 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03  03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZEO  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO  4  1284  AND 


09 
99 

I 


3 


i 

I 

I 


S-49 


Subject  Index 


Psychopharmacology  Abstract 


BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARI2ED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03-03 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN. 

242736  03-03 
DRUGS  AND  PUNISHED  RESPONDING  VI:  BODY  WEIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS. 

247845  04-04 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 
HALOPERIDOL. 

248274  04-03 
CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 
AMPHETAMINE-LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 
TEMPERATURE. 

249316  04-03 
BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFECTS  OF 
CHOLERA  TOXIN. 

252034  04-03 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN 

253041  04-15 
BONDING 

CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  POLYETHYLENE-GLYCOL-4000  BY  IR  SPECTRAL 
ANALYSIS. 

233276  02-01 
BONE 

UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04- 15 
BOSTON 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM. 

225722  01-15 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
BOUND 

ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC  ACID.  ACID. 

233278  02-01 
BOVINE 

INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 

ALBUMIN    ■  II.  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 
BRADYKININ 

EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
BRAIN 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5HYDR0XYTRYPTAMINE 

226400  01-03 
REGULATION  OF  5HYDR0XYTRYP1AMINE  METABOLISM  IN  MOUSE 

BRAIN  BY  ADRENAL  GLUCOCORTICOIDS. 

226401  01-03 


LSD  AND  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  VARIOUS  RAT 
BRAIN  AREAS. 

226406  0 1-0 
REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 

GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01 -C 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 

AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01 -C 
SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-C 
THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  BRAIN 
CATECHOLAMINES  AND  SEROTONIN. 

226726  01-C 
INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 

CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-C 
HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 

INNERVATION  IN  RAT  BRAIN. 

226739  01-C 
INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01-C 
THE  EFFECT  OF  ERGOTAMINE  AND  METHYSERGIDE  ON  SEROTONIN 
METABOLISM  IN  THE  RAT  BRAIN. 

226826  01-C 
DEPLETION  OF  S-ADENOSYL-L-METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS. 

226850  01-C 
ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN. 

226870  01-C 
RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L-TRYPTOPHAN  INJECTION. 

226873  01-C 
DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 

SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-C 
BRAIN  DYSFUNCTION  IN  CHRONIC  SEDATIVE  USERS. 

226922  01-1 
STEREOSPECIFIC  BINDING  OF  D-LYSERGIC-ACID-DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01-1 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01-C 
DIFFERENTIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 
SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN. 

227387  01-C 
THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 

ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS. 

227635  01-C 
COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMIN 

INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01-C 
SERUM  AMINO-ACIDS  AND  BRAIN  TRYPTOPHAN  UPTAKE. 

227712  01 -0 
ISOLATION  OF  AN  ENDOGENOUS  COMPOUND  FROM  THE  BRAIN  WITH 
PHARMACOLOGICAL  PROPERTIES  SIMILAR  TO  MORPHINE 

227774  01 -0 
RAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-0 
THE  ACTION  OF  CHLORPRO/WAZINE  ON  THE  PERMEABILITY  OF  THE  BRAI 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-0 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS. 

228550  01-0 
STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAl 
BRAIN. 

229435  01-0 
BRAIN  LIVER  INTERRELATIONSHIP  IN  BARBITURATE-TOLERANCE. 

229490  01-0 
THE  MECHANISM  OF  ACTION  OF  AMPHETAMINE  IN  BRAIN. 

229491  01  0 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  BRAIN  NUCLEAR  RNA. 

229494  01-0 
STUDY  OF  SEROTONIN  AND  ACTH  BRAIN  LEVELS  AND  BEHAVIOR. 

229498  0 10 
NEUROPHARMACOLOGY  OF  BRAIN  MONOAMINES  AND  BEHAVIOR 

229499  01-0 


S-50 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  AND 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  IN 
RATS 

230452  01-04 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 
PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE. 

230841  01-03 
TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  01-03 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  BRAIN  AMINE 
CONCENTRATION  AND  TURNOVER  IN  WHOLE  RAT  BRAIN  AND  IN 
VARIOUS  REGIONS  OF  THE  BRAIN. 

230856  01-03 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN. 

230863  01-14 
SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01-03 
INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

231002  01-03 
EFFECT  OF  METHAMPHETAMINE  ON  NOREPINEPHRINE  METABOLISM  IN 
VARIOUS  REGIONS  OF  BRAIN. 

231004  01-03 
THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-03 
THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION. 

231070  01-03 
A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01  03 
THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 
SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BRAIN 
NUCLEI.  (UNPUBLISHED  PAPER). 

232325  01-03 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 
THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290  02-03 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RAT 

BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02-03 
IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 

WITH  POTENT  OPIATE  AGONIST  ACTIVITY 

233300  02-01 
AN  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS. 

233336  0203 
VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

233870  02  11 
THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  0203 
EFFECT  OF  CHRONIC  TREATMENT  W'TH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIOR/.L  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-03 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN. 

233970  02-03 
SYMPATHETIC  NERVOUS  SYSTEM  EFFECTS  ON  RAT  BRAIN  METABOLISM 

234309  02-03 
PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD 

23431 1  02-03 
KINETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  RATS 
OF  DIFFERENT  AGES 

234316  02-03 
EFFECT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02  09 
DIFFERENTIAL  DRUG  EFFECTS  ON  BRAIN  SEROTONERGIC  SYSTEMS. 

234805  02-03 


DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-04 
DISRUPTION  OF  BRAIN  STIMULATION-INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE. 

235587  02-04 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMI NOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN. 

236370  02-03 
EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

236521  02-03 
THE  RELEASE  OF  GLUTAMIC-ACID  FROM  ISOLATED  BRAIN  TISSUES 

236522  02-03 
CORRELATION  OF  CHLORPROAAAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 

WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-03 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I.  GLUTAMIC  ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE    PART  1:  IS 

FENFLURAMINE  OR  NORFENFLURAMINE  INVOLVED  IN  THE  DECREASE 
OF  BRAIN  5-HYDROXYTRYPTAMINE?. 

237118  02-03 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE    PART  7.  INVOLVEMENT 

OF  BRAIN  AND  5-HYDROXYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 
OF  FENFLURAMINE. 

237119  02  03 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 

OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 

INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS 

237155  02-03 
EFFECTS  OF  TRAZODONE  ON  SEROTONIN  IN  THE  BRAIN  AND  PLATELETS 

OF  THE  RAT. 

237240  02-03 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 
INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P 

CHLOROAMPHETAMINE 

237242  02  03 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 

CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02-06 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02-04 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  i  ) 

AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
METABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 

INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN. 

237700  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS  -  ACUTE  MORPHINE  ADMINISTRATION 

237736  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS  -  CHRONIC  MORPHINE  ADMINISTRATION. 

237737  02  03 
EFFECT  OF  ANGIOTENSIN-II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 

OF  C14-5-HYDR0XYTRYPTAMINE  BY  RAT  BRAIN. 

237739  02-03 
EFFECT  OF  AMPHETAMINE  AND  FENFLURAMINE  ON  BRAIN 

NORADRENALINE  AND  M0PEG-S04. 

237740  02  03 
MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  THE 

ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  02  03 


C0 


eo 
> 


S-51 


Subject  index 


Psychopharmacology  Abstract 


THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT. 

237742  02-03 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 

AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  02-03 
BRAIN  DOPAMINE  AND  JUMPING  BEHAVIOUR  IN  MICE. 

237746  02-03 
EFFECT  OF  CATECHOLO  METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 

APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT. 

237747  02-03 
FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 

ALTER  FENFLURAMINEINDUCED  ANOREXIA. 

237748  02-03 
CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 
OF  THE  RAT. 

237862  02-03 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 

AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  IN 

THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  02-03 
DISSOCIATION  OF  RAT  BRAIN  POLYRIBOSOMES  IN  VIVO  BY 

AMPHETAMINES. 

237871  02-03 
5-HYDROXYTRYPTAMINE  BINDING  TO  SYNAPTIC  MEMBRANES  FROM  RAT 
BRAIN. 

237890  02-03 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE-LIKE 

DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-03 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 

ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN. 

237922  02-03 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
EFFECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY. 

238673  03-03 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 

INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  03-03 
DIFFERENTIAL  EFFECTS  OF  TRANYLCYPROMINE  AND  PARGYLINE  ON 

INDOLEAMINE  SYSTEMS  IN  BRAIN. 

238675  03-03 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED,  CORN-FED  RATS. 

238676  03-03 
MODULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE  (TPH)  ACTIVITY  BY 

BRAIN  TRYPTOPHAN  (TP)  CONTENT. 

238677  03-03 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 

RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
EFFECTS  OF  (-)DELTA9  TETRAHYDROCANNABINOL  ON  REGIONAL  BRAIN 
ACETYLCHOLINE  IN  THE  RAT 

238709  03-03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN. 

238715  03-03 
PROTECTION  AGAINST  STRESS  INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  03-04 
NECESSITY  OF  HYPERTHERMIA  FOR  L  DOPA  OR  D  AMPHETAMINE  TO 

DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03-03 


DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 

(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 

CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-( 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 

ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 

SYNAPTOSOMES. 

238729  03-1 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 

DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULAT 

CATECHOLAMINE  RECEPTORS. 

238734  03-1 
CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 

CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 

SYNAPTOSOMES. 

238738  03-1 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  03-i 
EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFIED  CHOLINOCEPTIVE 

CELLS  OF  THE  SNAIL  BRAIN. 

238740  03-1 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 

AMINES. 

238751  03-' 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  LOCUS- 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE. 

238759  03- 
THE  DYNAMICS  OF  DOPAMINE  METABOLISM  IN  VARIOUS  REGIONS  OF 
RAT  BRAIN. 

238761  03- 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE 
MOUSE  BRAIN. 

238765  03- 
EFFECTS  OF  BETA-HYDROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA. 

238777  03- 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMAA/ 
VINYL-GABA  (AMIN0-4-HEX-5-EN0IC-ACID)  AND  GAMAAA-ACETYLENK 
GABA  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03- 
INJECTIONS  OF  AMINO-ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREAS 

THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03- 
EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 

WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  R/ 
BRAIN. 

238790  03- 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  C 

BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03- 
BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 

INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC). 

238812  03- 
EFFECTS  OF  ANTIHISTAMINIC  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM. 

238838  03-' 
NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN. 

238840  03-' 
CATECHOLAMINES  IN  BRAIN  ISCHEMIA   -  EFFECTS  OF  ALPHA-METHYL-F 
TYROSINE  AND  PARGYLINE. 

239577  03-1 
TRYPTOPHAN  REGULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE. 

239581  03-1 
ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN 

239849  03-i 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOL 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-1 
EFFECT  OF  CLOZAPINE  ON  THE  METABOLISM  OF  SEROTONIN  IN  RAT 
BRAIN. 

239862  03-1 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALINI 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX-JACCHUS. 

239864  03-1 
EFFECTS  OF  P-CHLOROAMPHETAMINE  ON  LOCOMOTOR  ACTIVITY  AND 
BRAIN  5-HYDROXYINDOLES. 

239958  03-1 
QUIPAZINE:  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM,  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-1 


S-52 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


EVIDENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 
TRIPHOSPHATASES  FROM  BRAIN. 

239962  03-03 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  f  ) 
AMPHETAMINE  AND  (  t  OR)  P-CHLOROAMPHETAMINE. 

239976  03-03 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 
PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  03-03 
EFFECT  OF  DIPHENYLHYDANTOIN  ON  THE  ENDOGENOUS 
PHOSPHORYLATION  OF  BRAIN  PROTEIN. 

240746  03-03 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE  ACTIVITY:  MICROASSAY 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  03-03 
EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03-04 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3  5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 
EFFECTS  OF  DIETHYLDITHIOCARBAMATE  ON  THE  CATABOLISM  OF 
TYROSINE  IN  THE  RAT  BRAIN. 

241249  03-05 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE. 

241253  03-03 
EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3-ACETYLCH0LINE 

BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES. 

241254  03-03 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  (  + )  AMPHETAMINE. 

241257  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYOROXYTRYPTAMINE. 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 

HYDROXYINDOLES  BY  P-CHLOROAMPHETAMINE. 

241339  03-03 
EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 


ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

NEUROCHEMICAL  STANDPOINT. 

SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES 


1) 


241360  03-03 


241361  03-03 


THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 


SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN. 

241366  03-03 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (1).  RELATIONSHIP 
BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  THE  METABOLISM  OF 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  03-04 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AMINES 
WITH  PSYCHOTROPIC  DRUGS. 

241378  03-04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 

FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03-03 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 

GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-03 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (III). 

241394  03-03 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03  03 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5-HT) 

TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-03 
EFFECTS  OF  MORPHINE  ON  5-HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  IN 

THE  RAT  BRAIN  (III). 

241402  03-03 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE. 

241414  03-03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES. 

241416  03-03 
THE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 
AND  MONOAMINE  SYNTHESIS. 

241472  03-17 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE. 
(PH.D.  DISSERTATION). 

241576  03-03 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PHD 
DISSERTATION). 

241680  03-04 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 
ELEVATED  ENVIRONMENTAL  TEMPERATURE. 

241925  03-03 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

241979  03-04 
HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 
BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE. 

241989  03-03 
CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  THE 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  LOCOMOTOR  ACTIVITIES  IN 
THE  RAT. 

242205  03-04 
BRAIN,  BEHAVIOUR  AND  DRUGS. 

242265  03-17 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  THE 
REGULATION  OF  EMOTIONAL  REACTIVITY 

242544  03-03 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN. 

242736  03-03 
EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5-HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN. 

243777  04-03 
NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 

OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  04-03 
EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 

PERFUSED  RAT  BRAIN. 

243782  04-03 


iff 

•pa 

« 


I 


its 

3K 


S-53 


Subject  Index 


Psychopharmacology  Abstra( 


INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  04-03 
AXOPLASMIC  TRANSPORT  OF  NOREPINEPHRINE  IN  THE  RAT  BRAIN. 

243791  04-03 
NEONATAL  HYPERTHYROIDISM;  ALTERATIONS  IN  BEHAVIOURAL 

ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE 

243792  04-03 
DRUGS,  AROUSAL,  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-14 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-03 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN. 

244455  04-04 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5  HYOROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTAS-  AND  DELTA9-TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIX-JACCHUS. 

244681  04-03 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT    -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  IIL 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
BENZTROPINE-INDUCED  RELEASE  OF  DOPAMINE  FROM  BRAIN  IN  VIVO. 

245598  04-03 
EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  I- 

HYDROXY-3  AMINO-PYRROLIDONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04-03 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 

ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION. 

245600  04-04 
UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 

FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO 

246150  04-04 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS, 

246318  04  04 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE 

246661  04-03 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE. 

246662  04-03 
STUDIES  ON  ACCUMULATION  OF  (14C)  MESCALINE  IN  BRAIN 

HOMOGENATES:  EFFECTS  OF  PSYCHOTROPIC  AND  OTHER  AGENTS. 

246817  04-03 
FFFFCTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA  HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN 

246845  04-03 
EFFECT  OF  3P  TRIFLUOROMETHYLPHENOXY  N-METHYL  3 

PHENYLPROPYLAMINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN  BY  4- 
CHLOROAMPHETAMINE. 

246847  0403 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3  P  TRIFLUOROMETHYLPHENOXY-N- 
METHYL-3-PHENYLPROPYLAMINE 

246848  04-03 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 

CAPACITY  FOR  5  HYOROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04-03 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 

CORTICAL  SLICES. 

246850  04  03 


CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  0 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE 

246851  0/ 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSl 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROME: 

246993  0' 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CS 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES 

246994  0. 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION 

246996  0. 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPH 
LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  0. 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTO 
DERIVATIVE  TECHNIQUE. 

247131  a 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  I 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  0 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATION! 
THE  RAT  BRAIN. 

247213  0 
EFFECTS  OF  TRAZODONE  ON  BEHAVIOR  AND  BRAIN  AMINE  CONTENT 
MICE. 

247485  0 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMI NOBUTYRIC-ACID  LEVELS 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730  0 
THE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS. 

248159  0 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  0 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RAT 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREAT 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  0 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINER 
MECHANISMS  IN  RAT  BRAIN. 

248286  0 
DISTRIBUTION  OF  3H-ALPHA-MSH  IN  RAT  BRAIN. 

248349  0 
SYNAPTOSOAML  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P-CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  0 
ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 
CLOZAPINE  AND  CHLORPROMAZINE. 

248600  0 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVIT> 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS.  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  0 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 
ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS 
OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  0 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 

BRAIN  SYNAPTOSOMES. 

248701  0 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMIST 

AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  0 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMIST 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS 

248957  0 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCE 
GNAWING  OF  MICE. 

248960  0 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITO 
I-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  0 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVI' 
FOLLOWING  BRAIN  AMINE  DEPLETION. 

249138  0 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCEI 
RELEASE  OF  AMINES  FROM  RAT  BRAIN 

249233  0 
STUDIES  OF  METHYLPHENIDATE  14C  IN  RAT  BRAIN. 

249243  0 


S-54 


3LUME  14,  SUBJECT  INDEX 


Subject  Index 


STUDIES  ON  SULFATE  CONJUGATION  OF  ESTROGENS  IN  BRAIN  AND 
LIVER. 

249245  04-03 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  04-05 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE. 

249274  04-04 
ON  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 
PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS. 

249287  04-03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE 

249294  04-03 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04-03 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN. 

249300  04-03 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-03 
CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 

AMPHETAMINE-LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 
TEMPERATURE. 

249316  04-03 
BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 

COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N  N 
DIMETHYLTRYPTAMINE  AND  5-METH0XY-N,N  DIMETHYLTRYPTAMINE. 

249317  04-05 
EFFECT  OF  METOCLOPRAMIDE  ON  TURNOVER  OF  BRAIN  DOPAMINE 

NORADRENALINE  AND  5-HYDROXYTRYPTAMINE. 

249628  04-03 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
A  FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AND 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

249669  04  04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-04 
EFFECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04-03 
ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE 
MICROINJECTION  INTO  MOUSE  BRAIN. 

250062  04-04 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 

AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04-02 
DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 

INOOLEAMINES  IN  BRAIN. 

250081  04-03 
PROPRANOLOL  INHIBITS  RAT  BRAIN  MONOAMINE-OXIDASE 

250333  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHENOBARBITAL. 

250682  04-05 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO 

251175  04-03 
EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R0-4- 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM 

251181  04-03 
PREFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04-03 
ALTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 
(LIORESAL  (R)). 

251398  04-03 


CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT, 

251400  04-03 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS  INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN 

251416  04-03 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  04-03 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS 

251534  04-03 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04-03 
EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS. 

251990  04-04 
THE  REGIONAL  DISTRIBUTION  OF  A  MORPHINE-LIKE  FACTOR  ENKEPHALIN 
IN  MONKEY  BRAIN. 

252219  04-03 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5 

HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 

SEROTONIN  BIOSYNTHETIC  SYSTFM  IN  RAT  BRAIN. 

2525  M  04-03 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
CORRELATION  BETWEEN  NEUROLEPTICINDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 

RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-03 
AUTORADIOGRAPHIC  DISTRIBUTION  STUDY  OF  14C-D0PA  IN  CAT  BRAIN. 

253393  04  03 
EFFECT  OF  DELTA9TETRAHYDR0CANNABIN0L  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-03 
BRAIN-DYSFUNCTIONING 

METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHIIDREN. 

252798  04-11 
BRAINS 

BINDING  OF  GLYCINE  AND  GAMMA  AMINOBUTYRIC  ACID  TO 

SYNAPTO.SOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 
THE  BRAINS  DOPAMINE  RECEPTOR:  LABELING  WITH  3H-D0PAMINE  AND 
3H-HAL0PERID0L  . 

240077  03-03 
ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 
TREATED  AND  STRESSED  MICE. 

249299  04-03 
EFFECTS  OF  D  AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D  GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE 

249672  04-04 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET, 

249675  04-03 
BRAINSTEM 

TREATMENT  WITH  ACETAZOLAMIDF  OF  BRAINSTEM  AND  SPINAL 
PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01-13 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM 

237783  02-03 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 
DORSAL  ROOT  POTENTIALS 

239982  03-03 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

24 1 369  03-03 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION, 

241930  0303 


09 

i 


GO 


S-55 


Subject  Index 


Psychopharmacology  Abstrai 


EFFECT  OF  NOMIFENSINE  ON  ACETYLCIIOLINP  AND  CHOLINE  IN  THE  RAT 
STRIATUM  AND  BRAINSTEM. 

248291  04-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
IN  VIVO  AND  IN  VITRO  ACTIVATION  OF  SOLUBLE  TRYPTOPHAN- 
HYDROXYLASE  FROM  RAT  BRAINSTEM, 

249512  04-03 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 
BRANCH 

AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  03-15 
BRANCHED 

SOLUBILITY  OF  STRAIGHT-CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT  CHAIN  ALCOHOLS. 

238487  02-01 
BREAST 

DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE. 

230424  01-15 
BREATHING 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

23551 1  02-04 
BRED 

EFFECTS  OF  PENTOBARBITAL  IN  MICE  SELECTIVELY  BRED  FOR  DIFFERENT 
SENSITIVITIES  TO  ETHANOL. 

249261  04-04 
BROAAAZEPAM 

DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS  LIQUID  CHROMATOGRAPHY. 

229906  Oil  6 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03-03 
CLINICAL  EXPERIENCE  WITH  RO-5-3350  (BROMAZEPAM). 

245138  04-10 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
BROMISM 

MANIA  AND  BROMISM:  A  CASE  REPORT  AND  A  LOOK  TO  THE  FUTURE. 

236754  02-09 
BROMOCRIPTINE 

STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  t  )  AMPHETAMINE 
AND  L  DOPA 

249419  04-04 
BROMOCRIPTINE  TREATMENT  IN  PARKINSONS  DISEASE. 

251239  04-11 
THE  ANTIPARKINSONIAN  EFFICACY  OF  BROMOCRIPTINE. 

251649  04-07 
BS-100-141 

EFFECTS  OF  CLONIDINE  AND  BS  100  141  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS 

226728  01-03 
BUCCAL 

THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES. 

237981  02-02 
BUFOTENINE 

BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
DIMETHYLTRYPTAMINE  AND  5  METHOXY-N,N  DIMETHYLTRYPTAMINE. 

249317  04-05 
BULB 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01-04 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02-03 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 


CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  Af 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  0; 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  THE  METABOLISM  ( 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  0: 
BULBAR 

THE  EFFECT  OF  SEROTONIN  INJECTION  INTO  THE  BULBAR  STRUCTURE; 
ON  HEMODYNAMICS. 

236831  O: 
BULBECTOMIZED 

EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICII 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  0: 
BULBECTOMY 

CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  0 
BULLFROG 

DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFf 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  0 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  Oi 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  0 
BUNDLE 

INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  0 
AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  0 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCL 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  0 
BURIMAMIDE 

THE  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE- 
INDUCED  CATALEPSY  IN  THE  RAT. 

240238  0 
BURONIL 

EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  0 
BUTACLAAAOL 

THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORK 
(AY-23028)   A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  0 
BUTAPERAZINE 

BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  C 
STEADY-STATE  BLOOD  LEVELS. 

245842  0 
BUTYROPHENONE 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 
BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOL 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  0 
EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  0 
PILOT  OPEN-LABEL  STUDY  OF  LENPERONE  (AHR-2277),  A 
BUTYROPHENONE,  IN  ANXIETY. 

241278  0 
AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENO 
TRANQUILIZER  AZAPERONE, 

241359  0 
BUTYROPHENONE  INFLUENCES  ON  THE  OPIATE  RECEPTOR. 

250088  0 
BUTYROPHENONES 

INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  Tl 
CEREBELLUM. 

241386  0 
B6D2F1 

INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  0 
CAERULEIN 

VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS. 

244311  0 


S-56 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


CAFFEINE 

CAFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON. 

227571  01-11 
THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS 

231248  01  04 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DYSFUNCTION. 

235322  02-11 
THE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE. 

236249  02-03 
EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS. 

236371  02-04 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM   AND 
PENTOBARBITAL  ON  DRL  PERFORAAANCE  IN  RATS. 

241400  03-04 
METHYLPHENIDATE  AND  CAFFEINE  IN  THE  TREATMENT  OF  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION. 

245786  04-14 
CAFFEINE  AND  CHLORDIAZEPOXIDE:  EFFECTS  ON  MOTOR  ACTIVITY  IN 
THE  CHRONIC  THALAMIC  RAT. 

246388  04-04 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 
HYPERKINETIC  CHILDREN. 

247379  04-14 
THE  EFFECT  OF  CAFFEINE  ON  HUMAN  PERFORMANCE,  ALONE  AND  IN 
COMBINATION  WITH  ETHANOL. 

249674  04-14 
EFFECTS  OF  CAFFEINE  AND  ETHANOL  ON  THE  BLOOD-BRAIN  BARRIER  IN 
RATS. 

252222  04-03 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

252798  04-11 
CALCIUM 

lONOPHORES  X573A  AND  A23187,  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM 
(UNPUBLISHED  PAPER). 

236873  02-03 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 
TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY, 

243797  04-03 

:all 

diazepam  use  in  military  sick  call. 

240278  03-17 
:allithrix-jacchus 

AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALINE 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX-JACCHUS. 

239864  03-03 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTAS-  AND  DELTA9-TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIX-JACCHUS. 

244681  04-03 

:ajvmzepam 

camazepam  (sb-5833)  in  preparation  for  endoscopy  inspection: 
open  and  double-blind  study  versus  diazepam. 

241276  03-14 

:amp 

in  vivo  activation  of  rat  pineal  camp  phosphodiesterase  by 
isoproterenol.  (unpublished  paper). 

228032  01-03 
CAMP  CONTENT  AND  THE  REGULATION  OF  TYROSINE-3- 

MONOOXYGENASE  IN  RAT  STRIATUM.  (UNPUBLISHED  PAPER). 

232921  02-03 

:ancer 

counseling,  peak  experiences  and  the  human  encounter  with 
death:  an  empirical  study  of  the  efficacy  of  dpt-assisted 
counseling  in  enhancing  the  quality  of  life  of  persons  with 
terminal  cancer  and  their  closest  family  members.  (ph.d. 
dissertation). 

228686  01-11 
SCHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04-16 
lANINE 

CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 
TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 


AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG  --  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04-03 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES. 

252757  04-03 
CANNABICHROMENE 

INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-05 
CANNABIDIOL 

THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 
DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC- 
INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINE-DEPENDENT 
RATS. 

227702  01-04 
THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01-03 
CANNABIDIOL  AND  ITS  PHARMACOKINETIC  INTERACTION  WITH  DELTAl- 
TETRAHYDROCANNABINOL. 

233279  02-03 
INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-05 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 

RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-03 
INFLUENCE  OF  CANNABIDIOL  OF  DELTA9-TETRAHYDR0CANNABIN0L 
EFFECTS. 

243087  04-14 
INTERACTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS. 

244894  04-04 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9-THC  DURING 
ABSTINENCE  IN  MORPHINE  DEPENDENT  RATS. 

249001  04-04 
CANNABINOID 

CANNABINOID  PATTERN  IN  CANNABIS-SATIVA  L.  SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE. 

237982  02-01 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
PRECLINICAL  PHARAAACOLOGIC  PROFILE  OF  A  PSYCHOACTIVE 
CANNABINOID. 

249276  04-02 
CANNABINOIDS 

EFFECTS  OF  CANNABINOIDS  ON  THE  IN  VITRO  PERFUSED  RAT  HEART. 

238767  03-03 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03-03 
INHIBITION  OF  CORTICOSTEROIDOGENESIS  BY  CANNABINOIDS. 

238808  03-03 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 

RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-03 
DRUGS  DERIVED  FROM  CANNABINOIDS.  1.  NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROGEN 

AND  CARBOCYCLIC  ANALOGS. 

248647  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  5.  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  3.  SULFUR  ANALOGS, 

THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS 

248651  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 

SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  04-02 


i 


tf 


CO 

•a 

IS* 
3S 


S-57 


Subject  Index 


Psychopharmacology  Abstracts 


CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 
BRAIN  S/NAPTOSOMES. 

248701  04-03 
CANNABINOL 

PHARMACOLOGICAL  INTERACTION  BETWEEN  CANNABINOL  AND  DELTA9- 
TETRAHYDROCANNABINOL. 

225570  01-03 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 
DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC- 
INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINE-DEPENDENT 
RATS 

227702  01-04 
THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L.  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01-03 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL. 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-03 
CLINICAL  PHARMACOLOGY  OF  NABILONE,  A  CANNABINOL  DERIVATIVE. 

248628  04-12 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABINOL  IN 
MAN, 

249622  04-07 
CANNABIS 

EFFECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  MOUSE 

225569  01-04 
RECENT  PROGRESS  IN  THE  LONG-TERM  PHARMACOLOGICAL  RESEARCH 
ON  CANNABIS. 

229043  01-17 
CANNABIS:  EFFECTS  ON  HUNGER  AND  THIRST. 

234626  02-14 
CANNABIS  RESIN  AND  SEXUAL  BEHAVIOUR  IN  THE  LABORATORY 
MOUSE. 

237715  02-04 
THE  STABILITY  OF  CANNABIS  AND  ITS  PREPARATIONS  ON  STORAGE 

237784  02-01 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03  03 
DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04-13 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
FEEDING  AND  WITHDRAWAL. 

246310  04-04 
CANNABIS-SATIVA 

CANNABINOID  PATTERN  IN  CANNABIS-SATIVA  L.  SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE. 

237982  02-01 
CAPACITY 

THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01-03 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST 

236372  02  04 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN, 

246849  04-03 
EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS 

247588  04-03 
CAPTAGON 

TREATMENT  OF  THE  MINIMAL-BRAINDYSFUNCTION  SYNDROME  WITH 
PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON). 

230002  01-11 
CAPTURE 

THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02-03 
CAR 

REVERSAL  OF  THE  6-HYDROXYDOPAMINE-INOUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
CARBACHOL 

CARBACHOL  ELICITED  MOUSE  KILLING  BY  RATS   CIRCADIAN  RHYTHM 
AND  DOSE-RESPONSE. 

238006  02-04 


A  PRESSOR  RESPONSE  TO  INTRAVENTRICULAR  INJECTIONS  OF 
CARBACHOL 

251142  04-03 
CARBAMAZEPINE 

PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAAAAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01 -l-t 
DOSE-RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 

SECRETION  OF  ADH:  EFFECTS  OF  CLOFIBRATE  AND  CARBAAAAZEPINE. 

232638  02-1; 
PLACENTAL  TRANSFER  OF  CARBAMAZEPINE  IN  THE  RAT. 

237749  02-0; 
PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-1; 
BIOAVAILABILITY  OF  TWO  CARBAAAAZEPINE  PREPARATIONS  DURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS. 

242212  03- r 
KINETICS  OF  CARBAAAAZEPINE  AND  ITS  10,1 1  EPOXIDE  METABOLITE  IN 
CHILDREN. 

243086  04- 1 ; 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAAAAZEPINE  AND 
CHLORPROMAZINE. 

244352  04-0' 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAAAAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04-1 
THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-01 
CARBAAAAZEPINE  (TEGRETOL)   -  A  DOUBLE-BLIND  COMPARISON  WITH 
PHENYTOIN  (DILANTIN). 

251937  04-1: 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-1 
SERUM  CONCENTRATION  OF  CARBAAAAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

253011  04-a 
CARBANION 

PERMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 
WITH  VARYING  METHYLSULFINYLMETHIDE  CARBANION. 

238488  02-0 
CARBIDINE 

THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-0i 
CARBIDOPA 

INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 
AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES 

244664  04-0 
COMPARISON  OF  DOPA  DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

248612  04-1 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE 

248613  04-1 
CARBOCYCLIC 

DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROGEN 
AND  CARBOCYCLIC  ANALOGS 

248647  04-0 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 
SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  04-0 
CARBON 

EFFECTS  OF  CARBON  DISULFIDE  ON  OPERANT  BEHAVIOR  IN  PIGEONS. 
(PH.D.  DISSERTATION). 

238081  02-0 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-0 
THE  EFFECT  OF  CARBON  DISULFIDE  ON  THE  STEREOTYPIC  EFFECT  OF 
DOPAMINE  AGONISTS. 

250090  04-0 
CARBONATE 

FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 

CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIV 
STUDY  GROUP 

225718  01-0 
A  DOUBLE-BLIND  TRIAL  OF  LITHIUM  CARBONATE  AND  HALOPERIDOL  IN 
HUNTINGTONS-CHOREA. 

227550  01-1 


S-58 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN^ 

228226  01-09 
EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED  BY 
LITHIUM  CARBONATE. 

233499  02-15 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  02-09 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS;  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02-09 
LITHIUM  CARBONATE  IN  JUVENILE  AAANIC-DEPRESSIVE  ILLNESS. 

236663  02-10 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT. 

237716  02-14 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL. 

240074  03-14 
LITHIUM  CARBONATE  AND  HYPOTHYROIDISM. 

244113  04-15 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTPATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  IN 
PATIENTS  TAKING  LITHIUM  CARBONATE. 

249535  04-09 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY: 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04-15 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARMACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS. 

252198  04-03 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
CARCINOMA 

THE  MEASUREMENT  OF  PAIN  IN  TERMINAL  CARCINOMA. 

252143  04-11 
CARDIAC 

THE  EFFECT  OF  DIAZEPAM  AND  TRIFLUOPERAZINE  ON  BLOOD  SUPPLY 
AND  CARDIAC  ACTIVITY. 

228553  01-03 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS 

240064  03-03 
USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  CARDIAC 
CATHETERIZATION. 

244450  04-11 
CARDIORESPIRATORY 

METHYLPHENIDATE  IN  CHILDREN:  EFFECTS  UPON  CARDIORESPIRATORY 
FUNCTION  ON  EXERTION, 

247378  04-15 
CARDIOTOXIC 

CARDIOTOXIC  EFFECTS  OF  PSYCHOTROPIC  DRUGS, 

247784  04-15 
CARDIOVASCULAR 

MONOAMINE-OXIDASES  OF  THE  RAT  CARDIOVASCULAR  SYSTEM. 
(UNPUBLISHED  PAPER). 

227783  01-03 
CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS    -  A 
RISK  IN  THE  USE  OF  THESE  DRUGS, 

23131701-15 
A  REVIEW  OF  THE  CARDIOVASCULAR  EFFECTS  AND  TOXICITY  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

237909  02-15 
CHRONIC  CARDIOVASCULAR  EFFECTS  OF  0ELTA9 

TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  THE  MONGREL  DOGS 

238810  03-03 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03-03 


EFFECTS  OF  AZAPERONE  ON  CARDIOVASCULAR  AND  RESPIRATORY 
FUNCTIONS  IN  THE  HORSE. 

243759  04-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

243800  04-03 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
CARDIOVASCULAR  EFFECTS  OF  CENTRAL  MICROINJECTIONS  OF 
APOMORPHINE  IN  CATS. 

249033  04-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT, 

249418  04-03 
CARDIOVASCULAR  EFFECTS  OF  PROLONGED  DELTA9- 
TETRAHYDROCANNABINOL  INGESTION. 

253609  04-13 
CARDIOVERSION 

THE  USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  ELECTRIC 
CARDIOVERSION. 

244451  04-11 
CARE 

DRUG  THERAPY  IN  CHILD  CARE. 

243897  04-15 
CARROLL 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL, 

24.5971  04-06 
CARTAZOLATE 

ANTIDEPRESSANT  PREDICTABILITY:  CARTAZOLATE, 

242251  03-09 
CASUISTIC 

PIRACETAM  IN  A  CASE  OF  ACUTE  CEREBRAL  HYPOXEMIA:  CASUISTIC 
REPORT, 

229128  01-14 
ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  EXTRAPYRAMIDAL  MOTOR 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT, 

234291  02-11 
EXTRAPYRAMIDAL  SYMPTOMS  UNDER  CLOZAPINE:  A  CASUISTIC 
CONTRIBUTION 

238855  03-15 
CASUISTICAL 

THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 

CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN, 

233717  02-11 


CAT 


A  STUDY  OF  INHIBITORY  ANTAGONISM  IN  CAT  VISUAL  CORTEX, 

226397  01-03 
ANGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  AND 
BIOCHEMICAL  ANALYSIS,  (PHD,  DISSERTATION). 

227106  01-04 
DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT, 

232328  01-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT. 

232606  0203 
THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  0203 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT. 

237780  02-04 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME) 

238825  03-03 
6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 

FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC  ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS 

238826  03-03 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 

CONDITIONED  REFLEX  IN  THE  CAT. 

239275  03-04 


00 

s 


gpv 

SI 
IS 


S-59 


Subject  Index 


Psychopharmacology  Abstracts 


THE  ACTION  OF  CHLORPROMAZINE  ON  THE  ELECTRODERMAL  RESPONSE 

IN  THE  CAT. 

239963  03-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 

PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 

CAT. 

241255  03-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 

RESPONSE  TO  STI/W,ULATION  OF  ADRENERGIC  NERVES  USING  CAT 

ATRIA  IN  VITRO. 

241313  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARI2ED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 

BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 

NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM 

241386  03-03 
EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  04-04 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES- 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-03 
BICUCULLINE  REVERSAL  OF  DEPRIVATION  AMBLYOPIA  IN  THE  CAT. 

249983  04-03 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT. 

251820  04-03 
METHAMPHETAMINE  SELF-ADMINISTRATION  IN  THE  CAT. 

251976  04-04 
THE  EFFECTS  OF  5HYDR0XYTRYPT0PHAN  AND  L-TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT. 

252216  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 

SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04-03 
AUTORADIOGRAPHIC  DISTRIBUTION  STUDY  OF  14C-D0PA  IN  CAT  BRAIN. 

253393  04-03 
CATABOIISM 

EFFECTS  OF  DIETHYLDITHIOCARBAMATE  ON  THE  CATABOLISM  OF 
TYROSINE  IN  THE  RAT  BRAIN. 

241249  03-05 
EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  03-03 
CATALEPSY 

SEROTONERGIC  INVOLVEMENT  WITH  NEUROLEPTIC  CATALEPSY. 

237781  02-03 
THE  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE- 
INDUCED  CATALEPSY  IN  THE  RAT. 

240238  03-03 
AMT  CATALEPSY  AND  HYPOKINESIA:  INTERACTION  WITH  MORPHINE 
AND  COCAINE. 

241224  03-04 
HALOPERIDOL  CATALEPSY  IN  GROUPED  AND  ISOLATED  MICE. 

249624  04-04 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 
CATALEPSY  IN  THE  RAT. 

250084  04-03 


CATALYTIC 

A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL-GABA  (AMIN0-4-HEX-5-EN0IC-ACID)  AND  GAMAM-ACETYLENIC- 
GABA  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03-03 
CATATONIA 

THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
CATECHOL-O-METHYITRANSFERASE 

THE  EFFECT  OF  CATECHOLO-METHYLTRANSFERASE  INHIBITORS  ON 
BEHAVIOR  AND  DOPAMINE  METABOLISM. 

233969  02-03 
EFFECT  OF  CATECHOLO-METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT 

237747  02-03 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
O-METHYLTRANSFERASE, AND  FAMILY  HISTORY. 

246629  04-m 
CATECHOL-O-METHYLTRANSFERASE  FROM  RAT  LIVER:  TWO  FORMS 
HAVING  DIFFERENT  META:PARA  METHYLATION  RATIOS. 

249035  04-01 
CATECHOLAMINE 

EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  Ol-O; 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-00 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01-0: 
ASCENDING  CATECHOLAMINE  SYSTEMS  AND  MORPHINE  ANALGESIA. 

232915  02-00 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  {UNPUBLISHED 
PAPER). 

236875  02-Ot 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-0: 
THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT. 

237742  02-0; 
CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 
OF  THE  RAT. 

237862  02-0; 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY. 

238673  03-0; 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-0: 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03-0: 
EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03-0; 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERAAAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-0; 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-00 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-0^ 
THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04- 1; 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 


S-60 


OLUME  14,  SUBJECT  INDEX 

CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYOROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT. 

251400  04-03 
CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6- 
HYDROXYDOPAMINE  AND  DESIPRAMINE. 

252024  04-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 
FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS- 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 
kTECHOLAMINERGIC 

THE  EFFECT  OF  CATECHOLAMINERGIC  SUBSTANCES  ON  PROCONVULSIVE 
PROPERTIES  OF  THE  CAUDATE-NUCLEUS. 

231071  01-03 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS- 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02-03 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04-04 
REVERSAL  OF  THE  6-HYDROXYDOPAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 
CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE, 

250940  04-03 
JECHOLAMINES 
THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  BRAIN 
CATECHOLAMINES  AND  SEROTONIN. 

226726  01-03 
EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES. 

227212  01-07 
CATECHOLAMINES,  DRUGS,  AND  BEHAVIOR:  MUTUAL  INTERACTIONS. 

233968  02-04 
REGIONAL  ROLE  OF  CATECHOLAAAINES  IN  ALPHA-METHYL-M-TYROSINE 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROUSAL. 

234067  02-03 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  *  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  02-04 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS  -■  ACUTE  MORPHINE  ADMINISTRATION. 

237736  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS    -  CHRONIC  MORPHINE  ADMINISTRATION. 

237737  02-03 
MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  THE 

ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  02-03 
IHE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6  HYDROXYDOPAMINE  IN  RATS 

237743  02-03 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 


Subject  Index 

CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822  03-03 
CATECHOLAMINES  IN  BRAIN  ISCHEMIA  -  EFFECTS  OF  ALPHA-METHYL-P- 
TYROSINE  AND  PARGYLINE. 

239577  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES. 

241416  0303 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE. 
(PH.D.  DISSERTATION). 

241576  03-03 
SYNTHESIS  OF  O-TRANSMETHYLATED  CATECHOLAMINES  AND 
PSYCHODYSLEPTIC  BETA-PHENYLISOPROPYLAMINES    (PH  D 
DISSERTATION). 

242003  03-01 
NEUROLEPTICS,  CATECHOLAMINES,  AND  PSYCHOSES:  A  STUDY  OF  THEIR 
INTERRELATIONS, 

245510  04-09 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 
ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 
IN  THE  RAT. 

246843  04-03 
CHLORPROAAAZINE,  CATECHOLAMINES  AND  AGING  IN  MICE. 

247587  04-02 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE. 

249274  04-04 
CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

249311  04  03 
CATEGORIES 

INFLUENCE  OF  PSYCHOPHARMACEUTICALS  ON  ACHIEVEMENT 

MOTIVATION:  III.  DIFFERENTIAL  INFLUENCE  ON  CONTENT  CATEGORIES. 

240644  03-14 
CATEGORIZED 

STATE-DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST, 

243013  04-04 
CATHETERIZATION 

USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  CARDIAC 
CATHETERIZATION. 

244450  04  II 
CATIONS 

THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
CATS 

EFFECT  OF  5,5  DIPHENYLHYDANTOIN  (DPH)  ON  LEARNING  AND  MEMORY 
IN  CATS. 

229680  01-04 
EFFECT  OF  5,5  DIPHENYLHYDANTOIN  ON  FIXED  CONDITIONED  REFLEXES 

IN  CATS. 

229681  01-04 
ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01-03 
THE  SELECTIVE  EFFECTS  OF  ALPHA  METHYL  AROMATIC  AMINO-ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-03 
THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS. 

231069  01-04 
THE  INFLUENCE  OF  D,L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248  01-04 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01-04 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02-03 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARIJUANA  ON  LEG 
PATTERNS  IN  CATS. 

235564  02-03 


0 

£2 

3E 


S-61 


Subject  Index 


Psychopharmacology  Abstracts 


EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS 

236371  02-04 
RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02-04 
ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS. 

239978  03-04 
EFFECT  OF  l,2-BENZISOXAZOLE-3-ACETAMIDOXIME  ON  CAUDATO- 
THALAMO-CORTICAL  SYSTEM  IN  CATS. 

241383  03-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
VORACIOUSNESS  INDUCED  IN  CATS  BY  BENZODIAZEPINES. 

244690  04-04 
CARDIOVASCULAR  EFFECTS  OF  CENTRAL  MICROINJECTIONS  OF 
APOMORPHINE  IN  CATS. 

249033  04-03 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS 

249281  04-02 
CAUDATE 

THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248  01-04 
CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL-AMPHETAMINE  AND 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION. 

236235  02-03 
EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS. 

236371  02-04 
EFFECTS  OF  INTRACEREBROVENTRICULAR  L-DOPA  ON  CAUDATE  UNIT 
FIRING- 

238716  03-03 
CAUDATE-NUCLEUS 

THE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457  01-03 
THE  EFFECT  OF  CATECHOLAMINERGIC  SUBSTANCES  ON  PROCONVULSIVE 
PROPERTIES  OF  THE  CAUDATE-NUCLEUS. 

231071  01-03 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251  01  04 
RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02-04 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE  NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
DOPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE- 
NUCLEUS.  (PHD   DISSERTATION). 

238080  02-13 
CYTOCHEMICAL  AND  ELECTROPHYSIOLOGICAL  STUDIES  OF  DOPAMINE  IN 
THE  CAUDATE-NUCLEUS.  (UNPUBLISHED  PAPER). 

238471  02-03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS 

251392  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04-03 
CAUDATO-THALAMO-CORTICAl 

EFFECT  OF  I,2BENZISOXAZOLE-3-ACETAMIDOXIME  ON  CAUDATO- 
THALAMO-CORTICAL  SYSTEM  IN  CATS. 

241383  03-03 
CAUSAL 

MODEL  OF  CAUSAL  CONFRONTATION  IN  INTEGRATIVE  PSYCHOTHERAPY. 

234503  02-14 


CAUSISTIC 

EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
CAVAIN-MAGNESIUM-OROTATE 

THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN-MAGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 
STUDY. 

243180  04-11 
CA45 

ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATUM 
AND  HYPOTHALAMUS  SLICES. 

238714  03-03 
CBCH 

INHALATION  TOXICITY  OF  TURKISH  AAARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  0305 
CBD 

INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-05 
CDP-CHOLINE 

CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 
ANTIDEPRESSANT  TREATMENT. 

247969  04-09 
CEASING 

PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04-04 
CELL 

COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  089  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYOROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
OPIATE  RECEPTORS  AND  ADENYLATE-CYCLASE  IN  NEUROBLASTOMA  X 
GLIOMA  CELL  LINES.  (UNPUBLISHED  PAPER). 

238571  02-03 
OPIATE  RECEPTORS  IN  CELL  CULTURES.  (UNPUBLISHED  PAPER) 

239787  03-03 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04-03 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
CELLS 

DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01-03 
THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS. 

232917  02-03 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA. 

236863  02-03 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-03 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880  02-03 
PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 
NEUROBLASTOMA  CELLS. 

238692  03-03 
EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFIED  CHOLINOCEPTIVE 
CELLS  OF  THE  SNAIL  BRAIN. 

238740  0303 
A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE. 

241348  03-03 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

6UTYR0PHEN0NES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-03 
ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE 

244203  04-03 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04-03 


S-62 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


0ELTA9-TETRAHYDR0CANNABIN0Lt  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUMAN  AND  OTHER  MAMMALIAN  CELLS. 

251420  04-13 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
LLUIAR 
UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS 
(UNPUBLISHED  PAPER). 

226731  01-13 
CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMMA- 
GLUTAMYL-TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03-03 
CELLULAR  MEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC). 

238816  03-03 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS   III 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT 

252012  04-03 
NTRAl 
TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01-03 
COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01  04 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6-HYDROXYDOPAMINE 
TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS. 

228142  01-04 
A  HISTOCHEMICAL  STUDY  ON  THE  CENTRAL  EFFECT  OF  MONOAA/IINE 
PRECURSORS. 

229068  01-03 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 
BENZODIAZEPINES, 

229465  01-03 
NEUROLEPTICS  AND  ANTIDEPRESSANTS  ON  CENTRAL  MONOAMINE 
NEURONS. 

229483  01-03 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01  03 
EFFECTS  OF  BENZODIAZEPINES  ON  CENTRAL  SEROTONERGIC 

MECHANISMS. 

232508  01-03 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 

ACTIONS  OF  BENZODIAZEPINES. 

232511  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 
BENZODIAZEPINES 

232515  01-03 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02-03 
A  NEUROPHYSIOLOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 
PSYCHOTOMIMETICS  {LSD-25,  DOM  AND  KETAMINE). 

232703  02-04 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-03 
CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 


EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS 

236519  02-03 
THE  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT-TERM  MEMORY. 

23671 1  02-04 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-06 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (-t- )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02-04 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02-03 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARAAACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-03 
EFFECTS  OF  DOPAMINE  (DA)  DERIVATIVES  ON  CENTRAL  DOPAMINERGIC 
MECHANISMS. 

238700  03-03 
CENTRAL  ACTION  OF  AMPHETAMINE-INDUCED  MYDRIASIS  IN  THE  DOG. 

238772  03-03 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG;  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS. 

238798  03-03 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR. 

238800  03-04 
CENTRAL  ACTION  OF  NORMETANEPHRINE.  EFFECT  ON  THE  BEHAVIOR  OF 
RATS. 

240240  03-03 
EFFECTS  OF  6-HYDROXYDOPAMINE  ON  CENTRAL  NORADRENALINE 
NEURONS  DURING  ONTOGENY, 

241196  03-03 
ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

241921  03-03 
CF-25-397,  DIDEHYDRO  METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE,  A 
NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST, 

241927  03-04 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION? 

241932  03-04 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS, 

241979  03-04 
CENTRAL  GAMMA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

243762  04-03 
D-AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
CENTRAL  ACTIONS  OF  HALLUCINOGENIC  DRUGS. 

244071  04-12 


2 


s 

3I?» 

is 


S-63 


Subject  Index 


Psychopharmacology  Abstracts 


A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE 

246148  04-04 
REVERSAL  OF  THE  6HYDR0XYD0PAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RATS 
PRODUCED  BY  D-AMPHETAMINE. 

246820  04-04 
DOSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS. 

247206  04-04 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS-.  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS, 

24721 1  04-03 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  04-01 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
CARDIOVASCULAR  EFFECTS  OF  CENTRAL  MICROINJECTIONS  OF 
APOMORPHINE  IN  CATS. 

249033  04-03 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR. 

249301  04-03 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC). 

249309  04-03 
CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

249311  04-03 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  +  )  AMPHETAMINE 
AND  L-DOPA. 

249419  04-04 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 
THERMOSTATS. 

250078  04-03 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE 

250656  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 
SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 
CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE. 

250940  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 
PHARMACOLOGICAL  EVIDENCE  FOR  THE  CENTRAL  SEROTONERGIC 
EFFECTS  OF  MONOMETHOXYAMPHETAMINES. 

253108  04-04 
CENTRAL-NERVOUS-SYSTEM 

A  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ANTIDEPRESSANT. 

227695  01-02 
AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION, 

229169  01-15 
FUNCTIONAL  SIGNIFICANCE  OF  CENTRAL-NERVOUS  SYSTEM 

NOREPINEPHRINE  AND  DOPAMINE   A  PSYCHOPHARMACOLOGICAL 
STUDY.  (PH.D.  DISSERTATION). 

231437  01-04 


A  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM. 

233289  02-03 
INHIBITORY  SYNAPSES  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  THEIR 
PHARMACOLOGICAL  RESPONSES. 

236368  02-07 
3H-DELTA9-TETRAHYDR0CANNABIN0L  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE-OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK. 

237923  02-03 
CENTRAL-NERVOUS-SYSTEM  DEPRESSANTS.  13.  S- 
TRIAZOLOBENZODIAZEPIN-5-ONES. 

238478  02-01 
EFFECTS  OF  POLYAMINES  ON  THE  CENTRAL-NERVOUS-SYSTEM. 

242202  03-03 
EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA. 

243799  04-03 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
BARBITAL  ALTERATION  OF  CENTRAL-NERVOUS-SYSTEM  SENSITIVITY  TO 
HEXOBARBITAL  IN  THE  RAT. 

244688  04-03 
THE  ACTIONS  OF  SPERMIDINE  AND  SPERMINE  ON  THE  CENTRAL- 
NERVOUS-SYSTEM. 

245596  04-05 
SYNTHESIS  AND  CENTRAL-NERVOUS-SYSTEM  DEPRESSANT  ACTIVITY  OF 
SOME  BICYCLIC  AMIDES. 

248539  04-02 
CENTRAL-NERVOUS-SYSTEM  ACTIVE  5-OXOHEXAHYDROCINNOLINES. 

248649  04-02 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2-PHENYLETHYLAMINE  (PEA). 

249310  04-03 
MARIJUANA,  ABSINTHE  AND  THE  CENTRAL-NERVOUS-SYSTEM. 

249783  04-01 
SOME  STUDIES  OF  BETA-RECEPTOR  BLOCKING  DRUGS  ON  THE  CENTRAL- 
NERVOUS-SYSTEM  IN  MAN. 

251162  04-13 
DIFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 
TOURETTES  SYNDROME  AND  CENTRAL-NERVOUS-SYSTEM  STIMULANTS. 

251962  04-11 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-03 
BETA-BLOCKERS  AND  THE  CENTRAL-NERVOUS-SYSTEM. 

253529  04-17 
CENTRALLY 

STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01-03 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM: 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION, 

231039  01-03 
TOLERANCE  TO  CENTRALLY  ADMINISTERED  PHENOBARBITAL, 

241346  03-03 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP, 

248276  04-03 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS-INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN. 

251416  04-03 

CENTURY 

THE  TRANSMETHYLATION  HYPOTHESIS:  A  QUARTER  OF  A  CENTURY 
LATER 

235801  02- 15 
CERCOPITHECUS-AETHIOPS 

BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOPS).  AETHIOPS) 

230869  01  04 


S-64 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


iBELLAR 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBEUAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 
THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION 

236696  02-15 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04-04 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
iBEUUM 

INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

226935  01-03 
INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -   STUDIES 
ON  RAT  CEREBELLUM. 

229466  01-03 
EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 
BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM. 

232514  01-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880  02-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  03-03 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC  AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-03 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM 

244205  04-03 
EBRAl 

PIRACETAM  IN  A  CASE  OF  ACUTE  CEREBRAL  HYPOXEMIA:  CASUISTIC 
REPORT. 

229128  01-14 
FENMETRAZOLE  (DH  524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781  01-14 
COCAINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
METABOLISM  IN  VIVO, 

230834  01  03 
H3-P-CHL0R0AMPHETAMINE.  CEREBRAL  LEVELS  AND  DISTRIBUTION. 

232614  02-03 
THE  EFFECTS  OF  DIMETHYLAMINOETHANOL  (DEANOL)  ON  CEREBRAL 
CORTICAL  NEURONS. 

232621  02  03 
THE  EFFECT  OF  CHLORPROMAZINE  ON  CEREBRAL  CIRCULATION. 

236234  02  03 
THE  EFFECT  OF  CHRONIC  SELF  ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14  LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN 

237109  02-04 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  02  03 


NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

237756  02-03 
ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINS  F  IN  RAT 
CEREBRAL  CORTEX. 

237921  02-03 
DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTAZOL. 

237925  02-03 
CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMMA- 
GLUTAMYL-TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03-03 
EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-03 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  CEREBRAL  MONOAMINE 
TURNOVER. 

241392  03-03 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

24318)  04-04 
CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-04 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-03 
EFFECTS  OF  INTRAVENTRICULAR  P  CHLOROAMPHETAMINE  AND  ITS 
ANALOGUES  ON  CEREBRAL  5-HT. 

246151  04  03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG  -  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04  03 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM. 

247012  04-03 
ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CEREBRAL 
BLOOD  CIRCULATION. 

248552  04-03 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX, 

248699  04-03 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2  RECEPTOR  ANTAGONISTS  IN  THE 
RAT  CEREBRAL  CORTEX. 

248725  04-03 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14  LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04  03 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION, 

249286  04-03 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS 

249664  04  03 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS    PERFORMANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING 

250060  04  14 
LOCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX, 

250356  04-03 
EFFECTS  OF  ALPHA  RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX 

251394  04  03 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT, 

251820  04  03 


09 

I 

es 

I 

o 


es 

w 

•pBi 


S-65 


Subject  Index 


Psychopharmacology  Abstract 


UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS^ 

251964  04-03 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

25271 1  04-03 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04-11 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES. 

252757  04-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
CEREBROSIDE 

DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  0303 
CEREBROSIDES 

DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
CEREBROSPINAL 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS, 

226915  01-09 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS, 

230824  01-09 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDRGXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01  06 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03  03 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUAAAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  03-13 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROMATOGRAPHY. 

245300  04-03 
THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04-13 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE 

250657  04-13 
CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA 

251119  04-08 
CEREBROVASCULAR 

THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 
CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04- 11 
CERUIOPLASMIN 

THE  INFLUENCE  OF  LITHIUM  ON  SERUM  CERULOPLASMIN. 

237924  02-03 


CERVEAU 

EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-1 
CERVICAL 

INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS. 

239977  03-1 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04-1 
ELECTROPHORETIC  APPLICATION  OF  LIGNOCAINE  TO  THE  CERVICAL  ARI 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES. 

244467  04- 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-1 
CERVICIS 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04-1 
CESIUM 

CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

238318  02-1 
EVALUATION  OF  CESIUM  CHLORIDE  AS  ANTIDEPRESSANT. 

238836  03-1 
CESSATION 

DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  SENSITIVITY  OF 
TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMIN 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-1 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  KINETIC  PROPERTIES  ( 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-1 
CF-25-397 

CF-25-397,  DIDEHYDR0METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINE, 
NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST. 

241927  03-1 
CGMP 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  C 
DIAZEPAM. 

226857  01-1 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-1 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS-INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN. 

251416  04-( 
CHAIN 

THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  ( 
AMPHETAMINES. 

237981  02-( 
CHAMBER 

EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROM 
IN  RHESUS  MONKEYS. 

247889  04-( 
CHANCES 

CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHAR/WACOLOGICAL  METHODS. 

233681  02-( 
CHANGE 

INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES  -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINIC/ 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-( 
INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WITH 
PSYCHOACTIVE  DRUGS   -  NEW  METHODS  IN  THE  ASSESSMENT  OF 
CHANGE. 

235355  02-1 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02-C 
CHANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  03-C 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-C 
EFFECTS  OF  DRUG  STATE  CHANGE  ON  DISCRIMINATION  PERFORMANCE. 

244679  04-C 


S-66 


UME  14,  SUBJECT  INDEX 


Subject  Index 


HE  EFFECT  OF  SCOPOLAMINE  ON  THE  STIMULUS  CHANGE 
PHENOMENON. 

247863  04-04 
IGES 

(EHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226)86  01-04 
lEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT. 

226399  01-03 
LECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
AARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS 

226903  01-14 
kCUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 
INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN 

227386  01-04 
:HANGES  in  the  electroencephalogram  and  rem  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
iAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-03 
FFECTS  OF  HANDLING  BEFORE  CENTRAL  6-HYDROXYDOPAMINE 
TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS. 

228142  01-04 
AETHADONE-INDUCED  BEHAVIORAL  CHANGES:  CIRCULAR  MOVEMENTS, 
AGGRESSION,  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
:HANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  OM 3 
IXOTREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 
METABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
:HANGES  in  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01-04 
'ROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING.  (UNPUBLISHED 
PAPER). 

231771  01-04 
\N  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS. 

233336  02-03 
lEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS. 

233965  02-03 
:HANGES  in  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 
NEUROLEPTICS  AND  THYMOLEPTICS. 

234045  02-15 
ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 
OF  VARIOUS  PSYCHOACTIVE  DRUGS. 

234810  02-04 
:HANGES  in  ANTICOAGULANT  TOLERANCE:  I.  INFLUENCE  OF  SEDATIVES 
AND  PSYCHOPHARMACEUTICALS 

235336  02-15 
YCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  02-13 
HANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02  08 
ILTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02-03 
HANGES  IN  PSYCHOACTIVE  DRUG  USE  AMONG  ADULTS  IN 
METROPOLITAN  TORONTO  -  1971-1974 

236046  02  1 7 
HOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 
TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02-10 
HANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
FFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I,  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02  04 


PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER) 

237169  02  04 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR: 

ALTERATIONS  IN  3H  ALPRENOLOL  BINDING  AND  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

237170  02-03 
CLONAZEPAM-INDUCED  CHANGES  IN  5  HYDROXYTRYPTAMINE  (5-HT) 

METABOLISM  IN  ANIMALS  AND  MAN 

237977  02  13 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-04 
COMPARISON  OF  THYROID  RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
AGE-RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (AAA)  IN  MICE. 

238847  03-04 
CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS. 

239058  03  1 4 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL. 

240074  03  14 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIAAALS. 

240237  03-04 
CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE. 

241232  03-03 
SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN 

241366  03-03 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-03 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03-03 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03-03 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION. 

241930  03-03 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03  03 
HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 

BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE, 

241989  03-03 
CHANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 

NEUROLEPTIC  TREATMENT 

242868  04  11 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04  04 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE. 

244352  04-04 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3.5  CYCLIC  AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE, 

244514  04-03 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS, 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES 

244664  04  09 
HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 
CURARIZED  RATS 

244691  04  03 
BLOOD-PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE, 

244932  04  15 


s 

« 

0 


0 

S 


S-67 


Subject  Index 


Psychopharmacology  Abstra< 


DRUG  INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04-03 
SELECTIVE  FIELD  POTENTIAL  CHANGES  INDUCED  BY  L-DOPA. 

246145  04-03 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
FEEDING  AND  WITHDRAWAL. 

246310  04-04 
ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 

DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN. 

246992  04-13 
ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN?. 

247382  04-14 
ORGANIC  MENTAL  CHANGES  WITH  FLUOROURACIL  THERAPY. 

247978  04-15 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 

HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
DEPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04-03 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE 

248960  04-02 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 

ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE. 

249274  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS. 

249485  04-04 
CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE- 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS. 

250114  04-03 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04-12 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT. 

251400  04-03 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYvILIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
CHANGING 

CHANGING  PATTERNS  IN  THE  MANAGEMENT  OF  DEPRESSION. 

243863  04-09 
CHARACTER 

STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04-11 
CHARACTERISTIC 

CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE 

244352  04-04 
CHARACTERISTICS 

CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
ENDINGS 

237244  02-03 
CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 
INJECIIONS  OF  DRUGS 

240010  03-04 
FURTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULOINTERPEDUNCULAR 
NEURONS:  PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
CHARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 

REFRACTORINESS.  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS 

250278  04-03 
(  ORREl  ATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04-06 


THE  MAIN  PHARMACOLOGICAL  CHARACTERISTICS  OF  GRANDAXIN 
(TOFIZOPAM,  EGYT-341). 

252445  04 
CHARACTERIZATION 

CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  POLYETHYLENE-GLYC0L-400O  BY  IR  SPECTRAL 
ANALYSIS. 

233276  02 
PHARMACOLOGICAL  CHARACTERIZATION  OF  LITHIUM  REABSORPTION 
THE  RAT. 

237759  Oi 
PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCEI 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PH.D.  DISSERTATION). 

241994  O; 
CHARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAl-TETRAHYDROCANNABIN 
IN  MOUSE  LIVER. 

243787  0^ 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLIN 
IN  MICE. 

246852  0' 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTIOI 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  0' 
RESOLUTION,  PURIFICATION  AND  CHARACTERIZATION  OF  RABBIT 
SERUM  ATROPINESTERASE  AND  COCAINESTERASE. 

251180  0- 

CHARTS 

COMPENDIUM  OF  PHARMACOLOGY  DRUG  CHARTS. 

249768  0. 
CHE 

CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VI' 
PARAOXON  (PX)  ADMINISTRATION. 

249295  0. 

CHECKS 

CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  a 
CHEMICAL 

5-HYDR0XYTRYPTAMINE-14C  AND  DEXAMPHETAMINE-14C  UPTAKE  B' 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  0 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  0 
CHLORPROAAAZINE  EXCRETION:  ISOTOPE  VERSUS  CHEMICAL  ASSAY. 

229481  0 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  0 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  0 
CANNABINOID  PATTERN  IN  CANNABIS-SATIVA  L.  SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE 

237982  a 
PIGMENTATION  AND  THE  CHEMICAL  BASIS  OF  SCHIZOPHRENIA. 

239001  0 

CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  A 

CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  0 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTI 
OF  THEIR  CHEMICAL  STRUCTURE. 

241428  0 
THE  CHEMICAL  CONTROL  OF  NEURONAL  ACTIVITY.  (UNPUBLISHED 
PAPER) 

243183  0 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMIN 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY. 

248285  0 
CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-5 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  a 
CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES 
5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS. 

249318  0 
FOR  SENILE  DEMENTIA:  CHEMICAL  CORRECTION?. 

249351  0 


S-68 


)LUME  14,  SUBJECT  INDEX 


Subject  Index 


RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-17 
MICALLY 

EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS. 

244072  04-03 
MICALS 

INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS   -  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
MISTOR 

CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUAAAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02-06 
MISTRY 
THE  CHEMISTRY  OF  REWARD  AND  RELATED  BEHAVIORS. 

229475  01-04 
CHEMISTRY  AND  PHARMACOLOGY  OF  BIOGENIC  AMINE  UPTAKE. 

229478  01-03 
CHEMISTRY  OF  DOPAMINE  RECEPTORS. 

230600  01-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I,  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  04-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

248957  04-03 
CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-I54,  A  NEW  POTENTIAL 

NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND. 

251407  04-17 
MOSENSORY 

ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICALS. 

248163  04-02 
MOSTIMULATION 

HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 
CURARIZED  RATS. 

244691  04-03 
MOTHERAPY 

AN  EXPERIMENTAL  THERAPY  AND  RE-EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE.  (PH.D.  DISSERTATION). 

228750  01-11 
INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

231002  01-03 

:k 

ontogeny  of  behavioral  sensitivity  to  strychnine  in  the  chick 
embryo:  evidence  for  the  early  onset  of  cns  inhibition. 

228630  01-04 
EFFECTS  OF  DIAZEPAM  ON  THE  ISOLATED  CHICK  EMBRYO  HEART. 

230862  01-03 
CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-04 
RETROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK. 

237260  02-04 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE-OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK. 

237923  02-03 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK. 

238795  03-03 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK.  I.  EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245712  04-04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 

CHICK.  II.  EFFECTS  PRESENT  IN  BOTH  SEXES. 

245713  04-04 
FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04-03 


DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  BY 
PINEAL  METABOLITES. 

249240  04-03 
CHICKS 

INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS 

230878  01-04 
RETROACTIVE  AND  PROACTIVE  EFFECTS  OF  ANESTHESIA  ON  FOLLOWING 
IN  CHICKS. 

241330  03-04 
CHILD 

SLEEP  AND  ITS  DISTURBANCES  IN  THE  CHILD:  CONTRIBUTIONS  OF 
ELECTROPHYSIOLOGY. 

228091  01-11 
RECENT  ADVANCES  IN  CHILD  PSYCHOPHARMACOLOGY. 

229053  01-11 
IS  LITHIUM  USEFUL  IN  CHILD  PSYCHIATRY?. 

229081  01-14 
THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD:  DIAGNOSIS  AND 
TREATMENT. 

2335)3  02-17 
SUCCESS  WITH  LITHIUM  IN  A  DISTURBED  CHILD. 

236118  02-11 
DRUG  THERAPY  IN  CHILD  CARE, 

243897  04-15 
ASSESSMENT  OF  DIAZEPAM  AFTER  THREE  YEARS  USE  IN  CHILD 
PSYCHIATRY. 

249144  04-11 
CHILDHOOD 

COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 
ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  EXTRAPYRAMIDAL  MOTOR 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  02-11 
PRESENT  ASPECTS  OF  PSYCHOPHARMACOTHERAPY  IN  CHILDHOOD  AND 
ADOLESCENCE. 

236150  02-17 
BEHAVIOR  DISORDERS  IN  CHILDHOOD  AND  THEIR  TREATMENT. 

24071 1  03  II 
SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY. 

245344  04- 11 
UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04  13 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
PSYCHOPHARMACOLOGY  IN  CHILDHOOD  PSYCHOSIS. 

247386  04  17 
APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHILDHOOD 
HYPERKINESIS, 

249772  04  11 
CHILDREN 

DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOL  CHILDREN, 

225783  0M4 
HYPERACTIVITY  IN  CHILDREN. 

226069  01  14 
SULPIRIDE  IN  DEPRESSIVE  SCHOOL  PHOBIC  CHILDREN. 

227141  01-10 
COGNITIVE  EFFECTS  OF  METHYLPHENIDATE  ON  HYPERACTIVE  CHILDREN 
(PH.D.  DISSERTATION). 

228431  01-11 
THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHALOPATHY  IN  CHILDREN:  STUDY  OF  28  CASES. 

229083  01-11 
THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 

CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02- II 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DYSFUNCTION, 

235322  02-11 
THE  USE  OF  MEGAVITAMIN  TREATMENT  IN  CHILDREN  WITH  LEARNING 
DISABILITIES. 

235676  02-11 
DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02-10 


00 
SO 

S 
S 

cs 

0 


i 


SIS 


S-69 


Subject  Index 

PSYCHOSIS  FOLLOWING  INGESTION  OF  HEMP  IN  CHILDREN. 

237730  02- 15 
THE  USE  AND  MISUSE  OF  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

240522  03-17 
EFFECTS  OF  METHYLPHFNIDATE  ON  UNDERACHIEVING  CHILDREN. 

240538  03-11 
NON  MEDICATION  MANAGEMENT  OF  HYPERKINETIC  CHILDREN  IN  THE 
CLASSROOM.  (PHD   DISSERTATION) 

240977  03-11 
A  TEST  OF  THE  STATE-DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN.  (PH.D. 
DISSERTATION). 

241133  03-14 
KINETICS  OF  CARBAMAZEPINE  AND  ITS  10.1  1  EPOXIDE  METABOLITE  IN 
CHILDREN. 

243086  04-13 
BLOOD  PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE 

244932  04-15 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
V>/ITH  BEHAVIOR  AND  CHARA.CTER. 

244958  04-11 
IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AND 
ELECTROCARDIOGRAPHIC  ABNORMALITIES  IN  HYPERACTIVE 
CHILDREN. 

245001  04-14 
METHYLPHENIDATE  AND  CAFFEINE  IN  THE  TREATMENT  OF  CHILDREN 
WITH  MINIMAL  BRAIN-DYSFUNCTION. 

245786  04-14 
OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN 

246891  04  11 
DRUGS  HELP.  BUT  WONT  CURE.  MOST  HYPERACTIVE  CHILDREN. 

247143  04  17 
CONTROLLED  TRIAL  OF  METHYLPHENIDATE  IN  PRESCHOOL  CHILDREN 
WITH  MINIMAL  BRAIN-DYSFUNCTION. 

247375  04  11 
WHAT  IS  THE  PROPER  DOSE  OF  STIMULANT  DRUGS  IN  CHILDREN''. 

247376  04-17 
SIDE  EFFECTS  FROM  lONG  TERM  USE  OF  STIMULANTS  IN  CHILDREN. 

247377  04-15 
METHYLPHENIDATE  IN  CHILDREN:  EFFECTS  UPON  CARDIORESPIRATORY 

FUNCTION  ON  EXERTION 

247378  04  15 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 

HYPERKINETIC  CHILDREN 

247379  04-14 
CLINICAL  EFFECTS  OF  IMIPRAMINE  AND  METHYLPHENIDATE  IN 

HYPERACTIVE  CHILDREN 

247380  04-14 
CLINICAL  PHARMACOLOGICAL  MANAGE/ViENT  OF  HYPERKINETIC 

CHILDREN. 

247381  04  17 

ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN''. 

247382  04-14 
LEVODOPA  AND  LEVOAMPHETAMINE    A  CROSSOVER  STUDY  IN  YOUNG 

SCHIZOPHRENIC  CHILDREN. 

247480  04-08 
CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN      AN  EMPIRICAL  STUDY 

248593  04  11 
HYPFRACTIVITY  IN  CHIIDREN 

250931  04-14 
IHE  FFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHIIDREN 

251569  04  14 
PHENYTOIN  INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN 

251654  04  15 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPIIEPSY 

251949  04  II 
ACCIDENTAL  POISONING  WITH  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

252656  04  15 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN  DYSFUNCTIONING  CHILDREN 

252798  04-11 
HIE  fFFFCTS  OF  LONG  TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN 

253041  04  15 


Psychopharmacology  Abstra 


CHIMPANZEE 

CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 
BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  0 
CHIORAZEPATE 

CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  0 
CHLORDIAZEPOXIDE 

CHLOROIAZEPOXIDE  METABOLISM  IN  MICE  FOLLOWING  HEPATIC 
IRRADIATION. 

226840  0 
THE  DIFFERENTIAL  EFFECTS  OF  CHLORDIAZEPOXIDE  AND  OXAZEPAM 
HOSTILITY  IN  A  SWIALL  GROUP  SETTING. 

227569  C 
ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLOROIAZEPOXID 
AN  INTENSIVE  DESIGN  STUDY. 

228221  C 
EFFECTS  OF  D-AMPHETAMINE,  CHLORPROMAZINE,  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACE 
RESPONDING  SCHEDULES. 

229639  C 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 
FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL,  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING. 

229907  ( 
A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXI 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM. 

230104  ( 

CHLORDIAZEPOXIDE  AND  ISOLATION  INDUCED  TIMIDITY  IN  RATS. 

230828  ( 
RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 
CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFEC 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  ( 
CHLORDIAZEPOXIDE  AND  DIAZEPAM-INDUCED  MOUSE-KILLING  BY  R 

230838  I 
INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE 
CHLORDIAZEPOXIDE  ABSORPTION. 

237116  1 
SERUM  CREATINE-PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT. 

237928  I 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  , 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  I 
TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FIS 
(BETTASPLENDENS). 

242892  I 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONIS 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAi 
AND  CHLORDIAZEPOXIDE  IN  RATS. 

245301 
CAFFEINE  AND  CHLORDIAZEPOXIDE:  EFFECTS  ON  MOTOR  ACTIVITY  I 
THE  CHRONIC  THALAMIC  RAT. 

246388 
INTERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 

CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  R/ 

248394 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 
COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

2501 1 1 
SCHEDULE-DEPENDENT  EFFECTS  OF  CHLORDIAZEPOXIDE  ON  OPERAN 

BEHAVIOR  IN  RATS. 

251670 

CHLORHYDRATE 

A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 
ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOI 
ADIENE  CHLORHYDRATE  (CIBA-34276-BA). 

247554 

CHLORIDE 

THE  USE  OF  BETHANECHOL  CHLORIDE  WITH  TRICYCLIC 
ANTIDEPRESSANTS. 

EVALUATION  OF  CESIUM  CHLORIDE  AS  ANTIDEPRESSANT. 

EFFECT  OF  LITHIUM  CHLORIDE  ON  LIPID  METABOLISM. 

241986 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDA 
LEARNING  IN  RATS 

243804 


232864 
238836 


S-70 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE 

246664  0404 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  0403 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

249381  04-04 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARMACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS. 

252198  04-03 
ORIMIPRAMINE 

EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 
ORMETHIAZOLE 

A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIDE 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM. 

230104  01-11 
ORPROMAZINE 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM. 

225722  01-15 
A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROAAAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES. 

226412  C1-08 
INHIBITION  OF  4,ALPHA  DIMETHYL-M  TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROAAAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-09 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROMAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  01-05 
AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

229169  01-15 
AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  OF 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION. 

229439  01-16 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01-08 
CHLORPROMAZINE  METABOLISM  AND  CLINICAL  RESPONSE  IN  ACUTE 

SCHIZOPHRENIA:  A  PRELIMINARY  REPORT. 

229445  01-08 
CHLORPROMAZINE  EXCRETION:  ISOTOPE  VERSUS  CHEMICAL  ASSAY. 

229481  01-03 
PLASMA  CHLORPROMAZINE  IN  PSYCHIATRIC  MANAGEMENT. 

229492  01-13 
EFFECTS  OF  D-AMPHETAMINE,  CHLORPROMAZINE,  AND 
CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACED 
RESPONDING  SCHEDULES. 

229639  01  04 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN. 

230863  01-14 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 

EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
DISTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRACT 

OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01-03 
PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 
BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY. 

232623  02-13 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE 

232865  02-15 
COMPARISON  OF  THE  THERAPEUTIC  EFFECT  OF  CLOZAPINE  AND 
CHLORPROMAZINE. 

234420  02-14 


THE  IMMEDIATE  EFFECTS  OF  CHLORPROMAZINE  IN  NEWLY  ADMITTED 
SCHIZOPHRENIC  PATIENTS 

234700  02-08 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02-04 
A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
THE  EFFECT  OF  CHLORPROMAZINE  ON  CEREBRAL  CIRCULATION. 

236234  02-03 
EFFECT  OF  CHLORPROMAZINE  ON  THE  REACTION  OF  BLAST 
TRANSFORMATION  OF  LYMPHOCYTES. 

236373  02-03 
CORRELATION  OF  CHLORPROAAAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 
WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-03 
THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02-03 
COOMBS-POSITIVE  HEMOLYTIC  ANEMIA  PROVOKED  BY 
CHLORPROMAZINE 

237161  02-15 
MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245  02-03 
GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROMAZINE, 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM 

237750  02-06 
BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA. 

237872  02-13 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE  HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS.  (PH.D.  DISSERTATION). 

2380/9  02-03 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L  DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE 

238318  02-04 
DIFFERENTIAL  BLOCKADE  OF  ALPHA  ADRENERGIC  RECEPTORS  BY 
CHLORPROMAZINE. 

238672  03-03 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D  AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03-04 
INTERACTION  OF  TRIHEXYPHENIDYL  AND  CHLORPROMAZINE:  PROBABLE 
MECHANISM 

238732  03-03 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT. 

238755  03-04 
IMPROVED  ASSAYS  OF  CHLORPROMAZINE  AND  ITS  METABOLITES. 

238818  03-01 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC  AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 
ENCEPHALOPATHY  SUBSEQUENT  TO  ACCIDENTAL  POISONING  WITH 
CHLORPROMAZINE, 

239089  03-05 
INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS 

239848  03  04 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  ELECTRODERMAL  RESPONSE 
IN  THE  CAT. 

239963  03-03 
DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION 

240048  03-15 
EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR 
URINARY  CORTISOL,  URINARY  VOLUME.  AND  HEARTRATE  IN  THE 
DOG 

240916  03-04 
EFFECTS  OF  PERIMETAZINE  AND  CHLORPROMAZINE  ON  THE 
TRANSCALLOSAL  RESPONSE  IN  RABBITS 

241385  03-03 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 


a''-' 
1 


as 


S-71 


Subject  Index 


Psychopharmacology  Abstr 


COMPARISON  TRIAL  OF  TWO  ANTirCVrHOTir  DRUGS: 
CHLORPROMAZINE  AND  CLOZAPINE 

241760  03-08 
IMPAIRED  ABSORPTION  OF  CHLORPROMAZINE  IN  RATS  GIVEN 
TRIHEXYPHENIDYL. 

241920  0303 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04-03 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE:  CLINICO- 
CHEMICAL  CORRELATIONS. 

244050  04-08 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE 

244352  04-04 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAL  SCHEDULE. 

245303  04-04 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS. 

246311  04-03 
PREDICTION  OF  RESPONSE  TO  CHLORPROMAZINE  TREATMENT  IN 
SCHIZOPHRENICS 

246314  04-08 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 
«  246315  04-14 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG    -  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04-03 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04-03 
THE  EFFECT  OF  VARIOUS  CHLORPROAAAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYLASE  ACTIVITY. 

247212  04-03 
CHLORPROMAZINE,  CATECHOLAMINES  AND  AGING  IN  MICE. 

247587  04-02 
ENHANCEMENT  BY  CHLORPROMAZINE  OF  HYPERGYLCEMIC  ACTION  OF 
DIAZOXIDE. 

247715  04  15 
EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROME 
IN  RHESUS  MONKEYS. 

247889  04-04 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04-13 
ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 
CLOZAPINE  AND  CHLORPROMAZINE 

248600  04-03 
NATURE  OF  NEW  CLASS  OF  CHLORPROMAZINE  (CPZ)  METABOLITES  IN 
PRIMATE  URINES. 

249328  04-01 
RELATIONSHIP  BETWEEN  THE  BEHAVIORAL  AND 

ELECTROENCEPHALOGRAPHIC  EFFECTS  OF  CHLORPROMAZINE  AND 
FLUPHENAZINE  IN  RATS 

249623  04-02 
EFFECTS  OF  CHLORPROMAZINE  ON  AVOIDANCE  AND  ESCAPE 
RESPONDING  IN  HUMANS. 

250076  04  14 
INTERFERENCE  BETWEEN  ANTI-HLA  ANTIBODIES  AND  CHLORPROMAZINE. 

250476  04-07 
CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA. 

251119  04-08 
CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE. 

251777  04-06 
CHLORPROMAZINE  METABOLISM  VIII:  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS 

251778  04-16 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE. 

251989  04-04 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOZIDE 
AND  CHLORPROMAZINE  METABOLITES. 

252515  04-05 


CHIORPROAAAZINE-INDUCED 

CHLORPROMAZINE-INDUCED  ELECTROCARDIOGRAM  ABNORMALITIE 

231037 
FURTHER  STUDIES  ON  THE  CHLORPROAAAZINE-INDUCED  PROLONGA: 
OF  THE  DISAPPEARANCE  OF  MESCALINE  FROM  MOUSE  TISSUES. 

235670 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 
HYDROXYTRYPTOPHAN  AND  CHLORPROMAZINE-INDUCED  PROLA( 
RELEASE  IN  THE  RAT. 

243951 
CHLORPROTHIXENE 

PLASMA  LEVELS  OF  CHLORPROTHIXENE  IN  ALCOHOLICS. 

226413 
CLINICAL  PHYSIOGNOMY  OF  CHLORPROTHIXENE  AND  CLOPENTIXOL 

227766 
CHOICE 

DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN. 

240014 
CHOLECYSTOKININ 

CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE 
SATIETY  IN  RATS. 

245612 
CHOLERA 

BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFEC 
CHOLERA  TOXIN. 

252034 
CHOLINE 

HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGh 
INNERVATION  IN  RAT  BRAIN. 

226739 
DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 

CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS 
RAT  TISSUES. 

230451 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  ( 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLI 
MOUSE  BRAIN. 

238765 

6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  fi 

FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASI 

(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 

DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826 
SOME  PHARMACOLOGICAL  PROPERTIES  OF  CYCLOCHOLINE,  A  REAC 
ANALOG  OF  CHOLINE. 

238828 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF 
AMPHETAMINE  AND  (  i  OR-)  P  CHLOROAMPHETAMINE. 

239976 
EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIDE,  A  CHC 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINf 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146 
EFFECT  OF  NOMIFENSINE  ON  ACETYLCHOLINE  AND  CHOLINE  IN  THE 
STRIATUM  AND  BRAINSTEM 

248291 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 
ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBIT 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAL 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAI 

249300 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINS 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666 
CHOLINE  FOR  TARDIVE-DYSKINESIA. 

25041 7 i 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  I 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO. 

251175  1 
EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R( 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM. 

251181  ( 


S-72 


VOLUME  14,  SUBJECT  INDEX 


:houne-oeficient 

effects  of  a  choline-deficient  diet  on  the  induction  of  drug 
and  ethanol  metabolizing  enzymes  and  on  the  alteration  of 
rates  of  ethanol  degradation  by  ethanol  and 
phenobarbital. 

247032  04-03 
HOLINERGIC 

CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORMANCE  IN 
THE  RAT. 

226305  01-04 
HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 
INNERVATION  IN  RAT  BRAIN. 

226739  01-03 
BIOCHEMICAL  IDENTIFICATION  OF  THE  MAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR. 

227400  01-03 
DOPAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS. 

227703  01-04 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS 

228550  01-03 
DRUGS,  BEHAVIOR,  AND  THE  CHOLINERGIC  NERVOUS  SYSTEM. 

229485  01-04 
DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM;  EFFECTS  ON 
CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  OF 
RAT  TISSUES. 

230451  01-03 
CHOLINERGIC  MODULATION  OF  TONIC  IMMOBILITY  IN  THE  RABBIT 
(ORYCTOLAGUS-CUNICULUS). 

231701  01-03 
ACTION  OF  THE  BENZODIAZEPINES  ON  THE  CHOLINERGIC  SYSTEM. 

232510  01-03 
CHOLINERGIC  MEDIATION  OF  INSTRUMENTAL  AND  CONSUMMATORY 
BEHAVIORS. 

233448  02-04 
METHYLPHENIDATE  AS  A  CHOLINERGIC  AGONIST:  FURTHER 
OBSERVATIONS. 

238708  03-03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION. 

239086  0303 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241109  03-04 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5-HT) 
TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-03 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS   4TH 
REPORT.  COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION). 

241681  03-04 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION?. 

241932  0304 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY, 

245486  04-04 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04-03 
FURTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO-INTERPEDUNCULAR 
NEURONS:  PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR. 

249301  04-03 

MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE    INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS. 

250079  04-04 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 
CATALEPSY  IN  THE  RAT, 

250084  04-03 


Subject  Index 

INTERACTION  OF  ATROPINE  OR  METHYLATROPINIUM  WITH  FOUR 
EFFECTS  OF  TWO  CHOLINERGIC  DRUGS. 

251217  04-03 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOZIDE 
AND  CHLORPROMAZINE  METABOLITES. 

252515  04-05 
CHOLINESTERASE 

DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 
CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  OF 
RAT  TISSUES. 

230451  01-03 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02-10 
INHIBITION  OF  CHOLINESTERASE  BY  5-HYDROXYTRYPTAMINE. 

237117  02-03 
DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN  AND 
CHOLINESTERASE  INHIBITORS. 

242737  03-04 
THE  EFFECT  OF  SYMPATHOLYTIC  AND  SYMPATHOMIMETIC  AGENTS  ON 
ACETYLCHOLINESTERASE  AND  CHOLINESTERASE  ACTIVITY,  IN  VITRO. 

243794  04-03 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04-03 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-03 
CHOLINESTERASES 

PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01-03 
A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES. 

231072  01-06 
CHOLINOCEPTIVE 

EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFIED  CHOLINOCEPTIVE 
CELLS  OF  THE  SNAIL  BRAIN. 

238740  03-03 
CHOLINOMIMETICS 

MODIFICATION  OF  THE  BEHAVIORAL  EFFECTS  OF  CHOLINOMIMETICS  BY 
PHENTOLAMINE. 

237032  02-04 
CHOIINORECEPTORS 

THE  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT-TERM  MEMORY. 

236711  02-04 
CHOREA 

TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPA-DECARBOXYLASE  INHIBITOR, 

237733  02-11 
CHOREIFORM 

CLONAZEPAM  IN  THE  TREATMENT  OF  CHOREIFORM  ACTIVITY. 

250932  04-07 
CHOREOATHETOSIS 

PHENYTOIN-INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN. 

251654  04-15 
CHROMATOGRAPHIC 

A  GAS  CHROAAATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL- 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-16 
GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROAAAZINE 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM. 

237750  02-06 
CHROMATOGRAPHY 

DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROMATOGRAPHY. 

229906  01-16 
INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 


so 


00 


3K 


S-73 


Subject  Index 


Psychopharmacology  Abstracts 


n 

mm 


y.-A' 


'•v.t.; 


GAMMA  AMINOBUTYRICACID  AND  5  HYDROXYTRYPTOPHAN 
(UNPUBLISHED  PAPER), 

231278  01  06 
GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINF  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 
ON  THE  THIN  LAYER  CHROMATOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04-01 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROMATOGRAPHY. 

245300  04-03 
CHRONIC 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA. 

225867  01  08 
BRAIN  DYSFUNCTION  IN  CHRONIC  SEDATIVE  USERS. 

226922  01  15 
AN  OPEN  STUDY  OF  MESORIDAZINE  (SERFNTIl.)  IN  CHRONIC 
SCHIZOPHRENICS. 

227821  01  08 
DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 
CHRONIC  SCHIZOPHRENIA 

228325  01  08 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROMAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE, 

228554  01  05 
DRUG  TREATMENT  IN  A  REHABILITATION  CENTER  FOR  CHRONIC 
ALCOHOLICS 

228908  0111 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  DELTA9  TRANS- 
TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  GUINEA-PIGS. 

229033  01-03 
REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRONIC 
MARIJUANA  SMOKERS 

229039  01-15 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01-08 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES   -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL, 

229761  01-08 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHAIOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA 

230580  01  15 
NEUROENDOCRINE  EFFECTS  OF  HALOPERIDOL  THfRAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

230839  01  08 
TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  01-03 
SULPIRIDE  IN  CHRONIC  PSYCHOSES  OF  THE  PARANOID  TYPE. 

230991  01  11 
THE  RESOCIALIZING  EFFECT  OF  CLOTHIAPINF  IN  CHRONIC  PSYCHOSES. 

230993  01-11 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC. 

231367  01  08 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE-BLIND  CONTROLLED  TRIAL 

231609  01  08 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING.  (UNPUBLISHED 
PAPER) 

231771  01-04 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS    A  DOUBLE  BUND 
STUDY, 

232781  02  08 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  02-08 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE. 

232865  02- 1 5 
SCHEDULE-INDUCED  ORAL  NARCOTIC  SELF  ADMINISTRATION:  ACUTE 
AND  CHRONIC  EFFECTS. 

233293  0204 
THYROTROPIN-RELEASING  HORMONE  IN  CHRONIC  SCHIZOPHRENIA. 

233817  0208 


EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-03 
A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROAAAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
CHRONIC  MARIHUANA  INHALATION  TOXICITY  IN  RATS. 

235671  02-05 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
EVALUATION  OF  DISULFIRAM  TREATMENT  OF  CHRONIC  ALCOHOLISM. 

237026  02-11 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER). 

237169  02-04 
BEHAVIORAL  SUPERSENSITIVITY  TO  5-HYDROXYTRYPTOPHAN-INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT. 

237729  02-04 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS   -  CHRONIC  MORPHINE  ADMINISTRATION. 

237737  02-03 
A  PRELIMINARY  STUDY  WITH  PENFLURIDOL  IN  HOSPITALIZED  CHRONIC 
SCHIZOPHRENIC  PATIENTS. 

237897  0208 
LENPERONF:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

237899  02-08 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN 

237922  02-03 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PHD,  DISSERTATION). 

238157  02-03 
RESPONSFS  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 
METHOXAMINE  (M)  AND  0  AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-04 
PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  0304 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL, 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT. 

238722  03-04 
EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 

BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03  03 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE 

CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-04 
THE  EFFECT  OF  CHRONIC  MARIHUANA  SMOKING  ON  THE  BEAGLE  DOG. 

238806  03-03 
CHRONIC  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 

TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  THE  MONGREL  DOGS. 

238810  03-03 
BRAIN  SYNAPTIC  MEMBRANE  NAK  ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC). 

238812  03-03 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  0304 
EFFECTS  OF  LITHIUM  ON  CHRONIC  ETHANOL  CONSUMPTION  AND 
BEHAVIOR. 

238849  03-03 
ON  THE  MULTIFACTORIAL  TREATMENT  OF  CHRONIC  HEADACHES. 

238866  03-11 


S-74 


4 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 
POLYURIA. 

239046  03-05 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIOOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03  04 
ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  0304 
LORAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

241274  03-14 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE  EFFECTS  OF  CHRONIC  D- 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION. 

241307  03-04 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE. 

241338  03-03 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE 
(PH.D.  DISSERTATION). 

241576  03-03 
BIOAVAILABILITY  OF  TWO  CARBAMAZEPINE  PREPARATIONS  DURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS. 

242212  03-11 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  04-17 
A  TWO  YEAR  TRIAL  OF  LOXAPINE  SUCCINATE  IN  CHRONIC  PSYCHOTIC 
PATIENTS. 

244501  04-08 
PECULIAR  CLINICOPHARMACOLOGICAL  PROPERTIES  OF  CLOZAPINE 
REVEALED  IN  A  GROUP  OF  CHRONIC  SCHIZOPHRENICS. 

244587  04-08 
MOUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELTA9 
TETRAHYDROCANNABINOL  AND  PILOCARPINE. 

244682  04  04 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

245014  04  08 
EFFECTS  ON  OFFSPRING  OF  CHRONIC  MATERNAL  METHAMPHETAMINE 
EXPOSURE. 

245405  04-05 
PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04  04 
HUMAN  SLEEP  DURING  CHRONIC  MORPHINE  INTOXICATION. 

246304  04  1 3 
CAFFEINE  AND  CHLORDIAZEPOXIDE:  EFFECTS  ON  MOTOR  ACTIVITY  IN 
THE  CHRONIC  THALAMIC  RAT. 

246388  04-04 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246662  04-03 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS 

246842  04-03 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04- 13 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04  04 
AN  EARLY  CLINICAL  AND  TOXICITY  TRIAL  OF  EX-1 1-582A  IN  CHRONIC 
SCHIZOPHRENIA 

247481  04-07 


SUPERSENSITIVITY  Tn  D  AMPHETAMINE  AND  APOMORPHINE  INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D  AMPHETAMINE 
ADMINISTRATION. 

247683  04-04 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRONIC 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE 

247777  04-03 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  CI4-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICAL 
STATUS  OF  RHESUS  MONKEYS. 

249003  04-05 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  IIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 
ETHANOL  TOLERANCE  IN  THE  RAT. 

249264  04-04 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION 

249268  0403 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE. 

249294  04-03 
EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT 

249307  04-03 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS. 

249485  04  04 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC  BRAIN  SYNDROME. 

249625  04-1) 
CHRONIC  DELTA9-TETRAHYDR0CANNABIN0L    TRANSIENT  AND  LASTING 
EFFECTS  ON  AVOIDANCE  BEHAVIOR. 

250061  04-04 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG  TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04-08 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOIINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT 

251433  04-03 
A  LONG-TERM  STUDY  OF  PENFLURIDOL  IN  CHRONIC  SCHIZOPHRENIA. 

251829  04-08 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H  5  HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04-03 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT 

252519  04-03 
THE  DURATION  OF  MAINTENANCE  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

252763  04-08 
A  THREE-YEAR  DOUBLE-BLIND  INVESTIGATION  OF  PIMOZIDE  VERSUS 
FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  04-08 
LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 

CHRONIC  SCHIZOPHRENIA. 

253049  04-08 
THE  EFFECTS  OF  THIOTHIXENE  IN  GERIATRIC  PATIENTS  WITH  CHRONIC 

ORGANIC  BRAIN-SYNDROMF 

253050  04-11 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 

DRUGS  TO  PREPUBERTAL  MAI  E  RATS.  II.  LSD. 

253700  04-03 


0 


3E 


S-75 


Subject  Index 


Psychopharmacology  Abstracts 


CHRONICALIY 

DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04-04 
CHRONOTROPIC 

ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03-03 
CI-628 

EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES. 

239290  03-04 
CIBA-34276-BA 

MAPROTILINE  (LUDIOMIL,  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE  BLIND  CLINICAL  STUDY. 

242248  03-09 
A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 
ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE  CHLORHYDRATE  (CIBA  34276-BA) 

247554  04-09 
CICHIASOMA-NIGROFASCIATUM 

DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHIASOMA- 
NIGROFASCIATUM). 

230865  01-04 
CICHLID 

DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM). 

230865  01-04 
CIGAREHE 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM. 

225722  0115 
CINANSERIN 

ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03-04 
CIRCADIAN 

CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL 

234919  02-03 
CARBACHOL  ELICITED  MOUSE  KILI  ING  BY  RATS:  CIRCADIAN  RHYTHM 
AND  DOSE  RESPONSE. 

238006  02  04 
NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03  03 
CIRCLING 

SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIl  (MERIONES-UNGUICULATUS). 

241311  03-04 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS  COERULEUS  IN  RATS 

249076  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE  INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS. 

249485  04-04 
INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04  04 
CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS, 

250358  04-04 
CIRCULAR 

METHADONE-INDUCED  BEHAVIORAL  CHANGES:  CIRCULAR  MOVEMENTS, 
AGGRESSION.  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
MAGNETIC  CIRCULAR  DICHROISM  OF  SUBSTITUTED  INDOLES. 

229493  01-06 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  II,  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 
CIRCULATION 

THE  EFFECT  OF  CHLORPROMAZINE  ON  CEREBRAL  CIRCULATION 

236234  02-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG   -  DIAZEPAM,  CLOMIPRAMINE. 
AND  CHLORPROMAZINE. 

246319  04-03 


ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CEREBRAL 
BLOOD  CIRCULATION, 

248552  04-03 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT, 

251820  04-03 
INTESTINAL  ABSORPTION.  DEMETHYLATION.  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-13 
CIRCULATORY 

PSYCHOPHARMACOLOGY  OF  THE  CIRCULATORY  SYSTEM. 

229471  01-13 
THE  INFLUENCE  OF  IMIPRAMINE  ON  CIRCULATORY  EFFECTS  OF 
MIDODRINE. 

251415  04-03 
CIRRHOSIS 

NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
CLASS 

NATURE  OF  NEW  CLASS  OF  CHLORPROAAAZINE  (CPZ)  METABOLITES  IN 
PRIAAATE  URINES. 

249328  04-01 
CLASSICAL 

CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM. 

238787  03-04 
CLASSIFICATION 

MODERN  VIEWS  ON  DIAGNOSIS  AND  CLASSIFICATION  OF  DEPRESSIONS: 
II.  UNITED-KINGDOM. 

227205  01-09 
SCANDINAVIAN  STANDPOINT  ON  THE  LIEGE  CLASSIFICATION  OF 
NEUROLEPTICS. 

227761  01  17 
HYPNOTICS  AND  SLEEP:  CLASSIFICATION.  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS. 

228094  01  14 
A  PRACTICAL  CLASSIFICATION  OF  UNTOWARD  DRUG  EFFECTS. 

248909  04-15 
A  PRACTICAL  CLASSIFICATION  OF  MORBID  ANXIETY. 

251157  04-10 
CLASSIFICATIONS 

THE  MAIN  CLINICAL  CLASSIFICATIONS  OF  NEUROLEPTICS. 

227764  01-06 
CLASSIFIED 

FENMETRAZOLE  (DH-524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781  01-14 
CLASSROOM 

EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02  11 
NON-MEDICATION  MANAGEMENT  OF  HYPERKINETIC  CHILDREN  IN  THE 
CLASSROOM.  (PH.D.  DISSERTATION). 

240977  03-11 
CLEFT 

ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM 

229349  01-17 
CLEFTS 

ASSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 
CLEFTS. 

229350  01-15 
CLIMACTERIC 

THE  TREATMENT  OF  CLIMACTERIC  SYNDROME  WITH  TOFIZOPAM 
(GRANDAXIN). 

252450  04-1 1 
CLI/V\ACTERIUM 

THE  PSYCHIATRY  OF  THE  FEMALE  CLIMACTERIUM:  NEUROTIC  OR 
PSYCHOTIC  SYMPTOMS?. 

241875  03  09 
CLINIC 

DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-10 
THE  LITHIUM  CLINIC:  A  NEW  A/.ODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES 

234699  02-09 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  A  PAIN  CLINIC. 

252144  04-17 
CLINICAL 

THIORIDAZINE  PLASMA  LEVELS  AND  CLINICAL  RESPONSE. 

225932  01-08 
PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01  14 


4 


S-76 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


TREATMENT  WITH  DISULFIRAAA  IN  HUNTINGTONS-CHOREA:  A  NEGATIVE 
CLINICAL  AND  PHARMACOLOGICAL  STUDY. 

226430  01-07 
THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 
DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL 

226899  01-09 
EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL 

226902  01-16 
THE  CLINICAL  PHARMACOLOGY  OF  ANTIDEPRESSIVES. 

227209  01-17 
CLINICAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN). 

227210  01-07 
CLINICAL  PHARMACY  PRACTICE  IN  A  COMMUNITY  MENTAL-HEALTH 

CENTER. 

227560  01-17 
PHARMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS, 
WITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 
EFFECTS. 

227762  01  04 
BIOCHEMICAL  VS  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH 

SPECIAL  REFERENCE  TO  THEIR  ANTIMANIC  EFFECT. 

227763  01-04 
THE  MAIN  CLINICAL  CLASSIFICATIONS  OF  NEUROLEPTICS. 

227764  01-06 
CLINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE 

THIOXANTHENES. 

227765  01-08 
CLINICAL  PHYSIOGNOMY  OF  CHLORPROTHIXENE  AND  CLOPENTIXOL. 

227766  01-11 
CLINICAL  PHYSIOGNOMY  OF  FLUPENTHIXOL. 

227772  01-14 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS. 

227806  01-11 
COMPREHENSIVE  CLINICAL  STUDIES  WITH  THIOTHIXENE. 

227820  01-14 
CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01-09 
TRANQUILIZATION  EFFECT  OF  BETA-BLOCKADE  ALPRENOLOL;  A  CLINICAL 
STUDY. 

228311  01-11 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  (FK  880)  FOR  DEPRESSION. 

228334  01-09 
CLINICAL  EXPERIENCE  IN  USING  CLOXAZOLAM  (SEPAZON). 

229025  01-10 
CLINICAL  PHARMACOLOGY  OF  SO  10996,  A  POTENTIAL  ANTIDEPRESSIVE 
AGENT. 

229036  01-07 
THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 

FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE. 

229037  01-11 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  CLINICAL  OUTCOME. 

229443  01  09 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01-08 
CHLORPROMAZINE  METABOLISM  AND  CLINICAL  RESPONSE  IN  ACUTE 

SCHIZOPHRENIA   A  PRELIMINARY  REPORT, 

229445  01-08 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 

CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 

CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01   II 
CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  01  11 
CLINICAL  EXPERIMENTS  WITH  FLUPHENAZINE  DECANOATE  IN 

HOSPITALIZED  PATIENTS. 

229551  01  11 
CLINICAL  EXPERIMENTATION  OF  THE  LONG  ACTING  NEUROLEPTICS: 

METHODOLOGICAL  PROBLEMS 

229554  0116 
PSYCHOMETRIC  CLINICAL  EVALUATION,  THROUGH  OVERALL  AND 

GORHAMS  TEST,  OF  THERAPY  WITH  FLUPHENAZINE  DECANOATE 

229555  01   17 
ClINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE 

IN  TREATING  DISSOCIATIVE  SYNDROMES 

229560  01-11 
CLINICAL  EXPERIENCE  IN  USING  MENDON  (DIPOTASSIUM  CLORAZEPATE) 

229626  01-11 


CLINICAL  EXPERIENCE  IN  USING  MAPROTILINE,  A  NEW  ANTIDEPRESSIVE 
MEDICINE. 

229760  01-09 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 

SYNDROMES    -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
TREATMENT  OF  THE  MINIMAL-BRAIN  DYSFUNCTION  SYNDROME  WITH 

PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON). 

230002  01-11 
CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01  10 
CLINICAL  USE  OF  DRUGS  FOR  SLEEP  DISTURBANCES. 

230119  01  17 
A  CLINICAL  TRIAL  WITH  NOMIFENSIN,  A  NEW  ANTIDEPRESSANT  DRUG. 

231035  01-09 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 

DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01-10 
PREDICTABILITY  IN  PSYCHOPHARMACOLOGY:  PRECLINICAL  AND 

CLINICAL  CORRELATIONS. 

23111201  17 
TRICYCLIC  ANTIDEPRESSANT  OVERDOSE:  CLINICAL  PRESENTATION  AND 
PLASMA  LEVELS. 

23131801-13 
CLINICAL  PSYCHOPHARMACOLOGY  AND  PSYCHIATRY. 

231607  01-17 
CONCEPTS  OF  IMPULSIVITY:  A  CLINICAL  NOTE. 

231610  01-09 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS. 

232530  01-07 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  IHE  ANTIDEPRESSANTS 
AND  LITHIUM. 

232762  02-17 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 
PSYCHOTROPIC  DRUGS. 

233684  02- 1 7 
CLINICAL  STUDIES  OF  DOPAMINERGIC  MECHANISMS. 

233975  02-11 
CLINICAL  EXPERIENCE  WITH  CLOZAPINE. 

234419  02-11 
EFFECT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02-09 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

234797  02-09 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20-YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-17 
6ENZ0CTAMINE  IN  THE  TREATAylENT  OF  NEUROSIS  -    AN  UNCONTROLLED 
CLINICAL  STUDY 

235356  02-07 
ETAFENOXIN  IN  THE  TREATMENT  OF  NEUROSIS      AN  UNCONTROLLED 

CLINICAL  STUDY. 

235357  02  07 
LORAZEPAM  IN  THE  TREATMENT  OF  NEUROSIS    -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235358  02  07 
TRAZODONE  IN  THE  TREATMENT  OF  NEUROSIS    -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235359  02-07 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    -  1.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL 

235360  02-07 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    •  II    REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL 

235361  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    -  111.  STANDARD  CONTROLLED  CLINICAL 
TRIAL 

235362  02  09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -    IV.  A  SUMMARY  REPORT. 

235363  02-09 
PENFLURIDOL  IN  THE  TREATMENT  OF  SCHIZOPHRENIA    CLINICAL  AND 

PSYCHOMETRIC  FINDINGS 

235365  02-08 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II.  BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS, 

235367  02-09 


09 


S-77 


Subject  Index 


Psychopharmacology  Abstracts 


■-im 


TRAZODONE:  CLINICAL  AND  BIOCHtMICAL  STUDIES:  III. 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS. 

235368  0209 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  I,  AN 

UNCONTROLLED  ClINICAL  TRIAL  IN  DEPRESSION, 

235369  02-07 
THYROIROPIN  RELEASING  HORMONE  IN  DEPRESSION:  CLINICAL  AND 

ENDOCRINOLOGICAL  FINDINGS. 

235370  02-09 
A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 

ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS, 

235992  02-11 
CLINICAL  PSYCHOPHARMACOLOGY  AND  THE  ELDERLY  PATIENT. 

236300  02-17 
CLINICAL  EVALUATION  OF  THE  ANTIDEPRESSIVE  ACTION  OF  THE 
PREPARATION  AZAFEN 

236429  02-10 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAl  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
EXCIT.ATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARAAACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02-03 
CLINICAL  USE  OF  ANTIANXIETY  DRUGS. 

237165  02-10 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
CLINICAL  STUDIES  WITH  DOPAMINE  RECEPTOR  STIMULANTS. 

237725  02-08 
CLINICAL  LABORATORY  TEST  STANDARDS  FOR  A  SAMPLE  OF 

SCHIZOPHRENICS. 

237726  02-08 
PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 

MEDICATION,  (UNPUBLISHED  PAPER), 

238489  02-08 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 
ACTION  OF  DIAZEPAM. 

238531  02-13 
SLEEP  AND  HYPNOTIC  DRUGS:  THE  PHYSIOLOGY,  PHARMACOLOGY  AND 
CLINICAL  ASPECTS  OF  SLEEP. 

239029  03-14 
CLINICAL  PHARMACOLOGY  AND  THE  PRESCRIPTION  OF  PSYCHOTROPIC 
MEDICATION, 

239678  03-17 
RELATIONSHIP  BETWEEN  ANTIDEPRESSANT  EFFECT  AND  PLASMA  LEVEL 
OF  NORTRIPTYLINE.  CLINICAL  STUDIES, 

240217  03-09 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  I    INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03  08 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II,  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE 

240219  03-11 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  III    PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT 

240220  03-14 
CLINICAL  ASPECTS  OF  COCAINE.  ASSESSAAENT  OF  ACUTE  AND  CHRONIC 

EFFECTS  IN  ANIMALS  AND  MAN    (UNPUBLISHED  PAPER). 

240241  03-04 
DPH-INTOXICATION    -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03-15 
A  PRIMER  ON  THE  ClINICAL  EVALUATION  OF  PSYCHOTROPIC  DRUGS, 

240838  03-17 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME. 

241275  03-10 
DEPOT  NEUROLEPTICS  -  PRACTICAL  METBODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
MAPROIILINE  (LUDIOMIL.  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE-BLIND  CLINICAL  STUDY 

242248  03-09 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 

(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS 

242249  03-09 
CLINICAl  RESEARCH  WITH  DEMETRIN  IN  SURGERY  PATIENTS, 

242527  03-07 


CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANI/WALS  AND  MAN,  (UNPUBLISHED  PAPER 

243024  04- 1 7 
THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN-MAGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 
STUDY, 

243180  04-11 
CLINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE  NEW 
HYPNOSEDATIVE  K-2004. 

243198  04- n 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04  03 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

243819  04-13 
CLINICAL  USE  OF  TRICYCLIC  ANTIDEPRESSANTS. 

243861  04-09 
BIOCHEMICAL  PHARMACOLOGICAL  BASES  FOR  THE  CLINICAL  USE  OF  L- 
DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME. 

244039  04-17 
CLINICAL  EXPERIENCES  WITH  A  NEW  ANTIDEPRESSANT,  ICI-58834. 

244189  04-07 
INTERACTIONS  OF  HALLUCINOGENS  AT  THE  CLINICAL  LEVEL. 
(UNPUBLISHED  PAPER). 

244195  04-12 
CLINICAL  FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 
PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT. 

244476  04-11 
SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS 

244591  04-13 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04)  1 
CLINICAL  EXPERIENCE  WITH  RO-5-3350  (BROMAZEPAM) 

245138  04-10 
CLINICAL  OBSERVATIONS  ON  THE  TREATMENT  OF  TARDIVE-DYSKINESIA 
WITH  HALOPERIDOL. 

245967  0408 
LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  TRANQUILIZERS. 

246033  04-17 
RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WITH 
GER0VITAL-H3  TABLETS. 

246425  04-09 
THE  CLINICAL  COURSE  OF  PRIAAARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04-17 
CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE; 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
CLINICAL  EFFECTS  OF  IMIPRAMINE  AND  METHYLPHENIDATE  IN 
HYPERACTIVE  CHILDREN. 

247380  04  14 
CLINICAL  PHARMACOLOGICAL  MANAGEMENT  OF  HYPERKINETIC 

CHILDREN. 

247381  04-17 
AN  EARLY  CLINICAL  AND  TOXICITY  TRIAL  OF  EX-1 1-582A  IN  CHRONIC 

SCHIZOPHRENIA. 

247481  04-07 
A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 

ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE  CHLORHYDRATE  (CIBA-34276-BA). 

247554  04-09 
THE  CLINICAL  USES  OF  LEVODOPA 

247712  04-17 
CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 
ANTIDEPRESSANT  TREATMENT. 

247969  04-09 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
CLINICAL  PHARMACOLOGY  OF  NABILONE,  A  CANNABINOL  DERIVATIVE. 

248628  04-12 
CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-94) 
OF  NOVEL  CHEMICAL  FORMULATION 

248977  04-09 
THE  CLINICAL  PHARAMCOLOGY  OF  LILLY109514  IN  NORMAL 
VOLUNTEERS. 

249260  04-07 


S-78 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE-OXIDASE  INHIBITORS 
(MAOIS)^ 

249308  04-03 
A  CLINICAL  TRIAL  OF  TEMAZEPAM.  A  SLEEP  INDUCER,  IN  HOSPITAL 
PATIENTS. 

251006  04-07 
CLINICAL  TRIALS  OF  OXPRENOLOL  IN  ANXIETY. 

251159  04-10 
CLINICAL  EXPERIENCE  WITH  BETA-BLOCKERS  IN  CONSULTANT 
PSYCHIATRIC  PRACTICE. 

251165  04-10 
ON  THE  CLINICAL  RELEVANCE  OF  THE  INTRACELLULAR  RBC  LITHIUAA 
CONCENTRATION. 

251417  04-15 
CLINICAL  RESPONSE  TO  A  POTENTIAL  NONSEDATIVE  ANXIOLYTIC. 

251719  04-07 
EFFECT  OF  FLURAZEPAM  ON  COMMON  CLINICAL  LABORATORY  TESTS. 

251824  04-16 
A  CLINICAL  TRIAL  OF  TOFRANIL  IN  OSTEOARTHRITIS. 

252136  04-11 
A  CLINICAL  TRIAL  OF  TOFRANIL  IN  RHEUMATIC  PAIN  IN  GENERAL 
PRACTICE. 

252139  04-17 
CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS. 

252447  04-10 
THE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMENT  OF 

OUTPATIENTS  (A  MULTICENTRIC  STUDY). 

252448  04  07 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 

ACUTE  ALCOHOL  WITHDRAWAL. 

252694  04-11 
AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE 

253054  04-11 
AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253055  04-11 
A  COMPARISON  OF  TWO  UNCONTROLLED  CLINICAL  TRIALS  OF 

TRAZODONE, 

253056  04- 1 1 
A  PLACEBO  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253057  04-11 
A  STANDARD  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE  ON 

GERIATRIC  PATIENTS. 

253058  04-11 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3 

CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  04-11 
DIGITALIS:  CLINICAL  IMPLICATIONS  OF  NEW  FACTS  ABOUT  AN  01  D 
DRUG. 

253495  04-15 
ACUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS 

253617  04  09 
INICAUY 

THE  ANTINICOTINIC  EFFECTS  OF  DRUGS  WITH  CLINICALLY  USEFUl 
SEDATIVE  ANTIANXIETY  PROPERTIES. 

248009  04-03 
INICIAN 
PLASMA  CONCENTRATION  OF  OIPHENYLHYDANTOIN  IN  THE  EPILEPTIC: 
ITS  INTEREST  FOR  THE  CLINICIAN. 

240762  03-11 
INICO-CHEMICAl 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE:  CLINICO- 
CHEMICAL  CORRELATIONS. 

244050  04-08 
INICOPHARMACOLOGlCAl 
PECULIAR  CLINICOPHARMACOLOGICAL  PROPERTIES  OF  CLOZAPINE 
REVEALED  IN  A  GROUP  OF  CHRONIC  SCHIZOPHRENICS. 

244587  04-08 
OFIBRATE 
DOSE-RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 
SECRETION  OF  ADH:  EFFECTS  OF  CLOFIBRATE  AND  CARBAMAZEPINE. 

232638  02  13 
OMACRAN 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS 

231034  01-08 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS   -  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS 

235364  02-08 
OMIPRAMINE 
THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA. 

227139  01-03 
A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  01-09 


SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS   -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL. 

235360  02-07 
SYSTEAAATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -    II.  REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  02  09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -    III    STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS   -  IV.  A  SUMMARY  REPORT, 

235363  02-09 
SYNTHESIS  OF  3-CHL0R0-2-HYDR0XYIMIPRAMINE  AND  3-CHL0R0-8- 

HYDROXYIMIPRAMINE  (1),  HYPOTHETICAL  METABOLITES  OF 
CLOMIPRAMINE.  (UNPUBLISHED  PAPER). 

237174  02-01 
A  CONTROLIED  COMPARATIVE  TRIAL  OF  A  COMBINATION  OF 
OPIPRAMOI.  AND  CLOMIPRAMINE  AND  A  HIGHER  DOSE  OF 
CLOMIPRAMINE  ALONE. 

245468  04-09 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG    -  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04-03 
CLONAL 

NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCIE  CELL  LINES. 

243482  04-03 
CLONAZEPAAA 

THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHAIOPATHY  IN  CHILDREN:  STUDY  OF  28  CASES. 

229083  01-11 
ALTERED  5-HT  METABOLISAA  WITH  CLONAZEPAM,  DIAZEPAM  AND 
OIPHENYLHYDANTOIN. 

230855  01-03 
LONG-TERM  TREATMENT  OF  PETIT-MAL  WITH  CLONAZEPAM. 

231654  OT-TT 
INTENTION  MYOCLONUS:  SUCCESSFUL  TREATMENT  WITH  CLONAZEPAM. 

237825  02-1 1 
CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04- T I 
CLONAZEPAM  IN  THE  TREATAAENT  OF  CHOREIFORM  ACTIVITY 

250932  04-07 
ClONAZEPAM-INOUCED 

CLONAZEPAM  INDUCED  CHANGES  IN  5-HYDROXYrRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  MAN. 

237977  02-13 
CLONIC 

INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  04-03 
CLONIDINE 

EFFECTS  OF  CLONIDINE  AND  BS  100-141  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS 

226728  01-03 
AUTOMUTILATION  INDUCED  BY  CLONIDINE  IN  MICE. 

241398  03-04 
EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5  HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN. 

243777  04-03 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE. 

246148  04-04 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  fOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS. 

250089  04-04 
DIFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 
CLOPENTIXOL 

CLINICAL  PHYSIOGNOMY  OF  CHLORPROTHIXENE  AND  CLOPENTIXOL. 

227766  01  11 


ess 

OS 
I 


i 


S-79 


Subject  Index 


Psychopharmacology  Abstracts 


CIOPIMOZIDE 

CLOPIMOZIDE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-04 
CLORAZEPATE 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
CLINICAL  EXPERIENCE  IN  USING  MENDON  (DIPOTASSIUM  CLORAZEPATE). 

229626  01-11 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04-11 
ClOTHIAPINE 

A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROMAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES 

226412  01-08 
THE  RESOCIALIZING  EFFECT  OF  CLOTHIAPINE  IN  CHRONIC  PSYCHOSES. 

230993  01-11 
CLOXAZOLAM 

CLINICAL  EXPERIENCE  IN  USING  CLOXAZOLAM  (SEPAZON). 

229025  01-10 
CLOZAPINE 

CLOZAPINE  INCREASES  RAT  SERUM  PROLACTIN  LEVELS. 

226869  01  03 
INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
DETECTION  OF  THE  NEUROLEPTIC  PROPERTIES  OF  CLOZAPINE,  SULPIRIDE, 
AND  THIORIDAZINE. 

227135  01-04 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RAT 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02  03 
CLINICAL  EXPERIENCE  WITH  CLOZAPINE. 

234419  02-11 
COMPARISON  OF  THE  THERAPEUTIC  EFFECT  OF  CLOZAPINE  AND 

CHLORPROMAZINE 

234420  02-14 
AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 

PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  02-04 
EXTRAPYRAMIDAL  SYMPTOMS  UNDER  CLOZAPINE:  A  CASUISTIC 
CONTRIBUTION. 

238855  03-15 
EFFECT  OF  CLOZAPINE  ON  THE  METABOLISM  OF  SEROTONIN  IN  RAT 
BRAIN. 

239862  03  03 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM 

241252  03-03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES. 

241416  03-03 
COMPARISON  TRIAL  OF  TWO  ANTIPSYCHOTIC  DRUGS: 
CHLORPROMAZINE  AND  CLOZAPINE 

241760  03  08 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

241919  03  03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

243760  04-03 
EFFECT  OF  CLOZAPINE  ON  THE  MENTAL  AND  PHYSICAL  STATE  OF 
PATIENTS. 

243986  04  08 
PECULIAR  CLINICOPHARMACOLOGICAL  PROPERTIES  OF  CLOZAPINE 
REVEALED  IN  A  GROUP  OF  CHRONIC  SCHIZOPHRENICS. 

244587  04-08 
CLOZAPINE  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA,  A 
CRITICAL  APPRAISAL 

246671  04-03 
ANIAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS  ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04  06 
ACEIYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN    DISSIMILAR  EFFECTS  OF 
CLOZAPINE  AND  CHIORPROMAZINE 

248600  04-03 
LFFFCl  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
IHE  KINETIC  STATE  OF  TYROSINE  HYDROXYLASE  AND  ON  THE 


TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04-05 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS 

249629  04-04 
CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRENIC 
PATIENTS:  A  PILOT  STUDY. 

251828  04-08 
AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS:  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE. 

253052  04-08 
CLOZAPINE-INDUCED 

REVERSAL  BY  PHYSOSTIGMINE  OF  CLOZAPINE-INDUCED  DELIRIUM. 

237647  02-14 
CLUSTER 

CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
CNS 

INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 
INVERTEBRATE  SYNAPSES 

226398  01-03 
SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC. 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01-09 
ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO:  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01-04 
STUDIES  ON  THE  CNS  AVAILABILITY  OF  AMPHETAMINE  FROM 
AMPHETAMINIL. 

229041  01-03 
EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-03 
CNS  STIMULANTS  AND  ANABOLIC  SUBSTANCES  IN  GEROPSYCHIATRIC 
THERAPY. 

229459  01-11 
DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
-  AN  ANTIMIGRAINE  COMPOUND 

229473  01-13 
BIOGENIC  AMINE  EFFECTS  ON  CNS  PHOSPHOLIPID  METABOLISM. 

229482  01-03 
SELF-ADMINISTRATION  OF  CNS  STIMULANTS  BY  DOG. 

230879  01-04 
PHARMACOLOGICAL  STUDIES  OF  DRUG  ACTION  ON  CNS,  WITH  SPECIAL 
REFERENCE  TO  EFFECTS  OF  MAPROTILINE 

231316  01-04 
CNS  EFFECTS  OF  NEUROLEPTIC  AGENTS. 

231993  01  15 
NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 
PROPERTIES. 

232528  01-02 
CNS  TRANSMITTERS  AND  THE  HYPOTHALAMUS 

238784  03  03 
6-HYDROXYDOPAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS 

238826  03-03 
EFFECTS  OF  l,2-BENZISOXAZOLE-3-ACETAMIDOXIME  HYDROCHLORIDE 
(PF-257)  ON  THE  CNS  WITH  SPECIAL  REFERENCE  TO  MONOAMINE 
METABOLISM. 

241393  03  03 
CNS  PHOSPHOLIPID  METABOLISM  AND  NEURONAL  FUNCTION. 

244089  04  03 
A  COMPARISON  OF  THE  DISCRIMINABIE  CNS  EFFECTS  OF  KETAMINE, 
PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 

COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-04 
BACLOFEN  (BE)   AN  UNUSUAL  CNS  ACTIVE  AGENl 

249304  04-03 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D  AMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS 

250080  04-03 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04  04 
A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

250935  04  17 


S-80 


4 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


ALT 

APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
AIT-INDUCED 

NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT 

226399  01-03 
RA 

ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE. 

244203  04-03 
AINE 

COMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL. 

227137  01  04 
COCAINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
METABOLISM  IN  VIVO, 

230834  01-03 
THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED-RATIO  WATER 

REINFORCED  RESPONDING  IN  RATS. 

230842  01-04 
PRETRIAL  COCAINE  AND  PERFORMANCE  IN  RAT. 

237108  02-04 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER). 

237169  02-04 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM 

238694  03-04 
EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PFNTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES 

240015  03-04 
CLINICAL  ASPECTS  OF  COCAINE-  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  03-04 
AMT  CATALEPSY  AND  HYPOKINESIA    INTERACTION  WITH  MORPHINE 
AND  COCAINE. 

241224  03-04 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  04-17 
COMPARATIVE  PSYCHOPHARMACOLOGV  OF  COCAINE  AND 
AMPHETAMINE. 

243820  04-17 
NALTREXONE,  MORPHINE  AND  COCAINE  INTERACTIONS  IN  MICE. 

249269  04-04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 

MONKEYS  MAINTAINED  ON  NALTREXONE. 

249270  04  04 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 

PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION 

2501 1 1  04  04 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN 

252514  04  03 

:ainestera$e 

resolution,  purification  and  characterization  of  rabbit 
serum  atropinesterase  and  cocainesterase 

251180  04-01 

:kroach 

effects  of  physostigmine  on  avoidance  conditioning  and 
retention  in  the  isolated  cockroach  ganglion.  (ph.d. 
dissertation). 

228503  01  04 
}EINE 
FURTHER  STUDIES  ON  SELF  ADMINISTRATION  OF  ANTIPYRETIC 
ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITH 
CODEINE  IN  RHESUS  MONKEYS 

246855  04-04 
FFEE 
THE  MEDICAL  EFfECIS  OF  COFFEE. 

248862  04-15 


COGNITIVE 

COGNITIVE  EFFECTS  OF  METHYLPHENIDATE  ON  HYPERACTIVE  CHILDREN. 
(PH.D.  DISSERTATION). 

228431  01   II 
COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG-RANGE  L-DOPA  THERAPY 
IN  PARKINSONISM. 

229165  01-11 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  01-15 
A  REVIEW  OF  THE  EFFECTS  OF  DIAZEPAM  ON  COGNITIVE  AND 
PSYCHOMOTOR  PERFORMANCE. 

235236  02-14 
COGNITIVE  EFFECTS  OF  LONG  TERM  AAARIJUANA  USE.  (PH  D, 
DISSERTATION). 

238085  02-14 

COLCHICINE 

ANATOMICAL  AND  BEHAVIORAL  EFFECTS  OF  COLCHICINE 
ADMINISTRATION  TO  RATS  LATE  IN  UTERO. 

252148  04-05 
COLD 

RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
COLLABORATION 

AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  OF 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION 

229439  01-16 
COLLABORATIVE 

FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 

CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 
STUDY  GROUP. 

225718  01-09 
DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM. 

225722  01-15 
COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN 

228226  0 1  09 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
COLLEGIUM 

NINTH  CONGRESS  OF  THE  INTERNATIONAL 

NEUROPSYCHOPHARMACOLOGICUM  COLLEGIUM  OR  C.I.N. P.  (PARIS. 
JULY  7-12,  1974). 

250266  04  17 
COLLICULUS 

DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  03-03 
ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS. 

239978  03  04 
COLONIES 

BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 
MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

25 1 063  04-04 
COLOR 

EYE  COLOR  AND  TARDIVE-DYSKINESIA. 

253037  04  15 
COAAA 

ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20  YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-17 
COMBINATION 

PLASMA  CONCENTRATIONS  OF  L  DOPA  AND  3  METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L  DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE 

226349  01   14 
A  COMBINATION  OF  ANTIANXIETY  DRUGS    REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

228207  01   10 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 
FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING 

229907  01  14 


09 

SO 

0 


00 

I 


S-81 


Subject  Index 


Psychopharmacology  Abstract 


;Vv>^>;l 


'".v: 


STUDIES  ON  THF  AtriON  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN, 

232503  01-13 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE  BLIND 
STUDY. 

232781  02-08 
DRUGS  IN  COMBINATION  WITH  OTHER  THERAPIES, 

234378  02-17 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPriCS. 

235305  02-11 
PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL. 

237123  02-13 
PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID 

237705  02-04 
TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPADECARBOXYLASE  INHIBITOR. 

237733  02-11 
RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE-BEl  A-HYDROXYLASE 
(DBH)    EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8  BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03- 14 
THERAPEUTIC  COMBINATION  OF  PSYCHOPHARMACEUTICALS  AND  BETA- 
ADRENERGIC  BLOCKERS 

239783  03-15 
EXTRAPYRAMIDAl  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE;  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
LITHIUM  TREMOR   -  COMBINATION  TREATMENT  WITH  BETA-RECEPTOR 
BLOCKERS?. 

240741  03-14 
COMBINATION  OF  IRICYCLIC  ANTIDEPRESSANTS  AND  MAOI  IN 
DEPRESSION 

240839  03-09 
THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL.  (PH.D.  DISSERTATION). 

240933  03-03 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 
THE  ClINICAL  EFFECTIVENESS  OF  A  CAVAIN  MAGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE  BLIND 
STUDY. 

243180  04-1  1 
THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04-13 
A  CONTROLIED  COMPARATIVE  TRIAL  OF  A  COMBINATION  OF 
OPIPRAMOL  AND  CLOMIPRAMINE  AND  A  HIGHER  DOSE  OF 
CLOMIPRAMINE  ALONE 

245468  04-09 
THE  REIAIIVE  ROLE  OF  BRAIN  ACETYICHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZFPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION 

246694  04-11 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE  BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS. 

248975  04-10 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA  MULATTA 

249267  04-04 
THE  EFFECT  OF  CAFFEINE  ON  HUMAN  PERFORMANCE,  ALONE  AND  IN 
COMBINATION  WITH  ETHANOL. 

249674  04-14 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  04-03 


AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORME 
SINGLY  AND  IN  COMBINATION. 

253381  04-1 
COMBINATIONS 

THE  PHARMACOLOGIC  MEANING  OF  SUCCESSFUL  ANTIPSYCHOTIC 
ANTIDEPRESSANT  COMBINATIONS. 

230010  01-1 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTA8- 
TETRAHYDROCANNABINOL  (DELTA8-THC) 

241926  03-C 
FURTHER  STUDIES  ON  SELF-ADMINISTRATION  OF  ANTIPYRETIC 
ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITI 
CODEINE  IN  RHESUS  MONKEYS. 

246855  04-C 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 
COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-C 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMIN 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-C 
COMBINED 

A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  02-C 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORAAANCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02-1 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOP/ 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO-4  4602) 

233917  02-1 
IMPACT  OF  PSYCHOSOCIAI  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02-1 
EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02-) 
THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  02-0 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-1 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AN! 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-0 
DEPENDENCY  ON  COMBINED  METHAQUALONE  DIPHENHYDRAMINE. 

241870  03-1 
EFFECTS  OF  MARIHUANA  COMBINED  WITH  SECOBARBITAL. 

245648  04-] 
COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS-CHOREA:  PILOT  STUDY. 

248172  04-1 
COMPARISON  OF  DOPADECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

248612  04-1 
COMPARISON  OF  DOPADECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE, 

248613  04-1 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 

AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS. 

249272  04-0' 
APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHILDHOOD 
HYPERKINESIS. 

249772  04-1 
LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 
CHRONIC  SCHIZOPHRENIA. 

253049  04-Of 
COMBINING 

EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-11 
COMMUNITY 

CLINICAL  PHARMACY  PRACTICE  IN  A  COMMUNITY  MENTAL-HEALTH 
CENTER. 

227560  01-1/ 
LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS. 

229448  01 -0£ 
COMPARED 

SHORT-TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PLACEBO  IN  DEPRESSION:  A  DOUBLE-BLIND  STUDY. 

227214  01  05 


S-82 


* 


UME  14,  SUBJECT  INDEX 


Subject  Index 


.ORAZEPAM  COMPARED  WITH  PENTOBARBITAL  FOR  NIGHTTIME 
SEDATION 

232622  02-14 
'ERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 
NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA 

239023  03-08 
FRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS. 

244588  04-09 
IFFECTS  OF  THIENODIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04-07 
ANTICONVULSANT  ACTIVITY  OF  DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED  WITH  THREE  OTHER  DRUGS. 

248283  04-02 
PARING 

fHERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01-11 
.(QUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS. 

247877  04-07 
PARISON 

\  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 
THE  TREATMENT  OF  STATES  OF  ANXIETY. 

226410  01-10 
\  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

226414  01-11 
:OMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL 

227137  01-04 
i/ILOXAZINE  (VIVALAN)  COMPARISON  WITH  IMIPRAMINE. 

227215  01-09 
:AFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON 

227571  01-11 
COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01  04 
3ENZ0DIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 
CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-09 
^  DOUBLE  BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  01-09 
^  DOUBLE-BLIND  COMPARISON  OF  PENFLURIDOL  (EASER)  WITH 
PIMOZIDE  IN  SCHIZOPHRENIA. 

229026  01  07 
RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 
CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 
■FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE-DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-04 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

231034  01-08 
^  COMPARISON  OF  FENFLURAMINE  AND  AMPHETAMINE  IN  MAN. 

23131901-13 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01-04 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 
COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS. 

232530  01-07 
^  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM. 

233289  02-03 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS 

233832  02-13 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE, 

234114  02-11 


COMPARISON  OF  THE  THERAPEUTIC  EFFECT  OF  CLOZAPINE  AND 
CHLORPROMAZINE. 

234420  02  14 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    -  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02  08 
A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (ROOM)  AND  S 
AMPHETAMINE  IN  THE  RAT. 

237717  02-04 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS 

237828  02-08 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
METABOLISM  OF  DELTAl -TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02  03 
TRYPTOPHAN-HYDROXYLASE  IN  DISCRETE  NUCLEI:  COMPARISON  OF 
ACTIVITY  IN  VITRO  AND  IN  VIVO. 

238678  03  03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03  04 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03-04 
A  COMPARISON  OF  THf  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL-GABA  (AMINO-4  HEX  5  ENOIC  ACID)  AND  GAMMA-ACETYLENIC- 
GABA  (AMINO-4  HEX-5-YN0IC-ACID). 

238782  03  03 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR. 

238800  03  04 
THE  EFFECT  OF  DL-254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS. 

238846  03-03 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA. 

238996  03-08 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS, 

239818  03  10 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03- 1 1 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03  03 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYDROCANNABINOL. 

240645  03-14 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS 

241223  03  04 
CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03  14 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 
ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON 

241347  03  03 


09 

s 
S 


S-83 


Subject  Index 


Psychophormacology  Abstrac 


COMPARISON  OF  THE  EfFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULATION 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375  03-04 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS.  4TH 
REPORT.  COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
COMPARISON  TRIAL  OF  TWO  ANTIPSYCHOTIC  DRUGS: 
CHLORPROMAZINE  AND  CLOZAPINE. 

241760  03-08 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE.  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS-  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM   COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE. 

244513  04-03 
A  COMPARISON  OF  THE  EFFECTS  OF  FLURAZEPAM  30  MG  AND 
TRIAZOLAM  0.5  MG  ON  THE  SLEEP  OF  INSOMNIACS. 

244686  04-11 
EFFECTS  OF  DELTA9  TETRAHYDROCANNABINOL  ON  SOCIAL  BEHAVIOUR 

IN  MICE:  COMPARISON  BETWEEN  TWO  VEHICLES 

244687  04-04 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 

AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

245014  04-08 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT- 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL-BRAIN-DYSFUNCTION 

247878  04-11 
ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE;  COMPARISON 
WITH  D-AMPHETAMINE. 

248284  04-03 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE  OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM 

248603  04-03 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE 

248612  04- 11 
COMPARISON  OF  DOPA  DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
A  COMPARISON  OF  THE  DISCRIMINABLE  CNS  EFFECTS  OF  KETAMINE 

PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY 

249139  04-04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 
MONKEYS  MAINTAINED  ON  NALTREXONE 

249270  04-04 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  0403 
BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
DIMETHYLTRYPTAMINE  AND  S-METHOXY-N.N  DIMETHYLTRYPTAMINE. 

249317  04-05 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  i  )  AMPHETAMINE 
AND  L  DOPA 

249419  04-04 
COMPARISON  BETWEEN  INTRAVENOUS  AND  INTRAGASTRIC  ALCOHOL 
SELF  ADMINISTRATION 

250021  04-04 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBirORY  FACTOR  (MIF  I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
(LNIRAI   DOPAMINE  RECEPTORS 

250082  04-03 
ANIIACITYLCHOIINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

(  OMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS 

250360  04-02 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
(  I  )  TRANYLCYPROMINE  IN  AN  ANIMAL  MODEL. 

250376  04  03 
COMPARISON  OF  LOW  DOSES  OF  HALOPERIDOL  AND  DIAZEPAM  IN 
ANXIETY  STATES 

250491  04-10 


COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE-BLIND  MULTICENTRE  TRIAL. 

251118  04 
CARBAMAZEPINE  (TEGRETOL)   -  A  DOUBLE-BLIND  COMPARISON  WITH 
PHENYTOIN  (DILANTIN). 

251937  04 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04 
COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 
INCIDENCE  OF  SIDE-EFFECTS, 

252006  04 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301  1  04 
COMPARISON  OF  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE, 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  ANC 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04 
A  COMPARISON  OF  TWO  UNCONTROLLED  CLINICAL  TRIALS  OF 
TRAZODONE. 

253056  04 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AN( 
PSYCHOTIC  PATIENTS. 

253641  04 
COMPARISONS 

BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 

COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02 
COMPARISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECTS 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT. 

250939  04 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYl 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL  INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04 
COMPARTMENT 

RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS, 

238681  03- 
COMPENDIUM 

COMPENDIUM  OF  PHARMACOLOGY  DRUG  CHARTS. 

249768  04 
COMPETENT 

FUGUE  STATES  -  EPILEPSY  -    MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT   AUGUST  1,  1975. 

237476  02- 
COMPETING 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01- 
COMPETITION 

EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SQUIRREL-MONKEY 
INCENTIVE  COMPETITION  BEHAVIOR.  (PH.D.  DISSERTATION). 

241668  03- 
COMPETITIVE 

A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  0 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES 

23T072  01-I 
DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PH.D. 
DISSERTATION) 

240934  03-1 
COMPLEX 

DRUG-INDUCED  RHYTHM.ICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT 

235866  02-1 
INTRODUCTION:  COMPLEX  SCHEDULES  OF  DRUG  INJECTION, 

240012  03-( 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINEDEPENDEN 
RHESUS  MONKEYS. 

240019  03-( 
THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYTOCHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-( 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-C 


S-84 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX:  RELATION  TO 
ANALGESIC  ACTIVITY. 

250355  04-03 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

25)070  04-03 
tPUCATING 
FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY 

235286  02-15 
IPIICATION 

PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  OR 
NEUROLEPTIC  DOSAGE. 

252955  04-17 
IPLICATIONS 

COMPLICATIONS  OF  PSYCHOACTIVE  DRUGS  AS  SEEN  BY  FAMILY 
PRACTITIONERS. 

248851  04-15 
[POSITION 

THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN. 

253041  04-15 
IPREHENSIVE 
COMPREHENSIVE  CLINICAL  STUDIES  WITH  THIOTHIXENE. 

227820  01-14 
IPUISIVE 

DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03-04 
IPUTERIZED 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 
ICENTRATION 

INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 
CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-03 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  BRAIN  AMINE 
CONCENTRATION  AND  TURNOVER  IN  WHOLE  RAT  BRAIN  AND  IN 
VARIOUS  REGIONS  OF  THE  BRAIN. 

230856  01-03 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-16 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 
OF  THE  RAT. 

237862  02-03 
SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 
PSYCHIATRIC  PATIENTS. 

238552  02-13 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY. 

238673  03-03 
PLASMA  CONCENTRATION  OF  DIPHENYLHYDANTOIN  IN  THE  EPILEPTIC: 
ITS  INTEREST  FOR  THE  CLINICIAN. 

240762  03-11 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P  CHLOROAMPHETAMINE. 

241253  03-03 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE. 

241414  03-03 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03-10 
DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04-03 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 
ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION. 

245600  04-04 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04- 13 


THE  EFFECT  OF  PRETREATMENT  WITH  6-HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 
VAS-DEFERENS. 

248413  04-03 
ON  THE  CLINICAL  RELEVANCE  OF  THE  INTRACELLULAR  RBC  LITHIUM 
CONCENTRATION. 

251417  04  15 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301 1  04  07 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
CONCENTRATIONS 

PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE,  APPLICATION  OF 
MATHEAAATICAL  MODELS. 

232519  01  14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  01-13 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENTOBARBITAL 

ON  AUDITORY  EVOKED  RESPONSES. 

234682  02-03 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT. 

237747  02-03 
SERUM  CREATINE-PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT. 

237928  02-15 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
MARIJUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03-04 
PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-13 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  (  + )  AMPHETAMINE. 

241257  03-03 
CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04  13 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 
THE  RAT  BRAIN. 

247213  04-03 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL  CYCLIC-AMP. 

248276  04-03 


09 

CP 


as 

s 

I 

Si; 

7»-~ 


S-85 


Subject  Index 


Psychopharmacology  Abstra 


SELf  INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PIASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION, 

248955  04-10 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN 

252523  04-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
CONCEPT 

EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL 
FUNCTIONAL  AND  CLINICAL  DATA, 

237104  02-03 
CONCEPTS 

CONCEPTS  OF  IMPULSIVITY:  A  CLINICAL  NOTE 

231610  01-09 
CONCEPTUAL 

CONCEPTUAL  IMPLICATIONS  OF  DRUG  AND  NONSOMATIC  TREATMENT 
INTERACTION  STUDIES. 

229452  CM  7 
PSYCHOTHERAPY  AND  PHARMACOTHERAPY:  CONCEPTUAL  ISSUES 
(UNPUBIISHED  PAPER). 

238493  02  17 
CONDITION 

THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712  02-04 
CONDITIONAL 

REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT, 

232617  02-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA- 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 
CONDITIONED 

THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 
CONDITIONED  REFLEX  IN  RATS. 

227637  01-04 
EFFECT  OF  5,5  DIPHENYLHYDANTOIN  ON  FIXED  CONDITIONED  REFLEXES 
IN  CATS 

229681  01-04 
RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX   -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE. 

230570  01  04 
EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS.  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE 

230829  01-04 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT 

230860  01  03 
THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS. 

231069  01-04 
THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS 

231248  01-04 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE  NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251  01-04 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02-14 
THE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE 

236249  02-03 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION 

236257  02-04 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS 

236828  02  04 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 
PSYCHOMOTOR  STIMULANT  DRUGS   A  TEST  OF  HILLS  HYPOTHESIS, 

23771 1  02-04 
ATTENUATION  BY  ALPHA  METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 
CONDITIONED  TASTE  AVERSION  IN  RATS 

237713  02-04 
IHf  EFFECTS  OF  N  OIPROPYLACETATt  ON  THE  ACQUISITION  OF 

CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE. 

237723  02-04 


CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM. 

238787  O: 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 
CONDITIONED  REFLEX  IN  THE  CAT. 

239275  O: 
CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRUG 
AS  CONDITIONED  STIMULI.  (PH.D.  DISSERTATION). 

239523  O: 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULATI 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375  0: 
FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AN 
UCS  HABITUATION. 

241521  a 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES 

241980  0: 
DRUG-INDUCED  CONDITIONED  SUPPRESSION:  SPECIFICITY  DUE  TO  DR 
EMPLOYED  AS  UCS 

242750  a 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE. 

244352  0. 
EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  0. 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVK 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGI 
NERVOUS  SYSTEM. 

251397  0. 
INFLUENCE  OF  PHAR/\AACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD-PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS. 

251414  0- 
ANOREXIA  AND  CONDITIONED  TASTE  AVERSIONS  IN  THE  RAT. 

251629  0- 
HORMONAL  INFLUENCES  ON  THE  EXTINCTION  OF  CONDITIONED  TASTI 
AVERSION 

251980  0' 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSI 

251989  0' 
CONDITIONING 

THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINF  ON  TWC 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01 
EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDITIONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION.  (PH.D. 
DISSERTATION). 

228503  01 
CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM. 

238787  O; 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  PENTOBARBITAL 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING. 

244693  OA 
DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS 

251978  04 
CONDITIONS 

BIOTRANSFORMAnON  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS. 

226928  01 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRAN5AMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACI? 
UNDER  CONDITIONS  OF  MINIMAL  REST, 

236372  02 

THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 

POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY 

237721  02 
ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-MACHINE  TRACKING  SYSTEA 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATME 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  OTHER  PAINFUL  CONDITIONS. 

252142  04 
CONDUCT 

IMPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02 


S-86 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


NDUCTANCE 

HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS 

248514  04-04 
MDUCTIVITY 
BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
*IFINEMENT 
FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY:  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04-04 
«1FIRME0 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS,  (UNPUBLISHED  PAPER). 

240242  03-03 
^JFLICT 
EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03-04 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
»JFORMANT 
""HE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  0203 
MFORMATIONAl 

CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
MFORMATIONALIY 
CONFORMATIONALLY  CONSTRAINED  ANALOGS  OF  MESCALINE  II. 

233361  02-01 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04-03 
>JFRONTATION 
MODEL  OF  CAUSAL  CONFRONTATION  IN  INTEGRATIVE  PSYCHOTHERAPY. 

234503  02  14 
MFUSED 
DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS. 

229368  01  11 
hJFUSIONAL 
ACUTE  CONFUSIONAL  STATES. 

239607  03-17 
rjGENERS 
CONGENERS  OF  PHENOTHIAZINE  TRANQUILIZERS.  (PH.D.  DISSERTATION). 

240937  03-02 
^IGENITAL 
CONGENITAL  MALFORMATIONS  WITH  PSYCHOPHARMACOLOGIC 
AGENTS. 

230012  0115 
»JGRESS 
NINTH  CONGRESS  OF  THE  INTERNATIONAL 
NEUROPSYCHOPHARMACOLOGICUM  COLLEGIUM  OR  C.I.N. P.  (PARIS, 
JULY  7-12,  1974). 

250266  04- 1  7 
MJUGATION 

CONJUGATION  OF  L  DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  04- 1 5 
STUDIES  ON  SULFATE  CONJUGATION  OF  ESTROGENS  IN  BRAIN  AND 
LIVER. 

249245  04-03 
*4NECTIONS 
THE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS. 

248159  04-03 
MNERS 

CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN  --  AN  EMPIRICAL  STUDY. 

248593  04-1  1 
MSCIOUS 
DFITA9  TETRAHYDROCANNABINOL  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS 

238681  03-03 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
8R0MAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03  03 


CONSCIOUSNESS 

COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9  TRANS 
TETRAHYDROCANNABINOL. 

240645  03-14 
CONSENT 

DRUG  RESEARCH  AND  THE  QUESTION  OF  CONSENT. 

252314  04-17 
CONSOLIDATION 

THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES. 

241301  03-04 
CONSTANT 

STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATFD  CHOLINE 

247146  04-03 
CONSTRAINED 

CONFORMATIONALLY  CONSTRAINED  ANALOGS  OF  MESCALINE  II. 

233361  02-01 
CONSTRICTION 

EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
CONSULTANT 

CLINICAL  EXPERIENCE  WITH  BETA-BLOCKERS  IN  CONSULTANT 
PSYCHIATRIC  PRACTICE. 

251165  04-10 
CONSUMMATORY 

CHOLINERGIC  MEDIATION  OF  INSTRUMENTAL  AND  CONSUMMATORY 
BEHAVIORS. 

233448  02-04 
CONSUMPTION 

THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01-03 
LONG  TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIFT  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS. 

238741  03-03 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03  03 
EFFECTS  OF  LITHIUM  ON  CHRONIC  FTHANOL  CONSUMPTION  AND 
BEHAVIOR. 

238849  03  03 
CHANGE  IN  FTHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  03-03 
PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 

COUNTRY 

252990  04  17 
CONTINGENT 

CONTINGENT  NALOXONE  (N-ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01-14 
RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 

CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME' IN  NORMAL  WOMEN. 

230863  01-14 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION 

246093  04-04 
CONTRACTION 

EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
DIFFERENTIAL  EFFECTS  OF  ETHYLALCOHOL  ON  CONTRACTION  OF 

ARTERIAL  SMOOTH  MUSCLE 

251905  04-03 
DIFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAL  SMOOTH  MUSCLE 

2.S3I13  04-03 
CONTRACTIONS 

CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAl 
CONCENTRATIONS  OF  SEROIONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04  03 
CONTRACTOR 

CONTRACTOR  EFFECT  OF  BARBITURATES  ON  SMOOTH  MUSCLE. 

2304.54  01  03 


I 

SI. 


S-87 


Subject  Index 


Psychopharmacology  Abstrai 


CONTRALATERAL 

A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAfvMME-INDUCED 
CONTRALATERAL  ROTATION  IN  RATS, 

231301  01  04 
CONTRASTING 

CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 
BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  04-02 
CONTROL 

EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL 

226902  01-16 
SCOPOLAMINE  AND  AMPHETAMINE  EFFECTS  ON  DISCRIMINATION: 
INTERACTION  WITH  STIMULUS  CONTROL. 

227131  01-04 
LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01-04 
AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  OF 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION. 

229439  01-16 
SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATIONS 
RELATED  TO  STIMULUS  CONTROL. 

231005  01-04 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  02-04 
DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE;  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 
SCHIZOPHRENIA    RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 
CONTROL,  AND  FEATURE  EXTRACTION. 

238464  02-08 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
INTRODUCTION:  THE  CONTROL  OF  BEHAVIOR  BY  CONSEQUENT  DRUG 
INJECTIONS. 

240009  03-04 
STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 
CONTROL  BEHAVIOR. 

24001 1  03-04 
DRUG  EFFECTS  AND  THE  ENVIRONMENTAL  CONTROL  OF  BEHAVIOR. 

240021  03-04 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-11 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
THE  CHEMICAL  CONTROL  OF  NEURONAL  ACTIVITY.  (UNPUBLISHED 
PAPER). 

243183  04-17 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG- 
INFORMATION  CENTER:  THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04-13 
FRONTAL-STRIATAL  CONTROL  OF  BEHAVIORAL  INHIBITION  IN  THE  RAT. 

251138  04-04 
BETA-ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 
SYMPTOMS  -   A  CASE  FOR  CONTROLLED  STUDIES. 

251164  04-08 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
CONTROL  OF  LITHIUM  TREMOR  WITH  PROPRANOLOL. 

25I43I  04-15 
CONTROLLED 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA 

225867  01-08 
FLUPENTHIXOL  DECANOATE  -   CONTROLLED  INVESTIGATION  CONCERNING 
DOSAGE 

226408  01-08 
A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROMAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES. 

226412  01-08 
EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL. 

226902  01-16 


A  CONTROLLED  MULTICENTRE  THERAPEUTIC  TRIAL  OF  VILOXAZINE 
(VIVALAN). 

227216  01 
A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  0 
DOUBLE-BLIND  CONTROLLED  STUDY  OF  L-DOPA  THERAPY  IN 
SCHIZOPHRENIA. 

229064  0 
A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIt 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM. 

230104  0 
A  CONTROLLED  EVALUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS. 

230907  0 
A  CONTROLLED  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  IN  DEPRESSED 
OUTPATIENTS. 

231401  0 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE-BLIND  CONTROLLED  TRIAL. 

231609  0 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  0 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS   -  II.  REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  0 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  III.  STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  0 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARA' 

EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  0 
LENPERONE:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHREN 
PATIENTS. 

237899  0 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVEF 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  0 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  0 
A  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESSI 
ANXIETY  STATES. 

239938  0 
CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 
INJECTIONS  OF  DRUGS 

240010  0 
CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  0 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME 

241275  0 
PERSONALITY  FACTORS  AND  DRUG  EFFECTS  IN  A  CONTROLLED  STUD 
OF  CYCLAZOCINE. 

244298  0 
A  CONTROLLED  TRIAL  OF  AMANTADINE  IN  DRUG-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

244701  0 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUl 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  0 
A  CONTROLLED  COMPARATIVE  TRIAL  OF  A  COMBINATION  OF 
OPIPRAMOL  AND  CLOMIPRAMINE  AND  A  HIGHER  DOSE  OF 
CLOMIPRAMINE  ALONE. 

245468  C 
CONTROLLED  TRIAL  OF  METHYLPHENIDATE  IN  PRESCHOOL  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION. 

247375  0 
A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS. 

247483  0 
DOUBLE-BLIND  PLACEBO  CONTROLLED  EFFICACY  STUDY  OF  KETAZOL 
(U-28774). 

248532  0 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  0 
CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-' 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  0 


S-88 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-16 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 
CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04-11 
BETA-ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 
SYMPTOMS   -  A  CASE  FOR  CONTROLLED  STUDIES. 

251164  04-08 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04-11 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04-08 
A  PLACEBO  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253057  04-11 
A  STANDARD  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE  ON 

GERIATRIC  PATIENTS. 

253058  04-1 1 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY. 

253684  04-11 
CONTROLLING 

CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271  02-14 
CONVERGENCE 

USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION.  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04-03 
CONVERSION 

ENZYMATIC  CONVERSION  OF  MORPHINE  TO  PSEUDOMORPHINE. 

243780  04-03 
CONVICT 

DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM). 

230865  01-04 
CONVICTS 

TREATMENT  OF  PSYCHOLOGICAL  PROBLEMS  OF  CONVICTS. 

233079  02-11 
CONVULSANT 

DIFFERENTIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 
SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN. 

227387  01-03 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 
ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  04-03 
SPECIFIC  AXONAL  EFFECTS  OF  A  CONVULSANT  BARBITURATE. 

249258  04-03 
CONVULSION 

SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  04-05 
CONVULSIONS 

TWO  CASES  OF  CONVULSIONS  DURING  LITHIUM  THERAPY. 

228072  01-15 
RELATIONSHIPS  BETWEEN  ANESTHETIC  SUBSTANCES,  CONVULSIONS, 
AND  PSYCHIC  DISTURBANCES. 

229118  01-15 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-03 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST  DECAPITATION  CONVULSIONS  (PDC)  IN  MICE. 

238737  03-03 
EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
INTERACTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS. 

244894  04-04 
INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  04-03 
FAILURE  OF  PHENOBARBITONE  TO  PREVENT  FEBRILE  CONVULSIONS. 

251103  04-11 
CONVULSIVE 

THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHALOPATHY  IN  CHILDREN:  STUDY  OF  28  CASES. 

229083  01-11 


ANESTHESIOLOGIC  CONSIDERATIONS  IN  PSYCHIATRIC  CONVULSIVE 
THERAPY. 

249765  04-17 
COOMBS-POSITIVE 

COOMBS-POSITIVE  HEMOLYTIC  ANEMIA  PROVOKED  BY 
CHLORPROMAZINE. 

237161  02-15 
COORDINATION 

ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03-14 
CORD 

THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINE, 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  THE 
RAT  SPINAL  CORD. 

235863  02-03 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-03 
LOSS  OF  INHIBITION  IN  SPINAL  CORD  DURING  BARBITURATE 
WITHDRAWAL. 

238770  03-03 
EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FROG 
SPINAL  CORD. 

241922  03-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
CORN-FED 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L-TRYPTOPHAN  INJECTION. 

226873  01-03 
STIMULATION  OF  BRAIN  SEROTONIN  {5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED,  CORN-FED  RATS. 

238676  03-03 
CORNEA 

DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

240048  03-15 
CORPUS-STRIATUM 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS  ACCUMBENS  SEPT!  AND  CORPUS- 
STRIATUM. 

226937  01-04 
RELEASE  OF  H3-ALPHA-METHYL-TYRAMINE  FROM  CORPUS-STRIATUM  IN 
VITRO  AND  THE  EFFECTS  OF  GLUCOSE  DEPRIVATION. 

23873!  03-03 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTA8- 
TETRAHYDROCANNABINOL  (DELTA8-THC). 

241926  03-03 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-04 
EFFECT  OF  ETHANOL  ON  DOPAMINE  SYNTHESIS  AND  RELEASE  FROM  RAT 
CORPUS-STRIATUM. 

251178  04-03 
CORRECTION 

FOR  SENILE  DEMENTIA:  CHEMICAL  CORRECTION?. 

249351  04-11 
CORRECTIVES 

ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241763  03-15 
CORRELATE 

AN  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS. 

233336  02-03 
CORRELATES 

BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D- 
AMPHETAMINE  ADMINISTRATION. 

234809  02-04 
CORRELATES  OF  PLACEBO  REACTION  IN  AN  OUTPATIENT  POPULATION. 

235628  02-17 
THE  ANXIOLYTIC  EFFECT  OF  SAAALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 


2 


•ST'- 

I 

S3t;.. 


S-89 


Subject  Index 


Psychopharmacology  Abstracts 


PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEC  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  0303 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  ■•  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC  ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
THE  GENETIC,  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH.D.  DISSERTATION). 

241687  03-04 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
CORRELATION 

CORRELATION  OF  CHLORPROMAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 
WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-03 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE-LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-03 
AAJ-9022:  CORRELATION  BETWEEN  NEUROLEPTIC  POTENTIAL  AND 
STEREOTYPY. 

237903  02-08 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY 

238673  03-03 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03-03 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AMINES 
WITH  PSYCHOTROPIC  DRUGS 

241378  03-04 
CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  THE 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  lOCOMOrOR  ACTIVITIES  IN 
THE  RAT. 

242205  03-04 
CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE 

246851  04-03 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04  04 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEFN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS 

248466  0403 
CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 
AMPHETAMINE  LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 
TEMPERATURE. 

249316  04-03 
CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04-06 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYI  ASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 
CORRELATIONS 

PREDICTABILITY  IN  PSYCHOPHARMACOLOGY:  PRECLINICAL  AND 
CLINICAL  CORRELATIONS 

23111201  17 
CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL  AMPHETAMINE  AND 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION 

236235  02  03 
ELECTROCLINICAL  CORRELATIONS  IN  PSYCHOPATHIES, 

236793  02-14 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE:  CLINICO- 
CHEMICAL  CORRELATIONS 

244050  04-08 
EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC  ACID  DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 


CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 
5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS, 

249318  04-0: 
CORRELATIVE 

BENZODIAZEPINE-INDUCED  STATE-DEPENDENT  LEARNING:  A 
CORRELATIVE  OF  ABUSE  POTENTIAL?. 

252674  04-0 
CORTEX 

A  STUDY  OF  INHIBITORY  ANTAGONISM  IN  CAT  VISUAL  CORTEX. 

226397  01-0 
INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

226935  01-0 
A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01-0 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 
VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  02-0 
THE  EFFECT  OF  ^IHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  01 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-0 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  O2-0 
NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

237756  02-0 
LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-0 
ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINS-F  IN  RAT 
CEREBRAL  CORTEX. 

237921  O2-0 
DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTAZOI 

237925  02-C 
CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMMA- 
GIUTAMYL  TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX, 

238680  03-C 
EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-C 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATU^ 
AND  HYPOTHALAMUS  SLICES. 

238714  03-C 
INTRACRANIAL  SELF-STIMULATION  DERIVED  FROM  ENTORHINAL  CORTE) 

238757  03-C 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-C 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATI 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX 

239582  03-C 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-C 
BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX 

244684  04-C 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AN! 
3H  NOREPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAI 
CORTEX. 

248699  04C 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2-RECEPT0R  ANTAGONISTS  IN  THE 
RAT  CEREBRAL  CORTEX. 

248725  04-C 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  0 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN 

248961  04-C 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04-C 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 

NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES, 

248980  04-C 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 

CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION, 

249286  04-C 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  04-C 


S-90 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


LOCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX 

250356  04-03 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX^ 

251394  04-03 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX;  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS. 

251964  04-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

25341 1  04-03 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 
ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX. 

253691  04-03 
CORTICAL 

THE  EFFECT  OF  D.LAMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT. 

232606  02-03 
THE  EFFECTS  OF  DIMETHYLAMINOETHANOL  (DEANOL)  ON  CEREBRAL 
CORTICAL  NEURONS. 

23262!  02-03 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02-03 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02-03 
CORTICAL  OISINHIBITION:  A  POSSIBLE  MECHANISM  FOR  DRUG-INDUCED 
HALLUCINATIONS. 

238830  03-03 
DIPHENYLHYDANTOIN  INCREASES  CORTICAL  POSTSYNAPTIC  INHIBITION. 

241805  03-03 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  03-03 
EFFECTS  OF  0ELTA9-TETRAHYDR0CANNABIN0L  AND  PENTOBARBITAL  ON 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING. 

244693  04-03 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 
CORTICAL  SLICES. 

246850  04-03 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES; 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD 

248724  04-03 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  AND 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  04-06 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS. 

250089  04  04 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-03 
CORTICOIDS 

PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD, 

234311  02-03 
CORTICOSTEROID 

UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE;  CASE  REPORT. 

245856  04-13 
CORTICOSTEROIOOGENESIS 

INHIBITION  OF  CORTICOSTEROIOOGENESIS  BY  CANNABINOIDS. 

238808  03-03 
CORTICOSTEROIDS 

INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE. 

237706  02-03 
CORTICOSTERONE 

ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES.  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246661  04  03 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE. 

246662  04  03 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 

CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 


CORTISOL 

EFFECTS  OF  CHLORPkOMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG. 

240916  03-04 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN, 

252327  04-13 
CORTISONE 

EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 
AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS, 

251990  04-04 
COUNCILS 

A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
COUNSELING 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUAAAN  ENCOUNTER  WITH 
DEATH;  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR;  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04-10 
COUNTERACT 

DOES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 

239002  03-09 
COUNTRY 

PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 
COUNTRY. 

252990  04-17 
COURT 

FUGUE  STATES   -  EPILEPSY  -    MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL;  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT   AUGUST  1,  1975, 

237476  02-17 


CPK 


PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 
MEDICATION,  (UNPUBLISHED  PAPER). 

238489  02-08 
CPZ 

SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ,  AND 
SECOBARBITAL 

246303  04-14 
NATURE  OF  NEW  CLASS  OF  CHIORPROAAAZINE  (CPZ)  METABOLITES  IN 
PRIMATE  URINES. 

249328  04-01 
CRANIAL 

TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS;  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-11 
CREATINE-PHOSPHOKINASE 

PLASMA  CREATINE-PHOSPHOKINASE  LEVELS  IN  RATS  FOLLOWING 
LYSERGIC-ACID-DIETHYLAMIDE 

230826  01-03 
SERUM  CREATINE-PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT, 

237928  02-15 
CRICKET 

PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PH.D.  DISSERTATION), 

241994  03-04 
CRISIS 

INTRAVENOUS  LORAZEPAM  IN  THE  ACUTE  ANXIETY  CRISIS;  A 
PRELIMINARY  REPORT  ON  60  CASES, 

242250  03-10 
CRITERIA 

CRITERIA  FOR  AND  PITFALLS  IN  THE  IDENTIFICATION  OF  RECEPTORS, 

229436  01-03 
CRITICISM 

A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
CRITIQUE 

A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY. 

250175  04-15 
CROSS-TOLERANCE 

ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS  TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 


a;: 


S-91 


Subject  Index 


Psychopharmacology  Abstract 


BARBITAL-INDUCED  CROSS-TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
ANALGETIC  EFFECTS  OF  LANTHANUM:  CROSS-TOLERANCE  WITH 
MORPHINE. 

237870  02-03 
DEVELOPMENT  OF  CROSS-TOLERANCE  BETWEEN  DELTA9- 
TETRAHYDROCANNABINOL  AND  ETHANOL. 

249263  04-03 
CROSS-TOLERANCE  BETWEEN  MORPHINE  AND  OTHER  ANALGESICS. 

251408  04-17 
CROSSOVER 

THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE; 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  0111 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03-11 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 
HYPERKINE1IC  CHILDREN. 

247379  04-14 
LEVODOPA  AND  LEVOAMPHETAMINE:  A  CROSSOVER  STUDY  IN  YOUNG 
SCHIZOPHRENIC  CHILDREN. 

247480  04-08 
LIQUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS. 

247877  04-07 
LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERLAY 
(A  DOUBLE-BLIND  CROSSOVER  STUDY) 

250193  04-14 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04-08 
CRUCIAL 

SEROTONIN:  THE  CRUCIAL  SUBSTANCE  THAT  TURNS  DREAMS  ON  AND 
OFF. 

241505  03-12 
CRUDE 

CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
CRYSTAUOGRAPHIC 

DOPAMINE  RECEPTOR  BLOCKADE  AND  THE  NEUROLEPTICS,  A 
CRYSTALLOGRAPHIC  STUDY. 

226761  01-03 


CSF 


CUE 


PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5  HIAA)  IN  THE  RABBIT. 

230877  01-06 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II    VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04-13 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 

CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04-11 

DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE:  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 
PHYSOSTIGMINE  AS  A  DISCRIMINATIVE  CUE  IN  RATS. 

241258  03-04 
ON  THE  ABILITY  OF  NARCOTIC  ANTAGONISTS  TO  PRODUCE  THE 
NARCOTIC  CUE. 

251429  04-03 


CUES 


STATE-DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST. 

243013  04-04 


CULTURE 

A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE. 

241348  03-C 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-C 
CULTURE,  MORBIDITY,  AND  THE  EFFECTS  OF  DRUGS. 

252991  04-1 
CULTURED 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-C 
CULTURES 

OPIATE  RECEPTORS  IN  CELL  CULTURES.  (UNPUBLISHED  PAPER). 

239787  03-C 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-( 
CUMULATIVE 

THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-( 
CURARIZED 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  ANI 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-C 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-C 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE.  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-C 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THi 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-C 
HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 

CURARIZED  RATS. 

244691  04-C 
HIPPOCAMPAL  THETA-RHYTHM.  I.  DEPTH  PROFILES  IN  THE  CURARIZED 
RAT. 

251061  04-C 
CURB 

CURB  ON  BARBITURATES. 

231749  01-1 
CURE 

MAINTENANCE  ANTIPSYCHOTIC  THERAPY:  IS  THE  CURE  WORSE  THAN 
THE  DISEASE'. 

236307  02-C 
DRUGS  HELP,  BUT  WONT  CURE,  MOST  HYPERACTIVE  CHILDREN. 

247143  04-1 
CURVE 

SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS. 

244591  04-1 
CYCLANDELATE 

CYCLANOELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-1 
CYCLAZOCINE 

A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03-1 
PERSONALITY  FACTORS  AND  DRUG  EFFECTS  IN  A  CONTROLLED  STUDY 
OF  CYCLAZOCINE. 

244298  04-1 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04-0 
CYCLE 

CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-0 


S-92 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


LES 

CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 
NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANI/WALS. 

238971  03-03 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS 

242732  03-04 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS. 

,     244456  04-04 
ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING-SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6. 

249676  04-04 
Lie 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-03 
REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 
PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3:5,-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01-03 
CYCLIC  NUCLEOTIDES,  PROTEIN  PHOSPHORYLATION,  AND  NEURONAL 
FUNCTION. 

231021  01-17 
CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  02-13 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
CYCLIC  NUCLEOTIDES  AND  THEIR  POSSIBLE  RELEVANCE  TO  DISORDERS 
OF  NERVOUS  SYSTEM  FUNCTION.  (UNPUBLISHED  PAPER). 

237171  02-03 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN, 

241246  03-03 
CENTRAL  GAMMA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 
STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  04-03 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
.IC-AMP 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
MODULATORS  OF  CYCLIC-AMP  SYSTEMS. 

229464  01-03 
DOPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE- 
NUCLEUS.  (PH.D.  DISSERTATION). 

238080  02-13 
A  DOPAMINE  INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC  AMP  AND  DISRUPTABLE  BY  CYCLIC  GMP. 

238717  03-04 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA  PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS. 

238798  03-03 
CHL0RPR0MA2INE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 


EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  0303 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTEM 
IN  LIMBIC  FOREBRAIN. 

245115  04-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION. 

249286  04-03 
ON  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 

PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS. 

249287  04-03 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 

ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS. 

251964  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
CYCLIC-GMP 

A  DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP. 

238717  03-04 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  03-03 
CYCLOAIKANOL 

SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY: 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
CYCLOBARBITAL 

EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAL  TO  MICE. 

241403  03-03 
CYCLOBARBITAL-INDUCED 

EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
CYCLOCHOUNE 

SOME  PHARMACOLOGICAL  PROPERTIES  OF  CYCLOCHOLINE,  A  REACTIVE 
ANALOG  OF  CHOLINE. 

238828  03-03 
CYCLOHEXIMIDE 

DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-04 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  03  03 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-04 


'5P- 
I 


S-93 


Subject  Index 


Psychopharmacology  Abstraci 


CYCLOHEXIMIDE-INDUCED 

CYCLOHEXIMIDE-INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY  IN 
RATS 

242742  0304 
EFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCED  AMNESIA  IN  MICE. 

245614  04-02 
CYCLOPHOSPHAMIDE 

DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE, 

249296  04-02 
CYCLOPHRENIA 

LITHIUM  SALTS  IN  CYCLOPHRENIA  (MANIC-DEPRESSIVE  PSYCHOSIS). 

237013  02-09 
CYCLOPROPANE 

INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE.  BUT 
NOT  OF  DOPAMINE-BETA-HYDROXYLASE  FROM  GUINEA-PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER). 

247028  04-03 
CYCLOTHYMIC 

PSYCHOVEGETATIVE  DISORDERS  IN  CASES  OF  CYCLOTHYMIC 
DEPRESSION 

226777  01-09 
THE  LITTLE  KNOWN  THERAPEUTIC  PROPERTIES  OF  IMIPRAMINE  IN 
MANIC  STATES  OF  CYCLOTHYMIC  PSYCHOSES. 

231368  01-09 
CYNOMYS-LUOOVICIANUS 

TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 
DOGS  (CYNOMYS  LUDOVICIANUS). 

239863  03-04 
CYPROHEPTADINE 

ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-03 
CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS 

237900  02-10 
THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 
MONOAMINE-OXIDASE  IN  MAN. 

237927  02-13 
CYTOCHEMICAL 

CYTOCHEMICAL  AND  ELECTROPHYSIOLOGICAL  STUDIES  OF  DOPAMINE  IN 
THE  CAUDATE-NUCLEUS.  (UNPUBLISHED  PAPER). 

238471  02-03 
CYTOCHROME-P450 

THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYTOCHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-01 
CYTOLOGIC 

CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
C14-LEUCINE 

THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D  AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
C14-METHAQUALONE 

PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE 

238764  03-03 
CI  4-5-HYDROXYTRYPT  AMINE 

EFFECT  OF  ANGIOTENSIN  II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 
OF  C14-5-HYDROXYTRYPTAMINE  BY  RAT  BRAIN. 

237739  02-03 
D-AMPHETAMINE 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D- 
AMPHETAMINE  ON  TIMING  BEHAVIOR. 

226729  01-04 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 

MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT 

226852  01-04 
A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01  04 


1 


OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01  04 

FOOD  AND  DRUG-REINFORCED  RESPONDING:  EFFECTS  OF  DITA  AND  D- 
AMPHETAMINE. 

227127  01-04 
CAFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON. 

227571  0111 
DIFFERENTIAL  EFFECTS  OF  D-AMPHETAMINE  IN  MATURE  AND  IMMATURE 
RATS. 

228160  01-04 
EFFECTS  OF  D-AMPHETAMINE,  CHLORPROMAZINE,  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACED 
RESPONDING  SCHEDULES. 

229639  01-04 
THE  EFFECTS  OF  2.5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM).  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D- 
AMPHETAMINE  ADMINISTRATION. 

234809  02-04 
INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02-03 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE.  LOCOMOTOR  ACTIVITY.  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
EFFECTS  OF  D-AMPHETAMINE  ON  F-l  SHOCK  PRESENTATION  WITH 
SDELTA  PROBE. 

237699  02-04 
EFFECTS  OF  SCOPOLAMINE.  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  02-04 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT. 

237716  02-14 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE. 
COCAINE.  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03-04 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T).  5-HTP. 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  0304 
NECESSITY  OF  HYPERTHERMIA  FOR  L-DOPA  OR  O-AMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03-03 
ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMIC 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-03 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 
INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P-TYROSINE 
ON  SCHEDULE-CONTROLLED  PERFORAAANCE  IN  RATS. 

238844  03-04 
THE  EFFECT  OF  DL-254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS. 

238846  03  03 
D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272  03-04 
TEMPORAL  PARAMETERS  OF  D-AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT. 

239856  03-04 
PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE. 

METHYLPHENIDATE.  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 

DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  03-04 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE  EFFECTS  OF  CHRONIC  D- 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION, 

241307  03  04 
TOLERANCE  TO  THE  ACTIVITY  ENHANCING  EFFECT  OF  D-AMPHETAMINE. 
(PH.D.  DISSERTATION). 

241575  03-03 
TASTE  AVERSIONS  INDUCED  BY  D-AMPHETAMINE:  DOSE-RESPONSE 
RELATIONSHIP, 

242882  0404 
EFFECTS  OF  IMIPRAMINE.  D-AMPHETAMINE.  AND  TRIPELENNAMINE  ON 
MOUSE-KILLING  AND  FROG-KILLING  BY  THE  RAT. 

243346  04-04 


S-94 


HUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAL  SCHEOULE^ 

245303  04-04 
DOSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT 

2463 1 3  0404 
D-AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENIC 
AMINES  IN  SYNAPTOSOMES. 

246665  04-03 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RATS 
PRODUCED  BY  D-AMPHETAMINE. 

246820  04-04 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS:  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS. 

247211  04-03 
SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D-AMPHETAMINE 
ADMINISTRATION. 

24/683  04  04 
ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE,  COMPARISON 
WITH  D-AMPHETAMINE. 

248284  04-03 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  CI4-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-03 
EFFECTS  OF  D-AMPHETAMINE,  MONOMETHOXN  AMPHETAMINES  AND 
MESCALINE  ON  FIXED-INTERVAL  RESPONDING  IN  RATS. 

249275  04-04 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN. 

249300  04-03 
AMANTADINE  DECREASES  D-AMPHETAMINE  STIMULATION  AND 
INCREASES  D-AMPHETAMINE  ANOREXIA  IN  MICE. 

249459  04-03 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-04 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 
AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT. 

2500/4  04-04 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D  AMPHETAMINE  AND 
PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

250112  04-04 
SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORMANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDUIE 

252816  04-04 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS. 

253111  04-04 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485  04-04 
VMPHETAMINEINDUCED 
A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAMINEINDUCED 
CONTRALATERAL  ROTATION  IN  RATS 

231301  01-04 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
2-PHENYLETHYLAMINE  (PEA)  IN  D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

23884)  03-03 
DAMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS;  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
VMPHETAMINES 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
II:  N-ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D-AMPHETAMINES, 
AND  3ARYL0XYPR0PYLAMINES. 

248637  04-01 
HUCOSE 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  0-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-04 


0-GLUCOSE- 14C 

DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D-GLUC0SE14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
D-ISOMERS 

EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  03-03 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RFI  EASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX 

248699  04-03 
D-LSO 

THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSD  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  04-03 
D-LYSERGIC 

ANTAGONISM  OF  D-LYSERGIC  ACID  DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,5,6  TETRAHYDROPYRIDINE  N.N  DIETHYLCARBOXAMIDE 
(TMPC). 

230453  01-03 
D-LYSERGIC-AC(D-DIETHYLAMIDE 

STEREOSPECIFIC  BINDING  OF  D-LYSERGIC-ACID-DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01-12 
D-TRYPTOPHAN 

REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238698  03-04 
DAILY 

BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION. 

228224  01-08 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAIIY  ROUTINE. 

240055  03-09 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION. 

250019  04-04 
PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  OR 
NEUROLEPTIC  DOSAGE. 

252955  04-17 
DAMAGE 

AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

229169  0M5 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
CAN  PHENYTOINS  CAUSE  FETAL  DAMAGE?. 

248097  04-13 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAI  CORTICAL  DAMAGE  IN  RATS. 

250089  04-04 
DAMAGED 

THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
DAPOTUM-D 

EXPERIENCES  WITH  A  DEPOT  NEUROLEPTIC  (DAPOTUM-D). 

242503  03-08 
DATA 

ANALYSIS  AND  DISPLAY  OF  PSYCHOPHARMACOLOGICAL  DATA. 

228978  01-17 
PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY. 

232623  02-13 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL. 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02-03 
DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
OOPA  AND  L  5-HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  02-03 
PERFUSION  WITH  L-5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR, 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  02-03 


-re 


'5P- 
I 

2E 

3St 


S-95 


Subject  Index 


Psychopharmacology  Abstracts 


BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA. 

237872  02-13 
RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED 

252859  04-17 
DAYS 

EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS. 

242732  03-04 
DBH 

RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE-BETA-HYDROXYLASE 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
OEAMINATION 

PREFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04-03 
DEANOl 

DEANOL  IN  THE  TREATMENT  OF  TARDIVE-DYSKINESIA. 

227570  01-11 
THE  EFFECTS  OF  DIMETHYLAMINOETHANOL  (DEANOL)  ON  CEREBRAL 
CORTICAL  NEURONS. 

232621  02-03 
DEATH 

COUNSELING.  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH  D 
DISSERTATION). 

228686  01-11 
SUDDEN  UNEXPLAINED  DEATH  IN  A  PSYCHIATRIC  PATIENT  TAKING 
THIORIDAZINE. 

240243  03-15 
DEATH  AND  DRUG  TREATMENT  IN  A  PSYCHIATRIC  HOSPITAL. 

243716  04-15 
DECANOATE 

PHARMACOKINETICS  OF  FLUPENTHIXOL-DECANOATE.  DECANOATE. 

227767  01-08 
FLUPENTHIXOL  AND  FLUPENTHIXOL  DECANOATE,  WITH  SPECIAL 
REFERENCE  TO  THEIR  ANTIPSYCHOTIC  EFFECT. 

227770  01-08 
ANTIPARKINSONIAN  AGENTS  AND  FLUPHENAZINE-DECANOATE 
DECANOATE. 

236317  02-15 
DECAPITATION 

INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  0403 
DECARBOXYLASE 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

226915  01-09 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO-4-4602). 

233917  02-11 
DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
DOPA  AND  L-5-HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  02-03 
PERFUSION  WITH  L-5  HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR, 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  02-03 
INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE- 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE, 

245647  04  13 
THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  8ENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04-11 
DECAY 

CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-11 
DECOMPOSITION 

DECOMPOSITION  OF  AMITRIPTYLINE  HYDROCHLORIDE  IN  AQUEOUS 
SOLUTION:  IDENTIFICATION  OF  DECOMPOSITION  PRODUCTS. 

246317  04-01 
DEFECATION 

STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 
BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS, 

241370  03-04 


STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (II).  RELATIONSHIP 
BETWEEN  EMOTIONALITY  AND  DEFECATION. 

241371  03-04 
DEFENSIVE 

THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 
CONDITIONED  REFLEX  IN  RATS. 

227637  01-04 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01  04 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAAAAZEPINE  AND 
CHLORPROMAZINE. 

244352  04-04 
DEFICIENT 

AVOIDANCE  BEHAVIOR  IN  VITAMIN-B6  DEFICIENT  RATS. 

232639  0204 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  04-03 
DEFICIT 

NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
MEASUREMENT  OF  ATTENTION  DEFICIT  IN  THE  COURSE  OF 
INTOXICATIONS. 

244896  04-14 
DEFICITS 

NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01-03 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  01-15 
THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYDROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS. 

239087  03-03 
LONG-TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS. 

241300  03-04 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
DEFINED 

PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS. 

244072  04-03 
DEFINING 

USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
DEGENERATION 

BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION: 
POSTSYNAPTIC  SUPERSENSITIVITY? 

229434  01-03 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-03 
DEGRADATION 

EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
DEHYDRATED 

THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-03 
DEIAGRANGE 

TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DEIAGRANGE), 

239269  03- 1 1 
DELAY 

HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS. 

248514  04-04 
DELAYED 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01  09 


S-96 


IME  14,  SUBJECT  INDEX 


Subject  Index 


^ECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH-TO-SAMPLE 
TASK  IN  MONKEYS. 

230577  01-04 
lALYSIS  Of  THE  DISCREPANCY  IN  MAN-MACHINE  TRACKING  SYSTEMS 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03-14 
LAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION. 

245789  04-15 
LAYED  AND  INSIDIOUS  ONSET  OF  DIPHENYLHYDANTOIN  TOXICITY. 

246932  04-15 
)NOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

251063  04-04 
ATION 

\\P\  DELINEATION  Of  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
lUENT 

YCHOPHARMACOLOGY  IN  THE  PREVENTION  OP  ANTISOCIAL  AND 
DELINQUENT  BEHAVIOR. 

247385  04-17 
IM 
^ERSAL  BY  PHYSOSTIGMINE  OF  CLOZAPINE-INDUCED  DELIRIUM. 

237647  02-14 
lY 

E  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES. 

234699  02-09 

UGS  DERIVED  FROM  CANNABINOIDS.  5.  DELTA 
TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  04-02 
-TETRAHYDROCANNABINOL 
TERATION  OF  MEMBRANE  INTEGRITY  OF  DELTAI- 
TETRAHYDROCANNABINOL. 

229035  01-03 
.NNABIDIOL  AND  ITS  PHARMACOKINETIC  INTERACTION  WITH  DELTAl- 
TETRAHYDROCANNABINOL. 

233279  02-03 
JTABOLISM  OF  DELTAl-TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
lARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 
DIHYDROXYACID  METABOLITES  OF  DELTAl-TETRAHYDROCANNABINOL 
IN  MOUSE  LIVER. 

243787  04-03 
E  UPTAKE  OF  TRITIATED  DELTAl-TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VASDEFERENS  OF  THE  RAT. 

252200  04-03 
i-TETRAHYDROCANNABINOl 

TERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS  STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTA8- 
TETRAHYDROCANNABINOL  (DELTA8-THC). 

241926  03-03 
l-THC 

TERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS  STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTAS 
TETRAHYDROCANNABINOL  (DELTA8-THC). 

241926  03-03 
-TETRAHYDROCANNABINOL 

ARMACOLOGICAL  INTERACTION  BETWEEN  CANNABINOL  AND  DELTA9- 
TETRAHYDROCANNABINOL. 

225570  01-03 
TERACTIONS  OF  DELTA9-TETRAHYDR0CANNABIN0L,  ADRENAL 
STEROIDS,  AND  ETHANOL 

226763  01-03 
E  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 
LTA9  TETRAHYDROCANNABINOL  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
FECTS  OF  DELTA9  TETRAHYDROCANNABINOL  ON  MOUSE  SPLEENS. 

226944  01-05 
'LERANCE  TO  THE  EFFECTS  OF  DELTA9  TETRAHYDROCANNABINOL  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 
E  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  BRAIN  AMINE 
CONCENTRATION  AND  TURNOVER  IN  WHOLE  RAT  BRAIN  AND  IN 
VARIOUS  REGIONS  OF  THE  BRAIN 

230856  01-03 
■LUENCE  OF  DELTA9  TETRAHYDROCANNABINOL  ON  PARTIAL 
REINFORCEMENT  EFFECTS. 

230875  01-04 


THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION 

231010  01-03 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  THE  LABORATORY  MOUSE  AND  RAT. 

237727  02-04 
AN  INHALATION  AEROSOL  OF  DELTA9-TETRAHYDR0CANNABIN0L. 

237787  02-16 
EFFECTS  OF  (-)DELTA9-TETRAHYDR0CANNABIN0L  ON  REGIONAL  BRAIN 
ACETYLCHOLINE  IN  THE  RAT. 

238709  03-03 
RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE,  AND  MALE  MICE. 

238766  03-03 
STRUCTURE-ACTIVITY  RELATIONSHIPS  IN  ANALOGS  OF  DELTA9- 
TETRAHYDROCANNABINOL:  TACHYCARDIA  VS.  ANALGESIA. 

238805  03-02 
MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS. 

238809  03-03 
CHRONIC  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 

TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  THE  MONGREL  DOGS. 

238810  03-03 
BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 

INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC). 

238812  03-03 
DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC)  AND  1 1-0H-DELTA9- 

THC:  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS. 

238813  03-04 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 

PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
CELLULAR  MEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 

EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC). 

238816  03-03 
THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTION 

POTENTIALS  IN  THE  MOLLUSC  APLYSIA. 

239261  03-03 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
EFFECT  OF  DELTA9-TETRAHY0R0CANNABIN0L  ON  THE  METABOLISM  OF 
BRAIN  MONOAfilNES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  03  04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SQUIRREL-MONKEY 
INCENTIVE  COMPETITION  BEHAVIOR,  {PH.D.  DISSERTATION), 

241668  03-04 
INFLUENCE  OF  CANNABIDIOL  OF  DEL rA9  TETRAHYDROCANNABINOL 
EFFECTS. 

243087  04  14 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

243800  04-03 
UTEROTROPHIC  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
OVARIECTOMIZED  RATS 

243865  04-03 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTA8-  AND  DELTA9-TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIX  JACCHUS. 

244681  04-03 
MOUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELTA9- 

TETRAHYDROCANNABINOL  AND  PILOCARPINE. 

244682  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 

IN  MICE:  COMPARISON  BETWEEN  TWO  VEHICLES. 

244687  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  PENTOBARBITAL  ON 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING, 

244693  04  03 
INTERACTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY 
INDUCED  CONVULSIONS, 

244894  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04  04 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04  05 


00 


-n 


3B^ 


S-97 


Subject  Index 


Psychopharmacology  Abstract! 


ANTICONVULSANT  ACTIVITY  OF  DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED  WITH  THREE  OTHER  DRUGS. 

248283  04-02 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICEr  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT 

249223  04-03 
DEVELOPMENT  OF  CROSS-TOLERANCE  BETWEEN  DELTA9- 
TETRAHYDROCANNABINOL  AND  ETHANOL 

249263  04-03 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC) 

249309  04-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

249418  04-03 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABINOL  IN 
MAN. 

249622  04-07 
CHRONIC  DELTA9TETRAHYDR0CANNABIN0L.  TRANSIENT  AND  LASTING 
EFFECTS  ON  AVOIDANCE  BEHAVIOR. 

250061  04-04 
DELTA9-TETRAHYDR0CANNABIN0L:  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUMAN  AND  OTHER  MAM/WALIAN  CELLS. 

251420  04-13 
EFFECTS  ON  VISUAL  TRACKING  OF  DELTA9-TETRAHYDR0CANNABIN0L 
AND  PENTOBARBITAL. 

251825  04-14 
DELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAMINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT 

251979  04-04 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN, 

252327  04-13 
PHYTOHEMAGLUTININ-INDUCED  LYMPHOCYTE  TRANSFORMATION  IN 
HUMANS  RECEIVING  DELTA9-TETRAHYDR0CANNABIN0L, 

252825  04-13 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

/  253406  04-03 

CARDIOVASCULAR  EFFECTS  OF  PROLONGED  DELTA9- 
TETRAHYDROCANNABINOL  INGESTION. 

253609  04-13 
DELTA9-THC 

EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  DELTA9-TRANS- 
TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  GUINEA-PIGS. 

229033  01-03 
ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC. 

232615  02-04 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE  IN 
MOUSE  BRAIN. 

238765  03-03 
CHRONIC  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 

TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  THE  MONGREL  DOGS. 

238810  03-03 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEG  IN  THE 

NATURALLY  EPILEPTIC  BEAGLE 

238811  03-04 
DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC)  AND  n-0H-DELTA9- 

THC:  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS. 

238813  03-04 
CELLULAR  MEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 
EFFECTS  OF  DELTA9TETRAHYDR0CANNABIN0L  (DELTA9-THC) 

238816  03-03 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9-THC  DURING 
ABSTINENCE  IN  MORPHINE-DEPENDENT  RATS. 

249001  04-04 
DELTA9-TRANS-TETRAHY0ROCANNABINOI 

EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  DELTA9TRANS- 
TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  GUINEA-PIGS. 

229033  01-03 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYDROCANNABINOL 

240645  03-14 


DELUSION 

DEPRESSION,  DELUSION  AND  DRUG  RESPONSE. 

245784  04-0 
DELUSIONS 

PENTAZOCINE  PSYCHOSIS:  A  CASE  OF  PERSISTENT  DELUSIONS. 

225873  01-1 
DEMENTIA 

TREATABLE  ASPECTS  OF  THE  DEMENTIA  SYNDROME. 


PARKINSONISM  AND  DEMENTIA:  EFFECTS  OF  LEVODOPA. 
FOR  SENILE  DEMENTIA:  CHEMICAL  CORRECTION?. 
TREATMENT  OF  DIALYSIS  DEMENTIA  WITH  THIAMINE. 
DEMENTIA  INDUCED  BY  METHYLDOPA  WITH  HALOPERIDOL 


4 


240614  03-1 

245235  04-1 

249351  04-1 

251966  04-1 

253391  04-1 
DEMETHYLATION 

INTESTINAL  ABSORPTION,  DEMETHYLATION,  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-1 
DEMETRIN 

CLINICAL  RESEARCH  WITH  DEMETRIN  IN  SURGERY  PATIENTS. 

242527  03-0 
DEMONSTRATION 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-0 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-0 
DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-0: 
OENERVATED 

REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS 

243348  04-0 
DENERVATION 

THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-0 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-0 
DEPARTMENT 

ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02-1 ; 
DEPARTMENT  SEEKS  ADVICE  ON  SAFETY  OF  PSYCHOTROPICS. 

251232  04-1 : 
DEPENDENCE 

NITRAZEPAM  (MOGADON)  DEPENDENCE. 

225699  01 -li 
SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

229112  01-1; 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02-1' 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02- 1; 
DEVELOPMENT  OF  TOLERANCE  TO  AND  DEPENDENCE  ON  ENDOGENOUS 
NEUROTRANSMITTERS. 

234798  02-Of 
THE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE. 

236249  02-0; 
METHAQUALONE:  TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE 

237731  02-0' 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE-LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON. 

240205  03-0.' 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  ANO 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

241100  03-03 


S-98 


JME  14,  SUBJECT  INDEX 


Subject  Index 


TES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS' 

241223  03-04 
1ARMAC0L0GICAL  ASPECTS  OF  PHYSICAL  DEPENDENCE  ON  ETHANOL. 

241240  03-17 
STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE, 

241348  03-03 
3LERANCE,  PHYSICAL  DEPENDENCE  AND  OPIOID  SEEKING  BEHAVIOR; 
DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE. 

244202  04-04 
METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG 

244674  04-06 
INTAZOCINE  DEPENDENCE  -  TRUTH  AND  FICTION?. 

246707  04- 1 5 
ECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 
DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN. 

246992  04-13 
;NFLURID0L  blockade  of  APOMORPHINE:  dependence  OF  DURATION 
ON  SPECIES  AND  ENDPOINT. 

248406  04-02 
EPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04-03 
lORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04  03 
HARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 
lORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE:  INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS. 

250079  0404 
DME  PHARMACOLOGICAL  ASPECTS  OF  DRUG  DEPENDENCE. 

251561  04-13 
:FECT  of  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
HE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS 

253411  04-03 
IDENCY 
EPENDENCY  ON  COMBINED  METHAQUALONE  DIPHENHYDRAMINE. 

241870  03-17 
IDENT 

TTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC. 

232615  02-04 
OPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE 
NUCLEUS.  (PH.D.  DISSERTATION). 

238080  02-13 
AURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN. 

238715  03-03 
NDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES. 

238729  03-03 
NTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 
NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL  PHENOTHIAZINES. 

239662  03-03 
HE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYTOCHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-01 
ATE  DEPENDENT  DRUG  EFFECTS:  POSSIBLE  STATE-DEPENDENCY. 

242739  03-04 
ODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
ISONALIZATION 
.  CASE  OF  PHOBIC  ANXIETY  DEPERSONALIZATION  SYNDROME  (ROTH). 

243094  04- 1 7 
TED 

HE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457  01-03 
TION 

LABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01-03 


DEPLETION  OF  S-ADENOSYL-L-METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS 

226850  01-03 
EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHM 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918  02-03 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02  03 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  02-03 
FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE-INDUCED  ANOREXIA. 

237748  02-03 
STUDIES  ON  THE  MECHANISM  OF  DEPLETION  OF  STRIATAL  DOPAMINE 
BY  ALPHA-METHYL-M-TYROSINE. 

237873  02-03 
PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  03  04 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS. 

238798  03-03 
INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 
HYDROXYINDOLES  BY  P-CHLOROAMPHETAMINE. 

241339  03-03 
HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  P-CHLOROPHENYLALANINE. 

243878  0404 
EFFECT  OF  3-P  TRIFLUOROMETHYLPHENOXY-N-METHYL-3- 

PHENYLPROPYLAMINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN  BY  4- 
CHLOROAMPHETAMINE. 

246847  04-03 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 
FOLLOWING  BRAIN  AMINE  DEPLETION. 

249138  04-04 
DEPOLARISING 

EFFECT  OF  MORPHINE  ON  A  DEPOLARISING  DOPAMINE  RESPONSE. 

246998  04-03 
DEPOLARIZATION 

DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01-03 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
DEPOLARIZED 

BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
DEPOSITS 

DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

240048  03  15 
DEPOT 

ON  THE  PHARMACOLOGY  OF  DEPOT  PHTHORPHENAZINE. 

228547  01-04 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC. 

231367  01-08 
DEPOT  NEUROLEPTICS   -  PRACTICAL  METHODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
EXPERIENCES  WITH  A  DEPOT  NEUROLEPTIC  (DAPOTUM-D). 

242503  03-08 
FIVE  YEARS  OF  DEPOT  FLUPHENAZINE  THERAPY. 

244620  04-08 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION. 

245789  04-15 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE: 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04-03 
COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 
INCIDENCE  OF  SIDE-EFFECTS. 

252006  04-08 
DEPRENYL 

THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 


DC 


S-99 


Subject  Index 


Psychopharmacology  Abstracts 


DEPRESSANT 

A  CENTRALNERVOUSSYSTEM  DEPRESSANT  ANTIDEPRESSANT. 

227695  01-02 
NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 
PROPERTIES. 

232528  01-02 
LACK  OF  A  RELATION  BETWEEN  THE  ANTIPSYCHOTIC  AND  THE 

EXCITABILITY  DEPRESSANT  PROPERTIES  OF  MAJOR  TRANQUILIZERS. 

238710  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 
SYNTHESIS  AND  CENTRAL-NERVOUS- SYSTEM  DEPRESSANT  ACTIVITY  OF 
SOME  BICYCLIC  AMIDES. 

248539  04-02 
DEPRESSANTS 

INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 
INVERTEBRATE  SYNAPSES. 

226398  01-03 
CENTRAL  NERVOUS-SYSTEM  DEPRESSANTS,  13.  S- 
TRIAZOLOBENZODIAZEPIN-5-ONES. 

238478  02-0! 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS, 

250080  04-03 
DEPRESSED 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

226915  01-09 
THE  METHODOLOGY  OF  TRIALS  OF  ANTIDEPRESSANTS  FOR  DEPRESSED 
INPATIENTS 

227213  01-16 
CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01-09 
PHARMACODYNAMICS  OF  IMIPRAMINE  IN  DEPRESSED  PATIENTS. 

229437  01-09 
PREDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 
DEPRESSED  OUTPATIENTS. 

229449  01-09 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
A  CONTROLLED  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  IN  DEPRESSED 
OUTPATIENTS. 

231401  01-09 
EFFECT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS   -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL. 

235360  02-07 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  II.  REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  III.  STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -    IV.  A  SUMMARY  REPORT. 

235363  02-09 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE, 

236364  02-10 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION, 

236801  02-13 
A  DOUBLE  BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS, 

238981  03-10 
DOES  PIRACETAM  COUNTERACT  THE  ECT  INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 

239002  03-09 
DEPRESSED  5  HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR;  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03-13 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS 

241203  03-03 
EARLY  STRATEGIES  IN  TREATMENT  OF  THE  DEPRESSED  PATIENT. 

241435  03-17 


MAPROTILINE  (LUDIOMIL,  CIBA-34276BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  03-09 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 

(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-09 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
DIFFERENTIAL  EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  THE  SLEEP  OF 
DEPRESSED  PATIENTS. 

248)60  04-10 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS, 

248975  04-10 
PLASAAA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY 

253595  04-09 
DEPRESSION 

INTRAVENOUS  TYRAMINE  PRESSOR  RESPONSE  IN  DEPRESSION. 

226187  01-10 
PSYCHOVEGETATIVE  DISORDERS  IN  CASES  OF  CYCLOTHYMIC 
DEPRESSION. 

226777  01-09 
THE  CAUSES  AND  TREATMENT  OF  DEPRESSION. 

226794  01-09 
SHORT-TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PLACEBO  IN  DEPRESSION:  A  DOUBLE-BLIND  STUDY. 

227214  01-09 
A  DOPAMINE  RECEPTOR  STIMULATOR  IN  DEPRESSION.  (UNPUBLISHED 
PAPER). 

227785  01-09 
THE  NATURE  AND  TREATMENT  OF  DEPRESSION. 

228037  01-09 
DEPRESSION  AND  THE  ACUTE  SCHIZOPHRENIC  PROCESS. 

228240  01-08 
IMIPRAMINE  PAMOATE  IN  DEPRESSION. 

228243  01-11 
A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  01-09 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  (FK-880)  FOR  DEPRESSION. 

228334  01-09 
TREATMENT  OF  DEPRESSION  IN  GERIATRICS  WITH  ANAFRANIL. 

229370  01  11 
DRUGS  AND  PSYCHOTHERAPY  IN  DEPRESSION  REVISITED:  ISSUES  IN  THE 
ANALYSIS  OF  LONG-TERM  TRIALS. 

229450  01-09 
A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN-RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693  01-09 
THERAPY  OF  DEPRESSION  BY  PHENYLALANINE:  PRELIMINARY  NOTE. 

229827  01-09 
DOUBLE-BLIND  TRIAL  OF  SINTAMIL  IN  DEPRESSION. 

231603  01-10 
EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESSION 
(INTRODUCTORY  REPORT). 

234046  02-09 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION 

234203  02-09 
ATYPICAL  AND  SEVERE  FORMS  OF  DEPRESSION. 

234597  02-09 
PRELIMINARY  EXPERIENCE  WITH  PARENTERAL  SINTAMIL  IN  TREATMENT 
OF  DEPRESSION. 

235348  02-09 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  I.  AN 
UNCONTROLLED  CLINICAL  TRIAL  IN  DEPRESSION. 

235369  0207 
THYROTROPIN-RELEASING  HORMONE  IN  DEPRESSION:  CLINICAL  AND 

ENDOCRINOLOGICAL  FINDINGS. 

235370  0209 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 

AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 


S-100 


iLUME  14,  SUBJECT  INDEX 


DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTAZOL. 

237925  02-03 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE. 

237976  02-03 
TREATMENT  OF  UNIPOLAR  DEPRESSION. 

237994  02-10 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  AAICE. 

238318  02-04 
AMPHETAMINE  AND  THE  REWARD  SYSTEM:  EVIDENCE  FOR  TOLERANCE 
AND  POST-DRUG  DEPRESSION. 

239850  03-04 
A  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESSION 
ANXIETY  STATES. 

239938  03-10 
TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS   - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS. 

2402)6  03-09 
TRYPTOPHAN  AND  DEPRESSION. 

240773  03-09 
COMBINATION  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  AAAOI  IN 
DEPRESSION 

240839  03-09 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
THE  PSYCHOPHARMACEUTICAL  THERAPY  OF  DEPRESSION. 

241762  03-09 
CHANGING  PATTERNS  IN  THE  MANAGEMENT  OF  DEPRESSION. 

243863  04-09 
PROBLEMS  OF  POLYPHARMACY  IN  DEPRESSION. 

243864  04-09 
PHARMACEUTICAL  THERAPY  OF  MASKED  DEPRESSION. 

244040  04-10 
TRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS. 

244588  04-09 
RESERPINE  AND  THE  INDUCTION  OF  DEPRESSION:  A  CASE  REPORT. 

245016  04-09 
TREATMENT  OF  DEPRESSION  IN  ALCOHOLICS. 

245521  04-09 
DEPRESSION  AND  ANTIDEPRESSANT  DRUGS. 

245646  04-09 
DEPRESSION,  DELUSION  AND  DRUG  RESPONSE. 

245784  04-09 
RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WITH 
GER0VITAL-H3  TABLETS. 

246425  04-09 
THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04-17 
TRYPTOPHAN/IMIPRAMINE  IN  DEPRESSION. 

246623  04-09 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 
ORAL  PROTIRELIN  (TRH)  IN  DEPRESSION. 

247482  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
MEMORY  FUNCTIONS  IN  DEPRESSION:  IMPROVEMENT  WITH 
ANTIDEPRESSANT  MEDICATION. 

248583  04-09 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  04-10 
RAPHE  NEURONS:  DEPRESSION  OF  ACTIVITY  BY  L-5- 
HYDROXYTRYPTOPHAN. 

249078  04-03 
DEPRESSION  OF  DOPAMINE  RELEASE  DURING  THE  ETHANOL 
WITHDRAWAL  SYNDROME. 

249293  04-03 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 


Subject  Index 

DRUG  AND  PSYCHOTHERAPY  INTERACTIONS  IN  DEPRESSION. 

252941  04-09 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

252954  04-09 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3: 
CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  04-11 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE-BETA  HYDROXYLASE  INHIBITORS. 

253450  04-04 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
DEPRESSIONS 

MODERN  VIEWS  ON  DIAGNOSIS  AND  CLASSIFICATION  OF  DEPRESSIONS: 
II.  UNITED-KINGDOM. 

227205  01-09 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL  DECANOATE. 

239823  03-08 
CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS. 

252447  04-10 
DEPRESSIVE 

SULPIRIDE  IN  DEPRESSIVE  SCHOOL  PHOBIC  CHILDREN. 

227141  01-10 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOAAATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01-09 
TREATMENT  OF  DEPRESSIVE  SYNDROMES  IN  INVOLUTIONAL  SUBJECTS. 

230990  01-09 
A  CONTRIBUTION  TO  TREATMENT  OF  DEPRESSIVE  SYNDROMES:  USE  OF 
TRAZODONE  INTRAVENOUSLY. 

230992  01-09 
DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01-03 
DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02-10 
ISONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME:  A 
PILOT  TRIAL. 

236665  02-09 
THE  USE  OF  DOTHIEPIN  IN  THE  TREATMENT  OF  PSYCHONEUROTIC 
ANXIETY  WITH  DEPRESSIVE  FEATURES. 

237774  02-10 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE 

237976  02-03 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS. 

239818  03-10 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
INTRAVENOUS  TRAZODONE  WITH  DEPRESSIVE  SYNDROMES. 

244589  04-09 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUT 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  04-10 
IS  THERE  AN  INCREASE  IN  MONOAMINE-OXIDASE  ACTIVITY  IN 
DEPRESSIVE  ILLNESS?. 

245233  04-13 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIVE 
NEUROSIS. 

246300  04-10 
STUDIES  ON  THYROID  THERAPY  AND  THYROID  FUNCTION  IN  DEPRESSIVE 
PATIENTS. 

249123  04-13 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-16 
THIORIDAZINE  IN  THE  TREATMENT  OF  DEPRESSIVE  PATIENTS. 

252760  04-09 


00- 


ffi) 
-n 


I 


S-101 


Subject  Index 


Psychopharmacology  Abstf^! 


DEPRIVATION 

TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENSORY 
DEPRIVATION 

233418  02-03 
RELEASE  OF  H3-ALPHA-METHYLTYRAMINE  FROM  CORPUS-STRIATUM  IN 
VITRO  AND  THE  EFFECTS  OF  GLUCOSE  DEPRIVATION. 

238731  03-03 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYDROCANNABINOL 

240645  03- 14 
PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE, 

242746  04-04 
EFFECTS  OF  AMPHETAMINE,  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF-STIMULATION  IN  THE  RAT. 

244214  0404 
BICUCULLINE  REVERSAL  OF  DEPRIVATION  AMBLYOPIA  IN  THE  CAT 

249983  04-03 
Y-MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04-04 
DERIVATIVE 

A  PHENOTHIAZINE  DERIVATIVE  IN  THE  TREATMENT  OF  SPASTICITY. 

226960  01  11 
EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  01-14 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINEBETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINELIKE  PROPERTIES. 

246844  04-03 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTOPE 
DERIVATIVE  TECHNIQUE. 

247131  04-03 
CLINICAL  PHARMACOLOGY  OF  NABILONE.  A  CANNABINOL  DERIVATIVE. 

248628  04-12 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 
DERIVATIVES 

NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 
PROPERTIES 

232528  01-02 
BASIC  DERIVATIVES  OF  6,7  DIHYDROINDOLOBENZAZEPINE  AND  6H 
INDOLOBENZOXAZEPINE  AS  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

237834  02-02 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02-04 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I),  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES 

238563  02-03 
EFFECTS  OF  DOPAMINE  (DA)  DERIVATIVES  ON  CENTRAL  DOPAMINERGIC 
MECHANISMS 

238700  0303 
EFFECTS  OF  BETA  HYDROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA. 

238777  03-03 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES. 

241231  0304 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS.  4TH 
REPORT    COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
DIFFERENTIAL  PHARMACOTHERAPY  FOR  NEUROTIC  STATES 
(COMPARATIVE  EFFECTIVENESS  OF  BENZODIAZEPINE  DERIVATIVES). 

244349  04- 10 
EFFECTS  OF  THIENODIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04-07 
THE  EFFECT  OF  VARIOUS  CHLORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITEO  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYLASE  ACTIVITY 

247212  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 


SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 
CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE. 

250940  a 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  0 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERU/ 
ALBUMIN  ■■  I,  GEL  FILTRATION  STUDIES. 

251176  0 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUI 

ALBUMIN  -  11.  CIRCULAR  DICHROISM  STUDIES. 

251177  0 
DIESTER  DERIVATIVES  AS  APOMORPHINE  PRODRUGS. 

251699  0 
THE  STRUCTURE-ACTION  RELATIONSHIP  AND  KINETICS  OF  SOME 
NALOXONE  AND  NALTREXONE  DERIVATIVES. 

252223  0 
DERIVED 

INTRACRANIAL  SELF-STIMULATION  DERIVED  FROM  ENTORHINAL  COR 

238757  0 
NEUROAMINE  DERIVED  ALKALOIDS;  SUBSTRATE  PREFERRED  INHIBITC 
OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  C 
DRUGS  DERIVED  FROM  CANNA8IN0IDS.  1.  NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  C 
DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROG 

AND  CARBOCYCLIC  ANALOGS. 

248647  C 

DRUGS  DERIVED  FROM  CANNABINOIDS.  5,  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  C 
DRUGS  DERIVED  FROM  CANNABINOIDS.  3.  SULFUR  ANALOGS, 

THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  C 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 

SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  C 
DESCRIBE 

PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE, 

239658  C 
DESIGN 

ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLORDIAZEPOXID 
AN  INTENSIVE  DESIGN  STUDY, 

228221  C 
SOME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE-OXIDASE. 

233946  ( 
DESIPRAAAINE 

SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANOAI 
(UNPUBLISHED  PAPER). 

237274  ( 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION. 

246387  ( 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTI 
DERIVATIVE  TECHNIQUE 

247131  ( 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 
POISONING  IN  THE  RAT 

251419( 
POTENTIATION  BY  DESIPRAMINE  OF  NEURONAL  RESPONSES  TO 
MESCALINE. 

251705 ( 
CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6 
HYDROXYDOPAMINE  AND  DESIPRAMINE. 

252024  ( 
DESMETHYUMIPRAMINE 

RADIOIMMUNOASSAY  FOR  DESMETHYLIMIPRAMINE. 

236526  ( 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMIN 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  ( 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

2461 52  ( 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRON 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE. 

247777  { 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINEINDUCl 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233 ( 


S-102 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


>AIR 

PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
rRUCTION 

BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 
DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT: 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 
FRUCTIVE 

DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
iCT 

FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  04-04 
ICTING 

CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
ICTION 

DETECTION  OF  THE  NEUROLEPTIC  PROPERTIES  OF  CLOZAPINE,  SULPIRIDE, 
AND  THIORIDAZINE. 

227135  01-04 
SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

22911201-17 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 
■CTOR 

A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  OESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  02-06 
■RMINANT 

DRUGS  AND  PUNISHED  RESPONDING  Vh  BODY  WEIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS. 

247845  04-04 
■RMINANTS 

INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACUTE 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS, 

233377  02-12 
ERMINATION 

AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  OF 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION. 

229439  01-16 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01-16 
DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROMATOGRAPHY 

229906  01-16 
QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS. 

233277  02-06 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  OESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  02-06 
CURRENT  DETERMINATION  OF  LITHIUM  INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS. 

237110  02-04 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS 

237902  02- 13 
GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 
METHYLENEDIOXYAMPHETAMINE  (MDA)  FROM  PLASMA  AND  URINE, 

238484  02-06 
PKA  DETERMINATION  OF  METHAQUALONE. 

239659  03-01 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-04 


GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 
ADMINISTRATION:  DETERMINATION  OF  REINFORCEMENT  AAAGNITUD 

250010  04-04 
CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE 

251777  04-06 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301 1  04-07 
DETERMINATIONS 

DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  ( -i  )  AMPHETAMINE. 

241257  03-03 
DETERMINED 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
DETOXIFICATION 

PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES. 

242751  04-17 
DEUTERATED 

SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS. 
(UNPUBLISHED  PAPER). 

237274  02-16 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
DEUTEROPATHY 

DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 
CHRONIC  SCHIZOPHRENIA. 

228325  01-08 
DEVELOPING 

BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
ACTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE. 

241414  03-03 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PHD, 
DISSERTATION), 

241680  03-04 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM, 

243814  04-03 
A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE. 

251951  04-04 
PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 
COUNTRY, 

252990  04-17 
DEVELOPMENT 

NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT. 

226399  01-03 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROAAAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  01-05 
STRATEGIES  OF  BASIC  RESEARCH  IN  DEVELOPMENT  OF  DRUGS. 

229429  01-06 
ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS-TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 
PSYCHOTROPIC  DRUGS 

233684  02-17 


PS' 


-r6 


S-103 


Subject  Index 


Psychopharmacology  Abstra 


DEVELOPMENT  OF  TOLERANCE  TO  ANn  DEPENDENCE  ON  ENDOGENOUS 
NEUROTRANSMITTERS 

234798  02-08 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL, 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT. 

238722  03-04 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 

(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
6HYDR0XYD0PAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 

FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH).  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03-03 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIOUS. 

239851  03-03 
STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE-LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON. 

240205  03-05 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS, 

241245  03-04 
A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE. 

241348  03-03 
SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  PJkJ  BRAIN. 

241366  03-03 
DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES. 

244063  04-17 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04-04 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA  METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
DEVELOPMENT  OF  CROSS-TOLERANCE  BETWEEN  DELTA9- 
TETRAHYDROCANNABINOL  AND  ETHANOL. 

249263  04-03 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 

ETHANOL  TOLERANCE  IN  THE  RAT. 

249264  04-04 
STUDIES  ON  SINGLE  DOSE  TOLERANCE  DEVELOPMENT  TO  MORPHINE  IN 

MICE. 

249288  04-04 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 
CATALEPSY  IN  THE  RAT. 

250084  04-03 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-03 
DEVELOPMENTAL 

NUTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENTAL 
DISABILITIES, 

232815  02-15 
DEVELOPMENTS 

RECENT  DEVELOPMENTS  IN  THE  TREATMENT  OF  SCHIZOPHRENIA. 

235803  02-08 
RECENT  DEVELOPMENTS  IN  THE  DRUG  TREATMENT  OF  SCHIZOPHRENIA. 

236751  0208 
NEW  DEVELOPMENTS  IN  THE  USE  OF  PHENOBARBITAL  IN  PEDIATRICS. 

240723  03-17 
CURRENT  DEVELOPMENTS  IN  PSYCHOPHARMACOLOGY,  VOLUME  I. 

245873  04-17 


DEVICE 

CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  0 
DEVOID 

MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 
DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNt 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  0 
DEXAMETHASONE 

TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  III. 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS. 

235368  0 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANC 
TO  DEXAMETHASONE  SUPPRESSION. 

236801  C 
THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  II 
THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  0 
DEXAMPHET  AMINE- 1 4C 

5-HYDROXYTRYPTAMINE-MC  AND  DEXAMPHETAMINE-14C  UPTAKE  B 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERAAAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLE 
OF  THE  COMMON  RECEPTOR. 

226827  C 
DEXETIMIDE 

THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  AND 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  II 
RATS. 

230452  C 
DEXTROAMPHETAMINE 

EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFIED  CHOLINOCEPTIVE 
CELLS  OF  THE  SNAIL  BRAIN. 

238740  C 
LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  C 
METHYLPHENIDATE,  DEXTROAMPHETAMINE,  AND  LEVAMFETAMINE: 

EFFECTS  ON  SCHIZOPHRENIC  SYMPTOMS. 

239933  C 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDR( 
OR  MINIMAL-BRAIN-DYSFUNCTION. 

247878  0 
DEXTROMORAMIDE 

EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE. 

244513  0 
DFP 

DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIR: 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  0 
DH-524 

FENMETRAZOLE  (DH-524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781 0 
DI-N-PROPYLACETATE 

THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DI-N-PROPYLACETATE. 

241222  0 
DIABETES 

INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  0 
DIABETES-INSIPIDUS 

IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  I 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS. 

239851  0 
DIAGNOSES 

NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION. 

251149  0 
DIAGNOSIS 

MODERN  VIEWS  ON  DIAGNOSIS  AND  CLASSIFICATION  OF  DEPRESSId 
II.  UNITED-KINGDOM. 

227205  C 
ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  0 
THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD:  DIAGNOSIS  AND 
TREATMENT, 

233513  0: 
ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  EXTRAPYRAMIDAL  MOTi 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  O: 


S-104 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


DIAGNOSIS  AND  MANAGEMENT  OF  ETHANOL  WITHDRAWAL 
SYNDROMES. 

244107  04-11 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE. 

244355  04-15 
AGNOSTIC 

LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03-1 1 
AGRAM 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L  CARROLL 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
ALYSIS 

TREATMENT  OF  DIALYSIS  DEMENTIA  WITH  THIAMINE. 

251966  04-11 
AZEPAM 

A  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 
THE  TREATMENT  OF  STATES  OF  ANXIETY. 

226410  01-10 
EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 
DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  01-03 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 
LIVER. 

227696  01-03 
THE  EFFECT  OF  DIAZEPAM  AND  TRIFLUOPERAZINE  ON  BLOOD  SUPPLY 
AND  CARDIAC  ACTIVITY. 

228553  01-03 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM. 

229349  01-17 
ASSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 

CLEFTS 

229350  01-15 
DIAZEPAM  AND  PLASMA  TESTOSTERONE  LEVELS. 

229369  01-15 
BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN. 

229440  01-14 
DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01-03 
PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS: 
EFFECT  OF  DIAZEPAM  IN  MALES. 

229840  01-11 
MISUSE  AND  ABUSE  OF  DIAZEPAM:  AN  INCREASINGLY  COMMON 
MEDICAL  PROBLEM. 

229852  01-17 
DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE. 

230424  01-15 
THE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY 

230830  01-14 
ALTERED  5-HT  METABOLISM  WITH  CLONAZEPAM,  DIAZEPAM  AND 
DIPHENYLHYDANTOIN. 

230855  01-03 
EFFECTS  OF  DIAZEPAM  ON  THE  ISOLATED  CHICK  EMBRYO  HEART. 

230862  01-03 
A  CONTROLLED  EVALUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS. 

230907  01-08 
EFFECT  OF  ETHANOL  ON  DIAZEPAM  DISTRIBUTION  IN  RAT. 

231007  01-03 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01-10 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM: 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01-03 


THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  AAAN. 

232531  01-13 
EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
SUCCINATE. 

233001  02-13 
A  REVIEW  OF  THE  EFFECTS  OF  DIAZEPAM  ON  COGNITIVE  AND 
PSYCHOMOTOR  PERFORMANCE. 

235236  02-14 
ON  THE  INTRACELLULAR  MECHANISM  OF  ACTION  OF  IMIPRAMINE  AND 
DIAZEPAM. 

236232  02-03 
LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY:  DOUBLE-BLIND  TRIAL. 

236658  02-10 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
EFFECTS  OF  DIAZEPAM  AND  SCOPOLAMINE  ON  STORAGE,  RETRIEVAL 
AND  ORGANIZATIONAL  PROCESSES  IN  MEMORY. 

237722  02-14 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROMAZINE, 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM. 

237750  02-06 
ROLE  OF  DIAZEPAM  IN  THE  MANAGEMENT  OF  ECLAMPSIA. 

237898  02-11 
APPARENT  PHARAAACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901  02-13 
DRUG  PERMEATION  THROUGH  MEMBRANES  V:  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  02-02 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 
ACTION  OF  DIAZEPAM. 

238531  02-13 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03-04 
INFLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES. 

238711  03-14 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03-14 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  DIAZEPAM  ON  HIPPOCAMPAL 
EVOKED  RESPONSES. 

239961  03-03 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 

PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  03-04 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 

DORSAL  ROOT  POTENTIALS. 

239982  03-03 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 

BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03-03 
DIAZEPAM  USE  IN  MILITARY  SICK  CALL. 

240278  03-17 
CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTION: 
OPEN  AND  DOUBLE-BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  03-14 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AND 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-04 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03-10 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205  04-03 
EFFECT  OF  INTRAVENOUS  DIAZEPAM  ON  RENAL  FUNCTION. 

246273  04-15 
SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ,  AND 
SECOBARBITAL. 

246303  04-14 


■so 


0 


S-105 


Subject  Index 


Psychopharmacology  Abstracts 


EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEC  -  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE 

2463)9  04-03 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

246891  04- n 
ASSESSMENT  OF  DIAZEPAM  AFTER  THREE  YEARS  USE  IN  CHILD 
PSYCHIATRY. 

249144  04-n 
EFFECTS  OF  DIAZEPAM  ON  SIX  DRUG-INDUCED  LOCOMOTOR 
HYPERACTIVITIES  IN  MICE. 

249677  0404 
WITHDRAWAL  OF  DIAZEPAM. 

250056  04-15 
BILIARY  ELIMINATION  OF  DIAZEPAM  IN  MAN 

250423  04-13 
COMPARISON  OF  LOW  DOSES  OF  HALOPERIDOL  AND  DIAZEPAM  IN 
ANXIETY  STATES. 

250491  04-10 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETICS 
OF  (14C)IMIPRAMINE  IN  RAT:  ACUTE  STUDY. 

250655  04  03 
EXPOSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM, 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION. 

250727  04-10 
DIAZEPAM-INOUCED 

CHLORDIAZEPOXIDE  AND  DIAZFPAM-INDUCED  MOUSE-KILLING  BY  RATS. 

230838  01-04 
DIAZOXIDE 

ENHANCEMENT  BY  CHLORPROMAZINE  OF  HYPERGYLCEMIC  ACTION  OF 
DIAZOXIDE. 

247715  04-15 
DIBENAMINE 

RELATIONS  BETWEEN  ORIENTING.  PSEUDOCONDITIONFD  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX  ■■  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE. 

230570  01-04 
DIBt^NZOOIAZEPINES 

ANTIDOPAMINERGIC  AND  ANTIMUSCARINIC  EFFECTS  OF 
DIBENZ0DIA7EPINES:  RELATIONSHIP  TO  DRUG  INDUCED 
PARKINSONISM. 

241248  03-03 
DIBUTYRYl-CAMP 

RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE  BETA-HYDROXYLASE 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
DIBUTYRYI-CYCIIC-AMP 

BEHAVIORAL  EFFECTS  OF  DIBUTYRYL-CYCLIC-AMP  AND  BIOGENIC 
AMINES  IN  RATS. 

232484  01-04 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  04-03 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANAIFPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
OICHIORVOS 

DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 
CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  OF 
RAT  TISSUES. 

230451  01-03 
DICHROISM 

MAGNETIC  CIRCULAR  DICHROISM  OF  SUBSTITUTED  INDOLES. 

229493  01-06 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  II.  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 
DIDEHYDRO-METHYL-SBETA-PYRIOYLTHIOMETHYLERGOIINE 

CF  25-397,  DIDEHYDR0-METHYL-8BETA-PYRIDYLTHI0METHYLERG0LINF,  A 
NEW  CENTRAL  DOPAMINE  RECEPIOR  AGONIST. 

241927  03-04 
DIEIORIN 

THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY. 

227385  01-04 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  04-05 
OIENCEPHAIIC 

EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 


SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  01-04 
TOLERANCE,  PHYSICAL  DEPENDENCE  AND  OPIOID-SEEKING  BEHAVIOR: 
DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE. 

244202  04-04 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
DIESTER 

DIESTER  DERIVATIVES  AS  APOMORPHINE  PRODRUGS. 

251699  04-04 
DIET 

LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS. 

238741  03-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  "..^YPTOPHAN  DEFICIENT  DIET. 

249675  04-03 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
DIETARY 

THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
DIETHYLCARBOXAMIDE 

BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYOROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  01-03 
ANTAGONISM  OF  D-LYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,,5,6  TETRAHYOROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 
(THPC). 

230453  01-03 
DIETHYLDITHIOCARBAMATE 

EFFECTS  OF  DIETHYLDITHIOCARBAMATE  ON  THE  CATABOLISM  OF 
TYROSINE  IN  THE  RAT  BRAIN. 

241249  03-05 
DIFFERENTIALLY 

BINDING  OF  GLYCINE  AND  GAMMA-AMINOBUTYRIC-ACID  TO 

SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE 

238349  02-03 
D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272  03-04 
SALSOLINOL  DIFFERENTIALLY  AFFECTS  MICE  SELECTED  FOR  SENSITIVITY 
TO  ALCOHOL. 

244680  04-04 
LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIMULATION 
FACILITATED  BY  MORPHINE  AND  (4  )  AMPHETAMINE. 

249486  04-03 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE 

249672  04-04 
DIFFERENTIATION 

DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM). 

230865  01-04 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIOERAriON  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03  03 
DIFFICULTIES 

FLUPHENAZINE:  DIFFICULTIES  AND  LIMITATIONS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
DIFFUCAPS 

DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
DIGITALIS 

DIGITALIS:  CLINICAL  IMPLICATIONS  OF  NEW  FACTS  ABOUT  AN  OLD 
DRUG. 

253495  04-15 


S-106 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


IGITOXIN 

THE  EFFECT  OF  OUABAIN  AND  DIGITOXIN  ON  HEXOBARBITONE  SLEEPING 
TIME  IN  THE  MOUSE. 

225574  01-03 
IGOXIN 

TRIAL  OF  DIGOXIN  IN  MANIA. 

24771 1  04-09 
IHYDROERGOTAMINE 

ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241763  03-15 
IHYDROINDOIOBENZAZEPINE 

BASIC  DERIVATIVES  OF  6,7  DIHYDROINDOLOBENZAZEPINE  AND  6H 
INDOLOBENZOXAZEPINE  AS  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

237834  02-02 
IHYDROMORPHINE 

SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01-03 
IHYDROXYACID 

CHARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAl -TETRAHYDROCANNABINOL 
IN  MOUSE  LIVER. 

243787  04-03 
IHYDROXYCHLORPROMAZINE 

EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

236521  02-03 
IHYDROXYPEHNYLPtPERAZINE 

MECHANISMS  OF  A  DYSKINESIA  INDUCTION  BY  1-3,4 
DIHYDROXYPEHNYLPIPERAZINE  IN  THE  RAT. 

239964  03-04 
IHYDROXYPHENYIACETIC-ACID 

CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
IHYOROXYPHENYLAMINO 

3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
IHYOROXYTETRAHYDROISOQUINOLINE 

A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
IHYDROXYTRYPTAMINE 

IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE. 

226938  01-04 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02-03 
THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYDROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS. 

239087  03-03 
EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA. 

243799  04-03 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  04-04 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
IHYDHOXYTRYPTOPHAN 

EFFECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
lUNTIN 

INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 


CARBAMAZEPINE  (TEGRETOL)  -  A  DOUBLE-BLIND  COMPARISON  WITH 
PHENYTOIN  (DILANTIN). 

251937  04-13 
DIMENSIONS 

DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02-10 
DIMETHOXY-4-ETHYLAMPHET  AMINE 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
DIMETHOXY-4-METHYlAMPHETAMINE 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R- 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (R-DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  02-04 
BEHAVIORAL  AND  NEUROPHARAAACOLOGICAL  ANALYSIS  OF 

AMPHETAMINE  AND  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  IN 
RATS. 

237718  02-04 
DIMETHOXY-4-METHYLPHENYl 

METABOLIC  0-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  1  2.5 
DIMETHOXY-4-METHYLPHENYL  2  AMINOPROPANE. 

236520  02-03 
DIMETHOXYMETHYl-PHENOBARBITAL 

METABOLISM,  DISTRIBUTION  AND  ANTICONVULSANT  PROPERTIES  OF 
N,N  DIMETHOXYMETHYL-PHENOBARBITAL  IN  THE  RAT. 

237758  02-03 
DIMETHYL-M-TYRAMINE 

INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROAAAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
DIMETHYL-5-AMINOADAMANTAN 

NEUROPHARMACOLOGICAL  STUDIES  ON  D145  (1,3  DIMETHYL-5- 
AMINOADAMANTAN). 

227133  01-03 
DIMETHYLAMINOETHANOL 

THE  EFFECTS  OF  DIMETHYLAMINOETHANOL  (DEANOL)  ON  CEREBRAL 
CORTICAL  NEURONS. 

232621  02-03 
DIMETHYIDOPAMINE 

ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04-04 
DIMETHYL5ULFOXIDE 

EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 
PERFUSED  RAT  BRAIN. 

243782  04-03 
DIMETHYLTRYPTAMINE 

5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER). 

227802  01-04 
THE  PSYCHEDELIC  MODEL  OF  SCHIZOPHRENIA:  THE  CASE  OF  N,N 
DIMETHYLTRYPTAMINE. 

236750  02-08 
BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
DIMETHYLTRYPTAMINE  AND  5-METHOXY-N.N  DIMETHYLTRYPTAMINE. 

249317  04-05 
DIMETHYLTRYPT  AMINES 

CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 
5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS. 

249318  04-03 
DINUCLEOTIDE 

ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL  PHENOTHIAZINES. 

239662  03-03 
DIPHENHYDRAMINE 

DEPENDENCY  ON  COMBINED  METHAQUALONE  DIPHENHYDRAMINE. 

241870  03-17 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION, 

245593  04-05 
THE  EFFECTIVENESS  OF  DIPHENHYDRAMINE  HCL  IN  PEDIATRIC  SLEEP 
DISORDERS. 

251827  04-14 


as 


St: 


S-107 


Subject  Index 

DIPHENYLBUTYLPIPERIDINE 

CLOPIMOZIOE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-04 
DIPHENYLHYDANTOIN 

EFFECT  OF  5,5  DIPHENYLHYDANTOIN  (DPH)  ON  LEARNING  AND  MEMORY 
IN  CATS. 

229680  01-04 
EFFECT  OF  5,5  DIPHENYLHYDANTOIN  ON  FIXED  CONDITIONED  REFLEXES 

IN  CATS. 

229681  01-04 
ALTERED  5-HT  METABOLISM  WITH  CLONAZEPAM,  DIAZEPAM  AND 

DIPHENYLHYDANTOIN. 

230855  01-03 
DIPHENYLHYDANTOIN  POTENCY  AND  PLASMA  PROTEIN  BINDING. 

231003  01-03 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE-BUND 
STUDY. 

232781  02-08 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS 

232917  02-03 
EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
SUCCINATE. 

233001  02-13 
PAROXYSMAL  NIGHTMARES:  SEQUEL  OF  A  STROKE  RESPONSIVE  TO 
DIPHENYLHYDANTOIN. 

233295  02-14 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  02-03 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  DIAZEPAM  ON  HIPPOCAMPAL 
EVOKED  RESPONSES. 

239961  03-03 
EVIDENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 

TRIPHOSPHATASES  FROM  BRAIN. 

239962  03-03 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS- 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
EFFECT  OF  DIPHENYLHYDANTOIN  ON  THE  ENDOGENOUS 
PHOSPHORYLATION  OF  BRAIN  PROTEIN. 

240746  03-03 
PLASMA  CONCENTRATION  OF  DIPHENYLHYDANTOIN  IN  THE  EPILEPTIC- 
ITS  INTEREST  FOR  THE  CLINICIAN. 

240762  03-1 1 
DIPHENYLHYDANTOIN  INCREASES  CORTICAL  POSTSYNAPTIC  INHIBITION. 

241805  03-03 
DELAYED  AND  INSIDIOUS  ONSET  OF  DIPHENYLHYDANTOIN  TOXICITY. 

246932  04-15 
DIPHENYLHYDANTOIN  FACILITATION  OF  LABILE,  PROTEIN  INDEPENDENT 
MEMORY. 

253290  04-04 
OIPHOSPHONATE 

EFFECT  OF  HYDROCHLOROTHIAZIDE  ON  PHOSPHORUS  DURING 
TREATMENT  WITH  OIPHOSPHONATE. 

245651  04-13 
DIPIPERON 

PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03-11 
DIPOTASSIUM 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
CLINICAL  EXPERIENCE  IN  USING  MENDON  (DIPOTASSIUM  CLORAZEPATE). 

229626  01-11 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04-11 
DIPROPYLACETATE 

THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 

CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE. 

237723  02-04 


Psychopharmacology  Abstracts 


DIPROPYLTRYPTAMINE 

DIPROPYLTRYPTAMINE  IN  PSYCHOTHERAPY. 

251752  04- 17 
DIPSOGENIC 

DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04-04 
DIRECT 

BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS. 

233973  02-03 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02-06 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 
DISABILITIES 

NUTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENTAL 
DISABILITIES. 

232815  02-15 
THE  USE  OF  MEGAVITAMIN  TREATMENT  IN  CHILDREN  WITH  LEARNING 
DISABILITIES. 

235676  02-11 
DISABILITY 

PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY. 

250722  04-15 
DISABLED 

THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD:  DIAGNOSIS  AND 
TREATMENT. 

233513  02-17 
DISAGGREGATE 

NECESSITY  OF  HYPERTHERMIA  FOR  L-DOPA  OR  D-AMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03-03 
DISASTER 

LITHIUM   -  FUTILITY,  DISASTER  AND  TRIUMPH. 

227411  01-17 
DISCHARGE 

THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG- 
STAY  PSYCHIATRIC  PATIENT. 

227461  01-17 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR. 

238819  03-04 
DISCONTINUITY 

EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE-BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  OI-U 
DISCOURSE 

DISCOURSE  ON  THE  DOUBLE-BLIND  METHOD.  INSTITUTION  AND 
EXPERIMENTATION:  19366-RP. 

229078  01-16 
DISCOVERY 

DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
-  AN  ANTIMIGRAINE  COMPOUND. 

229473  01-13 
DISCREPANCY 

ANALYSIS  OF  THE  DISCREPANCY  IN  /WAN-MACHINE  TRACKING  SYSTEMS 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03-14 
DISCRIMINABLE 

BEHAVIORALLY  INDUCED  SENSITIVITY  TO  THE  DISCRIMINABLE 
PROPERTIES  OF  LSD. 

230876  01-04 
A  COMPARISON  OF  THE  DISCRIMINABLE  CNS  EFFECTS  OF  KETAMINE, 
PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 
DISCRIMINATED  ^ 

THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE    H 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES.  T 

241301  03-04 


S-108 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


SCRIMINATION 

SCOPOLAMINE  AND  AMPHETAMINE  EFFECTS  ON  DISCRIMINATION: 
INTERACTION  WITH  STIMULUS  CONTROL. 

227)31  01-04 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01-03 
SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATIONS 
RELATED  TO  STIMULUS  CONTROL. 

231005  01-04 
EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMAAATURE  RAT. 
(PH.D.  DISSERTATION). 

231533  01-04 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-03 
DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PH.D.  DISSERTATION). 

239533  03-04 
THEORETICAL  AND  METHODOLOGICAL  CONSIDERATIONS  ON  DRUG 
DISCRIMINATION  LEARNING. 

241228  03-04 
DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN  AND 
CHOLINESTERASE  INHIBITORS. 

242737  03-04 
EFFECTS  OF  DRUG  STATE  CHANGE  ON  DISCRIMINATION  PERFORAAANCE. 

244679  04-04 
DRUG  DISCRIMINATION  IN  RATS:  THE  EFFECTS  OF  PHENCYCLIDINE  AND 
DITRAN. 

245297  04-04 
EFFECT  OF  PHYSOSTIGMINE  ON  Y-MAZE  DISCRIMINATION  RETENTION  IN 
THE  RAT. 

251982  04-04 
SCRIMINATIVE 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  02-04 
A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R- 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (R-DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  02-04 
DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE:  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03-04 
TEMPORAL  PARAMETERS  OF  D-AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT. 

239856  03-04 
PHYSOSTIGMINE  AS  A  DISCRIMINATIVE  CUE  IN  RATS. 

241258  03-04 
THE  ROLE  OF  SEROTONIN  IN  THE  DISCRIMINATIVE  STIMULUS 
PROPERTIES  OF  MESCALINE.  (PH.D.  DISSERTATION). 

241573  03-03 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RATS 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04-04 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ETHANOL  AND  BARBITAL. 

249262  0404 
THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX:  RELATION  TO 
ANALGESIC  ACTIVITY. 

250355  04-03 
DELTA9-TETRAHYDR0CANNABIN0L.  ETHANOL,  AND  AMPHETAMINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  04-04 
SCUSSIONS 

SUMMARY  OF  THE  DISCUSSIONS  AT  THE  SYMPOSIUM  PSYCHOSIS  AND 
FREEDOM. 

246126  04-17 
SEASE 

THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  OMl 


THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOAAATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO-4-4602). 

233917  02-11 
THE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 
(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE. 

233974  02-11 
MAINTENANCE  ANTIPSYCHOTIC  THERAPY:  IS  THE  CURE  WORSE  THAN 
THE  DISEASE?. 

236307  02-08 
TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 
ROLE  OF  GROWTH  HORMONE. 

237253  02-1 1 
NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE. 

238516  02-11 
LORAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

24)274  03-14 
COMPARISON  OF  OOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

2486)2  04-]) 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

2486)3  04-)) 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

2504)4  04-)) 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY. 

250722  04)  5 
FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  )00  PATIENTS. 

250927  04-)) 
BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE 

250942  04-)) 
BROMOCRIPTINE  TREATMENT  IN  PARKINSONS  DISEASE. 

25)239  04-)) 
SIX-YEAR  RESULTS  OF  TREATMENT  WITH  LEVODOPA  PLUS  BENSERAZIDE 
IN  PARKINSONS  DISEASE. 

25)648  04-)) 
DISEASES 

AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATION 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES. 

2291)50)13 
CLINICAI   FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 
PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT 

244476  04)  1 
DISINHIBITING 

THE  DISINHIBITING  EFFECT  OF  N  (l-ETHYL-2-PYRROLIDINYL-METHYL  2- 
METHOXY-5-SULFAMIDOBENZAMIDE  (SULPIRIDE).  II. 

229529  0)-)4 
OISINHIBITION 

CORTICAL  OISINHIBITION:  A  POSSIBLE  MECHANISM  FOR  DRUG-INDUCED 
HALLUCINATIONS. 

238830  03-03 
BEHAVIORAL  OISINHIBITION  BY  MESCALINE. 

24)243  03-04 
DISINHIBITORY 

DISINHIBITORY  EFFECTS  OF  SEPTAL  LESIONS  AND  SCOPOLAMINE 
HYDROBROMIDE.  (PHD,  DISSERTATION). 

227099  0) -04 
DISMUTASE 

EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

23652)  02-03 
DISORDER 

PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03)  5 
TREATMENT  OF  STUDENTS  WITH  MENTAL  DISORDER. 

243092  04)  7 
THOUGHT  DISORDER  IN  AMPHETAMINE  PSYCHOSIS:  A  CASE  REPORT. 

250)96  04)  3 
DISORDERS 

DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOLCHILDREN. 

225783  0)  14 


35; 


-re 


ftmm 

a. 


S-109 


Subject  Index 


THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS.  LONG- 
TERM  EFFECTS  AND  SIDE-EFFECTS. 

226612  01-09 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER). 

226731  01-13 

PSYCHOVEGETATIVE  DISORDERS  IN  CASES  OF  CYCLOTHYMIC 
DEPRESSION. 

226777  01-09 
PHARMACOTHERAPY  IN  PSYCHOVEGETATIVE  DISORDERS. 

226778  01-09 
DRUGS  FOR  MENTAL  DISORDERS  OF  OLD  AGE. 

229315  01-11 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  01-13 
DRUG  TREATMENT  OF  MENTAL  DISORDERS. 

23111301-17 
DRUGS  FOR  EMOTIONAL  DISORDERS:  CURRENT  PROBLEMS. 

233514  02-17 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  02-09 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION, 

234203  02-09 
POSSIBILITIES  FOR  PHARMACOTHERAPY  IN  THE  COURSE  OF 
PSYCHOTHERAPY  FOR  MENTAL  DISORDERS. 

234438  02-17 
EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02-11 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 
DISORDERS. 

236303  02  17 
THE  COURSE  OF  TREATMENT  IN  SCHIZOPHRENIA  AS  RELATED  TO  THE 
APPEARANCE  OF  AFFECTIVE  DISORDERS. 

236421  02-08 
CONTROLLED,  DOUBLE  BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
CYCLIC  NUCLEOTIDES  AND  THEIR  POSSIBLE  RELEVANCE  TO  DISORDERS 
OF  NERVOUS  SYSTEM  FUNCTION,  {UNPUBLISHED  PAPER) 

237171  02-03 
2-PHENYLETHYLAMINE  (PEA)  IN  D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

238841  03-03 
PROPHYLAXIS  OF  AFFECTIVE  DISORDERS:  CURRENT  STATUS  OF 
KNOWLEDGE. 

239937  03-09 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
BEHAVIOR  DISORDERS  IN  CHILDHOOD  AND  THEIR  TREATMENT. 

240711  03-11 
BIOGENIC  AMINES  AND  AFFECTIVE  DISORDERS. 

241937  03-09 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  II:  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES.  (UNPUBLISHED  PAPER). 

244574  04-09 
A  CONTROLLED  TRIAL  OF  AMANTADINE  IN  DRUG-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

244701  04-15 
LITHIUM  PROPHYLAXIS  IN  AFFECTIVE  DISORDERS, 

245416  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERLAY 
(A  DOUBLE-BLIND  CROSSOVER  STUDY). 

250193  04-14 
PSYCHOTROPIC  DRUGS  IN  SOMATIC  DISORDERS. 

250856  04-17 
THE  EFFECTIVENESS  OF  DIPHENHYDRAMINE  HCL  IN  PEDIATRIC  SLEEP 
DISORDERS 

251827  04-14 
LONG-TERM  THERAPY  OF  NEUROLOGIC  DISORDERS  WITH  L-5- 
HYDROXYTRYPTOPHAN. 

251960  04-13 


J 
Psychopharmacoiogy  Abstracts' 

TETRABENAZINE  IN  THE  TREATMENT  OF  HYPERKINETIC  MOVEMENT 
DISORDERS. 

251961  04-11 
TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA- 
GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  04-07 
DISPERSED 

SELF-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST. 

246774  04-03 
DISPLAY 

ANALYSIS  AND  DISPLj'VY  OF  PSYCHOPHARAAACOLOGICAL  DATA. 

228978  01-17 
DISPOSITION 

PHENOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
FOR  SEVERAL  METABOLITES. 

238796  03-13 
NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
OISRUPTABLE 

A  DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP. 

238717  03-04 
DISRUPTION 

FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS.  (PH.D.  DISSERTATION). 

226991  01-12 
DISRUPTION  OF  BRAIN  STIMULATION-INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE. 

235587  02-04 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02-04 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE. 

238687  03-04 
DISSIMILAR 

ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 
CLOZAPINE  AND  CHLORPROMAZINE. 

248600  04-03 
DISSOCIATED 

RAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-03 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-03 
DISSOCIATION 

PHAR/WACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID. 

237705  02-04 
DISSOCIATION  OF  RAT  BRAIN  POLYRIBOSOMES  IN  VIVO  BY 
AMPHETAMINES. 

237871  02-03 
DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE.  (PH.D.  DISSERTATION). 

238159  02-03 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02-04 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04-14 
DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCCO- 
LINGUAL  DYSKINESIAS. 

252031  04-03 
DISSOCIATIVE 

CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE 
IN  TREATING  DISSOCIATIVE  SYNDROMES, 

229560  01-11 
STATE-DEPENDENT  (DISSOCIATIVE)  EFFECTS  OF  METHADONE  ON  HUMAN 
RETENTION.  (PH.D.  DISSERTATION). 

242151  03-14 
DISSOLUTION 

CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04-06 
DISTIGMINBROMIDE 

THERAPY  OF  PSYCHOPHARMACEUTICAL  SIDE-EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID,  BC-51). 

239782  03-15 


S-110 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


STRACTION 

ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION?. 

241932  0304 
STRIBUTION 

REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS. 

228550  01-03 
DISTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRACT 
OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01-03 
EFFECT  OF  ETHANOL  ON  DIAZEPAM  DISTRIBUTION  IN  RAT. 

231007  01-03 
H3-P-CHL0R0AMPHETAMINE:  CEREBRAL  LEVELS  AND  DISTRIBUTION. 

232614  02-03 
THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  02-03 
3H-DELTA9-TETRAHYDROCANNABINOL  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
METABOLISM,  DISTRIBUTION  AND  ANTICONVULSANT  PROPERTIES  OF 
N,N  DIMETHOXYMETHYL-PHENOBARBITAL  IN  THE  RAT. 

237738  02-03 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE  OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK 

237923  02-03 
PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  03-03 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE  IN  THE  MOUSE. 

239855  03-03 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALINE 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX  JACCHUS. 

239864  03-03 
5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE  ACTIVITY;  MICROASSAY 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  03-03 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DEI  TA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY, 

241242  03-03 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE. 

244355  04-15 
DISTRIBUTION  OF  3H-ALPHA-MSH  IN  RAT  BRAIN 

248349  04-03 
RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  04-01 
ABSORPTION,  DISTRIBUTION  AND  EXCRETION  OF  TRIFLUOPERAZINE  IN 
RATS. 

249036  04-03 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABINOL  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT. 

249223  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  0401 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE 

250379  04-03 
THE  REGIONAL  DISTRIBUTION  OF  A  MORPHINE-LIKE  FACTOR  ENKEPHALIN 
IN  MONKEY  BRAIN. 

252219  04-03 
AUTORADIOGRAPHIC  DISTRIBUTION  STUDY  OF  14C-D0PA  IN  CAT  BRAIN. 

253393  04-03 
5TRIBUTIONS 

REM  SLEEP  DISTRIBUTIONS  IN  POSTAODICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-04 
STURBANCE 
MENTAL  AND  EMOTIONAL  DISTURBANCE  WITH  PENTAZOCINE  (TALWIN) 
USE. 

233828  02-15 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION. 

245789  04-15 


DISTURBANCES 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01-13 
SLEEP  AND  ITS  DISTURBANCES  IN  THE  CHILD:  CONTRIBUTIONS  OF 
ELECTROPHYSIOLOGY 

228091  01-11 
RELATIONSHIPS  BETWEEN  ANESTHETIC  SUBSTANCES,  CONVULSIONS, 
AND  PSYCHIC  DISTURBANCES 

229118  01-15 
CLINICAL  USE  OF  DRUGS  FOR  SLEEP  DISTURBANCES. 

230119  01-17 
THE  THERAPY  OF  AUTONOMIC  REGULATORY  DISTURBANCES  THROUGH 
DRUGS. 

232260  01-15 
TWO  CASES  OF  PSYCHIC  DISTURBANCES 

232545  01-17 
ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACU1E  EXTRAPYRAMIDAL  MOTOR 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  02-11 
BETA-PHENYLETHYLAMINE  (PEA)  AND  THE  NEUROPSYCHIATRIC 
DISTURBANCES.  (UNPUBLISHED  PAPER). 

241474  03-14 
PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES. 

243985  04-09 
ANTIDEPRESSANT  TREATMENT  WITH  AMPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY. 

253684  04-11 
DISTURBED 

SUCCESS  WITH  LITHIUM  IN  A  DISTURBED  CHILD. 

236118  02-11 
DISTURBING 

STIMULANT  DRUGS  FOR  HYPERACTIVITY:  SOME  ADDITIONAL 
DISTURBING  QUESTIONS. 

240599  03-17 
DISULFIDE 

EFFECTS  OF  CARBON  DISULFIDE  ON  OPERANT  BEHAVIOR  IN  PIGEONS. 
(PH.D.  DISSERTATION). 

238081  02-04 
THE  EFFECT  OF  CARBON  DISULFIDE  ON  THE  STEREOTYPIC  EFFECT  OF 
DOPAMINE  AGONISTS. 

250090  04-04 
DISULFIRAM 

TREATMENT  WITH  DISULFIRAM  IN  HUNTINGTONS-CHOREA:  A  NEGATIVE 
CLINICAL  AND  PHARMACOLOGICAL  STUDY. 

226430  01-07 
EVALUATION  OF  DISULFIRAM  TREATMENT  OF  CHRONIC  ALCOHOLISM. 

237026  02-1 1 
TREATMENT  OF  ALCOHOLIC  METHADONE  /MAINTENANCE  PATIENTS  WITH 
DISULFIRAM. 

237624  02-11 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOIOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-15 
DITA 

FOOD  AND  DRUG-REINFORCED  RESPONDING:  EFFECTS  OF  DITA  AND  D- 
AMPHETAMINE. 

227127  01-04 
ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE,-  COMPARISON 
WITH  DAMPHETAMINE, 

248284  04-03 
DITRAN 

DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN  AND 
CHOLINESTERASE  INHIBITORS. 

242737  03-04 
DRUG  DISCRIMINATION  IN  RATS:  THE  EFFECTS  OF  PHENCYCLIDINE  AND 
DITRAN 

245297  04-04 
DIURETIC 

A  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

22641401-11 
DIURNAL 

INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE. 

243795  04-03 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  BY 
PINEAL  METABOLITES. 

249240  04-03 
DIV-154 

CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND. 

251407  04-17 


36: 


s-ni 


Subject  Index 


Psychopharmacology  Abstracts 


DIVIDED 

DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04-13 
Dl-AIPHA-METHYL-P-TYROSINE 

POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
DL-AMPHET  AMINE 

CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL-AMPHETAMINE  AND 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION. 

236235  02-03 
DL-AMPHETAMINES 

INHIBITION  OF  SYNAPTOSOAAAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
I:  N-ARYLALKYL  AND  N-ARYLOXYALKYL  DL-AMPHETAMINES  AND 
RELATED  COMPOUNDS. 

246316  04-03 
Dl-254 

THE  EFFECT  OF  DL  254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS. 

238846  03-03 
DMT 

THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
ONA 

IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
DOCTOR 

MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 
DOET 

THE  EFFECTS  OF  2,5  DIMETKOXY-4-METHYLAMPHETAMINE  (DOM)    2  5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS. 

230837  01-04 
DOG 

HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 

227389  01-03 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
SELF-ADMINISTRATION  OF  CNS  STIMULANTS  BY  DOG. 

230879  01-04 
THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-03 
METABOLISM  OF  DELTAl-TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
BIOTRANSFORMATION  OF  AMITRIPTYLINE  IN  THE  DOG. 

238684  03-03 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
CENTRAL  ACTION  OF  AMPHETAMINE-INDUCED  MYDRIASIS  IN  THE  DOG. 

238772  03-03 
THE  EFFECT  OF  CHRONIC  MARIHUANA  SMOKING  ON  THE  BEAGLE  DOG. 

238806  03-03 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME) 

238825  03-03 
EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG. 

240916  03-04 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES. 

241231  03-04 
A  METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG. 

244674  04-06 
DOGMATIl 

DOGMATIL  OR  SULPIRIDE:  AN  ATTEMPT  AT  SPECIFICATION. 

237015  02-17 


TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DELAGRANGE). 

239269  03- n 
DOG/WATIL  AND  BEHAVIORAL  PROBLEMS  IN  MIGRANT  WORKERS. 

249693  04-11 
DOGS 

THE  DEPENDENCE  OF  THE  /WAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE. 

236249  02  03 
3H-DELTA9-TETRAHYDR0CANNABIN0L  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
CHRONIC  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 

TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  THE  MONGREL  DOGS. 

238810  03-03 
TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 
DOGS  (CYNOMYS-LUDOVICIANUS). 

239863  03-04 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03-03 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDROXYDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS. 

242200  03-03 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE: 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04-03 
DOMESTIC 

EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK.  I.  EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245712  04-04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 

CHICK.  II.  EFFECTS  PRESENT  IN  BOTH  SEXES. 

245713  04-04 
DOMINAL 

TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  02-11 
DOMINANCE 

MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL-HEALTH 
POLICY. 

239298  03-17 
DOMINANT 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
DOPA 

NEW  PATHWAY  FOR  METABOLISM  OF  DOPA. 

246286  04-03 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04-03 
ALTERED  PATTERN  OF  DOPA  METABOLISM, 

251185  04-03 
DOPA-OECARBOXYLASE 

TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPA-DECARBOXYLASE  INHIBITOR. 

237733  02-11 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

248612  04-11 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
DOPA-INDUCED 

EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

248960  04-02 
DOPAMINE 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS. 

226185  01-04 
LSD  AND  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  VARIOUS  RAT 
BRAIN  AREAS. 

226406  01-03 


5-112 


UME  14,  SUBJECT  INDEX 


Subject  Index 


)OPAMINE  RECEPTOR  BLOCKADE  AND  THE  NEUROLEPTICS,  A 
CRYSTALLOGRAPHIC  STUDY, 

226761  01-03 
XUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-03 
HE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA. 

227139  01-03 
AIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  01-03 
:OMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01-04 
k  DOPAMINE  RECEPTOR  STIMULATOR  IN  DEPRESSION.  (UNPUBLISHED 
PAPER). 

227785  01-09 
lAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-03 
SD  AND  DOPAMINE  RECEPTORS. 

228050  01-03 
SD  AND  DOPAMINE  RECEPTORS  -  PIERI  REPLY. 

228051  01-03 
HE  EFFECTS  OF  ACETYLCHOLINE  AND  DOPAMINE  ON  THE  CAUDATE- 
NUCLEUS  DEPLETED  OF  BIOGENIC  AMINES. 

230457  01-03 

:hemistry  of  dopamine  receptors. 

230600  01-03 
)0PAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
)XOTREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 
METABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
;ABA  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA. 

231019  01-17 
\  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01-03 
FUNCTIONAL  SIGNIFICANCE  OF  CENTRAL-NERVOUS-SYSTEM 
NOREPINEPHRINE  AND  DOPAMINE:  A  PSYCHOPHARAAACOLOGICAL 
STUDY.  (PH.D.  DISSERTATION). 

231437  01-04 
:FFECTS  of  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 
REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  01-04 
)OPAMINE  AND  PSYCHOTIC  STATES:  PRELIMINARY  REMARKS. 

233961  02-13 
:ENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 
)OPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA: 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS. 

233967  02-08 
rHE  EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON 
BEHAVIOR  AND  DOPAMINE  METABOLISM. 

233969  02-03 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 

ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN. 

233970  0203 
)ISRUPTION  OF  BRAIN  STIMULATION-INDUCED  FEEDING  BY  DOPAMINE 

RECEPTOR  BLOCKADE. 

235587  02-04 
)OPAMINE  AND  SCHIZOPHRENIA. 

235802  02-08 
>ARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-04 
ONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER). 

236873  02-03 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02-03 


EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02-04 
CLINICAL  STUDIES  WITH  DOPAMINE  RECEPTOR  STIMULANTS. 

237725  02-08 
BRAIN  DOPAMINE  AND  JUMPING  BEHAVIOUR  IN  MICE. 

237746  02-03 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS. 

237782  02-03 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-03 
STUDIES  ON  THE  MECHANISM  OF  DEPLETION  OF  STRIATAL  DOPAMINE 
BY  ALPHA-METHYL-M-TYROSINE. 

237873  02-03 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS.  (PH.D.  DISSERTATION). 

238079  02-03 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
SCHIZOPHRENIA:  RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 
CONTROL,  AND  FEATURE  EXTRACTION. 

238464  02-08 
CYTOCHEMICAL  AND  ELECTROPHYSIOLOGICAL  STUDIES  OF  DOPAMINE  IN 
THE  CAUDATE-NUCLEUS.  (UNPUBLISHED  PAPER). 

238471  02-03 
PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE.  (UNPUBLISHED  PAPER) 

238491  02-13 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-04 
DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  03-03 
EFFECTS  OF  DOPAMINE  (DA)  DERIVATIVES  ON  CENTRAL  DOPAMINERGIC 

MECHANISMS. 

238700  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 

ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES. 

238729  03-03 
AMFONELIC-ACID  FACILITATION  OF  IMPULSE-INDUCED  STRIATAL 

DOPAMINE  RELEASE. 

238730  03-03 
EVIDENCE  FOR  A  DOPAMINE  RECEPTOR  ANTIBODY. 

238736  03  03 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE. 

238737  03-03 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  03  03 
THE  DYNAMICS  OF  DOPAMINE  METABOLISM  IN  VARIOUS  REGIONS  OF 
RAT  BRAIN. 

238761  03-03 
DOPAMINE  AND  PSYCHOACTIVE  DRUG  ACTION:  A  FURTHER 
EVALUATION. 

238768  03-04 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  03  03 


00 
pa 

* 


I 

I 


S-113 


Subject  Index 


THE  AMPHETAMINE-INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM. 

240065  03-03 

THE  BRAINS  DOPAMINE  RECEPTOR:  LABELING  WITH  3H-D0PAMINE  AND 
3H-HAL0PERID0L  . 

240077  03-03 

CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS 

240447  03-03 

NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETICACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEH.AVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM, 

241206  03-03 
EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 

PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  ( -h )  AMPHETAMINE. 

241257  03-03 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313  03-03 
EFFECTS  OF  THE  D-ISOMERS  AND  L  ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  03-03 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 
ADENYLATE  CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE 
NORADRENALINE  AND  Gi  UCAGON. 

241347  03-03 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTA8- 
TETRAHYDR0CANNA8IN0L  (DELTA8-THC). 

241926  03-03 
CF-25-397,  DIDEHYORO  METHYL  8BETAPYRIDYLTHI0METHYLERG0LINE  A 

NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST. 

241927  03-04 
IS  METOCLOPRAMIDE  A  DIRECTLY  ACTING  DOPAMINE  RECEPTOR 

ANTAGONIST?. 

241929  03-03 
EFFECTS  OF  DOPAMINE  RECEPTOR  BLOCKADE  ON  SELF-STIMULATION  IN 
THE  MONKEY. 

242748  04-04 
REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  04-04 
A  PRELIMINARY  REPORT:  NEUROENDOCRINE  EFFECTS  OF  DOPAMINE  AND 
NOREPINEPHRINE  RECEPTOR  STIMULATORS. 

243440  04-03 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04-03 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE. 

243792  04-03 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
THE  EFFECT  OF  AMPHETAMINE  STEREOISOMERS  ON  THE  FUNCTION  OF 
DOPAMINE  SYNAPSES  IN  VITRO 

244043  04-03 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE. 

244513  04-03 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE 

244514  04-03 
ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 

OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 


Psychopharmacology  Abstrad 

DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-1 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROAAATOGRAPHY. 

245300  04j 
BENZTROPINE-INDUCED  RELEASE  OF  DOPAMINE  FROM  BRAIN  IN  VIVO. 

245598  04^ 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE. 

245601  04j 
ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONIST: 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

2461  .SO  04-^ 
CLOZAPINE  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA,  A 
CRITICAL  APPRAISAL. 

246671  04^ 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RAT: 
PRODUCED  BY  D-AMPHETAMINE. 

246820  04-1 
EFFECT  OF  MORPHINE  ON  A  DEPOLARISING  DOPAMINE  RESPONSE. 

246998  04J 
ANTIDEPRESSANT  DRUGS  AFFECT  DOPAMINE  UPTAKE. 

247021  04j 
THE  SEARCH  FOR  THE  DOPAMINE  RECEPTOR:  TRIBULATIONS. 

247215  04J 
NEURAL  AND  NEUROENDOCRINE  FUNCTIONS  OF  DOPAMINE. 

247690  04- 
THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSD  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  04-1 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMINE 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY. 

248285  04^ 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-1 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIE[ 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-( 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  QA4 
POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES. 

248513  04-( 
RADIOPHARAAACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  04-( 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  OK 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04-C 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

248960  04-C 
DEPRESSION  OF  DOPAMINE  RELEASE  DURING  THE  ETHANOL 
WITHDRAWAL  SYNDROME. 

249293  04-C 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  ( -I- )  AMPHETAMINE 
AND  L-DOPA. 

249419  O4-0 
EFFECT  OF  METOCLOPRAMIDE  ON  TURNOVER  OF  BRAIN  DOPAMINE 
NORADRENALINE  AND  5-HYDROXYTRYPTAMINE. 

249628  04-0 
A  FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AN 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

249669  04-0 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 

SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-0 
LSD  AS  AN  AGONIST  AT  MESOLIMBIC  DOPAMINE  RECEPTORS. 

249680  04-0 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-0: 
DOPAMINE  RELEASE  IN  SUBSTANTIA-NIGRA?. 

249984  04-0: 


S-114 


UME  14,  SUBJECT  INDEX 


Subject  Index 


^  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  04-03 
AUTOMATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE  AND 
NORADRENALINE  TRANSMISSION. 

250086  04-04 
'HE  EFFECT  OF  CARBON  DISULFIDE  ON  THE  STEREOTYPIC  EFFECT  OF 
DOPAMINE  AGONISTS. 

250090  04-04 
.OCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX. 

250356  04-03 
IMITING  FACTORS  IN  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE. 

250359  04-03 
riME-DEPENDENT  EFFECTS  OF  PHENOTHIAZINES  ON  DOPAMINE 
TURNOVER  IN  PSYCHIATRIC  PATIENTS. 

250389  04-13 
;FFECT  of  ETHANOL  on  dopamine  synthesis  and  RELEASE  FROM  RAT 
CORPUS-STRIATUM. 

251178  04-03 
'REFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04-03 
WESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 
DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  04-03 
\LTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 
(LIORESAL  (R)). 

251398  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
ON  THE  ACTIONS  OF  COMPOUNDS  RELATED  TO  DOPAMINE  AT  A 
NEUROSECRETORY  SYNAPSE. 

251703  04-03 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS. 

252027  04-03 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5- 
HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM 

253593  04-04 
^MINE-BETA-HYDROXYLASE 

DOPAMINE-BETA-HYDROXYLASE  IN  NERVE  FUNCTION  AND  MENTAL- 
ILLNESS. 

225869  01-17 
EFFECTS  OF  A  DOPAMINE-BETA-HYDROXYLASE  INHIBITOR  ON 
AMPHETAMINE-INDUCED  HYPERACTI\'ITY  IN  RATS. 

226766  01-03 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

237103  02-04 
RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE-BETA-HYDROXYLASE 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
INHIBITION  OF  DOPAMINE-BETA-HYDROXYLASE  BY  SOME  ANALOGS  OF 

METHIMA20LE. 

238691  03-03 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  LOCUS- 

COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE. 

238759  03-03 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 
HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN.  (UNPUBLISHED  PAPER). 

239305  03-13 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIMARY  HYPERTENSION. 

241294  03-13 


ENDOGENOUS  INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  RAT 

ORGANS. 

244315  04-03 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 

ON  PLASAAA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 

IN  THE  RAT. 

246843  04-03 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 

NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 
INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE,  BUT 

NOT  OF  DOPAMINE-BETA-HYDROXYLASE  FROM  GUINEA-PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER). 

247028  04-03 
MODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE. 

248289  04-04 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

248964  04-04 
MECHANISMS  OF  TRANS- SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE-BETA-HYDROXYLASE  INHIBITORS 

253450  04-04 
DOPAMINE-DEPENDENT 

EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-04 
DOPAMINE-INDUCED 

THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  OOG. 

237160  02-03 
DOPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE- 
NUCLEUS.  (PH.D.  DISSERTATION). 

238080  02-13 
A  DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP 

238717  03-04 
IMPORTANCE  OF  O-METHYLATION  IN  DOPAMINE-INDUCED  MOTOR  AND 
BEHAVIORAL  PHENOMENA. 

251143  04-04 
DOPAMINERGIC 

DOPAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS. 

227703  01-04 
BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION: 
POSTSYNAPTIC  SUPERSENSITIVITY? 

229434  01  03 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RAT 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02-03 
EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS. 

233973  02-03 
THE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 

(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE. 

233974  02-11 
CLINICAL  STUDIES  OF  DOPAMINERGIC  MECHANISMS. 

233975  02-11 
EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 

ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS 

236519  02-03 
DOPAMINERGIC  EFFECTS  OF  PHENCYCLIDINE  IN  RATS  WITH 
NIGROSTRIATAL  LESIONS 

236523  02-04 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
EFFECTS  OF  DOPAMINE  (DA)  DERIVATIVES  ON  CENTRAL  DOPAMINERGIC 
MECHANISMS. 

238700  03-03 


Off 
7^ 


0 


S-115 


Subject  Index 


Psychopharnacology  Abstrac 


DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
D-AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  1- 
HYDROXY-3-AMINO-PYRROLIDONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04-03 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS:  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS 

247211  04-03 
APOMORPHINE-INDUCED  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS. 

247875  04-04 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN. 

248286  04-03 
DOPAMINERGIC  NATURE  OF  AMPHETAMINE-INDUCED  PECKING  IN 
PIGEONS. 

248408  04-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
SYNTHESIS  AND  DOPAMINERGIC  ACTIVITY  OF  (+  OR  -)-,  (-1^)-,  AND  (-)  2- 
DIPROPYLAMINO-5-HYDROXYTETRAHYDRONAPHTHALENE. 

248650  04-02 
ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-P-TYROSINE. 

249002  04-03 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04-04 
EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINERGIC  MECHANISMS. 

249305  04-06 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-03 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 
CATALEPSY  IN  THE  RAT. 

250084  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 

IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 

BY  BACLOFEN  AND  IIS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  04-03 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 
DORSAL 

DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01-03 
D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272  03-04 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 
DORSAL  ROOT  POTENTIALS 

239982  03-03 


AROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORS/ 
HIPPOCAMPUS. 

247420  04 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEU 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P-CHLOROPHENYLALANI 
AND  OF  ALPHA-METHYL-P-TYROSINE. 

250982  04 
DORSALIS 

EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THI 
NUCLEUS  RAPHE  DORSALIS. 

249249  04 
DORSET 

REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKAC 
IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21ST  1975 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  04 
DORSOLATERAL 

BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04 
DOSAGE 

FLUPENTHIXOL-DECANOATE  -  CONTROLLED  INVESTIGATION  CONCERNI 
DOSAGE. 

226408  01 
VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES  -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINK 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUII 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT 

230877  01 
PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY. 

232623  02 
PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD. 

23431 1  02 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239679  03 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239680  03 
OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 

PSYCHOTROPICS  DRUGS. 

239681  03 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS. 

242269  03 
IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AN 
ELECTROCARDIOGRAPHIC  ABNORAAALITIES  IN  HYPERACTIVE 
CHILDREN. 

245001  04 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  Oh 
STEADY-STATE  BLOOD  LEVELS. 

245842  04 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04 
CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

252954  04 
PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  01 

NEUROLEPTIC  DOSAGE. 

252955  04 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS. 

253018  04 
DOSE 

A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

227914  01- 
LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01- 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01- 


5-116 


UME  14,  SUBJECT  INDEX 

IMPLIFIEO  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01  16 
lEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES. 

239858  03-03 
IICOTINE-LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

239865  03-04 
1  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESSION 
ANXIETY  STATES. 

239938  03-10 
ONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-04 
lALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
I  CONTROLLED  COMPARATIVE  TRIAL  OF  A  COMBINATION  OF 
OPIPRAMOL  AND  CLOMIPRAMINE  AND  A  HIGHER  DOSE  OF 
CLOMIPRAMINE  ALONE. 

245468  04-09 
ilNGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIVE 
NEUROSIS. 

246300  04-10 
'ARAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTER 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04-17 
VHAT  IS  THE  PROPER  DOSE  OF  STIMULANT  DRUGS  IN  CHILDREN?. 

247376  04-17 
JALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA   -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
;TUDIES  on  single  dose  tolerance  DEVELOPMENT  TO  MORPHINE  IN 
MICE. 

249288  04-04 
lAETHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 
■RELATED 
)OSE-RELATED  EFFECTS  OF  METRAZOL  ON  RETENTION  AND  EEG. 

242733  03-04 
)OSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS. 

247206  04-04 
-RESPONSE 

\NGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  AND 
BIOCHEMICAL  ANALYSIS.  (PH.D.  DISSERTATION). 

227106  01-04 
)OSE-RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 
SECRETION  OF  ADH:  EFFECTS  OF  CLOFIBRATE  AND  CARBAMAZEPINE. 

232638  02-13 
)OSE-RESPONSE  EFFECTS  OF  SCOPOLAMINE  ON  ACTIVITY  IN  AN  OPEN- 
FIELD. 

237728  02-04 
:aRBACHOL  elicited  mouse-killing  BY  RATS:  CIRCADIAN  RHYTHM 
AND  DOSE-RESPONSE. 

238006  02-04 
\N  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
)OSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 
FASTE  AVERSIONS  INDUCED  BY  D-AMPHETAMINE:  DOSE-RESPONSE 
RELATIONSHIP. 

242882  04-04 
)OSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT. 

246313  04-04 
S 

FHE  LONG-TERM  USE  OF  HIGH  DOSES  OF  FLUPHENAZINE-ENANTHATE 
AND  FLUPHENAZINE-DECANOATE. 

225936  01-08 
FHE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE. 

236249  02-03 
VOVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 


Subject  Index 


ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-04 
THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 
MONOAMINE-OXIDASE  IN  MAN. 

237927  02-13 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORAAAL 
VOLUNTEERS. 

248629  04-13 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 
SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MICE 
SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL. 

250284  04-04 
PHARAAACOKINETICS  OF  METHOTRIMEPRAZINE  AFTER  SINGLE  AND 
MULTIPLE  DOSES. 

250422  04-07 
COMPARISON  OF  LOW  DOSES  OF  HALOPERIDOL  AND  DIAZEPAM  IN 
ANXIETY  STATES. 

250491  04  10 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  BY 
DIFFERENT  DOSES  OF  L-DOPA. 

251214  04-03 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY. 

251986  04-14 
DOTHIEPIN 

SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  WITH  PARTICULAR 
REFERENCE  TO  DOTHIEPIN. 

226897  CM  5 
THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAAAINE  (TOFRANIL)  CLINICAL 
TRIAL. 

226899  01-09 
THE  USE  OF  DOTHIEPIN  IN  THE  TREATMENT  OF  PSYCHONEUROTIC 
ANXIETY  WITH  DEPRESSIVE  FEATURES. 

237774  02-10 
A  RETROSPECTIVE  ASSESSMENT  OF  THE  LONG-TERM  EFFECTS  OF 
DOTHIEPIN. 

239820  03-09 
DOUBLE-BUND 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA. 

225867  01-08 
A  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 
THE  TREATMENT  OF  STATES  OF  ANXIETY. 

226410  01-10 
SHORT-TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PLACEBO  IN  DEPRESSION:  A  DOUBLE-BLIND  STUDY 

227214  01-09 
EFFECTS  OF  A  PROCAINE  PREPARATION  (GER0VITAL-H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  STUDY. 

227330  01-11 
A  DOUBLE-BLIND  TRIAL  OF  LITHIUM  CARBONATE  AND  HALOPERIDOL  IN 
HUNTINGTONS-CHOREA. 

227550  01-11 
CAFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON. 

227571  01-11 
VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS 

228223  01-08 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01-11 
A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  01-09 
A  DOUBLE-BLIND  COMPARISON  OF  PENFLURIDOL  (EASER)  WITH 
PIMOZIDE  IN  SCHIZOPHRENIA. 

229026  01-07 
DOUBLE-BLIND  CONTROLLED  STUDY  OF  L-DOPA  THERAPY  IN 
SCHIZOPHRENIA. 

229064  01-08 


iS" 


I 


s-n7 


Subject  Index 


Psychopharmacology  Abstrac 


DISCOURSE  ON  THE  DOUBLE-BLIND  METHOD.  INSTITUTION  AND 
EXPERIMENTATION:  )9366-RP. 

229078  0116 
EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE-BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  01-11 
DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS 

229368  01-11 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BUND  CLINICAL  STUDY. 

229504  01-11 
A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN-RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693  01-09 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS.  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 
DOUBLE-BLIND  TRIAL  OF  SINTAMIL  IN  DEPRESSION. 

231603  01-10 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE  BLIND  CONTROLLED  TRIAL. 

231609  01-08 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE-BLIND 
STUDY. 

232781  02-08 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02-09 
LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY:  DOUBLE-BLIND  TRIAL 

236658  02-10 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS. 

237828  02-08 
A  DOUBLE-BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS. 

238981  03-10 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 

RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03-11 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 

FLUPENTHIXOLDECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA. 

238996  03-08 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE-BLIND  TRIAL. 

239348  03-09 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS, 

239818  03-10 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN, 

240032  03-09 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-11 
THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY:  DOUBLE-BLIND 

STUDY  OF  HYDROSARPAN-711  IN  80  SUBJECTS. 

240166  03-11 
LORAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

241274  03-14 
CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTION: 
OPEN  AND  DOUBLE-BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  03-14 
MAPROTILINE  (LUDIOMIL,  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  03-09 


A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 
(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03 

THE  QUALITY  OF  INTELLECTUAL  LIFE:  DOUBLE-BLIND  STUDY  OF 
HYDROSARPAN-711  INVOLVING  80  SUBJECTS. 

242899  04 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-711  IN  A  HOSPICE  ENVIRONMENT. 

242900  04 
THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN-MAGNESIUM-OROTATE 

COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 
STUDY. 

243180  04 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHREh 
PATIENTS. 

245014  04 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE, 

247030  04 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLINI 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04 
DOUBLE-BLIND  PLACEBO  CONTROLLED  EFFICACY  STUDY  OF  KETAZOLA 
(U-28774). 

248532  04 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT, 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BUND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  04 

OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  ( 

THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBI 

IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENT 

248975  04 
A  DOUBLE-BUND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTI 

SCHIZOPHRENICS. 

248976  04 
LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERl 

(A  DOUBLE-BLIND  CROSSOVER  STUDY). 

250193  04 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDV 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04 
COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE-BLIND  MULTICENTRE  TRIAL. 

251118  04 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONI 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE, 

251374  04 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04 
CARBAMAZEPINE  (TEGRETOL)  -  A  DOUBLE-BLIND  COMPARISON  WITH 
PHENYTOIN  (DILANTIN). 

251937  04 
A  THREE- YEAR  DOUBLE-BLIND  INVESTIGATION  OF  PIMOZIDE  VERSUS 
FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  04 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  ANC 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS, 

253051  04 
DOUBLE-PULSE 

AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH.( 
DISSERTATION), 

241129  03 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04 
DOWNS-SYNDROME 

REVIEW  OF  DRUG  TREATMENT  FOR  DOWNS-SYNDROME  PERSONS. 

239074  03- 
DOXEPIN 

A  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 
THE  TREATMENT  OF  STATES  OF  ANXIETY. 

226410  01 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01- 
EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 
NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES. 

230818  01- 


S-118 


>LUME  14,  SUBJECT  INDEX 


Subject  Index 


OOXEPIN  IN  THE  TREATMENT  OF  OBSESSIVE-COMPULSIVE  NEUROSIS. 

235826  02-10 
EFFICACY  AND  TOLERANCE  OF  INJECTABLE  DOXEPIN. 

237775  02-10 

EFFECT  OF  5,5  DIPHENYLHYDANTOIN  (DPH)  ON  LEARNING  AND  MEMORY 
IN  CATS. 

229680  01-04 
DPH-INTOXICATION  -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03-15 
(.INTOXICATION 
DPH-INTOXICATION  -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03-15 

3,4  DIHYDROXYPHENYIAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
■ASSISTED 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION) 

228686  01-11 
\W-A-MAN 
DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02-10 
■AMS 
SEROTONIN:  THE  CRUCIAL  SUBSTANCE  THAT  TURNS  DREAMS  ON  AND 
OFF. 

241505  03-12 
NK 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO, 
DRUG  AND  A  FOOD  DRINK. 

239059  03-14 
INKING 
ANGIOTENSIN-INDUCED  DRINKING  IN  THE  CAT:  A  DOSE-RESPONSE  AND 
BIOCHEMICAL  ANALYSIS.  (PH.D.  DISSERTATION). 

227106  01-04 
PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

231700  01-03 
PITRESSIN-INDUCEO  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE. 

242746  04-04 
ANALYSIS  OF  HORMONAL  MEDIATION  OF  DRINKING  BEHAVIOR. 

244469  04-04 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

245929  04-02 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION. 

249032  04-04 
THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04-03 
IVE 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHIOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04-04 
IVERS 
THE  EFFECT  OF  GRANDAXIN  ON  LORRY  DRIVERS. 

252446  04-14 
IVING 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 
FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL,  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING. 

229907  01-14 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING, 

241417  03-15 
MENTAL  ILLNESS  AND  SIMULATED  DRIVING:  BEFORE  AND  DURING 
TREATMENT. 

241425  03-15 
THE  INTERACTION  BETWEEN  DRUGS,  ALCOHOL  AND  DRIVING  AN 
AUTOMOBILE. 

244453  04-15 
I 
CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORMANCE  IN 
THE  RAT. 

226305  01-04 


COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AND 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-04 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORAAAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION). 

241681  03-04 
DROPERIDOL 

THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  MAN. 

232531  01-13 
THE  ACTION  OF  CHLORPROAAAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02-03 
ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 
DROWSINESS 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM. 

225722  01-15 
DRUG 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM, 

225722  01-15 
DRUG  ACTION  IN  MANAGEMENT  OF  HYPERTENSION, 

225766  01-11 
EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  DRUG  METABOLISM. 

226829  01-13 
DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  01-03 
OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PHD. 
DISSERTATION), 

226992  01-04 
VIVALAN:  DRUG  PROFILE, 

227227  01-07 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS, 

227382  01-06 
DRUG  INTERACriONS. 

227412  01-17 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 
LIVER. 

227696  01-03 
GUIDELINES  FOR  ANTIPSYCHOTIC  DRUG  USE. 

227731  01-17 
A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP, 

227914  01-10 
ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT, 

228208  01-15 
NEW  DRUG  THERAPY  IN  THE  FIELD  OF  PSYCHIATRY. 

228211  01-17 
ISSUES  CONCERNING  DRUG  THERAPY  IN  THE  MENTAL  HOSPITAL. 

228322  01-17 
AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PH.D, 
DISSERTATION), 

228726  01-11 
DRUG  TREATMENT  IN  A  REHABILITATION  CENTER  FOR  CHRONIC 
ALCOHOLICS. 

228908  01-11 
THE  USE  OF  TRANQUILIZERS  IN  THE  TREATMENT  OF  MIXED  DRUG 
ABUSE. 

229044  01-11 
EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE-BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  01-11 
EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-03 
A  CONTRIBUTION  TO  PSYCHOACTIVE  DRUG  MEASUREMENT  TECHNIQUES. 

229442  01-16 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 
PREDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 
DEPRESSED  OUTPATIENTS, 

229449  01-09 
CONCEPTUAL  IMPLICATIONS  OF  DRUG  AND  NONSOMATIC  TREATMENT 
INTERACTION  STUDIES. 

229452  01-17 


as 


s-n9 


Subject  Index 


Psychopharmacoiogy  Abstrac 


A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  ^HE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS. 

229458  01-11 
DRUG  SCHEDULE  INTERACTIONS  AND  INTERCURRENT  BEHAVIOR. 

229479  01-04 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-10 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01-04 
EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01-04 
A  CLINICAL  TRIAL  WITH  NOMIFENSIN,  A  NEW  ANTIDEPRESSANT  DRUG. 

231035  01-09 
DRUG  TREATMENT  OF  MENTAL  DISORDERS. 

23111301-17 
PHARMACOLOGICAL  STUDIES  OF  DRUG  ACTION  ON  CNS,  WITH  SPECIAL 
REFERENCE  TO  EFFECTS  OF  MAPROTILINE. 

231316  01-04 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAAAATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I.  THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01-17 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  II.  FIVE 
EXPERIMENTS. 

232518  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  Ill    THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  01-13 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  V.  SUMMARY 
AND  CONCLUSIONS. 

232521  01-14 
NUTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENTAL 

DISABILITIES. 

232815  02-15 
INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02-17 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02- 14 
ANALYSIS  OF  VARIANCE  STUDY  OF  A  SLEEP  INDUCING  DRUG. 

233698  02-07 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02-17 
DIFFERENTIAL  DRUG  EFFECTS  ON  BRAIN  SEROTONERGIC  SYSTEMS. 

234805  02-03 
GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION. 

234811  02- 12 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02-17 
IMPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02-17 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 
PSYCHIATRIC  HOSPITAL. 

235545  02-17 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
CHANGES  IN  PSYCHOACTIVE  DRUG  USE  AMONG  ADULTS  IN 
METROPOLITAN  TORONTO  -  1971-1974. 

236046  02-17 
RECENT  DEVELOPMENTS  IN  THE  DRUG  TREATMENT  OF  SCHIZOPHRENIA. 

236751  02-08 
ASSISTING  MULTIPLE  DRUG  ADDICTS.  PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY. 

237095  02-11 
DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE   (PH.D.  DISSERTATION). 

238159  02-03 


1 


DRUG  PERMEATION  THROUGH  MEMBRANES  V:  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  02 
DOPAMINE  AND  PSYCHOACTIVE  DRUG  ACTION:  A  FURTHER 
EVALUATION. 

238768  03 
CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM. 

238787  03 
THERAPEUTIC  ATTEMPTS  WITH  LITHIUM  IN  YOUNG  DRUG  ADDICTS. 

238988  03 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACES 
DRUG  AND  A  FOOD  DRINK. 

239059  03 
REVIEW  OF  DRUG  TREATMENT  FOR  DOWNS- SYNDROME  PERSONS. 

239074  03 
DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PH.D.  DISSERTATION). 

239533  03 
DEPRESSED  5-HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTI' 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03 
INTRODUCTION:  THE  CONTROL  OF  BEHAVIOR  BY  CONSEQUENT  DRUG 
INJECTIONS. 

240009  03 
STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 
CONTROL  BEHAVIOR. 

24001 1  03 
INTRODUCTION:  COMPLEX  SCHEDULES  OF  DRUG  INJECTION. 

240012  03 
PHARAAACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 

DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03 
DRUG  EFFECTS  AND  CONCURRENT  PERFORMANCES. 

240016  03 
INTRODUCTION:  SCHEDULES  OF  TERMINATION  OF  DRUG  INJECTIONS. 

240017  03 
DRUG  EFFECTS  AND  THE  ENVIRONMENTAL  CONTROL  OF  BEHAVIOR. 

240021  03 
DRUG  INJECTIONS  AS  NEGATIVE  REINFORCERS. 

240022  03 
DRUG  TREATMENT  IN  PSYCHIATRY. 

240086  03 
EXPERIMENTAL  HUAAAN  DRUG  SELF-ADMINISTRATION:  METHODOLOO 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE. 

240831  03 
DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PH.D. 
DISSERTATION). 

240934  03 
THEORETICAL  AND  METHODOLOGICAL  CONSIDERATIONS  ON  DRUG 
DISCRIMINATION  LEARNING. 

241228  03 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234  03 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03 
DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN  A 
CHOLINESTERASE  INHIBITORS. 

242737  03 
RATE  DEPENDENT  DRUG  EFFECTS:  POSSIBLE  STATE-DEPENDENCY. 

242739  03 
DRUG-INDUCED  CONDITIONED  SUPPRESSION:  SPECIFICITY  DUE  TO  DRU 
EMPLOYED  AS  UCS. 

242750  04 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDROCANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04 
DEATH  AND  DRUG  TREATMENT  IN  A  PSYCHIATRIC  HOSPITAL. 

243716  04 
DRUG  THERAPY  IN  CHILD  CARE. 

243897  04 
PSYCHOPHARMACOLOGIC  AGENTS:  EFFECT  ON  DRUG  METABOLISM. 

244060  04 
DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES. 

244063  04 
PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS. 

244072  04 
PERSONALITY  FACTORS  AND  DRUG  EFFECTS  IN  A  CONTROLLED  STUDY 
OF  CYCLAZOCINE. 

244298  04- 


S-120 


/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  II;  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES.  (UNPUBLISHED  PAPER). 

244574  04-09 
EFFECTS  OF  DRUG  STATE  CHANGE  ON  DISCRIMINATION  PERFORMANCE. 

244679  04-04 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
(AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG, 

245295  04-04 
DRUG  DISCRIMINATION  IN  RATS:  THE  EFFECTS  OF  PHENCYCLIDINE  AND 
DITRAN. 

245297  04-04 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RATS 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04-04 
DRUG  THERAPY:  SULFASALAZINE. 

245307  04-13 
DEPRESSION,  DELUSION  AND  DRUG  RESPONSE. 

245784  04-09 
OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
DRUG  THERAPY:  NEUROLOGIC  SYNDROMES  ASSOCIATED  WITH 
ANTIPSYCHOTIC  DRUG  USE. 

246061  04-15 
DRUG  INTERACTIONS. 

246296  04-15 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION. 

246996  04-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL, 

247032  04-03 
DRUGS  AND  PUNISHED  RESPONDING  VI:  BODY  WEIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS. 

247845  04-04 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 

DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
THIRD  PSYCHOACTIVE  DRUG  USAGE  GUIDE. 

247880  04-17 
CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN  -  AN  EMPIRICAL  STUDY. 

248593  04-11 
INHIBITION  OF  DRUG  METABOLISM  BY  FLUOXETINE, 

248605  04-02 
A  PRACTICAL  CLASSIFICATION  OF  UNTOWARD  DRUG  EFFECTS. 

248909  04-15 
THE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA:  FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY 

249248  04-03 
DRUG  THERAPY  IN  MENTAL  HANDICAP. 

249525  04-17 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
COMPENDIUM  OF  PHARMACOLOGY  DRUG  CHARTS. 

249768  04-17 
EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  04-06 
DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 
INOOLEAMINES  IN  BRAIN. 

250081  04-03 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DORA 
TREATED  MICE. 

250656  04-03 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE:  RELATION 
TO  TISSUE  LEVELS  OF  THE  DRUG 

251131  04-03 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
SOME  PHARMACOLOGICAL  ASPECTS  OF  DRUG  DEPENDENCE. 

251561  0413 


URGENT  PHARMACOTHERAPY  FOR  DRUG  ABUSE. 

251755  04-17 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
DRUG  RESEARCH  AND  THE  QUESTION  OF  CONSENT. 

252314  04-17 
RECENT  ADVANCES  IN  THE  DRUG  TREATMENT  OF  THE  FUNCTIONAL 
PSYCHOSES. 

252653  04-09 
DRUG  AND  PSYCHOTHERAPY  INTERACTIONS  IN  DEPRESSION. 

252941  04-09 
PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 
COUNTRY. 

252990  04-17 
DIGITALIS:  CLINICAL  IMPLICATIONS  OF  NEW  FACTS  ABOUT  AN  OLD 
DRUG. 

253495  04-15 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS. 

253693  04-03 
DRUG-INDUCED 

EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01-04 
INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS. 

230878  01-04 
DOSE-RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 

SECRETION  OF  ADH:  EFFECTS  OF  CLOFIBRATE  AND  CARBAAAAZEPINE. 

232638  02-13 
DRUG-INDUCED  STEREOTYPED  BEHAVIOR:  SIMILARITIES  AND 
DIFFERENCES. 

233963  02-03 
DRUG-INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT. 

235866  02-03 
EFFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG-INDUCED  HYPOTHERMIA 
IN  MICE  AND  RATS, 

237100  02-03 
INHIBITION  OF  DRUG-INDUCED  ANOREXIA  IN  RATS  BY  METHYSERGIDE 

237745  02-04 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-03 
CORTICAL  DISINHIBITION:  A  POSSIBLE  MECHANISM  FOR  DRUG-INDUCED 
HALLUCINATIONS. 

238830  03-03 
ANTIDOPAMINERGIC  AND  ANTIMUSCARINIC  EFFECTS  OF 
DIBENZODIAZEPINES:  RELATIONSHIP  TO  DRUG  INDUCED 
PARKINSONISM. 

241248  03-03 
SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIL  (MERIONES-UNGUICULATUS). 

241311  03-04 
THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03-03 
PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PH.D.  DISSERTATION). 

241994  03-04 
DRUG-INDUCED  CONDITIONED  SUPPRESSION:  SPECIFICITY  DUE  TO  DRUG 
EMPLOYED  AS  UCS. 

242750  04-04 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D  GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
A  CONTROLLED  TRIAL  OF  AMANTADINE  IN  DRUG-INDUCED 
EXTRAPYRAMIDAL  DISORDERS. 

244701  04-15 
DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04-03 
DRUG-INDUCED  EXTRAPYRAMIDAL  EFFECTS  -■  A  REVIEW. 

246187  04-15 


'•n 


SSL 

^:. 


;??. 


S-121 


Subject  Index 


Psychopharmacology  Abstracts 


DRUG  INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT 

249250  04-03 
EFFECTS  OF  DIAZEPAM  ON  SIX  DRUG-INDUCED  LOCOMOTOR 
HYPERACTIVITIES  IN  MICE. 

249677  0404 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
HYPOTHALAMIC  LESIONS  AND  DRUG-INDUCED  ANOREXIA 

250938  04-03 
MANAGEMENT  OF  PATIENTS  WITH  SUSPECTED  DRUG-INDUCED 
PSYCHOSES 

252733  04-15 
DRUG-INFORAAATION-CENTER 

TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG- 
INFORMATION-CENTER;  THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04-13 
DRUG-NAIVE 

EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03-04 
DRUG-REINFORCED 

FOOD  AND  DRUG-REINFORCED  RESPONDING:  EFFECTS  OF  DITA  AND  D- 
AMPHETAMINE 

227127  01-04 
DRUGGING 

DRUGGING  TO  SUPPRESS  BEHAVIOR. 

252315  04-17 
DRUGS 

ACUTE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FOR 
ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS. 

225572  01-03 
DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOL  CHILDREN. 

225783  01-14 
fSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-08 
PSYCHOTROPIC  DRUGS  AND  THE  HUMAN  EEG 

226725  01-16 
INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 
CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-03 
DEPLETION  OF  S-ADENOSYL-L-METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS. 

226850  01-03 
RATE-DEPENDENT  EFFECTS  OF  DRUGS  ON  THE  VARIABLE-INTERVAL 
BEHAVIOR  OF  RATS. 

226854  01-04 
SIDE  EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  WITH  PARTICULAR 
REFERENCE  TO  DOTHIEPIN. 

226897  01-15 
PSYCHOTROPIC  DRUGS  AND  IMPARIMENT  OF  PSYCHOMOTOR 
FUNCTIONS 

227136  01-15 
TESTING  PSYCHOTROPIC  DRUGS  IN  GENERAL  PRACTICE. 

227223  01-16 
TRANSPLACENTAL  EFFECTS  OF  DRUGS  ON  HEARING,  VISION,  AND 
BEHAVIOUR 

227391  01-05 
THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG- 
STAY  PSYCHIATRIC  PATIENT. 

227461  0117 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  10 
ANTIPSYCHOTIC  DRUGS 

227808  01-15 
A  COMBINATION  OF  ANTIANXIETY  DRUGS:  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP, 

228207  01  10 
HOW  DRUGS  ACT    -11    DRUGS  AND  SLEEP. 

228997  01-13 
SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

22911201-17 
ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01-14 
DRUGS  FOR  MENTAL  DISORDERS  OF  OLD  AGE. 

229315  01-11 
THE  IMPORTANCE  OF  REINFORCEMENT  SCHEDULES  IN  DETERMINING 
EFFECTS  OF  DRUGS. 

229428  01-04 
STRATEGIES  OF  BASIC  RESEARCH  IN  DEVELOPMENT  OF  DRUGS. 

229429  01-06 


STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01-16 
DRUGS  AND  PSYCHOTHERAPY  IN  DEPRESSION  REVISITED:  ISSUES  IN  THE 
ANALYSIS  OF  LONG-TERM  TRIALS. 

229450  01-09 
RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS:  PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  01-11 
DRUGS,  BEHAVIOR,  AND  THE  CHOLINERGIC  NERVOUS  SYSTEM. 

229485  01-04 
ANALYSIS  OF  DRUGS  AND  PSYCHOACTIVE  PHENOLIC  AMINES. 

229486  01-03 
MODIFICATION  OF  THE  FRUSTRATION  EFFECT  WITH  DRUGS. 

229487  01-04 
DRUGS,  AGGRESSION,  AND  NEUROCHEMISTRY. 

229488  01-04 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  BRAIN  NUCLEAR  RNA. 

229494  01-03 
THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 
PSYCHIATRIC  INSTITUTIONS. 

229558  01-17 

FLUPHENAZINE-DECANOATE  IN  ASSOCIATION  WITH  OTHER 
PSYCHOTROPIC  DRUGS  (PRELIMINARY  NOTE). 

229561  01-17 
THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORAAANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY. 

229650  01-14 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  ON  PSYCHOTROPIC  DRUGS. 

229725  01-14 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES    -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01-10 
CLINICAL  USE  OF  DRUGS  FOR  SLEEP  DISTURBANCES. 

230119  01-17 
BEHAVIORAL  EFFECTS  OF  ANTIEPILEPTIC  DRUGS. 

230368  01-11 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
POISONING  BY  TRICYCLIC  ANTIDEPRESSANT  DRUGS:  GENERAL  AND 
PHARMACOKINETIC  CONSIDERATIONS. 

230820  0) -15 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  AAADOPAR  AND  PLACEBO. 

230823  01  08 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01  03 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 
RESEARCH. 

231066  01-14 

THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS. 

231069  01-04 
DRUGS  AND  BEHAVIOR:  A  PRIMER  IN  NEUROPSYCHOPHARMACOLOGY. 

23122701  17 
THE  USE  OF  ANTIDEPRESSANT  DRUGS  IN  SCHIZOPHRENIA. 

231277  01-08 
CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS  -■  A 
RISK  IN  THE  USE  OF  THESE  DRUGS. 

23131701-15 
STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 
ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PH.D. 
DISSERTATION). 

231438  01-03 
SIDE-EFFECT'=  OF  PSYCHOTROPIC  DRUGS. 

231991  01-15 
ADVERSE  REACTIONS  ASSOCIATED  WITH  MOOD-ALTERING  DRUGS. 

231995  01  15 
THE  THERAPY  OF  AUTONOMIC  REGULATORY  DISTURBANCES  THROUGH 
DRUGS 

232260  01  15 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 


S-122 


4 


HUME  14,  SUBJECT  INDEX 


Subject  Index 


ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS. 

232609  02-04 
ANXIOLYTIC  DRUGS. 

232704  02-10 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINEINDUCED  PGO  ACTIVITY). 

233077  02-04 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02- 14 
INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACUTE 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS. 

233377  02-12 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02-14 
DRUGS  FOR  EMOTIONAL  DISORDERS:  CURRENT  PROBLEMS. 

233514  02-17 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARMACOKINETICS  OF 

PSYCHOTROPIC  DRUGS. 

233682  02-17 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 

VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 

PSYCHOTROPIC  DRUGS. 

233684  02-17 
THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 

CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02-11 
XEROSTOMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 

THEIR  TREATMENT  WITH  TPMP  (TRITHIO-P-METHOXYPHENYLPROPENE). 

233718  02-15 
THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 

MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-03 
CATECHOLAMINES,  DRUGS,  AND  BEHAVIOR:  MUTUAL  INTERACTIONS. 

233968  02-04 
DRUGS  IN  COMBINATION  WITH  OTHER  THERAPIES. 

234378  02-17 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

234797  02-09 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 
OF  VARIOUS  PSYCHOACTIVE  DRUGS, 

234810  0204 
INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WITH 
PSYCHOACTIVE  DRUGS  -  NEW  METHODS  IN  THE  ASSESSMENT  OF 
CHANGE. 

235355  02-17 
HOW  DRUGS  ACT  -  26:  DRUGS  AND  THE  MENTAL  STATE. 

235638  02-17 
A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS, 

235992  02-11 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS, 

236265  02-03 
PRACTICAL  CONSIDERATIONS  ON  TREATMENT  WITH  ANTIPSYCHOTIC 
DRUGS 

236359  02-08 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN, 

236370  0203 
TESTING  OF  NEW  PSYCHOTROPIC  DRUGS  ON  OUTPATIENTS, 

236811  02-17 
CLINICAL  USE  OF  ANTIANXIETY  DRUGS, 

237165  02-10 
METABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN, 

237700  02-03 


A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS, 

237701  02-04 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE, 

237703  02-04 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESIS. 

237711  02-04 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-03 
BA,RBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 
COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION 

237874  02-04 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE-LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-03 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE-  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  PROSTAGLANDIN  BIOSYNTHESIS 
IN  \'ITRO. 

238320  0203 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS, 

238734  03-03 
LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS 

238741  03-03 
EFFECTS  OF  SOME  PSYCHOTROPIC  DRUGS  ON  AGGRESSIVE  BEHAVIOR  IN 
RATS, 

238754  03-04 
EFFECTS  OF  TRANQUILIZER  DRUGS  ON  GABA  RELEASE  IN  VITRO, 

238779  03-03 
EFFECTS  OF  ANTIHISTAMINIC  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM, 

238838  03-03 
SLEEP  AND  HYPNOTIC  DRUGS:  THE  PHYSIOLOGY,  PHARMACOLOGY  AND 
CLINICAL  ASPECTS  OF  SLEEP. 

239029  03-14 
EFFECT  OF  ANTIDIURETIC  DRUGS  IN  RATS  WITH  LITHIUM-INDUCED 
POLYURIA. 

239041  03-05 
EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 
CONDITIONED  REFLEX  IN  THE  CAT 

239275  03-04 
MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL  HEALTH 
POLICY 

239298  03-17 
CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRUGS 
AS  CONDITIONED  STIMULI.  (PH.D.  DISSERTATION). 

239523  03-04 
REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS 

239641  03-11 
EFFECTS  IF  SOME  DRUGS  ON  PSYCHOSEXUAL  RESPONSE  IN  MAN. 

239646  03-14 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239679  03- 1 7 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239680  03  17 
OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 

PSYCHOTROPICS  DRUGS. 

239681  03-17 
OPEN  WITHDRAWAL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 

INDUCED  PARKINSON  SYNDROME 

239822  03-15 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
EVALUATION  OF  PSYCHOTROPIC  DRUGS:  A  SYMPOSIUM. 

239846  03-17 
DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03-04 


ftmrna 

ClKU 

31SB" 
t 


4  "I' 

285 


S-123 


Subject  Index 


CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 
INJECTIONS  OF  DRUGS 

240010  03-04 

PSYCHOTROPIC  DRUGS  AS  NEGATIVE  REINFORCERS. 

240020  0304 
TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS   - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS, 

240216  03-09 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS,  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS, 

240237  03-04 
PSYCHOTROPIC  DRUGS  AND  THE  ANTIDEPRESSED  PERSONALITY. 

240251  03-15 
ASTONIN-H  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 
PSYCHOTROPIC  DRUGS, 

240261  03-15 
THE  USE  AND  MISUSE  OF  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

240522  03-17 
STIMULANT  DRUGS  FOR  HYPERACTIVITY:  SOME  ADDITIONAL 
DISTURBING  QUESTIONS. 

240599  03-17 
PHARMACOLOGY  OF  PSYCHOACTIVE  DRUGS. 

240704  03-17 
EFFICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS. 

240706  03-17 
PSYCHOPHARMACOLOGICAL  DRUGS  IN  NEUROLOGY. 

240708  03- 17 
DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION^. 

240802  03-13 
A  PRIMER  ON  THE  CLINICAL  EVALUATION  OF  PSYCHOTROPIC  DRUGS. 

240838  03-17 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH  D,  DISSERTATION), 

241109  03-04 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3.5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN, 

241246  03-03 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS    -  I,  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER, 

241297  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I,  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES, 

241315  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II,  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE, 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III,  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES 

241317  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV,  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY, 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 

ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON. 

241347  03-03 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETADIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE, 

241349  03-04 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS, 

241367  03-04 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AMINES 
WITH  PSYCHOTROPIC  DRUGS, 

241378  03-04 
EFFECTS  OF  DRUGS  ON  TREMORINE-INDUCED  TREMOR, 

241379  03-04 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 

FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS, 

241389  03-03 


Psychopharmacology  Abstracts 

EFFECTS  OF  ANTIANXIETY  DRUGS  ON  CEREBRAL  MONOAMINE 
TURNOVER. 

241392  03-03 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5-HT) 
TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-03 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIAAALS   4TH 
REPORT.  COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTION, 
OF  THEIR  CHEMICAL  STRUCTURE, 

241428  03-12 
VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE,  (PH,D,  DISSERTATION), 

241689  030' 
ARE  NEUROLEPTIC  DRUGS  ANTICARCINOGENIC?. 

241736  03-1; 
COMPARISON  TRIAL  OF  TWO  ANTIPSYCHOTIC  DRUGS: 
CHLORPROMAZINE  AND  CLOZAPINE. 

241760  03-0f 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  S-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS, 

241979  03-0' 
BRAIN,  BEHAVIOUR  AND  DRUGS. 

242265  03-1; 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS. 

242269  03-1: 
PSYCHOTROPIC  DRUGS  FROM  THE  PRACTITIONERS  POINT  OF  VIEW. 

242720  03-1: 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS 

243483  04-0: 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 
ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  04-0: 
EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-0. 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-0: 

CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

243819  04-1 

ANORECTIC  DRUGS. 

243869  04-1 
DRUGS   AROUSAL,  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-1 
COURSE  AND  RESULTS  OF  TREATMENT  WITH  THREE  ACTIVATING 
NEUROLEPTIC  DRUGS. 

244049  04-0 

CENTRAL  ACTIONS  OF  HALLUCINOGENIC  DRUGS. 

244071  04-1 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS 

244215  04-0 
THE  INTERACTION  BETWEEN  DRUGS,  ALCOHOL  AND  DRIVING  AN 
AUTOMOBILE. 

244453  04-1 
A  METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG. 

244674  04-0 

MEDICAL  PRACTICE  WITHOUT  ANTIANXIETY  DRUGS. 

245524  04-1 
DEPRESSION  AND  ANTIDEPRESSANT  DRUGS. 

245646  04-0 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE: 
FLURAZEPAM  AND  PENTOBARBITAL. 

245652  04-1 
EFFECTS  OF  DRUGS  ON  EPILEPTIC  PATIENTS, 

245884  04-1 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEC 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE, 

246148  O4-0 
THE  EFFECTS  OF  TRANQUILLIZING  DRUGS  ON  TIMING  BEHAVIOUR  IN 

RATS, 

246306  04-0 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAII 


S-124 


>LUME  14,  SUBJECT  INDEX 

MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS 

246318  04-04 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 

AND  CIRCULATION  RELATED  TO  EEG  -■  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04-03 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 

COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 
REVERSAL  OF  THE  6-HYDROXYDOPAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS- 

246818  04-04 
EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  04-04 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04-13 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM. 

247012  04-03 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 

LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  04-03 
ANTIDEPRESSANT  DRUGS  AFFECT  DOPAMINE  UPTAKE. 

247021  04-03 
EFFECTS  OF  ANTIDEPRESSANT  DRUGS  ON  AMYGDALOID  AFTER- 
DISCHARGE  IN  RATS. 

247039  04-03 
DRUGS  HELP,  BUT  WONT  CURE,  MOST  HYPERACTIVE  CHILDREN. 

247143  04-17 
MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 
GROUPS  OF  RATS. 

247207  04-04 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY?. 

247359  04-15 
WHAT  IS  THE  PROPER  DOSE  OF  STIMULANT  DRUGS  IN  CHILDREN?. 

247376  04-17 
EFFICACY  AND  TOLERANCE  LIMITS  IN  THE  USE  OF  ANTIDEPRESSANT 
DRUGS. 

247543  04-09 
ANTIDEPRESSANT  DRUGS  AND  ANESTHESIA. 

247544  04-15 
CARDIOTOXIC  EFFECTS  OF  PSYCHOTROPIC  DRUGS. 

247784  04-15 
DRUGS  AND  PUNISHED  RESPONDING  VI:  BODY  WEIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS. 

247845  04-04 
THE  ANTINICOTINIC  EFFECTS  OF  DRUGS  WITH  CLINICALLY  USEFUL 
SEDATIVE  ANTIANXIETY  PROPERTIES. 

248009  04-03 
ANTICONVULSANT  ACTIVITY  OF  DELTA9-TETRAHYDR0CANNABIN0L 
COMPARED  WITH  THREE  OTHER  DRUGS, 

248283  04-02 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 

HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
DRUGS  DERIVED  FROM  CANNABINOIDS.  1.  NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROGEN 

AND  CARBOCYCLIC  ANALOGS, 

248647  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS    5,  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE  CHAINS 

248648  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  3.  SULFUR  ANALOGS, 

IHIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 

SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  04-02 
SIDE  EFFECTS  OF  DRUGS  AS  MODELS  OF  ILLNESSES. 

248850  04  15 
COMPLICATIONS  OF  PSYCHOACTIVE  DRUGS  AS  SEEN  BY  FAMILY 

PRACTITIONERS. 

248851  04  15 
INTRAGASTRIC  SELF  ADMINISTRATION  OF  PSVCHOACTIVE  DRUGS  BY 

THE  RHESUS  MONKEY 

249004  04  06 


Subject  Index 

EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA-MULATTA. 

249267  04-04 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION 

249286  04-03 
CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 
AMPHETAMINE-LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 
TEMPERATURE. 

249316  04  03 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE. 

249678  04-04 

INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04-04 
SELF-ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS:  THE 

EFFECTS  OF  UNLIMITED  ACCESS. 

250066  04-04 
RATE-DEPENDENT  EFFECTS  OF  DRUGS:  A  REVIEW  OF  THE  LITERATURE. 

250070  04-04 
A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY. 

250175  04-15 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-01 
ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS. 

250360  04-02 
INAPPROPRIATE  PRESCRIBING  OF  PSYCHOACTIVE  DRUGS. 

250711  04-17 
THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  04-11 

PSYCHOTROPIC  DRUGS  IN  SOMATIC  DISORDERS. 

250856  04  17 

BETA-ADRENERGIC  BLOCKING  DRUGS  FOR  ANXIETY. 

251155  04-14 
REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 

IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21  ST  1975. 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  04-10 
SOME  STUDIES  OF  BETA-RECEPTOR  BLOCKING  DRUGS  ON  THE  CENTRAL 

NERVOUS-SYSTEM  IN  MAN. 

251162  04-13 
INTERACTION  OF  ATROPINE  OR  METHYLATROPINIUM  WITH  FOUR 
EFFECTS  OF  TWO  CHOLINERGIC  DRUGS. 

251217  04-03 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA  RECEPTOR  OF  RAT  CEREBRAL  CORTEX. 

251394  04-03 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATION 
IN  RATS. 

251409  04-04 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS-INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN. 

251416  04-03 
DELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAAAINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE. 

251981  04  04 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  RHEUMATOLOGY 

252135  04-17 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  OTHER  PAINFUL  CONDITIONS. 

252142  04-17 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  A  PAIN  CLINIC 

252144  04  17 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT 

252221  04  03 
SLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS. 

252230  04-11 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 


as 


S-125 


Subject  Index 


Psychopharmacology  Abstract* 


ANTICHOLINERGIC  ACTIVITY  Of  ANTIPSYCHOTIC  DRUGS  IN  RELATION  TO 
THEIR  EXTRAPYRAMIDAL  EFFECTS 

252520  0405 
ACCIDENTAL  POISONING  WITH  PSYCHOTROPIC  DRUGS  IN  CHILDREN, 

252656  04-15 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES, 

252711  04-03 
MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD 

252847  04-08 
CULTURE,  MORBIDITY,  AND  THE  EFFECTS  OF  DRUGS, 

252991  04-17 
DOSAGE  OF  ANTIPSYCHOTIC  DRUGS, 

253018  04-08 
NEW  PSYCHOACTIVE  DRUGS  IN  PSYCHOGERIATRICS. 

253060  04-11 
STRATEGIES  AND  TACTICS  IN  THE  USE  OF  ANTIOBESITY  DRUGS, 

253315  04-11 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS, 

253394  04-04 
METHAQUALONE  WITH  PSYCHOTROPIC  DRUGS:  ADVERSE  INTERACTION. 

253531  04-15 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS, 

253693  04-03 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS,  II.  LSD. 

253700  04-03 
DUAL 

DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03-04 
DUALISM 

DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PH.D. 
DISSERTATION), 

240934  03-03 
DUODENAL 

EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPINEPHRINE 
BY  THE  RAT  DUODENAL  MUCOSA. 

241299  03-03 
DURATION 

DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC)  AND  1 1-0H-DELTA9- 
THC:  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS. 

238813  03-04 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS, 

241377  03-04 
THE  DURATION  OF  TOLERANCE  TO  THE  ANOREXIGENIC  EFFECT  OF 
AMPHETAMINE  IN  RATS, 

245298  04-03 
PENFLURIDOL  BLOCKADE  OF  APOMORPHINE:  DEPENDENCE  OF  DURATION 
ON  SPECIES  AND  ENDPOINT, 

248406  04-02 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9TETRAHYDR0CANNABIN0L  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT. 

249223  04-03 
NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA   -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 
INCIDENCE  OF  SIDE-EFFECTS. 

252006  04-08 
THE  DURATION  OF  MAINTENANCE  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

252763  04-08 
DURATIONS 

BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 
COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02-04 
DYNAMIC 

EFFECTS  OF  ALCOHOL  AND  MARIJUANA  ON  DYNAMIC  VISUAL  ACUITY:  I. 
THRESHOLD  MEASUREMENTS. 

235759  02-14 
DYNAMICS 

THE  DYNAMICS  OF  DOPAMINE  METABOLISM  IN  VARIOUS  REGIONS  OF 
RAT  BRAIN. 

238761  0303 


DYSFUNCTION 

BRAIN  DYSFUNCTION  IN  CHRONIC  SEDATIVE  USERS. 

VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

THIORIDAZINE  AND  SEXUAL  DYSFUNCTION. 


226922  01-1: 

233870  02-1 
236318  02- 1 


DYSFUNCTIONS 

DOES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 

239002  03-0 
DYSKINESIA 

MECHANISMS  OF  A  DYSKINESIA  INDUCTION  BY  1-3,4 
DIHYDROXYPEHNYLPIPERAZINE  IN  THE  RAT. 

239964  03-0 
TREATMENT  OF  PHENOTHIAZINE-INDUCED  DYSKINESIA. 

253038  04-1 
DYSKINESIAS 

ANTIDOPAMINERGIC  EFFECTS  OF  APOMORPHINE  IN  PATIENTS  WITH 
DYSKINESIAS. 

251958  04-1 
DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCCO- 
LINGUAL  DYSKINESIAS. 

252031  04-0 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-1 
DYSKINETIC 

NEUROLEPTIC  ANTAGONISM  OF  DYSKINETIC  PHENOMENA. 

248407  04-0 
A  METHOD  FOR  EXPLAINING  DYSKINETIC  MOVEMENTS  -  A  FILM 
PRESENTATION.  y 

253034  04-1 
DYSMENORRHOEA 

ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 
PREMENSTRUAL  TENSION. 

245136  04-1 
DYSPHORIC 

DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENI/: 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-1 
DYSRHYTHMIA 

SCHIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY:  TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEG. 

228068  01 -C 
VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

233870  02-1 
DYSTONIA 

LONG-TERM  LEVODOPA  THERAPY  FOR  TORSION  DYSTONIA. 

249367  04-1 
PHENYTOIN-INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN. 

251654  04-1 
DYSTONIC 

THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 
CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02-1 
A  PRIMATE  MODEL  OF  ACUTE  DYSTONIC  REACTION  TO  NEUROLEPTICS. 

241934  03-C 
D14S 

NEUROPHARMACOLOGICAL  STUDIES  ON  D145  (1,3  DIMETHYL-5- 
AMINOADAMANTAN). 

227133  Ol-O 
EASER 

A  DOUBLE-BLIND  COMPARISON  OF  PENFLURIDOL  (EASER)  WITH 
PIMOZIDE  IN  SCHIZOPHRENIA. 

229026  01 -C 
EATING 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  Ol-O 
REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  04-C 
ECLAMPSIA 

ROLE  OF  DIAZEPAM  IN  THE  AAANAGEMENT  OF  ECLAMPSIA. 

237898  02-1 
ECONOMY 

THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 
PSYCHIATRIC  INSTITUTIONS. 

229558  01-1 


ECT 


EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01 -C 


S-126 


VOLUME  14,  SUBJECT  INDEX 

INTRAVENOUS  TRANQUILI IZATION  WITH  ECT. 


Subject  Index 


249537  04- 16 


CT-INOUCED 

DOES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 


EG 


239002  03-09 

PSYCHOTROPIC  DRUGS  AND  THE  HUMAN  EEC. 

226725  01  16 
EFFECTS  OF  CLONIDINE  AND  BS-100141  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS 

226728  01-03 
THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY. 

227385  01-04 
SCHIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY:  TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEG. 

228068  01-08 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01-03 
BEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS. 

233965  02-03 
CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  02- 13 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARIJUANA  ON  EEG 

PATTERNS  IN  CATS. 

235564  02-03 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWING  6- 

HYDROXYDOPAMINE  LESIONS. 

238735  03-03 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEG  IN  THE 
NATURALLY  EPILEPTIC  BEAGLE. 

238811  03-04 
ANXIETY  AND  EEG  ALPHA  ACTIVITY  IN  NEUROTIC  PATIENTS. 

239022  03-10 
EEG  SLEEP  STUDIES  OF  INSOMNIACS  UNDER  FLUNITRAZEPAM 
TREATMENT. 

239819  03-14 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES. 

239858  03-03 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (0RF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME 

241275  03-10 
THE  EFFECT  OF  MORPHINE  ON  THE  EEG  OF  THE  HYPOTHALAMUS  IN  THE 
RAT. 

241328  03-03 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  03-04 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  {III). 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390  03-03 
DOSE-RELATED  EFFECTS  OF  METRAZOL  ON  RETENTION  AND  EEG 

242733  03-04 
THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04- 1 3 
EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  1- 
HYDROXY-3-AMINO-PYRROLIDONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04-03 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE. 

246148  04-04 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG   -  DIAZEPAM,  CLOMIPRAMINE, 
AND  CHLORPROMAZINE. 

246319  04-03 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA-MULATTA. 

249267  04-04 
EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-03 


THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS. 

249771  04- 10 
EEL 

SERUM  LITHIUM  MEASUREMENT  OF  THE  EEL  FLAMEPHOTOMETER. 

241777  03-16 
EFFECTIVENESS 

EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 
NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES. 

230818  01-10 
ON  THE  EFFECTIVENESS  OF  PSYCHIATRIC  AMBULATORY  STATIONS. 

234289  02-1 1 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  02-11 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 
PHENOBARBITAL  ON  THE  MOTIVATIONAI    PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  03-04 
METHODOLOGY  OF  THERAPEUTIC  EFFECTIVENESS  TRIALS  IN 
PSYCHOPHARMACOLOGY. 

240444  03-17 
THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN-AMGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 
STUDY. 

243180  04-11 
PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES. 

243985  04-09 
DIFFERENTIAL  PHARMACOTHERAPY  FOR  NEUROTIC  STATES 
(COMPARATIVE  EFFECTIVENESS  OF  BENZODIAZEPINE  DERIVATIVES). 

244349  04-10 
TRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS. 

244588  04-09 
ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 
PREMENSTRUAL  TENSION. 

245136  04-11 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE: 
FLURAZEPAM  AND  PENTOBARBITAL. 

245652  04-11 
THE  EFFECTIVENESS  OF  DIPHENHYDRAMINE  HCL  IN  PEDIATRIC  SLEEP 
DISORDERS 

251827  04-14 
EFFICIENCY 

HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01-04 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 
VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
EFFICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS. 

240706  03-17 
PSYCHOMETRIC  ASSESSMENT  OF  THE  THERAPEUTIC  EFFICIENCY  OF 
ANTIDEPRESSANT  AGENTS. 

251004  04  10 
EFFLUX 

ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX.  STRIATUM 
AND  HYPOTHALAMUS  SLICES 

238714  03-03 
EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 
EGYT-341 

THE  MAIN  PHARMACOLOGICAL  CHARACTERISTICS  OF  GRANDAXIN 
(TOFIZOPAM,  EGYT-341) 

252445  04-02 
EJACULATORY 

INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  04  04 
ELDERLY 

PROVIDERS  AS  PRESCRIBERS  ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY.  • 

227923  01-11 
MANAGEMENT  OF  THE  ELDERLY  HYPERTENSIVE  IN  FOUR  PRACTICE 

SETTINGS. 

227924  01-11 
DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 

CONFUSED  HOSPITALISED  PATIENTS 

229368  01-11 


as 


S-127 


Subject  Index 


Psychopharmacology  Abstracts 


RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS:  PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  CM  1 
PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS: 
EFFECT  OF  DIAZEPAM  IN  MALES 

229840  01  11 
CLINICAL  PSYCHOPHARMACOLOGY  AND  THE  ELDERLY  PATIENT. 

236300  02- 17 
UTILIZATION  OF  PIRACETAM  (NOOTROPIL)  IN  ELDERLY  WITH 
NEURASTHENIC  STATES 

236794  02-11 
THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY:  DOUBLE-BLIND 
STUDY  OF  HYDROSARPAN-711  IN  80  SUBJECTS. 

240166  03-11 
ADAPTIVENESS  AND  BEHAVIOR  OF  THE  ELDERLY  SUBJECT. 

242898  04-11 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-711  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 
CLINICAL  FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 
PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT. 

244476  04-11 
EFFECTS  OF  PROPRANOLOL  HYDROCHLORIDE  ON  LEARNING  IN  ELDERLY 
SUBJECTS. 

246440  04-14 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 

ELECTRIC 

THE  USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  ELECTRIC 
CARDIOVERSION. 

244451  04-11 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  04-04 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
ELECTRICAL 

COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS 

232483  01-04 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYOROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE. 

239829  03-04 
EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 
PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
ELECTRICALLY-INDUCED 

INTERACTION  OF  0ELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS. 

244894  04-04 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  AND 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  04-06 
GAMMA  AMINOBUTYRICACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION. 

253392  04-04 
ELECTROCARDIOGRAM 

CHLORPROMAZINE  INDUCED  ELECTROCARDIOGRAM  ABNORMALITIES. 

231037  01-08 
ELECTROCARDIOGRAMS 

EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESSION 
(INTRODUCTORY  REPORT), 

234046  0209 
ELECTROCARDIOGRAPHIC 

IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AND 
ELECTROCARDIOGRAPHIC  ABNORMALITIES  IN  HYPERACTIVE 
CHILDREN 

245001  04-14 

ELECTROCLINICAl 

ElECTROCLINICAL  CORRELATIONS  IN  PSYCHOPATHIES, 

236793  02-14 


ELECTROCONVULSIVE 

NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINS-F  IN  RAT 
CEREBRAL  CORTEX 

237921  02-03 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

241979  0304 
ELECTROCORTICAL 

BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORAAATION. 

241930  03-03 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS. 

24631 1  04-03 
BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFECTS  OF 
CHOLERA  TOXIN. 

252034  04-03 

ELECTRODERMAL 

THE  ACTION  OF  CHLORPROMAZINE  ON  THE  ELECTRODERAAAL  RESPONSE 
IN  THE  CAT, 

239963  03-03 

ELECTRODES 

INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI,  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
ELECTROENCEPHALOGRAM 

CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 
EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED  BY 
LITHIUM  CARBONATE. 

233499  02-15 
EFFECT  OF  AZAFEN  ON  THE  ELECTROENCEPHALOGRAM. 

234430  02-13 
EFFECTS  OF  ALPHA-METHYL-P-TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-03 

ELECTROENCEPHALOGRAPHIC 

ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATION 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES. 

22911501-13 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  ON  PSYCHOTROPIC  DRUGS. 

229725  01  14 
THE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY. 

230830  01-14 
ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS-TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  02-09 
REGIONAL  ROLE  OF  CATECHOLAMINES  IN  ALPHA  METHYL-M  TYROSINE 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROUSAL 

234067  02-03 
ELECTROENCEPHALOGRAPHIC  FINDINGS  IN  PHENCYCLIDINE 
INTOXICATION. 

236667  02  15 
THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS. 

237696  02-14 


S-128 


JME  14,  SUBJECT  INDEX 

\MMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 
CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS- 

237826  02-03 
CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 
ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
AOIENE  CHLORHYDRATE  (CIBA-34276-BA). 

247554  04-09 
FECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS. 

248629  04-13 
LATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
■LATIONSHIP  BETWEEN  THE  BEHAVIORAL  AND 
ELECTROENCEPHALOGRAPHIC  EFFECTS  OF  CHLORPROMAZINE  AND 
FLUPHENAZINE  IN  RATS. 

249623  04-02 
lOENCEPHALOGRAPHICAl 

LINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE 
THIOXANTHENES. 

227765  01-08 
LINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE  NEW 
HYPNOSEDATIVE  K-2004. 

243198  04-11 

ROLYTIC 

CTIVITY   AVOIDANCE  LEARNING  AND  REGIONAL  5- 
HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
OIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
ROMETRY 

ENMETRAZOLE  (DH-524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781  01-14 
RON 

LECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA. 

238486  02-16 
ROPHORETIC 

LECTROPHORETIC  APPLICATION  OF  LIGNOCAINE  TO  THE  CERVICAL  AREA 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES. 

244467  04-10 
ROPHYSIOLOGICAL 

;\ETHADONE-INDUCED  BEHAVIORAL  CHANGES:  CIRCULAR  MOVEMENTS, 
AGGRESSION,  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
>ROBLEMS  IN  THE  ELECTROPHYSIOLOGICAL  ANALYSIS  OF  THE  SITE  OF 
ACTION  OF  BENZODIAZEPINES 

232512  01-03 
;XCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02  03 
lYTOCHEMICAL  AND  ELECTROPHYSIOLOGICAL  STUDIES  OF  DOPAMINE  IN 
THE  CAUDATE-NUCLEUS.  (UNPUBLISHED  PAPER). 

238471  02-03 
ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 
DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN. 

246992  04-13 
CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
ELECTROPHYSIOLOGICAL  EFFECTS  OF  TRIIODOTHYRONINE  AND 
PROPRANOLOL. 

251984  04-13 

TROPHYSIOLOGY 

SLEEP  AND  ITS  DISTURBANCES  IN  THE  CHILD:  CONTRIBUTIONS  OF 
ELECTROPHYSIOLOGY. 

228091  01-11 
TROSHOCK 

INJECTIONS  OF  AMINO-ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASE 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03-03 
INHIBITORY  EFFECTS  IF  6  HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  04-03 
SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  04-05 
ATED 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

23551 1  02  04 


Subject  Index 

OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 
ELEVATED  ENVIRONMENTAL  TEMPERATURE. 

241925  03-03 

ELEVATION 

CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 

POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE  HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL  ALPHA-METHYL  P 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04-03 

EUCITATION 

ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS. 

249272  04-04 

ELICITING 

EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  04-04 

ELICITS 

CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE  OF 
SATIETY  IN  RATS. 

245612  04-02 

ELIMINATION 

SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 
PSYCHIATRIC  PATIENTS. 

238552  02-13 
DPH-INTOXICATION  -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03  15 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04-15 

BILIARY  ELIMINATION  OF  DIAZEPAM  IN  MAN. 

250423  04-13 

EMBRYO 

ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO    EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION 

228630  01-04 
EFFECTS  OF  DIAZEPAM  ON  THE  ISOLATED  CHICK  EMBRYO  HEART. 

230862  01  03 

EMBRYOGENESIS 

EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT. 

252018  04  03 

EMBRYONIC 

POSTNATAL  ELEVATION  Of  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY  STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA  METHYL-P 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT 

248697  04  03 
EMD-I6923 

CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD  16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02  10 

EMERGENCY 

PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES 

242751  04  17 

EMOTIONAL 

THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS 

231069  01  04 
DRUGS  FOR  EMOTIONAL  DISORDERS    CURRENT  PROBLEMS 

233514  02-17 

MENTAL  AND  EMOTIONAL  DISTURBANCE  WITH  PENTAZOCINE  (TALWIN) 

USE. 

233828  02-15 

SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT 

241363  03  04 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  THE 
REGULATION  OF  EMOTIONAL  REACTIVITY 

242544  03-03 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN 

244455  04  04 


pa 


5© 


S-129 


Subject  Index 


Psychopharmacology  Abstra 


ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY. 

253684  04-11 
EMOTIONALITY 

EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6  HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS, 

228142  01-04 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (II).  RELATIONSHIP 
BETWEEN  EMOTIONALITY  AND  DEFECATION. 

241371  03-04 
EMPHASIS 

INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES  -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
EMPIRICAL 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN    -  AN  EMPIRICAL  STUDY. 

248593  04-11 
EMPLOYED 

DRUG-INDUCED  CONDITIONED  SUPPRESSION;  SPECIFICITY  DUE  TO  DRUG 
EMPLOYED  AS  UCS. 

242750  04-04 
EMPLOYING 

HEROIN  ADDICTION.  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS 

239939  03-11 
ENAMINE 

NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 
PROPERTIES. 

232528  01-02 
ENCEPHALOPATHY 

THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHALOPATHY  IN  CHILDREN;  STUDY  OF  28  CASES. 

229083  01-11 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  01-15 
CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY, 

235563  02-13 
ENCEPHALOPATHY  SUBSEQUENT  TO  ACCIDENTAL  POISONING  WITH 
CHLORPROMAZINE. 

239089  03-05 
ENCOUNTER 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH;  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION) 

228686  01  11 
ENDINGS 

CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
ENDINGS. 

237244  02-03 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
ENDOCRINE 

ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
BEHAVIOR  AND  ENDOCRINE  EFFECTS  OF  3,4,5 
TRIMETHOXYAMPHETAMINE  IN  MALE  MICE. 

251215  04-04 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  II.  LSD. 

253700  04-03 
ENDOCRINOLOGICAL 

THYROTROPIN-RELEASING  HORMONE  IN  DEPRESSION;  CLINICAL  AND 
ENDOCRINOLOGICAL  FINDINGS. 

235370  02-09 
ENDOGENOUS 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE. 

226400  01-03 


ISOLATION  OF  AN  ENDOGENOUS  COMPOUND  FROM  THE  BRAIN  WITH 
PHARMACOLOGICAL  PROPERTIES  SIMILAR  TO  MORPHINE. 

227774  0 
EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESS 
(INTRODUCTORY  REPORT). 

234046  0 
DEVELOPMENT  OF  TOLERANCE  TO  AND  DEPENDENCE  ON  ENDOGENOU 
NEUROTRANSMITTERS. 

234798  0, 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  O; 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE;  BIOCHEMICAL  AND 
PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  . 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINi 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  0 
THE  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 

NOREPINEPHRINE  BY  N-ETHYLAMPHETAMINE  AND  FENFLURAMINE. 

238688  0 

NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 

WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERM 

AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKI 

SUBSTANCE  IN  THE  RAT. 

238713  0 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES. 

238729  0 
EFFECT  OF  DIPHENYLHYDANTOIN  ON  THE  ENDOGENOUS 
PHOSPHORYLATION  OF  BRAIN  PROTEIN. 

240746  0 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES;  FAILURE  OF  NALOX 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  0 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESI! 
A  SINGLE  MOUSE  BRAIN;  8IPHASIC  EFFECTS  OF  (  O  AMPHETAMINI 

241257  0 
DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  SENSITIVITY  OF 
TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMI 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  0 
ENDOGENOUS  INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  RAT 
ORGANS. 

244315  0 
TRAZODONE;  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS. 

244588  0 
MORPHINES  PROCONVULSANT  ACTION;  IMPORTANCE  OF  ENDOGENOl 
NOREPINEPHRINE. 

248880  0 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIOEPRESSIVE  EFFECT 
HIGH  PLASMA  LEVELS;  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  0 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  0 
THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  0 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  0 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO. 

251175  0 
ENDOSCOPY 

CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTIC 
OPEN  AND  DOUBLE-BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  0: 
ENDPOINT 

PENFLURIDOL  BLOCKADE  OF  APOMORPHINE;  DEPENDENCE  OF  DURATI 
ON  SPECIES  AND  ENDPOINT. 

248406  0. 
ENERGY 

COCAINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
METABOLISM  IN  VIVO. 

230834  0 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM. 

247012  0- 
ENHANCEMENT 

MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  0 


S-130 


LUME  14,  SUBJECT  INDEX 


Subject  index 


RETROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK 

237260  02-04 

PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE, 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY-  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04-04 
ENHANCEMENT  BY  CHLORPROMAZINE  OF  HYPERGYLCEMIC  ACTION  OF 

OIAZOXIDE. 

247715  04-15 
ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-P-TYROSINE. 

249002  04-03 
IMIPRAMINE  ENHANCEMENT  OF  PENTOBARBITAL  TOXICITY  IN  RATS. 

249929  04-05 
OPIATE  RECEPTOR  BINDING   -  ENHANCEMENT  BY  OPIATE 
ADMINISTRATION  IN  VIVO. 

250378  04-03 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  BY 
DIFFERENT  DOSES  OF  L-DOPA 

251214  04-03 
ANCING 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  OPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
TOLERANCE  TO  THE  ACTIVITY  ENHANCING  EFFECT  OF  D-AMPHETAMINE. 
(PH.D.  DISSERTATION). 

241575  03-03 
EPHAUN 

THE  REGIONAL  DISTRIBUTION  OF  A  MORPHINE-LIKE  FACTOR  ENKEPHALIN 
IN  MONKEY  BRAIN. 

252219  04-03 
ICHED 

ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 
ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 

EROHEPATIC 

INTESTINAL  ABSORPTION,  DEMETHYLATION,  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-13 
ORHINAl 

INTRACRANIAL  SELF-STIMULATION  DERIVED  FROM  ENTORHINAL  CORTEX. 

238757  03-04 
JRESIS 
PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01-14 
IMIPRAMINE  IN  ENURESIS  -■  PSYCHOLOGICAL  AND  PHYSIOLOGICAL 

EFFECTS. 

247743  04-11 

/IRONMENT 

THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712  02-04 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT 

24 1 546  03-04 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDR0SARPAN-71I  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 
l/IRONMENTAl 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03  04 
PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03-04 
DRUG  EFFECTS  AND  THE  ENVIRONMENTAL  CONTROL  OF  BEHAVIOR 

240021  03-04 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5- 
HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (III) 

241394  03-03 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 
ELEVATED  ENVIRONMENTAL  TEMPERATURE. 

241925  03-03 
ZYMATIC 
ENZYMATIC  CONVERSION  OF  MORPHINE  TO  PSEUDOMORPHINE. 

243780  04-03 


ENZYME 

CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02  14 

INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS    -  I    STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 

RAT  LIVER. 

241297  03-03 

HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 
BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE. 

241989  03-03 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITALINDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04  03 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 

OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04  01 

USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
ENZYMES 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER). 

226731  01-13 

DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  01-03 

INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 
LIVER. 

227696  01-03 

NEUROPSYCHOPHARAAACOLOGY  OF  MONOAMINES  AND  I  HEIR 
REGULATORY  ENZYMES. 

233941  02-03 
INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN-INDUCED  HYPOPROTHROMBINEMIA 

237760  02-03 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES, 

237776  02-03 
NEUROPSYCHOPHARAAACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

237829  02- r/ 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS  -    I    STRUCTURE  ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9  TETRAHYDROCANNABINOL 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
ENZYMOLOGICAL 

TRYPTOLINES:  PHARMACOLOGICAL  AND  ENZYMOLOGICAL  STUDIES 
PH.D.  DISSERTATION). 

242002  03-02 
EPHEDRINE 

ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-05 
L-DOPA,  AMINOPHYLLINE,  EPHEDRINE    ANTAGONISTIC  INTERACTION 
WITH  ETHANOL  IN  HUMANS, 

238748  03-13 
EPIDEMIOLOGY 

EPIDEMIOLOGY  OF  TARDIVE-DYSKINESIA    PART  II 

244497  04-15 
EPIDEMIOLOGY  OF  TARDIVE-DYSKINESIA:  PART  I. 

250991  04-15 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM 

253661  04  15 


::SS 


S-131 


Subject  Index 


Psychopharmacology  Abstrac 


EPILEPSY 

NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT. 

226399  01-03 
BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY. 

226737  01-13 
SCHIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY:  TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEG. 

228068  01-08 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE 

230836  01-04 
FUGUE  STATES  -  EPILEPSY   -  MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT.  AUGUST  1,  1975. 

237476  02- 17 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04-11 
SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY. 

245344  04-11 
SCHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04-16 
FENFLURAMINE  WITHDRAWAL  AND  EPILEPSY. 

250944  04-11 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-11 
EPIIEPTIC 

INVOLUNTARY  MOVEMENTS  CAUSED  BY  PHENYTOIN  INTOXICATION  IN 
EPILEPTIC  PATIENTS 

225890  01-15 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEG  IN  THE 
NATURALLY  EPILEPTIC  BEAGLE. 

23881 1  03-04 
PLASMA  CONCENTRATION  OF  DIPHENYLHYDANTOIN  IN  THE  EPILEPTIC: 
ITS  INTEREST  FOR  THE  CLINICIAN. 

240762  03-11 
BIOAVAILABILITY  OF  TWO  CARBAMAZEPINE  PREPARATIONS  DURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS, 

242212  03  11 
EFFECTS  OF  DRUGS  ON  EPILEPTIC  PATIENTS. 

245884  04-11 
PHENYTOIN-INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN. 

251654  04  15 
EPILEPTICS 

EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL    NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03  14 
EPILEPTIFORM 

EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED  BY 
LITHIUM  CARBONATE. 

233499  02-15 
EPINEPHRINE 

CHANGES  IN  THE  SELF  STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE 

238566  02-04 
ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICALS. 

248163  04-02 
EPISODE 

APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS 

236732  02-09 
EPITHALAMIN 

INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L  DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS 

241983  03-05 
EPOXIDE 

KINETICS  OF  CARBAMAZEPINE  AND  ITS  10,1  1  EPOXIDE  METABOLITE  IN 
CHILDREN 

243086  04-13 


EQUIPMENT 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC-ACID  AND  5-HYDROXYTRYPTOPHAN. 
(UNPUBLISHED  PAPER). 

231278  01- 
ERGOCORNINE 

EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES. 

239290  03- 
ERGOT 

DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04- 
ERGOTAMINE 

THE  EFFECT  OF  ERGOTAMINE  AND  METHYSERGIDE  ON  SEROTONIN 
METABOLISM  IN  THE  RAT  BRAIN. 

226826  01- 
ERYTHROCYTE 

REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSI 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01- 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIAAARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  IN 
PATIENTS  TAKING  LITHIUM  CARBONATE. 

249535  04 
INCREASED  ERYTHROCYTE  NA  +   PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04 
ERYTHROCYTES 

RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03- 
IN  VITRO  AND  IN  VIVO  TRANSPORT  OF  LITHIUM  BY  HUMAN 
ERYTHROCYTES. 

246275  04 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 

246856  04 
ESCAPE 

5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFEC 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PARE 

227802  01 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXO 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03 
THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES. 

241301  03 
EFFECTS  OF  CHLORPROMAZINE  ON  AVOIDANCE  AND  ESCAPE 
RESPONDING  IN  HUMANS. 

250076  04 
ESTABLISH 

AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  01 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION. 

229439  01 
ESTAZOLAM 

CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03 
ESTERS 

ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONIST 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04 
DRUGS  DERIVED  FROM  CANNABINOIDS.  2.  BASIC  ESTERS  OF  NITROGEf 
AND  CARBOCYCLIC  ANALOGS. 

248647  04 
ESTIMATING 

USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS 

250354  04 
ESTIMATION 

ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITl 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04 


S-132 


UME  14,  SUBJECT  INDEX 

PPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 
ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  04-03 

DIOL 

FFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
FFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS, 

247588  04-03 
STRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 
BEHAVIOR  IN  FEMALE  RATS. 

250012  04-04 

)GEN 

FFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 

UTERI  OF  AGING  RATS. 

247588  04-03 
FFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR  OF 

THE  OVARIECTOMIZED  EWE. 

248223  04-04 
>GENS 

NCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 

NFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04-13 
JUDIES  ON  SULFATE  CONJUGATION  OF  ESTROGENS  IN  BRAIN  AND 

LIVER. 

249245  04-03 

'5 

FHE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 
(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE. 

233974  02-11 
ENOXIN 

ITAFENOXIN  IN  THE  TREATMENT  OF  NEUROSIS    -  AN  UNCONTROLLED 
CLINICAL  STUDY. 

235357  02-07 
NOl 

NTERACTIONS  OF  DELTA9-TETRAHYDR0CANNABIN0L,  ADRENAL 
STEROIDS,  AND  ETHANOL. 

226763  01-03 
3IAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  01-03 
ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  01  04 
EFFECT  OF  ETHANOL  ON  DIAZEPAM  DISTRIBUTION  IN  RAT. 

231007  01-03 
EFFECT  OF  ETHANOL  INTAKE  ON  PHENYTOIN  METABOLISM  IN 
VOLUNTEERS. 

233280  02-13 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  02-03 

EFFECT  OF  P-CHLOROPHENYLALANINE  ON  THE  ACQUISITION  OF 

TOLERANCE  TO  ETHANOL  AND  PENTOBARBITAL 

237720  02-04 
L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANTAGONISTIC  INTERACTION 

WITH  ETHANOL  IN  HUMANS. 

238748  03-13 
ETHANOL,  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 

SCHEDULE  OF  FOOD  PELLET  PRESENTATION. 

238749  03-04 
ETHANOL  PREFERENCE  IN  RATS:  POSSIBLE  UNDERLYING  MECHANISMS. 

238750  03-04 
EFFECTS  OF  ACUTE  ETHANOL  ADMINISTRATION  ON  BRAIN  BIOGENIC 

AMINES. 

238751  03-03 
RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 

ETHANOL  IN  LACTATING,  VIRGIN  FEMALE,  AND  MALE  MICE. 

238766  03-03 
EFFECTS  OF  LITHIUM  ON  CHRONIC  ETHANOL  CONSUMPTION  AND 
BEHAVIOR. 

238849  03-03 

THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL   (PH.D.  DISSERTATION) 

240933  03-03 


Subject  Index 

THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DIN  PROPYLACETATE. 

241222  03-03 
PHARMACOLOGICAL  ASPECTS  OF  PHYSICAL  DEPENDENCE  ON  ETHANOL. 

241240  03- 17 
CHANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  03-03 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  03-03 

DIAGNOSIS  AND  MANAGEMENT  OF  ETHANOL  WITHDRA.WAL 

SYNDROMES. 

244107  04-11 

ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES. 

246821  04-05 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 
CORTICAL  SLICES. 

246850  04-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES. 

248513  04-03 
EFFECTS  OF  PENTOBARBITAL  IN  MICE  SELECTIVELY  BRED  FOR  DIFFERENT 
SENSITIVITIES  TO  ETHANOL. 

249261  04-04 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ETHANOL  AND  BARBITAL. 

249262  04-04 
DEVELOPMENT  OF  CROSS-TOLERANCE  BETWEEN  DELTA9- 

TETRAHYDROCANNABINOL  AND  ETHANOL. 

249263  04-03 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 

ETHANOL  TOLERANCE  IN  THE  RAT 

249264  04-04 
DEPRESSION  OF  DOPAMINE  RELEASE  DURING  THE  ETHANOL 

WITHDRAWAL  SYNDROME. 

249293  04-03 
CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 

PHOSPHODIESTERASE  LEVELS  IN  MICE. 

249294  04-03 
THE  EFFECT  OF  CAFFEINE  ON  HUMAN  PERFORMANCE,  ALONE  AND  IN 

COMBINATION  WITH  ETHANOL. 

249674  04-14 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANOL 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH) 

250110  04-03 
SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MICE 
SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL. 

250284  04-04 
EFFECT  OF  ETHANOL  ON  DOPAMINE  SYNTHESIS  AND  RELEASE  FROM  RAT 
CORPUS-STRIATUM. 

251178  04-03 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM      EVIDENCE  FOR 

THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION 

251179  04-03 
DELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAMINE  AS 

DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
EFFECTS  OF  CAFFEINE  AND  ETHANOL  ON  THE  BLOOD-BRAIN  BARRIER  IN 
RATS. 

252222  04-03 
DIFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAL  SMOOTH  MUSCLE 

253113  04-03 

ETHER 

THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 
ETHERS 

SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY: 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
ETHICAL 

ETHICAL  AND  LEGAL  IMPLICATIONS  OF  INVESTIGATIONS  INTO  THE 
EFFICACY  OF  PSYCHIATRIC  TREATMENTS. 

235354  02-17 
ETHYLAICOHOI 

DIFFERENTIAL  EFFECTS  OF  ETHYLALCOHOL  ON  CONTRACTION  OF 
ARTERIAL  SMOOTH  MUSCLE. 

251905  04-03 


es 


S-133 


Subject  Index 


Psychopharmacology  Abstract 


ETIFOXINE 

tVAlUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237)02  02-14 
ETIIEFRINE 

ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241763  03-15 
ETORPHINE 

STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
EUFLAVINE 

EUFLAVINE    EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03-04 
EUPHORIANT 

FENMETRAZOLE  (DH  524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781  01-14 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT 

237716  02-14 
POSSIBLE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  OF 
MARIHUANA  BY  2-PHENYLETHYLAMINE  AND  BY  PHENYLACETIC-ACID. 

238820  03-03 
EUROPEAN 

AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS:  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE. 

253052  04-08 
EUROPIUM 

NMR  STUDY  OF  AMPHETAMINES  USING  EUROPIUM  SHIFT  REAGENTS. 

239660  03-01 
EVALUATING 

EVALUATING  POTENTIAL  ANTIDEPRESSANTS  IN  ANIMALS. 

227207  OT -06 
A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES. 

231072  OT -06 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-03 
A  BRIEF  ANXIETY  RATING  SCALE  IN  EVALUATING  ANXIOLYTICS. 

237926  02-11 
RELAY  TOXICITY   A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  AODITIVFS  TO  FARM  ANIMAL  FEED. 

245T14  04-06 
SIEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS 

252230  04  11 
EVALUATION 

EVALUATION  OF  SIDE  EFFECTS  ON  NEUROTICS   -  A  TEST  USING 
MESORIDAZINE  AND  PLACEBO. 

225686  01-15 
AN  EVAIUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5  HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE 

226400  01-03 
COMPARATIVE  EVALUATION  OF  FIURAZEPAM  AND  NITRAZEPAM  FOR 
OCCASIONAL  INSOMNIACS 

228315  01-11 
DOUBLE  BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS 

229368  01  11 
FVAIUATION  OF  NEW  COMPOUNDS  FOR  PSYCHOTROPIC  ACTIVITY 

229477  01-04 
lilt  CIINICAI  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
(lORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE.  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01  11 
PSYCHOMETRIC  CLINICAL  EVAIUATION,  THROUGH  OVERALL  AND 
GORHAMS  TEST,  OF  THERAPY  WITH  FLUPHENAZINE  DECANOATE. 

229555  01-17 
A  CONTROLLED  EVAIUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS 

230907  01-08 
IFFFCr  OF  I  .')  HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02-09 
EVAttlATiON  OT  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOIHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02  11 


CLINICAL  EVALUATION  OF  THE  ANTIDEPRESSIVE  ACTION  OF  THE        . « 
PREPARATION  AZAFEN.  ■  ^ 

236429  02-i 
EVALUATION  OF  DISULFIRAM  TREATMENT  OF  CHRONIC  ALCOHOLISM. 

237026  02-; 
EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237102  02-; 
EVALUATION  OF  LORAZEPAM  AND  PENTOBARBITAL  AS  SURGICAL 
PREMEDICANTS. 

237734  02-! 
LENPERONE:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

237899  02-(' 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-{ 
DOPAMINE  AND  PSYCHOACTIVE  DRUG  ACTION:  A  FURTHER 
EVALUATION. 

238768  03-( 
EVALUATION  OF  CESIUM  CHLORIDE  AS  ANTIDEPRESSANT. 

238836  03-( 
EVALUATION  OF  PSYCHOTROPIC  DRUGS:  A  SYMPOSIUM. 

239846  03-; 
A  BEHAVIORAL  PARADIGM  FOR  THE  EVALUATION  OF  NARCOTIC 
ANTAGONISTS. 

239941  03-1 
DPH-INTOXICATION  -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03-1 
A  PRIMER  ON  THE  CLINICAL  EVALUATION  OF  PSYCHOTROPIC  DRUGS, 

240838  03-1 
BEHAVIORAL  TERATOGENESIS:  A  CRITICAL  EVALUATION. 

242744  03-1 
A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS. 

247483  04-( 
CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 
ANTIDEPRESSANT  TREATMENT. 

247969  04-( 
APOMORPHINE-INDUCED  AGGRESSION:  AN  EVALUATION  OF  POSSIBLE 
SENSITIZING  FACTORS  IN  THE  RAT. 

248008  04-C 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  ANI 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAI 
CORTEX. 

248699  04-C 

OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OF 

THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 

IN  NEUROTIC.  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS. 

248975  04-1 
A  DOUBLE-BLIND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTE 

SCHIZOPHRENICS. 

248976  04-C 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 

IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04-1 
AN  EVALUATION  OF  PAPAVERINE  IN  TARDIVE-DYSKINESIA. 

251830  04-1 
EVALUATION  OF  THE  ANTINOCICEPTIVE  EFFECTS  OF  4,ALPHA-DIMETHYL 
M-TRYAMINE  (H77-77)  IN  THE  RAT 

252026  04-C 
THE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMENT  C 
OUTPATIENTS  (A  MULTICENTRIC  STUDY). 

252448  04-C 
EVENTS 

STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 
CONTROL  BEHAVIOR. 

24001 1  03-C 
EVIDENCE 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762  01 -C 
EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  0 
DIAZEPAM 

226857  01 -C 
ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO:  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION 

228630  01 -C 
EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-0 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  01-0 


S-134 


AB  14,  SUBJECT  INDEX 


Subject  Index 


lence  for  gaba  involvement  in  the  action  of  diazepam  on 
iesynaptic  nerve  terminals  in  bullfrog  sympathetic 
;nglia 

232513  01  03 
lENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 
^NZOOIAZEPINES;  STUDIES  ON  RAT  CEREBELLUM. 

232514  01-03 
FRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS;  EVIDENCE  FROM 
iECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
3PAMINE  TURNOVER. 

233964  02-14 
ICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
iYCHOTROPIC  DRUGS 

234797  02-09 
lEASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE: 
^IDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
^URONS. 

237881  0203 
WIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
UECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 
OXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
'ITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
H  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
JBSTANCE  IN  THE  RAT. 

238713  03-04 
)ENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
:EDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
)ENCE  FOR  A  DOPAMINE  RECEPTOR  ANTIBODY. 

238736  03-03 
NIOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
)R  SEVERAL  METABOLITES. 

238796  03-13 
ERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
RUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
HOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 
'HETAMINE  AND  THE  REWARD  SYSTEM:  EVIDENCE  FOR  TOLERANCE 
ND  POST-DRUG  DEPRESSION. 

239850  03-04 
3ENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 
RIPHOSPHATASES  FROM  BRAIN. 

239962  03-03 
3ENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
\OTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS 

241203  03  03 
JICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
SYCHOTROPIC  DRUGS. 

243819  04-13 
REASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
•HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
EFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
F-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
iF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
ilSPERSED  FIRST. 

246774  04-03 
EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
RYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
ODIUM  SENSITIVE  SITES. 

246856  04-13 
CTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 
lEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
/\AN 

246992  04-13 
FLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
iND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
;  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
VIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
lECEPTOR  ACTIVITY. 

248288  04-03 
iTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 
'REFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
IIVENTER  CERVICIS  MUSCLE. 

248409  0403 
tTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO-INTERPEDUNCULAR 
lEURONS:  PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
DENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
iECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE 

249257  04-03 
DENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
:ENTRAL  stimulant  and  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
ETRAHYOROCANNABINOL  (THC). 

249309  0403 


BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM   -  EVIDENCE  FOR 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179  04-03 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5  HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA 

251704  04-04 
EFFECTS  OF  LILLY-HOMO,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  inhibition  of  FEEDING. 

252522  04-03 
PHARMACOLOGICAL  EVIDENCE  FOR  THE  CENTRAL  SEROTONERGIC 
EFFECTS  OF  MONOMETHOXYAMPHETAMINES. 

253108  04-04 

EVOCATION 

EXPOSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM, 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION. 

250727  04-10 
EVOKED 

THE  EFFECT  OF  D,L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01-03 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM: 
FVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  01-03 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01-04 
ARE  HORMONES  PSYCHOACTIVE''  EVOKED  POTENTIAL  INVESTIGATIONS 
IN  AAAN. 

232532  0114 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENTOBARBITAL 
ON  AUDITORY  EVOKED  RESPONSES. 

234682  02-03 
THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
LOCAL  ANESTHETICS  AND  BARBITURATES   EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX 

237875  02-03 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D  TRYPTOPHAN. 

238698  03-04 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  03-03 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  DIAZEPAM  ON  HIPPOCAMPAL 
EVOKED  RESPONSES, 

239961  03-03 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 
DORSAL  ROOT  POTENTIALS. 

239982  03-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT. 

241255  03-03 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  PENTOBARBITAL  ON 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING. 

244693  04-03 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL    APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS 

244874  04-03 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY 

246629  04-09 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  BY 
DIFFERENT  DOSES  OF  L-DOPA. 

251214  0403 


U9 


OB 


3b: 


EWE 


EFFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR  OF 
THE  OVARIECTOMIZED  EWE 

248223  04-04 


S-135 


Subject  Index 


Psychopharmacology  Abstra< 


EX-1I-582A 

AN  EARLY  CLINICAL  AND  TOXICITY  TRIAL  GF  EX-n-5a2A  IN  CHRONIC 
SCHIZOPHRENIA. 

247481  04-07 
EXAMINATION 

OXPRENOLOL  IN  THE  TREATMENT  OF  EXAMINATION  NERVES. 

251160  04-10 
EXAMPLE 

AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS,  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE. 

253052  04-08 
EXCIPIENTS 

DRUG  PERMEATION  THROUGH  MEMBRANES  V-  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  02-02 
EXCITABILITY 

CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01-04 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-03 
LACK  OF  A  RELATION  BETWEEN  THE  ANTIPSYCHOTIC  AND  THE 

EXCITABILITY  DEPRESSANT  PROPERTIES  OF  MAJOR  TRANQUILIZERS. 

238710  03-03 
CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE. 

241232  03-03 
EXCITATION 

THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION 

231070  01-03 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS. 

23291  7  02-03 
THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-04 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA 

237104  02-03 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02-10 
ALPHA  BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE. 

244203  04-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
EXCITATORY 

INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 
INVERTEBRATE  SYNAPSES. 

226398  01-03 
5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER). 

227802  01-04 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
EXCITEMENT 

THE  PLACEBO  EFFECT  IN  PSYCHOPHARMACOTHERAPY  IN 

CONSIDERATION  OF  THE  EFFECT  OF  MEPIPRAZOL  ON  EXCITEMENT  IN 
PSYCHOTICS. 

234217  02-08 
EXCRETION 

BIOTRANSFORMATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS 

226928  01-03 
EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES. 

227212  01-07 
CHLORPROMAZINE  EXCRETION:  ISOTOPE  VERSUS  CHEMICAL  ASSAY. 

229481  01-03 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL. 

237123  02-13 


THE  EFFECTS  OF  ASCORBIC-ACID  (AA)  PRETREATMENT  ON 
AMPHETAMINE  (A)  EXCRETION  IN  MAN. 

238797  03 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE:  CLINICf 
CHEMICAL  CORRELATIONS 

244050  04 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04 
ABSORPTION,  DISTRIBUTION  AND  EXCRETION  OF  TRIFLUOPERAZINE  IN 
RATS. 

249036  04 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  0-! 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  C 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZI 

251985  0^ 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  {SQ-10996) 
HUAAANS. 

253323  0^ 
EXERTION 

METHYLPHENIDATE  IN  CHILDREN:  EFFECTS  UPON  CARDIORESPIRATOR' 
FUNCTION  ON  EXERTION. 

247378  0^ 
EXOCYTOTIC 

INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 

NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS.  (UNPUBLISHED 
PAPER). 

227777  01 
EXOGENOUS 

THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOU: 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01 
THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  OROPERIC 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  0; 
EXPERIENCE 

CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS. 

227806  01 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  (FK-880)  FOR  DEPRESSION 

228334  01 
CLINICAL  EXPERIENCE  IN  USING  CLOXAZOLAM  (SEPAZON). 

229025  01 
CLINICAL  EXPERIENCE  IN  USING  MENDON  (DIPOTASSIUM  CLORAZEPA' 

229626  01 
CLINICAL  EXPERIENCE  IN  USING  AAAPROTILINE,  A  NEW  ANTIDEPRESSI\ 
MEDICINE. 

229760  01 
EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TAS 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01 
EFFECTS  OF  PRIOR  EXPERIENCE  ON  DIFFERENTIAL  LEARNING  UNDER 
AMPHETAMINE. 

230868  01 
CLINICAL  EXPERIENCE  WITH  CLOZAPINE. 

234419  0; 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  O; 
PRELIMINARY  EXPERIENCE  WITH  PARENTERAL  SINTAMIL  IN  TREATMEI 
OF  DEPRESSION. 

235348  O; 
FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITI 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350). 

239748  O; 
CLINICAL  EXPERIENCE  WITH  RO-5-3350  (BROMAZEPAM). 

245138  0' 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  0' 
RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WIT 
GER0VITAL-H3  TABLETS. 

246425  0' 
CLINICAL  EXPERIENCE  WITH  BETA-BLOCKERS  IN  CONSULTANT 
PSYCHIATRIC  PRACTICE. 

251165  0' 
EXPERIENCED 

MARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS. 

226903  01 


S-136 


HUME  14,  SUBJECT  INDEX 


Subject  Index 


•ERIENCES 

COUNSELING    PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPTASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01-10 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY 

237458  02-10 
EXPERIENCES  WITH  A  DEPOT  NEUROLEPTIC  (DAPOTUM-D). 

242503  03-08 
CLINICAL  EXPERIENCES  WITH  A  NEW  ANTIDEPRESSANT,  ICI-58834. 

244189  04-07 
l>ERIMENTAL 
BIOTRANSFORAAATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS. 

226928  01-03 
AN  EXPERIMENTAL  THERAPY  AND  RE-EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE.  (PH.D.  DISSERTATION). 

228750  01-11 
THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE. 

229037  01-11 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  02-04 
PROFILE  OF  TRH  IN  EXPERIMENTAL  PSYCHOPHARMACOLOGY. 

237708  02-04 
NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03-03 
EXPERIMENTAL  HUMAN  DRUG  SELF-ADMINISTRATION:  METHODOLOGY 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE. 

240831  03-14 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 
EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

246152  04-03 
ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES. 

246821  04-05 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 
POISONING  IN  THE  RAT. 

251419  04-03 
(PERIMENTAllY-INDUCED 

RELATIONSHIP  BETWEEN  OBJECTIVE  AND  SUBJECTIVE  ASSESSMENT  OF 
EXPERIMENTALLY-INDUCED  FATIGUE, 

253587  04-12 
(PERIMENTATION 

DISCOURSE  ON  THE  DOUBLE-BLIND  METHOD   INSTITUTION  AND 
EXPERIMENTATION:  19366-RP. 

229078  01-16 
CLINICAL  EXPERIMENTATION  OF  THE  LONG-ACTING  NEUROLEPTICS: 
METHODOLOGICAL  PROBLEMS. 

229554  01-16 
FLUPHENAZINE:  DIFFICULTIES  AND  LIMITATIONS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
KPERIMENTS 

CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  01-11 
CLINICAL  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE  IN 

HOSPITALIZED  PATIENTS 

229551  0111 
CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE 

IN  TREATING  DISSOCIATIVE  SYNDROMES. 

229560  01-1 1 


DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  II.  FIVE 
EXPERIMENTS. 

232518  0114 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS. 

244591  04-13 
EXPLAINING 

A  METHOD  FOR  EXPLAINING  DYSKINETIC  MOVEMENTS    -  A  FILM 
PRESENTATION. 

253034  04-15 
EXPLANTS 

BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880  02-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  03-03 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205  04-03 
EXPLORATION 

EXPLORATION  OF  THE  ANTIDEPRESSANT  POTENTIAL  OF  IPRINDOLE. 

241241  03-04 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION? 

241932  03-04 

EXPLORATORY 

EFFECTS  OF  SCOPOLAMINE  ON  HABITUATION  OF  EXPLORATORY 
ACTIVITY  IN  RATS. 

235509  02-04 

EXPLOSIVELY 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PH.D. 
DISSERTATION). 

228726  01-11 
EXPOSED 

MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04-04 
EXPOSURE 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  01  04 
THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY. 

227385  01-04 
ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM. 

229349  01-17 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  03-04 
EFFECTS  ON  OFFSPRING  OF  CHRONIC  MATERNAL  METHAMPHETAMINE 
EXPOSURE. 

245405  04-05 
EXPOSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM, 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION. 

250727  04-10 
EXPRESSION 

THE  EFFECTS  OF  LSD  ON  THE  EXPRESSION  OF  AFFECT  IN 
PSYCHOTHERAPY  (PH.D.  DISSERTATION). 

231480  01-12 
EXTENSION 

RATE-DEPENDENT  EFFECT  OF  AMPHETAMINE  IN  RATS:  EXTENSION  TO 
BETWEEN  SUBJECTS  EFFECT. 

251988  04-04 
EXTINCTION 

THE  EFFECTS  OF  NEONATAL  6-HYDROXYDOPAMINE-INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION. 

226871  01-03 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 


ISO, 


S-137 


M^ssm 


Subject  Index 


Psychopharmacology  Abstrac 


EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 
ADMINISTRATION:  DETERMINATION  OF  REINFORCEMENT  MAGNITUD 

250010  04-04 
HORMONAL  INFLUENCES  ON  THE  EXTINCTION  OF  CONDITIONED  TASTE 
AVERSION 

251980  04-04 
EXTINCTION-INDUCED 

EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  04-06 
EXTRACEUUIAR 

CEREBRAL  ARTERIAL  SPASM   PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04-04 
EXTRACT 

N-HYDROXYAMPHETAMINE   A  MAJOR  METABOIITE  OF  AMPHETAMINE  IN 
RABBIT  LIVER  EXTRACT 

238682  03-03 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
EXTRACTION 

SCHIZOPHRENIA:  RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 
CONTROL,  AND  FEATURE  EXTRACTION. 

238464  02-08 
EXTRACTS 

IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  04-03 
EXTRAJUNCTIONAl 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04-03 
EXTRANEURONAL 

EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPmEPHRINE 
BY  THE  RAT  DUODENAt  MUCOSA. 

24)299  03-03 
EXTRAPINEAl 

EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
EXTRAPYRAMIDAL 

ON  THE  DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  EXTRAPYRAMIDAL  MOTOR 
DISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  02-11 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWING  6 
HYOROXYDOPAMINE  LESIONS. 

238735  03-03 
2-PHENYLETHYLAMINE  (PEA)  IN  D-AMPHETAMINE-INDUCED 
EXTRAPYRAMIDAL  DISORDERS 

238841  03-03 
EXTRAPYRAMIDAL  SYMPTOMS  UNDER  CLOZAPINE:  A  CASUISTIC 
CONTRIBUTION. 

238855  03-15 
EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE. 

244355  04-15 
A  CONTROILED  TRIAL  OF  AMANTADINE  IN  DRUG-INDUCED 
EXTRAPYRAMIDAl  DISORDERS. 

244701  04-15 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION 

245789  04-15 
DRUG-INDUCED  EXTRAPYRAMIDAL  EFFECTS      A  REVIEW 

246187  04-15 
ANTICHOLINERGIC  ACTIVITY  OF  ANTIPSYCHOTIC  DRUGS  IN  RELATION  TO 
THEIR  EXTRAPYRAMIDAL  EFFECTS, 

252520  04-05 
EXTRINSIC 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCIE 

248409  04-03 


I 


EYES 


F-l 


SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ,  AND 
SECOBARBITAL. 

246303  04-14 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS. 

249281  04-02' 
EYE  COLOR  AND  TARDIVE-DYSKINESIA. 

253037  04-15 

ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-03 


EYE 


DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION 

240048  03-15 


EFFECTS  OF  D-AMPHETAMINE  ON  F-l  SHOCK  PRESENTATION  WITH 
SDELTA  PROBE. 

237699  02-04 
FACIAL 

CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
FACILITATED 

LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIAAULATION 
FACILITATED  BY  MORPHINE  AND  (  f  )  AMPHETAMINE. 

249486  04  03 
FACILITATING 

REVERSAL  OF  THE  6-HYDROXYDOPAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
FACILITATION 

FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS.  (PH.D.  DISSERTATION). 

226991  01)2 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02-04 
AMFONELIC-ACID  FACILITATION  OF  IMPULSE-INDUCED  STRIATAL 
DOPAMINE  RELEASE. 

238730  03-03 
PIRACETAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAL  INFORMATION  IN  RATS. 

239861  03-04 
DIPHENYLHYDANTOIN  FACILITATION  OF  LABILE,  PROTEIN  INDEPENDENT 
MEMORY, 

253290  04-04 
FACT 

FACT  AND  FICTION  OF  MENOPAUSE. 

249975  04-17 
FAILS 

6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03-03 
FAILURE 

FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE-INDUCED  ANOREXIA. 

237748  0203 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT 

241244  03-04 
UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMINOBUTYRIC-ACID  LEVELS  TO 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730  04-03 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
FAILURE  OF  PHENOBARBITONE  TO  PREVENT  FEBRILE  CONVULSIONS. 

251103  04-11 
FAILURES 

LITHIUM  IN  TREATMENT  FAILURES 

230562  01-11 
MENTAL-HEALTH  PROGRAMS:  PROMISES?.  FULFILLMENT?.  FAILURES';'. 

236911  02-15 
FAMIUAL 

THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS. 

229552  01-17 
FAMILY 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH  D 
DISSERTATION). 

228686  0111 


S-138 


HUME  14,  SUBJECT  INDEX 

lEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03-11 
TRIAZOLAM  IN  INSOMNIAC  FAMILY  PRACTICE  PATIENTS. 

245649  04-11 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE.  AND  FAMILY  HISTORY. 

246629  04-09 
COMPLICATIONS  OF  PSYCHOACTIVE  DRUGS  AS  SEEN  BY  FAMILY 
PRACTITIONERS. 

248851  04-15 
RM 
RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
ST 
MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW. 

253407  04-03 
TAl 
FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY. 

235286  02-15 
TAUTIES 

PHENCYCLIDINE  -  STATES  OF  ACUTE  INTOXICATION  AND  FATALITIES. 

247147  04-15 
TE 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 

OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
TIGUE 

RELATIONSHIP  BETWEEN  OBJECTIVE  AND  SUBJECTIVE  ASSESSMENT  OF 
EXPERIMENTALLY-INDUCED  FATIGUE. 

253587  04-12 
,TTY-ACIDS 

THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 
iVOR 

THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 

246856  04-13 
AR 

EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG. 

240916  03-04 

ATURE 

SCHIZOPHRENIA:  RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 
CONTROL,  AND  FEATURE  EXTRACTION. 

238464  02-08 
IBRILE 

FAILURE  OF  PHENOBARBITONE  TO  PREVENT  FEBRILE  CONVULSIONS. 

251103  04-11 

;eo 

relay  toxicity:  a  new  approach  to  a  methodology  of 
evaluating  the  toxicity  of  additives  to  farm  animal  feed, 

245114  04-06 
:EOBACK 

EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR 

238800  03-04 
ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-MACHINE  TRACKING  SYSTEMS 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03-14 
D  AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS    MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04  13 
EEDING 

GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  01-04 
THE  EFFECTS  OF  SEROTONIN  ON  FEEDING  IN  THE  RABBIT. 

230872  01-04 
PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

231700  01  03 
EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS 

231707  01-04 


Subject  Index 

DISRUPTION  OF  BRAIN  STIMULATION  INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE. 

235587  0204 

MARIJUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT, 

238720  03-04 

HYPOTHALAMIC  NORADRENALINE  TURNOVER  IS  INCREASED  DURING 
GLUCOPRIVIC  FEEDING. 

238804  03-04 

VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS. 

244311  04-04 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

245929  04-02 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
FEEDING  AND  WITHDRAWAL. 

246310  04-04 

CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE. 

249294  04-03 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
EFFECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN  INDUCED  ANOREXIA,  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING, 

252522  04-03 

FELINE 

EFFECTS  OF  ANTIHISTAMINIC  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM. 

238838  03-03 

FEAAALE 

RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE,  AND  MALE  MICE. 

238766  03-03 
THE  PSYCHIATRY  OF  THE  FEMALE  CLIMACTERIUM:  NEUROTIC  OR 

PSYCHOTIC  SYMPTOMS-;', 

241875  03-09 

THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04- 17 
ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 

BEHAVIOR  IN  FEMALE  RATS 

250012  04-04 

TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT, 

250068  04-02 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE, 

251981  04-04 

FEMALES 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PHD 
DISSERTATION) 

228726  01-11 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYIHYDANTOIN  AND  NEUROLEPTICS-  A  DOUBLE-BLIND 
STUDY, 

232781  02-08 
PROLACTIN  AND  GONADOTROPHTN  ACTIVITY  IN  FEMALES  TREATED  FOR 
ANOREXIA  NERVOSA. 

240423  03- 11 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK    I    EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245712  04-04 
FENFLURAMINE 

EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG  INDUCED  CONDITIONED  TASTE 
AVERSIONS    STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01-04 
FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE  DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY, 

230874  01-04 
A  COMPARISON  OF  FENFLURAMINE  AND  AMPHETAMINE  IN  MAN, 

231319  01-13 
THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 

SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BRAIN 
NUCLEI,  (UNPUBLISHED  PAPER). 

232325  01-03 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  P-CHLOROAMPHETAMINE 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  02-03 


U9 
SO 


(S 


S-139 


Subject  Index 


Psychopharmacology  Abstracts 


FENFLURAMINE  AND  5-HYDROXYTRYPT AMINE.  PART  1:  IS 

FENFLURAMINE  OR  NORFENFLURAMINE  INVOLVED  IN  THE  DECREASE 
OF  BRAIN  5-HYDROXYTRYPTAMINE?. 

237118  02-03 
FENFLURAMINE  AND  5HYDR0XYTRYPTAMINE.  PART  2:  INVOLVEMENT 

OF  BRAIN  AND  5-HYDROXYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 
OF  FENFLURAMINE. 

237119  02-03 
EFFECT  OF  AMPHETAMINE  AND  FENFLURAMINE  ON  BRAIN 

NORADRENALINE  AND  M0PEG-S04. 

237740  02-03 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6HYDR0XYD0PAMINE  IN  RATS. 

237743  02-03 
THE  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 

NOREPINEPHRINE  BY  N-ETHYLAMPHETAMINE  AND  FENFLURAMINE. 

238688  03-03 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONOIMIN)  TREATMENT  IN 
MAN.  (UNPUBLISHED  PAPER). 

239305  03-13 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 
A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

250935  04-17 
THE  MECHANISM  OF  ACTION  OF  FENFLURAMINE. 

250936  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 

DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 
SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 

CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE. 

250940  04-03 
BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE. 

250942  04-1 1 
EFFECT  OF  FENFLURAMINE  ON  STEADY-STATE  PLASMA  LEVELS  OF 

AMITRIPTYLINE  (ABSTRACT). 

250943  04-07 
FENFLURAMINE  WITHDRAWAL  AND  EPILEPSY. 

250944  04-11 
SUBJECTIVE  EFFECTS  OF  TWO  ANOREXIGENIC  AGENTS  -  FENFLURAMINE 

AND  AN  448  IN  NORMAL  SUBJECTS, 

250945  04-07 
FENFIURAMINE-INDUCEO 

FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE-INDUCED  ANOREXIA. 

237748  02-03 
FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY;  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04-04 
FENMETRAZOLE 

FENMETRAZOLE  (DH-524):  EUPHORIANT  CLASSIFIED  BY  CEREBRAL 
ELECTROMETRY. 

230781  01-14 
FENTANYL 

THE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY, 

230830  01-14 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
CHARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 
FERNOOWN 

REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 
IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21  ST  1975. 
BETA-ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY 

251156  04-10 
FETAL 

PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  03-03 
CAN  PHENYTOINS  CAUSE  FETAL  DAMAGE'. 

248097  04-13 


FG4963 

NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-0: 
FICTION 

PENTAZOCINE  DEPENDENCE  -  TRUTH  AND  FICTION?. 

246707  04-11 
FACT  AND  FICTION  OF  MENOPAUSE. 

249975  04-1; 
FIGHTING 

TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04-0. 
FILM 

A  METHOD  FOR  EXPLAINING  DYSKINETIC  MOVEMENTS  -  A  FILM 
PRESENTATION. 

253034  04-1 
FILTRATION 

INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN  -  I.  GEL  FILTRATION  STUDIES. 

251176  04-0 
FINLAND 

ADDITIONAL  STUDIES  -  FINLAND. 

227222  01-0 
FIRING 

EFFECTS  OF  INTRACEREBROVENTRICULAR  L-DOPA  ON  CAUDATE  UNIT 
FIRING. 

238716  03-0: 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  R0-4-4602. 

239957  03-0: 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS:  COMPARATIVI 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS. 

24721 1  04-0: 
FISH 

TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04-0. 
FIXED 

EFFECT  OF  5,5  DIPHENYLHYDANTOIN  ON  FIXED  CONDITIONED  REFLEXES 
IN  CATS. 

229681  01-0 
FIXED-INTERVAL 

CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-0 
ETHANOL,  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION. 

238749  03-0. 
EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAt  SCHEDULE. 

245303  04-0 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-0 
EFFECTS  OF  D-AMPHETAMINE,  MONOMETHOXYAMPHETAMINES  AND 
MESCALINE  ON  FIXED  INTERVAL  RESPONDING  IN  RATS. 

249275  04-0 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

2501 1 1  04-0. 
SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORMANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDULE. 

252816  04-0 
FIXED-RATIO 

TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED-RATIO  WATER 
REINFORCED  RESPONDING  IN  RATS 

230842  01-0 
DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PH.D.  DISSERTATION). 

239533  03-a 
FK-880 

CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  (FK-880)  FOR  DEPRESSION. 

228334  01 -C 
FLAMEPHOTOMETER 

SERUM  LITHIUM  MEASUREMENT  OF  THE  EEL  FLAMEPHOTOMETER. 

241777  03-1. 
FLEXOR 

RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  OS-O- 


S-MO 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


CER 

THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY. 

251986  04-14 

V 

DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOVi^  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  SENSITIVITY  OF 
TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DOPAMINERGIC  NEURONS   -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 

EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION;  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW. 

253407  04-03 
D 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

226915  01-09 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01-09 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYOROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01-06 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-03 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L  DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03-03 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  03-13 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY.  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROMATOGRAPHY 

245300  04-03 
THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04-13 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE. 

250657  04  13 


CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA. 

251119  04-08 

FLUIDS 

SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

229112  01-17 

QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS. 

233277  02-06 

FLUNITRAZEPAM 

THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  OROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  AAAN. 

232531  01-13 
EEG  SLEEP  STUDIES  OF  INSOMNIACS  UNDER  FLUNITRAZEPAM 
TREATMENT. 

239819  03-14 

NARCOSIS  INTRODUCTION  WITH  FLUNITRAZEPAM  IN  ACCIDENT 
SURGERY. 

244045  04-11 

FLUORESCENCE 

A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-06 

FLUOROMETRIC 

CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE. 

251777  04-06 
FLUOROPHENAZINE 

HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 
BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE 

241989  03-03 
FLUOROURACIL 

ORGANIC  MENTAL  CHANGES  WITH  FLUOROURACIL  THERAPY. 

247978  04  15 
FLUOXETINE 

INHIBITION  OF  DRUG  METABOLISM  BY  FLUOXETINE. 

248605  04-02 
FLUPENTHIXOL 

FLUPENTHIXOL  AND  FLUPENTHIXOL  DECANOATE,  WITH  SPECIAL 
REFERENCE  TO  THEIR  ANTIPSYCHOTIC  EFFECT. 

227770  01-08 
ANTIAUTISTIC  EFFECT  OF  FLUPENTHIXOL. 

227771  01-08 
CLINICAL  PHYSIOGNOMY  OF  FLUPENTHIXOL. 

227772  01-14 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 

FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL,  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING 

229907  01-14 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC. 

231367  01  08 
FLUPENTHIXOL-DECANOATE 

FLUPENTHIXOL-DECANOATE    -  CONTROLLED  INVESTIGATION  CONCERNING 
DOSAGE. 

226408  01-08 
FLUPENTHIXOL-DECANOATE  •  IN  TREATMENT  OF  OUTPATIENTS. 

226409  01-08 
PHARMACOKINETICS  OF  FLUPENTHIXOL-DECANOATE.  DECANOATE. 

227767  01-08 
A  COMPARATIVE  TRIAL  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE. 

238975  03-08 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA. 

238996  03-08 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE, 

239823  03  08 
FLUPHENAZINE 

VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01-08 


33* 


S-141 


Subject  Index 


CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  01 -n 
FIVE  YEARS  OF  DEPOT  FLUPHENAZINE  THERAPY. 

244620  04-08 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 
FLUPHENAZINE:  DIFFICULTIES  AND  LIMITATIONS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 
ANALOGS  OF  FLUPHENAZINE. 

248538  0402 
RELATIONSHIP  BETWEEN  THE  BEHAVIORAL  AND 

ELECTROENCEPHALOGRAPHIC  EFFECTS  OF  CHLORPROAAAZINE  AND 
FLUPHENAZINE  IN  RATS. 

249623  04-02 
COMPARISON  OF  FLUPHENAZINE-DECANOATE.  ORAL  FLUPHENAZINE, 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04-08 
A  THREE-YEAR  DOUBLE-BUND  INVESTIGATION  OF  PIMOZIDE  VERSUS 

FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  04-08 
FlUPHENAZINE-DECANOATE 

THE  LONG-TERM  USE  OF  HIGH  DOSES  OF  FLUPHENAZINE-ENANTHATE 

AND  FLUPHENAZINE  DECANOATE. 

225936  01-08 
CLINICAL  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE  IN 

HOSPITALIZED  PATIENTS. 

229551  01-1 1 
PSYCHOMETRIC  CLINICAL  EVALUATION.  THROUGH  OVERALL  AND 

GORHAMS  TEST.  OF  THERAPY  WITH  FLUPHENAZINE-DECANOATE. 

229555  01-17 
OUTPATIENT  THERAPY  WITH  FLUPHENAZINE-DECANOATE  IN 

SCHIZOPHRENIC  PATIENTS. 

229556  01-08 
ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 

FLUPHENAZINE-DECANOATE. 

229557  01-14 
CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE 

IN  TREATING  DISSOCIATIVE  SYNDROMES. 

229560  01-11 
FLUPHENAZINE  DECANOATE  IN  ASSOCIATION  WITH  OTHER 

PSYCHOTROPIC  DRUGS  (PREIIMINARY  NOTE). 

229561  01-17 
ANTIPARKINSONIAN  AGENTS  AND  FLUPHENAZINE  DECANOATE 

DECANOATE. 

236317  02-15 
FLUPHENAZINE-DECANOATE. 

237646  02-08 
A  COMPARATIVE  TRIAL  OF  Fl  UPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE. 

238975  03-08 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE  DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA 

238996  03-08 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG  TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE 

239823  03-08 
FLUPHENAZINE  DECANOATE. 

240663  03-08 
PARKINSONISM  INDUCED  BY  FLUPHENAZINE-DECANOATE. 

242267  03-15 
TECHNIQUE  OF  FLUPHENAZINE-DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES. 

246186  04-08 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE: 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04-03 
COMPARISON  OF  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE, 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04-08 
FlUPHENAZINE-ENANTHATE 

THE  LONG  TERM  USE  OF  HIGH  DOSES  OF  FLUPHENAZINE-ENANTHATE 
AND  FLUPHENAZINE-DECANOATE 

225936  01-08 
A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 
PATIENTS. 

230780  01  08 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE: 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04-03 


1 

Psychopharmacology  Abstracts 

FLUPHENAZINE-HCL  M 

INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN  1 

ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  0308' 
FLUPHENAZINES 

COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 
INCIDENCE  OF  SIDE-EFFECTS. 

252006  04-08 
FLURAZEPAM 

COMPARATIVE  EVALUATION  OF  FLURAZEPAM  AND  NITRAZEPAM  FOR 
OCCASIONAL  INSOMNIACS. 

228315  01  11 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL. 
FINDINGS. 

232530  01-07 
HYPNOTIC  EFFICACY  OF  LORAZEPAM  AND  FLURAZEPAM. 

237115  02-14 
EFFECT  OF  FLURAZEPAM  ON  SLEEP  SPINDLES  AND  K-COMPLEXES 

238507  02-14 
THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE 

239010  03-15 
FLURAZEPAM,  A  NEW  HYPNOTIC  FOR  THE  TREATMENT  OF  INSOMNIA. 

242502  03-14 
A  COMPARISON  OF  THE  EFFECTS  OF  FLURAZEPAM  30  MG  AND 
TRIAZOLAM  0.5  MG  ON  THE  SLEEP  OF  INSOMNIACS. 

244686  04-11 
THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04-13 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE: 
FLURAZEPAM  AND  PENTOBARBITAL. 

245652  04-11 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
FLURAZEPAM  HYDROCHLORIDE,  A  BENZODIAZEPINE  HYPNOTIC. 

250780  04-17 
EFFECT  OF  FLURAZEPAM  ON  COMMON  CLINICAL  LABORATORY  TESTS. 

251824  04-16 
SLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS. 

252230  04-11 
FLUROTHYL 

RETROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK. 

237260  02-04 
MEMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT. 

239852  03-04 
FLUSPIRILENE 

THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE 

239823  03-08 
FLUTAAAIDE 

RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  04  04 
FOCI 

CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02-03 
FOCUSED 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  {  i  ) 
AMPHETAMINE  AND  (  t  OR-)  P  CHLOROAMPHETAMINE. 

239976  03-03 
FOLATE 

FOLATE  RESPONSIVE  SCHIZOPHRENIA. 

227711  0111 
SCHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04- 16 
FOLIC-ACID 

FOLIC-ACID  AND  BEHAVIOR. 

229476  01-03 
FOLLOW-UP 

PIPAMPERONE  (DIPIPERON,  R-3  345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03  11 
FOOD 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD 

225571  01-04 


S-142 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE. 

226938  01-04 
FOOD  AND  DRUG-REINFORCED  RESPONDING:  EFFECTS  OF  DITA  AND  D- 
AMPHETAMINE. 

227127  01  04 
NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01-03 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251  01-04 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  02-04 
INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE 

237097  0203 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  DAMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
AN  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
ETHANOL,  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION 

238749  03-04 
THE  INFLUENCE  OF  FOOD  ON  SIDE-EFFECTS  AND  ABSORPTION  OF 
LITHIUM. 

238998  03-15 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO, 
DRUG  AND  A  FOOD  DRINK. 

239059  03-14 
EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES. 

239290  03-04 
DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN 

240014  03-04 
EFFECTS  OF  AMPHETAMINE,  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF-STIMULATION  IN  THE  RAT, 

24--1214  04-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE. 

249678  04-04 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
EFFECTS  OF  ALCOHOL,  CHLOROIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION 

250111  0404 
THE  FOOD  ADDITIVE  HYPOTHESIS,  LEAD,  AND  HYPERACTIVITY, 

251572  04-11 
EFFECTS  OF  LILLY-HOMO,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA,  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING, 

252522  04-03 
REBRAIN 
LEARNING  IN  THE  ABSENCE  OF  FOREBRAIN  NORADRENALINE 

234917  02-04 
EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETARHYTHM 

MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE 

234918  02-03 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 

VARIOUS  STIMULUS  PARAMETERS:  VI,  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES, 

241229  03-04 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTEM 
IN  LIMBIC  FOREBRAIN, 

245115  04-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 


TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  0403 

FORMALDEHYDE 

METHYLENE-REDUCTASE:  RESPONSIBLE  FOR  THE  IN  VITRO  FORMATION 
OF  FORMALDEHYDE  FROM  5-METHYLTETRAHYDROFOLIC-ACID. 

232613  02-03 
FOR^AATION 

DIFFERENTIAL  EFFECTS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY. 

230840  01-03 
METHYLENE-REDUCTASE:  RESPONSIBLE  FOR  THE  IN  VITRO  FORMATION 
OF  FORAAALDEHYDE  FROM  5-METHYLTETRAHYDROFOLIC-ACID. 

232613  02-03 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  03  03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION. 

239086  03-03 
FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 
UCS  HABITUATION 

241521  03-04 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION. 

241930  03-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 

FORMING 

REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRONIC 
MARIJUANA  SMOKERS. 

229039  01-15 
FORMULATION 

EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-94) 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  04-09 
FORTE 

TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  02-11 
FOSTERING 

EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02-04 
FRACTIONS 

RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 
BINDING  OF  GLYCINE  AND  GAMMA  AMINOBUTYRIC-ACID  TO 

SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE 

238349  02-03 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES 

238674  03-03 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-03 
FRAGMENTOGRAPHIC 

ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA 

238486  02  16 


30 


S-143 


Subject  Index 


Psychopharmacology  Abstracts 


GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 
FRAGMENTOGRAPHY 

THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04-13 
FRANCE 

COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-17 
FREE 

EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 
LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

24701 3  04-03 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
FREE-OPERANT 

ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
FREEDOM 

PSYCHOPHARMACOLOGY,  PSYCHOSIS  AND  FREEDOM. 

246123  04-17 
SUMMARY  OF  THE  DISCUSSIONS  AT  THE  SYMPOSIUM  PSYCHOSIS  AND 
FREEDOM. 

246126  04-17 
FREQUENCY 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORAAANCE  OF 
RATS  AND  PIGEONS 

226853  01-04 
BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION, 

228224  01-08 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY. 

251986  04-14 
FREQUENT 

APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS. 

236732  02-09 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION. 

245789  04- 15 
FROG 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG. 

226855  01-03 
EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FROG 
SPINAL  CORD. 

241922  03-03 
PENTOBARBITAL:  ACTION  ON  FROG  MOTONEURONS. 

247513  04-03 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE. 

249257  04-03 
FROG-KILLING 

EFFECTS  OF  IMIPRAMINE,  D-AMPHETAMINE,  AND  TRIPELENNAMINE  ON 
MOUSE-KILLING  AND  FROG-KILLING  BY  THE  RAT. 

243346  04-04 
FRONTAL 

INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

226935  01-03 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS 

242741  03-03 
BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04-04 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS 

250089  04-04 
FRONTAl-STRIATAl 

FRONTAL-STRIATAL  CONTROL  OF  BEHAVIORAL  INHIBITION  IN  THE  RAT. 

251138  04-04 
FRUSTRATION 

MODIFICATION  OF  THE  FRUSTRATION  EFFECT  WITH  DRUGS. 

229487  01-04 


FS32 

PHARAAACOLOGICAL  STUDIES  ON  1  3-DIMETHYLAMINOPROPYL-PHENYL- 
METHYLINDAZOLE  HYDROCHLORIDE  (FS32)  (1). 

241399  03-04 
FUGUE 

FUGUE  STATES   -  EPILEPSY   -  MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT.  AUGUST  I,  1975. 

237476  02-17 
FULFILUAENT 

MENTAL-HEALTH  PROGRAMS:  PROMISES'.  FULFILLMENT?.  FAILURES?. 

236911  02- 15 
FUNCTION 

DOPAMINE-BETA-HYDROXYLASE  IN  NERVE  FUNCTION  AND  MENTAL- 
ILLNESS. 

225869  01-17 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  01-13 
DISTRIBUTION  OF  CHLORPROAAAZINE  IN  THE  GASTROINTESTINAL  TRACT 
OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01  03 
CYCLIC  NUCLEOTIDES,  PROTEIN  PHOSPHORYLATION,  AND  NEURONAL 
FUNCTION. 

231021  01-17 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 
REGULATION  OF  FUNCTION  OF  TRYPTOPHAN-HYDROXYLASE. 

233958  02-03 
CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION, 

236801  02-13 
CYCLIC  NUCLEOTIDES  AND  THEIR  POSSIBLE  RELEVANCE  TO  DISORDERS 
OF  NERVOUS  SYSTEM  FUNCTION.  (UNPUBLISHED  PAPER). 

237171  02-03 
INTRACRANIAL  SELF- STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTION 
OF  THEIR  CHEMICAL  STRUCTURE. 

241428  03  12 
VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE.  (PH.D.  DISSERTATION). 

241689  03-04 
THE  EFFECT  OF  AMPHETAMINE  STEREOISOMERS  ON  THE  FUNCTION  OF 
DOPAMINE  SYNAPSES  IN  VITRO. 

244043  04-03 
CNS  PHOSPHOLIPID  METABOLISM  AND  NEURONAL  FUNCTION. 

244089  04-03 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL   APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  I- 
HYDROXY-3-AMINO-PYRROLIDONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04-03 
EFFECT  OF  INTRAVENOUS  DIAZEPAM  ON  RENAL  FUNCTION. 

246273  04-15 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04-13 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION. 

246996  04  03 
METHYLPHENIDATE  IN  CHILDREN:  EFFECTS  UPON  CARDIORESPIRATORY 
FUNCTION  ON  EXERTION. 

247378  04  15 
STUDIES  ON  THYROID  THERAPY  AND  THYROID  FUNCTION  IN  DEPRESSIVE 
PATIENTS 

249123  04-13 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 

ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 


S-144 


IME  14,  SUBJECT  INDEX 

lONAL 

NCTIONAL  SIGNIFICANCE  OF  CENTRAL-NERVOUS-SYSTEM 
NOREPINEPHRINE  AND  DOPAMINE:  A  PSYCHOPHARMACOLOGICAL 
STUDY.  (PH.D.  DISSERTATION). 

231437  01-04 

'ALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 
PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02-11 
CITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02-03 
HAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  ( -l^ ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
IE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS. 

248159  04-03 
JRTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO  INTERPEDUNCULAR 
NEURONS    PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AND 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

249669  04-04 
IFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 
ECENT  ADVANCES  IN  THE  DRUG  TREATMENT  OF  THE  FUNCTIONAL 
PSYCHOSES. 

252653  04-09 

riONALlY 

ARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT. 

232606  02  03 
riONING 

FFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
RANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 
NEUROLEPTIC  TREATMENT. 

242868  04-11 

TIONS 

'SYCHOTROPIC  DRUGS  AND  IMPARIMENT  OF  PSYCHOMOTOR 
FUNCTIONS. 

227136  01-15 
HE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY. 

230830  01-14 
:FFECT  of  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS 

233962  02-03 
\  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR 

238800  03-04 

;ffects  of  azaperone  on  cardiovascular  and  respiratory 
functions  in  the  horse. 

243759  04-03 
MEURAL  and  NEUROENDOCRINE  FUNCTIONS  OF  DOPAMINE. 

247690  04-17 

wemory  functions  in  depression:  improvement  with 
antidepressant  medication. 

248583  04-09 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-11 

}Al 

5-HYDROXYTRYPTAMINE  I4C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 

LITY 

LITHIUM  ■    FUTILITY,  DISASTER  AND  TRIUMPH 

227411  01-17 
A 

REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 


Subject  Index 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 

THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-03 
DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 

SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01  03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 

BENZODIAZEPINES 

229465  01-03 

INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -  STUDIES 
ON  RAT  CEREBELLUM. 

229466  01-03 

GABA  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA. 

231019  01-17 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS 

232507  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01  03 

EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 
BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM. 

232514  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 

BENZODIAZEPINES. 

232515  01-03 
THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 

SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02  03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02  03 
EFFECTS  OF  TRANQUILIZER  DRUGS  ON  GABA  RELEASE  IN  VITRO. 

238779  03  03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 

LEVELS  IN  THE  MOUSE. 

238791  03-03 

SOME  THERAPEUTIC  USES  OF  GABA  IN  NEUROLOGY. 

239700  03- 1 1 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
SOME  RECENT  ADVANCES  IN  THE  BIOCHEMICAL  PHARMACOLOGY  OF 
GAMMA-AMINOBUTYRIC-ACID  (GABA)   (UNPUBLISHED  PAPER). 

240699  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03  03 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIMALS,  4TH 
REPORT    COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03  04 
DIAZEPAM  AND  CHLORDIAZEPOXIDE.  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205  04  03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

248957  04  03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04  03 
EFFECTS  OF  GABA  BLOCKADE  ON  LATERAL  HYPOTHALAMIC  SELF- 
STIMULATION 

252017  04  04 

BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  04  03 
GABA-TRANSAMINASE 

GAMMA  ACETYLENIC-GABA  (AMINO-4  HEX-5-YN0IC-ACID):  A  GABA 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY 

238781  03  04 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 

INHIBITORS  OF  MAMMALIAN  BRAIN  GABA  TRANSAMINASE  GAMMA- 
VINYL-GABA  (AMINO-4  HEX-5-EN0IC  ACID)  AND  GAMMA-ACETYLENIC- 
GABA  (AMIN0-4-HEX-5  YNOIC-ACID) 

238782  03  03 


^ 


CSS 


S-145 


Subject  Index 


Psychopharmacology  Abstract 


GAD 

6HYDR0XYD0PAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACf  TYITRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS, 

238826  03-03 
GAIN 

CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS 

237900  02-10 
LITHIUM  TREATMENT  AND  WEIGHT  GAIN. 

249927  04-15 
GAA«AA-ACETYIENIC-GABA 

GAMMA-ACETYLENIC-GABA  (AMIN0-4-HEX  5-YNOIC-ACID):  A  GABA- 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY. 

238781  03-04 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 

INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE,  GAMMA- 
VINYL  GABA  (AMINO-4  HEX-5  ENOIC  ACID)  AND  GAMMA-ACETYLENIC- 
GABA  (AMIN0-4HEX-5  YNOIC-ACID) 

238782  03-03 
GAAAAAA-AMINOBUTYRATE 

EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA  AMINOBUTYRATE  (GABA)  AND  GLUTAAAATE  (GLU) 
LEVELS  IN  IHf  MOUSE. 

238791  03-03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
GAMAAA-AMINOBUTYRIC-ACID 

REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA  AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 
INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC  ACID  AND  i-HYDROXYTRYPTOPHAN 
(UNPUBLISHED  PAPER). 

231278  01-06 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA  AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN. 

236370  02-03 
GAMMA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL. 

237786  02-03 
BINDING  OF  GLYCINE  AND  GAMMA-AMINOBUTYRIC  ACID  TO 
SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 
SOME  RECENT  ADVANCES  IN  THE  BIOCHEMICAL  PHARMACOLOGY  OF 
GAMMA-AMINOBUTYRIC-ACID  (GABA).  (UNPUBLISHED  PAPER). 

240699  0303 
CENTRAL  GAMMA  AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER) 

243041  04-03 
FAILURE  OF  INCREASED  BRAIN  GAMMA  AMINOBUTYRIC-ACID  LEVELS  TO 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730  04-03 
GAMMA-AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  lURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION 

253392  04-04 
GAAAMA-GIUTAMYL-TRANSPEPTIDASE 

CELLUIAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMMA- 
GLUTAMYL  TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03  03 
GAMMA-HYDROXYBUTYRATE 

GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAl  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  I- 
HYDROXY-3-AMINO-PYRROLIDONE  2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION 

245599  04-03 
GAAAMA-VINYl-GABA 

A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL  GABA  (AMINO  4  HEX  5-ENOIC-ACID)  AND  GAMMA-ACETYLENIC- 
GABA  (AMINO  4-HEX  5  YNOIC-ACID). 

238782  03-03 
GANGLIA 

THE  EFFECTS  OF  ADRENALINE.  RESERPINE,  AND  ATROPINE  ON 
ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS, 

227635  01-03 


DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFRO' 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01  ■( 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01-1 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  t 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-( 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-( 
INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03-( 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-( 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA 

244200  04-( 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD 

248724  04-( 
MECHANISMS  OF  TRANS  SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-( 
GANGLION 

EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDITIONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION.  (PH.D. 
DISSERTATION). 

228503  01-0 
INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION, 

232333  01 -C 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLIOf 
CELLS  IN  RABBIT  RETINA 

236863  02-C 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  O4-0 
GANGLIONIC 

THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-0 
DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04-0 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 
ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 
IN  THE  RAT. 

246843  04-0 
GANGLIOSIDES 

EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-0 
GAS 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

235511  02-a 
A  GAS  CHROAAATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS 

237152  02-11 
GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROMAZINE, 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM. 

237750  02-0< 
GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES, 

238774  03-0' 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROMATOGRAPHY, 

245300  04-0: 
GAS-LIQUlO 

DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROAAATOGRAPHY, 

229906  01 -K 


S-146 


ME  14,  SUBJECT  INDEX 


Subject  Index 


ANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
/ARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  OM 3 
JDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01-13 
ECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
3ASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  0303 
3INTESTINAL 

iTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRACT 
3F  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01-03 
IPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
-ROM  THE  GASTROINTESTINAL  TRACT  IN  MAN 

233296  02-13 
RAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

241274  03-14 
RAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERLAY 
A  DOUBLE-BLIND  CROSSOVER  STUDY) 

250193  04-14 

,S  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 

fERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
R 

YCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-08 
AllZATION 

FECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 
DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMMATURE  RAT. 
(PH.D.  DISSERTATION). 

231533  01-04 
NERALIZATION  OF  MORPHINE  AND  lYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04-04 
LTA9  TETRAHYDPOCANNABINOL,  ETHANOL,  AND  AMPHETAMINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  04-04 
ATING 

NTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS. 

238798  03-03 
TA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
:TI0N  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 
REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTEM 
IN  LIMBIC  FOREBRAIN. 

245115  04-03 
FECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SC), 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 

;is 

lARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS 

244874  04-03 
IC 

IE  GENETIC,  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH  D   DISSERTATION). 

241687  03-04 
CUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS. 

253617  04-09 
ICS 
ENETICS  AND  PSYCHOPHARMACOLOGY 

23)41001-17 
ULATE 

MERAL  GENICULATE  MULTIPLE-UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES. 

231719  01-03 
RUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO  4-1284  AND 


BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03  03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY, 

241319  03-03 
GERBIL 

SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIL  (MERIONES-UNGUICULATUS). 

241311  03-04 
GERIATRIC 

ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
EFFECTS  OF  A  PROCAINE  PREPARATION  (GER0VITAL-H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  STUDY. 

227330  0111 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271  02-14 
REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS. 

239641  03  11 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC-BRAIN-SYNDROME 

249625  04-11 
THE  EFFECTS  OF  THIOTHIXENE  IN  GERIATRIC  PATIENTS  WITH  CHRONIC 
ORGANIC-BRAIN-SYNDROME. 

253050  04-11 
A  STANDARD  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE  ON 
GERIATRIC  PATIENTS. 

253058  04  11 
GERIATRICS 

TREATMENT  OF  DEPRESSION  IN  GERIATRICS  WITH  ANAFRANIL 

229370  01-11 
GEROPSYCHIATRIC 

CNS  STIMULANTS  AND  ANABOLIC  SUBSTANCES  IN  GEROPSYCHIATRIC 
THERAPY. 

229459  01-11 
GEROVITAI-H3 

EFFECTS  OF  A  PROCAINE  PREPARATION  (GER0VITAL-H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE  BLIND  STUDY. 

227330  01  11 
GER0VITAL-H3    -  A  REVIEW  OF  THE  LITERATURE. 

229460  01   11 
RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WITH 

GER0VITAL-H3  TABLETS. 

246425  04-09 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3: 
CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  04-11 
GILLES-DE-IA-TOURETTES 

A  CASE  OF  GILLES-DE-LA-TOURETTES  SYNDROME 

228074  01-11 
THE  PROBLEMS  AND  TREATMENT  OF  PATIENTS  WITH  GILLES  DE-LA- 
TOURETTES  SYNDROME. 

229295  01-11 
TWO  CASES  OF  GILLES-DE-LA-TOURETTES  SYNDROME  TREATED  WITH 
HALOPERIDOL. 

246715  04-11 
GLABELLAR 

ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 

DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN. 

246992  04- 13 
GLAND 

THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL.  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT 

236528  02-03 


ess 


^S- 


S-147 


Subject  Index 


Psychopharmacology  Abstrac 


INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
GIC 

QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS. 

233277  02-06 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  02-06 
GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEDIOXYAMPHETAMINE  (MDA)  FROM  PLASMA  AND  URINE. 

238484  02-06 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
GLC  ANALYSIS  OF  THIORIDAZINE,  MESORIDAZINE  AND  THEIR 
METABOLITES. 

251776  04-16 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301 1  04-07 
GLIA 

NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04-03 
GLIAL 

ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE  CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 
A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE. 

241348  03-03 
GLIOMA 

OPIATE  RECEPTORS  AND  ADENYLATE  CYCLASE  IN  NEUROBLASTOMA  X 
GLIOMA  CELL  LINES    (UNPUBLISHED  PAPER). 

238571  02-03 
GLU 

EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA  AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  04-03 
GLUCAGON 

COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 
ADENYLATE  CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON, 

241347  03-03 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
GLUCOCORTICOIDS 

REGULATION  OF  5-HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
BRAIN  BY  ADRENAL  GLUCOCORTICOIDS 

226401  01-03 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-03 
GIUCOPRIVIC 

HYPOTHALAMIC  NORADRENALINE  TURNOVER  IS  INCREASED  DURING 
GLUCOPRIVIC  FEEDING 

238804  03-04 
GLUCOREGULATORY 

GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6- 
HYDROXYDOPAMINE  OR  LATERAl  HYPOTHALAMIC  LESIONS. 

227125  01-04 
GLUCOSE 

SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN 

229042  Oil  3 
VIOIENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION   A  NEW  SYNDROME, 

233870  02-11 
RELEASE  OF  H3  ALPHA  METHYL-TYRAMINE  FROM  CORPUS  STRIATUM  IN 
VITRO  AND  THE  EFFECTS  OF  GLUCOSE  DEPRIVATION. 

238731  03-03 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG  TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
GLUCURONIDATION 

STUDIES  ON  THE  GLUCURONIDATION  OF  7-HYDROXYCHLORPROMAZINE 
IN  VITRO 

249284  04  03 


GLUTAMATE 

EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ( 
BRAIN  GAMAAA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03- 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BR/s 
GLUTAAAATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  II 
THE  MOUSE. 

249292  04- 
GLUTAMIC-ACID 

THE  RELEASE  OF  GLUTAMIC-ACID  FROM  ISOLATED  BRAIN  TISSUES. 

236522  02- 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTR 
AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTR 
AND  BEHAVIOR;  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

248957  04 
GLUTAMIC-ACIO-DECARBOXYLASE 

6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RAT 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03 
GLUTAMIC-DECARBOXYLASE 

NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AN 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  04 
GLYCINE 

THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARAAACOLOGIC 
ACTIONS  OF  BENZODIAZEPINES. 

232511  01 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347  02 
BINDING  OF  GLYCINE  AND  GAM/WA-AMINOBUTYRIC-ACID  TO 

SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

241921  03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS. 

243762  04 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  04 
GlYOXYLIC-ACID 

A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENC 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02 
GNAWING 

EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCEt 
GNAWING  OF  MICE. 

237107  02 
DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING. 

242745  04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCEC 
GNAWING  OF  MICE 

248960  04 
GOLDFISH 

EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03 
GONADOTROPHIN 

PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FO 
ANOREXIA  NERVOSA. 

240423  03 
GOODENOUGHS 

DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOOOENOUGH; 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02 
GORHAMS 

PSYCHOMETRIC  CLINICAL  EVALUATION,  THROUGH  OVERALL  AND 
GORHAMS  TEST,  OF  THERAPY  WITH  FLUPHENAZINE-DECANOATE 

229555  01 
GPA-2640 

A  PILOT  STUDY  OF  THE  SHORT-TERM  PSYCHOTROPIC  EFFECTS  OF  GPA- 
2640. 

250516  04 


S-148 


JME  14,  SUBJECT  INDEX 


Subject  Index 


EO-RELEASE 

^E  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 
CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  0401 

DAXIN 

HE  MAIN  PHARMACOLOGICAL  CHARACTERISTICS  OF  GRANDAXIN 
(TOFIZOPAM,  EGYT-341). 

252445  04-02 
HE  EFFECT  OF  GRANDAXIN  ON  LORRY  DRIVERS. 

252446  04-14 
HE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMENT  OF 

OUTPATIENTS  (A  MULTICENTRIC  STUDY). 

252448  04-07 
REATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA- 

GRAVIS:  (GRANDAXIN,  A  NEW.  NONRELAXANT  TRANQUILLIZER). 

252449  04-07 
HE  TREATMENT  OF  CLIMACTERIC  SYNDROME  WITH  TOFIZOPAM 

(GRANDAXIN). 

252450  04-11 
ULAR 

ELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 

NTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 
ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03-04 
HE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA:  FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY. 

249248  04-03 
)MING 

OLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS. 

239978  03-04 
SYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PH.D.  DISSERTATION). 

241994  03-04 
IP 

ACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 
CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 
STUDY  GROUP. 

225718  01-09 
'ILOXAZINE  (VIVALAN)  -  GENERAL  PRACTITIONER  GROUP  STUDIES. 

227226  01-09 
HE  DIFFERENTIAL  EFFECTS  OF  CHLORDIAZEPOXIOE  AND  OXAZEPAM  ON 
HOSTILITY  IN  A  SMALL  GROUP  SETTING. 

227569  01-14 
»  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

227914  01-10 
^  COMBINATION  OF  ANTIANXIETY  DRUGS:  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

228207  01  10 
:OMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 
CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-09 
'REDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 
DEPRESSED  OUTPATIENTS. 

229449  01-09 
:OMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 
EVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
OYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03-11 
IXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ, 

241798  03-03 
'ECULIAR  CLINICOPHARMACOLOGICAL  PROPERTIES  OF  CLOZAPINE 
REVEALED  IN  A  GROUP  OF  CHRONIC  SCHIZOPHRENICS. 

244587  04-08 
3EHAVI0RAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04-04 
iXPOSURE  IN  VIVO  OF  AGORAPHOBICS:  CONTRIBUTIONS  OF  DIAZEPAM, 
GROUP  EXPOSURE,  AND  ANXIETY  EVOCATION 

250727  04-10 


EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

251070  04-03 
GROUPED 

HALOPERIDOL  CATALEPSY  IN  GROUPED  AND  ISOLATED  MICE. 

249624  04-04 
GROUPING 

EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485  04-04 
GROUPS 

MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 
GROUPS  OF  RATS. 

247207  04-04 

GROWING 

MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04  05 
GROWTH 

NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01  04 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 
ROLE  OF  GROWTH  HORMONE. 

237253  02-11 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  AFTER  PHENOTHIAZINE  TREATMENT. 

243193  04-10 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04  14 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  04-04 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246661  04-03 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE. 

246662  04-03 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 

WITH  PHENOBARBITAL. 

250682  04-05 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN  INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN, 

253041  04  15 
GSR 

EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237102  02-14 
GUANETHIDINE 

THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO- 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING 

227138  01  04 
GUANETHIDINE-INDUCED 

SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAl  BRAIN. 

241366  03-03 
GUANOSINE 

EFFECTS  OF  STIMULAFORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03  03 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
GUIDE 

THIRD  PSYCHOACTIVE  DRUG  USAGE  GUIDE. 

247880  04-17 


SO 


so 


as 


S-149 


Subject  Index 


Psychopharmacology  Abstrat 


GUIDELINES 

GUIDELINES  FOR  ANTIPSYCHOTIC  DRUG  USE. 

227731  01-17 
MONITORING  OF  LITHIUM  TREATMENT:  GUIDELINES  BASED  ON 
PHARMACOKINETIC  CONSIDERATIONS. 

236806  02- 16 
GUINEA-PIG 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762  01-03 
INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 

NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS.  (UNPUBLISHED 
PAPER). 

227777  01-03 
THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 
INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION. 

232333  01-03 
THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712  02-04 
AMPHETAMINE  TACHYPHYLAXIS  IN  THE  PITHED  GUINEA-PIG. 

238315  02-03 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC  AMP  GENERATING 
SYSTEMS. 

238798  03-03 
INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE,  BUT 
NOT  OF  DOPAMINE  BETA-HYDROXYLASE  FROM  GUINEA-PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER). 

247028  04-03 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  IN 
THE  GUINEA-PIG  INTESTINE. 

248703  04-03 
TOLERANCE  TO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA-PIG) 
THAT  METABOLIZE  IT  DIFFERENTLY. 

250723  04-03 
GUINEA-PIGS 

EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  DELTA9-TRANS- 
TETRAHYDROCANNABINOL  (DELTA9-THC)  IN  GUINEA-PIGS. 

229033  01-03 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-03 
GUTIMIN 

EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
HA-966 

EEG  SYNCHRONIZING  EFFECT  OF  GAMMA-HYDROXYBUTYRATE  AND  1- 
HYDR0XY-3-AMIN0  PYRROLIDONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04-03 
HABENULO-INTERPEDUNCULAR 

FURTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO-INTERPEDUNCULAR 
NEURONS    PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
HABIT 

FFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCEO  AMNESIA  IN  MICE 

245614  04-02 
HABITUATION 

ffFEf  TS  OF  D    AND  L  AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS 

227126  01-04 
EFFECTS  OF  SCOPOLAMINE  ON  HABITUATION  OF  EXPLORATORY 
ACTIVITY  IN  RATS 

235509  02-04 
P  (IILOROAMPHETAMINE  (PCA)r  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RFSPONSt  IN  RATS 

240062  03-04 
lORMAllON  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 
UCS  HABITUATION. 

241521  03-04 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT. 

241546  03-04 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
Of  EXPLORATION  AND  DISTRACTION'. 

241932  0304 


EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04 
HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SK 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS. 

248514  04 
HALLUCINATIONS 

CORTICAL  DISINHIBITION:  A  POSSIBLE  MECHANISM  FOR  DRUG-INDUCI 
HALLUCINATIONS. 

238830  03 
HALLUCINOGEN 

INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01 
THE  INDOLE  HALLUCINOGEN  MODEL:  IS  IT  WORTH  PURSUING?. 

241872  03 
HALLUCINOGENIC 

GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION. 

23481 1  0/ 
HALLUCINOGENIC  INDOLEAMINES:  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS. 

240073  O; 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTK 
OF  THEIR  CHEMICAL  STRUCTURE 

241428  03 
CENTRAL  ACTIONS  OF  HALLUCINOGENIC  DRUGS. 

244071  0-: 
HALLUCINOGENS 

EFFECTS  OF  HALLUCINOGENS  ON  OPERANT  BEHAVIOR. 

238814  0: 
INTERACTIONS  OF  HALLUCINOGENS  AT  THE  CLINICAL  LEVEL. 
(UNPUBLISHED  PAPER). 

244195  0': 
HALOGENATED 

RADIOPHARMACEUTICALS.  16    HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  0/ 
HALOPERIDOL 

INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 
HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATI 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZII 

227129  01 
HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 

227389  01 
A  DOUBLE-BLIND  TRIAL  OF  LITHIUM  CARBONATE  AND  HALOPERIDOL  I 
HUNTINGTONS-CHOREA. 

227550  01 
THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE 
INDUCED  AND  LSD  INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01 
THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  AND 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  IN 
RATS. 

230452  01 
NEUROENDOCRINE  EFFECTS  OF  HALOPERIDOL  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

230839  01 
A  TERATOGENIC  STUDY  OF  HALOPERIDOL. 

231604  01 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMI 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  0; 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  I 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE 

233291  O; 
EFFECTS  OF  HALOPERIDOL  ON  SCHEDULE-INDUCED  POLYDIPSIA. 

236708  O; 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDC 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  0: 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS 

237704  0-< 
GAMMA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHIN 
AND  HALOPERIDOL 

237786  O: 
RADIOIMMUNOASSAY  FOR  HALOPERIDOL. 

238776  O: 


S-150 


uUME  14,  SUBJECT  INDEX 


Subject  Index 


ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL,  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY 

239826  03-04 

CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I    INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-08 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
EFFECTS  OF  HALOPERIDOL  ON  AVERSIVE  THRESHOLD  OF  RATS 

240886  03-03 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313  03-03 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE, 

244513  04  03 
HALOPERIDOL. 

245621  04-14 
CLINICAL  OBSERVATIONS  ON  THE  TREATMENT  OF  TARDIVE-DYSKINESIA 
WITH  HALOPERIDOL. 

245967  04-08 
TWO  CASES  OF  GILLESDE-LA-TOURETTES  SYNDROME  TREATED  WITH 
HALOPERIDOL 

246715  04-11 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 
HALOPERIDOL. 

248274  04-03 
HALOPERIDOL  CATALEPSY  IN  GROUPED  AND  ISOLATED  MICE. 

249624  04-04 
COMPARISON  OF  LOW  DOSES  OF  HALOPERIDOL  AND  DIAZEPAM  IN 
ANXIETY  STATES. 

250491  04-10 
EFFECT  OF  HALOPERIDOL  ON  (  +  )  AMPHETAMINE  SELF-ADMINISTRATION. 

250658  04-04 
THE  EFFECT  OF  HALOPERIDOL  ON  STUTTERING. 

252793  04-11 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04-08 
DEMENTIA  INDUCED  BY  METHYLDOPA  WITH  HALOPERIDOL, 

253391  04-15 
OTHANE 

INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 
NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS,  (UNPUBLISHED 
PAPER) 

227777  01-03 
EFFECTS  OF  HALOTHANE  ANESTHESIA  ON  THE  BIODISPOSITION  OF 
KETAMINE  IN  RATS. 

250108  04  03 
STEAD-REITAN 

THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY 

229650  01-14 
HILTON 
THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL 

226899  01-09 
ASTER 

A  STUDY  ON  THE  DEVELOPMENT  OF  BARBITURATE-TOLERANCE  AND 
DEPENDENCE  IN  HAMSTER  GLIAL  CELLS  IN  CULTURE 

241348  03-03 
INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARMACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIAL 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR. 

244899  04-04 
4DBOOK 

HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01-06 
ilDICAP 
DRUG  THERAPY  IN  MENTAL  HANDICAP. 

249525  04-17 
IDLING 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6-HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS 

228142  01-04 


HANDS 

PSYCHOPHARMACEUTICALS  IN  THE  HANDS  OF  THE  GENERAL 

PRACTITIONERS  -  VERTIGO  STATES:  OVERVIEW  AND  SHORT  REPORTS 

239768  03-17 
HAPTEN 

HAPTEN  IMMUNOLOGICAL  STUDIES  ON  MESCALINE 

253536  04-03 
HARMALINE 

THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES 

246856  04-13 
HARMINE 

EFFECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04-03 

HASHISH 

EFFECTS  OF  HASHISH  ON  ISOLATION  INDUCED  AGGRESSION  IN  WILD 

MICE. 

237714  02-04 

THE  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG.  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
HATCHING 

CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIAIAMIDE  INJECTION. 

235317  02-04 

HEAD 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  O 
AMPHETAMINE  AND  (  f  OR-)  P-CHLOROAMPHETAMINE 

239976  03-03 

HOMOVANILLIC  ACID  AND  S-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY    I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLIC-ACID  AND  5  HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES, 

246994  04-13 
GAMMA-AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION, 

253392  04-04 
HEAD-TWITCHES 

STUDY  ON  HEAD-TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE, 

241.380  03-04 
HEADACHE 

CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
HEADACHES 

ON  THE  MULTIFACTORIAL  TREATMENT  OF  CHRONIC  HEADACHES 

238866  03-11 
HEALTHY 

ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
HEARING 

TRANSPLACENTAL  EFFECTS  OF  DRUGS  ON  HEARING,  VISION,  AND 
BEHAVIOUR, 

227391  01-05 
HEART 

NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 
RUBIDIUM  TREATMENT, 

230817  01-03 
EFFECTS  OF  DIAZEPAM  ON  THE  ISOLATED  CHICK  EMBRYO  HEART 

230862  01-03 
EFFECTS  OF  CANNABINOIDS  ON  THE  IN  VITRO  PERFUSED  RAT  HEART, 

238767  03-03 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER 

239044  0303 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE, 

241414  03  03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 


ES 


S-151 


Subject  Index 


Psychopharmacology  Abstra 


HEARTRATE 

THE  INFLUENCES  OF  METHYLPHENIDATE  Qm  HEAPJPATE  AND 
BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  MAN. 

232531  01-13 
EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG 

240916  03-04 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-04 
HELIUM 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

23551 1  02-04 
HELIX 

EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS  SYSTEM  OF  THE  SNAIL  HELIX  POMATIA. 

243799  04-03 
HEMISPHERE 

VERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE. 

251939  04-14 
HEMODYNAMICS 

THE  EFFECT  OF  SEROTONIN  INJECTION  INTO  THE  BULBAR  STRUCTURES 
ON  HEMODYNAMICS. 

236831  02-03 
HEMOLYTIC 

COOMBS-POSITIVE  HEMOLYTIC  ANEMIA  PROVOKED  BY 
CHLORPROMAZINE. 

237161  02-15 
HEMP 

PSYCHOSIS  FOLLOWING  INGESTION  OF  HEMP  IN  CHILDREN. 

237730  02-15 
HEPATIC 

CHLORDIAZEPOXIDE  METABOLISM  IN  MICE  FOLLOWING  HEPATIC 
IRRADIATION. 

226840  01-03 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  01-15 
INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN-INDUCED  HYPOPROTHROMBINEMIA. 

237760  02-03 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS  -■  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 
ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
HEPATITIS 

NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
HEPATOCYTES 

THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  03-06 
HEREDITARY 

IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS. 

239851  03-03 
PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS 

243979  04-09 
HEREDITY 

HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE  DAWLEY  RATS. 

230007  01-04 
HERNIA 

THE  RELATIONSHIP  BETWEEN  HIATUS  HERNIA  AND  TRICYCLIC 
ANTIDEPRESSANTS:  A  REPORT  OF  FIVE  CASES. 

245523  04-15 
HEROIN 

ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN 

226870  01-03 
HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS. 

239939  03-11 


THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AN 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  0 
DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN. 

240014  0 
HERRMANNS 

SERUM  CONCENTRATION  OF  CARBAAAAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301 1  0 
HETEROCYCLIC 

DRUGS  DERIVED  FROM  CANNABINOIDS.  5.  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  0 
HETEROGENEITY 

BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS 
CEREBELLUM:  PHARAAACOLOGICAL  HETEROGENEITY  CONFIRMED  8^ 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  0 
HEXOBARBITAL 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETI 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  0 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRI 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  0 
THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL.  (PH.D.  DISSERTATIO 

240933  0 
BARBITAL  ALTERATION  OF  CENTRAL-NERVOUS-SYSTEM  SENSITIVITY  ' 
HEXOBARBITAL  IN  THE  RAT. 

244688  0 
HEXOBARBITONE 

THE  EFFECT  OF  OUABAIN  AND  DIGITOXIN  ON  HEXOBARBITONE  SLEEP 
TIME  IN  THE  MOUSE. 

225574  0 
A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAIN! 

230870  0 
HIATUS 

THE  RELATIONSHIP  BETWEEN  HIATUS  HERNIA  AND  TRICYCLIC 
ANTIDEPRESSANTS:  A  REPORT  OF  FIVE  CASES. 

245523  0 
HIBERNATION 

THE  EFFECT  OF  IMIPRAMINE  ON  AROUSAL  FROM  HIBERNATION. 

228549  0 
HIGH-AVOIDANCE 

NICOTINE-LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

239865  0 
HILLS 

THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESIS 

237711  0 
HIPPOCAMPAL 

HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA-INDUCED 
HYPERACTIVITY  IN  THE  RAT. 

226734  0 
EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHi 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918  0: 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AN 
BEHAVIORAL  ACTIVITY  CORRELATES, 

239858  O: 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  DIAZEPAM  ON  HIPPOCAMPAL 
EVOKED  RESPONSES 

239961  O: 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  ANC 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  0- 
HIPPOCAMPAL  THETA-RHYTHM.  I.  DEPTH  PROFILES  IN  THE  CURARIZE 
RAT. 

251061  a 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS.  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  0' 
HIPPOCAMPUS 

CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATIC 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01 


S-152 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  02-04 
AROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 
HIPPOCAMPUS. 

247420  04-04 
5-HT  ANTAGONISTS  IN  RAT  HIPPOCAMPUS. 

251072  04-03 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS.  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04-03 
AMINE 

ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03-03 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2-RECEPT0R  ANTAGONISTS  IN  THE 
RAT  CEREBRAL  CORTEX. 

248725  04-03 
AMINE-INDUCED 

THE  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE- 
INDUCED  CATALEPSY  IN  THE  RAT. 

240238  03-03 
AMINERGIC 

STUDIES  ON  THE  EFFECTS  OF  HISTAMINERGIC  AGENTS  ON  SEIZURE 
SUSCEPTIBILITY  IN  MICE. 

251983  04-03 
OCHEMICAl 

A  HISTOCHEMICAL  STUDY  ON  THE  CENTRAL  EFFECT  OF  MONOAMINE 
PRECURSORS. 

229068  01-03 
OLOGY 

THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
rONE 

ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3- 
MONOOXYGENASE.  (UNPUBLISHED  PAPER). 

237172  02-03 
rORY 

LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 
UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
O-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
rOTOPOGRAPHY 

HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 
BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE. 

241989  03-03 
ME 

THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN-MAGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 
STUDY. 

243180  04-11 
MEOSTASIS 
THERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE. 

243815  04-03 
MOGENATES 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
STUDIES  ON  ACCUMULATION  OF  (14C)  MESCALINE  IN  BRAIN 
HOMOGENATES:  EFFECTS  OF  PSYCHOTROPIC  AND  OTHER  AGENTS. 

246817  04-03 
MOVANILLIC-ACID 
INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 
CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-03 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 


PROBENECID-  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01  06 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04-13 
HORMONAL 

CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 
ANALYSIS  OF  HORMONAL  MEDIATION  OF  DRINKING  BEHAVIOR. 

244469  04-04 
HORMONAL  INFLUENCES  ON  THE  EXTINCTION  OF  CONDITIONED  TASTE 
AVERSION. 

251980  04-04 

HORMONE 

CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01  09 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  AAAN. 

229042  01-13 
A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN-RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693  01  09 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
THYROTROPIN-RELEASING  HORMONE  IN  CHRONIC  SCHIZOPHRENIA. 

233817  02-08 
THYROTROPIN-RELEASING  HORMONE  IN  DEPRESSION:  CLINICAL  AND 
ENDOCRINOLOGICAL  FINDINGS. 

235370  02-09 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK- 
ACTING  BUT  SHORT-LASTING  ANTIDEPRESSANT. 

235630  02-09 
THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-04 
TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 
ROLE  OF  GROWTH  HORMONE. 

237253  02-11 
PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE.  (UNPUBLISHED  PAPER). 

238491  02  13 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROAAAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04- 15 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  AFTER  PHENOTHIAZINE  TREATMENT. 

243193  04-10 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION, 

243790  04-03 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04-14 
EFFECTS  OF  THYROTROPIN-RELEASING  HORMONE  IN  SCHIZOPHRENIA. 

244528  04-08 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246661  04-03 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE. 

246662  04-03 
BEHAVIORAL  EFFECTS  OF  L-DOPA  AND  THYROTROPIN-RELEASING 

HORMONE  IN  SCHIZOPHRENIC  PATIENTS:  A  PRELIMINARY  REPORT, 

249120  04-08 
STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN-RELEASING 
HORMONE  (TRH)  IN  RABBITS. 

249280  04-04 


iSSc 


ft 


HXS 


S-153 


Subject  Index 


Psychopharmacology  Abstracts 


INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPINRELEASING  HORMONE  IN  CATS. 

249281  04-02 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  04-03 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANOL 
SLEEP  BY  THYROTROPINRELEASING  HORMONE  (TRH) 

250110  04-03 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
HORMONES 

PSYCHOTROPIC  ACTION  OF  SEX  HORMONES. 

229470  01-14 
ARE  HORMONES  PSYCHOACTIVE?  EVOKED  POTENTIAL  INVESTIGATIONS 
IN  MAN. 

232532  01-14 
HORN 

DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01-03 
HORSE 

EFFECTS  OF  AZAPERONE  ON  CARDIOVASCULAR  AND  RESPIRATORY 
FUNCTIONS  IN  THE  HORSE. 

243759  04-03 
HOSPICE 

BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-71 1  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 
HOSPITAL 

ISSUES  CONCERNING  DRUG  THERAPY  IN  THE  MENTAL  HOSPITAL. 

228322  01-17 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 
PSYCHIATRIC  HOSPITAL 

235545  02-17 
INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271  02  14 
DEATH  AND  DRUG  TREATMENT  IN  A  PSYCHIATRIC  HOSPITAL. 

243716  04-15 
ALCOHOLISM:  A  GENERAL  HOSPITAL  MEETS  THE  CHALLENGE. 

244136  04-11 
CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS: 
LV  A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON  LIKE  ILLNESS 

245863  04-08 
A  CLINICAL  TRIAL  OF  TEMAZEPAM,  A  SLEEP  INDUCER.  IN  HOSPITAL 
PATIENTS 

251006  04-07 
HOSPITALISED 

DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS. 

229368  01  11 
HOSPITALIZED 

EFFECTS  OF  A  PROCAINE  PREPARATION  (GEROVITAL  H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  STUDY. 

227330  01  11 
CLINICAL  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE  IN 
HOSPITALIZED  PATIENTS 

229551  01-11 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DFPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02  17 
A  PRELIMINARY  STUDY  WITH  PENFLURIDOL  IN  HOSPITALIZED  CHRONIC 
SCHIZOPHRENIC  PATIENTS. 

237897  02  08 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS) 

241427  03-10 
A  DOUBLE  BLIND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTE 
SCHIZOPHRENICS 

248976  04-08 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIOOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  0408 
HOSPITALS 

A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS. 

229458  01-11 


HOSTILITY 

HOSTILITY,  SOMATIC  SYMPTOMS  AND  RECOVERY  WITH 
ANTIDEPRESSANTS. 

226898  01-09 
THE  DIFFERENTIAL  EFFECTS  OF  CHLORDIAZEPOXIDE  AND  OXAZEPAM  ON 
HOSTILITY  IN  A  SMALL  GROUP  SETTING. 

227569  01  14 
HOUSED 

BINDING  OF  GLYCINE  AND  GAMMA-AMINOBUTYRIC-ACID  TO 
SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-04 
HP-505 

PHARMACOLOGICAL  STUDIES  WITH  HP-505,  A  POTENTIAL 
ANTIDEPRESSANT  COMPOUND. 

238839  03-03 
HUMAN 

PSYCHOTROPIC  DRUGS  AND  THE  HUMAN  EEG. 

226725  01  16 
THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA. 

227139  01-03 
COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01-13 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS    I.  THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW 

2325170117 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUAMN  SUBJECTS.  II.  FIVE 
EXPERIMENTS 

232518  01  14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  Ill,  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS 

232519  01  14 
DRUG  INTERACTIONS-  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  IV    THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 

232520  01  13 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS    V.  SUMMARY 
AND  CONCLUSIONS. 

232521  01-14 
THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 

OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS. 

237696  02-14 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA. 

238486  02  16 
INFLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES 

238711  03- 14 
FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

239684  03-13 
EXPERIMENTAL  HUMAN  DRUG  SELF-ADMINISTRATION:  METHODOLOGY 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE 

240831  ( 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  03-13 
STATE-DEPENDENT  (DISSOCIATIVE)  EFFECTS  OF  METHADONE  ON  HUMAN 
RETENTION.  (PH.D.  DISSERTATION) 

242151  03-14 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUMAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN. 

244131  04  13 
IN  VITRO  AND  IN  VIVO  TRANSPORT  OF  LITHIUM  BY  HUMAN 
ERYTHROCYTES 

246275  04- 13 
HUMAN  SLEEP  DURING  CHRONIC  MORPHINE  INTOXICATION. 

246304  04  1,3 


S-154 


LUME  14,  SUBJECT  INDEX 

EFFECTS  OF  THIENOOIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04-07 
THE  EFFECT  OF  ADRENALINE  ON  HUMAN  PLATELET  MAO  ACTIVITY. 

246312  04- 13 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES   EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES 

246856  04- 13 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04-13 
MARUUANA  AND  HUMAN  PERFORMANCE. 

247217  04-14 
THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04-13 
THE  EFFECT  OF  CAFFEINE  ON  HUMAN  PERFORMANCE,  ALONE  AND  IN 
COMBINATION  WITH  ETHANOL. 

249674  04-14 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY-1 10140,  ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS 

250380  04-03 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE. 

250657  04-13 
DELTA9-TETRAHY0R0CANNABIN0L:  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUMAN  AND  OTHER  MAMMALIAN  CELLS. 

251420  04-13 

PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY, 

232623  02-13 
BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA. 

237872  02-13 
L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANTAGONISTIC  INTERACTION 
WITH  ETHANOL  IN  HUMANS. 

238748  03-13 
LITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 
IN  HUMANS. 

239728  0309 
PARAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTER 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE 

246969  04-17 
EFFECTS  OF  CHLORPROMAZINE  ON  AVOIDANCE  AND  ESCAPE 
RESPONDING  IN  HUMANS. 

250076  04  14 
PHYTOHEMAGLUTININ-INDUCED  LYMPHOCYTE  TRANSFORMATION  IN 
HUMANS  RECEIVING  DELTA9-TETRAHYDR0CANNABIN0L. 

252825  04-13 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  (SQ-10996)  IN 

HUMANS. 

253323  04-07 

MORAL 

NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03-03 

NGARIAN 

A  NEW  HUNGARIAN  PSYCHOPHARMACON. 

252444  04  17 

NGER 

CANNABIS:  EFFECTS  ON  HUNGER  AND  THIRST. 

234626  02  14 

NTINGTONS-CHOREA 

TREATMENT  WITH  DISULFIRAM  IN  HUNTINGTONS-CHOREA:  A  NEGATIVE 
CLINICAL  AND  PHARMACOLOGICAL  STUDY 

226430  01-07 
A  DOUBLE-BLIND  TRIAL  OF  LITHIUM  CARBONATE  AND  HALOPERIDOL  IN 
HUNTINGTONS-CHOREA 

227550  01  11 
TREATMENT  OF  HUNTINGTONS-CHOREA  WITH  TRIFLUOPERAZINE 

231369  01-11 
COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS-CHOREA-  PILOT  STUDY. 

248172  04  11 

LEVODOPA  IN  HUNFINGTONS-CHOREA. 

252131  04-11 

IRT 

MARIHUANA:  CAN  IT  HURT  YOU' 

237651  02-15 
'A 
EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS 

226915  01-09 


Subject  Index 

EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 

OF  s-hydroxyindoleacetic-acid  (5-hiaa)  and  HOMOVANILLIC- 

ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
PROBENECID   DOSAGE,  LEVELS  IN  PLASAAA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5  HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01-06 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 

HYDROCARBON 

EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04-03 

HYDROCHLOROTHIAZIDE 

EFFECT  OF  HYDROCHLOROTHIAZIDE  ON  PHOSPHORUS  DURING 
TREATMENT  WITH  DIPHOSPHONATE. 

245651  04-13 

HYDROGEN 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRAM. 

229038  01-07 
DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
-  AN  ANTIMIGRAINE  COMPOUND 

229473  01-13 

CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  P0LYETHYLENE-GLYCOL-4000  BY  IR  SPECTRAL 
ANALYSIS. 

233276  02-01 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  AMLEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 

HYDROSARPAN-711 

THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY.  DOUBLE-BLIND 

STUDY  OF  HYOROSARPAN-711  IN  80  SUBJECTS 

240166  03-11 
THE  QUALITY  OF  INTELLECTUAL  LIFE:  DOUBLE-BLIND  STUDY  OF 

HYDROSARPAN  71 1  INVOLVING  80  SUBJECTS. 

242899  04-11 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-71 1  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 

HYDROXIDE 

INFLUENCE  OF  M.AGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION 

237116  02-13 

HYDROXYLAMINE 

EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE.  I.  EFFECT  ON  THE 
MORPHINE  TOLERANCE. 

249030  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  II.  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE. 

249031  04-03 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION 

249032  04-04 

HYDROXYLASE 

EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  04-03 

HYDROXYLATION 

INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P 
CHLOROAMPHETAMINE. 

237242  02-03 
CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
ENDINGS 

237244  02-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  03-06 
PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 
NEUROBLASTOMA  CELLS. 

238692  03-03 

HYPERACTIVE 

COGNITIVE  EFFECTS  OF  METHYLPHENIDATE  ON  HYPERACTIVE  CHILDREN. 
(PH.D.  DISSERTATION). 

228431  01-11 
THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-11 


■SB 
-< 


^& 


S-155 


vJ^^^S^ 


Subject  Index 


Psychopharmacology  Abstracts 


THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD:  DIAGNOSIS  AND 
TREATMENT 

233513  02-17 
DEPRESSED  5-HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03-13 
A  TEST  OF  THE  STATE-DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN.  (PH.D. 
DISSERTATION). 

241133  03-14 
BLOOD  PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04-15 
IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AND 
ELECTROCARDIOGRAPHIC  ABNORMALITIES  IN  HYPERACTIVE 
CHILDREN. 

245001  04-14 
DRUGS  HELP,  BUT  WONT  CURE,  MOST  HYPERACTIVE  CHILDREN. 

247143  04-17 
CLINICAL  EFFECTS  OF  IMIPRAMINE  AND  METHYLPHENIDATE  IN 
HYPERACTIVE  CHILDREN. 

247380  04-14 
ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN?. 

247382  04-14 
THE  EFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHILDREN. 

251569  04-14 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN. 

253041  04-15 
HYPERACTIVITIES 

EFFECTS  OF  DIAZEPAM  ON  SIX  DRUG-INDUCED  LOCOMOTOR 
HYPERACTIVITIES  IN  MICE. 

249677  04-04 
HYPERACTIVITY 

HYPERACTIVITY  IN  CHILDREN. 

226069  01-14 
HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA-INDUCED 
HYPERACTIVITY  IN  THE  RAT. 

226734  01-04 
EFFECTS  OF  A  DOPAMINE-BETA-HYDROXYLASE  INHIBITOR  ON 
AMPHETAMINE-INDUCED  HYPERACTIVITY  IN  RATS. 

226766  01-03 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02-04 
STIMULANT  DRUGS  FOR  HYPERACTIVITY:  SOME  ADDITIONAL 
DISTURBING  QUESTIONS. 

240599  03-17 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 
HYPERACTIVITY  IN  CHILDREN. 

250931  04-14 
THE  FOOD  ADDITIVE  HYPOTHESIS,  LEAD,  AND  HYPERACTIVITY. 

251572  04  11 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT 

252519  04-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
HYPERGYLCEMIC 

ENHANCEMENT  BY  CHLORPROMAZINE  OF  HYPERGYLCEMIC  ACTION  OF 
DIAZOXIDE 

247715  04-15 
HYPERKINESIS 

DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 
APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHILDHOOD 
HYPERKINESIS. 

249772  04-11 
HYPERKINETIC 

THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 
CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02-11 


NON-MEDICATION  MANAGEMENT  OF  HYPERKINETIC  CHILDREN  IN  THE 
CLASSROOM   (PH.D.  DISSERTATION). 

240977  03- 11 
THE  EFFECT  OF  METHYLPHENIDATE  ON  SENSORY  PERCEPTION  IN 
VARYING  DEGREES  OF  HYPERKINETIC  BEHAVIOR. 

245012  04-14 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 
HYPERKINETIC  CHILDREN. 

247379  04-14 
CLINICAL  PHARMACOLOGICAL  MANAGEMENT  OF  HYPERKINETIC 
CHILDREN. 

247381  04- 17 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL-BRAIN-DYSFUNCTION. 

247878  04-11 
TETRABENAZINE  IN  THE  TREATMENT  OF  HYPERKINETIC  MOVEMENT 
DISORDERS. 

251961  04-11 
HYPERMOBILITY 

INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROAAAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
HYPERMOTILITY 

INHIBITION  AND  POTENTIATION  OF  APOMORPHINE-INDUCED 
HYPERMOTILITY  IN  RATS  BY  NEUROLEPTICS. 

252029  04-04 
HYPERPHAGIA 

HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  P-CHLOROPHENYIALANINE. 

243878  04-04 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  04-04 
HYPERPLASIA 

MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
HYPERREACTIVITY  J 

ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE  I 

MICROINJECTION  INTO  MOUSE  BRAIN.  I 

250062  04-04 
HYPERSEXUAUZED 

THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE. 

229037  01-11 
HYPERTENSION 

DRUG  ACTION  IN  MANAGEMENT  OF  HYPERTENSION. 

225766  01-11 
PROVIDERS  AS  PRESCRIBERS:  ATTITUDES  TOWARD  ASfECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  AAANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY. 

227923  01  11 
ASTONIN-H  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 

PSYCHOTROPIC  DRUGS 

240261  03-15 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIAAARY  HYPERTENSION. 

241294  03-13 
PROPRANOLOL  IN  THE  TREATMENT  OF  HYPERTENSION. 

251320  04-17 
HYPERTENSIVE 

MANAGEMENT  OF  THE  ELDERLY  HYPERTENSIVE  IN  FOUR  PRACTICE 
SETTINGS. 

227924  01-11 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
EFFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT. 

241365  03-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 

HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
THE  INFLUENCE  OF  THE  DECARBOXYLy\SE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04-11 
HYPERTHERMIA 

THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE- 
INDUCED  AND  LSD-INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01-05 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  P-CHLOROAMPHETAMINE 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  02-03 


S-156 


OLUME  14,  SUBJECT  INDEX 

THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-04 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT 

238713  03-04 
NECESSITY  OF  HYPERTHERMIA  FOR  L-DOPA  OR  D-AMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03-03 
APOMORPHINE-INDUCED  HYPERTHERMIA  IN  THE  RABBIT;  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE.  (PH.D.  DISSERTATION). 

240936  03-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT. 

241255  03-03 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RATS 
PRODUCED  BY  D-AMPHETAMINE. 

246820  04-04 
MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 
THERMOSTATS. 

250078  04-03 
fPERTHYROIDISM 

NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE. 

243792  04-03 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROMAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT. 

243951  04-03 
YPERVENTILATION 

THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04-11 
YPNOSEDATIVE 

CLINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE  NEW 
HYPNOSEDATIVE  K-2004. 

243198  04-11 

lYPNOSIS 

USE  OF  THE  IMMOBILITY  REFLEX  (ANIMAL  HYPNOSIS)  IN 
NEUROPHARMACOLOGICAL  STUDIES. 

250071  04-06 
lYPNOTHERAPY 

MIGRAINE  AND  HYPNOTHERAPY. 

252381  04-11 
lYPNOTIC 

SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS. 

232530  01-07 
HYPNOTIC  EFFICACY  OF  LORAZEPAM  AND  FLURAZEPAM. 

237115  02-14 
SLEEP  AND  HYPNOTIC  DRUGS:  THE  PHYSIOLOGY,  PHARMACOLOGY  AND 
CLINICAL  ASPECTS  OF  SLEEP 

239029  03-14 
FLURAZEPAM.  A  NEW  HYPNOTIC  FOR  THE  TREATMENT  OF  INSOMNIA. 

242502  03-14 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE: 
FLURAZEPAM  AND  PENTOBARBITAL 

245652  04-11 
HYPNOTIC  EFFICACY  OF  TRIAZOLAM  AND  METHYPRYLON  IN  INSOMNIAC 
IN-PATIENTS. 

248533  04-11 

SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MICE 
SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL. 

250284  04-04 
FLURAZEPAM  HYDROCHLORIDE,  A  BENZODIAZEPINE  HYPNOTIC. 

250780  04-17 
SLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS, 

252230  04-11 

HYPNOTICS 

HYPNOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 

HYPNOTICS, 

228094  01-14 

UNWANTED  EFFECTS  OF  MINOR  TRANQUILIZERS  AND  HYPNOTICS. 

231992  01  15 
CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP, 

241273  03-14 


Subject  Index 


EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 

INTERACTION  OF  ALCOHOL  AND  BENZODIAZEPINE  HYPNOTICS. 

242947  04-15 
ON  THE  THIN  LAYER  CHROAMTOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04-01 
THE  PRESCRIBING  OF  HYPNOTICS  IN  GENERAL  PRACTICE. 

245469  04- 1 1 

HYPOCHONDRIACAL 

PIMOZIDE  IN  THE  TREATMENT  OF  MONOSYMPTOMATIC 
HYPOCHONDRIACAL  PSYCHOSIS. 

239014  03-11 

HYPOGLYCEMIA 

DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 

HYPOINHIBITORY 

DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 

HYPOKINESIA 

AMT  CATALEPSY  AND  HYPOKINESIA:  INTERACTION  WITH  MORPHINE 

AND  COCAINE. 

241224  03-04 

HYPOMANIA 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  AAANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 

POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOMANIA 
SECONDARY  TO  ORGANIC-BRAIN-SYNDROME 

23471 1  02-09 

HYPOPROTHROMBINEMIA 

INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN-INDUCED  HYPOPROTHROMBINEMIA. 

237760  02-03 

HYPOSENSITIVITY 

ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL:  INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY 

239826  03-04 

HYPOTENSION 

ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241763  03  15 

HYPOTHAIAMIC 

IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE. 

226938  01  04 
GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6- 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  01-04 

NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME, 

227134  0103 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS, 

230763  01  13 
PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION 

231700  01-03 
EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-04 
MARIJUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  R.AT, 

238720  03-04 
HYPOTHALAMIC  NORADRENALINE  TURNOVER  IS  INCREASED  DURING 

GLUCOPRIVIC  FEEDING. 

238804  03-04 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF  STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION, 

239980  03  04 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 

PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  03-04 


30 


S-157 


Subject  Index 


Psychopharmacology  Abstract] 


AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS,  (PHD 
DISSERTATION) 

241129  03-03 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF  STIMULATION  AND  SLEEP  IN  THE 
RAT   (PH  0   DISSERTATION), 

241678  03-03 
INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  LDOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 
CURARIZED  RATS. 

244691  0403 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

245929  04-02 
INGESTION  IN  THE  SATIATED  RAT,  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION 

245930  04-02 
THE  MODE  OF  LIPOFUSCIN  REMOVAL  FROM  HYPOTHALAMIC  NEURONS. 

246587  04-03 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-03 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION. 

250019  04-04 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04-03 
HYPOTHALAMIC  LESIONS  AND  DRUG-INDUCED  ANOREXIA, 

250938  04-03 
EFFECTS  OF  GABA  BLOCKADE  ON  LATERAL  HYPOTHALAMIC  SELF- 
STIMULATION. 

25201  7  04-04 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
HYPOTHALAMUS 

COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01-04 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-03 
EFFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS, 

237099  02-03 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATUM 
AND  HYPOTHALAMUS  SLICES, 

238714  03-03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS, 

238744  03-04 
CNS  TRANSMITTERS  AND  THE  HYPOTHALAMUS, 

238784  03-03 
THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYOROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS 

239087  03-03 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM, 

239834  03-04 
THE  EFFECT  OF  MORPHINE  ON  THE  EEG  OF  THE  HYPOTHALAMUS  IN  THE 
RAT 

241328  03-03 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  03-04 
VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS, 

244311  04-04 
ACETYLCHOLINE,  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 
HYPOTHALAMUS 

248358  0403 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H-5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  0403 


HYPOTHERMIA 

EFFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG-INDUCED  HYPOTHERMIA 
IN  MICE  AND  RATS. 

237100  02-0 
HYPOTHERMIC 

CORRELATION  OF  CHLORPROMAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 
WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-0 
ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMK 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  O3-0 
ALTERED  HYPOTHERMIC  RESPONSIVENESS  TO  ( -i- )  AMPHETAMINE. 

239685  03-C 
HYPOTHESIS 

GABA  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA. 

231019  01-1 
THE  TRANSMETHYLATION  HYPOTHESIS:  A  QUARTER  OF  A  CENTURY 
LATER. 

235801  02-1 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESIS. 

237711  02-C 
EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-1 
AMPHETAMINE  PSYCHOSIS:  OVERVIEW  AND  A  HYPOTHESIS. 

245019  04-1 
CLOZAPINE  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA,  A 
CRITICAL  APPRAISAL. 

246671  04-C 
THE  FOOD  ADDITIVE  HYPOTHESIS,  LEAD,  AND  HYPERACTIVITY. 

251572  04-1 
HYPOTHETICAL 

SYNTHESIS  OF  3-CHLORO-2-HYDROXYIMIPRAMINE  AND  3-CHLORO-8- 
HYDROXYIMIPRAMINE  (1),  HYPOTHETICAL  METABOLITES  OF 
CLOMIPRAMINE.  (UNPUBLISHED  PAPER). 

2371  74  02-C 
HYPOTHYROIDISM 

PSYCHOLOGICAL  ANALYSES  OF  PATIENTS  SUFFERING  FROM 
HYPOTHYROIDISM. 

232364  01-1 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROAAAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT. 

243951  04-( 
LITHIUM  CARBONATE  AND  HYPOTHYROIDISM. 

244113  04-1 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

246152  04-( 
HYPOXEMIA 

PIRACETAM  IN  A  CASE  OF  ACUTE  CEREBRAL  HYPOXEMIA:  CASUISTIC 
REPORT. 

229128  01-1 
HYPOXIA 

THE  ACTION  OF  CHLORPROAMZINE  ON  THE  PERMEABILITY  OF  THE  BRAI 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01 -( 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL, 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT. 

238722  03-( 
HYSTERICAL 

THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS, 

249771  04-' 
H2-RECEPTOR 

ON  THE  SPECIFICITY  OF  HISTAMINE  H2-RECEPT0R  ANTAGONISTS  IN  TH( 
RAT  CEREBRAL  CORTEX, 

248725  04-( 
H3-ACETYLCHOIINE 

EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3-ACETYLCH0LINE 
BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES, 

241254  03-( 
H3-ALPHA-METHYL-TYRAMINE 

RELEASE  OF  H3  ALPHA-METHYL  TYRAMINE  FROM  CORPUS-STRIATUM  IN 
VITRO  AND  THE  EFFECTS  OF  GLUCOSE  DEPRIVATION. 

238731  O3-0 
H3-0OPAMINE 

THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESI' 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-« 
H3-MESCAIINE 

AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALIN! 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX-JACCHUS. 

239864  03-(l 


S-158 


OIUME  14,  SUBJECT  INDEX 

l-NOREPINEPHRINE 

EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3  NOREPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-03 
l-P-CHLOROAMPHETAMINE 

H3-P-CHL0R0AMPHETAMINE:  CEREBRAL  LEVELS  AND  DISTRIBUTION, 

232614  02-03 
1-TRIMETHOXY-BETA-PHENYlETHYLAMINE 

AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE  IN  THE  MOUSE 

239855  0303 

r7.77 

INHIBITION  OF  4,ALPHA  DIMETHYLM-TYRAMINE  H77-77  INDUCED 
HYPERMOBIIITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
EVALUATION  OF  THE  ANTINOCICEPTIVE  EFFECTS  OF  4,ALPHA-DIMETHYL- 
M-TRYAMINE  (H77-77)  IN  THE  RAT. 

252026  04-03 

I-S8834 

CLINICAL  EXPERIENCES  WITH  A  NEW  ANTIDEPRESSANT,  ICI-58834. 

244189  04-07 
ENTIFICATION 

BIOCHEMICAL  IDENTIFICATION  OF  THE  MAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR 

227400  01-03 
CRITERIA  FOR  AND  PITFALLS  IN  THE  IDENTIFICATION  OF  RECEPTORS. 

229436  01-03 
IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY. 

233300  02-01 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMI  AND  (  +) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEDIOXYAMPHETAMINE  (MDA)  FROM  PLASMA  AND  URINE. 

238484  02-06 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
DECOMPOSITION  OF  AMITRIPTYLINE  HYDROCHLORIDE  IN  AQUEOUS 
SOLUTION:  IDENTIFICATION  OF  DECOMPOSITION  PRODUCTS. 

246317  04-01 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  04-03 
3ENTIFIED 

EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFILD  CHOLtNOCEPTIVE 
CELLS  OF  THE  SNAIL  BRAIN. 

2387-40  03-03 
EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA 

243799  04-03 
DIOSYNCRATIC 

RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS.  PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  01-11 

GG 

EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 
ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
LEUM 

THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 

lEUS 

FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY, 

235286  02-15 
ILLNESS 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS. 

227806  01-1 1 
ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS.  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  01-15 
PSYCHOPHARMACOLOGY  AND  PSYCHOSOMATIC  ILLNESS. 

228242  01  11 
PRECLINICAL  STUDIES  OF  RUBIDIUM  IN  AFFECTIVE  ILLNESS. 

229495  01-02 
THE  FORGOTTEN  TREATMENT  MODALITY  IN  BIPOLAR  ILLNESS: 
PSYCHOTHERAPY. 

231611  01  09 


Subject  Index 

CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 
LITHIUM  CARBONATE  IN  JUVENILE  AAANIC-DEPRESSIVE  ILLNESS. 

236663  02- 10 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS. 

239818  03-10 
MENTAL  ILLNESS  AND  SIMULATED  DRIVING:  BEFORE  AND  DURING 
TREATMENT 

241425  03-15 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS-  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUT 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  04-10 
IS  THERE  AN  INCREASE  IN  MONOAMINE-OXIDASE  ACTIVITY  IN 
DEPRESSIVE  ILLNESS?. 

245233  04-13 
CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS: 
LV-A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS. 

245863  04-08 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 

ILLNESSES 

PSYCHOPHARMACOLOGICAL  THERAPY  AND  PROPHYLAXIS  OF  MANIC 
DEPRESSIVE  ILLNESSES. 

240707  03-09 
TECHNIQUE  OF  FLUPHENAZINE-DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES. 

246186  04-08 
SIDE-EFFECTS  OF  DRUGS  AS  MODELS  OF  ILLNESSES. 

248850  04-15 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-16 
IMIDAZOLINE 

3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 

IMIPRAMINE 

THE  HAMILTON  RATING  SCALE   AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 

TRIAL. 

226899  01-09 

BIOTRANSFORMATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDIIIONS. 

226928  01-03 
VILOXAZINE  (VIVALAN)  COMPARISON  WITH  IMIPRAMINE 

227215  01-09 

IMIPRAMINE  PAMOATE  IN  DEPRESSION. 

228243  01-11 
A  DOUBLE-BLIND  CONTROLLED  COMPARISON  OF  CLOMIPRAMINE 
(ANAFRANIL)  AND  IMIPRAMINE  ON  DEPRESSION. 

228327  01-09 
THE  EFFECT  OF  IMIPRAMINE  ON  AROUSAL  FROM  HIBERNATION. 

228549  01-04 
PHARMACODYNAMICS  OF  IMIPRAMINE  IN  DEPRESSED  PATIENTS 

229437  01-09 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  CLINICAL  OUTCOME. 

229443  01-09 
IMIPRAMINE,  BEHAVIOR  THERAPY,  AND  PHOBIA. 

229451  01-10 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC  ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPIN.AL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
THE  LITTLE  KNOWN  THERAPEUTIC  PROPERTIES  OF  IMIPRAMINE  IN 
MANIC  STATES  OF  CYCLOTHYMIC  PSYCHOSES. 

231368  01-09 
IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02- 13 
ON  THE  INTRACELLULAR  MECHANISM  OF  ACTION  OF  IMIPRAMINE  AND 
DIAZEPAM. 

236232  02-03 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR 

236529  02  06 


3C3 


3S 
IB* 


S-159 


Subject  Index 


Psychopharmacology  Abstract: 


IHE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-03 
SIAAULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS. 
(UNPUBLISHED  PAPER). 

237274  02-16 
PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID. 

237705  02-04 
THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE. 

237976  02-03 
EFFECTS  OF  RO-41284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  03-04 
MAPROTILINE  (LUDIOMIL,  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  03-09 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 

(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-09 
PLASMA  LEVELS  AND  ANTIDEPRESSIVE  EFFECT  OF  IMIPRAMINE. 

243089  04-13 
EFFECTS  OF  IMIPRAMINE,  D-AMPHETAMINE,  AND  TRIPELENNAMINE  ON 
MOUSE-KILLING  AND  FROG  KILLING  BY  THE  RAT. 

243346  04-04 
BLOOD-PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04-15 
IMIPRAMINE  DOSAGE  IN  CHILDREN:  A  COMMENT  ON  IMIPRAMINE  AND 
ELECTROCARDIOGRAPHIC  ABNORMALITIES  IN  HYPERACTIVE 
CHILDREN. 

245001  04-14 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAMINE 
AND  CHLORDIAZEPOXIDE  IN  RATS. 

245301  04-04 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIVE 
NEUROSIS. 

246300  04  10 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION. 

246387  04-13 
TRYPTOPHAN/IMIPRAMINE  IN  DEPRESSION. 

246623  04-09 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04-03 
EFFECTS  OF  PERPHENAZINE  ON  IMIPRAMINE  METABOLISM  IN  MAN. 

247210  04-13 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
CLINICAL  EFFECTS  OF  IMIPRAMINE  AND  METHYLPHENIDATE  IN 
HYPERACTIVE  CHILDREN. 

247380  04-14 
IMIPRAMINE  IN  ENURESIS    -  PSYCHOLOGICAL  AND  PHYSIOLOGICAL 
EFFECTS. 

247743  04-1 1 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-16 
IMIPRAMINE  ENHANCEMENT  OF  PENTOBARBITAL  TOXICITY  IN  RATS. 

249929  04  05 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETICS 
OF  (14C)IMIPRAMINE  IN  RAT:  ACUTE  STUDY 

250655  04-03 
COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE  BLIND  MULTICENTRE  TRIAL 

251118  04-09 
THE  INFLUENCE  OF  IMIPRAMINE  ON  CIRCULATORY  EFFECTS  OF 
MIDODRINE 

251415  04-03 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 
POISONING  IN  THE  RAT 

251419  04-03 
IMIPRAMINE  AND  RHEUMATOID  FACTOR. 

252137  04-17 


INTESTINAL  ABSORPTION,  DEMETHYLATION,  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-1 
IMIPRAMINE-INDUCED 

CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-1 
IMAAATURE 

DIFFERENTIAL  EFFECTS  OF  D-AMPHETAMINE  IN  MATURE  AND  IMMATUR 
RATS. 

228160  01-0 
EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMAMTURE  RAT. 
(PH.D.  DISSERTATION). 

231533  01-C 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINE; 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-0 
IMMERSION 

EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-0 
lA/WlOBILITY 

CHOLINERGIC  MODULATION  OF  TONIC  IMMOBILITY  IN  THE  RABBIT 
(ORYCTOLAGUS-CUNICULUS) 

231701  01-0 
USE  OF  THE  IMMOBILITY  REFLEX  (ANIAAAL  HYPNOSIS)  IN 
NEUROPHARAAACOLOGICAL  STUDIES. 

250071  04-0 
IMMUNITY 

PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-0 
IMMUNIZATION 

EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-0 
IMMUNIZED 

BARBITURATE  RESPONSE  IN  IMMUNIZED  MICE. 

249297  04-0 
IMMUNOCYTOCHEMICAl 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-0 
IMMUNOLOGIC 

IMMUNOLOGIC  INVESTIGATION  OF  BARBITURATE  PHARMACOLOGY. 

229480  01-0 
IMMUNOLOGICAL 

IMMUNOLOGICAL  METHODS  IN  PSYCHIATRIC  TREATMENT. 

23751 1  02-1 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICAL 
STATUS  OF  RHESUS  MONKEYS. 

249003  04-0 
HAPTEN  IMMUNOLOGICAL  STUDIES  ON  MESCALINE. 

253536  04-0 
IMMUNOREACTIVE 

SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN 

229042  OM 
IMPACT 

IMPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02-1 
IMPAIRED 

IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE. 

239841  03-0 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS. 

239851  03-0 
IMPAIRED  ABSORPTION  OF  CHLORPROMAZINE  IN  RATS  GIVEN 
TRIHEXYPHENIDYL. 

241920  03-0 
IMPAIRMENT 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE 

226926  0 1-0 
IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE 

226938  01-0 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAMINi 
AND  CHLORDIAZEPOXIDE  IN  RATS. 

245301  04-0< 


S-160 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


KRIMENT 

PSYCHOTROPIC  DRUGS  AND  IMPARIMENT  OF  PSYCHOMOTOR 
FUNCTIONS. 

227136  01-15 

ANTATION 

SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  04-05 

ANTED 

CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
EMENTATION 

OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 
PSYCHOTROPICS  DRUGS. 

239681  03-17 
.EMENTING 

ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
ROVEMENT 

PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE 

226349  01-14 
MEMORY  FUNCTIONS  IN  DEPRESSION:  IMPROVEMENT  WITH 
ANTIDEPRESSANT  MEDICATION. 

248583  04-09 
ULSE 

EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  SENSITIVITY  OF 
TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 

EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
'ULSE-INDUCED 
AMFONELIC-ACID  FACILITATION  OF  IMPULSE-INDUCED  STRIATAL 
DOPAMINE  RELEASE. 

238730  03-03 
'ULSIVITY 
CONCEPTS  OF  IMPULSIVITY:  A  CLINICAL  NOTE. 

231610  01-09 
PATIENTS 
HYPNOTIC  EFFICACY  OF  TRIAZOLAM  AND  METHYPRYLON  IN  INSOMNIAC 
IN-PATIENTS. 

248533  04-11 

^BIllTY 

INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY!  10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01-03 
INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 
HYOROXYINDOLES  BY  P-CHLOROAMPHETAMINE. 

241339  03-03 
»CTIVATION 
IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099. 

238686  03  03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
BRED 

ACTION  OF  ALPHA-METHYL  DOPA  ON  WAKING  SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6. 

249676  04-04 


Y-MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04-04 

INCENTIVE 

EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SQUIRREL-MONKEY 
INCENTIVE  COMPETITION  BEHAVIOR.  (PH.D.  DISSERTATION). 

241668  03-04 

INCIDENCE 

INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02- 15 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDENCE 
OF  OPHTHALMOLOGICAL  ABNORAAALITIES. 

244779  04-15 
THE  INCIDENCE  OF  SELF-MUTILATION  IN  MORPHINE  TOLERANT  SPRAGUE 

DAWLEY  MALE  RATS. 

249253  04-04 

COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 

INCIDENCE  OF  SIDE-EFFECTS. 

252006  04-08 

INCONTINENCE 

CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL 

237271  02  14 

INCREASING 

DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02  04 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 

INCREMENTAL 

PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES. 

239858  03-03 

INDEPENDENT 

ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES 

238729  03-03 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03  04 

DIPHENYLHYDANTOIN  FACILITATION  OF  LABILE,  PROTEIN  INDEPENDENT 
MEMORY. 

253290  04-04 

INDICATED 

PSYCHOTHERAPY  FOR  SCHIZOPHRENICS:  IS  IT  INDICATED'' 

225826  01  08 
INDICATION 

CANNABINOID  PATTERN  IN  CANNABIS-SATIVA  L    SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE. 

237982  02-01 
INDICATOR 

SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIMARY  HYPERTENSION. 

241294  03-13 

INDICES 

INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 

AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS 

249671  04  04 

INDIRECT 

5-HYDROXYTRYPTAMINE  14C  AND  DEXAMPHETAMINE  14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERAAAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 
BEHAVIORAL  EFFECTS  OF  DIRECT  AND  INDIRECT  ACTING  DOPAMINERGIC 
AGONISTS 

233973  02-03 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID  LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 
ALTERATION  IN  THE  ACTION  OF  CHOLINERGIC  AND  ANTICHOLINERGIC 
DRUGS  AFTER  CHRONIC  HALOPERIDOL    INDIRECT  EVIDENCE  FOR 
CHOLINERGIC  HYPOSENSITIVITY. 

239826  03-04 


■■as 


S-161 


Subject  Index 


Psychopharmacology  Abstrc 


FENFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY:  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

244911  04-04 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
INDIVIDUAL 

INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACUTE 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS 

233377  02-12 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DYSFUNCTION. 

235322  02  11 
AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  02-04 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 
AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
INDIVIDUALS 

EFFECT  OF  LONG  LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS. 

239992  03-14 
INDOLE 

THE  INDOLE  HALLUCINOGEN  MODEL:  IS  IT  WORTH  PURSUING?, 

241872  03-08 
INDOLEAMINE 

DIFFERENTIAL  EFFECTS  OF  TRANYLCYPROMINE  AND  PARGYLINE  ON 
INDOLEAMINE  SYSTEMS  IN  BRAIN. 

238675  03-03 
INDOIEAMINES 

HALLUCINOGENIC  INDOLEAMINES:  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS. 

240073  03-03 
DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 
INDOLEAMINES  IN  BRAIN. 

2.S0081  04-03 
INDOLES 

MAGNETIC  CIRCULAR  DICHROISM  OF  SUBSTITUTED  INDOLES. 

229493  01-06 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  04-03 
INDOLETHYLAMINE 

NMETHYLATION  OF  1-METHYLTRYPTAMINES  BY  INDOLETHYLAMINE  N- 
METHYLTRANSFERASE. 

249188  04-01 
INDOLOBENZOXAZEPINE 

BASIC  DERIVATIVES  OF  6,7  DIHYDR0IND0L08ENZAZEPINE  AND  6H 
INDOLOBENZOXAZEPINE  AS  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

237834  02-02 
INDOMETHACIN 

PHARMACOKINETICS  OF  INDOMETHACIN. 

245653  04-13 
INDONESIAN 

TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DELAGRANGE). 

239269  03-11 
INDUCED 

DIFFERENTIAL  EFFECTS  OF  SEROTONIN  ON  TURNING  AND  STEREOTYPY 
INDUCED  BY  APOMORPHINE 

226405  01-04 
TYROSINE  HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS, 

226856  01-03 
INHIBITION  OF  4,ALPHA  DIMETHYL  M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACERE8R0VENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN. 

227386  01-04 
CHLORDIAZEPOXIOE  AND  ISOLATION  INDUCED  TIMIDITY  IN  RATS. 

230828  01  04 
BEHAVIORALLY  INDUCED  SENSITIVITY  TO  THE  DISCRIMINABLE 
PROPERTIES  OF  LSD 

230876  01-04 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 


PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

231 700 C 
INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION. 

232333  C 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  P-CHLOROAMPHETAMI 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  C 
EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED 
LITHIUM  CARBONATE. 

233499 ( 
REGIONAL  ROLE  OF  CATECHOLAMINES  IN  ALPHA-METHYL-M-TYROSIf 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROUSAL. 

234067  i 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649 ( 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCEN 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  ( 
EFFECTS  OF  HASHISH  ON  ISOLATION  INDUCED  AGGRESSION  IN  WILC 
MICE. 

2377141 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTOI 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMIh 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  I 
DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE:  A  PERIPHERA 

INDUCED  DISCRIMINATIVE  CUE. 

237744  I 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 

SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347 1 
DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  I 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR. 

2388191 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  I 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE. 

239829  I 

IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTEI 

LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE. 

239841  I 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL. 

240074  I 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYDROCANNABINOL. 

240645  i 
CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE. 

241232 ' 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  Th 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284 
BY  P-CHLOROPHENYIALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315 
STUDY  ON  HEAD- TWITCHES  INDUCED  BY  INTRACEREBRALLY 
ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  "RETREATED  MIC 

241380 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIf 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391 
AUTOMUTILATION  INDUCED  BY  CLONIDINE  IN  MICE. 

241398 
EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCL0BAR8ITAL  TO  MICE. 

2414031 

ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM      , 

INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTAS-  I 

TETRAHYDROCANNABINOL  (DELTA8-THC).  ' 

241926 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFtJ| 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION. 

241930 
PARKINSONISM  INDUCED  BY  FLUPHENAZINE-DECANOATE. 

242267 


S-162 


aUME  14,  SUBJECT  INDEX 

TASTE  AVERSIONS  INDUCED  BY  D-AMPHETAMINE:  DOSE-RESPONSE 
REIATIONSHIP 

242882  04-04 
VORACIOUSNESS  INDUCED  IN  CATS  BY  BENZODIAZEPINES. 

244690  04-04 
INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION, 

245597  04-03 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE, 

245601  04-04 
SELECTIVE  FIELD  POTENTIAL  CHANGES  INDUCED  BY  L-DOPA 

246145  04-03 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  (  I  )  AMPHETAMINE  AND  RELATED  COMPOUNDS, 

246149  04-03 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D-AMPHETAMINE 
ADMINISTRATION. 

247683  04-04 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04  03 
EFFECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04  03 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  04-04 
THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN  II. 

252170  04  03 
DEMENTIA  INDUCED  BY  METHYLDOPA  WITH  HALOPERIDOL. 

253391  04-15 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  [EARNING  INDUCED 
BY  DOPAMINE  BETA-HYDROXYLASE  INHIBITORS. 

253450  04-04 
DUCER 
A  CLINICAL  TRIAL  OF  TEMAZEPAM,  A  SLEEP  INDUCER,  IN  HOSPITAL 
PATIENTS. 

251006  04-07 

DUCES 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE 

227343  01-03 
DUCING 
ANALYSIS  OF  VARIANCE  STUDY  OF  A  SLEEP  INDUCING  DRUG. 

233698  02-07 
IDUCTION 

REM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 
ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE  3- 
MONOOXYGENASE   (UNPUBLISHED  PAPER) 

237172  0203 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE 

237706  0203 
INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN  INDUCED  HYPOPROTHROMBINEMIA. 

237760  02-03 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL  DECANOATE. 

239823  03-08 
MECHANISMS  OF  A  DYSKINESIA  INDUCTION  BY  1  3,4 
DIHYDROXYPEHNYLPIPERAZINE  IN  THE  RAT 

239964  03  04 
INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS   OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03  03 


Subject  Index 

INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS    -  I    STRUCTURE  ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03  03 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE. 

243795  04-03 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
RESERPINE  AND  THE  INDUCTION  OF  DEPRESSION:  A  CASE  REPORT. 

245016  04  09 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT. 

250087  04  02 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN 

251071  04-12 
MECHANISMS  OF  TRANS- SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETAHYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE 

251393  04-03 
POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE  HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 

INEFFECTIVENESS 

EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 
PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  03-04 

INERT 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM 

23551  I  02-04 

INEXPENSIVE 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC  ACID  AND  5-HYDROXYTRYPTOPHAN. 
(UNPUBLISHED  PAPER). 

23127801  06 

INFANT 

A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY, 

250175  04-15 
INFANTILE 

PHARMACOTHERAPY  IN  EARLY  INFANTILE  AUTISM. 

229921  01-11 
INFARCTION 

STRESS  AND  MYOCARDIAL  INFARCTION 

229715  01-11 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS 

252713  04-11 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY 

253684  04-11 

INFERIOR 

DRUG  INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT 

235866  02-03 

INFLUENCE 

INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC  ACID 

CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-03 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 

BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS 

228550  01-03 
THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 

NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  0)  03 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 

SYNDROMES    -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAl 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 


S-163 


Subject  Index 


Psychopharmacology  Abstra 


INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  PARTIAL 
REINFORCEMENT  EFFECTS 

230875  01-04 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5  HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01-06 
THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01-03 
THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248  01-04 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02-14 
CHANGES  IN  ANTICOAGULANT  TOLERANCE:  I.  INFLUENCE  OF  SEDATIVES 
AND  PSYCHOPHARMACEUTICALS. 

235336  02-15 
THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION 

236257  02-04 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02  10 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT, 

236528  02  03 
THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  02-03 
INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION. 

237116  02-13 
THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-03 
METABOLISM  OF  5  HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN. 

237700  02-03 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02  03 
THE  INFLUENCE  OF  LITHIUM  ON  SERUM  CERULOPLASMIN. 

237924  02-03 
THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES. 

237981  02-02 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 
ACTION  OF  DIAZEPAM 

238531  02-13 
INFLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES. 

238711  03-14 
THE  INFLUENCE  OF  FOOD  ON  SIDE  EFFECTS  AND  ABSORPTION  OF 
LITHIUM 

238998  03  15 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03-04 
INDUCTION  OF  TYROSINE  HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS    OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NlfOllNIC  RECEPTOR  AGONISTS. 

239977  03-03 
IHF  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE- 
INDUCED  CATALEPSY  IN  THE  RAT 

240238  03-03 
INFLUENCE  OF  PSYCHOPHARMACEUTICALS  ON  ACHIEVEMENT 
MOTIVATION:  III    DIFFERENTIAL  INFLUENCE  ON  CONTENT  CATEGORIES. 

240644  03-14 
INIRACRANIAl  SELF  STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI    INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE.  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES 

241229  03-04 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 


INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  0 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AN 
PROTEINS    -  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION 
RAT  LIVER. 

241297  0 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETH' 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349 C 
ACTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICUL^RLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AN 
AGGRESSIVE  BEHAVIOR. 

241372 C 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  C 
INFLUENCE  OF  CANNABIDIOL  OF  DELTA9-TETRAHYDR0CANNABIN0L 
EFFECTS. 

243087  C 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLIS. 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  C 
INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARAAACOLOGICAI 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  AAATERI, 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR. 

244899 C 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGE 
AND  OLFACTORY  STIMULI. 

245406  C 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANT! 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  C 
LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARfi 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  F0( 
OF  NOVERIL. 

245971  C 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

246152 C 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMINOBUTYRIC-ACID  LEVEL! 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730  C 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  C 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RA" 
BRAIN  SYNAPTOSOMES. 

248701  C 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  C 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  8 
PINEAL  METABOLITES. 

249240  C 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MA( 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2  PHENYLETHYLAMINE  (PEA). 

249310 C 
MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE:  INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS. 

250079  C 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDl 
BY  AMPHETAMINE.  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  C 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVI 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERG 
NERVOUS  SYSTEM. 

251397 C 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATK 
IN  RATS. 

251409 C 
INFLUENCE  OF  PHARAAACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD-PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS 

251414f 
THE  INFLUENCE  OF  IMIPRAMINE  ON  CIRCULATORY  EFFECTS  OF 
MIDODRINE. 

251415C 
THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  01 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  If 
HYPERTENSIVE  PATIENTS 

251418C 


S-164 


IME  14,  SUBJECT  INDEX 


Subject  Index 


■LUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 

LEVELS. 

252027  04-03 
JSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOZIDE 
AND  CHLORPROAAAZINE  METABOLITES. 

2525)5  04  05 
E  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

252711  04-03 
E  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04-11 
NCES 

)PAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS. 

227703  01-04 
UROTRANSMITTER  INFLUENCES  ON  MATING  BEHAVIOR  IN  MALE 
RATS.  (PH.D.  DISSERTATION). 

228390  01-04 
ONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251  01-04 
IE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 
BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
IVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03-04 
IVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H  5 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
JTYROPHENONE  INFLUENCES  ON  THE  OPIATE  RECEPTOR. 

250088  04-03 
DRMONAL  INFLUENCES  ON  THE  EXTINCTION  OF  CONDITIONED  TASTE 
AVERSION. 

251980  04-04 
MATION 

RACETAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAL  INFORMATION  IN  RATS. 

239861  03-04 
ION 

EM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 
TEADY  STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE, 

247146  04-03 
TRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY. 

248947  04-03 
TION 

FFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  02-04 
SYCHOSIS  FOLLOWING  INGESTION  OF  HEMP  IN  CHILDREN. 

237730  02-15 
UIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02-15 
FFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS. 

244651  04-03 
MGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 
RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
HARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 
ARDIOVASCULAR  EFFECTS  OF  PROLONGED  DELTA9- 
TETRAHYDROCANNABINOL  INGESTION. 

253609  04-13 

SONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME:  A 
PILOT  TRIAL. 

236665  02-09 
lATION 
:HR0NIC  MARIHUANA  INHALATION  TOXICITY  IN  RATS. 

235671  02-05 
W  INHALATION  AEROSOL  OF  DELTA9-TETRAHYDR0CANNABIN0L. 

237787  02-16 
NHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-05 


INHIBIT 

THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 
MONOAMINE-OXIDASE  IN  MAN 

237927  02-13 

INHIBITING 

INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  R0-4-4602. 

239957  03-03 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  04-03 

INHIBITION 

THE  EFFECTS  OF  NEONATAL  6-HYDROXYDOPAMINE-INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION 

226871  01-03 
EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS, 

226915  01-09 
INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROAAAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01-03 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 

LIVER. 

227696  01-03 

INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 

NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS   (UNPUBLISHED 
PAPER). 

227777  01-03 

ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO-  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01  04 

SEROTONIN  INHIBITION  AND  SLEEP, 

229924  0114 
THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  AND 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  IN 

RATS. 

230452  01-04 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM: 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION, 

231039  01-03 
THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS, 

231248  01-04 
EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION  OF 
AGGRESSIVE  REACTIONS  OF  CATS, 

236371  02-04 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA, 

237104  02-03 
INHIBITION  OF  CHOLINESTERASE  BY  5-HYDROXYTRYPTAMINE. 

237117  02-03 
THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-03 
INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P 
CHLOROAMPHETAMINE. 

237242  02-03 
MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY 

237245  02-03 
EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING. 

237264  02-04 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02-04 
INHIBITION  OF  DRUG-INDUCED  ANOREXIA  IN  RATS  BY  METHYSERGIDE. 

237745  02-04 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
INHIBITION  OF  DOPAMINE-BETAHYDROXYLASE  BY  SOME  ANALOGS  OF 
METHIMAZOLE. 

238691  03  03 
INHIBITION  OF  NEURONAL  SEROTONIN  (5  NT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 


Sl> 


,1  ,■>' 

as: 


S-165 


Subject  Index 


Psychopharmacology  Abstrd 


1 


TUF  REVERSAL  OF  APOMORPHINE  FlICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINFIiHYDROXYLASE  ACTIVITY  BY 
NFUROIFPTICS 

238758  03-03 
LOSS  OF  INHIBIIION  IN  SPINAL  CORD  DURING  BARBITURATE 
Vl/ITHDRAWAL 

238770  03-03 
INHIBITION  OF  CORTICOSILROIDOGENESIS  BY  CANNABINOIDS. 

238808  03-03 
INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE  INDUCED 
LOCOMOTOR  ACTIVITY  IN  MICE, 

238842  0304 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE  OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2  ARYLIMIN0  3-ACErYLAMIN0  4-THIAZOLIDONYL  PHENOTHIAZINES 

239662  03-03 
LITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 

IN  HUMANS. 

239728  03-09 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO  4  4602 

239957  03-03 
THE  AMPHETAMINE  INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM, 

240065  03-03 
DOPAMINERGIC  NEURONS      ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW 

241295  03-03 
THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATFD  ESCAPE  RESPONSES. 

241301  03-04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4)    ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
DIPHENYLHYDANTOIN  INCREASFS  CORTICAL  POSTSYNAPTIC  INHIBITION. 

241805  03-03 
THE  SELECTIVr  INHIBITION  OF  5-HYDROXYTRYPTAMINE  REUPTAKE  BY 
ORG-6582 

241924  03-03 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P  CHLOROPHENYLALANINE 
UNRELATED  TO  IRYPTOPHAN-HYDROXYLASE  INHIBITION. 

241978  03-03 
PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR  )  MOUSE 

242746  04-04 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN  HYDROXYLASE  INHIBITION. 

243848  04-03 
D  AMPHETAMINl-INOUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY 

243882  04  03 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L  NOREPINEPHRINF 
I    N  ARYLALKYl  AND  N  ARYLOXYALKYL  DL-AMPHETAMINES  AND 
RELAIED  COMPOUNDS 

246316  04  03 
LIPID  PFROXILMTION  AS  THE  CAUSE  OF  THE  ASCORBIC  ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS 

246318  04-04 
SELF  STIMULATION  AND  NORADRENALINE    EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST 

246774  04  03 
IHE  EFIECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINFSTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCUIARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS 

246H42  04  03 
MONOAMINE  OXIDASE       III    FURTHER  STUDIES  OF  INHIBITION  BY 
PROPARGYLAMINES 

247020  0403 
INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  Of  NOREPINEPHRINE,  BUT 
NOT  OF  DOPAMINE-BETA  HYDROXYLASE  FROM  GUINEA  PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER) 

247028  04-03 
IHE  EFFECT  OF  VARIOUS  CHIORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE  ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYlASr  A(  TIVITY 

247212  04-03 
INHIBIIION  OF  DRUG  METABOMSM  BY  FLUOXETINE. 

248605  04  02 


INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
IT  N-ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D-AMPHETAMINEI 
AND  3-ARYLOXYPROPYLAMINES. 

248637  04-C 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  B 
THYROTROPIN-RELEASING  HORMONE  IN  CATS. 

249281  04-( 
ON  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 
PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS. 

249287  04-( 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVC 
PARAOXON  (PX)  ADMINISTRATION. 

249295  044. 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-( 
INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUA 

249679  04-C 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFOR/WANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04-' 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04-( 
INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE 

250984  04-( 
FRONTAL-STRIATAL  CONTROL  OF  BEHAVIORAL  INHIBITION  IN  THE  RAT. 

251138  04-( 
INHIBITION  OF  PHENYLETHYLAMINE  METABOLISM  IN  VIVO    -  EFFECT  Of 
ANTIDEPRESSANTS. 

251184  04-( 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  B 
DIFFERENT  DOSES  OF  L-DOPA. 

251214  04-( 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  Of 
MONOAMINE  OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINI 

251985  04- 
INHIBITION  AND  POTENTIATION  OF  APOMORPHINE-INDUCED 
HYPERMOTILITY  IN  RATS  BY  NEUROLEPTICS. 

252029  04-( 
EFFECTS  OF  LILLY-HOMO,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYFRYPTOPHAN-INDUCED  ANOREXIA.  EVIDENCE  FOR 
SFROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-1 
GAMMA-AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION 

253392  04-1 
THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-1 
INHIBITOR 

ACUTE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FC 
ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS. 

225572  01-1 
INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1  10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5HYDR0XYTRYPTAMINE  BY  L-DOPA. 

226765  01-1 
EFFECTS  OF  A  DOPAMINE-BETA  HYDROXYLASE  INHIBITOR  ON 

AMPHETAMINE  INDUCED  HYPERACTIVITY  IN  RATS 

226766  01-1 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOP 

AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIO  (R0-4-4602). 

233917  02- 
THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-( 
DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
DOPA  AND  L-5-HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  02-( 
PERFUSION  WITH  L  5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  02-1 
TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOF 

AND  A  PERIPHERAL  DOPA-DECARBOXYLASE  INHIBITOR. 

237733  02- 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-( 


S-166 


IME  14,  SUBJECT  INDEX 


Subject  Index 


IMMAACETYLENIC-GABA  (AMINO-4-HEX-5-YNOICACID)-  A  GABA- 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY 

238781  03-04 
UROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-03 
AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGEN-IC 
AMINES  IN  SYNAPTOSOMES. 

246665  04-03 
NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN;  3  P  TRIFLUOROMETHYLPHENOXY-N- 
METHYL-3-PHENYLPR0PYLAMIN£. 

246848  04-03 
IMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

248612  04-11 
)MPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
EVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 
ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04-03 
FLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2  PHENYLETHYLAMINE  (PEA). 

249310  04-03 
FECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY!  10140,  ON 
TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04-03 
FECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R0-4 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM. 

251181  04-03 
IE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04-11 
FECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5- 
HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHANINDUCED  ANOREXIA    EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING 

252522  04-03 
HE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 
TORS 

NEGIECTED  MODALITY  IN  PSYCHIATRIC  TREATMENT      THE 
MONOAMINE-OXIDASE  INHIBITORS. 

227825  01-10 
SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES 

231072  01  06 
DME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE-OXIDASE. 

233946  02  01 
ENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 
HE  EFFECT  OF  CATECHOL-0-METHYLTRANSFERASE  INHIBITORS  ON 
BEHAVIOR  AND  DOPAMINE  METABOLISM. 

233969  02-03 
=FECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETAHYDROXYLASE  ON  RAT  SELF  STIMULATION  AFTER 
RESERPINE  TREATMENT. 

237103  02-04 
"FECT  OF  CATECHOL  0  METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT 

237747  02-03 
FFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  0303 
COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA  TRANSAMINASE:  GAMMA- 
VINYl-GABA  (AMIN0-4-HEX-5EN0IC-ACID)  AND  GAMMA  ACETYLENIC 
GABA  (AMIN0-4-HEX-5  YNOIC  ACID) 

238782  03-03 
MONOAMINE  OXIDASE  ACTIVE  SITE;  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (I4C)  SELECTIVE  INHIBITORS 

241931  03-03 
'RUG  DISCRIMINATION  IN  RATS    EFFECTS  OF  MIXTURES  OF  OITRAN  AND 
CHOIINFSTERASE  INHIBITORS 

242737  03-04 


NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 
OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  04-03 

ENDOGENOUS  INHIBITORS  OF  DOPAMINE  BETA-HYDROXYLASE  IN  RAT 
ORGANS 

244315  04-03 
INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE- 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04-13 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04-03 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
MODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETAHYDROXYLASE. 

248289  04-04 
MAO  INHIBITORS  HAVE  POTENTIAL  FOR  ABUSE. 

248339  04-15 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE  OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM 

248603  04-03 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L  ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H  DOPAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX. 

248699  04-03 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETAHYDROXYLASE  ON  RAT  SELF  STIMUI ATION  AFTER 
RESERPINE  TREATMENT. 

248964  04-04 
EFFECTS  OF  MONOAMINE  OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D  AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-03 
A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE-OXIDASE  INHIBITORS 
(MAOIS). 

249308  04-03 
ANALOGUES  OF  S-ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-01 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES 

251700  0403 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE-BETA  HYDROXYLASE  INHIBITORS 

253450  04-04 
INHIBITORY 

A  STUDY  OF  INHIBITORY  ANTAGONISM  IN  CAT  VISUAL  CORTEX 

226397  01-03 
INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 

INVERTEBRATE  SYNAPSES 

226398  01-03 
5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-ME()  DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS    (UNPUBLISHED  PAPER). 

227802  01-04 
LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHFSUS  MONKEYS 

228139  01-04 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 
PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHFNIDATE 

230841  01-03 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS   INHIBITORY 
ACTION  OF  TAURINE 

233299  02-03 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  02-04 
INHIBITORY  SYNAPSES  IN  THE  CENTRAL  NERVOUS-SYSTEM  AND  THEIR 
PHARMACOLOGICAL  RESPONSES 

236368  02-07 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS 

237782  02-03 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  0303 
CELLULAR  MEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  (DELrA9THC) 

238816  03-03 


a 


S-167 


Subject  Index 

lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION 

238823  03-03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION. 

239086  03-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  03-03 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 
ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON. 

241347  03-03 
INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  04-03 
ACETYLCHOLINE,  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 
HYPOTHALAMUS. 

248358  04-03 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  04-03 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS. 

252149  04-04 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
INHIBITS 

PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

231700  01-03 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS. 

23291  7  02-03 
PROPRANOLOL  INHIBITS  RAT  BRAIN  MONOAMINE-OXIDASE. 

250333  04-03 
INITIAL 

ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 
INJECTABLE 

EFFICACY  AND  TOLERANCE  OF  INJECTABLE  DOXEPIN. 

237775  02-10 
USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  CARDIAC 
CATHETERIZATION. 

244450  04-11 
THE  USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  ELECTRIC 

CARDIOVERSION. 

244451  04-11 
INJECTED 

COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01-04 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA  NIGRA  OF  THE  RAT. 

238347  02-04 
THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYDROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS. 

239087  03-03 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  03-04 
ACTIONS  OF  6HYDR0XYD0PAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
EFFECTS  OF  BARBITURATES  ON  BLOOD  PRESSURE  IN  LIDOCAINE 
INJECTED  SHR. 

241405  03-03 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-03 
INJECTION 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L  TRYPTOPHAN  INJECTION. 

226873  01-03 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02-03 


Psychopharmacology  Abstracts 

CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-0 
DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-0- 
THE  EFFECT  OF  SEROTONIN  INJECTION  INTO  THE  BULBAR  STRUCTURES 
ON  HEMODYNAMICS. 

236831  02-0: 
METABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN. 

237700  02-0: 
ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704  02-0 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-0 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED,  CORN-FED  RATS. 

238676  03-0 
BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC). 

238812  03-0 
INTRODUCTION:  COMPLEX  SCHEDULES  OF  DRUG  INJECTION. 

240012  03-0 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-0 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-C 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-C 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-( 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  04-( 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 
ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION. 

245600  04-( 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

245929  04-( 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04-( 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-( 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  B^ 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-( 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P-CHLOROPHENYLALANIh 
AND  OF  ALPHA-METHYL-P-TYROSINE. 

250982  04-( 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04-1 
INJECTIONS 

IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE. 

226938  01-1 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROAAAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  OM 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-1 


S-168 


3LUME  14,  SUBJECT  INDEX 


Subject  Index 


FFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-04 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 
STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS  ACCUMBENS  SEPTI, 

238319  0204 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
INJECTIONS  OF  AMINO  ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASE 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03-03 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE 

239828  03-03 
INTRODUCTION:  THE  CONTROL  OF  BEHAVIOR  BY  CONSEQUENT  DRUG 
INJECTIONS. 

240009  03-04 
CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 

INJECTIONS  OF  DRUGS. 

240010  03-04 
STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 

CONTROL  BEHAVIOR. 

24001 1  03  04 
INTRODUCTION:  SCHEDULES  OF  TERMINATION  OF  DRUG  INJECTIONS. 

240017  03-04 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE  DEPENDENT 
RHESUS  MONKEYS. 

240019  03-04 
DRUG  INJECTIONS  AS  NEGATIVE  REINFORCERS. 

240022  03  04 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT. 

241546  03-04 
THE  EFFECTS  OF  INTRA  AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

241918  03-04 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN 

242736  03-03 
THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

243758  04-04 
THERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE. 

243815  04-03 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04-04 
AVERSIVE  EFFECTS  OF  REPEATED  INJECTIONS  OF  THC  IN  RATS. 

249158  04-04 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
A  PRESSOR  RESPONSE  TO  INTRAVENTRICULAR  INJECTIONS  OF 
CARBACHOL. 

251142  04-03 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS 

252149  04-04 
JURY 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04-13 
NERVATION 

HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 
INNERVATION  IN  RAT  BRAIN. 

226739  01-03 
OTROPIC 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYOROXYDOPAMINE  AND  ALPHA-METHYL  P-TYROSINE  IN  DOGS. 

242200  03-03 
PATIENT 
INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02-17 


INPATIENTS 

THE  METHODOLOGY  OF  TRIALS  OF  ANTIDEPRESSANTS  FOR  DEPRESSED 
INPATIENTS. 

227213  01-16 
INPUT 

THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAT 
ADRENAL  MEDULLA. 

243779  04-03 
INQUIRY 

SECONDARY  EFFECTS  OF  LITHIUM  TREATMENT.  PRELIMINARY  RESULTS 
OF  AN  INQUIRY. 

241765  03-15 
INSECTA 

PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PHD    DISSERTATION). 

241994  03-04 
INSIDIOUS 

DELAYED  AND  INSIDIOUS  ONSET  OF  OIPHENYLHYDANTOIN  TOXICITY. 

246932  04-15 
INSOMNIA 

FLURAZEPAM,  A  NEW  HYPNOTIC  FOR  THE  TREATMENT  OF  INSOMNIA. 

242502  03  14 
INSOMNIAC 

TRIAZOLAM  IN  INSOMNIAC  FAMILY  PRACTICE  PATIENTS. 

245649  04-11 
HYPNOTIC  EFFICACY  OF  TRIAZOLAM  AND  METHYPRYLON  IN  INSOMNIAC 
IN-PATIENTS. 

248533  04-11 
INSOMNIACS 

COMPARATIVE  EVALUATION  OF  FLURAZEPAM  AND  NITRAZEPAM  FOR 
OCCASIONAL  INSOMNIACS 

228315  01   11 
EEG  SLEEP  STUDIES  OF  INSOMNIACS  UNDER  FLUNITRAZEPAM 
TREATMENT. 

239819  03-14 
A  COMPARISON  OF  THE  EFFECTS  OF  FLURAZEPAM  30  MG  AND 
TRIAZOLAM  0.5  MG  ON  THE  SLEEP  OF  INSOMNIACS. 

244686  04-11 
INSPECTION 

CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTION: 
OPEN  AND  DOUBLE  BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  03-14 
INSTITUTION 

DISCOURSE  ON  THE  DOUBLE-BLIND  METHOD    INSTITUTION  AND 
EXPERIMENTATION:  19366  RP. 

229078  01-16 
INSTITUTIONS 

THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 
PSYCHIATRIC  INSTITUTIONS. 

229558  01-17 
INSTRUMENTAL 

CHOLINERGIC  MEDIATION  OF  INSTRUMENTAL  AND  CONSUMAAATORY 
BEHAVIORS. 

233448  02  04 
Y  MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04  04 
INSUUN 

SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02-03 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOAAAZIN)  IN  MENTAL  PATIENTS 

242863  04-15 
INSULIN-INDUCED 

DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN  INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
INTACT 

RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS 

238681  03-03 
INTAKE 

ASSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 
CLEFTS. 

229350  01-15 
EFFECT  OF  ETHANOL  INTAKE  ON  PHENYTOIN  METABOLISM  IN 
VOLUNTEERS 

233280  02-13 


XS 


52= 


S-169 


Subject  Index 


Psychopharmacology  Abstracts 


INTERACTION  EFFECTS  OF  OAMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02-03 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  DAMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUC1NE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
ETHANOL,  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION. 

238749  0304 
EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES. 

239290  03-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN 

248961  04-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE 

249678  04-04 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  DAMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE 

250657  04-13 
EFFECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYOROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-03 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS. 

253111  04-04 
INTAKES 

IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
OIHYDROXYTRYPTAMINE. 

226938  01  04 
INTEGRATED 

AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS 

241234  03-13 
INTEGRATIVE 

MODEL  OF  CAUSAL  CONFRONTATION  IN  INTEGRATIVE  PSYCHOTHERAPY. 

234503  02-14 
INTEGRITY 

ALTERATION  OF  MEMBRANE  INTEGRITY  OF  DELTAl- 
TETRAHYDROCANNABINOL. 

229035  01-03 
INTELLECTUAL 

THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY:  DOUBLE-BLIND 
STUDY  Of  HYDROSARPAN-711  IN  80  SUBJECTS. 

240166  03-11 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
THE  QUALITY  OF  INTELLECTUAL  LIFE:  DOUBLE-BLIND  STUDY  OF 
HYDROSARPAN-711  INVOLVING  80  SUBJECTS. 

242899  04-11 
BEHAVIOR  AND  INTELLECTUAL  ACTIVITY  OF  THE  ELDERLY:  DOUBLE- 
BLIND  STUDY  OF  HYDROSARPAN-711  IN  A  HOSPICE  ENVIRONMENT. 

242900  04-11 
INTENSITY 

EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMMATURE  RAT. 
(PH  D   DISSERTATION), 

231533  01-04 
EFFECTS  OF  AMPHETAMINE.  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF-STIMULATION  IN  THE  RAT. 

244214  04-04 

INTENSIVE 

ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLORDIAZEPOXIDE  IN 
AN  INTENSIVE  DESIGN  STUDY. 

228221  01-08 

INTENTION 

INTENTION  MYOCLONUS:  SUCCESSFUL  TREATMENT  WITH  CLONAZEPAM. 

237825  02-11 
INTER-GROUP 

INTERGROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 


INTER-MAIE 

EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485  04-04 
INTERACTING 

INTERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 

CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  RATS. 

248394  04-04 
INTERACTION 

PHARMACOLOGICAL  INTERACTION  BETWEEN  CANNABINOL  AND  DELTA9- 
TETRAHYDROCANNABINOL. 

225570  01  03 
POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848  01-05 
METHADONE  INTERACTION  WITH  APOMORPHINE  AND  AMPHETAMINE- 
INDUCED  TURNING. 

226945  01-04 
SCOPOLAMINE  AND  mMPHETAMINE  EFFECTS  ON  DISCRIMINATION: 
INTERACTION  WITH  STIMULUS  CONTROL. 

227131  01  04 
AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS. 

228225  01  08 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01-04 
CONCEPTUAL  IMPLICATIONS  OF  DRUG  AND  NONSOMATIC  TREATMENT 
INTERACTION  STUDIES. 

229452  01-17 
THE  INTERACTION  BETWEEN  ALPHA-METHYL-DOPA  AND  TRICYCLIC 
ANTIDEPRESSANTS. 

230819  01-03 
A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES. 

231072  01-06 
CANNABIDIOL  AND  ITS  PHARMACOKINETIC  INTERACTION  WITH  DELTAI- 
TETRAHYDROCANNABINOL. 

233279  02-03 
INTERACTION  EFFECTS  OF  DAMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02-03 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  I  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES. 

237698  02-03 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  4  )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02-04 
APPARENT  PHARMACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901  02-13 
DRUG  PERMEATION  THROUGH  MEMBRANES  V:  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  02-02 
EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS 

238695  03-03 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 

CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-W 
INTERACTION  OF  TRIHEXYPHENIDYL  AND  CHLORPROMAZINE:  PROBABLE 

MECHANISM 

238732  03-03 
L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANTAGONISTIC  INTERACTION 
WITH  ETHANOL  IN  HUMANS 

238748  03-13 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-03 
AMT  CATALEPSY  AND  HYPOKINESIA:  INTERACTION  WITH  MORPHINE 
AND  COCAINE. 

241224  03-0': 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROTHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-03 
INTERACTION  OF  ALCOHOL  AND  BENZODIAZEPINE  HYPNOTICS. 

242947  04-1; 
THE  INTERACTION  BETWEEN  DRUGS,  ALCOHOL  AND  DRIVING  AN 
AUTOMOBILE. 

244453  0415 


S-170 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  INTERACTION  Of  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  0403 
INTERACTION  OF  DELTA9TETRAHYDR0CANNABIN0L  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS 

244894  04-04 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS. 

246311  04-03 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  0403 
INTERACTION  Of  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 

ALBUMIN    -  II.  CIRCULAR  DICHROISM  STUDIES 

251177  04-01 
INTERACTION  OF  ATROPINE  OR  METHYLATROPINIUM  WITH  FOUR 

EFFECTS  OF  TWO  CHOLINERGIC  DRUGS. 

251217  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS;  INVOLVEMENT  OF  GABA. 

251399  04-03 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04  03 
METHAQUALONE  WITH  PSYCHOTROPIC  DRUGS:  ADVERSE  INTERACTION. 

253531  04-15 
ITERACTIONS 

INTERACTIONS  OF  DELTA9-TETRAHYDR0CANNABIN0L,  ADRENAL 
STEROIDS.  AND  ETHANOL. 

226763  01-03 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS. 

226849  01-03 
INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF- 
STIMULATION  BEHAVIOR  IN  RATS. 

226943  01  04 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
DRUG  INTERACTIONS. 

227412  01-17 
INTERACTIONS  Of  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 
BLOOD  VESSELS. 

229474  01-03 
DRUG  SCHEDULE  INTERACTIONS  AND  INTERCURRENT  BEHAVIOR. 

229479  01-04 
DRUG  INTERACTIONS:  THE  EFfECTS  Of  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I.  THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW, 

232517  01-17 
DRUG  INTERACTIONS:  THE  EffECTS  Of  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  II.  fIVE 
EXPERIMENTS 

232518  01-14 
DRUG  INTERACTIONS:  THE  EffECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  Ill    THE 
CONCENTRATIONS  Of  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EfFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  0113 
DRUG  INTf  RACTIONS;  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  V    SUMMARY 
AND  CONCLUSIONS 

232521  01-14 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 

DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS 

232609  0204 
INTERACTIONS  OF  OPIATE  RECEPTORS  WITH  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

232960  02-03 
CATECHOLAMINES.  DRUGS,  AND  BEHAVIOR;  MUTUAL  INTERACTIONS. 

233968  02-04 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  0203 


DIFFERENTIAL  INTERACTIONS  OF  PENTOBARBITAL  AND  PHENOBARBITAL 
WITH  BETA-ADRENtRGIC  MECHANISMS. 

238725  03-03 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 

INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P-TYROSINE 
ON  SCHEDULE-CONTROLLED  PERFORAAANCE  IN  RATS. 

238844  03-04 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PH  D. 
DISSERTATION). 

240934  03-03 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
INTERACTIONS  OF  HALLUCINOGENS  AT  THE  CLINICAL  LEVEL. 
(UNPUBLISHED  PAPER). 

244195  04-12 
INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE- 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04-13 
DRUG  INTERACTIONS. 

246296  04-15 
NEW  METHOD  FOR  DETECTING  AND  OUANTITATING  PHARAAACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9-THC  DURING 
ABSTINENCE  IN  MORPHINE-DEPENDENT  RATS 

249001  04-04 
NALTREXONE,  MORPHINE  AND  COCAINE  INTERACTIONS  IN  MICE. 

249269  04-04 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
DRUG  AND  PSYCHOTHERAPY  INTERACTIONS  IN  DEPRESSION. 

252941  04-09 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS 

253693  04-03 
INTERACTIVE 

THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
INTERCURRENT 

DRUG  SCHEDULE  INTERACTIONS  AND  INTERCURRENT  BEHAVIOR. 

229479  01-04 
EFFECTS  OF  D  AMPHETAMINE,  CHLORPROMAZINE,  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACED 
RESPONDING  SCHEDULES. 

229639  01-04 
INTERFERENCE 

IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02- 13 
INTERFERENCE  BETWEEN  ANTI  HLA  ANTIBODIES  AND  CHLORPROMAZINE. 

250476  04-07 
INTERHEMISPHERIC 

PIRACETAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAL  INFORMATION  IN  RATS. 

239861  03-04 
INTERIOR 

THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES 

246856  04-13 
INTERMITTENT 

EFfECTS  Of  INTERMITTENT  AND  REPEATED  ADMINISTRATION  Of  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS 

253111  0404 
INTERNAL 

CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS. 

227806  01-11 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-10 
DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROMATOGRAPHY. 

229906  01-16 
SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS. 
(UNPUBLISHED  PAPER), 

237274  0216 


s» 


S-171 


Subject  Index 


Psychopharmacology  Abstracts 


INTERNATIONAL 

ASSESSING  THE  SAFETY  AND  EFFICACY  OF  INTERNATIONAL  TRIALS  IN 
PSYCHOPHARMACOLOGY.  (UNPUBLISHED  PAPER). 

232902  02-16 
NINTH  CONGRESS  OF  THE  INTERNATIONAL 

NEUROPSYCHOPHARMACOLOGICUM  COLLEGIUM  OR  C.I.N. P.  (PARIS, 
JULY  7-12,  1974). 

250266  04- 17 
INTERNEURONS 

BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM:  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
INTERPRETATION 

ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  0114 
THE  INTERPRETATION  OF  RESPONSES  OF  MOTONEURONS  FIELD 
POTENTIALS  TO  5-HYDROXYTRYPTAMINE. 

241923  03-03 
INTERRELATIONS 

NEUROLEPTICS,  CATECHOLAMINES,  AND  PSYCHOSES:  A  STUDY  OF  THEIR 
INTERRELATIONS 

245510  04-09 
INTERRELATIONSHIP 

BRAIN  LIVER  INTERRELATIONSHIP  IN  BARBITURATE-TOLERANCE. 

229490  01-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
INTERVENTION 

NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION. 

251149  04-17 
INTESTINAL 

TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 
INTESTINAL  ABSORPTION,  DEMETHYLATION,  AND  ENTEROHEPATIC 
CIRCULATION  OF  IMIPRAMINE. 

252231  04-13 
INTESTINE 

RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  IN 
THE  GUINEA-PIG  INTESTINE, 

248703  04-03 
INTOXICATION 

INVOLUNTARY  MOVEMENTS  CAUSED  BY  PHENYTOIN  INTOXICATION  IN 
EPILEPTIC  PATIENTS. 

225890  01-15 
HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 

227389  01-03 
LITHIUM  INTOXICATION:  A  REPORT  OF  TWO  CASES. 

227745  01-15 
ELECTROENCEPHALOGRAPHIC  FINDINGS  IN  PHENCYCLIDINE 
INTOXICATION. 

236667  02-15 
CEREBELLAR  ATAXIA  DUE  TO  DIPHENYLHYDANTOIN  ADMINISTRATION   - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
DIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03-14 
BARBITURATE  INTOXICATION:  MORBIDITY  AND  MORTALITY. 

240843  03-15 
PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES. 

242751  04-17 
TWO  CASES  OF  SUICIDAL  LITHIUM  INTOXICATION. 

243438  04-15 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
HUMAN  SLEEP  DURING  CHRONIC  MORPHINE  INTOXICATION. 

246304  04-13 
PHENCYCLIDINE     STATES  OF  ACUTE  INTOXICATION  AND  FATALITIES. 

247147  04-15 
INTOXICATIONS 

MEASUREMENT  OF  ATTENTION  DEFICIT  IN  THE  COURSE  OF 
INTOXICATIONS 

244896  04-14 
INTRA-AMYGDALOID 

THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

241918  03-04 


I 


THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

243758  04-04' 
INTRABRAIN 

ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
INTRACAUDATE 

INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
GAMMA-AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION. 

253392  04-04 
INTRACELLULAR 

INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION. 

232333  01-03 
ON  THE  INTRACELLULAR  MECHANISM  OF  ACTION  OF  IMIPRAMINE  AND 
DIAZEPAM 

236232  02-03 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04-04 
ON  THE  CLINICAL  RELEVANCE  OF  THE  INTRACELLULAR  RBC  LITHIUM 
CONCENTRATION. 

251417  04-15 
INTRACEREBRAL 

REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

241100  03-03 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-03 
CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6- 
HYDROXYDOPAMINE  AND  DESIPRAMINE. 

252024  04-03 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  04-03 
INTRACEREBRALLY 

BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 
CONDITIONED  REFLEX  IN  THE  CAT. 

239275  03-04 
STUDY  ON  HEAD-TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE. 

241380  03-04 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 
INTRACEREBROVENTRICULAR 

ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN. 

227386  01  04 
EFFECTS  OF  INTRACEREBROVENTRICULAR  L-DOPA  ON  CAUDATE  UNIT 
FIRING. 

238716  03-03 
INTRACISTERNAL 

BARBITAL-INDUCED  CROSS-TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
METABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN. 

237700  02-03 


S-172 


rOLUME  14,  SUBJECT  INDEX 


Subject  Index 


MTRACISTERNALLY 

BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPING 
RATS 

232609  02-04 
'4TRACRANIAL 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT 

238755  03-04 
INTRACRANIAL  SELF-STIMULATION  DERIVED  FROM  ENTORHINAL  CORTEX. 

238757  03-04 
INTRACRANIAL  SELF  STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS;  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF-STIMULATION  AND  SLEEP  IN  THE 
RAT.  (PH.D.  DISSERTATION). 

241678  03-03 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-04 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  04-04 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 
FOLLOWING  BRAIN  AMINE  DEPLETION. 

249138  04-04 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION. 

250019  04-04 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P-CHLOROPHENYLALANINE 
AND  OF  ALPHA-METHYL-P-TYROSINE 

250982  04-04 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04-04 
NTRACTABLE 

SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY. 

245344  04-11 
NTRAGASTRIC 

INTRAGASTRIC  SELF-ADMINISTRATION  OF  PSYCHOACTIVE  DRUGS  BY 
THE  RHESUS  MONKEY. 

249004  04-06 
COMPARISON  BETWEEN  INTRAVENOUS  AND  INTRAGASTRIC  ALCOHOL 
SELF-ADMINISTRATION 

250021  04-04 
NTRAHYPOTHALAMIC 

THERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE. 

243815  04-03 
NTRAMUSCULAR 

PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE 

229446  01-08 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02-13 
SERUM  CREATINE-PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT. 

237928  02  15 
NTRAMUSCUIARLY 

INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN 
ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  03-08 
NTRAPERITONEAL 

THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT 

238755  03-04 


DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03-04 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
INTRASPECIES 

INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE. 

239829  03-04 
INTRASTRIATAL 

BEHAVIORAL  EFFECTS  IN  RATS  FOLLOWING  INTRASTRIATAL 
MICROINJECTION  OF  MANGANESE. 

226932  01-04 
INTRATHECAL 

INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

231002  01-03 
INTRAVENOUS 

INTRAVENOUS  TYRAMINE  PRESSOR  RESPONSE  IN  DEPRESSION. 

226187  01-10 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN  RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693  01-09 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  02-04 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03  04 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE-DEPENDENT 
RHESUS  MONKEYS. 

240019  03  04 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

24 1 256  03-03 
EFFECTS  OF  INTRAVENOUS  ANESTHETICS  ON  CONTINUOUS  AVOIDANCE 
BEHAVIOR  IN  THE  RAT. 

241314  03-04 
INTRAVENOUS  LORAZEPAM  IN  THE  ACUTE  ANXIETY  CRISIS:  A 
PRELIMINARY  REPORT  ON  60  CASES. 

242250  03  10 
INTRAVENOUS  TRAZODONE  WITH  DEPRESSIVE  SYNDROMES 

244589  04  09 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
EFFECT  OF  INTRAVENOUS  DIAZEPAM  ON  RENAL  FUNCTION 

246273  04-15 
CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  04-15 
INTRAVENOUS  TRANQUILLIZATION  WITH  ECT. 

249537  04-16 
COMPARISON  BETWEEN  INTRAVENOUS  AND  INTRAGASTRIC  ALCOHOL 
SELF-ADMINISTRATION. 

250021  04-04 
INTRAVENOUSLY 

A  CONTRIBUTION  TO  TREATMENT  OF  DEPRESSIVE  SYNDROMES:  USE  OF 
TRAZODONE  INTRAVENOUSLY. 

230992  01-09 
INTRAVENTRICULAR 

GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  01  04 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  01-04 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-04 


5»c 


S-173 


Subject  Index 

EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE 

239828  03-03 

SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I   COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 

HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  P-CHLOROPHENYLALANINE, 

243878  04-04 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  04-04 
EFFECTS  OF  INTRAVENTRICULAR  P-CHLOROAMPHETAMINE  AND  ITS 

ANALOGUES  ON  CEREBRAL  5-HT 

246151  04-03 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY. 

248947  04-03 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-03 
A  PRESSOR  RESPONSE  TO  INTRAVENTRICULAR  INJECTIONS  OF 
CARBACHOL 

251142  04-03 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
INTRA  VENTRICULARIY 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5-HYDR0XYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE. 

226400  01-03 
ACTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE, 

246852  04  04 
INVERSELY 

DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-03 
INVERTEBRATE 

INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 
INVERTEBRATE  SYNAPSES. 

226398  01-03 
INVESTIGATING 

VESTIBULAR  TEST  IN  INVESTIGATING  THE  SPECTRUM  OF  ACTION  OF 
PSYCHOTROPIC  AGENTS. 

236714  02-04 

INVESTIGATION 

FLUPENTHIXOL-DECANOATE   -  CONTROLLED  INVESTIGATION  CONCERNING 
DOSAGE 

226408  01  08 
UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER). 

226731  01-13 
AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMAIES   (PH.D. 
DISSERTATION). 

228726  01-11 
AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS  SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

229169  01-15 
IMMUNOLOGIC  INVESTIGATION  OF  BARBITURATE  PHARMACOLOGY, 

229480  01-03 
INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIOOL 

236369  02-03 


Psychopharmacology  Abstracts 


I 


AN  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  0303 
AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-OOPA  AND  5HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03-03 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT   -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
A  THREE-YEAR  DOUBLE-BLIND  INVESTIGATION  OF  PIMOZIDE  VERSUS 
FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  04-08 
INVESTIGATIONS 

PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01-14 
PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS: 
EFFECT  OF  DIAZEPAM  IN  MALES. 

229840  01-11 
ARE  HORMONES  PSYCHOACTIVE?  EVOKED  POTENTIAL  INVESTIGATIONS 
IN  MAN. 

232532  01-14 
ETHICAL  AND  LEGAL  IMPLICATIONS  OF  INVESTIGATIONS  INTO  THE 
EFFICACY  OF  PSYCHIATRIC  TREATMENTS. 

235354  02- 17 
NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE. 

238516  02-11 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I.  INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-06 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE. 

246148  04-0-1 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANOL 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH). 

250110  04-0: 

INVOLUNTARY 

INVOLUNTARY  MOVEMENTS  CAUSED  BY  PHENYTOIN  INTOXICATION  IN 
EPILEPTIC  PATIENTS. 

225890  01  i; 

INVOLUTIONAL 

TREATMENT  OF  DEPRESSIVE  SYNDROMES  IN  INVOLUTIONAL  SUBJECTS. 

230990  01-0? 
INVOLVED 

FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE.  PART  I:  IS 

FENFLURAMINE  OR  NORFENFLURAMINE  INVOLVED  IN  THE  DECREASE 
OF  BRAIN  5-HYDROXYTRYPTAMINE?. 

237118  02-0: 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-0: 
PROBLEMS  INVOLVED  IN  ADMINISTERING  L-DOPA 

239695  03-11 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-0' 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION?, 

241932  03-0' 
INVOLVEMENT 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01  O: 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01-0: 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 
BENZODIAZEPINES 

229465  01-0: 
INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -  STUDIES 

ON  RAT  CEREBELLUM. 

229466  01-0: 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMUIJ\NT  AND 

PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE, 

230841  01-0 
INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG-INDUCED  AGGRESSIVE 

PECKING  IN  CHICKS. 

230878  01 -a 


S-174 


XUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01-03 

EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01-03 
EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 

BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM. 

232514  01-03 
POSSIBLE  INVOLVEMENT  OF  GABA  IN  THE  CENTRAL  ACTIONS  OF 

BENZODIAZEPINES 

232515  01-03 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE.  PART  2:  INVOLVEMENT 

OF  BRAIN  AND  5HYDR0XYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 
OF  FENFLURAMINE. 

237119  02-03 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE. 

237706  02-03 
SEROTONERGIC  INVOLVEMENT  WITH  NEUROLEPTIC  CATALEPSY. 

237781  02-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT 

241255  03-03 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE 

245601  04-04 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RATS 
PRODUCED  BY  D-AMPHETAMINE. 

246820  04-04 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 
POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA. 

251704  04-04 
)INE 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
«4 
SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS. 
(UNPUBLISHED  PAPER). 

237274  02-16 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

238318  02-04 
M-STIMULATEO 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
MIC 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS. 

232917  02-03 
MIZATION 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA 

238486  02-16 
MOPHORES 
lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER). 

236873  02-03 
MS 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
MTOPHORETIC 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-03 


IPRINDOLE 

STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 
ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PH.D. 
DISSERTATION). 

231438  01-03 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN. 

237922  02-03 
EXPLORATION  OF  THE  ANTIDEPRESSANT  POTENTIAL  OF  IPRINDOLE. 

241241  03  04 
IPRONIAZID 

EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
IRRADIATION 

CHLORDIAZEPOXIDE  METABOLISM  IN  MICE  FOLLOWING  HEPATIC 
IRRADIATION. 

226840  01-03 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AAAP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION 

249286  04-03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS 

253106  04-03 
IRREVERSIBLE 

AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

229169  01-15 
IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099. 

238686  03-03 
IRRITABLE 

TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENSORY 
DEPRIVATION 

233418  02-03 
ISCHEMIA 

CATECHOLAMINES  IN  BRAIN  ISCHEMIA   -  EFFECTS  OF  ALPHA-METHYL-P 
TYROSINE  AND  PARGYLINE. 

239577  03-03 
ISOCARBOXAZID 

PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID. 

237705  02-04 
ISOCARBOXAZIDE 

STUDY  ON  HEAD- TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE 

241380  03-04 
ISOLATE 

RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM 

238694  03  04 
ISOLATED 

EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDITIONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION.  (PH.D. 
DISSERTATION) 

228503  01  04 
RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATEIETS,  AND 
ERYTHROCYTES. 

230739  01  13 
EFFECTS  OF  DIAZEPAM  ON  THE  ISOLATED  CHICK  EMBRYO  HEART. 

230862  01-03 
THE  RELEASE  OF  GLUTAMIC-ACID  FROM  ISOLATED  BRAIN  TISSUES 

236522  02-03 
CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
ENDINGS. 

237244  02-03 
LOCAL  ANESTHETICS  AND  BARBITURATES;  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-03 
METABOLISM  OF  DELTAl -TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  I IING.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  0306 
EFFECTS  OF  BETA-HYOROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA 

238777  03-03 
DIFFERENTIAL  EFFECTS  OF  PHENOBARBITAL  AND  PENTOBARBITAL  ON 
ISOLATED  NERVOUS  TISSUE. 

240474  03-03 


< 


S-175 


"^g^^i^ 


Subject  Index 

A  STUDY  Of  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO  ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 
PERFUSED  RAT  BRAIN. 

243782  04-03 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE  OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM, 

248603  04-03 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE. 

249257  04-03 
HALOPERIDOL  CATALEPSY  IN  GROUPED  AND  ISOLATED  MICE. 

249624  04-04 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  04-03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
THE  UPTAKE  OF  TRITIATED  DELTAl -TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VAS-DEFERENS  OF  THE  RAT. 

252200  04-03 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES. 

252757  04-03 
ISOLATION 

ISOLATION  OF  AN  ENDOGENOUS  COMPOUND  FROM  THE  BRAIN  WITH 
PHARMACOLOGICAL  PROPERTIES  SIMILAR  TO  MORPHINE. 

227774  01  03 
CHLORDIAZEPOXIDE  AND  ISOLATION  INDUCED  TIMIDITY  IN  RATS. 

230828  01-04 
ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID.  ACID. 

233278  02-01 
EFFECTS  OF  HASHISH  ON  ISOLATION  INDUCED  AGGRESSION  IN  WILD 
MICE. 

237714  02-04 
ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485  04-04 

ISOLE 

EFFECTS  OF  ALPHA  METHYL-P  TYROSINE  (AMPT)  ON  THE 

El  ECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-03 
ISOMERIC 

SYNTHESIS  AND  NEUROLEPTIC  ACTIVITY  OF  ISOMERIC 
THIENOBENZOTHIAZINES. 

248949  04-01 

ISOMERS 

EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE. 

241414  03-03 
CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAAAPHETAMINE. 

246851  04  03 
ISONIAZID 

ISONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME:  A 
PILOT  TRIAL. 

236665  02  09 

SUIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02  15 

ISOPRINOSINE 

ISOPRINOSINE  THERAPY  IN  SUBACUTE  SCLEROSING  PANENCEPHALITIS 

251952  04-11 

ISOPROPAMIDE 

DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE.  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 

ISOPROTERENOL 

IN  VIVO  ACTIVATION  OF  RAT  PINEAL  CAMP  PHOSPHODIESTERASE  BY 
ISOPROTERENOL    (UNPUBLISHED  PAPER). 

228032  01-03 
SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN  AND 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERTATION). 

228493  01-03 


Psychopharmacology  Abstract; 

BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVI 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM 

237880  02-0, 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-0 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-0 

ISOQUINOLINES 

POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES. 

248513  04-C 

ISOTOPE 

CHLORPROMAZINE  EXCRETION:  ISOTOPE  VERSUS  CHEMICAL  ASSAY. 

229481  01-C 
ISOXSUPRINE 

ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 

PREMENSTRUAL  TENSION. 

245136  04-1 

THE  OBJECTIVE  MEASUREMENT  Of  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04-1 

ITERATIVE 

HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALAAAR  SKir 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS. 

248514  04-( 

JAPAN 

ADDITIONAL  STUDIES  -  JAPAN. 

227220  01-1 

COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-1 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN 

252181  04- 

JOINTLY 

DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I.  THEORETICAI 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01- 

DRUG  INTERACTIONS:  THE  EFfECTS  Of  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  II.  fIVE 

EXPERIMENTS. 

232518  01- 

DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE,  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01- 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 

232520  01- 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  V.  SUMMARY 
AND  CONCLUSIONS. 

232521  01- 

JUDGMENT 

PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 

RESEARCH. 

231066  01- 

JUDICIAL 

ADMINISTRATIVE  AND  JUDICIAL  PROBLEMS  IN  PSYCHOPHARMACOLOC 

237121  02 

JUICE 

CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  B 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01 
STUDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01 

JUMPING 

BRAIN  DOPAMINE  AND  JUMPING  BEHAVIOUR  IN  MICE. 

237746  02 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS 

249272  04 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS. 

250354  041 


S-176 


)LUME  14,  SUBJECT  INDEX 

REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE 

250656  04-03 
ICTION 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG. 

226855  01-03 
A  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM. 

233289  02-03 
ENILE 
LITHIUM  CARBONATE  IN  JUVENILE  MANIC-DEPRESSIVE  ILLNESS. 

236663  02-10 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEN 
AND  OLFACTORY  STIMULI. 

245406  04-04 
OMPIEXES 
EFFECT  OF  FLURAZEPAM  ON  SLEEP  SPINDLES  AND  K-COMPLEXES. 

238507  02-14 
1)04 
CLINICAL  AND  ELECTROENCEPHALOGRAPHICAl  STUDIES  OF  THE  NEW 
HYPNOSEDATIVE  K-2004, 

243198  04-11 
917 
A  1,4  BENZODIAZEPINE,  TEMAZEPAM  (K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02-14 
AMINE 
A  NEUROPHYSIOLOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 
PSYCHOTOMIMETICS  (LSD-25,  DOM  AND  KETAMINE). 

232703  02-04 
THE  EFFECT  OF  PHENCYCLIDINE  AND  KETAMINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  PIGEON. 

237757  02-04 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK 

238795  03-03 
A  COMPARISON  OF  THE  DISCRIMINABLE  CNS  EFFECTS  OF  KETAMINE, 
PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  BY 
PINEAL  METABOLITES. 

249240  04-03 
BIODISPOSITION  OF  KETAMINE  IN  THE  RAT:  SELF  INDUCTION  OF 
METABOLISM. 

250107  04-03 
EFFECTS  OF  HALOTHANE  ANESTHESIA  ON  THE  BIODISPOSITION  OF 

KETAMINE  IN  RATS. 

250108  04-03 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D-AMPHETAMINE  AND 

PENTOBARBITAL  ON  SCHEDULE  CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

250112  04-04 
FAZOLAM 
DOUBLE-BLIND  PLACEBO  CONTROLLED  EFFICACY  STUDY  OF  KETAZOLAM 
(U-28774). 

248532  04-10 
rOCYClAZOCINE 
KETOCYCLAZOCINE:  BEHAVIORAL  EFFECTS  IN  PIGEONS  AND  MONKEYS. 

249246  04-04 
>NEY 
THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762  01-03 
MASE 
ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3 
MONOOXYGENASE.  (UNPUBLISHED  PAPER) 

237172  02-03 
SIDLED 
EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS, 
PAPIO-PAPIO. 

230475  01  03 
ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01  03 
SIOUNG 

PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING.  (UNPUBLISHED 
PAPER). 

231771  01  04 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS   (UNPUBLISHED  PAPER) 

237169  02-04 


Subject  Index 

PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
THE  EFFECTS  OF  TAURINE  ON  VARIOUS  STAGES  OF  THE  KINDLING 
PROCESS:  A  SUMMARY  OF  RESULTS. 

251929  04-04 

KINESTIC 

CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMAAA 
GLUTAMYL-TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03-03 

KINETIC 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS. 

226185  01-04 

EFFECT  OF  METHAMPHETAMINE  AND  NEUROLEPTIC  AGENTS  ON  THE 
KINETIC  PROPERTIES  OF  STRIATAL  TYROSINE-HYDROXYLASE. 

238693  03-03 
DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 
TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04  05 

KINETICS 

KINETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  RATS 
OF  DIFFERENT  AGES. 

234316  02-03 
ON  THE  MECHANISMS  OF  ACTION  AND  KINETICS  OF  LITHIUM 

240740  03-03 
KINETICS  OF  CARBAMAZEPINE  AND  ITS  10,1 1  EPOXIDE  METABOLITE  IN 

CHILDREN. 

243086  04-13 
PENFLURIDOL  STEADY-STATE  KINETICS  IN  PSYCHIATRIC  PATIENTS. 

245650  04  08 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 

ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE 

248700  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS 

250377  04-01 
THE  STRUCTURE  ACTION  RELATIONSHIP  AND  KINETICS  OF  SOME 
NALOXONE  AND  NALTREXONE  DERIVATIVES. 

252223  04  03 

KNOWLEDGE 

PROPHYLAXIS  OF  AFFECTIVE  DISORDERS:  CURRENT  STATUS  OF 

KNOWLEDGE. 

239937  03-09 

L-AMINOCYCLOPENTANE-1-CARBOXYLlC-ACID 

NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 

AMINOCYCLOPENTANE  1-CARBOXYLIC  ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES 

241298  03-03 

l-AMPHETAMINE 

EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01  04 
THE  EFFECT  OF  D.L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01-03 
THE  INFLUENCE  OF  D,L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248  01  04 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT. 

237716  02-14 
D  AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA, 

239272  03-04 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS:  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS 

247211  04  03 
DIFFERENTIAL  EFFECTS  OF  D    AND  L  AMPHETAMINE  ON  THE  SLEEP  OF 
DEPRESSED  PATIENTS. 

248160  04  10 

L-AROMATIC 

INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04  13 


o 


S-177 


Subject  Index 


Psychopharmacology  Abstrac 


1-CYSTEINE-35S-HYDROCHIORIDE 

THE  UPTAKE  OF  35S  BY  HYPOTHAIAMIC  AND  NbUkOHYPUHHYSIAL 
PROTEINS  FOUOWING  INTRAVENTRICULAR  INJECTION  OF  L  CYSTEINE- 
35S-HYDROCtllORID[  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-03 
L-DIHYDROXYPHENYLALANINE 

BIOCHEMICAL  PHARMACOLOGICAL  BASES  FOR  THE  CLINICAL  USE  OF  L- 
DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME, 

244039  04-17 
l-OOPA 

PLASMA  CONCENTRATIONS  OF  I  DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  0M4 
INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY!  I0I40)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA. 

226765  01  03 
DOUBLE-BLIND  CONTROl  OF  L  DORA  THERAPY  IN 

SCHIZOPHRENIA. 

229064  01-08 
COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG  RANGE  L  DOPA  THERAPY 
IN  PARKINSONISM. 

229165  Ol-n 
THE  EFFECT  OF  L  DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS.  A  DOUBLE 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO-4-4602). 

233917  02-11 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST 

236372  02-04 
DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
DOPA  AND  L  5-HTP:  POIYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  0203 
TREAIMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPA-DECARBOXYLASE  INHIBITOR. 

237733  02-1 1 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

238318  02-04 
EFFECTS  OF  INTRACERE8R0VENTRICULAR  L-DOPA  ON  CAUDATE  UNIT 
FIRING. 

238716  0303 
NECESSITY  OF  HYPERTHERMIA  FOR  L  DOPA  OR  DAMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES 

238719  03-03 
L-DOPA,  AMINOPHYLLINE,  EPHEDRINE:  ANIAUJNISIK.  INTERACTION 
WITH  ETHANOL  IN  HUMANS. 

238748  03-13 
AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-DOPA  AND  5-HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03-03 
PROBLEMS  INVOLVED  IN  ADMINISTERING  L-DOPA. 

239695  03-15 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L  DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03-03 
NARCOLEPSY:  REM  SLEEP  SUPPRESSION  BY  L-DOPA. 

240657  03-11 
INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA.  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN 

244455  04-04 
INTRAVENOUS  L  DOPA  PI  US  CARBIDOPA  IN  DEPRESSED  PATIENTS: 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
L-DOPA  THERAPY  AND  STEREOTAXIC  THALAMOTOMY  FOR 
PARKINSONISM. 

245986  04- 11 
SELECTIVE  FIELD  POTENTIAL  CHANGES  INDUCED  BY  L-DOPA. 

246145  04-03 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L  DOPA  AND  BY 
CLONIDINE 

246664  04-04 
ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  LDOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES. 

246821  04-05 
MODIFICATION  OF  THE  L  DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE  8ETA-HYDR0XYLASE. 

248289  04-04 


POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES. 

248513  04 
BEHAVIORAL  EFFECTS  OF  L-DOPA  AND  THYROTROPIN-RELEASING 
HORMONE  IN  SCHIZOPHRENIC  PATIENTS:  A  PRELIMINARY  REPORT. 

249120  04 
CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  04 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS 

249272  04 
STIMUIANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  +  )  AMPHETAMIN 
AND  L-DOPA. 

249419  04 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSON! 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY. 

250722  04 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES 
DIFFERENT  DOSES  OF  L-DOPA. 

25121404 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMIt 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA. 

251704  04 
NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  Al 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  (M 
L-DOPA-INDUCEO 

EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (MA)  IN  MICE. 

238847  O; 
L-GIUTAAAATE 

SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHI 
TREATMENT. 

251433  0-: 
L-ISOMERS 

EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMI 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  0; 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 
RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  A 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBR 
CORTEX. 

248699  0^ 
L-NOREPINEPHRINE 

EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPINEPHRI 
BY  THE  RAT  DUODENAL  MUCOSA. 

241299  0; 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRII 
I:  N-ARYLALKYL  AND  N-ARYLOXYALKYL  DL-AMPHETAMINES  AND 
RELATED  COMPOUNDS. 

246316  0^ 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRII 
II:  N-ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D-AMPHETA.MI^ 
AND  3-ARYLOXYPROPYLAMINES. 

248637  0- 
l-TRYPTOPHAN 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FE( 
RATS  FOLLOWING  L  TRYPTOPHAN  INJECTION. 

226873  O: 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  AMLNOURISHED,  CORN-FED  RATS 

238676  O; 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238698  O: 
THE  EFFECTS  OF  5-HYDROXYTRYPTOPHAN  AND  L-TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT. 

252216  0' 
L-5-HTP 

DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXYLASE  ON  L- 
DOPA  AND  L-5-HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  O: 
PERFUSION  WITH  L-5  HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITO 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  0: 
l-5-HYDROXYTRYPTOPHAN 

EFFECT  OF  L-5HYDR0XYTRYPT0PHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  O: 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  R 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  O; 


S-178 


UME  14,  SUBJECT  INDEX 


Subject  Index 


APHE  NEURONS:  DEPRESSION  OF  ACTIVITY  BY  L-5- 
HYDROXYTRYPTOPHAN 


249078  04-03 


ONG-TERM  THERAPY  OF  NEUROLOGIC  DISORDERS  WITH  L-5- 
HYDROXYTRYPTOPHAN 

251960  04  13 
B 
EHAVIORAL  EFFECT  OF  PHTHALAZINOPHTHALAZINEDIONE  (L-5418) 

241397  03  04 
ED 

.CCUMULATION  Of  LABELED  EPHEDRINE.  NOREPHEDRINE, 
AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTEO 
EYES  OF  BLACK  AND  WHITE  RATS 

230450  01-03 
ING 

HE  BRAINS  DOPAMINE  RECEPTOR:  LABELING  WITH  3H-D0PAMINE  AND 
3H-HAL0PERID0L  . 

240077  03-03 
lED 

FFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04-03 
E 

lIPHENYLHYDANTOIN  FACILITATION  OF  LABILE.  PROTEIN  INDEPENDENT 
MEMORY. 

253290  04-04 
RATORY 

FFECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  MOUSE 

225569  01-04 
INEXPECTED  LABORATORY  RESULTS  EFFECT  ON 
PSYCHOPHARMACOLOGY. 

226877  01-17 
HE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE, 

229037  01-11 

:annabis  resin  and  sexual  behaviour  in  the  laboratory 

MOUSE. 

2377)5  02-04 

:unical  laboratory  test  standards  for  a  sample  of 
schizophrenics. 

237726  02-08 
iFFECTS  of  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 

IN  THE  LABORATORY  MOUSE  AND  RAT. 

237727  02-04 
lEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 

FEEDING  AND  WITHDRAWAL. 

246310  04-04 
lAONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS 

251063  04-04 
;FFECT  of  FLURAZEPAM  on  common  CLINICAL  LABORATORY  TESTS. 

251824  04-16 
JLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS. 

252230  04-1 1 
ATE 

FHE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04-11 
ATING 

RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE.  AND  MALE  MICE. 

238766  03-03 
I 

EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIVAL 
OF  MALE  LAF-J  MICE. 

246586  04-03 
NA 

DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT 

232328  01-03 
;UAGE 

i/ERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE 

251939  04  14 
HANUM 

ANALGETIC  EFFECTS  OF  LANTHANUM:  CROSS-TOLERANCE  WITH 
MORPHINE. 

237870  02-03 
RAL 

GIUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6- 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  01-04 
NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME 

227134  01-03 


COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01  04 
LATERAL  GENICULATE  MULTIPLE-UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES. 

231719  01-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  02-03 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARAAACOLOGICAL  STUDIES. 

241315  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5 
HYDROXYTRYPTAMINE. 

241316  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES. 

241317  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03  03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  V   MISCELLANEOUS  COMPOUNDS    SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
ACETYLCHOLINE,  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 

HYPOTHALAMUS. 

248358  04-03 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION, 

250019  04-04 
EFFECTS  OF  GABA  BLOCKADE  ON  LATERAL  HYPOTHALAMIC  SELF- 
STIMULATION. 

252017  04  04 
LAYER 

ON  THE  THIN  LAYER  CHROMATOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04-01 
LDOPA 

EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT, 

240642  03-03 
LEAD 

THE  FOOD  ADDITIVE  HYPOTHESIS,  LEAD,  AND  HYPERACTIVITY 

251572  04  11 
LEARNED 

VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE   (PH  D.  DISSERTATION) 

241689  03  04 
LEARNING 

DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOL  CHILDREN 

225783  01  14 
THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY 

227385  01-04 
NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
STATE-DEPENDENT  LEARNING  IN  RETARDATES  USING  THIORIDAZINE 
(PH.D.  DISSERTATION), 

228420  0114 
EFFECT  OF  5,5  DIPHENYLHYDANTOIN  (DPH)  ON  LEARNING  AND  MEMORY 
IN  CATS 

229680  01-04 
EFFECTS  OF  PRIOR  EXPERIENCE  ON  DIFFERENTIAL  LEARNING  UNDER 
AMPHETAMINE, 

230868  01-04 
THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD    DIAGNOSIS  AND 
TREATMENT, 

233513  02  17 
LEARNING  IN  THE  ABSENCE  OF  FOREBRAIN  NORADRENALINE, 

234917  02  04 
THE  USE  OF  MEGAVITAMIN  TREATMENT  IN  CHILDREN  WITH  LEARNING 
DISABILITIES 

235676  02  11 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE,  (PH  D,  DISSERTATION) 

238157  02  03 


S-179 


Subject  Index 


Psychopharmacology  Abstra 


INFLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES. 

238711  03-14 
DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED  RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PHD    DISSERTATION), 

239533  03-04 
A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03-14 
A  TEST  OF  THE  STATE-DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN   (PH.D. 
DISSERTATION). 

241133  03-14 
THEORETICAL  AND  METHODOLOGICAL  CONSIDERATIONS  ON  DRUG 
DISCRIMINATION  LEARNING. 

241228  03-04 
EFFECTS  OF  VARIOUS  DRUGS  ON  LEARNING  BEHAVIOR  OF  ANIAAALS.  4TH 
REPORT.  COMPARISON  OF  GABA  AND  ITS  DERIVATIVES  WITH 
ADRENERGIC  AND  CHOLINERGIC  DRUGS. 

241401  03-04 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

243804  04-04 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS: 
AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAMINE 
AND  CHLORDIAZEPOXIDE  IN  RATS. 

245301  04-04 
DOSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT, 

246313  04-04 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
EFFECTS  OF  PROPRANOLOL  HYDROCHLORIDE  ON  LEARNING  IN  ELDERLY 
SUBJECTS. 

246440  04-14 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 
ETHANOL  TOLERANCE  IN  THE  RAT. 

249264  04-04 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE  TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

249381  04-04 
SYMPOSIUM  ON  PHARMACOLOGY  OF  LEARNING  AND  RETENTION. 

249787  04-17 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
Y  MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04-04 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT 

252173  04-03 
BENZODIAZEPINE-INOUCED  STATE-DEPENDENT  LEARNING:  A 
CORRELATIVE  OF  ABUSE  POTENTIAL'. 

252674  04-04 
BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 
BY  DOPAMINE  BETA-HYDROXYLASE  INHIBITORS. 

253450  04-04 
LEECH 

DRUG-INDUCED  CHANGES  IN  BEHAVIOUR  AND  GANGLIONIC 
ACETYLCHOLINE  CONCENTRATION  OF  THE  LEECH. 

245595  04-03 
LEFT 

AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  03-15 
LEGAL 

ETHICAL  AND  LEGAL  IMPLICATIONS  OF  INVESTIGATIONS  INTO  THE 
EFFICACY  OF  PSYCHIATRIC  TREATMENTS. 

235354  02-17 
LENPERONE 

LENPERONE:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS 

237899  02-08 
PILOT  OPEN  LABEL  STUDY  OF  LENPERONE  (AHR-2277),  A 
BUTYROPHENONE,  IN  ANXIETY. 

241278  03- 10 
LENS 

DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION 

240048  03-15 


LEPONEX 

AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  0: 
LEPTAZOL 

DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTA; 

237925  0 
LESION 

HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA-INDUCED 
HYPERACTIVITY  IN  THE  RAT. 

226734  0 
A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAMINE-INDUCED 
CONTRALATERAL  ROTATION  IN  RATS. 

231301  0 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  089  CELL  BODY  GRI 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AN 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  0 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTOR! 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  0 
PHARAAACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III) 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390 C 

LESIONED 

CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONE 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382 C 
LESIONING 

THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 
CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTIC 
THE  RAT. 

237742  C 

LESIONS 

CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORAAANCE 
THE  RAT. 

226305  C 
AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOW 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPL 
STRIATUM. 

226937  C 
DISINHIBITORY  EFFECTS  OF  SEPTAL  LESIONS  AND  SCOPOLAMINE 
HYDROBROMIDE.  (PH.D.  DISSERTATION). 

227099  ( 
GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6' 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

2271 25  ( 
MORPHINE  ANALGESIA:  BLOCKADE  BY  RAPHE  MAGNUS  LESIONS 

23261 1  ( 
DOPAMINERGIC  EFFECTS  OF  PHENCYCLIDINE  IN  RATS  WITH 
NIGROSTRIATAL  LESIONS 

236523  ( 
EFFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

237099 ( 
AT'!":NUATI0N  of  amphetamine  ANOREXIA  BY  UNILATERAL  NIGRAI 

STRIATAL  LESIONS. 

237777  ( 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG 
INDUCED  ROTATION  OF  RATS. 

237866  ( 
DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  ( 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWINC 
HYDROXYDOPAMINE  LESIONS. 

238735 ( 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE, 

239829  ( 

IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTEF 

LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE. 

239841  ( 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT. 

24 1 546  I 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF-STIMULATION  AND  SLEEP  IN 
RAT.  (PH.D.  DISSERTATION). 

241678  1 

CHOLINERGIC  MODIFICATION  OF  DRL  PERFORAAANCE  IN  NORMAL  R/ 

AND  PATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION) 

241681  I 


S-180 


IME  14,  SUBJECT  INDEX 


Subject  Index 


HAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04-04 
FECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-04 
lOUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 
HIPPOCAMPUS. 

247420  04-04 
'ORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 
ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

248287  04-02 
TERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 
CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  RATS. 

248394  04-04 
■NAPTOSOMAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P-CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04-05 
RCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS-COERULEUS  IN  RATS. 

249076  04-04 
HIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04-04 
FECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
MOTOR  ACTIVITY. 

250058  04-03 
RCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS. 

250358  04-04 
fPOTHALAMIC  LESIONS  AND  DRUG  INDUCED  ANOREXIA. 

250938  0403 
ii  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04-03 
CTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 
HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
OIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
EHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  0404 
tFETAMINE 

lETHYLPHENIDATE,  DEXTROAMPHETAMINE,  AND  LEVAMFETAMINE: 
EFFECTS  ON  SCHIZOPHRENIC  SYMPTOMS. 

239933  03-08 

LASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  01-16 
LOGO  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN. 

229440  01-14 
HE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT 

236528  02-03 
NATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  BY 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM, 

238503  02-03 
MANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS. 

239058  03-14 
ELATIONSHIP  BETWEEN  ANTIDEPRESSANT  EFFECT  AND  PLASMA  LEVEL 
OF  NORTRIPTYLINE.  CLINICAL  STUDIES. 

240217  03-09 
HE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
gTERACTIONS  OF  HALLUCINOGENS  AT  THE  CLINICAL  LEVEL. 
(UNPUBLISHED  PAPER). 

244195  04-12 
HERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLERIL) 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  04-08 
iROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 
HIPPOCAMPUS. 

247420  0404 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 


HIORIDAZINE  PLASMA  LEVELS  AND  CLINICAL  RESPONSE. 
'LASMA  LEVELS  OF  CHLORPROTHIXENE  IN  ALCOHOLICS. 


225932  01-08 
226413  01-11 


CLOZAPINE  INCREASES  RAT  SERUM  PROLACTIN  LEVELS. 

226869  01-03 
OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01-04 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01-04 
DIAZEPAM  AND  PLASMA  TESTOSTERONE  LEVELS. 

229369  01  15 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  CLINICAL  OUTCOME. 

229443  01-09 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROAAAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01  08 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 

CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 
STUDY  OF  SEROTONIN  AND  ACTH  BRAIN  LEVELS  AND  BEHAVIOR. 

229498  01-03 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01  09 
PLASMA  CREATINE-PHOSPHOKINASE  LEVELS  IN  RATS  FOLLOWING 
LYSERGIC-ACID-DIETHYLAMIDE. 

230826  01-03 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC  ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5  HIAA)  IN  THE  RABBIT. 

230877  01-06 
TRICYCLIC  ANTIDEPRESSANT  OVERDOSE:  CLINICAL  PRESENTATION  AND 
PLASMA  LEVELS. 

231318  0113 
H3-P-CHL0R0AMPHETAMINE:  CEREBRAL  LEVELS  AND  DISTRIBUTION. 

232614  02-03 
THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5  HYDROXYINDOLE 
LEVELS. 

233290  02-03 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II.  BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS. 

235367  02-05 
CORRELATION  OF  CHLORPROMAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 
WITH  ITS  HYPOTHERMIC  EFFECT 

236527  02  03 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE  HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS.  (PH.D.  DISSERTATION). 

238079  02-03 
PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE.  (UNPUBLISHED  PAPER). 

238491  02-13 
MODIFICATION  OF  PENTYLENETETRAZOL  INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 
PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA-AMI NOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIAAARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE 

239828  03-03 


TS' 


d-iS 


S-181 


Subject  Index 

DEPRESSED  5  HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE 

239936  03-13 
REGIONAL  LEVELS  OE  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  O 
AMPHETAMINE  AND  (  i  OR)  P-CHLOROAMPHETAMINE. 

239976  03-03 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I    STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234  03-13 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  03-04 
THE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 
AND  MONOAMINE  SYNTHESIS 

241472  03-17 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS   (PH  D. 
DISSERTATION), 

241680  03-04 
PLASMA  LEVELS  AND  ANTIDEPRESSIVE  EFFECT  OF  IMIPRAMINE. 

243089  04- 1 3 
TRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION.  COMPARED  WITH  BLOOD  LEVELS. 

244588  04-09 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROMATOGRAPHY. 

245300  04-03 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  ON 
STEADY-STATE  BLOOD  LEVELS 

245842  04-08 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION. 

246387  04-13 
rOMBINAllON  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04  I  I 
CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE. 

246851  04-03 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

246891  04-11 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
PARAMETHADIONE  AND  METABOIITE  SERUM  LEVELS  IN  HUMANS  AFTER 

A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04- 1  7 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 

LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  04-03 
FAIIURE  OF  INCREASED  BRAIN  GAMMA  AMINOBUTYRIC  ACID  LEVELS  TO 
INFIUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR 

247730  04  03 
ore  RIASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
SYNAPIOSOMAl  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
ARIAS  AFTER  P  CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04  05 
POSTNATAl  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
(  ATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
SELF  INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS   A  RANDOMIZED.  DOUBLE  BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION 

248955  04  10 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
I  NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04  03 


1 


Psychopharmacology  Abstra 


THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  0 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUS 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION 

249286  0; 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BF' 
GLUTAMATE  (GLU)  AND  GAMMA  AMINOBUTYRATE  (GABA)  LEVELS 
THE  MOUSE. 

249292  0 
CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE 

249294  C 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH) 

249298  0 
ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 

TREATED  AND  STRESSED  MICE. 

249299  0 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAir 

249300  C 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAC 

UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2-PHENYLETHYLAMINE  (PEA). 

249310 C 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  II 
PATIENTS  TAKING  LITHIUM  CARBONATE. 

249535  C 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACI 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCE 
BEHAVIORAL  EXCITATION 

250067  C 
EFFECT  OF  FENFLURAMINE  ON  STEADY-STATE  PLASMA  LEVELS  OF 
AMITRIPTYLINE  (ABSTRACT). 

250943  C 
CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA 

251119( 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE:  RELATL 
TO  TISSUE  LEVELS  OF  THE  DRUG. 

251131  ( 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  ( 
CHLORPROMAZINE  METABOLISM  VIII:  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIEI 

25) 778  ( 

SUSTAINED  RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUt 

SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  ( 

UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREf 

CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVE 

251964  ( 
EFFECT  OF  CORTISONE.  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LE 
OF  ADRENALECTOMIZED  RATS. 

251990  ( 
INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS. 

252027  ( 
EFFECTS  OF  MAZINDOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

252201  ( 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFI 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS 

253693  I 

LEVER 

EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ( 
FEEDING    LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  1 

LEVOAAAPHET  AMINE 

LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  I 
LEVODOPA  AND  LEVOAMPHETAMINE:  A  CROSSOVER  STUDY  IN  YOUl 
SCHIZOPHRENIC  CHILDREN 

247480  I 
LEVODOPA 

COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  \ 


S-182 


UME  14,  SUBJECT  INDEX 

f^AIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02-13 
EVODOPA  AND  PSYCHOMETRIC  TEST  PERFORMANCE  IN  PARKINSONISM 
-.  5  YEARS  LATER 

237141  02  14 
'ARKINSONISM  AND  DEMENTIA.  EFFECTS  OF  LEVODOPA. 

245235  04-11 
NTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04  13 
EVODOPA  AND  LEVOAMPHETAMINE:  A  CROSSOVER  STUDY  IN  YOUNG 
SCHIZOPHRENIC  CHILDREN. 

247480  04-08 
HE  CLINICAL  USES  OF  LEVODOPA 

247712  04  17 
;OMPARISON  OF  DOPADECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

24861 2  04- 1 1 
:OMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE 

248613  04  11 
.ONG-TERM  LEVODOPA  THERAPY  FOR  TORSION  DYSTONIA. 

249367  04-13 
■IVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04-11 
ilX-YEAR  RESULTS  OF  TREATMENT  WITH  LEVODOPA  PLUS  BENSERAZIDE 
IN  PARKINSONS  DISEASE. 

251648  04-11 
.EVODOPA  IN  HUNTINGTONS-CHOREA. 

252131  04  11 
METHIOMEPRAZINE 

;FFECTS  of  LONG-TERM  ADMINISTRATION  OF  LEVOMETHIOMEPRAZINE 
TO  RATS. 

241381  03-03 
TANIl 

-IVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH  A 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350), 

239748  03  14 

EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FORFBRAIN  BUNDLE  (MFB)  STIMULATION 

249255  04-03 
I 

EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT, 

240642  03  03 

LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
LI  <    SENSITIVE  MICROELECTRODE. 

235589  02  06 
UM 

TWENTY  FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04  04 

THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE, 

241364  03  04 
CAINE 

PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION;  RELATIONSHIP  TO  KINDLING    (UNPUBLISHED 
PAPFR). 

231771  01-04 
EFFECTS  OF  BARBITURATES  ON  BLOOD  PRESSURE  IN  IIDOCAINE 
INJECTED  SHR 

241405  03-03 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
E 

SCANDINAVIAN  STANDPOINT  ON  THE  LIEGE  CLASSIFICATION  OF 
NEUROLEPTICS 

227761  01-17 
THE  LIEGE  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH  SPECIAL  REFERENCE 
TO  THIOXANTHENES, 

227769  01-17 
SPECTRAL  MAPS  OF  THE  LIEGE  PHYSIOGNOMIES  OF  THE  NEUROLEPTICS. 

239683  03-06 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT  ASSISTED 


Subject  Index 


COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 
THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY-  DOUBLE-BLIND 
STUDY  OF  HYDROSARPAN-71]  IN  80  SUBJECTS. 

240166  03-11 
THE  QUALITY  OF  INTELLECTUAL  LIFE:  DOUBLE-BLIND  STUDY  OF 
HYDROSARPAN-71 1  INVOLVING  80  SUBJECTS. 

242899  04-11 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
LIGHT 

ON  ONE  OF  IHE  VARIANTS  OF  SIMPLE  SCHIZOPHRENIA  IN  THE  LIGHT  OF 
PSYCHOPHARMACOTHERAPY. 

236725  02-08 
LIGNOCAINE 

ELECTROPHORETIC  APPLICATION  OF  LIGNOCAINE  TO  THE  CERVICAl  AREA 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES. 

244467  04-10 
LILLY- 1095 14 

THE  CLINICAL  PHARMACOLOGY  OF  LILLY-109514  IN  NORMAL 
VOLUNTEERS. 

249260  04-07 
LILLY- 110140 

INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  LDOPA. 

226765  01  03 
EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INOUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (AAA)  IN  MICE. 

238847  03  04 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY-1 10140,  ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04  03 
EFFECTS  OF  LILLY-1  10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN  INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING 

252522  04-03 
LILlY-94939 

NISOXFIINT  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAI  BRAIN 

238840  03  03 
LIMBIC 

INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANIUIC  ACID 
CONCENTRATION  IN  THE  RAT  BRAIN. 

226727  01-03 
A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN 

231304  01  03 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-03 
EFFECTS  OF  MORPHINE  AND  BENZODIAZEPINES  ON  LIMBIC  SYSTEM. 

238702  03-03 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TRFAIMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGI'  'P  GENERATING  SYSTEM 

IN  LIMBIC  FOREBRAIN, 

245115  04-03 
EFFECT  OF  CLfJNIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINFRCir  MFCHANISMS. 

249305  04-06 
LIMITATIONS 

FLUPHENAZINE:  DIFFICULIIti  /\Nu  ilmiiAiiuNS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
LIMITING 

I IMITING  FACTORS-+N  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE  CYCLASE 

250359  04-03 
LIMITS 

EFFICACY  AND  TOLERANCE  LIMITS  IN  THE  USE  OF  ANTIDEPRESSANT 
DRUGS. 

247543  04-09 
LINKAGE 

ANALOGUES  OF  S  AOENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04  01 


SSii 

& 
< 


S-183 


Subject  Index 


Psychopharmacology  Abstrac 


UORESAL 

ALTERATION  OF  DOPAMINE  METABOLISM  IN!  RAT  BRA^M  BY  BACLOFEN 
(LIORESAL  (R)). 

251398  04-03 
UP 

ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM, 

229349  CM  7 
LIPID 

iONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER) 

236873  02-03 
EFFECT  OF  LITHIUM  CHLORIDE  ON  LIPID  METABOLISM. 

241986  03-03 
THE  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS 

246318  04-04 
LIPIDOSIS-UKE 

LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 
LIPIDS 

GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
LIPOFUSCIN 

THE  MODE  OF  LIPOFUSCIN  REMOVAL  FROM  HYPOTHALAMIC  NEURONS. 

246587  04-03 
LIPOPROTEINS 

BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN.  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

247129  04  03 
LIQUID 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA  AMINOBUTYRIC  ACID  AND  5-HYDROXYTRYPTOPHAN. 
(UNPUBLISHED  PAPER) 

231278  01-06 
LIQUID  LITHIUM  VS    SOLID  LITHIUM:  AN  OPEN.  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS 

247877  04-07 
LISURIDE 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRAM. 

229038  01-07 
DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
AN  ANTIMIGRAINE  COMPOUND. 

229473  01-13 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE,  AN 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  04-04 
LITERATURE 

GER0VITALH3    -  A  REVIEW  OF  THE  LITERATURE. 

229460  01-11 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I.  THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01-17 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20  YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-17 
THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  02-03 
RATE  DEPENDENT  EFFECTS  OF  DRUGS:  A  REVIEW  OF  THE  LITERATURE. 

250070  04-04 
LITHIUM 

BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 

CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 
STUDY  GROUP 

225718  01-09 
A  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

226414  OMl 
THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS.  LONG- 
TERM  EFFECTS  AND  SIDE-EFFECTS. 

226612  01-09 


MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG. 

226855  01- 
LITHIUM   -  FUTILITY,  DISASTER  AND  TRIUMPH. 

227411  01- 
LITHIUM  -    WHEN,  WHY  AND  HOW? 

227413  01- 
A  DOUBLE-BLIND  TRIAL  OF  LITHIUM  CARBONATE  AND  HALOPERIDOL  II 
HUNTINGTONS-CHOREA. 

227550  01 
LITHIUM  INTOXICATION:  A  REPORT  OF  TWO  CASES. 

227745  01 
TWO  CASES  OF  CONVULSIONS  DURING  LITHIUM  THERAPY. 

228072  01 
LITHIUM  IN  PSYCHIATRY. 

228217  01 
COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01 
IS  LITHIUM  USEFUL  IN  CHILD  PSYCHIATRY?. 

229081  01 
LITHIUM. 

229642  01 
LITHIUM  IN  TREATMENT  FAILURES. 

230562  01 
BETA-BLOCKADE  IN  LITHIUM  TREMOR. 

230742  01 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTIC 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  01 
NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AN[ 
RUBIDIUM  TREATMENT. 

230817  01 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  AAANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  01 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01 
SIMPLIFIED  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  ANTIDEPRESSANT 
AND  LITHIUM. 

232762  02 
COURSE  OF  MANIC-DEPRESSIVE  RECURRENCES  UNDER  LITHIUM. 

232779  02 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  02 
EPILEPTIFORM  ACTIVITY  IN  THE  ELECTROENCEPHALOGRAM  INDUCED  £ 
LITHIUM  CARBONATE. 

233499  02 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  05 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02 
THE  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES. 

234699  02 
POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOMANIA 
SECONDARY  TO  ORGANIC-BRAIN-SYNDROME. 

23471  I  02 
LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
i\+   SENSITIVE  MICROELECTROOE. 

235589  02 
SUCCESS  WITH  LITHIUM  IN  A  DISTURBED  CHILD. 

236118  02 
SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENT! 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361  02 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL.  SERUf 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02 
LITHIUM  CARBONATE  IN  JUVENILE  MANIC-DEPRESSIVE  ILLNESS. 

236663  02 
APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  C 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS. 

236732  02 
MONITORING  OF  LITHIUM  TREATMENT    GUIDELINES  BASED  ON 
PHARMACOKINETIC  CONSIDERATIONS. 

236806  02 
LITHIUM  SALTS  IN  CYCLOPHRENIA  (MANIC-DEPRESSIVE  PSYCHOSIS). 

237013  02 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTI 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02 


S-184 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D- 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT. 

237716  02-14 
PHARMACOLOGICAL  CHARACTERIZATION  OF  LITHIUM  REABSORPTION  IN 
THE  RAT. 

237759  02-03 
THE  INFLUENCE  OF  LITHIUM  ON  SERUM  CERULOPLASMIN. 

237924  02-03 
EFFECTS  OF  LITHIUM  ON  NEUROMUSCULAR  TRANSMISSION. 

238743  03-03 
EFFECTS  OF  LITHIUM  ON  CHRONIC  ETHANOL  CONSUMPTION  AND 
BEHAVIOR. 

238849  03-03 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
THERAPEUTIC  ATTEMPTS  WITH  LITHIUM  IN  YOUNG  DRUG  ADDICTS. 

238988  03-1 1 
THE  INFLUENCE  OF  FOOD  ON  SIDE-EFFECTS  AND  ABSORPTION  OF 
LITHIUM. 

238998  03-15 
ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 
POLYURIA. 

239046  03-05 
LITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 
IN  HUMANS. 

239728  03-09 
EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 

PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE. 

240055  03-09 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 

CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL. 

240074  03-14 
ON  THE  MECHANISMS  OF  ACTION  AND  KINETICS  OF  LITHIUM. 

240740  03-03 
LITHIUM  TREMOR  -  COMBINATION  TREATMENT  WITH  BETA-RECEPTOR 

BLOCKERS?. 

240741  03-14 
SECONDARY  EFFECTS  OF  LITHIUM  TREATMENT.  PRELIMINARY  RESULTS 

OF  AN  INQUIRY. 

241765  03-15 
SERUM  LITHIUM  MEASUREMENT  OF  THE  EEL  FLAMEPHOTOMETER. 

241777  03-16 
EFFECT  OF  LITHIUM  CHLORIDE  ON  LIPID  METABOLISM. 

241986  03-03 
TWO  CASES  OF  SUICIDAL  LITHIUM  INTOXICATION. 

243438  04-15 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

243804  04-04 
PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS. 

243979  04-09 
PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES. 

243985  04-09 
LITHIUM  CARBONATE  AND  HYPOTHYROIDISM. 

244113  04-15 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
LITHIUM  THERAPY:  PRACTICAL  ASPECTS. 

244498  04  09 
SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS 

244591  04-13 
EFFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS. 

244651  04-03 
LITHIUM  PROPHYLAXIS  IN  AFFECTIVE  DISORDERS. 

245416  04-09 
EFFECTS  OF  ALCOHOL  AND  LITHIUM  HABITUATION  ON  THE 

DEVELOPMENT  OF  ALCOHOL  AVERSIONS  THROUGH  CONTINGENT 
LITHIUM  INJECTION. 

246093  04-04 


IN  VITRO  AND  IN  VIVO  TRANSPORT  OF  LITHIUM  BY  HUMAN 
ERYTHROCYTES. 

246275  04-13 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL- 
O-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04-03 
STUDIES  ON  THE  MECHANISM  OF  LITHIUM  ACTION:  PRELIMINARY 
REPORT. 

247208  04-03 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
LIQUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS. 

247877  04-07 
LITHIUM  EFFECTS  UPON  COMPONENTS  OF  ACTIVITY  IN  RATS. 

248516  04-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  04-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 

AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

248957  04-03 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 

ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 
TREATED  AND  STRESSED  MICE. 

249299  04-03 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

249381  04-04 
LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIMULATION 
FACILITATED  BY  MORPHINE  AND  (  ^  )  AMPHETAMINE. 

249486  04-03 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  IN 
PATIENTS  TAKING  LITHIUM  CARBONATE. 

249535  04-09 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE 

249673  04-13 
WARNED  REACTION  TIMES  OF  MANIC  DEPRESSIVE  PATIENTS  WITH  AND 
WITHOUT  LITHIUM. 

249798  04-09 
LITHIUM  TREATMENT  AND  WEIGHT  GAIN. 

249927  04-15 
SIDE-EFFECTS  OF  LITHIUM  THERAPY. 

250209  04-15 
ABSORPTION  OF  LITHIUM  FOLLOWING  ADMINISTRATION  OF  SLOW- 
RELEASE  AND  CONVENTIONAL  PREPARATIONS 

250725  04-13 
LITHIUM  SALTS:  1970-1975, 

250928  04-17 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
ON  THE  CLINICAL  RELEVANCE  OF  THE  INTRACELLULAR  RBC  LITHIUM 
CONCENTRATION. 

251417  04-15 
CONTROL  OF  LITHIUM  TREMOR  WITH  PROPRANOLOL. 

251431  04-15 
SIDE-EFFECTS  OF  LITHIUM  THERAPY  AND  THEIR  TREATMENT. 

251712  04-15 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY: 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE 

251826  04-15 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARAAACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS. 

252198  04-03 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

252954  04-09 


S-185 


Subject  Index 

LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 
CHRONIC  SCHIZOPHRENIA. 

253049  04-08 
A  BIBLIOGRAPHY  ON  THE  BIOLOGY  AND  PHARMACOLOGY  OF  LITHIUM  - 
APPENDIX  II. 

253064  04-17 
INCREASED  ERYTHROCYTE  NA  f   PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04-13 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS 

253411  04-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
LITHIUM-INDUCED 

CURRENT  DETERMINATION  OF  LITHIUM-INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS, 

237110  02-04 
EFFECT  OF  ANTIDIURETIC  DRUGS  IN  RATS  WITH  LITHIUM-INDUCED 
POLYURIA. 

239041  03-05 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKAOF  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 
UVER 

DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  01-03 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 
LIVER. 

227696  01-03 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
BRAIN  LIVER  INTERRELATIONSHIP  IN  BARBITURATE-TOLERANCE. 

229490  01-03 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
METABOLISM  OF  DELTAI-TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
N-HYDROXYAMPHETAMINE:  A  MAJOR  METABOLITE  OF  AMPHETAMINE  IN 
RABBIT  UVER  EXTRACT. 

238682  03-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 

MICROSOMES.  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  03-06 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 

CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS  -  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04-03 
CHARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAI-TETRAHYDROCANNABINOL 
IN  MOUSE  LIVER. 

243787  04-03 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT   -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME;  III; 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
METABOLIC  FATE  OF  FLURAZEPAM  II;  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
METHAQUALONE  METABOLISM  BY  RAT  LIVER  MICROSOMES. 

247847  04-03 
CATECHOL  0-METHYLTRANSFERASE  FROM  RAT  LIVER;  TWO  FORMS 
HAVING  DIFFERENT  META;PARA  METHYLATION  RATIOS. 

249035  04-01 
N-HYDROXYLATION  OF  l-2,5-DIMETH0XY-4-METHYLPHENYL-2- 
AMINOPROPANE  BY  RABBIT  LIVER  MICROSOMES. 

249234  04-05 


Psychopharmacology  Abstracts 


I 


STUDIES  ON  SULFATE  CONJUGATION  OF  ESTROGENS  IN  BRAIN  AND 
LIVER. 

249245  04  03 
LIVING 

PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 
NEUROBLASTOMA  CELLS. 

238692  03-03 
LOAD 

SIMPLIFIED  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01-16 
LOBE 

ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02-03 
LOCAL 

LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-03 
IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099 

238686  03-03 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEUROI  AL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
LOCALE 

ROLE  OF  STIMULUS  LOCALE  ON  STRAJN  DIFFERENCES  IN  ACTIVE 

AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT. 

250074  04-04 
LOCALIZATION 

THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  IN 
THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  02-03 
CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAAAMA- 
GLUTAMYL-TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03-03 
LOCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX. 

250356  04-03 

LOCATED 

EFFECTS  OF  ALPHA-ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE-  AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  04-03 
LOCOMOTION 

TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 
DOGS  (CYNOMYS-LUDOVICIANUS). 

239863  03-04 
LOCOMOTOR 

OLFACTORY  BULB  REMOVAL  IN  MICE;  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION), 

227074  01-04 
TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE   , 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  02-04 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  ( +  )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02-04 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238698  03-04 
INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE-INDUCED 
LOCOMOTOR  ACTIVITY  IN  MICE. 

238842  03-04 
AGE-RELATED  CHANGES  OF  LOCOMOTOR  ACTIVITY  AFTER 
AMPHETAMINE  ADMINISTRATION. 

238845  03-04 
EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (AAA)  IN  MICE. 

238847  03  04 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 
EFFECTS  OF  P-CHLOROAMPHETAMINE  ON  LOCOMOTOR  ACTIVITY  AND 
BRAIN  5-HYDROXYINDOLES. 

239958  03-04 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORAAAL  AND 
AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04, 


S-186 


LUME  14,  SUBJECT  INDEX 

CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  THE 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  LOCOMOTOR  ACTIVITIES  IN 
THE  RAT 

242205  03-04 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMINE 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY 

248285  04-02 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 
ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

248287  0402 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY 

249273  04-03 
EFFECTS  OF  DIAZEPAM  ON  SIX  DRUG-INDUCED  LOCOMOTOR 
HYPERACTIVITIES  IN  MICE. 

249677  04-04 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L-DOPA. 

25)704  04-04 
JS-COERUIEUS 

RATE  OF  BIOSYNTHESIS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  LOCUS 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE. 

238759  03-03 
IMPAIP.ED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE. 

239841  03-04 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF-STIMULATION  AND  SLEEP  IN  THE 
RAT.  (PH.D.  DISSERTATION). 

241678  03-03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS-COERULEUS  IN  RATS. 

249076  04-04 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS.  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04-03 
EPRAMINE 

COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE-BLIND  MULTICENTRE  TRIAL. 

251118  04-09 
ilCAL 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 
EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
IG 

SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORMANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDULE. 

252816  04-04 
IG-ACTING 

LONG  ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS. 

229448  01-08 
PHARMACOLOGICAL  AND  TOXICOLOGICAL  PROBLEMS  CONNECTED  WITH 
THE  USE  OF  LONG-ACTING  NEUROLEPTICS 

229549  01-15 
CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 

LONG-ACTING  FLUPHENAZINE 

229550  01-11 
THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 

THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS 

229552  01-17 
SOCIOPSYCHIATRIC  ASPECTS  OF  LONG-ACTING  NEUROLEPTICS. 

229553  01-17 
CLINICAL  EXPERIMENTATION  OF  THE  LONG-ACTING  NEUROLEPTICS: 

METHODOLOGICAL  PROBLEMS. 

229554  01-16 
THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 

PSYCHIATRIC  INSTITUTIONS. 

229558  01-17 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC, 

231367  01-08 
CLOPIMOZIDE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-04 


Subject  Index 

PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
OUTPATIENT  TREATMENT  WITH  LONG-ACTING  PERPHENAZINE 
(PERPHENAZINE-ENANTHATE):  THREE  CASES. 

239615  03-09 

THE  LONG-ACTING  PHENOTHIAZINES. 

245841  04-08 
LONG-LASTING 

EFFECT  OF  LONG-LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 

REACTION  TIME  IN  NORMAL  INDIVIDUALS 

239992  03-14 
EFFECTS  OF  HYDROXYI.AMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  I,  EFFECT  ON  THE 

MORPHINE  TOLERANCE. 

249030  04  03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  II.  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE. 

249031  04-03 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION. 

249032  04-04 

LONG-RANGE 

COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG-RANGF  L  DOPA  THERAPY 
IN  PARKINSONISM. 

229165  01-11 

LONG-STAY 

THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG- 
STAY  PSYCHIATRIC  PATIENT. 

227461  01-17 

LONG-TERM 

THE  LONG-TERM  USE  OF  HIGH  DOSES  OF  FLUPHENAZINE-ENANTHATE 
AND  FLUPHENAZINE-DECANOATE. 

225936  01-08 
THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS.  LONG- 
TERM  EFFECTS  AND  SIDE-EFFECTS. 

226612  01-09 
REVIEW  OF  LONG-TERM  PSYCHIATRIC  MEDICATION     A  STUDY  OF 
WITHDRAWAL  SYMPTOMS. 

228214  01-15 
EFFECTS  OF  LONG-TERM  APPLICAFION  OF  PENFLURIDOL  (TLP-607)  FOR 
SCHIZOPHRENIA. 

228324  01-08 
RECENT  PROGRESS  IN  THE  LONG  TERM  PHARMACOLOGICAL  RESEARCH 
ON  CANNABIS. 

229043  01-17 
AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESUIT  OF  LONG-TERM 
CHLORPROMAZINF  MEDICATION. 

229169  01-15 
DRUGS  AND  PSYCHOTHERAPY  IN  DEPRFSSION  REVISITED:  ISSUES  IN  THE 
ANALYSIS  OF  LONG-TERM  TRIALS. 

229450  01-09 
LONG-TERM  TREATMENT  OF  PETIT  AAAL  WITH  CLONAZEPAM. 

231654  01-11 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
LONG-TERM  EFFECT  OF  PERPHENAZINE  ON  THE  5UBSTANTIA-NIGRA  IN 
RATS. 

237702  02-03 
COGNITIVE  EFFECTS  OF  LONG-TERM  AAARIJUANA  USE.  (PH.D. 
DISSERTATION) 

238085  02-14 
LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS. 

238741  03-03 
PRESENT  STATE  OF  LONG  TERM  NEUROLEPTIC  TREATMENT  OF 
SCHIZOPHRENIA. 

238864  03-08 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03-11 
A  RETROSPECTIVE  ASSESSMENT  OF  THE  LONG-TERM  EFFECTS  OF 
DOTHIEPIN 

239820  03-09 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE. 

239823  03-08 


S-187 


Subject  Index 


Psychopharmacology  Abstracts 


EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

240048  03-15 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
LONG-TERM  TREATMENT  OF  SCHIZOPHRENIA. 

240709  03-08 
LONG-TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS. 

241300  03-04 
EFFECTS  OF  LONG-TERM  ADMINISTRATION  OF  LEVOMETHIOMEPRAZINE 
TO  RATS. 

241381  03-03 
DEPOT  NEUROLEPTICS   -  PRACTICAL  METHODS  OF  LONG-TERM 
TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RATS 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04-04 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
SIDE-EFFECTS  FROM  LONG-TERM  USE  OF  STIMULANTS  IN  CHILDREN. 

247377  04-15 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04-03 
LONG-TERM  LEVODOPA  THERAPY  FOR  TORSION  DYSTONIA. 

249367  04-13 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-04 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04-08 
A  LONG  TERM  STUDY  OF  PENFLURIDOL  IN  CHRONIC  SCHIZOPHRENIA. 

251829  04-08 
LONG-TERM  THERAPY  OF  NEUROLOGIC  DISORDERS  WITH  L-5- 
HYDROXYTRYPTOPHAN. 

251960  04-13 
ANAFRANIL  IN  THE  MANAGEMENT  OF  LONG-TERM  PAIN:  A  PRELIMINARY 
REPORT, 

252141  04-07 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-17 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN. 

253041  04-15 
LOOKING 

LOOKING  AT  SCHIZOPHRENIA  FROM  A  UNITARY  POINT  OF  VIEW. 

236348  02-17 
lORAZEPAM 

RESPIRATORY  EFFECTS  OF  LORAZEPAM,  PENTOBARBITAL,  AND 
PENTAZOCINE. 

226828  01-15 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01-11 
A  CONTROLLED  EVALUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS. 

230907  01-08 
LORAZEPAM  COMPARED  WITH  PENTOBARBITAL  FOR  NIGHTTIME 
SEDATION. 

232622  02-14 
LORAZEPAM  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 
CLINICAL  STUDY. 

235358  02-07 
LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY:  DOUBLE-BLIND  TRIAL. 

236658  02-10 
HYPNOTIC  EFFICACY  OF  LORAZEPAM  AND  FLURAZEPAM. 

237115  02-14 


EVALUATION  OF  LORAZEPAM  AND  PENTOBARBITAL  AS  SURGICAL 
PREMEDICANTS. 

237734  02-14 
LORAZEPAM  IN  THE  AAANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY. 

241274  03-14 
INTRAVENOUS  LORAZEPAM  IN  THE  ACUTE  ANXIETY  CRISIS:  A 
PRELIMINARY  REPORT  ON  60  CASES. 

242250  03-10 
USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  CARDIAC 
CATHETERIZATION. 

244450  04-11 
THE  USE  OF  INJECTABLE  LORAZEPAM  IN  PREPARATION  FOR  ELECTRIC 

CARDIOVERSION. 

244451  04-11 
LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVERLAY 

(A  DOUBLE-BLIND  CROSSOVER  STUDY). 

250193  04-14 

LORDOSIS 

DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 

LORRY 

THE  EFFECT  OF  GRANDAXIN  ON  LORRY  DRIVERS. 

252446  04  14 

LOSS 

LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01-04 
LOSS  OF  INHIBITION  IN  SPINAL  CORD  DURING  BARBITURATE 
WITHDRAWAL. 

238770  03-03 
DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION?. 

240802  03-13 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 

LOW-LEVEL 

THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL-MONKEY. 

227385  01-04 

LOWERING 

EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-03 
LOXAPINE 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA. 

225867  01-08 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS. 

237828  02-08 
TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  LOXAPINE 
PARENTERALLY. 

238551  02-09 
A  TWO  YEAR  TRIAL  OF  LOXAPINE  SUCCINATE  IN  CHRONIC  PSYCHOTIC 
PATIENTS. 

244501  04-08 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

245014  04-08 
THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA:  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE. 

247968  04-08 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04-0e 

LOXITANE 

A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

245014  04-06 

A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS. 

247483  04-0fc 


LSD 


LSD  AND  DOPAMINE  SENSITIVE  ADENYLATE-CYCUSE  IN  VARIOUS  RAT 
BRAIN  AREAS. 

226406  01-03 
STEREOSPECIFIC  BINDING  OF  D-LYSERGIC-ACID-DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01  12 


S-188 


rOLUME  14,  SUBJECT  INDEX 


Subject  Index 


BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 

LSD  AND  DOPAMINE  RECEPTORS. 

LSD  AND  DOPAMINE  RECEPTORS  -  PIERI  REPLY. 


227692  01-03 
228050  01-03 


228051  01-03 
RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX  -■  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE. 

230570  01-04 
BEHAVIORALLY  INDUCED  SENSITIVITY  TO  THE  DISCRIMINABLE 
PROPERTIES  OF  LSD. 

230876  01-04 
THE  EFFECTS  OF  LSD  ON  THE  EXPRESSION  OF  AFFECT  IN 
PSYCHOTHERAPY  (PH.D.  DISSERTATION). 

231480  01-12 
ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID.  ACID. 

233278  02-01 
PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD. 

23431 1  02-03 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT. 

237780  02-04 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS 

237782  02-03 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  03-03 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 

METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-04 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 

ELEVATED  ENVIRONMENTAL  TEMPERATURE. 

241925  03-03 
GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04-04 
LSD  AS  AN  AGONIST  AT  MESOLIMBIC  DOPAMINE  RECEPTORS. 

249680  04-04 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT. 

251979  04-04 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  II.  LSD. 

253700  04-03 
SO-INDUCED 

THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE- 
INDUCED  AND  LSD-INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01-05 
S0-2S 

A  NEUROPHYSIOLOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 
PSYCHOTOMIMETICS  (LSD-25,  DOM  AND  KETAMINE). 

232703  02-04 
POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
UCCA 

INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
UDIOMIL 

A  CONTROLLED  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  IN  DEPRESSED 
OUTPATIENTS. 

231401  01-09 
A  DOUBLE-BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS. 

238981  03-10 
MAPROTILINE  (LUDIOMIL,  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS:  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  03-09 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 

(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-09 


LUMBAR 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
LUNG 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762  01-03 
METABOLISM  OF  DELTAl-TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION. 

249286  04  03 
LYMPH 

LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 
LYMPHOCYTE 

PHYTOHEMAGLUTININ-INDUCED  LYMPHOCYTE  TRANSFORAAATION  IN 
HU/WANS  RECEIVING  DELTA9-TETRAHYDR0CANNABIN0L. 

252825  04-13 
LYMPHOCYTES 

EFFECT  OF  CHLORPROMAZINE  ON  THE  REACTION  OF  BLAST 
TRANSFORMATION  OF  LYMPHOCYTES. 

236373  02-03 
LYSERGIC-ACID 

ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID   ACID. 

233278  02-01 
LYSERGIC-ACID-DIETHYLAMIDE 

PLASAAA  CREATINE-PHOSPHOKINASE  LEVELS  IN  RATS  FOLLOWING 
LYSERGIC-ACID-DIETHYLAMIDE. 

230826  01  03 
SOME  PROBLEMS  OF  PSYCHOTOXICOLOGY  EXEMPLIFIED  BY  LYSERGIC- 
ACID-DIETHYLAMIDE. 

234097  02-12 
GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS, 

244683  04  04 
EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW.  • 

246846  04-03 
LYSERGIC-ACID-DIETHYLAMIDE  AND  MESCALINE-INDUCED  ATTENUATION 
OF  THE  EFFECT  OF  PUNISHMENT  IN  THE  RAT. 

252824  04-04 
LYSERGIDE 

ISOLATION  OF  LYSERGIDE  (LSD)  WITH  AGAROSE  BOUND  ANTIBODIES  TO 
LYSERGIC-ACID.  ACID. 

233278  02-01 
LYSOSOMES 

THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
MACACA-MULATTA 

EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  AND 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINE- 
DEPENDENT  MACACA-MULATTA. 

249267  04  04 
STUDIES  WITH  1-ALPHA-ACETYLMETHADOL:  1,  TOLERANCE  IN  MACACA- 
MULATTA. 

249290  04-03 
MACDONALD 

MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 
MACROMOLECULAR 

DELTA9-TETRAHYDR0CANNABIN0L:  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUAAAN  AND  OTHER  MAMMALIAN  CELLS. 

251420  04-13 
MADOPAR 

THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO, 

230823  01-08 
MAGNESIUM 

EFFECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH  TO-SAMPLE 
TASK  IN  MONKEYS. 

230577  01  04 
INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION, 

237116  02-13 


S-189 


Subject  Index 


PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
CEREBRAL  ARTERIAL  SPASM   PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY, 

243797  04-03 
MAGNETIC 

MAGNETIC  CIRCULAR  DICHROISM  OF  SUBSTITUTED  INDOLES. 

229493  01-06 
AAAGNITUOE 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
THE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE 

236249  02-03 
NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA  -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 

ADMINISTRATIONt  DETERMINATION  OF  REINFORCEMENT  MAGNITUD 

250010  04-04 
^AAGNUS 

MORPHINE  ANALGESIA:  BLOCKADE  BY  RAPHE  MAGNUS  LESIONS. 

232611  02-03 
MAINTAINED 

EFFECTS  OF  D-AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 

MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT. 

226852  01-04 
COMPARISON  OF  PROGRESSIVE  RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL, 

227137  01-04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 
MONKEYS  MAINTAINED  ON  NALTREXONE. 

249270  04-04 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

250111  04-04 
MAINTENANCE 

OVERVIEW.  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  I.  SCHIZOPHRENIA. 

232827  0208 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 
DISORDERS. 

236303  02-17 
MAINTENANCE  ANTIPSYCHOTIC  THERAPY:  IS  THE  CURE  WORSE  THAN 
THE  DISEASE?. 

236307  02-08 
TREATMENT  OF  ALCOHOLIC  METHADONE  MAINTENANCE  PATIENTS  WITH 
DISULFIRAM. 

237624  02-1 1 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE 

240055  03-09 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  II:  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES.  (UNPUBLISHED  PAPER). 

244574  04-09 
THE  DURATION  OF  MAINTENANCE  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

252763  04-08 
MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 

MAJOR 

COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS 

233832  02-13 
ON  THE  QUESTION  OF  THE  RATIONAL  USE  OF  MAJOR  TRANQUILIZERS. 

236360  02-08 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.O,  DISSERTATION). 

238077  02-03 
N-HYDROXYAMPHETAMINE:  A  MAJOR  METABOLITE  OF  AMPHETAMINE  IN 
RABBIT  LIVER  EXTRACT 

238682  03-03 
LACK  OF  A  RELATION  BETWEEN  THE  ANTIPSYCHOTIC  AND  THE 

EXCITABILITY  DEPRESSANT  PROPERTIES  OF  MAJOR  TRANQUILIZERS. 

238710  03-03 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY'. 

247359  04-15 


Psychopharmacology  Abstrac 

BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  04- 
MALE 

NEUROTRANSMITTER  INFLUENCES  ON  MATING  BEHAVIOR  IN  MALE 
RATS.  (PH.D.  DISSERTATION). 

228390  01- 

THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 

FINDINGS:  TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE 

229037  01 
RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE,  AND  MALE  MICE. 

238766  03 
EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT. 

240642  03 
STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 

PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  03 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 

BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03 
TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  AAALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04 

SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  AAALE  RATS  TREATED  WITH 

METHADONE. 

243789  04 

VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  AAALE  RATS. 

244311  04 
EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIV 
OF  AAALE  LAF-J  MICE. 

246586  04 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATE 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04 
THE  INCIDENCE  OF  SELF-MUTILATION  IN  MORPHINE  TOLERANT  SPRAG 
DAWLEY  MALE  RATS. 

249253  O' 

BEHAVIOR  AND  ENDOCRINE  EFFECTS  OF  3,4,5 
TRIMETHOXYAMPHETAMINE  IN  MALE  MICE. 

251215  0^ 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONAT/i 
STAGE". 

251981  0- 

ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIV 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  II.  LSD. 

253700  0- 

MAIEATE 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRAA 

229038  0 
DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALE> 
--  AN  ANTIMIGRAINE  COMPOUND. 

229473  0 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  AAALEATE,  ^ 
ERGOT  DERIVATIVE,  IN  MICE. 

252028  0. 

AAALES 

PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS: 
EFFECT  OF  DIAZEPAAA  IN  MALES. 

229840  0 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK    I    EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245712  0 
47-XYY  AND  46-XY  AAALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDIN' 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  0 

MALFORMATIONS 

CONGENITAL  MALFORAAATIONS  WITH  PSYCHOPHARMACOLOGIC 
AGENTS 

230012  0 

MALNOURISHED 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FE 
RATS  FOLLOWING  L-TRYPTOPHAN  INJECTION. 

226873  0 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  AAALNOURISHED,  CORN-FED  RAT! 

238676  0 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR    SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  0 


S-190 


I/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


MAMAAAIIAN 

BIOCHEMICAL  IDENTIFICATION  OF  THE  MAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR. 

227400  01-03 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS. 

230602  01-13 
LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-03 
A  COMPARISON  OF  THE  BIOCHEMICAL  EFFECT  OF  TWO  CATALYTIC 
INHIBITORS  OF  MAMMALIAN  BRAIN  GABA-TRANSAMINASE:  GAMMA- 
VINYL-GABA  (AMIN0-4-HEX-5-EN0IC-ACID)  AND  GAMMA-ACETYLENIC- 
GA8A  (AMIN0-4-HEX-5-YN0IC-ACID). 

238782  03-03 
0ELTA9-TETRAHYDR0CANNABIN0L:  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUMAN  AND  OTHER  MAMAAALIAN  CELLS. 

251420  04-13 


MAN 


UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER). 

226731  01-13 
EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  01-14 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN. 

229440  01-14 
EFFECTS  OF  PROMETHAZINE  ON  NOCTURNAL  SLEEP  IN  NORMAL  MAN 

230867  01-14 
A  COMPARISON  OF  FENFLURAMINE  AND  AMPHETAMINE  IN  MAN. 

23131901-13 
STUDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01-13 
THE  EFFECT  OF  DIAZEPAM,  FLUNITRAZEPAM  AND  DROPERIDOL  WITH  AN 
ANALGESIC  ON  BLOOD-PRESSURE  AND  HEARTRATE  IN  MAN. 

232531  01-13 
ARE  HORMONES  PSYCHOACTIVE'  EVOKED  POTENTIAL  INVESTIGATIONS 

IN  MAN. 

232532  01-14 
IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 

FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02-13 
DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02- 10 
THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 
MONOAMINE-OXIDASE  IN  MAN. 

237927  02- 13 
CLONAZEPAM-INOUCED  CHANGES  IN  5-HYDROXYTRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  MAN. 

237977  02-13 
PHENOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
FOR  SEVERAL  METABOLITES 

238796  03-13 
THE  EFFECTS  OF  ASCORBIC-ACID  (AA)  PRETREATMENT  ON 

AMPHETAMINE  (A)  EXCRETION  IN  MAN. 

238797  03-13 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN.  (UNPUBLISHED  PAPER). 

239305  03-13 
EFFECTS  IF  SOME  DRUGS  ON  PSYCHOSEXUAL  RESPONSE  IN  MAN 

239646  03-14 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER). 

240241  03-04 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS 

241234  03-13 
CLINICAL  ASPECTS  OF  COCAINE:  ASSESSMENT  OF  ACUTE  AND  CHRONIC 
EFFECTS  IN  ANIMALS  AND  MAN.  (UNPUBLISHED  PAPER 

243024  04-17 
EFFECTS  OF  MARIHUANA  ON  MAN. 

245811  04-15 
THIORIDAZINE  STIMULATES  PROLACTIN  SECRETION  IN  MAN. 

245840  04-13 


EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
PLASMA  LEVELS  OF  IMIPRAM.INE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION 

246387  04-13 
ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 

DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN, 

246992  04-13 

EFFECTS  OF  PERPHENAZINE  ON  IMIPRAMINE  METABOLISM  IN  MAN, 

247210  04  13 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04-13 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABINOL  IN 
MAN. 

249622  04-07 

BILIARY  ELIMINATION  OF  DIAZEPAM  IN  AAAN. 

250423  04-13 
A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIAAALS  AND  AAAN. 

250935  04-17 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04-12 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN 

251129  0417 
SOME  STUDIES  OF  SETA-RECEPTOR  BLOCKING  DRUGS  ON  THE  CENTRAL- 
NERVOUS-SYSTEM  IN  MAN. 

251162  04-13 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
MAN-AAACHINE 

ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-MACHINE  TRACKING  SYSTEMS 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03  14 

MANAGEMENT 

DRUG  ACTION  IN  MANAGEMENT  OF  HYPERTENSION. 

225766  01-11 
DRUGS  IN  THE  MANAGEAAbNT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOL  CHILDREN. 

225783  01-14 

PROVIDERS  AS  PRESCRIBERS:  ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY. 

227923  01-11 
MANAGEMENT  OF  THE  ELDERLY  HYPERTENSIVE  IN  FOUR  PRACTICE 

SETTINGS. 

227924  01-11 
PLASMA  CHLORPROAAAZINE  IN  PSYCHIATRIC  MANAGEMENT. 

229492  01-13 
THE  MEDICAL  PHARMACOLOGICAL  MANAGEMENT  OF  ACUTE 
PSYCHOSES. 

22971 7  01-1 1 
ROLE  OF  DIAZEPAM  IN  THE  MANAGEMENT  OF  ECLAMPSIA. 

237898  02-1 1 
NON-MEDICATION  MANAGEMENT  OF  HYPERKINETIC  CHILDREN  IN  THE 
CLASSROOM.  (PH.D.  DISSERTATION). 

240977  03-1 1 
LORAZEPAM  IN  THE  MANAGEMENT  OF  ANXIETY  ASSOCIATED  WITH 
CHRONIC  GASTROINTESTINAL  DISEASE:  A  DOUBLE-BLIND  STUDY 

241274  03-14 
CHANGING  PATTERNS  IN  THE  MANAGEMENT  OF  DEPRESSION. 

243863  04-09 
DIAGNOSIS  AND  MANAGEMENT  OF  ETHANOL  WITHDRAWAL 
SYNDROMES. 

244107  0411 
CLINICAL  PHARMACOLOGICAL  MANAGEMENT  OF  HYPERKINETIC 
CHILDREN. 

247381  04-17 
ANAFRANIL  IN  THE  MANAGEMENT  OF  LONG-TERM  PAIN:  A  PRELIMINARY 
REPORT 

252141  0407 
MANAGEMENT  OF  PATIENTS  WITH  SUSPECTED  DRUG  INDUCED 
PSYCHOSES. 

252733  04  15 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY, 

253684  04  1 1 
MANGANESE 

BEHAVIORAL  EFFECTS  IN  RATS  FOLLOWING  INTRASTRIATAL 
MICROINJECTION  OF  MANGANESE 

226932  01-04 


9 


S-191 


Subject  Index 


Psychopharmacology  Abstract; 


MANIA 

COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHL0RPR0MA2INE  IN  MANIA;  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-09 
MANIA  AND  BROMISM:  A  CASE  REPORT  AND  A  LOOK  TO  THE  FUTURE. 

236754  02-09 
TRIAL  OF  DIGOXIN  IN  MANIA 

24771 1  04-09 
ACUTE  MANIA;  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS. 

253617  04-09 
MANIC 

REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE;  PRELIMINARY  OBSERVATIONS. 

230816  01-09 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01-09 
THE  LITTLE  KNOWN  THERAPEUTIC  PROPERTIES  OF  IMIPRAMINE  IN 
MANIC  STATES  OF  CYCLOTHYMIC  PSYCHOSES. 

231368  01  09 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
AAANIC-DEPRESSIVE 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 
COURSE  OF  MANIC-DEPRESSIVE  RECURRENCES  UNDER  LITHIUM. 

232779  02-09 
LITHIUM  CARBONATE  IN  JUVENILE  MANIC-DEPRESSIVE  ILLNESS. 

236663  02-10 
APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS. 

236732  02-09 
LITHIUM  SALTS  IN  CYCLOPHRENIA  (MANIC-DEPRESSIVE  PSYCHOSIS). 

237013  02-09 
PSYCHOPHARMACOLOGICAL  THERAPY  AND  PROPHYLAXIS  OF  MANIC- 
DEPRESSIVE  ILLNESSES. 

240707  03-09 
PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS. 

243979  04-09 
WARNED  REACTION  TIMES  OF  MANIC-DEPRESSIVE  PATIENTS  WITH  AND 
WITHOUT  LITHIUM. 

249798  04-09 
MANIC-MELANCHOLIC 

LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS;  ITS  ROLE  IN  THE  DAILY  ROUTINE. 

240055  03-09 
MANIFESTATIONS 

THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHALOPATHY  IN  CHILDREN;  STUDY  OF  28  CASES. 

229083  01-11 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04-04 
MANIPULATION 

MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN; 
BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PH.D. 
DISSERTATION). 

241680  03-04 
MANIPULATIONS 

TESTOSTERONE  MANIPULATIONS;  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04  02 
MANNITOl 

DIFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAL  SMOOTH  MUSCLE 

253113  04-03 
MAO 

THE  EFFECT  OF  ADRENALINE  ON  HUMAN  PLATELET  MAO  ACTIVITY. 

246312  04-13 
MAO  INHIBITORS  HAVE  POTENTIAL  FOR  ABUSE. 

248339  04-15 
MAOI 

COMBINATION  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  MAOI  IN 
DEPRESSION 

240839  03-09 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2-PHENYLETHYLAMINE  (PEA). 

249310  04  03 


MAOIS 

EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (AAAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-C 
A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE-OXIDASE  INHIBITORS 
(MAOIS). 

249308  04-C 
MAPROTILINE 

CLINICAL  EXPERIENCE  IN  USING  MAPROTILINE,  A  NEW  ANTIDEPRESSIVE 
MEDICINE. 

229760  01 -C 
PHARMACOLOGICAL  STUDIES  OF  DRUG  ACTION  ON  CNS,  WITH  SPECIAL 
REFERENCE  TO  EFFECTS  OF  MAPROTILINE. 

231316  Ol-C 
A  CONTROLLED  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  IN  DEPRESSED 
OUTPATIENTS. 

231401  Ol-C 
A  DOUBLE-BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS. 

238981  03-1 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS. 

239818  03-1 
MAPROTILINE  (LUDIOMIL,  CIBA-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS;  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  03-( 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  AAAPROTILINE 

(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-( 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION;  A  CONTROLLED  STUDY. 

253684  04-' 
MAPS 

SPECTRAL  MAPS  OF  THE  LIEGE  PHYSIOGNOMIES  OF  THE  NEUROLEPTICS 

239683  03-( 
MARIHUANA 

MARIHUANA  EFFECTS  ON  TAT  FORM  AND  CONTENT. 

230871  01- 
CHRONIC  MARIHUANA  INHALATION  TOXICITY  IN  RATS. 

235671  02-( 
MARIHUANA;  CAN  IT  HURT  YOU?. 

237651  02- 
THE  EFFECT  OF  CHRONIC  MARIHUANA  SMOKING  ON  THE  BEAGLE  DOG. 

238806  03-( 
INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 

(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-( 
POSSIBLE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  OF 

MARIHUANA  BY  2-PHENYLETHYLAMINE  AND  BY  PHENYLACETIC-ACIO 

238820  03-( 
A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  TH( 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03- 
EFFECTS  OF  MARIHUANA  COMBINED  WITH  SECOBARBITAL. 

245648  04- 
EFFECTS  OF  MARIHUANA  ON  MAN 

24581 1  04- 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICA 
STATUS  OF  RHESUS  MONKEYS. 

249003  04-1 
MARIJUANA 

MARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS. 

226903  01- 
TOXICITY  OF  MARUUANA  AND  TOBACCO  SMOKING  IN  THE  BEAGLE. 

229034  01-1 
REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRON 
MARIJUANA  SMOKERS. 

229039  01- 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARIJUANA  ON  EEG 
PATTERNS  IN  CATS. 

235564  02-( 
EFFECTS  OF  ALCOHOL  AND  MARUUANA  ON  DYNAMIC  VISUAL  ACUITY; 
THRESHOLD  MEASUREMENTS. 

235759  02- 
COGNITIVE  EFFECTS  OF  LONG-TERM  MARUUANA  USE.  (PH.D. 
DISSERTATION). 

238085  02- 
MARIJUANA  AND  T-LYMPHOCYTE  ROSETTES. 

243088  04- 
CERE8RAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243)81  04-( 


S-192 


LUME  14,  SUBJECT  INDEX 

MARIJUANA  AND  HUMAN  PERFORMANCE. 

247217  04-14 
MARIJUANA,  ABSINTHE  AND  THE  CENTRALNERVOUS-SYSTEM. 

249783  04-01 
IIJUANA-INOUCED 

MARIJUANA-INDUCED  ALTERAIIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03-04 
IKER 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENTRICULARLY  ADMINISTERED 
(3H)5-HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE 

226400  01-03 
[MOSET 

AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3-MESCALINE 
IN  THE  BRAIN  OF  THE  MARMOSET,  CALLITHRIX-JACCHUS. 

239864  03-03 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTAS-  AND  DELTA9-TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIX-JACCHUS. 

244681  04-03 
tROW 

UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
iKED 
PHARMACEUTICAL  THERAPY  OF  MASKED  DEPRESSION. 

244040  04-10 
iSACHUSEnS 

CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS: 
LV-A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS. 

245863  04-08 
rCH-TO-SAJV\PLE 
EFFECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH-TO-SAMPLE 
TASK  IN  MONKEYS. 

230577  01-04 
fERNAL 

ASSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 
CLEFTS. 

229350  01-15 
PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  03-03 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04-15 
EFFECTS  ON  OFFSPRING  OF  CHRONIC  MATERNAL  METHAMPHETAMINE 
EXPOSURE. 

245405  04-05 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 
THEMATICAl 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-14 
TING 
NEUROTRANSMITTER  INFLUENCES  ON  MATING  BEHAVIOR  IN  MALE 
RATS.  (PH.D.  DISSERTATION). 

228390  01-04 
TURATION 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01-04 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  04-03 
TURATIONAL 
NEONATAL  HYPERTHYROIDISM.  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
TURE 
EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIOR 
OF  MATURE  OFFSPRING 

226528  01-04 
DIFFERENTIAL  EFFECTS  OF  DAMPHETAMINE  IN  MATURE  AND  IMMATURE 
RATS. 

228160  01-04 


Subject  Index 


AAATURING 

EFFECTS  OF  RESERPINE  ON  MATURING  ADRENAL  MEDULLA. 

243796  04-03 
MAZE 

EFFECTS  OF  METHOXYLATED  AMPHETAMINES  ON  THE  MAZE 
PERFORMANCE  BY  THE  RAT. 

238788  03-04 
AAAZINDOl 

MAZINDOL  SELF-ADMINISTRATION  IN  THE  RHESUS  MONKEY. 

242747  04-04 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  DAMPHETAMINE 
OR  MAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
BEHAVIOURAL  EFFECTS  OF  A  NEW  NONPHENYLETHYLAMINE 
ANOREXIGENIC  AGENT:  MAZINDOL, 

252030  04-04 
EFFECTS  OF  MAZINDOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

252201  04-03 

MCLEAN 

CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS: 
LV-A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS 

245863  04-08 

MDA 

GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEDIOXY AMPHETAMINE  (MDA)  FROM  PLASAAA  AND  URINE. 

238484  02-06 
MEANING 

THE  PHARMACOLOGIC  MEANING  OF  SUCCESSFUL  ANTIPSYCHOTIC 
ANTIDEPRESSANT  COMBINATIONS. 

230010  01-11 
MEANING-RESPONSE 

STRONG  MEANING-RESPONSE  BIAS  IN  SCHIZOPHRENIA. 

245559  04-08 
MEASURE 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
MEASURED 

LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
LI+   SENSITIVE  MICROELECTRODE. 

235589  02-06 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-03 
MEASUREMENT 

A  CONTRIBUTION  TO  PSYCHOACTIVE  DRUG  MEASUREMENT  TECHNIQUES. 

229442  01  16 
SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS 
(UNPUBLISHED  PAPER). 

237274  02-16 
SERUM  LITHIUM  MEASUREMENT  OF  THE  EEL  FLAMEPHOTOMETER. 

241777  03-16 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING 

242745  04-04 
MEASUREMENT  OF  ATTENTION  DEFICIT  IN  THE  COURSE  OF 
INTOXICATIONS 

244896  04-14 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTOPE 
DERIVATIVE  TECHNIQUE 

247131  04-03 
MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 
GROUPS  OF  RATS 

247207  04-04 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD 

248724  04-03 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED  RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04-1  1 
THE  MEASUREMENT  OF  PAIN  IN  TERMINAL  CARCINOMA 

252143  04-11 


3 


S-193 


Subject  Index 


Psychopharmacology  Abstr 


e:i! 


MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 
MEASUREMENTS 

EFFECTS  OF  ALCOHOL  AND  MARIJUANA  ON  DYNAMIC  VISUAL  ACUITY:  I. 
THRESHOLD  MEASUREMENTS. 

235759  02-14 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241234  03-13 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  04-03 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS. 

253693  04-03 
MEASURES 

THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  IN  HYPERACTIVE  CHILDREN. 

231629  01-14 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04-04 
MEASURING 

AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH.D. 
DISSERTATION). 

241129  03-03 
MECAMYLAMINE 

NICOTINE  LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

239865  03-04 
MECHANISM 

HYPNOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS. 

228094  01-14 
THE  MECHANISM  OF  ACTION  OF  AMPHETAMINE  IN  BRAIN. 

229491  01-03 
STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 

ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PH.D. 
DISSERTATION). 

231438  01-03 
MECHANISM  OF  ACTION  OF  BENZODIAZEPINES. 

232506  01-03 
ON  THE  INTRACELLULAR  MECHANISM  OF  ACTION  OF  IMIPRAMINE  AND 
DIAZEPAM 

236232  02-03 
INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIDOL. 

236369  02-03 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02-03 
STUDIES  ON  THE  MECHANISM  OF  DEPLETION  OF  STRIATAL  DOPAMINE 
BY  ALPHA-METHYL-M-TYROSINE. 

237873  02-03 
EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
INTERACTION  OF  TRIHEXYPHENIDYL  AND  CHLORPROMAZINE:  PROBABLE 
MECHANISM. 

238732  03-03 
AMPHETAMINE-INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAIN 
DIFFERENCES.  POLYORUG  EFFECTS  AND  MECHANISM. 

238789  03-03 
MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS. 

238809  03-03 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
CORTICAL  DISINHIBITION:  A  POSSIBLE  MECHANISM  FOR  DRUG-INDUCED 
HALLUCINATIONS. 

238830  03-03 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

241919  03-03 


ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERG 
NEURONE. 

243760 
STUDIES  ON  THE  MECHANISM  OF  LITHIUM  ACTION:  PRELIMINARY 
REPORT. 

247208 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  AAAN, 

248224 
STUDIES  ON  THE  ROLE  OF  PHENETHYLAMINE  IN  METHYLAMPHETA/V 
ACTION  MECHANISM. 

248515 
ON  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 
PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS. 

249287 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANC 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH). 

250110 
THE  MECHANISM  OF  ACTION  OF  FENFLURAMINE. 

250936 
MECHANISMS 

MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIA/ 
(R2)  ON  RAT  STRIATUM. 

22685) 
ON  THE  MECHANISMS  OF  ACTION  OF  AMINOPYRINE. 

228552 
BEHAVIOR  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  ACTIO 
BENZODIAZEPINES. 

229461 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTIO 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462 
THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 
SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  f 
NUCLEI.  (UNPUBLISHED  PAPER). 

232325 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTK 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507 
EFFECTS  OF  BENZODIAZEPINES  ON  CENTRAL  SEROTONERGIC 
MECHANISMS. 

232508 
BEHAVIORAL  ANALYSIS  OF  THE  EFFECTS  AND  MECHANISMS  OF  AC 
OF  BENZODIAZEPINES. 

232509 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALA 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA, 

232610 
THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTC 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARMACOKINETICS 
PSYCHOTROPIC  DRUGS. 

233682 
CLINICAL  STUDIES  OF  DOPAMINERGIC  MECHANISMS 

233975 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCt 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONEI 
REACTION. 

236257 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTK 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS, 

236828 
MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  C 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245 
EFFECTS  OF  DOPAMINE  (DA)  DERIVATIVES  ON  CENTRAL  DOPAMINE 
MECHANISMS. 

238 70C 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHER> 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724 
DIFFERENTIAL  INTERACTIONS  OF  PENTOBARBITAL  AND  PHENOBARt 
WITH  BETA-ADRENERGIC  MECHANISMS. 

238725 
ETHANOL  PREFERENCE  IN  RATS:  POSSIBLE  UNDERLYING  MECHANIS 

23875C 
NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971 
MECHANISMS  OF  A  DYSKINESIA  INDUCTION  BY  1-3,4 
DIHYDROXYPEHNYLPIPERAZINE  IN  THE  RAT. 

239964 
ON  THE  MECHANISMS  OF  ACTION  AND  KINETICS  OF  LITHIUM 

24074C 


S-194 


>LUME  14,  SUBJECT  INDEX 

APOMORPHINE-INDUCED  HYPERTHERMIA  IN  THE  RABBIT:  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE,  (PH.D.  DISSERTATION). 

240936  03-03 
NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 
AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES. 

241298  03-03 
NEUROREGULATORS  AND  SLEEP  MECHANISMS. 

241902  03-17 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYOROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINEDEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-04 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
ONTOGENY  OF  THERMOREGULATORY  MECHANISMS  IN  THE  RAT. 

245608  04-02 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS. 

246311  04-03 
REVERSAL  OF  THE  6-HYDROXYDOPAMINEINDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
APOMORPHINE-INDUCED  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS. 

247875  04-04 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN. 

248286  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINERGIC  MECHANISMS. 

249305  04-06 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE  BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
EDAZEPAM 

CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE. 

241232  03-03 
EOIAL 

EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS. 

250358  04-04 
EDIATED 

IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02-13 
A  OOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC  GMP 

238717  03-04 
EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
CELLULAR  MEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9THC) 

238816  03-03 
RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN. 

244685  04-04 
lEDIATES 

D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272  03-04 
lEOIATING 

EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 


Subject  Index 


OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA 

237104  02-03 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
INGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04  02 
DIFFERENT  ALPHA-ADRENORECEPTORS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04-02 

MEDIATION 

HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA-INDUCED 
HYPERACTIVITY  IN  THE  RAT. 

226734  01-04 

EVIDENCE  FOR  AN  INVOLVEMENT  OF  GABA  IN  THE  MEDIATION  OF  THE 
CEREBELLAR  CGMP  DECREASE  AND  THE  ANTICONVULSANT  ACTION  OF 
DIAZEPAM. 

226857  01-03 

DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01-03 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA. 

232610  02-03 
CHOLINERGIC  MEDIATION  OF  INSTRUMENTAL  AND  CONSUMMATORY 

BEHAVIORS. 

233448  02-04 

POSSIBLE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  OF 
MARIHUANA  BY  2-PHENYLETHYLAMINE  AND  BY  PHENYLACETIC-ACID. 

238820  03-03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION. 

239086  03-03 
D-AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS    MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
ANALYSIS  OF  HORMONAL  MEDIATION  OF  DRINKING  BEHAVIOR. 

244469  04-04 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 

MEDIATOR 

GAMMA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL. 

237786  02  03 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS   (PH.D.  DISSERTATION). 

238077  02-03 
CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAAAINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE, 

248162  04-01 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9 
TETRAHYDROCANNABINOL  (THC), 

249309  04-03 
MEDIATORS 

MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW 

253407  04-03 

MEDICAL 

THE  MEDICAL  PHARMACOLOGICAL  MANAGEMENT  OF  ACUTE 
PSYCHOSES 

229717  01-11 
MISUSE  AND  ABUSE  OF  DIAZEPAM   AN  INCREASINGLY  COMMON 
MEDICAL  PROBLEM 

229852  01  17 
A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN 

235429  02-08 
MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL-HEALTH 
POLICY. 

239298  03- 17 


-9 


S-195 


Subject  Index 


Psychopharmacology  Abstro 


THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-15 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
MEDICAL  PRACTICE  WITHOUT  ANTIANXIETY  DRUGS. 

245524  04-17 
THE  TOKYO  ASSEMBLY  OF  THE  WORLD  MEDICAL  ASSOCIATION. 

248166  04-17 
THE  MEDICAL  EFFECTS  OF  COFFEE. 

248862  04-15 
MEDICAL  EFFECTS  OF  ABRUPT  NEUROLEPTIC  WITHDRAWAL. 

251996  04-08 
MEDICATION 

REVIEW  OF  LONG-TERM  PSYCHIATRIC  MEDICATION  -  A  STUDY  OF 
WITHDRAWAL  SYMPTOMS. 

228214  01-15 
DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 
CHRONIC  SCHIZOPHRENIA. 

228325  01-08 
EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE-BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  01-11 
AN  INVESTIGATION  INTO  THE  POSSIBILITY  OF  IRREVERSIBLE  CENTRAL- 
NERVOUS-SYSTEM  DAMAGE  AS  A  RESULT  OF  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

229169  01-15 
CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-13 
GETTING  PSYCHIATRIC  PATIENTS  TO  TAKE  THEIR  MEDICATION. 

230118  01-17 
FUGUE  STATES   -  EPILEPSY  -  MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT.  AUGUST  1,  1975. 

237476  02-17 
PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 
MEDICATION.  (UNPUBLISHED  PAPER). 

238489  02-08 
CLINICAL  PHARMACOLOGY  AND  THE  PRESCRIPTION  OF  PSYCHOTROPIC 
MEDICATION. 

239678  03-17 
DEPOSITS  IN  THE  LENS  AND  CORNEA  OF  THE  EYE  DURING  LONG-TERM 
CHLORPROMAZINE  MEDICATION. 

240048  03-15 
ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241763  03-15 
REMISSION  OF  VITILIGO  AND  SALT  MEDICATION. 

241849  03-09 
PARADOXICAL  RAGE  REACTIONS  DURING  PSYCHOTROPIC  MEDICATION. 

246184  04-15 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
MEMORY  FUNCTIONS  IN  DEPRESSION:  IMPROVEMENT  WITH 
ANTIDEPRESSANT  MEDICATION. 

248583  04-09 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN. 

253041  04-15 
DO  PSYCHIATRIC  PATIENTS  TAKE  THEIR  MEDICATION?.  THE  VIEW  OF 
THE  STAFF. 

253103  04-17 
MEDICATIONS 

ANXIOLYTIC  MEDICATIONS. 

241758  03-10 
CYCLIC  AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AND 
PSYCHOTIC  PATIENTS. 

253641  04-11 
MEDICINE 

DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-10 
CLINICAL  EXPERIENCE  IN  USING  MAPROTILINE,  A  NEW  ANTIDEPRESSIVE 
MEDICINE, 

229760  01-09 


MEDICINES 

MEDICINES  AND  MENTAL-ILLNESS  IN  OLD  AGE. 

227750  0 
MEDULLA 

THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  I 
ADRENAL  MEDULLA. 

243779  C 
EFFECTS  OF  RESERPINE  ON  MATURING  ADRENAL  MEDULLA. 

243796  C 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RA1 
ADRENAL  MEDULLA. 

251434 C 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  C 

EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPME! 

OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM 

2531  IOC 
MEGAVITAMIN 

THE  USE  OF  MEGAVITAMIN  TREATMENT  IN  CHILDREN  WITH  LEARNI^ 
DISABILITIES. 

235676  C 
AN  UPDATE  OF  MEGAVITAMIN  THERAPY  IN  ORTHOMOLECULAR 
PSYCHIATRY. 

235678  C 
MEGIMID 

AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATI 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES. 

2291 15 C 
MELANOCYTE 

A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIV/ 
CENTRAL  DOPAMINE  RECEPTORS. 

250082  C 
MELLERIl 

THERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLEF 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  0 
MEIYLAMINOPROPYLDIBENZOBICVCLOOCTADIENE 

A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 
ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOO 
ADIENE  CHLORHYDRATE  (CIBA-34276-BA). 

247554  C 
MEMBRANE 

ALTERATION  OF  MEMBRANE  INTEGRITY  OF  DELTAl- 
TETRAHYDROCANNABINOL. 

229035  0 
REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 
PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  AOENO 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  0 
BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC). 

238812  0 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUG 
PLUS  SEROTONIN. 

243813  0 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244 1 99  0 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  0 
MEMBRANES 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENAT/s 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  0 
STEREOSPECIFIC  BINDING  OF  D-LYSERGIC-ACID-DIETHYLAMIOE  (LSD)  ' 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS 

226936  0 
BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  0 
lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  Of 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER). 

236873  O: 
5-HYDROXYTRYPTAMINE  BINDING  TO  SYNAPTIC  MEMBRANES  FROM 
BRAIN. 

237890  O; 
DRUG  PERMEATION  THROUGH  MEMBRANES  V:  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  O: 


i 


S-196 


IME  14,  SUBJECT  INDEX 


Subject  Index 


E  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 
ilES 

RBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE. 

251939  04:14 
JV 

FECT  OF  5,5  DIPHENYLHYDANTOIN  (DPH)  ON  LEARNING  AND  MEMORY 
IN  CATS. 

229680  01-04 
t  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT-TERM  MEMORY. 

23671 1  02-04 
TROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK. 

237260  02-04 
FECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING. 

237264  02-04 
FECTS  OF  DIAZEPAM  AND  SCOPOLAMINE  ON  STORAGE,  RETRIEVAL 
AND  ORGANIZATIONAL  PROCESSES  IN  MEMORY. 

237722  02-14 
IE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-03 
FLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES. 

238711  03-14 
DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP. 

238717  03-04 
)ES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 

239002  03-09 
gTIBIOTICS  AND  MEMORY. 

239673  03-04 
EMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT. 

239852  03-04 
\RIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE.  (PH.D.  DISSERTATION). 

241689  03-04 
rCLOHEXIMIDE-INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY  IN 
RATS. 

242742  03-04 
FECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 
CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04- 14 
(■CLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-11 
EMORY  FUNCTIONS  IN  DEPRESSION:  IMPROVEMENT  WITH 
ANTIDEPRESSANT  MEDICATION. 

248583  04-09 
iPHENYLHYDANTOIN  FACILITATION  OF  LABILE,  PROTEIN  INDEPENDENT 
MEMORY. 

253290  04-04 
ON 

HE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
.INICAL  EXPERIENCE  IN  USING  MENDON  (DIPOTASSIUM  CLORAZEPATE). 

229626  01-11 
PAUSE 
\a  AND  FICTION  OF  MENOPAUSE. 

249975  04-17 
\L 
iSUES  CONCERNING  DRUG  THERAPY  IN  THE  MENTAL  HOSPITAL. 

228322  01-17 
RUGS  FOR  MENTAL  DISORDERS  OF  OLD  AGE. 

229315  01-11 
HE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY 

230830  01-14 
RUG  TREATMENT  OF  MENTAL  DISORDERS. 

23111301-17 
HE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION. 

233281  02-14 
lENTAL  AND  EMOTIONAL  DISTURBANCE  WITH  PENTAZOCINE  (TALWIN) 
USE. 

233828  02-15 


POSSIBILITIES  FOR  PHARMACOTHERAPY  IN  THE  COURSE  OF 
PSYCHOTHERAPY  FOR  MENTAL  DISORDERS. 

234438  02-17 
HOW  DRUGS  ACT  -  26:  DRUGS  AND  THE  MENTAL  STATE. 

235638  02-17 
CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271  02-14 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03-11 
MENTAL  ILLNESS  AND  SIMULATED  DRIVING:  BEFORE  AND  DURING 
TREATMENT. 

241425  03-15 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOAAAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
TREATMENT  OF  STUDENTS  WITH  MENTAL  DISORDER. 

243092  04-17 
EFFECT  OF  CLOZAPINE  ON  THE  MENTAL  AND  PHYSICAL  STATE  OF 
PATIENTS. 

243986  04-08 
CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-11 
ORGANIC  MENTAL  CHANGES  WITH  FLUOROURACIL  THERAPY. 

247978  04-15 
DRUG  THERAPY  IN  MENTAL  HANDICAP. 

249525  04-17 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04-11 
CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS. 

252447  04-10 
MENTAL-HEALTH 

CLINICAL  PHARMACY  PRACTICE  IN  A  COMMUNITY  MENTAL-HEALTH 
CENTER. 

227560  01-17 
MENTAL-HEALTH  PROGRAMS:  PROMISES'^.  FULFILLMENT?.  FAILURES?. 

236911  02-15 
MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL-HEALTH 
POLICY. 

239298  03-17 
MENTAL-ILLNESS 

DOPAMINE-BETA-HYDROXYLASE  IN  NERVE  FUNCTION  AND  MENTAL- 
ILLNESS. 

225869  01-17 
MEDICINES  AND  MENTAL-ILLNESS  IN  OLD  AGE. 

227750  01  11 
MONOAMINES  AND  MENTAL-ILLNESS. 

229489  01-03 
MENTAllY 

OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
MEPIPRAZOL 

THE  PLACEBO  EFFECT  IN  PSYCHOPHARMACOTHERAPY  IN 

CONSIDERATION  OF  THE  EFFECT  OF  MEPIPRAZOL  ON  EXCITEMENT  IN 
PSYCHOTICS. 

23421 7  02-08 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD  16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS. 

237025  02-10 
MEPIPRAZOLE 

THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-03 
MEPROBAAAATE 

THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I    THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01-17 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  II,  FIVE 
EXPERIMENTS. 

232518  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  III.  THE 


=6 


S-197 


Subject  Index 


Psychopharmacology  Abstract 


CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  01-13 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  V.  SUMMARY 
AND  CONCLUSIONS. 

232521  01-14 
THE  EFFECTS  OF  MEPROBAMATE  UPON  THE  AVERSIVE  THRESHOLD  OF 

RATS. 

242894  04-04 
MEPYRAMINE 

THE  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE- 
INDUCED  CATALEPSY  IN  THE  RAT. 

240238  03-03 
MER-25 

DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 
MERIONES-UNGUICULATUS 

SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIL  (MERIONES-UNGUICULATUS). 

241311  03-04 
MESCALINE 

FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS,  (PH.D.  DISSERTATION). 

226991  01-12 
5  METHOXY  N.N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER). 

227802  01-04 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES;  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE 

229264  01-04 
ANTAGONISM  OF  D-LYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1.2,5,6  TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 
(THPC). 

230453  01-03 
THE  EFFECTS  OF  2,5  DIMETH0XY-4METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY  4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIVE 
STIMULUS 

230837  01-04 
A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS 

230870  01-04 
ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS  TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 
CONFORMATIONAILY  CONSTRAINED  ANALOGS  OF  MESCALINE  II. 

233361  02-01 
FURTHER  STUDIES  ON  THE  CHLORPROMAZINE-INDUCED  PROLONGATION 
OF  THE  DISAPPEARANCE  OF  MESCALINE  FROM  MOUSE  TISSUES. 

235670  02-03 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION?. 

237732  02-04 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA  BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG 

238703  03-03 
BEHAVIORAL  DISINHIBITION  BY  MESCALINE, 

241243  03-04 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

24)349  03-04 
THE  ROLE  OF  SEROTONIN  IN  THE  DISCRIMINATIVE  STIMULUS 
PROPERTIES  OF  MESCALINE   (PH  D.  DISSERTATION) 

241573  03-03 
STUDIES  ON  ACCUMULATION  OF  (14C)  MESCALINE  IN  BRAIN 

HOMOGENATES:  EFFECTS  OF  PSYCHOTROPIC  AND  OTHER  AGENTS. 

246817  04-03 
EFFECTS  OF  D-AMPHETAMINE,  MONOMETHOXYAMPHETAMINES  AND 
MESCALINE  ON  FIXED-INTERVAL  RESPONDING  IN  RATS. 

249275  04-04 
POTENTIATION  BY  DESIPRAMINE  OF  NEURONAL  RESPONSES  TO 
MESCALINE. 

251705  0403 


HAPTEN  IMMUNOLOGICAL  STUDIES  ON  MESCALINE. 

253536  04-C 
MESCALINE-INDUCED 

INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  03-C 
LYSERGIC-ACID-DIETHYLAMIDE  AND  MESCALINE-INDUCED  ATTENUATlOt 
OF  THE  EFFECT  OF  PUNISHMENT  IN  THE  RAT. 

252824  04-C 
MESENCEPHALIC 

EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  CM 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT, 

244216  044 
EFFECTS  OF  ALPHA-METHYL-P- TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT. 

249307  04-( 
MESODIENCEPHAUC 

THE  EFFECT  OF  D,L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01-1 
MESOLIMBIC 

A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01-1 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-1 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMINE 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY. 

248285  04J 
LSD  AS  AN  AGONIST  AT  MESOLIMBIC  DOPAMINE  RECEPTORS 

249680  04-' 
MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 

DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  04- 
BEHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  04- 
MESORIDAZINE 

EVALUATION  OF  SIDE-EFFECTS  ON  NEUROTICS  -  A  TEST  USING 
MESORIDAZINE  AND  PLACEBO 

225686  01- 
AN  OPEN  STUDY  OF  MESORIDAZINE  (SERENTIL)  IN  CHRONIC 
SCHIZOPHRENICS 

227821  01- 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE, 

229446  01- 
GLC  ANALYSIS  OF  rhlORIDAZINE,  MESORIDAZINE  AND  THEIR 
METABOLITES 

251776  04- 

MESOSTRIATAl 

BEHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  04- 
META 

CATECHOL-OMETHYLTRANSFERASE  FROM  RAT  LIVER:  TWO  FORMS 
HAVING  DIFFERENT  META:PARA  METHYLATION  RATIOS. 

249035  04- 
METABOUC 

METABOLIC  O-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  I  5 
DIMETHOXY-4-METHYLPHENYL  2  AMINOPROPANE. 

236520  02- 
SUIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02- 
IN  VITRO  METABOLIC  STUDIES  USING  THE  METABONATES  OF 
AMPHETAMINE,  2-NITROSOl-PHENYLPROPANE  AND 
BENZYLMETHYLKETOXIME. 

237980  02- 
COMPARATIVE  AUTORADIOGRAPHIC  AND  METABOLIC  STUDY  OF 
DELTA8-  AND  DELTA9TETRAHYDR0CANNABIN0L  IN  THE  BRAIN  OF 
THE  MARMOSET  CALLITHRIXJACCHUS. 

244681  04- 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTE 

246971  04- 


S-198 


AE  14,  SUBJECT  INDEX 


Subject  Index 


JSM 

FE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FOR 
5  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
.YCHOACTIVE  DRUGS. 

225572  01-03 
JLATION  OF  5-HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
[AIM  BY  ADRENAL  GLUCOCORTICOIDS. 

226401  01-03 
EFFECT  OF  ERGOTAMINE  AND  METHYSERGIDE  ON  SEROTONIN 
ETABOLISM  IN  THE  RAT  BRAIN. 

226826  01-03 
CTS  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  DRUG  METABOLISM, 

226829  01-13 
)RDIAZEPOXIDE  METABOLISM  IN  MICE  FOLLOWING  HEPATIC 
RADIATION. 

226840  01-03 
iJOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM.  MECHANISM  OF 
•TION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
i-PNOTICS. 

228094  01-14 

drpromazine  metabolism  and  clinical  response  in  acute 
:hizophrenia:  a  preliminary  report. 

229445  01-08 
JENIC  amine  effects  on  CNS  phospholipid  METABOLISM. 

229482  01-03 
EDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
ETABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01-04 
EPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 
JBIDIUM  TREATMENT. 

230817  01-03 
AINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
.ETABOLISM  IN  VIVO. 

230834  01-03 
TREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 
lETABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
ERED  5HT  METABOLISM  WITH  CLONAZEPAM,  DIAZEPAM  AND 
IPHENYLHYDANTOIN. 

230855  01-03 
:CT  OF  METHAMPHETAMINE  ON  NOREPINEPHRINE  METABOLISM  IN 
ARIOUS  REGIONS  OF  BRAIN. 

231004  01-03 
;CTS  OF  DIPHENYLHYDANTOIN.  PHENOBARBITAL,  AND  DIAZEPAM  ON 
HE  METABOLISM  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
UCCINATE. 

233001  02-13 
;CT  OF  ETHANOL  INTAKE  ON  PHENYTOIN  METABOLISM  IN 
OLUNTEERS. 

233280  02-13 
USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
>ODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-03 
EFFECT  OF  CATECHOL-O-METHYLTRANSFERASE  INHIBITORS  ON 
EHAVIOR  AND  DOPAMINE  METABOLISM. 

233969  02-03 
;CTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
\ETABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES. 

233971  02-03 
APATHETIC  NERVOUS  SYSTEM  EFFECTS  ON  RAT  BRAIN  METABOLISM. 

234309  02-03 
ETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  RATS 
f  DIFFERENT  AGES. 

234316  02-03 
:CT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
lEPRESSEO  PATIENTS. 

234673  02-09 
^EPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
.DMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
LECTROCONVULSIVE  SHOCK. 

234804  02-03 
ECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
.CTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS. 

236519  02-03 
DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
>J  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
URVEY). 

236717  02-03 
ECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  02-03 
fABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
MJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
lAT  BRAIN, 

237700  02-03 
TABOLISM,  DISTRIBUTION  AND  ANTICONVULSANT  PROPERTIES  OF 
I.N  DIMETHOXYMETHYL-PHENOBARBITAL  IN  THE  RAT. 

237758  02-03 


CLONAZEPAM-INDUCED  CHANGES  IN  5-HYDROXYTRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  AAAN. 

237977  02-13 
METABOLISM  OF  DELTAl -TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG.  COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02-03 
AN  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
THE  DYNAMICS  OF  DOPAMINE  METABOLISM  IN  VARIOUS  REGIONS  OF 
RAT  BRAIN. 

238761  03-03 
EFFECTS  OF  ANTIHISTAMINE  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM. 

238838  03-03 
ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
EFFECT  OF  CLOZAPINE  ON  THE  METABOLISM  OF  SEROTONIN  IN  RAT 
BRAIN. 

239862  03-03 
QUIPAZINE:  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM.  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-03 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 

PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPINEPHRINE 

BY  THE  RAT  DUODENAL  MUCOSA, 

241299  03-03 
COMPARATIVE  EFFECT  OF  PHENOBARBITAL  AND  METHAQUALONE  ON 
WARFARIN  METABOLISM  IN  THE  RAT, 

241344  03-03 
THE  NATURE  OF  THE  455  NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYT0CHR0ME-P45U  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE, 

241350  03-01 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  THE  METABOLISM  OF 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR 

241373  03-04 
EFFECTS  OF  1.2-BENZIS0XAZ0LE-3-ACETAMID0XIME  HYDROCHLORIDE 
(PF-257)  ON  THE  CNS  WITH  SPECIAL  REFERENCE  TO  MONOAMINE 
METABOLISM 

241393  03-03 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 
ELEVATED  ENVIRONMENTAL  TEMPERATURE, 

241925  03-03 
EFFECT  OF  LITHIUM  CHLORIDE  ON  LIPID  METABOLISM, 

241986  03-03 
EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 
PERFUSED  RAT  BRAIN, 

243782  04-03 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION, 

243790  04-03 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE, 

243792  04-03 
PSYCHOPHARAAACOLOGIC  AGENTS:  EFFECT  ON  DRUG  METABOLISM 

244060  04-03 
CNS  PHOSPHOLIPID  METABOLISM  AND  NEURONAL  FUNCTION, 

244089  04-03 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN 

244455  04-04 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE, 

244513  04-03 
NEW  PATHWAY  FOR  METABOLISM  OF  DOPA, 

246286  04-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLISM 
AND  CIRCULATION  RELATED  TO  EEG  -  DIAZEPAM,  CLOMIPRAMINE. 
AND  CHLORPROMAZINE, 

246319  04-03 
AN  ANALYSIS  OF  THE  DRUGS  ACTING  ON  CEREBRAL  ENERGY 
METABOLISM, 

247012  04-03 


S-199 


Subject  Index 


Psychopharmacology  Abstr< 


J 


m 


Ef  FECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREF  ^ND  TOTAL  TRYPTOPHAN 
LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  iN  riATS. 

247013  04-03 
EFFECTS  OF  PERPHENAZINE  ON  IMIPRAMINE  METABOLISM  IN  MAN. 

247210  04-13 
METHAQUALONE  METABOLISM  BY  RAT  LIVER  MICROSOMES. 

247847  04-03 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
SCHIZOPHRENIA,  EPILEPSY.  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04-16 
INHIBITION  OF  DRUG  METABOLISM  BY  FLUOXETINE. 

248605  04-02 
DEPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04-03 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  04-05 
BIODISPOSITION  OF  KETAMINE  IN  THE  RAT:  SELF-INDUCTION  OF 
METABOLISM. 

250107  04-03 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM  -  EVIDENCE  FOR 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179  04-03 
EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  3-CHL0R0-4- 
STILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM. 

251181  04-03 
INHIBITION  OF  PHENYLETHYLAMINE  METABOLISM  IN  VIVO  -  EFFECT  OF 
ANTIDEPRESSANTS. 

251184  04-03 
ALTERED  PATTERN  OF  DOPA  METABOLISM. 

251185  04-03 
ALTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 

(LIORESAL  (R)). 

251398  04-03 
THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04-11 
CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE. 

251777  04-06 
CHLORPROMAZINE  METABOLISM  VIIL  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS. 

251778  04-16 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5- 

HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  V\/ITHDRAV\/AL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
METABOLITE 

DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE 

230424  01-15 
N  HYDROXYAMPHETAMINE:  A  MAJOR  METABOLITE  OF  AMPHETAMINE  IN 
RABBIT  LIVER  EXTRACT. 

238682  03-03 
AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONE 
TRANQUILIZER  AZAPERONE. 

241359  03-02 
KINETICS  OF  CARBAMAZEPINE  AND  ITS  10,11  EPOXIDE  METABOLITE  IN 
CHILDREN 

243086  04-13 
PARAMETHAOIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTER 
A  SINGLE  ORAL  PARAMETHAOIONE  DOSE. 

246969  04-17 
METABOLIC  FATE  OF  FLURAZEPAM  IL  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  0403 
THE  MONOAMINE-OXIDASE  8  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 
METABOLITES 

EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES. 

227212  01-07 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 


THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  01 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01 
THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01 
SYNTHESIS  OF  3-CHLORO-2-HYDROXYIMIPRAMINE  AND  3-CHLORO-8- 
HYDROXYIMIPRAMINE  (1),  HYPOTHETICAL  METABOLITES  OF 
CLOMIPRAMINE.  (UNPUBLISHED  PAPER). 

237174  0: 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFT 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASAAA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  O: 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URI 
OF  PSYCHIATRIC  PATIENTS. 

237902  O: 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  At 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  O; 
PHENOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
FOR  SEVERAL  METABOLITES. 

238796  O; 
IMPROVED  ASSAYS  OF  CHLORPROMAZINE  AND  ITS  METABOLITES. 

238818  0; 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  0; 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA? 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  A 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  0; 
CHARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAl-TETRAHYDROCANNABIN 
IN  MOUSE  LIVER. 

243787  0' 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE:.  CLINIC 
CHEMICAL  CORRELATIONS. 

244050  0' 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUMAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN. 

244131  0' 
IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPRO/WAZINE  AND  IT 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  0' 
ASSESSMENT  OF  CEREBROSPINAL  FLUID  LEVELS  OF  DOPAMINE 
METABOLITES  BY  GAS  CHROAAATOGRAPHY. 

245300  0' 
ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES. 

246821  0- 
THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUAAAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY 

248464  0' 
CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  0- 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK:  INFLUENCE  B\ 
PINEAL  METABOLITES. 

249240  a 
NATURE  OF  NEW  CLASS  OF  CHLORPROMAZINE  (CPZ)  METABOLITES  \t> 
PRIMATE  URINES. 

249328  a 
CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA. 

251119  a 
GLC  ANALYSIS  OF  THIORIDAZINE,  MESORIDAZINE  AND  THEIR 
METABOLITES. 

251776  0' 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOi 
AND  CHLORPROMAZINE  METABOLITES 

252515  0- 
METABOLIZE 

TOLERANCE  TO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA-PI 
THAT  METABOLIZE  IT  DIFFERENTLY. 

250723  0- 
METABOLIZING 

DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER. 

226927  0' 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 
LIVER. 

227696  0 


S-200 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04-03 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW/  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04  03 
VBONATES 

IN  VITRO  METABOLIC  STUDIES  USING  THE  METABONATES  OF 
AMPHETAMINE,  2-NITROSO-l-PHENYLPROPANE  AND 
BENZYLMETHYLKETOXIME. 

237980  02-01 
\CLOPRAMIDE 

EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINERGIC  MECHANISMS. 

249305  0406 
\l 

EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03-04 
MS 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

237098  02-03 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II,  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

237105  02-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 
AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  04-04 
EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMISTRY 

AND  BEHAVIOR;  I.  GLUTAMIC-ACID  AND  GABA  IN  BRAIN  REGIONS. 

248957  04-03 
HADONE 

POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848  01  05 
METHADONE  INTERACTION  WITH  APOMORPHINE  AND  AMPHETAMINE- 
INDUCED  TURNING 

226945  01-04 
ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC, 

232615  0204 
TREATMENT  OF  ALCOHOLIC  METHADONE  MAINTENANCE  PATIENTS  WITH 
DISULFIRAM. 

237624  02-11 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-15 
DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN. 

240014  03-04 
INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 
HYDROXYINDOLES  BY  P-CHLOROAMPHETAMINE, 

241339  03-03 
STATE-DEPENDENT  (DISSOCIATIVE)  EFFECTS  OF  METHADONE  ON  HUMAN 
RETENTION.  (PH.D.  DISSERTATION). 

242151  03-14 
SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  MALE  RATS  TREATED  WITH 
METHADONE. 

243789  04-03 
EFFECT  OF  METHADONE  AND  DEXTROMORAMIDE  ON  DOPAMINE 
METABOLISM:  COMPARISON  WITH  HALOPERIDOL  AND 
AMPHETAMINE. 

244513  04  03 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H-5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04-03 
HADONE-INDUCEO 

METHADONEINOUCED  BEHAVIORAL  CHANGES:  CIRCULAR  MOVEMENTS, 
AGGRESSION,  AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01  04 


METHAMPHETAMINE 

EFFECT  OF  METHAMPHETAMINE  ON  NOREPINEPHRINE  METABOLISM  IN 
VARIOUS  REGIONS  OF  BRAIN. 

231004  01-03 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST  AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE, 

237976  02  03 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE-HYDROXYLASE  ACTIVIIY  AND  ON  STRIATAL 
DOPAMINE  LEVELS.  (PH.D.  DISSERTATION). 

238079  02-03 
EFFECT  OF  METHAMPHETAMINE  AND  NEUROLEPTIC  AGENTS  ON  THE 
KINETIC  PROPERTIES  OF  STRIATAL  TYROSINE-HYDROXYLASE. 

238693  03-03 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AND 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-04 
EFFECTS  ON  OFFSPRING  OF  CHRONIC  MATERNAL  METHAMPHETAMINE 
EXPOSURE. 

245405  0405 
DEPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04  03 
METHAMPHETAMINE  SELF-ADMINISTRATION  IN  THE  CAT. 

251976  04-04 
EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS. 

251990  04-04 
INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS. 

252027  04-03 
METHAMPHETAMINE-INDUCED 

INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE-INDUCED 
LOCOMOTOR  ACTIVITY  IN  MICE 

238842  03-04 
METHAQUAIONE 

METHAQUALONE:  TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

237731  02-04 
INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN-INDUCED  HYPOPROTHROMBINEMIA. 

237760  02-03 
PKA  DETERMINATION  OF  METHAQUALONE 

239659  03  01 
COMPARATIVE  EFFECT  OF  PHENOBARBITAL  AND  METHAQUALONE  ON 
WARFARIN  METABOLISM  IN  THE  RAT. 

241344  03-03 
DEPENDENCY  ON  COMBINED  METHAQUALONE  DIPHENHYDRAMINE. 

241870  03  17 
METHAQUALONE  METABOLISM  BY  RAT  LIVER  MICROSOMES. 

247847  04-03 
CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS. 

250332  04  06 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE 

250657  04-13 
METHAQUALONE  WITH  PSYCHOTROPIC  DRUGS:  ADVERSE  INTERACTION. 

253531  04-15 
METHERGOLINE 

EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS 

238695  03-03 
METHIMA20LE 

INHIBITION  OF  DOPAMINE  BETA-HYDROXYLASE  BY  SOME  ANALOGS  OF 
METHIMAZOLE. 

238691  03  03 
METHIODIOE 

EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIOE,  A  CHOLINE 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594  04-04 
METHIONINE 

DIFFERENTIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 
SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN. 

227387  01-03 
SCHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04-16 
METHIOTHEPIN 

THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290  02-03 


» 


S-201 


Subject  Index 


Psychopharmacology  Abstract! 


METHOCHIORIDE 

COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINT  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
METHOD 

DISCOURSE  ON  THE  DOUBLE-BUND  METHOD.  INSTITUTION  AND 
EXPERIMENTATION:  19366-RP 

229078  01-16 
A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES. 

231072  01-06 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR 

236529  02-06 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE; 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-06 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-16 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03-03 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING. 

242745  04-04 
A  METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG. 

244674  04-06 
LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L.  CARROLL. 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL 

245971  04-06 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 
SERUM  CONCENTRATION  OF  CAR8AMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE 

25301 1  04-07 
A  METHOD  FOR  EXPLAINING  DYSKINETIC  MOVEMENTS  -  A  FILM 
PRESENTATION. 

253034  04-15 
METHODOLOGICAL 

CLINICAL  EXPERIMENTATION  OF  THE  LONG-ACTING  NEUROLEPTICS: 
METHODOLOGICAL  PROBLEMS. 

229554  01-16 
THEORETICAL  AND  METHODOLOGICAL  CONSIDERATIONS  ON  DRUG 
DISCRIMINATION  LEARNING. 

241228  03-04 
DEPOT  NEUROLEPTICS  -  PRACTICAL  METHODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
METHODOLOGY 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION. 

225721  01-17 
THE  METHODOLOGY  OF  TRIALS  OF  ANTIDEPRESSANTS  FOR  DEPRESSED 
INPATIENTS 

227213  01-16 
A  RAPID.  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE: 
II   A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  0206 
METHODOLOGY  OF  THERAPEUTIC  EFFECTIVENESS  TRIALS  IN 
PSYCHOPHARMACOLOGY 

240444  03- 1  7 
EXPERIMENTAL  HUMAN  DRUG  SELF-ADMINISTRATION:  METHODOLOGY 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE, 

240831  03-14 


RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-0 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

252798  04-1 
METHODS 

CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

231034  01-0 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-C 
INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WITH 
PSYCHOACTIVE  DRUGS  -  NEW  METHODS  IN  THE  ASSESSMENT  OF 
CHANGE 

235355  02-1 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    -  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02-C 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 
PSYCHIATRIC  HOSPITAL. 

235545  02-1 
IMMUNOLOGICAL  METHODS  IN  PSYCHIATRIC  TREATMENT. 

23751 1  02-1 
DEPOT  NEUROLEPTICS  -  PRACTICAL  METHODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS, 

241761  03-( 
ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  ASSA' 
WITH  CONVENTIONAL  METHODS. 

250360  04-C 
METHOTRIMEPRAZINE 

PHARAAACOKINETICS  OF  METHOTRIMEPRAZINE  AFTER  SINGLE  AND 
MULTIPLE  DOSES. 

250422  04-( 
METHOXAMINE 

ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  01 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-( 
THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-( 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 

METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-( 

METHOXY 

5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECT 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER 

227802  0 1  •( 
METHOXYLATED 

EFFECTS  OF  METHOXYLATED  AMPHETAMINES  ON  THE  MAZE 
PERFORMANCE  BY  THE  RAT. 

238788  03-( 
METHSCOPOLAMINE 

METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP 

243822  04- 
METHYL 

BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE. 

227692  01 -( 
ANTAGONISM  OF  D  LYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BV 
1  METHYL  1,2,5,6  TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDf 
(THPC). 

230453  01 -( 
METHYL-DOPA 

EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT. 

240642  03-( 
METHYLAMPHETAMINE 

STUDIES  ON  THE  ROLE  OF  PHENETHYLAMINE  IN  METHYLAMPHETAMINE 
ACT'ON  MECHANISM, 

248515  04-( 

METHYLATION 

CATECHOL-O-METHYLTRANSFERASE  FROM  RAT  LIVER:  TWO  FORMS 
HAVING  DIFFERENT  META:PARA  METHYLATION  RATIOS. 

249035  04-( 
METHYLATROPINIUM 

INTERACTION  OF  ATROPINE  OR  METHYLATROPINIUM  WITH  FOUR 
EFFECTS  OF  TWO  CHOLINERGIC  DRUGS. 

251217  04-( 


S-202 


)LUME  14,  SUBJECT  INDEX 


Subject  Index 


rHYlOOPA 

EFFECT  OF  METHYLDOPA  ON  TARDIVE-DYSKINESIA  IN  PSYCHOGERIATRIC 
PATIENTS 

247967  04-11 
THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04-n 
DEMENTIA  INDUCED  BY  METHYLDOPA  WITH  HALOPERIDOL. 

253391  04-15 
rHYlENE-REDUCTASE 
METHYLENE  REDUCTASE:  RESPONSIBLE  FOR  THE  IN  VITRO  FORMATION 
OF  FORMALDEHYDE  FROM  5-METHYLTETRAHYDROFOLIC-ACID. 

232613  02-03 
rHYLENEDIOXYAMPHET  AMINE 
GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEOIOXY AMPHETAMINE  (MDA)  FROM  PLASMA  AND  URINE. 

238484  02-06 
mYLPERONE 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03-14 
rHYlPHENIOATE 
COMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL. 

227137  01-04 
CAFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON. 

227571  01-11 
COGNITIVE  EFFECTS  OF  METHYLPHENIDATE  ON  HYPERACTIVE  CHILDREN. 
(PH.D.  DISSERTATION). 

228431  01-11 
DIFFERENTIAL  EFFECTS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY. 

230840  01-03 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 

PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE. 

230841  01-03 
EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMMATURE  RAT. 
(PH.D.  DISSERTATION). 

231533  01-04 
THE  INFLUENCES  OF  METHYLPHENIDATE  ON  HEARTRATE  AND 

BEHAVIORAL  MEASURES  OF  ATTENTION  'N  HYPERACTIVE  CHILDREN. 

231629  01-14 
EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-1 1 
DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS. 

233967  02-08 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DYSFUNCTION. 

235322  02-11 
METHYLPHENIDATE-  A  REVIEW. 

238510  02  11 
EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
METHYLPHENIDATE  AS  A  CHOLINERGIC  AGONIST    FURTHER 
OBSERVATIONS. 

238708  03-03 
METHYLPHENIDATE  ADDICTION    -  EFFECT  REVERSAL  IN  WITHDRAWAL. 

238862  03-15 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION 

239086  03-03 
PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE, 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
METHYLPHENIDATE,  DEXTROAMPHETAMINE,  AND  LEVAMFETAMINE: 
EFFECTS  ON  SCHIZOPHRENIC  SYMPTOMS. 

239933  03-08 
EFFECTS  OF  METHYLPHENIDATE  ON  UNDERACHIEVING  CHILDREN. 

240538  03-11 
A  TEST  OF  THE  STATE-DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN    (PHD 
DISSERTATION). 

241133  03-14 
TICS  FOLLOWING  METHYLPHENIDATE  ADMINISTRATION:  A  REPORT  OF 
20  CASES 

241990  03-15 
RADIOIMMUNOASSAY  OF  METHYLPHENIDATE. 

243834  04  06 


BLOOD-PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04-15 
THE  EFFECT  OF  METHYLPHENIDATE  ON  SENSORY  PERCEPTION  IN 
VARYING  DEGREES  OF  HYPERKINETIC  BEHAVIOR. 

245012  04-14 
METHYLPHENIDATE  AND  CAFFEINE  IN  THE  TREATMENT  OF  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION 

245786  04-14 
CONTROLLED  TRIAL  OF  METHYLPHENID,^TE  IN  PRESCHOOL  CHILDREN 
WITH  MINIAAAL-BRAIN-DYSFUNCTION. 

247375  04-11 
METHYLPHENIDATE  IN  CHILDREN:  EFFECTS  UPON  CARDIORESPIRATORY 
FUNCTION  ON  EXERTION 

247378  04-15 
CLINICAL  EFFECTS  OF  IMIPRAMINE  AND  METHYLPHENIDATE  IN 
HYPERACTIVE  CHILDREN. 

247380  04-14 
ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN''. 

247382  04-14 
BRAIN  2-PHENYLETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE. 

248162  04-01 
THE  EFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHILDREN. 

251569  04-14 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

252798  04- 11 
METHYLPHENIDATE-tNDUCED 

TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 
DOGS  (CYNOMYS-LUDOVICIANUS). 

239863  03-04 
METHYLPHENIDATE- 1 4C 

STUDIES  OF  METHYLPHENIDATE  14C  IN  RAT  BRAIN. 

249243  0403 
METHYLPREDNISOLONE 

EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM.  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
SUCCINATE. 

233001  02-13 
METHYISULFINYIMETHIDE 

PERMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 
WITH  VARYING  METHYLSUIFINYLMETHIDE  CARBANION 

238488  02-01 
METHYPRYION 

HYPNOTIC  EFFICACY  OF  TRIAZOLAM  AND  METHYPRYLON  IN  INSOMNIAC 
IN-PATIENTS. 

248533  04-11 
METHYSERGID 

EFFECT  OF  LILLY  1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (MA)  IN  MICE. 

238847  03-04 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUtOUCTAI   GRAY. 

239576  03-04 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT. 

241255  03-03 
METHYSERGIDE 

THE  EFFECT  OF  ERGOTAMINE  AND  METHYSERGIDE  ON  SEROTONIN 
METABOLISM  IN  THE  RAT  BRAIN 

226826  01  03 
BEHAVIORAL  SUPERSENSITIVITY  TO  5-HYDROXYTRYPTOPHAN-INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT. 

237729  02-04 
INHIBITION  OF  DRUG-INDUCED  ANOREXIA  IN  RATS  BY  METHYSERGIDE. 

237745  02-04 
METIAMIOE 

THE  EFFECTS  OF  METIAMIOE  ON  THE  ACTIVITY  STRESS  ULCER  IN  RATS. 

230835  01-03 
METIAPINE 

A  DOUBLE-BLIND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTE 
SCHIZOPHRENICS 

248976  0408 
METOCIOPRAMIDE 

IS  METOCLOPRAMIDE  A  DIRECTLY  ACTING  DOPAMINE  RECEPTOR 
ANTAGONIST'. 

241929  03  03 
EFFECT  OF  METOCLOPRAMIDE  ON  TURNOVER  OF  BRAIN  DOPAMINE 
NORADRENALINE  AND  5-HYDROXYTRYPTAMINE 

249628  04-03 
METRAZOl 

LATERAL  GENICULATE  MULTIPLE-UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES. 

231719  01-03 


S-203 


Subject  Index 


DOSE  RELATED  EFFECTS  OF  METRAZOL  ON  RETENTION  AND  EEC. 

242733  03-04 
METYROSINE 

POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04-08 
MFB 

EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
MHPG 

BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN. 

229440  01-14 
MICE 

EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIOR 
OF  MATURE  OFFSPRING 

226528  01  04 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BP^IN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01-04 
SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABIDIOL  AND 
CANNABINOL  ON  ETHER  ANAESTHESIA  IN  MICE. 

226764  01-04 
CHLORDIAZEPOXIDE  METABOLISM  IN  MICE  FOLLOWING  HEPATIC 
IRRADIATION. 

226840  01-03 
A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-04 
OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01-04 
TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNA8IN0L  IN 
MICE  ON  INTESTINAL  .MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 
BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROMAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  01-05 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01-04 
A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS. 

230870  01-04 
THYROFROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
EFFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG-INDUCED  HYPOTHERMIA 
IN  MICE  AND  RATS. 

237100  02-03 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AND 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  02-04 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE. 

237706  02-03 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS. 

237707  02-04 
EFFECTS  OF  HASHISH  ON  ISOLATION  INDUCED  AGGRESSION  IN  WILD 

MICE. 

237714  02-04 
THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 

CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE 

237723  02-04 
METHAQUALONE:  TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE, 

237731  02-04 


Psychopharmacology  Abstracts 

BRAIN  DOPAMINE  AND  JUMPING  BEHAVIOUR  IN  MICE. 

237746  02-03 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-03 
DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE.  (PH  D   DISSERTATION). 

238159  02-03 
CESIUM  ION:  ANTAGONISM  TO  CHLORPROMAZINE  AND  L-DOPA 
PRODUCED  BEHAVIOURAL  DEPRESSION  IN  MICE. 

238318  02-04 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
BINDING  OF  GLYCINE  AND  GAMMA-AMINOBUTYRIC-ACID  TO 
SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 
EFFECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE:  CORRELATION  WITH  AGGRESSIVITY. 

238673  03-03 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE. 

238737  03-03 
PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARAAACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 

DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  03-03 
RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 

ETHANOL  IN  LACTATING,  VIRGIN  FE/WALE,  AND  MALE  MICE. 

238766  03  03 
INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE-INDUCED 
LOCOMOTOR  ACTIVITY  IN  MICE. 

238842  03-04 
EFFECT  OF  LILLY-1 10140  AND  METHYSERGID  ON  L-DOPA-INDUCED 
CHANGES  IN  LOCOMOTOR  ACTIVITY  (AAA)  IN  MICE. 

238847  03-04 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
AMPHETAMINE  TOXICITY  IN  TEMPERATURE  ACCLIMATISED  MICE. 

239091  03-05 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE 

239284  03-04 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 

AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
REDUCTION  OF  ALCOHOL  SELECTION  BY  PARGYLINE  IN  MICE. 

241225  03-04 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCtD 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  03-04 
THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
STUDY  ON  HEAD-TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE. 

241380  03-04 
AUTOMUTILATION  INDUCED  BY  CLONIDINE  IN  MICE. 

241398  03  04 
EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAL  TO  MICE. 

241403  03-03 
CONCENTRATION  OF  AMPHETAMINE  ISOMERS  IN  BRAIN  AND  HEART  OF 
ADULT  AND  DEVELOPING  MICE 

241414  03-03 


S-204 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE. 
(PH.D.  DISSERTATION). 

241576  03-03 
THE  GENETIC,  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH.D.  DISSERTATION). 

241687  03-04 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 
ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
BENZODIAZEPINES  AND  REPRODUCTION  OF  SWISS  WEBSTER  MICE. 

243788  04-04 
EFFECTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYDROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE-DEPENDENT  TURNING  BEHAVIOUR  IN 
MICE. 

243803  04-04 
SALSOLINOL  DIFFERENTIALLY  AFFECTS  MICE  SELECTED  FOR  SENSITIVITY 
TO  ALCOHOL. 

244680  04-04 
RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN 

244685  04-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  MICE:  COMPARISON  BETWEEN  TWO  VEHICLES. 

244687  04-04 
INTERACTION  OF  DELTA9-TETRAHYDR0CANNABINGL  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS, 

244894  04-04 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEN 
AND  OLFACTORY  STIMULI. 

245406  04-04 
EFFECTS  OF  N-HYDROXYETHYLPYRROLIDINIUM  METHIODIDE,  A  CHOLINE 
ANALOGUE,  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE. 

245594  04-04 
EFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCED  AMNESIA  IN  MICE. 

245614  04-02 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
FEEDING  AND  WITHDRAWAL. 

246310  04-04 
EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIVAL 
OF  MALE  LAF-J  MICE. 

246586  04-03 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-04 
ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES 

246821  04-05 
DETERMINATION  AND  CHARACTERIZATION  OF  THE  ANTINOCICEPTIVE 
ACTIVITY  OF  INTRAVENTRICULARLY  ADMINISTERED  ACETYLCHOLINE 
IN  MICE. 

246852  04-04 
EFFECTS  OF  TRAZODONE  ON  BEHAVIOR  AND  BRAIN  AMINE  CONTENT  OF 
MICE. 

247485  04-04 
CHLORPROMAZINE,  CATECHOLAMINES  AND  AGING  IN  MICE. 

247587  04-02 
BENZODIAZEPINES  AND  AMPHETAMINE  ON  AVOIDANCE  BEHAVIOUR  IN 
MICE 

247778  04-02 
ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE,  COMPARISON 
WITH  D-AMPHETAMINE. 

248284  04-03 
HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE.  ITS  DELAY  BY 
PSYCHOANALEPTICS. 

248514  04-04 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA  INDUCED 
GNAWING  OF  MICE 

248960  04-02 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 
COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-04 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE.  I.  EFFECT  ON  THE 
MORPHINE  TOLERANCE 

249030  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  II,  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE, 

249031  04-03 


EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION. 

249032  0404 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT 

249223  04-03 
EFFECTS  OF  PENTOBARBITAL  IN  MICE  SELECTIVELY  BRED  FOR  DIFFERENT 
SENSITIVITIES  TO  ETHANOL. 

249261  04-04 
NALTREXONE,  MORPHINE  AND  COCAINE  INTERACTIONS  IN  MICE. 

249269  04-04 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE. 

249274  04-04 
THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  NOREPINEPHRINE  IN 
MICE. 

249283  04-03 
STUDIES  ON  SINGLE  DOSE  TOLERANCE  DEVELOPMENT  TO  MORPHINE  IN 
MICE. 

249288  04-04 

CHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 

PHOSPHODIESTERASE  LEVELS  IN  MICE. 

249294  04-03 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 

TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
BARBITURATE  RESPONSE  IN  IMMUNIZED  MICE. 

249297  04-03 

ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 

TREATED  AND  STRESSED  MICE. 

249299  04-03 

AMANTADINE  DECREASES  D-AMPHETAMINE  STIMULATION  AND 
INCREASES  D-AMPHETAMINE  ANOREXIA  IN  MICE. 

249459  04-03 
HALOPERIDOL  CATALEPSY  IN  GROUPED  AND  ISOLATED  MICE. 

249624  04-04 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS 

249629  04-04 
INTER-GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04-04 
EFFECTS  OF  D-AMPHETAMINE  ON  THE  INCORPORATION  OF  CARBON 
ATOMS  OF  D-GLUCOSE  INTO  THE  BRAINS  OF  DIFFERENTIALLY  HOUSED 
MICE. 

249672  04-04 
ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING  SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6 

249676  04-04 
EFFECTS  OF  DIAZEPAM  ON  SIX  DRUG-INDUCED  LOCOMOTOR 

HYPERACTIVITIES  IN  MICE. 

249677  04  04 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  1  RAINED  AND 

UNTRAINED  RATS  AND  MICE. 

249678  04-04 
INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 

WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04-04 
SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MICE 

SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL, 

250284  04-04 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04  03 
SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 
CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE. 

250940  04-03 
INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  04-04 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE 

251130  04-02 
BEHAVIOR  AND  ENDOCRINE  EFFECTS  OF  3,4,5 
TRIMETHOXY AMPHETAMINE  IN  MALE  MICE, 

251215  04-04 
STUDIES  ON  THE  EFFECTS  OF  HISTAMINERGIC  AGENTS  ON  SEIZURE 
SUSCEPTIBILITY  IN  MICE, 

251983  04-03 
DIRECT  DOPAMINERGIC  ACTION  OF  LISURIDE  HYDROGEN  MALEATE.  AN 
ERGOT  DERIVATIVE,  IN  MICE, 

252028  04-04 


S-205 


Subject  Index 


Psychopharmacology  Abstracts 


Y-MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE,  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04-04 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES 

25271 1  04-03 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04-04 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING.  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485  04-04 
MICROASSAY 

5-HYDROXY-L-TRYPTOPHAN  DECARBOXYLASE  ACTIVITY:  MICROASSAY 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  0303 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY 

252178  04-03 
MICROEIECTRODE 

LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
LI -I    SENSITIVE  MICROELECTRODE. 

235589  02-06 
MICROELECTROPHORETICAllY 

INTERACTION  BETVi/EEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT: 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-03 
MICROINJECTION 

BEHAVIORAL  EFFECTS  IN  RATS  FOLLOWING  INTRASTRIATAL 
MICROINJECTION  OF  MANGANESE, 

226932  01-04 
ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE 
MICROINJECTION  INTO  MOUSE  BRAIN, 

250062  04-04 
MICROINJECTIONS 

CARDIOVASCULAR  EFFECTS  OF  CENTRAL  MICROINJECTIONS  OF 
APOMORPHINE  IN  CATS, 

249033  04-03 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  04-03 
MICROSOMAL 

INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS  -  I,  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER, 

241297  03-03 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES 

243182  04-03 
MICROSOMES 

THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES, 

238683  03-06 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
METHAQUALONE  METABOLISM  BY  RAT  LIVER  MICROSOMES. 

247847  04-03 
N-HYOROXYLATION  OF  l-2,5-DIMETHOXY-4-METHYLPHENYL-2- 
AMINOPROPANE  BY  RABBIT  LIVER  MICROSOMES 

249234  04-05 
MICROWAVE 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  t  ) 
AMPHETAMINE  AND  (  i  OR-)  P-CHLOROAMPHETAMINE. 

239976  0303 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION, 

249286  04-03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRANON  IN  MOUSE  BRAIN  REGIONS, 

253106  04-03 
MIDBRAIN 

EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO, 

237)54  02  03 


D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA, 

239272  03-04 
PHARAAACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III), 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS, 

241390  03-03 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN. 

247214  04-05 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7  j 

DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE  ■ 

LESIONS  IN  THE  RAT.  1 

2521/3  04-03 
MIOODRINE 

THE  INFLUENCE  OF  IMIPRAMINE  ON  CIRCULATORY  EFFECTS  OF 
MIDODRINE. 

251415  04-0: 
MIF-I 

A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS, 

250082  04-0; 
MIGRAINE 

BASIC  TREATMENT  OF  MIGRAINE:  SOME  REFLECTIONS. 

237096  02-11 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  02-11 
MIGRAINE  AND  HYPNOTHERAPY. 

252381  04-11 
MIGRANT 

DOGMATIL  AND  BEHAVIORAL  PROBLEMS  IN  MIGRANT  WORKERS. 

249693  04-11 
MIUTARY 

DIAZEPAM  USE  IN  MILITARY  SICK  CALL. 

240278  03-1; 
MILK 

DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE. 

230424  01-1; 
MIMICKED 

EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHM 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918  02-a 
MINERALOCORTICOIDS 

EFFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS. 

244651  04  O: 
MINIMAL 

EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02-0- 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEINE 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

2.52798  04-11 
MINIMAL-BRAIN-DYSFUNCTION 

CAFFEINE  VERSUS  METHYLPHENIDATE  AND  D-AMPHETAMINE  IN 
MINIMAL-BRAIN-DYSFUNCTION:  A  DOUBLE-BLIND  COMPARISON 

227571  01-11 
TREATMENT  OF  THE  MINIMAL-BRAIN-DYSFUNCTION  SYNDROME  WITH 
PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON). 

230002  01-11 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DYSFUNCTION. 

235322  02-11 
LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03-1 1 
METHYLPHENIDATE  AND  CAFFEINE  IN  THE  TREATMENT  OF  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION. 

245786  04-N 
CONTROLLED  TRIAL  OF  METHYLPHENIDATE  IN  PRESCHOOL  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION, 

247375  04-11 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL-BRAIN-DYSFUNCTION, 

247878  04-11 
MINIMUM 

CURRENT  DETERMINATION  OF  LITHIUM-INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS, 

237110  02-0' 


S-206 


UUME  14,  SUBJECT  INDEX 


Subject  Index 


40R 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 
CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 
UNWANTED  EFFECTS  OF  MINOR  TRANQUILIZERS  AND  HYPNOTICS. 

231992  01-15 
EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHM 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918  02-03 
IROR 
EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  04-06 
>USE 
MISUSE  AND  ABUSE  OF  DIAZEPAM:  AN  INCREASINGLY  COMMON 
MEDICAL  PROBLEM 

229852  01-17 
THE  USE  AND  MISUSE  OF  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

240522  03-17 
rOCHONDRIA 
EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

236521  02-03 
EFFECTS  OF  BETA-HYDROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA. 

238777  03-03 
rOCHONDRIAL 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM   -  EVIDENCE  FOR 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179  04-03 
KED 
THE  USE  OF  TRANQUILIZERS  IN  THE  TREATMENT  OF  MIXED  DRUG 
ABUSE. 

229044  01-11 
PIPERACETAZINE  IN  THE  TREATMENT  OF  MIXED  NEUROTICS. 

247484  04-10 
XTURE 
INFLUENCE  OF  MAGNESIUM  AND  ALUMINUM  HYDROXIDE  MIXTURE  ON 
CHLORDIAZEPOXIDE  ABSORPTION, 

237116  02-13 
XTURES 
DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN  AND 
CHOLINESTERASE  INHIBITORS. 

242737  03-04 
-9022 
MJ-9022:  CORRELATION  BETWEEN  NEUROLEPTIC  POTENTIAL  AND 
STEREOTYPY. 

237903  02-08 

m 

MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
>DAUTIES 
PARTICIPATION  OF  ADRENO.  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-04 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
)OALITY 
A  NEGLECTED  MODALITY  IN  PSYCHIATRIC  TREATMENT  -  THE 
MONOAMINE-OXIDASE  INHIBITORS. 

227825  01-10 
THE  FORGOTTEN  TREATMENT  MODALITY  IN  BIPOLAR  ILLNESS: 
PSYCHOTHERAPY. 

231611  01-09 
)DE 
STUDIES  ON  MODE  OF  ANTAGONISM  BETWEEN  ADRENERGIC  BETA- 
MIMETICS  AND  BETA-BLOCKING  AGENTS  (I).  BETA-BLOCKING  ACTION 
OF  MESCALINE  AND  ITS  DERIVATIVES. 

238563  02-03 
THE  MODE  OF  LIPOFUSCIN  REMOVAL  FROM  HYPOTHALAMIC  NEURONS. 

246587  04-03 
)DEL 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02-11 


BEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS. 

233965  02-03 
MODEL  OF  CAUSAL  CONFRONTATION  IN  INTEGRATIVE  PSYCHOTHERAPY. 

234503  02-14 
THE  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES. 

234699  02-09 
CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL-AMPHETAMINE  AND 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION. 

236235  02-03 
THE  PSYCHEDELIC  MODEL  OF  SCHIZOPHRENIA:  THE  CASE  OF  N,N 
DIMETHYLTRYPTAMINE. 

236750  02-08 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE. 

237976  02-03 
PHARAAACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-13 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
THE  INDOLE  HALLUCINOGEN  MODEL:  IS  IT  WORTH  PURSUING?. 

241872  0308 
A  PRIMATE  MODEL  OF  ACUTE  DYSTONIC  REACTION  TO  NEUROLEPTICS. 

241934  03-05 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D-GLUC0SE-I4C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
(^-)  TRANYLCYPROMINE  IN  AN  ANIMAL  MODEL. 

250376  04  03 
SLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS. 

252230  04-1 1 
MODELS 

DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS    III.  THE 
.  CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE,  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-14 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 
SIDE-EFFECTS  OF  DRUGS  AS  MODELS  OF  ILLNESSES. 

248850  04-15 
MODIFICATION 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG. 

226855  01-03 
MODIFICATION  OF  THE  FRUSTRATION  EFFECT  WITH  DRUGS. 

229487  01-04 
COCAINE  AND  AMPHETAMINE  MODIFICATION  OF  CEREBRAL  ENERGY 
METABOLISM  IN  VIVO. 

230834  01-03 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
MODIFICATION  OF  BETA-PHENYLETHYLAMINE-INDUCED  STEREOTYPED 
BEHAVIOR  BY  NEUROLEPTIC  AGENTS. 

236672  02-04 
MODIFICATION  OF  THE  BEHAVIORAL  EFFECTS  OF  CHOLINOMIMETICS  BY 
PHENTOLAMINE. 

237032  02-04 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-03 
THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DI-N-PROPYLACETATE 

241222  03-03 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH  D.  DISSERTATION). 

241681  03-04 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDROXYDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS 

242200  03-03 
MODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE. 

248289  04-04 


S-207 


Subject  Index 


Psychopharmacology  Abstract* 


MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
MODIFICATIONS 

SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATIONS 
RELATED  TO  STIMULUS  CONTROL. 

231005  01  04 
BEHAVIORAL  EFFECTS  OF  INTRACEREBRALLY  ADMINISTERED 

CATECHOLAMINES  IN  MICE  AND  THEIR  MODIFICATIONS  BY  SOME 
ADRENERGIC  BLOCKING  AGENTS 

237707  02-04 
MODIFICATIONS  OF  EFFECIS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
ANALOGUES  OF  SADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-01 
MODIFIED 

ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01-14 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03-03 
MODIFIERS 

PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-08 
MODIFY 

THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-03 
MODIFYING 

EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-11 
MODITEN 

A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
MODULATION 

CHOLINERGIC  MODULATION  OF  TONIC  IMMOBILITY  IN  THE  RABBIT 
(ORYCTOLAGUS-CUNICULUS). 

231701  01-03 
MODULATION  OF  BRAIN  TRYPTOPHAN  HYDROXYLASE  (TPH)  ACTIVITY  BY 
BRAIN  TRYPTOPHAN  (TP)  CONTENT, 

238677  03-03 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822  03-03 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 

INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA  METHYL-P-TYROSINE 
ON  SCHEDULE  CONTROLLED  PERFORMANCE  IN  RATS 

238844  03  04 
MODULATORS 

MODULATORS  OF  CYCLIC-AMP  SYSTEMS 

229464  01-03 
MOGADON 

NITRAZEPAM  (MOGADON)  DEPENDENCE. 

225699  01-15 
MOLECULAR 

MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINOL 
(R2)  ON  RAT  STRIATUM. 

226851  01  03 
MOLINDONE 

EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS. 

236519  02-03 
MOLLUSC 

THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTION 
POTENTIALS  IN  THE  MOLLUSC  APLYSIA. 

239261  03-03 
MONGOLIAN 

SPONTANEOUS  AND  DRUG  INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 
THE  MONGOLIAN  GERBIL  (MERIONES-UNGUICULATUS). 

241311  03-04 
MONGREL 

CHRONIC  CARDIOVASCULAR  EFFECTS  OF  DELrA9 

TETRAHYDROCANNABINOL  (DELTA9  THC)  IN  THE  MONGREL  DOGS, 

238810  03  03 
MONITORING 

PLASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  Oil  6 
MONITORING  OF  LITHIUM  TREATMENT    GUIDELINES  BASED  ON 
PHARMACOKINETIC  CONSIDERATIONS 

236806  02-16 


i 

31 -T) 


MONKEY 

REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  Ol-O; 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUA 
DISCRIMINATION  PERFORMANCES. 

227384  01-0 
FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE-DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-1 

EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC  GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  03-0 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-C 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-C 
THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYDROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS, 

239087  03-C 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241 109  03-C 
MAZINDOL  SELF-ADMINISTRATION  IN  THE  RHESUS  MONKEY. 

242747  04-C 
EFFECTS  OF  DOPAMINE  RECEPTOR  BLOCKADE  ON  SELF-STIMULATION  IN 

THE  MONKEY. 

242748  04-C 
INTRAGASTRIC  SELF-ADMINISTRATION  OF  PSYCHOACTIVE  DRUGS  BY 

THE  RHESUS  MONKEY. 

249004  04-C 
THE  REGIONAL  DISTRIBUTION  OF  A  MORPHINE-LIKE  FACTOR  ENKEPHALI 
IN  MONKEY  BRAIN. 

252219  04-( 

MONKEYS 

LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01-( 
EFFECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH-TO-SAMPLE 
TASK  IN  MONKEYS. 

230577  01 -( 
BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOPS).  AETHIOPS). 

230869  01-( 
BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 

COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02-( 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03-( 
INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03-( 
PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03-( 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEY' 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-( 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECT! 
OF  DOSE    SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-( 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE-DEPENDEN' 
RHESUS  MONKEYS. 

240019  03-1 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 

UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

241250  03-1 

BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX 

244684  04-( 
FURTHER  STUDIES  ON  SELF  ADMINISTRATION  OF  ANTIPYRETIC 

ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WIT 
CODEINE  IN  RHESUS  MONKEYS. 

246855  04-1 
EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROM 
IN  RHESUS  MONKEYS. 

247889  04-1 


S-208 


i 


ILUME  14,  SUBJECT  INDEX 

PROltST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM^ 

248437  04-04 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICAL 
STATUS  OF  RHESUS  MONKEYS 

249003  04-05 
KETOCYCLAZOCINE:  BEHAVIORAL  EFFECTS  IN  PIGEONS  AND  MONKEYS. 

249246  04-04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 
MONKEYS  MAINTAINED  ON  NALTREXONE. 

249270  04-04 
NOAMINE 

A  HISTOCHEMICAL  STUDY  ON  THE  CENTRAL  EFFECT  OF  MONOAMINE 
PRECURSORS. 

229068  01-03 
NEUROLEPTICS  AND  ANTIDEPRESSANTS  ON  CENTRAL  MONOAMINE 
NEURONS. 

229483  01-03 

THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS 

230824  01-09 
THE  SELECTIVE  EFFECTS  OF  ALPHA-METHYL  AROMATIC  AMINO-ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-03 
EFFECT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02-09 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
EFFECTS  OF  ANTIHISTAMINIC  DRUGS  ON  FELINE  BRAIN  MONOAMINE 
METABOLISM. 

238838  03-03 
ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN 

241366  03-03 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  CEREBRAL  MONOAMINE 
TURNOVER. 

241392  03-03 
EFFECTS  OF  1 ,2-BENZISOXAZOLE-3-ACETAMIDOXIME  HYDROCHLORIDE 

(PF-257)  ON  THE  CNS  WITH  SPECIAL  REFERENCE  TO  MONOAMINE 
METABOLISM. 

241393  03-03 

THE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 

AND  MONOAMINE  SYNTHESIS. 

241472  03-17 

MONOAMINE  OXIDASE  ACTIVE  SITE;  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (14C)  SELECTIVE  INHIBITORS. 

241931  03-03 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  (  O  AMPHETAMINE  AND  RELATED  COMPOUNDS. 

246149  04-03 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY 

248288  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS.  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE 

250937  04  03 
MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS 

251063  04-04 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  0403 

ONOAMINE-OXIDASE 

A  NEGLECTED  MODALITY  IN  PSYCHIATRIC  TREATMENT      THE 
MONOAMINE  OXIDASE  INHIBITORS. 

227825  Olio 
PHARMACOLOGIC  STUDIES  OF  NARCOLEPSY  INVOLVING  SEROTONIN, 
ACETYLCHOLINE,  AND  MONOAMINE-OXIDASE.  (UNPUBLISHED  PAPER). 

232324  01  11 
SOME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE  OXIDASE 

233946  02-01 


Subject  Index 


THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN. 

233947  02-03 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-03 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE-OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK. 

237923  02  03 
THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 
MONOAMINE-OXIDASE  IN  MAN. 

237927  02-13 
EFFECT  OF  MONOAMINE  OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-03 
SYNTHESIS  OF  SUBSTITUTED  THI0BENZ0XAZ0LES/BENZ0THIAZ0LE5: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY 

239661  03-03 
QUIPAZINE-  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM,  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-03 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
MONOAMINE  OXIDASE  ACTIVE  SITE,  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (14C)  SELECTIVE  INHIBITORS. 

241931  03-03 
NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 
OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  04-03 
IS  THERE  AN  INCREASE  IN  MONOAMINE  OXIDASE  ACTIVITY  IN 

DEPRESSIVE  ILLNESS?. 

245233  04-13 

INTERACTIONS  OF  LEVODOPA  WITH  INHIBITORS  OF  MONOAMINE 
OXIDASE  AND  L-AROMATIC  AMINO  ACID  DECARBOXYLASE. 

245647  04-13 
MONOAMINE-OXIDASE       III:  FURTHER  STUDIES  OF  INHIBITION  BY 
PROPARGYLAMINES. 

247020  04-03 
A  COMPARISON  OF  6,7  DIHYOROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  IN 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121  04-08 
EFFECTS  OF  MONOAMINE  OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-03 
A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE-OXIDASE  INHIBITORS 
(MAOIS). 

249308  04-03 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2  PHENYLETHYLAMINE  (PEA). 

249310  04-03 
PROPRANOLOL  INHIBITS  RAT  BRAIN  MONOAMINE-OXIDASE. 

250333  04-03 
PREFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04-03 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE  OXIDASE.  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  0410 
THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION 

253643  04-04 

MONOAMINE-OXIDASES 

MONOAMINE  OXIDASES  OF  THE  RAT  CARDIOVASCULAR  SYSTEM. 
(UNPUBLISHED  PAPER). 

227783  01  03 

MONOAMINERGIC 

MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE  NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS 

231251  01  04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP 

241388  03  03 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 

MODALITIES, 

241980  03  03 


S-209 


Subject  Index 


Psychopharmacology  Abstrat 


.■■<1 


MONOAMINES 

MONOAMINES  AND  MENIAL  ILLNESS 

229489  01-03 
NEUROPHARMACOLOGY  OF  BRAIN  MONOAMINES  AND  BEHAVIOR. 

229499  01-04 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 
PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE. 

230841  01-03 
NEUROPSYCHOPHARMACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

233941  02-03 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA  PIGS,  AND  RABBITS. 

233962  02-03 
NEUROPSYCHOPHARMACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

237829  02-17 
EFFECTS  OF  6  HYDROXYDOPA  AND  5,6  OIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAAAINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

2) 
NEUROCHEMICAL  STANDPOINT 

241361  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 
BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 
EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  ON  THE  METABOLISM  OF 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  03-04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-04 
TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04-02 
MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW. 

253407  04-03 
MONOCHLORIMIPRAMINE 

CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02-10 
MONOHYDROXYACID 

CHARACTERIZATION  OF  THREE  MONOHYDROXYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAI -TETRAHYDROCANNABINOL 
IN  MOUSE  LIVER. 

243787  04-03 
MONOMETHOXYAMPHETAMINES 

EFFECTS  OF  D-AMPHETAMINE,  MONOMETHOXYAMPHETAMINES  AND 
MESCALINE  ON  FIXED-INTERVAL  RESPONDING  IN  RATS. 

249275  04-04 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-03 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE 

253107  04  03 
PHARMACOLOGICAL  EVIDENCE  FOR  THE  CENTRAL  SEROTONERGIC 

EFFECTS  OF  MONOMETHOXYAMPHETAMINES 

253108  04-04 
MONOPHOSPHATE 

EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3.5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 


CENTRAL  GAMMA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHA 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  QA 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  a< 

MONOPOLAR 

INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  05 
MONOSYMPTOMATIC 

PIMOZIDE  IN  THE  TREATMENT  OF  MONOSYMPTOMATIC 
HYPOCHONDRIACAL  PSYCHOSIS. 

239014  0; 
MOOD 

BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAN, 

229440  01 
THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE. 

239010  03 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALO 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATI 
AND  MOOD. 

239042  02 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  II:  ANTIMANIC  A 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECEK 
ADVANCES.  (UNPUBLISHED  PAPER) 

244574  04 
MOOD-ALTERING 

ADVERSE  REACTIONS  ASSOCIATED  WITH  MOOD-ALTERING  DRUGS. 

231995  01 
M0PEG-S04 

EFFECT  OF  AMPHETAMINE  AND  FENFLURAMINE  ON  BRAIN 
NORADRENALINE  AND  M0PEG-S04. 

237740  02 
MORBID 

A  PRACTICAL  CLASSIFICATION  OF  MORBID  ANXIETY. 

251157  04 
MORBIDITY 

AMPHETAMINE-INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAI 
DIFFERENCES,  POLYDRUG  EFFECTS  AND  MECHANISM. 

238789  03 
BARBITURATE  INTOXICATION:  MORBIDITY  AND  MORTALITY. 

240843  03 
CULTURE,  MORBIDITY,  AND  THE  EFFECTS  OF  DRUGS. 

252991  04 
MORNING 

THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04 
MORPHINE 

MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINI 
(R2)  ON  RAT  STRIATUM. 

226851  01 
ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN. 

226870  01 
PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL. 

227132  01 
CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01 
DOPAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS 

227703  01 
ISOLATION  OF  AN  ENDOGENOUS  COMPOUND  FROM  THE  BRAIN  WITH 
PHARMACOLOGICAL  PROPERTIES  SIMILAR  TO  MORPHINE. 

227774  01 
MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  01 
DIFFERENTIATION  BY  MORPHINE  OF  TWO  TYPES  OF  AGGRESSIVE 
BEHAVIOR  IN  THE  CONVICT  CICHLID  (CICHLASOMA- 
NIGROFASCIATUM). 

230865  01 


S-210 


4 


UME  14,  SUBJECT  INDEX 

lEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVITIES     . 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  01  03 
MORPHINE  ANALGESIA:  BLOCKADE  BY  RAPHE  MAGNUS  LESIONS. 

23261 1  02-03 
EDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT 

232617  02-03 
,SCENDING  CATECHOLAMINE  SYSTEMS  AND  MORPHINE  ANALGESIA. 

232915  0203 
FFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  0204 
FFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

237099  02-03 
FFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG-INDUCED  HYPOTHERMIA 

IN  MICE  AND  RATS. 

237100  02-03 
:HANGES  in  fixed-interval  behavior  during  CHRONIC  MORPHINE 

TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
tESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT;  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE 

237158  02-03 
IFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS  -  ACUTE  MORPHINE  ADMINISTRATION. 

237736  02-03 
;FFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS   -  CHRONIC  MORPHINE  ADMINISTRATION. 

237737  02-03 
IFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 

BEHAVIOR  OF  THE  SQUIRREL-MONKEY. 

237754  02  04 
\NALGETIC  EFFECTS  OF  LANTHANUM:  CROSS  TOLERANCE  WITH 
MORPHINE. 

237870  02  03 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE 

238687  03  04 
EFFECTS  OF  MORPHINE  AND  BENZODIAZEPINES  ON  LIMBIC  SYSTEM. 

238702  03-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID  LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE- 
CYCLASE  AND  ON  CYCLIC-GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA, 

238739  03-03 
ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 
ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  0304 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MiORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS. 

2398^1  03-03 
COMPARISON  OF  WITHDRAWAI  PRECIPTATING  PROPERTIES  OF  vXrIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 
GNAWING  OF  RATS. 

239860  03-04 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 
PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981  03-04 
DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PHD 
DISSERTATION). 

240934  03-03 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYOOPAMINE.  (PH.D.  DISSERTATION). 

241100  03-03 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  1,  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
AMT  CATALEPSY  AND  HYPOKINESIA:  INTERACTION  WITH  MORPHINE 

AND  COCAINE 

241224  0304 


Subject  Index 

INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  fOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES 

241229  03  04 
MORPHINE    PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS 

241250  03-04 
THE  EFFECT  OF  MORPHINE  ON  THE  EEG  OF  THE  HYPOTHALAMUS  IN  THE 
RAT. 

241328  03  03 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE. 

241338  03-03 
EFFECTS  OF  MORPHINE  ON  5  HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  IN 
THE  RAT  BRAIN  (III) 

241402  03-03 

EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FROG 

SPINAL  CORD. 

241922  03-03 
THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAT 
ADRENAL  MEDULLA. 

243779  04-03 

ENZYAAATIC  CONVERSION  OF  MORPHINE  TO  PSEUDOMORPHINE. 

243780  04-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 

RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS 

244215  04-04 

GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04-04 
PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04-04 
HUMAN  SLEEP  DURING  CHRONIC  MORPHINE  INTOXICATION. 

246304  04-13 
ACUTE  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES.  GROWTH 
HORMONE  AND  CORTICOSTERONE. 

246661  04-03 
CHRONIC  MORPHINE  EFFECTS  ON  REGIONAL  BRAIN  AMINES,  GROWTH 

HORMONE  AND  CORTICOSTERONE 

246662  04-03 
CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 

BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  0402 
EFFECT  OF  MORPHINE  ON  A  DEPOLARISING  DOPAMINE  RESPONSE. 

246998  04  03 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 
HALOPERIDOL. 

248274  04-03 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

2489/9  04-03 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADREN.a.LINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE.  I.  EFFECT  ON  THE 
MORPHINE  TOLERANCE, 

249030  04  03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE    II.  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE. 

249031  04-03 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE:  III.  EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION. 

249032  04-04 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 

FOLLOWING  BRAIN  AMINE  DEPLETION, 

249138  04-04 
EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 
NUCLEUS  RAPHE  DORSALIS. 

249249  04-03 
THE  INCIDENCE  OF  SELF  MUTILATION  IN  MORPHINE  TOIERANT  SPRAGUE 
OAWLEY  MALE  RATS 

249253  04-04 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION 

249268  04-03 
NALTREXONE    MORPHINE  AND  COCAINE  INTERACTIONS  IN  MICE 

249269  04-04 


5-211 


Subject  Index 


Psychopharmacology  Abstr 


€S 


NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA  -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
STUDIES  ON  SINGLE  DOSE  TOLERANCE  DEVELOPMENT  TO  MORPHINE  IN 
MICE. 

249288  04-04 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS 

249291  04-03 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 

GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE. 

249292  0403 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 

TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF-STIMULATION 
FACILITATED  BY  MORPHINE  AND  (-f  )  AMPHETAMINE. 

249486  04-03 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  04-03 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION 

250019  04-04 
ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE 
MICROINJECTION  INTO  MOUSE  BRAIN. 

250062  04-04 
MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 
THERMOSTATS. 

250078  04-03 
MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE:  INFLUENCE  OF 

CHOLINERGIC  AGONISTS  AND  ANTAGONISTS. 

250079  04-04 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE,  NALOXONE  AND 

NALORPHINE  IN  THE  SQUIRREL-MONKEY  AND  THE  PIGEON. 

250113  04-04 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 

POTENCIES  OF  MORPHINE  ANTAGONISTS. 

250354  04-04 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION 

251070  04-03 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT 

251400  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
CROSS  TOLERANCE  BETWEEN  MORPHINE  AND  OTHER  ANALGESICS. 

251408  04-17 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 
ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-03 
REM  SLEEP  DISTRIBUTIONS  IN  POSIADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS, 

251533  04-04 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT 

251975  04  04 
DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS. 

251978  04-04 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE. 

251989  04-04 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF  STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS 

252033  04-03 
MORPHINE-DEPENDENCE 

CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE- 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS. 

250114  04-03 
MORPHINE-DEPENDENT 

DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC- 
INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINE-DEPENDENT 
RATS, 

227702  01-04 


TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINEDEPENI 
RHESUS  MONKEYS. 

240019 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCEI 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEM 
OF  DOPAMINE. 

245601 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9-THC  DURING 
ABSTINENCE  IN  MORPHINE-DEPENDENT  RATS. 

249001 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONi 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORP 
DEPENDENT  MACACA-MULATTA. 

249267 
MORPHINE-INDUCED 

MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAV 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDR/ 
IN  RATS. 

249485 
MORPHINE-INDUCED  ROTATION  IN  NAIVE,  NONLESIONED  RATS. 

252209 
MORPHINE-LIKE 

THE  REGIONAL  DISTRIBUTION  OF  A  MORPHINE-LIKE  FACTOR  ENKEF 
IN  MONKEY  BRAIN, 

252219 
MORPHINES 

MORPHINES  PROCONVULSANT  ACTION:  IMPORTANCE  OF  ENDOGEN 
NOREPINEPHRINE. 

248880 
MORPHOLOGICAL 

NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT. 

226399 
DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS 

244638 
MORTALITY 

BARBITURATE  INTOXICATION:  MORBIDITY  AND  MORTALITY. 

240843 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECl 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428 
MOTHER 

MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTEI 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LAT 
PREGNANCY. 

243085 
MOTILITY 

TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTC 
ACTIVITY. 

2271 3C 
MOTIVATED 

EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR, 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THI 
DOG. 

240916 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVI 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486 
MOTIVATION 

INFLUENCE  OF  PSYCHOPHARMACEUTICALS  ON  ACHIEVEMENT 
MOTIVATION:  III.  DIFFERENTIAL  INFLUENCE  ON  CONTENT  CATEGI 

240644 
MOTIVATIONAL 

EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPA^ 
PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981 
MOTONEURONE 

THE  INTERPRETATION  OF  RESPONSES  OF  MOTONEURONE  FIELD 
POTENTIALS  TO  5-HYDROXYTRYPTAMINE. 

241923 
MOTONEURONS 

PENTOBARBITAL:  ACTION  ON  FROG  MOTONEURONS. 

247513 
MOTOR 

PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANC 


S-212 


ME  14,  SUBJECT  INDEX 


Subject  Index 


'ATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
0M8INATI0N  WITH  AMANTADINE. 

226349  01  14 
iS  Of  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
)OSE  Of  THIOBARBITURATE  IN  RHESUS  MONKEYS, 

228139  01-04 
THE  DIFfERENTIAL  DIAGNOSIS  Of  ACUTE  EXTRAPYRAMIDAL  MOTOR 
JISTURBANCES  IN  CHILDHOOD:  CASUISTIC  ACCOUNT. 

234291  02-11 
ECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
!ATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
ONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
1IZ0PHRENIA:  RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 
ONTROL,  AND  FEATURE  EXTRACTION. 

238464  02-08 
ECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
■REATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
DENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
lAOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
.ATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
'ETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
"HE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
riONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
NTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
:REASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
)-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
lUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELTA9- 
FETRAHYDROCANNABINOL  AND  PILOCARPINE. 

244682  04-04 
JFLURAMINE-INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY:  AN  INDIRECT  5-HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04-04 
FFEINE  AND  CHLORDIAZEPOXIDE:  EFFECTS  ON  MOTOR  ACTIVITY  IN 
LHE  CHRONIC  THALAMIC  RAT. 

246388  04-04 

e  effect  of  amphetamine  pretreatment  on  the  amphetamine- 
nduced  changes  in  motor  activity  and  brain 
:atecholamines  in  mice. 

249274  04-04 
AOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
response  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
■ECTS  OF  HARMINE  AND  BRAIN  LESIONS  ON  APOMORPHINE  INDUCED 
WOTOR  ACTIVITY. 

250058  04-03 
MBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 
OR  MAZINOOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
PORTANCE  OF  0-METHYLATION  IN  DOPAMINE-INDUCED  MOTOR  AND 
BEHAVIORAL  PHENOMENA. 

251143  14-04 

riNG 

■FERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-04 

■ECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  MOUSE. 

225569  01-04 
E  EFFECT  OF  OUABAIN  AND  DIGITOXIN  ON  HEXOBARBITONE  SLEEPING 
TIME  IN  THE  MOUSE. 

225574  01-03 
GULATION  OF  5-HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
BRAIN  BY  ADRENAL  GLUCOCORTICOIDS 

226401  01-03 
PLETION  OF  S-ADENOSYL-L-METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS. 

226850  01  03 
\AILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
FECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  MOUSE  SPLEENS. 

226944  01-05 
iPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-03 


NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 
RUBIDIUM  TREATMENT. 

230817  01-03 
DIPHENYLHYDANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTO/WA  CELLS. 

232917  02-03 
DIFFERENTIAL  BEHAVIORAL  AND  BIOCHEMICAL  EFFECTS  OF  REGIONAL 
INJECTION  OF  CYCLOHEXIMIDE  INTO  MOUSE  BRAIN. 

235320  02-04 
FURTHER  STUDIES  ON  THE  CHLORPROAAAZINE-INDUCED  PROLONGATION 
OF  THE  DISAPPEARANCE  OF  MESCALINE  FROM  MOUSE  TISSUES. 

235670  02-03 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
CANNABIS  RESIN  AND  SEXUAL  BEHAVIOUR  IN  THE  LABORATORY 
MOUSE. 

237715  02-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  THE  LABORATORY  MOUSE  AND  RAT 

237727  02-04 
MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  THE 
ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  02-03 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN. 

237922  02-03 
PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 
NEUROBLASTOMA  CELLS. 

238692  03-03 
THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE  IN 
MOUSE  BRAIN. 

238765  03-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA-AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
AUTORADIOGRAPHIC  STUDIES  ON  THE  DISTRIBUTION  OF  H3- 
TRIMETHOXY-BETA-PHENYLETHYLAMINE  IN  THE  MOUSE. 

239855  03-03 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  03-03 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  (  +  )  AMPHETAMINE. 

241257  03-03 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE. 

241338  03-03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES. 

241416  03-03 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-04 
PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE. 

242746  04-04 
CHARACTERIZATION  OF  THREE  MONOHYDRO,XYACID  AND  TWO 

DIHYDROXYACID  METABOLITES  OF  DELTAI -TETRAHYDROCANNABINOL 
IN  MOUSE  LIVER. 

243787  04-03 
EFFECTS  OF  ARECOLINE  AND  CHOLINESTERASE  INHIBITORS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  IN  MOUSE  BRAIN. 

246389  04  03 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  04-05 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN 

249265  04-05 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS. 

249272  04-04 


S-213 


Subject  Index 


Psychopharmacology  Abstra 


ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOUSE 
CEREBRAL  CORTEX  AND  I  UNO  FOI  LOWING  MICROWAVE 
IRRADIATION, 

249286  0403 
EFFECT  OF  ACUTE  AND  CHRONIC  MORPHINE  ADMINISTRATION  ON  BRAIN 
GLUTAMATE  (GLU)  AND  GAMMA-AMINOBUTYRATE  (GABA)  LEVELS  IN 
THE  MOUSE 

249292  04-03 
ANALGESIA  AND  HYPERREACTIVITY  FOLLOWING  MORPHINE 
MICROINJECTION  INTO  MOUSE  BRAIN. 

250062  0404 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D-AMPHETAMINE  AND 
PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

250112  04  04 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS. 

250354  04-04 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE. 

250656  04-03 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO 

251175  04-03 
EFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS  INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN. 

251416  04-03 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO 

251432  04  03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION;  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 
MOUSE-KIIUNG 

CHLORDIAZEPOXIDE  AND  DIAZEPAM-INDUCED  MOUSF-KILI ING  BY  RATS. 

230838  01-04 
CARBACHOL  ELICITED  MOUSE  KILLING  BY  RATS:  CIRCADIAN  RHYTHM 
AND  DOSE  RESPONSE. 

238006  02-04 
EFFECTS  OF  IMIPRAMINE.  D  AMPHETAMINE.  AND  IRIPELENNAMINE  ON 
MOUSE-KILLING  AND  FROG-KILLING  BY  THE  RAT. 

243346  04  04 
MOUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELTA9- 
TETRAHYDROCANNABINOL  AND  PILOCARPINE 

24^682  04-04 
INTERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 

CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  RATS. 

248394  04-04 
RAT  STRAIN  DIFFERENCES  IN  PILOCARPINE  INDUCED  MOUSE-KILLING 

250008  04-04 
MOVEMENT 

EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 
DIE  THYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHIORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT. 

249278  04-04 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS. 

249281  04  02 
TETRABENAZINE  IN  THE  TREATMENT  OF  HYPERKINETIC  MOVEMENT 
DISORDERS 

251961  04  11 
MOVEMENTS 

INVOIUNTARY  MOVEMENTS  CAUSED  BY  PHFNYTOIN  INTOXICATION  IN 
EPIIEPTIC  PATIENTS. 

225890  01-15 
METHADONE-INDUCED  BEHAVIORAl  CHANGES;  CIRCULAR  MOVEMENTS, 
AGGRESSION    AND  ELECTROPHYSIOLOGICAL  ASPECTS. 

229286  01-04 
SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ,  AND 
SECOBARBITAI 

246303  04  14 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  IHE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT, 

250087  04-02 
A  METHOD  FOR  EXPLAINING  DYSKINETIC  MOVEMENTS      A  FILM 
PRESENTATION 

253034  04  15 
MOVING 

CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS 

237270  02  06 
MUCOSA 

IXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L  NOREPINEPHRINE 
BY  THE  RAT  DUODENAI  MUCOSA 

241299  03-03 


MUITICENTER 

AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS:  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE 

253052  0 
MUITICENTRE 

A  CONTROLLED  MULTICENTRE  THERAPEUTIC  TRIAL  OF  VILOXAZINE 
(VIVALAN), 

227216 C 
MULTICENTRE  STUDIES  WITH  VILOXAZINE  (VIVALAN). 

227219 C 
MULTICENTRE  STUDIES  IN  GENERAL  PRACTICE. 

227225  C 
COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE  BLIND  MULTICENTRE  TRIAL, 

251118( 
MUITICENTRIC 

THE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMEN 
OUTPATIENTS  (A  Mill  TICENIRIC  STUDY). 

252448 ( 
MULTIDRUG 

PIRIBEDIL:  ITS  SYNERGISTIC  EFFECT  IN  MULTIDRUG  REGIMENS  FOR 
PARKINSONISM 

251651  ( 
MULTIFACTORIAL 

ON  THE  MULTIFACTORIAL  TREATMENT  OF  CHRONIC  HEADACHES, 

238866  ( 
MULTILABORATORY 

AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION 
PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION 

229439  I 
MULTIPLE 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  I 
ASSISTING  MULTIPLE  DRUG  ADDICTS.  PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY 

237095  I 
A  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESS 
ANXIETY  STATES. 

239938  I 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDINC 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

2412501 
PHARMACOKINETICS  OF  METHOTRIMEPRAZINE  AFTER  SINGLE  AND 
MULTIPLE  DOSES. 

250422  1 
MULTIPLE-UNIT 

LATERAL  GENICULATE  MULTIPLE  UNIT  ACTIVITY  RELATED  TO  METR/ 
POTENTIATED  AFTER  DISCHARGES. 

231719 
MULTISPECTRAL 

AN  EXAMPLE  OF  EUROPEAN  MULTICENTER  TRIALS:  MULTISPECTRAL 
ANALYSIS  OF  CLOZAPINE. 

253052 

MURICIDE 

EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURIC 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367 
EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  ON  THE  METABOLISM 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
01  FACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373 
MUS-MUSCULUS 

EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHEIAMINE  ON  INTER  MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS). 

253485 
MUSCARINIC 

BIOCHEMICAL  IDENTIFICATION  OF  THE  MAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR. 

227400 
INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICA 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS. 

239977 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR 

249301 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIM( 
AND  CHIORPROMAZINF  METABOLITES, 

252515 
MUSCLE 

CONTRA!  ruk  (FTFCT  OF  BARBITURATES  ON  SMOOTH  MUSCLE. 

230454 


S-214 


JME  14,  SUBJECT  INDEX 


Subject  Index 


HE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM^ 

230859  01-03 
EUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES^ 

243482  04-03 
(ELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-03 
JRTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 
PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04-03 
IFFERENTIAL  EFFECTS  OF  ETHYLALCOHOL  ON  CONTRACTION  OF 
ARTERIAL  SMOOTH  MUSCLE. 

251905  04-03 
IFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAL  SMOOTH  MUSCLE. 

253113  04-03 
LES 

=FECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
ULAR 

KCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 
ULARIS 

HE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  04-03 
AL 
ATECHOLAMINES,  DRUGS,  AND  BEHAVIOR:  MUTUAL  INTERACTIONS. 

233968  02-04 
THENIA-GRAVIS 

REATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA- 
GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  04-07 
lASIS 
ENTRAL  ACTION  OF  AMPHETAMINE-INDUCED  MYDRIASIS  IN  THE  DOG. 

238772  03-03 
310 

AYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
lARDIAL 
TRESS  AND  MYOCARDIAL  INFARCTION. 

22971501   11 
iNTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 
MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY. 

253684  04-11 

:iONus 

NTENTION  MYOCLONUS:  SUCCESSFUL  TREATMENT  WITH  CLONAZEPAM. 

237825  02-11 
ETYLATION 

XTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
ETYLTRANSFERASE 

)IURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE 

243795  04-03 
YINOROXYMORPHONE 

:ONTINGENT  NALOXONE  (N-ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01-14 
YlALKYl 

NHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
I:  N  ARYLALKYL  AND  N-ARYLOXYALKYL  DL  AMPHETAMINES  AND 
RELATED  COMPOUNDS. 

246316  04-03 
YIOXYAIKYI 

NHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
I;  N  ARYLALKYL  AND  N-ARYLOXYALKYL  DL  AMPHETAMINES  AND 
RELATED  COMPOUNDS, 

246316  04-03 
YIOXYAIKYIPHENTERMINES 

NHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
II:  N-ARYLOXYALKYLPHENTERMINES.  QUATERNARY  D-AMPHETAMINES, 
AND  3-ARYLOXYPROPYLAMINES. 

248637  04-01 


N-BUTYUMIDIAZOLE-2-THIOL 

PHENYLETHANOLA^\INE-N-METHYLTRANSFERASE:  S-METHYLATION  OF  N- 
BUTYLIMIDIAZOLE-2-THIOL. 

238762  03-01 
N-DESMETHYLDIAZEPAM 

GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROAAAZINE, 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM. 

237750  02-06 
N-ETHYLAMPHET  AMINE 

FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE-DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-04 
THE  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 

NOREPINEPHRINE  BY  N-ETHYLAMPHETAMINE  AND  FENFLURAMINE. 

238688  03-03 
N-HYDROXYAMPHETAMINE 

N-HYDROXYAMPHETAMINE:  A  MAJOR  METABOIITE  OF  AMPHETAMINE  IN 
RABBIT  LIVER  EXTRACT. 

238682  03-03 
N-HYDROXYETHYL-PYRROLIDINIUM 

EFFECTS  OF  N-HYDROXYETHYL-PYRROLIDINIUM  METHIODIDE,  A  CHOLINE 
ANALOGUE,  ON  PASSIVE  AVOIDANCF  BEHAVIOUR  IN  MICE. 

245594  04-04 
N-HYDROXYIATION 

N  HYDROXYLATION  OF  l-2,5-DIMETH0XY-1  METHYLPHENYL-2- 
AMINOPROPANE  BY  RABBIT  LIVER  MICROSOMES. 

249234  04  05 
N-METHYIATION 

N-METHYLATION  OF  1-METHYLTRYPTAMINFS  BY  INDOLETHYLAMINE  N- 
METHYLTRANSFERASE. 

249188  04-01 
N-METHYITRANSFERASE 

N-METHYLATION  OF  1-METHYLTRYPTAMINES  BY  INDOLETHYLAMINE  N- 
METHYLTRANSFERASE. 

249188  04-01 
NA^ 

INCREASED  ERYTHROCYTE  NA  i    PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THFRAPY. 

253137  04-13 
NAA 

ANTAGONISMS  BY  NEUTRAL  AMINO  ACIDS  (NAA)  OF  THE  HYPOTHERMIC 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-03 
NA8ILONE 

CLINICAL  PHARMACOLOGY  OF  NABILONE,  A  CANNABINOL  DERIVATIVE. 

248628  04-12 
NADH 

EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM  -  EVIDENCE  FOR 
IHE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179  04-03 
NAFTIDROFURYL 

DOUBLE  BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS. 

229368  01-11 
NAIVE 

MORPHINE-INDUCED  ROTATION  IN  NAIVE,  NONLESIONED  RATS. 

252209  04-04 
NAK-ATPASE 

BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 

238812  03-03 
INCREASED  ERYTHROCYTE  NA  i    PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04  13 
NAIORPHINE 

TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE  DEPENDENT 
RHESUS  MONKEYS. 

240019  03-04 
DRUG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NALORPHINE: 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISM.  (PH.D. 
DISSERTATION). 

240934  03-03 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE.  NALOXONE  AND 
NALORPHINE  IN  THE  SQUIRREL-MONKEY  AND  THE  PIGEON 

250113  04-04 
NALOXONE 

CONTINGENT  NALOXONE  (N-ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT 

226901  01-14 
PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL 

227132  01-04 
SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01-03 


S-215 


Subject  Index 


Psychopharmacology  Abstract 


PREVENTION  OF  REVERSAL  OF  OPERANT  bEHAViORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENi  WITH 
MORPHINE  BEFORE  OR  AFTER  NAI  OXONE 

238687  03-04 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT, 

238713  03-04 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03-11 
DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN. 

240014  03-04 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS 

241250  03-04 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04  03 
NALOXONE  BLOCKADE  OF  MORPHINE  ANALGESIA   -  A  DOSE  EFFECT 
STUDY  OF  DURATION  AND  MAGNITUDE. 

249271  04-02 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  04-03 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE,  NALOXONE  AND 
NALORPHINE  IN  THE  SQUIRREL-MONKEY  AND  THE  PIGEON. 

250113  04  04 
REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS 

251533  04-04 
THE  STRUCTURE  ACTION  RELATIONSHIP  AND  KINETICS  OF  SOME 
NALOXONE  AND  NALTREXONE  DERIVATIVES. 

252223  04-03 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04-04 
NALOXONE-INDUCED 

EFFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

237099  02-03 
NALTREXONE 

REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION, 

249268  04  03 
NALTREXONE,  MORPHINE  AND  COCAINE  INTERACTIONS  IN  MICE, 

249269  04-04 
COMPARISON  OF  THE  EFFECTS  OF  COCAINE  AND  AMPHETAMINE  IN 

MONKEYS  MAINTAINED  ON  NALTREXONE, 

249270  04-04 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 

NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-03 
THE  STRUCTURE-ACTION  RELATIONSHIP  AND  KINETICS  OF  SOME 
NALOXONE  AND  NALTREXONE  DERIVATIVES, 

252223  04-03 
NAPHAZOIINE 

A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE 

246148  04-04 
NARCOIEPSY 

PHARMACOLOGIC  STUDIES  OF  NARCOLEPSY  INVOLVING  SEROTONIN, 
ACETYLCHOLINE,  AND  MONOAMINE-OXIDASE.  (UNPUBLISHED  PAPER), 

232324  01-11 
NARCOLEPSY:  REM  SLEEP  SUPPRESSION  BY  L-DOPA, 

240657  03- II 
NARCOSIS 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

235511  02-04 
NARCOSIS  INTRODUCTION  WITH  FLUNITRAZEPAM  IN  ACCIDENT 
SURGERY, 

244045  04-11 
ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES, 

246821  04-05 


POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES, 

248513  04- 
THE  POTENTIATION  OF  BARBITURATE-INDUCED  NARCOSIS  BY 
PROCARBAZINE. 

250109  04- 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL 
CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04- 
NARCOTIC 

POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848  01- 
CONTINGENT  NALOXONE  (N-ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01- 
EFFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  02- 
SCHEDULE-INDUCED  ORAL  NARCOTIC  SELF-ADMINISTRATION:  ACUTE 

AND  CHRONIC  EFFECTS. 

233293  02- 
EFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 

BEHAVIOR  OF  THE  SQUIRREL-MONKEY 

237754  02- 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMW 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID  LIKE 
SUBSTANCE  IN  THE  RAT 

238713  03- 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03- 
A  BEHAVIORAL  PARADIGM  FOR  THE  EVALUATION  OF  NARCOTIC 
ANTAGONISTS. 

239941  03- 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECT 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN, 

240018  03- 
GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACID-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04- 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04- 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE  Al 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPHINI 
DEPENDENT  MACACA  MULATTA, 

249267  04- 
CHARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS, 

249289  04- 
THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX:  RELATION  TO 
ANALGESIC  ACTIVITY, 

250355  04- 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04- 
ON  THE  ABILITY  OF  NARCOTIC  ANTAGONISTS  TO  PRODUCE  THE 
NARCOTIC  CUE 

251429  04- 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04- 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-1 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  04-1 
NARCOTICS 

INTERACTIONS  OF  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 
BLOOD  VESSELS, 

229474  01-1 
NASSAU 

FUGUE  STATES  -  EPILEPSY   -  MEDICATION  -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V,  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT   AUGUST  1,  1975. 

237476  02- 
NATURAL 

ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01- 


S-216 


I 


HUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 
TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS 

247384  04-14 
TURAIISTIC 
NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION 

251149  04-17 
TURE 
THE  NATURE  AND  TREATMENT  OF  DEPRESSION. 

228037  01-09 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02-03 
THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYT0CHR0ME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE, 

241350  03-01 
DOPAMINERGIC  NATURE  OF  AMPHETAMINE-INDUCED  PECKING  IN 
PIGEONS. 

248408  04-03 
NATURE  OF  NEW  CLASS  OF  CHLORPROMAZINE  (CPZ)  METABOLITES  IN 
PRIMATE  URINES. 

249328  04-01 
CESSITY 
NECESSITY  OF  HYPERTHERMIA  FOR  L-DOPA  OR  D-AMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03  03 
CROSIS 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-03 
ED 
I.  PSYCHOPHARMACOLOGY  AND  THE  NEED  TO  KNOW. 

244875  04-17 
GATIVE 
TREATMENT  WITH  DISULFIRAM  IN  HUNTINGTONS-CHORFA:  A  NEGATIVE 
CLINICAL  AND  PHARMACOLOGICAL  STUDY. 

226430  01  07 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN. 

230863  01-14 
THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 
CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE. 

237723  02-04 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
PSYCHOTROPIC  DRUGS  AS  NEGATIVE  REINFORCERS. 

240020  03-04 
DRUG  INJECTIONS  AS  NEGATIVE  REINFORCERS. 

240022  03-04 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04-13 
;OCORTEX 
THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02  03 
fONATAl 
NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01  04 
THE  EFFECTS  OF  NEONATAL  6-HYDROXYDOPAMINE-INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION. 

226871  01-03 
NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
6-HYDROXYDOPAMINE  (6-OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
OECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03-03 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04-15 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 
ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE. 

243792  04-03 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04-04 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE. 

251981  04-04 


NEONATALLY 

DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04-02 
NEONATE 

DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE. 

230424  01-15 
EFFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT. 

241365  03-03 
NEOSTRIATAILY 

GAMAAA-AMINOBUTYRIC-ACID:  THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL. 

237786  02-03 
NEOSTRIATUM 

AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX. 

248699  04-03 
NERVE 

DOPAMINE-BETA-HYDROXYLASE  IN  NERVE  FUNCTION  AND  MENTAL- 
ILLNESS. 

225869  01-17 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01-03 
CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
ENDINGS. 

237244  02-03 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880  02-03 
DIFFERENTIATION  OF  SENSORY  MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03-03 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04-03 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE. 

249257  04-03 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04-12 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
NERVES 

THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO. 

241313  0303 
OXPRENOLOL  IN  THE  TREATMENT  OF  EXAMINATION  NERVES. 

251160  04  10 
NERVOSA 

PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FOR 
ANOREXIA  NERVOSA. 

240423  03-11 


S-217 


Subject  Index 


Psychopharmacology  Abstracts 


ass 


ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  Af  TER  PHENOTHIAZINE  TREATMENT 

243193  04-10 
SOMATIC  ORIENTED  TREATMENT  OF  ANOREXIA  NERVOSA. 

243194  04-10 
NERVOUS 

THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS 

226900  01-13 
SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN  AND 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERTATION). 

228493  01-03 
DRUGS,  BEHAVIOR,  AND  THE  CHOLINERGIC  NERVOUS  SYSTEM. 

229485  01-04 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
SYMPATHETIC  NERVOUS  SYSTEM  EFFECTS  ON  RAT  BRAIN  METABOLISM. 

234309  02-03 
CYCLIC  NUCLEOTIDES  AND  THEIR  POSSIBLE  RELEVANCE  TO  DISORDERS 
OF  NERVOUS  SYSTEM  FUNCTION.  (UNPUBLISHED  PAPER). 

237171  02-03 
DIFFERENTIAL  EFFECTS  OF  PHENOBARBITAL  AND  PENTOBARBITAL  ON 
ISOLATED  NERVOUS  TISSUE 

240474  03-03 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5HYDR0XYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

241979  0304 
MODIFICATION  OF  CONDITIONED  AVOIDANCE  AND  TURNING  BEHAVIOUR 
BY  BACLOFEN  AND  ITS  INFLUENCE  ON  CHOLINERGIC  DOPAMINERGIC 
NERVOUS  SYSTEM. 

251397  04-03 
NEIjRAL 

RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INrO  BRAIN. 

233970  02-03 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02  03 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR. 

238819  03-04 
THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAT 
ADRENAL  MEDULLA 

243779  04-03 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  ( -I- )  AMPHETAMINE  AND  RELATED  COMPOUNDS. 

246149  04-03 
NEURAL  AND  NEUROENDOCRINE  FUNCTIONS  OF  DOPAMINE. 

247690  04-17 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
NEURALGIA 

CLONAZEPAM  IN  FACIAL  NEURALGIA  AND  CLUSTER  HEADACHE: 
CLINICAL  AND  ELECTROPHYSIOLOGICAL  STUDY. 

246995  04-11 
NEURASTHENIC 

UTILIZATION  OF  PIRACETAM  (NOOTROPIL)  IN  ELDERLY  WITH 
NEURASTHENIC  STATES. 

236794  02-11 
NEUROAMINE 

NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 
OF  RAT  BRAIN  MONOAMINE  OXIDASE  IN  VITRO 

243778  04-03 
NEUROAMINERGIC 

APOMORPHINE-INDUCED  HYPERTHERMIA  IN  THE  RABBIT:  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE.  (PH  D,  DISSERTATION). 

240936  03-03 
NEUROBIOLOGICAL 

COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
NEUROBLASTOMA 

DIPHENYLHYOANTOIN  INHIBITS  IONIC  EXCITATION  OF  MOUSE 
NEUROBLASTOMA  CELLS 

232917  02-03 
OPIATE  RECEPTORS  AND  ADENYLATE-CYCLASE  IN  NEUROBLASTOMA  X 
GLIOMA  CELL  LINES  (UNPUBLISHED  PAPER), 

238571  02-03 


PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 
NEUROBLASTOMA  CELLS. 

238692  03-03 
NEUROCHEMICAL 

NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT-INDUCED  EPILEPSY  IN  THE  RAT. 

226399  01  03 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6-HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS 

228142  01-04 
ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01-14 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

234797  02-09 
BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D- 
AMPHETAMINE  ADMINISTRATION. 

234809  0204 
ON  NEUROCHEMICAL  ^^ECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  0204 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL, 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT. 

238722  03-04 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
SYMPOSIUM  II.  PHARAAACOLOGY  ON  BRAIN  MONOAMINES: 

2) 
NEUROCHEMICAL  STANDPOINT. 

241361  03-03 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE. 

243181  04-04 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS 

243819  04-13 
DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-03 
NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-03 
INFLUENCE  OF  DESMETHYLIMIPRAMINE  ON  SOME  NEUROCHEMICAL 
ALTERATIONS  DURING  EXPERIMENTAL  HYPOTHYROIDISM. 

246152  04-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION, 

250067  04-04 
NEUROCHEMICALS 

ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICALS. 

248163  04-02 
NEUROCHEMISTRY 

DRUGS,  AGGRESSION,  AND  NEUROCHEMISTRY. 

229488  01  -04 
NEUROElECTRICAl 

DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE.  (PH.D.  DISSERTATION). 

238159  0203 
NEUROENDOCRINE 

NEUROENDOCRINE  EFFECTS  OF  HALOPERIDOL  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

230839  01-08 
A  PRELIMINA,<Y  REPORT:  NEUROENDOCRINE  EFFECTS  OF  DOPAMINE  AND 
NOREPINEPHRINE  RECEPTOR  STIMULATORS, 

243440  04-03 
NEURAL  AND  NEUROENDOCRINE  FUNCTIONS  OF  DOPAMINE, 

247690  04-17 
NEUROGENIC  i 

THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE-INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG. 

237160  02-03! 


S-218 


mssssssm^ 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


>JEUROHORMONAL 

ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 
DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN, 

246992  04-13 
NEUROHUMORAL 

NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03-03 
gEUROHYPOPHYSIAL 

THE  UPTAKE  OF  353  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIOE  IN  RATS  DEHYDRATED  AND  RESERPINIZED 

248952  04-03 
NEUROLEPTIC 

THE  EFFECTS  OF  AZAPERONE.  A  SEDATIVE  NEUROLEPTIC  OF  THE 
BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
DETECTION  OF  THE  NEUROLEPTIC  PROPERTIES  OF  CLOZAPINE,  SULPIRIDE, 
AND  THIORIDAZINE. 

227135  01-04 
ATTEMPTS  AT  A  NEUROCHEMICAL  INTERPRETATION  OF  NATURAL 
BEHAVIOR  AND  BEHAVIOR  MODIFIED  BY  NEUROLEPTIC  DRUGS. 

229113  01-14 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC. 

231367  01-08 
CNS  EFFECTS  OF  NEUROLEPTIC  AGENTS. 

231993  01-15 
PHARMACOLOGICAL  PROPERTIES  OF  NEW  NEUROLEPTIC  COMPOUNDS. 

232502  01-03 
CLOPIMOZIDE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  0 1-04 
A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS. 

235992  02-11 
MODIFICATION  OF  BETA-PHENYLETHYLAMINE-INDUCED  STEREOTYPED 
BEHAVIOR  BY  NEUROLEPTIC  AGENTS. 

236672  0204 
SEROTONERGIC  INVOLVEMENT  WITH  NEUROLEPTIC  CATALEPSY. 

237781  02-03 
MJ-9022:  CORRELATION  BETWEEN  NEUROLEPTIC  POTENTIAL  AND 
STEREOTYPY. 

237903  02-08 
EFFECT  OF  METHAMPHETAMINE  AND  NEUROLEPTIC  AGENTS  ON  THE 
KINETIC  PROPERTIES  OF  STRIATAL  TYROSINE-HYDROXYLASE. 

238693  03-03 
THE  EFFECT  OF  DL-254  ON  THE  PHARMACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS 

238846  03-03 
PRESENT  STATE  OF  LONG-TERM  NEUROLEPTIC  TREATMENT  OF 
SCHIZOPHRENIA. 

238864  03-08 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03-03 
PSYCHOMETRIC  EFFECTS  OF  PERPHENAZINE  BELOW  THE  NEUROLEPTIC 
THRESHOLD. 

239682  03-15 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I,  INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-08 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
CLINICAl  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  III.  PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT 

240220  03-14 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 

ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE 
NORADRENALINE  AND  GLUCAGON 

241347  03-03 
ARE  NEUROLEPTIC  DRUGS  ANTICARCINOGENIC 

241736  03-15 
EXPERIENCES  WITH  A  DEPOT  NEUROLEPTIC  (OAPOTUM-0). 

242503  03  08 
CHANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 
NEUROLEPTIC  TREATMENT. 

242868  04  11 


COURSE  AND  RESULTS  OF  TREATMENT  WITH  THREE  ACTIVATING 
NEUROLEPTIC  DRUGS 

244049  04-08 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE 

244355  04-15 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
(AY.23028).  A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  04-04 
FLUPHENAZINE:  DIFFICULTIES  AND  LIMITATIONS  IN  ANIMAL 
EXPERIMENTATION  WITH  NEUROLEPTIC  SUBSTANCES. 

247151  04-04 
NEUROLEPTIC  ANTAGONISM  OF  DYSKINETIC  PHENOMENA. 

248407  04-04 
SYNTHESIS  AND  NEUROLEPTIC  ACTIVITY  OF  ISOMERIC 
THIENOBENZOTHIAZINES. 

248949  04-01 
INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04-04 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-15 
MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 

DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY. 

251395  0403 
MEDICAL  EFFECTS  OF  ABRUPT  NEUROLEPTIC  WITHDRAWAL. 

251996  04-08 
PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  OR 
NEUROLEPTIC  DOSAGE 

252955  04-17 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04  03 
NEUROLEPTIC-INOUCED 

NEUROIEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION; 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01-03 
OPEN  WITHDRAWAL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 
INDUCED  PARKINSON  SYNDROME. 

239822  03-15 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 
NEUROLEPTICS 

DOPAMINE  RECEPTOR  BLOCKADE  AND  THE  NEUROLEPTICS,  A 
CRYSTALLOGRAPHIC  STUDY 

226761  01-03 
ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-03 
THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 
CONDITIONED  REFLEX  IN  RATS. 

227637  01-04 
SCANDINAVIAN  STANDPOINT  ON  THE  LIEGE  CLASSIFICATION  OF 
NEUROLEPTICS. 

227761  01  17 
PHARMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS, 

WITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 
EFFECTS 

227762  01-04 
BIOCHEMICAL  VS  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH 

SPECIAL  REFERENCE  TO  THEIR  ANTIMANIC  EFFECT. 

227763  01-04 
THE  MAIN  CLINICAL  CLASSIFICATIONS  OF  NEUROLEPTICS. 

227764  01-06 
THE  LIEGE  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH  SPECIAL  REFERENCE 

TO  THIOXANTHENES 

227769  01  17 
NEUROLEPTICS  AND  ANTIDEPRESSANTS  ON  CENTRAL  MONOAMINE 
NEURONS. 

229483  01  -03 
PHARMACOLOGICAL  AND  TOXICOLOGICAL  PROBLEMS  CONNECTED  WITH 
THE  USE  OF  LONG-ACTING  NEUROLEPTICS 

229549  01-15 
THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS 

229552  01-17 
SOCIOPSYCHIATRIC  ASPECTS  OF  LONG  ACTING  NEUROLEPTICS. 

229553  01-17 
CLINICAL  EXPERIMENTATION  OF  THE  LONG-ACTING  NEUROLEPTICS: 

METHODOLOGICAL  PROBLEMS. 

229554  01-16 


S-219 


Subject  Index 


Psychopharmacology  Abstracts 


cs 


cs 


CYTOLOGIC  STUDY  Of  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
NONCNS  SIDE-EFFECTS  OF  NEUROLEPTICS. 

231994  0115 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE-BLIND 
STUDY. 

232781  02-08 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  02-08 
CHANGES  IN  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 
NEUROLEPTICS  AND  THYMOLEPTICS. 

234045  02- 15 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  02-11 
EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS. 

236519  02-03 
LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 
THE  REVERSAL  OF  APOMORPHINEELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE-HYDROXYLASE  ACTIVITY  BY 
NEUROLEPTICS. 

238758  03-03 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
SPECTRAL  MAPS  OF  THE  LIEGE  PHYSIOGNOMIES  OF  THE  NEUROLEPTICS 

239683  03-06 
THE  EFFECT  OF  NEUROLEPTICS  ON  SERUM  PROLACTIN  IN  SCHIZOPHRENIC 
PATIENTS. 

239931  03-08 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULATION 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375  03-04 
DEPOT  NEUROLEPTICS  -   PRACTICAL  METHODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
A  PRIMATE  MODEL  OF  ACUTE  DYSTONIC  REACTION  TO  NEUROLEPTICS. 

241934  03-05 
CHANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  03-03 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
NEUROLEPTICS,  CATECHOLAMINES,  AND  PSYCHOSES:  A  STUDY  OF  THEIR 
INTERRELATIONS. 

245510  04-09 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 
A  COMPARISON  OF  NARCOTIC  ANALGESICS  WITH  NEUROLEPTICS  ON 
BEHAVIORAL  MEASURES  OF  DOPAMINERGIC  ACTIVITY. 

249139  04-04 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS. 

249272  04-04 
LIMITING  FACTORS  IN  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE. 

250359  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 
INHIBITION  AND  POTENTIATION  OF  APOMORPHINE-INDUCED 
HYPERMOTILITY  IN  RATS  BY  NEUROLEPTICS, 

252029  04-04 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-17 
LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 
CHRONIC  SCHIZOPHRENIA. 

253049  04-08 
NEUROLOGIC 

DRUG  THERAPY:  NEUROLOGIC  SYNDROMES  ASSOCIATED  WITH 
ANTIPSYCHOTIC  DRUG  USE. 

246061  04- 15 


BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE. 

250942  04-11 
LONG-TERM  THERAPY  OF  NEUROLOGIC  DISORDERS  WITH  L-5- 
HYDROXYTRYPTOPHAN. 

251960  04-1: 
NEUROLOGICAL 

NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION. 

251149  04-1; 
THE  EFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHILDREN. 

251569  04-1/ 
NEUROLOGISTS 

THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS. 

249771  04- K 
NEUROLOGY 

SOME  THERAPEUTIC  USES  OF  GABA  IN  NEUROLOGY. 

239700  03-11 
PSYCHOPHARMACOLOGICAL  DRUGS  IN  NEUROLOGY. 

240708  03-1; 
NEUROMEDIATORS 

AN  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS. 

233336  02-0: 
NEUROMUSCULAR 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG. 

226855  01-0: 
A  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM. 

233289  02-0; 
EFFECTS  OF  LITHIUM  ON  NEUROMUSCULAR  TRANSMISSION. 

238743  03-03 
NEURON 

INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS. 

239848  03-04 
NEURONAL 

DIFFERENTIAL  EFFECTS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY. 

230840  01-03 
CYCLIC  NUCLEOTIDES,  PROTEIN  PHOSPHORYLATION,  AND  NEURONAL 
FUNCTION. 

231021  01-17 
EFFECTS  OF  MOLINDONE  ON  CENTRAL  DOPAMINERGIC  NEURONAL 
ACTIVITY  AND  METABOLISM:  SIMILARITY  TO  OTHER  NEUROLEPTICS. 

236519  02-03 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-03 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-03 
A  DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP. 

238717  03-04 
INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION, 

239086  03-03 
THE  CHEMICAL  CONTROL  OF  NEURONAL  ACTIVITY.  (UNPUBLISHED 
PAPER). 

243183  04-17 
CNS  PHOSPHOLIPID  METABOLISM  AND  NEURONAL  FUNCTION. 

244089  04-03 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 
THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-03 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  0403 


S-220 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


POTENTIATION  BY  OESIPRAMINE  OF  NEURONAL  RESPONSES  TO 
MESCALINE. 

251705  04-03 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT. 

252018  04-03 
lEURONE 

ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

241919  03-03 
ON  THE  MECHANISM  OF  ACTION  OF  CLOZAPINE  ON  THE  ADRENERGIC 
NEURONE. 

243760  04-03 
EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA 

243799  04-03 
EURONES 

EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES, 

233971  02-03 
ORGANIZATION  OF  RECEPTORS  FOR  NEUROTRANSMITTERS  ON  APLYSIA 
NEURONES, 

235588  0203 
LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 

LI  +  SENSITIVE  MICROELECTRODE. 

235589  02-06 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 

AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTAZOL. 

237925  02-03 
AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-DOPA  AND  5-HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03-03 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602. 

239957  03-03 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE- 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04-03 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOLINE  AND  L  GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-03 
EURONS 

TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01  03 

THE  EFFECT  OF  D,L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01-03 
NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-03 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

229462  01  03 
NEUROLEPTICS  AND  ANTIDEPRESSANTS  ON  CENTRAL  MONOAMINE 
NEURONS. 

229483  01-03 
THE  POSSIBLE  INVOLVEMENT  OF  GABA  MECHANISMS  IN  THE  ACTION  OF 
BENZODIAZEPINES  ON  CENTRAL  CATECHOLAMINE  NEURONS. 

232507  01-03 
THE  EFFECTS  OF  DIMETHYLAMINOETHANOL  (DEANOL)  ON  CEREBRAL 
CORTICAL  NEURONS 

232621  02-03 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02  03 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

.  n ,  „  r,  236265  02-03 

A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 

DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 

NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE. 

II,  A  DETAILED  DESCRIPTION  OF  METHODOLOGY   (UNPUBLISHED 

PAPER) 

236875  0206 


RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE 

237158  02-03 
THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT. 

237742  0203 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS. 

237785  02-03 
INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE: 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02-03 
AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH.D 
DISSERTATION). 

241129  03-03 
EFFECTS  OF  6-HYDROXYDOPAMINE  ON  CENTRAL  NORADRENALINE 
NEURONS  DURING  ONTOGENY. 

241196  03  03 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
DOPAMINERGIC  NEURONS    -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DOPAMINERGIC  NEURONS  -    ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE-HYDROXYLASE  AFTER  CESSATION  OF  IMPULSE  FLOW. 

241296  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03  03 
D  AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY 

243882  04  03 
PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS 

244072  04-03 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-03 
THE  MODE  OF  LIPOFUSCIN  REMOVAL  FROM  HYPOTHALAMIC  NEURONS. 

246587  04-03 
D-AAAPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS    COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS. 

24721 1  04-03 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-03 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS, 

248466  04-03 
FURTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO-INTERPEDUNCULAR 
NEURONS:  PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS. 

249074  04-03 
RAPHE  NEURONS:  DEPRESSION  OF  ACTIVITY  BY  L-5- 
HYDROXYTRYPTOPHAN 

249078  04  03 
EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 
NUCLEUS  RAPHE  DORSALIS 

249249  04-03 
CENTRAL  DOPAMINERGIC  NEURONS:  EFFECTS  OF  ALTERATIONS  IN 
IMPULSE  FLOW  ON  THE  ACCUMULATION  OF 
DIHYDROXYPHENYLACETIC-ACID. 

250085  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE 

250937  04-03 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA, 

252521  04-03 
NEUROPHARMACOLOGICAl 

NEUROPHARMACOLOGICAL  STUDIES  ON  D145  (1  3  DIMETHYL  5- 
AMINOADAMANTAN), 

227133  01-03 


S-221 


Subject  Index 


Psychopharmacology  Abstract! 


'"F, 


BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  ANALYSIS  OF 
AMPHETAMINE  AND  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  IN 
RATS. 

237718  02-04 
DRUGS  AND  POO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
NEUROPHARMACOLOGICAL  EFFECTS  OF  PENFLURIDOL,  A  NEW 
ANTIPSYCHOTIC  AGENT 

241384  03-03 
THE  BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  EFFECTS  OF  TAURINE. 
(PH  D    DISSERTATION). 

241574  03-03 
USE  OF  THE  IMMOBILITY  REFLEX  (ANIMAL  HYPNOSIS)  IN 
NEUROPHARMACOLOGICAL  STUDIES. 

250071  04-06 
NEUROPHARMACOLOGY 

NEUROPHARMACOLOGY  OF  PSYCHOPHARMACOLOGICAL  AGENTS, 

229484  01-04 
NEUROPHARMACOLOGY  OF  BRAIN  MONOAMINES  AND  BEHAVIOR. 

229499  01-04 
NEUROPHYSIOLOGICAL 

A  NEUROPHYSIOLOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 
PSYCHOTOMIMETICS  (LSD-25,  DOM  AND  KETAMINE). 

232703  02-04 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3: 
CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  04-11 
NEUROPSYCHIATRIC 

OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  TO 
ANTIPSYCHOTIC  DRUGS. 

227808  01-15 
BETA-PHENYLETHYLAMINE  (PEA)  AND  THE  NEUROPSYCHIATRIC 
DISTURBANCES.  (UNPUBLISHED  PAPER). 

241474  03-14 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDENCE 
OF  OPHTHALMOLOGICAL  ABNORMALITIES. 

244779  04-15 
NEUROPSYCHOLOGICAL 

THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY. 

229650  01-14 
NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE. 

238516  02-11 
DIPHENYLHYDANTOIN  SERUM  LEVELS.  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03-14 
DPH-INTOXICATION  -    CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION. 

240692  03-15 
NEUROPSYCHOPHARMACOLOGICUM 

NINTH  CONGRESS  OF  THE  INTERNATIONAL 

NEUROPSYCHOPHARMACOLOGICUM  COLLEGIUM  OR  C.I  N  P.  (PARIS, 
JULY  7-12,  1974), 

250266  04-17 
NEUROPSYCHOPHARMACOIOGY 

DRUGS  AND  BEHAVIOR:  A  PRIMER  IN  NEUROPSYCHOPHARMACOIOGY. 

231227  01-17 
NEUROPSYCHOPHARMACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

233941  02-03 
NEUROPSYCHOPHARMACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

237829  02-17 
NEUROREGULATORS 

NEUROREGULATORS  AND  SLEEP  MECHANISMS. 

241902  03-17 
NEUROSECRETORY 

ON  THE  ACTIONS  OF  COMPOUNDS  RELATED  TO  DOPAMINE  AT  A 
NEUROSECRETORY  SYNAPSE. 

251703  04-03 
NEUROSES 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUIIIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
PHARMACOTHERAPY  AND  PSYCHOTHERAPY  IN  THE  TREATMENT  OF 
NEUROSES. 

230640  Oil  7 


ELECTROPHORETIC  APPLICATION  OF  LIGNOCAINE  TO  THE  CERVICAL  ARE/ 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES. 

244467  04-1 
NEUROSIS 

A  CONTROLLED  EVALUATION  OF  LORAZEPAM  AND  DIAZEPAM  IN 
ANXIETY  NEUROSIS. 

230907  01-0 
BENZOCTAMINE  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLEC 
CLINICAL  STUDY. 

235356  02-0 
ETAFENOXIN  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235357  02-0 
LORAZEPAM  IN  THE  TREATMENT  OF  NEUROSIS  -  AN  UNCONTROLLED 

CLINICAL  STUDY, 

235358  02-G 
TRAZODONE  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235359  O2-0 
DOXEPIN  IN  THE  TREATMENT  OF  OBSESSIVE-COMPULSIVE  NEUROSIS. 

235826  02-1 
ANAFRANIL  IN  OBSESSIVE-COMPULSIVE  NEUROSIS. 

237896  02-1 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIV 
NEUROSIS. 

246300  04-1 
NEUROTIC 

EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 
NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES. 

230818  01-1 
TREATMENT  OF  NEUROTIC  SYNDROMES  WITH  TRANQUILIZERS. 

231983  01-1 
LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY:  DOUBLE-BLIND  TRIAL. 

236658  02-1 
CONTROLLED,  DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIV 
EFFECTIVENESS  OF  MEPIPRAZOL  (EMD-16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS, 

237025  02-1 
ANXIETY  AND  EEG  ALPHA  ACTIVITY  IN  NEUROTIC  PATIENTS. 

239022  03-1 
THE  PSYCHIATRY  OF  THE  FE/WALE  CLI/WACTERIUM:  NEUROTIC  OR 
PSYCHOTIC  SYMPTOMS?. 

241875  03-0 
DIFFERENTIAL  PHARAAACOTHERAPY  FOR  NEUROTIC  STATES 

(COMPARATIVE  EFFECTIVENESS  OF  BENZODIAZEPINE  DERIVATIVES). 

244349  04-1 

OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE  BLIND  PHASE  II  EVALUATION  OF 

THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 

IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS. 

248975  04-1 
THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  04-1 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AND 
PSYCHOTIC  PATIENTS. 

253641  04-1 
NEUROTICS 

EVALUATION  OF  SIDE-EFFECTS  ON  NEUROTICS  -  A  TEST  USING 
MESORIDAZINE  AND  PLACEBO. 

225686  01-1 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE. 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01-1 
PIPERACETAZINE  IN  THE  TREATMENT  OF  MIXED  NEUROTICS. 

247484  04-1 
NEUROTOXIC 

FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 
AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN, 

247214  04-0 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS, 

248834  04-0 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5HYDR0XYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-0 
NEUROTOXICITY 

NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES. 

241298  03-0: 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  04-0: 


S-222 


^mmm 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


lEUROTOXIN 

ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE 

244203  04-03 
lEUROTOXINS 

MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

251063  04-04 
lEUROTRANSMITTER 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS 
(UNPUBLISHED  PAPER). 

226731  01-13 
NEUROTRANSMITTER  INFLUENCES  ON  MATING  BEHAVIOR  IN  MALE 
RATS,  (PH.D.  DISSERTATION). 

228390  01-04 
THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA. 

236863  02-03 
AN  INVESTIGATION  ON  THE  DOSE-RESPONSE  RELATIONSHIP  BETWEEN 
CONVENTIONAL  ANTIOXIDANT  FOOD  ADDITIVES  AND 
NEUROTRANSMITTER  METABOLISM. 

238745  03-03 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES 

243482  04-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04-04 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 
CORTICAL  SLICES. 

246850  04-03 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 
BRAIN  SYNAPTOSOMES. 

248701  04-03 
lEUROTRANSMITTERS 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-03 
DEVELOPMENT  OF  TOLERANCE  TO  AND  DEPENDENCE  ON  ENDOGENOUS 
NEUROTRANSMITTERS. 

234798  02-08 
ORGANIZATION  OF  RECEPTORS  FOR  NEUROTRANSMITTERS  ON  APLYSIA 
NEURONES 

235588  02-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY 

241319  03-03 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE 

244199  04-03 
EUROTROPIC 

THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
EUROTROPIN 

CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  0304 
EUTRAL 

ANTAGONISMS  BY  NEUTRAL  AMINO-ACIDS  (NAA)  OF  THE  HYPOTHERMIC 
EFFECT  OF  D-AMPHETAMINE  (AMP). 

238726  03-03 
EW 

EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  01-14 
VILOXAZINE  (VIVALAN)   -  A  NEW  ANTIDEPRESSANT. 

227224  01  09 
NEW  DRUG  THERAPY  IN  THE  FIELD  OF  PSYCHIATRY. 

228211  01-17 


EVALUATION  OF  NEW  COMPOUNDS  FOR  PSYCHOTROPIC  ACTIVITY 

229477  01-04 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOAMTIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE  BLIND  CLINICAL  STUDY. 

229504  01-11 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-10 
CLINICAL  EXPERIENCE  IN  USING  AMPROTILINE,  A  NEW  ANTIOEPRESSIVE 
MEDICINE 

229760  01-09 
A  CLINICAL  TRIAL  WITH  NOMIFENSIN,  A  NEW  ANTIDEPRESSANT  DRUG. 

231035  01-09 
PHARMACOLOGICAL  PROPERTIES  OF  NEW  NEUROLEPTIC  COMPOUNDS. 

232502  01-03 
NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 
PROPERTIES. 

232528  01-02 
CLOPIMOZIDE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-04 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS 

232530  01-07 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 

PSYCHOTROPIC  DRUGS. 

233684  02  17 
VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

233870  02  11 
THE  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES. 

234699  02-09 
INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WITH 
PSYCHOACTIVE  DRUGS  -  NEW  METHODS  IN  THE  ASSESSMENT  OF 
CHANGE. 

235355  02-17 
LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
i\+   SENSITIVE  MICROELECTRODE. 

235589  02-06 
STUDY  OF  A  NEW  PSYCHOSTIMULANT    -  SIDNOCARB, 

236363  02-10 
INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIDOL. 

236369  02-03 
TESTING  OF  NEW  PSYCHOTROPIC  DRUGS  ON  OUTPATIENTS. 

236811  02-17 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA 

237104  02-03 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION 

238321  02-03 
BIOCHEMICAL  RESEARCH  INTO  PSYCHOSIS:  RESULTS  OF  A  NEW 
RESEARCH  STRATEGY. 

238997  03-13 
FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH  A 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350). 

239748  03- 14 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-11 
NEW  DEVELOPMENTS  IN  THE  USE  OF  PHENOBARBITAL  IN  PEDIATRICS. 

240723  03-17 
AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONE 
TRANQUILIZER  AZAPERONE 

241359  03-02 
NEUROPHARMACOLOGICAL  EFFECTS  OF  PENFLURIDOL,  A  NEW 
ANTIPSYCHOTIC  AGENT. 

241384  03-03 
BIOCHEMICAL  RESEARCH  IN  SCHIZOPHRENIA:  RESULTING  IN  A  NEW 
RESEARCH  STRATEGY. 

241912  03-08 
CF  25-397,  DIDEHYDR0-METHYL-8BETA  PYRIDYLTHIOMETHYLERGOLINE    A 
NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST 

241927  03-04 
FLURAZEPAM,  A  NEW  HYPNOTIC  FOR  THE  TREATMENT  Of  INSOMNIA. 

242502  03-14 
CLINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE  NEW 
HYPNOSEDATIVE  K-2004. 

243198  04-11 


S-223 


Subject  Index 


Psychopharmacology  Abstract; 


-.a 

2a 


CLINICAL  EXPERIENCES  WITH  A  NEW  ANTIDEPRESSANT,  ICI-58834. 

244189  04  07 
THE  EFFECTS  OF  TANOAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04-11 
RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
(AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  04-04 
NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 

UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-03 
NEW  PATHWAY  FOR  METABOLISM  OF  DOPA. 

246286  04-03 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3-P  TRIFLUOROMETHYLPHENOXY-N- 
METHYL-3-PHENYLPROPYLAMINE. 

246848  04-03 
METABOLIC  FATE  OF  FLURAZEPAM  IL  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM. 

246971  04-03 
A  CLINICAL  AND  ELECTROENCEPHALOGRAPHIC  STUDY  OF  A  NEW 

ANTIDEPRESSANT  AGENT,  MELYLAMINOPROPYLDIBENZOBICYCLOOCT 
ADIENE  CHLORHYDRATE  (CIBA-34276-BA). 

247554  04-09 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 
ANALOGS  OF  FLUPHENAZINE. 

248538  04-02 
CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-94) 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  04-09 
NATURE  OF  NEW  CLASS  OF  CHLORPROMAZINE  (CPZ)  METABOLITES  IN 
PRIMATE  URINES 

249328  04-01 
INTER  GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS. 

249668  04  04 
COMPARISON  OF  A  NEW  ANTIDEPRESSIVE,  LOFEPRAMINE  WITH 
IMIPRAMINE  IN  A  DOUBLE-BLIND  MULTICENTRE  TRIAL. 

251118  04-09 
CHEMISTRY  AND  PHARMACOLOGY  OF  DIV  154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND 

251407  04-17 
CHLORPROMAZINE  METABOLISM  VII.  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE. 

251777  04-06 
BEHAVIOURAL  EFFECTS  OF  A  NEW  NONPHENYLETHYLAMINE 
ANOREXIGENIC  AGENT:  MAZINDOL 

252030  04  04 
A  NEW  HUNGARIAN  PSYCHOPHARMACON. 

252444  04- 1  7 
TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  AAYASTHENIA- 
GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  04  07 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOHOL  WITHDRAWAL. 

252694  04-1  I 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE    COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

253011  04  07 
NEW  PSYCHOACTIVE  DRUGS  IN  PSYCHOGERIATRICS. 

253060  04  11 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  (SO  10996)  IN 
HUMANS 

253323  04-07 
DIGITALIS:  CLINICAL  IMPLICATIONS  OF  NEW  FACTS  ABOUT  AN  OLD 
DRUG 

253495  04-15 


NEW-VORK 

COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCES- 
NEW- YORK  AND  TEXAS. 

233829  02-01 
FUGUE  STATES  -  EPILEPSY  -  MEDICATION    -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK) 
NASSAU  COUNTY  COURT   AUGUST  1,  1975. 

237476  02-1 
NEWiy-ADMITTED 

A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 
(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-0' 
NIALAMIDE 

THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 
CONDITIONED  REFLEX  IN  RATS. 

227637  01-0. 
CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-a 
POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  04-0- 
EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVEL! 
OF  ADRENALECTOMIZED  RATS. 

251990  04-0- 
NICHOLIN 

CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 
ANTIDEPRESSANT  TREATMENT. 

247969  04-0< 
NICOTINAMIDE 

ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYL  PHENOTHIAZINES 

239662  03-0; 
NICOTINE 

RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-0: 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  O4-0j 
NICOTINE-LIKE 

NICOTINE  LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH  AVOIDANCE  RATS. 

239865  03-04 
NICOTINIC 

INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS. 

239977  03-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04-03 
NICOTINIC-ACID 

NICOTINIC-ACID  IN  THE  TREATMENT  OF  SCHIZOPHRENIAS:  PRACTICAL 
AND  THEORETICAL  CONSIDERATIONS. 

230812  01-08 
NIGHT 

CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03-14 
NIGHTMARES 

PAROXYSAAAL  NIGHTMARES:  SEQUEL  OF  A  STROKE  RESPONSIVE  TO 
DIPHENYLHYDANTOIN. 

233295  02-14 
NIGHTTIME 

LORAZEPAM  COMPARED  WITH  PENTOBARBITAL  FOR  NIGHTTIME 
SEDATION. 

232622  02-14 
NIGRAL 

RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE 

237158  02-03 
ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 
STRIATAL  LESIONS. 

237777  02-03 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS.  (PHD    DISSERTATION). 

238079  02-03 


S-224 


^is^s^im 


LUME  14,  SUBJECT  INDEX 


Subject  index 


INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS^ 

252027  04-03 
ROSTRIATAl 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  01-03 
DOPAMINERGIC  EFFECTS  OF  PHENCYCLIDINE  IN  RATS  WITH 
NIGROSTRIATAL  LESIONS. 

236523  02-04 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-03 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  03-03 
EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 
PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM. 

249899  04-03 
H-VA 

FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 
CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 
STUDY  GROUP. 

225718  01-09 
JXETINE 

NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN. 

238840  03-03 
:azepam 
NITRAZEPAM  (MOGADON)  DEPENDENCE. 

225699  01-15 
COMPARATIVE  EVALUATION  OF  FLURAZEPAM  AND  NITRAZEPAM  FOR 
OCCASIONAL  INSOMNIACS. 

228315  01-11 
THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE 

239010  03-15 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS. 

240237  03-04 
CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03-14 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS 

244456  04-04 
OGEN 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM 

235511  02-04 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  02  06 
THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES. 

237981  02-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  1    NITROGEN  ANALOGS, 
BENZOPYRANOPYRIDINES  AND  BENZOPYRANOPYRROLES. 

248646  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS   2.  BASIC  ESTERS  OF  NITROGEN 

AND  CARBOCYCLIC  ANALOGS. 

248647  04-02 

NMR  STUDY  OF  AMPHETAMINES  USING  EUROPIUM  SHIFT  REAGENTS. 

239660  03-01 
TURNAL 

EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  01-14 
PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01-14 
EFFECTS  OF  PROMETHAZINE  ON  NOCTURNAL  SLEEP  IN  NORMAL  MAN 

230867  0114 
ES 

LIPIDOSISLIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS 

237153  02-05 


NODOSE 

INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION. 

232333  01-03 
NOMIFENSIN 

A  CLINICAL  TRIAL  WITH  NOMIFENSIN,  A  NEW  ANTIDEPRESSANT  DRUG. 

231035  01-09 
NOMIFENSINE 

EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  02-03 
EFFECT  OF  NOMIFENSINE  ON  ACETYLCHOLINE  AND  CHOLINE  IN  THE  PAl 
STRIATUM  AND  BRAINSTEM. 

248291  04-03 
NON-CNS 

NON-CNS  SIDE-EFFECTS  OF  NEUROLEPTICS. 

231994  01-15 
NON-INDEPENDENT 

CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-04 
NON-MEDICATION 

NON-MEDICATION  MANAGEMENT  OF  HYPERKINETIC  CHILDREN  IN  THE 
CLASSROOM.  (PH.D.  DISSERTATION) 

240977  03-11 
NON-METABOLIZABLE 

NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID,  L- 

AMINOCYCLOPENTANE  1-CARBOXYLIC-ACID  (ACPC):  ACPC  TRANSPORT 
MECHANISMS  IN  TISSUES 

241298  03-03 
NONASSOCIATIVE 

TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04-04 
NONBARBITURETE 

ON  THE  THIN  LAYER  CHROMATOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04  01 
NONCHRONIC 

VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE  BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS, 

228223  01-08 
NONCONJUGATED 

QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS. 

237902  02-13 
NONCONTINGENT 

RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 

CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE 

230831  01  04 
NONCONTRIBUTION 

THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG 
STAY  PSYCHIATRIC  PATIENT. 

227461  01  17 
NONEXPERIENCED 

MARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS. 

226903  01   14 
NONHUMAN 

CHEMISTOR    A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02-06 
NONIESIONED 

THYROTROPIN  RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATION  IN 
THE  NONLESIONED  RAT 

247514  04-03 
MORPHINE  INDUCED  ROTATION  IN  NAIVE.  NONLESIONED  RATS. 

252209  04  04 
NONNARCOTIC 

DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  04  04 
NONPHENYLETHYLAMINE 

BEHAVIOURAL  EFFECTS  OF  A  NEW  NONPHENYLETHYLAMINE 
ANOREXIGENIC  AGENT:  MAZINDOL. 

252030  04-04 


S-225 


Subject  index 


a 


EFFECTS  OF  MAZINDOL.  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

25220 1  04-03 
NONPHYSIOLOGICAl 

CEREBRAL  ARTERIAL  SPASM,  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY, 

243797  04-03 
NONPIGMENTED 

ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450  01-03 
NONPSYCHIATRIST 

INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02-17 
NONPSYCHOTIC 

CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS. 

252447  04-10 
NONRELAXANT 

TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA- 
GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  04-07 
NONRESPONOERS 

ACUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONOERS  TO  TREATMENTS. 

253617  04-09 
NONSEDATIVE 

CLINICAL  RESPONSE  TO  A  POTENTIAL  NONSEDATIVE  ANXIOLYTIC. 

251719  04-07 
NONSOMATIC 

CONCEPTUAL  IMPLICATIONS  OF  DRUG  AND  NONSOMATIC  TREATMENT 
INTERACTION  STUDIES. 

229452  0)1 7 
NONSPECIFIC 

NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY 

240063  03-03 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
NONTOIERANT 

INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS. 

226849  01-03 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
3H  DELTA9-TETRAHYDR0CANNABIN0L  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
NONTRICYCLIC 

CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND. 

251407  04  17 
NONUSERS 

DIVIDED  ATIENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04-13 
NOOTROPIL 

UTILIZATION  OF  PIRACETAM  (NOOTROPIL)  IN  ELDERLY  WITH 
NEURASTHENIC  STATES, 

236794  02-11 
NORADRENALINE 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D  AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

227636  01-04 
CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-13 
RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES, 

230739  01-13 
LEARNING  IN  THE  ABSENCE  OF  FOREBRAIN  NORADRENALINE, 

234917  02-04 


Psychopharmacology  Abstrc 

EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTH 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918 C 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOUI 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN 
RAT  SPINAL  CORD. 

235863  C 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  C 
EFFECT  OF  AMPHETAMINE  AND  FENFLURAMINE  ON  BRAIN 
NORADRENALINE  AND  M0PEG-S04. 

237740  C 
HYPOTHALAMIC  NORADRENALINE  TURNOVER  IS  INCREASED  DURING 
GLUCOPRIVIC  FEEDING. 

238804  C 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPL/ 
OF  RAT  CEREBELLUM. 

239836  C 
EFFECTS  OF  6-HYDROXYDOPAMINE  ON  CENTRAL  NORADRENALINE 
NEURONS  DURING  ONTOGENY. 

241 196 C 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS 
ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE 
NORADRENALINE  AND  GLUCAGON. 

241347 C 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  THE  METABOLISM 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373 C 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  f 
NORADRENALINE  INTO  THE  BRAIN. 

242736  C 
SELF-STIMULATION  AND  NORADRENALINE;  EVIDENCE  THAT  INHIBITIC 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POC 
DISPERSED  FIRST. 

246774  0 
DOSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION 
BEHAVIOURAL  AROUSAL  IN  RATS. 

247206  0 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  0 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 

NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  0 
EFFECT  OF  METOCLOPRAMIDE  ON  TURNOVER  OF  BRAIN  DOPAMINE 

NORADRENALINE  AND  5-HYDROXYTRYPTAMINE. 

249628  0 
CYCLIC  AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS;  FAILURE  T( 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  0 
AUTOMATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE/ 
NORADRENALINE  TRANSMISSION. 

250086  0- 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION;  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMi 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  0. 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  S-HYDROXYTRYPTAiV 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATEO  W 
LITHIUM  OR  RUBIDIUM. 

253593  0- 
NORADRENERGIC 

TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01 
NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

237756  02 
INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE: 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02 
SYMPOSIUM  II.  PHARAAACOLOGY  ON  BRAIN  MONOAMINES; 

ABNORAMLITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTE/V 
IN  LIMBIC  FOREBRAIN. 

245115  04 


S-226 


»LUME  14,  SUBJECT  INDEX 


Subject  Index 


OAMPHETA/WINE  AND  LAMPHETAMINE  STEREOISOMERS:  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS 

247211  04-03 
EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINERGIC  MECHANISMS. 

249305  04-06 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE.  PHENETHYLAMINE  AND  APOMORPHINE 

250361  04-04 
SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST.  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS 

251534  04-03 
lEPHEDRINE 

ACCUMULATION  OF  LABELED  EPHEDRINE.  NOREPHEDRINE. 
AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS, 

230450  01-03 
[EPINEPHRINE 

INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 
NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS   (UNPUBLISHED 
PAPER). 

227777  01-03 
THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01-03 
NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 
RUBIDIUM  TREATMENT. 

230817  01-03 
EFFECT  OF  METHAMPHETAMINE  ON  NOREPINEPHRINE  METABOLISM  IN 
VARIOUS  REGIONS  OF  BRAIN 

231004  01-03 
FUNCTIONAL  SIGNIFICANCE  OF  CENTRAL  NERVOUS-SYSTEM 
NOREPINEPHRINE  AND  DOPAMINE:  A  PSYCHOPHARMACOLOGICAL 
STUDY.  (PH.D.  DISSERTATION). 

231437  01-04 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 
REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE   AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT, 

232332  01-04 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE. 

236713  02-03 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICULAR 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  AND 
DOPAMINE. 

238566  02-04 
THE  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 
NOREPINEPHRINE  BY  N-ETHYLAMPHETAMINE  AND  FENFLURAMINE. 

238688  03-03 
RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE  BETA-HYDROXYLASE 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES 

238718  03-04 
MARUUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03-04 
EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT 

238755  03-04 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS 

238798  0303 
NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN 

238840  03-03 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 
HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN,  (UNPUBLISHED  PAPER). 

239305  03-13 


NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR   -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION 

241205  03-04 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  (  O  AMPHETAMINE, 

241257  03-03 
THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES. 

241301  03-04 
EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN 

241.345  03-03 
A  PRELIMINARY  REPORT:  NEUROENDOCRINE  EFFECTS  OF  DOPAMINE  AND 
NOREPINEPHRINE  RECEPTOR  STIMULATORS 

243440  04-03 
EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5-HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN. 

243777  04-03 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  04-03 
AXOPLASMIC  TRANSPORT  OF  NOREPINEPHRINE  IN  THE  RAT  BRAIN. 

243791  04-03 
NEONATAL  HYPERTHYROIDISM:  ALTERATIONS  IN  BEHAVIOURAL 

ACTIVITY  AND  THE  METABOLISM  OF  BRAIN  NOREPINEPHRINE  AND 
DOPAMINE. 

243792  04-03 
TOLERANCE,  PHYSICAL  DEPENDENCE  AND  OPIOID-SEEKING  BEHAVIOR: 

DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE. 

244202  04-04 
ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAI   SAMPLES. 

244636  04-06 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES 

244678  04-03 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

24.5929  04  02 
ACCUMULATION  OF  NOREPINEPHRINE  (NE)  BY  RAT  ORGANS  IN  VIVO 

246822  04-03 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V    ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 
INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE,  BUT 
NOT  OF  DOPAMINE  BETA-HYDROXYLASE  FROM  GUINEA  PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER). 

247028  04  03 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRONIC 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE. 

247777  04-03 
THE  EFFECT  OF  PRETREATMENT  WITH  6-HYDROXYDOPAMINE  ON  IHE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 
VAS-DEFERENS. 

248413  04  03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
MORPHINES  PROCONVULSANT  ACTION:  IMPORTANCE  OF  ENDOGENOUS 
NOREPINEPHRINE 

248880  04  03 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY 

248947  04-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO. 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION 

249255  04  03 
THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  NOREPINEPHRINE  IN 
MICE. 

249283  04-03 
EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA).  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES, 

249313  04  03 


S-227 


Subject  Index 


Psychopharmacology  Abstra 


^4] 


ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 
BEHAVIOR  IN  FEMALE  RATS. 

250012  04-04 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC  AMP  LEVELS. 

251964  04-03 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS.  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT 

252012  04-03 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
NORFENFLURAMINE 

FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE.  PART  1:  IS 

FENFLURAMINE  OR  NORFENFLURAMINE  INVOLVED  IN  THE  DECREASE 
OF  BRAIN  5-HYDROXYTRYPTAMINE''. 

237118  02-03 
A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

250935  04-17 
NORMAL 

THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01  13 
EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  01-14 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN, 

230863  01-14 
EFFECTS  OF  PROMETHAZINE  ON  NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

230867  01-14 
REM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 
VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS. 

237696  02-14 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE, 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03-04 
EFFECT  OF  LONG-LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS. 

239992  03-14 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 

AMPHETAMINE-ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY 

240750  03-04 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES 

241231  03-04 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION). 

241681  03-04 
NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION. 

246996  04-03 
EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS. 

248629  04-13 
THE  CLINICAL  PHARMACOLOGY  OF  LILLY-109514  IN  NORMAL 
VOLUNTEERS. 

249260  04-07 
SUBJECTIVE  EFFECTS  OF  TWO  ANOREXIGENIC  AGENTS    -  FENFLURAMINE 
AND  AN  448  IN  NORMAL  SUBJECTS. 

250945  04-07 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04  02 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 


NORAAAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  A 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  0- 
NORMETANEPHRINE 

CENTRAL  ACTION  OF  NORMETANEPHRINE.  EFFECT  ON  THE  BEHAVIOR 
RATS. 

240240  O: 
NORMOTENSIVE 

EFFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT. 

241365  0: 
NORTRIPTYLINE 

EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LON( 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  O: 
RELATIONSHIP  BETWEEN  ANTIDEPRESSANT  EFFECT  AND  PLASMA  LEVI 
OF  NORTRIPTYLINE   CLINICAL  STUDIES. 

240217  0: 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  a 
SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT 
HIGH  PLASAAA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955  0. 
NOVERIl 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L  CARRi 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FOR 
OF  NOVERIL. 

245971  0. 
NUCLEAR 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  BRAIN  NUCLEAR  RNA. 

229494  0 
ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3- 
MONOOXYGENASE.  (UNPUBLISHED  PAPER). 

237172  0: 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

251070  0. 
NUCLEI 

THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 
SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BR, 
NUCLEI.  (UNPUBLISHED  PAPER), 

232325  0 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GRC 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AN 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  O; 
TRYPTOPHAN  HYDROXYLASE  IN  DISCRETE  NUCLEI:  COMPARISON  OF 
ACTIVITY  IN  VITRO  AND  IN  VIVO. 

238678  O: 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWING 
HYDROXYDOPAMINE  LESIONS. 

238735  O: 
5-HYDROXY-L  TRYPTOPHAN  DECARBOXYLASE  ACTIVITY:  MICROASSAV 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  0: 
CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE. 

241232  0: 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P  CHLOROAMPHETAMINE. 

241253  0; 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR 

243234  O-! 
CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS. 

250358  0^ 
NUCLEOTIDE 

EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  0/1 
NUCLEOTIDES 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS  IMMUNOCYTOCHEMICAL 
DEMONSTRATION, 

229318  01 
CYCLIC  NUCLEOTIDES,  PROTEIN  PHOSPHORYLATION,  AND  NEURONAL 
FUNCTION 

231021  01 


S-228 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


CYCLIC  NUCLEOTIDES  AND  THEIR  POSSIBLE  RELEVANCE  TO  DISORDERS 
OF  NERVOUS  SYSTEM  FUNCTION.  (UNPUBLISHED  PAPER). 

237171  02-03 

LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
LEUS 

BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 
VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 

NUCLEUS  RAPHE  DORSALIS. 

249249  04-03 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 

OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  PCHLOROPHENYLALANINE 

AND  OF  ALPHA-METHYL-P-TYROSINE. 

250982  04-04 
LEUS-ACCUMBENS 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPUS 
STRIATUM. 

ANTAGONISM  OF  APOMORPHINE  AND  D-AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 
STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI 

\PORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 
ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 

FFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

I  FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AND 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

HE  EFFECT  OF  LONG  TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

Il^g  249670  04-04 

HE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN  MAGNESIUM-OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE-BLIND 

TION  243180  04-1, 

UTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENTAL 
DISABILITIES 

232815  02-15 
TIONAl 

HE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 
AND  MONOAMINE  SYNTHESIS. 

241472  03-17 

EVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 
ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 
VlETHYl  249027  04-03 

)TENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT 

ETHVLATION  250087  04-02 

ETABOLIC  0-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  1  2  5 
DIMETHOXY-4-METHYLPHENYL  2  AMINOPROPANE 
HYlAT,ON  236520  02-03 

IPORTANCE  OF  O-METHYLATION  IN  DOPAMINE-INDUCED  MOTOR  AND 
BEHAVIORAL  PHENOMENA 

^METHYLATED  251143  04-04 

NTHESIS  OF  0-TRANSMETHYLATED  CATECHOLAMINES  AND 
PSYCHODYSLEPTIC  BETA-PHENYLISOPROPYLAMINES  (PH  D 
DISSERTATION). 

242003  03-01 


OBESITY 

HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  PCHLOROPHENYLALANINE. 

243878  04-04 
OBJECTIVE 

OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECTS  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

226411  01  09 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING. 

242745  04-04 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFOR/WANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04-11 
RELATIONSHIP  BETWEEN  OBJECTIVE  AND  SUBJECTIVE  ASSESSMENT  OF 
EXPERIMENTALLY-INDUCED  FATIGUE. 

253587  04-12 
OBSERVATIONS 

BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY. 

226737  01-13 
REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE:  PRELIMINARY  OBSERVATIONS. 

230816  01-09 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20-YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02- 1 7 
METHYLPHENIDATE  AS  A  CHOLINERGIC  AGONIST    FURTHER 
OBSERVATIONS. 

238708  03-03 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03-10 
CLINICAL  OBSERVATIONS  ON  THE  TREATMENT  OF  TARDIVE-DYSKINESIA 
WITH  HALOPERIDOL. 

245967  04-08 
OBSERVING 

EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAL  SCHEDULE. 

245303  04-04 
OBSESSIVE-COMPULSIVE 

DOXEPIN  IN  THE  TREATMENT  OF  OBSESSIVE-COMPULSIVE  NEUROSIS. 

235826  02-10 
ANAFRANIL  IN  OBSESSIVE-COMPULSIVE  NEUROSIS. 

237896  02-10 
OBSTACLES 

OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 
PSYCHOTROPICS  DRUGS. 

239681  03-17 
OBSTETRICAL 

A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY. 

250175  04-15 
OCCASIONAL 

COMPARATIVE  EVALUATION  OF  FLURAZEPAM  AND  NITRAZEPAM  FOR 
OCCASIONAL  INSOMNIACS. 

228315  01-11 
OCCIPITAL 

THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX. 

253691  04-03 
OCULOMOTOR 

ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  BY 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

«r,^„,  238503  02-03 

ODORS 

EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS, 

232905  02-03 
OFFENDING 

47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04-10 
OFFSPRING 

EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIOR 

OF  MATURE  OFFSPRING 

226528  01-04 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 

(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 

CHRONICALLY  TREATED  WITH  METHADONE. 
,,,„  ,  238723  03-03 

SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  MALE  RATS  TREATED  WITH 

METHADONE. 

243789  04-03 


5-229 


Subject  Index 


Psychopharmacology  Abstrc 


GS;;: 

a 

esj" 


C=:i 


EFrtCTS  ON  OFFSPRING  OF  CHRONIC  MATERNAL  METHAMPHETAMINE 
EXPOSURE 

245405  04-05 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 

MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING 

251428  04-05 
OLDER 

IMPLICATIONS  OF  PHENOTHIAZINE  SIDE-EFFECTS:  A  STUDY  OF 
ANTIPARKINSONIAN  AGENTS  IN  AN  OLDER  POPULATION. 

238978  03-15 
OLFACTORY 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01  04 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02-03 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  03-04 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-03 
EFFECT  OF  DELTA9-TETRAHVDR0CANNABIN0L  ON  THE  METABOLISM  OF 
BRAIN  MONOAMINES  WITH  SPECIAL  REFERENCE  TO  THE 
RELATIONSHIP  BETWEEN  NORADRENALINE  CONTENTS  OF  THE 
OLFACTORY  BULB  AND  MURICIDE  BEHAVIOR. 

241373  03-04 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03  03 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEN 
AND  OLFACTORY  STIMULI. 

245406  04-04 
OLIVARY 

DRUG-INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT. 

235866  02-03 
ONTOGENY 

ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO:  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01  04 
EFFECTS  OF  6-HYDROXYDOPAMINE  ON  CENTRAL  NORADRENALINE 
NEURONS  DURING  ONTOGENY. 

241196  03-03 
ONTOGENY  OF  THERMOREGULATORY  MECHANISMS  IN  THE  RAT. 

245608  04-02 
ONYCHOMYS-TORRIDUS 

EFFECTS  OF  P  CHLOROPHENYLALANINE  ON  THE  PREDATORY  BEHAVIOR 
OF  ONYCHOMYS-TORRIDUS. 

242749  04-04 
OOGENESIS 

THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHL0RPR0MA2INE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE 

228554  01-05 
OPEN 

OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN) 

227217  01-09 
OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN) 

227218  01-09 
AN  OPEN  STUDY  OF  MESORIDAZINE  (SERENTIL)  IN  CHRONIC 

SCHIZOPHRENICS 

227821  01-08 
OPEN  WITHDRAVi/AL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 
INDUCED  PARKINSON  SYNDROME 

239822  03  15 
CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTION: 
OPEN  AND  DOUBLE-BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  03-14 
IIOUID  IITHIUM  VS    SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS 

247877  04-07 
OPEN-FIELD 

BKKilNIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISIRATION  ON  OPEN  FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
DOSF  RESPONSE  EFFECTS  OF  SCOPOLAMINE  ON  ACTIVITY  IN  AN  OPEN- 
FlflO. 

237728  02  04 
IIIICIS  OF  NEONAFAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BIIIAVIOR  AND  IHYROID  ACTIVITY  IN  PATS. 

250013  04-04 


OPEN-LABEL 

PILOT  OPEN-LABEL  STUDY  OF  LENPERONE  (AHR-2277).  A 
BUTYROPHENONE,  IN  ANXIETY. 

241278 C 
OPERANT 

OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PH.D. 
DISSERTATION). 

226992  C 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENC 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  ( 
EFFECTS  OF  CARBON  DISULFIDE  ON  OPERANT  BEHAVIOR  IN  PIGEONS 
(PH.D.  DISSERTATION). 

238081  C 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE. 

233687  ( 
EFFECTS  OF  HALLUCINOGENS  ON  OPERANT  BEHAVIOR. 

238814 C 
CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRU( 
AS  CONDITIONED  STIMULI.  (PH.D.  DISSERTATION). 

239523  ( 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPO 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS 

241377 C 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  AN 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  C 
FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS 

249247  C 
SCHEDULE-DEPENDENT  EFFECTS  OF  CHLORDIAZEPOXIDE  ON  OPERANT 
BEHAVIOR  IN  RATS. 

251670 C 
OPHTHAlAAOLOGICAl 

OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  TO 
ANTIPSYCHOTIC  DRUGS. 

227808  C 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDEN 
OF  OPHTHALMOLOGICAL  ABNORMALITIES. 

244779  C 
OPIATE 

INTERACTIONS  OF  OPIATE  RECEPTORS  WITH  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

232960  C 
IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY 

233300  0 
OPIATE  RECEPTORS  AS  REGULATORS  OF  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

2371 75 G 
OPIATE  RECEPTORS  AND  ADENYLATE-CYCLASE  IN  NEUROBLASTOMA: 
GLIOMA  CELL  LINES   (UNPUBLISHED  PAPER). 

238571  0 
IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  WI2099. 

238686  0 
OPIATE  RECEPTORS  IN  CELL  CULTURES.  (UNPUBLISHED  PAPER). 

239787  0 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTIO^ 

246996  0 
FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  0 
BUTYROPHENONE  INFLUENCES  ON  THE  OPIATE  RECEPTOR. 

250088  0 
OPIATE  RECEPTOR  BINDING    -  ENHANCEMENT  BY  OPIATE 
ADMINISTRATION  IN  VIVO 

250378  0 
OPIATES 

ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  V 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  0. 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  I 
THE  GUINEA-PIG  INTESTINE. 

248703  0. 
OPIOID 

REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  A 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE    (PH  D    DISSERTATION). 

241 100  o: 


S-230 


mss^s^ 


UME  14,  SUBJECT  INDEX 


Subject  index 


)N  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 

TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
ID-LIKE 
WLOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 

WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA 

AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOIO-LIKE 

SUBSTANCE  IN  THE  RAT. 

238713  03-04 
lO-SEEKING 
OLERANCE,  PHYSICAL  DEPENDENCE  AND  OPIOID-SEEKING  BEHAVIOR 

DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE 

244202  04-04 
:amoi 
I  CONTROLLED  COMPARATIVE  TRIAL  OF  A  COMBINATION  OF 

OPIPRAMOL  AND  CLOMIPRAMINE  AND  A  HIGHER  DOSE  OF 

CLOMIPRAMINE  ALONE. 

245468  04-09 
SING 

IPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
SITE 

EDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS:  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03-03 
AL 

ORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE. 

246851  04-03 
INS 
PTIONS  FOR  TREATMENT  OF  THE  SCHIZOPHRENIC  PATIENT. 

251546  04-08 

PERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS   (PH  D 
DISSERTATION) 

226992  01-04 

LINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  IV    THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS 

227826  01-09 

ERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
SSOCIATION  BETWEEN  MATERNAL  INTAKE  OF  DIAZEPAM  AND  ORAL 
CLEFTS 

229350  01-1 5 
HANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-13 
HARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 
BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS-  I.  PUPILOMETRY. 

232623  02- 13 
-HEDULE-INDUCED  ORAL  NARCOTIC  SELF-ADMINISTRATION-  ACUTE 
AND  CHRONIC  EFFECTS 

233293  02-04 
RAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03-10 
LC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
VRAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTER 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04- 1 7 
m  PROTIRELIN  (TRH)  IN  DEPRESSION. 

247482  04-09 
OUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN   CROSSOVER   PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS. 

247877  04-07 
)NJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  04-15 
(ARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  0404 
ETHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE. 

250657  04-13 
PRFSSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
IMPARISON  or  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS 

253047  04  08 


ORAllY 

CLOPIMOZIDE  (R-29-764).  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-04 
ORAP 

VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES. 

244188  04-08 
ORDINARY 

DOUBLE  BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
ORF-8063 

CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME. 

241275  03  10 
ORG-GB-94 

CONTROLLED  CLINICAL  TRIAL  OF  A  NEW  ANTIDEPRESSANT  (ORG-GB-94) 
OF  NOVEL  CHEMICAL  FORMULATION. 

248977  04-09 
ORG-6582 

THE  SELECTIVE  INHIBITION  OF  S-HYDROXYTRYPTAMINE  REUPTAKE  BY 
ORG-6582. 

241924  03-03 
ORGAN 

MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04-03 
ORGANIC 

CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II   ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03-11 
ORGANIC  MENTAL  CHANGES  WITH  FLUOROURACIL  THERAPY. 

247978  04-15 
ORGANIC-BRAIN-SYNOROME 

POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOMANIA 
SECONDARY  TO  ORGANICBRAIN-SYNDROME. 

23471 1  02-09 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC-BRAIN-SYNDROME. 

249625  04-11 
THE  EFFECTS  OF  THIOTHIXENE  IN  GERIATRIC  PATIENTS  WITH  CHRONIC 
ORGANIC-BRAIN-SYNDROME. 

253050  04-11 
ORGANISM 

THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY). 

236717  0203 
ORGANIZATION 

ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 
FLUPHENAZINE-DECANOATE. 

229557  01-14 
ORGANIZATION  OF  RECEPTORS  FOR  NEUROTRANSMITTERS  ON  APLYSIA 
NEURONES 

235588  02  03 
ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  BY 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

238503  02-03 
ORGANS 

3HDELTA9  TETRAHYDROCANNABINOL  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS  SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PFRIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS 

237753  02-03 
ENDOGENOUS  INHIBITORS  OF  DOPAMINE  BETA-HYDROXYLASE  IN  RAT 
ORGANS 

244315  04-03 
ACCUMULATION  OF  NOREPINEPHRINE  (NE)  BY  RAT  ORGANS  IN  VIVO. 

246822  04-03 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRONIC 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE. 

247777  04-03 
ORIENTED 

SOMATIC  ORIENTED  TREATMENT  OF  ANOREXIA  NERVOSA. 

243194  04-10 
ORIENTING 

RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITIONFD  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX    -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE 

230570  01-04 


S-231 


Subject  Index 


Psychopharmacology  Abstn 


SQ. 


ORiGIN 

ENDOGENOUS  BRAIN  2-PHENYLETHYLA/viiNE:  dIQCHEMICAL  AND 

PHARAAACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMHHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINF  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN. 

240032  03-09 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHENOBARBITAL. 

250682  04-05 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT. 

252018  04-03 
ORO-BUCCO-llNGUAl 

DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCCO- 
LINGUAL  DYSKINESIAS. 

252031  04-03 
OROTATE 

LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARMACOKINETICS 
POLYDIPSIA  AND  POLYURIA  IN  RATS. 

252198  04-03 
ORTHOMOLECUIAR 

AN  UPDATE  OF  MEGAVITAAyilN  THERAPY  IN  ORTHOMOLECULAR 
PSYCHIATRY. 

235678  02-17 
ORTHOPTERA 

PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 
GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA).  (PHD    DISSERTATION). 

241994  03-04 
ORYCTOLAGUS-CUNICUIUS 

CHOLINERGIC  MODULATION  OF  TONIC  IMMOBILITY  IN  THE  RABBIT 
(ORYCTOLAGUS-CUNICULUS) 

231701  01  03 
OSTEOARTHRITIS 

A  CLINICAL  TRIAL  OF  TOFRANIL  IN  OSTEOARTHRITIS. 

252136  04-11 
OSTEOMALACIA 

OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
OUABAIN 

THE  EFFECT  OF  OUABAIN  AND  DIGITOXIN  ON  HEXOBARBITONE  SLEEPING 
TIME  IN  THE  MOUSE. 

225574  01-03 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
THE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDRO»YDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS. 

242200  03-03 
OUTCOME 

EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL. 

226902  01-16 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  CLINICAL  OUTCOME. 

229443  01-09 
OUTLINE 

OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDENCE 
OF  OPHTHALMOLOGICAL  ABNORMALITIES 

244779  04- 1 5 
OUTPATIENT 

EFFECTS  OF  DISCONTINUITY  OF  MEDICATION  ON  THE  RESULTS  OF  A 
DOUBLE-BLIND  DRUG  STUDY  IN  OUTPATIENT  ALCOHOLICS. 

229091  01-11 
OUTPATIENT  THERAPY  WITH  FLUPHENAZINE  DECANOATE  IN 
SCHIZOPHRENIC  PATIENTS 

229556  01-08 
INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02-17 
CORRELATES  OF  PLACEBO  REACTION  IN  AN  OUTPATIENT  POPULATION. 

235628  02-17 
OUTPATIENT  TREATMENT  WITH  LONG-ACTING  PERPHENAZINE 
(PERPHENAZINE-ENANTHATE):  THREE  CASES. 

239615  03-09 
REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS. 

239641  03-11 
FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH  A 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350), 

239748  03-14 


VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES. 

2441881 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043 
COMPARISON  OF  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSIOh 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661 
OUTPATIENTS 

FLUPENTHIXOL-DECANOATE  -  IN  TREATMENT  OF  OUTPATIENTS. 

226409 
PREDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  I 
DEPRESSED  OUTPATIENTS. 

229449 
A  CONTROLLED  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  IN  DEPRESSED 
OUTPATIENTS. 

231401 
TESTING  OF  NEW  PSYCHOTROPIC  DRUGS  ON  OUTPATIENTS. 

23681 1 
A  DOUBLE-BLIND  TRIAL  OF  MAPROTILINE  (LUDIOMIL)  AND 
AMITRIPTYLINE  IN  DEPRESSED  OUTPATIENTS. 

238981  I 
MAPROTILINE  (LUDIOMIL,  CI8A-34276-BA)  AND  IMIPRAMINE  IN 
DEPRESSED  OUTPATIENTS;  A  DOUBLE-BLIND  CLINICAL  STUDY. 

242248  I 

OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION 

THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACE 

IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIEf 

248975  I 
THE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMEN 
OUTPATIENTS  (A  MULTICENTRIC  STUDY). 

252448 ( 
OUTPUT 

STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THI 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  ( 
OVARIECTOMIZED 

UTEROTROPHIC  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
OVARIECTOMIZED  RATS. 

243865  ( 
EFFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR 
THE  OVARIECTOMIZED  EWE. 

248223  ( 
OVERDOSAGE 

THYROTROPIN  RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  C 
OVERDOSAGE  -    THE  RISE  AND  FALL  OF  TRICYCLIC  ANTIDEPRESSANT 

243064  C 
OVERDOSE 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  C 
TRICYCLIC  ANTIDEPRESSANT  OVERDOSE:  CLINICAL  PRESENTATION  Al 
PLASMA  LEVELS 

231318 C 
CASES  OF  OVERDOSE  WITH  VILOXAZINE  HYDROCHLORIDE  (VIVALAN) 

251003  0 
OVERDOSED 

MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RAT 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREAT 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  0 
OVERLAY 

LORAZEPAM  IN  GASTROINTESTINAL  DISORDERS  WITH  ANXIETY  OVER 
(A  DOUBLE-BLIND  CROSSOVER  STUDY). 

250193  0 
OVERVIEW 

OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  I.  SCHIZOPHRE 

232827  0 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 
DISORDERS. 

236303  O: 
PSYCHOPHARMACEUTICALS  IN  THE  HANDS  OF  THE  GENERAL 

PRACTITIONERS    -  VERTIGO  STATES:  OVERVIEW  AND  SHORT  REPOR 

239768  O: 
AMPHETAMINE  PSYCHOSIS:  OVERVIEW  AND  A  HYPOTHESIS. 

245019  0- 
AN  OVERVIEW  OF  PSYCHOPHARAAACOLOGY  OF  OLD  AGE. 

253062  0' 
OXAZEPAM 

THE  DIFFERENTIAL  EFFECTS  OF  CHLORDIAZEPOXIDE  AND  OXAZEPAM  ( 
HOSTILITY  IN  A  SMALL  GROUP  SETTING. 

227569  01 


S-232 


^e^m 


rOLUME  14,  SUBJECT  INDEX 


Subject  Index 


PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL 

237123  02-13 
ACUTE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE,  ALONE 
AND  IN  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
AND  MOOD. 

239042  03-14 
NORMAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE  BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS 

248975  04-10 
XIDASE 

MONOAMINE  OXIDASE  ACTIVE  SITE,  THE  BINDING  TO  AND  TITRATION 
OF  MONOAMINE-OXIDASE  WITH  (14C)  SELECTIVE  INHIBITORS. 

241931  03-03 
XIDATION 

EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM  -   EVIDENCE  FOR 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179  04-03 
XIDATIONS 

ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10-2  ARYLIMINO-3  ACETYLAMINO-4-THIAZOLIDONYL  PHENOTHIAZINES. 

239662  03-03 
XIDATIVE 

THE  NATURE  OF  THE  455-NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYTOCHROMEP450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE. 

241350  03-01 
XOTREMORINE 

OXOTREMORINE  AND  ATROPINE  INDUCED  CHANGES  OF  DOPAMINE 

METABOLISM  IN  THE  RAT  STRIATUM 

230854  01-03 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 

ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE   EFFECTS  OF 

OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  04-03 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 

UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 

DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO. 

251175  04-03 
XPRENOIOL 

CLINICAL  TRIALS  OF  OXPRENOLOL  IN  ANXIETY. 

251159  04  10 
OXPRENOLOL  IN  THE  TREATMENT  OF  EXAMINATION  NERVES. 

251160  04-10 
OXPRENOLOL  IN  SENILE  TREMOR. 

251163  04-11 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY. 

251986  04- 14 
(YBUTYRATE 

EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE   L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02  04 
(YGEN 

THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01-03 

DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME). 

238825  03-03 
(YPERTIN 

THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
-HIOROAMPHETAMINE 
THE  ACTION  OF  FENFLURAMINE  AND  P  CHLOROAMPHETAMINE  ON 

SEROTONERGIC  MECHANISMS,  A  COMPARATIVE  STUDY  IN  RAT  BRAIN 
NUCLEI    (UNPUBLISHED  PAPER). 

232325  01  03 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  PCHLOROAMPHETAMINE 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  02  03 
INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P- 
CHLOROAMPHETAMINE. 

237242  0203 


COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI. 

237863  02-03 

EFFECTS  OF  P-CHLOROAMPHETAMINE  ON  LOCOMOTOR  ACTIVITY  AND 
BRAIN  5-HYDROXYINDOLES. 

239958  03-04 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 

FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  ( -f  ) 
AMPHETAMINE  AND  (  +  OR-)  P-CHLOROAMPHETAMINE. 

239976  03-03 
P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE. 

24)253  03-03 
INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 
HYDROXYINDOLES  BY  P-CHLOROAMPHETAMINE 

241339  03-03 
EFFECTS  OF  INTRAVENTRICULAR  P-CHLOROAMPHETAMINE  AND  ITS 
ANALOGUES  ON  CEREBRAL  5-HT 

246151  04-03 
CORRELATION  BETWEEN  BRAIN  LEVELS  AND  BIOCHEMICAL  EFFECTS  ON 
THE  OPTICAL  ISOMERS  OF  P-CHLOROAMPHETAMINE. 

246851  04-03 
SYNAPTOSO/WAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P-CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04-05 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P  CHLOROAMPHETAMINE  ON 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN. 

249300  04-03 
P-CHIOROPHENYLALANINE 

EFFECT  OF  P-CHLOROPHENYLALANINE  ON  THE  ACQUISITION  OF 
TOLERANCE  TO  ETHANOL  AND  PENTOBARBITAL. 

237720  02-04 
STUDIES  ON  THE  BEHAVIOURAL  EFFECTS  OF  TRYPTOPHAN  AND  P- 
CHLOROPHENYLALANINE. 

239959  0303 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
SOME  PHARAAACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN-HYDROXYLASE  INHIBITION 

241978  03-03 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  THE  PREDATORY  BEHAVIOR 
OF  ONYCHOMYS-TORRIDUS. 

242749  04-04 
SOME  PHARAAACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN  HYDROXYLASE  INHIBITION, 

243848  04-03 
HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  P-CHLOROPHENYLALANINE. 

243878  0404 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04  04 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P  CHLOROPHENYLALANINE 
AND  OF  ALPHA-METHYL-P  TYROSINE. 

250982  04-04 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT 

252018  04-03 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT. 

252519  04-03 
PAIN 

MARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE    EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS. 

226903  01-14 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02-04 
A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY 

250175  04-15 
TOFRANIL  IN  THE  TREATMENT  OF  LOW  BACK  PAIN. 

252138  04-11 
A  CLINICAL  TRIAL  OF  TOFRANIL  IN  RHEUMATIC  PAIN  IN  GENERAL 

PRACTICE. 

252139  04-17 


S-233 


Subject  Index 


Psychopharmacology  Abstract 


-<: 
cs;: 

esi' 


cs 


ANAFRANIl  IN  THE  MANAGE/WENT  OF  LONG  TERM  PAIN:  A  PRELIMINARY 
REPORT, 

252141  04-07 
THE  MEASUREMENT  OF  PAIN  IN  TERMINAL  CARCINOMA. 

252143  04-11 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  A  PAIN  CLINIC. 

252144  04-17 
PAINFUL 

THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  OTHER  PAINFUL  CONDITIONS. 

252142  04-17 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 

HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
PALATE 

ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM. 

229349  01-17 
PAUMAR 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS 

248514  04-04 
PAIMITATE 

A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 
PATIENTS. 

230780  01-08 
PAMOATE 

IMIPRAMINE  PAMOATE  IN  DEPRESSION. 

228243  01-11 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIVE 
NEUROSIS, 

246300  04  10 
PANENCEPHALITIS 

ISOPRINOSINE  THERAPY  IN  SUBACUTE  SCLEROSING  PANENCEPHALITIS. 

251952  04  11 
PAPAVERINE 

ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS 

226478  01-11 
AN  EVALUATION  OF  PAPAVERINE  IN  TARDIVE-DYSKINESIA. 

251830  04-13 
PAPIO-PAPIO 

EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS, 
PAPIO-PAPIO. 

230475  01-03 
BIOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO. 

237755  02  04 
PARA 

CATECHOL  0-METHYLTRANSFERASE  FROM  RAT  LIVER:  TWO  FORMS 
HAVING  DIFFERENT  META:PARA  METHYLATION  RATIOS. 

249035  04-01 
PARACETAMOL 

WHY  DO  PEOPLE  USE  PARACETAMOL  FOR  SUICIDE^ 

241754  03-17 
PARADIGM 

CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM 

238787  03  04 
A  BEHAVIORAL  PARADIGM  FOR  THE  EVALUATION  OF  NARCOTIC 
ANTAGONISTS. 

239941  03-11 
PARADOXES 

PHARMACOTHERAPY  AND  PSYCHOTHERAPY.  PARADOXES,  PROBLEMS 
AND  PROGRESS. 

229240  01-17 
PARADOXICAL 

PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAl 

227132  01-04 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 
PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE 

230841  01  03 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4)   ROIE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP 

241388  03-03 
PARADOXICAL  RAGE  REACTIONS  DURING  PSYCHOTROPIC  MEDICATION. 

246184  04-15 
AMPIK  (AMINES  PARADOXICAL  EFFECTS  MAY  BE  PREDICTABLE. 

251154  04-14 


A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE. 

251951  04-( 
PARAFILM 

INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS. 

253693  04-( 
PARALYTIC 

FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY. 

235286  02- 
PARAMETERS 

A  1,4  BENZODIAZEPINE,  TEAMZEPAM  (K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02- 
TEMPORAL  PARAMETERS  OF  D-AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT. 

239856  03-1 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I.  INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-1 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIEN' 
WITH  CHRONIC  ORGANIC  BRAIN  DAAAAGE. 

240219  03- 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  III.  PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT. 

240220  03- 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 

VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE.  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-1 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03- 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04-1 
A  RELATIONSHIP  BETWEEN  CLINICAL  EFFICACY  AND  VARIOUS 

BIOCHEMICAL  PARAMETERS  OF  MONOAMINE  OXIDASE  INHIBITORS 
(MAOIS). 

249308  04^ 
CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  A! 
5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS. 

249318  04-1 
PARAMETHADIONE 

PARAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTE 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04-' 
PARANOID 

SULPIRIDE  IN  CHRONIC  PSYCHOSES  OF  THE  PARANOID  TYPE, 

230991  01- 
PARAOXON 

CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIV( 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-( 
PARATHION 

PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 
INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISU/ 
DISCRIMINATION  PERFORMANCES. 

227384  01-( 
SOME  EFFECTS  OF  PARATHION  ON  THE  SCHEDULE-CONTROLLED 
BEHAVIOR  OF  THE  PIGEON 

249266  04-C 
PARENTERAL 

PRELIMINARY  EXPERIENCE  WITH  PARENTERAL  SINTAMIL  IN  TREATMENT 
OF  DEPRESSION 

235348  02-( 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS    A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPAREC 
TO  FLUPENTHIXOL  DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-C 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

246891  04-1 
PARENTERALLY 

TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  LOXAPINE 
PARENTERALLY. 

238551  02-C 
PARGYLINE 

DIFFERENTIAL  EFFECTS  OF  TRANYLCYPROMINE  AND  PARGYLINE  ON 
INDOLEAMINE  SYSTEMS  IN  BRAIN. 

238675  n3-C 


S-234 


'OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THt  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 
NOREPINEPHRINE  BY  N  ETHYLAMPHETAMINE  AND  FENFLURAMINE. 

238688  03-03 
CATECHOLAMINES  IN  BRAIN  ISCHEMIA   -  EFFECTS  OF  ALPHA-METHYL-P- 
TYROSINE  AND  PARGYLINE. 

239577  03  03 
REDUCTION  OF  ALCOHOL  SELECTION  BY  PARGYLINE  IN  MICE. 

241225  0304 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  0403 
\K\S 

NINTH  CONGRESS  OF  THE  INTERNATIONAL 
NEUROPSYCHOPHARMACOLOGICUM  COLLEGIUM  OR  C.I.N. P.  (PARIS, 
JULY  712,  1974). 

250266  04-17 
^RKINSON 

OPEN  WITHDRAWAL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 
INDUCED  PARKINSON  SYNDROME. 

239822  03  1 5 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT    -  A  MODEL  FOR 
BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME.  Ill: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
^RKINSON-LIKE 

CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS. 
LV-A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS. 

245863  04-08 
\RKINSONIAN 

CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS 

249232  04  15 
\RKtN$ONISM 

PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01  14 
COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG-RANGE  L-DOPA  THERAPY 
IN  PARKINSONISM. 

229165  01  11 
LEVODOPA  AND  PSYCHOMETRIC  TEST  PERFORMANCE  IN  PARKINSONISM 
5  YEARS  LATER. 

237141  02  14 
ANTIDOPAMINERGIC  AND  ANTIMUSCARINIC  EFFECTS  OF 
DIBENZODIAZEPINES:  RELATIONSHIP  TO  DRUG  INDUCED 
PARKINSONISM. 

241248  03  03 
PARKINSONISM  INDUCED  BY  FLUPHENAZINE-DECANOATE. 

242267  03-15 
DRUG  INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III 
THE  INCORPORATION  OF  D  GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES 

244692  04-03 
PARKINSONISM  AND  DEMENTIA:  EFFECTS  OF  LEVODOPA. 

245235  04-11 
L  DOPA  THERAPY  AND  STEREOTAXIC  THALAMOTOMY  FOR 
PARKINSONISM. 

245986  04  I  I 
PIRIBEDIL    ITS  SYNERGISTIC  EFFECT  IN  MULTIDRUG  REGIMENS  FOR 
PARKINSONISM 

251651  04-07 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS   IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM 

251959  04-05 
VRKINSONS 

IWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L-DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO-4-4602) 

233917  02  11 
THE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 
(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE. 

233974  02  11 
TREATMENI  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 
ROLF  OF  GROWTH  HORMONE 

237253  02  11 
NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT  TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE 

238516  02  n 
BIOCHEMICAL  PMARMACOLOGICAI  BASFS  FOR  THE  CLINICAL  USE  OF  L 
DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME 

244039  04  1  / 


COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  IN  PARKINSONS 
DISEASE. 

248612  04-11 
COMPARISON  OF  DOPA-DECARBOXYLASE  INHIBITOR  (CARBIDOPA) 

COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 

DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY. 

250722  04-15 
FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04-11 
BROMOCRIPTINE  TREATMENT  IN  PARKINSONS  DISEASE. 

251239  04-11 
SIX-YEAR  RESULTS  OF  TREATMENT  WITH  LEVODOPA  PLUS  BENSERAZIDE 
IN  PARKINSONS  DISEASE. 

251648  04-11 
PAROLED 

CONTINGENT  NALOXONE  (N  ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01-14 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 
TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03- 11 
PAROXYSMAL 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01-13 
SCHIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY:  TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEC. 

228068  01-08 
PAROXYSMAL  NIGHTMARES:  SEQUEL  OF  A  STROKE  RESPONSIVE  TO 
DIPHENYLHYDANTOIN 

233295  02- 14 
PARSONS 

FUGUE  STATES    -  EPILEPSY    -  MEDICATION    -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V.  PARSONS,  371  N.Y.S.2D  840,  (NEW- YORK), 
NASSAU  COUNTY  COURT.  AUGUST  1,  1975. 

237476  02-17 
PARTIAL 

INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  PARTIAL 
REINFORCEMENT  EFFECTS. 

230875  01-04 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
PARTICIPATING 

PHARMACOIOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  10  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
PARTICIPATION 

PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 

MECHANISMS  Of  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-04 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  THE 
REGULATION  OF  EMOTIONAL  REACTIVITY 

242544  03-03 
PARTICULATE 

RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
PASSIVE 

PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6  OH-DOPAMINE, 

239841  03-04 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITALINDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
THE  EFFECT  Of  LITHIUM  CHLORIDE  ON  ONE  TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS 

243804  04  04 
EFFECTS  OF  N  HYDROXYETHYL  PYRROLIDINIUM  METHIODIDE,  A  CHOLINE 
ANALOGUE.  ON  PASSIVE  AVOIDANCE  BEHAVIOUR  IN  MICE 

245594  04-04 
DOSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT. 

24631-3  04-04 


S-235 


Subject  Index 


Psychopharmacology  Abstract 


SiCl 


cs; 

i 


EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS 

246819  04-04 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS. 

249381  04-04 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORMANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04-14 
PASSIVE-DEPENDENT 

THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIENTS 
WITH  PASSIVE-DEPENDENT  PERSONALITY  TRAITS. 

251717  04-11 
PATHOGENESIS 

EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
SCHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04- 16 
PATHOGENIC 

INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL;  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
PATHOLOGICAL 

CEREBELLAR  ATAXIA  DUE  TO  OIPHENYLHYDANTOIN  ADMINISTRATION  - 
CLINICAL  AND  PATHOLOGICAL  STUDIES  ON  TWO  CASES  OF  CHRONIC 
OIPHENYLHYDANTOIN  INTOXICATION. 

236696  02-15 
PATHWAY 

NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  03-03 
EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 
PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
D-AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04-03 
NEW  PATHWAY  FOR  METABOLISM  OF  DOPA. 

246286  04-03 
PATHWAYS 

BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 
DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
ARE  CENTRAL  CHOLINERGIC  PATHWAYS  INVOLVED  IN  THE  HABITUATION 
OF  EXPLORATION  AND  DISTRACTION' 

241932  03-04 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS. 

250075  04-04 
BEHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  04-04 
PATIENT 

THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG- 
STAY  PSYCHIATRIC  PATIENT. 

227461  01-17 
THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS. 

229552  01-17 
CLINICAL  PSYCHOPHARMACOLOGY  AND  THE  ELDERLY  PATIENT. 

236300  02-17 
SUDDEN  UNEXPLAINED  DEATH  IN  A  PSYCHIATRIC  PATIENT  TAKING 
THIORIDAZINE. 

240243  03-15 
EARLY  STRATEGIES  IN  TREATMENT  OF  THE  DEPRESSED  PATIENT. 

241435  03- 17 
CASE  REPORT  OF  THE  MCLEAN  HOSPITAL,  BELMONT,  MASSACHUSETTS: 
LV -A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS. 

245863  04-08 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 
OPTIONS  FOR  TREATMENT  OF  THE  SCHIZOPHRENIC  PATIENT. 

251546  04-08 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS:  DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS. 

253043  04-16 
PATIENTS 

INVOLUNTARY  MOVEMENTS  CAUSED  BY  PHENYTOIN  INTOXICATION  IN 
EPILEPTIC  PATIENTS. 

225890  01-15 


PLASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  II 
COMBINATION  WITH  AMANTADINE. 

226349  01- 
BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY. 

226737  01- 
EFFECT  OF  PERIPHERAL  DECARBOXYL^ASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

226915  01-1 
EFFECTS  OF  A  PROCAINE  PREPARATION  (GER0VITAL-H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  STUDY. 

227330  01- 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  TO 
ANTIPSYCHOTIC  DRUGS 

227808  01- 
CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASIN 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01-1 
VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLINO  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01 -I 
AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS 

228225  01-( 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01- 
THE  PROBLEMS  AND  TREATMENT  OF  PATIENTS  WITH  GILLES-DE-LA- 
TOURETTES  SYNDROME. 

229295  01  ■■ 
DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS. 

229368  01-1 
PHARMACODYNAMICS  OF  IMIPRAMINE  IN  DEPRESSED  PATIENTS. 

229437  01 -( 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  0 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01 -C 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE  BLIND  CLINICAL  STUDY. 

229504  01-1 
DOXEPIN,  A  NEW  ANTIDEPRESSANT  DRUG  FOR  PATIENTS  IN  THE 
INTERNAL  MEDICINE  CLINIC. 

229515  01-1 
CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  Oil 
CLINICAL  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE  IN 

HOSPITALIZED  PATIENTS. 

229551  OM 
OUTPATIENT  THERAPY  WITH  FLUPHENAZINE-DECANOATE  IN 

SCHIZOPHRENIC  PATIENTS. 

229556  01-0 
THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY. 

229650  01  1 
PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  CM 
CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01-11 
GETTING  PSYCHIATRIC  PATIENTS  TO  TAKE  THEIR  MEDICATION. 

230118  01-1 
EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  OM: 
A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 
PATIENTS 

230780  01  Of 
REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE:  PRELIMINARY  OBSERVATIONS. 

230816  01-« 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  AAADOPAR  AND  PLACEBO. 

230823  01 -0£ 


S-236 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS 

230824  01-09 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC-ACID  (5HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01-09 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

231034  01-08 
PSYCHOLOGICAL  ANALYSES  OF  PATIENTS  SUFFERING  FROM 
HYPOTHYROIDISM. 

232364  01-14 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

232840  02-08 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE. 

232865  02-15 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE. 

234044  02-09 
EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESSION 
(INTRODUCTORY  REPORT). 

234046  02-09 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
EFFECT  OF  L-5-HYDROXYTRYPTOPHAN  ON  BRAIN  MONOAMINE 
METABOLISM  AND  EVALUATION  OF  ITS  CLINICAL  EFFECT  IN 
DEPRESSED  PATIENTS. 

234673  02-09 
THE  IMMEDIATE  EFFECTS  OF  CHLORPROMAZINE  IN  NEWLY  ADMITTED 
SCHIZOPHRENIC  PATIENTS. 

234700  02-08 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS  -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL. 

235360  02-07 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS   -  II.  REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    -  III.  STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  IV.  A  SUMMARY  REPORT. 

235363  02  09 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS  -  A 

COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02-08 
A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 

CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02-17 
EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS 

235782  02-11 
INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENTS 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361  02  08 
CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDER 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE 

236364  02-10 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION 

236801  02-13 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  0216 


CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271  02-14 
TREATMENT  OF  ALCOHOLIC  METHADONE  /MAINTENANCE  PATIENTS  WITH 
DISULFIRAM. 

237624  02-11 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS. 

237828  02-08 
A  PRELIMINARY  STUDY  WITH  PENFLURIDOL  IN  HOSPITALIZED  CHRONIC 
SCHIZOPHRENIC  PATIENTS. 

237897  02-08 
LENPERONE:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

237899  02-08 
APPARENT  PHARAMCOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901  02-13 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS. 

237902  02-13 
TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  LOXAPINE 

PARENTERALLY. 

238551  02-09 
SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 

PSYCHIATRIC  PATIENTS. 

238552  02-13 
PLASMA  AND  ERYTHROCYTE  AAAGNESIUM  LEVELS  IN  PATIENTS  WITH 

PRIAAARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
DOES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS?. 

239002  03-09 
ANXIETY  AND  EEG  ALPHA  ACTIVITY  IN  NEUROTIC  PATIENTS. 

239022  03-10 
CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS. 

239058  03  14 
TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DELAGRANGE). 

239269  03-11 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE-BLIND  TRIAL 

239348  03-09 
THE  EFFECT  OF  NEUROLEPTICS  ON  SERUM  PROLACTIN  IN  SCHIZOPHRENIC 
PATIENTS. 

239931  03-08 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE. 

240055  03-09 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLE.PTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAAAAGE. 

240219  03  11 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (0RF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME 

241275  03-10 
ORAL  DIAZEPAM  IN  HOSPITALIZED  ANXIETY  PATIENTS  (WITH 
OBSERVATIONS  ON  CONCENTRATION  EFFECT  RELATIONSHIPS). 

241427  03-10 
BIOAVAILABILITY  OF  TWO  CARBAMAZEPINE  PREPARATIONS  DURING 
CHRONIC  ADMINISTRATION  TO  EPILEPTIC  PATIENTS. 

242212  0311 
A  DOUBLE-BLIND  COMPARATIVE  CLINICAL  TRIAL  WITH  MAPROTILINE 
(LUDIOMIL)  AND  IMIPRAMINE  IN  NEWLY-ADMITTED  DEPRESSED 
PATIENTS. 

242249  03-09 
CLINICAL  RESEARCH  WITH  DEMETRIN  IN  SURGERY  PATIENTS. 

242527  03-07 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS 

242863  04-15 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 
THE  CLINICAL  EFFECTIVENESS  OF  A  CAVAIN  MAGNESIUM  OROTATE 
COMBINATION  IN  NURSING  HOME  PATIENTS  IN  A  DOUBLE  BLIND 
STUDY. 

243180  04  II 


S-237 


Subject  Index 


Psychopharmacology  Abstraci 


3511 


CSi' 
cs; 


PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC  DEPRESSIVE 
PSYCHOSIS 

243979  04-09 

PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES 

243985  04-09 
EFFECT  OF  CLOZAPINE  ON  THE  MENTAL  AND  PHYSICAL  STATE  OF 

PATIENTS. 

243986  04-08 
THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  ACTIVITY 

IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

244495  04-09 
A  TWO  YEAR  TRIAL  OF  LOXAPINE  SUCCINATE  IN  CHRONIC  PSYCHOTIC 
PATIENTS. 

244501  04-08 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS-. 

AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I   OUTLINE  OF  THE  INCIDENCE 
OF  OPHTHALMOLOGICAL  ABNORMALITIES. 

244779  04-15 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

245014  04  08 
TRIAZOLAM  IN  INSOMNIAC  FAMILY  PRACTICE  PATIENTS. 

245649  04- n 
PENFLURIDOL  STEADY-STATE  KINETICS  IN  PSYCHIATRIC  PATIENTS. 

245650  04-08 
EFFECTS  OF  DRUGS  ON  EPILEPTIC  PATIENTS. 

245884  04-11 
THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04-17 
THERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLERIL) 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  04-08 
HOMOVANILLICACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLICACID  AND  5-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04  13 
CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 

MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR 

247022  04-11 
ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY' 

247359  04-15 
A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS 

247483  04-08 
EFFECT  OF  METHYLDOPA  ON  TARDIVE-DYSKINESIA  IN  PSYCHOGERIATRIC 
PATIENTS 

247967  04-11 
DIFFERENTIAL  EFFECTS  OF  D    AND  L  AMPHETAMINE  ON  THE  SLEEP  OF 
DEPRESSED  PATIENTS. 

248160  04- 10 
COMPARISON  OF  DOPADECARBOXYLASE  INHIBITOR  (CARBIDOPA) 
COMBINED  WITH  LEVODOPA  AND  LEVODOPA  ALONE  ON  THE 
CARDIOVASCULAR  SYSTEM  OF  PATIENTS  WITH  PARKINSONS  DISEASE. 

248613  04-11 
SELF-INHIBITING  ACTION  OF  NORTRIPTYl  INE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION 

248955  04-10 
BEHAVIORAL  EFFECTS  OF  L-DOPA  AND  THYROTROPIN  RELEASING 
HORMONE  IN  SCHIZOPHRENIC  PATIENTS:  A  PRELIMINARY  REPORT. 

249120  04-08 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE  OXIDASE  ACTIVITY  IN 

SCHIZOPHRtNIC  PATIENTS  ON  PHENOTHIAZINES 

249 1 21  04-08 
STUDIES  ON  THYROID  THERAPY  AND  THYROID  FUNCTION  IN  DEPRESSIVf 

PATIENTS. 

249123  04-13 


THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04- 
CONJUGATION  OF  L-DOPA  AND  ITS  METABOLITES  AFTER  ORAL  AND 
INTRAVENOUS  ADMINISTRATION  TO  PARKINSONIAN  PATIENTS. 

249232  04- 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  IN 
PATIENTS  TAKING  LITHIUM  CARBONATE. 

249535  04-1 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC-BRAIN-SYNDROME. 

249625  04- 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04- 
WARNED  REACTION  TIMES  OF  MANIC-DEPRESSIVE  PATIENTS  WITH  ANt 
WITHOUT  LITHIUM. 

249798  04-1 
TIME-DEPENDENT  EFFECTS  OF  PHENOTHIAZINES  ON  DOPAMINE 
TURNOVER  IN  PSYCHIATRIC  PATIENTS. 

250389  04- 
FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04- 
BEHAVIOURAL  AND  BIOCHEMICAL  EFFECTS  OF  FENFLURAMINE  IN 
PATIENTS  WITH  NEUROLOGIC  DISEASE. 

250942  04- 
A  CLINICAL  TRIAL  OF  TEMAZEPAM.  A  SLEEP  INDUCER,  IN  HOSPITAL 
PATIENTS. 

251006  04-1 
THE  INFLUENCE  OF  THE  DECARBOXYLASE  INHIBITOR  BENSERAZIDE  ON 
ANTIHYPERTENSIVE  EFFECT  AND  METABOLISM  OF  METHYLDOPA  IN 
HYPERTENSIVE  PATIENTS. 

251418  04- 
THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIENT! 
WITH  PASSIVE-DEPENDENT  PERSONALITY  TRAITS. 

251717  04- 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 

IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04- 
CHLORPROAAAZINE  METABOLISM  VML  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS 

251778  04-' 
CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRENIC 
PATIENTS:  A  PILOT  STUDY. 

251828  04-( 
ANTIDOPAMINERGIC  EFFECTS  OF  APOMORPHINE  IN  PATIENTS  WITH 
DYSKINESIAS 

251958  04-1 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINI 

251985  04-1 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS 

252713  04-1 
MANAGEMENT  OF  PATIENTS  WITH  SUSPECTED  DRUG-INDUCED 
PSYCHOSES 

252733  041 
THIORIDAZINE  IN  THE  TREATMENT  OF  DEPRESSIVE  PATIENTS. 

252760  04-C 
THE  EFFECTS  OF  THIOTHIXENE  IN  GERIATRIC  PATIENTS  WITH  CHRONIC 
ORGANIC-BRAIN-SYNDROME 

253050  04-1 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 

HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS. 

253051  04-0 
A  STANDARD  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE  ON 

GERIATRIC  PATIENTS 

253058  04-1 
DO  PSYCHIATRIC  PATIENTS  TAKE  THEIR  MEDICATION?.  THE  VIEW  OF 
THE  STAFF. 

253103  04-1 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-0 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AND 
PSYCHOTIC  PATIENTS. 

253641  04-1 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY 

253684  04-1 
PATTERN 

EFFECTS  OF  CLONIDINE  AND  BS-lOO-141  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS. 

226728  01-0: 


S-238 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


CANNABINOID  PATTERN  IN  CANNABIS  SATIVA  L.  SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE. 

237982  02  01 
DELTA9  TETRAHYDROCANNABINOL  (DELTA9THC)  AND  11  0HDELTA9- 
THC:  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS 

238813  03-04 
EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03  04 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT 

245929  04-02 
ALTERED  PATTERN  OF  DOPA  METABOLISM. 

251185  U4-03 
kHERNING 

SODIUM  AMYL0BAR6IT0NE  AND  THE  PATTERNING  EFFECT, 

244217  04-04 
kHERNS 

INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02- 17 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARUUANA  ON  EEG 
PATTERNS  IN  CATS. 

235564  02-03 
CHANGING  PATTERNS  IN  THE  MANAGEMENT  OF  DEPRESSION, 

243863  04-09 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS, 

249749  04-03 
THE  EFFECTS  OF  5-HYDROXYTRYPTOPHAN  AND  L  TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT, 

252216  04-03 
PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 
COUNTRY 

252990  04-17 
kVOR-NOCTURNUS 

PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  OR 
NEUROLEPTIC  DOSAGE. 

252955  04  17 
IZ 

RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE-BETA  HYDROXYLASE 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP 

238690  03-03 
:a 

P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE, 

250083  04-04 

;PA 

EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS 

238695  0303 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I,  PGO  WAVE  ACTIVITY  INDUCED  BY  RO  4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES, 

241315  03-03 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYIALANINE  (PCPA)  IN  THE  RAT, 

246674  04  04 
PA-INDUCEO 
HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA  INDUCED 
HYPERACTIVITY  IN  THE  RAT, 

226734  0 1  -04 
C 

THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 
PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE, 

238737  03  03 
A 

2-PHENYLETHYLAMINE  (PEA)  IN  D-AMPHETAMINEINDUCED 
EXTRAPYRAMIDAL  DISORDERS, 

238841  03-03 
BETA-PHENYLETHYLAMINE  (PEA)  AND  THE  NEUROPSYCHIATRIC 
DISTURBANCES  (UNPUBLISHED  PAPER), 

241474  03-14 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIf  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC), 

249309  04  03 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE  OXIDASE  INHIBITOR  (MAOI) 

UPON  THE  CENTRALNERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2-PHENYLETHYLAMINE  (PEA), 

249310  04-03 


CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

24931 1  04-03 
PEAK 

COUNSELING,  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH,  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS,  (PHD, 
DISSERTATION), 

228686  01-11 
PECKING 

INVOLVEMENT  OF  BIOGENIC  AMINES  IN  DRUG  INDUCED  AGGRESSIVE 
PECKING  IN  CHICKS, 

230878  01-04 
DOPAMINERGIC  NATURE  OF  AMPHETAMINE-INDUCED  PECKING  IN 
PIGEONS 

248408  04-03 
PEDIATRIC 

THE  EFFECTIVENESS  OF  DIPHENHYDRAMINE  HCL  IN  PEDIATRIC  SLEEP 
DISORDERS 

251827  04-14 
PEDIATRICS 

NEW  DEVELOPMENTS  IN  THE  USE  OF  PHENOBARBITAL  IN  PEDIATRICS. 

240723  03- 1  7 
PEER 

PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATbXHOLAMINE 
METABOLISM. 

248437  04-04 
PELLET 

CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01  03 
ETHANOL.  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-. NTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION, 

238749  03-04 
SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE, 

249254  04-05 
PELLETED 

TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  0403 
PELLETS 

REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION    EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS 

251533  04-04 
PEMOLINE 

EFFECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH-TO-SAMPLE 
lASK  IN  MONKEYS 

230577  01  04 
COMPARATIVE  PHARMACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  ON 
BIOGENIC  AMINE  SYSTEMS. 

238728  03-03 
PENFLURIDOL 

EFFECTS  OF  LONG  TERM  APPLICATION  OF  PENFLURIDOL  (TLP  607)  FOR 
SCHIZOPHRENIA, 

228324  01-08 
A  DOUBLE  BLIND  COMPARISON  OF  PENFLURIDOL  (LASER)  WITH 
PIMOZIDE  IN  SCHIZOPHRENIA, 

229026  01-07 
PENFLURIDOL  IN  THE  TREATMENT  OF  SCHIZOPHRENIA:  CLINICAL  AND 
PSYCHOMETRIC  FINDINGS 

235365  02-08 
A  PRELIMINARY  STUDY  WITH  PENFLURIDOL  IN  HOSPITALIZED  CHRONIC 
SCHIZOPHRENIC  PATIENTS 

237897  02-08 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG  ACTING 

NEUROLEPTICS,  A  DOUBLE  BUND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA 

239023  03-08 
THE  PROBLEM  OF  POST  PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION    LONG  TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE  BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE, 

239823  03-08 
BEHAVIORAL  EFFECTS  OF  PENFLURIDOL  IN  RATS 

241376  03-04 
NEUROPHARMACOLOGICAL  EFFECTS  OF  PENFLURIDOL,  A  NEW 
ANTIPSYCHOTIC  AGENT 

241384  03-03 
PENFLURIDOL  STEADY  STATE  KINETICS  IN  PSYCHIATRIC  PATIENTS, 

245650  04-08 
PENFLURIDOL  BLOCKADE  OF  APOMORPHINE:  DEPENDENCE  OF  DURATION 
ON  SPECIES  AND  ENDPOINT 

248406  04-02 


S-239 


Subject  Index 


Psychopharmacotogy  Abstract 


CS: 


THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-04 
A  LONG-TERM  STUDY  OF  PENFLURIDOL  IN  CHRONIC  SCHIZOPHRENIA. 

251829  0408 
PENTAPEPTIDES 

IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY. 

233300  02-01 
PENTAZOCINE 

PENTAZOCINE  PSYCHOSIS:  A  CASE  OF  PERSISTENT  DELUSIONS. 

225873  01-15 
RESPIRATORY  EFFECTS  OF  LORAZEPAM,  PENTOBARBITAL,  AND 
PENTAZOCINE. 

226828  01-15 
MENTAL  AND  EMOTIONAL  DISTURBANCE  WITH  PENTAZOCINE  (TALWIN) 
USE. 

233828  02-15 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS 

241250  03-04 
PENTAZOCINE  ABUSE  AND  PROBLEMS  OF  WITHDRAWAL. 

246617  04-17 
PENTAZOCINE  DEPENDENCE   -  TRUTH  AND  FICTION'. 

246707  04-15 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04-04 
PENTOBARBITAL 

RESPIRATORY  EFFECTS  OF  LORAZEPAM,  PENTOBARBITAL,  AND 
PENTAZOCINE. 

226828  01-15 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
LORAZEPAM  COMPARED  WITH  PENTOBARBITAL  FOR  NIGHTTIME 
SEDATION. 

232622  02-14 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENTOBARBITAL 
ON  AUDITORY  EVOKED  RESPONSES. 

234682  02-03 
EFFECT  OF  P-CHLOROPHENYLALANINE  ON  THE  ACQUISITION  OF 
TOLERANCE  TO  ETHANOL  AND  PENTOBARBITAL. 

237720  02-04 
EVALUATION  OF  LORAZEPAM  AND  PENTOBARBITAL  AS  SURGICAL 
PREMEDICANTS. 

237734  02-14 
EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS. 

238695  03-03 
DIFFERENTIAL  INTERACTIONS  OF  PENTOBARBITAL  AND  PHENOBARBITAL 
WITH  BETA  ADRENERGIC  MECHANISMS. 

238725  03-03 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  03-04 
EFFECTS  OF  ACUTE  AND  CHRONIC  PENTOBARBITAL  ADMINISTRATION  ON 
BRAIN  GAMMA  AMINOBUTYRATE  (GABA)  AND  GLUTAMATE  (GLU) 
LEVELS  IN  THE  MOUSE. 

238791  03-03 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL 

240074  03  1 4 
DIFFERENTIAL  EFFECTS  OF  PHENOBARBITAL  AND  PENTOBARBITAL  ON 
ISOLATED  NERVOUS  TISSUE. 

240474  03-03 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE 

241338  03-03 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AND 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03  04 
EFFECTS  OF  DELTA9  TETRAHYDROCANNABINOL  AND  PENTOBARBITAL  ON 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING. 

244693  04-03 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE: 
FLURAZEPAM  AND  PENTOBARBITAL 

245652  04-11 
PENTOBARBITAL:  ACTION  ON  FROG  MOTONEURONS. 

247513  04-03 
A  COMPARISON  OF  THE  DISCRIMINABLE  CNS  EFFECTS  OF  KETAMINE, 
PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 


EFFECTS  OF  PENTOBARBITAL  IN  MICE  SELECTIVELY  BRED  FOR  DIFFERENl 
SENSITIVITIES  TO  ETHANOL, 

249261  04-C 
IMIPRAMINE  ENHANCEMENT  OF  PENTOBARBITAL  TOXICITY  IN  RATS. 

249929  04-C 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

2501 1 1  04-( 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D-AMPHETAMINE  AND 

PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

2501 12  04-C 
SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MIC 

SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL 

250284  04-C 
EFFECTS  ON  VISUAL  TRACKING  OF  DELTA9-TETRAHYDR0CANNABIN0L 
AND  PENTOBARBITAL. 

251825  04-1 
SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORAAANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDULE. 

252816  04-C 
USF  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION:  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  0! 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-C 
PENTYLENETETRAZOL 

QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS. 

233277  02-C 
PENTYLENETETRAZOL-INDUCED 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  0 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01 -C 
EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-C 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATI 
CAfECHOLAMINE  RECEPTORS. 

238734  03-C 
PEOPLE 

FUGUE  STATES      EPILEPSY  -  MEDICATION    -  HELD  COMPETENT  TO 
STAND  TRIAL:  PEOPLE  V    PARSONS,  371  N.Y.S.2D  840,  (NEW-YORK), 
NASSAU  COUNTY  COURT.  AUGUST  1,  1975, 

237476  02-1 
WHY  DO  PEOPLE  USE  PARACETAMOL  FOR  SUICIDE?. 

241754  03-1 
PEPTIDES 

ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXON 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT, 

241244  03-0 
PERCEPTION 

THE  EFFECT  OF  METHYLPHENIDATE  ON  SENSORY  PERCEPTION  IN 
VARYING  DEGREES  OF  HYPERKINETIC  BEHAVIOR. 

245012  04-1 
PERCEPTUAL 

COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG-RANGE  L-OOPA  THERAP' 
IN  PARKINSONISM. 

229165  01-1 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-1 
PERFORMANCE 

CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORMANCE  IN 
THE  RAT. 

226305  01 -O- 
PLASMA  CONCENTRATIONS  OF  L  DOPA  AND  3  METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01-1. 
SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE  CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-0' 
COMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL. 

227137  01-0' 
THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY 

229650  01  1^ 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 


S-240 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


AND  THEIR  EFFECTS  ON  PERFORMANCE,  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  0114 
A  REVIEW  OF  THE  EFFECTS  OF  DIAZEPAM  ON  COGNITIVE  AND 
PSYCHOMOTOR  PERFORMANCE. 

235236  02-14 
EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237102  02-14 
PRETRIAL  COCAINE  AND  PERFORMANCE  IN  RAT. 

237108  02-04 
LEVODOPA  AND  PSYCHOMETRIC  TEST  PERFORMANCE  IN  PARKINSONISM 
-  5  YEARS  LATER 

237141  02-14 
EFFECTS  OF  METHOXYLATEO  AMPHETAMINES  ON  THE  MAZE 
PERFORMANCE  BY  THE  RAT. 

238788  0304 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 
INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P  TYROSINE 
ON  SCHEDULE-CONTROLLED  PERFORMANCE  IN  RATS. 

238844  03  04 
MEMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT 

239852  03-04 
PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE, 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 
NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY 

240473  03  15 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE,  DIAZEPAM,  AND 
PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-04 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION). 

241681  03-04 
EFFECTS  OF  DRUG  STATE  CHANGE  ON  DISCRIMINATION  PERFORMANCE. 

244679  04-04 
DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04-13 
MARUUANA  AND  HUMAN  PERFORMANCE. 

247217  04  14 
THE  EFFECT  OF  CAFFEINE  ON  HUMAN  PERFORMANCE,  ALONE  AND  IN 
COMBINATION  WITH  ETHANOL. 

249674  04-14 
PIMOZIDE  INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF  STIMULATION 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORMANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING, 

250060  04  14 
THE  OBJECTIVE  MEASUREMENT  OF  MENTAL  PERFORMANCE  IN 

CEREBROVASCULAR  DISEASE:  A  DOUBLE-BLIND  CONTROLLED  STUDY, 
USING  A  GRADED-RELEASE  PREPARATION  OF  ISOXSUPRINE. 

250414  04  II 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY 

251986  04  14 
SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORMANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDULE. 

252816  04-04 
ORMANCES 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES, 

227384  01-03 
THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION 

233281  02  14 
DRUG  EFFECTS  AND  CONCURRENT  PERFORMANCES 

240016  03  04 
ORMEO 

AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORMED 
SINGLY  AND  IN  COMBINATION 

253381  04  14 
'UNDATED 

EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO 

234522  02  03 
USED 

METABOLISM  OF  DELIAI  TETRAHYDROCANNABINOL  BY  THE  ISOLATED 
PERFUSED  DOG  LUNG    COMPARISON  WITH  IN  VITRO  LIVER 
METABOLISM. 

238316  02  03 


RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS 

238681  03-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES,  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES. 

238683  03  06 
EFFECTS  OF  CANNABINOIDS  ON  THE  IN  VITRO  PERFUSED  RAT  HEART. 

238767  03-03 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03-03 
EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 
PERFUSED  RAT  BRAIN 

243782  04-03 
PERFUSION 

INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION 

231002  01-03 
PERFUSION  WITH  L-5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR, 
IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237710  02-03 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION 

241930  03-03 
CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6- 
HYDROXYDOPAMINE  AND  DESIPRAMINE 

252024  04-03 
PERIAQUEDUCTAL 

ANTAGONISM  BY  METHYSERGID  AND  CINANSERIN  OF  THE 

ANTINOCICEPTIVE  ACTION  OF  MORPHINE  ADMINISTERED  INTO  THE 
PERIAQUEDUCTAL  GRAY. 

239576  03  04 
THE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA    FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY 

249248  04-03 
PERIMETAZINE 

EFFECTS  OF  PERIMETAZINE  AND  CHLORPROMAZINE  ON  THE 
TRANSCALLOSAL  RESPONSE  IN  RABBITS. 

241385  03  03 
PERINATAL 

METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04-05 
PERIODS 

AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH  D. 
DISSERTATION) 

24 1 1 29  03-03 
PERIPHERAL 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS 

226915  01  09 
THE  EFFECTS  OF  ADRENALINE.  RESERPINE,  AND  ATROPINE  ON 

ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS 

227635  01-03 
SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN  AND 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERTATION) 

228493  01  03 
CHANGES  IN  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 
NEUROLEPTICS  AND  THYMOLEPTICS 

234045  02-15 
THE  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT  TERM  MEMORY 

23671  1  02-04 
TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L  DOPA 
AND  A  PERIPHERAL  DOPA  DECARBOXYLASE  INHIBITOR 

237733  02-11 
3HDELTA9  TETRAHYDROCANNABINOL  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL  NERVOUS  SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD 

238724  03-03 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 
ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION 

2.15600  0404 
INFLUENCE  OF  A  PERIPHERAL  MONCJAMINE  OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL  NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2  PHENYLETHYl  AMINE  (PEA) 

249310  04-03 
CATECHOLAMINES  AND  2  PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES 

24931  I  04  03 


S-241 


Subject  index 


Psychopharmacology  Abstn 


cs- 

cs; 

3a. 


PERIPHERALLY 

DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE;  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 
PERAAANENT 

MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 
GROUPS  OF  RATS 

247207  04-04 
PERMEABILITY 

THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01-03 
lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM 
(UNPUBLISHED  PAPER). 

236873  02-03 
PERMEATION 

DRUG  PERMEATION  THROUGH  MEMBRANES  V:  INTERACTION  OF 
DIAZEPAM  WITH  COMMON  EXCIPIENTS. 

238485  02-02 
PERMETHYLATION 

PERMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 
WITH  VARYING  METHYLSULFINYLMETHIDE  CARBANION. 

238488  02  01 
PERORAL 

PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM 

237735  02-13 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE  BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL  DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA 

239023  03-08 
PEROXIDATION 

LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS 

246318  04-04 
PERPHENAZINE 

AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 
AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS. 

228225  01-08 
LONG  TERM  EFFECT  OF  PERPHENAZINE  ON  THE  SUBSTANTIA-NIGRA  IN 
RATS, 

237702  02-03 
OUTPATIENT  TREATMENT  WITH  LONG-ACTING  PERPHENAZINE 
(PERPHENAZINE-ENANTHATE):  THREE  CASES. 

239615  03-09 
PSYCHOMETRIC  EFFECTS  OF  PERPHENAZINE  BELOW  THE  NEUROLEPTIC 
THRESHOLD. 

239682  03-15 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION. 

245593  04-05 
EFFECTS  OF  PERPHENAZINE  ON  IMIPRAMINE  METABOLISM  IN  MAN 

247210  04-13 
PERPHENAZINE-ENANTHATE 

OUTPATIENT  TREATMENT  WITH  LONG-ACTING  PERPHENAZINE 
(PERPHENAZINE-ENANIHATE):  THREE  CASES. 

239615  0309 
PERSISTENCE 

PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS 

249485  04-04 
PERSISTENT 

PENTAZOCINE  PSYCHOSIS   A  CASE  OF  PERSISTENT  DELUSIONS. 

225873  01-15 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04-17 
PERSONAL 

PILLS  FOR  PERSONAL  PROBLEMS. 

253374  04-17 


PERSONALITY 

PSYCHOTROPIC  DRUGS  AND  THE  ANTIDEPRESSED  PERSONALITY 

240251  I 
CHANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 
NEUROLEPTIC  TREATMENT 

242868 
PERSONALITY  FACTORS  AND  DRUG  EFFECTS  IN  A  CONTROLLED  STUI 
OF  CYCLAZOCINE. 

244298 
THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIE 
WITH  PASSIVE-DEPENDENT  PERSONALITY  TRAITS, 

251717 
PERSONS 

COUNSELING.  PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WE 
DEATH:  AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPTASSISTEC 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  W 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS  (PH.[ 
DISSERTATION), 

228686 
NUTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENl 
DISABILITIES, 

232815 
REVIEW  OF  DRUG  TREATMENT  FOR  DOWNS-SYNDROME  PERSONS, 

239074 
PERVINCAMINE 

TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 
POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATI 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS, 

240033 
PETHIDINE 

MOUSE  BRAIN  CATECHOLAMINES,  5-HYDROXYTRYPTAMINE  AND  TH 
ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE, 

237741  I 
PETIT-MAL 

LONG-TERM  TREATMENT  OF  PETIT-MAL  WITH  CLONAZEPAM 

231654  1 
PF-257 

EFFECTS  OF  l,2-BENZISOXAZOLE-3-ACETAMIDOXIME  HYDROCHLORIC 
(PF-257)  ON  THE  CNS  WITH  SPECIAL  REFERENCE  TO  MONOAMINE 
METABOLISM, 

2413931 
PGO 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIV 

233077  I 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT, 

237780 ( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  TH 
CURARIZED  CAT:  I,  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4  1284 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES 

241315  ( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  TH 
CURARIZED  CAT:  II    PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE, 

241316( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  TH 
CURARIZED  CAT:  III,  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES 

241317( 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  TH 
CURARIZED  CAT:  IV,  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  ANO 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY, 

241318C 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THI 

CURARIZED  CAT:  V,  MISCELLANEOUS  COMPOUNDS,  SYNOPSIS  OF 

ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY 

24i:il9C 
PHARMACEUTICAL 

PHARMACEUTICAL  THERAPY  OF  MASKED  DEPRESSION 

244040  C 
PHARMACO-ELECTROENCEPHALOGRAM 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRA/ 

229038  0 
PHARMACODYNAMIC 

TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS  - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS, 

240216  0 

CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  C 

PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS    EFFECT  OF  X-RAY 

RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  II 

ANIMALS 

240237  0 
PHARMACODYNAMICS 

PHARMACODYNAMICS  OF  IMIPRAMINE  IN  DEPRESSED  PATIENTS, 

229437  0 


S-242 


lUME  14,  SUBJECT  INDEX 


Subject  Index 


CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X  RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS 

240237  03  04 
RMACOKINETIC 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE 

226865  01-03 
POISONING  BY  TRICYCLIC  ANTIDEPRESSANT  DRUGS:  GENERAL  AND 
PHARMACOKINETIC  CONSIDERATIONS. 

230820  Oil  5 
CANNABIDIOL  AND  ITS  PHARMACOKINETIC  INTERACTION  WITH  DELTA!- 
TETRAHYDROCANNABINOL 

233279  02  03 
MONITORING  OF  LITHIUM  TREATMENT    GUIDELINES  BASED  ON 
PHARMACOKINETIC  CONSIDERATIONS 

236806  02- 16 
PHARMACOKINETIC  STUDIES  IN  ABSORPTION  AND  EXCRETION  OF 
OXAZEPAM  IN  COMBINATION  WITH  ALCOHOL. 

237123  0213 
APPARENT  PHARMACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901  02-13 
PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-13 
TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS   - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS. 

240216  03-09 
NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARMACOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL 

247846  04-06 
>RMACOKINETICS 
PHARMACOKINETICS  OF  FLUPENTHIXOL-DECANOATE.  DECANOATE 

227767  01-08 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARMACOKINETICS  OF 
PSYCHOTROPIC  DRUGS 

233682  02  17 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-16 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS    EFFECT  OF  X  RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS 

240237  03-04 
PHARMACOKINETICS  OF  INDOMETHACIN. 

245653  04-13 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  ON 
STEADY-STATE  BLOOD  LEVELS 

245842  04-08 
PHARMACOKINETICS  OF  METHOTRIMEPRAZINE  AFTER  SINGLE  AND 
MULTIPLE  DOSES. 

250422  04-07 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETICS 
OF  (HOIMIPRAMINE  IN  RAT:  ACUTE  STUDY 

250655  04-03 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE    PHARMACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS 

252198  04-03 
kRMACOLOGIC 

THE  PHARMACOLOGIC  MEANING  OF  SUCCESSFUL  ANTIPSYCHOTIC 
ANTIDEPRESSANT  COMBINATIONS 

230010  DM  1 
PHARMACOLOGIC  STUDIES  OF  NARCOLEPSY  INVOLVING  SEROTONIN, 
ACETYLCHOLINE,  AND  MONOAMINE  OXIDASE    (UNPUBLISHED  PAPER) 

232324  0111 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 
ACTIONS  OF  BENZODIAZEPINES 

232511  01-03 
PASSIVE  BARBITURATE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS 

239939  03  1 1 
THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL.  (PHD    DISSERTATION). 

240933  03-03 
FURTHER  EVIDENCE  FOR  CHOLINERGIC  HABENULO  INTERPEDUNCULAR 
NEURONS:  PHARMACOLOGIC  AND  FUNCTIONAL  CHARACTERISTICS 

249074  04  03 
PRECLINICAL  PHARMACOLOGIC  PROFILE  OF  A  PSYCHOACTIVE 
CANNABINOID 

249276  04  02 


APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHILDHOOD 
HYPERKINESIS. 

249772  04-11 
PHARMACOlOGICAl 

PHARMACOLOGICAL  INTERACTION  BETWEEN  CANNABINOL  AND  DELTA9 
TETRAHYDROCANNABINOL. 

225570  01  03 
TREATMENT  WITH  DISULFIRAM  IN  HUNTINGTONS  CHOREA:  A  NEGATIVE 
CLINICAL  AND  PHARMACOLOGICAL  STUDY 

226430  01  07 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01  06 
PHARMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS, 
WITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 
EFFECTS 

227762  01-04 
ISOLATION  OF  AN  ENDOGENOUS  COMPOUND  FROM  THE  BRAIN  WITH 
PHARMACOLOGICAL  PROPERTIES  SIMILAR  TO  MORPHINE. 

227774  01  03 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  BEHAVIOR 
PHARMACOLOGICAL  ASPECTS. 

228309  01-17 
THE  CAPACITY  OF  ADRENERGIC  NERVES  TO  ACCUMULATE  EXOGENOUS 
NOREPINEPHRINE  UNDER  THE  INFLUENCE  OF  SOME 
PHARMACOLOGICAL  AGENTS. 

228551  01-03 
RECENT  PROGRESS  IN  THE  LONG-TERM  PHARMACOLOGICAL  RESEARCH 
ON  CANNABIS. 

229043  01   17 
PHARMACOLOGICAL  AND  lOXICOLOGICAL  PROBLEMS  CONNECTED  WITH 
THE  USE  OF  LONG-ACTING  NEUROLEPTICS 

229549  01-15 
THE  MEDICAL  PHARMACOLOGICAL  MANAGEMENT  OF  ACUTE 
PSYCHOSES. 

229717  01   II 
RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITlONEO  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX    -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE 

230570  01-0^ 
PHARMACOLOGICAL  STUDIES  OF  DRUG  ACTION  ON  CNS.  WITH  SPECIAL 
REFERENCE  TO  EFFECTS  OF  MAPROTILINE. 

231316  01-04 
PHARMACOLOGICAL  PROPERTIES  OF  NEW  NEUROLEPTIC  COMPOUNDS. 

232502  01-03 
SEDATIVE  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 

COMPARISON  WITH  FLURAZEPAM    PHARMACOLOGICAL  AND  CLINICAL 
FINDINGS 

232530  01-07 
PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  1    PUPILOMETRY, 

232623  02-13 
CHANCES  OF  DETECTING  AND  DIFFERENTIATION  CENTRAL  NERVOUS 
EFFECTS  OF  DRUGS  IN  ANIMAL  EXPERIMENTS  WITH  SPECIAL 
CONSIDERATION  OF  BEHAVIORAL  PHARMACOLOGICAL  METHODS. 

233681  02-06 
EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02-11 
INHIBITORY  SYNAPSES  IN  THE  CENTRAL  NERVOUS-SYSTEM  AND  THEIR 
PHARMACOLOGICAL  RESPONSES 

236368  02-07 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  0203 
PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID 

237705  02-04 
PHARMACOLOGICAL  CHARACTERIZATION  OF  LITHIUM  REABSORPTION  IN 
THE  RAT 

237759  02-03 
ENDOGENOUS  BRAIN  2  PHENYLETHYLAMINE    BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS   (PH  D.  DISSERTATION) 

238077  02-03 
PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

238317  02  01 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOIITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE 

238322  02  03 


mm^. 


S-243 


Subject  Index 


Psychopharmacology  Abstrc 


29' 

SSI 

esi; 

■ 

"TIP 


cs 


8  CHIORO(S)   AND    (R)  IO((S)   AND   (R)  3 

METHYLETHYLAMINOPYRROLIDINODIHYDRODIBENZOTHIEPINS 
SYNTHESIS  AND  PHARMACOLOGICAL  STUDIES. 

238475  02-01 
PHARMACOLOGICAL  STIMULATION  Of  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK. 

238795  03  03 
SOME  PHARMACOLOGICAL  PROPERTIES  OF  CYCLOCHOLINE,  A  REACTIVE 
ANALOG  OF  CHOLINE. 

238828  03-03 
PHARMACOLOGICAL  STUDIES  WITH  HP  505,  A  POTENTIAL 
ANTIDEPRESSANT  COMPOUND 

238839  03-03 
THE  EFFECT  OF  DL-254  ON  THE  PHARAAACOLOGICAL  ACTIVITIES  OF  D- 
AMPHETAMINE  AND  APOMORPHINE:  A  COMPARISON  WITH 
ANTIANXIETY  AND  NEUROLEPTIC  AGENTS 

238846  03-03 
THE  PROBLEM  OF  POST  PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG  TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE  BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE. 

239823  03-08 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS:  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  03-03 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE,  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS 

239943  03-15 
PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03-04 
BETA  ADRENERGIC  CONTROL  OF  CYCLIC  AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM    PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
APOMORPHINEINDUCED  HYPERTHERMIA  IN  THE  RABBIT:  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE.  (PH.D.  DISSERTATION). 

240936  03-03 
PHARMACOLOGICAL  ASPECTS  OF  PHYSICAL  DEPENDENCE  ON  ETHANOL. 

241240  03-17 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III) 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS 

241390  03-03 
PHARMACOLOGICAL  STUDIES  ON  1  3-DIMETHYLAMINOPROPYL-PHENYL- 
METHYLINDAZOLE  HYDROCHLORIDE  (FS32)  (1). 

241399  03-04 
THE  GENETIC,  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE,  (PH.D.  DISSERTATION). 

241687  03-04 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN-HYDROXYLASE  INHIBITION. 

241978  03-03 
PHARMACOLOGICAL  ANALYSIS  OF  SOME  ADRENOMIMETIC  EFFECTS  OF 
SEROTONIN. 

241982  03-05 
TRYPTOLINES:  PHARMACOLOGICAL  AND  ENZYMOLOGICAL  STUDIES 
PH.D.  DISSERTATION). 

242002  03-02 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04-03 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN  HYDROXYLASE  INHIBITION. 

243848  04-03 
DOPAMINERGIC  CHOLINERGIC  INTERACTIONS  IN  THE  CENTRAL-NERVOUS- 
SYSTEM:  BIOCHEMICAL  PHARMACOLOGICAL  ASPECTS. 

244038  04-17 
BIOCHEMICAL  PHARMACOLOGICAL  BASES  FOR  THE  CLINICAL  USE  OF  L- 

DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME. 

244039  04-17 
( LINICAL  FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 

PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT 

244476  04  11 
PIIARMACOIOGICAL  APPROACHES  TO  THE  FUNCTION  Of  CERTAIN 
NONSPfCIMC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GlNfSIS  OF  IHF  VISUAL  EVOKED  POTENTIAL    APPLICATIONS  TO  THE 
STUDY  Of   SFVFRAI   PSYCHOTROPICS 

244874  04-03 
NrURO(  IIEMK  Al   AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5  HT 
UPIAKE  INHIBITOR,  FG4963,  WITFI  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES 

245296  04-03 


CLINICAL  PHARMACOLOGICAL  MANAGEMENT  OF  HYPERKINETIC 
CHILDREN. 

247381  C 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES 
THE  GUINEA-PIG  INTESTINE. 

248703  C 
INFLUENCE  OF  A  PERIPHERAL  MONOAMINE-OXIDASE  INHIBITOR  (MAC 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2-PHENYLETHYLAMINE  (PEA). 

249310 C 
NATURALISTIC  ASSESSMENT  OF  NEUROLOGICAL  DIAGNOSES  AND 
PHARMACOLOGICAL  INTERVENTION, 

251 149 C 
SOME  PHARAAACOLOGICAL  ASPECTS  OF  DRUG  DEPENDENCE, 

251561  C 
Y-AAAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE,  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  C 
THE  MAIN  PHARMACOLOGICAL  CHARACTERISTICS  OF  GRANDAXIN 
(TOFIZOPAM,  EGYT-341). 

252445  C 
PHARMACOLOGICAL  EVIDENCE  FOR  THE  CENTRAL  SEROTONERGIC 
EFFECTS  OF  MONOMETHOXYAMPHETAMINES. 

253108  0 
PHARAAACOLOGICALIY 

THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARAAACOLOGICALIY  TREATED  FEAAALE  PATIENTS. 

246612  0 
INFLUENCE  OF  PHARAAACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD-PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS, 

251414  0 
PHARMACOLOGY 

ANIMAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN). 


227208  0 

227209  0 

227210  0 


THE  CLINICAL  PHARAAACOLOGY  OF  ANTIDEPRESSIVES. 
CLINICAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN), 

ON  THE  PHARMACOLOGY  OF  DEPOT  PHTHORPHENAZINE, 

228547  0 
CLINICAL  PHARMACOLOGY  OF  SQ-10996,  A  POTENTIAL  ANTIDEPRESS 
AGENT. 

229036  0 
CHEMISTRY  AND  PHARMACOLOGY  OF  BIOGENIC  AMINE  UPTAKE. 

229478  0 
IMMUNOLOGIC  INVESTIGATION  OF  BARBITURATE  PHARMACOLOGY. 

229480  0 
COMPARATIVE  PHARMACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  C 
BIOGENIC  AMINE  SYSTEMS. 

238728  O: 
PHARMACOLOGY  OF  R-806,  A  TETRACYCLIC  ANTIDEPRESSANT. 

238837  O: 
SLEEP  AND  HYPNOTIC  DRUGS:  THE  PHYSIOLOGY,  PHARMACOLOGY  Al 
CLINICAL  ASPECTS  OF  SLEEP. 

239029  O: 
CLINICAL  PHARMACOLOGY  AND  THE  PRESCRIPTION  OF  PSYCHOTROPI 
MEDICATION 

239678  O; 
SOME  RECENT  ADVANCES  IN  THE  BIOCHEMICAL  PHARAAACOLOGY  OF 
GAMMA-AMINOBUTYRIC-ACID  (GABA).  (UNPUBLISHED  PAPER) 

240699  O: 
PHARMACOLOGY  OF  PSYCHOACTIVE  DRUGS. 

240704  O: 
SYMPOSIUM  II    PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 


SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

NEUROCHEMICAL  STANDPOINT. 

SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 


241360  03 


241361  03 


THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RA 

241363  03 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDI 
(AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  04 
CLINICAL  PHARMACOLOGY  OF  NABILONE,  A  CANNABINOL  DERIVATIVE 

248628  04 
THE  CLINICAL  PHARMACOLOGY  OF  LILLY-109514  IN  NORMAL 
VOLUNTEERS. 

249260  04 
COMPENDIUM  OF  PHARMACOLOGY  DRUG  CHARTS. 

249768  04 
SYMPOSIUM  ON  PHARMACOLOGY  OF  LEARNING  AND  RETENTION 

249787  04- 


S-244 


ILUME  14,  SUBJECT  INDEX 

ANNUAL  REVIEW  OF  PHARMACOLOGY  AND  TOXICOLOGY. 

251238  04-17 
CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND 

251407  04-17 
SOME  ASPECTS  OF  THE  PHARMACOLOGY  OF  ANALGESIA. 

252134  04-17 
A  BIBLIOGRAPHY  ON  THE  BIOLOGY  AND  PHARMACOLOGY  OF  LITHIUM 
APPENDIX  II. 

253064  04-17 
R^AACOPSYCHOlOGICAl 

PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 
VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
.RAAACOTHERAPY 
PHARMACOTHERAPY  IN  PSYCHOVEGETATIVE  DISORDERS. 

226778  01-09 
PHARMACOTHERAPY  OF  PSYCHOSOMATIC  CASES. 

227818  01-11 
PHARMACOTHERAPY  AND  PSYCHOTHERAPY:  PARADOXES,  PROBLEMS 
AND  PROGRESS. 

229240  01  17 
PHARMACOTHERAPY  IN  EARLY  INFANTILE  AUTISM. 

229921  01-11 
PHARMACOTHERAPY  AND  PSYCHOTHERAPY  IN  THE  TREATMENT  OF 
NEUROSES. 

230640  01-17 
POSSIBILITIES  FOR  PHARMACOTHERAPY  IN  THE  COURSE  OF 
PSYCHOTHERAPY  FOR  MENTAL  DISORDERS. 

234438  02-17 
PSYCHOTHERAPY  AND  PHARMACOTHERAPY:  CONCEPTUAL  ISSUES. 
(UNPUBLISHED  PAPER). 

238493  02-17 
ANXIOLYTIC  PHARMACOTHERAPY  IN  GENERAL  PRACTICE. 

241759  03-10 
PHARMACOTHERAPY  OF  SCHIZOPHRENIA. 

241936  03-08 
DIFFERENTIAL  PHARMACOTHERAPY  FOR  NEUROTIC  STATES 
(COMPARATIVE  EFFECTIVENESS  OF  BENZODIAZEPINE  DERIVATIVES). 

244349  04-10 
URGENT  PHARMACOTHERAPY  FOR  DRUG  ABUSE. 

251755  04-17 
RMACY 

CLINICAL  PHARMACY  PRACTICE  IN  A  COMMUNITY  MENTAL-HEALTH 
CENTER. 

227560  01-17 
SES 

HYPNOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS. 

228094  01-14 
ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 
FLUPHENAZINE-DECANOATE 

229557  01-14 
APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS 

236732  0209 
SIC 

CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION. 

235317  02-04 
ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  BY 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

238503  02-03 
EFFECT  OF  CHLORPROMAZINE  ON  THE  INTERACTION  BETWEEN  PHASIC 
AND  TONIC  ELECTROCORTICAL  AROUSAL  MECHANISMS. 

24631 1  04-03 
^<CYCllOINE 

PROLONGED  PSYCHOSIS  ATTRIBUTED  TO  PHENCYCLIDINE   REPORT  OF 
THREE  CASES. 

234713  02-15 
DOPAMINERGIC  EFFECTS  OF  PHENCYCLIDINE  IN  RATS  WITH 
NIGROSTRIATAL  LESIONS. 

236523  02-04 
ELECTROENCEPHALOGRAPHIC  FINDINGS  IN  PHENCYCLIDINE 
INTOXICATION, 

236667  02-15 
THE  EFFECT  OF  PHENCYCLIDINE  AND  KETAMINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  PIGEON. 

237757  0204 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03  04 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-04 


Subject  Index 


DRUG  DISCRIMINATION  IN  RATS    THE  EFFECTS  OF  PHENCYCLIDINE  AND 
DITRAN. 

245297  04-04 
PHENCYCLIDINE  POISONING. 

247089  04-15 
PHENCYCLIDINE:  NINE  CASES  OF  POISONING. 

247090  04-15 
PHENCYCLIDINE  -  STATES  OF  ACUTE  INTOXICATION  AND  FATALITIES. 

247147  04-15 
A  COMPARISON  OF  THE  DISCRIMINABLE  CNS  EFFECTS  OF  KETAMINE, 
PHENCYCLIDINE  AND  PENTOBARBITAL. 

249025  04-04 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE,  D  AMPHETAMINE  AND 
PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

250112  04-04 
PHENELZINE 

A  MULTIPLE  DOSE,  CONTROLLED  STUDY  OF  PHENELZINE  IN  DEPRESSION 
ANXIETY  STATES. 

239938  03-10 
PHENELZINE  AND  PSYCHOSIS 

251128  04-09 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
PHENETHYLAMINE 

STUDIES  ON  THE  ROLE  OF  PHENETHYLAMINE  IN  METHYLAMPHETAMINE 
ACTION  MECHANISM. 

248515  04-03 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INDUCED 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361  04-04 
PHENINDAMINE 

PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE, 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
PHENITRONE 

SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS 

251534  04-03 
PHENOBARBITAl 

EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIOR 
OF  MATURE  OFFSPRING 

226528  01-04 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA  ALANINE 
ANALOG    POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
SUCCINATE. 

233001  02-13 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  02  03 
DIFFERENTIAL  INTERACTIONS  OF  PENTOBARBITAL  AND  PHENOBARBITAL 
WITH  BETA-ADRENERGIC  MECHANISMS, 

238725  03  03 
PHENOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
FOR  SEVERAL  METABOLITES 

238796  03-13 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF  STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM  AND 

PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR 

239981  03  04 
DIFFERENTIAL  EFFECTS  OF  PHENOBARBITAL  AND  PENTOBARBITAL  ON 

ISOLATED  NERVOUS  TISSUE, 

240474  03-03 
NEW  DEVELOPMENTS  IN  THE  USE  OF  PHENOBARBITAL  IN  PEDIATRICS. 

240723  03-17 
COMPARATIVE  EFFECT  OF  PHENOBARBITAL  AND  METHAOUALONE  ON 
WARFARIN  METABOLISM  IN  THE  RAT, 

241344  03  03 
TOLERANCE  TO  CENTRALLY  ADMINISTERED  PHENOBARBITAL, 

241346  03-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL, 

247032  04-03 


S-245 


Subject  Index 


Psychopharmacology  Abstn 


-a; 
esi' 


CS; 


ORIGIN  OF  BRAIN  GROWTH  R[TARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHfNOBARBITAL 

250682  0-1-05 
PHENOBARBITONE 

INTERACTION  OF  DELTA9  TETRAHYDROCANNABINOL  AND  CANNABIDIOL 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICALLY- 
INDUCED  CONVULSIONS. 

244894  04-04 
FAILURE  OF  PHENOBARBITONE  TO  PREVENT  FEBRILE  CONVULSIONS, 

251103  04-11 
PHENOFORMIN 

INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
PHENOLIC 

ANALYSIS  OF  DRUGS  AND  PSYCHOACTIVE  PHENOLIC  AMINES. 

229486  01-03 
PHENOMENA 

REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE    PRELIMINARY  OBSERVATIONS 

230816  01-09 
NEUROLEPTIC  ANTAGONISM  OF  DYSKINETIC  PHENOMENA 

248407  04  04 
IMPORTANCE  OF  O-METHYLATION  IN  DOPAMINE  INDUCED  MOTOR  AND 
BEHAVIORAL  PHENOMENA. 

251143  04  04 
PHENOTHIAZINE 

A  PHENOTHIAZINE  DERIVATIVE  IN  THE  TREATMENT  OF  SPASTICITY 

226960  0111 
BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION 

228224  01  08 
LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS 

229448  01  08 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS   A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02  11 
FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY 

235286  02- 1 5 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN 

237241  02-03 
EFFECTS  OF  BETA  HYDROXYLATED  PHENOTHIAZINE  DERIVATIVES  ON 
ISOLATED  BRAIN  MITOCHONDRIA. 

238777  03  03 
IMPIICATIONS  OF  PHENOTHIAZINE  SiDE-EFFECTS:  A  STUDY  OF 
ANTIPARKINSONIAN  AGENTS  IN  AN  OLDER  POPULAIION 

238978  03-15 
CONGENERS  OF  PHENOTHIAZINE  TRANOUIIIZERS   (PH  D    DISSERTATION). 

240937  03  02 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  AFTER  PHENOTHIAZINE  TREATMENT 

243193  04  10 
DELAYED  SEVERE  EXTRAPYRAMIDAL  DISTURBANCE  FOLLOWING 
FREQUENT  DEPOT  PHENOTHIAZINE  ADMINISTRATION. 

245789  04  15 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X  RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-01 
OUlPAlltNT  PHtNOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COIIABORAHVE  DRUG  SURVEIILANCL  PROGRAM 

253661  04  15 
PHENOTHIAZINE-INDUCED 

PHTNOrillAZINE  INDUCED  VENTRICULAR  TACHYCARDIA 

247148  04  15 
IRIATMFNT  OF  PHENOIHIAZINE  INDUCED  DYSKINESIA 

253038  04  15 
PHENOTHIAZINE-JAUNOICE 

PHFNOIHIAZINF  lAUNDICF  (A  REVIEW) 

240697  03  15 
PHENOTHIAZINES 

IN1ERA(  HON  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BIHAVIOR.  BODY  TEMPERATURE    AND  TISSUE  LEVELS  OF 
IIAIlUt  INOGfN  IN  ,V\ICE 

229264  01-04 
ANTK  ONVUISANT  ACTIVITY  AND  SELFCllVt  INHIBIHON  OF 

NKOIINAMIDl  ADENINl  1)INU(  IFOTIDE  DEPENDENT  OXIDATIONS  BY 
10  2ARY1IMINO  3AfFTYlAMIN0  4  THIAZOLIDONYl  PHENOTHIAZINES 

239662  03  03 
INIIRAtTION  BETWEEN  POSSIBLE  IRANSMITTERS  AND 

BUIYROPIIfNONfS  APPUfD  MICROEI  EC  I  ROPHORl  TICALLY  IN  THE 
(  IK'IBMIUM  AND  BASAI   GANGI  lA  Of   IHE  CAT,  2ND  REPORT 


EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  ' 
CEREBELLUM. 

241386 
DRUG  INDUCED  PARKINSONISM  IN  THE  RAT  •■  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  II 
THE  INCORPORATION  OF  DGLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692 
THE  LONG-ACTING  PHENOTHIAZINES. 

245841 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  II 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121 
TIME  DEPENDENT  EFFECTS  OF  PHENOTHIAZINES  ON  DOPAMINE 
TURNOVER  IN  PSYCHIATRIC  PATIENTS. 

250389 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF 
OCCIPITAL  CORTEX 

253691 
PHENOXY8ENZAAAINE 

POSSIBLE  ROLE  OF  THE  ALPHA  ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMIN 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752 
RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE  BETA  HYDROXYl 
(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690 
PHENTOLAMINE 

MODIFICATION  OF  THE  BEHAVIORAL  EFFECTS  OF  CHOLINOMIMETIC! 
PHENTOLAMINE. 

237032 
PHENYL-4-OXO-2-OXAZOllN-2-n-4-SUBSTITUTED 

ANTIDEPRESSANT  AND  ANTICONVULSANT  ACTIVITY  OF  PHENYL-4-0 
OXAZOLIN-2  YL-4-SUBSTITUTED  PIPERAZINES 

251701 
PHENYLACETIC-ACID 

POSSIBLE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  C 
MARIHUANA  BY  2  PHENYLETHYLAMINE  AND  BY  PHENYLACETIC-A 

238820 
PHENYLALANINE 

THERAPY  OF  DEPRESSION  BY  PHENYLALANINE:  PRELIMINARY  NOTE. 

229827 
PHENYLETHANOLAMINE-N-METHYLTRANSFERASE 

PHENYLETHANOLAMINE-N  METHYLTRANSFERASE:  S-METHYLATION  C 
BUTYLIMIDIAZOLE-2-THIOL. 

238762 
PHENYLETHYLAMINE 

DOES  PHENYLETHYLAMINE  CAUSE  SCHIZOPHRENIA? 

237993 
INHIBITION  OF  PHENYLETHYLAMINE  METABOLISM  IN  VIVO    -  EFFECT 
ANTIDEPRESSANTS. 

251184 
THE  MONOAMINE  OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  ( 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643 
PHENYLETHYLAMINES 

COMPARISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECT 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT. 

250939  I 
PHENYLETHYLAMINIC 

EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGH 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE 

249257  I 
PHENYLPROPANOLAMINE 

PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

2317001 
PHENYTOIN 

INVOLUNTARY  MOVEMENTS  CAUSED  BY  PHENYTOIN  INTOXICATION 
EPILEPTIC  PATIENTS 

225890 1 
EFFECT  OF  ETHANOL  INTAKE  ON  PHENYTOIN  METABOLISM  IN 
VOLUNTEERS. 

233280  ( 
CARBAMAZEPINE  (TEGRETOL)      A  DOUBLE  BLIND  COMPARISON  WIT 
PHENYTOIN  (DILANTIN) 

251937 ( 


S-246 


LUME  14,  SUBJECT  INDEX 


^YTOIN-INDUCED 

PHENYTOIN  INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN 

251654  04-15 
XYTOINS 
CAN  PHENYTOINS  CAUSE  FETAL  DAMAGE?. 


248097  04-13 

229451  01-10 
239346  03-11 


BIA 

IMIPRAMINE,  BEHAVIOR  THERAPY,  AND  PHOBIA. 

SULPIRIDE  IN  SCHOOL  PHOBIA. 

SIC 

SULPIRIDE  IN  DEPRESSIVE  SCHOOL  PHOBIC  CHILDREN. 

227141  01-10 
CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 
TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS. 

230015  01-10 
A  CASE  OF  PHOBIC  ANXIETY  DEPERSONALIZATION  SYNDROME  (ROTH) 

243094  04-17 
iPHOOIESTERASE 

IN  VIVO  ACTIVATION  OF  RAT  PINEAL  CAMP  PHOSPHODIESTERASE  BY 
ISOPROTERENOL.  (UNPUBLISHED  PAPER). 

228032  01-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
DN  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 
PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS, 

249287  04-03 
IHRONIC  ETHANOL  FEEDING  AND  BRAIN  ADENYLCYCLASE  AND 
PHOSPHODIESTERASE  LEVELS  IN  MICE, 

249294  04-03 
iPHOllPID 

BIOGENIC  AMINE  EFFECTS  ON  CNS  PHOSPHOLIPID  METABOLISM. 

229482  01-03 
:NS  PHOSPHOLIPID  METABOLISM  AND  NEURONAL  FUNCTION. 

244089  04-03 
IPHORUS 

;FFECT  of  HYDROCHLOROTHIAZIDE  ON  PHOSPHORUS  DURING 
TREATMENT  WITH  DIPHOSPHONATE, 

245651  04-13 
;PHORYLATION 

iEGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 
PERMEABILITY  BY  BETA  ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3.5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE 

231014  01-03 
.YCLIC  NUCLEOTIDES.  PROTEIN  PHOSPHORYLATION,  AND  NEURONAL 
FUNCTION. 

231021  01  17 
)OPAMINE  INDUCED  INCREASES  IN  CYCLIC  AMP   AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE 
NUCLEUS   (PHD   DISSERTATION). 

238080  02-13 
FFECT  OF  DIPHENYLHYDANTOIN  ON  THE  ENDOGENOUS 
PHOSPHORYLATION  OF  BRAIN  PROTEIN. 

240746  03-03 
ICAUY 

'HARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS^  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  03-03 

^JHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  BY 
DIFFERENT  DOSES  OF  L-DOPA. 

251214  04-03 
OGENIC 

FFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS 
PAPIO  PAPIO. 

2304  75  01-03 
OMYOCLONIC 

lOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO 

237755  02-04 
DSTIMUIATION 

ABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE    ITS  DELAY  BY 
PSYCHOANALEPTICS 

.,.,  248514  0404 

MAZINOPHTHALAZINEOIONE 

EHAVIORAL  EFFECT  OF  PHTHALAZINOPHTHALAZINEDIONE  (L-5418). 

241397  03  04 
JRPHENAZINE 
N  IHC  PHARMACOIOGY  OF  DEPOT  PHTHORPHENAZINE 

22854  7  01  04 


Subject  Index 

PHYSICAL 

METHAQUALONE:  TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

237731  02-04 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE 

238701  03-03 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEG  IN  THE 
NATURALLY  EPILEPTIC  BEAGLE. 

238811  03-04 
STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE-LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON 

240205  03-05 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE.  (PH.D.  DISSERTATION) 

241100  03-03 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS    I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
PHARAAACOLOGICAL  ASPECTS  OF  PHYSICAL  DEPENDENCE  ON  ETHANOL. 

241240  03-17 
EFFECT  OF  CLOZAPINE  ON  THE  MENTAL  AND  PHYSICAL  STATE  OF 
PATIENTS 

243986  04-08 
TOLERANCE,  PHYSICAL  DEPENDENCE  AND  OPIOID  SEEKING  BFHAVIOR: 
DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE 

244202  04-04 
A  METHOD  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
DRUGS  IN  DOG 

244674  04-06 
MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE    INFLUENCE  OF 
CHOLINERGIC  AGONISTS  AND  ANTAGONISTS 

250079  04-04 
PSYCHIATRIC  SYMPTOMS  DURING  L  DOPA  FHERAPY  FOR  PARKINSONS 
DISEASE  AND  TilEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY 

250722  04- 15 
PHYSICIANS 

INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02  17 
PHYSIO-ORGANIC 

THE  INFLUENCE  OF  NITROGEN.  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO  ORGANIC  PR0PER1IES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES 

237981  02-02 
PHYSIOGNOMIES 

SPECTRAL  MAPS  OF  THE  LIEGE  PHYSIOGNOMIES  OF  THE  NEUROLEPTICS. 

239683  03-06 
PHYSIOGNOMY 

PHARMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS 
WITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 
EFFECTS 

227762  01-04 
BIOCHEMICAL  VS  CLINICAL  PHYSIOGNOMY  OF  NFUROLEPTICS,  WITH 

SPECIAL  REFERENCE  TO  THEIR  ANTIMANIC  EFFECT 

227763  01-04 
CLINICAL  PHYSIOGNOMY  OF  CHLORPROTHIXENE  AND  CLOPENTIXOL. 

227766  01-11 
THE  LIEGE  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH  SPECIAL  REFERENCE 
TO  THIOXANTHENES 

227769  Oil  7 
CLINICAL  PHYSIOGNOMY  OF  FIUPENTHIXOL 

227772  01  14 
PHYSIOLOGICAL 

HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01  06 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01-10 
EFFECT  OF  CHRONIC  TREATMENl  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA  PIGS.  AND  RABBITS. 

233962  02  03 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL 
NEUROCHEMICAL  AND  BEHAVIORAL  DEVELOPMENT, 

238722  03-04 
IMIPRAMINE  IN  ENURESIS  ■    PSYCHOLOGICAL  AND  PHYSIOLOGICAL 
EFFECTS. 

247743  04-11 
PHYSIOLOGY 

SLEEP  AND  HYPNOTIC  DRUGS   THE  PHYSIOIOGY.  PHARMACOIOGY  AND 
CLINICAL  ASPECTS  OF  SLEEP. 

239029  03  14 


S-247 


Subject  Index 


Psychopharmacology  Abstri 


-3; 

cs;: 

I 


in. 


PHYSOSTIGMINE 

EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDI  I  lONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION,  (PH.D. 
DISSERTATION). 

228503  01-04 
REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE:  PRELIMINARY  OBSERVATIONS 

230816  01-09 
REM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD. 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
REVERSAL  BY  PHYSOSTIGMINE  OF  CLOZAPINE  INDUCED  DELIRIUM. 

237647  02-14 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE. 

239829  03-04 
PHYSOSTIGMINE  AS  A  DISCRIMINATIVE  CUE  IN  RATS. 

241258  03-04 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 

ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  04-03 
EFFECT  OF  PHYSOSTIGMINE  ON  Y  MAZE  DISCRIMINATION  RETENTION  IN 
THE  RAT. 

251982  04-04 
PHYTOHEMAGIUTININ-INDUCED 

PHYTOHEMAGLUTININ-INDUCED  LYMPHOCYTE  TRANSFORMATION  IN 
HUMANS  RECEIVING  DELTA9-TETRAHYDR0CANNABIN0L. 

252825  04-13 
PICOGRAM 

ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 
PICROTOXIN 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS 

232906  02-03 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 
AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO-ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 
DORSAL  ROOT  POTENTIALS. 

239982  03-03 
PIER! 

LSD  AND  DOPAMINE  RECEPTORS  -  PIERI  REPLY. 

228051  01-03 
PIGEON 

THE  EFFECT  OF  PHENCYCLIDINE  AND  KETAMINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  PIGEON. 

237757  02-04 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR    -  CONTENT  OF 
TRYPTOPHAN,  5  HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC  ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
SOME  EFFECTS  OF  PARATHION  ON  THE  SCHEDULE-CONTROLLED 
BEHAVIOR  OF  THE  PIGEON 

249266  04-04 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE,  NALOXONE  AND 
NALORPHINE  IN  THE  SQUIRREL  MONKEY  AND  THE  PIGEON. 

250113  04  04 
PIGEONS 

EFFECTS  OF  D  AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 

MAINTAINED  BY  A  SECOND  ORDER  SCHEDULE  OF  REINFORCEMENT. 

226852  01-04 
SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 

FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01  04 
EFFECTS  OF  CARBON  DISULFIDE  ON  OPERANT  BEHAVIOR  IN  PIGEONS. 

(PH.D.  DISSERTATION). 

238081  02  04 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

241250  03-04 
DOPAMINERGIC  NATURE  OF  AMPHETAMINE-INDUCED  PECKING  IN 
PIGEONS. 

248408  04-03 


KETOCYCLAZOCINE:  BEHAVIORAL  EFFECTS  IN  PIGEONS  AND  MONKE 

249246 
PIGMENTATION 

PIGMENTATION  AND  THE  CHEMICAL  BASIS  OF  SCHIZOPHRENIA. 

239001 
PIGMENTED 

ACCUMULATION  OF  LABELED  EPHEDRINE.  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMEN 
EYES  OF  BLACK  AND  WHITE  RATS. 

230450 
PILLS 

PILLS  FOR  PERSONAL  PROBLEMS. 

253374 
PILOCARPINE 

MOUSE-KILLING  AND  MOTOR  ACTIVITY:  EFFECTS  OF  CHRONIC  DELT, 
TETRAHYDROCANNABINOL  AND  PILOCARPINE. 

244682 
INTERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 

CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  R/ 

248394 
PILOCARPINE-INDUCEO 

RAT  STRAIN  DIFFERENCES  IN  PILOCARPINE-INDUCED  MOUSE-KILLINC 

250008 
PILOT 

ISONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME:  A 
PILOT  TRIAL, 

236665 
CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILO 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL. 

237271 
APPARENT  PHARMACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY. 

237901 
PILOT  OPEN-LABEL  STUDY  OF  LENPERONE  (AHR-2277),  A 
BUTYROPHENONE,  IN  ANXIETY. 

241278 
LIQUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS. 

247877 
COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS-CHOREA:  PILOT  STUDY. 

248172 
A  PILOT  STUDY  OF  THE  SHORT  TERM  PSYCHOTROPIC  EFFECTS  OF  GF 
2640. 

250516 
CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRE^ 
PATIENTS:  A  PILOT  STUDY. 

2518281 
PIMOZIDE 

A  DOUBLE-BLIND  COMPARISON  OF  PENFLURIDOL  (EASER)  WITH 
PIMOZIDE  IN  SCHIZOPHRENIA 

229026  I 
THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  ANE 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  I 
RATS. 

230452  I 
PIMOZIDE  IN  THE  TREATMENT  OF  MONOSYMPTOMATIC 
HYPOCHONDRIACAL  PSYCHOSIS. 

239014  1 
TARDIVE-DYSKINESIA  TREATED  WITH  PIMOZIDE. 

246699  ( 
COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS-CHOREA:  PILOT  STUDY. 

2481 72 ( 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMC 
AND  CHLORPROMAZINE  METABOLITES. 

252515 ( 
A  THREE- YEAR  DOUBLE-BLIND  INVESTIGATION  OF  PIMOZIDE  VERSUS 
FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  ( 
PIMOZIDE-INDUCED 

PIMOZIDE  INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATK 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICI 

249749  ( 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  DOR. 
TREATED  MICE 

250656  C 
PINCH 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  C 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR. 

238819 C 
PINEAL 

IN  VIVO  ACTIVATION  OF  RAT  PINEAL  CAMP  PHOSPHODIESTERASE  BV 
ISOPROTERENOL.  (UNPUBLISHED  PAPER) 

228032  0 


S-248 


OLUME  14,  SUBJECT  INDEX 


CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR: 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER). 

237170  02-03 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK. 

238795  03-03 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE. 

243795  04-03 
DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK-  INFLUENCE  BY 
PINEAL  METABOLITES. 

249240  04-03 
PAMERONE-INOUCED 

THE  EFFECTS  OF  OEXETIMIOE  ON  PIMOZIDE,  AND  HALOPERIDOL  AND 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION  IN 
RATS. 

230452  01-04 
PAMPERONE 

PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03  11 
'ERACETAZINE 

PIPERACETAZINE  IN  THE  TREATMENT  OF  MIXED  NEUROTICS. 

247484  04-10 
•ERAZINES 

ANTIDEPRESSANT  AND  ANTICONVULSANT  ACTIVITY  OF  PHENYL-4-0X0-2- 
0XAZ0LIN-2-YL-4-SUBSTITUTED  PIPERAZINES. 

251701  04-01 
•OTHIAZINE 

A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 
PATIENTS. 

230780  01-08 
•RADROl 

PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D-AMPHETAMINE. 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03-04 
lACETAM 

PIRACETAM  IN  A  CASE  OF  ACUTE  CEREBRAL  HYPOXEMIA    CASUISTIC 
REPORT. 

229128  01  14 
UTILIZATION  OF  PIRACETAM  (NOOTROPIL)  IN  ELDERLY  WITH 
NEURASTHENIC  STATES. 

236794  02-11 
DOES  PIRACETAM  COUNTERACT  THE  ECT-INDUCED  MEMORY 
DYSFUNCTIONS  IN  DEPRESSED  PATIENTS'. 

239002  03-09 
tACETAM-INDUCED 

PIRACETAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAL  INFORMATION  IN  RATS. 

239861  03-04 
ANDAMINE 

EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 

EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  0403 
IBEOIl 

THE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 

(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE 

233974  02- 1 1 
PIRIBEDIL:  ITS  SYNERGISTIC  EFFECT  IN  MULTIDRUG  REGIMENS  FOR 

PARKINSONISM. 

251651  04-07 
ITRAMIDE 

INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL 
PIRITRAMIOE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

r«..,  241229  03-04 

FAILS 

CRITERIA  FOR  AND  PITFALLS  IN  THE  IDENTIFICATION  OF  RECEPTORS. 

229436  01-03 
^ED 


AMPHETAMINE  TACHYPHYLAXIS  IN  THE  PITHED  GUINEA-PIG. 


238315  02-03 


Subject  Index 

MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS. 

238809  03-03 
PITRESSIN-INDUCEO 

PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE. 

242746  04-04 
PITUITARY 

EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  01  13 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02-03 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS    RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION. 

236801  02  13 
THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  IN 
THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  02  03 
PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE    (UNPUBLISHED  PAPER) 

238491  02-13 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE. 

239828  03  03 
CENTRAL  GAMAAA-AMINOBUTYRIC  ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
PKA 

PKA  DETERMINATION  OF  METHAQUALONE. 

239659  03-01 
PLACEBO 

EVALUATION  OF  SIDE-EFFECTS  ON  NEUROTICS    -  A  TEST  USING 
MESORIDAZINE  AND  PLACEBO. 

225686  01-15 
A  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

226414  0111 
SHORT-TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PLACEBO  IN  DEPRESSION:  A  DOUBLE-BLIND  STUDY. 

227214  01-09 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  L0RA7EPAM  WITH 
PLACEBO 

228241  01  11 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 
CLINICAL  AND  PHYSIOLOGICAL  ASSESSMENT  OF  CHLORAZEPATE, 
DIAZEPAM  AND  PLACEBO  IN  ANXIOUS  NEUROTICS. 

231036  01  10 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS 

232840  02  08 
THE  PLACEBO  EFFECT  IN  PSYCHOPHARMACOTHERAPY  IN 

CONSIDERATION  OF  THE  EFFECT  OF  MEPIPRAZOL  ON  EXCITEMENT  IN 
PSYCHOTICS. 

234217  02-08 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS  -  II    REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  02  09 
CORRELATES  OF  PLACEBO  REACTION  IN  AN  OUTPATIENT  POPULATION. 

235628  02- 17 
PIPAMPERONE  (DIPIPERON,  R.3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG  TERM  FOLLOW  UP 

238982  03-11 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO 
DRUG  AND  A  FOOD  DRINK. 

239059  03-14 
THE  PLACEBO  EFFECT. 

244023  04-17 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUT 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  04  10 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 
HYPERKINETIC  CHILDREN 

247379  04-14 
DOUBLE-BLIND  PLACEBO  CONTROLLED  EFFICACY  STUDY  OF  KETAZOLAM 
{U-28774). 

248532  04  10 


S-249 


Subject  Index 


Psychopharmacology  Abstract! 


29> 


■ 


39>. 


OXAZEPAM  PROTRIPTYLINE;  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OE 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS 

248975  04-10 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES 

249536  04-16 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY- 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04-15 
COMPARISON  OF  FLUPHENAZINEDECANOATE,  ORAL  FLUPHENAZINE, 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04-08 
A  PLACEBO  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253057  04-1 1 
PLACEBOS 

DO  PLACEBOS  ALTER  SLEEP? 

241753  03-17 
PLACENTAL 

PLACENTAL  TRANSFER  OF  PSYCHOTHERAPEUTICS  OF  THE  THIOXANTHENE 
TYPE 

237120  02-05 
PLACENTAL  TRANSFER  OF  CARBAMAZEPINE  IN  THE  RAT. 

237749  02-03 
PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  03-03 
PLANAR 

THE  INTERACTION  OF  HASHISH  COMPOUNDS  WITH  PLANAR  LIPID 
BILAYER  MEMBRANES  (BLM). 

244725  04-03 
PLASMA 

THIORIDAZINE  PLASMA  LEVELS  AND  CLINICAL  RESPONSE. 

225932  01  08 
PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-08 
.■^LASMA  CONCENTRATIONS  OF  L-DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01-14 
PLASMA  LEVELS  OF  CHLORPROTHIXENE  IN  ALCOHOLICS. 

226413  01-11 
THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTA.MINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA. 

227139  01-03 
DIAZEPAM  AND  PLASMA  TESTOSTERONE  LEVELS. 

229369  01-15 
PLASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  01-16 
AN  ATTEMPT  TO  ESTABLISH  QUALITY  CONTROL  IN  DETERMINATION  OF 

PLASMA  CHLORPROMAZINE  BY  A  MULTILABORATORY 
COLLABORATION. 

229439  01   16 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  CLINICAL  OUTCOME 

229443  01-09 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01-08 
PLASMA  CHLORPROMAZINE  IN  PSYCHIATRIC  MANAGEMENT. 

229492  01-13 
DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROMATOGRAPHY. 

229906  01-16 
PLASMA  CREATINE  PHOSPHOKINASE  LEVEL5  IN  RATS  FOLLOWING 
LYSERGIC  ACID-DIETHYLAMIDE. 

230826  01-03 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HiAA)  IN  THE  RABBIT. 

230877  01  06 
DIPHENYLHYDANTOIN  POTENCY  AND  PLASMA  PROTEIN  BINDING. 

231003  01-03 
TRICYCLIC  ANTIDEPRESSANT  OVERDOSE    CLINICAL  PRESENTATION  AND 
PLASMA  LEVELS 

oo  J  "J  I Q  n  1  - 1  "^ 

PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD. 

23431 1  02-03 
PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
PERORAI,  INTRAMUSCULAR.  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
EFFECT  OF  DIAZEPAM. 

237735  02  13 


GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEDIOXYAMPHETAMINE  (MDA)  FROM  PLASMA  AND  URINE. 

238484  020 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUAAAN  PLASMA. 

238486  02-1 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR. 

238800  03-0 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-1 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN.  (UNPUBLISHED  PAPER). 

239305  03- 1 
RELATIONSHIP  BETWEEN  ANTIDEPRESSANT  EFFECT  AND  PLASMA  LEVEL 
OF  NORTRIPTYLINE.  CLINICAL  STUDIES. 

2402 1  7  03-0 
PLASMA  CONCENTRATION  OF  '^.IPHENYLHYDANTOIN  IN  THE  EPILEPTIC: 
ITS  INTEREST  FOR  THE  CLINICIAN. 

240762  03- 1 
PLASAAA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1 1-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03-0: 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  AAALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-0. 
PLASMA  LEVELS  AND  ANTIDEPRESSIVE  EFFECT  OF  IMIPRAMINE. 

243089  04- 1: 
PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION. 

246387  04- 1; 
THERAPEUTIC  EFFECT  AND  PLASAAA  LEVEL  OF  THIORIDAZINE  (MELLERIL) 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  04-01 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 

PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-0; 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 

ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 
IN  THE  RAT. 

246843  04-0; 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

246891  04-11 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-0: 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUAAAN  SUBJECTS. 

246970  04-13 
SELF  INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION 

248955  04-IO 
THE  RELATIONSHIP  OF  PLASMA  TO  ERYTHROCYTE  LITHIUM  LEVELS  IN 
PATIENTS  TAKING  LITHIUM  CARBONATE 

249535  04-09 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 
EFFECT  OF  FENFLURAMINE  ON  STEADY-STATE  PLASMA  LEVELS  OF 
AMITRIPTYLINE  (ABSTRACT) 

250943  04-07 
PLATELET 

THE  EFFECT  OF  ADRENALINE  ON  HUAAAN  PLATELET  MAO  ACTIVITY. 

246312  04-13 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  IN 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121  04-08 
PLATELET-RICH 

THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5  HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET  RICH  PLASMA 

227139  01-03 
PLATELETS 

RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01-13 
EFFECTS  OF  TRAZODONE  ON  SEROTONIN  IN  THE  BRAIN  AND  PLATELETS 
OF  THE  RAT 

237240  02-03 


S-250 


OLUME  14,  SUBJECT  INDEX 

EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY-1 10140,  ON 
TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS, 

250380  04-03 
EGOMAZIN 

THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 
COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS. 

242863  04-15 
EXUS 
A  COMPARISON  OF  6,7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE-OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
IISON 
TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG- 
INFORMATION-CENTER:  THE  TRICYCLIC  ANTIDEPRESSANTS. 

t  245822  04-13 

IISONING 
POISONING  BY  TRICYCLIC  ANTIDEPRESSANT  DRUGS:  GENERAL  AND 
PHARMACOKINETIC  CONSIDERATIONS 

230820  01-15 
ENCEPHALOPATHY  SUBSEQUENT  TO  ACCIDENTAL  POISONING  WITH 
CHLORPROMAZINE. 

239089  03-05 
AMITRIPTYLINE  POISONING  CAUSING  LEFT  BUNDLE  BRANCH  BLOCK. 

241357  03-15 
ACUTE  POISONING  BY  MEANS  OF  A  VETERINARY  USED  SULFONE   A  CASE 
STUDY. 

245116  04-05 
PHENCYCLIDINE  POISONING 

247089  04- 1 5 
PHENCYCLIDINE:  NINE  CASES  OF  POISONING. 

247090  04  15 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 

POISONING  IN  THE  RAT. 

251419  04-03 
ACCIDENTAL  POISONING  WITH  PSYCHOTROPIC  DRUGS  IN  CHILDREN 

252656  04-15 
LAR 

EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS 

242741  03-03 
IICY 

MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL-HEALTH 
POLICY. 

239298  03  17 
lYAMINES 

EFFECTS  OF  POLYAMINES  ON  THE  CENTRAL-NERVOUS  SYSTEM. 

242202  03-03 
lYOIPSIA 

EFFECTS  OF  HALOPERIOOL  ON  SCHEDULE-INDUCED  POLYDIPSIA. 

236708  02-04 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE    PHARMACOKINETICS 
POLYDIPSIA  AND  POLYURIA  IN  RATS. 

252198  04-03 
LYORUG 

AMPHETAMINE  INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAIN 
DIFFERENCES,  POLYDRUG  EFFECTS  AND  MECHANISM 

238789  03-03 
lYETHYlENE-GLYCOt-4000 
CHARACTERIZAIION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  POLYETHYLENE-GLYCOL-4000  BY  IR  SPECTRAL 
ANALYSIS 

233276  02  01 
LYGRAPHIC 

DIFFERENTIAL  EFFECTS  OF  AN  INHIBITOR  OF  DECARBOXyLASE  ON  L- 
DOPA  AND  L-5  HTP:  POLYGRAPHIC  AND  BIOCHEMICAL  DATA. 

237709  02-03 
PERFUSION  WITH  L-5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR 

IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA 

237710  02  03 
IVPHARMACY 

PROBLEMS  OF  POLYPHARMACY  IN  DEPRESSION. 

243864  04-09 
LYPHASIC 

AMPHETAMINE-INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAIN 
DIFFERENCES,  POLYDRUG  EFFECTS  AND  MECHANISM, 

238789  03  03 
lYRIBOSOMES 
DISSOCIATION  OF  RAT  BRAIN  POLYRIBOSOMES  IN  VIVO  BY 
AMPHETAMINES. 

237871  02-03 
.YSOMES 

NECESSITY  OF  HYPERTHERMIA  FOR  L-DOPA  OR  D-AMPHETAMINE  TO 
DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03  03 


Subject  Index 


POLYURIA 

EFFECT  OF  ANTIDIURETIC  DRUGS  IN  RATS  WITH  LITHIUM-INDUCED 
POLYURIA. 

239041  03-05 
ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 
POLYURIA, 

239046  03-05 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARMACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS, 

252198  04-03 
POMATIA 

EFFECTS  OF  5,7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA 

243799  04-03 
PONOIMIN 

REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN    (UNPUBLISHED  PAPER), 

239305  03-13 
POOL 

BEHAVIORAL  AND  BIOCHEMICAL  INTERACTION  BETWEEN  AMT  AND  (  +  ) 
AMPHETAMINE:  RELEVANCE  TO  THE  IDENTIFICATION  OF  THE 
FUNCTIONAL  POOL  OF  BRAIN  CATECHOLAMINES, 

237698  02-03 
SELF  STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST 

246774  04-03 
POPULATION 

CORRELATES  OF  PLACEBO  REACTION  IN  AN  OUTPATIENT  POPULATION, 

235628  02-17 
IMPLICATIONS  OF  PHENOTHIAZINE  SIDE-EFFECTS:  A  STUDY  OF 
ANTIPARKINSONIAN  AGENTS  IN  AN  OLDER  POPULATION. 

238978  03-15 
POSITION 

THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 
PSYCHIATRIC  INSTITUTIONS. 

229558  01-17 
POSITIONS 

ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  01-04 
POSITIVE 

POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOMANIA 
SECONDARY  TO  ORGANIC-BRAIN-SYNDROME. 

234711  02-09 
EVIDENCE  FOR  A  BETA  ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
INFLUENCE  OF  CHLORPROMAZINE  ON  THE  POSITIVE  AND  NEGATIVE 
FEEDBACK  MECHANISM  OF  ESTROGENS  IN  MAN. 

248224  04  13 
POST-AMPHETAMINE 

METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE   ANTAGONISM  OF  POSl-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE 

237976  02-03 
POST-DECAPITATION 

THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE. 

238737  03-03 
POST-DRUG 

AMPHETAMINE  AND  THE  REWARD  SYSTEM:  EVIDENCE  FOR  TOLERANCE 
AND  POST  DRUG  DEPRESSION. 

239850  03-04 
POST-PSYCHOTIC 

THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION    LONG-TERM  STUDIES  WITH 
FLUSPIRILENF  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE  DECANOATE  AND  FLUPENTHIXOL  DECANOATE, 

239823  03-08 
POSTADDICT 

REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF  ADMINISTRATION    EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS 

251533  04-04 
POSTADDICTED 

REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE 

2.53112  04-04 
POSTCONCUSSION 

TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS   APPLICATION 
OF  A  DOUBIF  BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS 

240033  03-11 


S-251 


Subject  Index 


Psychopharmacology  Abstract' 


391  r. 

::iO 
«<'t. 


CS:. 


POSTERIOR 

EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF- STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

251070  0403 
POSTGANGLIONIC 

NEUROTRANSMITTERS  INCREASE  CYCLIC  NUCLEOTIDES  IN 
POSTGANGLIONIC  NEURONS:  IMMUNOCYTOCHEMICAL 
DEMONSTRATION. 

229318  01-03 
POSTNATAl 

THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY. 

237721  02-05 
SPONTANEOUS  AND  GUANETHIDINEINDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN. 

241366  03-03 
EFFECTS  OF  EARLY  POSTNATAL  ALPHA-METHYL-DOPA  TREATMENT  ON 
BEHAVIOR  IN  THE  RAT. 

245304  04-04 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 
CATALEPSY  IN  THE  RAT, 

250084  04-03 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS. 

252149  04-04 
POSTREMA 

DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
POSTSYNAPTIC 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS. 

226185  01-04 
REGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRIC-ACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 
EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE-  AND  POSTSYNAPTIC 
CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-03 
BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION: 
POSTSYNAPTIC  SUPERSENSITIVITY? 

229434  01  03 
STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 

DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN 

229435  01-03 
DIPHENYLHYDANTOIN  INCREASES  CORTICAL  POSTSYNAPTIC  INHIBITION. 

241805  03-03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-03 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
POSTSYNAPTICAILY 

EFFECTS  OF  ALPHA-ADRENOCEPTOR  AGONISTS  AND  ANTAGONISTS  OF 
PRE    AND  POSTSYNAPTICALLY  LOCATED  ALPHA-ADRENOCEPTORS. 

252025  0403 
POSTTRAUMATIC 

HOMOVANILLICACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES 

246993  04-13 
HOMOVANILLICACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  M.  VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04-13 


POTASSIUM 

BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-0 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  lON-STIMULATEC 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-0 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-0 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLO. 

246673  04-0 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-0 
POTENCIES 

A  COMPARISON  OF  THE  POTENCIES  OF  A  SERIES  OF  BARBITURATES  AT 
THE  NEUROMUSCULAR  JUNCTION  AND  ON  THE  CENTRAL-NERVOUS- 
SYSTEM. 

233289  02-0 
DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARMACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04-0 
D-AMPHETAMINE  AND  L-AMPHETAMINE  STEREOISOMERS:  COMPARATIV 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS. 

24721 1  04-0 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS. 

250354  04-0 
POTENCY 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-0 
DIPHENYLHYDANTOIN  POTENCY  AND  PLASMA  PROTEIN  BINDING. 

231003  01-0 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  020 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-0 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT. 

250087  04-0: 
DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS. 

251978  04-0 
POTENT 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-0. 
CLOPIMOZIDE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIDINE  SERIES. 

232529  01-0- 
IDENTIFICATION  OF  TWO  RELATED  PENTAPEPTIDES  FROM  THE  BRAIN 
WITH  POTENT  OPIATE  AGONIST  ACTIVITY. 

233300  02-0 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MEDIATING  NEURONAL 
INHIBITION. 

238321  02-0: 
THE  BEHAVIORAL  PHARMACOLOGY  OF  BUTACLAMOL  HYDROCHLORIDE 
(AY-23028),  A  NEW  POTENT  NEUROLEPTIC  DRUG. 

245295  040' 
METABOLIC  FATE  OF  FLURAZEPAM  II:  A  NEW  POTENT  METABOLITE 
OBTAINED  BY  IN  VITRO  LIVER  DRUG  METABOLIZING  ENZYME  SYSTEM 

246971  04-0; 
POTENTIAL 

EVALUATING  POTENTIAL  ANTIDEPRESSANTS  IN  ANIMALS. 

227207  01 -0< 
CLINICAL  PHARMACOLOGY  OF  SQ-10996,  A  POTENTIAL  ANTIDEPRESSIVE 
AGENT. 

229036  01-0/ 
ARE  HORA/.ONES  PSYCHOACTIVE'  EVOKED  POTENTIAL  INVESTIGATIONS 
IN  MAN. 

232532  01-1') 
BASIC  DERIVATIVES  OF  6,7  DIHYDROINDOLOBENZAZEPINE  AND  6H 
INDOLOBENZOXAZEPINE  AS  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

237834  02-02 
AAJ-9022:  CORRELATION  BETWEEN  NEUROLEPTIC  POTENTIAL  AND 
STEREOTYPY. 

237903  02-08 


S-252 


/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  TRANSCAUOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG 

238703  03-03 
PHARMACOLOGICAL  STUDIES  WITH  HP-505,  A  POTENTIAL 
ANTIDEPRESSANT  COMPOUND 

238839  03-03 
CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS, 

239058  03-14 
EXPLORATION  OF  THE  ANTIDEPRESSANT  POTENTIAL  OF  IPRINDOLE. 

241241  03-04 
DRUGS,  AROUSAL,  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-14 
THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE 

244199  04-03 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES. 

244316  04-02 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS 

244874  04-03 
NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES. 

245296  04-03 
SELECTIVE  FIELD  POTENTIAL  CHANGES  INDUCED  BY  L-DOPA. 

246145  04-03 
3-ARYLQUINOLIZIDINES,  POTENTIAL  ANTIDEPRESSANT  AGENTS. 

247586  04-01 
MAO  INHIBITORS  HAVE  POTENTIAL  FOR  ABUSE. 

248339  04-15 
DRUG-INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT. 

249250  04-03 
EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA)    POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  04-03 
CHEMISTRY  AND  PHARMACOLOGY  OF  DIV-154,  A  NEW  POTENTIAL 
NONTRICYCLIC  ANTIDEPRESSANT  COMPOUND. 

251407  04-17 
ANALOGUES  OF  SADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-01 
CLINICAL  RESPONSE  TO  A  POTENTIAL  NONSEDATIVE  ANXIOLYTIC. 

251719  04-07 
BEN20DIAZEPINE-INDUCED  STATE-DEPENDENT  LEARNING   A 
CORRELATIVE  OF  ABUSE  POTENTIAL^. 

252674  04-04 
3TENTIAIS 

THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
LOCAL  ANESTHETICS  AND  BARBITURATES:  EFFECTS  ON  EVOKED 
POTENTIALS  IN  ISOLATED  MAMMALIAN  CORTEX. 

237875  02-03 
THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTION 
POTENTIALS  IN  THE  MOLLUSC  APLYSIA. 

239261  0303 
THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOKED 
DORSAL  ROOT  POTENTIALS. 

239982  03-03 
THE  INTERPRETATION  OF  RESPONSES  OF  MOTONEURONE  FIELD 
POTENTIALS  TO  5-HYDROXYTRYPTAMINE. 

241923  03-03 
3TENTIATED 

LATERAL  GENICULATE  MULTIPLE  UNIT  ACTIVITY  RELATED  TO  METRAZOL 
POTENTIATED  AFTER-DISCHARGES. 

231719  01-03 
JTENTIATES 

THE  MONOAMINE  OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION. 

253643  04-04 
)TENTIATING 

THE  POTENTIATING  EFFECT  OF  LICL  ON  ADRENERGIC  DRUG-INDUCED 
AGGRESSIVE  BEHAVIOR  IN  MICE. 

241364  03-04 


POTENTIATING  EFFECT  OF  LITHIUM  CHLORIDE  ON  AGGRESSIVE 

BEHAVIOUR  INDUCED  IN  MICE  BY  NIALAMIDE  PLUS  L-DOPA  AND  BY 
CLONIDINE. 

246664  0404 
POTENTIATION 

CHANGES  IN  IMIPRAMINE-INDUCED  NORADRENALINE  POTENTIATION  BY 
VARYING  ACTIVITY  OF  GASTRIC  JUICE  UNDER  ORAL  MEDICATION. 

229826  01-13 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02  04 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESIS. 

237711  02-04 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK. 

238795  03-03 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
POTENTIATION  OF  ETHANOL  NARCOSIS  BY  DOPAMINE  AND  L-DOPA 
BASED  ISOQUINOLINES. 

248513  04-03 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

248960  04-02 
THE  POTENTIATION  OF  BARBITURATE-INDUCED  NARCOSIS  BY 
PROCARBAZINE. 

250)09  04-03 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04  08 
POTENTIATION  BY  DESIPRAMINE  OF  NEURONAL  RESPONSES  TO 
MESCALINE. 

251705  04  03 
INHIBITION  AND  POTENTIATION  OF  APOMORPHINE  INDUCED 
HYPERMOTILITY  IN  RATS  BY  NEUROLEPTICS 

252029  04  04 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT. 

252519  04-03 
POWERFUL 

DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  IN 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205  0403 
PRACTITIONER 

VILOXAZINE  (VIVALAN)      GENERAl  PRACTITIONER  GROUP  STUDIES 

227226  01  09 
A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

227914  0110 
A  COMBINATION  OF  ANTIANXIETY  DRUGS    REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

228207  01   10 
PRACTITIONERS 

PSYCHOPHARMACEUTICALS  IN  THE  HANDS  OF  THE  GENERAL 

PRACTITIONERS  -    VERTIGO  STATES:  OVERVIEW  AND  SHORT  REPORTS 

239768  03-17 
PSYCHOTROPIC  DRUGS  FROM  THE  PRACTITIONERS  POINT  OF  VIEW. 

242720  03-17 
COMPLICATIONS  OF  PSYCHOACTIVE  DRUGS  AS  SEEN  BY  FAMILY 
PRACTITIONERS. 

248851  04-15 
PRACTOlOl 

PRACTOLOL  IN  THE  TREATMENT  OF  WITHDRAWAL  SYNDROMES. 

234047  02  11 
PRAIRIE 

TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 
DOGS  (CYNOMYS-LUDOVICIANUS) 

239863  03  04 
PRECENTRAL 

INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS 

239848  03-04 
PRECIPITATED 

PARADOXICAL  ABSENCE  OF  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL. 

227132  01-04 


S-253 


Subject  Index 


Psychopharmacology  Abstrac 


C=l' 


ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC 

232615  02-04 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE 

238687  03-04 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  L  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  04-03 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT. 

251400  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
PRECIPTATING 

COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
PRECLINICAL 

PRECLINICAL  STUDIES  OF  RUBIDIUM  IN  AFFECTIVE  ILLNESS. 

229495  01  02 
PREDICTABILITY  IN  PSYCHOPHARAAACOLOGY:  PRECLINICAL  AND 
CLINICAL  CORRELATIONS, 

231112  01-17 
PRECLINICAL  PHARMACOLOGIC  PROFILE  OF  A  PSYCHOACTIVE 
CANNABINOID. 

249276  04-02 
PRECURSOR 

EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC-ACID-DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN;  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW. 

246846  04-03 
PRECURSORS 

A  HISTOCHEMICAL  STUDY  ON  THE  CENTRAL  EFFECT  OF  MONOAMINE 
PRECURSORS 

229068  01  03 
CENTRAL  DOPAMINE  FUNCTION  IN  AFFECTIVE  ILLNESS:  EVIDENCE  FROM 
PRECURSORS,  ENZYME  INHIBITORS,  AND  STUDIES  OF  CENTRAL 
DOPAMINE  TURNOVER. 

233964  02-14 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  03-13 
PREDATORY 

EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  THE  PREDATORY  BEHAVIOR 
OF  ONYCHOMYS-TORRIDUS 

242749  04-04 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04-04 
PREDICTABIUTY 

PREDICTABILITY  IN  PSYCHOPHARMACOLOGY:  PRECLINICAL  AND 
CLINICAL  CORRELATIONS. 

23111201-17 
ANTIDEPRESSANT  PREDICTABILITY:  CARTAZOLATE 

242251  03-09 
PREDICTABLE 

RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS:  PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  01-11 
AMPHETAMINES  PARADOXICAL  EFFECTS  MAY  BE  PREDICTABLE. 

251154  04-14 
PREDICTING 

PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 
VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
PREDICTION 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO  ELECTROENCEPHALOGRAM. 

229038  01-07 
PREDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 
DEPRESSED  OUTPATIENTS 

229449  01-09 
PREDICTION  OF  RESPONSE  TO  CHLORPROMAZINE  TREATMENT  IN 
SCHIZOPHRENICS 

246314  04-08 


LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 
UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHI 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04 
PREDICTOR 

THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  04 
PREDICTORS 

A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS 
INFANT  BEHAVIOR  VARIABILITY. 

250175  04 
PREDICTS 

DOPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 

PHARAAACOLOGICAL  POTENCIES  OF  ANTISCHIZOPHRENIC  DRUGS. 

243483  04 
PREDISPOSITION 

THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTA' 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES. 

252711  04 
PREDNISOLONE 

EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIV/ 
OF  MALE  LAF-J  MICE. 

246586  04 
PREFERENCE 

ETHANOL  PREFERENCE  IN  RATS:  POSSIBLE  UNDERLYING  MECHANISMS. 

238750  03 
PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03- 
PREFERENCES 

RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D- 
AMPHETAMINE  ON  TIMING  BEHAVIOR. 

226729  01- 
COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCE 
NEW-YORK  AND  TEXAS. 

233829  02- 
EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES. 

239290  03- 
PREFERENTIAL 

HALLUCINOGENIC  INDOLEAMINES:  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS. 

240073  03 
PREFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04- 
PREFERENTIALLY 

FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE. 

248409  04- 
PREGANGLIONIC 

AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-DOPA  AND  5-HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03- 
PREGNANCY 

MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04- 
METHADONE  DURING  PREGNANCY  IN  THE  RAT-  DOSE  LEVEL  EFFECTS  01 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING 

251428  04-1 
PREGNANT 

EFFECTS  OF  PHENOBARBITAL  GIVEN  TO  PREGNANT  MICE  ON  BEHAVIOR 
OF  MATURE  OFFSPRING 

226528  01-1 
PREMEDICANTS 

EVALUATION  OF  LORAZEPAM  AND  PENTOBARBITAL  AS  SURGICAL 
PREMEDICANTS. 

237734  02-1 
PREMENSTRUAL 

A  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

226414  01-1 
ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 
PREMENSTRUAL  TENSION. 

245136  04-1 
PRENATAL 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  OK 
ASSOCIATION  BETWEEN  CLEFT  LIP  WITH  OR  WITHOUT  CLEFT  PALATE 
AND  PRENATAL  EXPOSURE  TO  DIAZEPAM. 

229349  01-1 


S-254 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  AND 
POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOGY^ 

23772)  02-05 
EFFECTS  OF  CHRONIC  PRENATAL  HYPOXIA  ON  PHYSIOLOGICAL, 
NEUROCHE/WICAL  AND  BEHAVIORAL  DEVELOPMENT. 

238722  03-04 
INFLUENCE  OF  PRENATAL  D  AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  03-04 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-03 
PRENATALLY 

MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE. 

230864  01-04 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02  04 
PREOPERATIVE 

CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03-14 
PREOPTIC 

EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
PREPUBERAL 

ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
PREPUBERTAL 

ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  II.  LSD. 

253700  04-03 
PRESCHOOL 

CONTROLLED  TRIAL  OF  METHYLPHENIDATE  IN  PRESCHOOL  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION 

247375  04- n 
PRESCRIBERS 

PROVIDERS  AS  PRESCRIBERS:  ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY 

227923  01-11 
PRESCRIBING 

PROVIDERS  AS  PRESCRIBERS:  ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY. 

227923  01-11 
INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS 

232838  02-17 
THE  PRESCRIBING  OF  HYPNOTICS  IN  GENERAL  PRACTICE 

245469  04  1 1 
INAPPROPRIATE  PRESCRIBING  OF  PSYCHOACTIVE  DRUGS. 

250711  04-17 
PRESCRIPTION 

COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCES- 
NEW-YORK  AND  TEXAS. 

233829  02-08 
CLINICAL  PHARMACOLOGY  AND  THE  PRESCRIPTION  OF  PSYCHOTROPIC 
MEDICATION. 

239678  03-17 
PRESERVED 

CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR 

247022  04-11 
PRESSING 

EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-04 
PRESSOR 

INTRAVENOUS  TYRAMINE  PRESSOR  RESPONSE  IN  DEPRESSION 

226187  01  10 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  01-03 
PRESSOR  EFFECTS  OF  TRYPTAMINE  ANALOGUES. 

243798  04-03 
A  PRESSOR  RESPONSE  TO  INTRAVENTRICULAR  INJECTIONS  OF 
CARBACHOL 

251142  0403 


PRESSURE 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC-ACID  AND  5-HYDROXYTRYPTOPHAN 
(UNPUBIISHED  PAPER). 

231278  01-06 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
PRESSURES 

INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM. 

23551 1  02-04 
PRESUMPTIVE 

PHENOBARBITAL  (PB)  DISPOSITION  IN  MAN:  PRESUMPTIVE  EVIDENCE 
FOR  SEVERAL  METABOLITES. 

238796  03-13 
PRESYNAPTIC 

STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA. 

232513  01-03 
HALLUCINOGENIC  INOOLEAMINES    PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS 

240073  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM 

241247  03-03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART 

242204  03-03 
ANTIPSYCHOTIC  DRUGS:  DIRECT  CORRELATION  BETWEEN  CLINICAL 
POTENCY  AND  PRESYNAPTIC  ACTION  ON  DOPAMINE  NEURONS. 

248466  04-03 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 
ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX. 

251394  04-03 
PRETREATED 

STUDY  ON  HEAD  TWKCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE. 

241380  03-04 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT    -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME.  Ill: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  04-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5  HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
PRETREATMENT 

BEHAVIORAL  SUPERSENSITIVITY  TO  5-HYDROXYTRYPTOPHAN-INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT. 

237729  02-04 
PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 
MEDICATION.  (UNPUBLISHED  PAPER) 

238489  02-08 
THE  EFFECTS  OF  ASCORBIC-ACID  (AA)  PRETREATMENT  ON 
AMPHETAMINE  (A)  EXCRETION  IN  MAN 

238797  03-13 
THE  EFFECT  OF  PRETREATMENT  WITH  6-HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 
VAS  DEFERENS. 

248413  04-03 
THE  EFFECT  OF  AMPHETAMINE  PRETREATMENT  ON  THE  AMPHETAMINE- 
INDUCED  CHANGES  IN  MOTOR  ACTIVITY  AND  BRAIN 
CATECHOLAMINES  IN  MICE 

249274  04-04 
PRETRIAL 

PRETRIAL  COCAINE  AND  PERFORMANCE  IN  RAT. 

237108  02-04 
PREVENT 

INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5- 
HYDROXYINOOLES  BY  P-CHLOROAMPHETAMINE. 

241339  03-03 


S-255 


Subject  Index 


Psychopharmacology  Abstrad 


C3;. 

as. 


FAILURE  OF  PHENOBARBITONE  TO  PREVENT  FEBRILE  CONVULSIONS. 

251103  04-11 
MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 
PREVENTED 

MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  01-04 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238698  03-04 
PREVENTION 

PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE 

238687  03-04 
PSYCHOPHARMACOLOGY  IN  THE  PREVENTION  OF  ANTISOCIAL  AND 
DELINQUENT  BEHAVIOR. 

247385  04-17 
PREWEANING 

WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS 

252149  04-04 
PRIMARY 

PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03-15 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIMARY  HYPERTENSION. 

241294  03-13 
ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 
PREMENSTRUAL  TENSION. 

245136  04-11 
THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04-17 
PRIMATE 

A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01-03 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS 

237270  02-06 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 
A  PRIMATE  MODEL  OF  ACUTE  OYSTONIC  REACTION  TO  NEUROLEPTICS. 

241934  03-05 
NATURE  OF  NEW  CLASS  OF  CHLORPROMAZINE  (CPZ)  METABOLITES  IN 
PRIMATE  URINES. 

249328  04-01 
PRIMER 

DRUGS  AND  BEHAVIOR:  A  PRIMER  IN  NEUROPSYCHOPHARMACOLOGY. 

231227  01-17 
A  PRIMER  ON  THE  CLINICAL  EVALUATION  OF  PSYCHOTROPIC  DRUGS. 

240838  03-17 
PRIMING 

STUDIES  ON  ACOUSTIC  PRIMING    {PH.D.  DISSERTATION). 

238201  02-03 
THE  GENETIC,  BIOCHEMICAL  AND  PHARMACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH.D.  DISSERTATION). 

241687  03  04 
PRIMITIVE 

CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  III    PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT. 

240220  03  14 
PROACTIVE 

RETROACTIVE  AND  PROACTIVE  EFFECTS  OF  ANESTHESIA  ON  FOLLOWING 
IN  CHICKS. 

241330  03-04 
PROBE 

EFFECTS  OF  D  AMPHETAMINE  ON  F-l  SHOCK  PRESENTATION  WITH 
SDELTA  PROBE 

237699  02  04 
PROBENECID 

PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5  HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT 

230877  01  06 
CYCLIC  AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIVE 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  04-09 


THE  EFFECT  OF  PROBENECID  ON  CATECHOLAMINE  METABOLITES  IN 
HUMAN  CEREBROSPINAL  FLUID  ANALYZED  BY  MASS 
FRAGMENTOGRAPHY. 

248464  04- 
PROBLEM 

5-HYDROXYTRYPTAMINE-14C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-1 
MISUSE  AND  ABUSE  OF  DIAZEPAM:  AN  INCREASINGLY  COMMON 
MEDICAL  PROBLEM. 

229852  01- 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC. 

231367  01-1 
THE  PROBLEM  OF  POST  PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION    LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE 

239823  03-1 
PROBLEMS 

PHARMACOTHERAPY  AND  PSYCHOTHERAPY:  PARADOXES,  PROBLEMS 
AND  PROGRESS. 

229240  01- 
THE  PROBLEMS  AND  TREATMENT  OF  PATIENTS  WITH  GILLES-DE-LA- 
TOURETTES  SYNDROME. 

229295  01- 
PHARMACOLOGICAL  AND  TOXICOLOGICAL  PROBLEMS  CONNECTED  WIT 
THE  USE  OF  LONG-ACTING  NEUROLEPTICS. 

229549  01- 
CLINICAL  EXPERIMENTATION  OF  THE  LONG-ACTING  NEUROLEPTICS: 
METHODOLOGICAL  PROBLEMS. 

229554  01- 
PROBLEMS  IN  THE  ELECTROPHYSIOLOGICAL  ANALYSIS  OF  THE  SITE  OF 
ACTION  OF  BENZODIAZEPINES. 

232512  01 -( 
TREATMENT  OF  PSYCHOLOGICAL  PROBLEMS  OF  CONVICTS. 

233079  02- 
DRUGS  FOR  EMOTIONAL  DISORDERS:  CURRENT  PROBLEMS. 

233514  02-; 
SOME  PROBLEMS  OF  PSYCHOTOXICOLOGY  EXEMPLIFIED  BY  LYSERGIC- 
ACID  DIETHYLAMIDE. 

234097  02-1 
ADMINISTRATIVE  AND  JUDICIAL  PROBLEMS  IN  PSYCHOPHARMACOLOG' 

237121  02-1 
PROBLEMS  INVOLVED  IN  ADMINISTERING  L-DOPA. 

239695  03-1 
DEPOT  NEUROLEPTICS    -  PRACTICAL  METHODS  OF  LONG-TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS 

241761  03-C 
PROBLEMS  OF  POLYPHARMACY  IN  DEPRESSION. 

243864  04-C 
PENTAZOCINE  ABUSE  AND  PROBLEMS  OF  WITHDRAWAL. 

246617  04-1 
DOGMATIL  AND  BEHAVIORAL  PROBLEMS  IN  MIGRANT  WORKERS. 

249693  04-1 
CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS 

252447  04-1 
PATTERNS  AND  PROBLEMS  OF  DRUG  CONSUMPTION  IN  A  DEVELOPING 
COUNTRY. 

252990  04-1 
PILLS  FOR  PERSONAL  PROBLEMS. 

253374  04-1 
PROCAINE 

EFFECTS  OF  A  PROCAINE  PREPARATION  (GER0VITAL-H3)  IN 
HOSPITALIZED  GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  STUDY, 

227330  01-1 
EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-0 
PROCARBAZINE 

THE  POTENTIATION  OF  BARBITURATE-INDUCED  NARCOSIS  BY 
PROCARBAZINE 

250109  04-0: 
PROCEDURE 

A  GAS  CHROAAATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-11 
DISCRETE  TRIAL  CHOICE  PROCEDURE:  EFFECTS  OF  NALOXONE  AND 
METHADONE  ON  CHOICE  BETWEEN  FOOD  AND  HEROIN. 

240014  03-0' 
PROCEDURES 

CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  030' 


S-256 


)LUME  14,  SUBJECT  INDEX 


Subject  Index 


)CONVULSANT 

MORPHINES  PROCONVULSANT  ACTION:  IMPORTANCE  OF  ENDOGENOUS 
NOREPINEPHRINE. 

248880  04-03 
CONVULSIVE 
THE  EFFECT  OF  CATECHOLAMINERGIC  SUBSTANCES  ON  PROCONVULSIVE 
PROPERTIES  OF  THE  CAUDATE-NUCLEUS 

231071  01-03 
>CURING 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251  01-04 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  02-04 
>DRUGS 
DIESTER  DERIVATIVES  AS  APOMORPHINE  PRODRUGS. 

251699  04-04 
)DUCE 
00  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION?. 

240802  03-13 
ON  THE  ABILITY  OF  NARCOTIC  ANTAGONISTS  TO  PRODUCE  THE 
NARCOTIC  CUE. 

251429  04-03 
>DUCING 
AMITRIPTYLINE  PERPHENAZINE  OVERDOSE  PRODUCING  DELAYED 
HYPOMANIA  IN  MANIC-DEPRESSIVE  ILLNESS. 

227572  01-09 
SELECTED  BIBLIOGRAPHY  ON  DETECTION  OF  DEPENDENCE  PRODUCING 
DRUGS  IN  BODY  FLUIDS. 

22911201-17 
JDUCTS 
DECOMPOSITION  OF  AMITRIPTYLINE  HYDROCHLORIDE  IN  AQUEOUS 
SOLUTION:  IDENTIFICATION  OF  DECOMPOSITION  PRODUCTS. 

246317  04-01 
>FILE 
VIVALAN:  DRUG  PROFILE. 

227227  01-07 
PROFILE  OF  TRH  IN  EXPERIMENTAL  PSYCHOPHARMACOLOGY 

237708  02-04 
THE  BIOCHEMICAL  AND  BIOBEHAVIORAL  PROFILE  OF  5- 
METHOXYTRYPTAMINE.  (UNPUBLISHED  PAPER). 

239307  03-03 
PRECLINICAL  PHARMACOLOGIC  PROFILE  OF  A  PSYCHOACTIVE 
CANNABINOID. 

249276  04-02 
A  PROFILE  FOR  TRIMIPRAMINE. 

251005  04-10 
)FILES 
INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

231002  01-03 
EFFICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS. 

240706  03-17 
HIPPOCAMPAL  THETA-RHYTHM    I    DEPTH  PROFILES  IN  THE  CURARIZED 
RAT. 

251061  04-03 
JGENY 
THE  EFFECT  OF  CHRONIC  INJECTIONS  OF  CHLORPROMAZINE  ON 
OOGENESIS  AND  PROGENY  DEVELOPMENT  IN  ALBINO  MICE. 

228554  01-05 
JGNOSTIC 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-15 
3GRAM 
DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM 

225722  01-15 
AN  EXPERIMENTAL  THERAPY  AND  RE  EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE    (PH.D.  DISSERTATION) 

228750  01-11 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 
2GRAMS 
MENTAL-HEALTH  PROGRAMS:  PROMISES''    FULFILLMENT'.  FAILURES?. 

236911  02- 15 
>GRESS 
RECENT  PROGRESS  IN  THE  LONG  TERM  PHARMACOLOGICAL  RESEARCH 
ON  CANNABIS. 

229043  01-17 


PHARAAACOTHERAPY  AND  PSYCHOTHERAPY:  PARADOXES,  PROBLEMS 
AND  PROGRESS. 

229240  01-17 
PROGRESSIVE 

PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING.  (UNPUBLISHED 
PAPER). 

231771  01-04 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION    RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS.  (UNPUBLISHED  PAPER). 

237169  02-04 
PROGRESSIVE  BEHAVIORAL  CHANGES  DURING  CHRONIC  LIDOCAINE 
ADMINISTRATION:  RELATIONSHIP  TO  KINDLING. 

249005  04-04 
PROGRESSIVE-RATIO 

COMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL. 

227137  01-04 
PROJECTED 

CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02-03 
PROJECTION 

THE  EFFECT  OF  NEUROTROPIC  AGENTS  ON  EVOKED  POTENTIALS  OF  THE 
ASSOCIATIVE  AND  PROJECTION  AREAS  OF  THE  CAT  NEOCORTEX. 

236261  02-03 
PROLACTIC 

EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROMAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT. 

243951  04-03 
PROLACTIN 

CLOZAPINE  INCREASES  RAT  SERUM  PROLACTIN  LEVELS, 

226869  01-03 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE, 

239828  03-03 
THE  EFFECT  OF  NEUROLEPTICS  ON  SERUM  PROLACTIN  IN  SCHIZOPHRENIC 
PATIENTS. 

239931  03-08 
PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FOR 
ANOREXIA  NERVOSA. 

240423  03- 1 1 
EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT, 

240642  03-03 
STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 

PROLACTIN  SECRETION  IN  THE  MALE  RAT, 

240643  03-03 
THE  LEVEL  OF  THE  GROWTH  HORMONE  PROLACTIN  AND  INSULIN  IN  THE 

COURSE  OF  THE  ACUTE  ADMINISTRATION  OF  CHLORPROMAZINE 
(PLEGOMAZIN)  IN  MENTAL  PATIENTS, 

242863  04-15 
THIORIDAZINE  STIMULATES  PROLACTIN  SECRETION  IN  MAN. 

245840  04-13 
PROLONGATION 

FURTHER  STUDIES  ON  THE  CHLORPROMAZINE  INDUCED  PROLONGATION 
OF  THE  DISAPPEARANCE  OF  MESCALINE  FROM  MOUSE  TISSUES. 

235670  02  03 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  AAICE. 

238737  03-03 
PROLONGED 

THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION 

231070  01-03 
PROLONGED  PSYCHOSIS  ATTRIBUTED  TO  PHENCYCLIDINE    REPORT  OF 
THREE  CASES. 

234713  02  15 
A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS. 

235992  02  II 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE 

237158  02-03 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS 

244456  04  04 
EFFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS 

244651  04-03 
EFFECTIVENESS  OF  HYPNOTIC  DRUGS  WITH  PROLONGED  USE 
FLURAZEPAM  AND  PENTOBARBITAL, 

245652  04  11 


S-257 


y^^m: 


Subject  Index 


Psychopharmacology  Abstr 


3». 


DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
CARDIOVASCULAR  EFFECTS  OF  PROLONGED  DELTA9- 
TETRAHYDROCANNABINOL  INGESTION 

253609  04-13 
PROMAZINE 

ANXIETY/DEPRESSION  IN  ELDERLY  PATIENTS:  A  DOUBLE-BLIND 
COMPARATIVE  STUDY  OF  FLUPHENAZINE/NORTRIPTYLINE  AND 
PROMAZINE. 

247030  04-11 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-01 
PROMETHAZINE 

EFFECTS  OF  PROMETHAZINE  ON  NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

230867  01-14 
PROMISES 

MENTAL-HEALTH  PROGRAMS:  PROMISES?.  FULFILLMENT?.  FAILURES?. 

236911  02-15 
PROPARGYIAMINES 

MONOAMINE-OXIDASE  -    ML  FURTHER  STUDIES  OF  INHIBITION  BY 
PROPARGYLAMINES. 

247020  04-03 
PROPERTY 

SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES- 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
PROPHYLACTIC 

ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01-03 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE 

234044  02-09 
PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS. 

243979  04-09 
PROPHYLACTIC  EFFECTIVENESS  OF  LITHIUM  IN  PATIENTS  WITH 
AFFECTIVE  DISTURBANCES. 

243985  04-09 
PROPHYLACTICAUY 

SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY?. 

247359  04-15 
PROPHYLAXIS 

FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 

CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 
STUDY  GROUP 

225718  01-09 
LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV,  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02-09 
AMITRIPTYLINE  IN  THE  PROPHYLAXIS  OF  MIGRAINE:  EFFECTIVENESS  AND 
RELATIONSHIP  ON  ANTIMIGRAINE  AND  ANTIDEPRESSANT  EFFECTS. 

237138  02-11 
PROPHYLAXIS  OF  AFFECTIVE  DISORDERS:  CURRENT  STATUS  OF 
KNOWLEDGE. 

239937  03-09 
PSYCHOPHARMACOLOGICAL  THERAPY  AND  PROPHYLAXIS  OF  MANIC- 
DEPRESSIVE  ILLNESSES. 

240707  03-09 
LITHIUM  PROPHYLAXIS  IN  AFFECTIVE  DISORDERS. 

245416  04-09 
LITHIUM  CARBONATE  AND  AFFECTIVE  DISORDERS.  V:  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  OF  DEPRESSION  IN  BIPOLAR  ILLNESS. 

247582  04-09 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

252954  04-09 
PROPIONATE 

INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  04-04 
PROPORTIONAL 

DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-03 
PROPRANOLOL 

HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 

227389  01-03 


AN  EXPERIMENTAL  THERAPY  AND  RE-EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE.  (PH.D.  DISSERTATION). 

228750 
TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  !■ 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM. 

237880 
EFFECTS  OF  PROPRANOLOL  HYDROCHLORIDE  ON  LEARNING  IN  ELDE 
SUBJECTS. 

246440 

NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARAAACOKI^ 

DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOl 

247846 
PROPRANOLOL  INHIBITS  RAT  BRAIN  MONOAMINE-OXIDASE 

250333 
PROPRANOLOL  EFFECT  ON  TREMOR  IN  ALCOHOLIC  WITHDRAWAL. 

250779 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM  -■  EVIDENCE  I 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251179 
PROPRANOLOL  IN  THE  TREATMENT  OF  HYPERTENSION. 

251320 
CONTROL  OF  LITHIUM  TREMOR  WITH  PROPRANOLOL. 

251431 
ELECTROPHYSIOLOGICAL  EFFECTS  OF  TRIIODOTHYRONINE  AND 
PROPRANOLOL. 

251984 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITIC 
FLICKER  FREQUENCY. 

251986 
PROSTAGLANDIN 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  PROSTAGLANDIN  BIOSYNTH 
IN  VITRO. 

238320 
PROSTAGLANDIN-E1 

BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El 
NORADRENALINE  INTO  THE  BRAIN. 

242736 
PROSTAGLANDIN-LIKE 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAl 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (■)  TRANS-DELT 
TETRAHYDROCANNABINOL. 

226762 
PROSTAGLANDINS 

THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5HT  IN  TF 
CAT. 

241255 
ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CEREBI 
BLOOD  CIRCULATION. 

248552 
PROSTAGLANDINS-F 

ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINSF  IN  RAT 
CEREBRAL  CORTEX. 

237921  I 
PROTECTING 

INTERACTION  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  CANNABIC 
WITH  PHENOBARBITONE  IN  PROTECTING  MICE  FROM  ELECTRICAL! 
INDUCED  CONVULSIONS. 

244894  I 
PROTECTION 

PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 

NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

2387181 
PROTEIN 

DIPHENYLHYDANTOIN  POTENCY  AND  PLASMA  PROTEIN  BINDING. 

231003  ( 
REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 
PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENC 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  ( 
CYCLIC  NUCLEOTIDES,  PROTEIN  PHOSPHORYLATION,  AND  NEURONAl 
FUNCTION. 

231021  ( 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMIN 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN 

237109 C 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEir 
METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX 

237243  C 
EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIV 
AVOIDANCE  TRAINING. 

237264  0 


S-258 


I 


HUME  14,  SUBJECT  INDEX 


Subject  Index 


OOPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE- 
NUCLEUS.  (PH.D.  DISSERTATION) 

238080  02-13 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
EFFECT  OF  DIPHENYLHYDANTOIN  ON  THE  ENDOGENOUS 
PHOSPHORYLATION  OF  BRAIN  PROTEIN. 

240746  03-03 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUMAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN. 

244131  04-13 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUMAN  SUBJECTS. 

246970  04-13 
IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN?. 

248604  04-03 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D  AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14  LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORMANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04-14 
DIPHENYLHYDANTOIN  FACILITATION  OF  LABILE,  PROTEIN  INDEPENDENT 
MEMORY. 

253290  04-04 
3TEINS 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS    -  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  0403 
DTEST 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
3THIADEN 
THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 
DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL. 

226899  01-09 
3TIREUN 
ORAL  PROTIRELIN  (TRH)  IN  DEPRESSION. 

247482  04-09 
3TOZOAN 
ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICAIS. 

248163  04-02 
DTRIPTYIINE 
THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA. 

227139  01-03 
OXAZEPAM  PROTRIPTYLINE    A  DOUBLE  BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS 

248975  04-10 
3VI0ERS 
PROVIDERS  AS  PRESCRIBERS   ATTITUDES  TOWARD  ASPECTS  OF 
PRESCRIBING  AND  THEIR  RELATIONSHIP  TO  MANAGEMENT  OF 
HYPERTENSION  IN  THE  ELDERLY. 

227923  01-11 
9VOKE0 
COOMBS-POSITIVE  HEMOLYTIC  ANEMIA  PROVOKED  BY 
CHLORPROMAZINE. 

237161  02-15 
:UDOCON0ITIONE0 
RELATIONS  BETWEEN  ORIENTING.  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX  -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE. 

230570  01-04 
iUOOCONOITIONING 
THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01-04 


PSEUDOMORPHINE 

ENZYMATIC  CONVERSION  OF  MORPHINE  TO  PSEUDOMORPHINE. 

243780  04-03 
PSEUDONEUROTIC 

EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 
NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES 

230818  0110 
PSYCHEDELIC 

THE  PSYCHEDELIC  MODEL  OF  SCHIZOPHRENIA:  THE  CASE  OF  N,N 
DIMETHYLTRYPTAMINE. 

236750  02-08 
PSYCHIATRIC 

THE  NONCONTRIBUTION  OF  DRUGS  TO  THE  DISCHARGE  OF  THE  LONG- 
STAY  PSYCHIATRIC  PATIENT 

227461  01  17 
A  NEGLECTED  MODALITY  IN  PSYCHIATRIC  TREATMENT    -  THE 
MONOAMINE-OXIDASE  INHIBITORS. 

227825  01-10 
ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  01-15 
REVIEW  OF  LONG-TERM  PSYCHIATRIC  MEDICATION     A  STUDY  OF 
WITHDRAWAL  SYMPTOMS. 

228214  01  15 
DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 
CHRONIC  SCHIZOPHRENIA. 

228325  01-08 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATION 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES. 

229115  01-13 
PLASMA  CHLORPROMAZINE  IN  PSYCHIATRIC  MANAGEMENT 

229492  01   13 
THE  POSITION  OF  LONG-ACTING  DRUGS  IN  THE  ECONOMY  OF 
PSYCHIATRIC  INSTITUTIONS. 

229558  01-17 
THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY 

229650  01   14 
GETTING  PSYCHIATRIC  PATIENTS  TO  TAKE  THEIR  MEDICATION 

230118  01-17 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS 

230997  01-11 
ON  THE  EFFECTIVENESS  OF  PSYCHIATRIC  AMBULATORY  STATIONS 

234289  02-11 
ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02-17 
THE  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES 

234699  02-09 
ETHICAL  AND  LEGAL  IMPLICATIONS  OF  INVESTIGATIONS  INTO  THE 
EFFICACY  OF  PSYCHIATRIC  TREATMENTS. 

235354  02-17 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS  -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL. 

235360  02-07 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    -  II.  REPORT  ON  A  PLACEBO  CONTROLLED 
CLINICAL  TRIAL. 

235361  02  09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS    -  III.  STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02  09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  IV  A  SUMMARY  REPORT. 

235363  02  09 
METHODS  OF  ASSESSMENT  OF  DRUG  ADMINISTRATION  IN  A 

PSYCHIATRIC  HOSPITAL 

235545  02  17 
INVESTIGATION  OF  THE  INCIDENCE  OF  DIABETES  IN  PATIENTS  IN  THE 
LUCCA  PSYCHIATRIC  HOSPITAL:  PATHOGENIC  CONSIDERATIONS. 

235988  02-15 
IMMUNOLOGICAL  METHODS  IN  PSYCHIATRIC  TREATMENT 

23751  I  02-17 
APPARENT  PHARMACOKINETIC  INTERACTION  OF  DIAZEPAM  AND 
AMITRIPTYLINE  IN  PSYCHIATRIC  PATIENTS:  A  PILOT  STUDY 

237901  02  13 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS 

237902  02  13 
SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 

PSYCHIATRIC  PATIENTS. 

238552  02  13 


S-259 


Subject  Index 


Psychopharmacology  Abstr 


SJSi 
3a. 


CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS 

239058  03-14 
REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS. 

239641  03- 11 
FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH  A 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350) 

239748  03-14 
SUDDEN  UNEXPLAINED  DEATH  IN  A  PSYCHIATRIC  PATIENT  TAKING 
THIORIDAZINE 

240243  03-15 
PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES. 

242751  04-17 
DEATH  AND  DRUG  TREATMENT  IN  A  PSYCHIATRIC  HOSPITAL. 

243716  04-15 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE. 

244355  04-15 
PENFLURIDOL  STEADY-STATE  KINETICS  IN  PSYCHIATRIC  PATIENTS. 

245650  04-08 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS. 

248975  04-10 
ANESTHESIOLOGIC  CONSIDERATIONS  IN  PSYCHIATRIC  CONVULSIVE 
THERAPY. 

249765  04-17 
TIME-DEPENDENT  EFFECTS  OF  PHENOTHIAZINES  ON  DOPAMINE 
TURNOVER  IN  PSYCHIATRIC  PATIENTS. 

250389  04-13 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY. 

250722  04  15 
CLINICAL  EXPERIENCE  WITH  BETA-BLOCKERS  IN  CONSULTANT 
PSYCHIATRIC  PRACTICE. 

251165  04-10 
DO  PSYCHIATRIC  PATIENTS  TAKE  THEIR  MEDICATION?.  THE  VIEW  OF 
THE  STAFF. 

253103  04-17 
PSYCHIATRISTS 

COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCES: 
NEW  YORK  AND  TEXAS. 

233829  02-08 
PSYCHIATRY 

NEW  DRUG  THERAPY  IN  THE  FIELD  OF  PSYCHIATRY. 


228211  01-17 
228217  01  09 


LITHIUM  IN  PSYCHIATRY. 

IS  LITHIUM  USEFUL  IN  CHILD  PSYCHIATRY?. 

229081  01-14 
PLASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  01-16 
CLINICAL  PSYCHOPHARMACOLOGY  AND  PSYCHIATRY. 

231607  01-17 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  I.  SCHIZOPHRENIA. 

232827  02-08 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 
PSYCHOTROPIC  DRUGS. 

233684  02-17 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-17 
AN  UPDATE  OF  MEGAVITAMIN  THERAPY  IN  ORTHOMOLECULAR 
PSYCHIATRY. 

235678  02-17 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 
DISORDERS. 

236303  02-17 
CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY. 

237458  02  10 
DRUG  TREATMENT  IN  PSYCHIATRY. 

240086  03-17 
IHE  PSYCHIATRY  OF  THE  FEMALE  CLIMACTERIUM    NEUROTIC  OR 
PSYCHOTIC  SYMPTOMS'. 

241875  03-09 
ASSESSMENT  OF  DIAZEPAM  AFTER  THREE  YEARS  USE  IN  CHILD 
PSYCHIATRY. 

249144  04-11 
REPORT  OF  A  SYMPOSIUM  ON  BETA  ADRENERGIC  RECEPTOR  BLOCKADE 
IN  PSYCHIATRY,  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21ST  1975. 
BETA  ADRENERGIC  BLOCKING  DRUGS  IN  ANXIETY. 

251156  0410 


PSYCHIC 

RELATIONSHIPS  BETWEEN  ANESTHETIC  SUBSTANCES,  CONVULSION; 
AND  PSYCHIC  DISTURBANCES. 

229118 
TWO  CASES  OF  PSYCHIC  DISTURBANCES 

232545 

TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENI/ 

GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449 
PSYCHOACTIVE 

ACUTE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATION 
ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS. 

225572 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441 
A  CONTRIBUTION  TO  PSYCHOACTIVE  DRUG  MEASUREMENT  TECHNI 

229442 
A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERAN: 
ADMINISTRATION  HOSPITALS. 

229458 
ANALYSIS  OF  DRUGS  AND  PSYCHOACTIVE  PHENOLIC  AMINES. 

229486 
PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 
RESEARCH. 

231066 
ARE  HORMONES  PSYCHOACTIVE?  EVOKED  POTENTIAL  INVESTIGATK 
IN  AAAN. 

232532 
INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACL 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS. 

233377 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS:  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488 
ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATI 
OF  VARIOUS  PSYCHOACTIVE  DRUGS. 

234810 
INTRODUCTION  TO  THE  SYMPOSIUM  ON  SYSTEMATIC  STUDIES  WIT 
PSYCHOACTIVE  DRUGS  -    NEW  METHODS  IN  THE  ASSESSMENT  01 
CHANGE. 

235355 
CHANGES  IN  PSYCHOACTIVE  DRUG  USE  AMONG  ADULTS  IN 
METROPOLITAN  TORONTO-  1971-1974. 

236046 
DOPAMINE  AND  PSYCHOACTIVE  DRUG  ACTION:  A  FURTHER 
EVALUATION. 

238768 
MEDICAL  DOMINANCE:  PSYCHOACTIVE  DRUGS  AND  MENTAL-HEALT 
POLICY. 

239298 
PHARMACOLOGY  OF  PSYCHOACTIVE  DRUGS. 

240704 
THIRD  PSYCHOACTIVE  DRUG  USAGE  GUIDE. 

247880 
COMPLICATIONS  OF  PSYCHOACTIVE  DRUGS  AS  SEEN  BY  FAMILY 
PRACTITIONERS. 

248851 
INTRAGASTRIC  SELF-ADMINISTRATION  OF  PSYCHOACTIVE  DRUGS  B' 
THE  RHESUS  MONKEY. 

249004 
EEG  AND  BEHAVIORAL  EFFECTS  OF  NARCOTIC  ANTAGONISTS  ALONE 
IN  COMBINATION  WITH  OTHER  PSYCHOACTIVE  DRUGS  IN  MORPF 
DEPENDENT  MACACA-MULATTA. 

249267 
PRECLINICAL  PHARMACOLOGIC  PROFILE  OF  A  PSYCHOACTIVE 
CANNABINOID. 

249276  I 
ACTION  OF  PSYCHOACTIVE  DRUGS  ON  CYCLIC-AMP  LEVELS  IN  MOU 
CEREBRAL  CORTEX  AND  LUNG  FOLLOWING  MICROWAVE 
IRRADIATION. 

249286  I 
ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 
COMPARISON  OF  THE  (3H)QUINUCLIDINYL  BENZILATE  BINDING  AS 
WITH  CONVENTIONAL  METHODS 

250360 ( 
INAPPROPRIATE  PRESCRIBING  OF  PSYCHOACTIVE  DRUGS. 

250711 ( 
NEW  PSYCHOACTIVE  DRUGS  IN  PSYCHOGERIATRICS. 

253060  ( 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTI 
DRUGS  TO  PREPUBERTAL  MALE  RATS.  II.  LSD. 

253700  ( 
PSYCHOANALEPTICS 

HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  S 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS. 

248514 C 


S-260 


1 


LUME  14,  SUBJECT  INDEX 


:hooysieptic 

synthesis  of  0-transmethylated  catecholamines  and 
psychodysleptic  beta-phenylisopropylamines.  (ph  d 
dissertation). 

242003  03-01 
HOGENIC 

CLINICAL  FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 
PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT. 

244476  04-11 

HOGERIATRIC 

:OMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT- 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 

EFFECT  OF  METHYLDOPA  ON  TARDIVE-DYSKINESIA  IN  PSYCHOGERIATRIC 
PATIENTS 

247967  04-11 

HOGERIATRICS 

VIEW  PSYCHOACTIVE  DRUGS  IN  PSYCHOGERIATRICS. 

253060  04-11 

HOIEPTIC 

IHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS. 

240237  03-04 
HOLOGICAL 

'SYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01-14 
'SYCHOLOGICAL  ANALYSES  OF  PATIENTS  SUFFERING  FROM 
HYPOTHYROIDISM. 

232364  01-14 
REATMENT  OF  PSYCHOLOGICAL  PROBLEMS  OF  CONVICTS. 

233079  02- 11 
k  1,4  BENZODIAZEPINE,  TEMAZEPAM  (K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02-14 
MIPRAMINE  IN  ENURESIS  -  PSYCHOLOGICAL  AND  PHYSIOLOGICAL 
EFFECTS. 

247743  04-11 
f<OMETRIC 

'SYCHOMETRIC  CLINICAL  EVALUATION,  THROUGH  OVERALL  AND 
GORHAMS  TEST,  OF  THERAPY  WITH  FLUPHENAZINE-DECANOATE. 

229555  01-17 

'ENFLURIDOL  IN  THE  TREATMENT  OF  SCHIZOPHRENIA:  CLINICAL  AND 
PSYCHOMETRIC  FINDINGS. 

235365  02-08 
I  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 

CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
EVODOPA  AND  PSYCHOMETRIC  TEST  PERFORMANCE  IN  PARKINSONISM 

-  5  YEARS  LATER. 

237141  02-14 
SYCHOMETRIC  EFFECTS  OF  PERPHENAZINE  BELOW  THE  NEUROLEPTIC 
THRESHOLD. 

239682  03-15 
ERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES- 
PRELIMINARY  EXPERIMENTS. 

244591  04-13 
RE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN?. 

247382  04- 14 
SYCHOMETRIC  ASSESSMENT  OF  THE  THERAPEUTIC  EFFICIENCY  OF 
ANTIDEPRESSANT  AGENTS. 

251004  04-10 
lOMOTOR 

SYCHOTROPIC  DRUGS  AND  IMPARIMENT  OF  PSYCHOMOTOR 

FUNCTIONS, 

227136  01-15 
■FECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 

FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL    ON 

PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING 

229907  01-14 
HE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 

AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 

RECOVERY, 

230830  01-14 
3PAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA- 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS 

233967  02-08 
REVIEW  OF  THE  EFFECTS  OF  DIAZEPAM  ON  COGNITIVE  AND 
PSYCHOMOTOR  PERFORMANCE. 

235236  02-14 


Subject  Index 

THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESIS 

23771 1  02-04 
A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03-14 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
SELF-ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS   THE 
EFFECTS  OF  UNLIMITED  ACCESS. 

250066  04-04 
PSYCHONEUROTIC 

THE  USE  OF  DOTHIEPIN  IN  THE  TREATMENT  OF  PSYCHONEUROTIC 
ANXIETY  WITH  DEPRESSIVE  FEATURES. 

237774  02-10 
PSYCHOPATHIES 

ELECTROCLINICAL  CORRELATIONS  IN  PSYCHOPATHIES. 

236793  02-14 
PSYCHOPATHOLOGY 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION. 

225721  01-17 
APOMORPHINE  AND  PSYCHOPATHOLOGY. 

230743  01-11 
PSYCHOPHARMACEUTICAl 

ABUSE  OF  PSYCHOPHARMACEUTICAL  AGENTS  IN  DRUG  DEPENDENCE 
(ANALYSIS  OF  CASES  HOSPITALIZED  IN  A  PSYCHIATRIC  DEPARTMENT 
IN  THE  YEARS  1970  TO  1973). 

234653  02-17 
THERAPY  OF  PSYCHOPHARAAACEUTICAL  SIDE-EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID,  BC-51). 

239782  03-15 
THE  PSYCHOPHARMACEUTICAL  THERAPY  OF  DEPRESSION. 

241762  03-09 
ON  PSYCHOPHARMACEUTICAL  RESEARCH  AND  THE  UNDERSTANDING  OF 
SCHIZOPHRENIA. 

244037  04-17 
PSYCHOPHARMACEUTICALS 

CHANGES  IN  ANTICOAGULANT  TOLERANCE:  I.  INFLUENCE  OF  SEDATIVES 
AND  PSYCHOPHARMACEUTICALS. 

235336  02-15 
PSYCHOPHARMACEUTICALS  IN  THE  HANDS  OF  THE  GENERAL 

PRACTITIONERS  -  VERTIGO  STATES:  OVERVIEW  AND  SHORT  REPORTS. 

239768  03-17 
THERAPEUTIC  COMBINATION  OF  PSYCHOPHARMACEUTICALS  AND  BETA- 
ADRENERGIC  BLOCKERS. 

239783  03-15 
INFLUENCE  OF  PSYCHOPHARAAACEUTICALS  ON  ACHIEVEMENT 

MOTIVATION:  III.  DIFFERENTIAL  INFLUENCE  ON  CONTENT  CATEGORIES. 

240644  03-14 
PSYCHOPHARMACOLOGIC 

PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS- 
EFFECT  OF  DIAZEPAM  IN  MALES. 

229840  01-11 
CONGENITAL  MALFORMATIONS  WITH  PSYCHOPHARMACOLOGIC 
AGENTS. 

230012  01  15 
PSYCHOPHARMACOLOGIC  AGENTS:  EFFECT  ON  DRUG  METABOLISM. 

244060  04-03 
PSYCHOPHARMACOlOGICAl 

WORLDWIDE  TRENDS  IN  THE  PSYCHOPHARMACOLOGICAL  STUDIES. 

228323  01-17 
ANALYSIS  AND  DISPLAY  OF  PSYCHOPHARMACOLOGICAL  DATA. 

228978  01-17 
NEUROPHARMACOLOGY  OF  PSYCHOPHARMACOLOGICAL  AGENTS. 

229484  01-04 
FUNCTIONAL  SIGNIFICANCE  OF  CENTRAL-NERVOUS-SYSTEM 

NOREPINEPHRINE  AND  DOPAMINE:  A  PSYCHOPHARMACOLOGICAL 
STUDY.  (PH.D.  DISSERTATION). 

231437  0104 
PSYCHOPHARMACOLOGICAL  TREATMENT  OF  SCHIZOPHRENIA. 

235773  02  08 
NOVEL  ANALOGS  OF  TRICYCLIC  PSYCHOPHARMACOLOGICAL  AGENTS. 

238476  02-01 
PSYCHOPHARMACOLOGICAL  THERAPY  AND  PROPHYLAXIS  OF  MANIC- 
DEPRESSIVE  ILLNESSES. 

240707  03-09 
PSYCHOPHARMACOLOGICAL  DRUGS  IN  NEUROLOGY. 

240708  03-17 
PSYCHOPHARMACOLOGICAL  CHARACTERIZATION  OF  A  DRUG-INDUCED 

GROOMING  BEHAVIOR  IN  THE  CRICKET,  ACHETA-DOMESTICUS 
(INSECTA,  ORTHOPTERA)   (PH.D.  DISSERTATION), 

241994  03-04 


S-261 


Subject  Index 


Psychopharmacology  Abstro 


39: 


INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARMACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIAL 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR 

244899  04-04 
PSYCHOPHARMACOLOGY 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION. 

225721  01-17 
UNEXPECTED  LABORATORY  RESULTS  EFFECT  ON 
PSYCHOPHARMACOLOGY, 

226877  CM  7 
ADVANCES  IN  BIOCHEMICAL  PSYCHOPHARMACOLOGY. 

226961  01-17 
PSYCHOPHARMACOLOGY  AND  PSYCHOSOMATIC  ILLNESS. 

228242  01-11 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  APPROACH  TO 
SCHIZOPHRENIA, 

228308  01  08 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  BEHAVIOR 

PHARMACOLOGICAL  ASPECTS, 

228309  01-17 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  ITS  BIOCHEMICAL  ASPECT, 

228310  01-13 
'  _CENT  ADVANCES  IN  CHILD  PSYCHOPHARMACOLOGY. 

229053  01-11 
PSfCHOPHARMACOLOGY  OF  THE  CIRCULATORY  SYSTEM, 

229471  01-13 
PSYCHOPHARMACOLOGY  RESEARCH  CENTER. 

229497  01  03 
PREDICTABILITY  IN  PSYCHOPHARMACOLOGY    PRECLINICAL  AND 
CLINICAL  CORRELATIONS. 

2311120M7 
GENETICS  AND  PSYCHOPHARMACOLOGY. 

23141001-17 
CLINICAL  PSYCHOPHARMACOLOGY  AND  PSYCHIATRY. 

231607  01-17 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  ANTIDEPRESSANTS 
AND  LITHIUM 

232762  02  17 
ASSESSING  THE  SAFETY  AND  EFFICACY  OF  INTERNATIONAL  TRIALS  IN 
PSYCHOPHARMACOLOGY.  (UNPUBLISHED  PAPER). 

232902  02-16 
PSYCHOPHARMACOLOGY   A  BIOLOGICAL  APPROACH 

232938  02-17 
CLINICAL  PSYCHOPHARMACOLOGY  AND  THE  ELDERLY  PATIENT. 

236300  02  1  7 
ASSISTING  MULTIPLE  DRUG  ADDICTS.  PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY. 

237095  02-11 
ADMINISTRATIVE  AND  JUDICIAL  PROBLEMS  IN  PSYCHOPHARMACOLOGY. 

237121  02-17 
PROFILE  OF  TRH  IN  EXPERIMENTAL  PSYCHOPHARMACOLOGY. 

237708  02  04 
METHODOLOGY  OF  THERAPEUTIC  EFFECTIVENESS  TRIALS  IN 
PSYCHOPHARMACOLOGY. 

240444  03-17 
GENERAL  PRINCIPLES  OF  PSYCHOPHARMACOLOGY. 

240705  03- 17 
COMPARATIVE  PSYCHOPHARMACOLOGY  OF  COCAINE  AND 
AMPHETAMINE 

243820  04- 1  7 
I.  PSYCHOPHARMACOLOGY  AND  THE  NEED  TO  KNOW 

2'M875  04  17 
(  URRFNT  DEVELOPMENTS  IN  PSYCHOPHARMACOLOGY,  VOLUME  I. 

245873  04  17 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  TRANQUILIZERS 

246033  04- 1  7 
PSYCHOPHARMACOLOGY,  PSYCHOSIS  AND  FREEDOM 

246123  04-17 
PSYCHOPHARMACOLOGY  IN  THE  PREVENTION  OF  ANTISOCIAL  AND 
DELINQUFNT  BEHAVIOR 


PSYCHOPHARMACOLOGY  IN  CHILDHOOD  PSYCHOSIS. 
AN  OVIRVILW  or  PSYCHOPHARMACOLOGY  OF  OLD  AGE 

PSYCHOPHARMACON 

A  NfW  HUNGARIAN  PSYCHOPHARMACON. 


247385  04-17 

247386  04  17 
253062  04  17 

252444  04  17 
P5YCHOPHARMACOTHERAPY 

OPHIIIAIMOIOGICAI  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY:  II.  SEVEN  CASES  DUE  TO 
ANTIPSYCHOTIC  DRUGS 

227808  01-1 5 
NON  SPECIFIC  FACTORS  IN  PSYCHOPHARMACOTHERAPY 

228244  01   17 
IRFATMFNl  OF  THE  MINIMAL  BRAIN  DYSFUNCTION  SYNDROME  WITH 
PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON) 

23000?  0111 


RATIONAL  PSYCHOPHARMACOTHERAPY  AND  THE  RIGHT  TO  TREATM 

232937  Q 
THE  PLACEBO  EFFECT  IN  PSYCHOPHARAAACOTHERAPY  IN 

CONSIDERATION  OF  THE  EFFECT  OF  MEPIPRAZOL  ON  EXCITEMENT 
PSYCHOTICS. 

23421 7  C 
PRESENT  ASPECTS  OF  PSYCHOPHARMACOTHERAPY  IN  CHILDHOOD  A 
ADOLESCENCE. 

236150  0 
ON  ONE  OF  THE  VARIANTS  OF  SIMPLE  SCHIZOPHRENIA  IN  THE  LIGHT 
PSYCHOPHARMACOTHERAPY. 

236725  C 
OPHTHALMOLOGICAL  FINDINGS  ON  NEUROPSYCHIATRIC  PATIENTS 
DURING  PSYCHOPHARMACOTHERAPY.  I.  OUTLINE  OF  THE  INCIDEN' 
OF  OPHTHALMOLOGICAL  ABNORMALITIES. 

244779  0 
PSYCHOPHYSIOLOGICAl 

AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS 

241234  0 
PSYCHOSES 

THE  MEDICAL  PHARAAACOLOGICAL  AAANAGEMENT  OF  ACUTE 
PSYCHOSES. 

229717  0 
SULPIRIDE  IN  CHRONIC  PSYCHOSES  OF  THE  PARANOID  TYPE. 

230991  0 
THE  RESOCIALIZING  EFFECT  OF  CLOTHIAPINE  IN  CHRONIC  PSYCHOSE! 

230993  0 
THE  LITTLE  KNOWN  THERAPEUTIC  PROPERTIES  OF  IMIPRAMINE  IN 
MANIC  STATES  OF  CYCLOTHYMIC  PSYCHOSES. 

231368  0 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  0 
VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES. 

244188  0. 
NEUROLEPTICS,  CATECHOLAMINES,  AND  PSYCHOSES:  A  STUDY  OF  TH 
INTERRELATIONS. 

245510  a 
RECENT  ADVANCES  IN  THE  DRUG  TREATMENT  OF  THE  FUNCTIONAL 
PSYCHOSES. 

252653  Q. 
MANAGEMENT  OF  PATIENTS  WITH  SUSPECTED  DRUG-INDUCED 
PSYCHOSES. 

252733  0' 
PSYCHOSEXUAl 

EFFECTS  IF  SOME  DRUGS  ON  PSYCHOSEXUAL  RESPONSE  IN  MAN. 

239646  O; 
PSYCHOSIS 

PENTAZOCINE  PSYCHOSIS:  A  CASE  OF  PERSISTENT  DELUSIONS. 

225873  01 
ROUSSY  LEVY  SYNDROME  WITH  PSYCHOSIS. 

227746  01 
SCHIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY:  TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEG 

228068  01 
COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT. 

232635  02 
BEHAVIORAL  AND  EEG  CHANGES  IN  THE  AMPHETAMINE  MODEL  OF 
PSYCHOSIS 

233965  02 
PROLONGED  PSYCHOSIS  ATTRIBUTED  TO  PHENCYCLIDINE    REPORT  OF 
THREE  CASES 

234713  02 
SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENTS 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361  02 
APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  0 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS 

236732  02 
LITHIUM  SALTS  IN  CYCLOPHRENIA  (MANIC  DEPRESSIVE  PSYCHOSIS). 

237013  02 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION:  RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS   (UNPUBLISHED  PAPER). 

237169  02- 
PSYCHOSIS  FOLLOWING  INGESTION  OF  HEMP  IN  CHILDREN 

237730  02- 
8I0CHEMICAL  RESEARCH  INTO  PSYCHOSIS:  RESULTS  OF  A  NEW 
RESEARCH  STRATEGY 

238997  03 


S-262 


UME  14,  SUBJECT  INDEX 


Subject  Index 


IMOZIDE  IN  THE  TREATMENT  OF  MONOSYMPTOMATIC 
HYPOCHONDRIACAL  PSYCHOSIS 

239014  03-11 
ROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS 

243979  04-09 
MPHETAMINE  PSYCHOSIS:  OVERVIEW  AND  A  HYPOTHESIS. 

245019  04-15 
ASE  REPORT  OF  THE  MCLEAN  HOSPITAL.  BELMONT,  MASSACHUSETTS: 
LV -A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS. 

245863  04-08 
5YCH0PHARMACOLOGY,  PSYCHOSIS  AND  FREEDOM 

246123  04-17 
JMMARY  OF  THE  DISCUSSIONS  AT  THE  SYMPOSIUM  PSYCHOSIS  AND 
FREEDOM 

246126  04-17 
5YCH0PHARMAC0L0GY  IN  CHILDHOOD  PSYCHOSIS. 

247386  04-17 
HOUGHT  DISORDER  IN  AMPHETAMINE  PSYCHOSIS:  A  CASE  REPORT. 

250196  04-13 
HENELZINE  AND  PSYCHOSIS 

251128  04-09 
lOSOCIAL 

rtPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02- 17 
lOSOMATIC 

LINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS. 

227806  01-11 
HARMACOTHERAPY  OF  PSYCHOSOMATIC  CASES, 

227818  01-11 
5YCH0PHARMAC0L0GY  AND  PSYCHOSOMATIC  ILLNESS. 

228242  01-11 
HE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01-11 
■FICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS 

240706  03-17 
lOSTIMULANT 

JBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY: 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
rUDY  OF  A  NEW  PSYCHOSTIMULANT  -  SIDNOCARB. 

236363  02-10 
OTHERAPEUTIC 

/ALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 
PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS. 

235782  02- 11 
OTHERAPEUTICS 

.ACENTAL  TRANSFER  OF  PSYCHOTHERAPEUTICS  OF  THE  THIOXANTHENE 
TYPE. 

237120  02-05 
OTHERAPy 

iYCHOTHERAPY  FOR  SCHIZOPHRENICS:  IS  IT  INDICATED'' 

225826  01-08 

lARMACOTHERAPY  AND  PSYCHOTHERAPY:  PARADOXES    PROBLEMS 

AND  PROGRESS 

229240  01  17 

iEDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 

DEPRESSED  OUTPATIENTS 

229449  01-09 
?UGS  AND  PSYCHOTHERAPY  IN  DEPRESSION  REVISITED  ISSUES  IN  THE 
ANALYSIS  OF  LONG-TERM  TRIALS 

229450  01  09 
lARMACOTHERAPY  AND  PSYCHOTHERAPY  IN  THE  TREATMENT  OF 
NEUROSES 

230640  01-17 
IE  EFFECTS  OF  LSD  ON  THE  EXPRESSION  OF  AFFECT  IN 
PSYCHOTHERAPY  (PHD,  DISSERTATION) 

231480  01-12 
IE  FORGOTTEN  TREATMENT  MODALITY  IN  BIPOLAR  ILLNESS- 
PSYCHOTHERAPY. 

231611  0109 
)SSIBILITIES  FOR  PHARMACOTHERAPY  IN  THE  COURSE  OF 
PSYCHOTHERAPY  FOR  MENTAL  DISORDERS 

234438  02-17 
ODEL  OF  CAUSAL  CONFRONTATION  IN  INTEGRATIVE  PSYCHOTHERAPY 

234503  02-14 
IPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH 

235534  02  17 


ASSISTING  MULTIPLE  DRUG  ADDICTS   PSYCHOTHERAPY  AND 
PSYCHOPHARMACOLOGY. 

237095  02  11 
PSYCHOTHERAPY  AND  PHARMACOTHERAPY:  CONCEPTUAL  ISSUES. 
(UNPUBLISHED  PAPER). 

238493  02- 17 
PSYCHOTHERAPY  AND  TRICYCLIC  ANTIDEPRESSANTS. 

243860  04-09 
DIPROPYLTRYPTAMINE  IN  PSYCHOTHERAPY. 

251752  04-17 
DRUG  AND  PSYCHOTHERAPY  INTERACTIONS  IN  DEPRESSION. 

252941  04  09 
PSYCHOTIC 

CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  01-11 
THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG  ACTING  NEUROLEPTICS 

229552  01  17 
THE  TREATMENT  OF  PSYCHOTIC  ANXIETY, 

229559  01-10 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE. 

232865  02-15 
DOPAMINE  AND  PSYCHOTIC  STATES    PRELIMINARY  REMARKS. 

233961  02-13 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02- 17 
TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  lOXAPINE 
PARENTERALLY. 

238551  02  09 
TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DELAGRANGE) 

239269  03-11 
SEROTONIN  (5-HT)  SYSTEMS  IN  PSYCHOTIC  STATES. 

240076  03- 12 
THE  PSYCHIATRY  OF  THE  FEMALE  CLIMACTFRIUM    NEUROTIC  OR 
PSYCHOTIC  SYMPTOMS?. 

24)875  03-09 
A  TWO  YEAR  TRIAL  OF  LOXAPINE  SUCCINATE  IN  CHRONIC  PSYCHOTIC 
PATIENTS 

244501  04-08 
A  COMPARISON  OF  ANTIDEPRESSANT  MEDICATIONS  IN  NEUROTIC  AND 
PSYCHOTIC  PATIENTS. 

25364)  04-11 
PSYCHOTICS 

THE  PLACEBO  EFFECT  IN  PSYCHOPHARMACOTHERAPY  IN 

CONSIDERATION  OF  THE  EFFECT  OF  MEPIPRAZOL  ON  EXCITEMENT  IN 
PSYCHOTICS. 

234217  0208 
CHANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 
NEUROLEPTIC  TREATMENT. 

242868  04  1 1 
PSYCHOTOGENIC 

PSYCHOTOGENIC  DRUG  ACTION  ON  CHEMICALLY  DEFINED  NEURONS 

244072  04-03 
PSYCHOTOMIMETIC 

METABOLIC  O-DEMETHYLATION  OF  THE  PSYCHOTOMIMETIC  AMINE  1  2,5 
DIMETHOXY-4  METHYLPHENYL  2  AMINOPROPANE 

236520  0203 
PSYCHOTOMIMETICS 

A  NEUROPHYSIOIOGICAL  STUDY  ON  THE  CENTRAL  ACTION  OF 
PSYCHOTOMIMETICS  (LSD-25,  DOM  AND  KETAMINE). 

232703  0204 
PSYCHOTOXICOIOGY 

SOME  PROBLEMS  OF  PSYCHOTOXICOIOGY  EXEMPLIFIED  BY  LYSERGIC- 
ACID-DIETHYLAMIDE 

234097  02)  2 
PSYCHOTROPIC 

PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  0)08 
PSYCHOTROPIC  DRUGS  AND  THE  HUMAN  EEG 

226725  0116 
PSYCHOTROPIC  DRUGS  AND  IMPARIMENT  OF  PSYCHOMOTOR 
FUNCTIONS. 

227136  01-15 
TESTING  PSYCHOTROPIC  DRUGS  IN  GENERAL  PRACTICE 

227223  01)6 
PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRAM 

229038  01-07 
RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS:  PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  01-11 
PSYCHOTROPIC  ACTION  OF  SEX  HORMONES 

229470  01   )4 


S-263 


Subject  Index 


EVALUATION  OF  NEW  COMPOUNDS  TOP  PSYCHOTROPIC  ACTIVITY. 

229477  01-04 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  BRAIN  NUCLEAR  RNA. 

229494  01-03 
FLUPHENAZINEDECANOATE  IN  ASSOCIATION  WITH  OTHER 
PSYCHOTROPIC  DRUGS  (PRELIMINARY  NOTE). 

229561  01-17 
AN  ELECTROENCEPHALOGRAPHIC  STUDY  ON  PSYCHOTROPIC  DRUGS. 

229725  01  14 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES   -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS. 

231069  01-04 
SIDE-EFFECTS  OF  PSYCHOTROPIC  DRUGS. 

231991  0115 
INPATIENT  AND  OUTPATIENT  PATTERNS  OF  PSYCHOTROPIC  DRUG 
PRESCRIBING  BY  NONPSYCHIATRIST  PHYSICIANS. 

232838  02-17 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  RtM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY). 

233077  02-04 
BIOCHEMICAL  MECHANISMS  OF  ACTION  AND  PHARMACOKINETICS  OF 
PSYCHOTROPIC  DRUGS 

233682  02-17 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 

VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 

PSYCHOTROPIC  DRUGS 

233684  02-17 
XEROSTOMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 

THEIR  TREATMENT  WITH  TPMP  (TRITHIO-P-METHOXYPHENYLPROPENE). 

233718  02-15 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

234797  02-09 
AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX). 

236174  02-04 
THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEURONS 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  02-03 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN 

236370  02-03 
VESTIBULAR  TEST  IN  INVESTIGATING  THE  SPECTRUM  OF  ACTION  OF 
PSYCHOTROPIC  AGENTS. 

236714  02-04 
THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 

CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  02-03 
TESTING  OF  NEW  PSYCHOTROPIC  DRUGS  ON  OUTPATIENTS. 

236811  02-17 
EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR 

237102  02-14 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE;  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH  D.  DISSERTATION). 

238077  02-03 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  PROSTAGLANDIN  BIOSYNTHESIS 
IN  VITRO 

238320  02-03 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
EFFECTS  OF  SOME  PSYCHOTROPIC  DRUGS  ON  AGGRESSIVE  BEHAVIOR  IN 
RATS. 

238754  03-04 
REFLECTIONS  ON  PSYCHIATRIC  ASSISTANCE  IN  AN  OUTPATIENT 
GERIATRIC  CENTER:  THE  USE  OF  PSYCHOTROPIC  DRUGS. 

239641  03-11 
CLINICAL  PHARMACOLOGY  AND  THE  PRESCRIPTION  OF  PSYCHOTROPIC 
MEDICATION. 

239678  03-17 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239679  03- 1  7 
HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239680  03-17 


239846  0 


Psychopharmacology  Abstro 

EVALUATION  OF  PSYCHOTROPIC  DRUGS:  A  SYMPOSIUM. 

PSYCHOTROPIC  DRUGS  AS  NEGATIVE  REINFORCERS. 

240020  0 
PSYCHOTROPIC  DRUGS  AND  THE  ANTIDEPRESSED  PERSONALITY. 

240251  0 
ASTONIN-H  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 
PSYCHOTROPIC  DRUGS. 

240261  C 
THE  USE  AND  MISUSE  OF  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

240522  C 
A  PRIMER  ON  THE  CLINICAL  EVALUATION  OF  PSYCHOTROPIC  DRUGS 

240838  C 
AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  AAAN:  I.  STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 
BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS. 

241 234 C 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETH' 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349 C 
STUDIES  ON  THE  CORRELATION  BETWEEN  BEHAVIOR  AND  BRAIN  AM 
WITH  PSYCHOTROPIC  DRUGS. 

241378 C 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389 C 
ON  HYPOTENSION  AS  A  RESULT  OF  PSYCHOTROPIC  MEDICATION: 
COMPARATIVE  STUDY  OF  TWO  CORRECTIVES  (ETILEFRINE  AND 
DIHYDROERGOTAMINE). 

241 763 C 
PSYCHOTROPIC  DRUGS  FROM  THE  PRACTITIONERS  POINT  OF  VIEW. 

242720  C 
CYCLIC-AMP  IN  CEREBROSPINAL  FLUID  IN  PATIENTS  WITH  AFFECTIV! 
ILLNESS:  EFFECTS  OF  PROBENECID,  ACTIVITY,  AND  PSYCHOTROPIC 
MEDICATIONS.  (UNPUBLISHED  PAPER 

243023  0 
CLINICAL  EVIDENCE  FOR  NEUROCHEMICAL  ADAPTATION  TO 
PSYCHOTROPIC  DRUGS. 

243819  0 
PARADOXICAL  RAGE  REACTIONS  DURING  PSYCHOTROPIC  MEDICATIO 

246184  0 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCEI 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BF 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  0 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  CANINE  CEREBRAL  METABOLI 

AND  CIRCULATION  RELATED  TO  EEG  -  DIAZEPAM,  CLOMIPRAMINE 
AND  CHLORPROMAZINE. 

246319  0 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT: 

COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION. 

246694  0 
STUDIES  ON  ACCUMULATION  OF  (14C)  MESCALINE  IN  BRAIN 

HOMOGENATES:  EFFECTS  OF  PSYCHOTROPIC  AND  OTHER  AGENTS. 

246817  0 
CARDIOTOXIC  EFFECTS  OF  PSYCHOTROPIC  DRUGS. 

247784  0 
ON  THE  MECHANISM  OF  THE  INHIBITION  OF  BRAIN  CYCLIC-AMP 
PHOSPHODIESTERASE  BY  PSYCHOTROPIC  AGENTS. 

249287  0. 
A  PILOT  STUDY  OF  THE  SHORT-TERM  PSYCHOTROPIC  EFFECTS  OF  GPf 
2640. 

250516  0. 
PSYCHOTROPIC  DRUGS  IN  SOMATIC  DISORDERS. 

250856  0- 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULl 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONAT/ 
STAGE. 

251981  0- 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  RHEUMATOLOGY. 

252135  0' 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  OTHER  PAINFUL  CONDITIONS. 

252142  0' 
THE  USE  OF  PSYCHOTROPIC  DRUGS  IN  A  PAIN  CLINIC. 

252144  0' 
ACCIDENTAL  POISONING  WITH  PSYCHOTROPIC  DRUGS  IN  CHILDREN. 

252656  0' 
METHAQUALONE  WITH  PSYCHOTROPIC  DRUGS:  ADVERSE  INTERACTIO 

253531  0^ 
PSYCHOTROPICS 

OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 
PSYCHOTROPICS  DRUGS. 

239681  03 


S-264 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
DEPARTMENT  SEEKS  ADVICE  ON  SAFETY  OF  PSYCHOTROPICS. 

251232  04-17 
PSYCHOVEGETATIVE 

PSYCHOVEGETATIVE  DISORDERS  IN  CASES  OF  CYCLOTHYMIC 
DEPRESSION. 

226777  01-09 
PHARMACOTHERAPY  IN  PSYCHOVEGETATIVE  DISORDERS. 

226778  01-09 
PUIP 

EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOW/ING 
TOOTH  PULP  STIMULATION. 

251070  04  03 
PUISE 

BLOOD  PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04-15 
PUMP 

INCREASED  ERYTHROCYTE  NA  f    PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04-13 
PUNISHED 

EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03-04 

DRUGS  AND  PUNISHED  RESPONDING  VI:  BODY  W/EIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS. 

247845  04-04 
PUNISHMENT 

RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 
CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 

LYSERGIC-ACID-DIETHYLAMIDE  AND  MESCALINE-INDUCED  ATTENUATION 
OF  THE  EFFECT  OF  PUNISHMENT  IN  THE  RAT. 

252824  04-04 
PUPIIOMETRIC 

BIOAVAILABILITY  ANALYSIS  OF  CHLORPROMAZINE  IN  HUMANS  FROM 
PUPILOMETRIC  DATA. 

237872  02-13 
PUPIIOMETRY 

PHARMACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUMANS:  I.  PUPILOMETRY. 

232623  02  13 
PURIFICATION 

PURIFICATION  OF  (3H)TAURINE  OF  HIGH  SPECIFIC  ACTIVITY. 

238773  03-03 
RESOLUTION.  PURIFICATION  AND  CHARACTERIZATION  OF  RABBIT 
SERUM  ATROPINESTERASE  AND  COCAINESTERASE. 

2511800401 
PURKINJE 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  02-03 

INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT.  2ND  REPORT- 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM. 

241386  03-03 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 
FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS- 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
'URSUING 

THE  INDOLE  HALLUCINOGEN  MODEL:  IS  IT  WORTH  PURSUING'. 

241872  03-08 
'URSUIT 

EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUGH 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237102  02-14 
SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM    CPZ   AND 
SECOBARBITAL 

246303  04  14 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY 

251986  04-14 


PUTATIVE 

THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST.  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290  02-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02-03 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-03 
IHE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-03 
PYRAZIOOL 

INVESTIGATION  OF  THE  MECHANISM  OF  ACTION  OF  THE  NEW 
ANTIDEPRESSANT  PYRAZIDOL. 

236369  02-03 
PYRAZOLE 

EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
PYRIOOXINE 

THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
PYRITHIOXINE 

THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE. 

251991  04-04 
THE  INFLUENCE  OF  PYRITHIOXINE  HYPERVENTILATION  ASSOCIATION  ON 
CSF  LACTATE  IN  CEREBRAL  INFARCTION  PATIENTS. 

252713  04- 11 
QUANTIFICATION 

IDENTIFICATION  AND  QUANTIFICATION  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  ACUTE  EXPERIMENTAL  INTOXICATION. 

244462  04-06 
QUANTITATING 

NEW  METHOD  FOR  DETECTING  AND  QUANTITATING  PHARAMCOKINETIC 
DRUG  DRUG  INTERACTIONS  APPLIED  TO  ETHANOL  PROPRANOLOL. 

247846  04-06 
QUANTITATIVE 

PREDICTION  OF  PSYCHOTROPIC  PROPERTIES  OF  LISURIDE  HYDROGEN 
MALEATE  BY  QUANTITATIVE  PHARMACO-ELECTROENCEPHALOGRAM. 

229038  01-07 
A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01-16 
SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY- 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
QUANTITATIVE  GLC  DETERMINATION  OF  PENTYLENETETRAZOL  IN 
BIOLOGICAL  FLUIDS, 

233277  02-06 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS. 

237902  02-13 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS    LH  FEEDBACK 
AND  SEX  BEHAVIOR 

238800  03-04 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORE  8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME. 

241275  03-10 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING. 

242745  04-04 
CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE 

251777  04-06 
QUANTITIES 

ISOLATION  AND  RADIOENZYMIC  ESTIAAATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 


S-265 


Subject  Index 


Psychopharmacology  Abstract; 


SO 


QUANTUM 

CORRELATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 
5  HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAl  PARAMETERS, 

249318  0403 
QUARTER 

THE  TRANSMETHYLATION  HYPOTHESIS:  A  QUARTER  OF  A  CENTURY 
LATER. 

235801  02-15 
QUATERNARY 

INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
U:  N-ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D-AMPHETAMINES 
AND  3-ARYLOXYPROPYLAMINES. 

248637  0401 
QUESTION 

ON  THE  QUESTION  OF  THE  RATIONAL  USE  OF  MAJOR  TRANQUILIZERS. 

236360  02-08 
DRUG  RESEARCH  AND  THE  QUESTION  OF  CONSENT. 

252314  04-17 
QUICK-ACTING 

THYROTROPIN-RELFASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK- 
ACTING  BUT  SHORT-LASTING  ANTIDEPRESSANT. 

235630  02-09 
QUINIOINE 

MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245  02-03 
QUINOLIZIOINES 

SYNTHESIS  AND  BIOLOGICAL  ACTIONS  OF  2-SUBSTITUTED 
QUINOLIZIOINES. 

238477  02-02 
QUINUCUDINYl 

ANTIACETYLCHOLINE  ACTIVITIES  OF  PSYCHOACTIVE  DRUGS:  A 

COMPARISON  OF  THE  (3H)0UINUCLIDINYL  BENZILATE  BINDING  ASSAY 
WITH  CONVENTIONAL  METHODS 

250360  04-02 
QUIPAZINE 

QUIPAZINE:  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM,  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR 

239960  03-03 
ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-03 
RDOM 

A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R- 
2,5  DIMETHOXY  4-METHYLAMPHETAMINE  (R-DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  02-04 
R-29-764 

CLOPIMOZIOE  (R-29-764),  A  NEW  HIGHLY  POTENT  AND  ORALLY  LONG- 
ACTING  NEUROLEPTIC  OF  THE  DIPHENYLBUTYLPIPERIOINE  SERIES 

232529  01-04 
R-3-345 

PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03- 11 
R-806 

PHARMACOLOGY  OF  R-806,  A  TETRACYCLIC  ANTIDEPRESSANT. 

238837  03-03 
RABBIT 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  {-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL 

226762  01-03 
THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE- 
INDUCED  AND  LSD  INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01  05 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT 

230860  01-03 
THE  EFFECTS  OF  SEROTONIN  ON  FEEDING  IN  THE  RABBIT, 

230872  01-04 
PROBENECID:  DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5  HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT 

230877  01  06 
THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION 

231070  01-03 
CHOLINERGIC  MODULATION  OF  TONIC  IMMOBILITY  IN  THE  RABBIT 
(ORYCTOLAGUS-CUNICULUS), 

231701  01-03 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA, 

236863  02  03 


PERFUSION  WITH  L-5-HTP,  ALONG  WITH  A  DECARBOXYLASE  INHIBITOR, 
IN  THE  RABBIT.  POLYGRAPHIC  AND  BIOCHEMICAL  DATA 

237710  02-0: 
N-HYDROXYAMPHETAMINE:  A  MAJOR  METABOLITE  OF  AMPHETAMINE  l^ 
RABBIT  LIVER  EXTRACT, 

238682  03-0: 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX. 

239582  03  O: 
APOMORPHINE-INOUCED  HYPERTHERMIA  IN  THE  RABBIT:  A 

PHARAAACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE,  (PH.D.  DISSERTATION). 

240936  03-0: 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 
ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INOUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-0; 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART. 

242204  03-0: 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTLriASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS. 

246842  040: 
N-HYDROXYLATION  OF  l-2,5-DIMETH0XY-4-METHYLPHENYL-2- 
AMINOPROPANE  BY  RABBIT  LIVER  MICROSOMES. 

249234  04-0: 
RESOLUTION,  PURIFICATION  AND  CHARACTERIZATION  OF  RABBIT 
SERUM  ATROPINESTERASE  AND  COCAINESTERASE. 

251180  04  0' 
RABBITS 

CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01-0/ 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIh 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA-PIGS,  AND  RABBITS. 

233962  02-0; 
THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-0/ 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURES 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-0; 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  030: 
EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS. 

238695  0302 
EFFECT  OF  CONVULSIONS  AND  ANTICONVULSIVE  DRUGS  ON 
CEREBROSPINAL  FLUID  CYCLIC-AMP  IN  RABBITS. 

239090  03-02 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  ll-HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL. 

241256  03  03 
EFFECTS  OF  PERIMETAZINE  AND  CHLORPROMAZINE  ON  THE 
TRANSCALLOSAL  RESPONSE  IN  RABBITS. 

241385  03-03 
STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN-RELEASING 
HORMONE  (TRH)  IN  RABBITS. 

249280  04  04 
RACE 

CANNABINOID  PATTERN  IN  CANNABIS-SATIVA  L.  SEEDLINGS  AS  AN 
INDICATION  OF  CHEMICAL  RACE. 

237982  02  01 
RACEMIC 

A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL  BRAIN-DYSFUNCTION. 

247878  04-11 
RADIATION 

CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
R/.DIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS. 

240237  03  04 
RADIOACTIVE 

EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 
UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 
DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO 

2511/5  04  03 


S-266 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


RADIOENZYMtC 

ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
Of  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES, 

244636  04-06 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
RADIOIMMUNOASSAY 

RADIOIMMUNOASSAY  FOR  DESMETHYLIMIPRAMINE. 

236526  0206 
RADIOIMMUNOASSAY  OF  TRICYCLIC  ANTIDEPRESSANTS 

238775  03-01 
RADIOIMMUNOASSAY  FOR  HALOPERIDOL. 

238776  03-01 
PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 

RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1  1-HYDROXYTETRAHYDROCANNABINOL 
CANNABINOL,  AND  CANNABIDIOL. 

241256  0303 
RADIOIMMUNOASSAY  OF  METHYLPHENIDATE. 

243834  04-06 
RADIOISOTOPE 

MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTOPE 
DERIVATIVE  TECHNIQUE 

247131  04-03 
7ADIOLABELING 

RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS 

248537  04-01 
JAOIOPHARMACEUTICALS 

RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  0401 
(AGE 

PARADOXICAL  RAGE  REACTIONS  DURING  PSYCHOTROPIC  MEDICATION. 

246184  04-15 
RAINBOW 

MEMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT. 

239852  03  04 
tANACIDE 

TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT. 

250068  04  02 
lANDOMIZED 

SELF  INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDFPRESSIVE  EFFECT  AT 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE  BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION 

248955  04  10 
lAPHE 

HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA  INDUCED 
HYPERACTIVITY  IN  THE  RAT. 

226734  01  04 
MORPHINE  ANALGESIA    BLOCKADE  BY  RAPHE  MAGNUS  LESIONS 

232611  02-03 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAI  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTA.MINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT    EFFECTS  OF 
PHYSOSTIGMINE. 

239829  0304 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPIOPHAN    BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  R0-4-4602 

239957  03  03 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III) 
EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390  03-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALIY  APPIIED  DRUGS  IN  ACUTE  AND  LONG  TERM 
MORPHINE  TREATED  CATS 

24^215  04-04 
RAPHt  NEURONS:  DEPRESSION  OF  ACTIVITY  BY  L-5- 
IIYOROXYIRYPTOPHAN 

IFFfClS  OF  MORPHINE  ON  SINGIE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 
NUCirUS  RAPHE  DORSALIS 

249249  04  03 
(  IR(  I ING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NlJCiri  LISIONS  IN  RATS. 

250358  04  04 


INTRACRANIAL  SELF  STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P-CHLOROPHENYLALANINE 
AND  OF  ALPHA-METHYL-P-TYROSINE 

250982  04-04 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  FLFCTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
RAPID 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L  TRYPTOPHAN  INJECTION 

226873  01-03 
RAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN 

227996  01  03 
A  RAPID.  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC  ACID  INDUCED  FLUORESCENCE: 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY.  (UNPUBLISHED 
PAPER). 

236875  02-06 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR, 

ALTERATIONS  IN  3H  ALPRENOLOL  BINDING  AND  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER) 

237170  02-03 
A  NOVEL  METHOD  FOR  RAPID  DEVELOPMENT  OF  BARBITURATE- 
TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE. 

238701  03-03 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS. 

24928)  04-02 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 


RAT 


CHOLINERGIC  BLOCKADE.  SEPTAL  LESIONS   AND  DRL  PERFORMANCE  IN 
THE  RAT 

226305  01-04 
NEUROCHEMICAL  AND  MORPHOLOGICAL  CHANGES  DURING  THE 
DEVELOPMENT  OF  COBALT  INDUCED  EPILEPSY  IN  THE  RAT. 

226399  01-03 
LSD  AND  DOPAMINE-  SENSITIVE  ADENYLATE  CYCLASE  IN  VARIOUS  RAT 
BRAIN  AREAS 

226406  01-03 
INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 
CONCENTRATION  IN  THE  RAT  BRAIN, 

226727  01-03 
HIPPOCAMPAL  MEDIATION  OF  RAPHE  LESION  AND  PCPA-INDUCED 
HYPERACTIVITY  IN  THE  FMT 

226734  01  04 
HIGH  AFFINITY  CHOLINE  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 
INNERVATION  IN  RAT  BRAIN. 

226739  01  03 
THE  EFFECT  OF  ERGOTAMINE  AND  MFTHYSERGIDE  ON  SEROTONIN 
METABOLISM  IN  THE  RAT  BRAIN 

226826  01-03 
MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINOL 
(R2)  ON  RAT  STRIATUM. 

226851  01-03 
ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM 

226858  01-03 
SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
M.OUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE 

226865  01-03 
CLOZAPINE  INCREASES  RAT  SERUM  PROLAC  TIN  LEVELS 

226869  01-03 
ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 

SEROTONIN  IN  RAT  BRAIN. 

226870  01-03 
DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 

SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01-04 
DIAZEPAM,  ETHANOL  AND  DRUG  METABOLIZING  ENZYMES  IN  RAT 
LIVER 

226927  01  03 
AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS  ACCUMBENS  SEPTI  AND  CORPUS- 
STRIATUM 

226937  01-04 
IMPAIRMENT  OF  THERMOREGULATION.  FOOD  AND  WATER  INTAKES  IN 

THE  RAI  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5  6 
DIHYDROXYTRYPTAMINE. 

226938  01  04 


S-267 


Subject  Index 


Psychopharmacology  Abstract 


-n 


SB; 

3a. 


ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN. 

227386  01-04 
DIFFERENTIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 

SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN 

227387  01-03 
INHIBITION  OF  DRUG  METABOLIZING  ENZYMES  BY  DIAZEPAM  IN  RAT 

LIVER. 

227696  01-03 
MONOAMINE-OXIDASES  OF  THE  RAT  CARDIOVASCULAR  SYSTEM. 
(UNPUBLISHED  PAPER). 

227783  01-03 
IN  VIVO  ACTIVATION  OF  RAT  PINEAL  CAMP  PHOSPHODIESTERASE  BY 
ISOPROTERENOL   (UNPUBLISHED  PAPER). 

228032  01-03 
STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF  BENZODIAZEPINE  -  STUDIES 
ON  RAT  CEREBELLUM. 

229466  01-03 
DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 

CHOLINESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  OF 
RAT  TISSUES. 

230451  01-03 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
TYROSINE  HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  01-03 
OXOTREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 

METABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  BRAIN  AMINE 

CONCENTRATION  AND  TURNOVER  IN  WHOLE  RAT  BRAIN  AND  IN 
VARIOUS  REGIONS  OF  THE  BRAIN. 

230856  01-03 
ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS-TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 
DISTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRACT 
OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01-03 
SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 

BRAIN  TISSUE  IN  VITRO. 

230919  01-03 
EFFECT  OF  ETHANOL  ON  DIAZEPAM  DISTRIBUTION  IN  RAT. 

231007  01  03 
EFFECTS  OF  METHYLPHENIDATE  ON  AUDITORY  INTENSITY 

DISCRIMINATION  AND  GENERALIZATION  IN  THE  IMMATURE  RAT 
(PH.D.  DISSERTATION). 

231533  01-04 
THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 

SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BRAIN 
NUCLEI.  (UNPUBLISHED  PAPER). 

232325  01-03 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT, 

232332  01-04 
EVIDENCE  FOR  INVOLVEMENT  OF  GABA  IN  THE  ACTION  OF 
BENZODIAZEPINES:  STUDIES  ON  RAT  CEREBELLUM 

232514  01-03 
REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT. 

232617  02-03 
EFFECTS  OF  5,6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02-03 
CAMP  CONTENT  AND  THE  REGULATION  OF  TYROSINE-3- 

MONOOXYGENASE  IN  RAT  STRIATUM.  (UNPUBLISHED  PAPER). 

232921  02-03 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RAT 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02-03 
HYPERTHERMIA  INDUCED  BY  AMPHETAMINE,  P-CHLOROAMPHETAMINE 
AND  FENFLURAMINE  IN  THE  RAT. 

233301  02-03 
SYMPATHETIC  NERVOUS  SYSTEM  EFFECTS  ON  RAT  BRAIN  METABOLISM. 

234309  02-03 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO 

234522  02-03 


CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  O2-0 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02-C 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINE. 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  THI 
RAT  SPINAL  CORD. 

235863  02-C 
DRUG-INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT. 

235866  02-C 
ON  NEUROCHEMICAL  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
THE  HIPPOCAMPUS  ON  THE  RAT  FOOD  PROCURING  CONDITIONED 
REACTION. 

236257  02-C 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN. 

236370  02-C 
EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7,8 
DIHYDROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA. 

236521  02-C 
CORRELATION  OF  CHLORPROAAAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUW 
WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-C 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

237103  02-C 
PRETRIAL  COCAINE  AND  PERFORMANCE  IN  RAT. 

237108  02-0 
LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-0 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-0 
RAPID  CHANGES  IN  RAT  PINEAL  BETA-ADRENERGIC  RECEPTOR: 

ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER). 

237170  02-0 
EFFECTS  OF  TRAZODONE  ON  SEROTONIN  IN  THE  BRAIN  AND  PLATELETS 
OF  THE  RAT. 

237240  02-0 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  GLIAL  ENRICHED  FRACTIONS 
FROM  RAT  BRAIN. 

237241  02-0 
INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P- 

CHLOROAMPHETAMINE. 

237242  02-0: 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  PHENOBARBITAL  ON  PROTEIN 

METABOLISM  IN  THE  RAT  CEREBRAL  CORTEX. 

237243  02-0: 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 

RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02-0. 
METABOLISM  OF  5-HYDR0XYTRYPT0PHAN-14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN. 

237700  02-0: 
A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R- 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (R-DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  02-0^ 
EFFECTS  OF  DELTA9-TETRAHY0R0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  THE  LABORATORY  MOUSE  AND  RAT. 

237727  02-0' 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-0: 
EFFECT  OF  ANGIOTENSIN-II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 

OF  C14-5-HYDR0XYTRYPT AMINE  BY  RAT  BRAIN 

237739  02-0; 
THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT. 

237742  02-03 
EFFECT  OF  CATECHOL-O-METHYLTRANSFERASE  INHIBITORS  ON  BRAIN 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUR  IN 
THE  RAT. 

237747  02-03 


S-268 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE-INDUCED  ANOREXIA. 

237748  02-03 
PLACENTAL  TRANSFER  OF  CARBA/WAZEPINE  IN  THE  RAT 

237749  02-03 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 

POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
METABOLISM,  DISTRIBUTION  AND  ANTICONVULSANT  PROPERTIES  OF 
N,N  DIMETHOXYMETHYL-PHENOBARBITAL  IN  THE  RAT. 

237758  02-03 
PHARMACOLOGICAL  CHARACTERIZATION  OF  LITHIUM  REABSORPTION  IN 

THE  RAT. 

237759  02-03 
COMPARISON  OF  BICUCULLINE  METHOCHLORIDE  WITH  BICUCULLINE 

AND  PICROTOXIN  AS  ANTAGONISTS  OF  AMINO  ACID  AND 
MONOAMINE  DEPRESSION  OF  NEURONES  IN  THE  RAT  BRAINSTEM. 

237783  02-03 
CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 
OF  THE  RAT 

237862  02-03 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 

AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN-HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI, 

237863  02-03 
THE  AUTORADIOGRAPHIC  LOCALIZATION  OF  (3H)DEXAMETHAS0NE  IN 

THE  BRAIN  AND  PITUITARY  OF  THE  RAT. 

237864  02-03 
DISSOCIATION  OF  RAT  BRAIN  POLYRIBOSOMES  IN  VIVO  BY 

AMPHETAMINES. 

237871  02-03 
BIOELECTRIC  EFFECTS  OF  ISOPROTERENOL  AND  PROPRANOLOL  ON  NERVE 
CELLS  IN  EXPLANTS  OF  RAT  CEREBELLUM 

237880  02-03 
5-HYDROXYTRYPTAMINE  BINDING  TO  SYNAPTIC  MEMBRANES  FROM  RAT 
BRAIN. 

237890  02-03 
ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINS-F  IN  RAT 
CEREBRAL  CORTEX. 

237921  02-03 
DISTRIBUTION  OF  TYPE  A  AND  B  MONOAMINE-OXIDASE  ACTIVITIES  IN 
THE  CENTRAL-NERVOUS-SYSTEM  OF  RAT  AND  CHICK. 

237923  02-03 
DEPRESSION  OF  NEURONES  IN  THE  RAT  CEREBRAL  CORTEX  BY  LEPTAZOL. 

237925  02-03 
DOPAMINE-INDUCED  INCREASES  IN  CYCLIC-AMP,  AND  CYCLIC-AMP 
DEPENDENT  PROTEIN  PHOSPHORYLATION,  IN  THE  RAT  CAUDATE- 
NUCLEUS   (PH.D.  DISSERTATION). 

238080  02-13 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347  02-04 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  03-03 
CELLULAR  LOCALIZATION  AND  KINESTIC  PROPERTIES  OF  GAMMA- 
GLUTAMYL-TRANSPEPTIDASE  IN  RAT  CEREBRAL  CORTEX. 

238680  03-03 
THE  AROMATIC  HYDROXYLATION  OF  AMPHETAMINE  WITH  RAT  LIVER 
MICROSOMES.  PERFUSED  LIVER  AND  ISOLATED  HEPATOCYTES 

238683  03-06 
EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO, 

238689  03-03 
EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOLINDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
EFFECTS  OF  (-)0ELTA9-T£TRAHYDR0CANNA8IN0L  ON  REGIONAL  BRAIN 
ACETYLCHOLINE  IN  THE  RAT. 

238709  03-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA- 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT 

238713  03-04 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATUM 

AND  HYPOTHALAMUS  SLICES 

238714  03  03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN. 

238715  03-03 
NECESSITY  OF  HYPERTHERMIA  FOR  L  DOPA  OR  D-AMPHETAMINE  TO 

DISAGGREGATE  RAT  BRAIN  POLYSOMES. 

238719  03-03 


MARIJUANA-INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT. 

238720  03  04 
DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES. 

238729  03-03 
CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
THE  EFFECTS  OF  INTRACRANIAL  ADMINISTRATION  OF  NOREPINEPHRINE 
AND  INTRAPERITONEAL  CHLORPROMAZINE  ON  ATTENTION  IN  THE 
RAT, 

238755  03  04 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  LOCUS- 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE 

238759  03-03 
THE  DYNAMICS  OF  DOPAMINE  METABOLISM  IN  VARIOUS  REGIONS  OF 
RAT  BRAIN, 

238761  03-03 
EFFECTS  OF  CANNABINOIDS  ON  THE  IN  VITRO  PERFUSED  RAT  HEART. 

238767  03-03 
EFFECTS  OF  METHOXYLATED  AMPHETAMINES  ON  THE  MAZE 
PERFORAAANCE  BY  THE  RAT. 

238788  03-04 
EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03-03 
NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN. 

238840  03-03 
CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 
CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 
AND  LIVER. 

239044  03  03 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272  03-04 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE 

239829  03-04 
DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
INHIBITORY  ACTION  OF  NORADRENALINE  AND  CYCLIC-AMP  IN  EXPLANTS 
OF  RAT  CEREBELLUM. 

239836  03-03 
ACUTE  AND  CHRONIC  EFFECTS  OF  4  CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
TEMPORAL  PARAMETERS  OF  D  AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT 

239856  03-04 
EFFECT  OF  CLOZAPINE  ON  THE  METABOLISM  OF  SEROTONIN  IN  RAT 
BRAIN. 

239862  03-03 
QUIPAZINE:  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE 
METABOLISM.  MONOAMINE-OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03-03 
MECHANISMS  OF  A  DYSKINESIA  INDUCTION  BY  1-3,4 
DIHYDROXYPEHNYLPIPERAZINE  IN  THE  RAT. 

239964  03-04 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  O 
AMPHETAMINE  AND  (  i  OR-)  P-CHLOROAMPHETAMINE. 

239976  03-03 
THE  AMPHETAMINE-INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM 

240065  03  03 
THE  INFLUENCE  OF  MEPYRAMINE  AND  BURIMAMIDE  ON  HISTAMINE 
INDUCED  CATALEPSY  IN  THE  RAT. 

240238  03-03 
EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  LHRH  LDOPA 
METHYL-DOPA.  AND  STRESS  IN  MALE  RAT 

240642  03-03 
STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 

PROLACTIN  SECRETION  IN  THE  MALE  RAT 

240643  03-03 


S-269 


Subject  Index 


Psychopharmacology  Abstract 


"mi 


ens 


EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 
PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE  ACTIVITY:  MICROASSAY 

AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  03-03 
AMANTADINE:  AGGRESSIVE  EFFECT,  EFFECT  ON  APOMORPHINEINDUCED 

AGGRESSIVITY  IN  THE  RAT 

241227  03-04 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM 

241247  03-03 
EFFECTS  OF  DIETHYLDITHIOCARBAMATE  ON  THE  CATABOLISM  OF 
TYROSINE  IN  THE  RAT  BRAIN 

241249  03-05 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT- 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 

RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03-03 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5 

HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE 

241253  03-03 
EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3-ACETYLCH0LINE 

BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES. 

241254  03-03 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 

PROTEINS  -    I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-03 
EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPINEPHRINE 
BY  THE  RAT  DUODENAL  MUCOSA. 

241299  03-03 
EFFECTS  OF  INTRAVENOUS  ANESTHETICS  ON  CONTINUOUS  AVOIDANCE 
BEHAVIOR  IN  THE  RAT 

241314  03-04 
THE  EFFECT  OF  MORPHINE  ON  THE  EEG  OF  THE  HYPOTHALAMUS  IN  THE 
RAT. 

241328  03-03 
COMPARATIVE  EFFECT  OF  PHENOBARBITAL  AND  METHAQUALONE  ON 
WARFARIN  METABOLISM  IN  THE  RAT. 

241344  03-03 
EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 

UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT-BRAIN. 

241345  03-03 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 

ADENYLATE  CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON. 

241347  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 
EFFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT 

241365  03-03 
SPONTANEOUS  AND  GUANETHIDINE  INDUCED  CHANGES  OF  REGIONAL 

MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN. 

241366  03-03 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 

GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03  03 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5- 

HYDROXYTRYPTAMINE  (5  HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (III) 

24 1 394  03-03 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5  HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03  03 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5  HT) 

TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-03 
EFFECTS  OF  MORPHINE  ON  5  HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  IN 

THE  RAT  BRAIN  (III) 

241402  03  03 


THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF-STIMULATION  AND  SLEEP  IN  TH 

RAT.  (PH.D.  DISSERTATION). 

241678  03-G 
MANIPULATION  OF  ACETYLCHOLINE  LEVELS  IN  DEVELOPING  RAT  BRAIN: 

BIOCHEMICAL  AND  BEHAVIORAL  CONSIDERATIONS.  (PH.D. 

DISSERTATION). 

241680  03-C 
EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  A 

ELEVATED  ENVIRONMENTAL  TEMPERATURE. 

241925  03-C 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 

INDUCED  BY  COMBINATIONS  OF  STRESS  AND  0ELTA8- 
TETRAHYDROCANNABINOL  (DELTA8-THC). 

241926  03-C 
HISTOTOPOGRAPHY  OF  THE  CHANGES  IN  ENZYME  ACTIVITY  IN  THE  RAT 

BRAIN  UNDER  THE  EFFECT  OF  FLUOROPHENAZINE. 

241989  03-C 
CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  TH! 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  LOCOMOTOR  ACTIVITIES  IN 
THE  RAT. 

242205  03-C 
CENTRAL  GAMMA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER) 

243041  04-C 
IN  VIVO  AND  IN  VITRO  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L 
ON  RAT  LIVER  MICROSOMAL  DRUG  METABOLIZING  ENZYMES. 

243182  04-C 
EFFECTS  OF  IMIPRAMINE,  D-AMPHETAMINE,  AND  TRIPELENNAMINE  ON 
MOUSE-KILLING  AND  FROG-KILLING  BY  THE  RAT. 

243346  04-C 
EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5-HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN. 

243777  04-C 
NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 

OF  RAT  BRAIN  MONOAMINE-OXIDASE  IN  VITRO. 

243778  04-C 
THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAl 

ADRENAL  MEDULLA. 

243779  04-C 
EFFECTS  OF  DIMETHYLSULFOXIDE  ON  METABOLISM  OF  ISOLATED 

PERFUSED  RAT  BRAIN. 

243782  04-C 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  04-C 
AXOPLASMIC  TRANSPORT  OF  NOREPINEPHRINE  IN  THE  RAT  BRAIN 

243791  04-0 
EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 

HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES. 

243793  O4-0 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

243800  04-Q 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-0 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROMAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT 

24395)  04-0 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA, 

244200  04-0 
DIAZEPAM  AND  CHLORDIAZEPOXIDE:  POWERFUL  GABA  ANTAGONISTS  II 
EXPLANTS  OF  RAT  CEREBELLUM. 

244205  04-0 
EFFECTS  OF  AMPHETAMINE,  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF-STIMULATION  IN  THE  RAT. 

244214  04-0 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04-0 
ENDOGENOUS  INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  RAT 
ORGANS. 

244315  04-0: 
DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-RE0UCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-0^ 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN. 

244455  04-0- 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS.  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVC 


S-270 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE 

244514  04-03 
BARBITAL  ALTERATION  OF  CENTRAL-NERVOUS-SYSTEM  SENSITIVITY  TO 
HEXOBARBITAL  IN  THE  RAT. 

244688  04-03 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  0-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
EFFECTS  OF  EARLY  POSTNATAL  ALPHA-METHYL-DOPA  TREATMENT  ON 
BEHAVIOR  IN  THE  RAT 

245304  0404 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 
ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION 

245600  04-04 
ONTOGENY  OF  THERMOREGULATORY  MECHANISMS  IN  THE  RAT, 

245608  04-02 
PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT. 

245929  04-02 
INGESTION  IN  THE  SATIATED  RAT;  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 

OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04-04 
DOSE-RESPONSE  EFFECTS  OF  D-AMPHETAMINE  ON  PASSIVE  AVOIDANCE 
LEARNING  IN  THE  RAT. 

246313  04-04 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRAIN 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-04 
CAFFEINE  AND  CHLORDIAZEPOXIDE:  EFFECTS  ON  MOTOR  ACTIVITY  IN 
THE  CHRONIC  THALAMIC  RAT. 

246388  04-04 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04-04 
ACCUMULATION  OF  NOREPINEPHRINE  (NE)  BY  RAT  ORGANS  IN  VIVO. 

246822  04-03 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINC  AND  VINBLASTINE 
ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA  HYDROXYLASE 
IN  THE  RAT. 

246843  04-03 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN:  3-P  TRIFLUOROMETHYLPHENOXY-N 
METHYL-3-PHENYLPROPYLAMINE. 

246848  04-03 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 

CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04-03 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 

CORTICAL  SLICES. 

246850  04-03 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 

RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
LFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 
THE  RAT  BRAIN. 

247213  04-03 
THYROTROPIN-RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATION  IN 
THE  NONLESIONED  RAT 

247514  04-03 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY  ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 
NOREPINEPHRINE  CONTENT  OF  VARIOUS  RAT  ORGANS  AFTER  CHRONIC 
ADMINISTRATION  OF  DESMETHYLIMIPRAMINE 

247777  04-03 
METHAQUALONE  METABOLISM  BY  RAT  LIVER  MICROSOMES 

247847  04  03 
APOMORPHINE-INDUCED  AGGRESSION:  AN  EVALUATION  OF  POSSIBLE 
SENSITIZING  FACTORS  IN  THE  RAT 

248008  04-04 
APORPHINES  15:  ACTION  OF  APORPHINE  ALKALOIDS  ON  DOPAMINERGIC 
MECHANISMS  IN  RAT  BRAIN 

248286  04-03 


EFFECT  OF  NOMIFENSINE  ON  ACETYLCHOLINE  AND  CHOLINE  IN  THE  RAT 
STRIATUM  AND  BRAINSTEM. 

248291  04-03 
DISTRIBUTION  OF  3H  ALPHA-MSH  IN  RAT  BRAIN. 

248349  04-03 
ACETYLCHOLINE,  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 
HYPOTHALAMUS. 

248358  04-03 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
THE  EFFECT  OF  PRETREATMENT  WITH  6-HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 
VAS-DEFERENS. 

2484 1 3  04-03 
SYNAPTOSOMAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 

AREAS  AFTER  P-CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04-05 
ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 

CLOZAPINE  AND  CHLORPROAMZINE. 

248600  04-03 
AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX. 

248699  04-03 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 
BRAIN  SYNAPTOSOMES. 

248701  04-03 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2-RECEPT0R  ANTAGONISTS  IN  THE 

RAT  CEREBRAL  CORTEX. 

248725  04-03 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 

DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

248964  04-04 
MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 
NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04-03 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 

NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04-03 
ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
1-NAPHTHYLVINYLPYRIDINE  (NVP). 

249027  04-03 
CATECHOL-O-METHYLTRANSFERASE  FROM  RAT  LIVER:  TWO  FORMS 
HAVING  DIFFERENT  META:PARA  METHYLATION  RATIOS 

249035  04-01 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04-03 
STUDIES  OF  METHYLPHENIDATE-14C  IN  RAT  BRAIN 

249243  04-03 
DRUG-INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT 

249250  04  03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04  03 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 
ETHANOL  TOLERANCE  IN  THE  RAT. 

249264  04-04 
EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 

DIETHYIAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT. 

249278  04-04 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH) 

249298  04  03 
EFFECT  OF  D-AMPHETAMINE  AND  D,L  P-CHLOROAMPHETAMINE  ON 
REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN. 

249300  04-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

2494)8  04  03 
IN  VIVO  AND  IN  VITRO  ACTIVATION  OF  SOLUBLE  TRYPTOPHAN- 
HYDROXYLASE  FROM  RAT  BRAINSTEM. 

249512  04-03 


S-271 


Subject  Index 


Psychopharmacology  Abstracts 


si: 


DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
A  FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AND 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

249669  04-04 
EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04-04 
RAT  STRAIN  DIFFERENCES  IN  PILOCARPINE-INDUCED  MOUSE-KILLING. 

250008  04-04 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOR:  LEVELS  OF  AMINO-ACIDS 
IN  FOUR  AREAS  OF  THE  BRAIN  OF  THE  RAT  DURING  DRUG-INDUCED 
BEHAVIORAL  EXCITATION. 

250067  04-04 
TESTOSTERONE  MANIPULATIONS.  EFFECTS  ON  RANACIDE  AGGRESSION 

AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT 

250068  04-02 
ACUTE  TOLERANCE  TO  BARBITURATE  IN  THE  RAT. 

250077  04-04 
MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 

THERMOSTATS. 

250078  04-03 
POSTNATAL  DEVELOPMENT  OF  DOPAMINERGIC  AND  CHOLINERGIC 

CATALEPSY  IN  THE  RAT. 

250084  04-03 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT. 

250087  04-02 
BIODISPOSITION  OF  KETAMINE  IN  THE  RAT:  SELF-INDUCTION  OF 
METABOLISM. 

250107  04-03 
PROPRANOLOL  INHIBITS  RAT  BRAIN  MONOAMINE-OXIDASE. 

250333  04-03 
LOCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX. 

250356  04-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY-HOMO,  ON 
TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04-03 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETICS 
OF  (14C)IMIPRAMINE  IN  RAT:  ACUTE  STUDY. 

250655  04-03 
TOLERANCE  TO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA  PIG) 
THAT  METABOLIZE  IT  DIFFERENTLY. 

250723  04-03 
COMPARISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECTS  OF 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT 

250939  04-02 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  P  CHLOROPHENYLALANINE 
AND  OF  ALPHA  METHYL-P-TYROSINE. 

250982  04-04 
HIPPOCAMPAL  THETA  RHYTHM.  I.  DEPTH  PROFILES  IN  THE  CURARIZED 
RAT. 

251061  04-03 
5-HT  ANTAGONISTS  IN  RAT  HIPPOCAMPUS 

251072  04-03 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
FRONTALSTRIATAL  CONTROL  OF  BEHAVIORAL  INHIBITION  IN  THE  RAT. 

251138  04-04 
EFFECT  OF  ETHANOL  ON  DOPAMINE  SYNTHESIS  AND  RELEASE  FROM  RAT 
CORPUS  STRIATUM. 

251178  04  03 
PREFERENTIAL  DEAMINATION  OF  DOPAMINE  BY  AN  A  TYPE 
MONOAMINE-OXIDASE  IN  RAT  BRAIN. 

251225  04-03 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE  BETA  HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
EFFECTS  OF  ALPHA-RECEPTOR  BLOCKERS  AND  ANTIDEPRESSANT  DRUGS 

ON  THE  PRESYNAPTIC  ALPHA-RECEPTOR  OF  RAT  CEREBRAL  CORTEX 

251394  04-03 
ALTERATION  OF  DOPAMINE  METABOLISM  IN  RAT  BRAIN  BY  BACLOFEN 

(LIORESAL  (R)) 

251398  04-03 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT 

251400  04-03 


POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 
POISONING  IN  THE  RAT. 

251419  04-0; 
METHADONE  DURING  PREGNANCY  IN  THE  RAT:  DOSE  LEVEL  EFFECTS  ON 
MATERNAL  AND  PERINATAL  MORTALITY  AND  GROWTH  IN  THE 
OFFSPRING. 

251428  04  Of 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-0: 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 

AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-0; 
REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 

MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-0' 
ANOREXIA  AND  CONDITIONED  TASTE  AVERSIONS  IN  THE  RAT. 

251629  04-0! 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS. 

251964  04-0; 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT. 

251975  04-0' 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT 

251979  04-0/ 
EFFECT  OF  PHYSOSTIGMINE  ON  Y-MAZE  DISCRIMINATION  RETENTION  IN 
THE  RAT. 

251982  04-0' 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS,  III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT 

252012  04-0; 
EFFECTS  OF  P-CHLOROPHENYLALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT. 

252018  04-0; 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H-5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04-0: 
EVALUATION  OF  THE  ANTINOCICEPTIVE  EFFECTS  OF  4,ALPHA-DIMETHYL- 
M-TRYAMINE  (H77-77)  IN  THE  RAT. 

252026  04-0; 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-0: 
THE  UPTAKE  OF  TRITIATED  DELTAl -TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VAS-DEFERENS  OF  THE  RAT. 

252200  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04-03 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5- 
HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
COMPARISONS  BETWEEN  THE  ANTIANESTHETIC  ACTION  OF  DIBUTYRYL- 

CYCLIC-AMP  AND  ANALEPTIC  DRUGS  ON  AMOBARBITAL-INDUCED 
NARCOSIS  IN  THE  RAT. 

252221  04-03 
COCAINE  AND  LITHIUM    NEUROBIOLOGICAL  ANTAGONISM  IN  THE 

SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTE 
BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  THE 
RAT. 

252519  04-03 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  04-03 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 
LYSERGICACID-DIETHYLAMIDE  AND  MESCALINE-INDUCED  ATTENUATION 
OF  THE  EFFECT  OF  PUNISHMENT  IN  THE  RAT. 

252824  04  04 


S-272 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-17 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04  03 
EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 
ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX 

253691  04-03 
NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AND 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  04-03 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
THE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOMOTOR 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE  OF 
RECOVERY. 

230830  01-14 
EXPERIMENTAL  STUDIES  ON  THE  EFFECT  OF  SOME  PSYCHOTROPIC 
DRUGS  AND  PYRAZOLE  ON  THE  RATE  OF  ETHANOL  OXIDATION  IN 
VIVO  AND  IN  THE  PERFUNDATED  RAT  LIVER  IN  VITRO. 

234522  02-03 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE  BETA-HYDROXYLASE  IN  LOCUS- 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE 

238759  03-03 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03-03 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  03-04 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5 
HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (III). 

241394  03-03 
DRUG  INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN 

241395  03-03 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5-HT) 

TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-03 
MTE  DEPENDENT  DRUG  EFFECTS:  POSSIBLE  STATE-DEPENDENCY. 

242739  03-04 
\CTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 
APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC  AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
,    OF  BIOTRANSFORMATION  OF  SOME  ACTH4  9  ANALOGS. 

246853  04-04 
|;TEADY  STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
FFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04-05 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 
ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  04-03 
FFECTS  OF  MAZINDOL,  A  NONPHENYLETHYLAMINE  ANOREXIGENIC 
AGENT,  ON  BIOGENIC  AMINE  LEVELS  AND  TURNOVER  RATE. 

252201  04-03 
DECREASING 

ENFLURAMINE  AND  N  ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE  DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY 

230874  01-04 


RATE-OEPENDENT 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE  DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
RATE-DEPENDENT  EFFECTS  OF  DRUGS  ON  THE  VARIABLE-INTERVAL 

BEHAVIOR  OF  RATS. 

226854  01-04 
RATE-DEPENDENT  EFFECTS  OF  DRUGS:  A  REVIEW  OF  THE  LITERATURE. 

250070  04-04 
RATE-DEPENDENT  EFFECT  OF  AMPHETAMINE  IN  RATS:  EXTENSION  TO 
BETWEEN  SUBJECTS  EFFECT. 

251988  04-04 
RATES 

DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN    BIPHASIC  EFFECTS  OF  (  (  )  AMPHETAMINE 

241257  03-03 
EFFECTS  OF  A  CHOLINE-DEFICIENT  DIET  ON  THE  INDUCTION  OF  DRUG 
AND  ETHANOL  METABOLIZING  ENZYMES  AND  ON  THE  ALTERATION  OF 
RATES  OF  ETHANOL  DEGRADATION  BY  ETHANOL  AND 
PHENOBARBITAL. 

247032  04-03 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04  03 
RATING 

THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL. 

226899  01  09 
A  BRIEF  ANXIETY  RATING  SCALE  IN  EVALUATING  ANXIOLYTICS, 

237926  02  1 1 
LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING, 

239932  03-11 
THE  ROLE  OF  RATING  SCALES  IN  THE  USE  OF  ANTIDEPRESSANTS, 

243862  04  1  7 
DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES, 

244063  04  17 
CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN    -  AN  EMPIRICAL  STUDY 

248593  04  II 
THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS 

249771  04-10 
RATINGS 

PLASMA  CONCENTRATIONS  OF  L  DOPA  AND  3  METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L  DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE 

226349  01-14 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO, 
DRUG  AND  A  FOOD  DRINK 

239059  03-14 
MEASUREMENT  OF  ANXIETY  IN  OUTPATIENT  TRIALS    DETECTION  OF  BIAS 
IN  PATIENT  AND  DOCTOR  RATINGS, 

253043  04-16 
RATIONAL 

RATIONAL  PSYCHOPHARMACOTHERAPY  AND  THE  RIGHT  TO  TREATMENT, 

232937  02  1  7 
ON  THE  QUESTION  OF  THE  RATIONAL  USE  OF  MAJOR  TRANQUILIZERS 

236360  02  08 
RATIONALE 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION 

225721  01   17 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOHOL  WITHDRAWAL, 

252694  04  1  1 
RATIOS 

PERMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 
WITH  VARYING  METHYLSULFINYLMETHIDE  CARBANION 

238488  02-01 
CATECHOL  O-METHYLTRANSFERASE  FROM  RAT  LIVER    TWO  FORMS 
HAVING  DIFFERENT  METAPARA  METHYLATION  RATIOS 

249035  04  01 
RATS 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD 

225571  01  04 
ACUTE  SEDATIVE  PROPERTIES  OF  SKF  525  A  IN  RATS    IMPLICATIONS  FOR 

ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS 

225572  01  03 


S-273 


Subject  index 


Psychopharmacology  Absl 


-«t 


3»; 


BIOGENIC  AMINES  AND  THE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN  FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
BEHAVIORAL  CHANGES  IN  2M0NTH-0LD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  01-04 
EFFECTS  OF  CLONIDINE  AND  BS-100I4I  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS. 

226728  01-03 
RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D- 

AMPHETAMINE  ON  TIMING  BEHAVIOR. 

226729  01-04 
EFFECTS  OF  A  DOPAMINE-BETA-HYDROXYLASE  INHIBITOR  ON 

AMPHETAMINE-INDUCED  HYPERACTIVITY  IN  RATS. 

226766  01-03 
INTERACTIONS  Of  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS. 

226849  01  03 
SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE  DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS 

226853  01-04 
RATE-DEPENDENT  EFFECTS  OF  DRUGS  ON  THE  VARIABLE-INTERVAL 

BEHAVIOR  OF  RATS. 

226854  01-04 
RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 

RATS  FOLLOWING  L-TRYPfOPHAN  INJECTION. 

226873  01-03 
BIOTRANSFORMATION  AND  BILIARY  EXCRETION  OF  IMIPRAMINE  IN 
RATS  UNDER  VARIOUS  EXPERIMENTAL  CONDITIONS. 

226928  01-03 
BEHAVIORAL  EFFECTS  IN  RATS  FOLLOWING  INTRASTRIATAL 
MICROINJECTION  OF  MANGANESE. 

226932  01-04 
INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF- 
STIMULATION  BEHAVIOR  IN  RATS. 

226943  01-04 
FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS.  (PH.D.  DISSERTATION). 

226991  01-12 
OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PH.D 
DISSERTATION), 

226992  01-04 
GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6- 

HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  0104 
EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 

SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01-04 
ETHANOL  AS  A  REINFORCER  FOR  RATS.  EFFECTS  OF  CONCURRENT 

ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  01-04 
INHIBITION  OF  4,ALPHA  DIMETtlYL  MTYRAMINE  H77  77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINf  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 

DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  01-03 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS 

227636  01-04 
THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 

CONDITIONED  REFLEX  IN  RATS 

227637  01  04 
CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 

DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS 

227701  01-03 
DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC 

INDUCED  RESPONSES  DURING  ABSTINFNCE  IN  MORPHINE  DEPENDENT 
RATS 

227702  01-04 
DOPAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS 

227703  01-04 
5  METHOXY  N.NiDIMEIHYLTRYPTAMINE  (5-MEO  DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUI  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER). 

227802  01-04 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6  HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS 

228142  01-04 


NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  A 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

22814 
DIFFERENTIAL  EFFECTS  OF  D-AMPHETAMINE  IN  AAATURE  AND  IM^ 
RATS. 

22816 
NEUROTRANSMITTER  INFLUENCES  ON  MATING  BEHAVIOR  IN  MAL 
RATS.  (PHD   DISSERTATION). 

22839 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA 

22854 

SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  T 

BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGEN" 

22855 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

23000 
ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGME 
EYES  OF  BLACK  AND  WHITE  RATS. 

23045 
THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  A 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATIOI 
RATS 

23045 
PLAS/WA  CREATINE-PHOSPHOKINASE  LEVELS  IN  RATS  FOLLOWING 
LYSERGIC-ACID-DIETHYLAMIDE. 

23082 
CHLORDIAZEPOXIDE  AND  ISOLATION  INDUCED  TIMIDITY  IN  RATS. 

23082 
RESPONSE  SUPPRESSION  IN  RATS.  A  COMPARISON  OF  RESPONSE 
CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFf 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

23083 
THE  EFFECTS  OF  METIAMIDE  ON  THE  ACTIVITY  STRESS  ULCER  IN  I 

23083 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM), 

DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  , 

COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMIN> 

STIMULUS, 

23083 
CHLORDIAZEPOXIDE  AND  DIAZEPAM-INDUCEO  MOUSE-KILLING  BY 

23083 
TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED-RATIO  WA 
REINFORCED  RESPONDING  IN  RATS, 

23084 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RAT 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE, 

23086 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

23125 
A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAMINE-INDUCED 
CONTRALATERAL  ROTATION  IN  RATS. 

23130 
EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTION! 
FEEDING,  LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

23170 
BEHAVIORAL  EFFECTS  OF  DIBUTYRYi-CYCLIC-AMP  AND  BIOGENIC 
AMINES  IN  RATS. 

23248- 
BEHAVIORAL  AND  BIOCHEMICAL  INTERACTIONS  OF  5,7 
DIHYDROXYTRYPTAMINE  WITH  VARIOUS  DRUGS  WHEN 
ADMINISTERED  INTRACISTERNALLY  TO  ADULT  AND  DEVELOPINC 
RATS. 

232601 
ATTENUATION  OF  PRECIPITATED  ABSTINENCE  IN  METHADONE 
DEPENDENT  RATS  BY  DELTA9-THC. 

23261; 
AVOIDANCE  BEHAVIOR  IN  VITAMIN-B6  DEFICIENT  RATS. 

23263' 
AN  ATTEMPT  TO  CORRELATE  ANALGESIA  TO  CHANGES  IN  BRAIN 
NEUROMEDIATORS  IN  RATS 

23333< 
TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENS 
DEPRIVATION 

233411 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS.  GUINEA-PIGS,  AND  RABBITS. 

23396; 
KINETICS  AND  METABOLISM  OF  AMPHETAMINE  IN  THE  BRAIN  OF  I 
OF  DIFFERENT  AGES 

2343 1< 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURI 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE 

23473? 


S-274 


XUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  SCOPOLAMINE  ON  HABITUATION  OF  EXPLORATORY 
ACTIVITY  IN  RATS 

235509  0204 
INERT  GAS  NARCOSIS:  AVOIDANCE  BEHAVIOR  IN  RATS  BREATHING 
ELEVATED  PRESSURES  OF  NITROGEN  AND  HELIUM 

23551 1  02  04 
CHRONIC  MARIHUANA  INHALATION  TOXICITY  IN  RATS. 

235671  0205 
DOPAMINERGIC  EFFECTS  OF  PHENCYCLIDINE  IN  RATS  WITH 
NIGROSTRIATAL  LESIONS 

236523  02-04 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-04 
INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE 

237097  02  03 
EFFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

237099  02-03 
EFFECT  OF  MORPHINE  ANTAGONISTS  ON  DRUG  INDUCED  HYPOTHERMIA 

IN  MICE  AND  RATS. 

237100  0203 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 

TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS 

237106  02-04 
CURRENT  DETERMINATION  OF  LITHIUM-INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS, 

237110  02-04 
A  DISCRIMINATIVE  CONTROL  OF  OPERANT  BEHAVIOR  BY  INTRAVENOUS 
ADMINISTRATION  OF  DRUGS  IN  RATS. 

237701  02-04 
LONG-TERM  EFFECT  OF  PERPHENAZINE  ON  THE  SUBSTANTIA-NIGRA  IN 

RATS. 

237702  02-03 
-  PHARMACOLOGICAL  DISSOCIATION  BETWFEN  VOCALIZATION  AND 

BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
AND  ISOCARBOXAZID. 

23/705  02-04 
ATTENUATION  BY  ALPHA-METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 
I       CONDITIONED  TASTE  AVERSION  IN  RATS 

237713  02-04 
BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  ANALYSIS  OF 
AMPHETAMINE  AND  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  IN 
I      RATS. 

i  237718  02-04 

I  EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOl  AMINES 

AND  SEROTONIN  IN  RATS  -  ACUTE  MORPHINE  ADMINISTRATION 
!  237736  02  03 

I  EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS  -  CHRONIC  MORPHINE  ADMINISTRATION 

237737  02-03 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
I      AND  6-HYDROXYDOPAMINE  IN  RATS 

i  237743  02  03 

I  INHIBITION  OF  DRUG-INDUCED  ANOREXIA  IN  RATS  BY  METHYSERGIDE. 

237745  02-04 
j  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 

MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
I      INDUCED  ROTATION  OF  RATS 

237866  02-03 
CARBACHOL  ELICITED  MOUSE-KILLING  BY  RATS:  CIRCADIAN  RHYTHM 
AND  DOSE-RESPONSE 

238006  02  04 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE  OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02  04 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 
TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED.  CORN-FED  RATS 

238676  03-03 
EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG  NAIVE  RATS 

238697  03  04 
DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS 

238699  03-03 
RESPONSES  OF  FLEXOR  REFLEX  10  LSD.  TRYPTAMINE  (T).  5-HTP. 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238/04  03-04 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  0303 
COMPARISON  OF  THYROID-RLIEASING  HORMONE  (TRH)  AND 
AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 


FOLLOWING  INJECTIONS  INTO  THE  CAUDATE  NUCLEUS,  SEPTUM   AND 
HYPOTHALAMUS. 

238744  03-04 
ETHANOL  PREFERENCE  IN  RATS    POSSIBLE  UNDERLYING  MECHANISMS 

238750  03  04 
EFFECTS  OF  SOME  PSYCHOTROPIC  DRUGS  ON  AGGRESSIVE  BEHAVIOR  IN 
RATS. 

238754  03-04 
INJECTIONS  OF  AMINO-ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASE 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS 

238783  03-03 
INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIOIOL  (CBD)  IN  RATS. 

238807  03-05 
MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS 

238809  03-03 
DELTA9  TETRAHYDROCANNABINOL  (DELTA9-THC)  AND  I  I-0H-DELTA9 
THC.  ONSET,  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS 

238813  03-04 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822  03-03 
6-HYDROXYDOPAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  10  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS. 

238826  03  03 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 

INTERACTIONS  OF  D  AMPHETAMINE  AND  ALPHA  METHYL-P-TYROSINE 
ON  SCHEDULE  CONTROLLED  PERFORMANCE  IN  RATS 

238844  03-04 
EFFECT  OF  ANTIDIURETIC  DRUGS  IN  RATS  WITH  LITHIUM-INDUCED 
POLYURIA. 

239041  03-05 
ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 
POLYURIA. 

239046  03-05 
THE  ANXIOLYTIC  EFFECl  OF  SMAI L  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03  04 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 
RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS 

239851  03  03 
PERFORMANCE  ENHANCEMENT  EFFECTS  OF  D  AMPHETAMINE, 
METHYLPHENIDATE,  PIPRADROL  AND  PHENINDAMINE  IN  RATS. 

239857  03  04 
PHARMACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER 

DISCHARGES  IN  RATS.  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES 

239858  03-03 
DUAL  ACTION  OF  MORPHINE  AND  RELATED  DRUGS  ON  COMPULSIVE 

GNAWING  OF  RATS 

239860  03  04 
PIRACFTAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 

OF  VISUAL  INFORMATION  IN  RATS 

239861  0304 
NICOTINE-LIKE  BEHAVIORAL  EFFECT  AFTER  SMALL  DOSE  OF 

MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

239865  03-04 
INDUCTION  OF  TYROSINE  HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS    OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03  03 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS 

239979  03  04 
PCHLOROAMPHFTAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS 

240062  03-04 
CENTRAL  ACTION  OF  NORMETANEPHRINE    EFFECT  ON  THE  BEHAVIOR  OF 
RATS 

240240  03-03 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID 
EFFECTS  OF  THEOPHYLLINE,  L  DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS 

240447  03-03 
EFFECTS  OF  HALOPERIDOL  ON  AVERSIVF  THRESHOLD  OF  RATS. 

240886  03-03 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS 

241203  03  03 
THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DIN  PROPYLACETATE. 

241222  03  03 


S-275 


Subject  Index 


Psychopharmacology  Abstra 


SITES  OF  ACTION  OT  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  L  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS. 

241223  03-04 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  03-04 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES. 

241231  03-04 
INFLUENCE  OF  PRENATAL  D-AMPHETAMINE  ADMINISTRATION  ON 
DEVELOPMENT  AND  BEHAVIOR  OF  RATS. 

241245  03-04 
PHYSOSTIGMINE  AS  A  DISCRIMINATIVE  CUE  IN  RATS. 

241258  03-04 
LONG  TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS 

241300  03-04 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS. 

241360  03-03 
EFFECTS  OF  DRUGS  INJECTED  INTO  THE  HYPOTHALAMUS  ON  MURICIDE 
AND  EEG  IN  THE  OLFACTORY  BULBECTOMIZED  RATS. 

241367  03-04 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-03 
STUDIES  ON  BIOGENIC  AMINES  AND  BEHAVIOR  (I).  RELATIONSHIP 

BETWEEN  BRAIN  MONOAMINES  AND  DEFECATION  IN  RATS. 

241370  03-04 
ACTIONS  OF  6  HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 

INTO  DEVELOPING  RATS  (2),  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR. 

241372  03-04 
CENTRAL  NERVOUS  DEPRESSIVE  ACTIONS  OF  NEUROTROPIN  ON  MICE 
AND  RATS. 

241374  03-04 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULATION 

AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375  03-04 
BEHAVIORAL  EFFECTS  OF  PENFLURIDOL  IN  RATS. 

241376  03-04 
DIFFFRENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 

RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  03-04 
EFFECTS  OF  LONG  TERM  ADMINISTRATION  OF  LEVOMETHIOMEPRAZINE 

TO  RATS 

241381  03-03 
CYCLIC  AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION  INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 

FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03-03 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III). 

EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390  03-03 
COMBINED  EFFECTS  OF  METHAMPHETAMINE,  CAFFEINE.  DIAZEPAM,  AND 

PENTOBARBITAL  ON  DRL  PERFORMANCE  IN  RATS. 

241400  03-04 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 
DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM,  (PHD    DISSERTATION). 

241681  03-04 
THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 
HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS, 

241918  03-04 
IMPAIRED  ABSORPTION  OF  CHLORPROMAZINE  IN  RATS  GIVEN 
TRIHEXYPHENIDYL. 

241920  03  03 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5  HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

24)979  0304 


INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTIC 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  0 
CHANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS. 

241987  0 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION 
SLEEP  CYCLES  IN  RATS. 

242732  0 
DRUG  DISCRIMINATION  IN  RATS:  EFFECTS  OF  MIXTURES  OF  DITRAN 
CHOLINESTERASE  INHIBITORS. 

242737  0 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIM 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  0 
CYCLOHEXIMIDE-INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY 

RATS. 

242742  C 
THE  EFFECTS  OF  MEPROBAMATE  UPON  THE  AVERSIVE  THRESHOLD  01 

RATS. 

242894  0 
CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  AAANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  T 
MARIJUANA  SMOKE. 

243181  0 
REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  0 
THE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 

HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

243758  0 
SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  MALE  RATS  TREATED  WITH 
METHADONE. 

243789  0 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDAN 
LEARNING  IN  RATS. 

243804  0 
THERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE. 

243815  0 
UTEROTROPHIC  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
OVARIECTOMIZED  RATS, 

243865  0 
HYPERPHAGIA  AND  INCREASED  GROWTH  IN  RATS  AFTER 

INTRAVENTRICULAR  INJECTION  OF  5,7  DIHYDROXYTRYPTAMINE. 

243879  0 
VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS. 

244311  0- 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  0 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS 

244456  0. 
EFFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS, 

244651  0. 
HYPOTHALAMIC  CHEMOSTIMULATION  AND  AUTONOMIC  CHANGES  IN 
CURARIZED  RATS, 

244691  0' 
DRUG  INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES, 

244692  0' 
DRUG  DISCRIMINATION  IN  RATS:  THE  EFFECTS  OF  PHENCYCLIDINE  AN 

DITRAN 

245297  0' 
THE  DURATION  OF  TOLERANCE  TO  THE  ANOREXIGENIC  EFFECT  OF 

AMPHETAMINE  IN  RATS, 

245298  0^ 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  R/ 

TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS, 

245299  0^ 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAM 

AND  CHL0RDIA2EP0XIDE  IN  RATS, 

245301  0-1 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE 

245305  OA 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMEN 
OF  DOPAMINE. 

245601  04 


S-276 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT, 

245602  04-04 
CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE  OF 
SATIETY  IN  RATS. 

245612  0402 
THE  EFFECTS  OF  TRANQUILLIZING  DRUGS  ON  TIMING  BEHAVIOUR  IN 
RATS. 

246306  04  04 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  0403 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-04 
INVOLVEMENT  OF  CENTRAL  DOPAMINE  IN  THE  HYPERTHERMIA  IN  RATS 

PRODUCED  BY  D-AMPHETAMINE. 

246820  04-04 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 

LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  04-03 
EFFECTS  OF  ANTIDEPRESSANT  DRUGS  ON  AMYGDALOID  AFTER 
DISCHARGE  IN  RATS. 

247039  04-03 
DOSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS. 

247206  04-04 
MEASUREMENT  OF  THE  EFFECTS  OF  DRUGS  ON  ACTIVITY  OF  PERMANENT 

GROUPS  OF  RATS. 

247207  04-04 
AROUSAL  AND  ACTIVITY  LEVEL  OF  RATS  WITH  LESIONS  IN  THE  DORSAL 

HIPPOCAMPUS. 

247420  04-04 
EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS. 

247588  04-03 
ENDOCRINE  EFFECTS  OF  CHRONIC  INTRAVENTRICULAR  ADMINISTRATION 
OF  DELTA9-TETRAHYDR0CANNABIN0L  TO  PREPUBERAL  AND  ADULT 
MALE  RATS. 

248275  04-05 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 

ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL-CYCLIC-AMP. 

248276  04-03 
APORPHINES  16:  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 

ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 
NUCLEUS-ACCUMBENS. 

248287  04-02 
INTERACTING  EFFECTS  OF  AMYGDALA  LESIONS  WITH 
CHLORDIAZEPOXIDE  AND  PILOCARPINE  ON  MOUSE-KILLING  BY  RATS. 

248394  04-04 
LITHIUM  EFFECTS  UPON  COMPONENTS  OF  ACTIVITY  IN  RATS. 

248516  04-03 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 
WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES, 

248915  04-05 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 

248952  04-03 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
INTERACTIONS  BETWEEN  CANNABIDIOL  AND  DELTA9  THC  DURING 
ABSTINENCE  IN  MORPHINE-DEPENDENT  RATS. 

249001  04-04 
ABSORPTION,  DISTRIBUTION  AND  EXCRETION  OF  TRIFLUOPERAZINE  IN 
RATS, 

249036  04-03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS  COERULEUS  IN  RATS. 

249076  04-04 
AVERSIVE  EFFECTS  OF  REPEATED  INJECTIONS  OF  THC  IN  RATS. 

249158  04-04 
FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  04-04 
THE  INCIDENCE  OF  SELF-MUTILATION  IN  MORPHINE  TOLERANT  SPRAGUE- 
DAWLEY  MALE  RATS. 

249253  04-04 
EFFECTS  OF  D-AMPHETAMINE,  MONOMETHOXYAMPHETAMINES  AND 
MESCALINE  ON  FIXED-INTERVAL  RESPONDING  IN  RATS 

249275  04-04 


CHARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  04-03 
THE  EFFECT  OF  LITHIUM  CHLORIDE  ON  ONE-TRIAL  PASSIVE  AVOIDANCE 
LEARNING  IN  RATS 

249381  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS. 

249485  04-04 
RELATIONSHIP  BETWEEN  THE  BEHAVIORAL  AND 

ELECTROENCEPHALOGRAPHIC  EFFECTS  OF  CHLORPROMAZINE  AND 
FLUPHENAZINE  IN  RATS. 

249623  04-02 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  04-03 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  04-03 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE 

249678  04-04 
IMIPRAMINE  ENHANCEMENT  OF  PENTOBARBITAL  TOXICITY  IN  RATS, 

249929  04  05 
ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 
BEHAVIOR  IN  FEMALE  RATS. 

250012  04  04 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 

BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04-04 
COMBINATIONS  OF  SELECTED  CNS  DEPRESSANTS  WITH  D-AMPHETAMINE 

OR  AAAZINDOL  ON  FOOD  INTAKE  AND  MOTOR  ACTIVITY  OF  RATS. 

250080  04-03 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS. 

250089  04  04 
EFFECTS  OF  HALOTHANE  ANESTHESIA  ON  THE  BIODISPOSITION  OF 
KETAMINE  IN  RATS. 

250108  04  03 
CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS. 

250114  04-03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  ASYMMETRIC  MEDIAL  RAPHE 
NUCLEI  LESIONS  IN  RATS. 

250358  04-04 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-03 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOLATED  FROM  RATS  PRETREATED  WITH  PARGYLINE 

250379  04  03 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHENOBARBITAL. 

250682  04  05 
ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF-ADMINISTERING  RATS, 

250941  04  04 
MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

251063  04-04 
AN  AMNESIC  EFFECT  OF  BENZODIAZEPINES  IN  RATS?. 

251216  04-04 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS. 

251402  04-04 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATION 
IN  RATS. 

251409  04-04 
SCHEDULE-DEPENDENT  EFFECTS  OF  CHLORDIAZEPOXIDE  ON  OPERANT 
BEHAVIOR  IN  RATS 

251670  04-04 
A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINF 

251951  04  04 


S-277 


Subject  Index 


Psychopharmacology  Abstr 


esq; 


DIFFERFNTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS 

25)978  04-04 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE 

251981  04-04 
RATE-DEPENDENT  EFFECT  OF  AMPHETAMINE  IN  RATS:  EXTENSION  TO 
BETWEEN  SUBJECTS  EFFECT 

251988  04  04 
EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LEVELS 
OF  ADRENALECTOMIZED  RATS 

251990  04-04 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 

BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE, 

251991  04-04 
INHIBITION  AND  POTENTIATION  OF  APOMORPHINE  INDUCED 

HYPERMOTILITY  IN  RATS  BY  NEUROIEPTICS 

252029  04-04 
ANATOMICAL  AND  BEHAVIORAL  EFFECTS  OF  COLCHICINE 
ADMINISTRATION  TO  RATS  LATE  IN  UTERO. 

252148  04  05 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL'PREWEANING 

TAURINE  INJECTIONS  IN  RATS, 

252149  04  04 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS, 

252174  04-03 
LITHIUM  OROTATE,  CARBONATE  AND  CHLORIDE:  PHARMACOKINETICS, 
POLYDIPSIA  AND  POLYURIA  IN  RATS, 

252198  04-03 
MORPHINE  INDUCED  ROTATION  IN  NAIVE.  NONLESIONED  RATS, 

252209  04-04 
EFFECTS  OF  CAFFEINE  AND  ETHANOL  ON  THE  BLOOD-BRAIN  BARRIER  IN 
RATS, 

252222  04  03 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS, 

253111  04  04 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM, 

253593  04-04 
THE  MONOAMINE-OXIDASE  B  INHIBITOR  DEPRENYL  POTENTIATES 
PHENYLETHYLAMINE  BEHAVIOUR  IN  RATS  WITHOUT  INHIBITION  OF 
CATECHOLAMINE  METABOLITE  FORMATION 

253643  0404 
ENDOCRINE  EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  PSYCHOACTIVE 
DRUGS  TO  PREPUBERTAL  MALE  RATS,  II,  LSD, 

253700  04-03 
RBC 

ON  THE  CLINICAL  RELEVANCE  OF  THE  INTRACELLULAR  RBC  LITHIUM 
CONCENTRATION 

251417  04  15 
RE-EDUCATION 

AN  tXPERIMENTAL  THERAPY  AND  REEDUCATION  PROGRAM  TOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDkOCIUORIDE    (PH  D,  DISSERIATION) 

228750  Oil  I 
REABSORPTION 

PHARmAcOIOGKAI   (  HARACTFRI/AIION  of  LITHIUM  REABSORPTION  IN 
IHE  RAI 

237759  02  03 
REACTION 

IHr  FftFCl  OF  0,1  A/--  'HEIAMINL  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OT  MESODIENCFPHALIC 
STRUCTURES 

228546  01-03 
(  HIORPROMAZINE  ETEK  IS  UN  HRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIAIION)  AND  REACIION  IIMF  IN  NORMAL  WOMEN 

230863  01-14 
(  ORRTI  All  S  OF  PLA(  EBO  REACIION  IN  AN  OUIPAIIENT  POPULATION 

235628  02  17 
CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL  AMPHETAMINE  AND 
RfSIRPINE  ON  THE  MODEL  OE  THE  CAUDATE  REACTION  OF 
Rf  lARDAllON 

236235  02  03 
ON  NIUROC  HEMICAI  MECHANISMS  OF  THE  INHIBITORY  INFLUENCE  OF 
IHI  HIPPOCAMPUS  ON  IHE  RAT  FOOD  PROCURING  CONDITIONED 
RIA(  HON 

236257  02  04 
IMK  I  Of  CHLORPROMA/INI   ON   IHE  REACIION  OF  BIASI 
IRANSFORMATION  01   IYMPHO(  YITS 

236373  02  03 


RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712 
EFFECT  OF  LONG-LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS, 

239992 
A  PRIMATE  MODEL  OF  ACUTE  DYSTONIC  REACTION  TO  NEUROLEPTI 

241934 
WARNED  REACTION  TIMES  OF  MANIC-DEPRESSIVE  PATIENTS  WITH 
WITHOUT  LITHIUM. 

249798 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOl 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITIC 
FLICKER  FREQUENCY, 

251986 
EFFECTS  OF  SET,  SETTING,  AND  SEDATIVES,  ON  REACTION  TIME. 

252061 
REACTIONS 

THE  INFLUENCE  OF  D.L-AMPHETAMINE  AND  CAFFEINE  ON  CAUDATE 
INHIBITION  OF  CONDITIONED  AVOIDANCE  REACTIONS  IN  CATS. 

231248 
MONOAMINERGIC  INFLUENCES  OF  THE  CAUDATE-NUCLEUS  ON 
CONDITIONED  FOOD  PROCURING  REACTIONS  IN  RATS. 

231251 
ADVERSE  REACTIONS  ASSOCIATED  WITH  MOOD-ALTERING  DRUGS. 

231995 
INDIVIDUAL  DIFFERENCES  AND  SETTING  AS  DETERMINANTS  OF  ACL 
ADVERSE  REACTIONS  TO  PSYCHOACTIVE  DRUGS, 

233377 
EFFECT  OF  CAFFEINE  AND  AMPHETAMINE  ON  CAUDATE  INHIBITION 
AGGRESSIVE  REACTIONS  OF  CATS, 

236371 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIO 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS 

236828 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM 
SEROTONIN  IN  THE  RAT  BRAIN. 

244455 
PARADOXICAL  RAGE  REACTIONS  DURING  PSYCHOTROPIC  MEDICATI 

246184 
TREATMENT  OF  REACTIONS  TO  AMPHETAMINE-TYPE  STIMULANTS. 

251754 
REACTIVE 

A  DOUBLE  BUND  TRIAL  OF  INTRAVENOUS  THYROTROPIN-RELEASINC 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693 
SOME  PHARMACOLOGICAL  PROPERTIES  OF  CYCLOCHOLINE,  A  REAC 
ANALOG  OF  CHOLINE, 

238828 
REACTIVITY 

INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT,  EFFECTS  OF 
PHYSOSTIGMINE 

239829 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  T 
REGULATION  OF  EMOTIONAL  REACTIVITY 

242544 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 
REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  Sr-STI 
IN  LIMBIC  FOREBRAIN 

245115 
REAGENTS 

NMR  STUDY  OF  AMPHETAMINES  USING  EUROPIUM  SHIFT  REAGENT! 

239660 
REARING 

THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG 

2377121 

THE  INTERACTIVE  EFFECTS  OF  PRENATAL  IMIPRAMINE  EXPOSURE  A^ 

POSTNATAL  REARING  CONDITIONS  ON  BEHAVIOUR  AND  HISTOLOI 

237721  I 
REBOUND 

REBOUND  PHENOMENA  IN  MANIC  PATIENTS  FOLLOWING 
PHYSOSTIGMINE:  PRELIMINARY  OBSERVATIONS 

230816  1 
RECEIVE 

SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY'5, 

21 
RECEIVING 

SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  '<FCt 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY?, 

247359 ( 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE 

2491 24  ( 


S-278 


I 


UME  14,  SUBJECT  INDEX 


Subject  Index 


HYTOHEMAGLUTININ-INDUCED  LYMPHOCYTE  TRANSFORMATION  IN 
HUMANS  RECEIVING  0ELTA9-TETRAHYDR0CANNABIN0L. 

252825  04-13 
TOR 

EGIONAL  DISTRIBUTION  OF  POSTSYNAPTIC  RECEPTOR  BINDING  FOR 
GAMMA-AMINOBUTYRICACID  (GABA)  IN  MONKEY  BRAIN. 

226407  01-03 
OPAMINE  RECEPTOR  BLOCKADE  AND  THE  NEUROLEPTICS,  A 
CRYSTALLOGRAPHIC  STUDY. 

226761  01-03 
HYOROXYTRYPTAMINE-UC  AND  DEXAMPHETAMINE-I4C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01  03 
lOCHEMICAL  IDENTIFICATION  OF  THE  MAMMALIAN  MUSCARINIC 
CHOLINERGIC  RECEPTOR 

227400  01-03 
DOPAMINE  RECEPTOR  STIMULATOR  IN  DEPRESSION.  (UNPUBLISHED 
PAPER) 

227785  01-09 
TRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
HE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS. 

233290  02  03 
HE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 
(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE 

233974  02-11 
IRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 
ISRUPTION  OF  BRAIN  STIMULATION-INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE 

235.587  02-04 
WD  CHANGES  IN  RAT  PINEAL  BETA  ADRENERGIC  RECEPTOR: 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER), 

237170  02-03 
LINICAL  STUDIES  WITH  DOPAMINE  RECEPTOR  STIMULANTS, 

237725  02-08 
;REVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099 

238686  03  03 
/IDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE 

238727  03-03 
/IDENCE  FOR  A  DOPAMINE  RECEPTOR  ANTIBODY, 

238736  03  03 
■FECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE 

239043  03-05 
IDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS.  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03  03 
HE  BRAINS  DOPAMINE  RECEPTOR    LABELING  WITH  3H  DOPAMINE  AND 
3H-HAL0PERID0L  . 

240077  03-03 
CCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID 
EFFECTS  OF  THEOPHYLLINE.  L  DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS 

240447  0303 
?UG  RECEPTOR  INTERACTIONS  OF  MORPHINE  AND  NAIORPHINE 
COMPETITIVE  DUALISM  VERSUS  RECEPTOR  DUALISA/\   (PH  D 
DISSERTATION) 

240934  03-03 
ITINOCICEPriVE  ACTION  OF  QUIPAZINE    RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION 

241235  03-03 
■25  397,  DIDEHYDR0METHYL-8BETA  PYRIDYLTHIOMETHYIERGOLINE  A 
NEW  CENTRAL  DOPAMINE  RECEPTOR  AGONIST 

241927  0304 
MEIOCIOPRAMIDE  A  DIRECTLY  ACTING  DOPAMINE  RECEPTOR 
ANTAGONIST'^ 

241929  0303 
FECTS  OF  DOPAMINE  RECEPTOR  BLOCKADL  ON  SELF-STIMULATION  IN 
THE  MONKEY 

2^2748  04  04 
PRELIMINARY  REPORT:  NEUROENDOCRINE  EFFECTS  OF  DOPAMINE  AND 
NOREPINEPHRINE  RECEPTOR  STIMULATORS 

243440  04  03 
IPAMINE  RECEPTOR  BINDING  PREDICTS  CLINICAL  AND 
!PMARMACOLOGICAL  POUNtlES  OF  ANTISCHI70PHRENIC  DRUGS. 

243483  04  03 


EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5HYDR0XYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN 

243777  04-03 
OPIATE  RECEPTOR  IN  NORMAL  AND  DRUG  ALTERED  BRAIN  FUNCTION 

246996  04-03 
THE  SEARCH  FOR  THE  DOPAMINE  RECEPTOR:  TRIBULATIONS. 

247215  0403 
THE  DOPAMINE  RECEPTOR:  DIFFERENTIAL  BINDING  OF  D-LSO  AND 
RELATED  AGENTS  TO  AGONIST  AND  ANTAGONIST  STATES. 

247862  0-'-03 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS. 
EVIDENCE  FOR  INCREASED  5-HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY. 

248288  04-03 
RECEPTOR  BINDING  AND  PHARMACOLOGICAL  ACTIVITY  OF  OPIATES  IN 
THE  GUINEA  PIG  INTESTINE 

248703  04-03 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY. 

248947  04  03 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR. 


RECEPTOR  SENSITIVITY  IN  SCHIZOPHRENIA 
BUTYROPHENONE  INFLUENCES  ON  THE  OPIATE  RECEPTOR. 


249301  04-03 
249633  04-03 
250088  04-03 


OPIATE  RECEPTOR  BINDING  -■  ENHANCEMENT  BY  OPIATE 
ADMINISTRATION  IN  VIVO. 

250378  04-03 
REPORT  OF  A  SYMPOSIUM  ON  BETA-ADRENERGIC  RECEPTOR  BLOCKADE 
IN  PSYCHIATRY.  HELD  IN  FERNDOWN,  DORSET,  ON  JUNE  21ST  1975. 
BETA  ADRENERGIC  BLOCKING  DRUGS  IN  ANXIEIY. 

251156  04-10 
DIFFERENT  ALPHA  ADRENORECEPTORS  IN  THE  CENTIME  NERVOUS- 
SYSTEM  MEDIATING  BIOCHEMICAL  AND  FUNCTIONAL  EFFECTS  OF 
CLONIDINE  AND  RECEPTOR  BLOCKING  AGENTS. 

251226  04  02 
MUSCARINIC  CHOLINERGIC  RECEPTOR  BINDING:  INFLUENCE  OF  PIMOZIDE 
AND  CHLORPROMAZINE  METABOLITES. 

252515  04-05 
RECEPTORS 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS 

226185  01-04 
STEREOSPECIFIC  BINDING  OF  D-LYSERGIC  ACID-DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01  12 
RAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN 

227996  01-03 
ISD  AND  DOPAMINE  RECEPTORS 

228050  01  03 
LSD  AND  DOPAMINE  RECEPTORS     PIERI  REPLY. 

228051  0103 
EVIDENCE  FOR  DRUG  ACTIONS  ON  BOTH  PRE   AND  POSTSYNAPTIC 

CATECHOLAMINE  RECEPTORS  IN  THE  CNS. 

229431  01-03 
CRITERIA  FOR  AND  PITFALLS  IN  THE  IDENTIFICATION  OF  RECEPTORS. 

229436  01-03 
CHEMISTRY  OF  DOPAMINE  RECEPTORS. 

230600  01  03 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 
ACTIONS  OF  BENZODIAZEPINES. 

232511  01-03 
INTFRACTIONS  OF  OPIATE  RECEPTORS  WITH  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER) 

232960  02-03 
ORGANIZATION  OF  RECEPTORS  FOR  NEUROTRANSMITTERS  ON  APIYSIA 
NEURONES 

235588  02-03 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 

RECEPTORS    A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL, 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02  03 
OPIATE  RECEPTORS  AS  REGULATORS  OF  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER). 

237175  0203 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS 

237782  0203 
3,4  DIHYDROXYPHENYLAMINO  2  IMIDAZOLINE  (DPI),  A  NEW  POTENT 
AGONIST  AT  DOPAMINE  RECEPTORS  MFDIAIING  NEURONAL 
INHIBITION 

238321  0203 


S-279 


Subject  index 


Psychopharmacology  Abst 


es.- 

i 

O 


so. 

'la. 


OPIATE  RECEPTORS  AND  ADENYLATECYCi  A?F  IN  NEUROBLASTOMA  X 
GLIOMA  CELL  LINES   (UNPUBLISHED  PAPER), 

238571  02  03 
DIFFERENTIAL  BLOCKADE  OF  ALPHA-ADRENERGIC  RECEPTORS  BY 
CHLORPROMAZINE. 

238672  03  03 
MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-03 
OPIATE  RECEPTORS  IN  CELL  CULTURES.  (UNPUBLISHED  PAPER). 

239787  03-03 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYOROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  03-03 
HALLUCINOGENIC  INDOLEAMINES;  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS, 

240073  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT 

241255  03-03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS 

241921  03-03 
CENTRAL  GAMAAA-AMINOBUTYRIC  ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
BENZODIAZEPINES  AND  CENTRAL  GLYCINE  RECEPTORS, 

243762  04-03 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
INGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
ESTERS  OF  APOMORPHINE  AND  N,N  DIMETHYLDOPAMINE  AS  AGONISTS 
OF  DOPAMINE  RECEPTORS  IN  THE  RAT  BRAIN  IN  VIVO. 

246150  04-04 
FURTHER  EVIDENCE  THAT  EXTRINSIC  ACETYLCHOLINE  ACTS 

PREFERENTIALLY  ON  EXTRAJUNCTIONAL  RECEPTORS  IN  THE  CHICK 
BIVENTER  CERVICIS  MUSCLE, 

248409  04-03 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE, 

249257  04-03 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  (  )  AMPHETAMINE 
AND  L  DOPA. 

249419  04-04 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS  STRIATUM 

249670  04-04 
LSD  AS  AN  AGONIST  AT  MESOLIMBIC  DOPAMINE  RECEPTORS, 

249680  04-04 
CYCLIC-AMP  AND  CENTRAL  NORADRENALINE  RECEPTORS:  FAILURE  TO 
ACTIVATE  DIENCEPHALIC  ADRENERGIC  FEEDING  PATHWAYS, 

250075  04-04 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS, 

250082  04-03 
LOCALIZATION  OF  DOPAMINE  RECEPTORS  IN  THE  RAT  CEREBRAL 
CORTEX 

250356  04-03 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT, 

251820  04-03 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA, 

252521  04-03 
RECORDING 

INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA-PIG  NODOSE  GANGLION, 

232333  01-03 
SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS 
(UNPUBLISHED  PAPER) 

237274  02-16 


RECOVERY 

HOSTILITY,  SOMATIC  SYMPTOMS  AND  RECOVERY  WITH 
ANTIDEPRESSANTS, 

22689f 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 
INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  \ 
DISCRIMINATION  PERFORMANCES. 

22738' 
THE  EFFECT  OF  DIAZEPAM  AND  FENTANYL  ON  MENTAL,  PSYCHOM 
AND  ELECTROENCEPHALOGRAPHIC  FUNCTIONS  AND  THEIR  RATE 
RECOVERY, 

23083( 
RECRUITMENT 

EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

24696; 
RECTAL 

PLASMA  CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES 
PERORAL,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION: 
CORRELATION  BETWEEN  PLASAAA  CONCENTRATION  AND  SEDAT( 
EFFECT  OF  DIAZEPAM. 

23773; 
PLASMA  LEVELS  OF  DIAZEPAM  AFTER  PARENTERAL  AND  RECTAL 
ADMINISTRATION  IN  CHILDREN. 

24689 
RECURRENCES 

COURSE  OF  AAANIC-DEPRESSIVE  RECURRENCES  UNDER  LITHIUM. 

23277< 
RECURRENT 

LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLI 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION 

23420: 
THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

24661: 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

25295' 
RED 

THE  EFFECT  OF  LITHIUM  ON  RED  BLOOD  CELL  CHOLINESTERASE  AC 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

24449; 
BINDING  OF  CHLORPROMAZINE  AND  IMIPRAMINE  TO  RED  CELLS, 
ALBUMIN,  LIPOPROTEINS  AND  OTHER  BLOOD  COMPONENTS. 

2471 2S 
REDUCED 

REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238696 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE-BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT 
MAN.  (UNPUBLISHED  PAPER). 

23930' 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTI 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

24467^ 
REDUCES 

ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 
REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYS' 
IN  LIMBIC  FOREBRAIN, 

245115 
REDUCING 

BEHAVIORAL  EFFECTS  OF  REDUCING  THE  DAILY  FREQUENCY  OF 
PHENOTHIAZINE  ADMINISTRATION, 

228224 
REDUCTION 

REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CH 
MARIJUANA  SMOKERS, 

229039 
REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT, 

232617 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE.  (PHD.  DISSERTATION), 

241100 
REDUCTION  OF  ALCOHOL  SELECTION  BY  PARGYLINE  IN  MICE. 

241225 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE, 

241253 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  I 
SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES, 

249121 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANC 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH). 

250110 


S-280 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFIEX 

THE  EFFECTS  OF  NEUROLEPTICS  AND  NIALAMIDE  ON  DEFENSIVE 
CONDITIONED  REFLEX  IN  RATS 

227637  01-04 
STUDY  OF  THE  ACTION  OF  SOME  CENTRALLY  ACTING  DRUGS  ON  THE 
EEG  AND  ON  A  CONDITIONED  AVOIDANCE  REFLEX  IN  THE  RABBIT. 

230860  01  03 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 
MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-04 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 
METHOXAMINE  (M)  AND  D  AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-04 
EFFECT  OF  SOME  INTRACEREBRALLY  ADMINISTERED  DRUGS  ON  A 
CONDITIONED  REFLEX  IN  THE  CAT. 

239275  03-04 
USE  OF  THE  IMMOBILITY  REFLEX  (ANIMAL  HYPNOSIS)  IN 
NEUROPHARMACOLOGICAL  STUDIES. 

250071  04-06 
INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2F1  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  04-04 
EFIEXES 

EFFECT  OF  5,5  DIPHENYLHYDANTOIN  ON  FIXED  CONDITIONED  REFLEXES 
IN  CATS. 

229681  01-04 
THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS. 

231069  01-04 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-03 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT;  III.  PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT. 

240220  03  14 
ON  MONOAMINERGIC  MECHANISMS  OF  THE  AMYGDALA  COMPLEX 
IMPLEMENTING  CONDITIONED  REFLEXES  OF  VARIOUS  BIOLOGICAL 
MODALITIES. 

241980  03-03 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE. 

244352  04-04 
EFRACTORINESS 

USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 

REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS 

250278  04-03 
EFRACTORY 

VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01  08 
AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH.D 
DISSERTATION). 

241129  03  03 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
EGIMEN 

NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  ON 
STEADY-STATE  BLOOD  LEVELS. 

245842  04-08 
EGIMENS 

PIRIBEDIL:  ITS  SYNERGISTIC  EFFECT  IN  MULTIDRUG  REGIMENS  FOR 
PARKINSONISM. 

251651  04-07 
EGION 

A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN. 

231304  01  03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS-COERULEUS  IN  RATS 

249076  04-04 
IGISTRATION 

AUTOMATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE  AND 
NORADRENALINE  TRANSMISSION. 

250086  04-04 


REGULATING 

EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 
FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
REGULATION 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS. 

226185  01-04 
REGULATION  OF  5-HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
BRAIN  BY  ADRENAL  GLUCOCORTICOIDS. 

226401  01-03 
NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01-03 
REGULATION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSINE 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  01-03 
CAMP  CONTENT  AND  THE  REGULATION  OF  TYROSINE-3- 

MONOOXYGENASE  IN  RAT  STRIATUM.  (UNPUBLISHED  PAPER). 

232921  02-03 
REGULATION  OF  FUNCTION  OF  TRYPTOPHAN-HYDROXYLASE. 

233958  02-03 
TRYPTOPHAN  REGULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE. 

239581  03-03 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  THE 
REGULATION  OF  EMOTIONAL  REACTIVITY. 

242544  03-03 
CENTRAL  GAMAAA-AMINOBUTYRIC-ACID  RECEPTORS  AND  THE 

REGULATION  OF  35  CYCLIC  ADENOSINE  MONOPHOSPHATE  CONTENT 
IN  RAT  PITUITARY.  (UNPUBLISHED  PAPER). 

243041  04-03 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  AFTER  PHENOTHIAZINE  TREATMENT. 

243193  04  10 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR. 

243234  04-04 
NEUROTRANSMITTER  REGULATION  OF  ADENOSINE  3,5  MONOPHOSPHATE 
IN  CLONAL  NERVE,  GLIA,  AND  MUSCLE  CELL  LINES. 

243482  04-03 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04-03 
REGULATION  OF  ADRENAL  TYROSINE-HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

244314  04-03 
THYROTROPIN-RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATION  IN 
THE  NONLESIONED  RAT. 

247514  04-03 
ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CEREBRAL 
BLOOD  CIRCULATION. 

248552  04-03 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
MONOAMINES  AS  POSSIBLE  MEDIATORS  IN  THE  REGULATION  OF  FAST 
AXOPLASMIC  FLOW. 

253407  04-03 
REGULATORS 

OPIATE  RECEPTORS  AS  REGULATORS  OF  ADENYLATE-CYCLASE. 
(UNPUBLISHED  PAPER). 

237175  02-03 
REGULATORY 

THE  THERAPY  OF  AUTONOMIC  REGULATORY  DISTURBANCES  THROUGH 
DRUGS 

232260  01-15 
NEUROPSYCHOPHARAMCOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES. 

233941  02-03 
NEUROPSYCHOPHARMACOLOGY  OF  MONOAMINES  AND  THEIR 
REGULATORY  ENZYMES 

237829  02-17 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
ESTRADIOL  BENZOATE.  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 
BEHAVIOR  IN  FEMALE  RATS. 

250012  04-04 
REHABILITATION 

DRUG  TREATMENT  IN  A  REHABILITATION  CENTER  FOR  CHRONIC 
ALCOHOLICS. 

228908  01-11 
REINFORCED 

TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED  RATIO  WATER 
REINFORCED  RESPONDING  IN  RATS. 

230842  01  04 


S-281 


Subject  Index 


BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 

COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02-04 
REINFORCEMENT 

EFFECTS  OF  D-AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 
MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT 

226852  01-04 
SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 

FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
THE  IMPORTANCE  OF  REINFORCEMENT  SCHEDULES  IN  DETERMINING 

EFFECTS  OF  DRUGS. 

229428  01-04 
INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  PARTIAL 
REINFORCEMENT  EFFECTS. 

230875  01-04 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS  A  TEST  OF  HILLS  HYPOTHESIS. 

237711  02-04 
THE  EFFECTS  OF  N  DIPROPYLACETATE  ON  THE  ACQUISITION  OF 
CONDITIONED  BEHAVIOUR  WITH  NEGATIVE  REINFORCEMENT  IN  MICE. 

237723  02-04 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

241250  03-04 
EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 
ADMINISTRATION:  DETERMINATION  OF  REINFORCEMENT  MAGNITUD 

250010  04-04 
REINFORCER 

ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL 

227128  01-04 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
REINFORCERS 

PSYCHOTROPIC  DRUGS  AS  NEGATIVE  REINFORCERS. 


DRUG  INJECTIONS  AS  NEGATIVE  REINFORCERS. 


SB! 


240020  03-04 

240022  03-04 
REINFORCING 

FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE-DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-04 
ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF  ADMINISTERING  RATS. 

250941  04-04 
REINITIATION 

REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04-04 
REINSERTION 

THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS. 

229552  01-17 
REINSTATEMENT 

REINSTATEMENT  OF  EATING  BY  DOPAMINE  AGONISTS  IN  APHAGIC 
DOPAMINE  DENERVATED  RATS. 

243348  04-04 
RELAPSE 

MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE:  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 
WITHDRAWAL  CAUSES  RELAPSE?.  OUR  RESPONSE. 

252848  04-08 
RELAPSES 

SCHIZOPHRENIA:  AN  END  TO  RELAPSES. 

241459  03-08 
RELAPSING 

REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-04 
RELAY 

RELAY  TOXICITY:  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED 

245114  04-06 
RELEASE 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA-PIG  LUNG  BY  (-)  TRANS-DELTA9- 
TETRAHYDROCANNABINOL. 

226762  01-03 


Psychopharmacology  Abstracts 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG 

226855  01  03 
ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-03 
INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 

NOREPINEPHRINE  FROM  GUINEA-PIG  VAS-DEFERENS.  (UNPUBLISHED 
PAPER). 

227777  01-03 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS. 

228550  01-03 
THE  RELEASE  OF  GLUTAMIC-ACID  FROM  ISOLATED  BRAIN  TISSUES. 

236522  02-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYCROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
EFFECT  OF  ANGIOTENSIN  II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 
OF  C14-5-HYDR0XYTRYPTAMINE  BY  RAT  BRAIN. 

237739  02-03 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS. 

238681  03-03 
THE  EFFECT  OF  PARGYLINE  ON  THE  RELEASE  OF  ENDOGENOUS 

NOREPINEPHRINE  BY  N-ETHYLAMPHETAMINE  AND  FENFLURAMINE 

238688  03-03 
EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 

OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-03 
RELEASE  OF  NOREPINEPHRINE  (NE)  AND  DOPAMINE-BETA-HYOROXYLASE 

(DBH):  EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8-BROMO-CGMP  AND  DIBUTYRYL-CAMP. 

238690  03-03 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 

WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 

AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 

SUBSTANCE  IN  THE  RAT. 

238713  03-04 
EVIDENCE  FOR  A  BETA-ADRENERGIC  RECEPTOR  MEDIATED  POSITIVE 

FEEDBACK  MECHANISM  REGULATING  RELEASE  OF  NOREPINEPHRINE. 

238727  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 

ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 

SYNAPTOSOMES. 

238729  03-03 
AMFONELIC-ACID  FACILITATION  OF  IMPULSE-INDUCED  STRIATAL 

DOPAMINE  RELEASE. 

238730  03-03 
RELEASE  OF  H3-ALPHA-METHYL-TYRAMINE  FROM  CORPUS-STRIATUM  IN 

VITRO  AND  THE  EFFECTS  OF  GLUCOSE  DEPRIVATION. 

238731  03-03 
EFFECTS  OF  TRANQUILIZER  DRUGS  ON  GABA  RELEASE  IN  VITRO. 

238779  03-03 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE. 

239828  03-03 
A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM. 

241206  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-00PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
EFFECTS  OF  THE  D-ISOMERS  AND  L-ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE,  RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN 

241345  0303 
EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FROG 
SPINAL  CORD. 

241922  0303 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROAAAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT 

243951  04-03 
BENZTROPINE-INDUCED  RELEASE  OF  DOPAMINE  FROM  BRAIN  IN  VIVO. 

245598  04  03 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V,  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04  03 


S-282 


LUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  8RAIN 
CORTICAL  SLICES 

246850  04-03 
INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE,  BUT 
NOT  OF  OOPAMINE-BETA-HYDROXYLASE  FROM  GUINEA-PIG  VAS- 
DEFERENS  (UNPUBLISHED  PAPER) 

247028  04-03 
DEPOT  FLUPHENAZINE-ENANTHATE  AND  FLUPHENAZINE-DECANOATE- 
COMPARATIVE  RATES  OF  RELEASE  IN  DOGS. 

247130  04-03 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT. 

247731  04-03 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04-03 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04-03 
DEPRESSION  OF  DOPAMINE  RELEASE  DURING  THE  ETHANOL 
WITHDRAWAL  SYNDROME. 

249293  04-03 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOAAAL 
ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION. 

249295  04-03 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-03 
DOPAMINE  RELEASE  IN  SUBSTANTIA-NIGRA? 

249984  04-03 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 
EFFECT  OF  ETHANOL  ON  DOPAMINE  SYNTHESIS  AND  RELEASE  FROM  RAT 
CORPUS-STRIATUM. 

251178  04  03 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 
CORTEX.  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS. 

251964  04-03 
CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6- 
HYOROXYDOPAMINE  AND  DESIPRAMINE. 

252024  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04-03 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-03 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 
ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H-5  HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX 

253691  04-03 
IVSER 

3-AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENIC 
AMINES  IN  SYNAPTOSOMES. 

246665  04-03 
\SING 

^MPHETAMINE■  EVALUATION  OF  D-ISOMERS  AND  L-ISOMERS  AS 
RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H  DOPAMINE  AND 
3H  NOREPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX. 

248699  04-03 
VING 

^  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY. 

250175  04-15 

:HANGES  in  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
(EM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOIUNTEERS   (UNPUBLISHED  PAPER) 

232760  02-14 
FFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY). 

233077  02-04 
HE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT 

237780  02-04 
'AlUE  OF  REM  SLEEP. 

239258  03  14 


NARCOLEPSY:  REM  SLEF"  SUPPRESSION  BY  L-DOPA. 

240657  03-11 
REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-04 
REMISSION 

REMISSION  OF  VITILIGO  AND  SALT  MEDICATION 

241849  03-09 
REMITTED 

COMPARISON  OF  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE, 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04-08 
REMOVAL 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION). 

227074  01-04 
OLFACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 
LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  0304 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
THE  MODE  OF  LIPOFUSCIN  REMOVAL  FROM  HYPOTHALAMIC  NEURONS, 

246587  04-03 
RENAL 

UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE,  RENAL  FAILURE  AND  BRAIN  DAMAGE:  CASE  REPORT. 

245856  04-13 
EFFECT  OF  INTRAVENOUS  DIAZEPAM  ON  RENAL  FUNCTION. 

246273  04-15 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
RENIN 

RENAL  LITHIUM.  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF  LITHIUM  CARBONATE. 

249673  04-13 
RENSHAW 

ALPHA-BUNGAROTOXIN,  COBRA  NEUROTOXIN  AND  EXCITATION  OF 
RENSHAW  CELLS  BY  ACETYLCHOLINE 

244203  04-03 
REPEATED 

INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 

HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATION 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZINE. 

227129  01-04 
BEHAVIORAL  AND  NEUROCHEMICAL  CORRELATES  OF  REPEATED  D 
AMPHETAMINE  ADMINISTRATION. 

234809  02-04 
ADAPTIVE  CHANGES  IN  BEHAVIOR  AFTER  REPEATED  ADMINISTRATION 

OF  VARIOUS  PSYCHOACTIVE  DRUGS 

234810  02-04 
MODIFICATIONS  OF  EFFECTS  OF  CHLORPROMAZINE  ON  ADRENERGIC 

DRUGS  AND  BARBITURATES  BY  REPEATED  ADMINISTRATION  TO  RATS. 

241406  03-03 
EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS. 

248629  04-13 
ENHANCEMENT  OF  RESERPINE  ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL  P  TYROSINE. 

249002  04-03 
AVERSIVE  EFFECTS  OF  REPEATED  INJECTIONS  OF  THC  IN  RATS 

249158  04-04 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS 

253111  04  04 
REPLACEMENT 

EFFECTS  OF  INTRAVENTRICULAR  6  HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF  STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT, 

232332  01-04 
REPLETION 

RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L  TRYPTOPHAN  INJECTION 

226873  01-03 
REPLICATION 

LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL  BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03  1 1 


S-283 


Subject  Index 


Psychopharmacology  Abstract 


"=^1 


e 


so 

3»^ 


REPRODUCTION 

BENZODIAZEPINES  AND  REPRODUCTION  OF  SWISS-WEBSTER  MICE. 

243788  04-04 
REQUIREMENT 

CURRENT  DETERMINATION  OF  LITHIUM-INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS, 

237110  02-04 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N  ACFTYITRANSFERASE. 

243795  04-03 
REQUIREMENTS 

CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 
INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P-TYROSINE 
ON  SCHEDULE-CONTROLLED  PERFORMANCE  IN  RATS. 

238844  03-04 
RESEARCH 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION. 

225721  01-17 
A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

227914  01-10 
A  COMBINATION  OF  ANTIANXIETY  DRUGS:  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP. 

228207  01-10 
RECENT  PROGRESS  IN  THE  LONG  TERM  PHARMACOLOGICAL  RESEARCH 
ON  CANNABIS. 

229043  01-17 
STRATEGIES  OF  BASIC  RESEARCH  IN  DEVELOPMENT  OF  DRUGS. 

229429  01-06 
PSYCHOPHARMACOLOGY  RESEARCH  CENTER. 

229497  01-03 
PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 
RESEARCH. 

231066  01-14 
A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
IMPACT  OF  PSYCHOSOCIAL  FACTORS  ON  THE  CONDUCT  OF  COMBINED 
DRUG  AND  PSYCHOTHERAPY  RESEARCH. 

235534  02-17 
BIOCHEMICAL  RESEARCH  INTO  PSYCHOSIS:  RESULTS  OF  A  NEW 
RESEARCH  STRATEGY. 

238997  03-13 
BIOCHEMICAL  RESEARCH  IN  SCHIZOPHRENIA:  RESULTING  IN  A  NEW 
RESEARCH  STRATEGY. 

241912  03-08 
CLINICAL  RESEARCH  WITH  DEMETRIN  IN  SURGERY  PATIENTS. 

242527  03-07 
ON  PSYCHOPHARMACEUTICAL  RESEARCH  AND  THE  UNDERSTANDING  OF 
SCHIZOPHRENIA. 

244037  04-17 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES-  A 
SUMMARY  OF  RESEARCH  FINDINGS. 

247384  04-14 
DRUG  RESEARCH  AND  THE  QUESTION  OF  CONSENT 

252314  04-17 
RESERPINE 

INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

226935  01-03 
THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 

ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS. 

227635  01-03 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT. 

235649  02-03 
CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL-AMPHETAMINE  AIJD 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION. 

236235  02-03 
RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02-04 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE  BETA  HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

237103  02-04 


NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

237756  02-C 
INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE- 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02-C 
ANATOMICAL  ORGANIZATION  OF  THE  PHASIC  ACTIVITIES  PRODUCED  B' 
RESERPINE  AT  THE  LEVEL  OF  THE  OCULOMOTOR  SYSTEM. 

238503  02-C 
RATE  OF  BIOSYNTHESIS  OF  DOPAMINE-BETA-HYDROXYLASE  IN  LOCUS- 
COERULEUS  OF  RAT  BRAIN  AFTER  RESERPINE. 

238759  03-C 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE-BLIND  TRIAL. 

239348  03-C 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS. 

242732  03-C 
EFFECTS  OF  RESERPINE  ON  AAATURING  ADRENAL  MEDULLA. 

243796  04-C 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT  -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME:  III: 
THE  INCORPORATION  OF  D-GLUC0SE-14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-C 
RESERPINE  AND  THE  INDUCTION  OF  DEPRESSION:  A  CASE  REPORT. 

245016  04-C 
THE  EFFECTS  OF  GANGLIONIC  BLOCKADE,  RESERPINE  AND  VINBLASTINE 
ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETA-HYDROXYLASE 
IN  THE  RAT. 

246843  04-C 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA  HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-0 
MODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE. 

248289  04-0 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

248964  04-0 
EFFECTS  OF  PRENATAL  RESERPINE  ADMINISTRATION  ON  DEVELOPMENT 
OF  THE  RAT  ADRENAL  MEDULLA  AND  CENTRAL-NERVOUS-SYSTEM. 

253110  04-0 
RESERPINE-ELICITED 

ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL  P- TYROSINE. 

249002  04-0: 
RESERPINE-INDUCED 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 

ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY) 

233077  02-a 
RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-0: 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04-0: 
RESERPINE-LIKE 

RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOQUINOLIZINE  DERIVATIVE  WITH 
RESERPINE-LIKE  PROPERTIES. 

246844  04-03 
RESERPINIZEO 

THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZEO. 

248952  04-03 
RESERVE 

SELF-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST. 

246774  04-03 
RESIDUAL 

THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM,  ALONE  AND  IN  COMBINATION  WITH  ALCOHOL. 

244960  04-13 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION. 

249268  04-03 


S-284 


/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


tESIN 

EFFECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  AAOUSE 

225569  01-04 
CANNABIS  RESIN  AND  SEXUAL  BEHAVIOUR  IN  THE  LABORATORY 
MOUSE. 

237715  02-04 
lESISTANCE 

PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS:  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION. 

236801  02-13 
RESISTANCE  OF  ANDROGEN  MEDIATED  AGGRESSIVE  BEHAVIOR  IN  MICE 
TO  FLUTAMIDE,  AN  ANTIANDROGEN 

244685  04-04 
ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT. 

251820  04-03 
ESISTANT 

HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02-17 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE  BLIND  TRIAL 

239348  03-09 
ESOCIALIZING 

THE  RES0CIALI2ING  EFFECT  OF  CLOTHIAPINE  IN  CHRONIC  PSYCHOSES. 

230993  01  11 
ESPECTIVE 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L  CARROLL 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 
OF  NOVERIL. 

245971  04-06 
ESPIRATORY 

RESPIRATORY  EFFECTS  OF  LORAZEPAM,  PENTOBARBITAL   AND 
PENTAZOCINE. 

226828  01-15 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES- 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03  03 
EFFECTS  OF  AZAPERONE  ON  CARDIOVASCULAR  AND  RESPIRATORY 
FUNCTIONS  IN  THE  HORSE. 

243759  04-03 
ESPONDERS 

ACUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS, 

253617  04-09 
ESPONSE 

THIORIDAZINE  PLASMA  LEVELS  AND  CLINICAL  RESPONSE. 

225932  01-08 
INTRAVENOUS  TYRAMINE  PRESSOR  RESPONSE  IN  DEPRESSION. 

226187  01-10 
SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
THE  EFFECTS  OF  NEONATAL  6  HYDROXYDOPAMINE  INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION. 

226871  01  03 
EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  Of  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01-04 
BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES. 

227694  01-03 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN, 

229042  01-13 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS 

229444  01-08 
CHLORPROMAZINE  METABOLISM  AND  CLINICAL  RESPONSE  IN  ACUTE 

I         SCHIZOPHRENIA:  A  PRELIMINARY  REPORT. 

229445  01-08 
PREDICTION  OF  RESPONSE  TO  DRUG  AND  GROUP  PSYCHOTHERAPY  IN 

DEPRESSED  OUTPATIENTS. 

229449  01  09 
RESPONSE  OF  THE  ELDERLY  TO  PSYCHOTROPIC  DRUGS    PREDICTABLE  OR 
IDIOSYNCRATIC 

229457  01   H 
COGNITIVE  DEFICITS  ASSOCIATED  WITH  CHRONIC  HEPATIC 
ENCEPHALOPATHY  AND  THEIR  RESPONSE  TO  LEVODOPA. 

230580  01  15 


RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 

CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 
MODIFICATION  OF  THE  BEHAVIORAL  RESPONSE  TO  DRUGS  IN  RATS 
EXPOSED  PRENATALLY  TO  CHLORPROMAZINE 

230864  01-04 
PHARAAACOLOGICAL  RESPONSE  DATA  FOR  COMPARATIVE 

BIOAVAILABILITY  STUDIES  OF  CHLORPROMAZINE  ORAL  DOSAGE 
FORMS  IN  HUAAANS:  I.  PUPILOMETRY 

232623  02-13 
POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOAMNIA 
SECONDARY  TO  ORGANIC-BRAIN-SYNDROME 

23471 1  02  09 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
DIFFERENTIAL  RESPONSE  CONTROL  BY  ISOPROPAMIDE:  A  PERIPHERALLY 
INDUCED  DISCRIMINATIVE  CUE. 

237744  02-04 
INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RtSERPINE: 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02-03 
PRETREATMENT  CPK  AND  CLINICAL  RESPONSE  TO  ANTIPSYCHOTIC 
MEDICATION.  (UNPUBLISHED  PAPER). 

238489  02-08 
ANALYTICAL  STUDY  OF  ACQUISITION  ON  FREE-OPERANT  AVOIDANCE 
RESPONSE  FOR  EVALUATION  OF  PSYCHOTROPIC  DRUGS  IN  RATS. 

238564  02-04 
LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS 

238741  03-03 
PASSIVE  BARBITURATE  IMMUNITY  IN  Ay\ICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
RESPONSE  TO  DELTA9-TETRAHYDRUCANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING,  VIRGIN  FEMALE.  AND  MALE  MICE 

238766  03-03 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL:  POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK. 

238795  03-03 
ENVIRONMENTAL  INFLUENCES  ON  THE  BEHAVIORAL  RESPONSE  TO  ACUTE 
AND  CHRONIC  AMPHETAMINE  ADMINISTRATION. 

238843  03-04 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 

INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P- TYROSINE 
ON  SCHEDULE  CONTROLLED  PERFORMANCE  IN  RATS. 

238844  03-04 
CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRUGS 

AS  CONDITIONED  STIMULI.  (PH  D.  DISSERTATION). 

239523  03-04 
EFFECTS  IF  SOME  DRUGS  ON  PSYCHOSEXUAL  RESPONSE  IN  MAN. 

239646  03-14 
IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS-COERULEUS  BY  6-OH-DOPAMINE. 

239841  03-04 
EFFECT  OF  CANNABINOIDS  ON  THE  ABDOMINAL  CONSTRICTION 
RESPONSE  IN  MICE:  WITHIN  CANNABINOID  INTERACTIONS. 

239859  03-03 
LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMAL-BRAIN- 
DYSFUNCTION:  REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03-11 
DEPRESSED  5  HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR:  RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03-13 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  ELECTRODERMAL  RESPONSE 
IN  THE  CAT. 

239963  03-03 
P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS 

240062  03-04 
APOMORPHINE  INDUCED  HYPERTHERMIA  IN  THE  RABBIT,  A 

PHARMACOLOGICAL  STUDY  OF  THE  NEUROAMINERGIC  MECHANISMS 
UNDERLYING  THE  RESPONSE    (PH.D.  DISSERTATION). 

240936  03-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO 

241313  03  03 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF  STIMULATION 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375  03-04 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  0304 


S-285 


Subject  Index 


o 


EFFECTS  OF  PERIMETAZINE  AND  CH10RPR0MA2INE  ON  THE 
TRANSCALLOSAL  RESPONSE  IN  RABBITS 

241385  03-03 
VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE.  (PH.D.  DISSERTATION) 

241689  03-04 
EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES. 

241988  03-03 
EFFECT  OF  PROLONGED  LITHIUM  INGESTION  ON  THE  RESPONSE  TO 
MINERALOCORTICOIDS  IN  RATS. 

244651  04-03 
INTRAVENOUS  L-DOPA  PLUS  CARBIDOPA  IN  DEPRESSED  PATIENTS 
AVERAGE  EVOKED  RESPONSE,  LEARNING,  AND  BEHAVIORAL  CHANGES. 

244664  04-09 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  PENTOBARBITAL  ON 
A  CORTICAL  RESPONSE  EVOKED  DURING  CONDITIONING. 

244693  04-03 
DEPRESSION,  DELUSION  AND  DRUG  RESPONSE. 

245784  04-09 
PREDICTION  OF  RESPONSE  TO  CHLORPROMAZINE  TREATMENT  IN 
SCHIZOPHRENICS. 

246314  04  08 
LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE   CATECHOL- 
0-METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246629  04-09 
ELECTROPHYSIOLOGICAL  EVIDENCE  FOR  A  NEUROHORMONAL 

DEPENDENCE  IN  THE  CHANGES  OF  THE  LATE  GLABELLAR  RESPONSE  IN 
MAN. 

246992  04-13 
EFFECT  OF  MORPHINE  ON  A  DEPOLARISING  DOPAMINE  RESPONSE. 

246998  04-03 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
HABITUATION  TO  ITERATIVE  PHOTOSTIMULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE,  ITS  DELAY  BY 
PSYCHOANALEPTICS 

248514  04-04 
BARBITURATE  RESPONSE  IN  IMMUNIZED  MICE. 

249297  04-03 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS. 

249484  04-03 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
THE  ENDOGENOUS  NEUROTIC  DISTINCTION  AS  A  PREDICTOR  OF 
RESPONSE  TO  ANTIDEPRESSANT  DRUGS. 

250726  04-11 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-15 
A  PRESSOR  RESPONSE  TO  INTRAVENTRICULAR  INJECTIONS  OF 
CARBACHOL 

251142  04-03 
CLINICAL  RESPONSE  TO  A  POTENTIAL  NONSEDATIVE  ANXIOLYTIC. 

251719  04-07 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY- 
SERUM  LITHIUM  LEVELS.  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04-15 
A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE. 

251951  04-04 
THE  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  AND  LSD  ON  THE 
ACQUISITION  OF  AN  ACTIVE  AVOIDANCE  RESPONSE  IN  THE  RAT. 

251979  04-04 
THE  RELATIONSHIP  BETWEEN  ACETYLATOR  STATUS  AND  INHIBITION  OF 
MONOAMINE-OXIDASE,  EXCRETION  OF  FREE  DRUG  AND 
ANTIDEPRESSANT  RESPONSE  IN  DEPRESSED  PATIENTS  ON  PHENELZINE. 

251985  04-10 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE. 

251989  04-04 
DEPRESSION  OF  GROWTH  HORMONE  AND  CORTISOL  RESPONSE  TO 
INSULIN-INDUCED  HYPOGLYCEMIA  AFTER  PROLONGED  ORAL  DELTA9- 
TETRAHYDROCANNABINOL  ADMINISTRATION  IN  MAN. 

252327  04-13 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
WITHDRAWAL  CAUSES  RELAPSE?    OUR  RESPONSE. 

252848  04-08 
RELATIONSHIP  BETWEEN  DOSAGE  AND  RESPONSE  TO  LITHIUM 
PROPHYLAXIS  IN  RECURRENT  DEPRESSION. 

252954  04-09 


Psychopharmacology  Abstro 

THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAA 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  W 
LITHIUM  OR  RUBIDIUM. 

253593  0 
RESPONSES 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOW 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPU 
STRIATUM. 

226937  C 
DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC- 
INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINE-DEPENDE 
RATS. 

227702  Q 
ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLOROIAZEPOXIDl 
AN  INTENSIVE  DESIGN  STUDY. 

228221  0 
BLOOD  LEVEL,  MOOD,  AND  MHPG  RESPONSES  TO  DIAZEPAM  IN  MAh 

229440  0 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  0 
RELATIONS  BETWEEN  ORIENTING,  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX  -  A 
PHARMACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAML 

230570  0 
RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  0 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  B 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  0 
INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEP/ 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION. 

231039  0 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATIi 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE-BLIND 
STUDY. 

232781  O: 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  O; 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENT0BAR6ITA 
ON  AUDITORY  EVOKED  RESPONSES. 

234682  O: 
INDIVIDUAL  RESPONSES  TO  METHYLPHENIDATE  AND  CAFFEINE  IN 
CHILDREN  WITH  MINIMAL-BRAIN-DVSFUNCTION. 

235322  O; 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLIN 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  1 
RAT  SPINAL  CORD. 

235863  O: 
INHIBITORY  SYNAPSES  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  THEIf 
PHARMACOLOGICAL  RESPONSES. 

236368  OJ 
MORPHINE-INDUCED  INHIBITION  OF  DIFFERENT  PAIN  RESPONSES  IN 
RELATION  TO  THE  REGIONAL  TURNOVER  OF  RAT  BRAIN 
NORADRENALINE  AND  DOPAMINE. 

237697  02 
DRUG  DISSOCIATION  OF  NEUROELECTRICAL  AND  BEHAVIORAL 
RESPONSES  IN  MICE.  (PH.D.  DISSERTATION). 

238159  02 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02 
RESPONSES  OF  NORMAL  AND  ISOLATE  MONKEYS  TO  D-AMPHETAMINE 
COCAINE,  CHLORPROMAZINE  AND  DIAZEPAM. 

238694  03 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03- 
EFFECTS  OF  DIPHENYLHYDANTOIN  AND  DIAZEPAM  ON  HIPPOCAMPAL 
EVOKED  RESPONSES. 

239961  03- 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  II 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03- 


S-286 


VOLUME  14,  SUBJECT  INDEX 


ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AND 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS 

240064  03-03 
THE  EFFECTS  OF  NOREPINEPHRINE  BIOSYNTHESIS  INHIBITION  ON  THE 
CONSOLIDATION  OF  TWO  DISCRIMINATED  ESCAPE  RESPONSES. 

241301  03-04 
EFFECTS  OF  CHRONIC  ADMINISTRATION  OF  MORPHINE  ON 
PENTOBARBITAL  RESPONSES  IN  THE  MOUSE 

241338  03-03 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS. 

241389  03-03 
THE  GENETIC,  BIOCHEMICAL  AND  PHAR/WACOLOGICAL  CORRELATES  OF 
RESPONSES  TO  PRIMING  IN  MICE.  (PH.D.  DISSERTATION). 

241687  03-04 
THE  INTERPRETATION  OF  RESPONSES  OF  MOTONEURONE  FIELD 
POTENTIALS  TO  5-HYDROXYTRYPTAMINE 

241923  03-03 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS. 

241979  03-04 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN. 

242736  03-03 
RESPONSES  OF  NEURONES  IN  THE  CEREBRAL  CORTEX  AND  CAUDATE 
NUCLEUS  TO  AMANTADINE,  AMPHETAMINE  AND  DOPAMINE. 

243805  04-03 
DRUGS,  AROUSAL,  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-14 
EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAL  SCHEDULE. 

245303  04-04 
ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICALS. 

248163  04-02 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
DRUG-INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT. 

249250  04-03 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

251070  04-03 
INHIBITION  AND  ENHANCEMENT  OF  PHOTICALLY  EVOKED  RESPONSES  BY 
DIFFERENT  DOSES  OF  L-DOPA. 

251214  04-03 
POTENTIATION  BY  DESIPRAMINE  OF  NEURONAL  RESPONSES  TO 
MESCALINE. 

251705  04-03 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMAIf  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE. 

251981  04-04 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS   III 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04-03 
DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCCO- 
LINGUAL  DYSKINESIAS. 

252031  04-03 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
RESPONSIBLE 

METHYLENE-REDUCTASE:  RESPONSIBLE  FOR  THE  IN  VITRO  FORAMTION 
OF  FORMALDEHYDE  FROM  5-METHYLTETRAHYDROFOLIC-ACID. 

232613  02-03 
RESPONSIVE 

FOLATE  RESPONSIVE  SCHIZOPHRENIA. 

227711  0111 
PAROXYSMAL  NIGHTMARES:  SEQUEL  OF  A  STROKE  RESPONSIVE  TO 
DIPHENYLHYDANTOIN. 

233295  02-14 
RESPONSIVENESS 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE   (PH.D.  DISSERTATION). 

227074  01-04 


Subject  Index 

TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II    BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS. 

235367  02-09 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  III. 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS. 

235368  02  09 
ALTERED  HYPOTHERMIC  RESPONSIVENESS  10  (.  +  )  AMPHETAMINE. 

239685  03-03 
REST 

EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02  04 
RESTING 

THE  EFFECTS  OF  PUTATIVE  NEUROTRANSMITTERS  ON  THE  RESTING 
MEMBRANE  POTENTIAL  OF  DISSOCIATED  BRAIN  NEURONS  IN 
CULTURE. 

244199  04-03 
RESTLESSNESS 

CLINICAL  EXPERIENCES  WITH  THE  BENZODIAZEPINE  DERIVATIVE 
BROMAZEPAM  IN  CONNECTION  WITH  AN  ACUTE  STATES  OF 
RESTLESSNESS  AND  EXCITATION  IN  PSYCHIATRY, 

237458  02  10 
RESTORATION 

CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPRO/VWZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIAAAL  REST 

236372  02-04 
RESTRICTED 

EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  D- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS. 

253111  04-04 
RESTRICTION 

EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA- 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT 

249278  04-04 
RETAIN 

NORMAL  GLUTAMIC-DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AND 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA. 

253695  04-03 
RETARDATES 

STATE-DEPENDENT  LEARNING  IN  RETARDATES  USING  THIORIDAZINE 
(PH.D.  DISSERTATION). 

228420  01  14 
PIPAMPERONE  (DIPIPERON,  R-3-345)  IN  TROUBLESOME  MENTAL 
RETARDATES:  A  DOUBLE-BUND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03  1 1 
RETARDATION 

CORRELATIONS  BETWEEN  THE  EFFECTS  OF  DL-AMPHETAMINE  AND 
RESERPINE  ON  THE  MODEL  OF  THE  CAUDATE  REACTION  OF 
RETARDATION 

236235  02-03 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHENOBARBITAL. 

250682  0405 
RETARDED 

OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTALLY  RETARDED  CHILDREN. 

245806  04-15 
PHENYTOIN-INDUCED  DYSTONIA  AND  CHOREOATHETOSIS  IN  TWO 
RETARDED  EPILEPTIC  CHILDREN. 

251654  04-15 
RETENTION 

EFFECTS  OF  PHYSOSTIGMINE  ON  AVOIDANCE  CONDITIONING  AND 
RETENTION  IN  THE  ISOLATED  COCKROACH  GANGLION   (PH  D 
DISSERTATION). 

228503  01-04 
FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 
UCS  HABITUATION 

241521  03  04 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT 

241546  0304 
STATE-DEPENDENT  (DISSOCIATIVE)  EFFECTS  OF  METHADONE  ON  HUMAN 
RETENTION.  (PH.D.  DISSERTATION). 

242151  03-14 
DOSE-RELATED  EFFECTS  OF  METRAZOL  ON  RETENTION  AND  EEG 

242733  03-04 


S-287 


Subject  Index 


Psychopharmacology  Abstract 


O 


CSJ 

so 

3a: 


TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04-04 
STATE-DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST. 

243013  04  04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  ACTIVE  AVOIDANCE 
ACQUISITION  AND  PASSIVE  AVOIDANCE  RETENTION  IN  RATS  WITH 
AMYGDALOID  LESIONS. 

246819  04-04 
SYMPOSIUM  ON  PHARMACOLOGY  OF  LEARNING  AND  RETENTION. 

249787  04-17 
EFFECT  OF  PHYSOSTIGMINE  ON  Y-AAAZE  DISCRIMINATION  RETENTION  IN 
THE  RAT. 

251982  04-04 
RETICULAR 

DIFFERENTIAL  EFFECTS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY. 

230840  01-03 
CHOLINERGIC  MEDIATION  OF  THE  INHIBITORY  EFFECT  OF 

METHYLPHENIDATE  ON  NEURONAL  ACTIVITY  IN  THE  RETICULAR 
FORMATION, 

239086  03-03 
BLOCKADE  OF  THE  ELECTROCORTICAL  CHANGES  INDUCED  BY  PERFUSION 
OF  AMPHETAMINE  IN  THE  BRAINSTEM  RETICULAR  FORMATION. 

241930  03-03 
RETINA 

SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA. 

236863  02-03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
RETRIEVAL 

EFFECTS  OF  DIAZEPAM  AND  SCOPOLAMINE  ON  STORAGE,  RETRIEVAL 
AND  ORGANIZATIONAL  PROCESSES  IN  MEMORY. 

237722  02-14 
STATE-DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST. 

243013  04-04 
VERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE. 

251939  04-14 
RETROACTIVE 

RETROACTIVE  AND  PROACTIVE  EFFECTS  OF  ANESTHESIA  ON  FOLLOWING 
IN  CHICKS. 

241330  03-04 
RETROACTIVE  IMPAIRMENT  OF  COOPERATIVE  LEARNING  BY  IMIPRAMINE 
AND  CHLORDIAZEPOXIDE  IN  RATS. 

245301  04-04 
RETROGRADE 

RETROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK. 

237260  02-04 
RETROSPECTIVE 

A  RETROSPECTIVE  ASSESSMENT  OF  THE  LONG  TERM  EFFECTS  OF 
DOTHIEPIN. 

239820  03  09 
INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN 
ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  03-08 
REUPTAKE 

THE  SELECTIVE  INHIBITION  OF  5-HYDROXYTRYPTAMINE  REUPTAKE  BY 
ORG-6582 

241924  03-03 
D-AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENIC 
AMINES  IN  SYNAPTOSOMES. 

246665  04-03 
REUSABLE 

CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS 

237270  02-06 
REVERSAL 

REVERSAL  BY  PHYSOSTIGMINE  OF  CLOZAPINE-INDUCED  DELIRIUM 

237647  02-14 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE. 

238687  03-04 
NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA; 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 


THE  REVERSAL  OF  APOMORPHINE-ELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE- HYDROXYLASE  ACTIVITY  BY 
NEUROLEPTICS. 

238758  03-( 
METHYLPHENIDATE  ADDICTION    -  EFFECT  REVERSAL  IN  WITHDRAWAL. 

238862  03-' 
DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING, 
(PH.D.  DISSERTATION). 

239533  03-( 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLICAMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-( 
REVERSAL  OF  THE  6  HYDROXYDOPAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-( 
MODIFICATION  OF  THE  L-DOPA  REVERSAL  OF  RESERPINE  AKINESIA  BY 
INHIBITORS  OF  DOPAMINE-BETA-HYDROXYLASE. 

248289  04-( 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION, 

249268  04-1 
BICUCULLINE  REVERSAL  OF  DEPRIVATION  AMBLYOPIA  IN  THE  CAT. 

249983  04-1 
REVERSAL  BY  A  CENTRAL  ANTIACETYLCHOLINE  DRUG  OF  PIMOZIDE- 
INDUCED  INHIBITION  OF  MOUSE  JUMPING  IN  AMPHETAMINE  OOPA 
TREATED  MICE. 

250656  04-1 
REVERSIBILITY 

DRUG  ANTAGONISM  AND  REVERSIBILITY  OF  THE  BINDING  OF 
INDOLEAMINES  IN  BRAIN. 

250081  04-1 
REVERSIBLE 

A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  01 
REVERSIBLE  INHIBITORS  WITH  CHOLINESTERASES. 

231072  01-1 
REVIEW 

REVIEW  OF  LONG-TERM  PSYCHIATRIC  MEDICATION  -  A  STUDY  OF 
WITHDRAWAL  SYMPTOMS. 

228214  01- 
GER0VITAL-H3    -  A  REVIEW  OF  THE  LITERATURE. 

229460  01-' 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I,  THEORETICAL 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01-: 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20- YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE. 

234826  02-' 
A  REVIEW  OF  THE  EFFECTS  OF  DIAZEPAM  ON  COGNITIVE  AND 
PSYCHOMOTOR  PERFORMANCE. 

235236  02-' 
A  REVIEW  OF  THE  CARDIOVASCULAR  EFFECTS  AND  TOXICITY  OF 
TRICYCLIC  ANTIDEPRESSANTS. 

237909  02-1 
METHYLPHENIDATE:  A  REVIEW. 

238510  02-1 
REVIEW  OF  DRUG  TREATMENT  FOR  DOWNS- SYNDROME  PERSONS. 

239074  03-1 
PHENOTHIAZINE-JAUNDICE  (A  REVIEW). 

240697  03-1 
DRUG  INDUCED  EXTRAPYRAMIDAL  EFFECTS  -  A  REVIEW. 

246187  04-1 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-1 
RATE-DEPENDENT  EFFECTS  OF  DRUGS:  A  REVIEW  OF  THE  LITERATURE. 

250070  04-C 
A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

250935  04-1 
ANNUAL  REVIEW  OF  PHARMACOLOGY  AND  TOXICOLOGY 

251238  04-1 
REVISITED 

DRUGS  AND  PSYCHOTHERAPY  IN  DEPRESSION  REVISITED:  ISSUES  IN  THI 
ANALYSIS  OF  LONG-TERM  TRIALS. 

229450  01 -C 
REWARD 

THE  CHEMISTRY  OF  REWARD  AND  RELATED  BEHAVIORS 

229475  01-0 
AMPHETAMINE  AND  THE  REWARD  SYSTEM:  EVIDENCE  FOR  TOLERANCE 
AND  POST-DRUG  DEPRESSION. 

239850  O3-0 
AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS.  (PH.D. 
DISSERTATION). 

241129  03-0 


S-288 


I 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04-03 
WARDING 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980  03-04 
lESUS 
LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01-04 
FENFLURAMINE  AND  N-ETHYLAMPHETAMINE:  COMPARISON  OF  THE 
REINFORCING  AND  RATE-DECREASING  ACTIONS  IN  THE  RHESUS 
MONKEY. 

230874  01-04 
BARBITURATE  REINFORCED  RESPONDING  IN  RHESUS  MONKEYS: 
COMPARISONS  OF  DRUGS  WITH  DIFFERENT  DURATIONS  OF  ACTION. 

237874  02-04 
THYROTROPINRELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
;        CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-04 
PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS. 

240013  03-04 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-04 
,     NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE-DEPENDENT 
RHESUS  MONKEYS. 

240019  03-04 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 

THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241109  03-04 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 
UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

241250  03-04 
MAZINDOL  SELF-ADMINISTRATION  IN  THE  RHESUS  MONKEY. 

242747  04-04 
BEHAVIORAL  EFFECTS  OF  AMPHETAMINE  IN  A  GROUP  OF  RHESUS 
MONKEYS  WITH  LESIONS  OF  DORSOLATERAL  FRONTAL  CORTEX. 

244684  04-04 
FURTHER  STUDIES  ON  SELF-ADMINISTRATION  OF  ANTIPYRETIC 
ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITH 
CODEINE  IN  RHESUS  MONKEYS. 

246855  04-04 
EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROME 
IN  RHESUS  MONKEYS. 

247889  04-04 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04  04 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICAL 
STATUS  OF  RHESUS  MONKEYS. 

249003  04-05 
INTRAGASTRIC  SELF-ADMINISTRATION  OF  PSYCHOACTIVE  DRUGS  BY 

THE  RHESUS  MONKEY. 

249004  04-06 
UMATIC 

1  THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE 

CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO. 

228241  01-11 
A  CLINICAL  TRIAL  OF  TOFRANIL  IN  RHEUMATIC  PAIN  IN  GENERAL 
PRACTICE. 

252139  04  17 
J  UMATOIO 
'  IMIPRAMINE  AND  RHEUMATOID  FACTOR. 

252137  04  17 
'  UMATOIOGY 

IMF  USE  OF  PSYCHOTROPIC  DRUGS  IN  RHEUMATOLOGY. 

252135  04-17 


RHYTHM 

CARBACHOL  ELICITED  MOUSE-KILLING  BY  RATS    CIRCADIAN  RHYTHM 
AND  DOSE-RESPONSE. 

238006  02-04 
RHYTHMICAL 

DRUG-INDUCED  RHYTHMICAL  ACTIVITY  IN  THE  INFERIOR  OLIVARY 
COMPLEX  OF  THE  RAT. 

235866  02-03 
RICH 

A  FUNCTIONAL  EFFECT  OF  DOPAMINE  IN  THE  NUCLEUS-ACCUMBENS  AND 
IN  SOME  OTHER  DOPAMINE  RICH  PARTS  OF  THE  RAT  BRAIN. 

249669  04-04 
RIGHT 

RATIONAL  PSYCHOPHARMACOTHERAPY  AND  THE  RIGHT  TO  TREATMENT. 

232937  02-17 
VERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE. 

251939  04-14 
RIGID 

PHARAAACOLOGICAL  IMPLICATIONS  OF  THE  X  RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

238317  02-01 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04-03 
RING-SUBSTITUTED 

LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING  SUBSTITUTED  TRYPTAMINES 

238674  03-03 


RISK 


CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS      A 
RISK  IN  THE  USE  OF  THESE  DRUGS. 

2313170115 
RNA 

EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  BRAIN  NUCLEAR  RNA. 

229494  01-03 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE 

243795  04-03 
RO-4-J284 

EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL  INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03  04 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO  4  1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
RO-4-4602 

TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  L  DOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  (RO  4-4602) 

233917  02  11 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602 

239957  03  03 
RO-5-3350 

FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH  A 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350). 

239748  03-14 
CLINICAL  EXPERIENCE  WITH  RO-5-3350  (BROMAZEPAM) 

245138  04  10 
RODENTS 

ANTAGONISM  BY  SULPIRIDE  OF  THREE  APOMORPHINE-INDUCED  EFFECTS 
IN  RODENTS. 

252032  04-04 
ROLE 

PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-08 
THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS. 

226185  01  04 
POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER) 

226848  0105 
THE  ROLE  OF  CENTRAL  GLYCINE  RECEPTORS  IN  THE  PHARMACOLOGIC 
ACTIONS  OF  BENZODIAZEPINES, 

232511  01-03 
CATECHOLAMINERGIC  MECHANISMS  OF  THE  LATERAL  HYPOTHALAMUS: 
THEIR  ROLE  IN  THE  MEDIATION  OF  AMPHETAMINE  ANOREXIA, 

232610  02  03 
THE  ROLE  OF  CLINICAL  PSYCHIATRY  IN  THE  DEVELOPMENT  OF  NEW 
PSYCHOTROPIC  DRUGS 

233684  02  1 1 


S-289 


Subject  Index 


Psychopharmacology  Abs 


53' 


REGIONAL  ROLE  OF  CATECHOLAMINES  IN  ALPHA-METHYL-M-TYROSINE 
INDUCED  ELECTROENCEPHALOGRAPHIC  AROUSAL. 

234067  02-03 
ROLE  OF  BIOGENIC  AMINES  IN  THE  EFFECTS  OF  MARIJUANA  ON  EEG 
PATTERNS  IN  CATS 

235564  02-03 
THE  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT-TERM  MEMORY. 

23671102-04 
MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS. 

237140  02-03 
TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES   POSSIBLE 
ROLE  OF  GROWTH  HORMONE. 

237253  02-11 
SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES 

237776  02-03 
ROLE  OF  DIAZEPAM  IN  THE  MANAGEMENT  OF  ECLAMPSIA. 

237898  02-11 
ENDOGENOUS  BRAIN  2-PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS.  (PH.D.  DISSERTATION). 

238077  02-03 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE 
„„  ,  „  238737  03-03 

ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS 

239978  03-04 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE, 

240055  03-09 
STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 
PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  03-03 
EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIDECTOMIZED  RATS. 

241203  03-03 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
BEHAVIORAL  EFFECTS  OF  L-5  HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT- 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-04 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS,  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  0303 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP. 

241388  03-03 
THE  ROLE  OF  SEROTONIN  IN  THE  DISCRIMINATIVE  STIMULUS 
PROPERTIES  OF  MESCALINE.  (PH.D.  DISSERTATION). 

241573  03-03 
THE  ROLE  OF  THE  AMYGDALOID  NUCLEI  IN  THE  REGULATION  OF 
ADAPTIVE  BEHAVIOR, 

243234  04-04 
THE  ROLE  OF  NEURAL  INPUT  IN  THE  EFFECTS  OF  MORPHINE  ON  THE  RAT 
ADRENAL  MEDULLA, 

243779  04-03 
THE  ROLE  OF  RATING  SCALES  IN  THE  USE  OF  ANTIDEPRESSANTS, 

243862  04-17 
THE  RELATIVE  ROLE  OF  BRAIN  ACETYLCHOLINE  AND  HISTAMINE  IN 
PERPHENAZINE  CATATONIA  AND  INFLUENCE  OF  ANTIDEPRESSANTS 
AND  DIPHENHYDRAMINE  ALONE  AND  IN  COMBINATION, 

245593  04-05 
INGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION, 

245930  04-02 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS, 

247216  04-09 
THE  ROLE  OF  ADRENAL  CATECHOLAMINES  IN  THE  RELEASE  OF 
CORTICOSTERONE  AND  FATTY-ACIDS  BY  NICOTINE  IN  THE  RAT 

247731  04-03 


ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE-  COMR 
WITH  D-AMPHETAMINE. 

24821 
STUDIES  ON  THE  ROLE  OF  PHENETHYLAMINE  IN  METHYLAMPHET, 
ACTION  MECHANISM. 

2485 
ROLE  OF  THE  PROSTAGLANDINS  IN  THE  REGULATION  OF  THE  CER 
BLOOD  CIRCULATION. 

2485: 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY 

2489- 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 
AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREAT 

2500; 
EFFECT  OF  PROPRANOLOL  ON  ETHANOL  METABOLISM  -  EVIDENCI 
THE  ROLE  OF  MITOCHONDRIAL  NADH  OXIDATION. 

251 1; 
MECHANISMS  OF  TRANS- SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

2513^ 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYP 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATE 
LITHIUM  OR  RUBIDIUM, 

2535? 
ROLES 

SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERT, 

22849 
GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS 
HALLUCINOGENIC  DRUG  ACTION. 

23481 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  ( -(- )  AMPHETAMINE  AND  RELATED  COMPOUNDS. 

24614 
ROMAN 

NICOTINE-LIKE  BEHAVIORAL  EFFECT  AFTER  SAMLL  DOSE  OF 
MECAMYLAMINE  IN  ROMAN  HIGH-AVOIDANCE  RATS. 

23986 
ROOT 

THE  EFFECT  OF  DIAZEPAM  AND  PICROTOXIN  ON  BRAINSTEM  EVOI 
DORSAL  ROOT  POTENTIALS. 

23998 
ROSETTES 

REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CI 
MARIJUANA  SMOKERS. 

22903' 
MARIJUANA  AND  T-LYMPHOCYTE  ROSETTES. 

243081 
ROTATION 

A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAMINE-INDUCED 
CONTRALATERAL  ROTATION  IN  RATS. 

23130; 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  0 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRl 
INDUCED  ROTATION  OF  RATS. 

23786< 
SPONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVK 
THE  MONGOLIAN  GERBIL  (MERIONES-UNGUICULATUS). 

241311 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCE 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVE/V 
OF  DOPAMINE. 

245601 
THYROTROPIN-RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATIOI 
THE  NONLESIONED  RAT. 

2475  M 
MORPHINE-INDUCED  ROTATION  IN  NAIVE,  NONLESIONED  RATS, 

252209 
ROTATIONAL 

CYCLIC-AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESION 
UNILATERALLY  IN  SUBSTANTIA-NIGRA, 

241382 
ROTATORY 

ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347 
ROTH 

A  CASE  OF  PHOBIC  ANXIETY  DEPERSONALIZATION  SYNDROME  (ROT 

243094 
ROTOR 

EVALUATION  OF  THE  PSYCHOTROPIC  EFFECT  OF  ETIFOXINE  THROUG 
PURSUIT  ROTOR  PERFORMANCE  AND  GSR. 

237102 


S-290 


i/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAL 
FLICKER  FREQUENCY 

251986  04-14 
lOUSSY-LEVY 

ROUSSY-LEVY  SYNDROME  WITH  PSYCHOSIS 

227746  0109 
iOUTE 

BARBITALINDUCED  CROSS- TOLERANCE  TO  BARBITURATES  BY  THE 
INTRACISTERNAL  ROUTE  OF  ADMINISTRATION. 

231011  01-03 
INFLUENCE  OF  THE  ROUTE  OF  ADMINISTRATION  OF  THE  CLINICAL 
ACTION  OF  DIAZEPAM. 

238531  02-13 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE 

238756  03-04 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9TETRAHYDR0CANNABIN0L  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT. 

249223  04-03 
OUTES 

PLASMA  LEVELS  OF  IMIPRAMINE  AND  DESIPRAMINE  IN  MAN  AFTER 
DIFFERENT  ROUTES  OF  ADMINISTRATION. 

246387  04  13 
OUTINE 

LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE. 

240055  03  09 
UBIOIUM 

PRECLINICAL  STUDIES  OF  RUBIDIUM  IN  AFFECTIVE  ILLNESS 

229495  01-02 
NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 
RUBIDIUM  TREATMENT. 

230817  01-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
ULE 

PIM0Z1DE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION- 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
ADENOSYl-l-METHIONINE 

DEPLETION  OF  S-ADENOSYL-L-METHIONINE  IN  MOUSE  BRAIN  BY 
ANTIDEPRESSIVE  DRUGS. 

226850  01  03 
AOENOSYLHOMOCYSTEINE 

ANALOGUES  OF  S-ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5THI0ETHER  LINKAGE. 

251698  04-01 
AMPHETAMINE 

A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  R- 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (R  DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  02-04 
METHYLATION 

PHENYLETHANOLAMINE-N-METHYLTRANSFERASE:  S-METHYLATION  OF  N 
BUTYLIMIDIAZOLE-2-THIOL. 

238762  03-01 
TRIAZOlOBENZOOIAZEPIN-5-ONES 

CENTRAL-NERVOUS-SYSTEM  DEPRESSANTS    13   S- 
TRIAZOLOBENZODIAZEPIN  50NES 

238478  02-01 
kCRIFICE 

REGIONAL  LEVELS  OF  CHOLINE  AND  ACETYLCHOLINE  IN  RAT  BRAIN 
FOLLOWING  HEAD  FOCUSED  MICROWAVE  SACRIFICE:  EFFECT  OF  (  i  ) 
AMPHETAMINE  AND  (  i  OR  )  P-CHLOROAMPHETAMINE. 

239976  03-03 
«TY 

ASSESSING  THE  SAFETY  AND  EFFICACY  OF  INTERNATIONAL  TRIALS  IN 
PSYCHOPHARMACOLOGY.  {UNPUBLISHED  PAPER). 

232902  02-16 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS 

239943  03-15 
THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA-  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE 

247968  04  08 
OXAZEPAM  PROTRIPTYLINE:  A  DOUBLE-BLIND  PHASE  II  EVALUATION  OF 
THE  EFFICACY  AND  SAFETY  OF  THE  COMBINATION  VERSUS  PLACEBO 
IN  NEUROTIC,  DEPRESSED  AND  ANXIOUS  PSYCHIATRIC  OUTPATIENTS 

248975  04  10 
DEPARTMENT  SEEKS  ADVICE  ON  SAFETY  Of  PSYCHOTROPICS 

251232  04  17 


SALIVA 

INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS. 

253693  04  03 
SALIVARY 

THE  MECHANISM  BY  WHICH  DELTA9  TETRAHYDROCANNABINOL  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
SALIVATION 

THE  DEPENDENCE  OF  THE  MAGNITUDE  OF  CONDITIONED  SALIVATION  IN 
DOGS  ON  DOSES  OF  CAFFEINE. 

236249  0203 
SALSOLINOL 

SALSOLINOL  DIFFERENTIALLY  AFFECTS  MICE  SELECTED  FOR  SENSITIVITY 
TO  ALCOHOL 

244680  04-04 
A  COMPARISON  OF  6.7  DIHYDROXYTETRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE  OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM. 

248603  04-03 
SALT 

REMISSION  OF  VITILIGO  AND  SALT  MEDICATION. 

241849  03  09 
SALTS 

APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES,  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS 

236732  02-09 
LITHIUM  SALTS  IN  CYCLOPHRENIA  (MANIC-DEPRESSIVE  PSYCHOSIS). 

237013  02  09 
GLC  DETERMINATION  OF  PLASMA  DRUG  LEVELS  AFTER  ORAL 
ADMINISTRATION  OF  CLORAZEPATE  POTASSIUM  SALTS. 

246968  04-03 
LITHIUM  SALTS:  1970  1975. 

250928  04  1  7 
SAMPLE 

CLINICAL  LABORATORY  TEST  STANDARDS  FOR  A  SAMPLE  OF 
SCHIZOPHRENICS. 

237726  02  08 
SAMPLES 

GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYSIS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES. 

238774  03-01 
ISOLATION  AND  RADIOENZYMIC  ESTIMATION  OF  PICOGRAM  QUANTITIES 
OF  DOPAMINE  AND  NOREPINEPHRINE  IN  BIOLOGICAL  SAMPLES. 

244636  04-06 
SARCOLE/VUMA 

5-HYDROXYTRYPTAMINE- I4C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERAAAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR 

226827  01-03 
SARCOTUBULAR 

MECHANISMS  OF  QUINIDINE  AND  CHLORPROMAZINE  INHIBITION  OF 
SARCOTUBULAR  ATPASE  ACTIVITY. 

237245  02-03 
SARGANTS 

A  CRITICISM  OF  WILLIAM  SARGANTS  ATTACK  ON  THE  MEDICAL 
RESEARCH  COUNCILS  STUDY  OF  MODITEN. 

235429  02-08 
SATED 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE. 

227343  01-03 
SATIATED 

PATTERN  OF  DRINKING  AND  FEEDING  PRODUCED  BY  HYPOTHALAMIC 
NOREPINEPHRINE  INJECTION  IN  THE  SATIATED  RAT 

245929  04-02 
INGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
SATIETY 

CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE  OF 
SATIETY  IN  RATS 

245612  04-02 
SATURABLE 

SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01  03 
SB-S833 

CAMAZEPAM  (SB-5833)  IN  PREPARATION  FOR  ENDOSCOPY  INSPECTION: 
OPEN  AND  DOUBLE  BLIND  STUDY  VERSUS  DIAZEPAM. 

241276  03  14 


S-291 


Subject  Index 

SBP 

IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN-^, 

248604  04-03 
SCALE 

THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL. 

226899  01-09 
A  BRIEF  ANXIETY  RATING  SCALE  IN  EVALUATING  ANXIOLYTICS. 

237926  02-1) 
CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN    -  AN  EMPIRICAL  STUDY. 

248593  04-11 
SCALES 

THE  ROLE  OF  RATING  SCALES  IN  THE  USE  OF  ANTIDEPRESSANTS. 

243862  04-17 
DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES. 

244063  04-17 
THE  NEUROLOGISTS  USE  OF  RATING  SCALES.  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS. 

249771  04-10 
SCANDINAVIAN 

SCANDINAVIAN  STANDPOINT  ON  THE  LIEGE  CLASSIFICATION  OF 
NEUROLEPTICS. 

227761  01-17 
SCHEDULE 

EFFECTS  OF  D-AMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 

MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT. 

226852  01-04 
DRUG  SCHEDULE  INTERACTIONS  AND  INTERCURRENT  BEHAVIOR. 

229479  01-04 
ETHANOL.  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION. 

238749  03-04 
NALOXONE  AS  A  NEGATIVE  REINFORCER  IN  RHESUS  MONKEYS:  EFFECTS 
OF  DOSE,  SCHEDULE,  AND  NARCOTIC  REGIMEN. 

240018  03-04 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE-DEPENDENT 
RHESUS  MONKEYS. 

240019  03-04 
MORPHINE,  PENTAZOCINE  AND  NALOXONE  EFFECTS  ON  RESPONDING 

UNDER  A  MULTIPLE  SCHEDULE  OF  REINFORCEMENT  IN  RHESUS 
MONKEYS  AND  PIGEONS. 

241250  03-04 
EFFECTS  OF  CHLORPROMAZINE  AND  D-AMPHETAMINE  ON  OBSERVING 
RESPONSES  DURING  A  FIXED-INTERVAL  SCHEDULE. 

245303  04-04 
SOME  EFFECTS  OF  D-AMPHETAMINE  AND  PENTOBARBITAL  ON 
PERFORMANCE  UNDER  A  LONG  FIXED-INTERVAL  SCHEDULE. 

252816  04-04 
SCHEDULE-CONTROLLED 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
THE  EFFECT  OF  PHENCYCLIDINE  AND  KETAMINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  PIGEON. 

237757  02-04 
THE  EFFECTS  OF  ACUTE  AND  CHRONIC  PHENCYCLIDINE  ON  SCHEDULE- 
CONTROLLED  BEHAVIOR  IN  THE  RHESUS  MONKEY. 

238794  03-04 
MODULATION  BY  RESPONSE  REQUIREMENTS  OF  THE  EFFECTS  AND 
INTERACTIONS  OF  D-AMPHETAMINE  AND  ALPHA-METHYL-P-TYROSINE 
ON  SCHEDULE-CONTROLLED  PERFORMANCE  IN  RATS. 

238844  03-04 
CONTRASTING  EFFECTS  OF  MORPHINE  ON  SCHEDULE-CONTROLLED 
BEHAVIOR  IN  THE  CHIMPANZEE  AND  BABOON. 

246854  04-02 
SOME  EFFECTS  OF  PARATHION  ON  THE  SCHEDULE-CONTROLLED 
BEHAVIOR  OF  THE  PIGEON 

249266  04-04 
THE  EFFECTS  OF  PHENCYCLIDINE,  KETAMINE.  D-AMPHETAMINE  AND 
PENTOBARBITAL  ON  SCHEDULE-CONTROLLED  BEHAVIOR  IN  THE 
MOUSE. 

250112  04-04 
SCHEDULE-DEPENDENT 

SCHEDULE-DEPENDENT  EFFECTS  OF  CHLORDIAZEPOXIDE  ON  OPERANT 
BEHAVIOR  IN  RATS 

251670  04-04 
SCHEDULE-INDUCED 

EFFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE- 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  0204 
SCHEDULE  INDUCED  ORAL  NARCOTIC  SELF  ADMINISTRATION:  ACUTE 

AND  CHRONIC  EFFECTS 

233293  02  04 


Psychopharmacology  Abstr 


EFFECTS  OF  HALOPERIDOL  ON  SCHEDULE-INDUCED  POLYDIPSIA. 

236708 
SCHEDULED 

CHARACTERISTICS  OF  BEHAVIOR  CONTROLLED  BY  SCHEDULED 
INJECTIONS  OF  DRUGS. 

240010 
SCHEDULES 

THE  IMPORTANCE  OF  REINFORCEMENT  SCHEDULES  IN  DETERMININC 
EFFECTS  OF  DRUGS. 

229428 
EFFECTS  OF  D-AMPHETAMINE,  CHLORPROMAZINE.  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPAC 
RESPONDING  SCHEDULES. 

229639 
INTRODUCTION:  COMPLEX  SCHEDULES  OF  DRUG  INJECTION. 

240012 
CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONJ 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE  INTERVAL  PROCEDURES. 

240015 
INTRODUCTION:  SCHEDULES  OF  TERMINATION  OF  DRUG  INJECTION: 

240017 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE,  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  AAAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION. 

2501 1 1 
SCHIZOAFFECTIVE 

SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIE^ 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361 
SCHIZOPHRENIA 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA. 

225867 
PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  0 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935 
FOLATE  RESPONSIVE  SCHIZOPHRENIA. 

227711 
ANXIETY  IN  SCHIZOPHRENIA:  THE  RESPONSES  TO  CHLORDIAZEPOXIC 
AN  INTENSIVE  DESIGN  STUDY. 

228221 
VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  I 
RECENT  VIEWS  IN  PSYCHOPHARMACOLOGY:  APPROACH  TO 
SCHIZOPHRENIA. 

228308  I 
EFFECTS  OF  LONG-TERM  APPLICATION  OF  PENFLURIDOL  (TLP-607)  FC 
SCHIZOPHRENIA. 

228324  ( 
DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 

CHRONIC  SCHIZOPHRENIA. 

228325  ( 
A  DOUBLE-BLIND  COMPARISON  OF  PENFLURIDOL  (LASER)  WITH 

PIMOZIDE  IN  SCHIZOPHRENIA. 

229026  ( 
DOUBLE-BLIND  CONTROLLED  STUDY  OF  L-DOPA  THERAPY  IN 
SCHIZOPHRENIA. 

229064  ( 
CHLORPROMAZINE  METABOLISM  AND  CLINICAL  RESPONSE  IN  ACUTI 
SCHIZOPHRENIA:  A  PRELIMINARY  REPORT. 

229445  C 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 

CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  C 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE' 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  0 
NEUROENDOCRINE  EFFECTS  OF  HALOPERIDOL  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

230839  0 
GABA  AND  THE  DOPAMINE  HYPOTHESIS  OF  SCHIZOPHRENIA. 

2310190 
THE  USE  OF  ANTIDEPRESSANT  DRUGS  IN  SCHIZOPHRENIA. 

231277  0 
THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA:  TREATMENT  WITH  DEPC 
FLUPENTHIXOL.  A  LONG-ACTING  NEUROLEPTIC. 

231367  0 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE-BLIND  CONTROLLED  TRIAL 

231609  0 
OVERVIEW:  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  I.  SCHIZOPHREI 

232827  O: 
THYROTROPIN-RELEASING  HORMONE  IN  CHRONIC  SCHIZOPHRENIA. 

233817  0: 


S-292 


iUME  14,  SUBJECT  INDEX 


Subject  Index 


,  DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA: 
<  EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
I      AMPHETAMINE  IN  SCHIZOPHRENICS. 

233967  02-08 
1  PENFLURIDOL  IN  THE  TREATMENT  OF  SCHIZOPHRENIA:  CLINICAL  AND 
f      PSYCHOMETRIC  FINDINGS 

235365  02-08 
PSYCHOPHARMACOLOGICAL  TREATMENT  OF  SCHIZOPHRENIA. 
I  235773  02-08 

I  DOPAMINE  AND  SCHIZOPHRENIA. 

!  235802  02-08 

I  RECENT  DEVELOPMENTS  IN  THE  TREATMENT  OF  SCHIZOPHRENIA. 
i  235803  02-08 

'I  LOOKING  AT  SCHIZOPHRENIA  FROM  A  UNITARY  POINT  OF  VIEW. 
,  236348  02-17 

I  SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENTS 
I      SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361  02-08 
,  THE  COURSE  OF  TREATMENT  IN  SCHIZOPHRENIA  AS  RELATED  TO  THE 
,'     APPEARANCE  OF  AFFECTIVE  DISORDERS. 

236421  02-08 

Ion  one  of  the  variants  of  simple  schizophrenia  in  the  light  of 
psychopharmacotherapy. 

236725  02-08 
I  THE  psychedelic  MODEL  OF  SCHIZOPHRENIA:  THE  CASE  OF  N,N 
'      DIMETHYLTRYPTAMINE. 

,  236750  02-08 

RECENT  DEVELOPMENTS  IN  THE  DRUG  TREATMENT  OF  SCHIZOPHRENIA, 

236751  02-08 
'I  ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 
LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY. 

237124  02-08 
|THE  SOMATIC  THERAPY  OF  SCHIZOPHRENIA. 

'  237992  02-08 

DOES  PHENYLETHYLAMINE  CAUSE  SCHIZOPHRENIA?. 
I  237993  02-15 

!  SCHIZOPHRENIA:  RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 

CONTROL,  AND  FEATURE  EXTRACTION 
'  238464  02-08 

PITUITARY  HORMONE  LEVELS  IN  SCHIZOPHRENIA  BEFORE  AND  AFTER 
DOPAMINE  BLOCKADE.  (UNPUBLISHED  PAPER). 

238491  02-13 
PRESENT  STATE  OF  LONG-TERM  NEUROLEPTIC  TREATMENT  OF 
SCHIZOPHRENIA. 

238864  03-08 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA. 

238996  03-08 
PIGMENTATION  AND  THE  CHEMICAL  BASIS  OF  SCHIZOPHRENIA. 

239001  03  15 
PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG-ACTING 

NEUROLEPTICS:  A  DOUBLE-BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA. 

239023  03-08 
LONG-TERM  TREATMENT  OF  SCHIZOPHRENIA. 

240709  03-08 
TREATMENT  OF  ACUTE  SCHIZOPHRENIA  WITH  SULPHORIDAZINE. 

240850  03-08 
INTRAMUSCULARLY  ADMINISTERED  FLUPHENAZINE-HCL  IN 
ACUTE/SCHIZOPHRENIA:  A  RETROSPECTIVE  STUDY. 

241277  03-08 
SCHIZOPHRENIA:  AN  END  TO  RELAPSES. 

241459  03-08 
BIOCHEMICAL  RESEARCH  IN  SCHIZOPHRENIA:  RESULTING  IN  A  NEW 
RESEARCH  STRATEGY. 

241912  03-08 
PHARMACOTHERAPY  OF  SCHIZOPHRENIA. 

241936  03-08 
ON  PSYCHOPHARMACEUTICAL  RESEARCH  AND  THE  UNDERSTANDING  OF 
SCHIZOPHRENIA 

244037  04-17 
EFFECTS  OF  THYROTROPIN-RELEASING  HORMONE  IN  SCHIZOPHRENIA. 

244528  04-08 
STRONG  MEANING-RESPONSE  BIAS  IN  SCHIZOPHRENIA. 

245559  04-08 
:lOZAPINE  and  the  dopamine  hypothesis  of  SCHIZOPHRENIA,  A 
CRITICAL  APPRAISAL. 

246671  04-03 
\N  EARLY  CLINICAL  AND  TOXICITY  TRIAL  OF  EX-1 1 -582A  IN  CHRONIC 
SCHIZOPHRENIA. 

247481  04-07 
THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA:  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE. 

247968  0408 
>CHIZOPHRENIA,  EPILEPSY,  CANCER,  METHIONINE,  AND  FOLATE 
METABOLISM:  PATHOGENESIS  OF  SCHIZOPHRENIA. 

248543  04-16 


RECEPTOR  SENSITIVITY  IN  SCHIZOPHRENIA. 

249633  04-03 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-15 
CEREBROSPINAL  FLUID  LEVELS  OF  CHLORPROMAZINE  AND  ITS 
METABOLITES  IN  SCHIZOPHRENIA. 

251119  04-08 
A  LONG-TERM  STUDY  OF  PENFLURIDOL  IN  CHRONIC  SCHIZOPHRENIA. 

251829  04-08 
THE  DURATION  OF  MAINTENANCE  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA. 

252763  04-08 
A  THREE-YEAR  DOUBLE-BLIND  INVESTIGATION  OF  PIMOZIDE  VERSUS 
FLUPHENAZINE  IN  CHRONIC  SCHIZOPHRENIA. 

253048  04-08 
LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 

CHRONIC  SCHIZOPHRENIA. 

253049  04-08 
SCHIZOPHRENIAS 

NICOTINIC-ACID  IN  THE  TREATMENT  OF  SCHIZOPHRENIAS:  PRACTICAL 
AND  THEORETICAL  CONSIDERATIONS. 

230812  01-08 
SCHIZOPHRENIC 

A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROMAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES. 

226412  01-08 
AMITRIPTYLINE  PERPHENAZINE  INTERACTION  IN  AMBULATORY 
SCHIZOPHRENIC  PATIENTS. 

228225  01-08 
DEPRESSION  AND  THE  ACUTE  SCHIZOPHRENIC  PROCESS. 

228240  01-08 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS, 

229444  01  08 
OUTPATIENT  THERAPY  WITH  FLUPHENAZINE-DECANOATE  IN 
SCHIZOPHRENIC  PATIENTS 

229556  01-08 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES  -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 
PATIENTS. 

230780  01  08 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS:  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

231034  01-08 
RESPONSES  OF  CHRONIC  SCHIZOPHRENIC  FEMALES  TO  A  COMBINATION 
OF  DIPHENYLHYDANTOIN  AND  NEUROLEPTICS:  A  DOUBLE-BLIND 
STUDY. 

232781  02  08 
A  PLACEBO  CONTROLLED  STUDY  OF  LITHIUM  COMBINED  WITH 
NEUROLEPTICS  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS 

232840  02  08 
THE  IMMEDIATE  EFFECTS  OF  CHLORPROAAAZINE  IN  NEWLY  ADMITTED 
SCHIZOPHRENIC  PATIENTS. 

234700  02-08 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    -  A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02-08 
A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROAAAZINE  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
A  DOUBLE-BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS. 

237828  02-08 
A  PRELIMINARY  STUDY  WITH  PENFLURIDOL  IN  HOSPITALIZED  CHRONIC 
SCHIZOPHRENIC  PATIENTS. 

237897  02-08 
LENPERONE:  A  CONTROLLED  EVALUATION  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS. 

237899  02-08 
THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE-BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE. 

239823  03-08 
THE  EFFECT  OF  NEUROLEPTICS  ON  SERUM  PROLACTIN  IN  SCHIZOPHRENIC 
PATIENTS. 

239931  03-08 
METHYLPHENIDATE,  DEXTROAMPHETAMINE,  AND  LEVAMFETAMINE: 
EFFECTS  ON  SCHIZOPHRENIC  SYMPTOMS. 

239933  03-08 


S-293 


em 


3Q> 

66' 


Subject  Index 

VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 

SCHIZOPHRENIC  PSYCHOSES 

244188  04-08 
A  DOUBLE-BLIND  COMPARISON  OF  LOXITANE    LOXAPINE  SUCCINATE 

AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 

PATIENTS. 

245014  04-08 
CASE  REPORT  OF  THE  MCLEAN  HOSPITAL.  BELMONT,  MASSACHUSETTS- 
LV   A  PATIENT  WITH  BOTH  A  SCHIZOPHRENIC  PSYCHOSIS  AND  A 
PARKINSON-LIKE  ILLNESS, 

245863  04-08 
TECHNIQUE  OF  FLUPHENAZINE-DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES. 

246186  04-08 
THERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLERIL) 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  04-08 
LEVODOPA  AND  LEVOAMPHETAMINE:  A  CROSSOVER  STUDY  IN  YOUNG 
SCHIZOPHRENIC  CHILDREN 

247480  04-08 
A  CONTROLLED  EVALUATION  OF  LOXITANE  IN  SEVENTY-FIVE 
ADOLESCENT  SCHIZOPHRENIC  PATIENTS. 

247483  04-08 
BEHAVIORAL  EFFECTS  OF  L-DOPA  AND  THYROTROPIN  RELEASING 
HORMONE  IN  SCHIZOPHRENIC  PATIENTS;  A  PRELIMINARY  REPORT. 

249120  04-08 
REDUCTION  OF  BLOOD  PLATELET  MONOAMINE-OXIDASE  ACTIVITY  IN 

SCHIZOPHRENIC  PATIENTS  ON  PHENOTHIAZINES. 

249121  04-08 
BETA-ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 

SYMPTOMS   -  A  CASE  FOR  CONTROLLED  STUDIES. 

251164  04-08 
OPTIONS  FOR  TREATMENT  OF  THE  SCHIZOPHRENIC  PATIENT. 

251546  04-08 
CHLORPROMAZINE  METABOLISM  Vllh  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS. 

251778  04-16 
CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRENIC 
PATIENTS:  A  PILOT  STUDY. 

251828  04-08 
A  CONTROLLED  DOUBLE-BLIND  COMPARISON  BETWEEN  LOXAPINE  AND 
HALOPERIDOL  IN  ACUTE  NEWLY  HOSPITALIZED  SCHIZOPHRENIC 
PATIENTS 

253051  04  08 
SCHIZOPHRENICS 

PSYCHOTHERAPY  FOR  SCHIZOPHRENICS:  IS  IT  INDICATED'' 

225826  01-08 
AN  OPEN  STUDY  OF  MESORIDAZINE  (SERENTIL)  IN  CHRONIC 
SCHIZOPHRENICS. 

227821  01  08 
LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS. 

229448  01  08 
DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS 

233967  02-08 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY 

235629  02-08 
CLINICAL  LABORATORY  TEST  STANDARDS  FOR  A  SAMPLE  OF 
SCHIZOPHRENICS 

237726  02-08 
PECULIAR  CLINICOPHARMACOLOGICAL  PROPERTIES  OF  CLOZAPINE 
REVEALED  IN  A  GROUP  OF  CHRONIC  SCHIZOPHRENICS. 

244587  04-08 
PREDICTION  OF  RESPONSE  TO  CHLORPROMAZINE  TREATMENT  IN 
SCHIZOPHRENICS. 

246314  04-08 
A  DOUBLE  BLIND  EVALUATION  OF  METIAPINE  IN  HOSPITALIZED  ACUTE 
SCHIZOPHRENICS. 

248976  04-08 
POTfNllAriON  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG  TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE 

251374  04-08 
COMPARISON  OF  FLUPHENAZINE-DECANOATE,  ORAL  FLUPHENAZINE 
AND  PLACEBO  IN  REMITTED  OUTPATIENT  SCHIZOPHRENICS. 

253047  04-08 
SCHIZOPHRENIFORM 

S(  HIZOPHRENIFORM  PSYCHOSIS  OF  EPILEPSY    TWO  CASES  WITH 
PAROXYSMAL  DYSRHYTHMIA  ON  EEG. 

228068  01  08 
SCHOOL 

DRUGS  IN  THE  MANAGEMENT  OF  LEARNING  AND  BEHAVIOR  DISORDERS 
IN  SCHOOl  CHILDREN 

225783  01   14 


Psychopharmacology  Abstra< 

SULPIRIDE  IN  DEPRESSIVE  SCHOOL  PHOBIC  CHILDREN. 

227141  01 
SULPIRIDE  IN  SCHOOL  PHOBIA. 

239346  O; 
SCIATIC 

DIFFERENTIATION  OF  SENSORY-MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  O; 
EVIDENCE  FOR  ALPHA,  BETA  AND  PHENYLETHYLAMINIC  ADRENERGIC 
RECEPTORS  IN  ISOLATED  FROG  SCIATIC  NERVE. 

249257  Oi 
SCLEROSING 

ISOPRINOSINE  THERAPY  IN  SUBACUTE  SCLEROSING  PANENCEPHALITIS 

251952  0^ 
SCLEROSIS 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01 
SCOPOLAMINE 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPENDENT  EFFECTS  OF  AMPHETAMINE  A 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01 
DISINHIBITORY  EFFECTS  OF  SEPTAL  LESIONS  AND  SCOPOLAMINE 
HYDROBROMIDE.  (PH.D.  DISSERTATION). 

227099  01 
SCOPOLAMINE  AND  AMPHETAMINE  EFFECTS  ON  DISCRIMINATION- 
INTERACTION  WITH  STIMULUS  CONTROL. 

227131  01 
SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATION! 
RELATED  TO  STIMULUS  CONTROL. 

231005  01 
EFFECTS  OF  SCOPOLAMINE  ON  HABITUATION  OF  EXPLORATORY 
ACTIVITY  IN  RATS. 

235509  02 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  ANI 
LOCOMOTOR  ACTIVITY  IN  MICE 

237703  02 
EFFECTS  OF  DIAZEPAM  AND  SCOPOLAMINE  ON  STORAGE,  RETRIEVAL 
AND  ORGANIZATIONAL  PROCESSES  IN  MEMORY. 

237722  02 
DOSE-RESPONSE  EFFECTS  OF  SCOPOLAMINE  ON  ACTIVITY  IN  AN  OPEN- 
FIELD. 

237728  02 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  t  )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02 
THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT. 

241546  03. 
THE  EFFECT  OF  SCOPOLAMINE  ON  THE  STIMULUS  CHANGE 
PHENOMENON. 

247863  04- 
EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS. 

248629  04- 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 

AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT 

250074  04- 
SCREEN 

DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING 
(PH.D.  DISSERTATION). 

239533  03J 
SDELTA 

EFFECTS  OF  D-AMPHETAMINE  ON  F  I  SHOCK  PRESENTATION  WITH 
SDELTA  PROSE. 

237699  02-1 
SEARCH 

BIOCHEMISTRY  AND  THE  SEARCH  FOR  THERAPEUTIC  AGENTS. 

245949  04-( 
THE  SEARCH  FOR  THE  DOPAMINE  RECEPTOR:  TRIBULATIONS. 

247215  OM 
SECOBARBITAL 

COMPARISON  OF  PROGRESSIVE-RATIO  PERFORMANCE  MAINTAINED  BY 
COCAINE,  METHYLPHENIDATE  AND  SECOBARBITAL. 

227137  CM 
INFLUENCE  OF  SECOBARBITAL  AND  CHLORPROMAZINE  ON  PRECENTRAL 
NEURON  ACTIVITY  DURING  ATTENTIVE  BEHAVIOR  IN  MONKEYS 

239848  03-C 
EFFECTS  OF  MARIHUANA  COMBINED  WITH  SECOBARBITAL. 

245648  04-1 
SAy\OOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ   AND 
SECOBARBITAL. 

246303  04-1 


S-294 


1 


:JME  14,  SUBJECT  INDEX 


Subject  Index 


1  M.  ACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
>  f  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SF!    TRAL  ANALYSIS  TECHNIQUES 

249251  04-03 
:(  0-ORDER 

lECTS  OF  DAMPHETAMINE  ON  THE  BEHAVIOR  OF  PIGEONS 
MAINTAINED  BY  A  SECOND-ORDER  SCHEDULE  OF  REINFORCEMENT. 

226852  01-04 
:(  OARY 
SITiVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOMANIA 
ifCONDARY  TO  ORGANIC-BRAIN-SYNDROME. 

2347)1  02-09 
;ONDARY  EFFECTS  OF  LITHIUM  TREATMENT.  PRELIMINARY  RESULTS 
OF  AN  INQUIRY. 

241765  03-15 
SION 

JDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
A-ITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN. 

232503  01-13 
SF  RESPONSE  RELATIONS  IN  DRUG-INDUCED  INAPPROPRIATE 
.ECRETION  OF  ADH,  EFFECTS  OF  CLOFIBRATE  AND  CARBAMAZEPINE. 

232638  02-13 
MULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 
PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  03-03 
TH  TOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

'^ONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04-14 
'AZINE  STIMULATES  PROLACTIN  SECRETION  IN  MAN. 

245840  04-13 

1  AZEPAM  COMPARED  WITH  PENTOBARBITAL  FOR  NIGHTTIME 

EDATION. 

232622  02-14 
'  HE  EFFECTS  OF  OXAZEPAM,  DIAZEPAM  AND  METHYLPERONE   ALONE 
m  m  COMBINATION  WITH  ALCOHOL  ON  SEDATION,  COORDINATION 
-ME)  MOOD. 

239042  03-14 
A'E 

EFFECTS  OF  AZAPERONE.  A  SEDATIVE  NEUROLEPTIC  OF  THE 
i.il  tROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
I  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
/ITE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FOR 

S  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
SYCHOACTIVE  DRUGS. 

225572  01-03 
BIN  DYSFUNCTION  IN  CHRONIC  SEDATIVE  USERS. 

226922  01-15 
P  RMACOLOGICAL  VS.  CLINICAL  PHYSIOGNOMY  OF  NEUROLEPTICS 
ITH  SPECIAL  REFERENCE  TO  THEIR  SEDATIVE  AND  ANTIPSYCHOTIC 

227762  01-04 
.  E  HYPNOTIC  PROPERTIES  OF  A  NEW  BENZODIAZEPINE  IN 
)MPARISON  WITH  FLURAZEPAM:  PHARMACOLOGICAL  AND  CLINICAL 

NDINGS. 

232530  01-07 
P<>IBEE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  OF 
APIHUANA  BY  2-PHENYLETHYLAMINE  AND  BY  PHENYLACETIC-ACID. 

238820  03-03 
ENTAL  HUMAN  DRUG  SELF-ADMINISTRATION.  METHODOLOGY 
APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE. 

240831  03-14 
ID  FOR  BIOASSAY  OF  PHYSICAL  DEPENDENCE  ON  SEDATIVE 
.  IN  DOG, 

244674  04  06 
INICOTINIC  EFFECTS  OF  DRUGS  WITH  CLINICALLY  USEFUL 
VE  ANTIANXIETY  PROPERTIES. 

248009  04-03 

IN  ANTICOAGULANT  TOLERANCE:  I    INFLUENCE  OF  SEDATIVES 
^YCHOPHARMACEUTICALS. 

235336  02-15 
OF  SET,  SETTING,  AND  SEDATIVES,  ON  REACTION  TIME. 

252061  04- 14 

CONCENTRATIONS  OF  DIAZEPAM  AND  ITS  METABOLITES  AFTER 
U,  INTRAMUSCULAR,  AND  RECTAL  ADMINISTRATION 
I  ATION  BETWEEN  PLASMA  CONCENTRATION  AND  SEDATORY 
OF  DIAZEPAM. 

237735  0213 
IP  s 

"mo  PATTERN  IN  CANNABIS  SATIVA  L.  SEEDLINGS  AS  AN 

'  HON  OF  CHEMICAL  RACE. 

237982  0201 

ENT  SEEKS  ADVICE  ON  SAFETY  OF  PSYCHOTROPICS. 

251232  04-1/ 


SEGMENTAL 

ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  ON 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-03 
SEIZURE 

EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02-04 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE 

237706  02-03 
EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE    COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL-INDUCED  SEIZURE 
IN  THE  RAT. 

238706  03-04 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE 
(PH.D.  DISSERTATION). 

241576  03-03 
STUDIES  ON  THE  EFFECTS  OF  HISTAMINERGIC  AGENTS  ON  SEIZURE 
SUSCEPTIBILITY  IN  MICE. 

251983  04-03 
SEIZURES 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL  INDUCED  SEIZURES. 

227694  01-03 
EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS 
PAPIO-PAPIO 

230475  01-03 
PROGRESSIVE  CHANGES  IN  BEHAVIOR  AND  SEIZURES  FOLLOWING 
CHRONIC  COCAINE  ADMINISTRATION    RELATIONSHIP  TO  KINDLING 
AND  PSYCHOSIS    (UNPUBLISHED  PAPER) 

237169  02-04 
SUIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02-15 
ELECTRICALLY-INDUCED  HIPPOCAMPAL  AND  CORTICAL  SEIZURES  AND 
THEIR  EFFECTS  ON  OPERANT  BEHAVIOR. 

249241  04-06 
THE  INFLUENCE  OF  ANTICONVULSANT  DRUGS  ON  CEREBRAL  ASPARTATE 
AMINOTRANSFERASE  ACTIVITY  IN  MICE  WITH  PREDISPOSITION  TO 
AUDIOGENIC  SEIZURES 

252711  04-03 
SELECTION 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PHD 
DISSERTATION). 

228726  01-11 
REDUCTION  OF  ALCOHOL  SELECTION  BY  PARGYLINE  IN  MICE. 

241225  0304 
SELECTIVE 

THE  SELECTIVE  EFFECTS  OF  ALPHA  METHYL  AROMATIC  AMINO  ACIDS  ON 
BRAIN  MONOAMINE  METABOLITES  AND  BEHAVIOR  IN  CATS. 

231009  01-03 
THE  USE  OF  SELECTIVE  MONOAMINE-OXIDASE  INHIBITOR  DRUGS  TO 
MODIFY  AMINE  METABOLISM  IN  BRAIN 

233947  02-03 
THE  EFFECT  OF  SELECTIVE  LESIONING  OF  BRAIN  CATECHOLAMINE 

CONTAINING  NEURONS  ON  THE  ACTIVITY  OF  VARIOUS  ANORECTICS  IN 
THE  RAT 

237742  02-03 
SELECTIVE  MONOAMINE  OXIDASE  INHIBITOR  DRUGS  AS  AIDS  IN 
EVALUATING  THE  ROLE  OF  TYPE  A  AND  B  ENZYMES. 

237776  02-03 
SELECTIVE  BLOCKING  ACTION  OF  LSD  ON  INHIBITORY  DOPAMINE 
RECEPTORS. 

237782  02-03 

INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE- 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 
NEURONS. 

237881  02-03 
GAMMA-ACETYLENIC-GABA  (AMINO-4-HEX-5  YNOICACID).  A  GABA- 
TRANSAMINASE  INHIBITOR  WITH  SELECTIVE  ANTISEIZURE  ACTIVITY. 

238781  03-04 
ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
I0-2-ARYLIMINO  3-ACETYLAMINO  J  THIAZOEIDONYE  PHENOTHIAZINES. 

239662  03-03 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP 

241388  03-03 
THE  SELECTIVE  INHIBITION  OF  5  HYDROXYTRYPTAMINE  REUPTAKE  BY 
ORG-6582. 

241924  0303 


S-295 


Subject  index 


Psychopharmacology  Abstn 


MONOAMINE  OXIDASE  ACTIVE  SITE;  THF  RINDING  TO  AND  TITRATION 
OF  MONOAMINEOXIDASE  WITH  (MO  SELECTIVE  INHIBITORS. 

241931  03-03 
SELECTIVE  FIELD  POTENTIAL  CHANGES  INDUCED  BY  L-DOPA 

246145  04-03 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3  P  TRIFLUOROMETHYLPHENOXY-N- 
METHYL  3-PHENYLPROPYLAMINE. 

246848  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
MONOAMINE  NEUROTOXINS:  SELECTIVE  AND  DELAYED  EFFECTS  ON 
BEHAVIOR  IN  COLONIES  OF  LABORATORY  RATS. 

251063  04-04 
GAMMA  AMINOBUTYRIC-ACID:  SELECTIVE  INHIBITION  OF  ELECTRICALLY- 
INDUCED  HEAD  TURNING  FOLLOWING  INTRACAUDATE 
ADMINISTRATION. 

253392  04-04 
SELF-ADMINISTERING 

ASSESSMENT  OF  REINFORCING  PROPERTIES  OF  AMPHETAMINE 
ANALOGUES  IN  SELF-ADMINISTERING  RATS, 

250941  04-04 
SELF-ADMINISTRATION 

OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS.  (PH.D. 
DISSERTATION). 

226992  01-04 
DOPAMINERGIC  AND  CHOLINERGIC  INFLUENCES  ON  MORPHINE  SELF- 
ADMINISTRATION  IN  RATS 

227703  01-04 
SELF-ADMINISTRATION  OF  CNS  STIMULANTS  BY  DOG. 

230879  01-04 
SCHEDULE-INDUCED  ORAL  NARCOTIC  SELF-ADMINISTRATION:  ACUTE 
AND  CHRONIC  EFFECTS. 

233293  02-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE,  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

237109  02-04 
EXPERIMENTAL  HUMAN  DRUG  SELF-ADMINISTRATION:  METHODOLOGY 
AND  APPLICATION  TO  THE  STUDY  OF  SEDATIVE  ABUSE. 

240831  03-14 
MAZINDOL  SELF  ADMINISTRATION  IN  THE  RHESUS  MONKEY. 

242747  04-04 
FURTHER  STUDIES  ON  SELF-ADMINISTRATION  OF  ANTIPYRETIC 

ANALGESICS  AND  COMBINATIONS  OF  ANTIPYRETIC  ANALGESICS  WITH 
CODEINE  IN  RHESUS  MONKEYS 

246855  04-04 
THE  EFFECT  OF  CHRONIC  SELF-ADMINISTRATION  OF  D-AMPHETAMINE  ON 
FOOD  INTAKE.  LOCOMOTOR  ACTIVITY,  AND  C14-LEUCINE 
INCORPORATION  INTO  CEREBRAL  CORTEX  PROTEIN. 

248961  04-03 
INTRAGASTRIC  SELF-ADMINISTRATION  OF  PSYCHOACTIVE  DRUGS  BY 
THE  RHESUS  MONKEY. 

249004  04-06 
EXTINCTION  RESPONDING  FOLLOWING  AMPHETAMINE  SELF- 
ADMINISTRATION:  DETERMINATION  OF  REINFORCEMENT  MAGNITUD 

250010  04-04 
COMPARISON  BETWEEN  INTRAVENOUS  AND  INTRAGASTRIC  ALCOHOL 
SELF-ADMINISTRATION, 

250021  04-04 
SELF-ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS:  THE 
EFFECTS  OF  UNLIMITED  ACCESS, 

250066  04-04 
EFFECT  OF  HALOPERIDOL  ON  (  i  )  AMPHETAMINE  SELF-ADMINISTRATION. 

250658  04-04 
REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-04 
METHAMPHETAMINE  SELF-ADMINISTRATION  IN  THE  CAT. 

251976  04-04 
SELF-INDUCED 

PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY  STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-13 
SELF-INDUCTION 

BIODISPOSITION  OF  KETAMINE  IN  THE  RAT   SELF-INDUCTION  OF 
METABOLISM. 

250107  04-03 


SELF-INHIBITING 

SELF-INHIBITING  ACTION  OF  NORTRIPTYLINE  ANTIDEPRESSIVE  EFFEC 
HIGH  PLASMA  LEVELS:  A  RANDOMIZED,  DOUBLE-BLIND  STUDY 
CONTROLLED  BY  PLASMA  CONCENTRATIONS  IN  PATIENTS  WITH 
ENDOGENOUS  DEPRESSION. 

248955 
SELF-MUTILATION 

THE  INCIDENCE  OF  SELF-MUTILATION  IN  MORPHINE  TOLERANT  SPR/ 
DAWLEY  AAALE  RATS. 

249253 
SEIF-STIMULATION 

INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SI 
STIMULATION  BEHAVIOR  IN  RATS. 

226943 
THE  EFFECTS  OF  DEXETIMIDE  ON  PIMOZIDE,  AND  HALOPERIDOL  ANI 
PIPAMERONE-INDUCED  INHIBITION  OF  BRAIN  SELF-STIMULATION 
RATS. 

230452 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  ANI 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFT! 
RESERPINE  TREATMENT. 

237103 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMi; 

AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 

237105 
CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 
FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMEN' 
OF  THE  RAT. 

237862 
CHANGES  IN  THE  SELF-STIMULATION  BEHAVIOR  BY  INTRAVENTRICL 
INJECTION  OF  EPINEPHRINE,  NOREPINEPHRINE,  ISOPROTERENOL  A 
DOPAMINE. 

238566 
INTRACRANIAL  SELF-STIMULATION  DERIVED  FROM  ENTORHINAL  CO 

238757 
D-AMPHETAMINE  AND  L-AMPHETAMINE  DIFFERENTIALLY  MEDIATES 
SELF-STIMULATION  IN  RAT  DORSAL  MIDBRAIN  AREA. 

239272 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATIOI 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  TH 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION. 

239980 
EFFECTIVENESS  OF  MORPHINE  AND  INEFFECTIVENESS  OF  DIAZEPAM 
PHENOBARBITAL  ON  THE  MOTIVATIONAL  PROPERTIES  OF 
HYPOTHALAMIC  SELF-STIMULATION  BEHAVIOUR. 

239981 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYL, 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229 
LONG-TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  S 
STIMULATION  AFTER  6-HYDROXYDOPAAAINE  ADMINISTRATION  IN 
RATS. 

241300 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE  EFFECTS  OF  CHRO^ 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION. 

241307 
COMPARISON  OF  THE  EFFECTS  OF  NEUROLEPTICS  ON  SELF-STIMULA' 
AND  CONDITIONED  AVOIDANCE  RESPONSE  IN  RATS. 

241375 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF-STIMULATION  AND  SLEEP  Ih 
RAT.  (PH.D.  DISSERTATION). 

241678 
EFFECTS  OF  DOPAMINE  RECEPTOR  BLOCKADE  ON  SELF-STIMULATIO^ 
THE  MONKEY. 

242748  I 
EFFECTS  OF  AMPHETAMINE,  FOOD  DEPRIVATION  AND  CURRENT 
INTENSITY  ON  SELF  STIMULATION  IN  THE  RAT. 

244214  1 
DECREASED  INTRACRANIAL  SELF-STIMULATION  AFTER  NEUROLEPTIC 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  I 
SELF-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITK 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  P0( 
DISPERSED  FIRST. 

246774  ( 

EFFECT  OF  LITHIUM  AND  OTHER  ALKALI  METALS  ON  BRAIN  CHEMIS 

AND  BEHAVIOR:  II.  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR. 

248956  ( 


S-296 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE  BET/|i1YDR0XYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT 

248964  04-04 
EFFECT  OF  MORPHINE  ON  INTRACRANIAL  SELF-STIMULATION  BEHAVIOR 
FOLLOWING  BRAIN  AMINE  DEPLETION 

249138  04  04 
LITHIUM  DIFFERENTIALLY  ANTAGONISES  SELF  STIMULATION 
FACILITATED  BY  MORPHINE  AND  (  )  )  AMPHETAMINE^ 

249486  04-03 
PIMOZIDE-INDUCED  EXTINCTION  OF  INTRACRANIAL  SELF-STIMULATION: 
RESPONSE  PATTERNS  RULE  OUT  MOTOR  OR  PERFORMANCE  DEFICITS. 

249749  04-03 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF  STIMULATION. 

250019  04-04 
INTRACRANIAL  SELF-STIMULATION  FROM  THE  DORSAL  RAPHE  NUCLEUS 
OF  THE  RAT:  EFFECTS  OF  THE  INJECTION  OF  PCHLOROPHENYLALANINE 
AND  OF  ALPHA-METHYL  P-TYROSINE. 

250982  04  04 
COMPARISON  OF  THE  EFFECTS  OF  MORPHINE,  PENTAZOCINE, 
CYCLAZOCINE  AND  AMPHETAMINE  ON  INTRACRANIAL  SELF- 
STIMULATION  IN  THE  RAT 

251975  04  04 
EFFECTS  OF  GABA  BLOCKADE  ON  LATERAL  HYPOTHALAMIC  SELF- 
STIMULATION. 

252017  04-04 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF  STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  04  03 
SEMIALOEHYDE 

THE  EFFECT  OF  SUCCINIC  SEMIALOEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS 

226900  01-13 
SENEGALESE 

EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS, 
PAPIO-PAPIO. 

230475  01-03 
SENILE 

FOR  SENILE  DEMENTIA-  CHEMICAL  CORRECTION' 

249351  04  II 
OXPRENOLOL  IN  SENILE  TREMOR 

251163  04-11 
SENSITIVE 

LSD  AND  DOPAMINE  SENSITIVE  ADENYLATE  CYCLASE  IN  VARIOUS  RAT 
BRAIN  AREAS. 

226406  01-03 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  MAMMALIAN  BRAIN:  A 
POSSIBLE  SITE  OF  ACTION  OF  ANTIPSYCHOTIC  DRUGS 

230602  01  13 
A  DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  IN  ANTERIOR  LIMBIC 
CORTEX  AND  MESOLIMBIC  REGION  OF  PRIMATE  BRAIN 

231304  01  03 
LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
LI  1    SENSITIVE  MICROELECTRODE 

235589  02  06 
A  SENSITIVE  GLC  METHOD  FOR  THE  DETERMINATION  OF  IMIPRAMINE 
AND  DESMETHYLIMIPRAMINE  USING  A  NITROGEN  DETECTOR. 

236529  02-06 
A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE 
II.  A  DETAILED  DESCRIPTION  OF  METHODOLOGY    (UNPUBLISHED 
PAPER). 

236875  02-06 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL- 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02  16 
ACTIONS  OF  PHENOTHIAZINE  ANALOGS  ON  DOPAMINE  SENSITIVE 

ADENYLATE-CYCLASE  IN  NEURONAL  AND  Gl  lAI   ENRICHED  FRACTIONS 
FROM  RAT  BRAIN 

237241  02-03 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG:  LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC  AA/\P  GENERATING 
SYSTEMS. 

238798  03-03 
ACTION  OF  NEUROLEPTIC  AGENTS  ON  HISTAMINE  SENSITIVE  ADENYLATE- 
CYCLASE  IN  RABBIT  CEREBRAL  CORTEX 

239582  03-03 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5  HT  IN  THE 
CAT. 

241255  03  03 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING, 

242745  04-04 


DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES. 

244063  04- 1 7 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 

246856  04-13 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LEB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04-03 
LIMITING  FACTORS  IN  THE  ANTAGONISM  OF  NEUROLEPTICS  ON 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE. 

250359  04-03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC  AMP  METABOLISM. 

253135  04-03 
SENSITIVITIES 

RAPID  AND  DISSOCIATED  CHANGES  IN  SENSITIVITIES  OF  DIFFERENT 
DOPAMINE  RECEPTORS  IN  MOUSE  BRAIN. 

227996  01-03 
EFFECTS  OF  PENTOBARBITAL  IN  MICE  SELECTIVELY  BRED  FOR  DIFFERENT 
SENSITIVITIES  TO  ETHANOL. 

249261  04-04 
SENSITIVITY 

SIMILARITY  IN  CNS  SENSITIVITY  TO  HEXOBARBITAL  IN  THE  RAT  AND 
MOUSE  AS  DETERMINED  BY  AN  ANALYTICAL,  A  PHARMACOKINETIC, 
AND  AN  ELECTROENCEPHALOGRAPHIC  MEASURE. 

226865  01-03 
ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO    EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01  04 
BEHAVIORALLY  INDUCED  SENSITIVITY  TO  THE  DISCRIMINABLE 
PROPERTIES  OF  LSD. 

230876  01-04 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RAT 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02-03 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
INJECTIONS  OF  AMINO-ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASE 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03-03 
CELLULAR  AAEDIATED  DECREASES  IN  SENSITIVITY  TO  THE  INHIBITORY 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC). 

238816  03-03 
DOPAMINERGIC  NEURONS    -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW. 

241295  03-03 
DIFFERENTIAL  SENSITIVITY  OF  THE  RESPONSE  DURATION  AND  RESPONSE 
RATE  TO  IMIPRAMINE  DURING  OPERANT  BEHAVIOR  IN  RATS. 

241377  03-04 
INFLUENCE  OF  DIURNAL  CYCLES  ON  BIOCHEMICAL  PARAMETERS  OF 
DRUG  SENSITIVITY:  THE  PINEAL  GLAND  AS  A  MODEL. 

241471  03-17 
INCREASE  IN  HYPOTHALAMIC  SENSITIVITY  TO  THE  INHIBITORY  ACTION 
OF  ESTROGENS  CAUSED  BY  THE  USE  OF  L-DOPA,  DILANTIN, 
EPITHALAMIN,  AND  PHENOFORMIN  IN  OLD  RATS. 

241983  03-05 
SALSOLINOL  DIFFERENTIALLY  AFFECTS  MICE  SELECTED  FOR  SENSITIVITY 
TO  ALCOHOL 

244680  04-04 
BARBITAL  ALTERATION  OF  CENTRAL  NERVOUS-SYSTEM  SENSITIVITY  TO 
HEXOBARBITAL  IN  THE  RAT. 

244688  04-03 
THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS 

246842  04  03 
THE  EFFECT  OF  PRETREATMENT  WITH  6  HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 
VAS  DEFERENS 

248413  04  03 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY, 

248947  04  03 
FURTHER  STUDIES  ON  THE  SENSITIVITY  OF  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  04-04 


S-297 


Subject  Index 


Psychopharmacology  Abstract 


■ 

e 


CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS 

249485  04-04 
RECEPTOR  SENSITIVITY  IN  SCHIZOPHRENIA. 

249633  04-03 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-04 
DIFFERENTIAL  SENSITIVITY  TO  APOMORPHINE  AND  CLONIDINE 
FOLLOWING  FRONTAL  CORTICAL  DAMAGE  IN  RATS. 

250089  04-04 
CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE- 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS 

250114  04-03 
SENSITIVITY  TO  LOW  DOSES  OF  ETHANOL  AND  PENTOBARBITAL  IN  MICE 
SELECTED  FOR  SENSITIVITY  TO  HYPNOTIC  DOSES  OF  ETHANOL. 

250284  04-04 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTEO  MICE. 

253112  04-04 
SENSITIZATION 

EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01-04 
P-CHLOROAMPHETAMINE  (PCA),  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS 

240062  03-04 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE  EFFECTS  OF  CHRONIC  D- 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION. 

241307  03-04 
SENSITIZING 

APOMORPHINE-INDUCED  AGGRESSION,  AN  EVALUATION  OF  POSSIBLE 
SENSITIZING  FACTORS  IN  THE  RAT. 

248008  04-04 
SENSORY 

TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENSORY 
DEPRIVATION. 

233418  02-03 
COMPARISON  OF  ALTERED  STATES  OF  CONSCIOUSNESS  INDUCED  BY 
SHORT  SENSORY  DEPRIVATION  AND  BY  DELTA9-TRANS- 
TETRAHYDROCANNABINOL. 

240645  03-14 
CORRELATION  BETWEEN  THE  5-HYDROXYTRYPTAMINE  CONTENTS  IN  THE 
BRAIN  AND  DEGREES  OF  SENSORY,  AND  LOCOMOTOR  ACTIVITIES  IN 
THE  RAT 

242205  03-04 
THE  EFFECT  OF  METHYLPHENIDATE  ON  SENSORY  PERCEPTION  IN 
VARYING  DEGREES  OF  HYPERKINETIC  BEHAVIOR. 

245012  04-14 
SENSORY-MOTOR 

DIFFERENTIATION  OF  SENSORY  MOTOR  MECHANISMS  IN  PERIPHERAL 
NERVE  BLOCK  BY  MODIFIED  RAT  SCIATIC  BLOCK  METHOD. 

238724  0303 
SEPARATING 

SEPARATING  THE  EFFECTS  OF  RESPONSE  RATE  AND  REINFORCEMENT 
FREQUENCY  IN  THE  RATE-DEPFNDENT  EFFECTS  OF  AMPHETAMINE  AND 
SCOPOLAMINE  ON  THE  SCHEDULE-CONTROLLED  PERFORMANCE  OF 
RATS  AND  PIGEONS. 

226853  01-04 
SEPARATION 

GAS  CHROMATOGRAPHIC  SEPARATION  OF  CHLORPROMAZINE, 
DIAZEPAM  AND  N-DESMETHYLDIAZEPAM 

237750  02-06 
PROTEST  DESPAIR  RESPONSE  TO  PEER  SEPARATION  IN  RHESUS  MONKEYS 
AND  ITS  POTENTIATION  BY  ALTERATION  OF  CATECHOLAMINE 
METABOLISM. 

248437  04-04 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS 

252033  04-03 
SEPAZON 

CLINICAL  EXPERIENCE  IN  USING  CLOXAZOLAM  (SEPAZON) 

229025  01-10 
SEPTAL 

CHOLINERGIC  BLOCKADE,  SEPTAL  LESIONS,  AND  DRL  PERFORMANCE  IN 
THE  RAT. 

226305  01-04 
DISINHIBITORY  EFFECTS  OF  SEPTAL  LESIONS  AND  SCOPOLAMINE 
HYDROBROMIOE   (PH  D.  DISSERTATION). 

227099  01-04 
CHANGES  IN  EXCITABILITY  OF  AMYGDALOID  AND  SEPTAL  NUCLEI 
INDUCED  BY  MEDAZEPAM  HYDROCHLORIDE 

241232  03-03 


THE  EFFECTS  OF  SEPTAL  LESIONS  OR  SCOPOLAMINE  INJECTIONS  ON 
RETENTION  OF  HABITUATION  TO  A  NOVEL  ENVIRONMENT. 

241546  03-( 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS. 

249664  04-( 
SEPTI 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWINi 
6-OHDA  LESIONS  OF  THE  NUCLEUS-ACCUMBENS  SEPTI  AND  CORPUS- 
STRIATUM 

226937  01 -{ 
DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319  02-( 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIEC 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-( 
SEPTUM 

PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 

MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-( 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  ANC 
HYPOTHALAMUS. 

238744  03-( 
CHOLINERGIC  MODIFICATION  OF  DRL  PERFORMANCE  IN  NORMAL  RATS 
AND  RATS  WITH  LESIONS  OF  THE  SEPTUM.  (PH.D.  DISSERTATION). 

241681  03-( 
SEQUELAE 

BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION: 
POSTSYNAPTIC  SUPERSENSITIVITY^ 

229434  01 -C 
SEQUENCE 

CHOLECYSTOKININ  ELICITS  THE  COMPLETE  BEHAVIORAL  SEQUENCE  OF 
SATIETY  IN  RATS 

245612  04-C 
SEQUENTIAL 

HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS. 

239939  03-1 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03-1 
SERENTIL 

AN  OPEN  STUDY  OF  MESORIDAZINE  (SERENTIL)  IN  CHRONIC 
SCHIZOPHRENICS. 

227821  01-C 
SERIAL 

DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PH  D.  DISSERTATION). 

239533  O3-0 
SEROTONERGIC 

CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231119  01-0 
THE  ACTION  OF  FENFLURAMINE  AND  P-CHLOROAMPHETAMINE  ON 
SEROTONERGIC  MECHANISMS:  A  COMPARATIVE  STUDY  IN  RAT  BRAIt 
NUCLEI.  (UNPUBLISHED  PAPER). 

232325  01-0 
EFFECTS  OF  BENZODIAZEPINES  ON  CENTRAL  SEROTONERGIC 
MECHANISMS. 

232508  01-0 
DIFFERENTIAL  DRUG  EFFECTS  ON  BRAIN  SEROTONERGIC  SYSTEMS 

234805  02-0 
PARTICIPATION  OF  ADRENO,  DOPAMINE,  AND  SEROTONERGIC 

MECHANISMS  OF  THE  SEPTUM  IN  CONDITIONED  REFLEX  REACTIONS 
TO  VARIOUS  BIOLOGICAL  MODALITIES  IN  RATS. 

236828  02-0 
SEROTONERGIC  INVOLVEMENT  WITH  NEUROLEPTIC  CATALEPSY. 

237781  02-0: 
ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-a 
BEHAVIORAL  EFFECTS  OF  L-5-HYDROXYTRYPTOPHAN  AFTER 

DESTRUCTION  OF  ASCENDING  SEROTONERGIC  PATHWAYS  IN  THE  RAT 
THE  ROLE  OF  CATECHOLAMINERGIC  NEURONS. 

241251  03-(V 
PARTICIPATION  OF  THE  SEROTONERGIC  SYSTEM  OF  THE  BRAIN  IN  THE 
REGULATION  OF  EMOTIONAL  REACTIVITY. 

242544  03-0: 


S-298 


I 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC  ACIDDIETHYLAMIDE  ON 
EFFLUX  OE  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW 

246846  0403 
THE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS. 

248159  0403 
SOME  EFFECTS  OF  THE  8EHAVI0RALLY  ACTIVE  DRUG,  PHENITRONE,  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 
PHARMACOLOGICAL  EVIDENCE  FOR  THE  CENTRAL  SEROTONERGIC 
EFFECTS  OE  MONOMETHOXYAMPHETAMINES 

253)08  04  04 
BEHAVIORAL  STUDIES  FOLLOWING  LESIONS  OF  THE  MESOLIMBIC  AND 
MESOSTRIATAL  SEROTONERGIC  PATHWAYS. 

253255  0404 
SEROTONIN 

PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  POLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01  08 
DIFFERENTIAL  EFFECTS  OF  SEROTONIN  ON  TURNING  AND  STEREOTYPY 
INDUCED  BY  APOMORPHINE 

226405  01-04 
THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  BRAIN 
CATECHOLAMINES  AND  SEROTONIN. 

226726  01  03 
THE  EFFECT  OE  ERGOTAMINE  AND  METHYSERGIDE  ON  SEROTONIN 
METABOLISM  IN  THE  RAT  BRAIN. 

226826  01-03 
ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN. 

226870  01-03 
RAPID  REPLETION  OF  BRAIN  SEROTONIN  IN  MALNOURISHED  CORN-FED 
RATS  FOLLOWING  L-TRYPTOPHAN  INJECTION. 

226873  01-03 
STEREOSPECIFIC  BINDING  OF  D-LYSERGICACID  DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01-12 
DIFFERENTIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 
SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN 

227387  01-03 
STUDY  OF  SEROTONIN  AND  ACTH  BRAIN  LEVELS  AND  BEHAVIOR 

229498  01  03 
SEROTONIN  INHIBITION  AND  SLEEP 

229924  01-14 
THE  EFFECTS  OF  SEROTONIN  ON  FEEDING  IN  THE  RABBIT. 

2.30872  01  04 
PHARMACOLOGIC  STUDIES  OF  NARCOLEPSY  INVOLVING  SEROTONIN, 
ACETYLCHOLINE,  AND  MONOAMINE-OXIDASE    (UNPUBLISHED  PAPER) 

232324  01-11 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  01  04 
THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST.  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS 

233290  02-03 
THE  EFFECT  OF  SEROTONIN  INJECFION  INTO  THE  BULBAR  STRUCTURES 
ON  HEMODYNAMICS. 

236831  02-03 
EFFECTS  OF  TRAZODONE  ON  SEROTONIN  IN  THE  BRAIN  AND  PLATELETS 
OF  THE  RAT 

237240  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 
AND  SEROTONIN  IN  RATS  -  ACUTE  MORPHINE  ADMINISTRATION. 

237736  02-03 
EFFECTS  OF  MORPHINE  ON  THE  TURNOVER  OF  BRAIN  CATECHOLAMINES 

AND  SEROTONIN  IN  RATS  -•  CHRONIC  MORPHINE  ADMINISTRATION 

237737  02-03 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 

AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  02-03 
ON  THE  DIRECT  OR  INDIRECT  INFLUENCE  OF  APOMORPHINE  ON  CENTRAL 
SEROTONIN  NEURONS 

237785  02-03 
EFFECT  OF  ACUTE  AND  CHRONIC  IPRINDOLE  ON  SEROTONIN  TURNOVER 
IN  MOUSE  BRAIN. 

237922  0203 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED,  CORN-FED  RATS. 

238676  03-03 
RELATIONSHIP  BETWEEN  SEROTONIN  IN  THE  INTACT  BRAIN  AND 
RELEASE  OF  PROTEIN  INTO  THE  PERFUSED  CEREBROSPINAL  FLUID 
COMPARTMENT  OF  CONSCIOUS  AND  ANESTHETIZED  RABBITS 

238681  03-03 


MARIJUANA  INDUCED  ALTERATIONS  IN  FEEDING  BEHAVIOR  AND 
HYPOTHALAMIC  CONCENTRATIONS  OF  NOREPINEPHRINE  AND 
SEROTONIN  IN  THE  RAT, 

238720  03-04 

THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MICE. 

238737  03-03 
CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 

CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 

ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 
INJECTIONS  OF  AMINO  ACIDS  THAT  ALTER  BRAIN  SEROTONIN  INCREASE 
THE  SENSITIVITY  TO  ELECTROSHOCK  IN  RATS. 

238783  03-03 
EFFECT  OF  CLOZAPINE  ON  THE  METABOLISM  OF  SEROTONIN  IN  RAT 
BRAIN. 

239862  03-03 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602 

239957  03-03 
ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 
BEHAVIOUR  OF  CATS. 

239978  03-04 
HALLUCINOGENIC  INDOLEAMINES:  PREFERENTIAL  ACTION  UPON 
PRESYNAPTIC  SEROTONIN  RECEPTORS. 

240073  03-03 
SEROTONIN  (5-HT)  SYSTEMS  IN  PSYCHOTIC  STATES. 

240076  03-12 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -•  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN.  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES 

4) 
THE  ROLE  OF  BRAIN  SEROTONIN  IN  EMOTIONAL  BEHAVIOR  OF  THE  RAT. 

241363  03-04 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-03 
SEROTONIN    THE  CRUCIAL  SUBSTANCE  THAT  TURNS  DREAMS  ON  AND 
OFF 

241505  03-12 
THE  ROLE  OF  SEROTONIN  IN  THE  DISCRIMINATIVE  STIMULUS 
PROPERTIES  OF  MESCALINE   (PH  D   DISSERTATION). 

241573  03-03 
PHARMACOLOGICAL  ANALYSIS  OF  SOME  ADRENOMIMETIC  EFFECTS  OF 
SEROTONIN. 

241982  03-05 
CEREBRAL  ARTERIAL  SPASM    PART  4    IN  VITRO  EFFECTS  OF 

lEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN  INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-03 
HYPERPHAGIA  AND  OBESITY  FOLLOWING  SEROTONIN  DEPLETION  BY 
INTRAVENTRICULAR  P-CHLOROPHENYLALANINE 

243878  04-04 
EFFECTS  OF  L-DOPA  ON  EMOTIONAL  REACTIONS  AND  METABOLISM  OF 
SEROTONIN  IN  THE  RAT  BRAIN. 

244455  04-04 
DEMONSTRATION  OF  AN  INVERSEIY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  0403 
EFFECT  OF  3-P  TRIFLUOROMETHYLPHENOXY  N  METHYL-3 

PHENYLPROPYLAMINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN  BY  4- 
CHLOROAMPHETAMINE 

246847  04-03 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3  P  TRIFLUOROMETHYLPHENOXY  N- 
METHYL-3-PHENYLPROPYLAMINE 

246848  04-03 
FENFLURAMINE:  EVIDENCE  FOR  A  NEUROTOXIC  ACTION  ON  MIDBRAIN 

AND  A  LONG-TERM  DEPLETION  OF  SEROTONIN 

247214  04-05 
SYNAPTOSOMAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P  CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04-05 


S-299 


Subject  Index 


Psychopharmacology  Abstracts 


IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN''. 

248604  04-03 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN. 

249265  0405 
BEHAVIORAL  EVIDENCE  FOR  THE  RAPID  RELEASE  OF  CNS  SEROTONIN  BY 
PCA  AND  FENFLURAMINE. 

250083  04-04 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY!  10140,  ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04-03 
COCAINE  AND  LITHIUM:  NEUROBIOLOGICAL  ANTAGONISM  IN  THE 
SEROTONIN  BIOSYNTHETIC  SYSTEM  IN  RAT  BRAIN. 

252514  04-03 
SEROTONIN  ANTAGONISM  IN  ISOLATED  CANINE  CEREBRAL  ARTERIES. 

252757  04-03 
SEROTONIN-INDUCED 

CEREBRAL  ARTERIAL  SPASM.  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY. 

243797  04-03 
SEROTONINERGIC 

STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 
PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  0303 
POSSIBLE  INVOLVEMENT  OF  SEROTONINERGIC  MECHANISMS  IN  THE 
INDUCTION  OF  TURNING  BY  LSD-25  IN  THE  RAT. 

251405  04-03 
EFFECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-03 
SERUM 

CLOZAPINE  INCREASES  RAT  SERUM  PROLACTIN  LEVELS. 

226869  01-03 
SERUM  AMINO-ACIDS  AND  BRAIN  TRYPTOPHAN  UPTAKE. 

227712  01-03 
SERUM  GROWTH  HORMONE,  SERUM  IMMUNOREACTIVE  INSULIN  AND 
BLOOD  GLUCOSE  RESPONSE  TO  ORAL  AND  INTRAVENOUS  DIAZEPAM 
IN  MAN. 

229042  01-13 
RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES. 

230739  01-13 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-08 
CORRELATION  OF  CHLORPROMAZINE  LEVELS  IN  RAT  BRAIN  AND  SERUM 
WITH  ITS  HYPOTHERMIC  EFFECT. 

236527  02-03 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 

0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
A  GAS  CHROMATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL: 

A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-16 
GAMMA-HYDROXYBUTYRATE:  CORRELATION  OF  SERUM  AND 

CEREBROSPINAL  FLUID  LEVELS  WITH  ELECTROENCEPHALOGRAPHIC 
AND  BEHAVIORAL  EFFECTS. 

237826  02-03 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS. 

237902  02-13 
THE  INFLUENCE  OF  LITHIUM  ON  SERUM  CERULOPLASMIN. 

237924  02-03 
SERUM  CREATINE  PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT. 

237928  02-15 
SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 
PSYCHIATRIC  PATIENTS 

238552  02-13 
PASSIVE  BARBITURA.TE  IMMUNITY  IN  MICE:  EFFECT  ON  SERUM  LEVELS 
AND  PHARMACOLOGIC  RESPONSE  TO  ADMINISTERED  BARBITURATES. 

238763  03-03 
FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

239684  03- 1 3 


EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS:  ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE. 

239828  03-03 
THE  EFFECT  OF  NEUROLEPTICS  ON  SERUM  PROLACTIN  IN  SCHIZOPHRENIC 
PATIENTS. 

239931  03-08 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG-TERM 
LITHIUM  ADMINISTRATION. 

240054  03-13 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY, 

240473  03-15 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIAAARY  HYPERTENSION. 

241294  03-13 
SERUM  LITHIUM  MEASUREMENT  OF  THE  EEL  FLAMEPHOTOMETER. 

241777  03-16 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUAAAN  SERUM  PROTEIN  AND  HUAAAN  ALBUMIN. 

244131  04-13 
SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS. 

244591  04-13 
PARAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFTER 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04-17 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 
LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  04-03 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 
THE  RAT  BRAIN. 

247213  04-03 
METHAQUALONE  IN  HUMAN  SERUM  AND  CEREBROSPINAL  FLUID  AFTER 
ORAL  INTAKE. 

250657  04-13 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 
ALBUMIN    -  I.  GEL  FILTRATION  STUDIES. 

251176  04-01 
INTERACTION  OF  BENZODIAZEPINE  DERIVATIVES  WITH  BOVINE  SERUM 

ALBUMIN    -  II.  CIRCULAR  DICHROISM  STUDIES. 

251177  04-01 
RESOLUTION,  PURIFICATION  AND  CHARACTERIZATION  OF  RABBIT 

SERUM  ATROPINESTERASE  AND  COCAINESTERASE. 

251180  04-01 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY: 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04-15 
SERUM  CONCENTRATION  OF  CARBAMAZEPINE:  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301 1  04-07 
SERVICES 

THE  LITHIUM  CLINIC:  A  NEW  MODEL  FOR  THE  DELIVERY  OF 
PSYCHIATRIC  SERVICES. 

234699  02-09 
SETTINGS 

MANAGEMENT  OF  THE  ELDERLY  HYPERTENSIVE  IN  FOUR  PRACTICE 
SETTINGS. 

227924  OMl 
SEX 

PSYCHOTROPIC  ACTION  OF  SEX  HORMONES. 

229470  01-14 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 
AND  SEX  BEHAVIOR. 

238800  03-04 
47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04-10 
SEXES 

EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK    II.  EFFECTS  PRESENT  IN  BOTH  SEXES. 

245713  04-04 
SEXUAl 

THIORIDAZINE  AND  SEXUAL  DYSFUNCTION. 

236318  02-15 
CANNABIS  RESIN  AND  SEXUAL  BEHAVIOUR  IN  THE  LABORATORY 
MOUSE. 

237715  02  04 
INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE. 

242743  03-04 
EFFECTS  OF  ESTROGEN  AND  ANDROGEN  ON  THE  SEXUAL  BEHAVIOUR  OF 
THE  OVARIECTOMIZED  EWE. 

248223  04  04 


S-300 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


SHAKE 

APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE 

230836  01  04 
WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES, 

241231  03-04 
SHAKES 

REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT, 

23261  7  02-03 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 
HALOPERIDOL 

248274  04-03 
SHAKING 

POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT 

250087  04-02 
SHARES 

5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS   (UNPUBLISHED  PAPER), 

227802  01-04 
SHEEP 

A  STUDY  OF  THE  METABOLISM  AND  RELEASE  OF  DOPAMINE  AND 

AMINO-ACIDS  FROM  NERVE  ENDINGS  ISOLATED  FROM  SHEEP  CORPUS- 
STRIATUM, 

241206  03-03 
SHIFT 

NMR  STUDY  OF  AMPHETAMINES  USING  EUROPIUM  SHIFT  REAGENTS, 

239660  03-0! 
SHOCK 

NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
EFFECTS  OF  D-AMPHETAMINE  ON  F-l  SHOCK  PRESENTATION  WITH 
SDELTA  PROBE. 

237699  02-04 
ELECTROCONVULSIVE  SHOCK  RAISES  PROSTAGLANDINS-F  IN  RAT 
CEREBRAL  CORTEX. 

237921  02-03 
INTRASPECIES  AGGRESSION  INDUCED  BY  ELECTRICAL  SHOCK  AND 
REACTIVITY  AFTER  RAPHE  LESIONS  IN  THE  RAT.  EFFECTS  OF 
PHYSOSTIGMINE. 

239829  03-04 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS, 

241979  03-04 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  04-04 
EFFECTS  OF  ALCOHOL,  CHLORDIAZEPOXIDE.  COCAINE,  AND 
PENTOBARBITAL  ON  RESPONDING  MAINTAINED  UNDER  FIXED- 
INTERVAL  SCHEDULES  OF  FOOD  OR  SHOCK  PRESENTATION, 

2501 1 1  04-04 
INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYDROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04-03 
SHOCK-ELICITED 

WEIGHT  LOSS  AND  SHOCK  ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS 

249671  04-04 
SHORT-LASTING 

THYROTROPIN  RELEASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK- 
ACTING  BUT  SHORT  LASTING  ANTIDEPRESSANT. 

235630  02-09 
SHORT-TERM 

BIOGENIC  AMINES  AND  IHE  EFFECT  OF  SHORT-TERM  LITHIUM 
ADMINISTRATION  ON  OPEN-FIELD  ACTIVITY  IN  RATS. 

225573  01-04 
SIIORl  TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PIACEBO  IN  DEPRESSION:  A  DOUBLE  BLIND  STUDY. 

227214  01  09 


NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 
THE  ROLE  OF  CENTRAL  AND  PERIPHERAL  CHOLINORECEPTORS  IN  THE 
PROCESSES  OF  SHORT-TERM  MEMORY. 

23671 1  02-04 
NEUROPSYCHOLOGICAL  INVESTIGATIONS  ON  THE  SHORT-TERM  EFFECTS 
OF  BIPERIDEN  (AKINETON)  IN  PARKINSONS  DISEASE 

238516  02-11 
VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT  TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS. 

24431 1  04-04 
A  PILOT  STUDY  OF  THE  SHORT  TERM  PSYCHOTROPIC  EFFECTS  OF  GPA- 
2640. 

250516  04-10 
SHOWING 

FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
SHR 

EFFECTS  OF  BARBITURATES  ON  BLOOD  PRESSURE  IN  LIDOCAINE 
INJECTED  SHR. 

241405  03-03 
SHUTTLE 

MORPHINE  ENHANCEMENT  OF  SHUTTLE  AVOIDANCE  PREVENTED  BY 
ALPHA-METHYLTYROSINE. 

230825  01-04 
SHUTTLEBOX 

FACILITATION  AND  DISRUPTION  BY  MESCALINE  OF  SHUTTLEBOX 
AVOIDANCE  IN  RATS.  (PH,D,  DISSERTATION), 

226991  01-12 
5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5-MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS.  (UNPUBLISHED  PAPER). 

227802  01-04 
RELATIONS  BETWEEN  ORIENTING.  PSEUDOCONDITIONED  AND 
CONDITIONED  RESPONSES  IN  THE  SHUTTLEBOX      A 
PHAR/WACOLOGICAL  ANALYSIS  BY  MEANS  OF  LSD  AND  DIBENAMINE 

230570  01-04 
EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03-04 
ACUTE  EFFECTS  OF  MORPHINE  AND  CHLORPROMAZINE  ON  THE 

ACQUISITION  OF  SHUTTLEBOX  CONDITIONED  AVOIDANCE  RESPONSE 

251989  04  04 
SIALOGLYCOPROTEINS 

EFFECT  OF  DELTA9  TETRAHYDROCANNABINOL  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-03 
SIAMESE 

TWENTY  FOUR  HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENDENS). 

242892  04-04 
SICK 

DIAZEPAM  USE  IN  MILITARY  SICK  CALL, 

240278  03-17 
SICKNESS 

CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS    EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS, 

240237  03-04 
SIDE-CHAINS 

DRUGS  DERIVED  FROM  CANNABINOIDS.  5.  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS 

248648  04-02 
SIDE-EFFECTS 

EVALUATION  OF  SIDE-EFFECTS  ON  NEUROTICS    -  A  TEST  USING 
MES0RIDA2INE  AND  PLACEBO. 

225686  01  15 
OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECTS  OF 
TRICYCLIC  ANTIDEPRESSANTS 

226411  01  09 
THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS    LONG- 
TERM  EFFECTS  AND  SIDE  EFFECTS, 

226612  01-09 
SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  WITH  PARTICULAR 
REFERENCE  TO  DOTHIEPIN 

226897  0115 
CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS      A 
RISK  IN  THE  USE  OF  THESE  DRUGS. 

23I3I70I   15 
SIDE-EFFECTS  OF  PSYCHOTROPIC  DRUGS. 

231991  01  15 


S-301 


■< 

« 

e 


a, 

39. 


Subject  Index 

NONCNS  SIDE-EFFECTS  OF  NEUROLEPTICS. 

231994  0115 
IMPLICATIONS  OF  PHENOTHIAZINE  SIDE-EFFECTS   A  STUDY  OF 
ANTIPARKINSONIAN  AGENTS  IN  AN  OLDER  POPULATION. 

238978  03-15 
THE  INFLUENCE  OF  FOOD  ON  SIDE-EFFECTS  AND  ABSORPTION  OF 
LITHIUM. 

238998  03-15 
THERAPY  OF  PSYCHOPHARMACEUTICAL  SIDE-EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID,  BC-51). 

239782  03-15 
SIDE-EFFECTS  FROM  LONG-TERM  USE  OF  STIMULANTS  IN  CHILDREN 

SIDE-EFFECTS  OF  DRUGS  AS  MODELS  OF  ILLNESSES  ''    ^ 

248850  04-15 
SIDE-EFFECTS  OF  LITHIUM  THERAPY 

250209  04-15 
SIDE-EFFECTS  OF  LITHIUM  THERAPY  AND  THEIR  TREATMENT. 

251712  04-15 
SUSTAINED-RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE  BLIND  STUDY 
SERUM  LITHIUM  LEVELS,  SIDE-EFFECTS.  AND  PLACEBO  RESPONSE. 

COMPARISON  OF  DEPOT  FLUPHENAZINES:  DURATION  OF  ACTION  AND 

INCIDENCE  OF  SIDE-EFFECTS 
S.DMAN  252006  04-08 

BEHAVIORAL  DEPRESSION  IN  SIDMAN  AVOIDANCE  LEARNING  INDUCED 

BY  DOPAMINE-BETA  HYDROXYLASE  INHIBITORS. 

253450  04-04 
SIONOCARB 

STUDY  OF  A  NEW  PSYCHOSTIMULANT  -    SIDNOCARB. 

236363  02  10 
SIGNIFICANCE 

FUNCTIONAL  SIGNIFICANCE  OF  CENTRAL-NERVOUS-SYSTEM 

NOREPINEPHRINE  AND  DOPAMINE    A  PSYCHOPHARMACOLOGICAL 
STUDY   (PH.D.  DISSERTATION). 

231437  0104 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS,  DOES  IT  HAVE 

SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 
,,^,„,  233488  02-14 

ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-01 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE. 

250989  04-15 
SIGNS 

NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID  1  IKE 
SUBSTANCE  IN  THE  RAT 

238713  03-04 

THE  EFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHILDREN 

251569  04  14 
SILVER 

THE  SILVER  VIOLIN  STRING 

229236  01-09 
SIMILARITIES 

NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION- 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 
„„,,^  227134  01-03 

DRUG-INDUCED  STEREOTYPED  BEHAVIOR:  SIMILARITIES  AND 
DIFFERENCES. 

233963  02-03 
SIMPLE 

THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 
SCHIZOPHRENIA,  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

230823  01-08 

A  SIMPLE  METHOD  OF  EVALUATING  THE  COMPETITIVE  INTERACTION  OF 
REVERSIBLE  INHIBITORS  WITH  CHOIINESTERASES. 

231072  01-06 

ON  ONE  OF  THE  VARIANTS  OF  SIMPLE  SCHIZOPHRENIA  IN  THE  LIGHT  OF 
PSYCHOPHARMACOTHERAPY, 

236725  02-08 

A  RAPID,  SIMPLE  AND  MORE  SENSITIVE  METHOD  FOR  THE 
DEMONSTRATION  OF  CENTRAL  CATECHOLAMINE  CONTAINING 
NEURONS  AND  AXONS  BY  GLYOXYLIC-ACID  INDUCED  FLUORESCENCE- 
II    A  DETAILED  DESCRIPTION  OF  METHODOLOGY    (UNPUBLISHED 
PAPER). 

236875  02-06 
SIMPLIFIED 

SIMPLIFIED  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01  16 
SIMULATED 

MENTAL  ILLNESS  AND  SIMULATED  DRIVING,  BEFORE  AND  DURING 
TREATMENT 

241425  03-15 


Psychopharmacology  Abstrai 


SINEQUAN 

EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 

NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES. 

230818  01 
SINGLE 

INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 
HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATI 
OF  CHLORPROMAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZI^ 

227129  01 
A  SINGLE  DOSE  ANTIANXIETY  DRUG:  A  REPORT  FROM  THE  GENERAL 
PRACTITIONER  RESEARCH  GROUP 

227914  01 
PLASMA  LEVELS  OF  MESORIDAZINE  AND  ITS  METABOLITES  AND 
CLINICAL  RESPONSES  IN  ACUTE  SCHIZOPHRENIA  AFTER  A  SINGLE 
INTRAMUSCULAR  DRUG  DOSE. 

229446  01 
EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  02 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  ( -f )  AMPHETAMINE 

241257  03 
EFFECTS  OF  A  SINGLE  ADMINISTRATION  OF  CLOZAPINE  ON  MOUSE 
BRAIN  CATECHOLAMINES 

241416  03 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSI 
NEUROSIS. 

246300  04 
PARAMETHADIONE  AND  METABOLITE  SERUM  LEVELS  IN  HUMANS  AFT 
A  SINGLE  ORAL  PARAMETHADIONE  DOSE. 

246969  04 
EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THI 
NUCLEUS  RAPHE  DORSALIS. 

249249  04 
STUDIES  ON  SINGLE  DOSE  TOLERANCE  DEVELOPMENT  TO  MORPHINE  U 
MICE. 

249288  04 
PHARAAACOKINETICS  OF  METHOTRIMEPRAZINE  AFTER  SINGLE  AND 
MULTIPLE  DOSES. 

250422  04- 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

251070  04- 
BENZODIAZEPINES:  GABA  AND  GLYCINE  RECEPTORS  ON  SINGLE 
NEURONS  IN  THE  RAT  MEDULLA. 

252521  04- 
PAVOR-NOCTURNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  01 
NEUROLEPTIC  DOSAGE. 

252955  04- 
REINITIATION  OF  SENSITIVITY  TO  NALOXONE  BY  A  SINGLE  NARCOTIC 
INJECTION  IN  POSTADDICTED  MICE. 

253112  04- 
SINGLE-BLIND 

THE  PROBLEM  OF  POST-PSYCHOTIC  SCHIZOPHRENIC  DEPRESSIONS  AND 
THEIR  PHARMACOLOGICAL  INDUCTION:  LONG-TERM  STUDIES  WITH 
FLUSPIRILENE  AND  PENFLURIDOL  AND  SINGLE  BLIND  TRIAL  WITH 
FLUPHENAZINE-DECANOATE  AND  FLUPENTHIXOL-DECANOATE. 

239823  03-1 
SINGLY 

DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I    THEORETIC Al 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01- 
ORUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS    II    FIVE 
EXPERIMENTS. 

232518  01-1 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  III.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE;  APPLICATION  OF 
MATHEMATICAL  MODELS. 

232519  01-1 
DRUG  INTERACTIONS    THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS    IV   THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  01-1 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS   V   SUMMARY 
AND  CONCLUSIONS. 

232521  01-1 
COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT- 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS,  USED  SINGLY  AND  IN  COMBINATION, 

246694  04-1 


S-302 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORMED 
SINGLY  AND  IN  COMBINATION. 

253381  04- 14 
SINTAMIl 

DOUBLE-BUND  TRIAL  OF  SINTAMIL  IN  DEPRESSION. 

231603  01  10 
PRELIMINARY  EXPERIENCE  WITH  PARENTERAL  SINTAMIL  IN  TREATMENT 
OF  DEPRESSION. 

235348  02-09 
SITES 

STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RAT 
BRAIN. 

229435  01-03 
CIRCADIAN  CYCLES  IN  BINDING  OF  3H-ALPREN0L0L  TO  BETA 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 
SITES  OF  ACTION  OF  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  OF 
PHYSICAL  DEPENDENCE  IN  RATS:  I   COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS 

241223  03-04 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES;  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 
I  246856  04- 1 3 

ISITUATION 

COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
SKELETAL 

EFFECT  OF  AMPHETAMINE  AND  GUTIMIN  ON  ADAPTIVE  CHANGES  IN 
ARTERIAL  PRESSURE  ARISING  IN  RESPONSE  TO  CONTRACTION  OF  THE 
SKELETAL  MUSCLES 

241988  03-03 
SKELETAL  MUSCLE  NECROSIS  FOLLOWING  MEMBRANE  ACTIVE  DRUGS 
PLUS  SEROTONIN. 

243813  04-03 
SKF-S2S-A 

ACUTE  SEDATIVE  PROPERTIES  OF  SKF-525-A  IN  RATS:  IMPLICATIONS  FOR 
ITS  USE  AS  A  METABOLISM  INHIBITOR  IN  THE  STUDY  OF 
PSYCHOACTIVE  DRUGS. 

225572  01-03 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHYL- 
DIPHENYLPROPYLACETATE  (SKF-525-A)  ON  MESCALINE  INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE, 

241349  03-04 
SKILLS 

EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 
FLUPENTHIXOL,  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING. 

229907  01-14 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS.  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 
•KIN 

BENZODIAZEPINES:  A  COMPARISON  OF  THEIR  EFFECTS  IN  MICE  ON  THE 
MAGNITUDE  OF  THE  PALMAR  SKIN  CONDUCTIVITY  RESPONSE  AND  ON 
PENTYLENETETRAZOL-INDUCED  SEIZURES 

227694  01-03 
CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS. 

239058  03-14 
HABITUATION  TO  ITERATIVE  PHOTOSTIAAULATION  IN  THE  PALMAR  SKIN 
CONDUCTANCE  RESPONSE  OF  MICE.  ITS  DELAY  BY 
PSYCHOANALEPTICS 

248514  04-04 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04-12 
ilEEP 

EFFECTS  OF  CLONIDINE  AND  BS  100-141  ON  THE  EEG  SLEEP  PATTERN  IN 
RATS. 

226728  01-03 
EFFECTS  OF  A  NEW  BUTYROPHENONE  DERIVATIVE  (BURONIL)  ON 
NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

227140  0114 
CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01-03 
SLEEP  AND  ITS  DISTURBANCES  IN  THE  CHILD   CONTRIBUTIONS  OF 
ELECTROPHYSIOLOGY 

228091  01-11 
HYPNOTICS  AND  SLEEP:  CLASSIFICATION,  METABOLISM,  MECHANISM  OF 
ACTION  OF  HYPNOTICS  AND  ALTERATIONS  OF  PHASES  OF  SLEEP  BY 
HYPNOTICS. 

228094  01-14 


HOW  DRUGS  ACT  -  11.  DRUGS  AND  SLEEP 

228997  01-13 
ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 
FLUPHENAZINE-DECANOATE 

229557  01-14 
SEROTONIN  INHIBITION  AND  SLEEP. 

229924  01-14 
CLINICAL  USE  OF  DRUGS  FOR  SLEEP  DISTURBANCES. 

230119  01-17 
EFFECTS  OF  PROMETHAZINE  ON  NOCTURNAL  SLEEP  IN  NORMAL  MAN. 

230867  01-14 
REM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 
EFFECTS  OF  PSYCHOTROPIC  DRUGS  ON  THE  PGO  ACTIVITIES  (PGO 
ACTIVITY  IN  THE  REM  SLEEP  AND  RESERPINE-INDUCED  PGO  ACTIVITY). 

233077  02-04 
ANALYSIS  OF  VARIANCE  STUDY  OF  A  SLEEP  INDUCING  DRUG. 

233698  02-07 
A  1,4  BENZODIAZEPINE,  TEMAZEPAM  (K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR 

237122  02-14 
THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS 

237696  02-14 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT 

237780  02-04 
EFFECT  OF  FLURAZEPAM  ON  SLEEP  SPINDLES  AND  K-COMPLEXES 

238507  02-14 
SLEEP  AND  HYPNOTIC  DRUGS:  THE  PHYSIOLOGY,  PHARMACOLOGY  AND 
CLINICAL  ASPECTS  OF  SLEEP. 

239029  03  14 
CHANGES  IN  SKIN  POTENTIAL  LEVEL  DURING  SLEEP  IN  PSYCHIATRIC 
PATIENTS. 

239058  03-14 
SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO, 

DRUG  AND  A  FOOD  DRINK. 

239059  03-14 
VALUE  OF  REM  SLEEP. 

239258  03-14 
EEG  SLEEP  STUDIES  OF  INSOMNIACS  UNDER  FLUNITRAZEPAM 
TREATMENT. 

239819  03-14 
DOUBLE-BLIND  TRIAL  OF  DIFFUCAPS  AMITRIPTYLINE  AND  ORDINARY 
AMITRIPTYLINE  IN  SLEEP  DISORDERS  OF  DEPRESSIVE  ORIGIN 

240032  03-09 
SLEEP  ATTACKS. 

240260  03-11 
NARCOLEPSY:  REM  SLEEP  SUPPRESSION  BY  L-DOPA. 

240657  03-11 
STUDIES  ON  SLEEP  EFFECTS  OF  ALIMEMAZIN  (THERALENE). 

240710  03-11 
CONTROLLED  COMPARISON  OF  ESTAZOLAM  AND  NITRAZEPAM  AS 
HYPNOTICS  ON  THE  PREOPERATIVE  NIGHT  SLEEP. 

241273  03-14 
BRAIN  FUNCTION  AND  BIOGENIC  AMINES  (4).  ROLE  OF  MONOAMINERGIC 
MECHANISM  ON  SELECTIVE  INHIBITION  OF  PARADOXICAL  SLEEP 

241388  03-03 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF  STIMULATION  AND  SLEEP  IN  THE 
RAT.  (PH.D.  DISSERTATION). 

241678  03-03 
DO  PLACEBOS  ALTER  SLEEP'' 

241753  03-17 
NEUROREGULATORS  AND  SLEEP  MECHANISMS. 

241902  03-17 
EFFECT  OF  10  DAYS  RESERPINE  OR  APOMORPHINE  ADMINISTRATION  ON 
SLEEP  CYCLES  IN  RATS. 

242732  03-04 
ON  SLEEP. 

242861  04-17 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP 

243822  04-14 
THE  EFFECT  OF  PROLONGED  ADMINISTRATION  OF  NITRAZEPAM  ON 
SLEEP  CYCLES  IN  RATS 

244456  04-04 
A  COMPARISON  OF  THE  EFFECTS  OF  FLURAZEPAM  30  MG  AND 
TRIAZOLAM  0.5  MG  ON  THE  SLEEP  OF  INSOMNIACS. 

244686  04  11 
HUMAN  SLEEP  DURING  CHRONIC  MORPHINE  INTOXICATION. 

246304  04- 1 3 
EFFECTS  OF  THIENOOIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04-07 
DIFFERENTIAL  EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  THE  SLEEP  OF 
DEPRESSED  PATIENTS. 

248160  04-10 


S.303 


Subject  Index 


Psychopharmacology  Abstrac 


Ci 

e 


3, 


EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS 

248629  04-13 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS, 

249281  0402 
EFFECTS  OF  ALPHA-METHYL  P  TYROSINE  (AMPT)  ON  THE 

ELECTROENCEPHALOGRAM  (EEG)  OF  THE  CERVEAU  ISOLE  AND  SLEEP 
OF  THE  CHRONIC  MESENCEPHALIC  CAT 

249307  0403 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  RfOUCTION  OF  ETHANOL 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH). 

250110  04-03 
A  CLINICAL  TRIAL  OF  TEMAZEPAM,  A  SLEEP  INDUCER    IN  HOSPITAL 
PATIENTS, 

251006  04-07 
REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF  ADMINISTRATION    EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS 

251533  04-04 
THE  EFFECTIVENESS  OF  DIPHENHYDRAMINE  HCL  IN  PEDIATRIC  SLEEP 
DISORDERS. 

251827  04-14 
Y-MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE,  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP, 

252171  04-04 
THE  EFFECTS  OF  5-HYDROXYTRYPTOPHAN  AND  L-TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT. 

252216  04  03 
SLEEP  LABORATORY  STUDIES  OF  FLURAZEPAM:  A  MODEL  FOR 
EVALUATING  HYPNOTIC  DRUGS, 

252230  04-11 
SLEEP-WAKEFULNESS 

NEUROHUMORAL  MECHANISMS  RELATING  TO  CIRCADIAN  SLEEP- 
WAKEFULNESS  CYCLES  OF  HUMORAL  EXPERIMENTAL  ANIMALS. 

238971  03-03 
CHANGE  OF  THE  HEARTRATE  AND  SLEEP-WAKEFULNESS  CYCLE  AFTER 
ISOPROTERENOL  ADMINISTRATION  IN  WHITE  RATS. 

244449  04-04 
SLEEPING 

THE  EFFECT  OF  OUABAIN  AND  DIGITOXIN  ON  HEXOBARBITONE  SLEEPING 
TIME  IN  THE  MOUSE. 

225574  01-03 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01-04 
A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS. 

230870  01-04 
EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAL  TO  MICE. 

241403  03-03 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CYCLOBARBITAL-INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYME  ACTIVITIES  OF  C3H  MICE. 

242201  03-03 
SLICES 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE 

226651  01-02 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX.  STRIATUM 
AND  HYPOTHALAMUS  SLICES. 

238714  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3  ACETYLCHOLINE 
BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES. 

241254  03-03 
EFFECTS  OF  ETHANOL  ON  NEUROTRANSMITTER  RELEASE  BY  RAT  BRAIN 
CORTICAL  SLICES. 

246850  04  03 
AMPHETAMINE    EVALUATION  OF  D  ISOMERS  AND  L  ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINF  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX. 

248699  04-03 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04-03 
INFLUENCE  OF  MORPHINE  AND  NALOXONE  ON  THE  RELEASE  OF 
NORADRENALINE  FROM  RAT  CEREBELLAR  CORTEX  SLICES. 

248980  04-03 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO 


BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  04- 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04- 

UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBR> 

CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC-AMP  LEVELS 

251964  04- 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H  5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04- 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-00PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS. 

252217  04- 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04- 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS, 

25341 1  04- 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINtPHRINE  AND  3H-5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RA' 
OCCIPITAL  CORTEX, 

253691  04- 
SLOW 

DPH-INTOXICATION    -  CLINICAL  AND  NEUROPSYCHOLOGICAL 
EVALUATION  OF  A  SLOW  DPH  ELIMINATION, 

240692  03- 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP 

243822  04- 
DRUG-INDUCED  ALTERATIONS  OF  SLOW  POTENTIAL  RESPONSES  IN  THE 
RAT, 

249250  04-1 
INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  ! 
THYROTROPIN-RELEASING  HORMONE  IN  CATS, 

249281  04-1 
SLOW-RELEASE 

ABSORPTION  OF  LITHIUM  FOLLOWING  ADMINISTRATION  OF  SLOW- 
RELEASE  AND  CONVENTIONAL  PREPARATIONS, 

250725  04- 
SMOKE 

CEREBRAL  AND  CEREBELLAR  NEUROCHEMICAL  CHANGES  AND 

BEHAVIORAL  MANIFESTATIONS  IN  RATS  CHRONICALLY  EXPOSED  TO 
MARIJUANA  SMOKE, 

243181  04-( 
SMOKERS 

REDUCTION  IN  1  LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRON 
MARIJUANA  SMOKERS, 

229039  01- 
SMOKING 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM, 

225722  01-1 
TOXICITY  OF  MARIJUANA  AND  TOBACCO  SMOKING  IN  THE  BEAGLE 

229034  01 -C 
THE  EFFECT  OF  CHRONIC  MARIHUANA  SMOKING  ON  THE  BEAGLE  DOG. 

238806  03-C 
SMOOTH 

CONTRACTOR  EFFECT  OF  BARBITURATES  ON  SMOOTH  MUSCLE. 

230454  01-C 
THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01 -C 
SMOOTH  PURSUIT  EYE  MOVEMENTS,  AND  DIAZEPAM,  CPZ,  AND 
SECOBARBITAL 

246303  04-1 
DIFFERENTIAL  EFFECTS  OF  ETHYLALCOHOL  ON  CONTRACTION  OF 
ARTERIAL  SMOOTH  MUSCLE. 

251905  04-0 
DIFFERENTIAL  EFFECTS  OF  ETHANOL  AND  MANNITOL  ON  CONTRACTION 
OF  ARTERIAL  SMOOTH  MUSCLE. 

253113  04-0 
SNAIL 

LITHIUM  ACCUMULATION  BY  SNAIL  NEURONES  MEASURED  BY  A  NEW 
LM    SENSITIVE  MICROELECTRODE 

235589  02-0i 
EFFECT  OF  DEXTROAMPHETAMINE  ON  IDENTIFIED  CHOLINOCEPTIVE 
CELLS  OF  THE  SNAIL  BRAIN. 

238740  03  O: 


S-304 


fOLUME  14,  SUBJECT  INDEX 

EFFECTS  OF  5  7  OIHYOROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYOROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA, 

243799  04-03 

EFFECTS  OF  CANNABIS  RESIN  ON  SOCIAL  BEHAVIOUR  IN  THE 
LABORATORY  MOUSE 

225569  01-04 

LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS, 

229448  01-08 
THE  SOCIAL  FAMILIAL  REINSERTION  OF  THE  PSYCHOTIC  PATIENT 
THROUGH  THE  USE  OF  LONG-ACTING  NEUROLEPTICS. 

229552  01-17 

PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 

,  RESEARCH. 

231066  01-14 

'       EFFECTS  OF  DELTA9  TETRAHYDROCANNABINOL  ON  SOCIAL  BEHAVIOUR 
IN  THE  LABORATORY  MOUSE  AND  RAT 

237727  02-04 
BEHAVIORAL  EVIDENCE  OF  THE  INTERACTION  OF  PHENCYCLIDINE  WITH 
CATECHOLAMINES  IN  PRIMATE  SOCIAL  COLONIES. 

238696  03-04 
EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN, 

240475  03-14 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  ABNORMAL  SOCIAL  BEHAVIOR  IN 
THE  RHESUS  MONKEY.  (PH.D.  DISSERTATION). 

241109  03-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  MICE:  COMPARISON  BETWEEN  TWO  VEHICLES. 

244687  04-04 
THE  EFFECT  OF  PYRITHIOXINE  AND  PYRIDOXINE  ON  INDIVIDUAL 
BEHAVIOR,  SOCIAL  INTERACTIONS,  AND  LEARNING  IN  RATS 
MALNOURISHED  IN  EARLY  POSTNATAL  LIFE 

251991  04-04 
EFFECT  OF  AROUSAL  BY  SOCIAL  ISOLATION,  GROUPING,  AND  D- 
AMPHETAMINE  ON  INTER-MALE  AGGRESSION  IN  MICE  (MUS- 
MUSCULUS) 

253485  04-04 

iOCIOPSYCHIATRIC 

SOCIOPSYCHIATRIC  ASPECTS  OF  LONG-ACTING  NEUROLEPTICS. 

229553  01  17 
iOOIUM 

THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01-13 
EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM  OF  METHYLPREDNISGLONE  AND  ITS  SODIUM 
SUCCINATE, 

233001  02  13 
THE  EFFECT  OF  SMALL  CONCENTRATIONS  OF  SODIUM  PENTOBARBITAL 
ON  AUDITORY  EVOKED  RESPONSES. 

234682  02-03 
EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE,  L- 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02-04 
CURRENT  DETERMINATION  OF  LITHIUM  INDUCED  MINIMUM  SODIUM 
REQUIREMENT  IN  RATS 

237110  02-04 
EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATED 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN. 

237920  02-03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN 

238715  03-03 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL 

240074  03-14 
SODIUM  AMYLOBARBITONE  AND  THE  PATTERNING  EFFECT. 

244217  04-04 
SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY 

245344  04-11 
RENAL  LITHIUM,  SODIUM,  POTASSIUM,  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES.  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES. 

246856  04  13 
EFFECT  OF  RESTRICTION  OF  MOVEMENT  AND  BETA 

DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE  HYDROCHLORIDE  ON 
SODIUM  BARBITAL  ACTIVITY  IN  THE  RAT 

249278  04  04 


Subject  Index 


SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04  03 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H  5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES 

249667  04  03 
USE  OF  300-MSEC  MICROWAVE  IRRADIATION  FOR  ENZYME 

INACTIVATION-  A  STUDY  OF  EFFECTS  OF  SODIUM  PENTOBARBITAL  ON 
ACETYLCHOLINE  CONCENTRATION  IN  MOUSE  BRAIN  REGIONS. 

253106  04-03 

SOFT 

THE  EFFECTS  OF  METHYLPHENIDATE  ON  THE  SOFT  NEUROLOGICAL  SIGNS 
OF  HYPERACTIVE  CHILDREN 

251569  04-14 

SOLID 

LIQUID  LITHIUM  VS.  SOLID  LITHIUM:  AN  OPEN,  CROSSOVER,  PILOT 
STUDY  COMPARING  ORAL  PREPARATIONS 

247877  04  07 

CORRELATION  BETWEEN  DISSOLUTION  CHARACTERISTICS  AND 
ABSORPTION  OF  METHAQUALONE  FROM  SOLID  DOSAGE  FORMS, 

250332  04-06 

SOLUBILITY 

SOLUBILITY  OF  STRAIGHT  CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT-CHAIN  ALCOHOLS, 

238487  02-01 

SOLUBLE 

IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN-?, 

248604  04-03 

IN  VIVO  AND  IN  VITRO  ACTIVATION  OF  SOLUBLE  TRYPTOPHAN- 
HYDROXYLASE  FROM  RAT  BRAINSTEM 

249512  04  03 

SOLUTION 

DECOMPOSITION  OF  AMITRIPTYLINE  HYDROCHLORIDE  IN  AQUEOUS 
SOLUTION    IDENTIFICATION  OF  DECOMPOSITION  PRODUCTS, 

246317  04  01 
EFFECT  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE:  III    EFFECT  ON  PREFERRED 
DRINKING  OF  MORPHINE  SOLUTION 

249032  04-04 

SOLUTIONS 

OPERANT  ANALYSIS  OF  BEHAVIOR  ASSOCIATED  WITH  ORAL  SELF- 
ADMINISTRATION  OF  DRUG  SOLUTIONS  IN  RATS,  (PHD 
DISSERTATION), 

226992  01-04 

CHARACTERISTICS  OF  NARCOTIC  DEPENDENCE  PRODUCED  BY  ORAL 
INGESTION  OF  FENTANYL  SOLUTIONS  IN  RATS. 

249289  04-04 

SOLVENT 

SERUM  CREATINE  PHOSPHOKINASE  CONCENTRATIONS  AFTER 
INTRAMUSCULAR  CHLORDIAZEPOXIDE  AND  ITS  SOLVENT. 

237928  02-15 
SO/V\ATIC 

HOSTILITY,  SOMATIC  SYMPTOMS  AND  RECOVERY  WITH 
ANTIDEPRESSANTS. 


THE  SOMATIC  THERAPY  OF  SCHIZOPHRENIA. 

SOMATIC  ORIENTED  TREATMENT  OF  ANOREXIA  NERVOSA. 

PSYCHOTROPIC  DRUGS  IN  SOMATIC  DISORDERS. 


226898  01  09 
237992  02  08 
243194  04-10 
250856  04- 17 


SOMATOSENSORY 

BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
THALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT 

232606  02-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX 

232607  02  03 

SOMATOSTATIN 

ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRF)  AND  SOMATOSTATIN 

227386  01-04 

SOUND 

EFFECTS  OF  RO-4-1284,  IPRONIAZID,  METHYLPHENIDATE,  COCAINE  OR 
IMIPRAMINE  ON  SOUND  AND  PENTYLENETETRAZOL  INDUCED  SEIZURE 

IN  THE  RAT. 

238706  03-04 

SPACED 

EFFECTS  OF  D  AMPHETAMINE,  CHLORPROMAZINE.  AND 

CHLORDIAZEPOXIDE  ON  INTERCURRENT  BEHAVIOR  DURING  SPACED 
RESPONDING  SCHEDULES. 

229639  01  04 

SPAIN 

ADDITIONAL  STUDIES      SPAIN 

22/221  01  09 


S-305 


Subject  Index 


Psychopharmacology  Abstn 


e 

•n 


3» 


SPASM 

CEREBRAL  ARTERIAl  SPASM   PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERAfURE,  SEROTONIN  ANAIOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 
AND  MAGNESIUM  ON  SEROTONIN  INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY 

243797  04-03 
SPASTICITY 

A  PHENOTHIAZINE  DERIVATIVE  IN  THE  TREATMENT  OF  SPASTICITY. 

226960  01 -n 
SPATIAL 

RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D- 
AMPHETAMINE  ON  TIMING  BEHAVIOR. 

226729  01-04 
SPECIES 

PENFLURIDOL  BLOCKADE  OF  APOMORPHINE:  DEPENDENCE  OF  DURATION 

ON  SPECIES  AND  ENDPOINT. 

248406  04-02 
TOLERANCE  LO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA-PIG) 

THAT  METABOLIZE  IT  DIFFERENTLY. 

250723  04-03 
SPECIFIC 

NGN  SPECIFIC  FACTORS  IN  PSYCHOPHARMACOTHERAPY. 

228244  01-17 
DISCOVERY  OF  SPECIFIC  CNS  EFFECTS  OF  LISURIDE  HYDROGEN  MALEATE 
-  AN  ANTIMIGRAINE  COMPOUND. 

229473  01  13 
SOME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE-OXIDASE. 

233946  02-01 
SPECIFIC  EFFECTS  OF  NEUROTRANSMITTER  ANTAGONISTS  ON  GANGLION 
CELLS  IN  RABBIT  RETINA 

236863  02-03 
PURIFICATION  OF  (3H)TAURINE  OF  HIGH  SPECIFIC  ACTIVITY. 

238773  03-03 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03-03 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P 
CHLOROPHENYLAIANINE  (PCPA)  IN  THE  RAT. 

2466/4  04-04 
SPECIFIC  AXONAL  EFFECTS  OF  A  CONVULSANT  BARBITURATE. 

249258  04-03 
EFFECTS  OF  LILLY-1  10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN  INDUCED  ANOREXIA    EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-03 
SPECIFICATION 

DOGMATIL  OR  SULPIRIDE.  AN  ATTEMPl  AT  SPECIFICATION. 

237015  02  17 
SPECIFICITY 

DRUG-INDUCED  CONDITIONED  SUPPRESSION:  SPECIFICITY  DUE  TO  DRUG 
EMPLOYED  AS  UCS. 

242750  04-04 
ON  THE  SPECIFICITY  OF  HISTAMINE  H2RECEPT0R  ANTAGONISTS  IN  THE 
RAT  CEREBRAL  CORTEX 

248725  04-03 
THE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA:  FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY. 

249248  04-03 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 
INTRACEREBRAL  INJEtriON  OF  6-HYDROXYDOPAMINE  IN  THE 
NIGROSTRIATAL  DOPAMINE  SYSTEM, 

249899  04  03 
SPECTRAL 

CHARACTERIZATION  OF  HYDROGEN  BONDING  BETWEEN  SELECTED 
BARBITURATES  AND  P0LYETHYLENE-GLYC0L-4000  BY  IR  SPECTRAL 
ANALYSIS 

233276  02-01 
SPECTRAL  MAPS  Of  THE  LIEGE  PHYSIOGNOMIES  OF  THE  NEUROLEPTICS, 

239683  03-06 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
SPECTROPHOTOMETRIC 

SERUM  CONCENTRATION  OF  CARBAMA2EPINE.  COMPARISON  OF 
HERRMANNS  SPECTROPHOTOMETRIC  METHOD  AND  A  NEW  GLC 
METHOD  FOR  THE  DETERMINATION  OF  CARBAMAZEPINE. 

25301  1  04-07 
SPECTRUM 

AN  EXPERIMENTAL  STUDY  OF  THE  SPECTRUM  OF  INDIVIDUAL 
PSYCHOTROPIC  ACTIVITY  OF  CLOZAPINE  (LEPONEX) 

236174  02-04 
VESTIBULAR  TEST  IN  INVEST  IGALING  THE  SPECTRUM  OF  ACTION  OF 
PSYCHOTROPIC  AGENTS 

236714  02  04 


EFFICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS. 

240706  I 
SPERMIDINE 

THE  ACTIONS  OF  SPERMIDINE  AND  SPERMINE  ON  THE  CENTRAL- 
NERVOUS-SYSTEM. 

245596  I 
SPERMINE 

THE  ACTIONS  OF  SPERMIDINE  AND  SPERMINE  ON  THE  CENTRAL- 
NERVOUSSYSTEM. 

245596  I 
SPIKE 

THE  NATURE  OF  BACKGROUND  SPIKE  ACTIVITY  OF  CORTICAL  NEUR( 
UNDER  THE  ACTION  OF  PSYCHOTROPIC  DRUGS. 

236265  I 
SPINAL 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 
PAROXYSAAAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  I 
DEPRESSIVE  EFFECTS  OF  MORPHINE  UPON  LAMINA  V  CELLS  ACTIVIT 
IN  THE  DORSAL  HORN  OF  THE  SPINAL  CAT. 

232328  I 
THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLI 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN 
RAT  SPINAL  CORD. 

235863  ( 
ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINI 
CAT  SPINAL  CORD  SEGMENIAL  REFLEXES. 

237752  ( 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP. 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  C 
LOSS  OF  INHIBITION  IN  SPINAL  CORD  DURING  BARBITURATE 
WITHDRAWAL. 

238770  ( 
EFFECTS  OF  MORPHINE  ON  ACETYLCHOLINE  RELEASE  FROM  THE  FRQl 
SPINAL  CORD. 

241922  C 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCL 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO 
BRAINSTEM  (BS)  AND  LIMBIC  FCREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION. 

249255  C 
SPINDLE 

BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDINC 
THALAMIC  AND  CORTICAL  SO/WATOSENSORY  AREAS  IN  THE  CAT. 

232606  0 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  0 
SPINDLES 

EFFECT  OF  FLURAZEPAM  ON  SLEEP  SPINDLES  AND  K-COMPLEXES. 

238507  0 
SPIROPERIDOL 

INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES    -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINI 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  0 
SPLEENS 

EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  MOUSE  SPLEENS. 

226944  0 
SPONGIFORM 

CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  O: 
SPONTANEOUS 

THE  EFFECTS  OF  GABA,  PICROTOXIN  AND  BICUCULLINE  ON  THE 
SPONTANEOUS  BIOELECTRIC  ACTIVITY  OF  CULTURED  CEREBELLAR 
PURKINJE  CELLS. 

232906  O; 
EFFECTS  OF  SCOPOLAMINE,  D-AMPHETAMINE  AND  OTHER  DRUGS 
AFFECTING  CATECHOLAMINES  ON  SPONTANEOUS  ALTERNATION  AN 
LOCOMOTOR  ACTIVITY  IN  MICE. 

237703  O: 
THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 
REM  SLEEP  IN  THE  CAT. 

237780  05 
EFFECTS  OF  6-HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE 

238565  02 
REDUCED  SPONTANEOUS  LOCOMOTOR  ACTIVITY  EVOKED  BY  L- 
TRYPTOPHAN  &  PREVENTED  BY  D-TRYPTOPHAN. 

238698  03 


S-306 


loiUME  14,  SUBJECT  INDEX 


Subject  Index 


i      INHIBITION  OF  SPONTANEOUS  AND  METHAMPHETAMINE-INDUCED 

\  LOCOMOTOR  ACTIVITY  IN  MICE 

'  238842  03-04 

FACTORY  BULB  REMOVAL  RESULTS  IN  ELEVATED  SPONTANEOUS 

LOCOMOTOR  ACTIVITY  IN  MICE. 

239284  03-04 

ONTANEOUS  AND  DRUG-INDUCED  ROTATION  (CIRCLING  BEHAVIOR)  IN 

THE  MONGOLIAN  GERBIL  (MERIONES  UNGUICULATUS). 
I  241311  0304 

3      SPONTANEOUS  AND  GUANETHIDINE-INDUCED  CHANGES  OF  REGIONAL 

MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 

POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN. 

241366  03-03 
I      LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RATS 
i         TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 
'  245299  04-04 

EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  DAMPHETAMINE  STIMULATED  LOCOMOTOR 

i  ACTIVITY. 

249273  04-03 
>ONTANEOUSIY 
SYMPOSIUM  II.  PHARMACOLOGY  ON  BRAIN  MONOAMINES: 

1) 
ABNORMALITY  IN  CENTRAL  NORADRENERGIC  NEURONS  IN 
SPONTANEOUSLY  HYPERTENSIVE  RATS 

241360  03-03 
EFFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT 

241365  03-03 
MMGUE-DAWLEY 

HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01-04 
THE  INCIDENCE  OF  SELF-MUTILATION  IN  MORPHINE  TOLERANT  SPRAGUF 
DAWLEY  MALE  RATS. 

249253  04-04 
3O0996 

CLINICAL  PHARMACOLOGY  OF  SQ- 10996,  A  POTENTIAL  ANTIDEPRESSIVE 
AGENT. 

229036  01-07 
ABSORPTION  AND  EXCRETION  OF  A  NEW  ANTIDEPRESSIVE  (SQ-10996)  IN 
HUMANS. 

253323  04-07 
3UIRREI-MONKEY 

THE  EFFECTS  OF  LOW-LEVEL  DIELDRIN  EXPOSURE  ON  THE  EEG  AND 
LEARNING  ABILITY  OF  THE  SQUIRREL  MONKEY. 

227385  01-04 
EFFECTS  OF  MORPHINE  AND  NARCOTIC  ANTAGONISTS  ON  AVOIDANCE 
BEHAVIOR  OF  THE  SQUIRREL-MONKEY. 

237754  02-04 
EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SQUIRREL-MONKEY 
INCENTIVE  COMPETITION  BEHAVIOR   (PH.D.  DISSERTATION). 

241668  03  04 
SOME  BEHAVIORAL  EFFECTS  OF  MORPHINE,  NALOXONE  AND 
NALORPHINE  IN  THE  SQUIRREL  MONKEY  AND  THE  PIGEON. 

250113  04-04 
3UIRREI-MONKEYS 

INFLUENCE  OF  PHARMACOLOGICALLY  ACTIVE  SUBSTANCES  ON  A 
CONDITIONED  BLOOD  PRESSURE  INCREASE  IN  SQUIRREL-MONKEYS 

251414  04-03 
ABILITY 

THE  STABILITY  OF  AMPHETAMINIL;  SYNTHESES  WITH  AMPHETAMINIL 

232527  01-01 
THE  STABILITY  OF  CANNABIS  AND  ITS  PREPARATIONS  ON  STORAGE. 

237784  02-01 
AFF 

DO  PSYCHIATRIC  PATIENTS  TAKE  THEIR  MEDICATION''    THE  VIEW  OF 
THE  STAFF 

253103  04  17 
AGE 

DRUG  EFFECTS  ON  LEARNING   A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING. 
(PHD,  DISSERTATION). 

239533  03-04 
DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 
STAGE 

251981  04-04 
AGES 

THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS. 

237696  02  14 
EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 
VOLUNTEERS. 

248629  04  13 
THE  EFFECTS  OF  TAURINE  ON  VARIOUS  STAGES  OF  THE  KINDLING 
PROCESS    A  SUMMARY  OF  RESULTS. 

251929  04-04 


STAINING 

EUFLAVINE:  EFFECT  ON  BRAIN  HEAVY  METAL  CONTENT  AND  STAINING 
PATTERN,  AND  ON  SHUTTLEBOX  BEHAVIOR  IN  GOLDFISH. 

241221  03  04 
STANDARD 

VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE  BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01-08 
DETERMINATION  OF  BROMAZEPAM  IN  PLASMA  WITH  AN  INTERNAL 
STANDARD  BY  GAS-LIQUID  CHROMATOGRAPHY 

229906  01  16 
SYSTEAAATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS    -  III    STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02-09 
A  STANDARD  CONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE  ON 
GERIATRIC  PATIENTS. 

253058  04  11 
STANDARDS 

SIMULTANEOUS  MEASUREMENT  OF  IMIPRAMINE  AND  DESIPRAMINE  BY 
SELECTED  ION  RECORDING  WITH  DEUTERATED  INTERNAL  STANDARDS. 
(UNPUBLISHED  PAPER). 

237274  02  16 
CLINICAL  LABORATORY  TEST  STANDARDS  FOR  A  SAMPLE  OF 
SCHIZOPHRENICS. 

237726  02-08 
STARTLE 

EFFECTS  OF  D-  AND  L-AMPHETAMINE  ON  HABITUATION  AND 
SENSITIZATION  OF  THE  ACOUSTIC  STARTLE  RESPONSE  IN  RATS. 

227126  01-04 
P-CHLOROAMPHETAMINE  (PCA):  ACUTE  AND  CHRONIC  EFFECTS  ON 
HABITUATION  AND  SENSITIZATION  OF  THE  ACOUSTIC  STARTLE 
RESPONSE  IN  RATS. 

240062  03-04 
STATE 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS 

226185  01-04 
THE  ACTION  OF  CHLORPROMAZINE  ON  THE  PERMEABILITY  OF  THE  BRAIN 
AND  LIVER  LYSOSOMES  OF  RATS  IN  A  STATE  OF  HYPOXIA. 

228548  01-03 
THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
ClORAZEPATE  DIPOTASSIUM  (MENOON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOMATIC  DISEASE.  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE  BLIND  CLINICAL  STUDY. 

229504  01-11 
HOW  DRUGS  ACT  -    26:  DRUGS  AND  THE  MENTAL  STATE 

235638  02-17 
DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN 

235998  02-10 
CONTROLLING  INCONTINENCE  AMONG  GERIATRIC  PATIENTS:  A  PILOT 
STUDY  MADE  IN  A  STATE  MENTAL  HOSPITAL 

237271  02  14 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  FOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  OF  POST-AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE 

237976  02  03 
PRESENT  STATE  OF  LONG  TERM  NEUROLEPTIC  TREATMENT  OF 
SCHIZOPHRENIA. 

238864  03-08 
THE  AUTOMATED  ASSESSMENT  OF  THE  EFFECT  OF  FLURAZEPAM  AND 
NITRAZEPAM  ON  MOOD  STATE, 

239010  03-15 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL 

240074  03-14 
EFFECT  OF  CLOZAPINE  ON  THE  MENTAL  AND  PHYSICAL  STATE  OF 
PATIENTS 

243986  04  08 
EFFECTS  OF  DRUG  STATE  CHANGE  ON  DISCRIMINATION  PERFORMANCE 

244679  04  04 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE  HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04  05 
STATE-DEPENDENCY 

A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03-14 
RATE  DEPENDENT  DRUG  EFFECTS:  POSSIBLE  STATE  DEPENDENCY 

242739  03  04 
STATE-DEPENDENT 

STATE-DEPENDENT  LEARNING  IN  RETARDATES  USING  THIORIDAZINE 
(PHD    DISSERTATION). 

228420  Oil  4 


S-307 


Subject  Index 


Psychopharmacology  Abstr 


■ 

e 


> 

3» 


A  TEST  OF  THE  STATE  DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN.  (PH  D. 
DISSERTATION). 

241133  03  14 
STATE  DEPENDENT  (DISSOCIATIVE)  EFFECTS  OF  METHADONE  ON  HUMAN 
RETENTION    (PH  D.  DISSERTATION). 

242151  03-14 
STATE-DEPENDENT  ACCESSIBILITY  OF  RETRIEVAL  CUES  IN  THE 
RETENTION  OF  A  CATEGORIZED  LIST. 

243013  04-04 
BENZODIAZEPINE-INDUCED  STATE-DEPENDENT  LEARNING   A 
CORRELATIVE  OF  ABUSE  POTENTIAL?. 

252674  04-04 
STATIONS 

ON  THE  EFFECTIVENESS  OF  PSYCHIATRIC  AMBULATORY  STATIONS. 

234289  02-11 
STATISTICAL 

A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES 

249536  04-16 
STEADY 

DRUGS,  AROUSAL,  AND  BRAIN  STEADY  POTENTIAL  RESPONSES. 

243953  04-14 
STEADY-STATE 

PHARMACOKINETIC  MODEL  TO  DESCRIBE  SELF-INDUCED  DECREASES  IN 
STEADY-STATE  CONCENTRATIONS  OF  CARBAMAZEPINE. 

239658  03-13 
PENFLURIDOL  STEADY-STATE  KINETICS  IN  PSYCHIATRIC  PATIENTS. 

245650  04-08 
BUTAPERAZINE  PHARMACOKINETICS:  EFFECT  OF  DOSAGE  REGIMEN  ON 
STEADY-STATE  BLOOD  LEVELS. 

245842  04-08 
STEADY-STATE  CONCENTRATIONS  OF  CHOLINE  AND  ACETYLCHOLINE  IN 
RAT  BRAIN  PARTS  DURING  A  CONSTANT  RATE  INFUSION  OF 
DEUTERATED  CHOLINE. 

247146  04-03 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE  HYDROXYLASE  ACTIVITY, 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY-STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL  ALPHA-METHYL-P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT. 

248697  04-03 
APPLICATION  OF  PRINCIPLES  OF  STEADY-STATE  KINETICS  TO  THE 

ESTIMATION  OF  BRAIN  ACETYLCHOLINE  TURNOVER  RATE:  EFFECTS  OF 
OXOTREMORINE  AND  PHYSOSTIGMINE. 

248700  04-03 
EFFECT  OF  FENFLURAMINE  ON  STEADY-STATE  PLASMA  I  EVELS  OF 
AMITRIPTYLINE  (ABSTRACT). 

250943  04-07 
STEM 

ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5  7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
STEP 

SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
STEREOISOMERS 

DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA: 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS, 

233967  02-08 
THE  EFFECT  OF  AMPHETAMINE  STEREOISOMERS  ON  THE  FUNCTION  OF 
DOPAMINE  SYNAPSES  IN  VITRO. 

244043  04-03 
D  AMPHETAMINE  AND  L  AMPHETAMINE  STEREOISOMERS:  COMPARATIVE 
POTENCIES  IN  AFFECTING  THE  FIRING  OF  CENTRAL  DOPAMINERGIC 
AND  NORADRENERGIC  NEURONS. 

24721 1  04-03 
STEREOSPECIFIC 

STEREOSPECIFIC  BINDING  OF  D  LYSERGIC  ACID-DIETHYLAMIDE  (LSD)  TO 
BRAIN  MEMBRANES:  RELATIONSHIP  TO  SEROTONIN  RECEPTORS. 

226936  01-12 
COMPARISON  OF  WITHDRAWAL  PRECIPTATING  PROPERTIES  OF  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03  03 
STEREOSPECIFIC  BINDING  OF  ETORPHINE  IN  ISOLATED  NEURAL  CELLS 
AND  IN  RETINA,  DETERMINED  BY  A  SENSITIVE  MICROASSAY. 

252178  04-03 
STEREOTAXIC 

I  DOPA  THERAPY  AND  STEREOTAXIC  THALAMOTOMY  FOR 
PARKINSONISM 

245986  04-11 
STEREOTYPED 

DRUG  INDUCED  STEREOTYPED  BEHAVIOR    SIMILARITIES  AND 
DIFFERENCES 

233963  02-03 


MODIFICATION  OF  BETA-PHENYLETHYLAMINE-INDUCED  STEREOTYPE 
BEHAVIOR  BY  NEUROLEPTIC  AGENTS. 

236672 
ANTAGONISM  OF  APOMORPHINE  AND  D  AMPHETAMINE-INDUCED 
STEREOTYPED  BEHAVIOUR  BY  INJECTION  OF  LOW  DOSES  OF 
HALOPERIDOL  INTO  THE  CAUDATE-NUCLEUS  AND  THE  NUCLEUS- 
ACCUMBENS. 

237704 
EFFECT  OF  CATECHOL  O-METHYLTRANSFERASE  INHIBITORS  ON  BRAI 
APOMORPHINE  CONCENTRATIONS  AND  STEREOTYPED  BEHAVIOUI 
THE  RAT. 

237747 
NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR. 

238819 
AN  OBJECTIVE  AND  SENSITIVE  METHOD  FOR  QUANTITATIVE 
MEASUREMENT  OF  STEREOTYPED  GNAWING. 

242745 
SUPERSENSITIVITY  TO  D-AMPHETAMINE  AND  APOMORPHINE-INDUC 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D-AMPHETAMINI 
ADMINISTRATION. 

247683 
FAILURE  OF  INCREASED  BRAIN  GAMMA-AMINOBUTYRIC-ACID  LEVEI 
INFLUENCE  AMPHETAMINE-INDUCED  STEREOTYPED  BEHAVIOR. 

247730 
APOMORPHINE  INDUCED  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS. 

247875 
NORADRENERGIC  INFLUENCE  ON  THE  STEREOTYPED  BEHAVIOUR  INC 
BY  AMPHETAMINE,  PHENETHYLAMINE  AND  APOMORPHINE. 

250361 
DISSOCIATION  OF  STEREOTYPED  BITING  RESPONSES  AND  ORO-BUCC 
LINGUAL  DYSKINESIAS. 

252031 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 
STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  B 

252523 
STEREOTYPES 

EFFECT  OF  CORTISONE,  ALDOSTERONE  AND  NIALAMIDE  ON 

AMPHETAMINE  STEREOTYPES  AND  BRAIN  METHAMPHETAMINE  LI 
OF  ADRENALECTOMIZED  RATS. 

251990 
STEREOTYPIC 

DISSOCIATION  BY  THE  APOMORPHINE  DERIVATIVES  OF  THE 

STEREOTYPIC  AND  HYPERACTIVITY  RESPONSES  RESULTING  FROM 
INJECTIONS  INTO  THE  NUCLEUS-ACCUMBENS  SEPTI. 

238319 
THE  EFFECT  OF  CARBON  DISULFIDE  ON  THE  STEREOTYPIC  EFFECT  OF 
DOPAMINE  AGONISTS, 

250090 
STEREOTYPY 

DIFFERENTIAL  EFFECTS  OF  SEROTONIN  ON  TURNING  AND  STEREOTYI 
INDUCED  BY  APOMORPHINE. 

226405 
THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 
AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712 
MJ-9022:  CORRELATION  BETWEEN  NEUROLEPTIC  POTENTIAL  AND 
STEREOTYPY. 

237903 
STEROIDS 

INTERACTIONS  OF  DELTA9-TETRAHYDR0CANNABIN0L,  ADRENAL 
STEROIDS,  AND  ETHANOL. 

226763 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATI 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822 
STIMULANT 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXI 
PROPERTIES  OF  D-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION) 

227074  I 
INVOLVEMENT  OF  BRAIN  MONOAMINES  IN  THE  STIMULANT  AND 
PARADOXICAL  INHIBITORY  EFFECTS  OF  METHYLPHENIDATE. 

230841  I 
THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS.  A  TEST  OF  HILLS  HYPOTHESI: 

237711  ( 
CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  LDOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  ( 
STIMULANT  DRUGS  FOR  HYPERACTIVITY    SOME  ADDITIONAL 
DISTURBING  QUESTIONS. 

240599  { 
ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPON 
OF  RATS  TO  BRAIN  5-HYDROXYTRYPTAMINE  ACCUMULATION  ANC 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS 

241979  ( 


S-308 


Hume  i4,  subject  index 


Subject  Index 


WHAT  IS  THE  PROPER  DOSE  OF  STIMULANT  DRUGS  IN  CHILDREN'. 

247376  04  17 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS 

247384  04-14 
ROLE  OF  DA  IN  THE  STIMULANT  EFFECT  OF  DITA  IN  MICE;  COMPARISON 
WITH  D-AMPHETAMINE, 

248284  04-03 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC). 

249309  04  03 
STIMULANT  PROPERTIES  OF  BROMOCRIPTINE  ON  CENTRAL  DOPAMINE 
RECEPTORS  IN  COMPARISON  TO  APOMORPHINE,  (  i  )  AMPHETAMINE 
AND  L-DOPA. 

249419  04-04 
SELF-ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS:  THE 
EFFECTS  OF  UNLIMITED  ACCESS 

250066  04-04 
THE  EFFECTS  OF  LONG-TERM  STIMULANT  MEDICATION  ON  GROWTH  AND 
BODY  COMPOSITION  OF  HYPERACTIVE  CHILDREN. 

253041  04-15 
MULANTS 
INTERACTIONS  OF  ADRENERGIC  STIMULANTS  AND  BLOCKERS  ON  SELF- 
STIMULATION  BEHAVIOR  IN  RATS. 

226943  01  04 
CNS  STIMULANTS  AND  ANABOLIC  SUBSTANCES  IN  GEROPSYCHIATRIC 
THERAPY. 

229459  01-11 
THE  EFFECTS  OF  THREE  BENZODIAZEPINES  AND  OF  MEPROBAMATE  ON 
THE  ACTION  OF  SMOOTH  MUSCLE  STIMULANTS  ON  THE  GUINEA-PIG 
ILEUM. 

230859  01-03 
SELF-ADMINISTRATION  OF  CNS  STIMULANTS  BY  DOG. 

230879  01-04 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA  PIGS,  AND  RABBITS. 

233962  02-03 
DOPAMINE,  PSYCHOMOTOR  STIMULANTS,  AND  SCHIZOPHRENIA- 
EFFECTS  OF  METHYLPHENIDATE  AND  THE  STEREOISOMERS  OF 
AMPHETAMINE  IN  SCHIZOPHRENICS. 

233967  02-08 
CLINICAL  STUDIES  WITH  DOPAMINE  RECEPTOR  STIMULANTS. 

237725  02-08 
SIDE-EFFECTS  FROM  LONG-TERM  USE  OF  STIMULANTS  IN  CHILDREN. 

247377  04-15 
EFFECTS  OF  CHLORDIAZEPOXIDE,  CNS  STIMULANTS  AND  THEIR 

COMBINATIONS  ON  AVOIDANCE  BEHAVIOUR  IN  MICE. 

249026  04-04 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
EFFECTS  OF  DOPAMINERGIC  STIMULANTS  ON  CYCLIC  NUCLEOTIDE 
LEVELS  IN  MOUSE  BRAIN  IN  VIVO. 

251432  04-03 
TREATMENT  OF  REACTIONS  TO  AMPHETAMINE  TYPE  STIMULANTS. 

251754  04-15 
TOURETTES  SYNDROME  AND  CENTRAL-NERVOUS-SYSTEM  STIMULANTS. 

251962  04-11 
DlUlATE 

MODIFICATION  OF  PENTYLENETETRAZOL-INDUCED  CONVULSIONS  BY 
DRUGS  WHICH  ALTER  BRAIN  CATECHOLAMINE  LEVELS  OR  STIMULATE 
CATECHOLAMINE  RECEPTORS. 

238734  03-03 
SI  ULATEO 
SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
NEONATAL  HYPERTHYROIDISM:  MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01-04 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02-03 
EFFECTS  OF  MORPHINE  ON  DOPAMINE  STIMULATED  ADENYLATE 
CYCLASE  AND  ON  CYCLIC  GMP  FORMATION  IN  MONKEY  BRAIN 
AMYGDALA. 

238739  0303 
-ITHIUM  INHIBITION  OF  ADRENALINE  STIMULATED  ADENYLATE-CYCLASE 
IN  HUMANS 

239728  03-09 
-OMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ON 

ADENYLATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE 
,    NORADRENALINE  AND  GLUCAGON. 

241347  03-03 


EFFECTS  OF  MONOAMINE-OXIDASE  INHIBITORS  (MAOIS)  ON 

SPONTANEOUS  AND  D-AMPHETAMINE  STIMULATED  LOCOMOTOR 
ACTIVITY. 

249273  04-03 
THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04-17 
INTERRELATIONSHIP  BETWEEN  CATECHOLAMINE  STIMULATED 

FORMATION  OF  ADENOSINE  3,5  MONOPHOSPHATE  IN  CEREBELLAR 
SLICES  AND  INHIBITORY  EFFECTS  ON  CEREBELLAR  PURKINJE  CELLS: 
ANTAGONISM  BY  NEUROLEPTIC  COMPOUNDS. 

253109  04-03 
STIMULATES 

THIORIDAZINE  STIMULATES  PROLACTIN  SECRETION  IN  MAN. 

245840  04  13 
STIMULATING 

THE  USE  OF  A  DOPAMINERGIC  RECEPTOR  STIMULATING  AGENT 
(PIRIBEDIL,  ET-495)  IN  PARKINSONS  DISEASE. 

233974  02-11 
EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5-HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN. 

243777  04-03 
A  COMPARISON  BETWEEN  A  MELANOCYTE  STIMULATING  HORMONE 
INHIBITORY  FACTOR  (MIF-I)  AND  SUBSTANCES  KNOWN  TO  ACTIVATE 
CENTRAL  DOPAMINE  RECEPTORS 

250082  04-03 
SEPARATION  OF  INHIBITING  AND  STIMULATING  EFFECTS  OF  MORPHINE 
ON  SELF-STIMULATION  BEHAVIOUR  BY  INTRACEREBRAL 
MICROINJECTIONS. 

252033  04-03 
INTERACTIONS  BETWEEN  DRUGS  AND  SALIVA  STIMULATING  PARAFILM 
AND  THEIR  IMPLICATIONS  IN  MEASUREMENTS  OF  SALIVA  DRUG 
LEVELS. 

253693  04-03 
STIMULATION 

TYROSINE-HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01-03 
HANDBOOK  OF  DRUG  AND  CHEMICAL  STIMULATION  OF  THE  BRAIN: 
BEHAVIORAL,  PHARMACOLOGICAL  AND  PHYSIOLOGICAL  ASPECTS. 

227382  01-06 
THE  EFFECT  OF  D,L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES 

228546  01-03 
CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES. 

231 119  01  04 
PHENYLPROPANOLAMINE  INHIBITS  FEEDING,  BUT  NOT  DRINKING, 
INDUCED  BY  HYPOTHALAMIC  STIMULATION. 

231700  01-03 
COMPARISON  OF  DEFENSIVE  BEHAVIOR  EVOKED  BY  CHEMICAL  AND 
ELECTRICAL  STIMULATION  OF  THE  HYPOTHALAMUS  IN  CATS. 

232483  01  04 
RESERPINE  ACTION  ON  THE  ARREST  REACTION  FOLLOWING 
STIMULATION  OF  THE  CAUDATE-NUCLEUS  IN  CATS. 

236712  02-04 
EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02-03 
CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02-06 
CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS 

237900  02-10 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L- 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED.  CORN  FED  RATS 

238676  03-03 
PHARMACOLOGICAL  STIMULATION  OF  THE  PINEAL    POTENTIATION  OF 
KETAMINE  RESPONSE  IN  THE  CHICK 

238795  03-03 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION. 

238815  03-03 
ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS    MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS 

238822  03-03 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF  STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION 

239980  03  04 


S-309 


Subject  Index 


Psychopharmacology  Abstra 


< 


> 


EFFECTS  OF  ELECTRICAL  STIMULATION  OF  THE  NIGROSTRIATAL 
PATHWAY  OF  THE  RAT  ON  DOPAMINE  METABOLISM. 

241207  03-03 
INTRACRANIAL  SELF  STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI    INFLUENCE  OF  FENTANYL 
PIRITRAMIOE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNDLE 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

241229  0304 
ANTINOCICEPTIVE  ACTION  OF  QUIPAZINE:  RELATION  TO  CENTRAL 
SEROTONERGIC  RECEPTOR  STIMULATION. 

241235  03-03 
EFFECTS  OF  SOME  DOPAMINE  ANALOGS  AND  HALOPERIDOL  ON 
RESPONSE  TO  STIMULATION  OF  ADRENERGIC  NERVES  USING  CAT 
ATRIA  IN  VITRO 

241313  03-03 
CHANGES  IN  CARDIOVASCULAR  RESPONSES  TO  BRAIN  STIMULATION 
FOLLOWING  OLFACTORY  BULBECTOMY  AND  THE  EFFECTS  OF 
PSYCHOTROPIC  DRUGS  IN  RATS 

241389  03-03 
PHARMACOLOGICAL  STUDIES  ON  THE  MIDBRAIN  RAPHE  SYSTEM  (III). 

EFFECTS  OF  MIDBRAIN  RAPHE  STIMULATION  AND  LESION  ON  EEG 
ACTIVITY  IN  RATS. 

241390  03-03 
INGESTION  IN  THE  SATIATED  RAT:  ROLE  OF  ALPHA  AND  BETA 

RECEPTORS  IN  MEDIATING  EFFECTS  OF  HYPOTHALAMIC  ADRENERGIC 
STIMULATION. 

245930  04-02 
STIMULATION  OF  A  SPECIFIC  DRIVE  (PREDATORY  BEHAVIOUR)  BY  P- 
CHLOROPHENYLALANINE  (PCPA)  IN  THE  RAT. 

246674  04-04 
RELEASE  OF  NOREPINEPHRINE  AND  DOPAMINE-BETA-HYDROXYLASE  BY 
NERVE  STIMULATION.  V.  ENHANCED  RELEASE  ASSOCIATED  WITH  A 
GRANULAR  EFFECT  OF  A  BENZOOUINOLIZINE  DERIVATIVE  WITH 
RESERPINE  LIKE  PROPERTIES 

246844  04-03 
DOSE-RELATED  EFFECTS  OF  CENTRAL  NORADRENALINE  STIMULATION  ON 
BEHAVIOURAL  AROUSAL  IN  RATS. 

247206  04-04 
EFFECTS  OF  CHEMICAL  STIMULATION  OF  THE  MESOLIMBIC  DOPAMINE 
SYSTEM  UPON  LOCOMOTOR  ACTIVITY. 

248285  04-02 
EFFECT  OF  CLONIDINE  ON  THE  NOREPINEPHRINE  (NE)  SENSITIVE  CYCLIC- 
AMP  GENERATING  SYSTEM  IN  SLICES  OF  RAT  SPINAL  CORD  (SO, 
BRAINSTEM  (BS)  AND  LIMBIC  FOREBRAIN  (LFB)  AND  ON  MEDIAL 
FOREBRAIN  BUNDLE  (MFB)  STIMULATION 

249255  04-03 
AMANTADINE  DECREASES  D-AMPHETAMINE  STIMULATION  AND 
INCREASES  D  AMPHETAMINE  ANOREXIA  IN  MICE. 

249459  04-03 
STIMULATION  BY  MORPHINE  OF  ACETYLCHOLINE  OUTPUT  FROM  THE 
CEREBRAL  CORTEX  OF  SEPTAL  RATS 

249664  04-03 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04  04 
ADDICTIVE  AGENTS  AND  INTRACRANIAL  STIMULATION:  DAILY 
MORPHINE  AND  LATERAL  HYPOTHALAMIC  SELF-STIMULATION. 

250019  04-04 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 

REFRACTORINESS.  SUMMATION,  CONVERGENCE.  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04  03 
EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION 

251070  04-03 
THE  ACTION  OF  NOREPINEPHRINE  IN  THE  RAT  HIPPOCAMPUS    III. 
HIPPOCAMPAL  CELLULAR  RESPONSES  TO  LOCUS-COERULEUS 
STIMULATION  IN  THE  AWAKE  RAT. 

252012  04  03 
STIMULATION-INDUCED 

DISRUPTION  OF  BRAIN  STIMULATION  INDUCED  FEEDING  BY  DOPAMINE 
RECEPTOR  BLOCKADE 

235587  02-04 
LONG  TERM  DEFICITS  IN  STIMULATION  INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6-HYDROXYDOPAMINE  ADMINISTRATION  IN 
RATS 

241300  03-04 
CYCLIC  AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION  INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA 

241382  03-04 
STIMULATOR 

A  DOPAMINE  RECEPTOR  STIMULATOR  IN  DEPRESSION.  (UNPUBLISHED 
PAPER). 

227785  01-09 


STIMULATORS 

A  PRELIMINARY  REPORT:  NEUROENDOCRINE  EFFECTS  OF  DOPAMINE  f 
NOREPINEPHRINE  RECEPTOR  STIMULATORS. 

243440  0. 
STIMULATORY 

STIMULATORY  ROLE  FOR  BRAIN  SEROTONINERGIC  SYSTEM  ON 
PROLACTIN  SECRETION  IN  THE  MALE  RAT. 

240643  0 
EFFECTS  OF  STIMULATORY  AND  DEPRESSANT  DRUGS  ON  CYCLIC 
GUANOSINE  3,5  MONOPHOSPHATE  AND  ADENOSINE  3,5 
MONOPHOSPHATE  LEVELS  IN  MOUSE  BRAIN. 

241246  0: 
DIFFERENTIAL  EFFECTS  OF  ALPHA  MT  ON  ANORECTIC  AND 
STIMULATORY  ACTION  OF  AMPHETAMINES. 

247729  0 
STIMULI 

CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRUG 
AS  CONDITIONED  STIMULI.  (PHD   DISSERTATION). 

239523  O: 
STIMULI  ASSOCIATED  WITH  DRUG  INJECTIONS  AS  EVENTS  THAT 
CONTROL  BEHAVIOR 

2400)1  O: 
AGGRESSIVE  BEHAVIOR  OF  JUVENILE  MICE:  INFLUENCE  OF  ANDROGEf 
AND  OLFACTORY  STIMULI 

245406  0. 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIR! 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  0 
DELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAMINE  A 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 
DRUGS. 

251977  a 
DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THI 

CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS. 

251978  0. 
STIMULUS 

SCOPOLAMINE  AND  AMPHETAMINE  EFFECTS  ON  DISCRIMINATION: 
INTERACTION  WITH  STIMULUS  CONTROL. 

227131  0 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,« 

DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  ANC 

COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIV 

STIMULUS. 

230837  O: 
SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATION! 
RELATED  TO  STIMULUS  CONTROL, 

231005  0] 
REDUCTION  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT 

232617  0; 
A  COMPARISON  OF  THE  DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  f 
2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (R-DOM)  AND  S- 
AMPHETAMINE  IN  THE  RAT. 

237717  05 
DISCRIMINATIVE  PENTOBARBITAL  STIMULUS  AFTER  INTRAVENOUS 
ADMINISTRATION:  A  COMPARISON  WITH  THE  INTRAPERITONEAL 
ROUTE. 

238756  O; 
TEMPORAL  PARAMETERS  OF  0  AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT. 

239856  02 
INTRACRANIAL  SELF-STIMULATION  IN  RATS  AS  A  FUNCTION  OF 
VARIOUS  STIMULUS  PARAMETERS:  VI.  INFLUENCE  OF  FENTANYI 
PIRITRAMIDE,  AND  MORPHINE  ON  MEDICAL  FOREBRAIN  BUNT 
STIMULATION  WITH  MONOPOLAR  ELECTRODES. 

2412/v  uj 
THE  ROLE  OF  SEROTONIN  IN  THE  DISCRIMINATIVE  STIMULUS 
PROPERTIES  OF  MESCALINE.  (PH.D.  DISSERTATION) 

241573  03 
GENERALIZATION  OF  MORPHINE  AND  LYSERGIC-ACIO-DIETHYLAMIDE 
(LSD)  STIMULUS  PROPERTIES  TO  NARCOTIC  ANALGESICS. 

244683  04 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  R/ 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04 
EFFECTS  OF  SELECTED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT 

246967  04 
THE  EFFECT  OF  SCOPOLAMINE  ON  THE  STIMULUS  CHANGE 
PHENOMENON. 

247863  04 
DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ETHANOL  AND  BARBITAL. 

249262  04 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 
AVOIDANCE  AFTER  SCOPOLAMINE  OR  D  AMPHETAMINE  TREATMENT 

250074  04 
THE  NARCOTIC  DISCRIMINATIVE  STIMULUS  COMPLEX    RELATION  TO 
ANALGESIC  ACTIVITY. 

250355  04- 


S-310 


iUME  14,  SUBJECT  INDEX 


Subject  Index 


DISCRIMINATIVE  STIMULUS  PROPERTIES  OF  ANALGESIC  DRUGS: 
NARCOTIC  VERSUS  NONNARCOTIC  ANALGESICS. 

253394  04-04 
MACH 

THE  EFFECTS  OF  CHRONIC  GANGLION  BLOCKADE  AND  CHRONIC 
CHOLINESTERASE  INHIBITION  ON  THE  SENSITIVITY  OF  RABBIT 
STOMACH  MUSCULARIS  TO  CHOLINERGIC  AND  ADRENERGIC 
AGONISTS 

246842  04-03 
PPING 

DEUTEROPATHY  AFTER  STOPPING  PSYCHIATRIC  MEDICATION  FOR 
CHRONIC  SCHIZOPHRENIA 

228325  01-08 
RAGE 

THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 
NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
EFFECTS  OF  DIAZEPAM  AND  SCOPOLAMINE  ON  STORAGE,  RETRIEVAL 
AND  ORGANIZATIONAL  PROCESSES  IN  MEMORY. 

237722  02-14 
THE  STABILITY  OF  CANNABIS  AND  ITS  PREPARATIONS  ON  STORAGE. 

237784  02-01 
IS  THE  SEROTONIN  BINDING  PROTEIN  (SBP)  A  SOLUBLE  STORAGE  FORM 
FOR  SEROTONIN?. 

248604  04-03 
MGHT-CHAIN 

SOLUBILITY  OF  STRAIGHT-CHAIN  AND  BRANCHED  ALKYL  BARBITURATES 
IN  STRAIGHT-CHAIN  ALCOHOLS 

238487  02  01 

CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  t  )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY,  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES 

237778  02-04 
AMPHETAMINE-INDUCED  POLYPHASIC  MORBIDITY:  STUDIES  ON  STRAIN 
DIFFERENCES,  POLYDRUG  EFFECTS  AND  MECHANISM. 

238789  03-03 
STRAIN  DIFFERENCES  DURING  INTRAVENTRICULAR  INFUSION  OF 
NOREPINEPHRINE:  POSSIBLE  ROLE  OF  RECEPTOR  SENSITIVITY. 

248947  04-03 
RAT  STRAIN  DIFFERENCES  IN  PILOCARPINE-INDUCED  MOUSE-KILLING. 

250008  04-04 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 
AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHtTAMINE  TREATMENT 

250074  04-04 
MNS 

A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS. 

230870  01-04 
FURTHER  STUDIES  ON  BRAIN  CONCENTRATIONS  OF  AMPHETAMINE  AND 
ITS  METABOLITES  IN  STRAINS  OF  MICE  SHOWING  DIFFERENT 
SENSITIVITY  TO  PHARMACOLOGICAL  EFFECTS  OF  AMPHETAMINE. 

238322  02-03 
CATECHOLAMINE  CONCENTRATION  IN  DISCRETE  AREAS  OF  BRAIN  OF 
SEVERAL  STRAINS  OF  MICE;  CORRELATION  WITH  AGGRESSIVITY, 

238673  03-03 
ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING-SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6 

249676  04  04 
Y-MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP. 

252171  04-04 
IVTEGIES 
STRATEGIES  OF  BASIC  RESEARCH  IN  DEVELOPMENT  OF  DRUGS. 

229429  0 1  -06 
EARLY  STRATEGIES  IN  TREATMENT  OF  THE  DEPRESSED  PATIENT 

241435  03-17 
STRATEGIES  AND  TACTICS  IN  THE  USE  OF  ANTIOBESITY  DRUGS. 

253315  04  11 
ATEGY 

BIOCHEMICAL  RESEARCH  INTO  PSYCHOSIS:  RESULTS  OF  A  NEW 
RESEARCH  STRATEGY. 

238997  03-13 
BIOCHEMICAL  RESEARCH  IN  SCHIZOPHRENIA:  RESULTING  IN  A  NEW 
RESEARCH  STRATEGY 

241912  03  08 
ENGTH 

VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE    (PH  D.  DISSERTATION) 

241689  03-04 
ESS 

THE  EFFECTS  OF  ADRENALINE,  RESERPINE,  AND  ATROPINE  ON 
ACETYLCHOLINE  CONTENT  OF  THE  BRAIN  AND  PERIPHERAL  GANGLIA 
IN  STRESS 

227635  01  03 
STRESS  AND  MYOCARDIAL  INFARCTION. 

229715  01-11 
THE  EFFECTS  OF  MFTIAMIDE  ON  THE  ACTIVITY  STRESS  ULCER  IN  RATS, 

230835  01-03 


I 


THE  EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  CONDITIONED  REFLEXES 
AFTER  AN  EMOTIONAL  STRESS  IN  CATS 

231069  01-04 
GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION 

234811  02-12 
DOES  INCREASING  STRESS  CHANGE  THE  BEHAVIORAL  ACTION  OF 
MESCALINE  FROM  DISRUPTION  TO  FACILITATION';' 

237732  0''-04 
CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  4  )  AMPHETAMINE  ON 
LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 
VARIABLES. 

237778  02-04 
EFFECTS  OF  AGING  ON  LH  AND  PROLACTIN  AFTER  IHRH  LDOPA, 
METHYL-DOPA,  AND  STRESS  IN  MALE  RAT. 

240642  03-03 
BETA-BLOCKERS  IN  ANXIETY  AND  STRESS. 

240694  03-10 
THE  EFFECT  OF  ETHANOL  STRESS  IN  COMBINATION  ON  THE 

PHARMACOLOGIC  ACTION  OF  HEXOBARBITAL.  (PH.D.  DISSERTATION). 

240933  03-03 
FFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-03 
ALTERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS-STRIATUM 
INDUCED  BY  COMBINATIONS  OF  STRESS  AND  DELTA8- 
TETRAHYDROCANNABINOL  (DELTAS  THC). 

241926  03-03 
STRESS-INDUCED 

PROTECTION  AGAINST  STRESS-INDUCED  DEPLETION  OF  BRAIN 
NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  03-04 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVEIS.  ABSENCE  OF  STRESS  INDUCED 
PITUITARY  PROLACTIN  RELEASE. 

239828  03-03 
FFFECTS  OF  CENTRALLY  ACTING  DRUGS  ON  STRESS-INDUCED  INCREASE 
OF  CGMP  IN  MOUSE  BRAIN 

251416  04-03 
STRESSED 

ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 
TREATED  AND  STRESSED  MICE. 

249299  04-03 
STRESSES 

PROTECTION  AGAINST  STRESS  INDUCED  DEPLETION  OF  BRAIN 

NOREPINEPHRINE  AFTER  PRIOR  EXPOSURE  TO  CHRONIC  STRESSES. 

238718  03-04 
STRIATAL 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
RECEPTORS 

226185  01-04 
INFLUENCE  OF  DRUGS  ON  STRIATAL  AND  LIMBIC  HOMOVANILLIC-ACID 
CONCENTRATION  IN  THE  RAT  BRAIN 

226727  01-03 
ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 
STRIATAL  LESIONS. 

237777  02-03 
STUDIES  ON  THE  MECHANISM  OF  DEPLETION  OF  STRIATAL  DOPAMINE 
BY  ALPHA-METHYL  M  TYROSINE. 

2;!7873  02  03 
EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS   (PH  D.  DISSERTATION). 

238079  02-03 
EFFECT  OF  METHAMPHETAMINE  AND  NEUROLEPTIC  AGENTS  ON  THE 
KINETIC  PROPERTIES  OF  STRIATAL  TYROSINE-HYDROXYLASE. 

238693  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES 

238729  03-03 
AMFONELIC  ACID  FACILITATION  OF  IMPULSE  INDUCED  STRIATAL 

DOPAMINE  RELEASE. 

238730  03-03 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 

AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY 

240063  03-03 
INDIVIDUAL  DIFFERENCES  AMONG  MICE  IN  NORMAL  AND 
AMPHETAMINE  ENHANCED  LOCOMOTOR  ACTIVITY:  RELATIONSHIP  TO 
BEHAVIORAL  INDICES  OF  STRIATAL  ASYMMETRY. 

240750  03-04 
DECREASE  IN  RAT  STRIATAL  ACETYLCHOLINE  LEVELS  BY  SOME  DIRECT 
AND  INDIRECT  ACTING  DOPAMINERGIC  ANTAGONISTS. 

248410  04-03 
EFFECT  OF  METACLOPRAMIDE  ON  LIMBIC  NORADRENERGIC  AND 
STRIATAL  AND  LIMBIC  DOPAMINERGIC  MECHANISMS 

249305  04-06 


S-311 


Subject  Index 


Psychopharmacology  Abstract 


INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 
LEVELS^ 

252027  04-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE  NUCLEUS. 

252217  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC  AMP  METABOLISM 

253135  04-03 
STRIATO-NIGRAL 

D-AMPHETAMINE-INDUCED  INHIBITION  OF  CENTRAL  DOPAMINERGIC 
NEURONS:  MEDIATION  BY  A  STRIATO-NIGRAL  FEEDBACK  PATHWAY. 

243882  04  03 
STRIATUM 

MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINOL 
(R2)  ON  RAT  STRIATUM. 

226851  01-03 
ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-03 
OXOTREMORINE  AND  ATROPINE-INDUCED  CHANGES  OF  DOPAMINE 
METABOLISM  IN  THE  RAT  STRIATUM. 

230854  01-03 
CAMP  CONTENT  AND  THE  REGULATION  OF  TYROSINE-3- 

MONOOXYGENASE  IN  RAT  STRIATUM.  (UNPUBLISHED  PAPER). 

232921  02-03 
RELEASE  OF  PHOSPHODIESTERASE  ACTIVATOR  FROM  PARTICULATE 
FRACTIONS  OF  CEREBELLUM  AND  STRIATUM  BY  PUTATIVE 
NEUROTRANSMITTERS.  (UNPUBLISHED  PAPER). 

236674  02-03 
EFFECT  OF  NOMIFENSINE  ON  MOTOR  ACTIVITY,  DOPAMINE  TURNOVER 
RATE  AND  CYCLIC  3,5  ADENOSINE  MONOPHOSPHATE 
CONCENTRATIONS  OF  RAT  STRIATUM. 

237156  02-04 
ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX,  STRIATUM 
AND  HYPOTHALAMUS  SLICES. 

238714  03-03 
THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
THE  AMPHETAMINE-INDUCED  INHIBITION  OF  DOPAMINE  BIOSYNTHESIS 
IN  RAT  STRIATUM. 

240065  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
IN  VIVO  ACTIONS  OF  CLOZAPINE  AND  HALOPERIDOL  ON  THE  TURNOVER 
RATE  OF  ACETYLCHOLINE  IN  RAT  STRIATUM. 

241252  03-03 
ACTION  OF  OPIATES,  ANTIPSYCHOTICS,  AMPHETAMINE  AND 

APOMORPHINE  ON  DOPAMINE  RECEPTORS  IN  RAT  STRIATUM:  IN  VIVO 
CHANGES  OF  3,5  CYCLIC-AMP  CONTENT  AND  ACETYLCHOLINE 
TURNOVER  RATE. 

244514  04-03 
EFFECT  OF  NOMIFENSINE  ON  ACETYLCHOLINE  AND  CHOLINE  IN  THE  RAT 
STRIATUM  AND  BRAINSTEM. 

248291  04-03 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS 

248698  04-05 
INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM, 

249679  04-04 
ACCUMULATION  OF  CGMP  IN  STRIATUM  OF  RATS  INJECTED  WITH 
NARCOTIC  ANALGESICS:  ANTAGONISM  BY  NALTREXONE. 

250362  04-03 
MESOLIMBIC  AREA  AND  C.  STRIATUM:  RELATIVE  INCREASES  IN 

DOPAMINE  TURNOVER  BY  NEUROLEPTIC  AND  RELATED  COMPOUNDS 
DEVOID  OF  ANTIPSYCHOTIC  ACTIVITY 

251395  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS 

251402  04-04 
NORMAL  GLUTAMIC  DECARBOXYLASE  ACTIVITY  IN  RAT  STRIATUM  AND 
RETAIN  FOLLOWING  ADMINISTRATION  OF  L-DOPA 

253695  04  03 
STRING 

THE  SILVER  VIOLIN  STRING. 

229236  01  09 


STROKE 

PAROXYSMAL  NIGHTMARES:  SEQUEL  OF  A  STROKE  RESPONSIVE  TO 
DIPHENYLHYDANTOIN. 

233295  021 
STRONG 

STRONG  MEANING-RESPONSE  BIAS  IN  SCHIZOPHRENIA. 

245559  04-C 
STRUCTURE 

PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

23831  7  02-C 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTIOC 
OF  THEIR  CHEMICAL  STRUCTURE. 

241428  03-1 
CORRELATION  BETWEEN  STRUCTURE,  BEHAVIORAL  ACTIVITY  AND  RATE 
OF  BIOTRANSFORMATION  OF  SOME  ACTH4-9  ANALOGS. 

246853  04-C 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  TH 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-C 
STRUCTURE-ACTION 

THE  STRUCTURE-ACTION  RELATIONSHIP  AND  KINETICS  OF  SOME 
NALOXONE  AND  NALTREXONE  DERIVATIVES. 

252223  04-C 
STRUCTURE-ACTIVITY 

STRUCTURE-ACTIVITY  RELATIONSHIPS  FOR  AGONIST  AND  ANTAGONIST 
DRUGS  AT  PRESYNAPTIC  AND  POSTSYNAPTIC  RECEPTOR  SITES  IN  RA 
BRAIN. 

229435  01-C 
SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVIT^i 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-C 
STRUCTURE-ACTIVITY  RELATIONSHIPS  IN  ANALOGS  OF  DELTA9- 
TETRAHYDROCANNABINOL:  TACHYCARDIA  VS.  ANALGESIA. 

238805  03-C 
INFLUENCE  OF  DRUGS  AND  CHEMICALS  UPON  HEPATIC  ENZYMES  AND 
PROTEINS    -  I.  STRUCTURE-ACTIVITY  RELATIONSHIP  BETWEEN 
VARIOUS  BARBITURATES  AND  MICROSOMAL  ENZYME  INDUCTION  IN 
RAT  LIVER. 

241297  03-C 
STRUCTURES 

THE  EFFECT  OF  D,L-AMPHETAMINE  ON  THE  REACTION  OF  CORTICAL 
NEURONS  EVOKED  BY  STIMULATION  OF  MESODIENCEPHALIC 
STRUCTURES. 

228546  01 -C 
DIFFERENTIAL  SENSITIVITY  OF  TWO  DOPAMINERGIC  STRUCTURES  IN  RA 
BRAIN  TO  HALOPERIDOL  AND  TO  CLOZAPINE. 

233291  02-C 
EXCITABILITY  OF  THE  HYPOTHALAMUS  AND  LIMBIC  BRAIN  STRUCTURE! 
OF  RABBITS  UNDER  THE  EFFECT  OF  GLUCOCORTICOIDS  AND  ACTH. 

236716  02-C 
THE  EFFECT  OF  SEROTONIN  INJECTION  INTO  THE  BULBAR  STRUCTURES 
ON  HEMODYNAMICS. 

236831  O2-0 
DEMONSTRATION  OF  AN  INVERSELY  PROPORTIONAL  RELATIONSHIP 
BETWEEN  DOPAMINE  AND  SEROTONIN  IN  CERTAIN  CEREBRAL 
STRUCTURES:  NEUROCHEMICAL  AND  MORPHOLOGICAL  ASPECTS. 

244638  04-0 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-0 
STRYCHNINE 

ONTOGENY  OF  BEHAVIORAL  SENSITIVITY  TO  STRYCHNINE  IN  THE  CHICK 
EMBRYO:  EVIDENCE  FOR  THE  EARLY  ONSET  OF  CNS  INHIBITION. 

228630  01-0 
STUDENTS 

TREATMENT  OF  STUDENTS  WITH  MENTAL  DISORDER. 

243092  04-1 
STUDYING 

A  GAS  CHROAAATOGRAPHIC  METHOD  FOR  DETERMINING  HALOPERIDOL 
A  SENSITIVE  PROCEDURE  FOR  STUDYING  SERUM  CONCENTRATION 
AND  PHARMACOKINETICS  OF  HALOPERIDOL  IN  PATIENTS. 

237152  02-1; 
EXTINCTION-INDUCED  MIRROR  RESPONDING  AS  A  BASELINE  FOR 
STUDYING  DRUG  EFFECTS  ON  AGGRESSION. 

250073  OA-Ol 
STUTTERING 

THE  EFFECT  OF  HALOPERIDOL  ON  STUTTERING. 

252793  04-1 
SUBACUTE 

ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-0, 
CYCLIC  EEG  CHANGES  IN  SUBACUTE  SPONGIFORM  AND  ANOXIC 
ENCEPHALOPATHY. 

235563  02-1 


S-312 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING 

241417  03-15 
ISOPRINOSINE  THERAPY  IN  SUBACUTE  SCLEROSING  PANENCEPHALITIS. 

251952  04-11 
UBANESTHETIC 

LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01-04 
UBCELLULAR 

EFFECTS  OF  ELECTROCONVULSIVE  SHOCK  AND  CYCLOHEXIMIDE  ON  THE 
INCORPORATION  OF  AMINO-ACIDS  INTO  PROTEINS  OF  MOUSE  BRAIN 
SUBCELLULAR  FRACTIONS. 

237155  02-03 
3H-DELTA9-TETRAHYDROCANNABINOL  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  03-03 
RELATIONSHIP  BETWEEN  THE  SUBCELLULAR  DISTRIBUTION  OF  DELTA9- 
TETRAHYDROCANNABINOL  AND  ITS  METABOLITES  IN  RAT  BRAIN  AND 
THE  DURATION  OF  THE  EFFECT  ON  MOTOR  ACTIVITY. 

241242  03-03 
EXTRAPINEAL  AMINE  N-ACETYLATION  IN  RAT  BRAIN:  REGIONAL  AND 
SUBCELLULAR  DISTRIBUTION  AND  ENZYME  KINETICS. 

250377  04-01 
EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  GANGLIOSIDES  AND 
SIALOGLYCOPROTEINS  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN. 

253406  04-03 
UBCORTICAl 

DELTA9-TETRAHYDR0CANNABIN0L  ALTERS  FLOW  OF  BLOOD  TO 
SUBCORTICAL  AREAS  OF  THE  CONSCIOUS  RAT  BRAIN. 

226874  01  04 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE, 

233299  02  03 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  TO  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS. 

244874  04-03 
UBCUTANEOUS 

REM  SLEEP  DISTRIBUTIONS  IN  POSTADDICT  RAT  RELAPSING  TO 
MORPHINE  SELF-ADMINISTRATION:  EFFECTS  OF  NALOXONE 
SUBCUTANEOUS  PELLETS. 

251533  04-04 
UBFORNICAl 

THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04-03 
UBGROUP 

MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY, 

253595  04-09 
JBJECT 

ADAPTIVENESS  AND  BEHAVIOR  OF  THE  ELDERLY  SUBJECT. 

242898  04-11 
JBJECTIVE 

SUBJECTIVE  RATINGS  OF  SLEEP  QUALITY  AND  ANXIETY  AFTER  PLACEBO 
DRUG  AND  A  FOOD  DRINK, 

239059  03-14 
THE  EFFECTS  OF  LITHIUM  CARBONATE  UPON  SUBJECTIVE  STATE 
CHANGES  INDUCED  BY  SODIUM  PENTOBARBITAL. 

240074  03-14 
SUBJECTIVE  EFFECTS  OF  TWO  ANOREXIGENIC  AGENTS   -  FENFLURAMINE 
AND  AN  448  IN  NORMAL  SUBJECTS. 

250945  04-07 
RELATIONSHIP  BETWEEN  OBJECTIVE  AND  SUBJECTIVE  ASSESSMENT  OF 
EXPERIMENTALLY-INDUCED  FATIGUE. 

253587  04-12 
JBJECTS 

ELECTROENCEPHALOGRAPHIC  AND  BEHAVIORAL  CHANGES  ASSOCIATED 
WITH  PAPAVERINE  ADMINISTRATION  IN  HEALTHY  GERIATRIC 
SUBJECTS. 

226478  01-11 
THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01-13 
MARUUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS. 

226903  01-14 
ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 
FLUPHENAZINE-DECANOATE 

229557  01-14 


TREATMENT  OF  DEPRESSIVE  SYNDROMES  IN  INVOLUTIONAL  SUBJECTS. 

230990  01-09 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I    THEORETICAL 

CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01  17 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUAAAN  SUBJECTS.  II    FIVE 
EXPERIMENTS. 

232518  01  14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS,  III,  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD 
AND  THEIR  EFFECTS  ON  PERFORMANCE,  APPLICATION  OF 
MATHEMATICAL  MODELS, 

232519  01-14 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS,  IV.  THE 
CONCENTRATIONS  OF  ALCOHOL  AND  MEPROBAMATE  IN  THE  BLOOD. 

232520  01-13 
DRUG  INTERACTIONS:  THE  EFFECT  OF  ALCOHOL  AND  MEPROBAAAATE 

APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  V    SUMMARY 
AND  CONCLUSIONS. 

232521  01-14 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 

VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02-17 
THE  EFFECTS  OF  AMOXAPINE  ON  ELECTROENCEPHALOGRAPHIC  STAGES 
OF  SLEEP  IN  NORMAL  HUMAN  SUBJECTS, 

237696  02-14 
THE  QUALITY  OF  INTELLECTUAL  LIFE  IN  THE  ELDERLY:  DOUBLE  BLIND 
STUDY  OF  HYDROSARPAN-711  IN  80  SUBJECTS, 

240166  03  11 
THE  QUALITY  OF  INTELLECTUAL  LIFE:  DOUBLE-BLIND  STUDY  OF 
HYDROSARPAN-711  INVOLVING  80  SUBJECTS 

242899  04-11 
EFFECTS  OF  PROPRANOLOL  HYDROCHLORIDE  ON  LEARNING  IN  ELDERLY 
SUBJECTS. 

246440  04-14 
PLASMA  PROTEIN  BINDING  OF  DRUGS  AS  A  FUNCTION  OF  AGE  IN  ADULT 
HUAAAN  SUBJECTS. 

246970  04-13 
SUBJECTIVE  EFFECTS  OF  TWO  ANOREXIGENIC  AGENTS      FENFLURAMINE 
AND  AN  448  IN  NORMAL  SUBJECTS 

250945  04-07 
RATE-DEPENDENT  EFFECT  OF  AMPHETAMINE  IN  RATS:  EXTENSION  TO 
BETWEEN  SUBJECTS  EFFECT. 

251988  04-04 
SUBLETHAL 

SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  MALE  RATS  TREATED  WITH 
METHADONE. 

243789  04-03 
SUBNANOMOLES 

A  NOVEL  APPROACH  TO  QUANTITATIVE  DETERMINATION  OF 
SUBNANOMOLES  OF  PSYCHOACTIVE  DRUGS  IN  BLOOD. 

229441  01  16 
SUBORDINATE 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SERIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

'  225571  01-04 
SUBSENSITIVITY 

SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT 

237756  02  03 
SUBSEQUENT 

EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6-HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS. 

228142  01-04 
EFFECT  OF  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03  03 
ENCEPHALOPATHY  SUBSEQUENT  TO  ACCIDENTAL  POISONING  WITH 
CHLORPROAAAZINE, 

239089  03-05 
LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 


S-313 


Subject  Index 


Psychopharmacology  Abstracts 


e 


SUBSTANCE 

NALOXONE  ANTAGONISM  OF  CONDITIONAL  REVERSAL  OF  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA: 
AN  INDIRECT  EVIDENCE  FOR  RELEASE  OF  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT 

238713  03-04 
SEROTONIN:  THE  CRUCIAL  SUBSTANCE  THAT  TURNS  DREAMS  ON  AND 
OFF. 

241505  03-12 
SUBSTANTIA-NIGRA 

LONG-TERM  EFFECT  OF  PERPHENAZINE  ON  THE  SUBSTANTIA-NIGRA  IN 
RATS. 

237702  02-03 
ROTATORY  BEHAVIOR  INDUCED  BY  GLYCINE  INJECTED  INTO  THE 
SUBSTANTIA-NIGRA  OF  THE  RAT. 

238347  02-04 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE  EFFECTS  OF  CHRONIC  D- 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION. 

241307  03-04 
CYCLIC  AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
DOPAMINE  RELEASE  IN  SUBSTANTIA-NIGRA?. 

249984  04  03 
SUBSTITUTED 

MAGNETIC  CIRCULAR  DICHROISM  OF  SUBSTITUTED  INDOLES. 

229493  01  06 
SUBSTITUTED  CYCLOALKANOL  ETHERS  OF  PSYCHOSTIMULANT  ACTIVITY: 
STUDIES  ON  QUANTITATIVE  STRUCTURE-ACTIVITY  RELATIONSHIPS. 

231008  01-03 
ANTICONVULSANT  ACTIVITY  OF  NEWER  SUBSTITUTED  TRIAZOLES. 

238712  03-03 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03-03 
THE  SUBSTITUTED  BENZAMIDES. 

247546  04-17 
SUBSTITUTION 

THE  INFLUENCE  OF  NITROGEN,  CHAIN  AND  RING  SUBSTITUTION  ON 
SOME  PHYSIO-ORGANIC  PROPERTIES  AND  ON  BUCCAL  ABSORPTION  OF 
AMPHETAMINES 

237981  02-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 
SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  04-02 
SUBSTRATE 

SOME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE-OXIDASE, 

233946  02-01 
NEUROAMINE  DERIVED  ALKALOIDS:  SUBSTRATE  PREFERRED  INHIBITORS 
OF  RAT  BRAIN  MONOAMINE  OXIDASE  IN  VITRO. 

243778  04-03 
SUCCINATE 

LOXAPINE  SUCCINATE:  A  CONTROLLED  DOUBLE-BLIND  STUDY  IN 
CHRONIC  SCHIZOPHRENIA 

225867  01  08 
THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01-13 
EFFECTS  OF  DIPHENYLHYDANTOIN,  PHENOBARBITAL,  AND  DIAZEPAM  ON 
THE  METABOLISM  OF  METHYLPREDNISOLONE  AND  ITS  SODIUM 
SUCCINATE. 

233001  02-13 
A  DOUBLE  BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS 

237828  02  08 
A  TWO  YEAR  TRIAL  OF  LOXAPINE  SUCCINATE  IN  CHRONIC  PSYCHOTIC 
PATIENTS. 

244501  04-08 
A  DOUBLE  BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS, 

245014  04-08 
THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA:  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE. 

247968  04-08 
SUCCINIC 

THE  EFFECT  OF  SUCCINIC  SEMIALDEHYDE  AND  SODIUM  SUCCINATE  ON 
THE  HIGHER  NERVOUS  ACTIVITY  IN  NORMAL  SUBJECTS. 

226900  01  13 
SUDDEN 

SUDDEN  UNEXPLAINED  DEATH  IN  A  PSYCHIATRIC  PATIENT  TAKING 
THIORIDAZINE 

240243  03-15 


SUFFERING 

PSYCHOLOGICAL  ANALYSES  OF  PATIENTS  SUFFERING  FROM 
HYPOTHYROIDISM, 

232364  01-14: 
SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENTS 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA. 

236361  02-08 
SUGGEST 

RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED 

252859  04-17 

243438  04-15 


SUICIDAL 

TWO  CASES  OF  SUICIDAL  LITHIUM  INTOXICATION. 


SUICIDE 

WHY  DO  PEOPLE  USE  PARACETAMOL  FOR  SUICIDE?. 


241754  03-17 


SUIDICAL 

SUIDICAL  INGESTION  OF  ISONIAZID:  AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02-15 
SULFASALAZINE 

DRUG  THERAPY   SULFASALAZINE. 

245307  04-13 
SULFATE 

OLFACTORY  BULB  REMOVAL  IN  MICE:  ACTIVITY  LEVELS  AND 

RESPONSIVENESS  TO  THE  LOCOMOTOR  STIMULANT  AND  ANOREXIC 
PROPERTIES  OF  O-AMPHETAMINE  SULFATE.  (PH.D.  DISSERTATION) 

227074  01-04 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
STUDIES  ON  SULFATE  CONJUGATION  OF  ESTROGENS  IN  BRAIN  AND 
LIVER. 

249245  04-03 
SULFATIDE 

DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03  03 
SULFONE 

ACUTE  POISONING  BY  MEANS  OF  A  VETERINARY  USED  SULFONE:  A  CASE 
STUDY 

245116  04-05 
SULFOXIDE 

A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  LEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHLORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS. 

229444  01-08 
CHLORPROMAZINE  METABOLISM  VII:  NEW  QUANTITATIVE 

FLUOROMETRIC  DETERMINATION  OF  CHLORPROMAZINE  AND  ITS 
SULFOXIDE 

251777  04-06 
CHLORPROMAZINE  METABOLISM  Vllh  BLOOD  LEVELS  OF 

CHLORPROMAZINE  AND  ITS  SULFOXIDE  IN  SCHIZOPHRENIC  PATIENTS. 

251778  04-16 
SULFOXIMINE 

OIFFERENIIAL  REGIONAL  EFFECTS  OF  THE  CONVULSANT  METHIONINE 
SULFOXIMINE  ON  SEROTONIN  TURNOVER  IN  THE  RAT  BRAIN 

227387  01-03 
SULFUR 

DRUGS  DERIVED  FROM  CANNABINOIDS.  3    SULFUR  ANALOGS, 
THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  04-02 
DRUGS  DERIVED  FROM  CANNABINOIDS.  4.  EFFECT  OF  ALKYL 

SUBSTITUTION  IN  SULFUR  AND  CARBOCYCLIC  ANALOGS. 

248652  04  02 
SULPHORIDAZINE 

TREATMENT  OF  ACUTE  SCHIZOPHRENIA  WITH  SULPHORIDAZINE. 

240850  03-08 
SULPIRIDE 

DETECTION  OF  THE  NEUROLEPTIC  PROPERTIES  OF  CLOZAPINE,  SULPIRIDE, 
AND  THIORIDAZINE, 

227135  01-04: 
SULPIRIDE  IN  DEPRESSIVE  SCHOOL  PHOBIC  CHILDREN, 

227141  0110 
CLINICAL  EXPERIENCE  IN  USING  SULPIRIDE  FOR  INTERNAL 
PSYCHOSOMATIC  ILLNESS 

227806  01 -ir 
CLINICAL  EXPFRIENCE  IN  USING  SULPIRIDE  (FK-880)  FOR  DEPRESSION,        I 

228334  01-09' 

THE  DISINHIBITING  EFFECT  OF  N  (l-ETHYL-2  PYRROLIDINYL-METHYL  2        j 

METHOXY-5  SULFAMIDOBENZAMIDE  (SULPIRIDE).  II.  i 

229529  01  14; 
SULPIRIDE  IN  CHRONIC  PSYCHOSES  OF  THE  PARANOID  TYPE, 

230991  01-11 


S-314 


s'''.5v',-. ' 


237015  02- 17 


VOLUME  14,  SUBJECT  INDEX 

DOGMATIl  OR  SULPIRIDE   AN  ATTEMPT  AT  SPECIFICATION. 

SULPIRIDE  IN  SCHOOL  PHOBIA 

239346  03- 11 
SULPIRIDE  AS  A  CURRENT  ANTIDEPRESSIVE  TECHNIQUE:  WHAT  CAN  BE 
SAID  AND  THOUGHT  ABOUT  IT  TODAV 

244433  0-1-17 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04-14 
ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04  06 
ANTAGONISM  BY  SULPIRIDE  OF  THREE  APOMORPHINE-INDUCED  EFFECTS 
IN  RODENTS. 

252032  04  04 
SUITHIAME 

EFFECTS  OF  SULTHIAME  UPON  INTELLECTUAL,  NEUROPSYCHOLOGICAL, 
AND  SOCIAL  FUNCTIONING  ABILITIES  AMONG  ADULT  EPILEPTICS: 
COMPARISON  WITH  DIPHENYLHYDANTOIN. 

240475  03  14 
SUMMATION 

USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 
REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS. 

250278  04-03 
SUPERIOR 

DOPAMINE  AGONIST  INDUCED  ASYMMETRY  AFTER  LESIONS  OF 
SUPERIOR  COLLICULUS  IN  RATS. 

238699  03-03 
INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS;  OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS 

239977  03-03 
ROLE  OF  SUPERIOR  COLLICULUS  SEROTONIN  IN  THE  GROOMING 

BEHAVIOUR  OF  CATS 

239978  03-04 
EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 

ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04-03 
THE  EFFECT  OF  ATROPINE  UPON  ACETYLCHOLINE  RELEASE  FROM  CAT 
SUPERIOR  CERVICAL  GANGLIA  AND  RAT  CORTICAL  SLICES: 
MEASUREMENT  BY  A  RADIOENZYMIC  METHOD. 

248724  04  03 
SUPEROXIDE 

EFFECTS  OF  SUPEROXIDE  DISMUTASE  ON  THE  AUTOOXIDATION  OF  7.8 
DIHYOROXYCHLORPROMAZINE  IN  THE  PRESENCE  OF  RAT  BRAIN 
MITOCHONDRIA 

236521  02-03 
SUPERSENSITIVITY 

BEHAVIOURAL  SEQUELAE  OF  DOPAMINERGIC  DEGENERATION 
POSTSYNAPTIC  SUPERSENSITIVITY-? 

229434  01-03 
BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02  04 
BEHAVIORAL  SUPERSENSITIVITY  TO  5-HYDROXYTRYPTOPHAN  INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT, 

237729  02  04 
NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

2377.56  02-03 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6-HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY 

240063  03  03 
SUPERSENSITIVITY  TO  0  AMPHETAMINE  AND  APOMORPHINE  INDUCED 
STEREOTYPED  BEHAVIOR  INDUCED  BY  CHRONIC  D  AMPHETAMINE 
ADMINISTRATION 

247683  04  04 
ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-PTYROSINE. 

249002  04  03 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 
ACETYLCHOLINE  AND  L-GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  0403 
SUPPORTS 

HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS 

239939  03  1 1 
SUPPRESS 

DRUGGING  TO  SUPPRESS  BEHAVIOR. 

252315  04  17 


Subject  Index 


SUPPRESSION 

RESPONSE  SUPPRESSION  IN  RATS;  A  COMPARISON  OF  RESPONSE 

CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER,  CHLORDIAZEPOXIDE. 

230831  01-04 
APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01-04 
TOTAL  SUPPRESSION  OF  IRRITABLE  AGGRESSION  IN  RATS  BY  SENSORY 
DEPRIVATION 

233418  0203 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES;  III. 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS 

235368  02-09 
PITUITARY  ADRENAL  FUNCTION  IN  DEPRESSED  PATIENTS;  RESISTANCE 
TO  DEXAMETHASONE  SUPPRESSION. 

236801  02-13 
CONDITIONED  SUPPRESSION  OF  AN  OPERANT  RESPONSE  USING  DRUGS 
AS  CONDITIONED  STIMULI    (PH.D.  DISSERTATION) 

239523  03-04 
PHARAAACOLOGICAL  SUPPRESSION  OF  PHOTICALLY  EVOKED  AFTER- 
DISCHARGES  IN  RATS;  INCREMENTAL  DOSE,  HIPPOCAMPAL  EEG  AND 
BEHAVIORAL  ACTIVITY  CORRELATES. 

239858  03-03 
NARCOLEPSY;  REM  SLEEP  SUPPRESSION  BY  L-DOPA. 

240657  03-11 
DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION? 

240802  03-13 
DRUG-INDUCED  CONDITIONED  SUPPRESSION    SPECIFICITY  DUE  TO  DRUG 
EMPLOYED  AS  UCS. 

242750  04-04 
METHSCOPOLAMINE;  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04-14 
VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT-TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS. 

24431  1  04-04 
THE  SUPPRESSION  OF  BEHAVIOUR  IN  RATS  BY  PREVIOUS  EXPERIENCE 
AND  ELECTRIC  SHOCK  AND  ITS  ANTAGONISM  BY  ATROPINE. 

245305  04-04 
REVERSAL  OF  THE  6-HYDROXYDOPAMINE-INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 
MECHANISMS. 

246818  04-04 
CORRELATION  BETWEEN  NEUROLEPTIC-INDUCED  SUPPRESSION  OF 

STEREOTYPED  BEHAVIOUR  AND  HVA  CONCENTRATIONS  IN  RAT  BRAIN. 

252523  04-03 
SUPRAMEDULLARY 

INHIBITION  OF  CENTRALLY  EVOKED  PRESSOR  RESPONSES  BY  DIAZEPAM; 
EVIDENCE  FOR  AN  EXCLUSIVELY  SUPRAMEDULLARY  ACTION 

231039  01-03 
SURGERY 

( LINICAL  RESEARCH  WIIH  DEMEIRIN  IN  SURGERY  PATIENTS. 

242527  03-07 
NARCOSIS  INTRODUCTION  WITH  FLUNITRAZEPAM  IN  ACCIDENT 
SURGERY. 

244045  04-11 
SURGICAL 

EVALUATION  OF  LORAZEPAM  AND  PENTOBARBITAL  AS  SURGICAL 
PREMEDICANTS 

237734  02-14 
CHANGES  IN  BRAINSTEM  MONOAMINE  NEURONS  AFTER  SURGICAL  AND 
CHEMICAL  DENERVATION  OF  THE  OLFACTORY  BULB  (OB)  IN  RATS. 

241369  03-03 
SURVEIllANCE 

DROWSINESS  DUE  TO  CHLORPROMAZINE  IN  RELATION  TO  CIGARETTE 
SMOKING:  A  REPORT  FROM  THE  BOSTON  COLLABORATIVE  DRUG 
SURVEILLANCE  PROGRAM 

225722  01-15 
OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION;  A 
REPORT  FROM  THE  DRUG  FPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM 

253661  04-15 
SURVEY 

A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS 

229458  01-11 
COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCES; 
NEW  YORK  AND  TEXAS 

233829  02-08 
THE  DISTRIBUTION  AND  METABOLISM  OF  ETHANOL  AND  BARBITURATES 
IN  THE  ORGANISM  DURING  THEIR  COMBINED  USE  (LITERATURE 
SURVEY) 

236717  02-03 


S-315 


Subject  index 


Psychopharmacology  Abstracts 


SURVIVAL 

EFFECT  OF  BETA-AMINOPROPIONITRILE  OR  PREDNISOLONE  ON  SURVIVAL 
OF  MALE  LAF-J  MICE, 

246586  04-03 
FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA- 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04-11 
SUSCEPTIBILITY 

A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS 

230870  01-04 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE. 

234739  02-04 
INVOLVEMENT  OF  CORTICOSTEROIDS  IN  ACOUSTIC  INDUCTION  OF 
AUDIOGENIC  SEIZURE  SUSCEPTIBILITY  IN  MICE. 

237706  02-03 
THE  EFFECT  OF  ACUTE  AND  CHRONIC  AMPHETAMINE  ADMINISTRATION 
ON  SEIZURE  SUSCEPTIBILITY  AND  BRAIN  CATECHOLAMINES  IN  MICE 
(PHD    DISSERTATION). 

241576  03-03 
EFFECT  OF  AGE  OF  HABIT  ON  SUSCEPTIBILITY  TO  CYCLOHEXIMIDE- 
INDUCED  AMNESIA  IN  MICE. 

2456)4  04-02 
SUSCEPTIBILITY  TO  ELECTROSHOCK  CONVULSION  AFTER  BARBITURATE 
PELLET  IMPLANTATION  IN  THE  MOUSE. 

249254  04-05 
STUDIES  ON  THE  EFFECTS  OF  HISTAMINERGIC  AGENTS  ON  SEIZURE 
SUSCEPTIBILITY  IN  MICE. 

251983  04-03 
SUSPECTED 

MANAGEMENT  OF  PATIENTS  WITH  SUSPECTED  DRUG-INDUCED 
PSYCHOSES 

252733  04-15 
SUSPENDING 

A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS. 

235992  02-11 
SUSPENSION 

STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER. 

244958  04-11 
SUSTAINED-RELEASE 

SUSTAINED  RELEASE  LITHIUM  CARBONATE  IN  A  DOUBLE-BLIND  STUDY- 
SERUM  LITHIUM  LEVELS,  SIDE  EFFECTS,  AND  PLACEBO  RESPONSE. 

251826  04-15 
SWALLOWED 

RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY    NOT  JUST 
TASTED, 

252859  04-17 
SWIMMING 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-04 
SWISS-WEBSTER 

BENZODIAZEPINES  AND  REPRODUCTION  OF  SWISS-WEBSTER  MICE. 

243788  04-04 
SWR-J 

PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE. 

242746  04-04 
SYDENHAMS 

TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPA-DECARBOXYLASE  INHIBITOR. 

237733  02-11 
SYMPATHECTOMY 

THE  EFFECTS  OF  NEONATAL  6-HYDROXYDOPAMINE-INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION, 

226871  01-03 
SYMPATHETIC 

DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA? 

229463  01-03 
OPPOSING  RESPONSES  IN  SYMPATHETIC  NERVE  ACTIVITY  INDUCED  BY 
CENTRAL  INJECTIONS  OF  OUABAIN. 

231006  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA, 

232513  01-03 
SYMPATHETIC  NERVOUS  SYSTEM  EFFECTS  ON  RAT  BRAIN  METABOLISM, 

234309  0203 


RESERPINE-INDUCED  CATECHOLAMINE  DEPLETION  FROM  SMALL  CELLS  IN 
RAT  SYMPATHETIC  GANGLIA. 

237738  02-03 
BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

237751  02  03 
AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-DOPA  AND  5-HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03-03 
SERUM  DOPAMINE-BETA-HYDROXYLASE  AS  AN  INDICATOR  OF 
SYMPATHETIC  ACTIVITY  AND  PRIAAARY  HYPERTENSION. 

241294  03-13 
CHANGES  IN  THE  ARTERIAL  BLOOD-PRESSURE  RESPONSES  OF 
HYPERTENSIVE  RATS  TO  SOME  DRUGS  ACTING  ON  THE  CENTRAL 
SYMPATHETIC  MECHANISMS. 

248551  04-03 
CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTION 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04  12 
MECHANISMS  OF  TRANS-SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE-BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04-03 
SYMPATHOLYTIC 

THE  EFFECT  OF  SYMPATHOLYTIC  AND  SYMPATHOMIMETIC  AGENTS  ON 
ACETYLCHOLINESTERASE  AND  CHOLINESTERASE  ACTIVITY,  IN  VITRO. 

243794  04-03 
SYMPATHOMIMETIC 

THE  EFFECT  OF  SYMPATHOLYTIC  AND  SYMPATHOMIMETIC  AGENTS  ON 
ACETYLCHOLINESTERASE  AND  CHOLINESTERASE  ACTIVITY,  IN  VITRO. 

243794  04-03 
A  STUDY  OF  THE  CENTRAL  EFFECTS  OF  SYMPATHOMIMETIC  DRUGS:  EEG 
AND  BEHAVIOURAL  INVESTIGATIONS  ON  CLONIDINE  AND 
NAPHAZOLINE. 

246148  04-04 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY.  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 
SYMPTOM 

DEVELOPMENT  OF  DRUG  SENSITIVE  SYMPTOM  RATING  SCALES. 

244063  04  17 
SYMPTOMS 

HOSTILITY,  SOMATIC  SYMPTOMS  AND  RECOVERY  WITH 
ANTIDEPRESSANTS. 

226898  01  09 
REVIEW  OF  LONG-TERM  PSYCHIATRIC  MEDICATION  -  A  STUDY  OF 
WITHDRAWAL  SYMPTOMS. 

228214  01-15 
THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS. 

230824  01-09 
ALLEVIATING  AGITATION,  APPREHENSION,  AND  RELATED  SYMPTOMS  IN 
GERIATRIC  PATIENTS:  A  DOUBLE-BLIND  COMPARISON  OF  A 
PHENOTHIAZINE  AND  A  BENZODIAZEPINE. 

234114  02-11 
EFFECT  OF  DELTA9-THC  ON  PHYSICAL  SYMPTOMS  AND  EEG  IN  THE 
NATURALLY  EPILEPTIC  BEAGLE 

238811  03-04 
EXTRAPYRAMIDAL  SYMPTOMS  UNDER  CLOZAPINE:  A  CASUISTIC 
CONTRIBUTION. 

238855  03-15 
EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03  15 
METHYLPHENIDATE.  DEXTROAMPHETAMINE,  AND  LEVAMFETAMINE: 
EFFECTS  ON  SCHIZOPHRENIC  SYMPTOMS. 

23993?  03-08 
THE  PSYCHIATRY  OF  THE  FEMALE  CLI/WACTERIUM:  NEUROTIC  OR 
PSYCHOTIC  SYMPTOMS?. 

241875  03-09 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE. 

244355  04-15 
THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS. 

249771  04-10 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY 

250722  04-15 
BETA-ADRENERGIC  BLOCKADE  IN  THE  CONTROL  OF  SCHIZOPHRENIC 
SYMPTOMS    -  A  CASE  FOR  CONTROLLED  STUDIES 

251164  04-08 


S-316 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


SYNAPSE 

ON  THE  ACTIONS  OF  COMPOUNDS  RELATED  TO  DOPAMINE  AT  A 
NEUROSECRETORY  SYNAPSE 

251703  04-03 
SYNAPSES 

INHIBITORY  AND  EXCITATORY  EFFECTS  OF  CNS  DEPRESSANTS  ON 
INVERTEBRATE  SYNAPSES 

226398  01-03 
INHIBITORY  SYNAPSES  IN  THE  CENTRAL  NERVOUS-SYSTEM  AND  THEIR 
PHARMACOLOGICAL  RESPONSES 

236368  02-07 
THE  EFFECT  OF  AMPHETAMINE  STEREOISOMERS  ON  THE  FUNCTION  OF 
DOPAMINE  SYNAPSES  IN  VITRO. 

244043  04-03 
SYNAPTIC 

BEHAVIORAL  CHANGES  IN  2-MONTH-OLD  RATS  FOLLOWING  PRENATAL 
EXPOSURE  TO  ANTIBODIES  AGAINST  SYNAPTIC  MEMBRANES. 

226186  01-04 
THE  INFLUENCE  OF  CARBIOINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
5-HYDROXYTRYPTAMINE  BINDING  TO  SYNAPTIC  MEMBRANES  FROM  RAT 
BRAIN. 

237890  02-03 
BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DELTA9  TETRAHYDROCANNABINOL  (THC). 

238812  03-03 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS. 

251392  04-03 
SYNAPTOSOMAL 

BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  METHYL  1,2,5,6 
TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIOE. 

227692  01-03 
BINDING  OF  GLYCINE  AND  GAMMA  AMINOBUTYRIC  ACID  TO 

SYNAPTOSOMAL  FRACTIONS  OF  THE  BRAINS  OF  DIFFERENTIALLY 
HOUSED  MICE. 

238349  02-03 
THE  REVERSAL  OF  APOMORPHINE-ELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE-HYDROXYLASE  ACTIVITY  BY 
NEUROLEPTICS. 

238758  03-03 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
I:  N-ARYLALKYL  AND  N  ARYLOXYALKYL  DL-AMPHETAMINES  AND 
RELATED  COMPOUNDS. 

246316  04-03 
THE  EFFECT  OF  VARIOUS  CHLORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYLASE  ACTIVITY 

247212  04-03 
SYNAPTOSOMAL  UPTAKE  AND  LEVELS  OF  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P  CHLOROAMPHETAMINE  OR  B-9  LESIONS. 

248414  04-05 
INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
II:  N-ARYLOXYALKYLPHENTERMINES,  QUATERNARY  DAMPHETAMINES, 
AND  3-ARYLOXYPROPYLAMINES 

248637  04-01 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION 

249295  04-03 
EFFECT  OF  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC-AMP  METABOLISM. 

253135  04-03 
SYNAPTOSOMES 

EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN 

236370  02-03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN 

238715  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES 

238729  03  03 
CONFORMATIONAL  REQUIREMENTS  FOR  BLOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES. 

238738  03-01 
EFFECTS  OF  ANTICONVULSANT  AND  CONVULSANT  DRUGS  ON  THE 
ATPASE  ACTIVITIES  OF  SYNAPTOSOMES  AND  THEIR  COMPONENTS. 

243801  04-03 
D  AMPHETAMINE  AS  A  RELEASER  OR  REUPTAKE  INHIBITOR  OF  BIOGENIC 
AMINES  IN  SYNAPTOSOMES. 

246665  04  03 


A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3-P  TRIFLUOROMETHYLPHENOXYN- 
METHYL-3-PHENYLPROPYLAMINE. 

246848  04-03 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 
BRAIN  SYNAPTOSOMES. 

248701  04-03 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04  03 
CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 
MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04  03 
SYNCHRONIZING 

EEG  SYNCHRONIZING  EFFECT  OF  GAMAM-HYDROXYBUTYRATE  AND  1- 
HYDR0XY-3-AMIN0-PYRR0LID0NE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION. 

245599  04  03 
SYNDROME 

NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION: 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01  03 
ROUSSY-LEVY  SYNDROME  WITH  PSYCHOSIS. 

227746  01-09 
A  CASE  OF  GILLES-DE-LA-TOURETTES  SYNDROME. 

228074  01-11 
THE  PROBLEMS  AND  TREATMENT  OF  PATIENTS  WITH  GILLES-DE-LA 
TOURETTES  SYNDROME. 

229295  01-11 
TREATMENT  OF  THE  MINIMAL-BRAIN-DYSFUNCTION  SYNDROME  WITH 
PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON) 

230002  01  II 
THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 

CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

23371 7  0211 
VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION:  A  NEW  SYNDROME. 

233870  02  11 
ISONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME.  A 
PILOT  TRIAL. 

236665  02  09 
BIOGENIC  AMINES  AND  THE  PHOTOMYOCLONIC  SYNDROME  IN  THE 
BABOON,  PAPIO-PAPIO. 

237755  02-04 
DOSE-RESPONSE  STUDIES  ON  EFFECTS  OF  AMPHETAMINE  ON  ACTIVITY 
AND  OXYGEN  CONSUMPTION  IN  DOG  AND  CAT  MODELS  OF 
HYPERKINESIS  (HYPOINHIBITORY  SYNDROME) 

238825  03  03 
OPEN  WITHDRAWAL  OF  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC 
INDUCED  PARKINSON  SYNDROME 

239822  03-15 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS 

240033  03  1 1 
TREATABLE  ASPECTS  OF  THE  DEMENTIA  SYNDROME 

240614  03-17 
THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DI-N-PROPYLACETATE 

241222  03-03 
CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEG  STUDIES  OF 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME 

241275  03  10 
A  CASE  OF  PHOBIC  ANXIETY  DEPERSONALIZATION  SYNDROME  (ROTH) 

243094  04- 1  7 
BIOCHEMICAL  PHARMACOLOGICAL  BASES  FOR  THE  CLINICAL  USE  OF  L- 
DIHYDROXYPHENYLALANINE  IN  PARKINSONS  SYNDROME. 

244039  04- 1  7 
DRUG-INDUCED  PARKINSONISM  IN  THE  RAT    -  A  MODEL  FOR 

BIOCHEMICAL  INVESTIGATION  OF  THE  PARKINSON  SYNDROME.  Ill 
THE  INCORPORATION  OF  D-GLUCOSE  14C(U)  IN  AMINO-ACIDS  OF 
BRAIN  AND  LIVER  FROM  RATS  PRETREATED  WITH  RESERPINE  OR 
WITH  PHENOTHIAZINES. 

244692  04-03 
TWO  CASES  OF  GILLESDE  LA  TOURETTES  SYNDROME  TREATED  WITH 
HALOPERIDOL. 

246715  04  11 
A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL-BRAIN-DYSFUNCTION. 

247878  04-11 
EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROME 
IN  RHESUS  MONKEYS 

247889  04-04 
DEPRESSION  OF  DOPAMINE  RELEASE  DURING  THE  ETHANOL 
WITHDRAWAL  SYNDROME. 

249293  04-03 


f 


:■ 


S-317 


Subject  Index 


Psychopharmacology  Abstracts 


S 


cs 

s 


TOURETTES  SYNDROME  AND  CENTRALNERVOUS-SYSTEM  STIMULANTS. 

251962  04-11 
THE  TREATMENT  OF  CLIMACTERIC  SYNDROME  WITH  TOFIZOPAM 
(GRANDAXIN). 

252450  04-11 
SYNDROMES 

A  CONTROLLED  TRIAL  OF  CLOTHIAPINE  AND  CHLORPROMAZINE  IN 
ACUTE  SCHIZOPHRENIC  SYNDROMES. 

226412  01-08 
CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE  DECANOATE 
IN  TREATING  DISSOCIATIVE  SYNDROMES 

229560  01-11 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  ON  CHRONIC  SCHIZOPHRENIC 
SYNDROMES   -  WITH  SPECIAL  EMPHASIS  ON  THE  CHANGE  IN  CLINICAL 
PROCESS  WITH  A  RELATIVELY  HIGH  DOSAGE  OF  SPIROPERIDOL. 

229761  01-08 
EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 
NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES, 

230818  01  10 
TREATMENT  OF  DEPRESSIVE  SYNDROMES  IN  INVOLDTIONA!  SUBJECTS 

230990  01-09 
A  CONTRIBUTION  TO  TREATMENT  OF  DEPRESSIVE  SYNDROMES:  USE  OF 
TRAZODONE  INTRAVENOUSLY 

230992  01  09 
TREATMENT  OF  NEUROTIC  SYNDROMES  WITH  TRANQUILIZERS 

231983  01-10 
PRACTOLOL  IN  THE  TREATMENT  OF  WITHDRAWAL  SYNDROMES. 

234047  02-11 
PSYCHIATRIC  EMERGENCY  CAUSED  BY  ACUTE  INTOXICATION  AND 
DETOXIFICATION  SYNDROMES, 

24275)  04-17 
DIAGNOSIS  AND  MANAGEMENT  OF  ETHANOL  WITHDRAWAL 
SYNDROMES, 

244107  04-11 
INTRAVENOUS  TRAZODONE  WITH  DEPRESSIVE  SYNDROMES, 

244589  04  09 
DRUG  THERAPY,  NEUROLOGIC  SYNDROMES  ASSOCIATED  WITH 
ANTIPSYCHOTIC  DRUG  USE, 

246061  04-15 
HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY,  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246993  04-13 
HOMOVANILLIC  ACID  AND  5-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 

OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II    VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSFTRAUMATIC  SYNDROMES. 

246994  04  13 
SYNERGISTIC 

PIRIBEDIL    ITS  SYNERGISTIC  EFFECT  IN  MULTIDRUG  REGIMENS  FOR 
PARKINSONISM. 

251651  04-07 
SYNOPSIS 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
SYNTHESES 

THE  STABILITY  OF  AMPHETAMINII :  SYNTHESES  WITH  AMPHETAMINIL. 

232527  01  01 
SYNTHESIS 

ACUTE  AND  SUBACUTE  EFFECTS  OF  NEUROLEPTICS  ON  DOPAMINE 
SYNTHESIS  AND  RELEASE  IN  THE  RAT  STRIATUM. 

226858  01-03 
SYNTHESIS,  RELEASE  AND  DISTRIBUTION  OF  ACETYLCHOLINE  IN  THE 
BRAIN  OF  RATS  UNDER  THE  INFLUENCE  OF  CHOLINERGIC  AGENTS. 

228550  01-03 
SYNTHESIS  OF  3  CHLORO  2  HYDROXYIMIPRAMINE  AND  3-CHIORO-8- 
HYDROXYIMIPRAMINE  (1),  HYPOTHETICAL  METABOLITES  OF 
CLOMIPRAMINE.  (UNPUBLISHED  PAPER), 

237174  02-01 
EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING 

237264  0204 
8-CHL0R0-(S)-  AND   (R)-IO  ((S)   AND   (R)  3 

METHYLETHYLAMINOPYRROLIDINODIHYDRODIBENZOTHIEPINS, 
SYNTHESIS  AND  PHARMACOLOGICAL  STUDIES 

238475  02-01 
SYNTHESIS  AND  BIOLOGICAL  ACTIONS  OF  2-SUBSriTUTED 
QUINOLIZIDINES 

238477  02-02 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L 

TRYPTOPHAN  (TRP)  INJECTION  IN  MALNOURISHED,  CORN-FED  RATS. 

238676  03-03 
ENDOGENOUS  DOPAMINE  RELEASE  DEPENDENT  AND  INDEPENDENT 
ACTIVATION  OF  DOPAMINE  SYNTHESIS  IN  RAT  BRAIN  STRIATAL 
SYNAPTOSOMES. 

238729  03  03 


CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR, 

238769  03-03 
SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03  03 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602. 

239957  03-03 
THE  ROLE  OF  PRESYNAPTIC  RECEPTORS  IN  THE  RELEASE  AND  SYNTHESIS 
OF  H3-D0PAMINE  BY  SLICES  OF  RAT  STRIATUM. 

241247  03-03 
DETERMINATIONS  OF  ENDOGENOUS  CONCENTRATIONS  OF 

NOREPINEPHRINE  AND  DOPAMINE  AND  THEIR  RATES  OF  SYNTHESIS  IN 
A  SINGLE  MOUSE  BRAIN:  BIPHASIC  EFFECTS  OF  {  i  )  AMPHETAMINE 

241257  03-03 
THE  EFFECT  OF  NUTRITIONAL  FACTORS  ON  BRAIN  AMINO-ACID  LEVELS 
AND  MONOAMINE  SYNTHESIS. 

241472  03-17 
SYNTHESIS  OF  0-TRANSMETHYLATED  CATECHOLAMINES  AND 
PSYCHODYSLEPTIC  BETA-PHENYLISOPROPYLAMINES.  (PH.D. 
DISSERTATION). 

242003  03-01 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N-ACETYLTRANSFERASE. 

243795  04-03 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
SELF-STIMULATION  AND  NORADRENALINE:  EVIDENCE  THAT  INHIBITION 
OF  SYNTHESIS  ABOLISHES  RESPONDING  ONLY  IF  THE  RESERVE  POOL  IS 
DISPERSED  FIRST. 

246774  04-03 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
RADIOPHARAAACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6-IODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS. 

248537  04-01 
SYNTHESIS  AND  BIOLOGICAL  ACTIVITY  OF  NEW  2-SUBSTITUTED 

ANALOGS  OF  FLUPHENAZINE. 

248538  04-02 
SYNTHESIS  AND  CENTRAL  NERVOUS-SYSTEM  DEPRESSANT  ACTIVITY  OF 

SOME  BICYCLIC  AMIDES. 

248539  04-02 
ACETYLCHOLINE  SYNTHESIS  IN  RAT  BRAIN:  DISSIMILAR  EFFECTS  OF 

CLOZAPINE  AND  CHLORPROMAZINE. 

248600  04-03 
SYNTHESIS  AND  DOPAMINERGIC  ACTIVITY  OF  (  t   OR  -)-.  ( -^ )-,  AND  (-)  2- 
DIPROPYLAMlNO-5-HYDROXYTETRAHYDRONAPHTHALENE 

248650  04-02 
SYNTHESIS  AND  NEUROLEPTIC  ACTIVITY  OF  ISOMERIC 
THIEN08ENZ0THIAZINES. 

248949  04-01 
CHOLINESTERASE  (CHE)  INHIBITION  AND  SYNAPTOSOMAL 

ACETYLCHOLINE  (ACH)  SYNTHESIS  AND  RELEASE  FOLLOWING  IN  VIVO 
PARAOXON  (PX)  ADMINISTRATION 

249295  0403 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

249303  04-03 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORAAANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04-14 
EFFECT  OF  ETHANOL  ON  DOPAMINE  SYNTHESIS  AND  RELEASE  FROM  RAT 
CORPUS-STRIATUM. 

251178  04-03 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
DELTA9-TETRAHYDR0CANNABIN0L:  EFFECT  ON  MACROMOLECULAR 
SYNTHESIS  IN  HUMAN  AND  OTHER  MAMMALIAN  CELLS. 

251420  04-13 
ANALOGUES  OF  S-ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION,  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE, 

251698  04-01 
SYNTHESIZED 

ACUTE  EFFECTS  OF  HEROIN  AND  MORPHINE  ON  NEWLY  SYNTHESIZED 
SEROTONIN  IN  RAT  BRAIN 

226870  01-03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H-D0PAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE-NUCLEUS, 

252217  04-03 


S-318 


VOLUME  14,  SUBJECT  INDEX 

^^"introduction  to  the  symposium  on  systematic  studies  with 
psychoactive  drugs  -  new  methods  in  the  assessment  of 

^"*^^^-  235355  02,7 

SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS   -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 

TRIAL 

235360  02-07 

SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS  -  II.  REPORT  ON  A  PLACEBO  CONTROLLED 

CLINICAL  TRIAL. 

235361  02-09 
SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  III.  STANDARD  CONTROLLED  CLINICAL 
TRIAL. 

235362  02-09 

SYSTEMATIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 
PSYCHIATRIC  PATIENTS  -  IV,  A  SUMMARY  REPORT 

235363  02-09 
AN  INTRODUCTION  TO  SYSTEMATIC  STUDIES  OF  TRAZODONE. 

253053  04-07 
A  SUMMARY  OF  SYSTEMATIC  STUDIES  OF  TRAZODONE. 

253059  04-11 

SYSTEMICALIY 

DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-03 
SYSTEMS 

MODULATORS  OF  CYCLIC-AMP  SYSTEMS 

229464  01-03 
CHANGES  IN  EXCITABILITY  OF  THE  HIPPOCAMPUS  AFTER  STIMULATION 
OF  SEROTONERGIC  SYSTEMS  IN  RABBITS  OF  DIFFERENT  AGES 

231119  01-04 
ASCENDING  CATECHOLAMINE  SYSTEMS  AND  MORPHINE  ANALGESIA 

232915  02-03 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6-HYDROXYDOPAMINE  ADMINISTRATION 
INTO  BRAIN 

233970  02-03 
DIFFERENTIAL  DRUG  EFFECTS  ON  BRAIN  SEROTONERGIC  SYSTEMS. 

234805  02-03 
DIFFERENTIAL  EFFECTS  OF  TRANYLCYPROMINE  AND  PARGYLINE  ON 
INDOLEAMINE  SYSTEMS  IN  BRAIN, 

238675  03-03 
COMPARATIVE  PHARMACOLOGY  OF  AMPHETAMINE  AND  PEMOLINE  ON 
BIOGENIC  AMINE  SYSTEMS. 

238728  03-03 
CENTRAL  DEPLETION  OF  NOREPINEPHRINE  IN  GUINEA-PIG   LACK  OF 
EFFECT  ON  NOREPINEPHRINE  SENSITIVE  CYCLIC-AMP  GENERATING 
SYSTEMS. 

238798  03  03 

SEROTONIN  (5-HT)  SYSTEMS  IN  PSYCHOTIC  STATES 

240076  03-12 
BETA-ADRENERGIC  CONTROL  OF  CYCLIC-AMP  GENERATING  SYSTEMS  IN 
CEREBELLUM-  PHARMACOLOGICAL  HETEROGENEITY  CONFIRMED  BY 
DESTRUCTION  OF  INTERNEURONS.  (UNPUBLISHED  PAPER). 

240242  03-03 
ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-MACHINE  TRACKING  SYSTEMS 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03-14 
THE  ROLES  OF  MONOAMINE  NEURAL  SYSTEMS  IN  THE  ANOREXIA 
INDUCED  BY  (  O  AMPHETAMINE  AND  RELATED  COMPOUNDS 

246149  04-03 
EFFECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE-BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 
THE  SEROTONERGIC  SYSTEM  IN  THE  BRAIN  AND  ITS  POSSIBLE 
FUNCTIONAL  CONNECTIONS  WITH  OTHER  AMINERGIC  SYSTEMS 

248159  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
USES  OF  DOUBLE-PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 

REFRACTORINESS,  SUMMATION,  CONVERGENCE,  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS 

250278  04-03 
SOME  EFFECTS  OF  FENFLURAMINE  AND  ITS  DERIVATIVES  ON  THE 
CENTRAL  CATECHOLAMINERGIC  SYSTEMS  OF  MICE, 

250940  04-03 
INTERACTION  OF  BENZODIAZEPINES  WITH  NEUROLEPTICS  AT  CENTRAL 
DOPAMINERGIC  SYSTEMS:  INVOLVEMENT  OF  GABA. 

251399  04-03 


Subject  Index 


SOME  EFFECTS  OF  THE  BEHAVIORALLY  ACTIVE  DRUG,  PHENITRONE.  A 
PURPORTED  HASHISH  AND  LSD  ANTAGONIST,  ON  BRAIN 
NORADRENERGIC  AND  SEROTONERGIC  SYSTEMS. 

251534  04-03 

T-IYMPHOCYTE 

MARUUANA  AND  T-LYMPHOCYTE  ROSETTES 

243088  04-15 

T-LYMPHOCY7ES 

REDUCTION  IN  T-LYMPHOCYTES  FORMING  ACTIVE  ROSETTES  IN  CHRONIC 
MARIJUANA  SMOKERS. 

229039  01-15 

TABLETS 

RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WITH 
GER0VITAL-H3  TABLETS, 

246425  04-09 

TACHYCARDIA 

STRUCTURE-ACTIVITY  RELATIONSHIPS  IN  ANALOGS  OF  DELTA9- 
TETRAHYDROCANNABINOL:  TACHYCARDIA  VS,  ANALGESIA. 

238805  03-02 

PHENOTHIAZINE-INDUCED  VENTRICULAR  TACHYCARDIA 

247148  04-15 

TACHYPHYLAXIS 

AMPHETAMINE  TACHYPHYLAXIS  IN  THE  PITHED  GUINEA  PIG. 

238315  02-03 

TACTICS 

STRATEGIES  AND  TACTICS  IN  THE  USE  OF  ANTIOBESITY  DRUGS, 

253315  04-11 

TAIL 

TAIL  PINCH  INDUCES  EATING  IN  SATED  RATS  WHICH  APPEARS  TO 
DEPEND  ON  NIGROSTRIATAL  DOPAMINE 

227343  01  03 

NEURAL  DISCHARGE  ASSOCIATED  WITH  TAIL  PINCH  INDUCED 
STEREOTYPED  BEHAVIOR, 

238819  03-04 

TALWIN 

MENTAL  AND  EMOTIONAL  DISTURBANCE  WITH  PENTAZOCINE  (TALWIN) 

USE, 

233828  02-15 

TANOAMINE 

THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 
ACTIVITIES, 

244316  04-02 
EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE,  NEW  POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5-HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 
EFFFCTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES 

249313  04-03 
TARDIVE-DYSKINESIA 

DEANOL  IN  THE  TREATMENT  OF  TARDIVE-DYSKINESIA, 

227570  01 -n 
TARDIVE-DYSKINESIA, 

241900  03  15 
EPIDEMIOLOGY  OF  TARDIVE-DYSKINESIA:  PART  II 

244497  04-15 
CLINICAL  OBSERVATIONS  ON  THE  TREATMENT  OF  TARDIVE-DYSKINESIA 
WITH  HALOPERIDOL, 

245967  04-08 

TARDIVE-DYSKINESIA  TREATED  WITH  PIMOZIDE 

246699  04-15 
EFFECT  OF  METHYLDOPA  ON  TARDIVE  DYSKINESIA  IN  PSYCHOGERIATRIC 
PATIENTS 

247967  04-11 

CHOLINE  FOR  TARDIVE  DYSKINESIA. 

250417  04-13 
EPIDEMIOLOGY  OF  TARDIVE-DYSKINESIA-  PART  I. 

250991  04- 15 
AN  EVALUATION  OF  PAPAVERINE  IN  TARDIVE-DYSKINESIA 

251830  04-13 
TREMOGRAPHIC  STUDIES  IN  TARDIVE-DYSKINESIA 

253036  04-15 

EYE  COLOR  AND  TARDIVE-DYSKINESIA. 

253037  04-15 

TARDIVE-DYSKINESIA. 

253154  04  15 

TASK 

EFFECTS  OF  MAGNESIUM  PEMOLINE  ON  A  DELAYED  MATCH-TO-SAMPLE 
TASK  IN  MONKEYS. 

230577  01  04 

THE  INFLUENCE  OF  ALCOHOL  AND  OTHER  DRUGS  ON  MENTAL  TASK 
PERFORMANCES  UNDER  THEIR  COMBINED  ADMINISTRATION 

233281  02-14 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE    STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION) 

238157  02-03 


S-319 


Subject  Index 


Psychopharmacology  Abstracts 


I 

0 


3» 


TASKS 

A  TEST  OF  STATE-DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS 

239853  03-14 
AMPHETAMINE  AND  BARBITURATE  EFFECTS  ON  TWO  TASKS  PERFORMED 
SINGLY  AND  IN  COMBINATION 

253381  04-14 
TASTE 

EFFECTS  OF  DRUG  EXPERIENCE  ON  DRUG-INDUCED  CONDITIONED  TASTE 
AVERSIONS:  STUDIES  WITH  AMPHETAMINE  AND  FENFLURAMINE. 

230829  01  04 
ATTENUATION  BY  ALPHA  METHYLTYROSINE  OF  AMPHETAMINE-INDUCED 
CONDITIONED  TASTE  AVERSION  IN  RATS. 

237713  02-04 
EFFECTS  OF  ERGOCORNINE  AND  CI-628  ON  FOOD  INTAKE  AND  TASTE 
PREFERENCES 

239290  03-04 
FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 
UCS  HABITUATION. 

241521  03-04 
CYCLOHEXIMIDE-INDUCED  AMNESIA  FOR  TASTE  AVERSION  MEMORY  IN 
RATS. 

242742  03-04 
TASTE  AVERSIONS  INDUCED  BY  D  AMPHETAMINE:  DOSE  RESPONSE 
RELATIONSHIP, 

242882  04-04 
ANOREXIA  AND  CONDITIONED  TASTE  AVERSIONS  IN  THE  RAT. 

251629  0405 
DIFFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS, 

251978  04-04 
HORMONAL  INFLUENCES  ON  THE  EXTINCTION  OF  CONDITIONED  TASTE 
AVERSION. 

251980  04-04 
TASTED 

RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-17 
TAT 

MARIHUANA  EFFECTS  ON  TAT  FORM  AND  CONTENT. 

230871  01-14 
TAURINE 

BIOCHEMICAL  OBSERVATIONS  FOLLOWING  ADMINISTRATION  OF 
TAURINE  TO  PATIENTS  WITH  EPILEPSY 

226737  01-13 
INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA-AMINOBUTYRIC  ACID  AND  5  HYDROXYTRYPTOPHAN. 
(UNPUBLISHED  PAPER) 

231278  01-06 
CORTICAL  AND  SUBCORTICAL  PROJECTED  FOCI  IN  CATS:  INHIBITORY 
ACTION  OF  TAURINE. 

233299  02-03 
TAURINE:  A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN 

238715  03-03 
PURIFICATION  OF  (3H)TAURINE  OF  HIGH  SPECIFIC  ACTIVITY. 

238773  03-03 
THE  BEHAVIORAL  AND  NEUROPHARMACOLOGICAL  EFFECTS  OF  TAURINE. 
(PH.D.  DISSERTATION) 

241574  03-03 
THE  EFFECTS  OF  TAURINE  ON  VARIOUS  STAGES  OF  THE  KINDLING 
PROCESS   A  SUMMARY  OF  RESULTS. 

251929  04  04 
WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS 

252149  04-04 
TEACHER 

CONNERS  TEACHER  RATING  SCALE  FOR  USE  IN  DRUG  STUDIES  WITH 
CHILDREN    -  AN  EMPIRICAL  STUDY 

248593  04-11 
TECHNIQUE 

SULPIRIDE  AS  A  CURRENT  ANTIDEPRESSIVE  TECHNIQUE:  WHAT  CAN  BE 
SAID  AND  THOUGHT  ABOUT  IT  TODAY?, 

244433  04  17 
TECHNIQUE  OF  FLUPHENAZINE-DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES 

246186  04-08 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTOPE 
DERIVATIVE  TECHNIQUE. 

247131  04-03 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONIC 
SCHIZOPHRENICS:  A  LONG-TERM  TRIAL  USING  DOUBLE  BLIND 
CROSSOVER  TECHNIQUE 

251374  04  08 


TECHNIQUES 

EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL. 

226902  01-16 
PLASMA/BLOOD  LEVEL  MONITORING  TECHNIQUES  IN  PSYCHIATRY. 

229438  01-16 
A  CONTRIBUTION  TO  PSYCHOACTIVE  DRUG  MEASUREMENT  TECHNIQUES. 

229442  01-16 
AN  ANALYSIS  OF  THE  DOUBLE-PULSE  TECHNIQUES  USE  IN  MEASURING 
HYPOTHALAMIC  REFRACTORY  PERIODS  IN  REWARD  NEURONS   (PH.D. 
DISSERTATION). 

241129  03-03 
CHARACTERIZATION  OF  EEG  EFFECTS  PRODUCED  BY  THE  INTERACTION 
OF  SECOBARBITAL  WITH  PSYCHOMOTOR  STIMULANTS  USING 
SPECTRAL  ANALYSIS  TECHNIQUES. 

249251  04-03 
USE  OF  BETA-BLOCKERS  AS  AN  ADJUNCT  IN  BEHAVIOURAL  TECHNIQUES. 

251158  04-10 
TEGMENTUM 

CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 
OF  THE  RAT. 

237862  02  03 
BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6-OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04-04 
TEGRETOL 

THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-03 
CARBAMAZEPINE  (TEGRETOL)   -  A  DOUBLE-BLIND  COMPARISON  WITH 
PHENYTOIN  (DILANTIN). 

251937  04-13 
EFFECT  OF  CARBAMAZEPINE  (TEGRETOL)  ON  ATTENTIONAL  AND 
PERCEPTUAL  FUNCTIONS  OF  CHILDREN  WITH  EPILEPSY. 

251949  04-11 
TELENCEPHALIC 

A  TELENCEPHALIC  LESION  SITE  FOR  D-AMPHETAMINE-INDUCED 
CONTRALATERAL  ROTATION  IN  RATS. 

231301  01-04 
TELESTIMUIATION 

CHEMISTOR:  A  REUSABLE  TELESTIMULATION  DEVICE  FOR  DIRECT 
CHEMICAL  STIMULATION  OF  THE  NONHUMAN  PRIMATE  BRAIN  IN 
FREELY  MOVING  ANIMALS. 

237270  02  06 
TEMAZEPAM 

A  1,4  BENZODIAZEPINE,  TEMAZEPAM  {K-3917),  ITS  EFFECT  ON  SOME 
PSYCHOLOGICAL  PARAMETERS  OF  SLEEP  AND  BEHAVIOUR. 

237122  02  14 
A  CLINICAL  TRIAL  OF  TEMAZEPAM,  A  SLEEP  INDUCER,  IN  HOSPITAL 
PATIENTS. 

251006  04-07 
TEMPERATURE 

TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 
INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE 

229264  01  04 
INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 
TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02  03 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE-LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-03 
CORRELATION  BETWEEN  THE  EFFECTS  OF  SEVERAL  CANNABINOIDS  ON 
CATECHOLAMINE  SYNTHESIS,  BODY  TEMPERATURE,  AND  BEHAVIOR. 

238769  03-03 
AMPHETAMINE  TOXICITY  IN  TEMPERATURE  ACCLIMATISED  MICE. 

239091  03-05 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5- 

HYDROXYTRYPTAMINE  (5  HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (III). 

241394  03-03 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03-03 
EFFECT  OF  LSD  ON  RAT  BRAIN  5  HYDROXYTRYPTAMINE  METABOLISM  AT 

ELEVATED  ENVIRONMENTAL  TEMPERATURE, 

241925  03-03 
BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN  El  AND 
NORADRENALINE  INTO  THE  BRAIN 

242736  03-03 
CEREBRAL  ARTERIAL  SPASM,  PART  4:  IN  VITRO  EFFECTS  OF 

TEMPERATURE,  SEROTONIN  ANALOGUES,  LARGE  NONPHYSIOLOGICAL 
CONCENTRATIONS  OF  SEROTONIN,  AND  EXTRACELLULAR  CALCIUM 


S-320 


DLUME  14,  SUBJECT  INDEX 


Subject  Index 


AND  MAGNESIUM  ON  SEROTONIN-INDUCED  CONTRACTIONS  OF  THE 
CANINE  BASILAR  ARTERY,  243797  04-03 

CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 
AMPHETAMINE  LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 

^^^'^^^'^^'  2493,6  04-03 

BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFECTS  OF 

CHOLERA  TOXIN 

252034  04-03 

MPERATURES 

BODY  TEMPERATURE  RESPONSES  AT  DIFFERENT  AMBIENT 

TEMPERATURES  FOLLOWING  INJECTIONS  OF  PROSTAGLANDIN-El  AND 
NORADRENALINE  INTO  THE  BRAIN. 

242736  03-03 

MPIDON 

STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE-LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON. 

240205  03-05 

MPORAl 

TEMPORAL  PARAMETERS  OF  D-AMPHETAMINE  AS  A  DISCRIMINATIVE 
STIMULUS  IN  THE  RAT. 

239856  03-04 

NSION 

A  COMPARISON  BETWEEN  LITHIUM,  PLACEBO  AND  A  DIURETIC  IN 
PREMENSTRUAL  TENSION. 

226414  01-11 
ISOXSUPRINE  IN  PRIMARY  DYSMENORRHOEA:  ITS  EFFECTIVENESS  IN 
PREMENSTRUAL  TENSION. 

245136  04-11 

THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT,  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG. 

238703  03-03 

iRATOGENESIS 

BEHAVIORAL  TERATOGENESIS:  A  CRITICAL  EVALUATION. 

242744  03-17 

ERATOGENIC 

A  TERATOGENIC  STUDY  OF  HALOPERIDOL. 

231604  01-05 

;rminal 

COUNSELING    PEAK  EXPERIENCES  AND  THE  HUMAN  ENCOUNTER  WITH 
DEATH    AN  EMPIRICAL  STUDY  OF  THE  EFFICACY  OF  DPT-ASSISTED 
COUNSELING  IN  ENHANCING  THE  QUALITY  OF  LIFE  OF  PERSONS  WITH 
TERMINAL  CANCER  AND  THEIR  CLOSEST  FAMILY  MEMBERS.  (PH.D. 
DISSERTATION). 

228686  01-11 

THE  MEASUREMENT  OF  PAIN  IN  TERMINAL  CARCINOMA. 

252143  04-11 
ERMINALS 

DIAZEPAM  DEPOLARIZATION  OF  PRESYNAPTIC  TERMINALS  IN  BULLFROG 
SYMPATHETIC  GANGLIA:  MEDIATION  THROUGH  GABA-? 

229463  01-03 
EVIDENCE  FOR  GABA  INVOLVEMENT  IN  THE  ACTION  OF  DIAZEPAM  ON 
PRESYNAPTIC  NERVE  TERMINALS  IN  BULLFROG  SYMPATHETIC 
GANGLIA 

232513  01-03 

UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-03 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 

ERMINATION 

INTRODUCTION:  SCHEDULES  OF  TERMINATION  OF  DRUG  INJECTIONS. 

240017  03-04 
TERMINATION  OF  A  SCHEDULE  COMPLEX  ASSOCIATED  WITH 

INTRAVENOUS  INJECTIONS  OF  NALORPHINE  IN  MORPHINE-DEPENDENT 
RHESUS  MONKEYS 

240019  03-04 


EST 


EVALUATION  OF  SIDE  EFFECTS  ON  NEUROTICS  -   A  TEST  USING 
MESORIDAZINE  AND  PLACEBO. 

225686  01-15 

PSYCHOMETRIC  CLINICAL  EVALUATION,  THROUGH  OVERALL  AND 
GORHAMS  TEST,  OF  THERAPY  WITH  FLUPHENAZINE  DECANOATE. 

229555  01  1  7 
THE  EFFECTS  OF  DRUGS  ON  PSYCHIATRIC  PATIENTS  PERFORMANCE  ON 
THE  HALSTEAD-REITAN  NEUROPSYCHOLOGICAL  TEST  BATTERY. 

229650  01-14 
PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS 

229684  01-14 
SIMPLIFIED  LITHIUM  DOSE  ADJUSTMENT  BY  LOAD  TEST. 

230866  01-16 


A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINt  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02-08 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  III 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS. 

235368  02-09 

DEPRESSIVE  STATE  AND  DIMENSIONS  OF  THE  MAN  ON  GOODENOUGHS 
DRAW-A-MAN  TEST  IN  CHILDREN. 

235998  02  10 

VESTIBULAR  TEST  IN  INVESTIGATING  THE  SPECTRUM  OF  ACTION  OF 

PSYCHOTROPIC  AGENTS 

236714  02-04 

LEVODOPA  AND  PSYCHOMETRIC  TEST  PERFORMANCE  IN  PARKINSONISM 

-  5  YEARS  LATER. 

237141  02-14 

THE  POTENTIATION  OF  CONDITIONED  REINFORCEMENT  BY 

PSYCHOMOTOR  STIMULANT  DRUGS   A  TEST  OF  HILLS  HYPOTHESIS. 

23771 1  02-04 
THE  EFFECTS  OF  TEST  ENVIRONMENT  AND  REARING  CONDITION  ON 

AMPHETAMINE-INDUCED  STEREOTYPY  IN  THE  GUINEA-PIG. 

237712  02  04 

CLINICAL  LABORATORY  TEST  STANDARDS  FOR  A  SAMPLE  OF 

SCHIZOPHRENICS.  „^  „„ 

237726  02-08 

THE  ANXIOLYTIC  EFFECT  OF  SMALL  CUMULATIVE  DOSES  OF  OXYPERTIN 
IN  RATS  IN  AN  ANXIETY  TEST  AND  THE  POSSIBLE  NEUROCHEMICAL 
CORRELATES  IN  THE  HYPOTHALAMUS  AND  STRIATUM. 

239834  03-04 
A  TEST  OF  STATE  DEPENDENCY  IN  MARIHUANA  INTOXICATION  FOR  THE 
LEARNING  OF  PSYCHOMOTOR  TASKS. 

239853  03  14 

A  TEST  OF  THE  STATE  DEPENDENT  LEARNING  EFFECTS  OF 
METHYLPHENIDATE  IN  HYPERACTIVE  CHILDREN.  (PH.D. 
DISSERTATION). 

24113303-14 

THE  PERIAQUEDUCTAL  GRAY  AND  ANALGESIA:  FURTHER  STUDIES  OF 
DRUG  AND  TEST  SPECIFICITY. 

249248  04  03 
USE  OF  THE  MOUSE  JUMPING  TEST  FOR  ESTIMATING  ANTAGONISTIC 
POTENCIES  OF  MORPHINE  ANTAGONISTS 

250354  04  04 

TESTING 

TESTING  PSYCHOTROPIC  DRUGS  IN  GENERAL  PRACTICE 

227223  01   16 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE 

234739  02-04 

TESTING  OF  NEW  PSYCHOTROPIC  DRUGS  ON  OUTPATIENTS 

23681  1  02  17 

INTER  GROUP  AGGRESSION  IN  MICE:  A  NEW  METHOD  FOR  TESTING  THE 
EFFECTS  OF  CENTRALLY  ACTIVE  DRUGS 

249668  04-04 

TESTOSTERONE 

DIAZEPAM  AND  PLASMA  TESTOSTERONE  LEVELS. 

229369  01-15 
A  QUANTITATIVE  COMPARISON  OF  RELATIONSHIPS  BETWEEN  PLASMA 
TESTOSTERONE  (T)  AND  TWO  CENTRAL  FUNCTIONS:  LH  FEEDBACK 

AND  SEX  BEHAVIOR.  „    „ 

238800  03-04 

INTRACRANIAL  CYCLOHEXIMIDE:  EFFECT  ON  MALE  MOUSE  SEXUAL 
BEHAVIOR  AND  PLASMA  TESTOSTERONE 

242743  03  04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK    I    EFFECTS  PRESENT  IN  MALES  BUT  NOT  IN  FEMALES. 

245/12  04-04 
EFFECTS  OF  TESTOSTERONE  ON  THE  BEHAVIOUR  OF  THE  DOMESTIC 
CHICK.  II    EFFECTS  PRESENT  IN  BOTH  SEXES 

245713  04-04 
TESTOSTERONE  MANIPULATIONS:  EFFECTS  ON  RANACIDE  AGGRESSION 
AND  BRAIN  MONOAMINES  IN  THE  ADULT  FEMALE  RAT 

250068  04  02 
INHIBITION  OF  THE  EJACULATORY  REFLEX  IN  B6D2FI  MICE  BY 
TESTOSTERONE  PROPIONATE. 

250984  04  04 

TESTS 

EFFECT  OF  FLURAZEPAM  ON  COMMON  CLINICAL  LABORATORY  TESTS 

251824  04  16 
DELTA9-TETRAHYDR0CANNABIN0L,  ETHANOL,  AND  AMPHETAMINE  AS 
DISCRIMINATIVE  STIMULI  GENERALIZATION  TESTS  WITH  OTHER 

DRUGS 

251977  04  04 

TETRABENAZINE 

COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS  CHOREA    PILOT  STUDY 

2481 /2  04  11 


S-321 


Subject  Index 


Psychopharmacology  Abstrac 


C 

P. 


TETRABENAZINE  INI  THE  TREATMENT  OF  HYPERKINETIC  MOVEMENT 
DISORDERS 

251961  04-11 
TETRACYCIIC 

PHARMACOLOGY  OF  R  806,  A  TETRACYCLIC  ANTIDEPRESSANT, 

238837  03-03 
TETRAHYDROCANNABINOL 

PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 
TETRAHYDROCANNABINOL,  1  I  HYDROXYTETRAHYDROCANNABINOL 
CANNABINOl.  AND  CANNABIDIOL 

241256  03-03 
TETRAHYDROCANNABINOL  ATTENUATED  ABSTINENCE  AND  INDUCED 
ROTATION  IN  MORPHINE-DEPENDENT  RATS:  POSSIBLE  INVOLVEMENT 
OF  DOPAMINE 

245601  04-04 
DRUGS  DERIVED  FROM  CANNABINOIDS,  5.  DELTA 

TETRAHYDROCANNABINOL  AND  HETEROCYCLIC  ANALOGS 
CONTAINING  AROMATIC  SIDE-CHAINS. 

248648  0402 
TETRAHYDROCANNABINOLS 

EFFECTS  OF  TETRAHYDROCANNABINOLS  ON  KINDLED  AMYGDALOID 
SEIZURES  AND  PHOTOGENIC  SEIZURES  IN  SENEGALESE  BABOONS 
PAPIO-PAPIO, 

230475  01-03 
ANTIEPILEPTIC  AND  PROPHYLACTIC  EFFECTS  OF 

TETRAHYDROCANNABINOLS  IN  AMYGDALOID  KINDLED  CATS. 

230478  01-03 
EFFECT  OF  TETRAHYDROCANNABINOLS  ON  H3-ACETYLCH0LINE 
BIOSYNTHESIS  IN  VARIOUS  RAT  BRAIN  SLICES 

241254  03-03 
TETRAHYDROPAPAVEROLINE 

A  COMPARISON  OF  6.7  DIHYDROXYTFTRAHYDROISOQUINOLINE, 
SALSOLINOL  AND  TETRAHYDROPAPAVEROLINE  AN  INHIBITORS  OF 
MONOAMINE  OXIDASE  WITHIN  THE  ADRENERGIC  NERVE  PLEXUS  OF 
THE  ISOLATED  MOUSE  ATRIUM, 

248603  04-03 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5- 
HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
TETRAHYDROPYRIOINE 

BLOCKAGE  OF  LSD  BINDING  AT  ITS  HIGH  AFFINITY  SITE  ON 
SYNAPTOSOMAL  MEMBRANES  BY  1  MFTHYL  12  5  6 
TETRAHYDROPYRIOINE  N.N  DIETHYLCARBOXAMIDE, 

227692  01-03 
ANTAGONISM  OF  D  lYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,5.6  TETRAHYDROPYRIDINE  N,N  DIETHYLCARBOXAMIDE 
(THPC), 

230453  01-03 
TEXAS 

COMPARATIVE  SURVEY  OF  PSYCHIATRISTS  PRESCRIPTION  PREFERENCES- 
NEW-YORK  AND  TEXAS. 

233829  02-08 
THALAMIC 

DIFFERENTIAL  EFFECIS  OF  METHYLPHENIDATE  ON  RETICULAR 
FORMATION  AND  THALAMIC  NEURONAL  ACTIVITY, 

230840  01-03 
BARBITURATE  SPINDLE  ACTIVITY  IN  FUNCTIONALLY  CORRESPONDING 
IHALAMIC  AND  CORTICAL  SOMATOSENSORY  AREAS  IN  THE  CAT. 

232606  02  03 
BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX. 

232607  02-03 
CAFFEINE  AND  CHLORDIAZEPOXIDE;  EFFECTS  ON  MOTOR  ACTIVITY  IN 

THE  CHRONIC  THALAMIC  RAT 

246388  04-04 
EFFECTS  OF  SELECIED  DRUGS  ON  AN  AUDITORY  OR  THALAMIC 
CONDITIONED  STIMULUS  ELICITING  RECRUITMENT  IN  THE  CAT. 

246967  04-04 
THALAMOTOMY 

L-DOPA  THERAPY  AND  STEREOTAXIC  THALAMOTOMY  FOR 
PARKINSONISM, 

245986  04  11 


THC 


BRAIN  SYNAPTIC  MEMBRANE  NAK-ATPASE  FOLLOWING  CHRONIC 
INJECTION  OF  DEL TA9  TETRAHYDROCANNABINOL  (THC) 

238812  03-03 
THE  MECHANISM  BY  WHICH  DELTA9-TETRAHYDR0CANNABIN0L  (THC) 
PRODUCES  A  DECREASE  IN  SALIVARY  FLOW  FOLLOWING  ELECTRICAL 
STIMULATION 

238815  03  03 
AVERSIVE  EFFECTS  OF  REPEATED  INJECTIONS  OF  THC  IN  RATS 

249158  04-04 
EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9- 
TETRAHYDROCANNABINOL  (THC). 

249309  04-03 


THC-INDUCED 

DIFFERENTIAL  EFFECT  OF  CANNABINOL  AND  CANNABIDIOL  ON  THC- 
INDUCED  RESPONSES  DURING  ABSTINENCE  IN  MORPHINEDEPENDEN 
RATS. 

227702  01 
THEOPHYLLINE 

CYCLIC  ADENOSINE  MONOPHOSPHATE  IN  CEREBROSPINAL  FLUID: 
EFFECTS  OF  THEOPHYLLINE,  L-DOPA  AND  A  DOPAMINE  RECEPTOR 
STIMULANT  IN  RATS. 

240447  03 
THEORETICAL 

NICOTINIC-ACID  IN  THE  TREATMENT  OF  SCHIZOPHRENIAS:  PRACTICAL 
AND  THEORETICAL  CONSIDERATIONS. 

230812  01 
DRUG  INTERACTIONS:  THE  EFFECTS  OF  ALCOHOL  AND  MEPROBAMATE 
APPLIED  SINGLY  AND  JOINTLY  IN  HUMAN  SUBJECTS.  I.  THEORETIC/! 
CONSIDERATIONS  AND  LITERATURE  REVIEW. 

232517  01 
THEORETICAL  AND  METHODOLOGICAL  CONSIDERATIONS  ON  DRUG 
DISCRIMINATION  LEARNING. 

241228  03 
THEORY 

PSYCHOACTIVE  DRUGS  AND  SOCIAL  JUDGMENT:  THEORY  AND 
RESEARCH. 

231066  0) 
THERALENE 

STUDIES  ON  SLEEP  EFFECTS  OF  ALIMEAMZIN  (THERALENE). 

240710  03 
THERAPEUTIC 

EFFECTS  OF  CONTROL  TECHNIQUES  ON  THERAPEUTIC  OUTCOME  IN  A 
CONTROLLED  CLINICAL  TRIAL, 

226902  01 
A  CONTROLLED  MULTICENTRE  THERAPEUTIC  TRIAL  OF  VILOXAZINE 
(VIVALAN). 

227216  01 
CLINICAL  THERAPEUTIC  EXPERIMENTS  ON  PSYCHOTIC  PATIENTS  WITH 
LONG-ACTING  FLUPHENAZINE. 

229550  01 
CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOA' 
IN  TREATING  DISSOCIATIVE  SYNDROMES. 

229560  01 
THE  LITTLE  KNOWN  THERAPEUTIC  PROPERTIES  OF  IMIPRAMINE  IN 
MANIC  STATES  OF  CYCLOTHYMIC  PSYCHOSES. 

231368  01 
PHARMACOPSYCHOLOGICAL  STUDIES  IN  NORMAL  SUBJECTS  WITH  A 
VIEW  TO  PREDICTING  THE  THERAPEUTIC  EFFICIENCY  OF 
PSYCHOTROPIC  DRUGS. 

233683  02 
COMPARISON  OF  THE  THERAPEUTIC  EFFECT  OF  CLOZAPINE  AND 
CHLORPROMAZINE. 

234420  02: 
POSITIVE  THERAPEUTIC  RESPONSE  TO  LITHIUM  IN  HYPOAAANIA 
SECONDARY  TO  ORGANIC-BRAIN-SYNDROME. 

23471 1  02^ 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES.  II.  BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS, 

235367  02- 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES;  III, 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS, 

235368  02- 
THERAPEUTIC  DOSES  OF  CYPROHEPTADINE  DO  NOT  INHIBIT 

MONOAMINE-OXIDASE  IN  MAN. 

237927  02- 
THERAPEUTIC  ATTEMPTS  WITH  LITHIUM  IN  YOUNG  DRUG  ADDICTS, 

238988  03- 
SOME  THERAPEUTIC  USES  OF  GABA  IN  NEUROLOGY. 

239700  03- 
THERAPEUTIC  COMBINATION  OF  PSYCHOPHARAAACEUTICALS  AND  BET> 
ADRENERGIC  BLOCKERS. 

239783  03- 
TRIAL  OF  A  NEW  THERAPEUTIC  AGENT,  PERVINCAMINE.  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS:  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS. 

240033  03- 
METHODOLOGY  OF  THERAPEUTIC  EFFECTIVENESS  TRIALS  IN 
PSYCHOPHARMACOLOGY, 

240444  03- 
THERAPEUTIC  USEFULNESS  OF  HALLUCINOGENIC  DRUGS  AS  A  FUNCTIO 
OF  THEIR  CHEMICAL  STRUCTURE, 

241428  03- 
PROPHYLACTIC  AND  THERAPEUTIC  EFFECTS  OF  LITHIUM  AND 
HEREDITARY  FACTORS  IN  PATIENTS  WITH  MANIC-DEPRESSIVE 
PSYCHOSIS, 

243979  04-( 
TRAZODONE:  THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS, 

244588  04-( 


S-322 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


BIOCHEMISTRY  AND  THE  SEARCH  FOR  THERAPEUTIC  AGENTS 

245949  04-06 
THERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLERIL) 

IN  SCHIZOPHRENIC  PATIENTS.  ,.6672  04-08 

FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04  1 1 
PSYCHOMETRIC  ASSESSMENT  OF  THE  THERAPEUTIC  EFFICIENCY  OF 
ANTIDEPRESSANT  AGENTS.  251004  04-, 0 

CLINICAL  AND  THERAPEUTICAL  PROBLEMS  OF  MILD  (NONPSYCHOTIC) 
MENTAL  DEPRESSIONS.  252447  04-10 

■lERAPIES 

DRUGS  IN  COMBINATION  WITH  OTHER  THERAPIES 

234378  02  17 

4ERAPY 

TWO  CASES  OF  CONVULSIONS  DURING  LITHIUM  THERAPY 

228072  01-15 
NEW  DRUG  THERAPY  IN  THE  FIELD  OF  PSYCHIATRY 

228211  01  17 
THERAPY  OF  ANXIETY  IN  PATIENTS  WITH  RHEUMATIC  DISEASE: 
CROSSOVER  DOUBLE-BLIND  STUDY  COMPARING  LORAZEPAM  WITH 
PLACEBO 

228241  01  11 
ISSUES  CONCERNING  DRUG  THERAPY  IN  THE  MENTAl  HOSPITAL. 

228322  01  17 
AN  EXPERIMENTAL  THERAPY  AND  RE-EDUCATION  PROGRAM  FOR 
ALCOHOLICS  INCLUDING  CHEMOTHERAPY  WITH  PROPRANOLOL 
HYDROCHLORIDE   (PH.D.  DISSERTATION) 

228750  01  11 
DOUBLE-BLIND  CONTROLLED  STUDY  OF  L  DOPA  THERAPY  IN 
SCHIZOPHRENIA. 

229064  0 1  -08 
COGNITIVE  AND  PERCEPTUAL  EFFECTS  OF  LONG  RANGE  L  DOPA  THERAPY 
IN  PARKINSONISM. 

229165  01-11 
A  PRELIMINARY  REPORT  ON  CLINICAL  RESPONSE  AND  BLOOD  lEVELS  OF 
CHLORPROMAZINE  AND  ITS  SULFOXIDE  DURING  CHIORPROMAZINE 
THERAPY  IN  CHRONIC  SCHIZOPHRENIC  PATIENTS 

22944-1  01-08 
LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 
COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS. 

229448  01-08 
IMIPRAMINE,  BEHAVIOR  THERAPY,  AND  PHOBIA 

229451  01-10 
CNS  STIMULANTS  AND  ANABOLIC  SUBSTANCES  IN  GEROPSYCHIATRIC 
THERAPY. 

229459  0111 

PSYCHOMETRIC  CLINICAL  EVALUATION.  THROUGH  OVERALL  AND 
GORHAMS  TEST.  OF  THERAPY  WITH  FLUPHENAZINE  DECANOATE. 

229555  01  17 
OUTPATIENT  THERAPY  WITH  FLUPHENAZINE  DECANOATE  IN 

SCHIZOPHRENIC  PATIENTS. 

229556  01  08 

THERAPY  OF  DEPRESSION  BY  PHENYLALANINE    PRFIIMINARY  NOTE. 

229827  01-09 
NEUROENDOCRINE  EFFECTS  OF  HALOPERIDOi  THERAPY  IN  CHRONIC 
SCHIZOPHRENIA 

230839  01-08 

THE  THERAPY  OF  AUTONOMIC  REGULATORY  DISTURBANCES  THROUGH 

DRUGS 

232260  01  15 

EFFECTS  OF  INTRAVENTRICULAR  6  HYOROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF-STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT 

232332  01-04 

NUTRITION  AND  DRUG  THERAPY  FOR  PERSONS  WITH  DEVELOPMENTAL 
DISABILITIES 

232815  02  15 

OVERVIEW    MAINTENANCE  THERAPY  IN  PSYCHIATRY    I    SCHIZOPHRENIA. 

232827  02-08 
TWO  YEAR  COMBINED  THERAPY  OF  PARKINSONS  DISEASE  WITH  LDOPA 
AND  THE  DECARBOXYLASE  INHIBITOR  BENSERAZID  {RO-4.4602) 

233917  02-11 
ATROPINE  COMA  THERAPY  IN  PSYCHIATRY:  CLINICAL  OBSERVATIONS 
OVER  A  20- YEAR  PERIOD  AND  A  REVIEW  OF  THE  LITERATURE 

234826  02  17 
FATAL  PARALYTIC  ILEUS  COMPLICATING  PHENOTHIAZINE  THERAPY. 

235286  02-15 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS 

235419  02-17 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 


SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 

'^''^''  235629  02-08 

AN  UPDATE  OF  MEGAVITAMIN  THERAPY  IN  ORTHOMOLECULAR 

-^S^^^'^^^^  235678  02-17 

OVERVIEW'  MAINTENANCE  THERAPY  IN  PSYCHIATRY:  II.  AFFECTIVE 

°'^°^^^^^  236303  02-17 

MAINTENANCE  ANTIPSYCHOTIC  THERAPY    IS  THE  CURE  WORSE  THAN 

THE  DISEASE'' 

236307  02  08 

ADVANTAGES  OF  THE  INITIAL  THERAPY  OF  ACUTE  SCHIZOPHRENIA  WITH 

LARGE  DOSES  OF  DROPERIDOL:  A  COMPARATIVE  STUDY 

THE  SOMATIC  THERAPY  OF  SCHIZOPHRENIA 

237992  02-08 
THERAPY  OF  PSYCHOPHARMACEUTICAL  SIDE-EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID.  BC-51) 

239782  03-15 
EXTRAPYRAMIDAL  SYMPTOMS  IN  A  COMBINATION  OF  LITHIUM  LONG- 
TERM  THERAPY  WITH  NORTRIPTYLINE:  A  CAUSISTIC  REPORT  ON 
PATHOGENESIS  AND  HYPOTHESIS  FORMULATION. 

239835  03-15 
PSYCHOPHARMACOLOGICAL  THERAPY  AND  PROPHYLAXIS  OF  MANIC- 
DEPRESSIVE  ILLNESSES.  ^^„„ 

240707  03-09 

THE  PSYCHOPHARMACEUTICAL  THERAPY  OF  DEPRESSION 

241762  03-09 

DRUG  THERAPY  IN  CHILD  CARE. 

243897  04  15 

PHARMACEUTICAL  THERAPY  OF  MASKED  DEPRESSION 

244040  04  10 
THE  RELEVANCE  TO  DIFFERENTIAL  DIAGNOSIS  OF  THE  DISTRIBUTION  OF 
EXTRAPYRAMIDAL  SYMPTOMS  RESULTING  FROM  NEUROLEPTIC 
THERAPY  IN  PSYCHIATRIC  PRACTICE 

244355  04-15 

LITHIUM  THERAPY-  PRACTICAL  ASPECTS. 

244498  04-09 

FIVE  YEARS  OF  DEPOT  FLUPHENAZINE  THERAPY 

244620  04-08 

DRUG  THERAPY:  SULFASALAZINE 

245307  04-13 

OSTEOMALACIA  ASSOCIATED  WITH  ANTICONVULSANT  DRUG  THERAPY 
IN  MENTAl  LY  RETARDED  CHILDREN 

245806  04  1 5 

L-DOPA  THERAPY  AND  STEREOTAXIC  THALAMOTOMY  FOR 

PARKINSONISM  „     „     ,, 

245986  04  11 

DRUG  THERAPY:  NEUROLOGIC  SYNDROMES  ASSOCIATED  WITH 
ANTIPSYCHOTIC  DRUG  USE 

246061  04  15 
TECHNIQUE  OF  FLUPHENAZINE  DECANOATE  THERAPY  IN  ACUTE 
SCHIZOPHRENIC  ILLNESSES 

246186  04-08 

COMBINATION  DRUG  THERAPY  FOR  THE  PSYCHOGERIATRIC  PATIENT. 
COMPARISON  OF  DOSAGE  LEVELS  OF  THE  SAME  PSYCHOTROPIC 
DRUGS   USED  SINGLY  AND  IN  COMBINATION. 

246694  04-11 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIVE 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY''. 

247359  04-15 
ORGANIC  MENTAL  CHANGES  WITH  FLUOROURACIL  THERAPY 

247978  04  15 
COMBINED  THERAPY  WITH  TETRABENAZINE  AND  PIMOZIDE  IN 
HUNTINGTONS-CHOREA:  PILOT  STUDY. 

248172  04  11 

47-XYY  AND  46  XY  MALES  WITH  ANTISOCIAL  AND-OR  SEX  OFFENDING 
BEHAVIOR.  ANTIANDROGEN  THERAPY  PLUS  COUNSELING 

248222  04-10 
STUDIES  ON  THYROID  THERAPY  AND  THYROID  FUNCTION  IN  DEPRESSIVE 

PATIENTS 

249123  04-13 

LONG  TERM  LEVODOPA  THERAPY  FOR  TORSION  DYSTONIA. 

249367  04-13 

DRUG  THERAPY  IN  MENTAL  HANDICAP 

249525  04-17 
ANESTHESIOLOGIC  CONSIDERATIONS  IN  PSYCHIATRIC  CONVULSIVE 

THERAPY 

249765  04-17 

APPROACH  TO  A  COMBINED  PHARMACOLOGIC  THERAPY  OF  CHIIDHOOD 

HYPERKINESIS  ^^     ,, 

249772  04-11 

SIDE-EFFECTS  OF  LITHIUM  THERAPY 

250209  04-15 
PSYCHIATRIC  SYMPTOMS  DURING  L-DOPA  THERAPY  FOR  PARKINSONS 
DISEASE  AND  THEIR  RELATIONSHIP  TO  PHYSICAL  DISABILITY 

250722  04  15 


S-323 


r 


Subject  Index 


Psychopharmacoiogy  Abstrac 


< 

c 


3- 
J. 

I 

''5 


SIDE  EFFECTS  OF  LITHIUM  THERAPY  AND  THEIR  TREATMENT. 

251712  04-15 
ISOPRINOSINE  THERAPY  IN  SUBACUTE  SCLEROSING  PANENCEPHALITIS. 

251952  04-11 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
LONG-TERM  THERAPY  OF  NEUROLOGIC  DISORDERS  WITH  L-5- 

HYOROXYTRYPTOPHAN. 

251960  04-13 
THE  DURATION  OF  MAINTENANCE  THERAPY  IN  CHRONIC 

SCHIZOPHRENIA, 

252763  04-08 
RAT  DATA  WHICH  SUGGEST  ALCOHOLIC  BEVERAGES  SHOULD  BE 
SWALLOWED  DURING  CHEMICAL  AVERSION  THERAPY,  NOT  JUST 
TASTED. 

252859  04-17 
INCREASED  ERYTHROCYTE  NA  t    PUMP  AND  NAK-ATPASE  ACTIVITY 
DURING  LITHIUM  THERAPY. 

253137  04-13 
MMPI  DELINEATION  OF  A  SUBGROUP  OF  DEPRESSED  PATIENTS 
REFRACTORY  TO  LITHIUM  CARBONATE  THERAPY. 

253595  04-09 
THERMAL 

5-HYDROXYTRYPTAMINE  14C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
THERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE. 

243815  04-03 
THERMOREGULATION 

IMPAIRMENT  OF  THERMOREGULATION,  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPTAMINE 

226938  01-04 
DEPENDENCE  ON  AGE  OF  METHAMPHETAMINE  PRODUCED  CHANGES  IN 
THERMOREGULATION  AND  METABOLISM. 

248951  04-03 
INFLUENCE  OF  AGE  AND  DRUGS  ON  BEHAVIORAL  THERMOREGULATION 
IN  RATS. 

251409  04-04 
THERMOREGULATORY 

THERMOREGULATORY  DEFICITS  IN  THE  MONKEY  PRODUCED  BY  5,6 
DIHYDROXYTRYPTAMINE  INJECTED  INTO  THE  HYPOTHALAMUS 

239087  03-03 
EFFECTS  OF  DIAZEPAM  AND  PHENOBARBITAL  ON  SELF-STIMULATION  IN 
POSTERIOR  HYPOTHALAMIC  AND  PREOPTIC  REGIONS  AND  ON  THE 
THERMOREGULATORY  RESPONSES  TO  REWARDING  BRAIN 
STIMULATION 

239980  03-04 
ONTOGENY  OF  THERMOREGULATORY  MECHANISMS  IN  THE  RAT. 

245608  04-02 
THERMOREGULATORY  RESPONSES  TO  INTRAVENTRICULAR 

NOREPINEPHRINE  IN  NORMAL  AND  HYPOTHALAMIC  DAMAGED  RATS. 

252174  04-03 
THERMOSTATS 

MORPHINE  HYPERTHERMIA  IN  THE  RAT:  AN  ACTION  ON  THE  CENTRAL 
THERMOSTATS. 

250078  04-03 
THETA-RHYTHM 

EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHM 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE. 

234918  02-03 
HIPPOCAMPAL  THETA  RHYTHM.  I    DEPTH  PROFILES  IN  THE  CURARIZED 
RAT 

251061  04-03 
THIAMINE 

TREATMENT  OF  DIALYSIS  DEMENTIA  WITH  THIAMINE, 

251966  04-11 
THIENOBENZOPYRANS 

DRUGS  DERIVED  FROM  CANNABINOIDS,  3.  SULFUR  ANALOGS, 
THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  04-02 
THIENOBENZOTHIAZINES 

SYNTHESIS  AND  NEUROLEPTIC  ACTIVITY  OF  ISOMERIC 
THIENOBENZOTHIAZINES 

248949  04-01 
THIENOOIAZEPINE 

EFFECTS  OF  THIENODIAZEPINE  DERIVATIVES  ON  HUMAN  SLEEP  AS 
COMPARED  TO  THOSE  OF  BENZODIAZEPINE  DERIVATIVES. 

246309  04  07 


THIN 

ON  THE  THIN  LAYER  CHROMATOGRAPHY  OF  SOME  NONBARBITURETE 
HYPNOTICS  AND  ATARACTICS. 

243340  04 
THIOBARBITURATE 

LOSS  OF  INHIBITORY  MOTOR  CONTROL  FOLLOWING  A  SUBANESTHETIC 
DOSE  OF  THIOBARBITURATE  IN  RHESUS  MONKEYS. 

228139  01 
THIOBENZOXAZOLES 

SYNTHESIS  OF  SUBSTITUTED  THIOBENZOXAZOLES/BENZOTHIAZOLES: 
INHIBITION  OF  CELLULAR  RESPIRATORY  AND  MONOAMINE-OXIDASE 
ACTIVITIES  AND  ANTICONVULSANT  PROPERTY. 

239661  03 
THIOPENTONE 

CHANGES  OF  SKIN  NERVE  SYMPATHETIC  ACTIVITY  DURING  INDUCTIOI 
OF  GENERAL  ANESTHESIA  WITH  THIOPENTONE  IN  MAN. 

251071  04 
THIOPYRANOBENZOPYRANS 

DRUGS  DERIVED  FROM  CANNABINOIDS.  3.  SULFUR  ANALOGS. 
THIOPYRANOBENZOPYRANS  AND  THIENOBENZOPYRANS. 

248651  04 
THIORIDAZINE 

THIORIDAZINE  PLASAAA  LEVELS  AND  CLINICAL  RESPONSE. 

225932  01 
INHIBITION  OF  4,ALPHA  DIMETHYL-M-TYRAMINE  H77-77  INDUCED 
HYPERMOBILITY  IN  RATS  BY  SINGLE  AND  REPEATED  ADMINISTRATI 
OF  CHLORPROAAAZINE  HALOPERIDOL,  CLOZAPINE  AND  THIORIDAZIN 

227129  01 
DETECTION  OF  THE  NEUROLEPTIC  PROPERTIES  OF  CLOZAPINE,  SULPIRII 
AND  THIORIDAZINE. 

227135  01 
STATE-DEPENDENT  LEARNING  IN  RETARDATES  USING  THIORIDAZINE. 
(PH.D.  DISSERTATION). 

228420  01 
THE  EFFECTS  OF  HALOPERIDOL  AND  THIORIDAZINE  ON  APOMORPHINE 
INDUCED  AND  LSD-INDUCED  HYPERTHERMIA  IN  THE  RABBIT. 

228977  01 
THIORIDAZINE  AND  SEXUAL  DYSFUNCTION. 

236318  02 
QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URI 
OF  PSYCHIATRIC  PATIENTS. 

237902  02 
SERUM  CONCENTRATION  AND  ELIMINATION  OF  THIORIDAZINE  IN 
PSYCHIATRIC  PATIENTS. 

238552  02 
SUDDEN  UNEXPLAINED  DEAl  H  IN  A  PSYCHIATRIC  PATIENT  TAKING 
THIORIDAZINE. 

240243  03 
BINDING  OF  THIORIDAZINE  AND  SOME  IT  OF  ITS  METABOLITES  TO 
HUAAAN  SERUM  PROTEIN  AND  HUMAN  ALBUMIN. 

244131  04 
THIORIDAZINE  STIMULATES  PROLACTIN  SECRETION  IN  MAN. 

245840  04 
EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  AA/ 

246315  04 
THERAPEUTIC  EFFECT  AND  PLASMA  LEVEL  OF  THIORIDAZINE  (MELLERI 
IN  SCHIZOPHRENIC  PATIENTS. 

246672  04 

ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIE 

INTRACEREBRALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAl 

NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04 
EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  0 
THE  KINETIC  STATE  OF  TYROSINE-HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS 

248698  04 
EFFECTS  OF  THIORIDAZINE  AND  DIAZEPAM  ON  THE  PHARMACOKINETI 
OF  (14C)IMIPRAMINE  IN  RAT:  ACUTE  STUDY. 

250655  04 
POTENTIATION  BY  METYROSINE  OF  THIORIDAZINE  EFFECTS  IN  CHRONL 
SCHIZOPHRENICS:  A  LONG  TERM  TRIAL  USING  DOUBLE-BLIND 
CROSSOVER  TECHNIQUE. 

251374  04 
GLC  ANALYSIS  OF  THIORIDAZINE,  MESORIDAZINE  AND  THEIR 
METABOLITES. 

251776  04 
THIORIDAZINE  IN  THE  TREATMENT  OF  DEPRESSIVE  PATIENTS. 

252760  04 
THIOTHIXENE 

COMPREHENSIVE  CLINICAL  STUDIES  WITH  THIOTHIXENE. 

227820  01 
THE  ASSESSMENT  OF  THIOTHIXENE  IN  CHRONIC  SCHIZOPHRENIA:  A 
DOUBLE-BLIND  CONTROLLED  TRIAL 

231609  01 


S-324 


3LUME  14,  SUBJECT  INDEX 


Subject  Index 


A  COMPARATIVE  STUDY  OF  THIOTHIXENE  AND  CHLORPROMAZINE  IN 
CHRONIC  SCHIZOPHRENIC  PATIENTS:  APPLICATION  OF  SPECIAL 
PSYCHOMETRIC  TEST  BATTERY. 

235366  02  08 
THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA:  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE. 

247968  04  08 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC-BRAIN-SYNDROME. 

249625  04-11 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE:  RELATION 

TO  TISSUE  LEVELS  OF  THE  DRUG 

251131  04-03 
THE  EFFECTS  OF  THIOTHIXENE  IN  GERIATRIC  PATIENTS  WITH  CHRONIC 
ORGANIC-BRAIN-SYNDROME, 

253050  04-1! 

IIOXANTHENE 

PLACENTAL  TRANSFER  OF  PSYCHOTHERAPEUTICS  OF  THE  THIOXANTHENE 

TYPE 

237120  02-05 

IIOXANTHENES 

CLINICAL  AND  ELECTROENCEPHALOGRAPHICAL  STUDIES  OF  THE 
THIOXANTHENES. 

227765  01-08 

ATARAXIC  AND  ANTIMANIC  EFFECTS  OF  THIOXANTHENES. 

227768  01-09 
THE  LIEGE  PHYSIOGNOMY  OF  NEUROLEPTICS,  WITH  SPECIAL  REFERENCE 

TO  THIOXANTHENES. 

227769  01-17 

SOME  ASPECTS  OF  THE  ROLES  OF  ISOPROTERENOL,  ANGIOTENSIN  AND 
THE  PERIPHERAL  NERVOUS  SYSTEM  IN  THIRST.  (PH.D.  DISSERTATION). 

228493  01-03 
CANNABIS:  EFFECTS  ON  HUNGER  AND  THIRST. 

234626  02-14 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04-04 

HOUGHT 

SULPIRIDE  AS  A  CURRENT  ANTIDEPRESSIVE  TECHNIQUE:  WHAT  CAN  BE 
SAID  AND  THOUGHT  ABOUT  IT  TODAY';'. 

244433  04-17 

THOUGHT  DISORDER  IN  AMPHETAMINE  PSYCHOSIS:  A  CASE  REPORT, 

250196  04-13 

HPC 

ANTAGONISM  OF  D-LYSERGIC  ACID-DIETHYLAMIDE  AND  MESCALINE  BY 
1  METHYL  1,2,5,6  TETRAHYDROPYRIDINE  N,N  OIETHYLCARBOXAMIDE 

(THPC). 

230453  01-03 

HREAT 

TWENTY-FOUR-HOUR  RETENTION  OF  CHLORDIAZEPOXIDE  (LIBRIUM) 
ATTENUATED  THREAT  BEHAVIOR  IN  MALE  SIAMESE  FIGHTING  FISH 
(BETTA-SPLENOENS). 

242892  04-04 

HRESHOID 

EFFECTS  OF  ALCOHOL  AND  MARIJUANA  ON  DYNAMIC  VISUAL  ACUITY:  I. 
THRESHOLD  MEASUREMENTS. 

235759  02-14 
PSYCHOMETRIC  EFFECTS  OF  PERPHENAZINE  BELOW  THE  NEUROLEPTIC 

THRESHOLD. 

239682  03-15 

EFFECTS  OF  HALOPERIDOL  ON  AVERSIVE  THRESHOLD  OF  RATS. 

240886  03-03 
ON  THE  ROLE  OF  ENDOGENOUS  OPIOID  PEPTIDES:  FAILURE  OF  NALOXONE 
TO  INFLUENCE  SHOCK  ESCAPE  THRESHOLD  IN  THE  RAT. 

241244  03-04 
THE  EFFECTS  OF  MEPROBAMATE  UPON  THE  AVERSIVE  THRESHOLD  OF 

RATS. 

242894  04-04 

MVMOLEPTICS 

BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOPS).  AETHIOPS). 

230869  01-04 

CHANGES  IN  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 
NEUROLEPTICS  AND  THYMOLEPTICS. 

234045  02-15 
EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 
-      CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA-INDUCED 
GNAWING  OF  MICE. 

237107  02-04 

EFFECTS  OF  THYMOLEPTICS  ON  BEHAVIOUR  ASSOCIATED  WITH 

CHANGES  IN  BRAIN  DOPAMINE:  I.  POTENTIATION  OF  DOPA  INDUCED 
GNAWING  OF  MICE. 

248960  04  02 

HYROIO 

EFFECT  OF  LITHIUM  ON  HYPOTHALAMIC  PITUITARY  THYROID  FUNCTION 
IN  PATIENTS  WITH  AFFECTIVE  DISORDERS. 

230763  01-13 


THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
INFLUENCE  OF  THYROID  HORMONE  ON  NOREPINEPHRINE  METABOLISM 
IN  RAT  BRAIN  DURING  MATURATION. 

243790  04-03 
STUDIES  ON  THYROID  THERAPY  AND  THYROID  FUNCTION  IN  DEPRESSIVE 

PATIENTS. 

249123  04-13 

THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 

CARBONATE.  „     ,  , 

249124  04-14 

EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS. 

250013  04-04 

THYROID-RELEASING 

COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE-NUCLEUS,  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03-04 

THYROIOECTOMIZED 

EVIDENCE  FOR  THE  ROLE  OF  BRAIN  BIOGENIC  AMINES  IN  DEPRESSED 
MOTOR  ACTIVITY  SEEN  IN  CHEMICALLY  THYROIOECTOMIZED  RATS. 

241203  03-03 

THYROTROPIN 

THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 

THYROTROPIN-REIEASING 

ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN 
RELEASING  FACTOR  (TRF)  AND  SOAAATOSTATIN. 

227386  01-04 
CLINICAL  AND  CNS  EFFECTS  OF  ORAL  AND  I.V.  THYROTROPIN-RELEASING 
HORMONE  IN  DEPRESSED  PATIENTS. 

227826  01-09 

A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN  RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION. 

229693  01-09 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AND  ITS  BETA  ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02  03 

THYROTROPIN  RELEASING  HORMONE  IN  CHRONIC  SCHIZOPHRENIA. 

233817  02-08 
THYROTROPIN-RELEASING  HORMONE  IN  DEPRESSION:  CLINICAL  AND 
ENDOCRINOLOGICAL  FINDINGS. 

235370  02  09 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK 
ACTING  BUT  SHORT-LASTING  ANTIDEPRESSANT 

235630  02-09 
THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02  04 

THYROTROPIN  RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
EFFECTS  OF  THYROTROPIN-RELEASING  HORMONE  IN  SCHIZOPHRENIA. 

244528  04-08 
THYROTROPIN-RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATION  IN 
THE  NONLESIONED  RAT. 

247514  04-03 

BEHAVIORAL  EFFECTS  OF  L  DOPA  AND  THYROTROPIN-RELEASING 
HORMONE  IN  SCHIZOPHRENIC  PATIENTS:  A  PRELIMINARY  REPORT. 

249120  04-08 
STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN-RELEASING 

HORMONE  (TRH)  IN  RABBITS. 

249280  04-04 

INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPIN-RELEASING  HORMONE  IN  CATS. 

249281  04-02 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANOL 

SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH) 

250110  04  03 

THYROXINE 

NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT 

226532  01  04 
IN  VIVO  REVERSAL  OF  THYROXINE  INDUCTION  OF  DNA  SYNTHESIS  BY 
DIBUTYRYL-CYCLIC-AMP  IN  DEVELOPING  RAT  CEREBELLUM. 

243814  04-03 
EFFECTS  OF  NEONATAL  THYROXINE  STIMULATION  ON  ADULT  OPEN-FIELD 
BEHAVIOR  AND  THYROID  ACTIVITY  IN  RATS 

250013  04-04 


S-325 


s 


c 

OO' 

i 


Subject  Index 

TICS 

PSYCHOLOGICAL  TEST  INVF5TIGATI0NS  OF  PATIENTS  TREATED  WITH 
CARBAMAZfPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  0)  1/1 
TICS  FOLLOWING  METHYLPHENIDATE  ADMINISTRATION:  A  REPORT  OF 
20  CASES 

241990  03  15 
TIME 

THE  EFFECT  OF  OUABAIN  AND  OIGITOXIN  ON  HEXOBARBITONE  SLEEPING 
TIME  IN  THE  MOUSE 

225574  01  03 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES 

227384  01  03 
CHANGES  IN  THE  ELECTROENCEPHALOGRAM  AND  REM  SLEEP  TIME 
DURING  MORPHINE  ABSTINENCE  IN  PELLET  IMPLANTED  RATS. 

227701  01  03 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WISTAR  AND  SPRAGUE-DAWLEY  RATS 

230007  01-04 
TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED  RATIO  WAFER 
REINFORCED  RESPONDING  IN  RATS 

230842  01  04 
CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN. 

230863  01   14 
A  RELATIONSHIP  BETWEEN  HEXOBARBITONE  SLEEPING  TIME  AND 
SUSCEPTIBILITY  TO  MESCALINE  IN  MICE  FROM  DIFFERENT  STRAINS. 

230870  01-04 
CHICK  PHASIC  BIOELECTRIC  ACTIVITY  AT  THE  TIME  OF  HATCHING  AND 
THE  EFFECTS  OF  PREVIOUS  NIALAMIDE  INJECTION 

235317  02-04 
LEVOAMPHETAMINE  VS  DEXTROAMPHETAMINE  IN  MINIMALBRAIN- 
DYSFUNCTION    REPLICATION,  TIME  RESPONSE,  AND  DIFFERENTIAL 
EFFECT  BY  DIAGNOSTIC  GROUP  AND  FAMILY  RATING. 

239932  03  1 1 
EFFECT  OF  LONG  LASTING  TRIOXAZIN  ADMilNISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS. 

239992  03-14 
EFFECT  OF  ANTIPHENOBARBITAL  ANTIBODIES  ON  SLEEPING  TIME 
INDUCED  BY  CYCLOBARBITAI   TO  MICE 

241403  03-03 
EFFECTS  OF  PASSIVE  IMMUNIZATION  WITH  RABBIT 

ANTIPHENOBARBITAL  IGG  ON  CY(  LOBARBITAL  INDUCED  SLEEPING 
TIME  AND  HEPATIC  ENZYMF  ACTIVITIES  OF  C3H  MICE 

242201  03-03 
INFLUENCE  OF  THE  ADMINISTRATION  OF  PSYCHOPHARMACOLOGICAL 
COMPOUNDS  ON  THE  TAKE  UP  TIME  OF  AN  ALIMENTARY  MATERIAL 
IN  THE  HAMSTER  AND  A  STUDY  OF  RELATED  BEHAVIOR. 

24-1899  04-04 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 
ADMINISTRATION  OF  MORPHINE  IN  MICE.  II    TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE 

249031  04  03 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  IHE  ACUTE  TOXICITY,  LOCOMOTOR  AC  TIVIFY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE, 

251  130  04  02 
THE  EFFECTS  OF  HIGH  DOSES  OF  OXPRENOLOL  AND  OF  PROPRANOLOL 
ON  PURSUIT  ROTOR  PERFORMANCE,  REACTION  TIME  AND  CRITICAl 
FUCKER  FREQUENCY, 

251986  04  14 
EFFECTS  OF  P  CHLOROPHEN^'LALANINE  ON  TIME  OF  NEURONAL  ORIGIN 
DURING  EMBRYOGENESIS  IN  THE  RAT, 

252018  04  03 
EFFECrS  OF  SET,  SETTING,  AND  SEDAIIVFS,  ON  REACTION  TIME 

252061  04  14 
TIME-DEPENDENT 

I  IMF  DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVAFFD  BEHAVIORS 
NONASSOCIATIVE  EFFECTS  OF  CHOI  INCRGK   AND 
CATFCHOLAMINLRGIC  ACTIVITY 

245486  O-l  04 
IIME  DEPENDENT  EFFECTS  OF  PHENOTHIAZINFS  ON  DOPAMINE 
TURNOVER  IN  PSYCHIATRIC  PATIENTS 

250389  04  n 

TIMES 

WARNED  REACTION  IIMFS  OF  MANIC  DEPRESSIVE  PATIENIS  WITH  AND 
WITHOUT  IITHIUM. 

249798  04  09 
INHIBITION  OF  CERERRAl  PROTEIN  SYNTHESIS    PERFORMANCE  AT 
niFIERINT  IIMFS  AFTfR  PASSIVE  AVOIDANCE  TRAINING 

250060  04  14 
TIMIDITY 

CIIIOPniAZEPOXIDF  AND  ISOLATION  INDUCED  IIMIDITY  IN  RATS 

230828  0 1  04 


Psychopharmacology  Abstrac 


TIMING 

RELATIONSHIP  OF  RATS  SPATIAL  PREFERENCES  TO  EFFECTS  OF  D 
AMPHETAMINE  ON  TIMING  BEHAVIOR, 

226729  01 
THE  EFFECTS  OF  TRANQUILLIZING  DRUGS  ON  TIMING  BEHAVIOUR  IN 
RATS 

246306  04 
TISSUE 

INTERACTION  OF  MESCALINE  WITH  PHENOTHIAZINES:  EFFECT  ON 
BEHAVIOR,  BODY  TEMPERATURE,  AND  TISSUE  LEVELS  OF 
HALLUCINOGEN  IN  MICE. 

229264  01 
SATURABLE  BINDING  OF  DIHYDROMORPHINE  AND  NALOXONE  TO  RAT 
BRAIN  TISSUE  IN  VITRO. 

230919  01 
INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

231002  01 
THE  INFLUENCE  OF  DELTA9-TETRAHYDR0CANNABIN0L,  CANNABINOL 
AND  CANNABIDIOL  ON  TISSUE  OXYGEN  CONSUMPTION. 

231010  01 
SOME  CONSIDERATIONS  IN  THE  DESIGN  OF  SUBSTRATE  AND  TISSUE 
SPECIFIC  INHIBITORS  OF  MONOAMINE-OXIDASE. 

233946  O: 
3HDELTA9  TETRAHYDROCANNABINOL  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  O; 
PLACENTAL  TRANSFER  AND  AAATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C14-METHAQUAL0NE  IN  MICE. 

238764  O; 
DIFFERENTIAL  EFFECTS  OF  PHENOBARBITAL  AND  PENTOBARBITAL  ON 
ISOLATED  NERVOUS  TISSUE. 

240474  O: 
INFLUENCE  OF  PSYCHOTROPIC  DRUGS  AND  BETA-DIETHYLAMINOETHY 
DIPHENYLPROPYLACETATE  {SKF.525-A)  ON  MESCALINE-INDUCED 
BEHAVIOR  AND  ON  TISSUE  LEVELS  OF  MESCALINE  IN  MICE. 

241349  0; 
MEASUREMENT  OF  DESIPRAMINE  IN  BRAIN  TISSUE  BY  A  RADIOISOTO 
DERIVATIVE  TECHNIQUE. 

247131  Q. 
RADIOPHARMACEUTICALS    16    HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6  lODODOPAMINE  AND  TISSU! 
DISTRIBUTION  STUDIES  IN  ANIMALS 

248537  a 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTA 
AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  0. 
IDENTIFICATION  AND  DISTRIBUTION  OF  BENZYLAMINE  IN  TISSUE 
EXTRACTS  ISOIAIED  FROM  RATS  PRETREATED  WITH  PARGYLINE. 

250379  0. 
BIOCHEMICAL  AND  BEHAVIOURAL  EFFECTS  OF  THIOTHIXENE:  RELATIC 
TO  TISSUE  LEVELS  OF  THE  DRUG. 

251131  a 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
REIEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  0. 
TISSUES 

DICHLORVOS  AND  THE  CHOLINERGIC  SYSTEM:  EFFECTS  ON 

CHOI  INESTERASE  AND  ACETYLCHOLINE  AND  CHOLINE  CONTENTS  0 
RAT  TISSUES 

230451  0 
FURTHER  STUDIES  ON  THE  CHIORPROMAZINE-INDUCED  PROLONGATK 
OF  THE  DISAPPEARANCE  OF  MESCALINE  FROM  MOUSE  TISSUES. 

235670  O; 
THE  RELEASE  OF  GLUTAMIC  ACID  FROM  ISOLATED  BRAIN  TISSUES. 

236522  O: 
NEUROTOXICITY  OF  A  NON-METABOLIZABLE  AMINO  ACID.  L- 

AMINOCYCLOPENTANE-1-CARBOXYLIC  ACID  (ACPC):  ACPC  TRANSP( 
MECHANISMS  IN  TISSUES. 

24 1 298  O: 
COMPARISON  OF  THE  INHIBITORY  EFFECTS  OF  NEUROLEPTIC  DRUGS  ( 
ADENYIATE-CYCLASE  IN  RAT  TISSUES  STIMULATED  BY  DOPAMINE, 
NORADRENALINE  AND  GLUCAGON 

241347  0: 
EFFECT  OF  BENZOPYRENE  AND  CHLORPROMAZINE  ON  ARYL 
HYDROCARBON  HYDROXYLASE  ACTIVITY  FROM  RAT  TISSUES 

243793  0. 
TITRATION 

MONOAMINE  OXIDASE  ACTIVE  SITE;  THE  BINDING  TO  AND  TITRATIOf 
OF  MONOAMINE  OXIDASE  WITH  (14C)  SELECTIVE  INHIBITORS, 

241931  O: 
TlP-607 

EFFECTS  OF  LONG-TERM  APPLICATION  OF  PENFLURIDOL  (TLP-607)  FOF 
SCHIZOPHRENIA 

228324  0 


S-326 


OLUME  14,  SUBJECT  INDEX 


w 

INHIBITION  OF  NEURONAL  SEROTONIN  (S-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 

WACCO 

TOXICITY  OF  MARUUANA  AND  TOBACCO  SMOKING  IN  THE  BEAGLE. 

229034  01-04 

)BIAS 

MAINTENANCE  ANTIPSYCHOTIC  DRUGS  DO  PREVENT  RELAPSE;  A  REPLY 
TO  TOBIAS  AND  MACDONALD. 

252847  04-08 

jnZOPAM 

THE  MAIN  PHARAAACOLOGICAL  CHARACTERISTICS  OF  GRANDAXIN 
(TOFIZOPAM.  EGYT-341) 

252445  04-02 
THE  TREATMENT  OF  CLIMACTERIC  SYNDROME  WITH  TOFIZOPAM 

(GRANDAXIN). 

252450  04-11 

3FRANII 

THE  HAMILTON  RATING  SCALE.  AN  ASSESSMENT  BASED  ON  A 

DOTHIEPIN  (PROTHIADEN)  VERSUS  IMIPRAMINE  (TOFRANIL)  CLINICAL 
TRIAL 

226899  01-09 

A  CLINICAL  TRIAL  OF  TOFRANIL  IN  OSTEOARTHRITIS, 

252136  04-11 
TOFRANIL  IN  THE  TREATMENT  OF  LOW  BACK  PAIN. 

252138  04-11 
A  CLINICAL  TRIAL  OF  TOFRANIL  IN  RHEUMATIC  PAIN  IN  GENERAL 

PRACTICE. 

252139  04-17 

OKEN 

EFFECTS  OF  COMBINING  METHYLPHENIDATE  AND  CLASSROOM  TOKEN 
SYSTEM  IN  MODIFYING  HYPERACTIVE  BEHAVIOR. 

232807  02-11 

OKYO 

THE  TOKYO  ASSEMBLY  OF  THE  WORLD  MEDICAL  ASSOCIATION. 

248166  04-17 
OLERANCE 

MARIJUANA  PRODUCED  CHANGES  IN  PAIN  TOLERANCE.  EXPERIENCED 
AND  NONEXPERIENCED  SUBJECTS, 

226903  01   14 
TOLERANCE  TO  THE  EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE  ON  INTESTINAL  MOTILITY,  TEMPERATURE  AND  LOCOMOTOR 
ACTIVITY. 

227130  01-04 

ELECTROENCEPHALOGRAPHIC  STUDIES  ON  THE  DEVELOPMENT  OF 
TOLERANCE  AND  CROSS-TOLERANCE  TO  MESCALINE  IN  THE  RAT. 

230880  01-04 

PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD. 

23431 1  02-03 
DEVELOPMENT  OF  TOLERANCE  TO  AND  DEPENDENCE  ON  ENDOGENOUS 
NEUROTRANSMITTERS. 

234798  02-08 
GOOD  TRIP  OR  BAD  TRIP:  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION 

234811  02  12 
CHANGES  IN  ANTICOAGULANT  TOLERANCE:  I.  INFLUENCE  OF  SEDATIVES 
AND  PSYCHOPHARMACEUTICALS 

235336  02-15 
EFFECT  OF  P  CHLOROPHENYLALANINE  ON  THE  ACQUISITION  OF 
TOLERANCE  TO  ETHANOL  AND  PENTOBARBITAL. 

237720  02-04 
METHAQUALONE    TOLERANCE  AND  PHYSICAL  DEPENDENCE  IN  MICE 

237731  02-04 
EFFICACY  AND  TOLERANCE  OF  INJECTABLE  DOXEPIN. 

237775  02  10 
DELTA9-TETRAHYDR0CANNABIN0L  (DELTA9-THC)  AND  1I-0H-DELTA9 
THC:  ONSET.  PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS 

238813  0304 
AMPHETAMINE  AND  THE  REWARD  SYSTEM    EVIDENCE  FOR  TOLERANCE 
AND  POST-DRUG  DEPRESSION 

239850  03-04 
IMPAIRED  DEVELOPMENT  OF  TOLERANCE  TO  MORPHINE  ANALGESIA  IN 

RATS  WITH  HEREDITARY  DIABETES-INSIPIDUS 

239851  03-03 
TOLERANCE  IN  METHYLPHENIDATE-INDUCED  LOCOMOTION  IN  PRAIRIE 

DOGS  (CYNOMYS-LUDOVICIANUS) 

239863  03-04 
GLUCOSE  TOLERANCE  AND  SERUM  LIPIDS  IN  MAN  AFTER  LONG  TERM 
LITHIUM  ADMINISTRATION 

240054  03  1 3 
STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE  LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON 

240205  03  05 


Subject  Index 

REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYDROXYDOPAMINE.  (PH  D.  DISSERTATION). 

241100  03-03 
LACK  OF  TOLERANCE  OR  SENSITIZATION  TO  THE-EFFECTS  OF  CHRONIC  D- 
AMPHETAMINE  ON  SUBSTANTIA-NIGRA  SELF-STIMULATION 

241307  03-04 
TOLERANCE  TO  CENTRALLY  ADMINISTERED  PHENOBARBITAL. 

241346  03-03 
TOLERANCE  TO  THE  ACTIVITY  ENHANCING  EFFECT  OF  D-AMPHETAMI.'JE. 
(PH.D.  DISSERTATION). 

241575  03-03 
EFFECTS  OF  FRONTAL  POLAR  CORTICAL  ABLATION  AND  CYCLOHEXIMIDE 
ON  ETHANOL  TOLERANCE  IN  RATS. 

242741  03-03 
TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9- 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

243800  04-03 
TOLERANCE.  PHYSICAL  DEPENDENCE  AND  OPIOIDSEEKING  BEHAVIOR: 
DEPENDENCE  ON  DIENCEPHALIC  NOREPINEPHRINE 

244202  04-04 
STUDY  OF  THE  TOLERANCE  AND  CLINICAL  EFFECT  OF  CARBAMAZEPINE 
IN  A  NEW  SUSPENSION  IN  38  CHILDREN  AND  ADOLESCENTS  FROM  2- 
18  YEARS  OLD,  AFFECTED  WITH  EPILEPSY  SOMETIMES  ASSOCIATED 
WITH  BEHAVIOR  AND  CHARACTER 

244958  04-11 

THE  DURAIION  OF  TOLERANCE  TO  THE  ANOREXIGENIC  EFFECT  OF 
AMPHETAMINE  IN  RATS. 

245298  04  03 
EFFICACY  AND  TOLERANCE  LIMITS  IN  IHE  USE  OF  ANTIDEPRESSANT 
DRUGS. 

247543  04-09 

MORPHINE  TOLERANCE  AND  DEPENDENCE  IN  NORADRENALINE 

NEURONES  OF  THE  RAT  CEREBRAL  CORTEX. 

248979  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG-LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  1.  EFFECT  ON  THE 

MORPHINE  TOLERANCE 

249030  04-03 
EFFECTS  OF  HYDROXYLAMINE  ON  THE  CONSEQUENCES  OF  LONG  LASTING 

ADMINISTRATION  OF  MORPHINE  IN  MICE.  II.  TIME  COURSE  OF  THE 
HYDROXYLAMINE  EFFECT  ON  MORPHINE  TOLERANCE. 

249031  04-03 
THE  CONTRIBUTION  OF  LEARNING  TO  THE  DEVELOPMENT  OF  CHRONIC 

ETHANOL  TOLERANCE  IN  THE  RAT 

249264  04-04 
REVERSAL  OF  RESIDUAL  TOLERANCE  TO  MORPHINE  AND  BLOCKADE  OF 
EFFECTS  OF  MORPHINE  WITH  CHRONIC  NALTREXONE 
ADMINISTRATION 

249268  04-03 
STUDIES  ON  SINGLE  DOSE  TOLERANCE  DEVELOPMENT  TO  MORPHINE  IN 
MICE 

249288  04-04 
STUDIES  WITH  l-ALPHA-ACETYLMETHAOOL:  1.  TOLERANCE  IN  MACACA- 
MULATTA 

249290  04-03 

TOLERANCE  TO  THE  CARDIOVASCULAR  EFFECTS  OF  DELTA9 
TETRAHYDROCANNABINOL  IN  THE  RAT. 

249418  04-03 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  IINIIATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS 

249484  04-03 
ACUTE  TOLERANCE  TO  BARBITURATE  IN  THE  RAl 

250077  0404 
MORPHINE  TOLFRANCF  AND  PHYSICAL  DEPENDENCE    INFLUENCE  OF 
CHOLINFRGK  AGONISTS  AND  ANTAGONISTS 

250079  04-04 
TOLERANCE  TO  AMPHETAMINE  IN  TWO  SPECIES  (RAT  AND  GUINEA  PIG) 
THAT  METABOLIZE  IT  DIFFFRENTLY. 

250723  04-03 

TOLERANT 

INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PENTOBARBITAL  TOLERANT  AND  NONTOLERANT  RATS. 

227390  01-03 
3H  DELTA9  TETRAHYDROCANNABINOl  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CFNTRAL-NERVOUS-SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS 

237753  02-03 
THE  INCIDENCE  OF  SELF  MUTILATION  IN  MORPHINE  TOLERANT  SPRAGUE- 
DAWLEY  MALE  RATS 

249253  04-04 

TONIC 

CHOLINERGIC  MODULATION  OF  TONIC  IMMOBIIITY  IN  IHE  RABBIT 
(ORYCTOLAGUS-CUNICULUS) 

231701  01-03 
EFFECT  OF  CHLORPROMAZINE  ON  IHE  INFRACTION  BETWEEN  PHASIC 
AND  TONIC  ElECTROCORTICAl  AROUSAl  MECHANISMS 

246311  04  03 


S-327 


Subject  Index 


Psychopharmacology  Abstrac 


1 


0 


s 


TOOl 

STUDIES  ON  THE  MECHANISM  OF  ACTION  0^  TRICYCLiC 
ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PH.D. 
DISSERTATION), 

231438  01  03 
TOOTH 

EEEECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION. 

25t 070  04-03 
TORONTO 

CHANGES  IN  PSYCHOACTIVE  DRUG  USE  AMONG  ADULTS  IN 
METROPOLITAN  TORONTO   -  1971-1974. 

236046  02-17 
TORSION 

LONG  TERM  LEVODOPA  THERAPY  FOR  TORSION  DYSTONIA, 

249367  04-13 
TORTOISE 

APOMORPHINE-INDUCED  STEREOTYPED  BITING  IN  THE  TORTOISE  IN 
RELATION  TO  DOPAMINERGIC  MECHANISMS 

247875  04-04 
TOURETTES 

TOURETTES  SYNDROME  AND  CENTRAL-NERVOUS-SYSTEM  STIMULANTS. 

251962  04-11 
TOXIC 

POSSIBLE  ROLE  OF  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER). 

226848  01-05 
TOXICITY 

A  STUDY  OF  THE  EFFECT  OF  D-AMPHETAMINE  ON  THE  TOXICITY, 
ANALGESIC  POTENCY  AND  SWIMMING  IMPAIRMENT  CAUSED  BY 
POTENT  ANALGESICS  IN  MICE. 

226926  01-04 
TOXICITY  OF  MARIJUANA  AND  TOBACCO  SMOKING  IN  THE  BEAGLE. 

229034  01-04 
CHRONIC  MARIHUANA  INHALATION  TOXICITY  IN  RATS. 

235671  02-05 
A  REVIEW  OF  THE  CARDIOVASCULAR  EFFECTS  AND  TOXICITY  OF 
TRICYCLIC  ANTIDEPRESSANTS, 

237909  02-15 
INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03-05 
EFFECTS  OF  CATECHOLAMINE  RECEPTOR  BLOCKING  AGENTS  ON 
TOXICITY  AND  THERMAL  RESPONSES  INDUCED  BY  AMPHETAMINE 
ISOMERS  IN  ADULT  AND  DEVELOPING  MICE. 

239043  03-05 
AMPHETAMINE  TOXICITY  IN  TEMPERATURE  ACCLIMATISED  MICE. 

239091  03-05 
DIPHENYLHYDANTOIN  SERUM  LEVELS,  TOXICITY,  AND 

NEUROPSYCHOLOGICAL  PERFORMANCE  IN  PATIENTS  WITH  EPILEPSY. 

240473  03-15 
RELAY  TOXICITY;  A  NEW  APPROACH  TO  A  METHODOLOGY  OF 

EVALUATING  THE  TOXICITY  OF  ADDITIVES  TO  FARM  ANIMAL  FEED. 

245114  04-06 
DELAYED  AND  INSIDIOUS  ONSET  OF  DIPHENYLHYDANTOIN  TOXICITY. 

246932  04-15 
AN  EARLY  CLINICAL  AND  TOXICITY  TRIAL  OF  EX-1 1-582A  IN  CHRONIC 
SCHIZOPHRENIA 

247481  04-07 
IMIPRAMINE  ENHANCEMENT  OF  PENTOBARBITAL  TOXICITY  IN  RATS 

249929  04-05 
EFFECT  OF  ACETYLATED  DERIVATIVES  OF  SOME  SYMPATHOMIMETIC 
AMINES  ON  THE  ACUTE  TOXICITY,  LOCOMOTOR  ACTIVITY  AND 
BARBITURATE  ANESTHESIA  TIME  IN  MICE. 

251130  04-02 
THE  TOXICITY  OF  DIRECT  ACTING  DOPAMINE  AGONISTS:  IMPLICATIONS 
FOR  THE  THERAPY  OF  PARKINSONISM. 

251959  04-05 
TOXICOIOGICAL 

PHARMACOLOGICAL  AND  TOXICOLOGICAL  PROBLEMS  CONNECTED  WITH 
THE  USE  OF  LONG  ACTING  NEUROLEPTICS. 

229549  01-15 
TOXICOLOGY 

TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG 
INFORMATION-CENTER    THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04-13 
ANNUAL  REVIEW  OF  PHARMACOLOGY  AND  TOXICOLOGY. 

251238  04-17 
TOXIN 

BEHAVIOURAL,  ELECTROCORTICAL  AND  BODY  TEMPERATURE  EFFECTS  OF 
CHOLERA  TOXIN. 

252034  04  03 


TPH 


MODULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE  (TPH)  ACTIVITY  BY 
BRAIN  TRYPTOPHAN  (TP)  CONTENT 

238677  03-03 


TPMP 

XEROSTOMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 
THEIR  TREATMENT  WITH  TPMP  (TRITHIO-P-METHOXYPHENYLPROPEN 

233718  02. 
TRACE 

A  DOPAMINE-INDUCED  NEURONAL  MEMORY  TRACE,  MEDIATED  BY 
CYCLIC-AMP  AND  DISRUPTABLE  BY  CYCLIC-GMP. 

238717  03 
TRACKING 

ANALYSIS  OF  THE  DISCREPANCY  IN  MAN-AAACHINE  TRACKING  SYSTE^ 
UNDER  CONDITIONS  OF  DELAYED  FEEDBACK. 

242702  03 
EFFECTS  ON  VISUAL  TRACKING  OF  DELTA9-TETRAHYDR0CANNABIN0L 
AND  PENTOBARBITAL. 

251825  04 
TRACT 

DISTRIBUTION  OF  CHLORPROMAZINE  IN  THE  GASTROINTESTINAL  TRAC 
OF  THE  RAT  AND  ITS  EFFECT  ON  ABSORPTIVE  FUNCTION. 

230918  01 
IMIPRAMINE  MEDIATED  INTERFERENCE  WITH  LEVODOPA  ABSORPTION 
FROM  THE  GASTROINTESTINAL  TRACT  IN  MAN. 

233296  02 
TRAINED 

THE  EFFECTS  OF  2,5  DIMETHOXY-4-METHYLAMPHETAMINE  (DOM),  2,5 
DIMETHOXY-4-ETHYLAMPHETAMINE  (DOET),  D-AMPHETAMINE,  AND 
COCAINE  IN  RATS  TRAINED  WITH  MESCALINE  AS  A  DISCRIMINATIV 
STIMULUS. 

230837  01 
ANALYSIS  OF  CARDIAC  CHRONOTROPIC  RESPONSES  TO  DIAZEPAM  AN 
BROMAZEPAM  IN  CONSCIOUS  TRAINED  DOGS. 

240064  03 
LONG-TERM  EFFECTS  OF  BARBITAL  ON  SPONTANEOUS  ACTIVITY  OF  RP 
TRAINED  TO  USE  THE  DRUG  AS  A  DISCRIMINATIVE  STIMULUS. 

245299  04 
EFFECTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 
UNTRAINED  RATS  AND  MICE. 

249678  04 
TRAINING 

EFFECTS  OF  PROTEIN  SYNTHESIS  INHIBITION  ON  MEMORY  FOR  ACTIVE 
AVOIDANCE  TRAINING. 

237264  02 
INHIBITION  OF  CEREBRAL  PROTEIN  SYNTHESIS:  PERFORAAANCE  AT 
DIFFERENT  TIMES  AFTER  PASSIVE  AVOIDANCE  TRAINING. 

250060  04 
TRAITS 

THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIENT 
WITH  PASSIVE-DEPENDENT  PERSONALITY  TRAITS. 

251717  04 
TRANQUILIZATION 

TRANQUILIZATION  EFFECT  OF  BETA-BLOCKADE  ALPRENOLOL;  A  CLINIC 
STUDY. 

228311  01 
TRANQUILIZER 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSO/WATIC  DISEASE,  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BLIND  CLINICAL  STUDY. 

229504  01 
STUDIES  ON  THE  ACTION  OF  AN  ANTICHOLINERGIC  IN  COMBINATION 
WITH  A  TRANQUILIZER  ON  GASTRIC  JUICE  SECRETION  IN  MAN 

232503  01- 
EFFECTS  OF  TRANQUILIZER  DRUGS  ON  GABA  RELEASE  IN  VITRO 

238779  03- 
FIVE  YEARS  EXPERIENCE  IN  OUTPATIENT  PSYCHIATRIC  PRACTICE  WITH 
NEW  TRANQUILIZER,  LEXOTANIL  (RO-5-3350). 

239748  03- 
AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONI 
TRANQUILIZER  AZAPERONE. 

241359  03- 
SHOULD  PATIENTS  RECEIVING  MAJOR  TRANQUILIZER  THERAPY  RECEIV 
ANTIPARKINSON  DRUGS  PROPHYLACTICALLY?. 

247359  04- 
TRANQUILIZERS 

THE  USE  OF  TRANQUILIZERS  IN  THE  TREATMENT  OF  MIXED  DRUG 
ABUSE. 

229044  01- 
TREATMENT  OF  NEUROTIC  SYNDROMES  WITH  TRANQUILIZERS. 

231983  01- 
UNWANTED  EFFECTS  OF  MINOR  TRANQUILIZERS  AND  HYPNOTICS. 

231992  DI- 
ON THE  QUESTION  OF  THE  RATIONAL  USE  OF  MAJOR  TRANQUILIZERS. 

236360  02- 
LACK  OF  A  RELATION  BETWEEN  THE  ANTIPSYCHOTIC  AND  THE 

EXCITABILITY  DEPRESSANT  PROPERTIES  OF  MAJOR  TRANQUILIZERS. 

238710  03- 
EFFICIENCY  PROFILES  OF  TRANQUILIZERS  AND  BROAD  SPECTRUM 
PSYCHOSOMATIC  DRUGS 

240706  03- 


S-328 


VOLUME  14,  SUBJECT  INDEX 

CONGENERS  OF  PHENOTHIAZINE  TRANQUILIZERS   (PH  D.  DISSERTATION)^ 

240937  03  02 
CHANGE  IN  ETHANOL  CONSUMPTION  BY  ALBINO  RATS  UNDER  THE 
EFFECT  OF  NEUROLEPTICS  AND  TRANQUILIZERS 

241987  0303 
PRACTICAL  CLINICAL  PSYCHOPHARMACOLOGY:  THE  TRANQUILIZERS. 

246033  04-17 
THE  NEUROLOGISTS  USE  OF  RATING  SCALES,  EEG,  AND  TRANQUILIZERS 
IN  DEALING  WITH  HYSTERICAL  SYMPTOMS 

249771  04-10 

TRANQUILLISERS 

EFFECT  OF  MINOR  TRANQUILLISERS  ON  HIPPOCAMPAL  THETA-RHYTHM 
MIMICKED  BY  DEPLETION  OF  FOREBRAIN  NORADRENALINE 

234918  02  03 

TRANOUIILIZATION 

INTRAVENOUS  TRANQUILLIZATION  WITH  ECT. 

249537  04-16 

TRANQUILLIZER 

RESPONSE  SUPPRESSION  IN  RATS:  A  COMPARISON  OF  RESPONSE 

CONTINGENT  AND  NONCONTINGENT  PUNISHMENT  AND  THE  EFFECT  OF 
THE  MINOR  TRANQUILLIZER.  CHLORDIAZEPOXIDE. 

230831  01-04 
STUDY  OF  DEVELOPMENT  OF  TOLERANCE  TO  AND  BARBITURATE  LIKE 
PHYSICAL  DEPENDENCE  ON  THE  TRANQUILLIZER  TEMPIDON. 

240205  03-05 
TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA- 
GRAVIS    (GRANOAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  04  07 
TRANQUILLIZERS 

FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN. 

239684  03- 1 3 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUT 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  04  10 

TRANQUILLIZING 

THE  EFFECTS  OF  TRANQUILLIZING  DRUGS  ON  TIMING  BEHAVIOUR  IN 

RATS 

246306  04-04 

TRANS-DELTA9-TETRAHYDROCANNABINOL 

THE  EVIDENCE  OF  THE  RELEASE  OF  PROSTAGLANDIN-LIKE  MATERIAL 
FROM  RABBIT  KIDNEY  AND  GUINEA  PIG  LUNG  BY  (  )  TRANS-DELTA9 
TETRAHYDROCANNABINOL. 

226762  01  03 

TRANS-SYNAPTIC 

EFFECTS  OF  AXOTOMY  ON  THE  TRANS-SYNAPTIC  REGULATION  OF 
ENZYME  ACTIVITY  IN  ADULT  RAT  SUPERIOR  CERVICAL  GANGLIA. 

244200  04  03 
MECHANISMS  OF  TRANS  SYNAPTIC  INDUCTION  OF  TYROSINE 

HYDROXYLASE  (TH)  AND  DOPAMINE  BETA-HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA:  ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 

251393  04  03 
TRANSAMINE 

EFFECT  OF  SODIUM  OXYBUTYRATE,  AMPHETAMINE.  TRANSAMINE,  L 
DOPA  ON  THE  PROCESSES  OF  RESTORATION  OF  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST 

236372  02  04 

TRANSCALLOSAL 

EFFECTS  OF  PERIMETAZINE  AND  CHLORPROMAZINE  ON  THE 
TRANSCALLOSAL  RESPONSE  IN  RABBITS. 

241385  03  03 

TRANSCALLOSALLY 

THE  TRANSCALLOSALLY  EVOKED  POTENTIAL  (TEP)  FOLLOWING 
ADMINISTRATION  OF  LSD,  MESCALINE,  DMT.  APOMORPHINE  AND 
METHOXAMINE  IN  THE  DOG 

238703  03  03 

TRANSFER 

DIAZEPAM  AND  ACTIVE  METABOLITE  IN  BREAST  MILK  AND  THEIR 
TRANSFER  TO  THE  NEONATE 

230424  01   15 
PLACENTAL  TRANSFER  OF  PSYCHOTHERAPEUTICS  OF  THE  THIOXANTHENE 
TYPE 

237120  02  05 

PLACENTAL  TRANSFER  OF  CARBAMAZEPINE  IN  THE  RAT, 

237749  02  03 
PLACENTAL  TRANSFER  AND  MATERNAL  AND  FETAL  TISSUE 
DISTRIBUTION  OF  C  14  METHAQUALONE  IN  MICE 

238764  03  03 
PIRACETAM  INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAl  INFORMATION  IN  RATS 

239861  03  04 
TRANSFORMATION 

IFFE(  I  OF  CHLORPROMAZINE  ON  IHE  REACTION  OF  BLAST 
IRANSFORMATION  OF  LYMPHOCYTES. 

2363/3  02  03 
PIIYIOHEMAGLUTININ  INDUCED  LYMPHOCYTE  TRANSFORMATION  IN 
HUMANS  RECMVING  DEI  TA9  TETRAHYDROCANNABINOL 

252825  0-1  13 


Subject  Index 


TRANSIENT 

CHRONIC  DELTA9-TETRAHYDR0CANNABIN0L.  TRANSIENT  AND  LASTING 
EFFECTS  ON  AVOIDANCE  BEHAVIOR 

250061  04  04 

TRANSITIONS 

THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE. 

236715  02  03 

TRANSLOCATION 

ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3- 
MONOOXYGENASE.  (UNPUBLISHED  PAPER). 

237172  02-03 

TRANSMETHYLATION  ^^    ^  ,„^, 

THE  TRANSMETHYLATION  HYPOTHESIS:  A  QUARTER  OF  A  CENTURY 

LATER, 

235801  02-15 
ANALOGUES  OF  S  ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION    SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE 

251698  04-01 

TRANSMISSION 

THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION 

231070  01-03 

SCHIZOPHRENIA    RELATIONSHIPS  TO  DOPAMINE  TRANSMISSION,  MOTOR 

CONTROL,  AND  FEATURE  EXTRACTION 

238464  02-08 

EFFECTS  OF  LITHIUM  ON  NEUROMUSCULAR  TRANSMISSION. 

238743  03  03 
PRESYNAPTIC  AND  POSTSYNAPTIC  ORIGIN  OF  LITHIUM-INDUCED  ACUTE 
BLOCKADE  ON  ADRENERGIC  TRANSMISSION  IN  RABBIT  HEART 

242204  03-03 
AUTOAAATIC  REGISTRATION  OF  BEHAVIOUR  RELATED  TO  DOPAMINE  AND 
NORADRENALINE  TRANSMISSION 

250086  04  04 

TRANSMITTER 

MODIFICATION  BY  LITHIUM  OF  TRANSMITTER  RELEASE  AT  THE 
NEUROMUSCULAR  JUNCTION  OF  THE  FROG 

226855  01  03 
EFFECTS  OF  ALTERATIONS  IN  IMPULSE  FLOW  ON  TRANSMITTER 
METABOLISM  IN  CENTRAL  DOPAMINERGIC  NEURONES 

233971  02-03 
TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID 

24121003  13 

ACETYLCHOLINE.  AN  INHIBITORY  TRANSMITTER  IN  THE  RAT  LATERAL 
HYPOTHALAMUS 

248358  04  03 

USES  OF  DOUBLE  PULSE  STIMULATION  BEHAVIORALLY  TO  INFER 

REFRACTORINESS,  SUMMATION,  CONVERGENCE.  AND  TRANSMITTER 
CHARACTERISTICS  OF  HYPOTHALAMIC  REWARD  SYSTEMS 

250278  04  03 

TRANSMITTERS 

CNS  TRANSMITTERS  AND  THE  HYPOTHALAMUS 

238784  03-03 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION 

238823  03  03 
INTERACTION  BETWEEN  POSSIBLE  TRANSMITTERS  AND 

BUTYROPHENONES  APPLIED  MICROELECTROPHORETICALLY  IN  THE 
CEREBELLUM  AND  BASAL  GANGLIA  OF  THE  CAT    2ND  REPORT 
EFFECTS  OF  SOME  PHENOTHIAZINES  ON  THE  PURKINJE  CELLS  OF  THE 
CEREBELLUM 

241386  03  03 

TRANSPLACENTAL 

TRANSPLACENTAL  EFFECTS  OF  DRUGS  ON  HEARING,  VISION,  AND 
BEHAVIOUR 

227391  01-05 

TRANSPORT 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS. 
(UNPUBLISHED  PAPER) 

226731  01   13 

THE  INFLUENCE  OF  PSYCHOTROPIC  AND  ANTICONVULSANT  AGENTS  ON 
CONFORMANT  TRANSITIONS  IN  THE  TRANSPORT  ATPASE 

236715  02-(J3 

NEUROTOXICITY  OF  A  NON  METABOLIZABLE  AMINO  ACID,  L 

AMINOCYCLOPENTANE  1  CARBOXYLIC  ACID  (ACPC)    ACPC  TRANSPORT 

MECHANISMS  IN  TISSUES 

241298  03-03 
AXOPIASMIC  TRANSPORT  OF  NOREPINEPHRINE  IN  THE  RAT  BRAIN 

243791  04  03 
IN  VITRO  AND  IN  VIVO  TRANSPORT  OF  LITHIUM  BY  HUMAN 
ERYTHROCYTES 

246275  04  13 


S-329 


Subject  Index 


Psychopharmacology  Abstracts 


I 
c 

I 

0 


s 


THE  EFFECTS  OF  HARMALINE  ON  SODIUM  TRANSPORT  IN  HUMAN 
ERYTHROCYTES:  EVIDENCE  IN  FAVOR  OF  ACTION  AT  INTERIOR 
SODIUM  SENSITIVE  SITES 

246856  04  13 
NEUROTOXICITY  OF  DIELDRIN  IN  RELATION  TO  THE  SEROTONIN 
METABOLISM  AND  ACID  TRANSPORT  IN  MOUSE  BRAIN 

249265  04  05 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR.  LILLY!  10140,  ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS, 

250380  04-03 
TRANSSYNAPTIC 

ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3 
MONOOXYGENASE    (UNPUBLISHED  PAPER) 

237172  02-03 
TRANXENE 

CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOLIC  PATIENTS  AFTER  WITHDRAWAL. 

251718  04-11 
TRANYLCYPROMINE 

DIFFERENTIAL  EFFECTS  OF  TRANYLCYPROMINE  AND  PARGYLINE  ON 
INDOLEAMINE  SYSTEMS  IN  BRAIN 

238675  03-03 
COMPARISON  OF  THE  APPARENT  ANTIDEPRESSANT  ACTIVITY  OF  (-)  AND 
(  .  )  TRANYLCYPROMINE  IN  AN  ANIMAL  MODEL. 

250376  04-03 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L  DOPA. 

251704  04-04 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM 

253593  04-04 
TRAUMAS 

TRIAL  OF  A  NEW  THERAPEUTIC  AGENT.  PERVINCAMINE,  IN  THE 

POSTCONCUSSION  SYNDROME  OF  CRANIAL  TRAUMAS.  APPLICATION 
OF  A  DOUBLE-BLIND  CONTROL  AND  SEQUENTIAL  ANALYSIS 

240033  03-11 
TRAZODONE 

A  CONTRIBUTION  TO  TREATMENT  OF  DEPRESSIVE  SYNDROMES:  USE  OF 
TRAZODONE  INTRAVENOUSLY 

230992  01-09 
TRAZODONE  IN  THE  TREATMENT  OF  NEUROSIS      AN  UNCONTROLLED 
CLINICAL  STUDY 

235359  02-07 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES    II.  BLOOD  LEVELS 
AND  THERAPEUTIC  RESPONSIVENESS 

235367  02-09 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  III 

DEXAMETHASONE  SUPPRESSION  TEST  RESULTS  AND  THERAPEUTIC 
RESPONSIVENESS 

235368  02  09 
TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  I    AN 

UNCONTROLLED  CLINICAL  TRIAL  IN  DEPRESSION. 

235369  02  07 
EFFECTS  OF  TRAZODONE  ON  SEROTONIN  IN  THE  BRAIN  AND  PLATELETS 

OF  THE  RAT. 

237240  02  03 
TRAZODONE    THERAPEUTIC  EFFECTIVENESS  IN  ENDOGENOUS 
DEPRESSION,  COMPARED  WITH  BLOOD  LEVELS 

244588  04-09 
INTRAVENOUS  TRAZODONE  WITH  DEPRESSIVE  SYNDROMES. 

244589  04  09 
EFFECTS  OF  TRAZODONE  ON  BEHAVIOR  AND  BRAIN  AMINE  CONTENT  OF 

MICE 

24  7485  04  04 
AN  INTRODUCTION  TO  SYSTEMATIC  STUDIES  OF  TRAZODONE. 

253053  04  07 
AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253054  04-1 
AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

253055  04  1 
A  COMPARISON  OF  TWO  UNCONTROLLED  CLINICAL  TRIALS  OF 

TRAZODONE 

253056  04  1 
A  PIACEBO  CONTROILED  CLINICAL  TRIAL  OF  TRAZODONE 

253057  04  I 
A  SIANDARD  CONIROLLID  ftlNlf  Al   TRIAI   OF  TRAZODONE  ON 

(.LRIAIRK    PATIENTS 

253058  04  I 
A  SUMMARY  Of  SYSIFMAIK    STIIDIfS  01    TRAZODONE 

?')3()S9  01  I 
TREATABLE 

IRIAIAHII   ASI'KISOl    Illl    lUMl  N  I  lA  SYNDROM! 

2406 1  4  03  I  / 


TREATED 

PLASMA  CONCENTRATIONS  OF  L  DOPA  AND  3-METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE. 

226349  01-14 
SUBSENSITIVITY  OF  NORADRENALINE  STIMULATED  CYCLIC-AMP 
ACCUMULATION  IN  BRAIN  SLICES  OF  D-AMPHETAMINE  TREATED 
MICE. 

226651  01-02 
ORGANIZATION  OF  SLEEP  PHASES  IN  SUBJECTS  TREATED  WITH 
FLUPHENAZINE-DECANOATE. 

229557  01-14 
PSYCHOLOGICAL  TEST  INVESTIGATIONS  OF  PATIENTS  TREATED  WITH 
CARBAMAZEPINE  FOR  NOCTURNAL  ENURESIS  AND  TICS. 

229684  01-14 
THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA.  TREATED  WITH  NEUROLEPTIC  DRUGS:  A  DOUBLE-      I 
BLIND  CROSSOVER  TRIAL  WITH  AAADOPAR  AND  PLACEBO 

230823  01-08 
CYTOLOGIC  STUDY  OF  CEREBROSPINAL  FLUID  IN  CHRONIC  PSYCHIATRIC 
PATIENTS  TREATED  WITH  NEUROLEPTICS. 

230997  01-11 
ANTINUCLEAR  ANTIBODIES  IN  CHRONIC  PSYCHOTIC  PATIENTS  TREATED 
WITH  CHLORPROMAZINE. 

232865  02-15 
EFFECTS  OF  TESTING  AGE  AND  FOSTERING  EXPERIENCE  ON  SEIZURE 
SUSCEPTIBILITY  OF  RATS  TREATED  PRENATALLY  WITH 
CHLORPROMAZINE 

234739  02-04 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY 

235629  02-08 
DEVELOPMENT  OF  BRAIN  CEREBROSIDES  AND  CEREBROSIDE  SULFATE 
(SULFATIDE)  IN  OFFSPRING  OF  CONTROL  RATS  AND  RATS 
CHRONICALLY  TREATED  WITH  METHADONE. 

238723  03-03 
PROLACTIN  AND  GONADOTROPHIN  ACTIVITY  IN  FEMALES  TREATED  FOR 
ANOREXIA  NERVOSA 

240423  03  11 
EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE-OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
SUBLETHAL  EFFECTS  ON  OFFSPRING  OF  MALE  RATS  TREATED  WITH 
METHADONE 

243789  04-03 
INTRACAUDATE  NEUROTRANSMITTER  PROCESSES  IN  RELATION  TO 
RAPHE  NEUROTRANSMITTER  PROCESSES:  A  BEHAVIOURAL  ANALYSIS 
OF  INTRACEREBRALLY  APPLIED  DRUGS  IN  ACUTE  AND  LONG-TERM 
MORPHINE  TREATED  CATS. 

244215  04  04 
BLOOD-PRESSURE  AND  PULSE  CHANGES  IN  HYPERACTIVE  CHILDREN 
TREATED  WITH  IMIPRAMINE  AND  METHYLPHENIDATE. 

244932  04  15 
THE  CLINICAL  COURSE  OF  PRIMARY  RECURRENT  DEPRESSION  IN 
PHARMACOLOGICALLY  TREATED  FEMALE  PATIENTS. 

246612  04-17 
TARDIVE  DYSKINESIA  TREATED  WITH  PIMOZIDE 

246699  04-15 
TWO  CASES  OF  GILLES  DE  LA  TOURETTES  SYNDROME  TREATED  WITH 
HALOPERIDOL. 

246715  04-11 
ARE  BEHAVIORAL  AND  PSYCHOMETRIC  CHANGES  RELATED  IN 
METHYLPHENIDATE  TREATED,  HYPERACTIVE  CHILDREN''. 

247382  04-14 
MEASUREMENTS  OF  BRAIN  AMOBARBITAL  CONCENTRATIONS  IN  RATS 
ANESTHETIZED  AND  OVERDOSED  WITH  AMOBARBITAL  AND  TREATED 
CENTRALLY  WITH  DIBUTYRYL  CYCLIC  AMP 

248276  04  03 
DEVELOPMENT  AND  ADULT  BEHAVIORAL  ABNORMALITIES  IN  MICE 
TREATED  NEONATALLY  WITH  CYCLOPHOSPHAMIDE. 

249296  04  02 
ACETYLCHOLINE  LEVELS  AND  TURNOVER  IN  BRAINS  OF  LITHIUM 
TREATED  AND  STRESSED  MICE 

249299  04-03 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEM 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04-03 
PLASMA  RENIN  ACTIVITY  IN  DEPRESSED  PATIENTS  TREATED  WITH 
INCREASING  DOSES  OF'  LITHIUM  CARBONATE 

249673  04  1 3 
REVLRSAI   BY  A  CENTRAL  AN  riACETYlCHOLINf  DRUG  OF  PIMOZIDF 
INDUCED  INHIBIIION  OF  MOUSE  lUMPING  IN  AMPHETAMINE  DOPA 
TREATED  MICE 

250656  04  03 


5-330 


VOLUME  14,  SUBJECT  INDEX 


Subject  Index 


ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 
WITH  PHENOBARBITAL  250682  04-05 

A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE.  ^^^^^^  ^^^^ 

DIFFERENTIAL  BEHAVIORAL  RESPONSES  OF  MALE  AND  FEMALE  ADULT 
RATS  TREATED  WITH  FIVE  PSYCHOTROPIC  DRUGS  IN  THE  NEONATAL 

^^^^^  251981  04-04 

TREATING 

THE  USE  OF  CLONAZEPAM  IN  TREATING  CONVULSIVE  MANIFESTATIONS 
WITH  ENCEPHALOPATHY  IN  CHILDREN:  STUDY  OF  28  ^^^SES^^^^^  ^^  ^^ 

DOUBLE-BLIND  EVALUATION  OF  NAFTIDROFURYL  IN  TREATING  ELDERLY 
CONFUSED  HOSPITALISED  PATIENTS  229368  01-11 

CLINICAL  THERAPEUTIC  EXPERIMENTS  WITH  FLUPHENAZINE-DECANOATE 
IN  TREATING  DISSOCIATIVE  SYNDROMES 

229560  01-11 

CONTROLLED    DOUBLE-BLIND,  CROSSOVER  STUDY  OF  THE  COMPARATIVE 
EFFECTIVENESS  OF  MEPIPRAZOl  (EMD  16923)  AND  DIAZEPAM  IN 
TREATING  NEUROTIC  DISORDERS  ^^_^^^^  ^^^^ 

FACTORS  ASSOCIATED  WITH  TREATMENT  SUCCESS  IN  LITHIUM 

CARBONATE  PROPHYLAXIS:  REPORT  OF  THE  NIMH-VA  COLLABORATIVE 

5^^°^"^°^'-  225718  01-09 

TREATMENT  WITH  ACETAZOLAMIDE  OF  BRAINSTEM  AND  SPINAL 

PAROXYSMAL  DISTURBANCES  IN  MULTIPLE  SCLEROSIS. 

226351  01-13 
FLUPENTHIXOL-DECANOATE  -  IN  TREATMENT  OF  OUTPATIENTS. 

226409  01-08 
A  DOUBLE-BLIND  COMPARISON  BETWEEN  DOXEPIN  AND  DIAZEPAM  IN 

THE  TREATMENT  OF  STATES  OF  ANXIETY 

226410  01-10 

TREATMENT  WITH  DISULFIRAM  IN  HUNTINGTONS-CHOREA:  A  NEGATIVE 

CLINICAL  AND  PHARMACOLOGICAL  STUDY 

226430  01-07 

THE  LONG-TERM  LITHIUM  TREATMENT  OF  AFFECTIVE  DISORDERS    LONG- 
TERM  EFFECTS  AND  SIDE-EFFECTS. 

226612  01-09 

THE  CAUSES  AND  TREATMENT  OF  DEPRESSION. 

226794  01-09 
CONTINGENT  NALOXONE  (N  ALLYLNOROXYMORPHONE)  TREATMENT  OF 
THE  PAROLED  NARCOTIC  ADDICT. 

226901  01  14 
A  PHENOTHIAZINE  DERIVATIVE  IN  THE  TREATMENT  OF  SPASTICITY. 

226960  01  11 
HALOPERIDOL  AND  PROPRANOLOL  IN  THE  TREATMENT  OF  ACUTE 
AMPHETAMINE  INTOXICATION  IN  THE  DOG. 


DEANOL  IN  THE  TREATMENT  OF  TARDIVE-DYSKINESIA. 

A  NEGLECTED  MODALITY  IN  PSYCHIATRIC  TREATMENT 
MONOAMINE-OXIDASE  INHIBITORS 


227389  01-03 

227570  01  11 
THE 

227825  01  10 

THE  NATURE  AND  TREATMENT  OF  DEPRESSION. 

228037  01  09 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6  HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 

CHANGES  IN  RATS.  „,  „, 

228142  01-04 

ANTINUCLEAR  ANTIBODIES  IN  PSYCHIATRIC  ILLNESS:  THEIR 
RELATIONSHIP  TO  DIAGNOSIS  AND  DRUG  TREATMENT. 

228208  01  15 
VERY  HIGH  DOSAGE  VS  STANDARD  DOSAGE  FLUPHENAZINE  IN 
SCHIZOPHRENIA:  A  DOUBLE-BLIND  STUDY  OF  NONCHRONIC 
TREATMENT  REFRACTORY  PATIENTS. 

228223  01-08 

COMPARISON  OF  EFFICACY  OF  LITHIUM  CARBONATE  AND 

CHLORPROMAZINE  IN  MANIA:  REPORT  OF  COLLABORATIVE  STUDY 
GROUP  ON  TREATMENT  OF  MANIA  IN  JAPAN. 

228226  01-09 

AN  INVESTIGATION  OF  THE  SELECTION  PROCESS  AND  DRUG  TREATMENT 
OF  EXPLOSIVELY  AGGRESSIVE  ADOLESCENT  FEMALES.  (PH  D 

DISSERTATION) 

228726  01  11 

DRUG  TREATMENT  IN  A  REHABILITATION  CENTER  FOR  CHRONIC 

ALCOHOLICS  „     ,, 

228908  01-11 

THE  CLINICAL  APPLICATION  OF  LABORATORY  ANIMAL  EXPERIMENTAL 
FINDINGS    TREATMENT  OF  HYPERSEXUALIZED  BEHAVIOR  IN  A  MALE 

229037  01-11 
THE  USE  OF  TRANQUILIZERS  IN  THE  TREATMENT  OF  MIXED  DRUG 

ABUSE 

229044  01   11 


THE  PROBLEMS  AND  TREATMENT  OF  PATIENTS  WITH  GILLES  DE-LA- 

TOURETTES  SYNDROME,  22929501-11 

TREATMENT  OF  DEPRESSION  IN  GERIATRICS  WITH  ANAFRANIL 

LONG-ACTING  PHENOTHIAZINE  AND  SOCIAL  THERAPY  IN  THE 

COMMUNITY  TREATMENT  OF  ACUTE  SCHIZOPHRENICS.     ^^^^^  ^^  ^^ 

CONCEPTUAL  IMPLICATIONS  OF  DRUG  AND  NONSOMATIC  TREATMENT 
INTERACTION  STUDIES.  229452  01-17 

THE  CLINICAL  EVALUATION  OF  A  NEW  MINOR  TRANQUILIZER 
CLORAZEPATE  DIPOTASSIUM  (MENDON)  IN  THE  TREATMENT  OF 
PATIENTS  WITH  PSYCHOSOAAATIC  DISEASE.  NEUROSES  AND 
DEPRESSIVE  STATE  IN  A  DOUBLE-BUND  CLINICAL  STUDY.  ^^^^^^  ^^^  ^ 

THE  TREATMENT  OF  PSYCHOTIC  ANXIETY.  ^^^^^^  ^^^^ 

A  DOUBLE-BLIND  TRIAL  OF  INTRAVENOUS  THYROTROPIN  RELEASING 
HORMONE  IN  THE  TREATMENT  OF  REACTIVE  DEPRESSION.^^^^^^  ^^^^ 

EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  CHLORDIAZEPOXIDE  OR 
FLUPENTHIXOL  ALONE  OR  IN  COMBINATION  WITH  ALCOHOL,  ON 
PSYCHOMOTOR  SKILLS  RELATED  TO  DRIVING.  ^^^  ^^  ^^ 

TREATMENT  OF  THE  MINIMAL-BRAIN-DYSFUNCTION  SYNDROME  WITH 
PSYCHOPHARMACOTHERAPY  (A  CLINICAL  STUDY  WITH  CAPTAGON) 

230002  01-11 

CLINICAL  EXPERIENCES  WITH  ANTIDEPRESSANT  DRUGS  IN  THE 

TREATMENT  OF  ANXIOUS  PHOBIC  PATIENTS.  ^^^^^  ^^^^ 

A  CONTROLLED  TRIAL  OF  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIDE 
IN  THE  TREATMENT  OF  THE  ACUTE  WITHDRAWAL  PHASE  OF 
ALCOHOLISM.  230104  01-11 

LITHIUM  IN  TREATMENT  FAILURES  ^nnc.o  ^,  i , 

23U jo^  U  I  *  I  I 

PHARMACOTHERAPY  AND  PSYCHOTHERAPY  IN  THE  TREATMENT  OF 
-NEUROSES  230640  01-17 

A  COMPARATIVE  STUDY  WITH  PIPOTHIAZINE  PALMITATE  AND 

FLUPHENAZINE-ENANTHATE  IN  THE  TREATMENT  OF  SCHIZOPHRENIC 

P'^^'f^^^  230780  01-08 

NICOTINIC-ACID  IN  THE  TREATMENT  OF  SCHIZOPHRENIAS    PRACTICAL 

AND  THEORETICAL  CONSIDERATIONS.  230812  01-08 

NOREPINEPHRINE  METABOLISM  IN  MOUSE  HEART  AFTER  LITHIUM  AND 

RUBIDIUM  TREATMENT.  230817  01-03 

EFFECTIVENESS  OF  SINEQUAN  (DOXEPIN)  IN  THE  TREATMENT  OF 

NEUROTIC  AND  PSEUDONEUROTIC  SYNDROMES 

230818  0110 

THE  EFFECT  OF  LITHIUM  TREATMENT  ON  MANIC  SYMPTOMS  AND 
LEVELS  OF  MONOAMINE  METABOLITES  IN  CEREBROSPINAL  FLUID  OF 
MANIC  DEPRESSIVE  PATIENTS.  230824  01-09 

EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF  5-HYDROXYINDOLEACETIC  ACID  (5  HIAA)  AND  HOMOVANILLIC 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS 

230827  0109 

TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  0103 

TREATMENT  OF  DEPRESSIVE  SYNDROMES  IN  INVOLUTIONAL  SUBJECTS 

230990  01-09 
A  CONTRIBUTION  TO  TREATMENT  OF  DEPRESSIVE  SYNDROMES:  USE  OF 
TRAZODONE  INTRAVENOUSLY  ^^^^^^  ^^  ^^ 

CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    A 
COMPARISON  OF  TWO  ASSESSMENT  METHODS, 

231034  01  08 

DRUG  TREATMENT  OF  MENTAL  DISORDERS 

THE  PROBLEM  OF  CHRONIC  SCHIZOPHRENIA    TREATMENT  WITH  DEPOT 
FLUPENTHIXOL,  A  LONG-ACTING  NEUROLEPTIC 

231 367  01  -08 
TREATMENT  OF  HUNTINGTONS-CHOREA  WITH  TRIFLUOPERAZINE. 

231369  0111 
THE  FORGOTTEN  TREATMENT  MODALITY  IN  BIPOLAR  ILLNESS: 

PSYCHOTHERAPY  23,61,01-09 

LONG  TERM  TREATMENT  OF  PETIT-MAL  WITH  CLONAZEPAM 

231 654  01-11 

TREATMENT  OF  NEUROTIC  SYNDROMES  WITH  TRANQUILIZERS 

231983  0,-10 

BEHAVIORAL  SUPERSENSITIVITY  TO  APOMORPHINE  AND  AMPHETAMINE 
AFTER  CHRONIC  HIGH  DOSE  HALOPERIDOL  TREATMEN 

232616  02-04 


S-331 


Subject  Index 


S 


1 


rOAAPUTERI^ED  fLECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT 

232635  02-11 
RATIONAL  PSYCHOPHARMACOTHERAPY  AND  THE  RIGHT  TO  TREATMENT. 

232937  02-17 
TREATMENT  OF  PSYCHOLOGICAL  PROBLEMS  OF  CONVICTS. 

233079  02- n 
THE  LEARNING  DISABLED  OR  HYPERACTIVE  CHILD    DIAGNOSIS  AND 
TREATMENT 

233513  02-17 
XEROSTOMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 
THEIR  TREATMENT  WITH  TPMP  (TRITHIO  P-METHOXYPHENYLPROPENE) 

233718  02-15 
EFFECT  OF  CHRONIC  TREATMENT  WITH  CENTRAL  STIMULANTS  ON  BRAIN 
MONOAMINES  AND  SOME  BEHAVIORAL  AND  PHYSIOLOGICAL 
FUNCTIONS  IN  RATS,  GUINEA  PIGS,  AND  RABBITS. 

233962  02-03 
ELECTROENCEPHALOGRAPHIC  STUDIES  IN  PATIENTS  WITH  AFFECTIVE 
DISORDERS  DURING  PROPHYLACTIC  TREATMENT  WITH  LITHIUM 
CARBONATE 

234044  02-09 
CHANGES  IN  PERIPHERAL  BLOOD  DURING  TREATMENT  WITH  SOME 

NEUROLEPTICS  AND  THYMOLEPTICS 

234045  02-15 
PRACTOLOL  IN  THE  TREATMENT  OF  WITHDRAWAL  SYNDROMES. 

234047  02-11 
TREATMENT  OF  ENDOGENOUS  PSYCHOSES  WITH  DOMINAL  AND 
DOMINAL  FORTE  IN  COMBINATION  WITH  HIGHLY  ACTIVE 
NEUROLEPTICS. 

235305  02-11 
PRELIMINARY  EXPERIENCE  WITH  PARENTERAL  SINTAMIL  IN  TREATMENT 
OF  DEPRESSION. 

235348  02  09 
BENZOCTAMINE  IN  THE  TREATMENT  OF  NEUROSIS    -  AN  UNCONTROLLED 
CLINICAL  STUDY. 

235356  02-07 
ETAFENOXIN  IN  THE  TREATMENT  OF  NEUROSIS  -    AN  UNCONTROLLED 

CLINICAL  STUDY 

235357  02-07 
LORAZEPAM  IN  THE  TREATMENT  OF  NEUROSIS    -  AN  UNCONTROLLED 

CLINICAL  STUDY 

235358  02-07 
TRAZODONE  IN  THE  TREATMENT  OF  NEUROSIS      AN  UNCONTROLLED 

CLINICAL  STUDY 

235359  02-07 
CLOMACRAN  IN  THE  TREATMENT  OF  SCHIZOPHRENIC  PATIENTS    -  A 

COMPARISON  OF  TWO  ASSESSMENT  METHODS. 

235364  02-08 
PENFLURIDOL  IN  THE  TREATMENT  OF  SCHIZOPHRENIA   CLINICAL  AND 

PSYCHOMETRIC  FINDINGS 

235365  02-08 
HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 

RESISTANT  PSYCHOTIC  PATIENTS. 

235419  02  17 
ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 
PITUITARY  INDUCED  BY  RESERPINE  TREATMENT 

235649  02  03 
THE  USE  OF  MEGAVITAMIN  TREATMENT  IN  CHILDREN  WITH  LEARNING 
DISABILITIES. 

235676  02-11 
PSYCHOPHARMACOLOGICAL  TREATMENT  OF  SCHIZOPHRENIA. 

235773  02  08 
EVALUATION  OF  COMBINED  PHARMACOLOGICAL  AND 

PSYCHOTHERAPEUTIC  TREATMENT  IN  PATIENTS  WITH  FUNCTIONAL 
ABDOMINAL  DISORDERS 

235782  02-11 
RECENT  DEVELOPMENTS  IN  THE  TREATMENT  OF  SCHIZOPHRENIA 

235803  02  08 
DOXEPIN  IN  THE  TREATMENT  OF  OBSESSIVE-COMPULSIVE  NEUROSIS. 

235826  02  10 
A  CLINICAL  CONTRIBUTION  ON  THE  EFFECTS  OF  SUSPENDING 
ANTIPARKINSONIAN  DRUGS  IN  PROLONGED  TREATMENT  WITH 
NEUROLEPTIC  DRUGS. 

235992  02  11 
PRACTICAL  CONSIDERATIONS  ON  TREATMENT  WITH  ANTIPSYCHOTIC 
DRUGS. 

236359  02  08 
SCHIZOAFFECTIVE  PSYCHOSIS  AND  LITHIUM  TREATMENT  OF  PATIENTS 
SUFFERING  FROM  SCHIZOAFFECTIVE  SCHIZOPHRENIA, 

236361  02  08 
THE  COURSE  OF  TREATMENT  IN  SCHIZOPHRENIA  AS  RELATED  TO  THE 
APPEARANCE  OF  AFFECTIVE  DISORDERS. 

236421  02-08 
LORAZEPAM  AND  DIAZEPAM  IN  THE  TREATMENT  OF  NEUROTIC 
ANXIETY    DOUBLE-BLIND  TRIAL. 

236658  02-10 


Psychopharmacology  Abstracts 

ISONIAZID  (INH)  IN  THE  TREATMENT  OF  DEPRESSIVE  SYNDROME   A 
PILOT  TRIAL. 

236665  02-09 
APPLICATION  OF  LITHIUM  SALTS  NOT  ONLY  IN  MANIC-DEPRESSIVE 
PSYCHOSIS  WITH  FREQUENT  PHASES.  BUT  ALSO  FOR  TREATMENT  OF 
EVERY  PHASE  (EPISODE)  OF  PSYCHOSIS. 

236732  02-09 
RECENT  DEVELOPMENTS  IN  THE  DRUG  TREATMENT  OF  SCHIZOPHRENIA. 

236751  02-08 
MONITORING  OF  LITHIUM  TREATMENT:  GUIDELINES  BASED  ON 
PHARAAACOKINETIC  CONSIDERATIONS. 

236806  02-16 
EVALUATION  OF  DISULFIRAM  TREATMENT  OF  CHRONIC  ALCOHOLISM. 

237026  02-11 
BASIC  TREATMENT  OF  MIGRAINE:  SOME  REFLECTIONS. 

237096  02  II 
INTERACTION  EFFECTS  OF  D-AMPHETAMINE  TREATMENT  AND  AMBIENT 

TEMPERATURE  ON  RATS  FOOD  INTAKE. 

237097  02-03 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 

DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

237103  02-04 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

237106  02-04 
LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  0205 
RESPONSE  OF  NIGRAL  DOPAMINE  NEURONS  TO  ACUTE  AND  PROLONGED 
MORPHINE  TREATMENT:  EFFECT  OF  EXPOSURE  TO  COLD, 
PHYSOSTIGMINE  AND  NICOTINE. 

237158  02-03 
TREATMENT  OF  PARKINSONS  DISEASE  WITH  APORPHINES:  POSSIBLE 
ROLE  OF  GROWTH  HORMONE. 

237253  02-11 
RETROGRADE  ENHANCEMENT  OF  MEMORY  BY  MILD  FLUROTHYL 
TREATMENT  IN  THE  CHICK. 

237260  02-04 
IMMUNOLOGICAL  METHODS  IN  PSYCHIATRIC  TREATMENT. 

237511  02-17 
TREATMENT  OF  ALCOHOLIC  METHADONE  MAINTENANCE  PATIENTS  WITH 
DISULFIRAM. 

237624  02-11 
ATTENUATION  OF  THE  EUPHORIANT  AND  ACTIVATING  EFFECTS  OF  D 
AMPHETAMINE  AND  AND  L-AMPHETAMINE  BY  LITHIUM  CARBONATE 
TREATMENT 

237716  02-14 
TREATMENT  OF  SYDENHAMS  CHOREA  WITH  A  COMBINATION  OF  L-DOPA 
AND  A  PERIPHERAL  DOPA  DECARBOXYLASE  INHIBITOR. 

237733  02-11 
NORADRENERGIC  SUBSENSITIVITY  AND  SUPERSENSITIVITY  OF  THE 
CEREBRAL  CORTEX  AFTER  RESERPINE  TREATMENT. 

237756  02-03 
THE  USE  OF  DOTHIEPIN  IN  THE  TREATMENT  OF  PSYCHONEUROTIC 
ANXIETY  WITH  DEPRESSIVE  FEATURES. 

237774  02-10 
INTENTION  MYOCLONUS:  SUCCESSFUL  TREATMENT  WITH  CLONAZEPAM. 

237825  02  11 
TREATMENT  OF  UNIPOLAR  DEPRESSION. 

237994  02-10 
TREATMENT  OF  ACUTE  PSYCHOTIC  PATIENTS  WITH  LOXAPINE 
PARENTERALLY, 

238551  02-09 
EFFECTS  OF  6  HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTOPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-03 
PREVENTION  OF  REVERSAL  OF  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEFORE  OR  AFTER  NALOXONE. 

238687  03  04 
PRESENT  STATE  OF  LONG-TERM  NEUROLEPTIC  TREATMENT  OF 
SCHIZOPHRENIA. 

238864  03  08 
ON  THE  MULTIFACTORIAL  TREATMENT  OF  CHRONIC  HEADACHES. 

238866  03  II 
PLASMA  AND  ERYTHROCYTE  MAGNESIUM  LEVELS  IN  PATIENTS  WITH 
PRIMARY  AFFECTIVE  DISORDER  DURING  CHRONIC  LITHIUM 
TREATMENT. 

238977  03  15 
A  DOUBLE-BLIND  COMPARISON  OF  FLUPHENAZINE-DECANOATE  AND 
FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF  ACUTE 
SCHIZOPHRENIA. 

238996  03-08 
PIMOZIDE  IN  THE  TREATMENT  OF  MONOSYMPTOMATIC 
HYPOCHONDRIACAL  PSYCHOSIS. 

239014  03  11 


S-332 


OLUME  14,  SUBJECT  INDEX 


Subject  Index 


PERORAL  AND  PARENTERAL  ADMINISTRATION  OF  LONG  ACTING 

NEUROLEPTICS:  A  DOUBLE  BLIND  STUDY  OF  PENFLURIDOL  COMPARED 
TO  FLUPENTHIXOL-DECANOATE  IN  THE  TREATMENT  OF 
SCHIZOPHRENIA, 

239023  03-08 
REVIEW  OF  DRUG  TREATMENT  FOR  DOWNS-SYNDROME  PERSONS. 

239074  03- 1 1 
TREATMENT  OF  UNSELECTED  INDONESIAN  PSYCHOTIC  PATIENTS  WITH 
DOGMATIL  (DELAGRANGE) 

239269  03-11 
REDUCED  PLASMA  NOREPINEPHRINE  AND  DOPAMINE  BETA- 

HYDROXYLASE  DURING  FENFLURAMINE  (PONDIMIN)  TREATMENT  IN 
MAN    (UNPUBLISHED  PAPER). 

239305  03-13 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE  BLIND  TRIAL 

239348  03  09 
OUTPATIENT  TREATMENT  WITH  LONG-ACTING  PERPHENAZINE 
(PERPHENAZINE-ENANTHATE):  THREE  CASES 

239615  03-09 
DOUBLE-BLIND  COMPARISON  OF  MAPROTILINE  WITH  AMITRIPTYLINE  IN 
THE  TREATMENT  OF  DEPRESSIVE  ILLNESS 

239818  03-10 
EEG  SLEEP  STUDIES  OF  INSOMNIACS  UNDER  FLUNITRAZEPAM 

TREATMENT. 

239819  03-14 
A  CONTROLLED  COMPARISON  OF  CYCLAZOCINE  AND  NALOXONE 

TREATMENT  OF  THE  PAROLED  NARCOTIC  ADDICT. 

239824  03  11 
MEMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT. 

239852  03-04 
HEROIN  ADDICTION:  SEQUENTIAL  TREATMENT  EMPLOYING 
PHARMACOLOGIC  SUPPORTS. 

239939  03-11 
THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-15 
COMPARISON  BETWEEN  CHRONIC  CHLORDIAZEPOXIDE  TREATMENT  AND 
SHOCK  REMOVAL  IN  A  CONFLICT  SITUATION  IN  RATS. 

239979  03-04 
LITHIUM  MAINTENANCE  TREATMENT  OF  MANIC-MELANCHOLIC 
PATIENTS:  ITS  ROLE  IN  THE  DAILY  ROUTINE. 

240055  03-09 
DRUG  TREATMENT  IN  PSYCHIATRY. 

240086  03  17 
TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS    - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS. 

240216  0309 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 
TREATMENT:  I.  INVESTIGATIONS  WITH  HALOPERIDOL. 

240218  03-08 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  II.  ANTIPSYCHOTIC  EFFECT  OF  HALOPERIDOL  IN  PATIENTS 
WITH  CHRONIC  ORGANIC  BRAIN  DAMAGE. 

240219  03  11 
CLINICAL  AND  BIOCHEMICAL  PARAMETERS  DURING  NEUROLEPTIC 

TREATMENT:  III.  PRIMITIVE  REFLEXES  DURING  NEUROLEPTIC 
TREATMENT. 

240220  03-14 
ASTONIN  H  IN  THE  TREATMENT  OF  ARTERIAL  HYPERTENSION  DUE  TO 

PSYCHOTROPIC  DRUGS 

240261  03-15 
LONG  TERM  TREATMENT  OF  SCHIZOPHRENIA. 

240709  03  08 
BEHAVIOR  DISORDERS  IN  CHILDHOOD  AND  THEIR  TREATMENT, 

240711  03-11 
LITHIUM  TREMOR      COMBINATION  TREATMENT  WITH  BETA-RECEPTOR 
BLOCKERS''. 

240741  03-14 
TREATMENT  OF  ACUTE  SCHIZOPHRENIA  WITH  SULPHORIDAZINE 

240850  03-08 
EFFECT  OF  SUBACUTE  TREATMENT  WITH  HYPNOTICS,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  PSYCHOMOTOR  SKILLS  RELATED 
TO  DRIVING. 

241417  03-15 
MENTAL  ILLNESS  AND  SIMULATED  DRIVING:  BEFORE  AND  DURING 
TREATMENT. 

241425  03-15 
EARLY  STRATEGIES  IN  TREATMENT  OF  THE  DEPRESSED  PATIENT. 

241435  03  17 
DEPOT  NEUROLEPTICS   -  PRACTICAL  METHODS  OF  LONG  TERM 

TREATMENT  AND  METHODOLOGICAL  PROBLEMS  OF  CLINICAL  TRIALS. 

241761  03-08 
SECONDARY  EFFECTS  OF  LITHIUM  TREATMENT.  PRELIMINARY  RESULTS 
OF  AN  INQUIRY 

241765  03  15 


FLURAZEPAM   A  NEW  HYPNOTIC  FOR  THE  TREATMENT  OF  INSOMNIA. 

242502  03  14 
CHANGES  IN  THE  PERSONALITY  FUNCTIONING  OF  PSYCHOTICS  WITH 
NEUROLEPTIC  TREATMENT. 

242868  04-11 
MATERNAL  AND  NEONATAL  ELIMINATION  OF  AMOBARBITAL  AFTER 
TREATMENT  OF  THE  MOTHER  WITH  BARBITURATES  DURING  LATE 
PREGNANCY. 

243085  04  15 
TREATMENT  OF  STUDENTS  WITH  MENTAL  DISORDER. 

243092  04- 1  7 
ON  GROWTH  HORMONE  REGULATION  IN  ANOREXIA  NERVOSA  BEFORE 
AND  AFTER  PHENOTHIAZINE  TREATMENT. 

243193  04  10 
SOMATIC  ORIENTED  TREATMENT  OF  ANOREXIA  NERVOSA. 

243194  04-10 
DEATH  AND  DRUG  TREATMENT  IN  A  PSYCHIATRIC  HOSPITAL. 

243716  04-15 

COURSE  AND  RESULTS  OF  TREATMENT  WITH  THREE  ACTIVATING 

NEUROLEPTIC  DRUGS. 

244049  04-08 

VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES. 

244188  04-08 
ELECTROPHORETIC  APPLICATION  OF  LIGNOCAINE  TO  THE  CERVICAL  AREA 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES. 

244467  04-10 
CLINICAL  FINDINGS  IN  DISEASES  IN  THE  ELDERLY  WITH  A  CLEAR 
PSYCHOGENIC  COMPONENT  WITH  PARTICULAR  RESPECT  TO  THEIR 
PHARMACOLOGICAL  TREATMENT. 

244476  04-11 
THE  DRUG  TREATMENT  OF  MOOD  DISORDERS.  PART  IT  ANTIMANIC  AND 
ANTIDEPRESSANT  AGENTS,  MAINTENANCE  TREATMENT,  AND  RECENT 
ADVANCES   (UNPUBLISHED  PAPER). 

244574  04-09 
EFFECTS  OF  EARLY  POSTNATAL  ALPHA-METHYL  DOPA  TREATMENT  ON 
BEHAVIOR  IN  THE  RAT 

245304  04-04 
SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY. 

245344  04-11 

TREATMENT  OF  DEPRESSION  IN  ALCOHOLICS. 

245521  04-09 
PERSISTENCE  OF  CHRONIC  MORPHINE  EFFECTS  UPON  ACTIVITY  IN  RATS 
8  MONTHS  AFTER  CEASING  THE  TREATMENT. 

245602  04-04 
EFFECT  OF  HYDROCHLOROTHIAZIDE  ON  PHOSPHORUS  DURING 
TREATMENT  WITH  DIPHOSPHONATE. 

245651  04  13 
METHYLPHENIDATE  AND  CAFFEINE  IN  THE  TREATMENT  OF  CHILDREN 
WITH  MINIMAL-BRAIN-DYSFUNCTION 

245786  04-14 
CLINICAL  OBSERVATIONS  ON  THE  TREATMENT  OF  TARDIVE  DYSKINESIA 
WITH  HALOPERIDOL 

245967  04-08 
SINGLE  DOSE  IMIPRAMINE  PAMOATE  IN  THE  TREATMENT  OF  DEPRESSIVE 
NEUROSIS. 

246300  04-10 
PREDICTION  OF  RESPONSE  TO  CHLORPROMAZINE  TREATMENT  IN 
SCHIZOPHRENICS. 

246314  04-08 

EFFECT  OF  TWO  WEEKS  TREATMENT  WITH  THIORIDAZINE, 

CHLORPROMAZINE,  SULPIRIDE  AND  BROMAZEPAM,  ALONE  OR  IN 
COMBINATION  WITH  ALCOHOL,  ON  LEARNING  AND  MEMORY  IN  MAN. 

246315  04  14 
RECENT  CLINICAL  EXPERIENCE  WITH  TREATMENT  OF  DEPRESSION  WITH 

GEROVITAL  H3  TABLETS. 

246425  04-09 
DIPSOGENIC  EFFECTS  OF  INTRACELLULAR  AND  EXTRACELLULAR  THIRST 
STIMULI  BEFORE  AND  AFTER  CHRONIC  DFP  TREATMENT. 

247209  04-04 
USE  OF  SYNTHESIS  INHIBITORS  IN  DEFINING  A  ROLE  FOR  BIOGENIC 
AMINES  DURING  IMIPRAMINE  TREATMENT  IN  DEPRESSED  PATIENTS. 

247216  04-09 
A  PLACEBO  CROSSOVER  STUDY  OF  CAFFEINE  TREATMENT  OF 
HYPERKINETIC  CHILDREN. 

247379  04-14 
THE  NATURAL  HISTORY  OF  HYPERACTIVITY  IN  CHILDHOOD  AND 

TREATMENT  WITH  STIMULANT  MEDICATION  AT  DIFFERENT  AGES:  A 
SUMMARY  OF  RESEARCH  FINDINGS 

247384  04  14 
PIPERACETAZINE  IN  THE  TREATMENT  OF  MIXED  NEUROTICS. 

247484  04-10 
EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS. 

247588  04-03 


S-333 


^masim 


Subject  Index 


Psychopharmacology  Abstrac 


I 


S 


c 

OB' 

I 


A  COMPARISON  OF  DEXTROAMPHETAMINE  AND  RACEMIC 

AMPHETAMINE  IN  THE  TREATMENT  OF  THE  HYPERKINETIC  SYNDROME 
OR  MINIMAL-BRAINDYSFUNCTION. 

247878  04-11 

THE  EFFICACY  AND  SAFETY  OF  LOXAPINE  SUCCINATE  IN  THE  TREATMENT 
OF  SCHIZOPHRENIA:  A  COMPARATIVE  STUDY  WITH  THIOTHIXENE 

247968  04  08 
CLINICAL  EVALUATION  OF  CDP-CHOLINE  (NICHOLIN):  EFFICACY  AS 

ANTIDEPRESSANT  TREATMENT, 

247969  04-09 
MYELOID  HYPERPLASIA  IN  GROWING  RATS  AFTER  CHRONIC  TREATMENT 

WITH  DELTA9-THC  AT  BEHAVIORAL  DOSES. 

248915  04-05 
CHANGES  IN  FIXED-INTERVAL  BEHAVIOR  DURING  CHRONIC  MORPHINE 
TREATMENT  AND  MORPHINE  ABSTINENCE  IN  RATS. 

248959  04-04 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT. 

248964  04-04 
ENHANCEMENT  OF  RESERPINE-ELICITED  DOPAMINERGIC 

SUPERSENSITIVITY  BY  REPEATED  TREATMENT  WITH  APOMORPHINE 
AND  ALPHA-METHYL-P-TYROSINE. 

249002  04-03 
DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE:  EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION.  AND 
DURATION  OF  TREATMENT. 

249223  04-03 
DIFFERENCES  BETWEEN  THE  EFFECTS  OF  ACUTE  AND  LONG-TERM 
TREATMENT  WITH  DESMETHYLIMIPRAMINE  ON  RESERPINE-INDUCED 
RELEASE  OF  AMINES  FROM  RAT  BRAIN. 

249233  04  03 
ELICITATION  OF  MOUSE  JUMPING  BY  COMBINED  TREATMENT  WITH 
AMPHETAMINE  AND  L-DOPA:  BLOCKADE  BY  KNOWN  NEUROLEPTICS. 

249272  04-04 
CHANGES  IN  SENSITIVITY  OF  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AFTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS, 

249485  04-04 
A  STATISTICAL  REVIEW  OF  CONTROLLED  TRIALS  OF  IMIPRAMINE  AND 
PLACEBO  IN  THE  TREATMENT  OF  DEPRESSIVE  ILLNESSES. 

249536  04-16 
THIOTHIXENE  IN  THE  TREATMENT  OF  GERIATRIC  PATIENTS  WITH 
CHRONIC  ORGANIC-BRAIN-SYNDROME 

249625  04-11 
THE  EFFECT  OF  LONG-TERM  PENFLURIDOL  TREATMENT  ON  THE 
SENSITIVITY  OF  THE  DOPAMINE  RECEPTORS  IN  THE  NUCLEUS- 
ACCUMBENS  AND  IN  THE  CORPUS-STRIATUM. 

249670  04-04 
LITHIUM  TREATMENT  AND  WEIGHT  GAIN 

249927  04-15 
ROLE  OF  STIMULUS  LOCALE  ON  STRAIN  DIFFERENCES  IN  ACTIVE 

AVOIDANCE  AFTER  SCOPOLAMINE  OR  D-AMPHETAMINE  TREATMENT. 

250074  04-04 
FIVE  YEARS  TREATMENT  OF  PARKINSONS  DISEASE  WITH  LEVODOPA: 
THERAPEUTIC  RESULTS  AND  SURVIVAL  OF  100  PATIENTS. 

250927  04-11 
CLONAZEPAM  IN  THE  TREATMENT  OF  CHOREIFORM  ACTIVITY. 

250932  04-07 
DYSPHORIC  RESPONSE  TO  NEUROLEPTIC  TREATMENT  IN  SCHIZOPHRENIA 
AND  ITS  PROGNOSTIC  SIGNIFICANCE 

250989  04  15 
OXPRENOLOL  IN  THE  TREATMENT  OF  EXAMINATION  NERVES. 

251160  04  10 
NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA-ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
BROMOCRIPTINE  TREATMENT  IN  PARKINSONS  DISEASE. 

251239  04-11 
PROPRANOLOL  IN  THE  TREATMENT  OF  HYPERTENSION. 

251320  04- 17 
TREATMENT  OF  EXPERIMENTAL  IMIPRAMINE  AND  DESIPRAMINE 
POISONING  IN  THE  RAT. 

251419  04-03 
SUPERSENSITIVITY  OF  CORTICAL  NEURONES  OF  THE  RAT  TO 

ACETYLCHOLINE  AND  L  GLUTAMATE  FOLLOWING  CHRONIC  MORPHINE 
TREATMENT. 

251433  04-03 
OPTIONS  FOR  TREATMENT  OF  THE  SCHIZOPHRENIC  PATIENT. 

251546  04-08 
SIX-YEAR  RESULTS  OF  TREATMENT  WITH  LEVODOPA  PLUS  BENSERAZIDE 
IN  PARKINSONS  DISEASE. 

251648  04-11 
SIDE-EFFECTS  OF  LITHIUM  THERAPY  AND  THEIR  TREATMENT. 

251712  04-15 
TREATMENT  OF  REACTIONS  TO  AMPHETAMINE-TYPE  STIMULANTS. 

251754  04  15 


CLOZAPINE  IN  THE  TREATMENT  OF  NEWLY  ADMITTED  SCHIZOPHRENIC 
PATIENTS:  A  PILOT  STUDY. 

251828  04 
TETRABENAZINE  IN  THE  TREATMENT  OF  HYPERKINETIC  MOVEMENT 
DISORDERS. 

251961  04 
TREATMENT  OF  DIALYSIS  DEMENTIA  WITH  THIAMINE. 

251966  04 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H-5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES. 

252023  04 
TOFRANIL  IN  THE  TREATMENT  OF  LOW  BACK  PAIN. 

252138  04 
THE  CLINICAL  EVALUATION  OF  GRANDAXIN  USED  IN  THE  TREATMENT 
OUTPATIENTS  (A  MULTICENTRIC  STUDY). 

252448  OA 
TREATMENT  OF  PSYCHIC  DISORDERS  ACCOMPANYING  MYASTHENIA 

GRAVIS:  (GRANDAXIN,  A  NEW,  NONRELAXANT  TRANQUILLIZER). 

252449  0-1 
THE  TREATMENT  OF  CLIMACTERIC  SYNDROME  WITH  TOFIZOPAM 

(GRANDAXIN). 

252450  0^ 
POTENTIATION  OF  AMPHETAMINE-INDUCED  HYPERACTIVITY  BY  ACUTI 

BUT  NOT  BY  CHRONIC  P-CHLOROPHENYLALANINE  TREATMENT  IN  Tl 
RAT. 

252519  0/ 
RECENT  ADVANCES  IN  THE  DRUG  TREATMENT  OF  THE  FUNCTIONAL 
PSYCHOSES. 

252653  0/ 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  0 
ACUTE  ALCOHOL  WITHDRAWAL. 

252694  0-: 
THIORIDAZINE  IN  THE  TREATMENT  OF  DEPRESSIVE  PATIENTS. 

252760  0^ 
METHODOLOGY  USED  IN  ASSESSING  METHYLPHENIDATE  AND  CAFFEIN 
TREATMENT  OF  MINIMAL  BRAIN-DYSFUNCTIONING  CHILDREN. 

252798  0/ 
TREATMENT  OF  PHENOTHIAZINE-INDUCED  DYSKINESIA. 

253038  0/ 
LITHIUM  COMBINED  WITH  NEUROLEPTICS  IN  THE  TREATMENT  OF 
CHRONIC  SCHIZOPHRENIA. 

253049  0^ 
TREATMENT  OF  DEPRESSION  IN  THE  AGED  WITH  GER0VITAL-H3: 
CLINICAL  EFFICACY  AND  NEUROPHYSIOLOGICAL  EFFECTS. 

253061  0^ 
ANTIDEPRESSANT  TREATMENT  WITH  MAPROTILINE  IN  THE 

MANAGEMENT  OF  EMOTIONAL  DISTURBANCES  IN  PATIENTS  WITH 
ACUTE  MYOCARDIAL  INFARCTION:  A  CONTROLLED  STUDY. 

253684  0^ 
TREATMENTS 

ETHICAL  AND  LEGAL  IMPLICATIONS  OF  INVESTIGATIONS  INTO  THE 
EFFICACY  OF  PSYCHIATRIC  TREATMENTS. 

235354  02 
ACTION  OF  VARIOUS  ANTIDEPRESSANT  TREATMENTS  REDUCES 

REACTIVITY  OF  NORADRENERGIC  CYCLIC-AMP  GENERATING  SYSTE^ 
IN  LIMBIC  FOREBRAIN. 

245115  0/ 
ACUTE  MANIA:  CLINICAL  AND  GENETIC  STUDY  OF  RESPONDERS  AND 
NONRESPONDERS  TO  TREATMENTS. 

253617  0/ 
TREMOGRAPHIC 

TREMOGRAPHIC  STUDIES  IN  TARDIVE-DYSKINESIA. 

253036  0/ 
TREMOR 

BETA-BLOCKADE  IN  LITHIUM  TREMOR. 

230742  01 
LITHIUM  TREMOR    -  COMBINATION  TREATMENT  WITH  BETA-RECEPTOI 
BLOCKERS-^. 

240741  03 
EFFECTS  OF  DRUGS  ON  TREMORINE-INDUCED  TREMOR 

241379  03 
PROPRANOLOL  EFFECT  ON  TREMOR  IN  ALCOHOLIC  WITHDRAWAL. 

250779  04 
OXPRENOLOL  IN  SENILE  TREMOR. 

251163  04 
CONTROL  OF  LITHIUM  TREMOR  WITH  PROPRANOLOL. 

251431  04 
TREMORGENIC 

BRAIN  BUFOTENINE  FROM  ADMINISTERED  ACETYLBUFOTENINE: 
COMPARISON  OF  ITS  TREMORGENIC  ACTIVITY  WITH  THAT  OF  N,N 
OIMETHYLTRYPTAMINE  AND  5  METHOXY-N.N  DIMETHYLTRYPTAMIN 

249317  04 
TREMORINE-INDUCED 

EFFECTS  OF  DRUGS  ON  TREMORINE  INDUCED  TREMOR 

241379  03 
TRENDS 

WORLDWIDE  TRENDS  IN  THE  PSYCHOPHARMACOLOGICAL  STUDIES. 

228323  01 


S-334 


OLUME  14,  SUBJECT  INDEX 

ACUTE  BEHAVIORAL  CHANGES  INDUCED  IN  THE  RAT  BY  THE 

INTRACEREBROVENTRICULAR  ADMINISTRATION  OF  THYROTROPIN- 
RELEASING  FACTOR  (TRE)  AND  SOMATOSTATIN. 

227386  01-04 
THYROTROPIN-RELEASING  FACTOR  (TRF)  REGULATION  OF  ROTATION  IN 
THE  NONLESIONED  RAT. 

247514  04-03 

lU 

THYROTROPIN  RELEASING  HORMONE  (TRH)  AND  ITS  BETA-ALANINE 
ANALOG:  POTENTIATION  OF  THE  ANTICONVULSANT  POTENCY  OF 
PHENOBARBITAL  IN  MICE. 

232618  02-03 
THYROTROPIN-RELEASING  HORMONE  (TRH)  AS  A  POSSIBLE  QUICK- 
ACTING  BUT  SHORT-LASTING  ANTIDEPRESSANT. 

235630  0209 
PROFILE  OF  TRH  IN  EXPERIMENTAL  PSYCHOPHARMACOLOGY. 

237708  02-04 
EFFECT  OF  PCPA  AND  METHERGOLINE  ON  THE  PENTOBARBITAL  TRH 
INTERACTION  IN  RABBITS. 

238695  03-03 
COMPARISON  OF  THYROID-RELEASING  HORMONE  (TRH)  AND 

AMPHETAMINE  (AMP)  ON  CHANGES  IN  ACTIVITY  LEVELS  OF  RATS 
FOLLOWING  INJECTIONS  INTO  THE  CAUDATE  NUCLEUS.  SEPTUM,  AND 
HYPOTHALAMUS. 

238744  03  04 

THYROTROPIN-RELEASING  HORMONE  (TRH)  AN  ANTIDOTE  TO 
AMOBARBITAL  OVERDOSAGE  IN  THE  RHESUS  MONKEY. 

238792  03-03 
ORAL  PROTIRELIN  (TRH)  IN  DEPRESSION. 

247482  04-09 
THYROID  FUNCTION  LEVELS  AND  THYROTROPIN  RESPONSES  TO  TRH 
ADMINISTRATION  IN  MANIC  PATIENTS  RECEIVING  LITHIUM 
CARBONATE. 

249124  04-14 
STUDIES  ON  THE  ANALEPTIC  ACTION  OF  THYROTROPIN  RELEASING 
HORMONE  (TRH)  IN  RABBITS 

249280  04-04 
POTENCY  OF  THE  N3IM-METHYL  ANALOG  OF  TRH  IN  THE  INDUCTION  OF 
SHAKING  MOVEMENTS  IN  THE  RAT 

250087  04-02 
INVESTIGATIONS  INTO  THE  MECHANISM  OF  REDUCTION  OF  ETHANOL 
SLEEP  BY  THYROTROPIN-RELEASING  HORMONE  (TRH). 

250110  04-03 
RHINDUCED 

THYROTROPIN-RELEASING  HORMONE  TRH-INDUCED  HYPERTHERMIA  AND 
BEHAVIORAL  EXCITATION  IN  RABBITS. 

236524  02-04 

RIAZOLAM 

A  COMPARISON  OF  THE  EFFECTS  OF  FLURAZEPAM  30  MG  AND 
TRIAZOLAM  0.5  MG  ON  THE  SLEEP  OF  INSOMNIACS. 

244686  04-11 
THE  MORNING  AFTER:  RESIDUAL  EEG  EFFECTS  OF  TRIAZOLAM  AND 
FLURAZEPAM   ALONE  AND  IN  COMBINATION  WITH  ALCOHOL 

244960  04  13 
TRIAZOLAM  IN  INSOMNIAC  FAMILY  PRACTICE  PATIENTS 

245649  04  11 
HYPNOTIC  EFFICACY  OF  TRIAZOLAM  AND  METHYPRYLON  IN  INSOMNIAC 
INPATIENTS 

248533  04-11 

RIAZOLES 

ANTICONVULSANT  ACTIVITY  OF  NEWER  SUBSTITUTED  TRIAZOLES 

238712  03  03 
RIBULATIONS 

THE  SEARCH  FOR  THE  DOPAMINE  RECEPTOR    TRIBULATIONS 

247215  04-03 

RICYCIIC 

OBJECTIVE  ASSESSMENT  OF  ANTICHOLINERGIC  SIDE-EFFECIS  OF 
i  TRICYCLIC  ANTIDEPRESSANTS 

.;  226411  01  09 

I        EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  DRUG  METABOLISM 

226829  01   13 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  BARBITURATES  IN 
BARBITURATE-TOLERANT  AND  NONTOLERANT  RATS 

226849  0103 
SIDE  EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  WITH  PARTICULAR 
REFERENCE  TO  DOTHIEPIN 

226897  01-15 
INTERACTIONS  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  PENTOBARBITAL 
IN  PfNTOBARBIlAI   TOIERANT  AND  NONTOLTRANT  RATS 

227390  01  03 
IMF  INTERAC  TION  BFIWEEN  AIPHAMFTHYI   DOPA  AND  IRICYCLIC 
ANTIDEPRESSANTS 

230819  01  03 
i        POISONING  BY  TRICYCIK   AN  1 IDEPRESSAN  T  DRUGS    GENERAL  AND 
'  PHARMACOKINI  lie  CONSIDTRATIONS 

730820  01   15 


Subject  Index 


CARDIOVASCULAR  SIDE-EFFECTS  OF  TRICYCLIC  ANTIDEPRESSANTS   -  A 
RISK  IN  THE  USE  OF  THESE  DRUGS. 

23131701-15 

TRICYCLIC  ANTIDEPRESSANT  OVERDOSE:  CLINICAL  PRESENTATION  AND 

PLASMA  LEVELS. 

23131801-13 

STUDIES  ON  THE  MECHANISM  OF  ACTION  OF  TRICYCLIC 

ANTIDEPRESSANT  DRUGS,  USING  IPRINDOLE  AS  A  TOOL.  (PH.D. 

DISSERTATION). 

231438  01-03 

NEW  TRICYCLIC  ENAMINE  DERIVATIVES  WITH  CNS  DEPRESSANT 

PROPERTIES- 

232528  01  02 

THE  USE  OF  BETHANECHOL  CHLORIDE  WITH  TRICYCLIC 
ANTIDEPRESSANTS. 

232864  02  15 

EFFECT  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE 

ELECTROCARDIOGRAMS  OF  PATIENTS  WITH  ENDOGENOUS  DEPRESSION 
(INTRODUCTORY  REPORT). 

234046  02-09 
NOREPINEPHRINE  METABOLISM  AFTER  SHORT-TERM  AND  LONG-TERM 
ADMINISTRATION  OF  TRICYCLIC  ANTIDEPRESSANT  DRUGS  AND 
ELECTROCONVULSIVE  SHOCK. 

234804  02-03 

LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 
AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 
NEUROLEPTICS. 

237153  02-05 

DO  TRICYCLIC  ANTIDEPRESSANTS  WORK?. 

237162  02  17 
A  REVIEW  OF  THE  CARDIOVASCULAR  EFFECTS  AND  TOXICITY  OF 
TRICYCLIC  ANTIDEPRESSANTS 

237909  02-15 
PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

238317  02-01 
NOVEL  ANALOGS  OF  TRICYCLIC  PSYCHOPHARMACOLOGICAL  AGENTS. 

238476  02-01 
ELECTRON  BEAM  IONIZATION  MASS  FRAGMENTOGRAPHIC  ANALYSIS  OF 
TRICYCLIC  ANTIDEPRESSANTS  IN  HUMAN  PLASMA. 

238486  02  16 
RADIOIMMUNOASSAY  OF  TRICYCLIC  ANTIDEPRESSANTS. 

238775  03-01 
INFLUENCE  OF  TRICYCLIC  ANTIDEPRESSANTS  ON  THE  ADENYLATE- 
CYCLASE  PHOSPHODIESTERASE  SYSTEM  IN  THE  RAT  CORTEX. 

239085  03-03 
TREATMENT  WITH  RESERPINE  OF  PATIENTS  RESISTANT  TO  TRICYCLIC 
ANTIDEPRESSANTS:  A  DOUBLE-BLIND  TRIAL. 

239348  03-09 
FACTORS  AFFECTING  THE  BINDING  OF  TRICYCLIC  TRANQUILLIZERS  AND 
ANTIDEPRESSANTS  TO  HUMAN  SERUM  ALBUMIN 

239684  03-13 
TREATMENT  OF  DEPRESSION  WITH  TRICYCLIC  DRUGS  - 
PHARMACOKINETIC  AND  PHARMACODYNAMIC  ASPECTS. 

240216  03-09 
COMBINATION  OF  TRICYCLIC  ANTIDEPRESSANTS  AND  MAOI  IN 
DEPRESSION. 

240839  03  09 
OVERDOSAGE      THE  RISE  AND  FALL  OF  TRICYCLIC  ANTIDEPRESSANTS 

243064  04  15 
PSYCHOTHERAPY  AND  TRICYCLIC  ANTIDEPRESSANTS 

243860  04-09 
CLINICAL  USE  OF  TRICYCLIC  ANTIDEPRESSANTS. 

243861  04-09 
THE  RELATIONSHIP  BETWEEN  HIATUS  HERNIA  AND  TRICYCLIC 

ANTIDEPRESSANTS:  A  REPORT  OF  FIVE  CASES 

245523  04  15 
TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG 
INFORMATION-CENTER:  THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04-13 
TRICYCLIC  ANTIDEPRESSANTS  AND  THE  CENTRAL  CHOLINERGIC 
MUSCARINIC  RECEPTOR- 

249301  04  03 
DEVELOPMENT  QF  THE  INFLUENCES  OF  SODIUM.  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES 

249667  04  03 
THE  EFFECT  OF  TRICYCLIC  ANTIDEPRESSANT  COMPOUNDS  ON  PATIENTS 
WITH  PASSIVE  DEPENDENT  PERSONALITY  TRAITS. 

251717  04-1  1 
PAVOR  NOCTIJRNUS:  A  COMPLICATION  OF  SINGLE  DAILY  TRICYCLIC  OR 
NEUROLEPTIC  DOSAGE 

252955  04  17 

DO  IRICYCLIC  ANTIDEPRESSANTS  WORK'^ 

253314  04  09 
THE  EFFFCT  OF  VARIOUS  PHENOTHIAZINE  S  AND  TRICYCIIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H 


S-335 


Subject  Index 


Psychopharmacology  Abstract 


c 

or 

I 

> 

I 

1 

"1 

9 
i 

Jt 


NOREPINEPHRINE  AND  3H  5  HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX 

253691  04-03 
TRIFLUBAZAM 

CONTROLLED  CLINICAL  AND  QUANTITATIVE  EEC  STUDIES  OE 

TRIFLUBAZAM  (ORF-8063)  IN  PATIENTS  WITH  ANXIETY  SYNDROME. 

241275  03  10 
TRIFLUOPERAZINE 

THE  EFFECT  OF  DIAZEPAM  AND  TRIFLUOPERAZINE  ON  BLOOD  SUPPLY 
AND  CARDIAC  ACTIVITY. 

228553  01  03 
THE  EFFECT  OF  TRIFLUOPERAZINE  ON  THE  TRANSMISSION  OF 
EXCITATION  IN  THE  RABBIT  BRAIN  DURING  PROLONGED 
ADMINISTRATION  OF  THE  PREPARATION. 

231070  01-03 
TREATMENT  OF  HUNTINGTONS-CHOREA  WITH  TRIFLUOPERAZINE. 

231369  01  11 
THE  ACTION  OF  CHLORPROMAZINE,  TRIFLUOPERAZINE  AND  DROPERIDOL 
ON  THE  CAPTURE  AND  ACCUMULATION  OF  EXOGENOUS 
NOREPINEPHRINE 

236713  02-03 
A  DOUBLE  BLIND  COMPARISON  OF  LOXAPINE  SUCCINATE  AND 

TRIFLUOPERAZINE  IN  NEWLY  ADMITTED  SCHIZOPHRENIC  PATIENTS. 

237828  02-08 
CHARACTERISTIC  CHANGES  IN  CONDITIONED  DEFENSIVE  REFLEXES 
CAUSED  BY  TRIFLUOPERAZINE,  CARBAMAZEPINE  AND 
CHLORPROMAZINE. 

244352  04-04 
A  DOUBLE  BLIND  COMPARISON  OF  LOXITANE:  LOXAPINE  SUCCINATE 
AND  TRIFLUOPERAZINE  HYDROCHLORIDE  IN  CHRONIC  SCHIZOPHRENIC 
PATIENTS, 

245014  04  08 
ABSORPTION,  DISTRIBUTION  AND  EXCRETION  OF  TRIFLUOPERAZINE  IN 
RATS. 

249036  04-03 
TRIFLUOROMETHYl.PHENOXV-N-METHYL-3-PHENYlPROPYLAMINE 
EFFECT  OF  3  P  TRIFLUOROMETHYLPHENOXY-N-METHYL-3- 

PHENYLPROPYLAMINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN  BY  4- 
CHLOROAMPHETAMINE 

246847  04-03 
A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3  P  TRIFLUOROMETHYLPHENOXY  N- 
METHYL-3  PHENYLPROPYLAMINE. 

246848  04  03 
TRIGGERED 

GAMMA-AMINOBUTYRIC-ACID    THE  ESSENTIAL  MEDIATOR  OF 

BEHAVIOUR  TRIGGERED  BY  NEOSTRIATALLY  APPLIED  APOMORPHINE 
AND  HALOPERIDOL 

237786  02-03 
TRIHEXYPHENIDYL 

INTERACTION  OF  TRIHEXYPHENIDYL  AND  CHLORPROMAZINE    PROBABLE 
MECHANISM 

238732  03-03 
IMPAIRED  ABSORPTION  OF  CHLORPROMAZINE  IN  RATS  GIVEN 
TRIHEXYPHENIDYL 

241920  03  03 
TRIIODOTHYRONINE 

NEONATAL  HYPERTHYROIDISM    MATURATIONAL  ACCELERATION  AND 
LEARNING  DEFICIT  IN  TRIIODOTHYRONINE  STIMULATED  RATS. 

228143  01  04 
ELECTROPHYSIOLOGICAL  EFFECTS  OF  TRIIODOTHYRONINE  AND 
PROPRANOLOL 

251984  04-13 
TRIMETHADIONE 

INHIBITION  OF  NEURONAL  SEROTONIN  (5  HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 
TRIMETHOXYAMPHETAMINE 

BEHAVIOR  AND  ENDOCRINE  EFFECTS  OF  3,4,5 
TRIMETHOXYAMPHETAMINE  IN  MALE  MICE. 

251215  04  04 
TRIMIPRAMINE 

A  PROFILE  FOR  TRIMIPRAMINE 

251005  04  10 
TRIOXAZIN 

EFFECT  OF  LONG-LASTING  TRIOXAZIN  ADMINISTRATION  ON  THE 
REACTION  TIME  IN  NORMAL  INDIVIDUALS. 

239992  03  14 
TRIP 

GOOD  TRIP  OR  BAD  TRIP,  THE  ROLES  OF  TOLERANCE  AND  STRESS  IN 
HALLUCINOGENIC  DRUG  ACTION 

234811  0212 
TRIPELENNAMINE 

EFFECTS  OF  IMIPRAMINE,  D  AMPHETAMINE,  AND  TRIPELENNAMINE  ON 
MOUSE  KILLING  AND  FROG  KILLING  BY  THE  RAT 

243346  04  04 


TRIPHOSPHATASE 

EFFECTS  OF  ALDEHYDES  ON  SODIUM  PLUS  POTASSIUM  ION-STIMULATE 
ADENOSINE  TRIPHOSPHATASE  OF  MOUSE  BRAIN, 

237920  02-( 
LIPID  PEROXIDATION  AS  THE  CAUSE  OF  THE  ASCORBIC-ACID  INDUCED 
DECREASE  OF  ADENOSINE  TRIPHOSPHATASE  ACTIVITIES  OF  RAT  BRA 
MICROSOMES  AND  ITS  INHIBITION  BY  BIOGENIC  AMINES  AND 
PSYCHOTROPIC  DRUGS. 

246318  04-1 
TRIPHOSPHATASES 

EVIDENCE  THAT  DIPHENYLHYDANTOIN  DOES  NOT  AFFECT  ADENOSINE 
TRIPHOSPHATASES  FROM  BRAIN. 

239962  03-1 
TRIPHOSPHATE 

CHOLINESTERASE  ACTIVITY  AND  CONTENT  OF  ADENOSINE 

TRIPHOSPHATE  IN  DEPRESSED  PATIENTS  AND  THEIR  CHANGES  UNDEI 
THE  INFLUENCE  OF  MONOCHLORIMIPRAMINE. 

236364  02- 
TRITHIO-P-METHOXYPHENYLPROPENE 

XEROSTOMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 
THEIR  TREATMENT  WITH  TPMP  (TRITHIO  P-METHOXYPHENYLPROPENI 

233718  02- 
TRITIATED 

THE  UPTAKE  OF  TRITIATED  DELTAl -TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VAS  DEFERENS  OF  THE  RAT. 

252200  04- 
TRIUMPH 

LITHIUM       FUTILITY,  DISASTER  AND  TRIUMPH. 

227411  01- 
TROUBLESOME 

PIPAMPERONE  (DIPIPERON.  R-3-345)  IN  TROUBLESOME  MENTAL 

RETARDATES:  A  DOUBLE-BLIND  PLACEBO  CONTROLLED  CROSSOVER 
STUDY  WITH  LONG-TERM  FOLLOW-UP. 

238982  03- 
TROUT 

MEMORY  PERFORMANCE  AFTER  FLUROTHYL  TREATMENT  IN  RAINBOW 
TROUT. 

239852  03-1 
TRP 

STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L 

TRYPTOPHAN  (TRP)  INJECTION  IN  AAALNOURISHED,  CORN-FED  RATS. 

238676  03-1 
TRUTH 

PENTAZOCINE  DEPENDENCE  -  TRUTH  AND  FICTION''. 

246707  04- 
TRYPT  AMINE 

ACTIONS  OF  METHOXAMINE  AND  TRYPTAMINE  AND  THEIR 

INTERACTIONS  WITH  CYPROHEPTADINE  AND  PHENOXYBENZAMINE  0 
CAT  SPINAL  CORD  SEGMENTAL  REFLEXES. 

237752  02-1 
RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP, 
METHOXAMINE  (M)  AND  D  AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-1 
GAS  CHROMATOGRAPHY  MASS  FRAGMENTOGRAPHIC  (GC-MF)  ANALYS 
OF  TRYPTAMINE  IN  BIOLOGICAL  SAMPLES 

238774  03-1 
PRESSOR  EFFECTS  OF  TRYPTAMINE  ANALOGUES. 

243798  04  I 
TRVPTAMINES 

LSD  BINDING  IN  SUBCELLULAR  FRACTIONS  OF  RAT  BRAIN  AND 
INHIBITORY  EFFECTS  OF  RING-SUBSTITUTED  TRYPTAMINES. 

238674  03-1 
TRYPTOUNES 

TRYPTOLINES:  PHARMACOLOGICAL  AND  ENZYMOLOGICAL  STUDIES. 
PH  D    DISSERTATION) 

242002  03-( 
TRYPTOPHAN 

PSYCHOTROPIC  DRUGS  AND  GENDER  AS  MODIFIERS  OF  THE  ROLE  OF 
PLASMA  TRYPTOPHAN  AND  SEROTONIN  IN  SCHIZOPHRENIA. 

225935  01-( 
SERUM  AMINO  ACIDS  AND  BRAIN  TRYPTOPHAN  UPTAKE. 

227712  01-( 
PLASMA  CORTICOIDS  AND  BRAIN  TRYPTOPHAN  AFTER  ACUTE  AND 
TOLERANCE  DOSAGE  OF  LSD 

234311  02-C 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  OF 
TRYPTOPHAN  IN  CHLORPROMAZINE  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  OF  DRUG 
THERAPY. 

235629  02-( 
INHIBITION  OF  RAT  BRAIN  TRYPTOPHAN  HYDROXYLATION  WITH  P- 
CHLOROAMPHETAMINE. 

237242  02-f 
THE  INCREASE  IN  BRAIN  TRYPTOPHAN  CAUSED  BY  AMPHETAMINE  LIKE 
DRUGS:  CORRELATION  WITH  AN  INCREASE  IN  BODY  TEMPERATURE. 

237891  02-C 


S-336 


»/OLUME  14,  SUBJECT  INDEX 


Subject  Index 


MODULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE  (TPH)  ACTIVITY  BY 
BRAIN  TRYPTOPHAN  (TP)  CONTENT.  ^^^^^^  ^^^^ 

LONG-TERM  CONSUMPTION  OF  A  TRYPTOPHAN  POOR  DIET  ALTERS  THE 
BEHAVIORAL  RESPONSE  TO  DRUGS.  23874103-03 

TRYPTOPHAN  REGULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE. 

239581  03-03 

INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602.  239957  03-03 

STUDIES  ON  THE  BEHAVIOURAL  EFFECTS  OF  TRYPTOPHAN  AND  P- 

CHLOROPHENYLALANINE.  239959  03-03 

TRYPTOPHAN  AND  DEPRESSION 

240773  03-09 

NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN,  5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03-04 

TRYPTOPHAN/IMIPRAMINE  IN  DEPRESSION. 

246623  04-09 
EFFECTS  OF  VARIOUS  DRUGS  ON  SERUM  FREE  AND  TOTAL  TRYPTOPHAN 
LEVELS  AND  BRAIN  TRYPTOPHAN  METABOLISM  IN  RATS. 

247013  04-03 
EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM.  CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 

THE  RAT  BRAIN. 

247213  04-03 

CORRELATION  OF  THE  INCREASE  IN  BRAIN  TRYPTOPHAN  PRODUCED  BY 

AMPHETAMINE-LIKE  DRUGS  WITH  AN  INCREASE  IN  BODY 

TEMPERATURE. 

249316  04-03 

THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  04-03 

TRYPTOPHAN-HYDROXYLASE 

REGULATION  OF  FUNCTION  OF  TRYPTOPHAN-HYDROXYLASE. 

233958  02-03 
COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN  HYDROXYLASE  AND 
5  HYDROXYTRYPTAMINE  IN  RAT  BRAIN  NUCLEI 

237863  02-03 
MODULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE  (TPH)  ACTIVITY  BY 

BRAIN  TRYPTOPHAN  (TP)  CONTENT 

238677  03-03 

TRYPTOPHAN-HYDROXYLASE  IN  DISCRETE  NUCLEI:  COMPARISON  OF 
ACTIVITY  IN  VITRO  AND  IN  VIVO. 

238678  03-03 

TRYPTOPHAN  REGULATION  OF  BRAIN  TRYPTOPHAN-HYDROXYLASE. 

239581  03  03 
REDUCTION  OF  TRYPTOPHAN-HYDROXYLASE  ACTIVITY  AND  5- 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE. 

241253  03  03 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN  HYDROXYLASE  INHIBITION. 

241978  03  03 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN-HYDROXYLASE  INHIBITION. 

243848  04-03 
IN  VIVO  AND  IN  VITRO  ACTIVATION  OF  SOLUBLE  TRYPTOPHAN- 
HYDROXYLASE  FROM  RAT  BRAINSTEM. 

249512  04-03 

TURKEY 

CHLORPROMAZINE  AND  HORMONAL  ELEVATION  OF  CYCLIC-AMP 

CONTENTS  IN  TURKEY  ERYTHROCYTES  AND  PERFUSED  RAT  HEART 

AND  LIVER.  „„„ 

239044  03-03 

TURKISH 

INHALATION  TOXICITY  OF  TURKISH  MARIHUANA,  CANNABICHROMENE 
(CBCH)  AND  CANNABIDIOL  (CBD)  IN  RATS. 

238807  03  05 

TURNS 

SEROTONIN:  THE  CRUCIAL  SUBSTANCE  THAT  TURNS  DREAMS  ON  AND 

OFF. 

241505  03  12 

TWO-WAY 

THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO- 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01  04 


TYPICAL 

ANTAGONISM  OF  THE  HYPERACTIVITY  INDUCED  BY  DOPAMINE  APPLIED 
INTRACERE8RALLY  TO  THE  NUCLEUS-ACCUMBENS  SEPTI  BY  TYPICAL 
NEUROLEPTICS  AND  BY  CLOZAPINE,  SULPIRIDE  AND  THIORIDAZINE. 

248290  04-06 

^^""^TRAVENOUS  TYRAMINE  PRESSOR  RESPONSE  IN  DEPRESSION. 

2261 87  01*10 
THE  EFFECT  OF  ADRENALINE,  TYRAMINE  AND  GUANETHIDINE  ON  TWO- 
WAY  AVOIDANCE  CONDITIONING  AND  ON  PSEUDOCONDITIONING. 

227138  01-04 

ACCUMULATION  OF  LABELED  EPHEDRINE,  NOREPHEDRINE, 

AMPHETAMINE  AND  TYRAMINE  IN  PIGMENTED  AND  NONPIGMENTED 
EYES  OF  BLACK  AND  WHITE  RATS.  230450  01-03 

STUDY  ON  HEAD-TWITCHES  INDUCED  BY  INTRACEREBRALLY 

ADMINISTERED  TYRAMINE  IN  ISOCARBOXAZIDE  PRETREATED  MICE. 

241380  03-04 

CHARACTERISTICS  OF  TYROSINE  HYDROXYLATION  IN  ISOLATED  NERVE 
E^D"^GS.  237244  02-03 

PROPERTIES  OF  TYROSINE  HYDROXYLATION  IN  LIVING  MOUSE 

NEUROBLASTOMA  CELLS.  238692  03-03 

NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN    5-HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYDROXYINDOLEACETIC  ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

EFFECTS  OF  DIETHYiDITHIOCARBAMATE  ON  THE  CATABOLISM  OF 

TYROSINE  IN  THE  RAT  BRAIN.  241249  03-05 

TYROSINE-HYDROXYLASE 

THE  REGULATION  OF  THE  KINETIC  STATE  OF  STRIATAL  TYROSINE- 
HYDROXYLASE  AND  THE  ROLE  OF  POSTSYNAPTIC  DOPAMINE 
-RECEPTORS.  226185  01-04 

TYROSINE  HYDROXYLASE:  ALLOSTERIC  ACTIVATION  INDUCED  BY 
STIMULATION  OF  CENTRAL  NORADRENERGIC  NEURONS. 

226856  01  -03 

INCREASED  TYROSINE-HYDROXYLASE  ACTIVITY  IN  FRONTAL  CORTEX 
AND  CEREBELLUM  AFTER  RESERPINE. 

TYROSINE-HYDROXYLASE  ACTIVITY  IN  RAT  BRAIN  REGIONS  AFTER 
CHRONIC  TREATMENT  WITH  PLUS/MINUS  PROPRANOLOL. 

230853  01-03 

EFFECTS  OF  5  6  DIHYDROXYTRYPTAMINE  ON  TYROSINE-HYDROXYLASE 
ACTIVITY  IN  CENTRAL  CATECHOLAMINERGIC  NEURONS  OF  THE  RAT. 

232624  02-03 

EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINE-BETA-HYDROXYLASE  ON  RAT  SELF  STIMULATION  AFTER 
RESERPINE  TREATMENT.  237103  02-04 

INCREASE  OF  TYROSINE-HYDROXYLASE  ACTIVITY  AFTER  RESERPINE. 
EVIDENCE  FOR  THE  SELECTIVE  RESPONSE  OF  NORADRENERGIC 

^^•^^O^S  237881  02-03 

EFFECTS  OF  METHAMPHETAMINE  AND  CHLORPROMAZINE  ON  NIGRAL 
AND  STRIATAL  TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL 
DOPAMINE  LEVELS   (PHD    DISSERTATION).  238079  02  03 

EFFECT  OF  METHAMPHETAMINE  AND  NEUROLEPTIC  AGENTS  ON  THE 
KINETIC  PROPERTIES  OF  STRIATAL  TYROSINE-HYDROXYLASE. 

238693  03-03 

THE  REVERSAL  OF  APOMORPHINE-ELICITED  INHIBITION  OF 
SYNAPTOSOMAL  TYROSINE  HYDROXYLASE  ACTIVITY  BY 

^^^J^"^^^^'"  238758  03-03 

6  HYDROXYDOPAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE  HYDROXYLASE 
(TH)   CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC  ACID 
DECARBOXYLASE  (GAD)  IN  THE  CNS 

238826  03-03 
INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  THE  SUPERIOR  CERVICAL 
GANGLIA  OF  RATS   OPPOSITE  INFLUENCE  OF  MUSCARINIC  AND 
NICOTINIC  RECEPTOR  AGONISTS  ^^^^^^  ^^^^ 

DOPAMINERGIC  NEURONS  -  ALTERATION  IN  THE  SENSITIVITY  OF 

TYROSINE-HYDROXYLASE  TO  INHIBITION  BY  ENDOGENOUS  DOPAMINE 
AFTER  CESSATION  OF  IMPULSE  FLOW 

241295  03  03 
DOPAMINERGIC  NEURONS    -  ALTERATION  IN  THE  KINETIC  PROPERTIES  OF 

TYROSINE  HYDROXYIASE  AFTER  CESSATION  OF  IMPULSE  FLOW 

241296  03-03 
REGULATION  OF  ADRENAL  TYROSINE  HYDROXYLASE  ACTIVITY: 

NEURONAL  VERSUS  LOCAL  CONTROL  STUDIED  WITH  APOMORPHINE. 

2443  M  04  03 


S-337 


Subject  Index 


.3 
•5! 


Sf 


31 


fffECTS  OF  RESERPINE  ON  ACTIVITIES  AND  AMOUNTS  OF  TYROSINE- 
HYDROXYLASE  AND  DOPAMINE  BETA-HYDROXYLASE  IN 
CATECHOLAMINE  NEURONAL  SYSTEMS  IN  RAT  BRAIN. 

246845  04-03 

THE  EFFECT  OF  VARIOUS  CHLORPROMAZINE  DERIVATIVES  ON  THE 
APOMORPHINE-ELICITED  INHIBITION  OF  SYNAPTOSOMAL  TYROSINE- 
HYDROXYLASE  ACTIVITY. 

247212  04-03 
POSTNATAL  ELEVATION  OF  BRAIN  TYROSINE-HYDROXYLASE  ACTIVITY 
WITHOUT  CONCURRENT  INCREASES  IN  STEADY  STATE 
CATECHOLAMINE  LEVELS,  RESULTING  FROM  DL-ALPHA-METHYL  P- 
TYROSINE  ADMINISTRATION  DURING  EMBRYONIC  DEVELOPMENT 
,,,,   ^  248697  04-03 

EFFECT  OF  THIORIDAZINE,  CLOZAPINE  AND  OTHER  ANTIPSYCHOTICS  ON 
THE  KINETIC  STATE  OF  TYROSINE  HYDROXYLASE  AND  ON  THE 
TURNOVER  RATE  OF  DOPAMINE  IN  STRIATUM  AND  NUCLEUS- 
ACCUMBENS. 

248698  04-05 
EFFECTS  OF  VARIOUS  INHIBITORS  OF  TYROSINE-HYDROXYLASE  AND 
DOPAMINEBETA-HYDROXYLASE  ON  RAT  SELF-STIMULATION  AFTER 
RESERPINE  TREATMENT 

^      „  248964  04-04 

TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  FOREBRAIN  DURING 

NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 

RATS. 

249291  04-03 
MECHANISMS  OF  TRANS  SYNAPTIC  INDUCTION  OF  TYROSINE- 
HYDROXYLASE  (TH)  AND  DOPAMINE  BETA  HYDROXYLASE  (DBH)  IN 
ORGAN  CULTURES  OF  RAT  SYMPATHETIC  GANGLIA   ROLE  OF 
DEPOLARIZATION  OF  THE  POSTSYNAPTIC  MEMBRANE. 
,    ^  251393  04-03 

LACK  OF  CORRELATION  BETWEEN  CHANGES  IN  CYCLIC  NUCLEOTIDES 
AND  SUBSEQUENT  INDUCTION  OF  TYROSINE-HYDROXYLASE  IN  RAT 
ADRENAL  MEDULLA. 

251434  04-03 
INFLUENCE  OF  METHAMPHETAMINE  ON  NIGRAL  AND  STRIATAL 
TYROSINE-HYDROXYLASE  ACTIVITY  AND  ON  STRIATAL  DOPAMINE 

252027  04-03 
TYROS(NE-3-MONOOXYGENASE 

CAMP  CONTENT  AND  THE  REGULATION  OF  TYROSINE-3- 

MONOOXYGENASE  IN  RAT  STRIATUM.  (UNPUBLISHED  PAPER). 

232921  02-03 

ACTIVATION  AND  NUCLEAR  TRANSLOCATION  OF  HISTONE  KINASE 
DURING  THE  TRANSSYNAPTIC  INDUCTION  OF  TYROSINE-3- 
MONOOXYGENASE.  (UNPUBLISHED  PAPER). 

237172  02-03 
U-28774 

DOUBLE  BLIND  PLACEBO  CONTROLLED  EFFICACY  STUDY  OF  KETAZOLAM 

(U-28774), 

248532  04-10 
UBRETIO 

THERAPY  OF  PSYCHOPHARMACEUTICAL  SIDE  EFFECTS  WITH 
DISTIGMINBROMIDE  (UBRETID,  BC  51) 

239782  03  15 
DCS 

FORMATION  AND  RETENTION  OF  CONDITIONED  TASTE  AVERSIONS  AND 

UCS  HABITUATION 

241521  03-04 
DRUG  INDUCED  CONDITIONED  SUPPRESSION:  SPECIFICITY  DUE  TO  DRUG 

EMPLOYED  AS  UCS. 

242750  04-04 
ULCER 

THE  EFFECTS  OF  METIAMIDE  ON  THE  ACTIVITY  STRESS  ULCER  IN  RATS. 

230835  01-03 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03  03 
UlTRASENSITIVE 

ULTRASENSITIVE  CHEMOSENSORY  RESPONSES  BY  A  PROTOZOAN  TO 
EPINEPHRINE  AND  OTHER  NEUROCHEMICALS 

248163  0402 
UlTRASTRUCTURAl 

ULTRASTRUCTURAL  CHANGES  IN  THE  NEURAL  LOBE  OF  THE  RAT 

PITUITARY  INDUCED  BY  RESERPINE  TREATMENT 

235649  02  03 
LIPIDOSIS-LIKE  ULTRASTRUCTURAL  ALTERATIONS  IN  RAT  LYMPH  NODES 

AFTER  TREATMENT  WITH  TRICYCLIC  ANTIDEPRESSANTS  OR 

NEUROLEPTICS. 

237153  0205 
UNCOMMON 

SUIDICAL  INGESTION  OF  ISONIAZID   AN  UNCOMMON  CAUSE  OF 
METABOLIC  ACIDOSIS  AND  SEIZURES. 

237813  02-15 
UNCONDITIONED 

CONDITIONED  AND  UNCONDITIONED  DRUG  EFFECTS  IN  A  CLASSICAL 
CONDITIONING  PARADIGM 

238787  03  04 


Psychopharmacology  Abstracts 

UNCONTROLLED 

BENZOCTAMINE  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 
CLINICAL  STUDY. 

235356  02-07 
ETAFENOXIN  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 

CLINICAL  STUDY. 
,„„    ,^  235357  02  07 

LORAZEPAM  IN  THE  TREATMENT  OF  NEUROSIS   -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235358  02-07 
TRAZODONE  IN  THE  TREATMENT  OF  NEUROSIS  -  AN  UNCONTROLLED 

CLINICAL  STUDY. 

235359  02-07 
SYSTEAMTIC  CLINICAL  STUDIES  WITH  CLOMIPRAMINE  IN  DEPRESSED 

PSYCHIATRIC  PATIENTS  -  I.  REPORT  ON  AN  UNCONTROLLED  CLINICAL 
TRIAL. 

235360  02  07 


TRAZODONE:  CLINICAL  AND  BIOCHEMICAL  STUDIES:  I.  AN 
UNCONTROLLED  CLINICAL  TRIAL  IN  DEPRESSION. 

AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 

AN  UNCONTROLLED  CLINICAL  TRIAL  OF  TRAZODONE. 


235369  02-07 
253054  04  II 


253055  04-11 
A  COMPARISON  OF  TWO  UNCONTROLLED  CLINICAL  TRIALS  OF 

TRAZODONE. 

253056  04  I  I 
UNDERACHIEVING 

EFFECTS  OF  METHYLPHENIDATE  ON  UNDERACHIEVING  CHILDREN. 

240538  03-11 
UNDERSTANDING 

COMPUTERIZED  ELECTROENCEPHALOGRAM:  A  MODEL  OF 

UNDERSTANDING  THE  BRAIN  FUNCTION  IN  CHILDHOOD  PSYCHOSIS 
AND  ITS  TREATMENT 

232635  02-11 
CONDITIONED  AVERSION  BY  PSYCHOACTIVE  DRUGS-  DOES  IT  HAVE 
SIGNIFICANCE  FOR  AN  UNDERSTANDING  OF  DRUG  DEPENDENCE 

233488  02-14 
THE  DYSTONIC  HYPERKINETIC  SYNDROME:  A  CASUISTICAL 

CONTRIBUTION  TO  THE  UNDERSTANDING  OF  THE  ACTIONS  OF  DRUGS 
IN  CHILDREN. 

233717  02-11 
EXCITATION  MEDIATING  AND  INHIBITION  MEDIATING  DOPAMINE 
RECEPTORS:  A  NEW  CONCEPT  TOWARDS  A  BETTER  UNDERSTANDING 
OF  ELECTROPHYSIOLOGICAL,  BIOCHEMICAL,  PHARMACOLOGICAL 
FUNCTIONAL  AND  CLINICAL  DATA. 

237104  02  03 
ON  PSYCHOPHARMACEUTICAL  RESEARCH  AND  THE  UNDERSTANDING  OF 
SCHIZOPHRENIA. 

244037  04  17 
UNILATERAL 

ATTENUATION  OF  AMPHETAMINE  ANOREXIA  BY  UNILATERAL  NIGRAL 
STRIATAL  LESIONS. 

237777  02  03 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-03 
THE  EFFECTS  OF  UNILATERAL  LOCUS-COERULEUS  LESIONS  ON 

HYPOTHALAMIC  INTRACRANIAL  SELF  STIMULATION  AND  SLEEP  IN  THE 
RAT   (PH  D.  DISSERTATION). 

241678  03-03 
CIRCLING  BEHAVIOUR  PRODUCED  BY  UNILATERAL  LESIONS  IN  THE 
REGION  OF  THE  LOCUS-COERULEUS  IN  RATS. 

249076  04  04 
BILATERAL  ELECTROENCEPHALOGRAPHIC  RESPONSE  AND  UNILATERAL 
TOLERANCE  TO  UNILATERAL  INTRACEREBRAL  MORPHINE  INJECTIONS 

249484  04  (1 
INHIBITION  OF  TURNING  BEHAVIOUR  BY  CLOZAPINE  IN  MICE  WITH 
UNILATERAL  DESTRUCTION  OF  DOPAMINERGIC  NERVE  TERMINALS. 

249629  04-04 
INHIBITION  OF  CIRCLING  BEHAVIOR  3Y  NEUROLEPTIC  DRUGS  IN  MICE 
WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM 

249679  04-04 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AFTER  UNILATERAL  INACTIVATION  OF  THE  STRIATUM 
IN  RATS 

251402  04-04 
UNILATERALLY 

CYCLIC  AMP  AS  A  POSSIBLE  MEDIATOR  IN  DOPAMINERGIC 

STIMULATION-INDUCED  ROTATIONAL  BEHAVIOR  OF  RATS  LESIONED 
UNILATERALLY  IN  SUBSTANTIA-NIGRA. 

241382  03-04 
UNIPOLAR 

LITHIUM  CARBONATE  IN  AFFECTIVE  DISORDERS:  IV.  A  DOUBLE-BLIND 
STUDY  OF  PROPHYLAXIS  IN  UNIPOLAR  RECURRENT  DEPRESSION. 

234203  02-09 


S-338 


HUME  14,  SUBJECT  INDEX 

TREATMENT  OF  UNIPOLAR  DEPRESSION.  ^^^^^  ^^^^ 

LITHIUM  CARBONATE  RESPONSE  IN  DEPRESSION:  PREDICTION  BY 

UNIPOLAR/BIPOLAR  ILLNESS,  AVERAGE  EVOKED  RESPONSE,  CATECHOL 
0  METHYLTRANSFERASE,  AND  FAMILY  HISTORY. 

246o2V  U4-UV 

EFFECTS  OF  INTRACEREBROVENTRICULAR  L  DOPA  ON  CAUDATE  UNIT 
™^^^  238716  03-03 

HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS 

239679  03-17 

HIGHER  UNIT  DOSAGE  OF  PSYCHOTROPIC  DRUGS. 

239680  03-17 
OBSTACLES  IN  IMPLEMENTATION  OF  HIGHER  UNIT  DOSAGE  OF 

PSYCHOTROPICS  DRUGS  23968,03  17 

EFFECTS  OF  MORPHINE  ON  SINGLE  UNIT  ACTIVITY  OF  NEURONS  IN  THE 

NUCLEUS  RAPHE  DORSALIS.  249249  04-03 

EFt^ECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 

COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 

TOOTH  PULP  STIMULATION 

251070  04  03 

OUTPATIENT  PHENOTHIAZINE  USE  AND  BONE  MARROW  DEPRESSION:  A 
REPORT  FROM  THE  DRUG  EPIDEMIOLOGY  UNIT  AND  THE  BOSTON 
COLLABORATIVE  DRUG  SURVEILLANCE  PROGRAM. 

253661  04-15 

NITARY 

LOOKING  AT  SCHIZOPHRENIA  FROM  A  UNITARY  POINT  OF  VIEW. 

236348  02-17 

NITEO-KINGOOM 

MODERN  VIEWS  ON  DIAGNOSIS  AND  CLASSIFICATION  OF  DEPRESSIONS: 

II    UNITED-KINGDOM. 

227205  01-09 

NITS 

EFFECTS  OF  INSULIN  INJECTION  ON  RESPONSES  OF  OLFACTORY  BULB 
AND  AMYGDALA  SINGLE  UNITS  TO  ODORS. 

232905  0203 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBITORY  INTERACTION. 

238823  03  03 
EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ. 

241798  03-03 

INIIMITEO 

SELF  ADMINISTRATION  OF  PSYCHOMOTOR  STIMULANT  DRUGS:  THE 
EFFECTS  OF  UNLIMITED  ACCESS. 

250066  04  04 

JNPUNISHED 

EFFECTS  OF  BENZODIAZEPINE  ANTIANXIETY  AGENTS  ON  PUNISHED 
(CONFLICT)  AND  UNPUNISHED  BEHAVIOR  IN  DRUG-NAIVE  RATS. 

238697  03  04 

UNRELATED 

SOME  PHARMACOLOGICAL  EFFECTS  OF  P  CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN-HYDROXYLASE  INHIBITION 

241978  03-03 
SOME  PHARMACOLOGICAL  EFFECTS  OF  P-CHLOROPHENYLALANINE 
UNRELATED  TO  TRYPTOPHAN  HYDROXYLASE  INHIBITION. 

243848  04-03 

JNSTIMULATED 

THE  EFFFCT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

SlIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04  17 

UNTOWARD 

A  PRACTICAL  ClASSIFICATION  OF  UNTOWARD  DRUG  EFFECTS. 

248909  04  1  5 

UNTRAINED 

(FFFCTS  OF  ANTIANXIETY  DRUGS  ON  FOOD  INTAKE  IN  TRAINED  AND 

UNTRAINED  RATS  AND  MICE 

249678  04-04 

UNWANTED 

UNWANTED  EFFECTS  OF  MINOR  TRANQUILIZERS  AND  HYPNOTICS. 

231992  01-15 
UNWANTED  CORTICOSTEROID  EFFECTS  IN  CHILDHOOD  BONE  MARROW 
FAILURE    RENAL  FAILURE  AND  BRAIN  DAMAGE    CASE  REPORT. 

245856  04  13 

UPDATE 

AN  UPDATE  OF  MEGAVITAMIN  THERAPY  IN  ORTHOMOLECULAR 

PSYCHIATRY 

235678  02-17 

TOXICOLOGY  UPDATE  OF  THE  ARKANSAS  POISON  CONTROL  DRUG- 
INFORMAIION  CENTER    THE  TRICYCLIC  ANTIDEPRESSANTS. 

245822  04  13 


Subject  Index 

HIGH  AFFINITY  CHOLINt  UPTAKE:  AN  EARLY  INDEX  OF  CHOLINERGIC 
INNERVATION  IN  RAT  BRAIN.  ^^^^^^  ^^^^ 

INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY-1 10140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L-DOPA^ 

226765  01  03 

5-HYDROXYTRYPTAMINE- 14C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMAAA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR  226827  01-03 

THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5  HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA  227139  01-03 

SERUM  AMINO-ACIDS  AND  BRAIN  TRYPTOPHAN  UPTAKE.     ^^^^^^^^  ^^ 

CHEMISTRY  AND  PHARMACOLOGY  OF  BIOGENIC  AMINE  UPTAKE. 

229478  01-03 
EFFECT  OF  PSYCHOTROPIC  DRUGS  ON  (H3)  GAMMA-AMINOBUTYRIC- 
ACID  UPTAKE  BY  SYNAPTOSOMES  OF  THE  RAT  BRAIN.       ^^^^^^  ^^^^ 

MECHANISM  OF  ACTION  OF  ANTICONVULSANTS:  ROLE  OF  THE 
DIFFERENTIAL  EFFECTS  ON  THE  ACTIVE  UPTAKE  OF  PUTATIVE 
NEUROTRANSMITTERS.  237140  02-03 

EFFECT  OF  ANGIOTENSIN-II  AND  ITS  ANALOGS  ON  UPTAKE  AND  RELEASE 
OF  C14-5-HYDROXYTRYPTAMINE  BY  RAT  BRAIN 

2.  S 1 1  Jit   Ut'UO 

BARBITURATES  BLOCK  CALCIUM  UPTAKE  BY  STIMULATED  AND 
POTASSIUM  DEPOLARIZED  RAT  SYMPATHETIC  GANGLIA. 

2.-J  1 1  u  \    \j/.'\j-j 

EFFECT  OF  MONOAMINE-OXIDASE  INHIBITORS  ON  RELEASE  AND  UPTAKE 
OF  H3-N0REPINEPHRINE  IN  RAT  CEREBRAL  CORTEX  IN  VITRO. 

238689  03-03 

ALTERATIONS  IN  CA45  UPTAKE  AND  EFFLUX  IN  RAT  CORTEX.  STRIATUM 
AND  HYPOTHALAMUS  SLICES.  238714  03-03 

TAURINE    A  SODIUM  DEPENDENT  HIGH  AFFINITY  UPTAKE  SYSTEM  INTO 
SYNAPTOSOMES  OF  RAT  BRAIN.  238715  03-03 

CONFORMATIONAL  REQUIREMENTS  FOR  BIOCKING  UPTAKE  OF 
CATECHOLAMINES  AND  SEROTONIN  INTO  CRUDE  RAT  BRAIN 
SYNAPTOSOMES,  238738  03-01 

INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-03 

THE  EFFECT  OF  DELTA9-THC  ON  HIGH  AND  LOW  AFFINITY  UPTAKE  OF 
CHOLINE  AND  ITS  RELATIONSHIP  TO  TURNOVER  OF  ACETYLCHOLINE  IN 
MOUSE  BRAIN 

238765  03-03 

NISOXETINE  (LILLY-94939)  SELECTIVELY  BLOCKS  THE  UPTAKE  OF 
NOREPINEPHRINE  IN  VITRO  AND  IN  VIVO  IN  RAT  BRAIN. 

238840  03-03 
EXTRANEURONAL  UPTAKE  AND  METABOLISM  OF  (3H)L-N0REPINEPHRINE 

BY  THE  RAT  DUODENAL  MUCOSA. 

241299  03-03 

EFFECTS  OF  THE  D  ISOMERS  AND  L  ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE    RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE,  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN 

241345  03-03 
SPONTANEOUS  AND  GUANETHIDINE  INDUCED  CHANGES  OF  REGIONAL 
MONOAMINE  CONTENT  AND  MONOAMINE  UPTAKE  DURING 
POSTNATAL  DEVELOPMENT  OF  THE  RAT  BRAIN. 

241366  03-03 
AITERATIONS  IN  DOPAMINE  UPTAKE  IN  RAT  CORPUS  STRIATUM 
INDUCED  BY  C0MB:NATI0NS  OF  STRESS  AND  DELTA8- 
TETRAHYDROCANNABINOL  (DELTAS  THC). 

241926  03-03 
THE  EFFECTS  OF  TANDAMINE,  A  NEW  POTENTIAL  ANTIDEPRESSANT 
AGENT,  ON  BIOGENIC  AMINE  UPTAKE  MECHANISMS  AND  RELATED 

ACTIVITIES.  „    „^ 

244316  04-02 

EFFECTS  OF  TANDAMINE  AND  PIRANDAMINE.  NEW  POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5  HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES. 

244678  04-03 

NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 

PROPERTIES  „    „^ 

245296  04-03 

A  NEW  SELECTIVE  INHIBITOR  FOR  UPTAKE  OF  SEROTONIN  INTO 

SYNAPTOSOMES  OF  RAT  BRAIN:  3-P  TRIFLUOROMETHYLPHENOXY-N- 
METHYL-3  PHENYLPROPYLAMINE 

246848  04-03 

ANTIDEPRESSANT  DRUGS  AFFECT  DOPAMINE  UPTAKE. 

247021  04-03 


S-339 


=4: 


% 


I 

s 

2 


Subject  Index 

SYNAPTOSOMAL  UPTAKE  AND  LEVELS  OE  SEROTONIN  IN  RAT  BRAIN 
AREAS  AFTER  P-CHLOROAMPHETAAAINE  OR  B-9  LESIONS. 

248414  04-05 

AMPHETAMINE:  EVALUATION  OF  D-ISOMERS  AND  L  ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 

248699  04-03 
CANNABINOIDS:  INFLUENCE  ON  NEUROTRANSMITTER  UPTAKE  IN  RAT 
BRAIN  SYNAPTOSOMES 

248701  04-03 
ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04-03 
THE  UPTAKE  OF  35S  BY  HYPOTHALAMIC  AND  NEUROHYPOPHYSIAL 
PROTEINS  FOLLOWING  INTRAVENTRICULAR  INJECTION  OF  L-CYSTEINE- 
35S-HYDROCHLORIDE  IN  RATS  DEHYDRATED  AND  RESERPINIZED. 
■,.  r  ^r,  248952  04-03 

THE  CONTRIBUTION  OF  NEURONAL  UPTAKE  BLOCKADE  TO  THE 
ANTIEPILEPTIC  ACTION  OF  CARBAMAZEPINE  (TEGRETOL). 

249242  04-03 
EFFECT  OF  LABELLED  ACETYLCHOLINE  (ACCH)  UPTAKE  BY  RAT  BRAIN 
SLICES  ON  ENDOGENOUS  LEVELS  OF  ACCH  AND  CHOLINE  (CH). 

249298  04-03 
SODIUM  DEPENDENT  HIGH  AFFINITY  CHOLINE  UPTAKE  AS  A 
REGULATORY  STEP  IN  ACETYLCHOLINE  SYNTHESIS. 

EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA)    POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  04-03 
COMPARISON  OF  THE  MONOMETHOXYAMPHETAMINES  ON  THE  UPTAKE 

AND  RELEASE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

249315  04-03 
DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 

TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5- 

HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 
„.    ^  249667  04-03 

ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 

THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 

UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

249930  04-03 
EFFECTS  OF  SEROTONIN  UPTAKE  INHIBITOR,  LILLY-1 10140   ON 

TRANSPORT  OF  SEROTONIN  IN  RAT  AND  HUMAN  BLOOD  PLATELETS. 

250380  04-03 
EFFECT  OF  OXOTREMORINE  ON  ENDOGENOUS  ACETYLCHOLINE  AND  ON 

UPTAKE  AND  BIOTRANSFORMATION  OF  RADIOACTIVE  CHOLINE  IN 

DISCRETE  REGIONS  OF  MOUSE  BRAIN  IN  VIVO. 

251175  04-03 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS. 

.r^.rr.  251392  0403 

CONFORMATIONALLY  RIGID  AMPHETAMINE  ANALOGS  AS  INHIBITORS  OF 

MONOAMINE  UPTAKE  BY  BRAIN  SYNAPTOSOMES. 

251700  04-03 
UPTAKE  AND  RELEASE  OF  NOREPINEPHRINE  BY  SLICES  OF  RAT  CEREBRAL 

CORTEX:  EFFECTS  OF  AGENTS  WHICH  INCREASE  CYCLIC  AMP  LEVELS. 
,^,^  251964  04-03 

EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 

UPTAKE  OF  3H-5  HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 

SLICES 

252023  04-03 
THE  UPTAKE  OF  TRITIATED  DELTAl-TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VAS-DEFERENS  OF  THE  RAT. 

252200  04-03 
EFFECTS  OF  LILLY-1 10140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN-INDUCED  ANOREXIA    EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04-03 
COMPARATIVE  ACTIONS  OF  MONOMETHOXYAMPHETAMINES  ON  THE 
RELEASE  AND  UPTAKE  OF  BIOGENIC  AMINES  IN  BRAIN  TISSUE. 

253107  04-03 
THE  UPTAKE  OF  LOW  CONCENTRATIONS  OF  LITHIUM  IONS  INTO  RAT 
CEREBRAL  CORTEX  SLICES  AND  ITS  DEPENDENCE  ON  CATIONS. 

253411  04-03 
URGENT 

URGENT  PHARMACOTHERAPY  FOR  DRUG  ABUSE. 

251755  04-17 
URINARY 

EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES. 

227212  01-07 
COMPARISON  OF  SERUM  LEVELS  AND  URINARY  EXCRETION  OF  THREE 
MAJOR  ANTICONVULSANTS  BETWEEN  CHILDREN  AND  ADULTS. 

233832  02-13 


Psychopharmacology  Abstracts 


EFFECTS  OF  CHLORPROMAZINE  ON  FEAR  MOTIVATED  BEHAVIOR 
URINARY  CORTISOL,  URINARY  VOLUME,  AND  HEARTRATE  IN  THE 
DOG. 

240916  03-04 
URINARY  EXCRETION  OF  METABOLITES  OF  CHLORPROMAZINE-  CLINICO- 
CHEMICAL  CORRELATIONS 

^,,,  ,,  244050  04-08 

THE  EFFECT  OF  LITHIUM  ON  UNSTIMULATED  AND  GLUCAGON 

STIMULATED  URINARY  CYCLIC  AMP  EXCRETION  IN  RAT  AND  MAN. 

251129  04  17 
URINE 

QUANTITATIVE  DETERMINATION  OF  THIORIDAZINE  AND 

NONCONJUGATED  THIORIDAZINE  METABOLITES  IN  SERUM  AND  URINE 
OF  PSYCHIATRIC  PATIENTS. 

237902  02-13 
GLC  IDENTIFICATION  AND  DETERMINATION  OF  3,4 

METHYLENEDIOXYAMPHETAMINE  (MDA)  FROM  PLASAAA  AND  URINE. 

238484  02-06 
URINES 

NATURE  OF  NEW  CLASS  OF  CHLORPROAAAZINE  (CPZ)  METABOLITES  IN 
PRIAAATE  URINES. 

249328  04-01 
USAGE 

THE  MEDICAL  SAFETY  OF  THE  COMBINED  USAGE  OF  DISULFIRAM  AND 
METHADONE:  PHARMACOLOGICAL  TREATMENT  FOR  ALCOHOLIC 
HEROIN  ADDICTS. 

239943  03-15 
THIRD  PSYCHOACTIVE  DRUG  USAGE  GUIDE. 

247880  04-17 
THE  EFFECT  OF  CHRONIC  MARIHUANA  USAGE  ON  THE  IMMUNOLOGICAL 
STATUS  OF  RHESUS  MONKEYS. 

249003  04-05 
COMPARATIVE  ANALYSIS  OF  PERSISTENT  DYSKINESIAS  OF  LONG-TERM 
USAGE  WITH  NEUROLEPTICS  IN  FRANCE  AND  IN  JAPAN. 

252181  04  17 
USERS 

BRAIN  DYSFUNCTION  IN  CHRONIC  SEDATIVE  USERS. 

226922  01-15 
DIVIDED  ATTENTION  PERFORMANCE  OF  CANNABIS  USERS  AND 
NONUSERS  FOLLOWING  CANNABIS  AND  ALCOHOL. 

246305  04- 13 
UTERI 

EFFECT  OF  ESTROGEN  TREATMENT  ON  ESTRADIOL  BINDING  CAPACITY  IN 
UTERI  OF  AGING  RATS. 

247588  04-03 
UTERINE 

EFFECT  OF  CANNABIS  EXTRACT  ON  THE  UTERINE  MONOAMINE  OXIDASE 
ACTIVITY  OF  NORMAL  AND  ESTRADIOL  TREATED  RATS. 

241343  03-03 
UTEROTROPHIC 

UTEROTROPHIC  EFFECT  OF  DELTA9-TETRAHYDR0CANNABIN0L  IN 
OVARIECTOMIZED  RATS. 

243865  04-03 
UTIU2ATION 

UTILIZATION  OF  CELLULAR  STUDIES  OF  NEUROTRANSMITTER  RELATED 
ENZYMES  AND  TRANSPORT  PROCESSES  IN  MAN  FOR  THE 
INVESTIGATION  OF  BIOLOGICAL  FACTORS  IN  BEHAVIORAL  DISORDERS 
(UNPUBLISHED  PAPER). 

226731  01  13 

UTILIZATION  OF  PIRACETAM  (NOOTROPIL)  IN  ELDERLY  WITH 
NEURASTHENIC  STATES. 

236794  02  11 

NORADRENALINE  SYNTHESIS  AND  UTILIZATION:  CONTROL  BY  NERVE 
IMPULSE  FLOW  UNDER  NORMAL  CONDITIONS  AND  AFTER  TREATMENT 
WITH  ALPHA  ADRENORECEPTOR  BLOCKING  AGENTS. 

251227  04-02 
UTILIZING 

DRUG  EFFECTS  ON  LEARNING:  A  TWO  STAGE  DRUG  SCREEN  UTILIZING 
FIXED-RATIO  AND  SERIAL  DISCRIMINATION  REVERSAL  LEARNING 
(PH.D.  DISSERTATION). 

239533  03-04 
VAGINAL 

ANALGESIC  EFFECT  OF  VAGINAL  STIMULATION  IN  RATS:  MODULATION 
BY  CATECHOLAMINES  AND  STEROIDS. 

238822  03-03 
VAUUM 

DO  YOU  TAKE  VALIUM^ 

230027  01-15 
INFLUENCE  OF  DIAZEPAM  (VALIUM)  ON  HUMAN  LEARNING  AND 
MEMORY  PROCESSES. 

238711  03-14 
VALPROATE 

SODIUM  VALPROATE  IN  THE  TREATMENT  OF  INTRACTABLE  CHILDHOOD 
EPILEPSY 

245344  04-11 
VALUATION 

AN  INTEGRATED  APPROACH  FOR  THE  VALUATION  OF  PSYCHOTROPIC 
DRUG  IN  MAN:  I    STUDIES  ON  AMPHETAMINE.  RELATIONSHIP 


I 


S-340 


fOLUME  14,  SUBJECT  INDEX 


Subject  Index 


BETWEEN  DRUG  LEVELS  AND  PSYCHOPHYSIOLOGICAL 
MEASUREMENTS.  241234  03-13 

'*^  AN  ELECTROENCEPHALOGRAPHIC  STUDY  OF  THE  VALUE  OF  ACTIVATION 
BY  MEGIMID  IN  PSYCHIATRIC  DISEASES.  229115  01-13 

VALUE  OF  REM  SLEEP,  239258  03-14 

VALUE  AND  ADVANTAGES  OF  ORAP  IN  OUTPATIENT  TREATMENT  OF 
SCHIZOPHRENIC  PSYCHOSES 

244188  04-08 

A  CRITIQUE  OF  OBSTETRICAL  PAIN  RELIEVING  DRUGS  AS  PREDICTORS  OF 
INFANT  BEHAVIOR  VARIABILITY, 

250175  04-15 

/ARIABLE-INTERVAL  ^,„„., 

RATE  DEPENDENT  EFFECTS  OF  DRUGS  ON  THE  VARIABLE-INTERVAL 

BEHAVIOR  OF  RATS, 

226854  01-04 

CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE  INTERVAL  PROCEDURES, 

240015  03-04 

i/ARlABLES 

CENTRAL  EFFECTS  OF  SCOPOLAMINE  AND  (  t  )  AMPHETAMINE  ON 

LOCOMOTOR  ACTIVITY:  INTERACTION  WITH  STRAIN  AND  STRESS 

VARIABLES, 

237778  02-04 

PHARMACOLOGICAL  AND  ENVIRONMENTAL  VARIABLES  AFFECTING 
DRUG  PREFERENCE  IN  RHESUS  MONKEYS, 

240013  03-04 

SERUM  LITHIUM  CURVE  AND  CLINICAL  PSYCHOMETRIC  VARIABLES: 
PRELIMINARY  EXPERIMENTS, 

244591  04-13 

LOGICAL  ANALYSIS  OF  THE  RESPECTIVE  INFLUENCE  OF  THREE 

EXPERIMENTAL  VARIABLES  BY  MEANS  OF  A  DIAGRAM  OF  L,  CARROLL, 
APPLICATION  OF  THIS  METHOD  TO  A  CLINICAL  TRIAL  OF  TWO  FORMS 

OF  NOVERIL, 

245971  04-06 

ETHANOL  NARCOSIS  IN  MICE:  EFFECTS  OF  L-DOPA,  ITS  METABOLITES 
AND  OTHER  EXPERIMENTAL  VARIABLES, 

246821  04-05 

VARIANCE 

ANALYSIS  OF  VARIANCE  STUDY  OF  A  SLEEP  INDUCING  DRUG, 

233698  02-07 

VARIANTS 

ON  ONE  OF  THE  VARIANTS  OF  SIMPLE  SCHIZOPHRENIA  IN  THE  LIGHT  OF 
PSYCHOPHARMACOTHERAPY. 

236725  02-08 

VARIATION 

CHLORPROMAZINE  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN, 

230863  01-14 
PERMETHYLATION  OF  BARBITURATES:  VARIATION  IN  PRODUCT  RATIOS 
WITH  VARYING  METHYLSULFINYLMETHIDE  CARBANION. 

238488  02-01 
DIURNAL  VARIATION  IN  THE  REQUIREMENT  FOR  RNA  SYNTHESIS  IN  THE 
INDUCTION  OF  PINEAL  N  ACETYLTRANSFERASE, 

243795  04-03 

VARIATIONS 

CONCURRENT  SCHEDULES  OF  COCAINE  INJECTION  IN  RHESUS  MONKEYS: 
DOSE  VARIATIONS  UNDER  INDEPENDENT  AND  NON-INDEPENDENT 
VARIABLE-INTERVAL  PROCEDURES. 

240015  03-04 

VARIATIONS  IN  EFFECT  OF  MEMORY  ALTERING  DRUGS  AS  A  FUNCTION 
OF  THE  STRENGTH  OF  THE  LEARNED  RESPONSE.  (PH  D.  DISSERTATION). 

241689  03-04 
TIME-DEPENDENT  VARIATIONS  IN  AVERSIVELY  MOTIVATED  BEHAVIORS: 
NONASSOCIATIVE  EFFECTS  OF  CHOLINERGIC  AND 
CATECHOLAMINERGIC  ACTIVITY. 

245486  04-04 

VAS-DEFERENS 

INHIBITION  BY  HALOTHANE  OF  EXOCYTOTIC  RELEASE  OF 

NOREPINEPHRINE  FROM  GUINEA  PIG  VAS-DEFERENS.  (UNPUBLISHED 

PAPER). 

227777  01-03 

INHIBITION  BY  CYCLOPROPANE  OF  RELEASE  OF  NOREPINEPHRINE,  BUT 
NOT  OF  DOPAMINE  BETA  HYDROXYLASE  FROM  GUINEA  PIG  VAS 
DEFERENS  (UNPUBLISHED  PAPER). 

247028  04-03 

THE  EFFECT  OF  PRETREATMENT  WITH  6  HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 

VAS-DEFERENS 

248413  04  03 

THE  UPTAKE  OF  TRITIAIEO  DELTAl  TETRAHYDROCANNABINOL  BY  THE 
ISOLATED  VAS  DEFERENS  OF  THE  RAT 

252200  04  03 


VASCULAR 

ADRENERGIC  RECEPTORS  AND  VASCULAR  RESISTANCE  IN  CEREBRAL 
CIRCULATION  OF  THE  CAT.  251820  04-03 

VASOCONSTRICTOR 

MECHANISM  OF  VASOCONSTRICTOR  ACTION  OF  DELTA9- 

TETRAHYDROCANNABINOL  IN  PITHED  AND  ANESTHETIZED  RATS, 

238809  03-03 

VASODILATION 

THE  INFLUENCE  OF  IMIPRAMINE  ON  DOPAMINE  INDUCED  GANGLIONIC 
INHIBITION  AND  NEUROGENIC  VASODILATION  IN  THE  DOG 

2371 60  02-03 

VASODILATOR 

CYCLANDELATE  CHECKS  MENTAL  DECAY:  AGED  PATIENTS  IQ  AND 
MEMORY  PRESERVED  WITH  USE  OF  VASODILATOR. 

247022  04-11 

VASOPRESSIN 

ACUTE  AND  CHRONIC  EFFECTS  OF  VASOPRESSIN  IN  RATS  WITH  LITHIUM 

''"^^^^"^  239046  03-05 

VEGETATIVE 

ELECTROPHORETIC  APPLICATION  OF  IIGNOCAINE  TO  THE  CERVICAL  AREA 
FOR  THE  TREATMENT  OF  VEGETATIVE  NEUROSES, 

244467  04-10 

DISTRIBUTION  STUDIES  OF  (14C)DELTA9-TETRAHYDR0CANNABIN0L  IN 
MICE    EFFECT  OF  VEHICLE,  ROUTE  OF  ADMINISTRATION,  AND 
DURATION  OF  TREATMENT.  249223  04-03 

EFFECTS  OF  DELTA9-TETRAHYDR0CANNABIN0L  ON  SOCIAL  BEHAVIOUR 
IN  MICE-  COMPARISON  BETWEEN  TWO  VEHICLES, 

244687  04  04 

BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6  OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04  04 

COMPARISON  OF  CENTRAL  EFFECTS  OF  NORADRENALINE  AND  DOPAMINE 
INJECTED  INTO  THE  LATERAL  BRAIN  VENTRICLE  IN  RATS. 

VENTRICULAR 

TRANSMITTER  PRECURSORS  AND  METABOLITES  IN  HUMAN 
VENTRICULAR  CEREBROSPINAL  FLUID. 

241210  03-13 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC-ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II    VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES, 

246994  04  13 
PHENOTHIAZINE-INDUCED  VENTRICULAR  TACHYCARDIA. 

247148  04-15 
THE  EFFECT  OF  SUBFORNICAL  ORGAN  LESIONS  AND  VENTRICULAR 
BLOCKADE  ON  DRINKING  INDUCED  BY  ANGIOTENSIN-II. 

252170  04  03 

VENTRICUIOCISTERNAL 

INTRATHECAL  CHEMOTHERAPY:  BRAIN  TISSUE  PROFILES  AFTER 
VENTRICULOCISTERNAL  PERFUSION. 

VENTROBASAl 

EFFECT  OF  MORPHINE  ON  SINGLE  UNIT  RESPONSES  IN  VENTROBASAL 
COMPLEX  (VB)  AND  POSTERIOR  NUCLEAR  GROUP  (PO)  FOLLOWING 
TOOTH  PULP  STIMULATION  251070  04-03 

VENTROMEDIAL 

EFFECT  OF  VENTROMEDIAL  HYPOTHALAMIC  PROCAINE  INJECTIONS  ON 
FEEDING    LEVER  PRESSING,  AND  OTHER  BEHAVIOR  IN  RATS. 

231707  01-04 

EFFECTS  OF  LESIONS  OF  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE-INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

23/099  02  03 

CATECHOLAMINE  CONCENTRATION  OF  DISCRETE  BRAIN  AREAS 

FOLLOWING  SELF-STIMULATION  IN  THE  VENTROMEDIAL  TEGMENTUM 

0^^^^^^^  237862  02-03 

VENTROMEDIAL  HYPOTHALAMUS  AND  SHORT  TERM  FEEDING 
SUPPRESSION  BY  CAERULEIN  IN  MALE  RATS 

244311  04  04 

VENTROPOSTERIOR 

BARBITURATE  SPINDLE  ACTIVITY  IN  THE  THALAMIC  LATERAL 

VENTROPOSTERIOR  NUCLEUS  AND  THE  SECOND  SOMATOSENSORY 
AREA  OF  THE  CORTEX  „-,  „^  „. 

232607  02-03 

VERATRUM 

INTRACELLULAR  RECORDING  OF  AFTER-DISCHARGE  INDUCED  BY 
VERATRUM  ALKALOIDS  IN  THE  GUINEA  PIG  NODOSE  GANGLION. 

232333  01  03 


S-341 


Subject  Index 


Psychopharmacology  Abstracts 


0 


g 


c 

3 
i 

k 

X. 

m 


I 


> 


VERBAL 

VERBAL  RETRIEVAL  OF  RIGHT  HEMISPHERE  MEMORIES  ESTABLISHED  IN 
THE  ABSENCE  OF  LANGUAGE 

251939  04-14 
VERSATILE 

HIGH  DOSAGE  AND  VERSATILE  DRUG  THERAPY  WITH  TREATMENT 
RESISTANT  PSYCHOTIC  PATIENTS, 

235419  02-17 
VERTICAL 

EFFECTS  OF  CHLORPROMAZINE  ON  THE  VERTICAL  CHAMBER  SYNDROME 
IN  RHESUS  MONKEYS 

247889  04  04 
VERTIGO 

PSYCHOPHARMACEUTICALS  IN  THE  HANDS  OF  THE  GENERAL 

PRACTITIONERS   -  VERTIGO  STATES:  OVERVIEW  AND  SHORT  REPORTS, 

239768  03-17 
VERVET 

BEHAVIOURAL  EFFECTS  OF  THYMOLEPTICS  IN  VERVET  MONKEYS 
(CERCOPITHECUS-AETHIOPS).  AETHIOPS). 

230869  01-04 
VESICLES 

THE  INFLUENCE  OF  CARBIDINE  ON  THE  ADRENERGIC 

NEUROTRANSMITTER  CONTENT  AND  STORAGE  IN  SYNAPTIC  VESICLES. 

236233  02-03 
UPTAKE  OF  BIOGENIC  AMINES  INTO  SYNAPTIC  VESICLES  OF  THE 
CAUDATE-NUCLEUS, 

251392  04-03 
VESSELS 

INTERACTIONS  OF  ALCOHOL,  BARBITURATES,  AND  NARCOTICS  WITH 
BLOOD  VESSELS 

229474  01-03 
VESTIBULAR 

VESTIBULAR  TEST  IN  INVESTIGATING  THE  SPECTRUM  OF  ACTION  OF 
PSYCHOTROPIC  AGENTS. 

236714  02-04 
lONTOPHORETIC  APPLICATION  OF  ANTAGONISTS  TO  PUTATIVE 
TRANSMITTERS  ON  VESTIBULAR  UNITS  INVOLVED  IN  A  SPECIFIC 
INHIBirORY  INTERACTION. 

238823  03  03 
ANTAGONISTIC  EFFECTS  OF  GABA  AND  BENZODIAZEPINES  ON 
VESTIBULAR  AND  CEREBELLAR  NEURONES. 

240523  03-03 
VETERANS 

A  SURVEY  OF  PSYCHOACTIVE  DRUG  USE  IN  THE  AGED  IN  VETERANS 
ADMINISTRATION  HOSPITALS. 

229458  01-11 
VETERINARY 

AZAPEROL,  A  NEW  METABOLITE  OF  THE  VETERINARY  BUTYROPHENONE 
TRANQUILIZER  AZAPERONE. 

241359  03-02 
ACUTE  POISONING  BY  MEANS  OF  A  VETERINARY  USED  SULFONE:  A  CASE 
STUDY 

245116  04-05 
VIDEO 

VIDEO  METHODOLOGY  FOR  RESEARCH  IN  PSYCHOPATHOLOGY  AND 
PSYCHOPHARMACOLOGY:  RATIONALE  AND  APPLICATION. 

225721  01  17 
VILOXAZINE 

ANIMAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVAIAN) 

227208  01  02 
CLINICAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN). 

227210  01  07 
EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES 

227212  01-07 

short-term  effects  of  viloxazine  (vivalan)  compared  with 
Placebo  in  depression:  a  double-blind  study. 

227214  01-09 
viloxazine  (VIVALAN)  COMPARISON  WITH  IMIPRAMINE. 

227215  01  09 
A  CONTROLLED  MULTICENTRE  THERAPEUTIC  TRIAL  OF  VILOXAZINE 

(VIVALAN). 

227216  01-09 

227217  01-09 

227218  01-09 

227219  01-07 


OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN). 
OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN). 
MULTICENTRE  STUDIES  WITH  VILOXAZINE  (VIVALAN). 

VILOXAZINE  (VIVALAN)      A  NEW  ANTIDEPRESSANT, 

227224  01-09 
VILOXAZINE  (VIVALAN)  -   GENERAL  PRACTITIONER  GROUP  STUDIES. 

227226  01-09 
A  PLACEBO  CONTROLLED  TRIAL  OF  VILOXAZINE  WITH  AND  WITHOUT 
TRANQUILLIZERS  IN  DEPRESSIVE  ILLNESS. 

245137  04-10 
CASES  OF  OVERDOSE  WITH  VILOXAZINE  HYDROCHLORIDE  (VIVALAN) 

251003  04- 1 5 


VIMINOl 

MOLECULAR  MECHANISMS  IN  THE  ACTION  OF  MORPHINE  AND  VIMINOL 
(R2)  ON  RAT  STRIATUM 

226851  01  03 
VINBLASTINE 

THE  EFFECTS  OF  GANGLIONIC  BLOCKADE.  RESERPINE  AND  VINBLASTINE 
ON  PLASMA  CATECHOLAMINES  AND  DOPAMINE-BETAHYDROXYLASE 
IN  THE  RAT. 

246843  04-03 
VIOLENT 

VIOLENT  BEHAVIOR,  BRAIN  DYSRHYTHMIA,  AND  GLUCOSE 
DYSFUNCTION    A  NEW  SYNDROME. 

233870  02  11 
VIOLIN 

THE  SILVER  VIOLIN  STRING. 

229236  01-09 
VIRAL 

NORAAAL  DISPOSITION  OF  OXAZEPAM  IN  ACUTE  VIRAL  HEPATITIS  AND 
CIRRHOSIS. 

241730  03-13 
VIRGIN 

RESPONSE  TO  DELTA9-TETRAHYDR0CANNABIN0L,  BARBITURATES  AND 
ETHANOL  IN  LACTATING.  VIRGIN  FEMALE,  AND  MALE  MICE. 

238766  03-03 
VISION 

TRANSPLACENTAL  EFFECTS  OF  DRUGS  ON  HEARING,  VISION,  AND 
BEHAVIOUR. 

227391  01-05 
VISUAL 

A  STUDY  OF  INHIBITORY  ANTAGONISM  IN  CAT  VISUAL  CORTEX. 

226397  01  03 
PARATHION  ADMINISTRATION  IN  THE  MONKEY:  TIME  COURSE  OF 

INHIBITION  AND  RECOVERY  OF  BLOOD  CHOLINESTERASES  AND  VISUAL 
DISCRIMINATION  PERFORMANCES. 

227384  01  03 
SCOPOLAMINE  EFFECTS  ON  VISUAL  DISCRIMINATION:  MODIFICATIONS 
RELATED  TO  STIMULUS  CONTROL. 

231005  01  04 
EFFECTS  OF  ALCOHOL  AND  MARUUANA  ON  DYNAMIC  VISUAL  ACUl  I 
THRESHOLD  MEASUREMENTS 

235759  (u  1 4 
PIRACETAM-INDUCED  FACILITATION  OF  INTERHEMISPHERIC  TRANSFER 
OF  VISUAL  INFORMATION  IN  RATS 

239861  03-04 
PHARMACOLOGICAL  APPROACHES  TO  THE  FUNCTION  OF  CERTAIN 
NONSPECIFIC  SUBCORTICAL  STRUCTURES  PARTICIPATING  IN  THE 
GENESIS  OF  THE  VISUAL  EVOKED  POTENTIAL.  APPLICATIONS  10  THE 
STUDY  OF  SEVERAL  PSYCHOTROPICS, 

244874  04  03 
EFFECTS  ON  VISUAL  TRACKING  OF  DELTA9  TETRAHYDROCANNABINOL 
AND  PENTOBARBITAL. 

251825  04-14 

232639  02  04 

241849  03  09 


VITAAAIN-B6 

AVOIDANCE  BEHAVIOR  IN  VITAMIN-B6  DEFICIENT  RATS. 


VITILIGO 

REMISSION  OF  VITILIGO  AND  SALT  MEDICATION. 


VIVALAN 

ANIMAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN) 

227208  01  02 
CLINICAL  PHARMACOLOGY  OF  VILOXAZINE  (VIVALAN). 

227210  01  07 
EFFECT  OF  VILOXAZINE  (VIVALAN)  ON  THE  URINARY  EXCRETION  OF 
CATECHOLAMINES  AND  THEIR  METABOLITES. 

227212  01-07 
SHORT-TERM  EFFECTS  OF  VILOXAZINE  (VIVALAN)  COMPARED  WITH 
PLACEBO  IN  DEPRESSION:  A  DOUBLE-BLIND  STUDY. 

227214  01  09 
VILOXAZINE  (VIVALAN)  COMPARISON  WITH  IMIPRAMINE. 

227215  01  09 
A  CONTROLLED  MULTICENTRE  THERAPEUTIC  TRIAL  OF  VILOXAZINE 

(VIVALAN). 

227216  01-09 

227217  01  09 

227218  01-09 

227219  01  07 


OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN). 

OPEN  STUDIES  WITH  VILOXAZINE  (VIVALAN). 

MULTICENTRE  STUDIES  WITH  VILOXAZINE  (VIVALAN), 

VILOXAZINE  (VIVALAN)      A  NEW  ANTIDEPRESSANT. 

227224  01  09 
VILOXAZINE  (VIVALAN)      GENERAL  PRACTITIONER  GROUP  STUDIES, 

227226  01  09 
VIVALAN:  DRUG  PROFILE. 

227227  01-07 
CASES  OF  OVERDOSE  WITH  VILOXAZINE  HYDROCHLORIDE  (VIVALAN) 

251003  04  I 


S-342 


VOLUME  14,  SUBJECT  INDEX 

VOCALIZATION 

PHARMACOLOGICAL  DISSOCIATION  BETWEEN  VOCALIZATION  AND 
BITING  PRODUCED  IN  RATS  BY  THE  COMBINATION  OF  IMIPRAMINE 
ANDISOCARBOXAZID  237705  02-04 

PSYCHOPHARMACOLOGIC  INVESTIGATIONS  IN  ELDERLY  VOLUNTEERS: 
EFFECT  OF  DIAZEPAM  IN  MALES. 

229840  01-11 

REM  SLEEP  INDUCTION  BY  PHYSOSTIGMINE  INFUSION  DURING  SLEEP  IN 
NORMAL  VOLUNTEERS.  (UNPUBLISHED  PAPER). 

232760  02-14 

EFFECT  OF  ETHANOL  INTAKE  ON  PHENYTOIN  METABOLISM  IN 

VOLUNTEERS. 

233280  02- 13 

EFFECTS  OF  REPEATED  DOSES  OF  SCOPOLAMINE  ON  THE 
ELECTROENCEPHALOGRAPHIC  STAGES  OF  SLEEP  IN  NORMAL 

VOLUNTEERS. 

248629  04-13 

THE  CLINICAL  PHARMACOLOGY  OF  LILLY-109514  IN  NORMAL 

VOLUNTEERS. 

249260  04-07 

VORACIOUSNESS 

VORACIOUSNESS  INDUCED  IN  CATS  BY  BENZODIAZEPINES. 

244690  04-04 

WAKEFULNESS 

THE  EFFECTS  OF  5-HYDROXYTRYPTOPHAN  AND  L-TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT. 

252216  04-03 

WAKING-SLEEP 

ACTION  OF  ALPHA-METHYL-DOPA  ON  WAKING-SLEEP  CYCLES  IN  TWO 
INBRED  STRAINS  OF  MICE,  C57BR  AND  C57BL/6. 

249676  04-04 

WARFARIN 

COMPARATIVE  EFFECT  OF  PHENOBARBITAL  AND  METHAQUALONE  ON 
WARFARIN  METABOLISM  IN  THE  RAT 

241344  03-03 

WARFARIN-INDUCED 

INDUCTION  OF  HEPATIC  ENZYMES  BY  METHAQUALONE  AND  EFFECT  ON 
WARFARIN-INDUCED  HYPOPROTHROMBINEMIA. 

237760  02-03 

WARNED 

WARNED  REACTION  TIMES  OF  MANIC-DEPRESSIVE  PATIENTS  WITH  AND 
WITHOUT  LITHIUM. 

249798  04-09 

WATER 

IMPAIRMENT  OF  THERMOREGULATION.  FOOD  AND  WATER  INTAKES  IN 
THE  RAT  AFTER  HYPOTHALAMIC  INJECTIONS  OF  5,6 
DIHYDROXYTRYPT  AMINE. 

226938  01-04 
ETHANOL  AS  A  REINFORCER  FOR  RATS:  EFFECTS  OF  CONCURRENT 
ACCESS  TO  WATER  AND  ALTERNATE  POSITIONS  OF  WATER  AND 
ETHANOL. 

227128  01  04 

NEUROLEPTIC-INDUCED  DEFICITS  IN  FOOD  AND  WATER  REGULATION. 
SIMILARITIES  TO  THE  LATERAL  HYPOTHALAMIC  SYNDROME. 

227134  01-03 
TIME  COURSE  FOR  THE  EFFECTS  OF  COCAINE  ON  FIXED-RATIO  WATER 
REINFORCED  RESPONDING  IN  RATS 

230842  01-04 

EFFECTS  OF  NARCOTIC  AGONISTS  AND  ANTAGONISTS  ON  SCHEDULE 
INDUCED  WATER  AND  MORPHINE  INGESTION. 

233292  02-04 
ETHANOL,  WATER  AND  FOOD  INTAKE  UNDER  A  FIXED-INTERVAL  (Fl) 
SCHEDULE  OF  FOOD  PELLET  PRESENTATION. 

238749  03-04 
EFFECTS  OF  LOWERING  THE  SEROTONIN  CONTENT  IN  THE  RAT  BRAIN  ON 
GASTRIC  ULCER  INDUCED  BY  WATER  IMMERSION  STRESS. 

241391  03-03 
PITRESSIN-INDUCED  INHIBITION  OF  DRINKING  FOLLOWING  WATER 
DEPRIVATION  IN  THE  SWR-J  MOUSE. 

242746  04-04 
RENAL  LITHIUM,  SODIUM,  POTASSIUM.  AND  WATER  EXCRETION  AND 
PLASMA  RENIN  ACTIVITY  IN  RATS  IN  THE  COLD. 

246673  04-03 
EFFECTS  OF  INTERMITTENT  AND  REPEATED  ADMINISTRATION  OF  0- 
AMPHETAMINE  ON  RESTRICTED  WATER  INTAKE  IN  RATS. 

253111  04-04 

WAVE 

THE  EFFECT  OF  LSD  UPON  SPONTANEOUS  PGO  WAVE  ACTIVITY  AND 

REM  SLEEP  IN  THE  CAT 

237780  02-04 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZEO  CAT:  I    PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  PCHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES 

241315  03-03 


Subject  Index 


DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT.  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-03 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES.  2413,7  03-03 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT   V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAL  NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

241319  03-03 
METHSCOPOLAMINE:  SUPPRESSION  OF  SLEEP  RELATED  GROWTH 

HORMONE  SECRETION  AND  DISSOCIATION  FROM  SLOW  WAVE  SLEEP. 

243822  04-14 

INHIBITION  OF  SLOW  WAVE  SLEEP  AND  RAPID  EYE  MOVEMENT  SLEEP  BY 
THYROTROPINRELEASING  HORMONE  IN  CATS. 

249281  04-02 

WAVES 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  I.  PGO  WAVE  ACTIVITY  INDUCED  BY  RO-4-1284  AND 
BY  P-CHLOROPHENYLALANINE  (PCPA)  AS  A  BASIS  FOR 
NEUROPHARMACOLOGICAL  STUDIES. 

241315  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT:  II.  PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE. 

241316  03-03 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  III.  PGO  WAVE  ACTIVITY  AND  BRAIN 
CATECHOLAMINES.  ., 

241317  03-03 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT:  IV.  THE  EFFECTS  OF  ACETYLCHOLINE,  GABA  AND 
BENZODIAZEPINES  ON  PGO  WAVE  ACTIVITY. 

241318  03-03 
DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 

CURARIZED  CAT   V.  MISCELLANEOUS  COMPOUNDS.  SYNOPSIS  OF  THE 
ROLE  OF  CENTRAl   NEUROTRANSMITTERS  ON  PGO  WAVE  ACTIVITY. 

2413)9  03-03 

WEAK 

WEAK  INHIBITORY  BEHAVIORAL  EFFECTS  OF  POSTNATAL/PREWEANING 
TAURINE  INJECTIONS  IN  RATS. 

252149  04-04 

WEIGHT 

NEONATAL  THYROXINE  ADMINISTRATION,  BEHAVIORAL  MATURATION, 
AND  BRAIN  GROWTH  IN  MICE  OF  DIFFERENT  BRAIN  WEIGHT. 

226532  01-04 
THE  INFLUENCE  OF  DIETARY  IODINE  ON  LITHIUM  BLOOD  LEVEL,  SERUM 
0T4  AND  THYROID  GLAND  WEIGHT. 

236528  02-03 
CYPROHEPTADINE:  WEIGHT  GAIN  AND  APPETITE  STIMULATION  IN 
ESSENTIAL  ANOREXIC  ADULTS 

237900  02-10 

DO  ANORECTIC  DRUGS  PRODUCE  WEIGHT  LOSS  BY  APPETITE 
SUPPRESSION-^ 

240802  03-13 

DRUGS  AND  PUNISHED  RESPONDING  VI:  BODY  WEIGHT  AS  A 
DETERMINANT  OF  DRUG  EFFECTS 

247845  04-04 
WEIGHT  LOSS  AND  SHOCK-ELICITED  AGGRESSION  AS  INDICES  OF 
MORPHINE  ABSTINENCE  IN  RATS. 

249671  04-04 

LITHIUM  TREATMENT  AND  WEIGHT  GAIN 

249927  04-15 
ESTRADIOL  BENZOATE,  NOREPINEPHRINE,  AND  WEIGHT  REGULATORY 

BEHAVIOR  IN  FEMALE  RATS. 

2500 1 2  04-04 

WET 

APPEARANCE  OF  WET  DOG  SHAKE  BEHAVIOR  DURING  COBALT 
EXPERIMENTAL  EPILEPSY  IN  THE  RAT  AND  ITS  SUPPRESSION  BY 
RESERPINE. 

230836  01  04 

WET  DOG  SHAKE  BEHAVIOR  IN  NORMAL  RATS,  ELICITED  BY 
BENZYLIDENEAMINOOXYCARBONIC-ACID  DERIVATIVES 

241231  03-04 

WISTAR 

THE  EFFECTS  OF  AZAPERONE,  A  SEDATIVE  NEUROLEPTIC  OF  THE 

BUTYROPHENONE  SFRIES,  ON  DOMINANT  SUBORDINATE  BEHAVIOUR 
IN  WISTAR  RATS  COMPETING  FOR  FOOD. 

225571  01-04 
HEREDITY  OF  HEXOBARBITAL  SLEEPING  TIME  AND  EFFICIENCY  OF  DRUG 
METABOLISM  IN  WiSTAR  AND  SPRAGUE-DAWLEY  RATS. 

230007  01  04 


S-343 


Subject  Index 


Psychopharmacology  Abstracts 


f 


% 


% 

IS 


•0 

J:: 
0)'' 

Z' 


WITHORAWAl 

POSSIBLE  ROLE  Of  THE  ALPHA-ADRENERGIC  SYSTEM  IN  NARCOTIC 
WITHDRAWAL:  TOXIC  INTERACTION  BETWEEN  METHADONE  AND 
PHENOXYBENZAMINE.  (UNPUBLISHED  PAPER) 

226848  01-05 
PARADOXICAL  ABSENCE  Of  AGGRESSION  DURING  NALOXONE 
PRECIPITATED  MORPHINE  WITHDRAWAL. 

227132  01-04 
REVIEW  Of  LONG-TERM  PSYCHIATRIC  MEDICATION  -  A  STUDY  Of 
WITHDRAWAL  SYMPTOMS. 

228214  01  15 
A  CONTROLLED  TRIAL  Of  CHLORMETHIAZOLE  AND  CHLORDIAZEPOXIDE 
IN  THE  TREATMENT  Of  THE  ACUTE  WITHDRAWAL  PHASE  Of 
ALCOHOLISM. 

230104  01-11 
REDUCTION  Of  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY  A 
CONDITIONAL  STIMULUS  IN  THE  RAT. 

232617  02-03 
PRACTOLOL  IN  THE  TREATMENT  Of  WITHDRAWAL  SYNDROMES. 

234047  02-11 
CHANGES  IN  SERUM  TRYPTOPHAN  AND  ALBUMIN  BINDING  Of 
TRYPTOPHAN  IN  CHLORPROMAZINf  TREATED  CHRONIC 
SCHIZOPHRENICS  ON  WITHDRAWAL  AND  RESTORATION  Of  DRUG 
THERAPY. 

235629  02  08 
EffECTS  Of  LESIONS  Of  THE  VENTROMEDIAL  HYPOTHALAMUS  ON 
NALOXONE  INDUCED  MORPHINE  WITHDRAWAL  IN  RATS. 

237099  02  03 
METHAMPHETAMINE  WITHDRAWAL  AS  A  MODEL  fOR  THE  DEPRESSIVE 
STATE:  ANTAGONISM  Of  POST  AMPHETAMINE  DEPRESSION  BY 
IMIPRAMINE. 

237976  02-03 
PREVENTION  Of  RfVERSAL  Of  OPERANT  BEHAVIORAL  DISRUPTION 
DURING  PRECIPITATED  WITHDRAWAL  BY  TREATMENT  WITH 
MORPHINE  BEfORE  OR  AfTER  NALOXONE. 

238687  03  04 
NALOXONE  ANTAGONISM  Of  CONDITIONAL  REVERSAL  Of  NARCOTIC 
WITHDRAWAL  SIGNS  AND  CONDITIONAL  MORPHINE  HYPERTHERMIA- 
AN  INDIRECT  EVIDENCE  fOR  RELEASE  Of  ENDOGENOUS  OPIOID-LIKE 
SUBSTANCE  IN  THE  RAT. 

238713  03-04 
LOSS  Of  INHIBITION  IN  SPINAL  CORD  DURING  BARBITURATE 
WITHDRAWAL. 

238770  03-03 
EffECT  Of  CHRONIC  BARBITAL  ADMINISTRATION  AND  SUBSEQUENT 
WITHDRAWAL  ON  CATECHOLAMINE  CONTENT  AND  TURNOVER  IN  RAT 
BRAIN. 

238790  03-03 
METHYLPHENIDATE  ADDICTION       EffECT  REVERSAL  IN  WITHDRAWAL 

238862  03-15 
OPEN  WITHDRAWAL  Of  ANTIPARKINSON  DRUGS  IN  THE  NEUROLEPTIC- 
INDUCED  PARKINSON  SYNDROME 

239822  03  15 
COMPARISON  Of  WITHDRAWAL  PRECIPTATING  PROPERTIES  Of  VARIOUS 
MORPHINE  ANTAGONISTS  AND  PARTIAL  AGONISTS  IN  RELATION  TO 
THEIR  STEREOSPECIFIC  BINDING  TO  BRAIN  HOMOGENATES. 

239854  03-03 
THE  MODIFICATION  OF  THE  ETHANOL  WITHDRAWAL  SYNDROME  IN 
RATS  BY  DI-N-PROPYLACETATE. 

241222  03  03 
SITES  Of  ACTION  Of  MORPHINE  INVOLVED  IN  THE  DEVELOPMENT  Of 

PHYSICAL  DEPENDENCE  IN  RATS:  I.  COMPARISON  OF  PRECIPITATED 
MORPHINE  WITHDRAWAL  AFTER  INTRAPERITONEAL  AND 
INTRAVENTRICULAR  INJECTION  OF  MORPHINE  ANTAGONISTS 

241223  03  04 
DIAGNOSIS  AND  MANAGEMENT  Of  ETHANOL  WITHDRAWAL 

SYNDROMES 

244107  04-11 
BEHAVIOURAL  CHANGES  IN  LABORATORY  MICE  DURING  CANNABIS 
fEEDING  AND  WITHDRAWAL 

246310  04-04 
PENTAZOCINE  ABUSE  AND  PROBLEMS  OF  WITHDRAWAL 

246617  04-17 
BLOCKADE  OF  MORPHINE  WITHDRAWAL  BODY  SHAKES  BY 
HALOPERIDOL 

248274  04  03 
FURTHER  STUDIES  ON  THE  SENSITIVITY  Of  OPERANT  BEHAVIOR  TO 
DETECT  OPIATE  WITHDRAWAL  IN  RATS. 

249247  04  04 
TYROSINE-HYDROXYLASE  ACTIVITY  IS  LOWER  IN  fOREBRAIN  DURING 
NALOXONE  PRECIPITATED  WITHDRAWAL  IN  MORPHINE  PELLETED 
RATS. 

249291  04-03 
DEPRESSION  Of  DOPAMINE  RELEASE  DURING  THE  ETHANOL 
WITHDRAWAL  SYNDROME. 

249293  04  03 


CHANGES  IN  SENSITIVITY  Of  MORPHINE-INDUCED  CIRCLING  BEHAVIOUR 
AfTER  CHRONIC  TREATMENT  AND  PERSISTENCE  AFTER  WITHDRAWAL 
IN  RATS. 

249485  04  04 
WITHDRAWAL  OF  DIAZEPAM. 

250056  04  15 
CHANGES  IN  SENSITIVITY  TO  APOMORPHINE  DURING  MORPHINE- 
DEPENDENCE  AND  WITHDRAWAL  IN  RATS. 

250114  04-03 
PROPRANOLOL  EFFECT  ON  TREMOR  IN  ALCOHOLIC  WITHDRAWAL. 

250779  04  11 
FENFLURAMINE  WITHDRAWAL  AND  EPILEPSY. 

250944  04  1 1 
CHANGES  IN  BRAIN  CATECHOLAMINE  TURNOVER  DURING  PRECIPITATED 
MORPHINE  WITHDRAWAL  IN  THE  RAT. 

251400  04-03 
EFFECT  OF  DOPAMINE  AGONISTS  AND  ANTAGONISTS  ON  ASYMMETRIC 
BEHAVIOUR  OCCURRING  DURING  PRECIPITATED  MORPHINE 
WITHDRAWAL  AfTER  UNILATERAL  INACTIVATION  Of  THE  STRIATUM 
IN  RATS. 

251402  04-04 
CLORAZEPATE  DIPOTASSIUM  (TRANXENE):  A  CONTROLLED  EVALUATION 
IN  ALCOHOLIC  PATIENTS  AfTER  WITHDRAWAL. 

251718  04  11 
DIfFERENTIAL  POTENCY  OF  TASTE  AND  AUDIOVISUAL  STIMULI  IN  THE 
CONDITIONING  OF  MORPHINE  WITHDRAWAL  IN  RATS. 

251978  04  04 
MEDICAL  EFFECTS  OF  ABRUPT  NEUROLEPTIC  WITHDRAWAL. 

251996  04  08 
CLINICAL  APPLICATIONS  OF  A  NEW  RATIONALE  IN  THE  TREATMENT  OF 
ACUTE  ALCOHOL  WITHDRAWAL. 

252694  04-11 
WITHDRAWAL  CAUSES  RELAPSE';'.  OUR  RESPONSE. 

252848  04-08 
EFFECT  Of  NARCOTIC  DEPENDENCE  AND  WITHDRAWAL  ON  STRIATAL 
DOPAMINE  SENSITIVE  ADENYLATE-CYCLASE  AND  SYNAPTOSOMAL 
CYCLIC  AMP  METABOLISM. 

253135  04-03 
WOMEN 

CHLORPROMAZINF  EFFECTS  ON  BRAIN  ACTIVITY  (CONTINGENT  NEGATIVE 
VARIATION)  AND  REACTION  TIME  IN  NORMAL  WOMEN 

230863  01-14 
WORK 

DO  TRICYCLIC  ANTIDEPRESSANTS  WORK?. 

237162  02-17 
DO  TRICYCLIC  ANTIDEPRESSANTS  WORK?. 

253314  04-09 
WORKERS 

DOGMATIL  AND  BEHAVIORAL  PROBLEMS  IN  MIGRANT  WORKERS. 

249693  04-11 
WORKING 

EFFECT  Of  SODIUM  OXYBUTYRATE,  AMPHETAMINE,  TRANSAMINE    L- 
DOPA  ON  THE  PROCESSES  Of  RESTORATION  Of  WORKING  CAPACITY 
UNDER  CONDITIONS  OF  MINIMAL  REST. 

236372  02-04 
WORLD 

THE  TOKYO  ASSEMBLY  OF  THE  WORLD  MEDICAL  ASSOCIATION. 

248166  04-17 
WORLDWIDE 

WORLDWIDE  TRENDS  IN  THE  PSYCHOPHARMACOLOGICAL  STUDIES 

228323  01  17 
WORRYING 

WORRYING  ABOUT  ANXIETY. 

251161  04  10 
WORSE 

MAINTENANCE  ANTIPSYCHOTIC  THERAPY:  IS  THE  CURE  WORSE  THAN 
THE  DISEASE';'. 

236307  02  08 
WORTH 

THE  INDOLE  HALLUCINOGEN  MODEL:  IS  IT  WORTH  PURSUING''. 

241872  03  08 
W 12099 

IRREVERSIBLE  INACTIVATION  OF  THE  OPIATE  RECEPTOR  BY  THE 
ALKYLATING  LOCAL  ANESTHETIC  W12099 

238686  03-03 
X-RAY 

PHARMACOLOGICAL  IMPLICATIONS  OF  THE  X-RAY  STRUCTURE  OF  A 
RIGID  ANALOG  OF  THE  TRICYCLIC  ANTIDEPRESSANTS. 

238317  02  01 
CHANGES  IN  THE  PHARMACODYNAMICS  AND  PHARMACOKINETICS  OF 
PSYCHOLEPTIC  DRUGS  IN  RADIATION  SICKNESS.  EFFECT  OF  X-RAY 
RADIATION  ON  PHARMACODYNAMIC  ACTIVITY  OF  NITRAZEPAM  IN 
ANIMALS 

240237  03  04 
ANTIPSYCHOTIC  PHENOTHIAZINE  DRUGS  AND  THE  SIGNIFICANCE  OF  THE 
X-RAY  STRUCTURE  OF  PROMAZINE  HCL. 

250357  04-01 


S-344 


HUME  14,  SUBJECT  INDEX 


'"xROsioMIA  AND  ASIALIA  CAUSED  BY  PSYCHOTROPIC  DRUGS  AND 

THEIR  TREATMENT  WITH  TPMP  (TRITHIO  P  METHOXYPHENYLPROPENE), 

23371 8  02-1 5 

73A 

lONOPHORES  X573A  AND  A23187:  EFFECTS  ON  THE  PERMEABILITY  OF 
LIPID  BIMOLECULAR  MEMBRANES  TO  DOPAMINE  AND  CALCIUM. 
(UNPUBLISHED  PAPER)  236873  02-03 

EFFECT  OF  PHYSOSTIGMINE  ON  Y  MAZE  DISCRIMINATION  RETENTION  IN 
THE  RAT.  2519820404 

Y  MAZE  LEARNING  IN  TWO  INBRED  STRAINS  OF  MICE.  EFFECTS  OF 
INSTRUMENTAL  AND  PHARMACOLOGICAL  DEPRIVATION  OF  SLEEP, 

252171  0404 

)HIMBINE 

THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  BRAIN 
CATECHOLAMINES  AND  SEROTONIN 

12-0/ lo  U  I  -Uj 

THE  EFFECT  OF  YOHIMBINE  ON  THE  TURNOVER  OF  NOREPINEPHRINE  IN 
'^"-^  249283  04  03 

3UNG 

THE  EFFECT  OF  L-DOPA  ON  YOUNG  PATIENTS  WITH  SIMPLE 

SCHIZOPHRENIA    TREATED  WITH  NEUROLEPTIC  DRUGS    A  DOUBLE- 
BLIND  CROSSOVER  TRIAL  WITH  MADOPAR  AND  PLACEBO. 

THERAPEUTIC  ATTEMPTS  WITH  LITHIUM  IN  YOUNG  DRUG  ADDICTS 

238988  03  11 
LEVODOPA  AND  LEVOAMPHETAMINE:  A  CROSSOVER  STUDY  IN  YOUNG 

SCHIZOPHRENIC  CHILDREN.  247480  04-08 

DIURNAL  ACTION  OF  KETAMINE  IN  THE  YOUNG  CHICK    INFLUENCE  BY 

PINEAL  METABOLITES 

249240  04  03 

EFFECT  OF  AMPHETAMINE  AND  APOMORPHINE  ON  BRAIN  MONOAMINES 
AND  BEHAVIOUR  IN  THE  IMMATURE  AND  YOUNG  ADULT  RAT. 

249785  04  04 
ORIGIN  OF  BRAIN  GROWTH  RETARDATION  IN  YOUNG  RATS  TREATED 

WITH  PHENOBARBITAL. 

250682  04  05 

-ALPHA-ACETYLMETHADOL 

STUDIES  WITH  I -ALPHA-ACETYLMETHADOL    1.  TOLERANCE  IN  MACACA- 

^^^^^^^-  249290  04-03 

.ETHYL-2-PYRROLIDINYL-METHYL 

THE  DISINHIBITING  EFFECT  OF  N  (l-ETHYL-2-PYRROLIDINYL  METHYL  2 
METHOXY-5-SULFAMIDOBENZAMIDE  (SULPIRIDE)    II 

I -HYDROXY-3-AMINO-PYRROLIDONE-2 

EEG  SYNCHRONIZING  EFFECT  OF  GAMMA  HYDROXYBUTYRATE  AND  1 
HYDROXY-3  AMINO  PYRROLIUONE-2  (HA-966)  IN  RELATION  OF 
DOPAMINERGIC  BRAIN  FUNCTION 

I -METHYLTRYPT  AMINES 

N-METHYLATION  OF  1  METHYLTRYPTAMINES  BY  INDOLETHYLAMINE  N- 

METHYLTRANSFERASE,  ^    ^, 

249188  04-01 

10-2-ARYLIMINO-3-ACETYLAMINO-4-THIAZOLIDONYI 

ANTICONVULSANT  ACTIVITY  AND  SELECTIVE  INHIBITION  OF 

NICOTINAMIDE  ADENINE  DINUCLEOTIDE  DEPENDENT  OXIDATIONS  BY 
10  2-ARYLIMIN0  3-ACETYLAMIN0  4-THIAZOLIDONYL  PHENOTHIAZINES 

239662  03-03 

11 -HYDROXYTETR  AHYDROCANNABINOL 

PLASMA  CANNABINOIDS  MEASURED  BY  RADIOIMMUNOASSAY  IN 
RABBITS  AFTER  INTRAVENOUS  INJECTION  OF 

TETRAHYDROCANNABINOL,  1  1  HYDROXYTETRAHYDROCANNABINOL, 
CANNABINOL,  AND  CANNABIDIOL.  19S6  03  03 

11  OH-DELTA9-THC 

DELTA9-TETRAHYDR0CANNABIN01  (DELTA9  THC)  AND  11  OH  DELTA9 
FHC    ONSET    PATTERN  AND  DURATION  OF  BEHAVIORAL  EFFECTS  AND 
TOLERANCE  IN  RATS.  2388,3  03-04 

14C-DOPA 

MJTORADIOGRAPHIC  DISTRIBUTION  STUDY  OF  14C-D0PA  IN  CAT  BRAIN 

253393  04  03 

19366-RP 

DISCOURSE  ON  IHE  DOUBLE  BLIND  METHOD    INSTITUTION  AND 
EXPERIMENTATION,  19366  RP 

2290/8  01   16 

2-BENZISOXAZOLE-3-ACETAMIDOXIME 

EFFECT  OF  1.2  BENZISOXAZOLE  3  ACETAMIUOXIME  ON  CAUDATO 
IllALAMO  CORflCAL  SYSTEM  IN  CATS 

24 1 383  03  03 


Subject  Index 

EFFECTS  OF  1  2  BENZISOXAZOLE-3-ACETAMIDOXIME  HYDROCHLORIDE 
(PF  257)  ON  THE  CNS  WITH  SPECIAL  REFERENCE  TO  MONOAMINE 
METABOLISM,  241393  03-03 

2-DIPROPYLAMINO-5-HYDROXYTETRAHYDRONAPHTHAIENE  ^,,„,,^ 

SYNTHESIS  AND  DOPAMINERGIC  ACTIVITY  OF  (  I    OR  -)-,  (  •  )  .  AND  (-)  2- 
DIPROPYLAMINO-5  HYDROXYTETRAHYDRONAPHTHALENE. 

2486jU  U4-U/ 

2-METHOXY-5-SULFAMIDOBENZAMIDE 

THE  DISINHIBITING  EFFECT  OF  N  (1-ETHYL  2  PYRROLIDINYL  METHYL  2- 
METHOXY  5  SULFAMIDOBENZAMIDE  (SULPIRIDE),  II 

2-NITROSO-l -PHENYIPROPANE 

IN  VITRO  METABOLIC  STUDIES  USING  THE  METABONATES  OF 
AMPHETAMINE    2  NITROSO  1  PHENYLPROPANE  AND 
BENZYLMETHYLKETOXIME,  237980  02-01 

2-PHENYlETHYLAMINE 

ENDOGENOUS  BRAIN  2  PHENYLETHYLAMINE:  BIOCHEMICAL  AND 

PHARMACOLOGICAL  STUDIES  ON  ITS  ORIGIN  AND  POSSIBLE  ROLE  AS 
A  MAJOR  MEDIATOR  OF  THE  CENTRAL  ACTIONS  OF  AMPHETAMINE 
AND  OTHER  PSYCHOTROPIC  DRUGS    (PHD    DISSERTATION)^^^_^^  ^^^_^ 

POSSIBLE  MEDIATION  OF  THE  EUPHORIANT  AND  SEDATIVE  EFFECT  OF 
MARIHUANA  BY  2-PHENYLETHYLAMINE  AND  BY  P^'^'^^L^2"8^^o'^03°03 

2-PHENYLETHYLAMINE  (PEA)  IN  D-AMPHETAMINE-INDUCED 

EXTRAPYRAMIDAL  DISORDERS,  ^^^^^^  ^3  ^3 

BRAIN  2-PHENYlETHYLAMINE  AS  A  MAJOR  MEDIATOR  FOR  THE 
CENTRAL  ACTIONS  OF  AMPHETAMINE  AND  METHYLPHENIDATE, 

EVIDENCE  FOR  2-PHENYLETHYLAMINE  (PEA)  AS  A  MEDIATOR  FOR  THE 
CENTRAL  STIMULANT  AND  ANTITREMORGENIC  ACTIONS  OF  DELTA9 
TETRAHYDROCANNABINOL  (THC),  ^^^3^^  ^^^3 

INFLUENCE  OF  A  PERIPHERAL  MONOAMINE  OXIDASE  INHIBITOR  (MAOI) 
UPON  THE  CENTRAL-NERVOUS-SYSTEM  LEVELS  AND 
PHARMACOLOGICAL  EFFECTS  OF  2  PHENYLETHYLAMINE  (P|A)^^^  ^^^^^ 

CATECHOLAMINES  AND  2-PHENYLETHYLAMINE  (PEA)  IN  THE  CENTRAL 
AND  PERIPHERAL  ACTIONS  OF  AMPHETAMINES. 

24931  1  04-03 

2-SUBSTITUTED 

SYNTHESIS  AND  BIOLOGICAL  ACTIONS  OF  2  SUBSTITUTED 

QU'^OL'^'^'^E^  238477  02.02 

SYNTHESIS  AND  BIOLOGICAL  ACTIVIIY  OF  NEW  2  SUBSTIIUTED 

ANALOGS  OF  FLUPHENAZINE.  248538  04-02 

3-ARYlOXYPROPYLAMINES 

INHIBITION  OF  SYNAPTOSOMAL  ACCUMULATION  OF  L-NOREPINEPHRINE 
II    N  ARYLOXYALKYLPHENTERMINES,  QUATERNARY  D  AMPHETAMINES, 
AND  3  ARYLOXYPROPYLAMINES 

24863/  l)4-UI 

3-ARYlQUINOLIZIDINES 

3-ARYLQUINOLIZIDINES,  POTENTIAL  ANTIDEPRESSANT  AGENTS, 

247586  04  01 

3-CHIORO-2-HYDROXYIM1PRAMINE 

SYNTHESIS  OF  3-CHLORO-2  HYDROXYIMIPRAA/\INE  AND  3  CHLORO-8- 
HYDROXYIMIPRAMINE  (I),  HYPOTHETICAL  METABOUTES  OF 
CLOMIPRAMINE,  (UNPUBLISHED  PAPER),  ^^^^_^^  ^^^^^^ 

3-CHIORO-4-STILBAZOIE 

EFFECTS  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBIIOR  3  CHLORO  4 
SlILBAZOLE  ON  BRAIN  ACETYLCHOLINE  METABOLISM, 

251  181  04-03 

3-CHLORO-8.HYDROXYIM1PRAMINE  ,,,,^nr^  o 

SYNTHESIS  OF  3  CHLORO-2-HYDROXYIMIPRAMINE  AND  3  CHLORO  8 
HYDROXYIMIPRAMINE  (1),  HYPOTHETICAL  METABOLITES  OF 
CLOMIPRAMINE    (UNPUBLISHED  PAPER),  r\mA  02  01 

3.DIMETHYLAMINOPROPYI-PHENYI.-METHYLINDAZOLE 

PHARMACOLOGICAL  STUDIES  ON  1  3-DIMETHYLAMINOPROPYL-PHENYL 
METHYLINDAZOLE  HYDROCHLORIDE  (FS32)  (1),  ^^^^^^  ^^  ^^ 

3-METHOXYDOPA  ,,,^^ 

PIASMA  CONCENTRATIONS  OF  t-DOPA  AND  3  METHOXYDOPA  AND 
IMPROVEMENT  IN  CLINICAL  RATINGS  AND  MOTOR  PERFORMANCE  IN 
PATIENTS  WITH  PARKINSONISM  TREATED  WITH  L-DOPA  ALONE  OR  IN 
COMBINATION  WITH  AMANTADINE  226349  01   14 

3-METHYLETHYLAMINOPYRROLIDINOOIHYDRODIBENZOTHIEPINS 

8-CHL0R0-(S)   AND    (R)  IO-((S)    AND  -(R)  3 

MEIHYLEJHYLAMINOPYRROIIDINODIHYUKODIBENZOIHIEPINS 
SYNTHESIS  AND  PHARMACOLOGICAL  STUDIES  s  f '  01 


S-345 


11 


Subject  Index 

3H-AIPHA-MSH 

DISTRIBUTION  OF  3H  ALPHA  MSH  IN  RAT  BRAIN. 

248349  04-03 
3H-ALPRENOLOI 

CIRCADIAN  CYCLES  IN  BINDING  OF  3HALPREN0L0L  TO  BETA- 
ADRENERGIC  RECEPTOR  SITES  IN  RAT  PINEAL. 

234919  02-03 
RAPID  CHANGES  IN  RAT  PINEAL  BETA  ADRENERGIC  RECEPTOR- 
ALTERATIONS  IN  3H-ALPREN0L0L  BINDING  AND  ADENYLATE-CYCLASE 
(UNPUBLISHED  PAPER) 

237170  02-03 
3H-DEITA9-TETRAHYDROCANNABINOL 

3H-DELTA9-TETRAHYDR0CANNABIN0L  TISSUE  AND  SUBCELLULAR 
DISTRIBUTION  IN  THE  CENTRAL  NERVOUS  SYSTEM  AND  TISSUE 
DISTRIBUTION  IN  PERIPHERAL  ORGANS  OF  TOLERANT  AND 
NONTOLERANT  DOGS. 

237753  02-03 
3H-DOPAMINE 

THE  BRAINS  DOPAMINE  RECEPTOR    LABELING  WITH  3H-D0PAMINE  AND 

3H-HAL0PERID0L 

240077  03-03 
AMPHETAMINE:  EVALUATION  OF  0-ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 

3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 

CORTEX 

248699  04  03 
NICOTINIC  EFFECT  OF  ACETYLCHOLINE  ON  THE  RELEASE  OF  NEWLY 
SYNTHESIZED  3H  DOPAMINE  IN  RAT  STRIATAL  SLICES  AND  CAT 
CAUDATE  NUCLEUS. 

252217  04-03 
3H-HAIOPERI0OL 

THE  BRAINS  DOPAMINE  RECEPTOR:  LABELING  WITH  3H-D0PAMINE  AND 
3H-HAL0PERID0L 

240077  03-03 
3H.NOREPINEPHRINE 

AMPHETAMINE    EVALUATION  OF  0  ISOMERS  AND  L-ISOMERS  AS 

RELEASING  AGENTS  AND  UPTAKE  INHIBITORS  FOR  3H-D0PAMINE  AND 
3H-N0REPINEPHRINE  IN  SLICES  OF  RAT  NEOSTRIATUM  AND  CEREBRAL 
CORTEX 

248699  04-03 

THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H  5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX. 

253691  04-03 
3H-SEROTONIN 

EFFECTS  OF  CHLORIMIPRAMINE  AND  LYSERGIC  ACID-DIETHYLAMIDE  ON 
EFFLUX  OF  PRECURSOR  FORMED  3H-SER0T0NIN:  CORRELATIONS  WITH 
SEROTONERGIC  IMPULSE  FLOW 

246846  04-03 
3H-5-HYDROXYTRYPT  AMINE 

DEVELOPMENT  OF  THE  INFLUENCES  OF  SODIUM,  CATECHOLAMINE  AND 
TRICYCLIC  ANTIDEPRESSANT  DRUG  ON  THE  UPTAKE  OF  3H-5 
HYDROXYTRYPTAMINE  BY  RAT  BRAIN  SYNAPTOSOMES. 

249667  04-03 
EFFECTS  OF  ACUTE  AND  CHRONIC  METHADONE  TREATMENT  ON  THE 
UPTAKE  OF  3H-5-HYDROXYTRYPTAMINE  IN  RAT  HYPOTHALAMUS 
SLICES 

252023  04-03 
THE  EFFECT  OF  VARIOUS  PHENOTHIAZINES  AND  TRICYCLIC 

ANTIDEPRESSANTS  ON  THE  ACCUMULATION  AND  RELEASE  OF  3H- 
NOREPINEPHRINE  AND  3H  5-HYDROXYTRYPTAMINE  IN  SLICES  OF  RAT 
OCCIPITAL  CORTEX. 

253691  04-03 
4-CHlOROAMPHETAMINE 

ACUTE  AND  CHRONIC  EFFECTS  OF  4-CHLOROAMPHETAMINE  ON 
MONOAMINE  METABOLISM  IN  THE  RAT  BRAIN. 

239849  03-03 
EFFECT  OF  3  P  TRIFLUOROMETHYLPHENOXY-N-METHYL-3- 

PHENYLPROPYLAMINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN  BY  4- 
CHLOROAMPHETAMINE. 

246847  04-03 
4- 1  -NAPHTH  YIVIN  YlPYRrOINE 

ELEVATION  OF  AMPHETAMINE  LEVELS  IN  RAT  BRAIN  AFTER 

ADMINISTRATION  OF  THE  CHOLINE  ACETYLTRANSFERASE  INHIBITOR  4- 
I  NAPHTHYLVINYLPYRIDINE(NVP). 

249027  04-03 
4S5-NM 

THE  NATURE  OF  THE  455  NM  ABSORBING  COMPLEX  FORMED  DURING 
THE  CYT0CHROME-P450  DEPENDENT  OXIDATIVE  METABOLISM  OF 
AMPHETAMINE 

241350  03-01 
46-XY 

47  XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04-10 


Psychopharmacology  Abstrac 


47-XYY 

47-XYY  AND  46-XY  MALES  WITH  ANTISOCIAL  AND/OR  SEX  OFFENDING 
BEHAVIOR:  ANTIANDROGEN  THERAPY  PLUS  COUNSELING. 

248222  04- 
S-0IMETHOXY-4-METHYLPHENYL-2AMINOPROPANE 

N-HYDROXYLATION  OF  l-2,5-DIMETHOXY-4-METHYLPHENYL-2- 
AMINOPROPANE  BY  RABBIT  LIVER  MICROSOMES. 

249234  04- 
5-HIAA 

EFFECT  OF  PERIPHERAL  DECARBOXYLASE  INHIBITION  ON  HVA  AND  5- 
HIAA  IN  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

226915  01- 
EFFECT  OF  ECT  AND  IMIPRAMINE  TREATMENT  ON  THE  CONCENTRATIOI 
OF  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  FLUID  OF  DEPRESSED  PATIENTS. 

230827  01- 
PROBENECID:  DOSAGE.  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  FLUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC-ACID 
(HVA)  AND  5-HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01- 
S-HT 

ALTERED  5-HT  METABOLISM  WITH  CLONAZEPAM,  DIAZEPAM  AND 
DIPHENYLHYDANTOIN. 

230855  01- 
CLONAZEPAM-INDUCED  CHANGES  IN  5-HYDROXYTRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  AAAN. 

237977  02- 
STIMULATION  OF  BRAIN  SEROTONIN  (5-HT)  SYNTHESIS  BY  L 

TRYPTOPHAN  (TRP)  INJECTION  IN  AMLNOURISHED,  CORN-FED  RATS. 

238676  03-' 
THE  ROLE  OF  DOPAMINE  (DA)  AND  SEROTONIN  (5-HT)  IN  THE 

PROLONGATION  OF  POST-DECAPITATION  CONVULSIONS  (PDC)  IN  MIC 

238737  03-1 
INHIBITION  OF  NEURONAL  SEROTONIN  (5-HT)  UPTAKE  AND  THE 
ANTICONVULSANT  ACTION  OF  TRIMETHADIONE  (TMD). 

238753  03-1 
SEROTONIN  (5-HT)  SYSTEMS  IN  PSYCHOTIC  STATES. 

240076  03- 
THE  INVOLVEMENT  OF  METHYSERGID  SENSITIVE  RECEPTORS  AND 
PROSTAGLANDINS  IN  THE  HYPERTHERMIA  EVOKED  BY  5-HT  IN  THE 
CAT. 

241255  03-( 
EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5- 

HYDROXYTRYPT AMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (II 

241394  03-( 
DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241395  03-( 
EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5  HT) 

TURNOVER  RATE  IN  THE  RAT  BRAIN. 

241396  03-( 
EFFECTS  OF  MORPHINE  ON  5-HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  I 

THE  RAT  BRAIN  (III). 

241402  03-C 
NEUROCHEMICAL  AND  PHARMACOLOGICAL  STUDIES  ON  A  NEW  5-HT 
UPTAKE  INHIBITOR,  FG4963,  WITH  POTENTIAL  ANTIDEPRESSANT 
PROPERTIES 

245296  04-C 
EFFECTS  OF  INTRAVENTRICULAR  P-CHLOROAMPHETAMINE  AND  ITS 
ANALOGUES  ON  CEREBRAL  5-HT. 

246151  04-C 
EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS,  ON  THE  UPTAKE  OP  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES 

249313  04-0 
5-HT  ANTAGONISTS  IN  RAT  HIPPOCAMPUS. 

251072  04-0 
5-HTP 

RESPONSES  OF  FLEXOR  REFLEX  TO  LSD,  TRYPTAMINE  (T),  5-HTP. 
METHOXAMINE  (M)  AND  D-AMPHETAMINE  (A)  IN  ACUTE  AND 
CHRONIC  SPINAL  RATS. 

238704  03-0 
AN  INVESTIGATION  ON  THE  EFFECTS  OF  L-DOPA  AND  5-HTP  ON 
SYMPATHETIC  PREGANGLIONIC  NEURONES. 

238771  03-0 
S-HYDROXY-l-TRYPTOPHAN-DECARBOXYLASE 

5-HYDROXY-L-TRYPTOPHAN-DECARBOXYLASE  ACTIVITY:  MICROASSAY 
AND  DISTRIBUTION  IN  DISCRETE  RAT  BRAIN  NUCLEI. 

241208  03-0: 
S-HYDROXYINDOLE 

THE  MECHANISMS  BY  WHICH  METHIOTHEPIN,  A  PUTATIVE  SEROTONIN 
RECEPTOR  ANTAGONIST,  INCREASES  BRAIN  5-HYDROXYINDOLE 
LEVELS, 

233290  02-0: 
DEPRESSED  5-HYDROXYINDOLE  LEVELS  ASSOCIATED  WITH  HYPERACTIVE 
AND  AGGRESSIVE  BEHAVIOR   RELATIONSHIP  TO  DRUG  RESPONSE. 

239936  03- 1: 


S-346 


HUME  14,  SUBJECT  INDEX 

'TF°a  of^a^AN"  MIPRAMINE  TREATMENT  ON  THE  CONCENTRATION 
OF'SrHYDROXYINOOLEACETIC-ACID  (5  HIAA)  AND  HOMOVANILLIC- 
ACID  (HVA)  IN  THE  CEREBROSPINAL  ELUID  OF  DEPRESSED^PM^I|NTS.^^ 

PROBENECID    DOSAGE,  LEVELS  IN  PLASMA  AND  CEREBROSPINAL  F.LUID 
(CSF)  AND  INFLUENCE  UPON  CSF  LEVELS  OF  HOMOVANILLIC  ACID 
(HVA)  AND  5  HYDROXYINDOLEACETIC-ACID  (5-HIAA)  IN  THE  RABBIT. 

230877  01-06 

NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR  -  CONTENT  OF 
TRYPTOPHAN    5-HYDROXYTRYPTOPHAN,  SEROTONIN.  5- 
HYDROXYINDOLEACETIC-ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

7A\ZUb  UJ-U4 

HOMOVANILLIC  ACID  AND  5-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  I.  LUMBAR  CSF 
CONCENTRATION  IN  CHRONIC  BRAIN  POSTTRAUMATIC  SYNDROMES 

HOMOVANILLIC-ACID  AND  5-HYDROXYINDOLEACETIC  ACID  IN  THE  CSF 
OF  PATIENTS  AFTER  A  SEVERE  HEAD  INJURY.  II   VENTRICULAR  CSF 
CONCENTRATIONS  IN  ACUTE  BRAIN  POSTTRAUMATIC  SYNDROMES. 

246994  04  13 

HYDROXYINDOIES 

EFFECTS  OF  P-CHLOROAMPHETAMINE  ON  LOCOMOTOR  ACTIVITY  AND 
BRAIN  5-HYDROXYINDOLES  239958  03-04 

INABILITY  OF  METHADONE  TO  PREVENT  THE  DEPLETION  OF  BRAIN  5 
HYOROXYINDOLES  BY  P-CHLOROAMPHETAMINE, 

EFFECTS  OF  BENZODIAZEPINES  ON  THE  BINDING  OF  TRYPTOPHAN  IN 
SERUM    CONSEQUENCES  ON  5-HYDROXYINDOLES  CONCENTRATIONS  IN 

^»^^^'^^^^^  2472,3  04-03 

INTERACTION  OF  DIET  AND  DRUGS  IN  THE  REGULATION  OF  BRAIN  5- 
HYOROXYINDOLES  AND  THE  RESPONSE  TO  PAINFUL  ELECTRIC  SHOCK. 

252516  04  03 

-HYDROXYTRYPTAMINE  ^„^^ 

AN  EVALUATION  OF  THE  USE  OF  INTRAVENIRICULARLY  ADMINISTERED 
(3H)5  HYDROXYTRYPTAMINE  AS  A  MARKER  FOR  ENDOGENOUS  BRAIN 
5-HYDROXYTRYPTAMINE.  226400  0,-03 

REGULATION  OF  5  HYDROXYTRYPTAMINE  METABOLISM  IN  MOUSE 
BRAIN  BY  ADRENAL  GLUCOCORTICOIDS 

226401  0,  03 
INABILITY  OF  AN  INHIBITOR  OF  AMINE  UPTAKE  (LILLY  ,  ,0140)  TO 
BLOCK  DEPLETION  OF  BRAIN  5-HYDROXYTRYPTAMINE  BY  L  DOPA. 

226765  0)  (B 
THE  EFFECTS  OF  PROTRIPTYLINE  AND  CLOMIPRAMINE  IN  VITRO  ON  THE 
UPTAKE  OF  5-HYDROXYTRYPTAMINE  AND  DOPAMINE  IN  HUMAN 
PLATELET-RICH  PLASMA.  227,39  01-03 

THE  EFFECTS  OF  BETA-CARBOLINES  ON  RESPONSES  TO  ACETYLCHOLINE, 
NORADRENALINE,  5-HYDROXYTRYPTAMINE  AND  AMINO-ACIDS  IN  THE 

RAT  SPINAL  CORD.  .  „  ,  „o 

235863  02  03 

INHIBITION  OF  CHOLINESTERASE  BY  5  HYDROXYTRYPTAMINE 

237117  02-03 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE    PART  1:  IS 

FENFLURAMINE  OR  NORFENFLURAMINE  INVOLVED  IN  THE  DECREASE 
OF  BRAIN  S-HYDROXYTRYPTAMINE-^ 

237118  02  03 
FENFLURAMINE  AND  5-HYDROXYTRYPTAMINE,  PART  2    INVOLVEMENT 

OF  BRAIN  AND  5-HYDROXYTRYPTAMINE  IN  THE  ANORECTIC  ACTIVITY 

OF  FENFLURAMINE.  „  „„  „o 

237,19  02-03 

EFFECTS  OF  DOPAMINERGIC  AGONISTS  AND  ELECTRICAL  STIMULATION 
OF  THE  MIDBRAIN  RAPHE  ON  THE  RELEASE  OF  5- 
HYDROXYTRYPTAMINE  FROM  THE  CAT  BRAIN  IN  VIVO. 

237154  02  03 
MOUSE  BRAIN  CATECHOLAMINES,  5  HYDROXYTRYPTAMINE  AND  THE 
ANTINOCICEPTIVE  ACTIVITY  OF  PETHIDINE. 

237741  0203 
FAILURE  OF  DEPLETION  OF  RAT  BRAIN  5-HYDROXYTRYPTAMINE  TO 
ALTER  FENFLURAMINE  INDUCED  ANOREXIA. 

COMPARISON  OF  THE  EFFECTS  OF  LESION  IN  THE  0B9  CELL  BODY  GROUP 
AND  P-CHLOROAMPHETAMINE  ON  TRYPTOPHAN  HYDROXYLASE  AND 
5-HYDROXYTRYPTAMINF  IN  RAT  BRAIN  NUCLEI 

237863  02-03 

5  HYDROXYTRYPTAMINE  BINDING  ,0  SYNAPTIC  MEMBRANES  FROM  RAT 

^'^"'^  237890  02-03 

CLONAZEPAMINDUCED  CHANGES  IN  5  HYDROXYTRYPTAMINE  (5-HT) 
METABOLISM  IN  ANIMALS  AND  MAN 

237977  02  13 

QUIPAZINE-  ITS  EFFECTS  ON  RAT  BRAIN  5-HYDROXYTRYPT AMINE 
METABOLISM    MONOAMINE  OXIDASE  ACTIVITY  AND  BEHAVIOUR. 

239960  03  03 


Subject  Index 

REDUCTION  OF  TRYPTOPHAN  HYDROXYLASE  ACTIVITY  AND  5 
HYDROXYTRYPTAMINE  CONCENTRATION  IN  CERTAIN  RAT  BRAIN 
NUCLEI  AFTER  P-CHLOROAMPHETAMINE 

241253  Uj-u3 

DRUGS  AND  PGO  WAVES  IN  THE  LATERAL  GENICULATE  BODY  OF  THE 
CURARIZED  CAT    II    PGO  WAVE  ACTIVITY  AND  BRAIN  5- 
HYDROXYTRYPTAMINE.  24,316  03-03 

EFFECTS  OF  THE  D-ISOMERS  AND  L  ISOMERS  OF  AMPHETAMINE  ON 
UPTAKE    RELEASE  AND  CATABOLISM  OF  NOREPINEPHRINE.  DOPAMINE 
AND  5-HYDROXYTRYPTAMINE  IN  SEVERAL  REGIONS  OF  RAT  BRAIN. 

241345  03  03 

EFFECTS  OF  ENVIRONMENTAL  TEMPERATURE  ON  5 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN  (lia 

241394  03-03 

DRUG-INDUCED  CHANGES  IN  BODY  TEMPERATURE  AND  5- 

HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  RATE  IN  THE  RAT  BRAIN_ 

EFFECTS  OF  CHOLINERGIC  DRUGS  ON  5-HYDROXYTRYPTAMINE  (5-HT) 
TURNOVER  RATE  IN  THE  RAT  BRAIN.  ^^^^^^  ^^^^ 

EFFECTS  OF  MORPHINE  ON  5-HYDROXYTRYPTAMINE  (5-HT)  TURNOVER  IN 
THE  RAT  BRAIN  (III).  241402  03-03 

EXCITATORY  EFFECTS  OF  5-HYDROXYTRYPTAMINE,  HISTAMINE  AND 
POTASSIUM  IONS  ON  MUSCULAR  GROUP  IV  AFFERENT  UNITS:  A 
COMPARISON  WITH  BRADYKININ.  24U9a  03-03 

THE  INTERPRETATION  OF  RESPONSES  OF  MOTONEURONE  FIELD 
POTENTIALS  TO  5-HYDROXYTRYPTAMINE 

241923  U3  U3 

THE  SELECTIVE  INHIBITION  OF  5  HYDROXY, RYPTAMINE  REUPTAKE  BY 
ORG-6582.  241924  03-03 

EFFECT  OF  LSD  ON  RAT  BRAIN  5-HYDROXYTRYPTAMINE  METABOLISM  AT 
ELEVATED  ENVIRONMENTAL  TEMPERATURE 

241925  U3-UO 

ELECTROCONVULSIVE  SHOCK  INCREASES  THE  BEHAVIOURAL  RESPONSES 
OF  RATS  TO  3RAIN  5  HYDROXYTRYPTAMINE  ACCUMULATION  AND 
CENTRAL  NERVOUS  SYSTEM  STIMULANT  DRUGS.  ^^^^^^  ^^^^ 

CORRELATION  BETWEEN  THE  5  HYDROXYTRYPTAMINE  CONTENTS  IN  THE 
BRAIN  AND  DEGREES  OF  SENSORY.  AND  LOCOMOTOR  ACTIVITIES  IN 
^^^'^'^^  242205  03  04 

EFFECT  OF  THE  NOREPINEPHRINE  RECEPTOR  STIMULATING  AGENT 
CLONIDINE  ON  THE  TURNOVER  OF  5-HYDROXYTRYPTAMINE  IN  SOME 
AREAS  OF  THE  RAT  BRAIN.  243777  04-03 

EFFECTS  OF  5.7  DIHYDROXYTRYPTAMINE  ON  AN  IDENTIFIED  5- 
HYDROXYTRYPTAMINE  CONTAINING  NEURONE  IN  THE  CENTRAL- 
NERVOUS-SYSTEM  OF  THE  SNAIL  HELIX  POMATIA. 

243799  04  03 

EFFFCTS  OF  DRUGS  ACTING  ON  CEREBRAL  5-HYOROXYTRYPTAMINE 
MECHANISMS  ON  DOPAMINE  DEPENDENT  TURNING  BEHAVIOUR  IN 

^'"  243803  04-04 

EFFECIS  OF  TANDAMINE  AND  PIRANDAMINE.  NEW  POTENTIAL 

ANTIDEPRESSANTS,  ON  THE  BRAIN  UPTAKE  OF  NOREPINEPHRINE  AND 
5  HYDROXYTRYPTAMINE  AND  RELATED  ACTIVITIES 

2'i4678  04-03 

FENFLURAMINE  INDUCED  ENHANCEMENT  OF  CONFINEMENT  MOTOR 
ACTIVITY    AN  INDIRECT  5  HYDROXYTRYPTAMINE  LIKE  ACTION?. 

24491 1  04  04 
EFFECTS  OF  LITHIUM  CHLORIDE  ON  PARAMETERS  OF  BIOSYNTHETIC 
CAPACITY  FOR  5-HYDROXYTRYPTAMINE  IN  RAT  BRAIN. 

246849  04  03 
THE  EFFECT  OF  MEPIPRAZOLE  ON  CENTRAL  MONOAMINE  NEURONS 
EVIDENCE  FOR  INCREASED  5  HYDROXYTRYPTAMINE  AND  DOPAMINE 
RECEPTOR  ACTIVITY.  248288  04-03 

ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5  HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS. 

248834  04  U3 

EFFECTS  OF  PIRANDAMINE  (PA)  AND  TANDAMINE  (TA),  POTENTIAL 
ANTIDEPRESSANTS    ON  THE  UPTAKE  OF  NOREPINEPHRINE  (NE)  AND  5- 
HYDROXYTRYPTAMINE  (5-HT)  AND  RELATED  ACTIVITIES. 

249313  04-03 

CORREIATIONS  BETWEEN  THE  ACTIVITY  OF  DIMETHYLTRYPTAMINES  AS 
5-HYDROXYTRYPTAMINE  ANTAGONISTS  AND  THEIR  QUANTUM 
CHEMICAL  PARAMETERS.  249318  04  03 

EFFECT  OF  METOCLOPRAMIDE  ON  TURNOVER  OF  BRAIN  DOPAMINE 
NORADRENALINE  AND  5  HYDROXYTRYPTAMINE. 

249628  04-03 


S-347 


Subject  index 


Psychopharmacology  Abstract 


3 

m 

1= 


Si 


ii 

Off 
> 
IS 


J.1 


ON  THE  USE  OF  SELECTIVE  NEUROTOXIC  AMINE  ANALOGS  TO  MEASURE 
THE  BLOCKADE  OF  NOREPINEPHRINE  AND  5-HYDROXYTRYPTAMINE 
UPTAKE  SYSTEMS  BY  ANTIDEPRESSANTS, 

249930  04-03 
ON  THE  IN  VIVO  AND  IN  VITRO  ACTIONS  OF  FENFLURAMINE  AND  ITS 
DERIVATIVES  ON  CENTRAL  MONOAMINE  NEURONS,  ESPECIALLY  5- 
HYDROXYTRYPTAMINE  NEURONS,  AND  THEIR  RELATION  TO  THE 
ANORECTIC  ACTIVITY  OF  FENFLURAMINE. 

250937  04-03 
EVIDENCE  CONCERNING  THE  INVOLVEMENT  OF  5-HYDROXYTRYPTAMINE 
IN  THE  LOCOMOTOR  ACTIVITY  PRODUCED  BY  AMPHETAMINE  OR 
TRANYLCYPROMINE  PLUS  L  DOPA. 

251704  04-04 
ACTIVITY,  AVOIDANCE  LEARNING  AND  REGIONAL  5- 

HYDROXYTRYPTAMINE  FOLLOWING  INTRABRAIN  STEM  5,7 
DIHYDROXYTRYPTAMINE  AND  ELECTROLYTIC  MIDBRAIN  RAPHE 
LESIONS  IN  THE  RAT. 

252173  04-03 
EFFECTS  OF  TETRAHYDROPAPAVEROLINE  ON  DOPAMINE  AND  5- 
HYDROXYTRYPTAMINE  METABOLISM  IN  RAT  BRAIN  IN  VIVO. 

252220  04-03 
EFFECTS  OF  LILLY-110140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN  INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING 

252522  04-03 
THE  ROLE  OF  NORADRENALINE,  DOPAMINE  AND  5-HYDROXYTRYPTAMINE 
IN  THE  HYPERACTIVITY  RESPONSE  RESULTING  FROM  THE 
ADMINISTRATION  OF  TRANYLCYPROMINE  TO  RATS  PRETREATED  WITH 
LITHIUM  OR  RUBIDIUM. 

253593  04-04 
5-HYDROXYTRYPTAMINE- 14C 

5-HYDR0XYTRYPTAMINE-I4C  AND  DEXAMPHETAMINE-14C  UPTAKE  BY 
FUNDAL  SARCOLEMMA  PREPARATIONS:  EFFECT  OF  THERMAL  AND 
CHEMICAL  ALTERATIONS  AS  INDIRECT  APPROACH  TO  THE  PROBLEM 
OF  THE  COMMON  RECEPTOR. 

226827  01-03 
5-HYDROXYTRYPTOPHAN 

INEXPENSIVE  EQUIPMENT  FOR  HIGH  PRESSURE  LIQUID 

CHROMATOGRAPHY:  APPLICATION  TO  ASSAYS  FOR  TAURINE, 
GAMMA  AMINOBUTYRIC  ACID  AND  5-HYDROXYTRYPTOPHAN 
(UNPUBLISHED  PAPER). 

231278  01-06 
INHIBITION  OF  FIRING  OF  RAPHE  NEURONES  BY  TRYPTOPHAN  AND  5- 
HYDROXYTRYPTOPHAN:  BLOCKADE  BY  INHIBITING  SEROTONIN 
SYNTHESIS  WITH  RO-4-4602. 

239957  03-03 
NEUROCHEMICAL  CORRELATES  OF  BEHAVIOUR    -  CONTENT  OF 
TRYPTOPHAN,  5  HYDROXYTRYPTOPHAN,  SEROTONIN,  5- 
HYOROXYINDOLEACETIC  ACID,  TYROSINE,  DOPAMINE  AND 
NOREPINEPHRINE  IN  FOUR  BRAIN  PARTS  OF  THE  PIGEON  DURING 
BEHAVIOURAL  DEPRESSION  FOLLOWING  AN  INJECTION. 

241205  03  04 
EFFECTS  OF  HYPOTHYROIDISM  AND  HYPERTHYROIDISM  ON  5- 

HYDROXYTRYPTOPHAN  AND  CHLORPROMAZINE-INDUCED  PROLACTIC 
RELEASE  IN  THE  RAT. 

243951  04-03 
THE  EFFECT  OF  TRYPTOPHAN  AND  A  TRYPTOPHAN/5- 

HYDROXYTRYPTOPHAN  COMBINATION  ON  INDOLES  IN  THE  BRAINS  OF 
RATS  FED  A  TRYPTOPHAN  DEFICIENT  DIET. 

249675  0403 
THE  EFFECTS  OF  5-HYDROXYTRYPTOPHAN  AND  L-TRYPTOPHAN  ON 
WAKEFULNESS  AND  SLEEP  PATTERNS  IN  THE  CAT. 

252216  04-03 
5-HYDROXYTRYPTOPHAN-INDUCED 

BEHAVIORAL  SUPERSENSITIVITY  TO  5  HYDROXYTRYPTOPHAN-INDUCED 
BY  CHRONIC  METHYSERGIDE  PRETREATMENT. 

237729  02  04 
EFFECTS  OF  LILLY  110140,  A  SPECIFIC  INHIBITOR  OF  5- 

HYDROXYTRYPTAMINE  UPTAKE,  ON  FOOD  INTAKE  AND  ON  5- 
HYDROXYTRYPTOPHAN  INDUCED  ANOREXIA.  EVIDENCE  FOR 
SEROTONINERGIC  INHIBITION  OF  FEEDING. 

252522  04  03 
5-HYDROXYTRYPTOPHAN- 1 4C 

METABOLISM  OF  5  HYDROXYTRYPTOPHAN  14C  AFTER  INTRACISTERNAL 
INJECTION  WITH  AND  WITHOUT  THE  INFLUENCE  OF  DRUGS  IN  THE 
RAT  BRAIN 

237700  02-03 
5-HYROXYTRYPAMINE 

RESPONSES  OF  ISOLATED  HUMAN  BASILAR  ARTERIES  TO  5- 

HYROXYTRYPAMINE,  NORADRENALINE,  SERUM,  PLATELETS,  AND 
ERYTHROCYTES 

230739  01-13 
5-MEO-DMT 

5  METHOXY  N,N:DIMETHYLTRYPTAMINE  (5  MEO-DMT)  SHARES 

INHIBITORY  EFFECTS  WITH  MESCALINE  BUT  NOT  EXCITATORY  EFFECTS 
ON  SHUTTLEBOX  ESCAPE/AVOIDANCE  IN  RATS    (UNPUBLISHED  PAPER). 

227802  01  04 


5-METHOXYTRYPT  AMINE 

THE  BIOCHEMICAL  AND  BIOBEHAVIORAL  PROFILE  OF  5- 
METHGXYTRYPTAMINE    (UNPUBLISHED  PAPER). 

239307  03-( 
THE  CONCENTRATION  OF  5-METHOXYTRYPTAMINE  IN  RAT  BRAIN  AND 
ITS  EFFECTS  ON  BEHAVIOUR  FOLLOWING  ITS  PERIPHERAL  INJECTION 

245600  04-( 
5-METHYITETRAHYDROK3LIC-ACID 

METHYLENE-REDUCTASE:  RESPONSIBLE  FOR  THE  IN  VITRO  FORMATION 
OF  FORMALDEHYDE  FROM  5-METHYLTETRAHYDROFOLIC-ACID. 

232613  02-( 
5  -MONOPHOSPHATE 

REGULj^TION  OF  PROTEIN  PHOSPHORYLATION  AND  MEMBRANE 

PERMEABILITY  BY  BETA-ADRENERGIC  AGENTS  AND  CYCLIC  ADENOSII 
3:5-MONOPHOSPHATE  IN  THE  AVIAN  ERYTHROCYTE. 

231014  0|.( 
5-OXOHEXAHYDROCINNOUNES 

CENTRAL-NERVOUS-SYSTEM  ACTIVE  5  OXOHEXAHYDROCINNOLINES. 

248649  04-( 
5-THIOETHER 

ANALOGUES  OF  S  ADENOSYLHOMOCYSTEINE  AS  POTENTIAL  INHIBITORS 
OF  BIOLOGICAL  TRANSMETHYLATION.  SYNTHESIS  OF  ANALOGUES 
WITH  MODIFICATIONS  AT  THE  5-THIOETHER  LINKAGE. 

251698  04-( 
5ALPHA-REDUCED 

DIFFERENTIAL  EFFECTS  OF  THE  ANTIESTROGEN  MER-25  AND  OF  THREE 
5ALPHA-REDUCED  ANDROGENS  ON  MOUNTING  AND  LORDOSIS 
BEHAVIOR  IN  THE  RAT. 

244343  04-( 
6-HYDROXYDOPA 

EFFECTS  OF  6  HYDROXYDOPA  AND  5,6  DIHYDROXYTRYPTQPHAN 
TREATMENT  ON  SPONTANEOUS  MOTOR  ACTIVITY  AND  BRAIN 
MONOAMINES  IN  MICE. 

238565  02-( 
CHOLINE  ACETYLTRANSFERASE  ACTIVITY  INCREASES  IN  THE  BRAINSTEA 
OF  RATS  TREATED  AT  BIRTH  WITH  6-HYDROXYDOPA. 

249666  04( 
6-HYDROXYDOP  AMINE 

GLUCOREGULATORY  FEEDING  BY  RATS  AFTER  INTRAVENTRICULAR  6- 
HYDROXYDOPAMINE  OR  LATERAL  HYPOTHALAMIC  LESIONS. 

227125  01. ( 
EFFECTS  OF  HANDLING  BEFORE  CENTRAL  6  HYDROXYDOPAMINE 

TREATMENT  ON  SUBSEQUENT  EMOTIONALITY  AND  NEUROCHEMICAL 
CHANGES  IN  RATS. 

228142  Ol-C 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  AND 

REPLACEMENT  THERAPY  WITH  NOREPINEPHRINE,  DOPAMINE,  AND 
SEROTONIN  ON  SELF  STIMULATION  IN  DIENCEPHALIC  AND 
MESENCEPHALIC  REGIONS  IN  THE  RAT. 

232332  Ol-C 
RELATIONSHIP  OF  DOPAMINE  NEURAL  SYSTEMS  TO  THE  BEHAVIORAL 
ALTERATIONS  PRODUCED  BY  6  HYDROXYDOPAMINE  ADMINISTRATIOI 
INTO  BRAIN. 

233970  02-C 
THE  EFFECT  OF  NOMIFENSINE  ON  THE  DEPLETION  OF  BRAIN  SEROTONIN 
AND  CATECHOLAMINES  INDUCED  RESPECTIVELY  BY  FENFLURAMINE 
AND  6-HYDROXYDOPAMINE  IN  RATS. 

237743  02-C 
UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  NIGROSTRIATAL  OR 
MESOLIMBIC  DOPAMINE  CONTAINING  TERMINALS  AND  THE  DRUG- 
INDUCED  ROTATION  OF  RATS. 

237866  02-0 
THE  EFFECT  OF  CHRONIC  CENTRAL  ADRENERGIC  DENERVATION  ON 
LEARNING  AND  MEMORY  OF  AN  AVERSIVE  DISCRIMINATION  TASK  IN 
MICE:  STUDIES  WITH  6-HYDROXYDOPAMINE.  (PH.D.  DISSERTATION). 

238157  02-0 
ALTERATIONS  OF  THE  EEG  OF  EXTRAPYRAMIDAL  NUCLEI  FOLLOWING  6- 
HYDROXYDOPAMINE  LESIONS. 

238735  03-0 
6  HYDROXYDOPAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH),  CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC  ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS 

238826  03-0 
EFFECTS  OF  INTRAVENTRICULAR  6-HYDROXYDOPAMINE  INJECTIONS  ON 
SERUM  PROLACTIN  AND  LH  LEVELS   ABSENCE  OF  STRESS-INDUCED 
PITUITARY  PROLACTIN  RELEASE 

239828  03-0, 
DESTRUCTIVE  ACTION  OF  SYSTEMICALLY  ADMINISTERED  6- 
HYDROXYDOPAMINE  ON  THE  RAT  AREA  POSTREMA. 

239832  03-0: 
NONSPECIFIC  SUPERSENSITIVITY  OF  STRIATAL  DOPAMINE  RECEPTORS 
AFTER  6  HYDROXYDOPAMINE  LESION  OF  THE  NIGROSTRIATAL 
PATHWAY. 

240063  03-0: 
REDUCTION  IN  MORPHINE  TOLERANCE  AND  PHYSICAL  DEPENDENCE  AND 
OPIOID  SEEKING  BEHAVIOR  BY  INTRACEREBRAL  6- 
HYOROXYDOPAMINE    (PH.D.  DISSERTATION) 

241  100  03-0: 


S-348 


JME  14,  SUBJECT  INDEX 


Subject  Index 


^FECTS  OF  6-HYDROXYDOPAMINE  ON  CENTRAL  NORADRENALINE 
NEURONS  DURING  ONTOGENY.  241196  03-03 

3NG  TERM  DEFICITS  IN  STIMULATION-INDUCED  BEHAVIORS  AND  SELF- 
STIMULATION  AFTER  6  HYDROXYDOPAMINE  ADMINISTRATION  IN 

''^^^  24)300  03-04 

FFECT  OF  6-HYDROXYDOPAMINE  ON  THE  NEONATE  SPONTANEOUSLY 
HYPERTENSIVE  RAT  AND  NORMOTENSIVE  RAT.  ^^^^^^  ^^^^ 

CTIONS  OF  6-HYDROXYDOPAMINE  INJECTED  INTRAVENTRICULARLY 
INTO  DEVELOPING  RATS  (2).  INFLUENCE  ON  MOTOR  ACTIVITIES  AND 
AGGRESSIVE  BEHAVIOR.  241372  03-04 

HE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 
HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

241918  03-04 

HE  MODIFICATION  OF  INOTROPIC  ACTION  OF  OUABAIN  BY  6- 
HYDROXYDOPAMINE  AND  ALPHA-METHYL-P-TYROSINE  IN  DOGS. 

iHE  EFFECTS  OF  INTRA-AMYGDALOID  INJECTIONS  OF  6- 
HYDROXYDOPAMINE  ON  AVOIDANCE  RESPONDING  IN  RATS. 

243758  04-04 

FHERMAL  HOMEOSTASIS  IN  RATS  AFTER  INTRAHYPOTHALAMIC 
INJECTIONS  OF  6-HYDROXYDOPAMINE.  ^^^^^  ^  ^^^^ 

DECREASED  INTRACRANIAL  SELF  STIMULATION  AFTER  NEUROLEPTICS  OR 
6-HYDROXYDOPAMINE:  EVIDENCE  FOR  MEDIATION  BY  MOTOR 
DEFICITS  RATHER  THAN  BY  REDUCED  REWARD. 

244676  04-04 

INHIBITORY  EFFECTS  IF  6-HYDROXYDOPAMINE  ON  THE  CLONIC 
CONVULSIONS  INDUCED  BY  ELECTROSHOCK  AND  DECAPITATION. 

245597  04-03 

APORPHINES  16'  ACTION  OF  APORPHINE  ALKALOIDS  ON  LOCOMOTOR 
ACTIVITY  IN  RATS  WITH  6-HYDROXYDOPAMINE  LESIONS  OF  THE 

NUCLEUS-ACCUMBENS.  „on,  ^.  no 

248287  04-02 

THE  EFFECT  OF  PRETREATMENT  WITH  6  HYDROXYDOPAMINE  ON  THE 
NOREPINEPHRINE  CONCENTRATION  AND  SENSITIVITY  OF  THE  RAT 

^^^■^'''^'^'  248413  04-03 

INHIBITION  OF  CIRCLING  BEHAVIOR  BY  NEUROLEPTIC  DRUGS  IN  MICE 

WITH  UNILATERAL  6-HYDROXYDOPAMINE  LESIONS  OF  THE  STRIATUM. 

249679  04-04 
SPECIFICITY  OF  DOPAMINERGIC  NEURONAL  DEGENERATION  INDUCED  BY 

INTRACEREBRAL  INJECTION  OF  6-HYDROXYDOPAMINE  IN  THE 

NIGROSTRIATAL  DOPAMINE  SYSTEM.  ^^^^^^  ^^^^ 

A  PARADOXICAL  RESPONSE  TO  AMPHETAMINE  IN  DEVELOPING  RATS 
TREATED  WITH  6-HYDROXYDOPAMINE. 

251951  04-04 

CATECHOLAMINE  RELEASE  BY  INTRACEREBRAL  PERFUSION  OF  6 
HYDROXYDOPAMINE  AND  DESIPRAMINE. 

YDROXYDOPAMINE-INDUCED 

THE  EFFECTS  OF  NEONATAL  6-HYDROXYDOPAMINE  INDUCED 
SYMPATHECTOMY  ON  RESPONSE  INHIBITION  IN  EXTINCTION. 

226871  01  -03 

REVERSAL  OF  THE  6  HYDROXYDOPAMINE  INDUCED  SUPPRESSION  OF  A 
CAR  BY  DRUGS  FACILITATING  CENTRAL  CATECHOLAMINERGIC 

^E^^'^^'S^^  246818  04-04 

DDODOPAMINE  „^^ 

RADIOPHARMACEUTICALS.  16.  HALOGENATED  DOPAMINE  ANALOGS. 
SYNTHESIS  AND  RADIOLABELING  OF  6  lODODOPAMINE  AND  TISSUE 
DISTRIBUTION  STUDIES  IN  ANIMALS 

IMPAIRED  ACQUISITION  OF  A  PASSIVE  AVOIDANCE  RESPONSE  AFTER 
LESIONS  INDUCED  IN  THE  LOCUS  COERULEUS  BY  6-OH  DOPAMINE. 

AMPHETAMINE  AND  APOMORPHINE  RESPONSES  IN  THE  RAT  FOLLOWING 
6-OHDA  LESIONS  OF  THE  NUCLEUS  ACCUMBENS  SEPTI  AND  CORPUS- 

^^"^"^^^^  226937  01-04 

6-HYDROXYDOPAMINE  (6  OHDA)  ADMINISTRATION  TO  NEONATAL  RATS 
FAILS  TO  AFFECT  THE  DEVELOPMENT  OF  TYROSINE-HYDROXYLASE 
(TH)   CHOLINE  ACETYLTRANSFERASE  (CAT)  AND  GLUTAMIC-ACID- 
DECARBOXYLASE  (GAD)  IN  THE  CNS.  238826  0303 

BEHAVIOURAL  AND  ANATOMICAL  EFFECTS  OF  6  OHDA  INJECTIONS  IN 
THE  VENTRAL  MESENCEPHALIC  TEGMENTUM  IN  THE  RAT. 

244216  04-04 

HYDROXYCHLORPROMAZINE  „„„„..  „„K,r 

STUDIES  ON  THE  GLUCURONIDATION  OF  7-HYDROXYCHLORPROMAZINE 

'^^'^'^^  249284  04-03 


'°°^A  REVIEW  OF  THE  CNS  EFFECTS  OF  FENFLURAMINE,  780SE  AND 
NORFENFLURAMINE  ON  ANIMALS  AND  MAN. 

25UV35  U4- 1  / 

COMPARISONS  BETWEEN  THE  BEHAVIOURAL  AND  ANOREXIC  EFFECTS  OF 
780SE  AND  OTHER  PHENYLETHYLAMINES  IN  THE  RAT.        ^^^^^  ^^^^ 

°"^''re'l°ase°of''norepinephrine  (ne)  and  DOPAMINE-BETA-HYDROXYLASE 

(DBH)    EFFECT  OF  PHENOXYBENZAMINE  (PBZ)  ALONE  AND  IN 
COMBINATION  WITH  8  BROMO  CGMP  AND  DIBUTYRYL  CAMP^ 

23o6VU  Uj-Uj 

8-CHLORO- 

8-CHLORO  (S)-  AND  -(R)-IO  ((S)   AND   (R)  3- 

METHYLETHYLAMINOPYRROLIDINODIHYDRODIBENZOTHIEPINS 

SYNTHESIS  AND  PHARMACOLOGICAL  STUDIES  ^^^^^^  ^^^^ 


i  U.S.  GOVERNMENT  PRINTING  OFFICE:  \m-2Vl-l,o2  V2264 


S-349 


,■3 


Si 


I 
I 


-3* 

h 

z 


Computer  Information  Services  of  the  Notional 
Clearinghouse  for  Mental  Health  Information 


Searches  of  the  NCMHI  computer-based  information  system  will  be  done  on  request, 
■hese  reader-generated  bibliographies  are  available  without  charge  to  anyone  within  the 
lental  health  community. 

Requests  for  a  printout  on  a  topic  not  covered  by  the  abstracts  in  this  issue  or  other 
JCMHl  publications  should  be  sent  directly  to  the  Clearinghouse.  The  request  should 
iclude  the  inquirer's  name,  address,  professional  affdiation,  and  phone  number,  along 
/ith  a  clear  and  specific  statement  of  the  information  desired.  Either  a  letter  or  the  order 
ilank  below  should  be  sent  to  the  following  address: 

National  Clearinghouse  for  Mental 

Health  Information 
Alcohol,  Drug  Abuse,  and 

Mental  Health  Adnnnistration 
5600  Fishers  Lane  ' 
Rockville.  Maryland  20852 


Date 


\lame  of  requester. 
Ad  d  ress 


Organization. 


Phone  number  (include  area  code). 


Information  requested  (please  be  as  specific  as  possible) 


"V- 


Z' 


PSYCHOPHARMACOLOGY  ABSTRACTS 


Questions  about  Clearinghouse  service  should  be  addressed  to: 

Psychopharmacology  Abstracts 

National  Clearinghouse  for  Mental  Heahh  Information 

Alcohol,  Drug  Abuse,  and  Mental  Health  Administration 

5600  Fishers  Lane 

Rockville,  Maryland  20852 

For  information  on  subscriptions  and  the  purchase  of  single  copies  of  ihc  Abstracts  (Vol. 
7  onward),  please  refer  to  page  ii  of  this  issue. 


DEPARTMENT  OF 

HEALTH,   EDUCATION,  AND  WELFARE 

PUBLIC   HEALTH   SERVICE 

ALCOHOL,   DRUG  ABUSE.   AND 

MENTAL    HEALTH   ADMINISTRATION 

5600   FISHERS   LANE 

ROCKVILLE,    MARYLAND    20857 


OFFICIAL   BUSINESS 
Penalty  for  private  use,  $300 


POSTAGE   AND    FEES    PAID 

U.S.    DEPARTMENT   OF   H.E.W. 

HEW  389 


FOURTH  CLASS 
BOOK  RATE 


NOTICE  OF  MAILING  CHANGE 

n  Check  here  if  you  wish  to  discontinue  receiving  this  type  of  publication. 

n  Check  here  if  your  address  has  changed  and  you  wish  to  continue  receiving  this 
type  of  publication.  (Be  sure  to  furnish  your  complete  address  including  zip  code.) 

Tear  off  cover  with  address  label  still  affixed  and  send  to: 

Alcohol,  Drug  Abuse,  and  Mental  Health  Administration 
Printing  and  Publications  Management  Section 
5600  Fishers  Lane  (Rm.  6-105) 
Rockvllle,  Maryland    20857 


DHEW  Publication  No.  (ADM)  78  -  150 
Printed  1978 


f 


% 


I 

r. 

0)1 


^